5,256 Matching Annotations
  1. Sep 2022
    1. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      This study performed whole genome sequencing (WGS) on a large cohort of hypoplastic left heart syndrome (HLHS) patients and their families to identify candidate. Nine candidate genes with rare, predicted damaging homozygous variants were identified. Of the candidate HLHS gene homologs tested, cardiac-specific knockdown (KD) of the mitochondrial contact site and cristae organization system (MICOS) complex subunit dCHCHD3/6 resulted in drastically compromised heart contractility, diminished levels of sarcomeric actin and myosin, reduced cardiac ATP levels, and mitochondrial fission-fusion defects. These heart defects were similar to those inflicted by cardiac KD of ATP synthase subunits of the electron transport chain (ETC), consistent with the MICOS complex's role in maintaining cristae morphology and ETC complex assembly. Analysis of 183 genomes of HLHS patient-parent trios revealed five additional HLHS probands with rare, predicted damaging variants in CHCHD3 or CHCHD6. Hypothesizing an oligogenic basis for HLHS, the authors tested 60 additional prioritized candidate genes in these cases for genetic interactions with CHCHD3/6 in sensitized fly hearts. Moderate KD of CHCHD3/6 in combination with Cdk12 (activator of RNA polymerase II), RNF149 (E3 ubiquitin ligase), or SPTBN1 (scaffolding protein) caused synergistic heart defects, suggesting the potential involvement of a diverse set of pathways in HLHS.

      General Comments:

      The authors performed an elegant series of experiments that implicate variants of dCHCHD3/6 in HLHS patients as contributing to mitochondrial and sarcomeric defects and contractile function defects. Demonstrating in Drosphilia the functional and biochemical implications of knocking out dCHCHD3/6 provides some potentially important insights into the functional and biochemical implications of dCHCHD3/6 variants in HLHS patients. The data is also complemented by hiPSC-CM studies in which knockdown of CHCHD6 and CHCHD3 showed similar alterations in ATP synthase and mitochondrial morphology.

      The authors nicely show that knock down of the subunit dCHCHD3/6 resulted in drastically compromised heart contractility, diminished levels of sarcomeric actin and myosin, reduced cardiac ATP levels, and mitochondrial fission-fusion defects in the Drosphilia. What is not clear is how these changes mirror the phenotype of HLHS in humans. It would helpful to speculate to a greater extent as to how these changes would manifest as a decreased left ventricular development in HLHS.

      Specific Comments:

      Line 139: Figure 1A does not show echos from the siblings.

      Line155: This table is listed as "Table 1" not Supplemental Table 1.

      Significance

      This is a highly significant study. The main audience would be pediatric cardiologists and geneticists.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      In this manuscript titled "mitochondrial MICOS complex genes, implicated in hypoplastic left heart syndrome, maintain cardiac contractility and actomyosin integrity", Katja Birker et al. reveal that CHCHD3/6 cardiac-specific KD caused reduced contractility and decreased sarcomeric F-Actin and Myosin staining in fly due to impaired ATP synthase. The findings shown in this manuscript are interesting. However, the additional experiments are needed to confirm the conclusion before publication.

      Major comments:

      1. The authors mentioned that the heart dysfunction observed upon CHCHD3/6 KD may be mediated via defects in ATP synthase. Then, how does CHCHD3/6 KD affect ATP synthase? Additionally, OPA1 also affects ATP synthase, why does OPA1 KD just reduce fractional shortening (S.T.2) without reducing F-actin staining?
      2. It has been reported that CHCHD3 KD in HeLa cells causes fragmented mitochondria, so how does CHCHD3/6 KD caused mitochondrial aggregation? What is the mechanism?
      3. The ultrastructure of mitochondria (especially aggregated mitochondria) in control and CHCHD3/6 KD heart of drosophila should be analyzed by TEM.

      Significance

      The manuscript partially illustrate the relationship between MICOS complex with Hypoplastic left heart syndrome (HLHS), which is intertesing to the reader.

  2. Aug 2022
    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Reply to the Reviewers

      We thank the reviewers for dedicating time to review our manuscript and providing highly valuable feedback. Please find below a point-by-point answer.

      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      Summary:

      In the present manuscript, van der Plas et al. compellingly illustrated a novel technique for engendering a whole-brain functional connectivity map from single-unit activities sampled through a large-scale neuroimaging technique. With some clever tweaks to the restricted Boltzmann Machine, the cRBM network is able to learn a low-dimensional representation of population activities, without relying on constrained priors found in some traditional methods. Notably, using some 200 hidden layer neurons, the employed model was able to capture the dynamics of over 40,000 simultaneously imaged neurons with a high degree of accuracy. The extracted features both illustrate the anatomical topography/connectivities and capture the temporal dynamics in the evolution of brain states. The illustrated technique has the potential for wide-spread applications spanning diverse recording techniques and animal species. Furthermore, the prospectives of modeling whole-brain network dynamics in 'neural trajectory' space and of generating artificial data in silico make for very enticing reasons to adopt cRBM.

      Major comments:

      1. Line 164. The authors claim that conventional methods "such as k-means, PCA and non-negative matrix factorization" cannot be quantitatively assessed for quality on the basis that they are unable to generate new artificial data. Though partly true, in most neuroscience applications, this is hardly cause for concern. Most dimensionality reduction methods (with few exceptions such as t-sne) allow new data points to be embedded into the reduced space. As such, quality of encoding can be assessed by cross-validation much in the same way as the authors described, and quantified using traditional metrics such as percentage explained variance. The authors should directly compare the performance of their proposed model against that of NNMF and variational auto-encoders. Doing so would offer a more compelling argument for the advantage of their proposed method over more widely-used methods in neuroscience applications. Furthermore, a direct comparison with rastermap, developed by Stringer lab at Janelia (https://github.com/MouseLand/rastermap), would be a nice addition. This method presents itself as a direct competitor to cRBM. Additionally, the use of GLM doesn't do complete justice to the comparison point used, since a smaller fraction of data were used for calculating performance using GLM, understandably due to its computationally intensive nature.

      PLANNED REVISION #2

      We thank the reviewer for the comment, and certainly agree that there are multiple methods for unsupervised feature extraction from data and that they can be validated for encoding quality by cross-validation. However, we stress that reconstructing through a low-dimensional, continuous bottleneck is a different (and arguably, easier) task, than generating whole distributions. Reconstruction delineates the manifold of possible configurations, whereas generative modeling must weigh such configurations adequately. Moreover, none of the methodologies mentioned can perform the same tasks as cRBMs. For instance, NNMF learns localized assemblies, but cannot faithfully model inhibitory connections since, by definition, only non-negative weights are learnt. Also, the connection between the learnt assemblies and the underlying connectivity is unclear. Similarly, rastermap is an algorithm for robustly i) sorting neurons along a set number of dimensions (typically 1 or 2) such that neighboring neurons are highly correlated, and ii) performing dimensionality reduction by clustering along these dimensions. Because Rastermap uses k-means as the basis for grouping together neurons, it does not quantify connections between neurons and assemblies, nor assign neurons to multiple assemblies. Moreover, it is not a generative model, and thus cannot predict perturbation experiments, infer connectivities or assign probabilities to configurations. Therefore, we do not believe that NNMF or Rastermap would be a suitable alternative for cRBM in our study. We nonetheless appreciate the reviewer’s suggestions and agree that we should motivate more clearly why these methods are not applicable for our purposes. Therefore, to emphasize the relative merit of cRBM with respect to other unsupervised algorithms, we now provide a table (Supplementary Table 2) that lists their specific characteristics. We stress that we do not claim that cRBM are consistently better than these classical tools for dimensionality reduction, but focus only on the properties relevant to our study.

      Further, we agree that VAEs, which also jointly learn a representation and distribution of data, are close competitors of cRBMs. In Tubiana et al. Neural Computation 2019, we previously compared sparse VAEs with cRBMs for protein sequence modeling, and found that RBMs consistently outperformed VAEs in terms of the interpretability-performance trade-off. In the revised manuscript, we propose to repeat the comparison with VAE for zebrafish neural recordings, and expect similar conclusions.

      As for GLM, it is true that the comparison involved subsampling of the neurons (due to the very high computational cost of GLM, where we could estimate the connectivity of 1000 neurons per day). This was already denoted in the relevant figure caption, as the reviewer has seen, but we have now also clarified this point in Methods 7.10.3. Still, we performed our GLM analysis on 5000 neurons (using all neurons as regressors), which is 10% of all neurons, and we believe this is a sufficient number for comparison. This emphasizes the ability of our optimized cRBMs to handle very large datasets, such as the presently used zebrafish whole brain recordings.

      Line 26. The authors describe their model architecture as a formalization of cell assemblies. Cell assemblies, as originally formulated by Hebb, pertains to a set of neurons whose connectivity matrix is neither necessarily complete nor symmetric. Critically, in the physiological brain, the interactions between the individual neurons that are part of an assembly would occur over multiple orders of dependencies. In a restricted Boltzmann machine, neurons are not connected within the same layer. Instead, visible layer neurons are grouped into "assemblies" indirectly via a shared connection with a hidden layer neuron. Furthermore, a symmetrical weight matrix connects the bipartite graph, where no recurrent connectivities are made. As such, the proposed model still only elaborates symmetric connections pertaining to first-order interactions (as illustrated in Figure 4C). Such a network may not be likened with the concept of cell assemblies. The authors should refrain from detailing this analogy (of which there are multiple instances of throughout the text). It is true that many authors today refer to cell assemblies as any set of temporally-correlated neurons. However, saying "something could be a cell assembly" is not the same as saying "something is a cell assembly". How about sticking with cRBM-based cell assemblies (as used in section 2.3) and defining it beforehand?

      We thank the reviewer for this excellent question. We agree that there is, in general, a discrepancy between computationally-defined assemblies and conceptual/neurophysiological definition of cell assemblies. We have added a clarification in Results 2.1 to clarify the use of this term when it first occurs in Results. However, we still believe that our work contributes to narrowing the gap. Indeed, our RBM-defined assemblies are i) localized, ii) overlapping, iii) rooted in connectivity patterns (both excitatory and inhibitory), and iv) cannot be reduced to a simple partitioning of the brain with full & uniform connectivity within and between partitions. This is unlike previous work based on clustering (no overlaps or heterogeneous weights), NNMF (no inhibition) or correlation network analysis (no low-dimensional representation).

      Regarding the specific comments pointed here, we stress that:

      • Effective interactions between neurons are not purely pairwise (“First order”), due to the usage of the non-quadratic potential. (see Eqn 12-13). If the reviewer means by “First-order” interactions the lack of hierarchical organization, we agree, to some extent: in the current formulation, correlations between assemblies are mediated by overlaps between their weights. Fully-hierarchical organization, e.g. by using Deep Boltzmann Machines or pairwise connections within the hidden layer is an interesting future direction, but on the other hand may make it hard to clearly identify assemblies as they might be spread out over multiple layers
      • Neurons that participate in a given assembly (as defined by a specific hidden unit) are not all connected with one another with equal strength. Indeed, these neurons may participate in other assemblies, resulting in heterogeneity of connections (see Eqn. 15-17) and interactions between assemblies.
      • We acknowledge that the constraint of symmetrical connections is a core limitation of our method. Arguably, asymmetric connections are critical for predicting temporal evolution but less important for inferring a steady-state distribution from data, as we do here. In the revised submission, we added a new paragraph in the discussion section (lines 351-357) in which these limitations are discussed, including the imposed symmetry of the connections and the lack of hierarchical structures, copied below. We trust that this addresses the reviewer’s criticism:

      In sum, cRBM-inferred cell assemblies display many properties that one expects from physiological cell assemblies: they are anatomically localized, can overlap, encompass functionally identified neuronal circuits and underpin the collective neural dynamics (Harris, 2005, 2012; Eichenbaum, 2018). Yet, the cRBM bipartite architecture lacks many of the traits of neurophysiological circuits. In particular, cRBMs lack direct neuron-to-neuron connections, asymmetry in the connectivity weights and a hierarchical organization of functional dependencies beyond one hidden layer. Therefore, to what extent cRBM-inferred assemblies identify to neurophysiological cell assemblies, as postulated by Hebb (1949) and others, remains an open question.


      I would strongly recommend adding a paragraph discussing the limitation of using the cRBM, things future researchers need to keep in mind before using this method. One such recommendation is moving the runtime-related discussion for cRBM, i.e. 8-12 hrs using 16 CPU from Methods to Discussion, since it's relevant for an algorithm like this. Additionally, a statement mentioning how this runtime will increase with the length of recordings and/or with the number of neurons might be helpful. What if the recordings were an hour-long rather than 25mins. This would help readers decide if they can easily use a method like this.

      We thank the reviewer for the suggestion, and agree that it is important to cover the computational cost in the main text. Regarding the runtime for longer recordings, the general rule of thumb is that the model requires a fixed number of gradient updates to converge (20-80k depending on the data dimensionality) rather than a fixed number of epochs. Thus, runtime should not depend on recording length, as the number of epochs can be reduced for longer recordings. While we did not verify this rule for neural recordings, this is what we previously observed when modeling protein/DNA sequence data sets, whose size range from few hundreds to hundreds of thousands of samples (Tubiana et al., 2019, eLife; Tubiana et al. 2019, Neural Computation; Bravi et al. Cell Systems 2021; Bravi et al. PLOS CB 2021; Fernandez de Cossio Diaz et al. Arxiv 2022 Di Gioacchino et al. BiorXiv 2022). We have now added a summary of these points in Methods 7.7.2, also refer to this with explicit mention of the runtime in the Discussion, end of 2nd paragraph:


      By implementing various algorithmic optimizations (Methods 7.7), cRBM models converged in approximately 8-12 hours on high-end desktop computers (also see Methods 7.7.2).


      Line 515. A core feature of the proposed compositional RBM is the addition of a soft sparsity penalty over the weight matrix in the likelihood function. The authors claim that "directed graphical models" are limited by the a priori constraints that they impose on the data structure. Meanwhile, a more accurate statistical solution can be obtained using a RBM-based model, as outlined by the maximum entropy principle. The problem with this argument is that the maximum entropy principle no longer applies to the proposed model with the addition of the penalty term. In fact, the lambda regularization term, which was estimated from a set of data statistics motivated by the experimenter's research goals (Figure S1), serves to constrict the prior probability. Moreover, in Figure S1F, we clearly see that reconstruction quality suffers with a higher penalty, suggesting that the principle had indeed been violated. That being said, RBMs are notoriously hard to train, possibly due to the unconstrained nature of the optimization. I believe that cRBM can help bring RBM into wider practical applications. The authors could test their model on a few values of the free parameter and report this as a supplementary. I believe that different parameters of lambda could elaborate on different anatomical clusters and temporal dynamics. Readers who would like to implement this method for their own analysis would also benefit tremendously from an understanding of the effects of lambda on the interpretation of their data. Item (1) on line 35 (and other instances throughout the text) should be corrected to reflect that cRBM replaces the hard constraints found in many popular methods with a soft penalty term, which allows for more accurate statistical models to be obtained.

      We thank the reviewer for their analysis and suggestion. Indeed, adding the regularization term - not present in the classical formulation of the RBM (Hinton & Salakhutdinov, 2006, Science) - was critical for significantly enhancing its performance, which allowed us to implement this model on our large scale datasets (~50K visible units). We agree that providing more information on the effect of the regularization term will benefit readers who would like to use this method, and we propose to add this in the revised manuscript, which would implement the reviewer’s suggestion. See “PLANNED REVISION #1”.

      The reviewer’s comment on the Maximum Entropy issue calls for some clarification. The maximum entropy principle is a recipe for finding the least constrained model that reproduces specified data-dependent moments. However, it cannot determine which moments are statistically meaningful in a finite-sized data set. A general practice is to only include low-order moments (1st and 2nd), but this is sometimes already too much for biological data. Regularization provides a practical means to select stable moments to be fitted and others to be ignored. This can be seen from the optimality condition, which writes, e.g., for the weights wi,mu:

      | i h,mu>data - i h,mu>model | i,mu = 0.

      i h,mu>data - i h,mu>model | = lambda sign(wi,mu) if |wi,mu| > 0.

      Essentially, this lets the training decide which subset of the constraints should actually be used. Thus, regularized models are closer to the uniform distribution (g=w=0), and actually have higher entropy than unregularized one (see, e.g., Fanthomme et al. Journal of Statistical Mechanics, 2022). Therefore, we believe that a regularized maximum entropy model can still be considered a bona fide MaxEnt model. This formulation should not be confused with another formulation (that perhaps the reviewer has in mind) where a weighted sum of the entropy and the regularization term is maximized under the same moment-matching constraints. In this case, we agree that maximum entropy principle (MaxEnt) would be violated.

      The choice of regularization value should be dictated by bias-variance trade-off considerations. Ideally, we would use the same criterion as for training, i.e., maximization of log-likelihood for the held-out test set, but it is intractable. Thus, we used a consensus between several tractable performance metrics as a surrogate; we believe this consensus to be principally independent of the research goal. While the reconstruction error indeed increases for large regularization values, this is simply because too few constraints are retained at high regularizations.

      Essentially, the parameters selected by likelihood maximization find the finest assembly scale that can be accommodated by the data presented. Thus, the number and size of the assemblies are not specified by the complexity of the data set alone. Rather, the temporal resolution and length of the recordings play a key role; higher resolution recordings will allow the inference of a larger number of smaller assemblies, and enable the study of their hierarchical organization.

      That being said, we fully agree that the regularization strength and number of hidden units have a strong impact on the nature of the representation learnt. In the revised manuscript, we will follow the reviewer’s suggestion and provide additional insights on the effect of these parameters on the representation learnt (please see revision plan).

      Minor comments:

      From a neuroscience point of view, it might be interesting to show what results are achieved using different values of M (say 100 or 300), rather than M=200, while still maintaining the compositional phase. Is there any similarity between the cRBM-based cell assemblies generated at different values of M? Is there a higher chance of capturing certain dynamics either functional or structural using cRBM? For example, did certain cRBM-based cell assemblies pop up more frequently than others at all values of M (100,200,300)?

      This point will be addressed in the future, as detailed in our response to reviewer 2 (see PLANNED REVISION #1).

      The authors have mentioned that this approach can be readily applied to data obtained in other animal models and using different recording techniques. It might be nice to see a demonstration of that.

      We agree that showing additional data analysis would be interesting, but we feel that it would overburden the supplementary section of the manuscript, which is already lengthy. In previous works, we and collaborators have used cRBMs for analyzing MNIST data (Tubiana & Monasson, 2017, PRL; Roussel et al. 2022 PRE), protein sequence data (Tubiana et al., 2019, eLife; Tubiana et al. 2019, Neural Computation; Bravi et al. Cell Systems 2021; Bravi et al. PLOS CB 2021; Fernandez de Cossio Diaz et al. Arxiv 2022), DNA sequences (Di Gioacchino et al. BiorXiv 2022), spin systems (Harsh et al. J. Phys. A 2020), etc. Many are included as example notebooks - next to the zebrafish data - in the linked code repository. For neural data, we have recently shared our code with another research group working on mice auditory cortex (2-photon, few thousands of neurons, Léger & Bourdieu). Preliminary results are encouraging, but not ready for publication yet.

      Line 237. The justification for employing a dReLU transfer function as opposed to ReLU is unclear, at least within the context of neurobiology. Given that this gives rise to a bimodal distribution for the activity of HUs, the rationale should be clearly outlined to facilitate interpretability.

      We thank the reviewer for the question. As we detail in the manuscript (Methods), the dReLU potential is one of the sufficient requirements for the RBM to achieve the compositional phase. The compositional phase is characterized by localized assemblies that co-activate to generate the whole-brain neural dynamics. This property reflects neurobiological systems (Harris, 2005, Neuron), which is one of the reasons why we employed compositional RBMs for this study.

      As the reviewer points out, the HUs that we infer exhibit bimodal activity (Figure 4). Importantly, the HU activity is not constrained by the model to take this shape, as dReLU potentials allow for several activity distributions (see Methods 7.5.4; “Choice of HU potential”). In fact, ReLU potentials are a special case of dReLU (by $(\gamma_{\mu, -} \to \infty)$), so our model allows HU potentials to behave like ReLUs, but in practice they converge to a double-well potential for almost all HUs, leading to bimodal activity distributions.

      Following the suggestion of the reviewer, we have now added this detail for clarity in Methods 7.5.4 and referenced this Methods section at line 237.

      Reviewer #1 (Significance (Required)):

      van der Plas et al. highlighted a novel dimensionality reduction technique that can be used with success for discerning functional connectivities in large-scale single-unit recordings. The proposed model belongs to a large collection of dimensionality reduction techniques (for review, Cunningham, J., Yu, B. Dimensionality reduction for large-scale neural recordings. Nat Neurosci 17, 1500-1509 (2014). https://doi.org/10.1038/nn.3776; Paninski, L., & Cunningham, J. P. (2018). Neural data science: accelerating the experiment-analysis-theory cycle in large-scale neuroscience. Current opinion in neurobiology, 50, 232-241.). The authors themselves highlighted some of the key methods, such as PCA, ICA, NNMF, variational auto-encoders, etc. The proposed cRBM model has also been published a few times by the same authors in previous works, although specifically pertaining to protein sequences. The use of RBM-like methods in uncovering functional connectivities is not novel either (see Hjelm RD, Calhoun VD, Salakhutdinov R, Allen EA, Adali T, Plis SM. Restricted Boltzmann machines for neuroimaging: an application in identifying intrinsic networks. Neuroimage. 2014 Aug 1;96:245-60. doi: 10.1016/j.neuroimage.2014.03.048.). However, given that the authors make a substantial improvement on the RBM network and have demonstrated the value of their model using physiological data, I believe that this paper would present itself as an attractive alternative to all readers who are seeking better solutions to interpret their data. However, as I mentioned in my comments, I would like to see more definitive evidence that the proposed solution has a serious advantage over other equivalent methods.

      Reviewer's expertise:

      This review was conducted jointly by three researchers whose combined expertise includes single-unit electrophysiology and two-photon calcium imaging, using which our lab studies the neurobiology of learning and memory and spatial navigation. We also have extensive experience in computational neuroscience, artificial neural network models, and machine learning methods for the analysis of neurobiological data. We are however limited in our knowledge of mathematics and engineering principles. Therefore, our combined expertise is insufficient to evaluate the correctness of the mathematical developments.

      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      In their manuscript, van der Plas et al. present a generative model of neuron-assembly interaction. The model is a restricted Boltzmann machine with its visible units corresponding to neurons and hidden units to neural assemblies. After fitting their model to whole-brain neural activity data from larval zebrafish, the authors demonstrate that their model is able to replicate several data statistics. In particular, it was able to replicate the pairwise correlations between neurons as well as assemblies that it was not trained on. Moreover, the model allows the authors to extract neural assemblies that govern the population activity and compose functional circuits and can be assigned to anatomical structures. Finally, the authors construct functional connectivity maps from their model that are then shown to correlate with established structural connectivity maps.

      Overall, the authors present convincing evidence for their claims. Furthermore, the authors state that their code to train their restricted Boltzmann machine models is already available on GitHub and that the data underlying the results presented in this manuscript will be made publicly available upon publication, which will allow people to reproduce the results and apply the methods to their data.

      One thing the authors could maybe discuss a bit more is the "right" parameter value M, especially since they used the optimal value of 200 found for one sample also for all the others. More specifically, how sensitive are the results to this value?

      PLANNED REVISION #1

      In the following we jointly address three of the reviewers’ questions (2 from reviewer 1, and 1 from reviewer 2).

      Shortly summarized, the cRBM model has 2 free parameters; the number of hidden units M and the regularization parameter lambda. In figures 2 and S1 we optimize their values through cross-validation, and then perform our further analyses on models with these optimal values. The reviewers ask us to examine the outcome of the model for slightly different values of both parameters, in particular in relation to the sensitivity of the cRBM results to selecting the optimal parameters and the change in inferred assemblies and their dynamics.

      We thank the reviewers for these questions and appreciate their curiosity to understand the effects of changing either of these two free parameters.

      We inspected these models when we performed the model selection (of Figures 2 and S1), but did not formalize our findings into figures for the manuscript. We found that small changes in the parameter setting did not abruptly change the inferred assemblies (e.g., M=100) apart from slightly changing in size, so we expect that the statistics that we intend to include in the proposed supplementary figure would reflect that, and it would definitely benefit the manuscript to include this analysis. Very-low-M settings are interesting to include, because assemblies are much larger - essentially merging smaller assemblies of higher-M models - at the cost of model performance.

      We propose to create additional supplementary figures that address these questions. As suggested, we will pick a few example cRBMs with different parameter settings (below-optimal M, above-optimal M, and same for lambda), as well as very low M settings (M~20 or 50). We will then show example assemblies and assembly dynamics, as well as the relevant statistics (assembly size, dynamics time scale etc) that describe them.

      And, what happens if one would successively increase that number, would the number of assemblies (in the sense of hidden units that strongly couple to some of the visible units) eventually saturate?

      This point will be addressed by inspecting models at different M values (see Revision Plan #1). We would like to further answer this question by referring to past work. In Tubiana et al., 2019, elife (Appendix 1) we have done this analysis, and the result is consistent with the reviewer’s intuition. Because of the sparsity regularization, if M becomes larger than its optimum, the assemblies further sparsify without benefiting model performance, and eventually new assemblies duplicate previous assemblies or become totally sparse (i.e., all weights = 0) to not further induce a sparsity penalty in the loss function. So the ‘effective’ number of assemblies indeed saturates for high M.

      Moreover, regarding the presentation, I have a few minor suggestions and comments that the authors also might want to consider:

      * In Figure 6C, instead of logarithmic axes, it might be better to put the logarithmic connectivity on a linear axis. This way the axes can be directly related to the colour bars in Figures 6A and B.

      We agree and thank you for the suggestion. We have changed this accordingly (and also in the equivalent plots in figure S6).

      * In Equation (8), instead of $\Gamma_{\mu}(I)$ it should be $\Gamma_{\mu}(I_{\mu}(v))$.

      Done, thank you.

      * In Section 7.0.5, it might make sense to have the subsection about the marginal distributions before the ones about the conditional distributions. The reason would be that if one wants to confirm Equation (8) one necessarily has to compute the marginal distribution in Equation (12) first.

      We thank the reviewer for the suggestion, but respectfully propose to leave the section ordering as is. We understand what the reviewer means, but Equation (8) can also be obtained by factorizing P(v,h) Equation (7) and removing the v_i dependency. In Equation (8), \Gamma can then be obtained by normalization. We believe this flow aligns better with the main text (where conditionals come first, when used for sampling, followed by the marginal of P(v) used for the functional connectivity inference).

      * In Line 647f, the operation the authors are referring to is strictly speaking not an L1-norm of the matrix block. It might be better to refer to that e.g. as a normalised L1-norm of the matrix block elements.

      Done, thank you.

      * In Line 22, when mentioning dimensionality reduction methods to identify assemblies, it might make sense to also reference the work by Lopes-dos-Santos et al. (2013, J. Neurosci. Methods 220).

      Done, thank you for the suggestion.

      Reviewer #2 (Significance (Required)):

      The work presented in this manuscript is very interesting for two reasons. First, it has long been suggested that assemblies are a fundamental part of neural activity and this work seems to support that by showing that one can generate realistic whole-brain population activity imposing underlying assembly dynamics. Second, in recent years much work has been devoted to developing methods to find and extract neural assemblies from data and this work and the modelling approach can also be seen as a new method to achieve that. As such, I believe this work is relevant for anyone interested in neural population activity and specifically neural assemblies and certainly merits publication.

      Regarding my field of expertise, I used to work on data analysis of neural population activity and in particular on the question of how one can extract neural assemblies from data. I have to say that I have not much experience with fitting statistical models to data, so I can't provide any in-depth comments on that part of the work, although what has been done seems plausible.

      Reviewer #3 (Evidence, reproducibility and clarity (Required)):

      Summary: Understanding the organization of neural population activities in the brain is one of the most important questions in neuroscience. Recent technique advance has enabled researchers to record a large number of neurons and some times the whole brain. Interpreting and extracting meaningful insights from such data sets are challenging. van der Pals \textit{et al} applied a generative model called compositional Restricted Boltzmann Machine (cRBM) to discover neuron assemblies from spontaneous activities of zebra fish brain. They found that neurons can be grouped into around 200 assemblies. Many of them have clear neurophysiological meaning, for example, they are anatomically localized and overlapped with known neural circuits. The authors also inferred a coarse-grained functional connectivity which is similar to known structural connectivity.

      The structure of the paper is well organized, the conclusion seems well supported by their numerical results. While this study provides a compelling demonstration that cRBM can be used to uncover meaningful structures from large neural recordings, the following issues limit my enthusiasm.

      Major:

      1) The overall implication is not clear to me. Although the authors mentioned this briefly in the discussion. It is not clear what else do we learn from discovered assemblies beyond stating that they are consist with previous study. For example, the author could have more analysis of the assembly dynamics, such as whether there are low dimensional structure etc.

      First, we will comment on our analysis of the assemblies, before we continue to discuss the main implications of our work, which we believe are the inferred generative model of the zebrafish brain and the perturbation-based connectivity matrix that we discovered. Further, we have implemented the reviewer’s suggestion of analyzing the low-dimensional structure of the hidden unit activity, as further detailed in Question 7.

      Indeed, the example assemblies that we show in Figure 3 have been thoroughly characterized in previous studies, which is why we chose to showcase these examples. Previous studies (including our own) typically focused on particular behaviors or sensory modalities, and aimed at identifying the involved neural circuit. Here, we demonstrate that by using cRBM on spontaneous activity recordings, one can simultaneously identify many of those circuits. In other words, these functional circuits/assemblies activate spontaneously, but in many different combinations and perhaps infrequently, so that it is very difficult to infer them from the full neural dynamics that they generate. cRBM has been able to do so, and Figure 3 (and supplementary video 1) serve to illustrate the variety of (known) circuits and assemblies that it inferred, some of which may represent true but not yet characterized circuits, which thus provide hypotheses for subsequent studies.

      Further, we believe that the implication of our study goes beyond the properties of the assemblies we’ve identified, in several ways.

      We demonstrate the power of cRBM’s generative capacity for inferring low-dimensional representations in neuroscience. Unlike standard dimensional reductionality methods, generative models can be assessed by comparing the statistics of experimental vs in-silico generated data. This is a powerful approach to validate a model, rarely used in neuroscience because of the scarcity of generative models compatible with large-scale data, and we hope that our study will inspire the use of this method in the field. We have made our cRBM code available, including notebook tutorials, to facilitate this.

      The generative aspect of our model allowed us to predict the effect of single-neuron perturbations between all ~ 10^9 pairs of neurons per fish, resulting in a functional connectivity matrix.

      We believe that the functional connectivity matrix is a major result for the field, similar to the structural connectivity matrix from Kunst et al., 2019, Neuron. The relation between functional and structural connectivity is unknown and of strong interest to the community (e.g., Das & Fiete, 2020, Nature Neuroscience). Our results allowed for a direct comparison of whole-brain region-by-region structural and functional connectivity. We were thus able to quantify the similarity between these two maps, and to identify specific region-pair matches and non-matches of functional and structural connectivity - which will be of particular interest to the zebrafish neuroscience community for developing future research questions.

      Further, using these trained models - that will be made public upon publication - anyone can perform any type of in silico perturbation experiments, or generate endless artificial data with matching data statistics to the in vivo neural recordings.

      We hope that this may convince the reviewer of the multiple directions of impact of our study. We will further address their comment on analysis of assembly dynamics below (question 7).

      2) The learning algorithm of cRBM can be interpreted as matching certain statistics between the model and the experiment. For a general audience, it is not easy to understand $\langle h_{\mu} \rangle_{data}, \langle v_ih_{\mu}\rangle_{data}$. Since these are not directly calculated from experimental observed activities $v_i$, but rather the average is conditioned on the empirical distribution of $p(v_i)$. For example, the meaning of $\langle v_ih_{\mu}\rangle_{data}$ means

      \begin{equation}

      \langle v_ih_{\mu}\rangle_{data} = \frac{1}{l}\sum_{\mathbf{v}\in S} \mathbb{E}{p(\mathbf{h|v})}(v_ih{\mu}),

      \end{equation}

      where $S$ is the set of all observed neural activities: $S = {\mathbf{v}^1, \cdots, \mathbf{v}^l}$. The authors should explain this in the main text or method, since they are heavily loaded in figure 2.

      We thank the reviewer for their suggestion, and have now implemented this. Their mathematics are correct; and we agree that it is not easy to understand without going through the full derivation of the (c)RBM. At the same time, we have tried not to alienate readers who might be more interested in the neuroscience findings than in understanding the computational method used. Therefore, we have kept mathematical details in the main text to a minimum (and have used schematics to indicate the statistics in Figures 2C-G), while explaining it in detail in Methods.

      Accordingly, we have now extended section 7.10.2 (“Assessment of data statistics”) that explains how the data statistics were computed in Methods (and have referenced this in Results and in Methods 7.5.5), using the fact that we already explain the process of conditioning on __v __in Methods 7.5.1. The following sentences were added:


      [..] However, because (c)RBM learn to match data statistics to model statistics (see Methods

      7.5.5), we can directly compare these to assess model performance. [..]

      [..]

      For each statistic 〈 fk〉 we computed its value based on empirical data 〈 fk〉_data and on the model 〈 fk〉_model, which we then quantitatively compared to assess model performance. Data statistics 〈 fk〉_data were calculated on withheld test data (30% of recording). Naturally, the neural recordings consisted only of neural data v and not of HU data h. We therefore computed the expected value of __ht at each time point t conditioned on the empirical data _v_t, as further detailed in Methods 7.5.1.

      [..]


      3) As a modeling paper, it would be great to have some testable predictions.

      We thank the reviewer for the enthusiasm and suggestion. We agree, and that is why we have included this in the form of functional connectivity matrices in Figures 5 and 6. To achieve this, we leveraged the generative aspect of the cRBM to perform in silico single-neuron perturbation experiments, which we aggregated to connectivity matrices. In other words, we have used our model to predict the functional connectivity between brain regions using the influence of single-neuron perturbations.

      Obtaining a measure of functional connectivity/influence using single-neuron perturbations is also possible using state-of-the-art neuro-imaging experiments (e.g., Chettih & Harvey, 2019, Nature), though not at the scale of our in silico experiments. We therefore verify our predictions using structural data from Kunst et al., 2019, which we have extended substantially. We provide our functional connectivity result in full, and hope that this can inspire future zebrafish research by predicting which regions are functionally connected, which includes many pairs of regions that have not yet directly been studied in vivo.

      Minor:

      1) The assembly is defined by the neurons that are strongly connected with a given hidden unit. Thus, some neurons may enter different assemblies. A statistics of such overlap would be helpful. For example, a ven diagram in figure 1 that shows how many of them assigned to 1, 2, etc assemblies.

      We thank the reviewer for this excellent suggestion. Indeed, neurons can be embedded in multiple assemblies. This is an important property of cRBMs, which deserves to be quantified in the manuscript. We have now added this analysis as a new supplementary figure 4. Neurons are embedded in an assembly if their connecting weight w_{i, \mu} is ‘significantly’ non-zero, depending on what threshold one uses. We have therefore shown this statistic for 3 values of the threshold (0.001, 0.01 and 0.1) - demonstrating that most neurons are strongly embedded in at least 1 assembly and that many neurons connect to more than 1 assembly.

      Updated text in Results:


      Further, we quantified the number of assemblies that each neuron was embedded in, which showed that increasing the embedding threshold did not notably affect the fraction of neurons embedded in at least 1 assembly (93% to 94%, see Figure S4).


      2) What does the link between hidden units in Figure 1B right panel mean?

      Thank you for the question, and we apologize for the confusion: if we understand the question right, the reviewer asks why the colored circles under the title ‘Neuronal assemblies of Hidden Units’ are linked. This schematic shows the same network of neurons as shown in gray at the left side of Fig 1B, but now colored by the assembly ‘membership’ of each neuron. Hence, the circles shown are still neurons (and not HUs), and their links still represent synaptic connections between neurons. We apologize for the confusion, and have updated the caption of Fig 1B to explain this better:


      “[..] The neurons that connect to a given HU (and thus belong to the associated assembly), are depicted by the corresponding color labeling (right panel).[..]”.


      3) A side-by-side comparison of neural activity predicted by model and the experimentally recorded activities would help the readers to appreciate the performance of the model. Such comparison can be done at both single neuron level or assembly level.

      We thank the reviewer for this suggestion. The cRBM model is a statistical model, meaning that it fits the statistics of the data, and not the dynamics. The data that it generates therefore (should) adhere to the statistics of the training data, but does not reflect their dynamics. We believe that showing generated activity side-by-side of empirical activity is therefore not a meaningful example of generated data, as this would exemplify the dynamics, which this model is not designed to capture. Instead, in Figure 2, we show the statistics of the generated data versus the statistics of the empirical data (e.g., Fig 2C for the mean activity of all neurons). We believe that this is a better example representation of the generative performance of the model.

      4) Definition of reconstruction quality in line 130.

      We thank the reviewer for the suggestion, and have added the following sentence after line 130:


      The reconstruction quality is defined as the log-likelihood of reconstructed neural data v___{recon} (i.e., __v that is first transformed to the low-dimensional h, and then back again to the high-dimensional __v___{recon}, see Methods 7.10.2).


      Further, please note that Methods describes the definition in detail (Eq 18 of the submitted manuscript), although we agree with the reviewer that more detail was required in the Results section at line 130.

      5) Line 165. If PCA is compared with cRBM, why other dimensionality reduction methods, such as k-means and non-negative matrix factorization, can not be compared in terms of the sparsity?

      Please see answer to question 1 from R1 and Revision Plan #2.

      6) Line 260, please provide minimum information about how the functional connectivity is defined based on assemblies discovered by cRBM.

      We apologize if this was not clear. The first paragraph of this section (lines 248-259) of the submitted manuscript, provides the detail that the reviewer asks for, and we realize that the sentence of line 260 is better placed in the first paragraph, as it has come across as a very minimal explanation of how functional connectivity is defined.

      We have now moved this sentence to the preceding paragraph, as well as specified the Method references (as suggested by this reviewer below), for additional clarity. We thank the reviewer for pointing out this sentence.

      7) Some analysis of the hidden units population activities. Such as whether or not there are interesting low dimensional structure from figure 4A.

      We thank the reviewer for their suggestion. In our manuscript we have used the cRBM model to create a low-dimensional (M=200) representation of zebrafish neural recordings (N=50,000). The richness of this model owes to possible overlaps between HUs/assemblies that can result in significant correlation in their activities. The latter is illustrated in Figure 4A-C: the activity of some HUs can be strongly correlated.

      The reviewer’s suggestion is similar; to perform some form of dimensionality reduction on the low-dimensional HU activity shown in Fig 4. We have now added a PCA analysis to Figure 4 to quantify the degree of low-dimensional structure in the HU dynamics, and show the results in a new panel Figure 4D.

      The following text has been added to the Results section:


      These clusters of HUs with strongly correlated activity suggest that much of the HU variance could be captured using only a small number of variables. We quantified this by performing PCA on the HU dynamics, finding that indeed 52% of the variance was captured by the first 3 PCs, and 85% by the first 20 PCs (Figure 4D).


      We believe that further visualization of these results, such as plotting the PC trajectories, would not further benefit the manuscript. The manuscript focuses on cRBM, and the assemblies/HUs it infers. Unlike PCA, these are not ranked/quantified by how much variance they explain individually, but rather they together ‘compose’ the entire system and explain its (co)variance (Figure 2). Breaking up a dominant activity mode (as found by PCA), such as the ARTR dynamics, into multiple HUs/assemblies, allows for some variation in activity of individual parts of the ARTR circuit (such as tail movement and eye movement generation), even though at most times the activity of these HUs is coordinated. We hope the reviewer agrees with our motivation to keep the manuscript focused on the nature of cRBM-inferred HUs.

      8) Figure 4B right panel, how did the authors annotate the cluster manually? As certain assembly may overlap with several different brain regions, for example, figure 4D.

      We thank the reviewer for this question, and we presume they meant to reference figure 3D as an example? For figure 4, as well as Figure 3, we used the ZBrain Atlas (Randlett et al., 2015) for definition of brain regions. This atlas presents a hierarchy of brain regions: for example, many brain regions are part of the rhombencephalon/hindbrain. This is what we used for midbrain/hindbrain/diencephalon. Further, many assemblies are solely confined to Optic Tectum (see Fig 3L), which we therefore used (split by hemisphere). Then, many brain regions are (partly) connected to the ARTR circuit, such as the example assembly of Figure 3D that the reviewer mentions. These we have all labeled as ARTR (left or right), though technically only part of their assembly is the ARTR. These two clusters therefore rather mean ‘ARTR-related’, in particular because their activity is locked to the rhythm of the ARTR (see Fig 4A). The final category is ‘miscellaneous’ (like Figure 3G).

      However we agree that this wasn’t clear from the manuscript text, so we have changed the figure 4C caption to mention that ‘ARTR’ stands for ARTR-related assemblies, which we hope clarifies that ARTR-clustered assemblies can exist of multiple, disjoint groups of neurons, which relate to the ARTR circuit.

      9) Better reference of the methods cited in the main text. The method part is quite long, it would be helpful to cite the section number when referring it in the main text.

      We thank the reviewer for this helpful suggestion, we agree that it would benefit the manuscript to reference specific sections of the Methods. We have now changed all references to Methods to incorporate this.

      10) Some discussion about the limitation of cRBM would be great.

      We thank the reviewer for this suggestion, and have now included this. As Reviewer 1 had the same suggestion, we refer our answer to questions 2 and 3 from R1 for more detail.

      Reviewer #3 (Significance (Required)):

      This work provides a timely new technique to extract meaningful neural assemblies from large scale recordings. This study should be interested to both researchers doing either experiments and computation/theory. I am a computational neuroscientist.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      Summary:

      Understanding the organization of neural population activities in the brain is one of the most important questions in neuroscience. Recent technique advance has enabled researchers to record a large number of neurons and some times the whole brain. Interpreting and extracting meaningful insights from such data sets are challenging. van der Pals \textit{et al} applied a generative model called compositional Restricted Boltzmann Machine (cRBM) to discover neuron assemblies from spontaneous activities of zebra fish brain. They found that neurons can be grouped into around 200 assemblies. Many of them have clear neurophysiological meaning, for example, they are anatomically localized and overlapped with known neural circuits. The authors also inferred a coarse-grained functional connectivity which is similar to known structural connectivity.

      The structure of the paper is well organized, the conclusion seems well supported by their numerical results. While this study provides a compelling demonstration that cRBM can be used to uncover meaningful structures from large neural recordings, the following issues limit my enthusiasm.

      Major:

      1. The overall implication is not clear to me. Although the authors mentioned this briefly in the discussion. It is not clear what else do we learn from discovered assemblies beyond stating that they are consist with previous study. For example, the author could have more analysis of the assembly dynamics, such as whether there are low dimensional structure etc.
      2. The learning algorithm of cRBM can be interpreted as matching certain statistics between the model and the experiment. For a general audience, it is not easy to understand $\langle h_{\mu} \rangle_{data}, \langle v_ih_{\mu}\rangle_{data}$. Since these are not directly calculated from experimental observed activities $v_i$, but rather the average is conditioned on the empirical distribution of $p(v_i)$. For example, the meaning of $\langle v_ih_{\mu}\rangle_{data}$ means \begin{equation} \langle v_ih_{\mu}\rangle_{data} = \frac{1}{l}\sum_{\mathbf{v}\in S} \mathbb{E}{p(\mathbf{h|v})}(v_ih{\mu}), \end{equation} where $S$ is the set of all observed neural activities: $S = {\mathbf{v}^1, \cdots, \mathbf{v}^l}$. The authors should explain this in the main text or method, since they are heavily loaded in figure 2.
      3. As a modeling paper, it would be great to have some testable predictions.

      Minor:

      1. The assembly is defined by the neurons that are strongly connected with a given hidden unit. Thus, some neurons may enter different assemblies. A statistics of such overlap would be helpful. For example, a ven diagram in figure 1 that shows how many of them assigned to 1, 2, etc assemblies.
      2. What does the link between hidden units in Figure 1B right panel mean?
      3. A side-by-side comparison of neural activity predicted by model and the experimentally recorded activities would help the readers to appreciate the performance of the model. Such comparison can be done at both single neuron level or assembly level.
      4. Definition of reconstruction quality in line 130.
      5. Line 165. If PCA is compared with cRBM, why other dimentionality reduction methods, such as k-means and non-negative matrix factorization, can not be compared in terms of the sparsity?
      6. Line 260, please provide minimum information about how the functional connectivity is defined based on assemblies discovered by cRBM.
      7. Some analysis of the hidden units population activities. Such as whether or not there are interesting low dimensional structure from figure 4A.
      8. Figure 4B right panel, how did the authors annotate the cluster manually? As certain assembly may overlap with several different brain regions, for example, figure 4D.
      9. Better reference of the methods cited in the main text. The method part is quite long, it would be helpful to cite the section number when referring it in the main text.
      10. Some discussion about the limitation of cRBM would be great.

      Significance

      This work provides a timely new technique to extract meaningful neural assemblies from large scale recordings. This study should be interested to both researchers doing either experiments and computation/theory. I am a computational neuroscientist.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      In their manuscript, van der Plas et al. present a generative model of neuron-assembly interaction. The model is a restricted Boltzmann machine with its visible units corresponding to neurons and hidden units to neural assemblies. After fitting their model to whole-brain neural activity data from larval zebrafish, the authors demonstrate that their model is able to replicate several data statistics. In particular, it was able to replicate the pairwise correlations between neurons as well as assemblies that it was not trained on. Moreover, the model allows the authors to extract neural assemblies that govern the population activity and compose functional circuits and can be assigned to anatomical structures. Finally, the authors construct functional connectivity maps from their model that are then shown to correlate with established structural connectivity maps.

      Overall, the authors present convincing evidence for their claims. Furthermore, the authors state that their code to train their restricted Boltzmann machine models is already available on GitHub and that the data underlying the results presented in this manuscript will be made publicly available upon publication, which will allow people to reproduce the results and apply the methods to their data.

      One thing the authors could maybe discuss a bit more is the "right" parameter value M, especially since they used the optimal value of 200 found for one sample also for all the others. More specifically, how sensitive are the results to this value? And, what happens if one would successively increase that number, would the number of assemblies (in the sense of hidden units that strongly couple to some of the visible units) eventually saturate?

      Moreover, regarding the presentation, I have a few minor suggestions and comments that the authors also might want to consider: - In Figure 6C, instead of logarithmic axes, it might be better to put the logarithmic connectivity on a linear axis. This way the axes can be directly related to the colour bars in Figures 6A and B. - In Equation (8), instead of $\Gamma_{\mu}(I)$ it should be $\Gamma_{\mu}(I_{\mu}(v))$. - In Section 7.0.5, it might make sense to have the subsection about the marginal distributions before the ones about the conditional distributions. The reason would be that if one wants to confirm Equation (8) one necessarily has to compute the marginal distribution in Equation (12) first. - In Line 647f, the operation the authors are referring to is strictly speaking not an L1-norm of the matrix block. It might be better to refer to that e.g. as a normalised L1-norm of the matrix block elements. - In Line 22, when mentioning dimensionality reduction methods to identify assemblies, it might make sense to also reference the work by Lopes-dos-Santos et al. (2013, J. Neurosci. Methods 220).

      Significance

      The work presented in this manuscript is very interesting for two reasons. First, it has long been suggested that assemblies are a fundamental part of neural activity and this work seems to support that by showing that one can generate realistic whole-brain population activity imposing underlying assembly dynamics. Second, in recent years much work has been devoted to developing methods to find and extract neural assemblies from data and this work and the modelling approach can also be seen as a new method to achieve that. As such, I believe this work is relevant for anyone interested in neural population activity and specifically neural assemblies and certainly merits publication.

      Regarding my field of expertise, I used to work on data analysis of neural population activity and in particular on the question of how one can extract neural assemblies from data. I have to say that I have not much experience with fitting statistical models to data, so I can't provide any in-depth comments on that part of the work, although what has been done seems plausible.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      Summary:

      In the present manuscript, van der Plas et al. compellingly illustrated a novel technique for engendering a whole-brain functional connectivity map from single-unit activities sampled through a large-scale neuroimaging technique. With some clever tweaks to the restricted Boltzmann Machine, the cRBM network is able to learn a low-dimensional representation of population activities, without relying on constrained priors found in some traditional methods. Notably, using some 200 hidden layer neurons, the employed model was able to capture the dynamics of over 40,000 simultaneously imaged neurons with a high degree of accuracy. The extracted features both illustrate the anatomical topography/connectivities and capture the temporal dynamics in the evolution of brain states. The illustrated technique has the potential for wide-spread applications spanning diverse recording techniques and animal species. Furthermore, the prospectives of modeling whole-brain network dynamics in 'neural trajectory' space and of generating artificial data in silico make for very enticing reasons to adopt cRBM.

      Major comments:

      Line 164. The authors claim that conventional methods "such as k-means, PCA and non-negative matrix factorization" cannot be quantitatively assessed for quality on the basis that they are unable to generate new artificial data. Though partly true, in most neuroscience applications, this is hardly cause for concern. Most dimensionality reduction methods (with few exceptions such as t-sne) allow new data points to be embedded into the reduced space. As such, quality of encoding can be assessed by cross-validation much in the same way as the authors described, and quantified using traditional metrics such as percentage explained variance. The authors should directly compare the performance of their proposed model against that of NNMF and variational auto-encoders. Doing so would offer a more compelling argument for the advantage of their proposed method over more widely-used methods in neuroscience applications. Furthermore, a direct comparison with rastermap, developed by Stringer lab at Janelia (https://github.com/MouseLand/rastermap), would be a nice addition. This method presents itself as a direct competitor to cRBM. Additionally, the use of GLM doesn't do complete justice to the comparison point used, since a smaller fraction of data were used for calculating performance using GLM, understandably due to its computationally intensive nature.

      Line 26. The authors describe their model architecture as a formalization of cell assemblies. Cell assemblies, as originally formulated by Hebb, pertains to a set of neurons whose connectivity matrix is neither necessarily complete nor symmetric. Critically, in the physiological brain, the interactions between the individual neurons that are part of an assembly would occur over multiple orders of dependencies. In a restricted Boltzmann machine, neurons are not connected within the same layer. Instead, visible layer neurons are grouped into "assemblies" indirectly via a shared connection with a hidden layer neuron. Furthermore, a symmetrical weight matrix connects the bipartite graph, where no recurrent connectivities are made. As such, the proposed model still only elaborates symmetric connections pertaining to first-order interactions (as illustrated in Figure 4C). Such a network may not be likened with the concept of cell assemblies. The authors should refrain from detailing this analogy (of which there are multiple instances of throughout the text). It is true that many authors today refer to cell assemblies as any set of temporally-correlated neurons. However, saying "something could be a cell assembly" is not the same as saying "something is a cell assembly". How about sticking with cRBM-based cell assemblies (as used in section 2.3) and defining it beforehand?

      I would strongly recommend adding a paragraph discussing the limitation of using the cRBM, things future researchers need to keep in mind before using this method. One such recommendation is moving the runtime-related discussion for cRBM, i.e. 8-12 hrs using 16 CPU from Methods to Discussion, since it's relevant for an algorithm like this. Additionally, a statement mentioning how this runtime will increase with the length of recordings and/or with the number of neurons might be helpful. What if the recordings were an hour-long rather than 25mins. This would help readers decide if they can easily use a method like this.

      Line 515. A core feature of the proposed compositional RBM is the addition of a soft sparsity penalty over the weight matrix in the likelihood function. The authors claim that "directed graphical models" are limited by the a priori constraints that they impose on the data structure. Meanwhile, a more accurate statistical solution can be obtained using a RBM-based model, as outlined by the maximum entropy principle. The problem with this argument is that the maximum entropy principle no longer applies to the proposed model with the addition of the penalty term. In fact, the lambda regularization term, which was estimated from a set of data statistics motivated by the experimenter's research goals (Figure S1), serves to constrict the prior probability. Moreover, in Figure S1F, we clearly see that reconstruction quality suffers with a higher penalty, suggesting that the principle had indeed been violated. That being said, RBMs are notoriously hard to train, possibly due to the unconstrained nature of the optimization. I believe that cRBM can help bring RBM into wider practical applications. The authors could test their model on a few values of the free parameter and report this as a supplementary. I believe that different parameters of lambda could elaborate on different anatomical clusters and temporal dynamics. Readers who would like to implement this method for their own analysis would also benefit tremendously from an understanding of the effects of lambda on the interpretation of their data. Item (1) on line 35 (and other instances throughout the text) should be corrected to reflect that cRBM replaces the hard constraints found in many popular methods with a soft penalty term, which allows for more accurate statistical models to be obtained.

      Minor comments:

      From a neuroscience point of view, it might be interesting to show what results are achieved using different values of M (say 100 or 300), rather than M=200, while still maintaining the compositional phase. Is there any similarity between the cRBM-based cell assemblies generated at different values of M? Is there a higher chance of capturing certain dynamics either functional or structural using cRBM? For example, did certain cRBM-based cell assemblies pop up more frequently than others at all values of M (100,200,300)?

      The authors have mentioned that this approach can be readily applied to data obtained in other animal models and using different recording techniques. It might be nice to see a demonstration of that.

      Line 237. The justification for employing a dReLU transfer function as opposed to ReLU is unclear, at least within the context of neurobiology. Given that this gives rise to a bimodal distribution for the activity of HUs, the rationale should be clearly outlined to facilitate interpretability.

      Significance

      van der Plas et al. highlighted a novel dimensionality reduction technique that can be used with success for discerning functional connectivities in large-scale single-unit recordings. The proposed model belongs to a large collection of dimensionality reduction techniques (for review, Cunningham, J., Yu, B. Dimensionality reduction for large-scale neural recordings. Nat Neurosci 17, 1500-1509 (2014). https://doi.org/10.1038/nn.3776; Paninski, L., & Cunningham, J. P. (2018). Neural data science: accelerating the experiment-analysis-theory cycle in large-scale neuroscience. Current opinion in neurobiology, 50, 232-241.). The authors themselves highlighted some of the key methods, such as PCA, ICA, NNMF, variational auto-encoders, etc. The proposed cRBM model has also been published a few times by the same authors in previous works, although specifically pertaining to protein sequences. The use of RBM-like methods in uncovering functional connectivities is not novel either (see Hjelm RD, Calhoun VD, Salakhutdinov R, Allen EA, Adali T, Plis SM. Restricted Boltzmann machines for neuroimaging: an application in identifying intrinsic networks. Neuroimage. 2014 Aug 1;96:245-60. doi: 10.1016/j.neuroimage.2014.03.048.). However, given that the authors make a substantial improvement on the RBM network and have demonstrated the value of their model using physiological data, I believe that this paper would present itself as an attractive alternative to all readers who are seeking better solutions to interpret their data. However, as I mentioned in my comments, I would like to see more definitive evidence that the proposed solution has a serious advantage over other equivalent methods.

      Reviewer's expertise:

      This review was conducted jointly by three researchers whose combined expertise includes single-unit electrophysiology and two-photon calcium imaging, using which our lab studies the neurobiology of learning and memory and spatial navigation. We also have extensive experience in computational neuroscience, artificial neural network models, and machine learning methods for the analysis of neurobiological data. We are however limited in our knowledge of mathematics and engineering principles. Therefore, our combined expertise is insufficient to evaluate the correctness of the mathematical developments.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      In this paper, Staneva et al describe a novel complex found at RNA PolII promoters that they term the SPARC. The manuscript focuses on defining the core components of the complex and the pivotal role of SET27 in defining its function, and role in PolII transcription. This manuscript is a logical follow on from an initial paper (Staneva et al, 2021) by the same authors where they systematically analyzed chromatin factors, and their role in both transcription start and termination. What is also very clear, is that this complex is one made of histone readers and writers which suggests its function is to change the chromatin structure around a PolII promoters. The authors show that this complex is necessary for the correct positioning of PolII and directionality of transcription.

      This was a well-designed study and well written and clear manuscript that provides fascinating insight transcription control in bloodstream form parasites.

      I have no major comments only a few minor ones.

      1) Localisation of the different SPARC components appears to be either nuclear or nuclear and cytoplasmic. - Both SET27 and CRD1 show a nuclear and cytoplasmic localisation in the bloodstream form IFA (Supplementary Fig 1B), but only a nuclear localisation procyclic form.

      Did the authors attempt C terminally tagging SET27, CRD1 to see if this resulted in a change in the pattern?

      We have not tagged either protein at the C terminus, however SET27 (Tb927.9.13470) has been tagged both N- and C-terminally in procyclic form (PF) cells as part of the TrypTag project (http://tryptag.org). In both cases, SET27 localized to the nucleus, suggesting that the differences in localization we observe for SET27 depend on the life cycle stage, and not on the position of the tag. One caveat is that in the TrypTag project proteins are tagged with mNeonGreen whereas in our study proteins were tagged with YFP. Based on our images, CRD1 appears to be predominantly nuclear in both bloodstream form (BF) and PF parasites. CRD1 (Tb927.7.4540) has been tagged only N-terminally in PF cells as part of the TrypTag project where it has also been classified as mostly nuclear with only 10% of cells showing cytoplasmic localization for CRD1.

      We are well aware that tags can alter the behaviour of a protein. Absolute confirmation of location will require the generation of antibodies that detect untagged proteins. However, this is a longer-term undertaking. We have added the following statement to the Results section to address the point raised:

      “We tagged the proteins on their N termini to preserve 3′ UTR sequences involved in regulating mRNA stability (Clayton, 2019). We note, however, that the presence of the YFP tag and/or its position (N- or C-terminal) might affect protein expression and localization patterns”.

      • The point is made that JBP2 shows a 'distinct cytoplasmic localisation' in PF cells. by this logic, the SET27 localisation in BF is also distinctly cytoplasmic and a nuclear enrichment is not clear.

      Indeed the reviewer is correct - we have inadvertently over accentuated the significance of this difference in the text. We had emphasized the predominantly cytoplasmic localization of JBP2 in PF trypanosomes as potentially related to its weaker association with other (predominantly nuclear) SPARC components in the mass spectrometry experiments. The presence of SET27 in the nuclei of both BF and PF cells is confirmed by a positive ChIP signal. We have revised the manuscript text by changing “distinct cytoplasmic” to “predominantly cytoplasmic” to describe JBP2 localization in PF cells. We hope that this resolves the issue.

      • Why would the localisation pattern change between life cycle stages? Surely PolII transcription should remain the same?

      Although our analysis suggests that there may be some shift in SET27 and JBP2 localization between BF and PF stages, sufficient amounts of these proteins may be present in the nucleus for proper SPARC assembly and RNAPII transcription regulation in both life cycle forms. The proportion of SET27 and JBP2 proteins that localizes to the cytoplasm may have functions unrelated to transcription.

      2) Several of the images in Supplementary Fig 1B seem to show foci in the nucleus (CSD1, PWWP1, CRD1). Do you see foci throughout the cell cycle or just in G1/S phase cells as shown here?

      We have not systematically investigated protein localization at different cell cycle stages, so we do not have microscopy images for all proteins at all stages of the cell cycle. However, the images we did collect suggest the punctate pattern is preserved for CRD1 in the G2 phase in both BF and PF cells (see below) as we showed in Supplemental Figure S1B for cells with 1 kinetoplast and 1 nucleus (G1/S phase cells). The significance of these puncta remains to be determined.

      3) In Figure 6, what does 'TE' stand for?

      TE denotes transposable elements. We have added this to the figure legend.

      4) The authors show this interesting link between SPARC complex and subtelomeric VSG gene silencing. -In the CRD1 ChIP or RBP1 ChIP, are there any other peaks in telomere adjacent regions in the WT cells similar to that seen on chromosome 9A? And does the sequence at this point resemble a PolII promoter?

      Apart from peaks located on Chromosome 9_3A, there are other CRD1 and RPB1 ChIP peaks in chromosomal regions adjacent to telomeres in WT cells. We observed broadening of RPB1 distribution in these regions upon SET27 deletion, similar to what we show for Chromosome 9_3A. In particular, wider RPB1 distribution on Chromosome 8_5A coincides with upregulation of 10 VSG transcripts. These two loci explain most of the differentially expessed genes (DEGs) detected, but other subtelomeric regions show a similar pattern. We have added the following statement to the Results section to highlight that the phenotype shown for Chromosome 9_3A is not unique:

      “We also observed a similar phenotype at other subtelomeric regions, such as Chromosome 8_5A where 10 VSGs and a gene encoding a hypothetical protein were upregulated upon SET27 deletion (Supplemental Table S3)”.

      Cordon-Obras et al. (2022) have recently defined key sequence elements present at one RNAPII promoter. We searched for similar sequence motifs but failed to identify them as underlying CRD1 and RPB1 ChIP peaks, highlighting the likely sequence heterogeneity amongst trypanosome RNAPII promoters. To address this point, we have added the following sentence to the Discussion:

      “Sequence-specific elements have recently been found to drive RNAPII transcription from a T. brucei promoter (Cordon-Obras et al., 2022), however, we were unable to identify similar motifs underlying CRD1 or RPB1 ChIP-seq peaks, suggesting that T. brucei promoters are perhaps heterogeneous in composition”.

      -In the FLAG-CRD1 IP (Figure 3B), the VSG's seen here are not represented (as far as I can tell) in Figure 6B and C. If my reading is correct could, is this a difference in the FC cut off for what is significant in these experiments?

      The VSGs detected in the FLAG-CRD1 IP from set27D/D cells are indeed different from the ones shown in Figure 6 (even after setting the same fold change cutoffs). We have highlighted this by adding the following statement to the Results section: “Gene ontology analysis of the upregulated mRNA set revealed strong enrichment for normally silent VSG genes (Figure 6B-D) which were distinct from the VSG proteins detected in the FLAG-CRD1 immunoprecipitations from set27D/D cells (Figure 3B)”.

      The VSGs in the mass spectrometry experiments likely represent unspecific interactors of FLAG-CRD1. To clarify this, we have added the following statement to the Results section: ”Instead, several VSG proteins were detected as being associated with FLAG-CRD1 in set27D/D cells, though it is likely that these represent unspecific interactions”.

      Reviewer #1 (Significance (Required)):

      Trypanosomes are unusual in the way that they transcribe protein coding genes. Recent advances have defined the chromatin composition at the TSS and TTS, and the recent publication of a PolII promoter sequence(s) further adds to our understanding of how transcription here is regulated. Defining the SPARC complex now add to this understanding and highlights the role of potential histone readers and writers. I think that this will be of interest to the kinetoplastid community especially those working on control of gene expression.

      Our lab studies gene expression and antigenic variation in T. brucei.

      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      In this manuscript, the authors identify a six-membered chromatin-associated protein complex termed SPARC that localizes to Transcription Start Regions (TSRs) and co-localizes with and (directly or indirectly) interacts with RNA polymerase II subunits. Careful deletion studies of one of its components, SET27, convincingly show the functional importance of this complex for the genomic localization, accuracy, and directionality of transcription initiation. Overall, the experiments are well and logically designed and executed, the results are well presented, and the manuscript is easy to read.

      There are a few minor points that would benefit from clarification and/or from a more detailed discussion:

      1) The concomitant expression of many VSGs (37) in a SET27 deletion strain is remarkable and has important implications for their normally monoallelic expression. It is well established that VSG expression in wild-type T. brucei can only occur from one of ~15 subtelomeric bloodstream expression sites, which include the ESAGs. This result implies that VSG genes are also transcribed from "archival VSG sites" in the genome, not only from expression sites. Are there VSGs from the silent BESs among the upregulated VSGs? Is there precedence in the literature for the expression of VSGs from chromosomal regions besides the subtelomeric expression sites?

      Our analysis of differentially expressed genes (DEGs) revealed that 43 VSG genes (37 of which are subtelomeric) and 2 ESAG genes are upregulated in the absence of SET27. Both ESAGs but none of the upregulated VSGs in set27D/D cells are annotated as located in BES regions. While it is possible that recombination events have resulted in gene rearrangements between the reference strain and our laboratory’s strain, at least some of the upregulated VSGs are likely to be transcribed from non-BES archival sites. VSG transcript upregulation from non-BES regions was also recently described by López-Escobar et al (2022).

      We note that the upregulated mRNAs in set27D/D are still relatively lowly expressed (Figure 6C). This is presumably insufficient to coat the surface of T. brucei, and expression from BES sites instead may be required to achieve this. We have revised the manuscript Discussion section to make these points more clear:

      “Bloodstream form trypanosomes normally express only a single VSG gene from 1 of ~15 telomere-adjacent bloodstream expression sites (BESs). In contrast, in set27D/D cells we detected upregulation of 43 VSG transcripts, none of which were annotated as located in BES regions. Recently, López-Escobar et al (2022) have also observed VSG mRNA upregulation from non-BES locations, suggesting that VSGs might sometimes be transcribed from other regions of the genome. However, the VSG transcripts we detect as upregulated in set27D/D were relatively lowly expressed (Figure 6C) and may not be translated to protein or be translated at low levels compared to a VSG transcribed from a BES site”.

      2) The role of SPARC in defining transcription initiation is compelling. It's less clear to the reviewer if the observed transcriptional silencing within subtelomeric regions can also ascribed to SPARC. Have the authors considered the possibility that some components of the SPARC may be shared by other chromatin complexes, which could be responsible for the transcriptional activation of silent genes in SET27 deletion mutants?

      We cannot rule out indirect effects through the participation of some SPARC components in other complexes operating independently of SPARC. Indeed, the transcriptional defect within the main body of chromosomes appears to be somewhat different from that observed at subtelomeric regions, particularly with respect to distance from SPARC. We have added a statement in the Discussion section to highlight the possibility raised by the reviewer:

      “However, an alternative possibility is that transcriptional repression in subtelomeric regions is mediated by different protein complexes which share some of their subunits with SPARC, or whose activity is influenced by it”.

      3) The authors mention that the observed interaction of FLAG-CRD1 with VSGs in the immunoprecipitations (Fig. 3B) is evidence for the actual expression of normally silent VSGs on the protein level. This is true, but it should be spelled out that this interaction is nevertheless likely an artifact, at least the physiological relevance of these interactions is questionable.

      We agree that these are likely background associations and have added the following statement to the Results section to clarify this point:

      “Instead, several VSG proteins were detected as associated with FLAG-CRD1 in set27D/D cells, though it is likely that these represent unspecific interactions”.

      To avoid unnecessary confusion we have also removed the following sentence from the revised Discussion:

      “The interactions of FLAG-CRD1 with VSGs in the affinity selections from set27Δ/Δ cells indicate that some of the normally silent VSG genes are also translated into proteins in the absence of SET27”.

      4) "ophistokont" is misspelled in the introduction

      Thanks for noticing. We have corrected it to “Opisthokonta”.

      Reviewer #2 (Significance (Required)):

      The manuscript by Staneva et al. addresses the fundamental regulatory mechanism of gene transcription in the protozoan parasite Trypanosoma brucei, a highly divergent eukaryotic organism that is renowned for unusual features and mechanisms in gene regulation, metabolism, and other cellular processes. While post-transcriptional regulation is prevalent and relatively well established in T. brucei, much less is known about the mechanism of transcription initiation and transcriptional control, in part due to the general paucity of well-defined conventional promoter regions in this organism (only very few have been identified thus far). In this context, the work by Staneva et al. is highly significant and represents an important contribution to the field of gene regulation and chromatin biology in T. brucei and other related kinetoplastid parasites.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      In this manuscript, the authors identify a six-membered chromatin-associated protein complex termed SPARC that localizes to Transcription Start Regions (TSRs) and co-localizes with and (directly or indirectly) interacts with RNA polymerase II subunits. Careful deletion studies of one of its components, SET27, convincingly show the functional importance of this complex for the genomic localization, accuracy, and directionality of transcription initiation. Overall, the experiments are well and logically designed and executed, the results are well presented, and the manuscript is easy to read.

      There are a few minor points that would benefit from clarification and/or from a more detailed discussion:

      1. The concomitant expression of many VSGs (37) in a SET27 deletion strain is remarkable and has important implications for their normally monoallelic expression. It is well established that VSG expression in wild-type T. brucei can only occur from one of ~15 subtelomeric bloodstream expression sites, which include the ESAGs. This result implies that VSG genes are also transcribed from "archival VSG sites" in the genome, not only from expression sites. Are there VSGs from the silent BESs among the upregulated VSGs? Is there precedence in the literature for the expression of VSGs from chromosomal regions besides the subtelomeric expression sites?
      2. The role of SPARC in defining transcription initiation is compelling. It's less clear to the reviewer if the observed transcriptional silencing within subtelomeric regions can also ascribed to SPARC. Have the authors considered the possibility that some components of the SPARC may be shared by other chromatin complexes, which could be responsible for the transcriptional activation of silent genes in SET27 deletion mutants?
      3. The authors mention that the observed interaction of FLAG-CRD1 with VSGs in the immunoprecipitations (Fig. 3B) is evidence for the actual expression of normally silent VSGs on the protein level. This is true, but it should be spelled out that this interaction is nevertheless likely an artifact, at least the physiological relevance of these interactions is questionable.
      4. "ophistokont" is misspelled in the introduction

      Significance

      The manuscript by Staneva et al. addresses the fundamental regulatory mechanism of gene transcription in the protozoan parasite Trypanosoma brucei, a highly divergent eukaryotic organism that is renowned for unusual features and mechanisms in gene regulation, metabolism, and other cellular processes. While post-transcriptional regulation is prevalent and relatively well established in T. brucei, much less is known about the mechanism of transcription initiation and transcriptional control, in part due to the general paucity of well-defined conventional promoter regions in this organism (only very few have been identified thus far). In this context, the work by Staneva et al. is highly significant and represents an important contribution to the field of gene regulation and chromatin biology in T. brucei and other related kinetoplastid parasites.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      In this paper, Staneva et al describe a novel complex found at RNA PolII promoters that they term the SPARC. The manuscript focuses on defining the core components of the complex and the pivotal role of SET27 in defining its function, and role in PolII transcription. This manuscript is a logical follow on from an initial paper (Staneva et al, 2021) by the same authors where they systematically analyzed chromatin factors, and their role in both transcription start and termination. What is also very clear, is that this complex is one made of histone readers and writers which suggests its function is to change the chromatin structure around a PolII promoters. The authors show that this complex is necessary for the correct positioning of PolII and directionality of transcription.

      This was a well-designed study and well written and clear manuscript that provides fascinating insight transcription control in bloodstream form parasites.

      I have no major comments only a few minor ones.

      1. Localisation of the different SPARC components appears to be either nuclear or nuclear and cytoplasmic.
        • Both SET27 and CRD1 show a nuclear and cytoplasmic localisation in the bloodstream form IFA (Supplementary Fig 1B), but only a nuclear localisation procyclic form. Did the authors attempt C terminally tagging SET27, CRD1 to see if this resulted in a change in the pattern?
        • The point is made that JBP2 shows a 'distinct cytoplasmic localisation' in PF cells. by this logic, the SET27 localisation in BF is also distinctly cytoplasmic and a nuclear enrichment is not clear.
        • Why would the localisation pattern change between life cycle stages? Surely PolII transcription should remain the same?
      2. Several of the images in Supplementary Fig 1B seem to show foci in the nucleus (CSD1, PWWP1, CRD1). Do you see foci throughout the cell cycle or just in G1/S phase cells as shown here?
      3. In Figure 6, what does 'TE' stand for?
      4. The authors show this interesting link between SPARC complex and subtelomeric VSG gene silencing.
        • In the CRD1 ChIP or RBP1 ChIP, are there any other peaks in telomere adjacent regions in the WT cells similar to that seen on chromosome 9A? And does the sequence at this point resemble a PolII promoter?
        • In the FLAG-CRD1 IP (Figure 3B), the VSG's seen here are not represented (as far as I can tell) in Figure 6B and C. If my reading is correct could, is this a difference in the FC cut off for what is significant in these experiments?

      Significance

      Trypanosomes are unusual in the way that they transcribe protein coding genes. Recent advances have defined the chromatin composition at the TSS and TTS, and the recent publication of a PolII promoter sequence(s) further adds to our understanding of how transcription here is regulated. Defining the SPARC complex now add to this understanding and highlights the role of potential histone readers and writers. I think that this will be of interest to the kinetoplastid community especially those working on control of gene expression.

      Our lab studies gene expression and antigenic variation in T. brucei.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Reviewers 1 and 2 are very positive about our manuscript, while reviewer 3 is surprisingly critical.

      However, except for the first observation, most of reviewer 3´s comments are based on incorrect interpretations of our results.

      We have integrated the useful comment into our revised version, and we will discuss in the following sections why reviewer 3’s remaining criticisms should be disregarded.

      Reviewer 1:

      Reviewer 1 has only minor suggestions and is satisfied that we prove convincingly our claims. The reviewer also finds our results reinforce our previously proposed hypothesis that the glands and the trachea evolved from common metamerically repeated ancient primordia.

      We have introduced the following changes to the text to accommodate Reviewer’s 1 minor suggestions.

      Main suggestion: Insert a paragraph in discussion explaining the relevance of new insights to more basal insects that do not form a ring gland.

      RESPONSE:We have introduced at the end of Discussion the following paragraph:

      “Our analysis of snail activation in the CA and PG shows that these glands and the trachea share similar upstream regulators, reinforcing the hypothesis that both diverged from an ancient segmentally repeated organ. In Drosophila melanogaster the CA and the PG primordia experiment a very active migration after which they fuse to the corpora cardiaca forming the ring gland (Sanchez-Higueras and Hombria, 2016). This differs from more basal insects where the CA fuses to the corpora cardiaca but not to the PG, and from the Crustacea where the three equivalent glands are independent of each other (Chang and O'Connor, 1977; Laufer et al., 1987; Nijhout, 1994; Wigglesworth, 1954). As the mechanisms we here describe relate to the early specification of the glandular primordia in Drosophila, it will be interesting to investigate if the equivalent genes are also involved in the endocrine gland specification of more distant arthropods”.

      Additional comment 1: Introduction, pg 3, a paragraph starting with "In comparison to the extensive knowledge we have of ..." - consider omitting or greatly shortening, this text breaks a flow as it is focused on tracheal development. I understand the authors' logic, but this information distracts from the main focus on CA and PG. RESPONSE:We agree that the trachea description paragraph breaks the flow of the introduction to gland development. As suggested by the reviewer, we have deleted most of the descriptive text on trachea development but left all the references so that interested readers can find the information.

      Additional comment 2: Beginning of discussion, pg 11: - change 2nd sentence to: " Our results indicate that the HH and the Wnt pathways act indirectly to negatively regulate the spatial activation ..." - the following sentence, starting with "Engrailed activation off hh transcription ...." is way too long and hard to follow, consider breaking into two sentences. RESPONSE:We have changed both sentences as suggested

      Additional comment 3: In Fig 4B, mx and lb segments should be labeled so this panel is consistent with labeling in 4A. RESPONSE:We have changed Fig.4B labels to be consistent with 4A

      Additional comment 4: In Fig 6, reduce a font size for labels on right-hand side (A1, A2, A1+A2 proximal, etc), so that they are visualy distinct from panel labels on left-hand side (A, B, C,..).

      RESPONSE:We have changed Fig.6 Font size as suggested

      Reviewer 2

      The reviewer is positive and agrees that the results we present in “this paper add to our understanding of how the CA and PG primordia are specified and highlights important similarities with the specification of the tracheal primordia”. The reviewer’s comments focus specially on the activation vs. maintenance of sna.

      Specific Comment a): Referring to Fig 1G-J, the reviewer says: It is not clear to me from either this figure or from the text whether the initial pattern of expression of the sna-rg reporter in stage 11 embryos is WT and then disappears at stage 12, or whether it is always defective. In trying to understand the activation process, I think it would be important to know for sure whether rg enhancer activity during the initiation phase in stage 11 is WT or not.

      RESPONSE: As suggested by the reviewer, we have included st11 embryos in Fig. 1 as panels G,J which illustrate that early sna-rg activation occurs normally in snaΔrgR2embryos prior to apoptosis kicking in. To make space for these images, we have taken out the st12 embryos that we had in our previous submitted version. This does not affect the manuscript’s message, as st12 phenotypes are similar to those at st13 which are presented in Fig. 1H,J.

      Moreover, in this revised version, the embryos in Fig. 1G-J have also been double stained with the apoptosis marker DCP1 to highlight the cell death observed in the gland primordia of snaΔrgR2 embryos (Fig. 1G’-J’).

      Specific Comment b) The authors argue that the rg deletion removes the only region driving sna expression in CA/PG. I'm not convinced that necessity necessarily implies sufficiency with respect to the requirements for rescue. While the sna-rg reporter is expressed in a pattern that seems to mimic the endogenous gene, do we know that a rg-sna transgene would fully rescue the rg deletion mutant?

      RESPONSE: In our previous paper (Sanchez-Higueras 2014) we presented evidence that in sna null embryos, a Snail BAC gene lacking the sna-rg CRM can fully rescue the mesoderm phenotypes but not the ring gland ones. This proved that in the BAC transgene there was no shadow CRM capable of rescuing the gland formation in the absence of sna-rg. In the current paper we show that deleting the endogenous sna-rg CRM in the sna locus results in the absence of sna transcription from the gland primordia.

      Making a sna-rg- construct expressing sna to test if this rescues the snaΔrgR2 homozygous mutants could be done, but it will delay this publication without adding much to the paper: we already know that sna-rg is sufficient to drive activation in all the CA and the PG cells (Sanchez-Higueras 2014 Fig 2J-M) and it would be expected to rescue the gland formation in snaΔrgR2 homozygous mutants.

      Having said that, we have changed the wording in the manuscript to one that may be acceptable to the reviewer.

      Instead of:

      “These results prove that snaΔrgR2 deletes the only regulatory region driving sna expression in the CA and PG gland primordia…”

      We now say:

      “These results prove that the snaΔrgR2 deletes mutation inactivates the only regulatory region driving sna expression in the CA and PG gland primordia…”

      Specific Comment c) is Sna required for maintaining sna expression?

      RESPONSE:This experiment is relevant to the maintenance mechanism of sna expression in the ring gland, and not to its activation which is the main focus of this paper.

      The search for the maintenance mechanisms is currently been followed in the laboratory and we prefer not deal with it in this paper. Providing a negative answer to this question would not be satisfactory, as we would need to search for the factors controlling sna’s maintenance.

      Specific comment d) The authors show that there is an expansion in the number of sna-rg reporter expressing cells along the AP axis when upd is ectopically expressed using a sal-Gal4 driver. Though not mentioned in the text at this juncture, sal is expressed in the PG primordia, while seven-up (svp) is expressed in the CA primordia. I assume that the upd induced expansion is only observed for the PG primorida (LB) and not the CA primordia (Mx)-at least this is what the figure looks like. (…) How about svp driven upd-assuming there is a svp-Gal4 driver-does it cause an expansion of Ca but not PG.

      RESPONSE: As the reviewer has noticed, there is a stronger expansion of sna-rg-GFP expression in the labial segment than in the maxillary segment. This is not due to the use of the sal-Gal4 line. We see the same effect with arm-Gal4 which drives similar expression on the maxilla and the labium. To illustrate this point, we have included two new panels (Fig.5D-E) where the ectopic expression of Upd has been induced with arm-Gal4. These embryos have been stained with anti-Sal to label the PG. This experiment shows clearly that the PG has expanded much more than the CA.

      There are several reasons why expansion of the glands could be more efficient in the labium than in the maxilla. One possible reason is the temporal response to Upd activation. Upd induction by the arm-Gal4 and sal-Gal4 lines may occur after the cells in the maxilla are no longer capable of activating sna-rg but still capable of activating it in the labium. This temporal hypothesis is based on our results showing that the CA expresses more transiently the upd gene and that STAT activation lasts for longer in the labium than in the maxilla (Fig. 4A-D)].

      A second possibility, that we favour, is the existence of dorso-ventral repressor genes modulating sna-rg expression intrasegmentally. Some of our results point towards the sna-rg CRM receiving repressor inputs that modulate intrasegmental spatial expression in the dorso-vental axis. When we delete the A2 distal region of the sna-rg enhancer, its expression in the labium expands ventrally (Fig. 6E,G and Sup.Fig. 4D). If a similar repressor was also modulating sna-rg in the maxilla it could be blocking its expansion. However, at this stage we have no solid data to support any of these hypotheses. As explained before for the maintenance mechanisms of sna-rg expression, our ongoing work aims to isolate and characterize further elements controlling the ring gland gene network, including these negative regulators.

      In the revised manuscript we now describe the different effects of Upd ectopic activation on the expression of sna-rg in the maxilla and the labium (underlined text is new to this revised version):

      “To test if generalised Upd expression in the maxilla and labium can activate sna-rg expression independently of other upstream positive or negative inputs, we induced UAS-upd with either the sal-Gal4 or the arm-Gal4 lines. We observe that, these embryos have expanded sna-rg expression along the antero-posterior axis in the maxillary and labial segments (Fig. 5C). Analysis of Sal expression, which labels the PG primordium (Sanchez-Higueras et al., 2014), shows that Upd ectopic expression induces a moderate expansion of the CA primordia while resulting a much larger increase of the PG primordium (Fig. 5D-E). This expansion occurs mostly in the anterior and posterior axis from cells where the Hh and the Wnt pathways are normally blocking sna-rg expression, while expansion is less noticeable in the dorso-ventral axis. This indicates that most of the antero-posterior intrasegmental inputs provided by the segment polarity genes converge on Upd transcription but that the dorso-ventral information is registered downstream of Upd.”

      The differential response of sna-rg to Upd activation in the maxillary and labial segments is also mentioned in Fig. 5 legend. (see Continuation comment d).

      * Continuation comment d) “It looks to me also like the vvl domain is expanding as well. This information should be clarified.*

      RESPONSE: Yes, ectopic upd expression also expands vvl1+2 expression. We have previously published that vvl1+2 is a direct target of JAK/STAT signalling in the trachea (Sanchez-Higueras 2019 and Sotillos et al. 2010 Dev.Biol). Although vvl1+2 expands dorsally in the Mx, those cells do not activate sna-rg dorsally. The ventral restriction of sna-rg in the maxilla is controlled by Dfd while in the labium its dorsal expression depends on Scr. We explain this in Fig.5’s figure legend where we now say (underlined text is new to this revised version):

      (C) Ectopic Upd expression driven with sal-Gal4 induces ectopic sna-rg and vvl1+2 expression in the gnathal segments, which for sna-rg is more pronounced in the labium than in the maxilla. Note that in the maxillary segment Upd can induce ectopic dorsal vvl1+2 but not sna-rg expression, this is expected as Dfd only induces sna-rg ventrally in the maxilla. (D-E) sna-rg-GFP embryos stained with anti-GFP (green) and anti-Sal (red). In control embryos (D) Sal labels the PG primordium but not the CA. In arm-Gal4 embryos ectopically expressing Upd, the PG is more expanded than the CA as shown by number of cells co-expressing Sal and GFP.

      Specific Comment e) The authors note a difference between CA and PG in the requirement for STAT binding sites in the enhancers. Is that related to the fact that svp is expressed in CA and sal is expressed in PG? Would driving svp expression using the sal-Gal4 driver maintain sna-rg expression.

      RESPONSE: During our preliminary ongoing experiments on sna maintenance mechanisms we looked in svp mutants and did not notice a change in sna-rg expression, thus it is unlikely that Svp is responsible for the difference. As said above, we continue looking for genes involved in gland formation. Sal could be involved in the maintenance of sna in the PG, but as Sal is expressed in the maxilla and labial segments before gland formation, it is difficult to disentangle if Sal is required for sna activation or maintenance (or both).

      Specific Comment f) Do svp or sal have a role in initiating sna expression when upd is present or maintaining sna expression after upd disappears? Presumably there is already published data that would answer these questions.

      RESPONSE: As explained above we did not find any effect of svp on activation of sna-rg, however we find that in sal mutants the labium does not express sna-rg. This shows that sal is likely to be another positive input. As in sal mutants both trh and Ubx become ectopically expressed in the Lb (Casanova1989 Roux's archives of developmental biology 198: 137-140; Castelli-Gair 1998 IJDB42:437-444) we have done the experiment in sal trh double mutants and in sal Ubx,abdA,Abd-B mutants. In both cases we still see a failure of sna activation in the Lb reinforcing the idea that Sal is an additional positive input. However, we prefer not to add the sal experiments as they would complicate the paper which currently focuses on the similar requirement of the Wnt, Hh and JAK/STAT signalling pathways.

      Reviewer 3

      Reviewer is very critical. We accept some of the points raised and have modified the manuscript accordingly. However, as we detail below, the most serious criticisms are incorrect and do not affect the conclusions reached by our work.

      We agree with the following comment:

      “In the Dfd Scr double mutant, both the CA and PG expression of the snail-rg-GFP reporter is still there - admittedly, the gland cells look abnormal at late stages, but this reporter that is supposed to function as a proxy for gland induction is still expressed. That either means that expression of sna-rg-GFP is not a proxy or that the glands are still being specified in the absence of the Hox genes that are proposed to specify these organs. The reporter should not be expressed if these Hox genes are what specify these endocrine organs.”

      RESPONSE: The reviewer has made a good observation. The expression of sna-rg-GFP is not completely absent in Dfd Scr mutant embryos (Fig. 5F in this revised version), which indicates that although the Hox genes are required to activate upd in the maxilla and labium and in their absence the gland primordia become apoptotic, there must be other positive inputs to the enhancer. However, this does not mean the Hox gene input is irrelevant for gland specification. Not only the Hox genes are required to keep normal levels of upd expression in the Mx and Lb primordia and gland viability, but previously we also showed that cephalic Hox genes influence the dorso-ventral position inside the vvl1+2 expressing cells where the sna-rg enhancer is activated: in the maxilla Dfd induces the ventral vvl1+2 expressing cells to activate sna-rg, while in the labium Scr induces the dorsal vvl1+2 cells to activate sna-rg (Sanchez Higueras 2014). The data presented in this paper indicate that the input of both Dfd and Scr over sna-rg CRM activation are indirect.

      As a result of the reviewer’s criticism, we have tested if the additional positive input could be provided by Ci. In our previous submitted version, we showed that the repressor form of Ci blocks sna-rg activation. In this revised version, we have tested what is the effect of expressing the activator form of Ci. In embryos overexpressing the activator CiPKA isoform, we have observed that the expression of sna-rg and upd are expanded, indicating that Ci can provide the additional Hox-independent positive input. In the revised version we present these new results as Fig.3G and Fig. 4I. We have modified accordingly the scheme that appears in panel 3I to include this. In the main text we describe the result in the Hh regulation section where we have added:

      “Although the above results indicate Ci is not absolutely required for sna-rg expression, we observed that overexpression of CiPKA, the active form of Ci, causes a non-fully penetrant expansion of sna-rg expression (Fig. 3G) suggesting the possibility that sna-rg may be responsive to Ci and to a second activator.”

      … and in the “Regulation of Upd ligand expression by the Wg and Hh pathways” section

      where we say:

      “We also found that ectopic expression of the activator Ci protein results in a non-fully penetrant expansion of upd expression in stage 10 embryos (Fig. 4H-I).”

      We have also modified the final scheme in Fig. 7 to mention that Dfd and Scr prevent the apoptosis of the gland primordia, and that there must be an additional positive input controlling upd activation besides the Hox input. However, in the figure we do not define Ci as the activating input as we would like to have additional evidence before making such claim.

      To clarify that the Hox input is not absolutely required we have modified the text in several places. Where we said:

      “Expression of the sna-rg reporter in the maxilla and the labium requires Dfd and Scr function …”

      We now say:

      “Development of the CA and PG and normal expression of the sna-rg reporter in the maxilla and the labium require Dfd and Scr function …”

      We also mention this in Fig. 5 legend where we have added:

      “In Dfd Scr mutant embryos (F), although the gland primordia become apoptotic, residual GFP expression indicates that there must exist Hox independent inputs activating the sna-rg enhancer.”

      As a result of reviewer 3’s comment, we have noticed a further example of similarity between the gland and the trachea specification, which we have commented in the revised discussion where we added the following paragraph:

      “Another interesting similarity between glands and trachea is that, although ectopic Hox gene expression can ectopically induce sna-rg and trh outside their normal domain, the lack of Hox expression does not completely abolish their endogenous expression, indicating that in both cases a second positive input can compensate for the absence of Hox mediated activation. Our results suggest that, in the glands, this redundant input could be provided by the activating Ci form (Figs. 3G and 4I), but further analysis to confirm this possibility and discard alternative sna-rg activators should be performed.”

      We disagree with the following comments:

      The finding that the CA and PGs form in slightly different DV positions from each other and slightly different DV positions from the trachea (based on the vvl1+2 mCherry reporter staining combined with that of the sna-rg-GFP reporter staining in Figure 5A, where staining does not overlap except where the CA cells have started to migrate over the vvl1+2 mCherry expressing cells) argues pretty strongly against the CA and PG being homologous to each other or absolutely homologous to the trachea primordia

      RESPONSE: This erroneous claim was based on Fig. 5A, that showed a double stained embryo where co-expression is difficult to appreciate without separating the channels. Co-expression of these two reporter lines in the ring gland has been previously documented beyond doubt in our 2014 publication, cited throughout the manuscript, where we presented eight different panels of glands clearly co-expressing both markers at various developmental stages (Current Biology 2014 Fig.2B-I). To prevent any readers reaching the same conclusion as the reviewer, we have modified Fig. 5A to show a double stained sna-rg-GFP vvl1+2-mCherry embryo alongside with the two separate channels (panels 5A’ and A’’) to make the co-expression evident.

      Although we are not including it in this manuscript, the reviewer will also be able to find images in the same 2014 Current Biology publication (Fig.3), where the ectopic activation of Dfd in the trunk leads to the activation of the sna-rg-GFP reporter in the vvl1+2 tracheal cells, proving that the glands and the trachea are formed at homologous positions.

      Having made clear that sna-rg activation in both the CA and the PG occurs in vvl1+2 expressing cells, we now refute a second criticism: The reviewer is puzzled that despite the glands being formed at different dorso-ventral positions in the vvl1+2 expressing patch of cells, we claim both groups of cells are homologous to the trachea.

      We are not saying that the CA are formed at homologous positions to those giving rise to the PG. What we say is that both the CA and the PG are formed at positions homologous to those giving rise to the trachea in the trunk segments.

      To make this clear in the revised version, we have changed the wording of a sentence in the Introduction section that might have originated the confusion.

      Instead of saying:

      “First, the CA, the PG and the traqueal primordia are specified in the lateral ectoderm at homologous positions”.

      Now, it reads:

      “First, the CA and the PG are specified in the cephalic lateral ectoderm at homologous positions to those forming the tracheal primordia in more posterior trunk segments.”

      It has been shown that each tracheal primordium (which are labelled by vvl1+2-mCherry) gives rise to different tracheal branches depending on the positions where they are specified: the dorsal cells give rise to the dorsal tracheal branches, the ventral cells to the ganglionic branches, the medial cells to the dorsal trunk etc. (for illustration see Fig.12 in Manning and Krasnow 1993). Each of these tracheal branches have a different shape and migrate to different positions. We believe that a similar positional specification occurs in the vvl1+2 cells in the maxilla and the labium. In the maxilla only the vvl1+2 ventral cells activate sna and svp (among other genes) to give rise to the CA. In the labium vvl1+2 dorsal cells activate sna, sal, phm (among other genes) to give rise to the PG. This regionalization is similar to what happens during tracheal branch specification, with the only difference that the interaction with Dfd and with Scr is what makes the positional outcome in the maxilla and the labium different (see in our Current Biology 2014 publication Fig. 3E-F and H-J). Thus, when the reviewer considers the equivalence between the CA/PG/trachea homology with that of the wing/haltere or that of the thoracic leg1/2/3 saying: “Indeed, the situation with these endocrine glands and the trachea is completely unlike the situation with the wing and haltere, wherein both structures arise from the same DV position in adjacent segments, or with legs 1, 2 and 3, which arise from the same DV position in adjacent segments

      …the reviewer should think about the coxa and the tarsi in the legs. The coxa in T1 is not homologous to the tarsi in T2 or T3, but when considering the leg structure as a whole, the coxa and the tarsi form part of the same homologous structure in T1, T2 and T3 despite being formed at different positions inside the leg primordia.

      The reviewer also doubts that the activation of upd occurs in the sna-rg primordium when saying: “Likewise, the STAT10X-GFP staining does not overlap with the sna-rg-mCherry staining (I see red cells and I see green cells - there are no yellow cells). If activation of snail is through Upd activation of STAT signaling, we should see that the snail reporter expression is within the domain of STAT10X-GFP expression.”

      RESPONSE: This is due to the fact that upd activation in the CA is extremely transient, leading to the loss of the x10STAT-GFP expression before the sna-rg-mCherry levels are robust enough in the maxilla. This criticism does not apply to the PG where due to upd expression lasting longer, co-expression of sna-rg-mCherry and x10STAT-GFP in panel 4B should be evident to the reviewer.

      To try to sort the CA co-expression problem, we are currently repeating the experiment but instead of analysing sna-rg-mCherry activation with the RFP antibody, we will do an mcherry RNA in situ. We hope that the mcherry transcript will be detectable earlier than the protein and the co-expression will be evident.

      We strongly disagree when the reviewer says: “This paper provides a strong basis for arguing that the CA and PG are induced independently of Jak/Stat signaling, whereas trachea require this signaling pathway.”

      RESPONSE: When making this claim, the reviewer is ignoring a large number of experiments presented in the manuscript. If the CA and the PG are induced independently of JAK/STAT signalling:

      (1) Why sna-rg expression disappears from the glands in mutants lacking the Upd ligands (Fig. 5B and 6K)?

      (2) Why deleting the region containing the putative STAT binding sites in the sna-rg enhancer causes the loss of enhancer expression (Fig. 6C)?

      (3) Why the smaller enhancer mentioned in point (2) recovers gland expression when adding a STAT binding site from an unrelated gene (Fig. 6G)?

      (4) Why the regained expression of the construct mentioned in (3) is lost by the mutation of two bases affecting this single STAT site (Fig. 6H)?

      The reviewer’s conclusion rests on giving an excessive importance to his reservations to CA co-expression in panel 4A while, surprisingly, disregarding the co-expression in the PG shown in panel 4B and all the experiments presented in Fig. 5 and Fig.6.

      Reviewer 3 Minor comments: RESPONSE: Both comments have been taken into account in the revised version.

      In summary, in this revised version we have answered most queries raised by reviewers 1 and 2. Moreover, reviewers 1 and 2 agree that the results presented in this manuscript reinforce the hypothesis that the CA and the PG glands and the trachea derive from the divergent evolution of a metamerically repeated homologous organ.

      Reviewer 3 has made a good point that we have taken into account and has improved the revised submission.

      However, reviewer 3 is wrong when concluding:

      This paper provides a strong basis for arguing that the CA, PG and trachea are not homologous structures, and when saying: the CA and PG are induced independently of Jak/Stat signaling, whereas trachea require this signaling pathway”.

      As we argue above, these conclusions are erroneous because:

      (1) Are based on the incorrect interpretation of Fig 5A and ignore previous published evidence cited throughout the manuscript.

      (2) It does not take into account key experiments presented in this work, while giving too much weigh to a result that can be easily interpreted.

      (3) It misinterprets the arguments justifying the positional homology between the CA/PG glands and trachea primordia.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      Summary:

      This paper focuses on the specification of two endocrine glands that form from head ectoderm, the corpora allata (CA), which forms in the maxillary segment and secretes Juvenile hormone, and the prothoracic glands (PG), which form in the labial segment and secrete Ecdysone. Secretion of both hormones results in a larval molt. Secretion of only Ecdysone induces metamorphosis, the transition of the larvae into the adult forms. Both the CA and PGs form in positions homologous to the tracheal primordia (approximately) and previous reports indicate that ectopic expression of the appropriate Hox genes can result in homeotic transformations of the glands into tracheal primordia and of tracheal primordia into glands. Using a GFP reporter construct for the snail gene as a proxy for gland specification, the authors show that CA and PG formation is regulated by two segment polarity genes: Hh and Wnt, with Hh signaling activating reporter gene expression and Wnt signaling inhibiting reporter gene expression. They also suggest that their endocrine gland GFP reporter is regulated by the two Hox proteins expressed in those segments: Dfd (maxillary) and Scr (labial) (although figure 5D,E argue against this conclusion). They presumably show that reporter gene regulation by Wnt signaling and Hh signaling is indirect and through localized transcriptional activation of the JAK/STAT signaling pathway ligand gene upd (however, the STAT reporter and the snail reporter are expressed in different cells (fig 4B) - so I'm not so convinced of this conclusion). The authors also find that the CA and PG primordia form at slightly different dorsal ventral positions and that DV positional information is controlled downstream of upd JAK/STAT signaling.

      Major comments:

      The paper is well written and makes for a nice story, but the corresponding data are not supportive of most of the conclusions drawn by the authors.

      First, in the Dfd Scr double mutant, both the CA and PG expression of the snail-rg-GFP reporter is still there - admittedly, the gland cells look abnormal at late stages, but this reporter that is supposed to function as a proxy for gland induction is still expressed. That either means that expression of sna-rg-GFP is not a proxy or that the glands are still being specified in the absence of the Hox genes that are proposed to specify these organs. The reporter should not be expressed if these Hox genes are what specify these endocrine organs. This finding might explain why mutating the Hox consensus binding sites had no effect on expression of the smaller snail reporters.

      The finding that the CA and PGs form in slightly different DV positions from each other and slightly different DV positions from the trachea (based on the vvl1+2 mCherry reporter staining combined with that of the sna-rg-GFP reporter staining in Figure 5A, where staining does not overlap except where the CA cells have started to migrate over the vvl1+2 mCherry expressing cells) argues pretty strongly against the CA and PG being homologous to each other or absolutely homologous to the trachea primordia. Likewise, the STAT10X-GFP staining does not overlap with the sna-rg-mCherry staining (I see red cells and I see green cells - there are no yellow cells). If activation of snail is through Upd activation of STAT signaling, we should see that the snail reporter expression is within the domain of STAT10X-GFP expression. This would be consistent with observing a loss of upd mRNA in the maxillary and labial segments with loss of Dfd and Scr, but not seeing a loss of the sna-rg-GFP reporter. This would also argue against the proposed homology between the glands and the trachea. Indeed, the situation with these endocrine glands and the trachea is completely unlike the situation with the wing and haltere, wherein both structures arise from the same DV position in adjacent segments, or with legs 1, 2 and 3, which arise from the same DV position in adjacent segments. This paper provides a strong basis for arguing that the CA, PG and trachea are not homologous structures and that the CA and PG are induced independently of Jak/Stat signaling, whereas trachea require this signaling pathway.

      Minor comments:

      Page 3: tracheal is misspelled in the first paragraph, line 3.

      Page 5, end of first sentence in first full paragraph: "lethal" should be changed to "non-viable". I think the authors mean that homozygous embryos die, not that they cause the death of other life forms.

      Significance

      Nature of significance of advance:

      I think the significant finding is that the CA, PG, and trachea are not homologous structures. But that is not what the authors are concluding. The only findings consistent with the data provided are that Wg signaling represses expression of the snail reporter and Hh signaling activates its expression (Figures 1 - 3). Most of the other conclusions do not seem to be sufficiently supported by the data.

      Context of the work:

      These authors have published that the CA and PG are structures specified in homologous positions to the trachea. It has already been published that CA, PG and trachea primordia express the Vvl transcription factor - although I did not go back to see how that was determined. It has already been published that ectopic expression of specific Hox genes can transform the gland primordia into trachea and vice versa (these experiments may also warrant a closer look). So, idea that CA, PG and TR arose from divergent evolution of a segmentally repeated ancient structure has been proposed.

      Best target audience:

      With the findings that are consistent with the story line (figures 1 - 3), Drosophila embryologists working on the formation of these glands would be interested.

      My field of expertise:

      Drosophila development.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      This manuscript from Garcia-Ferres et al., describes studies aimed at understanding the specification of precursor cells to two ring gland organs, the corpora allata (CA) and the prothoracic gland (PG). These two glands are specified in the lateral ectoderm at positions that match the tracheae in more posterior segments, and like tracheal cells, the CA/PG primordia express ventral veinless (Vvl). The specification of CA/PG primordia requires the Hox genes Deformed (Dfd) and Sex combs reduced (Scr), while the trachea dependent on BX-C complex genes. CA/PG precursor cells also differ from tracheal precursors in that the former requires the expression of "mesodermal" gene snail (sna), while tracheal cells require trachealess. The sna gene has a complex regulatory region, with distinct enhancers for expression in the mesoderm and in the CA/PG primordia. Garcia-Ferres et al have used a reporter carrying the sna CA/PG enhancer, rg, to studying the mechanisms of CA/PG specification.

      In the first set of experiments, using a Crispr deletion the authors showed that the rg enhancer in the endogenous Sna gene is essential for CA/PG specification. The next used the sna-rg to examine the effects of mutations in (potentially) upstream signaling pathways on CA/PG specification. The CA/PG primordia are located outside of the wingless (wg) (parasegmental) expression domain; however, the authors found that two sets of lateral ectodermal cells express sna-rg in wg mutants. Conversely ectopic expression of wg or armS10 in the maxillia and labium eliminates sna-rg expression indicating that wg is a negative regulator of sna. Unlike wg, mutations in hedgehog (hh) and engrailed (en) eliminate sna-rg expression, indicate that both of these genes are required to promote CA/PG specification. The failure to express sna-rg is due at least in part to repressive activities of Cubitus interruptus (Ci) as sna-rg expression is restored in an en, ci double mutant. Sna-rg expression also depends upon JAK/STAT signaling and is in a deficiency that deletes the three upd genes. A upd dependent reporter is activated in CA/PG primordia in stage10/11 embryo, while upd itself appears to be express in the same cells. Consistent with the idea that the JAK/STAT maybe controlling sna-rg expression in response to wg and hh signaling, the authors finding that expression of upd expands in wg mutants, while it disappears in hh mutants. upd expression appears to be controlled by inputs not only from wg and hh, but also by Dfd and Scr as Dfd Scr mutant embryos lack upd expression. In contrast, the pattern of wg and en expression in the Dfd Scr mutant is normal.

      To confirm that JAK/STAT signaling is required for activating the sna-rg reporter, the authors undertook a functional dissection of the rg enhancers. When they split a truncated rg enhancer, rgR2, into two fragments, A1 and A2, there was no expression of the reporter. As fragment A2 has three STAT binding sites, the authors tested whether expression could be rescued by adding a generic STAT site to A1-it could be. On the other hand, when they mutated the three STAT sites in A2, they found that only PG expression is lost. This result suggests that there is a Upd responsive element in A1+A2; however, activation is likely indirect since the activity of this element is tissue specific. They also putative Hox-Exd-Hth bindings sites in the rgR2 enhancer; however. these sites do not appear to be required for reporter expression.

      This paper adds to our understanding of how the CA and PG primordia are specified and highlights important similarities with the specification of the tracheal primordia. There are some questions that should be addressed.

      Specific Comments:

      There are two phases to sna expression in CA/PG primordia. In the first phase (stage 11) hh signaling to neighboring cells prevents of the Ci repressor protein which would in turn activate upd expression in these cells. However, wg expression anterior in anterior cells blocks Upd expression so that it is turned on only a single set of cells posterior to the hh expressing cells. Upd in turn activates the sna via the STAT binding sites in the rg enhancer. upd expression also depends on the Hox genes Dfd and Scr, and when they are mutant upd is not expressed and sna is not turned on. Upd expression is only transient, and so after it disappears a maintenance mechanism ensures that that sna is expressed until at least stage 16. The authors don't really address the maintenance mechanism so it isn't clear what elements or factors are needed to keep the rg enhancer active after upd expression disappears.

      • a) In Fig. 1, G-J the authors show sna-rg reporter expression in WT and in their sna-rg deletion mutant. The images in G and I are of stage 12 embryos. At this point there is clearly little if any rg reporter expression in the deletion mutant, while high levels are observed in the WT. However, this is after sna expression is supposed to be activated by Upd, which is in stage 11. Moreover, upd expression is turned off in stage 12. (Assuming I didn't miss something) It is not clear to me from either this figure or from the text whether the initial pattern of expression of the sna-rg reporter in stage 11 embryos is WT and then disappears at stage 12, or whether it is always defective. In trying to understand the activation process, I think it would be important to know for sure whether rg enhancer activity during the initiation phase in stage 11 is WT or not. The expectation-at least from what is written in the manuscript-is that the initial expression of the sna-rg reporter will be the same as WT in the sna-rg deletion mutant.
      • b) The authors argue that the rg deletion removes the only region driving sna expression in CA/PG. I'm not convinced that necessity necessarily implies sufficiency with respect to the requirements for rescue. While the sna-rg reporter is expressed in a pattern that seems to mimic the endogenous gene, do we know that a rg-sna transgene would fully rescue the rg deletion mutant?
      • c) If sna protein is not required for initiating (see a) sna expression, is it required for maintaining sna expression?
      • d) The authors show that there is an expansion in the number of sna-rg reporter expressing cells along the AP axis when upd is ectopically expressed using a sal-Gal4 driver. Though not mentioned in the text at this juncture, sal is expressed in the PG primordia, while seven-up (svp) is expressed in the CA primordia. I assume that the upd induced expansion is only observed for the PG primorida (LB) and not the CA primordia (Mx)-at least this is what the figure looks like.<br /> It looks to me also like the vvl domain is expanding as well. This information should be clarified. How about svp driven upd-assuming there is a svp-Gal4 driver-does it cause an expansion of Ca but not PG.
      • e) The authors note a difference between CA and PG in the requirement for STAT binding sites in the enhancers. Is that related to the fact that svp is expressed in CA and sal is expressed in PG? Would driving svp expression using the sal-Gal4 driver maintain sna-rg expression
      • f) Do svp or sal have a role in initiating sna expression when upd is present or maintaining sna expression after upd disappears? Presumably there is already published data that would answer these questions.

      Significance

      This manuscript will be of interest to scientists seeking to understand fate specification-and how the same pathways/interactions can generate completely different organs-- in this case ring glands as opposed to trachea. The paper does however leave many questions unanswered. This is to be expected given that not all of the key players have been identified, and for those that have, the functions are not fully understood.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      In this study, the authors focus on understanding the regulation of development of corpora allata (CA) and prothoracic gland (PG) in Drosophila. Through a series of well designed experiments they convincingly show that interactions between Scr, Dfd, and JAK/STAT pathways induce localized expression of unpaired (upd) gene, which in turn controls snail (a key regulator of early gland development). Overall, this is an excellent study that extends authors' previous work on evolution and divergence of glands (in head) and respiratory organs (in trunk) from common, metamerically repeated primordia. Specifically, this work provides new information regarding CA and PG specification and as such will be of interest to a broad range of developmental biologists. Text is very well written, and figures are well organized and convey results in a clear way. I have several small comments (detailed below), but other than that this manuscript is ready for publication.

      Aleksandar Popadić

      Main suggestion:

      As the formation of the ring gland is an exclusively dipteran trait, it would be helpful to insert a paragraph in discussion explaining the relevance of new insights to other, more basal insects. In a sense, studies of a ring gland present a tail end of evolution, what do results obtain tell us about the regulation of the PG and CA development in other insects?

      Additional comments:

      1. Introduction, pg 3, a paragraph starting with "In comparison to the extensive knowledge we have of ..." - consider omitting or greatly shortening, this text breaks a flow as it is focused on tracheal development. I understand the authors' logic, but this information distracts from the main focus on CA and PG.
      2. Beginning of discussion, pg 11:
        • change 2nd sentence to: " Our results indicate that the HH and the Wnt pathways act indirectly to negatively regulate the spatial activation ..."
        • the following sentence, starting with "Engrailed activation off hh transcription ...." is way too long and hard to follow, consider breaking into two sentences.
      3. In Fig 4B, mx and lb segments should be labeled so this panel is consistent with labeling in 4A.
      4. In Fig 6, reduce a font size for labels on right-hand side (A1, A2, A1+A2 proximal, etc), so that they are visualy distinct from panel labels on left-hand side (A, B, C,..).

      Significance

      While this is a strictly Drosophila study, it does provide a significant new insight into development of corpora allot and prothoracic gland (which are critical organs for insect growth and development). As such this work will be of interest to a wide audience of biologists (please see my comments below for details).

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Reviewer #1 (Evidence, reproducibility and clarity (Required):

      *In this manuscript, Dr. Huiping Liu and colleagues investigate the role of CD81 in breast cancer metastasis, cancer stem cells, and extracellular vesicles (EVs). CD81 is a tetraspanin protein that has unclear roles in cancer. The authors discover that CD81 can form a complex with CD44 on cell surface and instigate cell clustering (important for CTC dissemination), self renewal and metastasis using multiple cell lines and xenografts. Multi-omic studies led them to CD81-regualted EVs, which they found to play critical roles in driving stemness and cell clustering. Furthermore, they found that CD81 is co-expressed with CD44 and affects patient outcomes. Overall, the novelty of the work is high, and the amount of data is impressive and of high quality. The experiments presented are well controlled and rigorous. However, there are some concerns as listed below: *

      We appreciate the positive comments on the high novelty and high quality of the work. The concerns below have been addressed with point-to-point answers.

      *Major: 1. The conclusion of EVs made by TICs to reprogram non-TICs into TICs is based on adding large amounts of EVs isolated from WT tumor cells. The amount may not be achievable in physiological conditions. Further, if the EVs released by TICs are sufficient to reprogram neighboring tumor cells, this event would be expected to self-propagate and all the tumor cells would become TICs. *

      We are thankful to the reviewer for the valuable thoughts and input. While the EVs used to educate and reprogram non-TICs may seem to be large amounts, the doses are justified as below and in the Method section to address pathophysiologically relevant questions using testable models.

      First, we add this section of “Exosome or sEV education” to the Method section.

      The EV education/reprogramming doses were determined based on literature reports and our own measurements. From published reports (reference PMID: 27599779), EVs could be detected in human/mouse plasma with high levels in the patients with cancer (>1x109/mL higher in cancer patients than healthy controls), as well as mouse plasma (>1x109/ml higher EV counts in the tumor bearing mice than non-tumor mice). In our studies, triple negative breast cancer (TNBC) cells do secret large amounts of EVs, with a yield of 0.2~1x109 EVs /mL supernatant (MDA-MB-231 or 4T1 cell culture) as measured on NTA as well as Apogee micro flow vesiclometer (MFV). Please note the small EV collecting efficiency is only ~10% by ultracentrifugation at 100,000xg for 70 min during the EV purification and we end up obtaining 1-2% EVs after two spins (one or two washes) (200 mL culture to yield 60-75 µg EV protein). Therefore, we utilized an amount of the EVs purified from 50x larger volume of culture supernatants for EV educating culture. For example, 10-15 µg purified EVs purified from ~50mL supernatant were used for 1 mL educating culture to make 2~5x108 EVs/mL for reprograming CD81KO cells. The dose is pathophysiologically relevant to the EV concentrations in the plasma and culture media.

      Second, we admit that the boundary and heterogeneity between TICs and non-TICs are more drastic in patient/mouse tumors in vivo than cultured tumor cells in vitro. Considering the complexity that the educational effects of cancer EVs on surrounding cells in vivo interplay with many other variables such as spatial restrictions, EV-dilution by interstitial fluids, EV release into blood, and mixed tumor-suppressing factors in the microenvironment, we have adopted the simplified EV education models in vitro to quantify the reprogramming effects of TIC EVs on non-TIC tumor cells (CD81KO cells). This model is mainly utilized to examine the effects of EV proteins CD44 and CD81 in measurable reprograming activities. Notably, we observed that CD44+CD81+ TICs tend to gradually dominate in culture whereas non-TIC populations gradually lose and thus a high percentage of cells may become tumorigenic TICs. Our data demonstrate that EV-education effects can contribute to the outcomes in a CD44- and CD81-dependent manner.

      • The conclusion that CD44 switched from membrane to intracellular locations adherent vs. suspension cultures is not well supported by the data presented in Fig 1E. It appears that the cells expressing membrane CD44 did not change much, but the cells population expressing intracellular CD44 expanded in the suspension culture. *

      We appreciate the comment and have clarified the observation and the conclusion accordingly in updated Figure 1C-D:

      “CD44 was observed mostly on the cytoplasmic membrane in WT MDA-MB-231 cells, both adherent and in suspension, but the intracellular CD44 accumulated specifically in the cells in suspension (P=0.03) (Figure 1C-D)”

      • Fig 6E-H experiments are a bit flawed. Metastasis degree is unlikely to be proportional to the primary tumor size, so it is not proper to normalize the metastatic burden to the primary tumor weight. These data can be removed without significantly weakening the major conclusions. *

      Thanks for the suggestion. We have removed the normalized panel of original Fig 6H and updated as below with tumor weight and lung metastasis signals.

      • Fig 3J appears to have different lanes pasted together. ¬¬Therefore, it is unclear whether the results could be compared, calling into the question of the statements involving the proteins studied including OCT4, pSTAT3 and FAK. *

      Sorry for the confusion. We must clarify that all the lanes are from the same blot which has been stripped and reblotted for multiple proteins. The full blots of previous Fig 3J (new supplementary Fig S8A) are included below for reference.

      • The authors state that EVs were comparable between WT and 44ko and 84ko cells partly based on the western blot presented in Fig 3E. While TSG101 appears similar, the other markers appear quite different. This needs explanation. *

      We conducted three independent immunoblots for EV proteins in Fig 3E and quantified the protein intensities in 3F which demonstrates that both CD44 and CD81 are significantly lost in the EVs of CD81KO cells and CD44KO cells, CD63 slightly reduced in the EVs of CD44KO cells, whereas no significant differences in EV markers TSG101 and LAMP2b comparing the KO EVs with the WT EVs (the levels normalized by b-actin loading control). These data suggest that CD81 and CD44 are required for each other’s localization or packaging to the EV.

      • The rationale for different cut-offs in Fig 4A-C is unclear. Auto cut-offs should not be used to maximize the detection of difference. The exact public dataset used should be stated. *

      Thanks for the insightful suggestions. In Supplementary Figure S8, we have added new Kaplan-Meier plots based on Liu_2014 cohort (TNBC) with cutoffs at lower 25%, median and upper 25% of CD81 protein levels, respectively, most of which show significant differences in overall survival (OS), relapse-free survival (RFS), and distant metastasis-free survival (DMSF) between CD81 high and low groups (CD81 as an unfavorable marker). These are consistent with and strengthening the data of the KM plots with auto cut offs in Fig 4A-C.

      • Minor The description regarding the screen leading to CD81 is confusing. Including a diagram may help. *

      Thanks again and we have added a schematic to Supplementary Figure. S1A with the experimental procedure details of sorting CD44 +/- cells and performing CD44 knockdown in PDX tumors for mass spectrometry comparisons. CD81 is one of 38 overlapped proteins differently shown in two comparisons.

      • Fig 1E, the phrase "ratio of cells expressing" is bit confusing. Did the authors mean % of cells expressing their indicated markers? *

      Yes, the y axis label is equivalent to % (1=100%) and now specified as “Proportion of CD44+ or CD88+ cells” in Figure 1E.

      • Cryo-EM shows detects impaired membrane integrity of EVs of 81ko but 44ko. Yet, Fig 2 shows that ko of either 44 or 81 disruptions the localization and therefore the function of the other. Explanation is needed for why 44ko did not affect 81 regulation of EVs. *

      We appreciate the thoughtful comments. After repeating and reanalyzing the experimental data from multiple cryo-EM and immunoblotting experiments, we updated Figure 2 which shows both CD81KO and CD44KO impaired the membrane integrity of EVs. Furthermore, the immunoblot validated that CD44 is deficient in the EVs of CD81KO cells, suggesting a possible role of CD81 and in recruiting CD44 to EV and strengthening the EV membrane integrity. In the meantime, CD81 localization on the membrane is dependent on the presence of membrane CD44 in Fig 1E.

      • Fig S8C is not a robust correlation analysis. A scatter plot should be presented. *

      A scatter plot is included (new Fig S9C) with R = 0.29 and p = 0.015.

      • There are a few typos. For example "cytoplastic membranes" should be cytoplasmic membranes. The following sentence is awkward: "Among the siCD81-upregulated genes, SEMA7a, a glycosylphosphatidylinositol membrane anchor promoting osteoclast and blood cell differentiation (58, 59), when further depleted in CD81KO cells, siSEMA7a partially rescued or restored mammosphere formation in these cells (Supplementary Figure S2D-F),.."* Typos were corrected. The sentence has been updated to:

      Among the siCD81-upregulated genes, SEMA7a, a glycosylphosphatidylinositol membrane anchor promoting osteoclast and blood cell differentiation (50, 51), was depleted in CD81KO cells by siSEMA7a which transfection partially rescued or restored mammosphere formation in these cells (Supplementary Figure S2D-F), suggesting a novel role of SEMA7a in inhibiting self-renewal of breast cancer cells.

      Reviewer #2

      The experiments are generally well performed and convincing, except that all mouse experiments seem to have been performed only once, with small groups of mice (between 4 and 6 with several sites of tumor injection per mouse). Reproducing at least once these experiments should be shown.

      We appreciate the positive comments as well as instructive suggestions. We would like to clarify that the mouse studies in Figures 5 and 6 were originally completed with two to three different models using both human and mouse TNBC cells. While one of the tumorigenic experiments in Figure 5 (where three different models were used) was done once due to the pandemic disruption and increased costs for NSG mice, Figure 6 data was originally generated by multiple in vivo experiments. Nevertheless, we have managed to repeat the in vivo tumorigenic experiments. We updated Figure 5 (see next page) with new results from 2-3 experiments for each panel/model with increased number of injections to 8-20 in 2-5 mice per group in each of three different tumor models. Furthermore, we also selectively repeated 4T1 experiments in Figure 6M with updated legend showing the experiment was consistently repeated.

      “These experiments were repeated at least twice to show consistent conclusions”.

      *Another unsatisfying aspect is the claim that CD44 and CD81 are specifically required for secretion of the subtype of EVs called exosomes, which forms in intracellular multivesicular endosomes. This claim is based on the (wrong) assertion that CD81 (together with CD9, CD63 and TSG101) is an exosome marker, based on ref 46,47 published in 2006 and 2011: the field has evolved a lot since then, and it is now becoming clear that CD63 (which normally accumulates in multivesicular endosomes) may be enriched in exosomes, but that neither CD9 nor CD81 are, since they mainly localize at the plasma membrane, and thus probably are released more prominently in small microvesicles (see Kowal, J., et al. (2016). Proc Natl Acad Sci U S A 113: E968. and Mathieu, M., et al. (2021). Nat Commun 12(1): 4389.). *

      Thanks for the comment on the evolving literature of CD81. To avoid confusion and follow the EV nomenclature guidelines, we used the more acceptable and general term “extracellular vesicles (EVs)” instead of “exosomes” in our manuscript. We have also cited the two new publications in PNAS 2016 and Nat Commu 2021 (ref 38 and 39) with modified statement on CD81 as below.

      “We performed mass spectrometry proteomic profiling of TNBC patient-derived xenografts (PDX) tumor cells that cluster and discovered that one of the altered proteins upon CD44 depletion was CD81, a tetraspanin protein enriched in extracellular vesicles (EVs) (38-39).”

      *In figure 3, the authors show empty internal compartments in cells with deleted CD44 or CD81, which (if these compartments are altered MVBs) should then lead to fewer exosomes recovered extracellularly. However, the authors observe instead more particles recovered from these cells. When analyzing the composition of these EVs, the authors show maybe a decrease in CD63 in EVs from both CD44 and CD81 ko cells, but contradictory effects on the presence of Lamp2 (which is a more convincing marker of late endosome/lysosome-derived exosomes): increased in CD44 but decreased in CD81 ko. These results, however, are not really interpretable, since the authors show only a single Western Blot, thus no evidence of reliable changes in protein composition. In any case, I would suggest that the authors do not, in the current state of the article, try to claim any specific subcellular origin of the EVs affected by CD44 and CD81. *

      We appreciate the comments and would like to clarify our observations. When the CD44/CD81 KO cells show increased empty internal compartments, it is a sign for loss of cellular mass. Therefore, it might be surprising but also reasonable to link such phenotype with an increased quantity of draining EVs in low quality (disrupted membrane) from CD44KO and CD81KO cells that show active endocytosis and/or exocytosis pathways.

      To better quantify the proteins of the EVs derived from WT, CD44KO and CD81KO cells, we repeated the western blots three times and in new Fig 3F we reported the levels of CD44, CD81, and other EV proteins (CD63, TSP101, and LAMP2b). Compared to WT EVs, CD44 and CD81 are relatively compromised in the EVs of CD81KO and CD44KO, respectively. CD63 slightly decreases in CD44KO EVs whereas LAMP2b shows no significant changes in both KO cells. We modified the text below reporting the EV phenotypes without specifying subcellular origin of EVs.

      After purified from the culture supernatants of CD44KO and CD81KO cells via 100,000 xg ultracentrifugation (Supplementary Fig S6A), the sizes of small EVs (ev44KO and ev81KO) were relatively comparable to the WT control, as characterized by nanoparticle tracking analysis (NTA) and immunoblotting with EV markers (Figure 3E-F, Supplementary Figure S6B). However, when examined by cryo-EM, ev81KO displayed impaired membrane integrity (Figure 3E-F), indicating an essential role for CD81 in modulating EV biogenesis and packaging of membrane proteins.

      *In addition, the EVs are only quantified by the vesicle flow cytometry established by the authors, but then, in functional assay, and in Western blots, EVs are quantified in terms of proteins. It would be important to show if CD44 and CD81 ko also decrease the amount of proteins recovered in the EV preparations, and the number of particles quantified by NTA, as they apparently decrease the number of events detected by vesicle flow cytometry, or not, and if not, why did the authors chose to show only the vesicle flow cytometry results (this is not a very commonly used technic in the field). *

      Thanks for the suggestion. We have quantified the EVs by vesicle flow cytometry (MFV) and NTA which show consistent EV counts of WT, CD44KO, and CD81 KO (see table below). We utilize EV protein to normalize the EV education as all the samples had about 6x108 EVs/ µg protein.

      We have also calculated the EV production data (counts/cell) as measured by NTA in Supplementary Fig SD which is relatively consistent with the MFV analysis in Fig 3C, demonstrating that CD44KO and CD81KO cells release a higher number of EVs than WT cells.

      We have also calculated the EV production data (counts/cell) as measured by NTA in Supplementary Fig SD which is relatively consistent with the MFV analysis in Fig 3C, demonstrating that CD44KO and CD81KO cells release a higher number of EVs than WT cells.

      *Finally, a somehow frustrating aspect of the paper is that the link between the observed effect of CD44 or CD81 ko on EV release and their in vitro functions on mammosphere formation (fig3), and the effect on in vivo tumor growth and metastasis (fig 5-6) end up as two separate observations (the authors rightly do not claim that impaired exosome release in vivo is responsible for the impaired metastasis). The observation also of clustered CD81 and CD44+ circulating tumor cells in patients (fig4) is also somehow a separate observation. Thus there are several stories put together in this article. *

      We appreciate the comment and apologize for disconnected data presentation. We have reorganized the paper to highlight machine learning-assisted discoveries of CD81 functions and molecular network in partnership with CD44 in promoting cancer stemness which is connected to endocytosis-related EV phenotypes. We admit that in addition to massive manpower and financial support, there are technical limitations in the EV-mediated functional studies in animal models. As proof-of-concept, we therefore utilized the simulated models in vitro to test the hypothesis of EV-CD44 and EV-CD81 in promoting cancer stemness of recipient cells. Our follow-up studies on EV-educated animals are ongoing but beyond the scope of the current manuscript. We are also open to the suggestion leaving the EV part out if that’s recommended by all editors and all reviewers.

      Please see updated title “Machine learning-assisted elucidation of CD81-CD44 interactions in promoting cancer stemness and extracellular vesicle integrity” and the abstract.

      Tumor-initiating cells with reprogramming plasticity or stem-progenitor cell properties (stemness) are thought to be essential for cancer development and metastatic regeneration in many cancers; however, elucidation of the underlying molecular network and pathways remains demanding. Combining machine learning and experimental investigation, here we report CD81, a tetraspanin transmembrane protein known to be enriched in extracellular vesicles (EVs), as a newly identified driver of breast cancer stemness and metastasis. Using protein structure modeling and interface prediction-guided mutagenesis, we demonstrate that membrane CD81 interacts with CD44 through their extracellular regions in promoting tumor cell cluster formation and lung metastasis of triple negative breast cancer (TNBC). In-depth global and phosphoproteomic analyses of tumor cells deficient with CD81 or CD44 unveils endocytosis-related pathway alterations, leading to further identification of a quality-keeping role of CD44 and CD81 in EV secretion as well as in EV-associated stemness-promoting function. CD81 is co-expressed along with CD44 in human circulating tumor cells (CTCs) and enriched in clustered CTCs that promote cancer stemness and metastasis, supporting the clinical significance of CD81 in association with patient outcomes. Our study highlights machine learning as a powerful tool in facilitating the molecular understanding of new molecular targets in regulating stemness and metastasis of TNBC.

      Reviewer #2 (Significance (Required)):

      These results are interesting as showing a novel molecule whose high expression may promote tumor progressions (CD81, as a cluster with CD44). The novelty lies in the functional interaction between CD44 and CD81 leading to the pro-metastatic effect described. Interaction between CD44 and CD81 had been previously observed in a generic proteomic study of EVs (Perez-Hernandez, D., et al. (2013). J Biol Chem 288: 11649), but not more explored in terms of consequent functions. A pro-metastatic effect of CD81 expression in tumors, especially TNBC, has also been recently demonstrated (Vences-Catalan, F., et al. (2021). Proc Natl Acad Sci U S A 118.). These two articles should be quoted in the current paper. My field of expertise is extracellular vesicles, and their roles in cancer progression. I can only judge superficially the modeling part of the article,

      Thank you for highlighting the novelty of CD81 interaction with CD44 as a cluster in promoting tumor progression. We are grateful to the reviewer for providing the CD81 literature information which has been included and cited in the discussion (ref 65, 68), serving as a cross-validation for part of our work.

      A study by Perez-Hernandez et al. also observed CD44 among the EV protein interactome network pulled down by CD81 peptides without exploring their relevance to EV functions (65)… A potential anti-CD81 therapeutic strategy was identified that may block the pro-metastatic effect of CD81 in animal studies (68).

      Reviewer #3

      *Major Comments:

      The authors suggest that CD44 and CD81 interact and colocalize inside breast cancer cells. However, staining data presented shows very modest co-localization and immunoprecipitation experiments only employed beads as a negative control. To reinforce their conclusions, the authors should quantify co-localization using standard methods (Mander's or Pearson's coefficients). In addition, the authors should perform negative control immunoprecipitation experiments with antibodies against a target protein not expected to interact with CD81 to show that CD44 binding is specific. *

      We are grateful for the instructive suggestions. To reinforce our conclusion about the membrane CD44-CD81 interactions, we repeated the Co-IP using anti-CD44 along with two negative controls (new Fig 1F), one of which is the IgG-bead control and the other is CD44KO cell lysate negative control). CD81 was only detected in the protein complex of the WT lysate (TN1 PDX or MDA-MB-231) pulled down by anti-CD44 (new Fig 1F). We also quantified the colocalization using Pearson’s coefficients with average r=0.57 from three different experiments which is now included in Supplementary Fig S2A.

      From TEM and quantification in figures 3A, B the authors conclude that there is increased vacuolization with cells. They suggest that purple arrows point to multivesicular endosomes and yellow arrows vacuoles. In fact, the electron dense organelles indicated by purple arrows look more like lysosomes, whereas the yellow arrows appear more like early endosomes/endocytic vesicles. The authors should reassess their vesicle classification system and also provide a breakdown of the proportions of these structures within the graph.

      Thanks for the comments. We agree with the reviewer that yellow arrows in Fig 3A could be vacuoles of early endosomes. And we added lysosome images and quantification in Supplementary Fig S6C, showing significant differences among three types of cells (WT, CD44KO, and CD81KO). That may help explain the phenotypes of altered EV release in CD44KO and CD81KO cells.

      *Given that CD81+/CD44+ EVs are proposed to drive the aggregation and self-renewal of tumor initiating cells, it is somewhat counterintuitive that CD44 and CD81 KO cells show increased levels of EV secretion relative to WT controls. Additionally, it is perplexing that CD44 and CD81 secretion in EVs is unaffected (or my even increase) in knockout cells despite the fact these membrane proteins are supposed to interact and are mutually required for proper expression/localization. How do the authors reconcile these potentially contradictory observations? *

      We appreciate the diligence and apologize for the lack of quantification and normalized loading in the original western blotting. We have repeated the EV western blots for protein density quantifications three times in new Fig 3E-F (see next page) that demonstrate a dramatic loss of CD44 in CD81 KO-EVs and a partial loss of CD81 in CD44KO EVs.

      *The EV rescue experiments in figure 3H, I show recovery of mammosphere formation in CD81 KO cells treated with EVs from WT cells, suggesting that WT EVs are sufficient to rescue self-renewal. However, it's unclear from their studies whether exosome secretion of CD81/CD44 is actually necessary for aggregation and self-renewal phenotypes. Since CD81 has also been shown to be important for the trafficking of membrane proteins, the loss of self self renewal could relate to cell autonomous alterations in vesicular trafficking in CD81 KO cells. To reconcile between these possibilities, the authors should evaluate how depletion of factors necessary for CD81 secretion (e.g. Rab27a (PMID: 26305877; supplemental data), ESCRT components (PMID: 32049272), or others?) affects mammosphere formation. In either case the results would be extremely interesting and help to determine whether self-renewal is controlled by CD81 via cell autonomous or non-cell autonomous mechanisms. *

      We are thankful for the extremely intriguing question about cell autonomous and non-cell autonomous roles of CD81 in controlling self-renewal. To address the question, we did transfect siRNAs to knock down Rab27a levels in TNBC cells and found a decreased efficiency in mammosphere formation of these cells in comparison to scrambled (Scr) control cells (Supplementary Fig S8D) (see next page), suggesting a possible non-cell autonomous mechanism of CD81 promoted self-renewal.

      Furthermore, when the expression of the EV secretion-regulating gene Rab27a was downregulated in MDA-MB-231 cells by siRNA mediated transfection, the mammosphere formation was significantly reduced (The authors observe that CD81 depletion profoundly impairs primary tumor development and metastasis in pre-clinical models. In fact, the defect in metastasis appears to be secondary to the robust impairment in tumorigenesis. What is the fate of CD81 KO cells in mammosphere assays and transplant models? Do CD81 KO cells have reduced viability and/or proliferation in vitro and in vivo? Can the defects in mammosphere formation and tumorigenesis in CD81 KO cells be rescued via re-introduction of wtCD81? What about mutant CD81 that is deficient for CD44 binding? These studies will help to delineate the role of CD81 in primary tumor development and whether interaction with CD44 is require for this process.

      Thanks for the comments and questions. We included the data on slightly slower cell proliferation of human CD81KO and mouse Cd81KO cells (no obvious cell death) in Supplementary Fig S1E-F (see next page). We have also reintroduced wtCD81 in two sets of distinct vectors into CD81KO cells and observed wtCD81 in both HA and GFP vectors rescued the defects of CD81KO cells while mutant CD81 deficient for CD44 binding failed to do so, demonstrating the role of CD81-CD44 interaction in promoting self-renewal.

      *In the authors model, they show CD81 interactions with CD44 facilitating EV secretion which enhances self-renewal and CD44 alone facilitates tumor cell clustering. However, they show that CD81 can also binding CD44. Does the CD81-CD44 interaction also serve to facilitate clustering between tumor cells? *

      Yes, we conducted the tumor cell clustering experiment and added the new Supplementary Fig 12D which demonstrates that CD81 WT rescues the clustering of CD81KO cells and the CD81 truncated mutant does not.

      *Minor Points:

      In a number of figures (e.g. Fig, 1C; Fig 3E, H) the authors show representative immunoblots but there are no indications in the legends of how many times the experiment was performed. Presumably at least 3 independent experiments were performed. The authors should also include quantification of these data to support that these effects are reproducible and significant. All data points should be plotted within graphs so that the reader can note the distribution of the data. *

      Thanks for the suggestions. We have included all raw data points in all quantified bar graphs and quantified the western blots from at least three independent experiments. Representative is shown below (next page).

      *While the manuscript was generally well written, there are a couple of grammatical mistakes that can be fixed. *

      We appreciate the positive comment and have corrected the grammatical mistakes by native /professional writers.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      Summary:

      The manuscript of Ramos et al describes studies focused on understanding the relationship between membrane proteins CD44 and CD81 in the self-renewal of tumor initiating cells and breast cancer metastasis. They demonstrate CD81 and CD44 are protein binding partners, and that loss of either component affects the clustering and self-renewal of tumor initiating cells. Proteomics from CD44 and CD81 deficient cells revealed alterations in levels and phosphorylation status of proteins associated with endocytosis and lysosomes, suggesting that impaired tumor cell self-renewal was related to perturbations in the endolysosome pathway. Digging deeper into this connection, the authors found that loss of CD44 and CD81 resulted in increased vacuolization inside cells and greater release of EVs. Moreover, EVs from wildtype, but not CD44 or CD81 deficient cells, modestly rescued the self-renewal defects observed in cells lacking CD81. Importantly, Ramos et al find that CD81 is enriched within aggregated CTCs from TNBC patients with metastatic disease and its levels are negatively correlated with patient survival. Consistent with an important role for CD81 in TNBC, the authors find that depletion of CD81 severely impairs tumorigenesis and metastasis in pre-clinical models using PDX, 4T1 and MDA-MB-231 cells. Altogether, these observations lead the authors to propose that CD81 partners with CD44 to promote exosome biogenesis, tumor cluster formation, and lung metastasis in triple negative breast cancer.

      Major Comments:

      The authors suggest that CD44 and CD81 interact and colocalize inside breast cancer cells. However, staining data presented shows very modest co-localization and immunoprecipitation experiments only employed beads as a negative control. To reinforce their conclusions, the authors should quantify co-localization using standard methods (Mander's or Pearson's coefficients). In addition, the authors should perform negative control immunoprecipitation experiments with antibodies against a target protein not expected to interact with CD81 to show that CD44 binding is specific.

      From TEM and quantification in figures 3A,B the authors conclude that there is increased vacuolization with cells. They suggest that purple arrows point to multivesicular endosomes and yellow arrows vacuoles. In fact, the electron dense organelles indicated by purple arrows look more like lysosomes, whereas the yellow arrows appear more like early endosomes/endocytic vesicles. The authors should reassess their vesicle classification system and also provide a breakdown of the proportions of these structures within the graph.

      Given that CD81+/CD44+ EVs are proposed to drive the aggregation and self-renewal of tumor initiating cells, it is somewhat counterintuitive that CD44 and CD81 KO cells show increased levels of EV secretion relative to WT controls. Additionally, it is perplexing that CD44 and CD81 secretion in EVs is unaffected (or my even increase) in knockout cells despite the fact these membrane proteins are supposed to interact and are mutually required for proper expression/localization. How do the authors reconcile these potentially contradictory observations?

      The EV rescue experiments in figure 3H, I show recovery of mammosphere formation in CD81 KO cells treated with EVs from WT cells, suggesting that WT EVs are sufficient to rescue self-renewal. However, it's unclear from their studies whether exosome secretion of CD81/CD44 is actually necessary for aggregation and self-renewal phenotypes. Since CD81 has also been shown to be important for the trafficking of membrane proteins, the loss of self self renewal could relate to cell autonomous alterations in vesicular trafficking in CD81 KO cells. To reconcile between these possibilities, the authors should evaluate how depletion of factors necessary for CD81 secretion (e.g. Rab27a (PMID: 26305877; supplemental data), ESCRT components (PMID: 32049272), or others?) affects mammosphere formation. In either case the results would be extremely interesting and help to determine whether self-renewal is controlled by CD81 via cell autonomous or non-cell autonomous mechanisms.

      The authors observe that CD81 depletion profoundly impairs primary tumor development and metastasis in pre-clinical models. In fact, the defect in metastasis appears to be secondary to the robust impairment in tumorigenesis. What is the fate of CD81 KO cells in mammosphere assays and transplant models? Do CD81 KO cells have reduced viability and/or proliferation in vitro and in vivo? Can the defects in mammosphere formation and tumorigenesis in CD81 KO cells be rescued via re-introduction of wtCD81? What about mutant CD81 that is deficient for CD44 binding? These studies will help to delineate the role of CD81 in primary tumor development and whether interaction with CD44 is require for this process.

      In the authors model, they show CD81 interactions with CD44 facilitating EV secretion which enhances self-renewal and CD44 alone facilitates tumor cell clustering. However, they show that CD81 can also binding CD44. Does the CD81-CD44 interaction also serve to facilitate clustering between tumor cells?

      Minor Points:

      In a number of figures (e.g. Fig, 1C; Fig 3E, H) the authors show representative immunoblots but there are no indications in the legends of how many times the experiment was performed. Presumably at least 3 independent experiments were performed. The authors should also include quantification of these data to support that these effects are reproducible and significant.

      All data points should be plotted within graphs so that the reader can note the distribution of the data.

      While the manuscript was generally well written, there are a couple of grammatical mistakes that can be fixed.

      Significance

      Given that the complex mechanisms contributing to self-renewal of tumor initiating cells and disease progression in TNBC are poorly understood, this work is both clinically important and addresses the biology from a unique perspective. In addition, this reviewer finds the study to be reasonably logical and well controlled. Nevertheless, there are a number of areas where additional experiments are necessary in order to strengthen the conclusions of the manuscript and provide support for the authors model.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      The article by Liu et al describes a novel partner interaction between two transmembrane proteins, CD44 and CD81, which associate in tumor cells and in extracellular vesicles released by these cells. The authors have previously shown, by KD or KO strategies, that CD44 expression by tumors participates in their migration and metastatic properties. Here the authors show that CD81 deletion in tumors similarly decreases both tumor local growth and formation of metastasis. Since CD81 has been described on small EVs, the authors also evaluate the effect of CD44 or CD81 (or both) KO in the capacity of tumors to release small EVs, and in the ability of these EVs to reconstitute migration of tumor cells depleted of CD81 in vitro. Finally, the authors show a negative correlation between CD81 expression and clinical outcome in breast cancer patients, and observe clusters of circulating tumor cells expressing CD81 and CD44 in these patients.

      The experiments are generally well performed and convincing, except that all mouse experiments seem to have been performed only once, with small groups of mice (between 4 and 6 with several sites of tumor injection per mouse). Reproducing at least once these experiments should be shown.

      Another unsatisfying aspect is the claim that CD44 and CD81 are specifically required for secretion of the subtype of EVs called exosomes, which forms in intracellular multivesicular endosomes. This claim is based on the (wrong) assertion that CD81 (together with CD9, CD63 and TSG101) is an exosome marker, based on ref 46,47 published in 2006 and 2011: the field has evolved a lot since then, and it is now becoming clear that CD63 (which normally accumulates in multivesicular endosomes) may be enriched in exosomes, but that neither CD9 nor CD81 are, since they mainly localize at the plasma membrane, and thus probably are released more prominently in small microvesicles (see Kowal, J., et al. (2016). Proc Natl Acad Sci U S A 113: E968. and Mathieu, M., et al. (2021). Nat Commun 12(1): 4389.). In figure 3, the authors show empty internal compartments in cells with deleted CD44 or CD81, which (if these compartments are altered MVBs) should then lead to fewer exosomes recovered extracellularly. However, the authors observe instead more particles recovered from these cells. When analyzing the composition of these EVs, the authors show maybe a decrease in CD63 in EVs from both CD44 and CD81 ko cells, but contradictory effects on the presence of Lamp2 (which is a more convincing marker of late endosome/lysosome-derived exosomes): increased in CD44 but decreased in CD81 ko. These results, however, are not really interpretable, since the authors show only a single Western Blot, thus no evidence of reliable changes in protein composition. In any case, I would suggest that the authors do not, in the current state of the article, try to claim any specific subcellular origin of the EVs affected by CD44 and CD81. In addition, the EVs are only quantified by the vesicle flow cytometry established by the authors, but then, in functional assay, and in Western blots, EVs are quantified in terms of proteins. It would be important to show if CD44 and CD81 ko also decrease the amount of proteins recovered in the EV preparations, and the number of particles quantified by NTA, as they apparently decrease the number of events detected by vesicle flow cytometry, or not, and if not, why did the authors chose to show only the vesicle flow cytometry results (this is not a very commonly used technic in the field). Another important point to change is the presentation of results as bar graphs: all such graphs must be replaced by graphs showing the position of individual replicates, to illustrate the reproducibility of the presented results (eg fig1B, S1C, 3C, 3G-H, 5C, 5E, 5G, 6B, 6H, 6K, etc). (as explained in Weissgerber et al, Plos Biol 2015 13(4): e1002128).

      Finally, a somehow frustrating aspect of the paper is that the link between the observed effect of CD44 or CD81 ko on EV release and their in vitro functions on mammosphere formation (fig3), and the effect on in vivo tumor growth and metastasis (fig 5-6) end up as two separate observations (the authors rightly do not claim that impaired exosome release in vivo is responsible for the impaired metastasis). The observation also of clustered CD81 and CD44+ circulating tumor cells in patients (fig4) is also somehow a separate observation. Thus there are several stories put together in this article.

      Significance

      These results are interesting as showing a novel molecule whose high expression may promote tumor progressions (CD81, as a cluster with CD44). The novelty lies in the functional interaction between CD44 and CD81 leading to the pro-metastatic effect described. Interaction between CD44 and CD81 had been previously observed in a generic proteomic study of EVs (Perez-Hernandez, D., et al. (2013). J Biol Chem 288: 11649), but not more explored in terms of consequent functions. A pro-metastatic effect of CD81 expression in tumors, especially TNBC, has also been recently demonstrated (Vences-Catalan, F., et al. (2021). Proc Natl Acad Sci U S A 118.). These two articles should be quoted in the current paper.

      My field of expertise is extracellular vesicles, and their roles in cancer progression. I can only judge superficially the modeling part of the article,

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      In this manuscript, Dr. Huiping Liu and colleagues investigate the role of CD81 in breast cancer metastasis, cancer stem cells, and extracellular vesicles (EVs). CD81 is a tetraspanin protein that has unclear roles in cancer. The authors discover that CD81 can form a complex with CD44 on cell surface and instigate cell clustering (important for CTC dissemination), self renewal and metastasis using multiple cell lines and xenografts. Multi-omic studies led them to CD81-regualted EVs, which they found to play critical roles in driving stemness and cell clustering. Furthermore, they found that CD81 is co-expressed with CD44 and affects patient outcomes. Overall, the novelty of the work is high, and the amount of data is impressive and of high quality. The experiments presented are well controlled and rigorous. However, there are some concerns as listed below:

      Major:

      1. The conclusion of EVs made by TICs to reprogram non-TICs into TICs is based on adding large amounts of EVs isolated from WT tumor cells. The amount may not be achievable in physiological conditions. Further, if the EVs released by TICs are sufficient to reprogram neighboring tumor cells, this event would be expected to self-propagate and all the tumor cells would become TICs.
      2. The conclusion that CD44 switched from membrane to intracellular locations adherent vs. suspension cultures is not well supported by the data presented in Fig 1E. It appears that the cells expressing membrane CD44 did not change much, but the cells population expressing intracellular CD44 expanded in the suspension culture.
      3. Fig 6E-H experiments are a bit flawed. Metastasis degree is unlikely to be proportional to the primary tumor size, so it is not proper to normalize the metastatic burden to the primary tumor weight. These data can be removed without significantly weakening the major conclusions.
      4. Fig 3J appears to have different lanes pasted together. ¬¬Therefore, it is unclear whether the results could be compared, calling into the question of the statements involving the proteins studied including OCT4, pSTAT3 and FAK.
      5. The authors state that EVs were comparable between WT and 44ko and 84ko cells partly based on the western blot presented in Fig 3E. While TSG101 appears similar, the other markers appear quite different. This needs explanation.
      6. The rationale for different cut-offs in Fig 4A-C is unclear. Auto cut-offs should not be used to maximize the detection of difference. The exact public dataset used should be stated.

      Minor

      1. The description regarding the screen leading to CD81 is confusing. Including a diagram may help.
      2. Fig 1E, the phrase "ratio of cells expressing" is bit confusing. Did the authors mean % of cells expressing their indicated markers?
      3. Cryo-EM shows detects impaired membrane integrity of EVs of 81ko but 44ko. Yet, Fig 2 shows that ko of either 44 or 81 disruptions the localization and therefore the function of the other. Explanation is needed for why 44ko did not affect 81 regulation of EVs.
      4. Fig S8C is not a robust correlation analysis. A scatter plot should be presented.
      5. There are a few typos. For example "cytoplastic membranes" should be cytoplasmic membranes. The following sentence is awkward: "Among the siCD81-upregulated genes, SEMA7a, a glycosylphosphatidylinositol membrane anchor promoting osteoclast and blood cell differentiation (58, 59), when further depleted in CD81KO cells, siSEMA7a partially rescued or restored mammosphere formation in these cells (Supplementary Figure S2D-F),.."

      Significance

      This work has high significance in CTC formation and metastasis. While CD44 has been reported by this group previously in 2019 Cancer Discovery to promote clustering formation and collective dissemination, this work takes a step further to identify a new interaction partner of CD81 on cell membrane and implicate the regulation of EVs as mechanism to promote stemness. This manuscript has broad interest in the Cancer Research community. This reviewer expertise is breast cancer and rodent models of breast cancer.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      Summary: Klein and colleagues generate an ES cell model system with inducible FACT depletion to understand how loss of FACT affects gene regulation in ES cells. They find that FACT is critical for ES cell maintenance through multiple mechanisms including direct regulation of key pluripotency transcription factors (Sox2, Oct4, and Nanog), maintaining open chromatin at enhancers, and regulated enhancer RNA transcription. The paper is well-written, the experiments are generally well-controlled and appropriately interpreted and placed within the context of the field.

      We appreciate the Reviewer’s support of this manuscript.

      Major comments: 1. In general, the ChIP-seq and CUT&RUN data are not that similar. Although correlation seems reasonable (S2A), looking at the heatmaps in S2B/C these seem pretty different. It's not very clear if this is a case where CUT&RUN has higher specificity (and signal-to-noise, which is very clear from example tracks) or if these two methods are picking up biologically different sites. Could the authors include some overlap analysis of peaks and comment on these discrepancies. Looking at the example tracks in Figure 2B, it seems likely that prior SPT16 and SSRP1 ChIP-seq were relatively high-noise.

      We have identified overlapping peaks between the two techniques, and while CUT&RUN identified substantially more peaks overall, percentage of peaks shared between datasets were relatively consistent (1-6% of total) between the individual ChIP-seq datasets and the CUT&RUN dataset (Response Figure 1). We note that the biological classes identified through all datasets were remarkably consistent (Fig. 2D), and therefore attribute the discrepancies to the greater number of reproducible peaks called from CUT&RUN data. As discussed in the paper, peak calling algorithms designed for the specific data types were used, and therefore peak calling could also contribute to differences.

      Response Figure 1. ChIP-seq and CUT&RUN peak overlap. Pie chart depicting the unique and overlapping peaks called from V5-SPT16 CUT&RUN data and FACT ChIP-seq data. These data are included in the revised manuscript (as a new Figure panel 2E). Peaks must have been identified in at least two technical or biological replicates.

      Are motifs described in Figure 2E CUT&RUN only, and do prior ChIP-seq experiments also identify these motifs?

      The motifs shown in Figure 2E (now 2F) are indeed CUT&RUN peaks only. We were unable to confidently assign enriched motifs to the ChIP-seq datasets (the most enriched motifs were approximately p = 10-18). By analyzing all SPT16 ChIP-seq peaks, rather than only intersected SPT16 ChIP-seq peaks, we were able to identify motifs recognized by two of the top three CUT&RUN motif hits (SOX2 and OCT4/SOX2/TCF/NANOG); however, enrichment was quite poor (p = 10-3). By limiting the analysis to intergenic regions, we were able to identify strong enrichment for motifs recognized by CTCF and BORIS (p = 10-58 and 10-51, respectively). As validation, we also called motifs from peak files published as supplementary material to the original Tessarz lab manuscript but were still unable to confidently call motifs (all p > 10-7 for SPT16 peaks, p > 10-15 for SSRP1 peaks). Related to major comment 1, we suspect that the weak motif enrichment is due to high background in ChIP-seq datasets compared to CUT&RUN datasets.

      The authors state that FACT depletion affects eRNA transcription and measured this using TT-seq. The analysis in Figure 3B seems to be all the different types of sites looked at together (genes, PROMPTs, etc). Is there evidence that eRNAs specifically are regulated by FACT loss.

      We apologize for the confusion and have clarified that Figure 3B (now 3A) is referring to mRNAs only in the text and figure. Our analysis of eRNA regulation by FACT is predominantly contained within Fig. 4B (TT-seq from DHSs, but no histone mark overlap assessment), Supp Fig. S4 (as in Fig 4B, but at DHSs overlapping H3K27ac or H3K4me1), Fig. 5E (FACT localization to putative enhancers, defined as in S4), and Fig. 6D (ATAC-seq demonstrating loss of accessibility at putative enhancers upon FACT depletion). Based on these results, we believe there are many eRNAs specifically misregulated by FACT loss and that potential direct targets (based on change in depletion and containing FACT binding) are in Fig 5E.

      Could these be compared to DHS sites that lack FACT binding to support a direct role for FACT at these sites?

      We appreciate the suggestion and have performed this analysis (see Response Figure 2). Relatedly, we analyzed putative silencers, defined as DHSs marked by H3K27me3, for FACT binding and expression changes (measured by TT-seq) following FACT depletion (Supp Fig. S7). As expected, FACT does not bind these putative silencer DHSs and transcription does not markedly increase or decrease from these regions after FACT depletion. Complicating the matter, FACT binds at many DHSs, even those that did not to meet our stringent peak-calling criteria (see Response Figure 2, middle cluster).

      __Response Figure 2. Overlap between FACT binding sites and gene-distal DHSs. __Individual clusters are sorted by V5-SPT16 binding. Clusters were assigned based on direct overlap between called V5-SPT16 peaks and assigned gene-distal DHSs. Overall, 17.6% of DHSs overlapped a FACT peak identified in at least one CUT&RUN replicate (8.5% of DHSs overlapped a peak present in multiple replicates).

      One mechanism proposed for how FACT regulates enhancers is that it is required for maintaining a nucleosome free area, and when FACT is depleted nucleosomes invade the site (Figure 7). It wasn't clear if they compared distal DHS sites were FACT normal bound to those without FACT binding in the MNase experiments, which could help support the direct role or specificity of FACT in regulating those enhancers (or a subset of them).

      We have subset the V5-SPT16 CUT&RUN peaks and distal DHSs into groups and have identified increased nucleosome occupancy after depletion at both FACT-bound and FACT-unbound DHSs suggesting both direct and indirect regulation (Fig. 6A, D). There is disruption to nucleosome arrays at non-FACT-bound DHSs (although more modest relative to the FACT bound locations), and therefore we speculate that a nucleosome remodeler is involved downstream of FACT (possibly CHD1, per recent work out of Patrick Cramer and François Robert’s labs, among others).

      1. Data quality for nucleosome occupancy was a little strange (Figure 7F), where the two clones had very different MNase patterns at TSS sites. Could the authors comment on why there is such a strong difference between clones here.

      We agree that the trends identified by visualizing differential MNase-seq signal near TSSs do not fully replicate; however, in examining the nondifferential MNase-seq heatmaps, we see a more expected distribution (see new Figure 7A). Per our newly-added Supp Fig. S9B, all MNase-seq replicates had a pairwise Pearson correlation value of at least 0.73 (SPT16-depleted clone 1/rep 1 vs untagged rep 3), and the vast majority of samples had pairwise correlations of above 0.85, suggesting that these discrepancies are not due to strong differences in sequencing depth or MNase-protected regions. We therefore suspect that the clonal distinctions are a result of different background occupancy of nucleosomes near the TSS, resulting in an array with increased occupancy in one clone and more generalized increased occupancy in the other clone. We also added the MNase-seq data over TSSs in a non-differential form in Fig 7A, and believe the difference between the clones is due to the differential analysis, and have commented accordingly in the revised manuscript.

      More details on some of the analysis steps would be really helpful in evaluating the experiments. Specifically, was any normalization done other than depth normalization? I ask this because the baseline levels for many samples in metaplots look quite different. For example, see Figure 7B where either clone 1 has a globally elevated (at least out 2kb) ratio of nucleosome in the IAA samples relative to the EtOH, or there is some technical difference in MNase. One suggestion is to look at methods in the CSAW R package to allow TMM based normalization strategies which may help.

      We appreciate the suggestion – we have expanded our explanation of normalization methodology in the paper. We initially used quartile and RPGC normalizations to attempt to mitigate technical differences in MNase-seq data. Size distribution plots did not suggest differences in MNase digestion between samples, and neither quartile/RPGC nor TMM-based normalization fully resolved this issue. Because our ATAC-seq datasets agree with the general trends identified by MNase-seq (which are consistent, despite technical differences between clones), we do not believe that the differences constitute true biological difference, but rather experimental noise.

      1. I appreciated the speculation section, and the possible relationship between FACT and paused RNAPII is interesting. While further experiments may be outside the scope of this work and I am not suggesting they do them, I am wondering if others have information on locations of paused RNAPII in ESC that would allow them to test if genes with paused RNAPII have a special requirement for FACT that they could use their current data to assess.

      We agree that experiments to test the relationship between paused RNAPII and FACT are an intriguing next step, and plan to dissect those in the near future.

      Minor comments: 1. When describing the peaks found in the text related to Figure 2 they refer to 'nonunique' peaks. Does this mean the intersection of the independent peak calls? Could they clarify this.

      We apologize for the confusion and have clarified in the text that nonunique peaks does indeed refer to the intersection of independent peak calls (now specified on manuscript page 8, line 15).

      In the text they refer to H3K56ac data in S2D and I don't see that panel. The color scheme for the 1D heatmaps (Figure 5A) is tough to appreciate the differences. I'd suggest something more linear rather than this spectral one might be easier to see.

      We apologize for the confusion and removed the remaining H3K56ac-related data and references in the text. We appreciate the suggestion regarding the 1D heatmap color scheme and have adjusted the colors to a linear (white à red) scheme.

      For the 2D heatmaps of binding, could they include the number of elements they are looking at for each group?

      We appreciate the suggestion and have included numbers of elements visualized wherever applicable in the figure panels and legends.

      1. Also for 2D heatmaps, I think the scale is Log2 (IAA/EtoH), but could they confirm that and include it in the figure?

      We apologize for the confusion; the only heatmaps displaying log2(IAA:EtOH) are those in Fig. 6; for those panels, we have clarified the scale in the figure and legend.

      Reviewer #1 (Significance (Required)):

      • The use of degrader based approaches to depleting a protein allows refined kinetic and temporal assays which I think are important. Several papers showed a rapid invasion of nucleosomes after SWI/SNF loss using these kinds of approaches and revealed surprisingly fast replacement of SWI/SNF. This paper is consistent with those models, showing that another remodeler behaves the same, suggesting there may be general requirements for active chromatin remodeling to maintain the expression of these genes. It also highlights a key gap in how specificity works to target these enzymes remains somewhat unknown.

      • This work will be of interest to those studying detailed mechanisms of gene regulation. Compared to some other chromatin regulators, FACT is understudied and so this work will allow comparison between different chromatin remodeling complexes.

      • My experience: chromatin, gene regulation, cancer, genomics

      We appreciate the thorough review and hope that we have sufficiently addressed your concerns.

      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      The authors propose that the FACT complex can regulate pluripotency factors along with their regulatory targets through non-genic locations. They find that acute depletion of FACT leads to a "reduction" in pluripotency in mouse embryonic stem cell by disrupting transcription of master regulators of pluripotency. They also show FACT depletion affected the transcription of gene distal regulatory sites, but not silencers. They also stated that SPT16 depletion resulted in both, a reduction of chromatin accessibility and increase of nucleosome occupancy over FACT bound sites.

      Overall the study appears technically well executed. The use of an Auxin induced depletion system is a good model to study the acute effects of FACT depletion. However, I have a number of concerns relating to specificity and interpretation of the results that need to be addressed. We appreciate the careful review and have addressed your comments below:

      Major points o Authors claimed that depletion of the FACT complex "triggers a reduction in pluripotency". As evidence supporting this statement they present images of alkaline phosphatase assays of a time course performed upon depletion of FACT. These experiments indeed show that ESCs are destabilized in the absence of SPT16. However, some key questions regarding the phenotype remain unresolved: o What is are the kinetics of expression of selected naïve pluripotency and early differentiation markers? Are differentiation markers upregulated, consistent with normal differentiation upon FACT depletion?

      We appreciate the suggestion and have emphasized the decrease in pluripotency factor expression, accompanied by an increase in differentiation marker expression across all three germ layers. We graphed 7 pluripotency factors and 7 differentiation markers for each germ layer; generally speaking, pluripotency factors are decreased while differentiation markers are increased (Response Figure 4; pluripotency factors are included in the new Fig. 3B, while differentiation markers are included in the new Supp Fig. S3 F-H).

      We have also performed an immunocytochemistry (ICC) timecourse, per Reviewer 3’s suggestion. This ICC timecourse allows us to orthogonally assess decreased pluripotency factor expression, to pair with the OCT4 Western blot shown in Supp Fig. S1B. These new ICC data are shown in the new Fig. 1D and included here for convenience (Response Figure 5). In addition, we have added alkaline phosphatase staining at 12 hours of depletion to Fig. 1C.

      __Response Figure 4. Plots of DESeq2 analysis across experimental timecourse. __Shown are lineage markers denoting: A. Pluripotency B. Endoderm C. Mesoderm and D. Ectoderm. Generally, expression of pluripotency factors decrease over time, while differentiation markers of each lineage increase over time. These data are shown in Figure 3B and Supplemental Figure S3F-H.

      __Response Figure 5. Immunocytochemistry timecourse depicting DAPI staining (left panels, blue) and OCT4 immunofluorescence (right panels, green). __Images are representative of plate-wide immunofluorescence changes.

      O Is only ESC identity affected or does loss of FACT impair viability also of cells that have exited pluripotency? To address this, growth curves and/or cell cycle analysis upon FACT depletion could be performed. Alternatively, the authors could utilize surface markers to distinguish naïve pluripotent form differentiated cells in the cell cycle analysis experiments to identify a potential differential response of pluripotent and differentiated cells to FACT depletion.

      We have performed a growth curve with FACT depletion as suggested; as the two points are related, we will explain further below:

      o Another key question is whether it is only the metastable pluripotent state of ESCs in heterogeneous FCS/LIF conditions which is affected by FACT loss, and whether cells cultured in the more homogeneous and more robust 2i-LIF conditions can tolerate FACT removal. If that is indeed the case it would enable the authors to address one main concern I have with this manuscript, which is that it is nearly impossible to distinguish the direct effect of FACT loss from differences induced by differentiation (and maybe cell death, see comment above). This is a critical concern that needs to be addressed and discussed appropriately.

      We apologize for the confusion – all original experiments for this project were performed in the presence of LIF as well as GSK and MEK inhibitors CHIR99021 and PD0325091, respectively (2i+LIF conditions). To address the reviewers question, we have now performed a timecourse growth assay under both LIF-only and 2i+LIF conditions (Response Figure 6 and new Supp Fig S1F), and as suggested by the reviewer, observe a stronger effect of FACT depletion on cell viability in LIF-alone (FACT-depletion results in ~90% death within ~24 hours, with differences in growth observed by 12 hours) than in 2i+LIF (FACT-depletion results ~80% death within 48 hours, with differences in growth observed starting around 18 hours). Overall, ES cells in LIF alone are indeed more sensitive to FACT loss, supporting our decision to perform the experiments throughout the manuscript in 2i+LIF conditions.

      LIF alone LIF + 2i

      Response Figure 6. __Growth assays in LIF (left) and 2i+LIF (right) conditions. __Cells were treated with either EtOH or 3-IAA and counted at the indicated times. Viability was assessed using trypan blue exclusion. Error bars indicate standard deviation for biological triplicate experiments.

      o A further major concern is about the specificity of the effect of FACT depletion. The authors claim that FACT is required to maintain pluripotency. From the data presented this is unclear. FACT appears to be part of the general transcription machinery in ESCs. It appears generally associated with active promoters and active genes, according to the data in this manuscript. Whether there is any specific link to pluripotency remains to be shown. It is unclear how enrichment analyses have been performed. If they haven't been performed using a background list of genes actively transcribed in ES cells, they will obviously show enrichment of ESC specific GO categories, because ESCs express ESC specific genes robustly expressed in ESCs?

      We apologize for the confusion and have updated our methods section to include more comprehensive details on our pathway enrichment analyses. We have confirmed that pluripotency-related categories are still highly enriched in FACT-regulated DEGs, even when using a background dataset of all transcribed genes, per our TT-seq datasets (baseMean ≥ 1 in DESeq2 output).

      In line with this: the authors show that FACT bound loci well overlap with Oct4 bound regions. But which proportion of FACT targets loci are actually Oct4 bound too?Is FACT binding exclusive to Oct4 regulated enhancers and promoters? In other words, will FACT be recruited to all actively transcribed genes in ES cells? In that case, a specific effect on pluripotency network regulation cannot be claimed.

      We appreciate the suggestion, and have added the number of OCT4/SOX2/NANOG-bound FACT peaks and vice versa in the text and legend of Fig 3E-F. We have also summarized this information in Response Table 1, below (and included these data as Table 2 in the revised manuscript).

      OCT4 peaks

      Sox2 Peaks

      Nanog Peaks

      Any of OSN

      V5 Peaks

      8,544

      5,948

      5,307

      9,682

      OSN Peaks

      45,476

      19,211

      16,817

      52,899

      % of OSN peaks bound by FACT

      18.33%

      30.72%

      31.40%

      17.91%

      % of V5 peaks bound by pluripotency factor(s)

      52.41%

      36.85%

      32.94%

      59.63%

      V5-bound promoters

      4,261

      2,719

      2,327

      4,452

      OSN-bound promoters

      6,550

      1,542

      666

      6,948

      V5- and OSN-bound promoters

      2,040

      801

      343

      2,202

      OSN-bound gene-distal peaks

      38,926

      17,669

      16,151

      45,938

      V5-bound gene-distal OSN peaks

      6,504

      5,147

      4,964

      7,480

      __Response Table 1. Overlapping CUT&RUN and ChIP-seq peaks shared between OCT4, SOX2, NANOG, and V5-SPT16 under various stratifications. __Shown are numbers or percentages of peaks overlapping between V5 and OSN. The last column are peaks containing any of OCT4, SOX2, and/or NANOG. The first four rows include all peaks, regardless of location, and the last five rows are broken down by promoter (as defined by an annotated mRNA) or gene-distal location (defined by a minimum of +/- 1kb from a gene).

      Of the 45,865 OCT4 peaks, 3,688 are located at promoters, and 1,209 of these peaks are bound by V5-SPT16 (32.8%). Inversely, 13,228 of 42,177 gene-distal OCT4 peaks are called as SPT16-V5 peaks in at least one CUT&RUN replicate (31.36%), suggesting a relationship between OCT4 binding and FACT binding, which has long been identified with genic transcription, but has roles extending beyond gene-proximal regulation. We observe similar trends with NANOG and SOX2.

      o It is disappointing that neither raw data (GEO submission set to private) nor any Supplemental Tables containing differentially expressed transcripts and ChIP or Cut and Run peaks and associated genes were made available. This strongly reduces the depth of review that can be performed.

      We apologize if the reviewer token in the cover letter was not accessible. The GEO datasets (including differentially expressed transcripts, raw fastq files, and analyzed datasets) will be made public upon publication; in the meantime, the GEO entry (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE181624) can still be accessed using the previously provided reviewer token: wvkvwmwynjeffux.

      o To what extent do FACT bound loci overlap with genes differentially expressed 24h after FACT depletion? This analysis would help determine the direct targets of FACS regulation.

      We appreciate the suggestion. This analysis can be found in the original Figure S6, broken down by FACT-repressed (expression increased upon FACT depletion), unchanged, and FACT-stimulated (expression decreased upon FACT depletion) DESeq2 results (ordered left-to-right, respectively). Figure S6A-C shows that V5-SPT16 binding is enriched, but not exclusive to, genes with FACT-regulated expression, while Fig. S6D-F shows TT-seq data for each group, sorted by log2-fold change assigned by DESeq2.

      o The paper mainly relies on NGS analysis. Therefore, it is crucial that authors show as Supplemental Material some basic QC of these data. PCA analyses to show congruency of replicates are the minimum requirement.

      We appreciate the suggestion and have included a new Supp. Fig S9, with pairwise comparative Pearson correlation scatterplots and heatmaps for replicates in each dataset, in addition to the scatterplots shown for CUT&RUN and ChIP-seq data in the original Supp Fig. S2A.

      o Did the authors perform any filtering for gene expression levels before analysis? Are genes in the analysis robustly expressed in at least one of the conditions?

      We apologize for the confusion. Due to the sensitive nature of TT-seq and the germ layer-inconsistent pattern of cell differentiation following FACT depletion, we did not perform filtering for gene expression prior to any analyses. For the vast majority of genes analyzed, however, we are able to identify transcription via TT-seq, even in those that do not significantly change expression upon FACT depletion (see Supp Fig S6E). As discussed above, we did include a cutoff for expressed genes in our revised pathway analysis.

      o Wherever p values were reported for enrichment analyses, adjusted p values should be used

      We apologize for the oversight; the p values were in fact adjusted p values and have updated the text and figures to make it explicit that the adjusted p values were used wherever applicable.

      o I cannot follow the logic used by the authors to explain discrepant results from Chen et al about the role of FACT in ESCs. Chen et al showed that FACT disruption by SSRP1 depletion is compatible with ESC survival and leads to ERV deregulation. The authors of the present study attribute these differences to potential FACT independent roles of SSRP1. However, I would assume that if there are indeed FACT independent roles of SSRP1, then the phenotype of SSRP1 KOs in which FACT and other processes should be dysfunctional should be even stronger than a plain FACT KO. This needs a proper and careful explanation.

      We apologize that our discussion of FACT-independent roles of SSRP1 was not clear and have clarified our wording in the text (page 4, line 49 – page 5, line 4)in the revised manuscript); we intended to reconcile the results of Chen et al. 2020 with Goswami et al. 2022 and Cao et al. 2003; despite SSRP1 knockout viability in embryonic stem cells, SSRP1 knockout is lethal in mice between 5-40 weeks and general SSRP1 knockout is lethal 3.5 days post-conception (per Goswami et al. 2022). We therefore posit that the general requirement for SSRP1 may be due to distinct roles from those carried out by the FACT complex in ES cells, as discussed by Spencer et al. 1999, Zeng et al. 2002, Li et al. 2007, and Marciano et al. 2018.

      We note that our findings are in agreement with papers from the Gurova lab and others in that depletion of mRNA or protein of SPT16 leads to concomitant loss of SSRP1; we therefore do not expect total SSRP1 loss to have a stronger effect than SPT16 depletion. We therefore expect, and confirmed via Western blotting (Figure 1B, Supplemental Figure 1), that depletion of SPT16 leads to loss of both FACT subunits, and therefore all FACT subunit activity, complex-dependent or -independent.

      Also, did the authors observe any evidence for ERV deregulation upon acute SPT16 depletion?

      We did indeed observe ERV deregulation upon SPT16 depletion. When reviewing our TT-seq datasets, 7.1% of ERVs were derepressed, while 2.4% decreased in expression upon 24h FACT depletion (mm10 ERVs sourced from gEVE, Nakagawa and Takahashi, 2016). Further, we identified increased chromatin accessibility after FACT depletion at annotated LTR elements, as shown in the table below (Response Table 2). Here we are displaying the calculated enrichment score for accessibility detected at these locations. A negative value indicates lower accessibility than expected by region size, while a positive score indicates that reads are more enriched than expected at the indicated region.

      ATAC-seq enrichment score for locations losing accessibility with FACT depletion

      3h

      6h

      12h

      24h

      LTR Enrichment

      -1.445

      -1.299

      -0.917

      -0.559

      Intergenic Enrichment

      -6.046

      -4.765

      -3.926

      -2.972

      Promoter Enrichment

      3.335

      2.789

      2.726

      2.233

      ATAC-seq enrichment score for locations gaining accessibility with FACT depletion

      3h

      6h

      12h

      24h

      LTR Enrichment

      -1

      -0.436

      1.103

      1.13

      Intergenic Enrichment

      -1

      0.134

      0.435

      0.236

      Promoter Enrichment

      -1

      -3.585

      1.171

      1.39

      __Response Table 2. Changes in ATAC-seq peak enrichment for selected regions, annotated via HOMER. __At regions differentially accessible between SPT16-depleted and SPT16-undepleted samples, regions were assigned to an annotated genomic feature using HOMER annotatePeaks.pl and assigned an enrichment score based on the ratio of ATAC-seq signal to region size. Over time, LTR elements become more enriched among the ATAC-seq peaks both gaining and losing accessibility, indicating a role for FACT in maintaining LTR accessibility.

      We do wish to note, however, that Lopez et al. 2016 identified SPT16-independent regulation of LEDGF/HIV-1 replication by SSRP1, and therefore cannot rule out effects on ERV dysregulation due to SSRP1 loss that accompanies SPT16 depletion.

      Minor points o Figure S2A is very small and resolution is low. Page 10: "...while all four Yamanaka factors (Pou5f1, Sox2, Klf4, and Myc) and Nanog were significantly 24 reduced after 24 hours (Fig. 3A, S3A-B)". No data for myc is being shown.

      We apologize for the figure resolution and have included a larger image. Because pairwise comparative scatterplots are not space-efficient, we opted to display the Pearson correlations for the datasets including more samples (TT-seq and ATAC-seq timecourses) as heatmaps in the new Supp Fig S9. We have added Myc labeling to the volcano plot (now in Fig. 3A) and included a trace of Myc expression over time to the new pluripotency factor graph in Fig. 3B.

      o Are the two bands in the middle in figure 1B is supposed to be a ladder? This should be clarified.

      We thank the reviewer for noticing this and apologize for the oversight.

      o Figure 3C- This Figure is complicated to read. Also, information appears redundant with the Table 1, I recommend to remove this panel.

      We have moved the panel to the supplement (now Supp Fig. S3A). While the information is somewhat redundant with Table 1, we chose to include the former panel 3C as a visual representation of the consistent deregulation over depletion time across transcript categories.

      o Figure 6 and figure 7 could be presented in one single figure since both aspects are complementary and target related aspects.

      While we thank the reviewer for this suggestion, we do not believe that the information contained in Figs. 6 and 7 can effectively be conveyed in a single figure. While both figures focus on chromatin accessibility and nucleosome occupancy, Fig. 6 is designed to address the changes in chromatin accessibility over time, while Fig.­­­ 7 is more relevant to the biological mechanism through which FACT co-regulates targets of the core pluripotency network (OCT4/SOX2/NANOG) after 24 hours of depletion.

      o Are the authors certain that the effects observed are directly linked to the FACT complex in contrast to FACT independent roles of SPT16, if any exist? The experiment to address this would be to deplete SSRP1 and investigate whether the effects are identical, which would be the hypothesis to be tested.

      We thank the reviewer for this suggestion. We did attempt to create additional SSRP1-AID-tagged lines; however, generating these lines proved to be technically challenging, and comparison of the FACT-dependent and -independent roles of the individual subunits is beyond the scope of this work. Further complicating the matter, SSRP1 is effectively depleted within 6 hours of 3-IAA addition in SPT16-AID lines due to the interdependence of FACT subunits. We again thank the reviewer for their suggestion and will consider this work for a future study.

      Reviewer #2 (Significance (Required)):

      My expertise is pluripotency and GRNs.

      I would judge the significance of the study as presented as low, mainly because at this moment it remains unclear what FACT indeed does concerning regulation of pluripotency.

      We respect the reviewer’s opinion and hope that our revisions have made more clear how the FACT complex prevents nonspecific differentiation from occurring, thereby maintaining pluripotency and self-renewal in embryonic stem cells. Importantly, neither untagged cells treated with 3-IAA nor tagged cells treated with vehicle display the growth defects, loss of pluripotency factor expression, increased differentiation marker expression, phenotypic evidence of differentiation, and reduced alkaline phosphatase staining that the FACT-depleted cells do, highlighting a key requirement for FACT in pluripotent cells. Beyond this, we believe the novel gene distal regulatory role we have identified for FACT presents an exciting new role for this complex in gene regulation.

      Reviewer #3 (Evidence, reproducibility and clarity (Required)):

      In this manuscript, Klein, et al. addressed function of FACT complex in mouse ESCs, using cut&run, TT-seq, ATAC-seq, MNase-seq, together with Auxin-mediated FACT degradation system. The authors first reported that efficient and acute depletion of SPT16 with the Auxin-mediated degradation system resulted in over 5,000 up- and 5,000 down-regulated genes within 24 hours, including down-regulation of pluripotent gens. Then, they demonstrated that many of FACT binding sites overlap with Oct4, Sox2, Nanog binding sites by Cut&Run, and those loci increase nucleosome occupancy 24 hour after removal of FACT.

      The Auxin-mediated degradation system seems to be working very well (while I would like to see an over exposed version of Western blotting), and efficient degradation might explain the different phenotypes from the previous reported phenotypes by shRNA and the chemical inhibitor, which might not deplete FACT function completely and/or might have off-target effects. The Cut&Run data also have much sharper peaks than previously reported SSRP1, SPT16 ChIP-seq data. Doing ATAC-seq, MNase-seq upon removal of FACT is excellent. WIth the excellnet degradation system, depletion of FACT resulted in loss and gain of gene expression and differentiation. However, unfortunately it was not very clear to me what was the direct consequences of FACT removal and its mechanisms, waht was consequence of differentiation.

      We appreciate the kind words regarding our choice and execution of techniques and the reviewer’s time spent on this manuscript. We have made a number of changes to the manuscript in order to clarify the direct role of FACT and the consequences of FACT loss on embryonic stem cells.

      Although we did not develop the blots for a longer period when we performed the Westerns, we have artificially overexposed our V5-SPT16 Western blot from Figure S1 (in Adobe Illustrator) to highlight the more subtle bands at later depletion timepoints; we hope that this helps to clarify the effectiveness of the degron system.

      Response Figure 7. V5-SPT16 Western blot with adjusted exposure. We manually adjusted the entire blots’ exposures using Adobe Illustrator. L indicates ladders, and the timecourse depletion is shown above the blot.

      In my opinion, doing many of the analysis 24 hours after FACT depletion, where differential expressed (coding) genes (DEGs) are >10,000 (Table 1)), is too late to understand what the direct consequences are. Seeing 214 up- and 174 down-regulated DEGs 6 hours after FACT depletion, I do agree that FCAT seems to do both suppression and activation of target genes. It could have been really interesting to investigate what % of FACT bindign sites change chromatin accesibility and nucleosome occupancy at that time point, if those loci are close to any of the up- or down-regualted DEGs.

      We appreciate the suggestion and have included more information regarding the percentage of FACT binding sites with altered chromatin accessibility, as well as included some analyses to address the directness of FACT’s contribution to DEGs at all timepoints (see Supp Figs S4, S6). We would like to note that, we performed the TT-seq and ATAC-seq experiments at 0, 3, 6, 12, and 24 hours post 3-IAA treatment in order for us to explore the progressive change in both the transcriptome and chromatin accessibility, with only the MNase-seq limited to 24 hours. As originally shown in our Sankey plot in Supp Fig 4, we see a progressive change in expression for a small subset of genes over our timecourse running from 0-24 hours, with the largest effect observed at 24 hours, once the FACT protein levels are almost entirely depleted. Similarly, we see a progressive change in ATAC-seq signal over the same regions, with the strongest effects over the same regions visible at 24 hours post-depletion. Due to our observation that SPT16 is not depleted at 3 or 6 hours, with significant depletion seen at 24 hours (see Response Figure 7) and because we intended to study the FACT complex’s role in preventing differentiation, we were most interested in the effects at 24 hours of depletion, which allow us to analyze both the disruption of pluripotency factor expression and the facilitation of differentiation marker expression across all three germ layers (see Response Figure 4).

      Followings are reasons of above my judgement and suggestions to improve the manuscript.

      Major points 1. Figure 1. ALP staining is not very sensitive way to evaluate ESC differentiation. I recommend Immunofluorescence for pluripotency genes (NANOG and/or SOX2) and quantification. Or present changes of pluripotency genes in graphs over time course from RNA-seq data.

      We appreciate the suggestions and have taken both into account. We have included a new panel in Figure 3 (new 3B) to display the changes of pluripotency factor expression over our timecourse. We have also included some data showing differentiation factors as part of a response to Reviewer 1, which can be found above (Response Figure 4). In addition, we performed immunocytochemistry to examine OCT4 abundance over a depletion timecourse and have added a 12-hour to our alkaline phosphatase assay to address the sensitivity of differentiation over time (Figure 1C, D and Response Figure 5).

      1. Fig 2A, 3E, 3F. How many transcription start sites are shown here? (Throughout the manuscript, it is hard to know how many loci are shown in the heatmaps. It should be described within the figures)

      We apologize for the omission and have added numbers of loci shown to relevant Figure panels throughout the paper.

      It is nice to see nascent transcription high sites have high FACT binding, but can you also show actual nascent transcription of these loci as a heatmap, before and after FACT depletion? These heatmaps should be shown in a descending order of FACT Cut&Run signalling, as FACT binding is important in this manuscript.

      We appreciate the suggestion and have plotted those data below (see Response Figure 8).

      Response Figure 8. Nascent transcription from sites with high FACT binding. Top: TPM-normalized TT-seq signal after 12-hour treatment, oriented to mRNA strand and plotted as entire mRNA length, ± 500 bp. Data are sorted by SPT16 CUT&RUN signal over 1kb upstream of annotated TSSs. n = 1 over 22,597 rows (RefSeq Select mRNAs). Bottom: TPM-normalized TT-seq signal after 24-hour treatment, oriented to mRNA strand and plotted as entire mRNA length, ± 500 bp. Data are sorted by SPT16 CUT&RUN signal over 1kb upstream of annotated TSSs. n = 3 (mean) over 22,597 rows (RefSeq Select mRNAs).

      Strong FACT binding sites have strong transcription. Is FACT really supressing transcription?

      We agree that it is very difficult to disentangle FACT function due to its binding correlation with transcription; however, we see a clear trend of FACT binding at promoters that are sensitive to FACT depletion (Supp Fig. S6A/D and C/F). Intriguingly, the genes that see the greatest derepression by DESeq2 analysis are those that are directly bound by FACT (per ChIP-seq and CUT&RUN; Supplemental Figure S6A/D), while the greatest decrease in expression occurs at genes that are less bound by FACT (Supp Fig S6C/F). In our opinion, this trend lends credence to both direct repression by FACT and distal gene regulation. We note that others (e.g., Kolundzic et al. 2018) have shown direct repression of gene expression by FACT, in line with that aspect of our data.

      1. Fig 3ABD. It is more important to show 3h, 6h 12 h time points. The same apply to Fig 4. What %, how many of DEGs (coding and non-coding) at each time point had FACT binding nearby in ESCs?

      We agree that the early timepoints are important and have added volcano plots to the supplemental material for earlier timepoints, with genes of interest specifically annotated. We have also examined pluripotency and differentiation markers at earlier timepoints, per other reviewers’ suggestions, and have included the percentage of DEGs with nearby FACT binding in the manuscript. Specifically, 2013 replicated V5 peaks (out of 16,054; 12.54%) occurred within 1000 bp of a RefSeq Select TSS.

      Timepoint

      Total DEGs (up)

      V5-bound DEGs (up)

      Total DEGs (down)

      V5-bound DEGs (down)

      3h

      58

      16 (27.59%)

      5

      1 (20%)

      6h

      214

      38 (17.76%)

      174

      31 (17.82%)

      12h

      1366

      123 (9.00%)

      1932

      281 (14.54%)

      24h

      5398

      431 (7.98%)

      5000

      663 (13.26%)

      __Response Table 3. Table of DESeq2-assigned DEGs that are bound by SPT16-V5. __To be defined as V5-SPT16-bound, a DEG must have SPT16-V5 binding within 1000 bp upstream of its RefSeq-select annotated TSS.

      We believe that these earliest depletion timepoints are in line with FACT-mediated gene regulation occurring distal to the regulated genes’ promoters.

      Fig 3EF. Interesting data and the overlap between SPT16 binding sites and pluripotency binding sites look very strong. But it is difficult to know what % is overlapping from these figures.

      We appreciate the difficulty in quantifying the overlap between pluripotency factor binding sites and FACT binding sites; we have added those data to the manuscript below Figure 3E for OCT4; for other pluripotency factors, these data can be found in Response Figure 9 and Response Table 1. Briefly, 18.33% of OCT4 ChIP-seq peaks are bound by V5-SPT16 and 52.41% of V5-SPT16 peaks are bound by OCT4. Interestingly, 34.6% of gene-distal OCT4 ChIP-seq peaks are bound by V5-SPT16, implying greater convergence between FACT and pluripotency factors at gene-distal sites, in line with known trends for OCT4 binding. Overall, 59.63% of V5-SPT16 peaks are co-bound by at least one of OCT4, SOX2, or NANOG.

      Can you show 1 heatmap split into 3 groups, a. SPT16-V5 unique, common between SPT16-V5 and Oct4 ChIP-seq, Oct4 ChIP-seq unique, with indication of numbers each group has? Also make the same figures for Sox2 and Nanog. (E is less important. If the authors want, they can use the published FACT ChIP-seq data in the same loci.)

      We appreciate the suggestion and have plotted V5-SPT16 CUT&RUN data and pluripotency factor ChIP-seq over unique and shared regions for OCT4 (top) SOX2 (middle) and NANOG (bottom). Interestingly, although some peaks in the non-overlapping cluster were not called as peaks by the algorithms’ threshold, one can observe that a subset do seem to have overlapping binding. We again appreciate the suggestion and think that this was an excellent way to display the data and have included these data as a new panel (Fig. 3E) but also show below in Response Figure 9.

      Fig. 5. Basic information what % (how many) of SPT16-V5 CUT&RUN peaks belong to this 'enhancer' category is missing.

      We apologize for the oversight and have added numbers to the figure and legend.

      I am not sure the meaning of separating enhancers and TSS of coding genes in the analyses, though. If majority of SPT16-V5 CUT&RUN peaks overlap with Oct4 binding sites, it is not surprising that SPT16-V5 CUT&RUN peaks overlaps with ATAC-seq signal and enhancer marks.

      We agree that it is unsurprising that V5-SPT16 overlaps with accessible chromatin and enhancers, given the extensive overlap with OCT4 ChIP-seq peaks. We wanted to emphasize our novel finding of gene-distal FACT binding, given the more established trend of binding at promoters.

      1. Fig 6A. I could not figure out what % of DHSs overlaps with FACT binding sites.

      We have added this percentage to Fig 5C and included an analysis of altered chromatin accessibility in a new Table 3 (page 20). Briefly, 11,234 replicated V5-SPT16 peaks (out of 16,043; 70%) directly overlap a gene distal DHS. Orthogonally, 11,234 DHSs (out of 132,555; 8.5%) directly overlap a V5-SPT16 peak.

      I do not see the point of showing DHSs which do not overlap with FACT binding sites.

      In agreement with Reviewer 1, we believe that it is important to include FACT-unbound DHSs for a clearer understanding of the direct vs indirect effects of FACT depletion. We have condensed some of these data into a single heatmap, clustered between FACT-bound DHSs, non-FACT-bound DHSs, and FACT-bound non-DHS sites to streamline the information (now shown in Fig 3E).

      Response Figure 9. Heatmaps of clustered SPT16 and OSN binding data. Shown are clustered heatmaps depicting V5-SPT16 CUT&RUN binding overlapping ChIP-seq peaks for OCT4 (top) SOX2 (middle) and NANOG (bottom). In each set of heatmaps the top cluster is pluripotency factor-unique, the middle cluster is shared, and the V5-unique cluster is on the bottom. Each cluster is sorted by descending strength of V5-SPT16 binding (CUT&RUN). Clusters were assigned by directly overlapping peaks.

      How ATAC-seq signal changes upon depletion of FACT at FACT binding sites (Fig 6B) is important. Can you explain why ATAC-seq signals increase at the FACT binding site flanking regions (across +/- 2kb) where FACT binding is strong (without changing the chromatin accessibility at the FACT binding sites)? Perhaps authors need to show actual ATAC-seq track with EtOH or 3-IAA treatment over ~10kb regions flanking FACT binding sites. It is difficult to understand what is happening seeing only the changes (ratio) of ATAC-seq read counts, how big the differences are.

      We agree that the local window and ratio of ATAC-seq signal somewhat muddles the true biological trends. We have plotted non-differential ATAC-seq signal for each SPT16-AID clone over V5 binding sites, ±10 kb, to more accurately depict the local chromatin status (shown below in Response Figure 10). There is an apparent trend at V5-SPT16 CUT&RUN peaks of accessible chromatin, and this high local accessibility very likely contributes to the high ATAC-seq signal immediately flanking V5 binding sites; over the binding sites themselves, however, FACT depletion consistently triggers decreased accessibility (see Fig. 6).

      Can you identify differentially open loci based on 3-IAA- and Et-OH treated ATAC-seq data at each time point, and then how many of them overlap with FACT binding sites? There are a few tools to identify differential open regions with ATAC-seq data. That could help to understand the direct roles of FACT binding.

      We appreciate the suggestion and have performed this analysis using a combination of PEPATAC and HOMER (see Response Tables 4-6 below). FACT depletion leads to the following accessibility changes:

      3-hour

      6-hour

      12-hour

      24-hour

      Decreased accessibility

      220 (0.35%)

      3,713 (5.99%)

      6,885 (11.11%)

      8,441 (13.62%)

      Increased accessibility

      2 (0.00%)

      12 (0.02%)

      276 (0.45%)

      6,031 (9.73%)

      Response Table 4. Accessibility changes over consensus ATAC-seq peaks. Consensus ATAC-seq peaks were defined per PEPATAC standards (peaks called by MACS2 in (n/2)+1 samples, irrespective of condition.

      3-hour

      6-hour

      12-hour

      24-hour

      Decreased accessibility

      848 (1.64%)

      1870 (3.51%)

      2525 (4.83%)

      4,092 (7.90%)

      Increased accessibility

      107 (0.21%)

      283 (0.55%)

      534 (1.03%)

      2,449 (4.73%)

      Response Table 5. Accessibility changes over regions bound by V5-SPT16.

      Response Figure 10. ATAC-seq data shown over a 20kb window. Heatmaps depicting non-differential ATAC-seq data over FACT binding sites for SPT16-AID clones 1 (top) and 2 (bottom). Data are sorted by V5-SPT16 binding strength.

      All

      3-hour

      6-hour

      12-hour

      24-hour

      Decreased accessibility

      3,294 (2.46%)

      3,175 (2.37%)

      3,636 (2.71%)

      7,018 (5.23%)

      Increased accessibility

      102 (0.08%)

      313 (0.23%)

      1,797 (1.34%)

      5,975 (4.45%)

      V5-bound DHSs (11,234 total)

      3-hour

      6-hour

      12-hour

      24-hour

      Decreased accessibility

      1 (0.01%)

      9 (0.08%)

      96 (0.85%)

      2006 (17.86%)

      Increased accessibility

      5 (0.04%)

      28 (0.25%)

      71 (0.63%)

      87 (0.77%)

      Response Table 6. Accessibility changes over gene-distal DHSs and over only FACT-bound gene-distal DHSs.

      Together with Fig 1A and Fig 6C, do they mean the more FACT binding, the more transcription (Fig 1A). Also the higher transcription rate, the more increased chromatin accessibility upon depletion of FACT (Fig 6C)?

      While we do see that FACT binding correlates with transcription and with FACT-dependent chromatin accessibility, we do not wish to make the argument that FACT binding alone is indicative of high transcription, nor that transcription is necessarily the deciding factor in FACT-depleted chromatin accessibility changes. We do want to note that transcriptional disruption is a likely contributor to increased chromatin accessibility in the absence of FACT as it pertains to paused RNAPII, as speculated in our discussion, but that experiments to truly test this hypothesis are beyond the scope of this work. That being said, in response to Reviewer 1, we did assess the potential correlation of FACT binding to locations with greater paused RNAPII (Response Figure 3) and see a connection. We are excited to explore this more in future work.

      Perhaps plotting nascent transcripts at 12hr, 24 hr of FACT depletion next to these heatmaps might show if it colleates with transcription changes as well?

      We appreciate the suggestion, and have included this plot in Response Figure 8, sorted by FACT binding to gene promoters; however, we find it difficult to visualize differences in transcription with non-differential heatmaps.

      Sites losing chromatin accessibility (bottom half of Fig 6C) seem not to have FACT binding (bottom half of Fig 1A), thus it is likely to be indirect effects. It is better to make figures focussing on 'direct effects'.

      We agree that there are sites with reduced chromatin accessibility upon FACT depletion that are not bound by FACT; however, given the extensive binding of FACT at gene-distal regulatory regions (F2D, F4A, F5, F6A/D), we would suggest that these “indirect” effects are possibly the result of FACT-dependent gene-distal regulation.

      Fig 1A and Fig 6C indicated that FACT binding sites (i.e. TSS) decrease chromatin accessibility. I thought it does not fit with the idea of increasing nucleosome occupancy. But actually the data (Fig 7F) shows that TSS does not show increased nucleosome occupancy unlike Fig 7A-E. In fact, Fig 6B showed that about bottom 50% of weaker V5 binding sites decreased chromatin accessibility at 24 hr, which fits with increased nucleosome occupancy in Fig 7A. But then if you looked at only top 50% of stronger V5 binding sites, which did not decrease chromatin accessibility, nucleosome occupancy did not change as well? Why don't you make heatmap of MNase-seq next to Fig 6B?

      We have added heatmaps of non-differential MNase-seq data to Fig. 7A to address both concerns. Regarding Figure 6B, we note that the V5-SPT16 peaks themselves invariantly show decreased chromatin accessibility, and that it is the surrounding chromatin, not the V5-SPT16 peak itself, that shifts from increased to decreased chromatin accessibility at 12-24 hours of depletion. We would also like to clarify that the original heatmaps in Fig 6B were sorted by change in chromatin accessibility at 24h, rather than V5 binding.

      We disagree that the TSSs do not show increased nucleosome occupancy in Fig. 7F, as there is an increase in signal above background directly over the TSS in both replicates, per the differential metaplot shown in Fig. 7B, that is specific to the AID-tagged lines. However, the two clones did show variable results. To address this, we have plotted the non-differential MNase-seq plots (Fig. 7A), which show more consistent trends; it appears that the transformation of the data into differential at this location was the cause of the slightly variable plots over TSSs.

      1. I could not follow based on which data the model in Fig 8 is made. Again it is better to focus in the direct effects.

      Thank you for the suggestion; we have updated our model to focus more on the direct effects.

      Minor points. 10. Line 1 page 5, Kolundzic paper did not have MEF reprograming data. They reported human fibroblast reprogramming was enhanced by FACT KD.

      We appreciate the correction and have clarified the language to specify that the work of Kolundzic et al. included human fibroblast reprogramming and Shen et al. performed MEF reprogramming.

      1. Line 3, I disagree with "these data establish FACT as essential in pluripotent cells". One paper said FACT KD increased proliferation of mESCs, the other paper said chemical inhibition of FACT was necessary for passaging ESCs, but not proliferation. Importance of FACT in pluripotent cells was very unclear to me.

      We have clarified our language to specify that pluripotent cells have a FACT dependency that differentiated cells do not. We note that we were unable to recapitulate a relationship between FACT and trypsinization/passaging of ES cells, suggesting a more nuanced role for FACT in pluripotent cells, in line with work from the Tessarz and Gurova labs.

      Line 7 Page 7, reference the paper with the ChIP-seq data.

      We apologize for the oversight and have added the reference.

      Line 16, Page 7. It doesn't seem the the Cut&run and previously published ChIP-seq data agree well.. >50% look different. It is nothing the authors can do, but can you show venn diagram of peak overlap?

      In response to Reviewer 1, we have generated Response Figure 1 where we display a pie chart of the overlap. In addition to displaying this again to the right in Response Figure 11 this, we have included another analysis below in Response Figure 11, to address this comment. Specifically, we have plotted peak overlaps as a Venn diagram to compare peaks identified in at least two experimental replicates from either the CUT&RUN or ChIP-seq data (left). We have also overlapped replicated peaks between the individual targets and displayed them as a pie chart (right; same as Response Figure 1). While the CUT&RUN data do display a greater signal:noise ratio and call far more peaks, we note that more peak conservation between experiments is relatively consistent (1-6%) between all datasets, including the ChIP-seq experiments profiling opposite factors.

      Overall, we see strongly reproducible trends (albeit with less sharp definition in the ChIP-seq), complemented by highly similar biological feature assignment in Fig. 2D and Pearson correlation values of between 0.76 and 0.78 between SPT16 ChIP-seq and V5-SPT16 CUT&RUN (Supp Fig. S2A).

      __Response Figure 11. Overlaps between SPT16-V5 CUT&RUN, SPT16 ChIP-seq, and SSRP1 ChIP-seq. __Called peaks were compared between V5-SPT16 CUT&RUN, SPT16 ChIP-seq, and SSRP1 ChIP-seq, using both our own analysis pipeline (left) and the peaks published with the original manuscript by Tessarz et al. (2018; right). While our ChIP-seq peak-calling appears to have applied more stringent thresholds, trends are generally agreeable.

      Line 12, 22 page 10. Fig.3AB is 24 hrs. Do not match with the text.

      We apologize for the error and have changed the references in the text to the new panel 3C.

      1. Line 23, 24, page 10, Highlight Klf4 and Myc in the volcano plot.

      We have added KLF4 and MYC annotation to the volcano plot in Fig. 3A, as well as plotted their log2FC over time in the new panel 3B.

      1. Line 18, 19, page 16. This is not accurate statement. Sample 2 increased the accessibility at 6 hours. Sample 1 decreased, but even the control did so.

      We apologize for the unclear wording; we intended to suggest that all timepoints after 6 hours (i.e., 12 and 24 hours) display decreased accessibility directly over the DHS. We have corrected the text.

      1. Line 48-50, page 16. Two replicates show very different patterns. Difficult to agree with the statement based on the figure.

      We agree that the differential replicate patterns are not ideal; however, both replicates display an increase in nucleosome-sized reads over the promoter region, consistent with our ATAC-seq results presented in Fig 6C. Size distribution plots did not suggest differences in MNase digestion between samples, and neither quartile/RPGC nor TMM-based normalization fully solved this issue. Because our ATAC-seq datasets agree with the general trends identified by MNase-seq (which are consistent, despite technical differences between clones), we do not believe that the differences constitute biological difference, but rather experimental noise. We have included a heatmap of non-differential MNase-seq signal around TSSs in Fig 7A to highlight the experimental reproducibility between replicates. Based on this analysis it appears that the transformation of the data into differential at this location was the cause of the slightly variable plots over TSSs.

      1. Line 15, page 19. Where does "1.5 times" come from? which is 1.5 times more, and is that different from the proportion of those?

      We apologize for the unclear reference to the altered transcripts in Table 1 and have changed our wording to be more precise.

      1. Line 32, page 19. Is Fig S2B correct figure?

      We appreciate the correction; the text should have referred to Fig. 4 and has been fixed.

      Line 35-39, page 21. I understand FACT does not bind to silenced loci. If FACT does not bind, it is not surprising that expression from those loci does not change upon FACT deletion. I do not understand what the authors said.

      We agree that a lack of binding and unchanged expression after FACT depletion at putative silencers are unsurprising; given FACT’s extensive genic and gene-distal binding, we wished to show a class of transcribed regions unbound by FACT as a control, to show that non-FACT-regulated transcription was not affected by FACT transcription. We have clarified our wording in the text to emphasize that a lack of change was expected at silencers.

      Reviewer #3 (Significance (Required)):

      Previously it has been shown that Oct4 physically interacts with the FAcilitates Chromatin Transactions (FACT) complex. Seemingly contradicting phenotypes have been reporting upon suppression of FACT function in the maintenance and induction of pluripotent cells. Mylonas has reported that knockdown of SSRP1, a component of FACT complex, increased ESC proliferation (2018). Shen has described that chemical inhibition of FACT complex affected passaging of ESCs, but proliferation was not affected without passaging. Kolundzic has found that both SSRP1 and SUPT16H, another component of FACT complex, enhance human fibroblast reprogramming into iPSCs (2018), while Shen has reported that chemical inhibition of FACT blocks mouse iPSC generation form MEFs.

      My expertise lies on pluripotent stem cells and transcriptional regulations. I did like the Auxin-mediated FACT degradation system these authors used and acute depletion of FACT is an excellent way of evaluating FACT function in ESC, compared to previously published shRNA based knockdown or use of a chemical inhibitor. However, as I described above, it was not very clear what could the direct effects and I feel looking at 24 hours after depletion might be to late to address this question.

      We appreciate the review and agree that acute depletion of FACT has great potential to understand the complex’s function in ES cells. We understand that the nature of gene-distal regulation does make it difficult to cleanly elucidate direct regulation, and hope that our revisions have clarified that our goal was to examine direct, gene-distal regulation, rather than indirect effects. We would like to note that we examined transcription and chromatin accessibility after 3, 6, 12, and 24 hours of 3-IAA treatment, with all these data included in the original manuscript, and saw minimal change (likely because FACT was not fully depleted until later timepoints); to capture the true biological effects of FACT depletion, we explored most thoroughly the 24 hour 3-IAA treatment to understand the downstream effects between FACT loss and cellular differentiation. However, we have expanded discussion and analyses of the earlier timepoints in this revised manuscript.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      In this manuscript, Klein, et al. addressed function of FACT complex in mouse ESCs, using cut&run, TT-seq, ATAC-seq, MNase-seq, together with Auxin-mediated FACT degradation system. The authors first reported that efficient and acute depletion of SPT16 with the Auxin-mediated degradation system resulted in over 5,000 up- and 5,000 down-regulated genes within 24 hours, including down-regulation of pluripotent gens. Then, they demonstrated that many of FACT binding sites overlap with Oct4, Sox2, Nanog binding sites by Cut&Run, and those loci increase nucleosome occupancy 24 hour after removal of FACT.

      The Auxin-mediated degradation system seems to be working very well (while I would like to see an over exposed version of Western blotting), and efficient degradation might explain the different phenotypes from the previous reported phenotypes by shRNA and the chemical inhibitor, which might not deplete FACT function completely and/or might have off-target effects. The Cut&Run data also have much sharper peaks than previously reported SSRP1, SPT16 ChIP-seq data. Doing ATAC-seq, MNase-seq upon removal of FACT is excellent. WIth the excellnet degradation system, depletion of FACT resulted in loss and gain of gene expression and differentiation. However, unfortunately it was not very clear to me what was the direct consequences of FACT removal and its mechanisms, waht was consequence of differentiation.

      In my opinion, doing many of the analysis 24 hours after FACT depletion, where differential expressed (coding) genes (DEGs) are >10,000 (Table 1)), is too late to understand what the direct consequences are. Seeing 214 up- and 174 down-regulated DEGs 6 hours after FACT depletion, I do agree that FCAT seems to do both suppression and activation of target genes. It could have been really interesting to investigate what % of FACT bindign sites change chromatin accesibility and nucleosome occupancy at that time point, if those loci are close to any of the up- or down-regualted DEGs.

      Followings are reasons of above my judgement and suggestions to improve the manuscript.

      Major points

      1. Figure 1. ALP staining is not very sensitive way to evaluate ESC differentiation. I recommend Immunofluorescence for pluripotency genes (NANOG and/or SOX2) and quantification. Or present changes of pluripotency genes in graphs over time course from RNA-seq data.
      2. Fig 2A, 3E, 3F. How many transcription start sites are shown here? (Throughout the manuscript, it is hard to know how many loci are shown in the heatmaps. It should be described within the figures) It is nice to see nascent transcription high sites have high FACT binding, but can you also show actual nascent transcription of these loci as a heatmap, before and after FACT depletion? These heatmaps should be shown in a descending order of FACT Cut&Run signalling, as FACT binding is important in this manuscript. Strong FACT binding sites have strong transcription. Is FACT really supressing transcription?
      3. Fig 3ABD. It is more important to show 3h, 6h 12 h time points. The same apply to Fig 4. What %, how many of DEGs (coding and non-coding) at each time point had FACT binding nearby in ESCs?
      4. Fig 3EF. Interesting data and the overlap between SPT16 binding sites and pluripotency binding sites look very strong. But it is difficult to know what % is overlapping from these figures. Can you show 1 heatmap split into 3 groups, a. SPT16-V5 unique, common between SPT16-V5 and Oct4 ChIP-seq, Oct4 ChIP-seq unique, with indication of numbers each group has? Also make the same figures for Sox2 and Nanog. (E is less important. If the authors want, they can use the published FACT ChIP-seq data in the same loci.)
      5. Fig. 5. Basic information what % (how many) of SPT16-V5 CUT&RUN peaks belong to this 'enhancer' category is missing. I am not sure the meaning of separating enhancers and TSS of coding genes in the analyses, though. If majority of SPT16-V5 CUT&RUN peaks overlap with Oct4 binding sites, it is not surprising that SPT16-V5 CUT&RUN peaks overlaps with ATAC-seq signal and enhancer marks.
      6. Fig 6A. I could not figure out what % of DHSs overlaps with FACT binding sites. I do not see the point of showing DHSs which do not overlap with FACT binding sites. How ATAC-seq signal changes upon depletion of FACT at FACT binding sites (Fig 6B) is important. Can you explain why ATAC-seq signals increase at the FACT binding site flanking regions (across +/- 2kb) where FACT binding is strong (without changing the chromatin accessibility at the FACT binding sites)? Perhaps authors need to show actual ATAC-seq track with EtOH or 3-IAA treatment over ~10kb regions flanking FACT binding sites. It is difficult to understand what is happening seeing only the changes (ratio) of ATAC-seq read counts, how big the differences are. Can you identify differentially open loci based on 3-IAA- and Et-OH treated ATAC-seq data at each time point, and then how many of them overlap with FACT binding sites? There are a few tools to identify differential open regions with ATAC-seq data. That could help to understand the direct roles of FACT binding.
      7. Together with Fig 1A and Fig 6C, do they mean the more FACT binding, the more transcription (Fig 1A). Also the higher transcription rate, the more increased chromatin accessibility upon depletion of FACT (Fig 6C)? Perhaps plotting nascent transcripts at 12hr, 24 hr of FACT depletion next to these heatmaps might show if it colleates with transcription changes as well? Sites losing chromatin accessibility (bottom half of Fig 6C) seem not to have FACT binding (bottom half of Fig 1A), thus it is likely to be indirect effects. I beleive it is better to make figures focussing on 'direct effects'.
      8. Fig 1A and Fig 6C indicated that FACT binding sites (i.e. TSS) decrease chromatin accessibility. I thought it does not fit with the idea of increasing nucleosome occupancy. But actually the data (Fig 7F) shows that TSS does not show increased nucleosome occupancy unlike Fig 7A-E. In fact, Fig 6B showed that about bottom 50% of weaker V5 binding sites decreased chromatin accessibility at 24 hr, which fits with increased nucleosome occupancy in Fig 7A. But then if you looked at only top 50% of stronger V5 binding sites, which did not decrease chromatin accessibility, nucleosome occupancy did not change as well? Why don't you make heatmap of MNase-seq next to Fig 6B?
      9. I could not follow based on which data the model in Fig 8 is made. Again it is better to focus in the direct effects.

      Minor points.

      1. Line 1 page 5, Kolundzic paper did not have MEF reprograming data. They reported human fibroblast reprogramming was enhanced by FACT KD.
      2. Line 3, I disagree with "these data establish FACT as essential in pluripotent cells". One paper said FACT KD increased proliferation of mESCs, the other paper said chemical inhibition of FACT was necessary for passaging ESCs, but not proliferation. Importance of FACT in pluripotent cells was very unclear to me.
      3. Line 7 Page 7, reference the paper with the ChIP-seq data.
      4. Line 16, Page 7. It doesn't seem the the Cut&run and previously published ChIP-seq data agree well.. >50% look different. It is nothing the authors can do, but can you show venn diagram of peak overlap?
      5. Line 12, 22 page 10. Fig.3AB is 24 hrs. Do not match with the text.
      6. Line 23, 24, page 10, Highlight Klf4 and Myc in the volcano plot.
      7. Line 18, 19, page 16. This is not accurate statement. Sample 2 increased the accessibility at 6 hours. Sample 1 decreased, but even the control did so.
      8. Line 48-50, page 16. Two replicates show very different patterns. Difficult to agree with the statement based on the figure.
      9. Line 15, page 19. Where does "1.5 times" come from? which is 1.5 times more, and is that different from the proportion of those?
      10. Line 32, page 19. Is Fig S2B correct figure?
      11. Line 35-39, page 21. I understand FACT does not bind to silenced loci. If FACT does not bind, it is not surprising that expression from those loci does not change upon FACT deletion. I do not understand what the authors said.

      Significance

      Previously it has been shown that Oct4 physically interacts with the FAcilitates Chromatin Transactions (FACT) complex. Seemingly contradicting phenotypes have been reporting upon suppression of FACT function in the maintenance and induction of pluripotent cells. Mylonas has reported that knockdown of SSRP1, a component of FACT complex, increased ESC proliferation (2018). Shen has described that chemical inhibition of FACT complex affected passaging of ESCs, but proliferation was not affected without passaging. Kolundzic has found that both SSRP1 and SUPT16H, another component of FACT complex, enhance human fibroblast reprogramming into iPSCs (2018), while Shen has reported that chemical inhibition of FACT blocks mouse iPSC generation form MEFs.

      My expertise lies on pluripotent stem cells and transcriptional regulations. I did like the Auxin-mediated FACT degradation system these authors used and acute depletion of FACT is an excellent way of evaluating FACT function in ESC, compared to previously published shRNA based knockdown or use of a chemical inhibitor. However, as I described above, it was not very clear what could the direct effects and I feel looking at 24 hours after depletion might be to late to address this question.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      The authors propose that the FACT complex can regulate pluripotency factors along with their regulatory targets through non-genic locations. They find that acute depletion of FACT leads to a "reduction" in pluripotency in mouse embryonic stem cell by disrupting transcription of master regulators of pluripotency. They also show FACT depletion affected the transcription of gene distal regulatory sites, but not silencers. They also stated that SPT16 depletion resulted in both, a reduction of chromatin accessibility and increase of nucleosome occupancy over FACT bound sites.

      Overall the study appears technically well executed. The use of an Auxin induced depletion system is a good model to study the acute effects of FACT depletion. However, I have a number of concerns relating to specificity and interpretation of the results that need to be addressed.

      Major points

      • Authors claimed that depletion of the FACT complex "triggers a reduction in pluripotency". As evidence supporting this statement they present images of alkaline phosphatase assays of a time course performed upon depletion of FACT. These experiments indeed show that ESCs are destabilized in the absence of SPT16. However, some key questions regarding the phenotype remain unresolved:
      • What is are the kinetics of expression of selected naïve pluripotency and early differentiation markers? Are differentiation markers upregulated, consistent with normal differentiation upon FACT depletion?
      • Is only ESC identity affected or does loss of FACT impair viability also of cells that have exited pluripotency? To address this, growth curves and/or cell cycle analysis upon FACT depletion could be performed. Alternatively, the authors could utilize surface markers to distinguish naïve pluripotent form differentiated cells in the cell cycle analysis experiments to identify a potential differential response of pluripotent and differentiated cells to FACT depletion.
      • Another key question is whether it is only the metastable pluripotent state of ESCs in heterogeneous FCS/LIF conditions which is affected by FACT loss, and whether cells cultured in the more homogeneous and more robust 2i-LIF conditions can tolerate FACT removal. If that is indeed the case it would enable the authors to address one main concern I have with this manuscript, which is that it is nearly impossible to distinguish the direct effect of FACT loss from differences induced by differentiation (and maybe cell death, see comment above). This is a critical concern that needs to be addressed and discussed appropriately.
      • A further major concern is about the specificity of the effect of FACT depletion. The authors claim that FACT is required to maintain pluripotency. From the data presented this is unclear. FACT appears to be part of the general transcription machinery in ESCs. It appears generally associated with active promoters and active genes, according to the data in this manuscript. Whether there is any specific link to pluripotency remains to be shown. It is unclear how enrichment analyses have been performed. If they haven't been performed using a background list of genes actively transcribed in ES cells, they will obviously show enrichment of ESC specific GO categories, because ESCs express ESC specific genes Will results hold true if these experiments are performed using background lists of genes robustly expressed in ESCs? In line with this: the authors show that FACT bound loci well overlap with Oct4 bound regions. But which proportion of FACT targets loci are actually Oct4 bound too? Is FACT binding exclusive to Oct4 regulated enhancers and promoters? In other words, will FACT be recruited to all actively transcribed genes in ES cells? In that case, a specific effect on pluripotency network regulation cannot be claimed.
      • It is disappointing that neither raw data (GEO submission set to private) nor any Supplemental Tables containing differentially expressed transcripts and ChIP or Cut and Run peaks and associated genes were made available. This strongly reduces the depth of review that can be performed.
      • To what extent do FACT bound loci overlap with genes differentially expressed 24h after FACT depletion? This analysis would help determine the direct targets of FACS regulation.
      • The paper mainly relies on NGS analysis. Therefore, it is crucial that authors show as Supplemental Material some basic QC of these data. PCA analyses to show congruency of replicates are the minimum requirement.
      • Did the authors perform any filtering for gene expression levels before analysis? Are genes in the analysis robustly expressed in at least one of the conditions?
      • Wherever p values were reported for enrichment analyses, adjusted p values should be used
      • I cannot follow the logic used by the authors to explain discrepant results from Chen et al about the role of FACT in ESCs. Chen et al showed that FACT disruption by SSRP1 depletion is compatible with ESC survival and leads to ERV deregulation. The authors of the present study attribute these differences to potential FACT independent roles of SSRP1. However, I would assume that if there are indeed FACT independent roles of SSRP1, then the phenotype of SSRP1 KOs in which FACT and other processes should be dysfunctional should be even stronger than a plain FACT KO. This needs a proper and careful explanation. Also, did the authors observe any
      • evidence for ERV deregulation upon acute SPT16 depletion?

      Minor points

      • Figure S2A is very small and resolution is low. Page 10: "...while all four Yamanaka factors (Pou5f1, Sox2, Klf4, and Myc) and Nanog were significantly 24 reduced after 24 hours (Fig. 3A, S3A-B)". No data for myc is being shown.
      • Are the two bands in the middle in figure 1B is supposed to be a ladder? This should be clarified.
      • Figure 3C- This Figure is complicated to read. Also, information appears redundant with the Table 1, I recommend to remove this panel.
      • Figure 6 and figure 7 could be presented in one single figure since both aspects are complementary and target related aspects.
      • Are the authors certain that the effects observed are directly linked to the FACT complex in contrast to FACT independent roles of SPT16, if any exist? The experiment to address this would be to deplete SSRP1 and investigate whether the effects are identical, which would be the hypothesis to be tested.

      Significance

      My expertise is pluripotency and GRNs.

      I would judge the significance of the study as presented as low, mainly because at this moment it remains unclear what FACT indeed does concerning regulation of pluripotency.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      Summary:

      Klein and colleagues generate an ES cell model system with inducible FACT depletion to understand how loss of FACT affects gene regulation in ES cells. They find that FACT is critical for ES cell maintenance through multiple mechanisms including direct regulation of key pluripotency transcription factors (Sox2, Oct4, and Nanog), maintaining open chromatin at enhancers, and regulated enhancer RNA transcription. The paper is well-written, the experiments are generally well-controlled and appropriately interpreted and placed within the context of the field.

      Major comments:

      1. In general, the ChIP-seq and CUT&RUN data are not that similar. Although correlation seems reasonable (S2A), looking at the heatmaps in S2B/C these seem pretty different. It's not very clear if this is a case where CUT&RUN has higher specificity (and signal-to-noise, which is very clear from example tracks) or if these two methods are picking up biologically different sites. Could the authors include some overlap analysis of peaks and comment on these discrepancies. Looking at the example tracks in Figure 2B, it seems likely that prior SPT16 and SSRP1 ChIP-seq were relatively high-noise.
      2. Are motifs described in Figure 2E CUT&RUN only, and do prior ChIP-seq experiments also identify these motifs?
      3. The authors state that FACT depletion affects eRNA transcription and measured this using TT-seq. The analysis in Figure 3B seems to be all the different types of sites looked at together (genes, PROMPTs, etc). Is there evidence that eRNAs specifically are regulated by FACT loss. Could these be compared to DHS sites that lack FACT binding to support a direct role for FACT at these sites?
      4. One mechanism proposed for how FACT regulates enhancers is that it is required for maintaining a nucleosome free area, and when FACT is depleted nucleosomes invade the site (Figure 7). It wasn't clear if they compared distal DHS sites were FACT normal bound to those without FACT binding in the MNase experiments, which could help support the direct role or specificity of FACT in regulating those enhancers (or a subset of them).
      5. Data quality for nucleosome occupancy was a little strange (Figure 7F), where the two clones had very different MNase patterns at TSS sites. Could the authors comment on why there is such a strong difference between clones here.
      6. More details on some of the analysis steps would be really helpful in evaluating the experiments. Specifically, was any normalization done other than depth normalization? I ask this because the baseline levels for many samples in metaplots look quite different. For example, see Figure 7B where either clone 1 has a globally elevated (at least out 2kb) ratio of nucleosome in the IAA samples relative to the EtOH, or there is some technical difference in MNase. One suggestion is to look at methods in the CSAW R package to allow TMM based normalization strategies which may help.
      7. I appreciated the speculation section, and the possible relationship between FACT and paused RNAPII is interesting. While further experiments may be outside the scope of this work and I am not suggesting they do them, I am wondering if others have information on locations of paused RNAPII in ESC that would allow them to test if genes with paused RNAPII have a special requirement for FACT that they could use their current data to assess.

      Minor comments:

      1. When describing the peaks found in the text related to Figure 2 they refer to 'nonunique' peaks. Does this mean the intersection of the independent peak calls? Could they clarify this.
      2. In the text they refer to H3K56ac data in S2D and I don't see that panel. The color scheme for the 1D heatmaps (Figure 5A) is tough to appreciate the differences. I'd suggest something more linear rather than this spectral one might be easier to see.
      3. For the 2D heatmaps of binding, could they include the number of elements they are looking at for each group?
      4. Also for 2D heatmaps, I think the scale is Log2 (IAA/EtoH), but could they confirm that and include it in the figure?

      Significance

      • The use of degrader based approaches to depleting a protein allows refined kinetic and temporal assays which I think are important. Several papers showed a rapid invasion of nucleosomes after SWI/SNF loss using these kinds of approaches and revealed surprisingly fast replacement of SWI/SNF. This paper is consistent with those models, showing that another remodeler behaves the same, suggesting there may be general requirements for active chromatin remodeling to maintain the expression of these genes. It also highlights a key gap in how specificity works to target these enzymes remains somewhat unknown.
      • This work will be of interest to those studying detailed mechanisms of gene regulation. Compared to some other chromatin regulators, FACT is understudied and so this work will allow comparison between different chromatin remodeling complexes.
      • My experience: chromatin, gene regulation, cancer, genomics
    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      We were pleased with the overall very positive comments by the reviewers considering our study as convincing, well written and of importance for researchers not only in the fields of adrenal and gonadal disease, but also for endocrinology, tumorigenesis, sexual dimorphism and beyond.

      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      Lyraki et.al. investigated the molecular basis of sexual dimorphism in adrenocortical hyperplasia. They use genetically modified mice, ectopically overexpressing R-spondin in SF1-experessing tissues (Sf1-Rspo1-gain-of-function [GOF]), causing overactivation of WNT signalling. Effects of R-spondin overexpression is nicely visualized using RNA Scope in situ hybridization and immunofluorescence; Ectopic R-spondin overexpression resulted in sex-specific adrenocortical hyperplasia (female) and degeneration (male), without observed changes in overall steroidogenic activity. Comparisons of the transcriptome of both male and female GOF and control mice of 4 weeks of age using RNA-sequencing demonstrated differential expression of genes involved in the cell cycle and immune response, in a sex-specific manner. Consequently, a BrdU proliferation assay confirmed increased proliferation in the inner cortex of female GOF mice but not male GOF mice. In contrast, male GOF mice showed increased CD68 staining, suggestive for increased macrophage infiltration. Next, using a sex reversal mice model, they show that the sexual dimorphism in adrenal hyperplasia is dependent on testicular androgens rather than chromosomal sex. When female GOF mice were treated daily with dihydrotestosterone, their adrenal weight and adrenal proliferation (BrdU assay) reduced. Moreover, knocking out the androgen receptor in the adrenal cortex of both female and male mice overexpressing R-spondin resulted in increased adrenal weight in male mice to a level comparable to the weight of female adrenals.

      Altogether, I believe this manuscript convincingly shows that androgens act on adrenocortical cells and contribute to the sex-dependent susceptibility to adrenocortical hyperplasia. I have a few comments:

      1. Can the authors please briefly specify why for Figure 1D, three different statistical tests were performed? Based on the graphs it seems probable that this decided based on tests for normality and unequal variances? Were tests for normality and equal variances performed?

      We apologize for not further explaining the reasons for choosing different tests. Different versions of one-way ANOVA were performed for this figure to assess whether adrenal weight differs between groups of different sex and genotype. The choice of statistical test was based on different normality distributions and unequal variances. More specifically, most groups for the 3 weeks, 6 weeks, and 6 months timepoints displayed Gaussian distributions according to Shapiro-Wilk test. On the contrary, all the groups in the 12-month timepoint failed the Shapiro-Wilk normality test, prompting us to use a non-parametric test instead of ANOVA for this specific timepoint (the Kruskal-Wallis test). In addition, we tested for equality of variance using the Brown-Forsythe test. While the groups in the other timepoints display more or less equal variances, we confirmed significantly unequal standard deviations among the different groups in the 6-week timepoint (pThe manuscript will be amended accordingly.

      Would it be an idea to perform a two-way ANOVA (or equivalent test) instead to study the interactive effect of ectopic R-spondin overexpression and sex on adrenal weight as well as BrdU expression?

      We will perform the two-way ANOVA test as suggested.

      Based on the images of Axin2 expression in Figure 3B, Axin2 expression seems higher in the outer cortex of the female adrenal, compared to the outer cortex of the male adrenal (and the opposite in the inner cortex). Can you please explain why the opposite trend is seen in Figure 3D for the outer cortex?

      For our analysis we separated the adrenal into two regions with the outer cortex representing the region

      Please clearly state the number of mice used for each experiment, either in the results section or in the methods section. At line 146, it is stated that n=6 mice "are analysed". At the other sentences just the n was provided. Therefore, I was wondering if not all mice were analysed here? How many mice were used? Also, at line 169 it is stated that 9 female Sf1-Rspo1GOF mice were used, while at line 170, only 8 aging Sf1-Rspo1GOF mice weer checked for carcinoma. Please explain.

      We apologize for not having been more specific. The statement “n=6 mice analysed” in line 146 refers to the total number of animals analysed in this age group. We will clarify this by rephrasing the sentence: “At 6 weeks, all the male Sf1-Rspo1GOF adrenals (n=6) exhibited these degenerative changes to a varying degree….’

      We will also review the entire manuscript and provide the number of samples used for each experiment.

      Because of the low number, I am (based on this data only) not convinced that the presence of adrenocortical carcinoma in 1 of 8 female adrenals versus 0 of 8 male adrenals suggests sexual dimorphism (line 172).

      The massive hyperplasia observed in female, but not in male mice in combination with the observed tumour in the female cohort strongly suggests that tumour formation in Rspo1GOF mice is sex specific. However, we agree with the reviewer that the low number of mice analysed does not allow us to draw a firm conclusion. We will therefore soften our statement and instead discuss that the increased proliferation is very likely to lead to a higher risk of developing adrenal tumours in females.

      At line 159, please specify the age of the mice when steroid hormone levels were quantified.

      Steroid hormone levels were quantified in 6 weeks old animals and this information will be included in the revised version of our manuscript.

      I would suggest rephrasing sentence 186-188. Principle component analysis indeed nicely separates the samples on sex and Rspondin overexpression. However, I am not sure if one could say that sex was the “second most important factor” underlying the variation in gene expression.

      We will change the respective phrase to: “Strikingly, sex was responsible for 26.3% of the variation in gene expression patterns among our experimental groups…”

      The manuscript is well written, although the manuscript (especially the introduction) is quit lengthy and could be written more concisely.

      We will review and shorten the manuscript.

      Reviewer #1 (Significance (Required)): Of note, I am working in a specific endocrinological research niche and a bit distanced from this field. However, sexual dimorphism in (adrenal) diseases is a well-recognized phenomenon and the role of androgens and the androgen receptor in adrenal proliferation have previously been studied. Novel studies, like this study, are required to understand the mechanisms of sexual dimorphism in adrenal disease. This study is interesting especially (but not exclusively) for researchers working on adrenal or gonadal diseases or sexual dimorphism.

      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      Summary: In this paper, the authors focus on the molecular cause of the sexual dysmorphism observed in the adrenocortical phenotype induced by moderate Wnt/b-catenin activation due to the gain of function of Rspo1 (Sf1-Rspo1GOF mice). Indeed, while the phenotype is similar before puberty, the females later develop adrenocortical hyperplasia with increase in proliferation and adrenal weight whereas the adrenal cortex of the males becomes thinner with ages and presents recruitment of macrophages and monocytes. Interestingly, the proliferation in the adrenal cortex is suppressed by androgen treatment in female and increases by Ar KO in male supporting an important role of androgen in the regulation of adrenocortical proliferation.

      Major comments: - The authors describe an increase of Axin 2 expression in the outer part of the adrenal cortex in males compared to females but could the authors add a higher magnification of the outer cells in Sf1-Rspo1GOF to better illustrate this difference? Also, is this difference driven by an increase of dot per cell or an increase of the numbers of Axin 2 positive cells in this area?

      High power views of the Axin2 RNA-Scope analysis will be included. The metric for the data that we provide is dots/cell and thus reflects the expression of Axin2 per cell. This information will be added to the revised version of the manuscript.

      • The authors show that DHT injection in females leads to decrease proliferation but also increase the expression of Axin 2, a b-catenin target gene. As b-catenin is known to increase cell proliferation, did the authors look for instance, at the consequence on the expression of CCND1 or others b-catenin target genes involved in cell cycle regulation?

      MYC expression (a b-catenin target gene) was analysed, but was not found to be changed upon DHT treatment. qPCR analysis for CCND1, as suggested by this reviewer, will be performed.

      • Does DHT treatment in females or Ar KO in males affect the nucleo-cytoplasmic accumulation of b-catenin compared to controls? These results could help determine if Ar acts through b-catenin signaling or independently.

      Measuring b-catenin activity in DHT treated females and AR KO is also a very good suggestion. We will analyse samples by immunofluorescent staining, and (as nuclear b-catenin is notoriously difficult to detect) by Axin2 expression which can be used as a readout for canonical b-catenin signalling.

      • The authors did not mention if AS-RspoGOF males have macrophages and monocytes accumulation in the adrenal cortex as observed in Sf1-RspoGOF, this is an important information to better understand their origin and to know if they are due to mature or early embryonic dysregulation as AS-cre is activated later in time than Sf1-cre.

      This is an interesting point and we will provide immunostaining for CD68 and IBA1 on AS-RspoGOF animals.

      Minor comments: - In figure S8, could the authors add a H&E staining of AS-RspoGOF male adrenals in order to have all the controls?

      This information will be added to Figure S8

      • Based on the results presented here, the macrophage and monocyte observed in Sf1-RSPO1GOF males does not sound to be due to androgens as they are not observed in females treated with DHT. The authors should discuss these results and potential hypothesis explaining the macrophage recruitment.

      A sentence discussing this point will be included.

      • The authors should add a sentence or two to integrate their results in the ones previously published by Dumontet and collaborators (PMID: 29367455) regarding the consequences of DHT treatment on the regulation of Wnt signaling.

      A sentence putting our study into context with findings in Dumontet et al. will be added.

      Reviewer #2 (Significance (Required)):

      Although the potential role of DHT in the sexual dysmorphism has previously been suggested in mouse models developing adrenocortical tumors, the demonstration of the direct role of the androgen receptor in this regulation demonstrated here is an important key in the understanding of molecular causes of this phenomenon that is observed both in human and mice adrenocortical tumorigenesis. Moreover, this model opens new perspectives to study the importance of the immune system in the regulation of the adrenal cortex homeostasis. Based on my expertise on adrenocortical homeostasis, I know that this manuscript will be of particular interest for researchers in the field of adrenocortical function and tumorigenesis but also, more generally for people working on the consequences of DHT and sexual dysmorphism.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      Summary:

      In this paper, the authors focus on the molecular cause of the sexual dysmorphism observed in the adrenocortical phenotype induced by moderate Wnt/b-catenin activation due to the gain of function of Rspo1 (Sf1-Rspo1GOF mice). Indeed, while the phenotype is similar before puberty, the females later develop adrenocortical hyperplasia with increase in proliferation and adrenal weight whereas the adrenal cortex of the males becomes thinner with ages and presents recruitment of macrophages and monocytes. Interestingly, the proliferation in the adrenal cortex is suppressed by androgen treatment in female and increases by Ar KO in male supporting an important role of androgen in the regulation of adrenocortical proliferation.

      Major comments:

      • The authors describe an increase of Axin 2 expression in the outer part of the adrenal cortex in males compared to females but could the authors add a higher magnification of the outer cells in Sf1-Rspo1GOF to better illustrate this difference? Also, is this difference driven by an increase of dot per cell or an increase of the numbers of Axin 2 positive cells in this area?
      • The authors show that DHT injection in females leads to decrease proliferation but also increase the expression of Axin 2, a b-catenin target gene. As b-catenin is known to increase cell proliferation, did the authors look for instance, at the consequence on the expression of CCND1 or others b-catenin target genes involved in cell cycle regulation?
      • Does DHT treatment in females or Ar KO in males affect the nucleo-cytoplasmic accumulation of b-catenin compared to controls? These results could help determine if Ar acts through b-catenin signaling or independently.
      • The authors did not mention if AS-RspoGOF males have macrophages and monocytes accumulation in the adrenal cortex as observed in Sf1-RspoGOF, this is an important information to better understand their origin and to know if they are due to mature or early embryonic dysregulation as AS-cre is activated later in time than Sf1-cre.

      Minor comments:

      • In figure S8, could the authors add a H&E staining of AS-RspoGOF male adrenals in order to have all the controls?
      • Based on the results presented here, the macrophage and monocyte observed in Sf1-RSPO1GOF males does not sound to be due to androgens as they are not observed in females treated with DHT. The authors should discuss these results and potential hypothesis explaining the macrophage recruitment.
      • The authors should add a sentence or two to integrate their results in the ones previously published by Dumontet and collaborators (PMID: 29367455) regarding the consequences of DHT treatment on the regulation of Wnt signaling.

      Significance

      Although the potential role of DHT in the sexual dysmorphism has previously been suggested in mouse models developing adrenocortical tumors, the demonstration of the direct role of the androgen receptor in this regulation demonstrated here is an important key in the understanding of molecular causes of this phenomenon that is observed both in human and mice adrenocortical tumorigenesis. Moreover, this model opens new perspectives to study the importance of the immune system in the regulation of the adrenal cortex homeostasis. Based on my expertise on adrenocortical homeostasis, I know that this manuscript will be of particular interest for researchers in the field of adrenocortical function and tumorigenesis but also, more generally for people working on the consequences of DHT and sexual dysmorphism.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      Lyraki et.al. investigated the molecular basis of sexual dimorphism in adrenocortical hyperplasia. They use genetically modified mice, ectopically overexpressing R-spondin in SF1-experessing tissues (Sf1-Rspo1-gain-of-function [GOF]), causing overactivation of WNT signalling. Effects of R-spondin overexpression is nicely visualized using RNA Scope in situ hybridization and immunofluorescence; Ectopic R-spondin overexpression resulted in sex-specific adrenocortical hyperplasia (female) and degeneration (male), without observed changes in overall steroidogenic activity. Comparisons of the transcriptome of both male and female GOF and control mice of 4 weeks of age using RNA-sequencing demonstrated differential expression of genes involved in the cell cycle and immune response, in a sex-specific manner. Consequently, a BrdU proliferation assay confirmed increased proliferation in the inner cortex of female GOF mice but not male GOF mice. In contrast, male GOF mice showed increased CD68 staining, suggestive for increased macrophage infiltration.

      Next, using a sex reversal mice model, they show that the sexual dimorphism in adrenal hyperplasia is dependent on testicular androgens rather than chromosomal sex. When female GOF mice were treated daily with dihydrotestosterone, their adrenal weight and adrenal proliferation (BrdU assay) reduced. Moreover, knocking out the androgen receptor in the adrenal cortex of both female and male mice overexpressing R-spondin resulted in increased adrenal weight in male mice to a level comparable to the weight of female adrenals.

      Altogether, I believe this manuscript convincingly shows that androgens act on adrenocortical cells and contribute to the sex-dependent susceptibility to adrenocortical hyperplasia. I have a few comments:

      1. Can the authors please briefly specify why for Figure 1D, three different statistical tests were performed? Based on the graphs it seems probable that this decided based on tests for normality and unequal variances? Were tests for normality and equal variances performed?

      Would it be an idea to perform a two-way ANOVA (or equivalent test) instead to study the interactive effect of ectopic R-spondin overexpression and sex on adrenal weight as well as BrdU expression? 2. Based on the images of Axin2 expression in Figure 3B, Axin2 expression seems higher in the outer cortex of the female adrenal, compared to the outer cortex of the male adrenal (and the opposite in the inner cortex). Can you please explain why the opposite trend is seen in Figure 3D for the outer cortex? 3. Please clearly state the number of mice used for each experiment, either in the results section or in the methods section. At line 146, it is stated that n=6 mice "are analysed". At the other sentences just the n was provided. Therefore, I was wondering if not all mice were analysed here? How many mice were used? Also, at line 169 it is stated that 9 female Sf1-Rspo1GOF mice were used, while at line 170, only 8 aging Sf1-Rspo1GOF mice weer checked for carcinoma. Please explain. 4. Because of the low number, I am (based on this data only) not convinced that the presence of adrenocortical carcinoma in 1 of 8 female adrenals versus 0 of 8 male adrenals suggests sexual dimorphism (line 172). 5. At line 159, please specify the age of the mice when steroid hormone levels were quantified. 6. I would suggest rephrasing sentence 186-188. Principle component analysis indeed nicely separates the samples on sex and Rspondin overexpression. However, I am not sure if one could say that sex was the "second most important factor" underlying the variation in gene expression. 7. The manuscript is well written, although the manuscript (especially the introduction) is quit lengthy and could be written more concisely.

      Significance

      Of note, I am working in a specific endocrinological research niche and a bit distanced from this field. However, sexual dimorphism in (adrenal) diseases is a well-recognized phenomenon and the role of androgens and the androgen receptor in adrenal proliferation have previously been studied. Novel studies, like this study, are required to understand the mechanisms of sexual dimorphism in adrenal disease. This study is interesting especially (but not exclusively) for researchers working on adrenal or gonadal diseases or sexual dimorphism.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      The authors do not wish to provide a response at this time.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      In this work, Sil et al. use fluorescent microscopy and biochemical reconstitution to study the ribonucleoparticles formed by one of the two L1 transposon proteins: ORF1p. Authors show that fluorescently tagged ORF1p forms puncta in HeLa cells within several hours of induced expression. The authors use this system to test how various mutations in the ORF1p affect its ability to form puncta in cells. They then correlate this property to the ability to induce transposition, which is quantified using a reporter system. Mutants that fail to form puncta are also unable to induce transposition. This leads the authors to conclude that condensation of ORF1p is required for L1 retrotransposition. A two-color colocalization assay demonstrates that ORF1p is immobile within the observed puncta, showing no evidence of exchange and mixing with a co-expressed ORF1p labeled with a different fluorescent protein. In addition, the authors purify the ORF1p protein, and various mutant variants, and test their ability to undergo phase separation in vitro in various conditions where they vary the concentrations of ORF1p, the salt, and RNA. The simple phase separation assays are complemented with a biophysical characterization of the condensates, where the post-fusion relaxation into a circular shape of the droplet is quantified and used to determine the inverse capillary velocity, which reflects the condensate viscosity and surface tension. These properties and then correlated with the ability of the variants to form puncta and facilitate retrotransposition.

      It is an interesting and well-written article. The figures are neat and well documented. The experimental methods are described in sufficient detail. However, I believe that the conclusions made are not sufficiently supported by the presented evidence. The authors show correlation, not causation, of the ORF1p condensation and transposition. The evidence that the ORF1p particles form co-translationally, that they are condensates, and that they directly mediate transposition is insufficient. The in vitro work is interesting, but too preliminary and needs a more careful quantification. I encourage the authors to address my comments experimentally as much as they can. Where not possible, they could tone down the language and address the comments in writing and point out the limitations in the article text.

      Major comments:

      1. What is the evidence that ORF1p forms condensates in an endogenous situation? A more thorough discussion of the evidence, based on the literature is needed. Alternatively, authors could use antibodies (if available) to demonstrate that such structures indeed exist in cell culture of tissues.
      2. The model that the observed puncta form co-translationally through co-condensation of ORF1p and its encoding mRNA is intriguing and would indeed provide an elegant biophysical explanation for the discussed cis preference of transposition. In my opinion, this idea is the strongest part of the paper. I would advise the authors to provide more compelling evidence for this idea, as currently, it is not well-supported by the data. At the least, the authors need to show that the L1 mRNA is actually present in the studied condensates (for example, using smFISH on fixed cells). This will also allow the determination of the number of L1 mRNAs present in each condensate.
      3. If authors have access to a microscope that can perform FRAP measurements, I would strongly suggest such an assay, where the individual cytoplasmic and nuclear ORF1p puncta can be examined for their material properties as a function of time (compare 6 hours post-induction and 72 hours post-induction).
      4. Please provide a more detailed analysis of the formation of nuclear ORF1p condensates. How much later do they appear? The nucleus is the place where transposition occurs. Do the authors suggest that the co-translationally formed condensates enter the nucleus? Or do they form there de-novo? Is there also no colocalization in the nuclear foci? This could be addressed by a quantitative time-course.
      5. The in vitro assays only use the L1 mRNA fragment. Do other RNAs (for example total RNA, rRNA, mRNA) similarly affect ORF1p condensates? Other studies showed that the presence of specific RNA could nucleate the formation of condensates in vitro, particularly where non-specific RNA is also present, mimicking the cellular environment (Maharana et al. Science 2018, PMID: 29650702; Elguindy and Mendell, Nature 2021, PMID: 34108682). The authors should test if the observed effect of L1 mRNA fragment is sequence-specific. Length dependence should also be addressed, as it may be the key parameter for the "co-translational assembly and gelation" model.

      Minor comments:

      1. The K3/K4 and R261 variants don't form puncta and do not promote transposition, yet phase separate at a similar concentration in vitro. The stammer mutants phase separate less efficiently in vitro, yet form puncta and promote transposition. This suggests that the in vitro phase separation assay is not very informative of the protein's behavior in cells. To me, it suggests that the puncta observed in cells might not be formed through phase separation. Other mechanisms of puncta formation should be explored.
      2. Based on the fluorescent images, can the authors estimate what percent of the ORF1p protein is actually present in distinct condensates and how much is diffuse in the cytoplasm or nucleoplasm? How does the outside (diffuse) concentration change upon increased expression or ORF1p? Is there any evidence of a saturation concentration?
      3. Does the ORF1-Halo and ORF1-mNG2 colocalization change at longer time-points where larger condensates are observed?
      4. The authors often refer to the "the total area of condensed phase". This parameter is not very useful, as it highly depends on the experimental condition. Instead, authors should determine the apparent saturation concentration for each studied mutant in the presence and absence of RNA at a relevant RNA concentration. This requires increasing the resolution at the protein concentration axis and an unbiased analysis pipeline.
      5. It is shown that decreasing ORF1p protein concentration at a fixed salt concentration decreased the total condensed phase area but increased the protein partition coefficient. The DNA/RNA binding mutant R261A does not show this trend. Moreover, it is the only mutant that shows a change in the phase diagram upon the addition of RNA. One explanation is that there are nucleic acid contaminants present in the protein prep. In fact, the R261A mutant seems to also have a lower 260 nm peak relative to 280nm peak at the chromatogram. That the enrichment of the ORF-1p protein changes with increasing concentration strongly suggests that we are already looking at a multi-component system here, where the contaminant would be a second component. The authors do include an extra step in the purification protocol to reduce nucleic acid contamination. However, they could also run an ion-exchange chromatography to improve the purity. Alternatively, they could test if adding benzonase, RNAse or DNAse changes the phase diagram of the ORF1p alone.
      6. It would be great to see how the StammerDel behaves in vitro. The authors could at least try the purification with their current protocol. Full-length proteins often behave very differently than the fragments alone.

      Significance

      The model that the proteins encoded by the L1 transposon form condensates co-translationally and that these assemblies are functional units of the transposon that explain the cis-preference is a significant, important and interesting concept. In my opinion, this idea is the strongest part of the paper. However, unless supported by more evidence (such as experiments and analysis suggested above), it remains just an idea. This work would be of interest of the phase separation community as well as general cell biology and genetics field.

      My field of expertise is: biomolecular phase separation, quantitative microscopy, cell biology, protein biochemistry, developmental biology and genetics.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      This paper revisits aggregate formation by ORF1p, a nucleic acid (NA) binding protein encoded by the L1 retrotransposon. This topic dates to 1996 (Hohjoh and Singer - 1996 Embo J 15: 630) and was extensively examined again in 2012 using highly purified ORF1p by Callahan et al (Callahan et al - 2012 Nucleic Acids Res., 40, 813), to determine the effect of salt and nucleic acid on this process. The earlier studies employed chemical cross linking and gel electrophoresis to examine ORF1p aggregates in the presence and absence of NA and neither were cited in the present study. As ORF1p contains several intrinsically disordered regions (IDRs) ORF1p aggregates can form phase separated condensates (droplets) which were characterized microscopically in the present study, and the authors assume that condensate formation is intrinsic to the function of ORF1p in retrotransposition, or as they state on page 2: "...we hypothesized that ORF1p undergoes condensation to carry out its roles in L1 RNP formation...". The authors attempt to correlate the ability of L1 encoded ORF1p complexed or not with RNA to form phase separated condensates in parallel with retrotransposition assays. They couple these observations with in vitro studies on condensate formation by the purified protein.

      I have the following major comments:

      • (A) The functional relevance of condensate formation by IDR-containing proteins has been questioned (Martin, E. W. and A. S. Holehouse - 2020; Emerging Topics in Life Sciences 4: 307). These authors conclude their review as follows: "In summary, IDRs are ubiquitous and play a wide range of functional roles across the full spectrum of biology, and in a large number (likely the majority) of cases their biological function has nothing to do with the ability to form large macroscopic liquid droplets. The notion that the presence of an IDR means a protein has evolved to phase separate is an inaccurate inference that has unfortunately been used to justify questionable lines of inquiry and questionable experimental design." And in terms of ORF1p this admonition is exemplified by the findings of Newton et al (2021, Biophys J 120;2181) cited by the present authors. This study showed that phase separated condensates readily form by just the N-terminal 152 amino acids (NTD + coiled coil). As this region of ORF1p cannot bind NA, condensate formation is indifferent to RNA binding, an obviously critical function of ORF1p.
      • (B) Earlier studies (Ostertag et al - 2000; NAR 28:1418) showed that sufficient retrotransposition events have occurred by 48 hours after introduction of an L1 retrotransposition reporter to be readily detectable by whole cell staining for the retrotransposition-generated reporter gene product. The 48-hour lag presumably reflects the time to accumulate sufficient L1RNPs or their retrotransposed products to be detectable. Does this mean that the puncta (Fig 1F) accumulating during the first 24 hours after introduction of their full-length L1 retrotransposition reporter (Fig 1C) are the L1RNPs generated by the reporter? If not, what are they? If they are L1RNPs, are they thought to be or expected to exhibit the properties of phase separated condensates or are such properties just a feature of disembodied ORF1p that the authors posit could form an active L1RNP? The Ostertag paper should be cited here given its relevance to this issue.
      • (C) Four of the IDRs in ORF1p harbor or are juxtaposed to phosphorylation sites essential for retrotransposition (their citation - Cook et al, 2015). As the authors expressed their purified proteins in E. coli, it is not phosphorylated and would not only be inactive for retrotransposition and given the structural effects of phosphorylation (e.g., Bah, A., et al.;2015; Nature, 510, 106) it would differ significantly from the structure of the active protein. As variables they introduce into ORF1p several not too subtle mutations particularly regarding the ORF1 coiled coil. They thereby aim to assess the role or particulars of ORF1p condensate formation for L1 retrotransposition. In their Abstract they state (p.1, l. 11) "...we propose that ORF1p oligomerization on L1 RNA drives the formation of a dynamic L1 condensate that is essential for retrotransposition."
      • (D) Although the authors provide no direct experimental evidence for the above statement and whatever the authors mean by "dynamic L1 condensate" how does this conclusion materially differ from the conclusions published by Naufer et al, in 2016 (NAR; 44,281), which also was not cited by the authors. Naufer et al used single molecule studies and highly purified ORF1p that had been expressed in insect cells (and thus was fully phosphorylated, Cook et al, 2015). They showed that oligomerization of nucleic acid (NA)-ORF1p complexes to a compacted stably bound polymer was positively correlated with retrotransposition. Both properties could be eliminated by coiled coil mutations that had no effect on biochemical assays of ORF1p activity - high affinity NA binding and NA chaperone activity. As both properties map to the carboxy terminal-half of ORF1p, the inactivating coiled coil mutations are an example of the numerous instances of strong epistasis exerted by amino acid substitutions in the coiled coil on the retrotransposition activity of ORF1p. In some cases epistasis is exerted at the single residue level (e.g., Martin,et al - 2008, Nucleic Acids Res., 36, 5845; Furano, et al. - 2020, PLOS Genetics 16 e1008991.)

      While the authors are apparently also not mindful of the PLOS Genetics paper examining the effect of a single inactivating coiled coil substitution at the level of microscopically observed condensates could have provided compelling evidence linking their formation and retrotransposition. On the other hand, lack of a condensate-based readout for single amino acid inactivating coiled coil mutations would question the validity of equating ORF1p condensates with retrotransposition competence. - (E) The afore mentioned Callahan et al study (2012, NAR, 40, 813) in addition to producing results partly recapitulated in Fig. 2 of the present paper, showed that ORF1p polymerization was mediated by interactions between the highly conserved RRM-containing region of ORF1p. This observation is consistent with previous studies showing RRM-mediated protein interactions of other proteins (Clery, et al 2008, Curr. Opin. Struct. Biol., 18, 290; Kielkopf, et al Genes Dev., 18, 1513)

      As well as including the missing citations of the L1 literature, implications of the above considerations need to be addressed before publication.

      I have the following additional comments and issues:

      1. p.2. l. 8, the citation to TPRT should include Luan,et al.- 1993, Cell 72: 595
      2. p. 5, middle of 2nd para - what does "different diffusivity" mean? - what are "stereotyped puncta"?

      Any invocation of cis preference should cite the foundational study by Kaplan, N., et al. (1985). "Evolution and extinction of transposable elements in Mendelian populations." Genetics 109 459. 3. p.10 middle paragraph, the authors state: "The decreased phase separation of the R261A mutant was unexpected, as we predicted that mutating a core RNA-binding residue would only affect condensation in the presence of RNA. We also noted that the protein partition coefficients of the R261A condensed phases were higher than their counterparts for WT and K3A/K4A. Taken together, these experiments showed that K3/K4 and R261 are not essential for protein condensation in vitro."

      these findings would have been predicted by the afore mentioned findings of Newton et al, which should be cited here. 4. p. 14, first paragraph "we predicted that stammer-deleted ORF1p would maintain an elongated coiled coil conformation that might disfavor trimer- trimer interactions that are mediated by the N terminal half of the protein (Figure 4A, left two cartoons)."

      It seems that the authors are stating that different fully formed trimers can form larger complexes mediated by interactions between their coiled coils, an idea apparently based on results published by Khazina and Weichenreider (2018). This paper states that "Additional biophysical characterizations suggest that L1ORF1p trimers form a semi-stable structure that can partially open up, indicating how trimers could form larger assemblies of L1ORF1p on LINE-1 RNA." However, the cited Khazina structural data ((PDB) entry 6FIA)) were derived from coiled coils that had been solubilized to monomers in guanidinium HCl from inclusion bodies (insoluble aggregates) that had accumulated during their synthesis in E. coli...a common condition for highly expressed proteins. Fully denatured ORF1p coiled coils such as these, which also lack the entire NTD are an in vitro artifact and never exist in "nature". It is almost certain that ORF1p monomers trimerize while being synthesized on adjacent ribosomes (e.g., Bertolini et al.- 2021; Science 371: 57). I am not aware of any biochemical evidence from the Martin laboratory on mouse ORF1p or the Weichenrieder or Furano laboratories on human ORF1p indicating that the coiled coils of fully formed trimers synthesized in vivo can unravel to mediate interactions between different trimers. In fact, the authors' results in Fig 1F supports this contention. 5. p.10, Legend to Figure 1G The cells were stained simultaneously with two Halo ligand dyes (Halo-JF549 and Halo- JF646), giving a positive control for colocalization.

      Why is staining the same ligand (Halo) with two different dyes a colocalization control? 6. The authors conclude their paper with the statement "The L1 system characterized in this work employs a uniquely powerful combination of biochemical reconstitution, live-cell imaging, and functional phenotyping in cells. In vitro reconstitution allows us to study the biophysical properties of condensates in a minimal and controllable system."

      However, there are several instances where the in vitro biochemical properties of ORF1p variants are somewhat discordant with their in vivo results. In the case of their coiled coil mutants. replacement of the coiled coil stammer, MEL (uniquely invariant for more than 50 Myr of primate coiled coil evolution) with AAA or AEA exhibited reduced retrotransposition that was not accompanied by a corresponding reduction in condensate formation (Fig 4). In another instance, while mutation of the highly conserved residue (R261) necessary for RNA binding eliminated retrotransposition it did not have a corresponding effect on condensate formation even in the presence of RNA (Fig 3).

      General comments on the Figures - Although I rather liked the cartoon version of ORF1p (Fig 1B) and when used to show the location of mutated site, versions that purport to show the effect of mutations on structure (Fig 4A) are misleading and should be eliminated.

      Closing Comment:

      Overall, I enjoyed reading this paper, and feel that when the issues I raised are appropriately addressed and the relevant missing citations are included it would make a useful contribution. However, it seems that the authors could make a more compelling case that dissociates condensate formation of ORF1p and its activity in retrotransposition, consistent with the Martin and Holehouse review cited above. So, I urge them to reconsider their conclusions. I did not find the highly speculative discussion about the relevance of phase separation / condensate formation to cis preference at all convincing as it is just as it is just as likely (maybe more so) to be enforced at the level of selection - evolutionary failures, by definition, are not propagated.

      Significance

      Although this paper addresses a long-studied topic in L1 biology, namely how the L1 encoded proteins assemble into an L1 RNP (the retrotransposition intermediate), the authors posit that the formation of phase/separated protein condensates (visible as microscopic droplets) are involved. Such droplets are a currently popular biochemical feature exhibited by some proteins, but their functional relevance is a currently a contentious topic in protein biochemistry. I do not think that the authors make a convincing case that condensate formation is involved, rather I think that their evidence provides reasonable evidence that condensation has no role. I urge the authors to consider this possibility, but whatever which conclusion proves to be correct, their study would make a useful contribution to the field.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      This study shows that the ORF1 protein of the LINE-1 retroelement forms puncta in vivo that they define as cytoplasmic biomolecular condensates based on the characterization of the biophysical properties of ORF1p condensates in vitro.

      Defective retrotransposition of some ORF1p mutants correlates with defects in puncta formation in vivo and alteration of biophysical properties of in vitro condensates leading the authors to conclude that condensation of ORF1p is required for retrotransposition.

      The study combines biochemical reconstitution, biophysic analysis and live-cell imaging. In particular, the authors take advantage of a new powerful tool they have developed based on the tagging of ORF1 within a functional L1 reporter element. The fluorescent tag allows following the dynamics of ORF1p by live-cell imaging.

      The key conclusion is that ORF1p condensation is important for L1 retrotransposition. The correlation is clearly shown but raises several questions: Is the defect in ORF1p condensation the only explanation for the retrotransposition defects of the ORF1p mutants analyzed here? Can we exclude that the mutations in ORF1p affect other functions of the protein such as its binding to RNA (as in the case of the R261 mutant) and cis-preference, or its binding to other factors involved in L1 replication? Could the loss of these functions affect L1 retrotransposition independently of ORF1p condensation?

      Major comments:

      On several occasions, the authors propose that ORF1p-HALO dynamics in vivo is linked to its co-translational association with L1 RNA. However, they never show the presence of L1 RNAs in ORF1p-HALO puncta in vivo. To strengthen the conclusion that the puncta observed in vivo are L1 RNPs, the authors should add experiments showing the presence of L1 RNA in the cytoplasmic puncta (by RNA FISH) or that the puncta are dependent on the presence of L1 RNA (expressing ORF1p-HALO alone should not be sufficient for puncta formation). These experiments seem to be realistic in few weeks with the tools already available in the laboratory.

      Apart from this comment, the authors are cautious in their conclusions. It is clear, as they indicate in the Discussion, that showing that ORF1p condensation is also required for the mobility of other retroelements will strengthen the implication of ORF1p condensation in L1 replication.

      The data are well presented and the methods described in detail so that others should be able to use them. The experiments seem to be adequately replicated and the statistical analysis adequate.

      Minor comments:

      Figure 1F: Having the pictures of cell nuclei (like in Figure 1D) would be nice to know how many cells we are looking at in this panel.

      Figure 2E: it is surprising that there is no correlation between the ORF1p:RNA ratio and the number of individual fusion events (i.e. curves of ORF1p+RNA 10000:1 and 1000:1 overlap while 3000:1 is different). Could the authors discuss this point?

      Previous studies are appropriately referenced. Text and figures are clear and precise.

      Referees cross-commenting

      The main critical points shared by all reviewers are: 1) the need to show the presence of LINE1 RNAs in ORF1p condensates in vivo and 2) the lack of evidence for causality between ORF1 condensate formation and L1 transposition efficiency (At this stage, the authors should moderate their conclusions, especially in the abstract). Regarding the other reviews, we noticed the need to cite additional relevant studies in the field (reviewer #2) and the interesting points raised by reviewer #3 to investigate the formation of ORF1 condensates in an endogenous situation, and whether other RNAs do affect ORF1p condensates.

      Significance

      The study is technically interesting in that it describes a new system for tracking ORF1p puncta formation in vivo. The findings are not unexpected because it comes after the publication of Newton et al. in 2021 (PMID : 33798566), describing that ORF1p does phase separation in vitro. Furthermore, the fact that RNPs form "membrane-less" structures is already established in other situations as the authors point out. Compared to Newton et al., condensates are better-defined biochemically, especially for RNA association features and in vivo dynamics.

      The ORF1 protein is widely studied for its role in L1 retrotransposition. The protein forms a homotrimer in vitro, binds to L1 mRNA in a cis-preferential manner, and is required for retrotransposition. On the other hand, RNA-binding proteins are often involved in the formation of membrane-less organelles (stress granules, RNA processing bodies...). These observations suggest that ORF1p may also form RNP condensates required for L1 retrotransposition. A study published in Biophysical Journal in 2021 (Newton et al. PMID: 33798566) has already reported the phase separation of the LINE-1 ORF1p that is mediated by the N-terminus and coiled-coil domain. This former study was based on in vitro microscopy and NMR approaches and is cited in the submitted manuscript. The study submitted to Rev commons goes further by analyzing the biochemical properties of ORF1p condensates in the presence of L1 RNA and by following in vivo condensates of ORF1p (WT or mutants) expressed from a functional L1 reporter element by live-cell imaging. The findings will interest a wide audience investigating the biology of retroelements and more particularly scientists who study the L1 retrotransposon.

      I am an expert in retrotransposon biology but I do not work on L1. I am not expert enough to assess the quality and relevance of the biophysical experiments in the paper. In particular, panels 2D, 3B and 3D were difficult to analyze.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      • *

      The authors proposed that the stable and opened membrane neck that connects the bud to the cytoplasm may persist for a long time in the infected cell during active RNA production. The viral ring-shaped nsPs is supposed to have an important role of maintaining this stable high-curvature membrane neck. It is suggested that the nsP1 dodecamer may pull together the membrane inner surface in the neck region via electrostatic interactions. Namely the authors observed that in the absence of negatively charged membrane lipids nsP1 did not bind appreciably to the membrane. The presented experimental data and theoretical consideration suggest that the CHIKV spherule consists of a membrane bud filled with viral RNA, and has a macromolecular complex gating the opening of this bud to the cytoplasm.

      The presented results are interesting, the manuscript is well written and can be published after revision. The following comments are offered to the authors' consideration.

      We thank the reviewer for this positive overall assessment.

      1.Since there is no protein coating over the curved surface of the membrane bud, the authors concluded that the membrane neck must be stabilised by specific mechanism involving nsP1. It was further assumed that the viral protein nsP1 serves as a base for the assembly of of a larger protein complex at the neck of the membrane bud. In addition to suggested mechanism of the neck stabilization, thin highly curved membrane neck can be stabilised also by accumulation of the membrane components having the appropriate membrane curvature (i. E. negative intrinsic curvature or anisotropic intrinsic curvature), see Kralj-Iglic et al., Eur. Phys. J. B., 10: 5-8 (1999), https://doi.org/10.1007/s100510050822.

      Please discuss this issue in the manuscript.

      This is a good point, thank you for making it. In the revised manuscript we discuss both the possibility of lipid sorting into the neck region by nsP1 (lines 217-222), and the mentioned paper regarding anisotropic inclusions (lines 268-271).

      • *

      2.In Eq. (1) the Gaussian curvature term (appearing in Helfrich bending energy term) is not included. Usually this term is omitted in the case of closed membrane shapes (i.e. so-called spherical topology) due to validity of the Gauss-Bonnet theorem. In the present manuscript/work the shape equation was solved for the membrane patch. Can you therefore please explain shortly to the reader why you can omit the Gaussian curvature term from Eq.(1). For example due fixed inclination angle and foxed curvature at the boundary, .....

      Thanks for finding this omission. We have now revised the manuscript to describe why we can omit the Gaussian curvature term (lines 241-245).

      • *

      • *

      3.«Sigma« and »P« can be considered also as global Lagrange multipliers for the constraint of the fixed total membrane area of the bud (including the neck membrane) and the constraint of the fixed volume of the bud. If you then take into account separately also the equation for the fixed membrane area you could predict different shapes of the bud (by solving the shape equation) at fixed area of the bud, calculated for different values of the model parameters (and different boundary conditions) - in this case Sigma is the result of variational procedure (as well P if you consider also the constraint for the fixed volume of the bud). See for example Medical & Biological Engineering & Computing, vol. 37, pp. 125-129, 1999 and J. Phys. Condens. Matter, vol. 4, pp. 1647-1657, 1992. Can you please shortly discuss in the manuscript also this issue.

      This is an interesting point. We now discuss this and cite the mentioned papers at the end of the theory section in the supplementary information (lines 203-205) as well as briefly mentioning it when discussing Eq. 1 (lines 240-242).

      • *

      **Referees cross-commenting**

      I agree as well.

      • *

      Reviewer #1 (Significance (Required)):

      The presented experimental and theoretical results are interesting, the manuscript is well written and can be published after revision.

      We thank the reviewer for this appreciative comment.

      • *

      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      Summary:

      In their manuscript "Architecture of the chikungunya virus replication organelle" Laurent and colleagues show:

      • *

      - the 3D structure of the "neck complex" that forms the gateway between the Chikungunya virus replication/transcription organelle (termed "spherule") and the cytoplasm of infected cells. The structure was obtained by native electron cryo-tomography and sub-tomogram averaging of BHK cells infected with a single-cycle replicon system encoding all components of the viral replication machinery. The nominal resolution of the structure is 28 Å. The viral nsP1 protein, for which two high-resolution structures have previously been published, could unambiguously be located within the density of the neck complex.

      • *

      - nsP1 interaction with membranes relies on lipids with a single negative net charge, such as POPS, POPG and PI, whereas two different PIPs with a negative net charge greater than one support nsP1 binding less efficiently. These membrane determinants for nsP1 binding were elucidated using two complementary methods: multilamellar vesicle pulldown assays and confocal imaging of fluorescently labeled giant unilamellar vesicles in the presence of fluorescently labeled nsP1. Purified nsP1 was produced in E. coli.

      • *

      - nsP1 recruits nsP2 (another component of the neck complex) to membranes with suitable lipid composition. This observation was made using the same multilamellar vesicle pulldown assay.

      • *

      - the 3D organization of the viral genome within the spherule, demonstrating that each spherule contains one copy of the genome as a double-stranded RNA molecule. This analysis was carried out by segmentation of the same tomograms that were used to visualize the neck complex.

      • *

      - the force exerted by RNA polymerization within the spherules is sufficient to drive membrane remodeling. This is a theoretical argument based on mathematical modelling.

      • *

      Major comments:

      The article is written clearly and all major claims seem justified. The biochemical assays are presented in duplicates or triplicates, which is sufficient to derive the provided conclusions. The workflow for electron cryo-tomography analysis seems sound, even though the low number of individual particles (=64) for sub-tomogram averaging of the neck complex limits the resolution of its final structure. Given the strong competition in the field, and considering the high experimental workload that would be required for further improvement of the resolution, I do not recommend any additional benchwork for this paper.

      We thank the reviewer for this assessment, especially for recognising the challenge in obtaining a larger number of spherule subtomograms under the complex replicon particle protocol we had to use in order to study the BSL3 CHIKV under BSL2 conditions.

      • *

      My only concern is the accuracy of the experimental genome length measurements, which has important implications for their mechanistic interpretation. The type of tomograms that have been recorded here inherently suffers from anisotropy with respect to both resolution and contrast. This makes accurate tracing of tangled filaments very challenging, and in this light, I congratulate the authors for the impressively good agreement of their average experimentally determined genome length with the theoretical genome length (Figure 4C). As to be expected, however, the second supplementary video clearly shows multiple gaps in the traced genome, implying that there must necessarily be errors in the length measurements. Unless there is a possibility to confidently estimate the magnitude of these errors, my preferred interpretation would be that the vast majority of imaged spherules - regardless of their temporary volume in the moment of sample freezing - likely contains precisely one copy of the double-stranded RNA genome, and not fractions thereof as is suggested in the text (for example, line 305: "Analysis of the cryo-electron tomograms gave a clear answer to the question of the membrane bud contents: the lumen of full-size spherules consistently contains 0.8-0.9 copies."). I feel that this subject deserves more discussion in the manuscript. If the authors prefer to keep their original interpretation that the majority of spherules contains only fractions of full genomes, I invite them to provide an explanation for why their experimental genome length measurements are sufficiently accurate to favor this rather surprising conclusion over my more trivial interpretation. If I understand correctly, my preferred interpretation has implications for the mathematical model for membrane remodeling (Equation 2).

      This is a good point. In fact, we agree that our original manuscript and wording was unclear and we agree with the reviewer’s interpretation (“my preferred interpretation would be that the vast majority of imaged spherules - regardless of their temporary volume in the moment of sample freezing - likely contains precisely one copy of the double-stranded RNA genome”). We have now changed the text to reflect that we believe we have a 10-20% false negative rate in the filament tracing and that the most likely interpretation is indeed that each spherule has exactly one genome copy (lines 207-210). In addition, we looked at the possible consequences of the slight underestimation of the filament length for the mathematical model, and describe on lines 257-264 why this in fact would have no impact on the conclusions of the modeling.

      • *

      Minor comments:

      Virus taxa should be capitalized and written in italics wherever applicable. I recommend adhering to the following rules:

      https://talk.ictvonline.org/information/w/faq/386/how-to-write-virus-species-and-other-taxa-names

      Thank you for helping us clarify this. In response to this we have now italicized and capitalized all virus taxa.

      Figure 2I looks as if the pink cross-section of nsP1 has not been scaled correctly. Comparison to Figure 2H gives me the impression that the diameter of the pink nsP1 ring in Figure 2I should be scaled down relative to the greyscale neck complex.

      We would like to than the reviewer for their keen eye. There was indeed a scaling problem, which we have now solved in the updated Fig. 2.

      • *

      The caption of Figure 2 calls more panels than are provided in the figure. The caption "panel E" seems to be obsolete.

      Thanks for finding this mistake. We have now revised Fig. 2 and its legend.

      • *

      In the methods, centrifugation speed should be given in units of relative centrifugal force (rcf) instead of revolutions per minute (rpm), especially for the MLV pulldown assay where no rotor is indicated.

      We agree and have changed this on lines 482,490,524,531,543 and 597 of the manuscript

      • *

      In the methods for the MLV assay, the lipid:protein ratio is given with 500:1. It should be specified whether this is a mass ratio or a molar ratio.

      It was molar ratio which we have now specified on line 595.

      In the methods, the buffer composition for the mass photometry measurement should be indicated.

      Good point. We added this on lines 632-633.

      • *

      **Referees cross-commenting**

      • *

      I agree to the other reviewers' remarks.

      • *

      Reviewer #2 (Significance (Required)):

      • *

      Chikungunya virus is a very important human pathogen, and research on the architecture of its replication/transcription organelle holds great promise for the development of future therapies. Laurent and colleagues advanced this field by providing pioneering low-resolution 3D structures of the membrane-bound viral protein complex and the viral RNA content of this organelle in situ. In addition, they also assessed the lipid requirements for membrane interaction of the primary viral membrane anchor of this complex, nsP1, in vitro. Underlining the importance of these results, a competing group submitted a partially overlapping study to BioRXiv three months ahead (https://doi.org/10.1101/2022.04.08.487651). Whereas the competing group describes the structure of the neck complex at a much higher resolution, it neither analyzes the RNA content of the spherules nor does it address the lipid preferences of nsP1. The present study by Laurent and colleagues should therefore be of great interest to many virologists and cellular biologists.

      • *

      I am a structural virologist with a focus on envelope glycoproteins. Of relevance to this review, I have experience with cellular electron cryo-tomography and sub-tomogram averaging, as well as in-vitro protein/liposome interaction assays. I do not feel qualified to evaluate the details of the mathematical model for membrane remodeling that is used in the last results section of this manuscript.

      We thank reviewer 2 for this positive overall assessment of our work.

      • *

      Reviewer #3 (Evidence, reproducibility and clarity (Required)):

      • *

      This is an interesting and well written paper describing the replication spherules generated by Chikungunya virus. Cryo-electron tomography was used to determine a low-resolution structure of the spherule, suggesting that nsP1 is located at the neck of the spherule. Segmentation of the tomograms combined with mathematical modeling was used to produce a structural model for RNA organization in the spherule, suggesting that each spherule contained approximately one copy of a full double-stranded RNA genome. I have a few minor comments:

      • *

      We are thankful for this positive overall assessment of our work.

      • *

      The structural studies were complemented with lipid binding assays, showing that nsP1 has an affinity for anionic lipids. While interesting, the connection of these experiments to the rest of the study seems tenuous. There is no further mention of them in the discussion or how they relate to the tomography and their replication model.

      We agree that those data were not as well integrated into the paper as they could have been, and are thankful that the reviewer pointed this out. To improve the integration of these data into the manuscript, we have expanded on two ways in which the reconstitution data relate to the rest of the paper: (i) the tomography led us to hypothesise that nsP1 recruits other nsPs to the membrane, which we could confirm with the reconstitution (lines 151-152, and throughout that parapgraph), and (ii) the lipid preferences of nsP1 that we could measure using the titrating pulldown experiments inform the possible models for how the spherule memebrane is remodeled since nsP1 binds lipids that cannot on their own stabilize a neck shape (lines 217-222). We have also slightly expanded the discussion of the biochemistry and its relation to other data in the paper (lines 307-311).

      • *

      It is a nice match between the calculated length of the RNA (assumed to be ds) and the length of the vector, but the segmentation of the RNA is not completely convincing based on the provided images. It is difficult to distinguish the RNA strands from the noise and other components in the spherule and, at least by eye, the segments do not seem very connected. Please provide some more details on the tracing algorithm. Has it been validated on a known system?

      We appreciate this comment and recognise that we did not sufficiently explain the tracing algorithm. This software was in fact custom written (by others, ca 10 years ago) for cryo-electron tomography and has since been used by others in several studies of cellular cryo-electron tomograms, e.g. to study actin cytoskeleton. We now mention this in the results (lines 195-196) and methods (lines 462-463).

      The tomogram video is nice, but it would be good to see a raw image as well, preferably covering a wider view that includes the whole cell, as well as a tomogram that represents the entire field of the reconstruction.

      This is a good suggestion. We unfortunately cannot provide images covering the entire cells since this is beyond the field of view of the electron microscope (and an image montage was not acquired at the time of data collection). However, we are now providing an additional supplementary movie that shows the entire field of view of the tomogram. In addition, we have uploaded two of the tomograms (including the uncropped tomogram from Figure 1) to EMDB where they will be downloadable by everyone after publication. We hope the reviewer appreciates that this is all that is technically possible at the moment.

      • *

      In figure 2, the panels are mislabeled relative to the legend, which refers to the color guide as its own panel.

      Thanks for pointing this out, we have rectified this in the revised Fig. 2 and its legend.

      Line 405: C36 symmetry? Why? Shouldn't it be C12 symmetry?

      36-fold symmetry was applied to the lipid membrane part to smoothen it further. The membrane part of the structure is simply outlining the neck shape and this is better visualised in this smoothened representation as also done e.g. in the study of the coronavirus neck complex (Wolff et al, Science 2020). We changed the methods text to make this more clear (line 449).

      • *

      Line 409: "fit" should be "fitted"

      Thanks, Corrected in the revised manuscript line 454.

      **Referees cross-commenting**

      • *

      I think we are all in good agreement, and I believe that the concerns raised can be addressed though a better explanation of the methods and improved discussion of their results.

      We also agree and believe we have addressed all of the remaining concerns in the revised manuscript.

      • *

      • *

      Reviewer #3 (Significance (Required)):

      • *

      This is a rather focused study, showing tomography data on the alphavirus replication complex. The main significance of the study is the description of the spherule's dimension and its relationship to the nature of the RNA, which provided a model for the replication process. While somewhat narrow in scope, the study should be of interest to people working in the virus replication and virus structure field. The lipid data are interesting, but does not seem well integrated with the rest of the study.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      This is an interesting and well written paper describing the replication spherules generated by Chikungunya virus. Cryo-electron tomography was used to determine a low-resolution structure of the spherule, suggesting that nsP1 is located at the neck of the spherule. Segmentation of the tomograms combined with mathematical modeling was used to produce a structural model for RNA organization in the spherule, suggesting that each spherule contained approximately one copy of a full double-stranded RNA genome. I have a few minor comments:

      The structural studies were complemented with lipid binding assays, showing that nsP1 has an affinity for anionic lipids. While interesting, the connection of these experiments to the rest of the study seems tenuous. There is no further mention of them in the discussion or how they relate to the tomography and their replication model.

      It is a nice match between the calculated length of the RNA (assumed to be ds) and the length of the vector, but the segmentation of the RNA is not completely convincing based on the provided images. It is difficult to distinguish the RNA strands from the noise and other components in the spherule and, at least by eye, the segments do not seem very connected. Please provide some more details on the tracing algorithm. Has it been validated on a known system?

      The tomogram video is nice, but it would be good to see a raw image as well, preferably covering a wider view that includes the whole cell, as well as a tomogram that represents the entire field of the reconstruction.

      In figure 2, the panels are mislabeled relative to the legend, which refers to the color guide as its own panel.

      Line 405: C36 symmetry? Why? Shouldn't it be C12 symmetry? Line 409: "fit" should be "fitted"

      Referees cross-commenting

      I think we are all in good agreement, and I believe that the concerns raised can be addressed though a better explanation of the methods and improved discussion of their results.

      Significance

      This is a rather focused study, showing tomography data on the alphavirus replication complex. The main significance of the study is the description of the spherule's dimension and its relationship to the nature of the RNA, which provided a model for the replication process. While somewhat narrow in scope, the study should be of interest to people working in the virus replication and virus structure field. The lipid data are interesting, but does not seem well integrated with the rest of the study.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      Summary:

      In their manuscript "Architecture of the chikungunya virus replication organelle" Laurent and colleagues show:

      • the 3D structure of the "neck complex" that forms the gateway between the Chikungunya virus replication/transcription organelle (termed "spherule") and the cytoplasm of infected cells. The structure was obtained by native electron cryo-tomography and sub-tomogram averaging of BHK cells infected with a single-cycle replicon system encoding all components of the viral replication machinery. The nominal resolution of the structure is 28 Å. The viral nsP1 protein, for which two high-resolution structures have previously been published, could unambiguously be located within the density of the neck complex.
      • nsP1 interaction with membranes relies on lipids with a single negative net charge, such as POPS, POPG and PI, whereas two different PIPs with a negative net charge greater than one support nsP1 binding less efficiently. These membrane determinants for nsP1 binding were elucidated using two complementary methods: multilamellar vesicle pulldown assays and confocal imaging of fluorescently labeled giant unilamellar vesicles in the presence of fluorescently labeled nsP1. Purified nsP1 was produced in E. coli.
      • nsP1 recruits nsP2 (another component of the neck complex) to membranes with suitable lipid composition. This observation was made using the same multilamellar vesicle pulldown assay.
      • the 3D organization of the viral genome within the spherule, demonstrating that each spherule contains one copy of the genome as a double-stranded RNA molecule. This analysis was carried out by segmentation of the same tomograms that were used to visualize the neck complex.
      • the force exerted by RNA polymerization within the spherules is sufficient to drive membrane remodeling. This is a theoretical argument based on mathematical modelling.

      Major comments:

      The article is written clearly and all major claims seem justified. The biochemical assays are presented in duplicates or triplicates, which is sufficient to derive the provided conclusions. The workflow for electron cryo-tomography analysis seems sound, even though the low number of individual particles (=64) for sub-tomogram averaging of the neck complex limits the resolution of its final structure. Given the strong competition in the field, and considering the high experimental workload that would be required for further improvement of the resolution, I do not recommend any additional benchwork for this paper.

      My only concern is the accuracy of the experimental genome length measurements, which has important implications for their mechanistic interpretation. The type of tomograms that have been recorded here inherently suffers from anisotropy with respect to both resolution and contrast. This makes accurate tracing of tangled filaments very challenging, and in this light, I congratulate the authors for the impressively good agreement of their average experimentally determined genome length with the theoretical genome length (Figure 4C). As to be expected, however, the second supplementary video clearly shows multiple gaps in the traced genome, implying that there must necessarily be errors in the length measurements. Unless there is a possibility to confidently estimate the magnitude of these errors, my preferred interpretation would be that the vast majority of imaged spherules - regardless of their temporary volume in the moment of sample freezing - likely contains precisely one copy of the double-stranded RNA genome, and not fractions thereof as is suggested in the text (for example, line 305: "Analysis of the cryo-electron tomograms gave a clear answer to the question of the membrane bud contents: the lumen of full-size spherules consistently contains 0.8-0.9 copies."). I feel that this subject deserves more discussion in the manuscript. If the authors prefer to keep their original interpretation that the majority of spherules contains only fractions of full genomes, I invite them to provide an explanation for why their experimental genome length measurements are sufficiently accurate to favor this rather surprising conclusion over my more trivial interpretation. If I understand correctly, my preferred interpretation has implications for the mathematical model for membrane remodeling (Equation 2).

      Minor comments:

      Virus taxa should be capitalized and written in italics wherever applicable. I recommend adhering to the following rules: https://talk.ictvonline.org/information/w/faq/386/how-to-write-virus-species-and-other-taxa-names

      Figure 2I looks as if the pink cross-section of nsP1 has not been scaled correctly. Comparison to Figure 2H gives me the impression that the diameter of the pink nsP1 ring in Figure 2I should be scaled down relative to the greyscale neck complex.

      The caption of Figure 2 calls more panels than are provided in the figure. The caption "panel E" seems to be obsolete.

      In the methods, centrifugation speed should be given in units of relative centrifugal force (rcf) instead of revolutions per minute (rpm), especially for the MLV pulldown assay where no rotor is indicated.

      In the methods for the MLV assay, the lipid:protein ratio is given with 500:1. It should be specified whether this is a mass ratio or a molar ratio.

      In the methods, the buffer composition for the mass photometry measurement should be indicated.

      Referees cross-commenting

      I agree to the other reviewers' remarks.

      Significance

      Chikungunya virus is a very important human pathogen, and research on the architecture of its replication/transcription organelle holds great promise for the development of future therapies. Laurent and colleagues advanced this field by providing pioneering low-resolution 3D structures of the membrane-bound viral protein complex and the viral RNA content of this organelle in situ. In addition, they also assessed the lipid requirements for membrane interaction of the primary viral membrane anchor of this complex, nsP1, in vitro. Underlining the importance of these results, a competing group submitted a partially overlapping study to BioRXiv three months ahead (https://doi.org/10.1101/2022.04.08.487651). Whereas the competing group describes the structure of the neck complex at a much higher resolution, it neither analyzes the RNA content of the spherules nor does it address the lipid preferences of nsP1. The present study by Laurent and colleagues should therefore be of great interest to many virologists and cellular biologists.

      I am a structural virologist with a focus on envelope glycoproteins. Of relevance to this review, I have experience with cellular electron cryo-tomography and sub-tomogram averaging, as well as in-vitro protein/liposome interaction assays. I do not feel qualified to evaluate the details of the mathematical model for membrane remodeling that is used in the last results section of this manuscript.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      The authors proposed that the stable and opened membrane neck that connects the bud to the cytoplasm may persist for a long time in the infected cell during active RNA production. The viral ring-shaped nsPs is supposed to have an important role of maintaining this stable high-curvature membrane neck. It is suggested that the nsP1 dodecamer may pull together the membrane inner surface in the neck region via electrostatic interactions. Namely the authors observed that in the absence of negatively charged membrane lipids nsP1 did not bind appreciably to the membrane. The presented experimental data and theoretical consideration suggest that the CHIKV spherule consists of a membrane bud filled with viral RNA, and has a macromolecular complex gating the opening of this bud to the cytoplasm.

      The presented results are interesting, the manuscript is well written and can be published after revision. The following comments are offered to the authors' consideration.

      1. Since there is no protein coating over the curved surface of the membrane bud, the authors concluded that the membrane neck must be stabilised by specific mechanism involving nsP1. It was further assumed that the viral protein nsP1 serves as a base for the assembly of of a larger protein complex at the neck of the membrane bud. In addition to suggested mechanism of the neck stabilization, thin highly curved membrane neck can be stabilised also by accumulation of the membrane components having the appropriate membrane curvature (i. E. negative intrinsic curvature or anisotropic intrinsic curvature), see Kralj-Iglic et al., Eur. Phys. J. B., 10: 5-8 (1999), https://doi.org/10.1007/s100510050822.<br /> Please discuss this issue in the manuscript.
      2. In Eq. (1) the Gaussian curvature term (appearing in Helfrich bending energy term) is not included. Usually this term is omitted in the case of closed membrane shapes (i.e. so-called spherical topology) due to validity of the Gauss-Bonnet theorem. In the present manuscript/work the shape equation was solved for the membrane patch. Can you therefore please explain shortly to the reader why you can omit the Gaussian curvature term from Eq.(1). For example due fixed inclination angle and foxed curvature at the boundary, .....
      3. «Sigma« and »P« can be considered also as global Lagrange multipliers for the constraint of the fixed total membrane area of the bud (including the neck membrane) and the constraint of the fixed volume of the bud. If you then take into account separately also the equation for the fixed membrane area you could predict different shapes of the bud (by solving the shape equation) at fixed area of the bud, calculated for different values of the model parameters (and different boundary conditions) - in this case Sigma is the result of variational procedure (as well P if you consider also the constraint for the fixed volume of the bud). See for example Medical & Biological Engineering & Computing, vol. 37, pp. 125-129, 1999 and J. Phys. Condens. Matter, vol. 4, pp. 1647-1657, 1992. Can you please shortly discuss in the manuscript also this issue.

      Referees cross-commenting

      I agree as well.

      Significance

      The presented experimental and theoretical results are interesting, the manuscript is well written and can be published after revision.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      The current resubmission is our revision plan only. Therefore the authors do not wish to provide a response at this time. We will include our response to reviewers with our full resubmission.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      Summary:

      Nguyen and Goetz here explore the roles of Tau tubulin kinase 2 (TTBK2) in ciliary stability. Using a murine conditional null MEF model, they ablate TTBK2 from cells with established cilia and monitor the impact on ciliary structures. They observe loss of cilia over time, acoompanied by changes in centriolar satellites, axonemal microtubule composition and intraflagellar transport protein levels at the basal body. They note changes in autophagy proteins in the absence of TTBK2 and find that pharmacological manipulation of actin dynamics impacts on the ciliary phenotypes seen in TTBK2 deficient cells.

      Major comments:

      1. The phrase 'centrosomal compartment' is potentially ambiguous. This is not a generally-used term and its use to mean the base of the cilium, PCM and satellites is spatially uninformative; there is not a 'compartment' meant here in the sense of a discrete structure. Especially in the context of the title, I suggest this phrase should be revised for greater clarity, but it may also be useful to rephrase it in the Discussion.
      2. As a question for discussion/ consideration: Is TTBK2 a satellite component, or is it envisaged that these functions are all derived from a CEP164-associated fraction? This point is related to the point raised above about a 'compartment', in that different populations of TTBK2 might be involved differently in cilium regulation. An experimental approach to this might be to use a CEP164-TTBK2 fusion (such as was described by Cajanek and Nigg in PNAS 2014) and test if this can rescue the TTBK2 deficiency.
      3. The statement on p.8 that 'Loss of TTBK2 results in increased actin activity' is not directly supported by the data, so should be revised. The actin analyses are indirect and show attenuated effects, so some caution is warranted in the interpretation of these findings (as is the case in the Discussion). With that point in mind, I am unsure if the title's inclusion of an actin-based mechanism for TTBK2 functions in cilium stability is optimal.
      4. A key technical issue is that the description of how intensity measurements were made should be improved. It is not clear what area or volume was used for this in the various experiments that measured axonemal/ centrosomal/ peri-centrosomal regions, particularly when the centrioles are further apart from one another. As the intensity measurements form a key part of the paper, this should be clarified throughout.
      5. From the images presented in Fig. 2A, the classification of the number of buds/ axonemal breaks is not clear. Improved images of the different outcomes of TTBK2 removal should be shown to make the basis for the proposed differentiation between these phenotypes more convincing. This is visible in the movies, but the still images are not ideal.
      6. A control should be presented for the loss of TTBK2 in the drug treatment experiments in Figure 4, to confirm that there is no impact on the recombination.
      7. A control for the relative expression level of the rescuing TTBK2-GFP protein should be provided in support of the data in Fig. S1D. This should also be included for the data in Fig. S4.

      Minor comments:

      1. Fig. 1B- 'lambda tubulin' should be corrected. Fig 7A should also correct the tubulin designation.
      2. It would be helpful to indicate in individual figures throughout that the bar graphs show means +/- SEM (it is stated in the Methods, but it would be desirable to have the Figures be entirely self-contained).
      3. Fig S1E does not show individual experiments as data points; this should be corrected for consistency.
      4. The phospho-Aurora A staining in Fig. S2C should be quantitated; there appears to be an increased level of this signal in the absence of TTBK2.
      5. The Ac-Tub staining shown in Fig. 3A is confusing, given the intensity measurements presented. More representative images should be shown.
      6. It is unclear whether there is a decline in PCM1 intensity levels over the timecourse of the (vehicle only) experiment in Fig. 5B. This should be tested for. It should also be specified in the Figure Legend that these cells remain serum starved for the duration of the timecourse (assuming the experiment follows the design outlined in Fig. 1A).
      7. The images in Figure 7A and 7C are not at sufficient resolution to distinguish IFT88 or IFT140 signals; blow-up panels should be included.
      8. Scale bars should be included in Figs. 2, S2, 3, 5, S3, S4, 6, 7.
      9. Details of the serum starvation regime should be provided in the Methods (% serum).

      Referees cross-commenting

      The comments from Reviewers 1 and 2 are detailed and constructive. There is good convergence between all three reviewers on a requirement for additional data on the involvement of actin and on the analysis of the centriolar satellites. As these are the main themes of the study, such information seems essential to support the principal conclusions drawn.

      I question Reviewer 1's stipulation that a quantitative proteomic analysis of PCM1 interactors is needed to sustain the conclusion that the satellites are substantively altered upon TTBK2 depletion. This would be a very strong experiment, but I feel that the analysis of a selection of individual satellite components, as done here, is sufficient to support the conclusion that the satellites are impacted by TTBK loss. Obviously, the more detailed the analysis (i.e., the more proteins examined), the better, but I am not convinced that this will bring us so much closer to the mechanism of TTBK2. I concur with the point raised for revision by Reviewer 2, that the actual role of the satellites in cilium stability should be addressed more robustly, however.

      Significance

      The importance of the primary cilium as a signalling organelle makes TTBK2 function a theme of general interest. A potential role for TTBK2 in the maintenance of cilium stability through a link to the centriolar satellites is new. Readership would include people working on centrosomes/ cilia and related themes.

      My expertise: cell biology of centrosomes/ cilia.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      Summary:

      This study by Nguyen and Goetz, explores the role of Tau tubulin kinase 2 (TTBK2) in cilium integrity in cultured cells. TTBK2 is a serine-threonine kinase that plays a key role in cilium initiation and has been implicated in maintaining assembled cilia in adult mice. The authors developed an inducible system to deplete TTBK2 once cilia are assembled to investigate the role of this kinase in cilium stability in a cell culture system. Using this system and live- and fluorescent- imaging approaches, the authors find that TTBK2 promotes cilium stability.

      The authors suggest three parallel pathways by which TTBK2 maintains cilia: 1) through tubulin polyglutamylation and actin dynamics, 2) through regulation of IFT pools at the centrosome, and 3) through regulation of centriolar satellite composition. Some of these conclusions (especially 1 and 3) need to be revisited and need some additional experiments (detailed below).

      Major comments:

      1. In the abstract and discussion, the authors suggest that TTBK2 functions via centriolar satellites to promote cilium stability. While the data support a role for TTBK2 in centriolar satellite homeostasis, it is unclear whether satellites contribute to cilium stability. Given that restoration of centriolar satellite composition using rapamycin does not rescue cilia loss upon TTBK2 depletion, these sections need to be revised.
      2. The authors show that TTBK2 regulates centriolar satellite composition via its kinase activity. Is TTBK2's kinase activity important for cilium stability, actin dynamics and IFT localization?
      3. Do changes in tubulin poly-glutamylation precede the loss of cilia phenotype observed upon depletion of TTBK2? Currently changes in tubulin post-translational modifications are assessed at 72h post-tamoxifen treatment. In order to support the hypothesis that changes in tubulin poly-glutamylation drives cilia loss upon TTBK2 depletion (as suggested in the abstract), these experiments must be repeated at an earlier time points, such as 24-48 h post tamoxifin treatment).
      4. By using small molecule inhibitors that alter actin dynamics, the authors suggest that loss of TTBK2 regulates actin polymerization leading to cilium instability. Are there any observable changes in cellular F-actin upon loss of TTBK2? Phalloidin staining and/or a biochemical assay to directly assess soluble vs. filamentous actin would be helpful to bolster the claim that TTBK2 regulates actin dynamics.

      Minor comments:

      The manuscript is well written, and easy to follow. Prior studies are referenced appropriately. I have some minor points that would improve the presentation and clarity of the manuscript:

      1. I would recommend the authors improve the presentation of figures by making the size of graphs more consistent across figures. For example, graphs in Figure 4 should be increased in size as they are currently very hard to read. Importantly, scale bars are missing from most immunofluorescence images.
      2. Statistical tests are missing in Figure S1 A and S1 E.
      3. Are the additional puncta observed around the centrosome in the TTBK2 immunofluorescence images (Figure 1B) non-specific signals? Also, gamma-tubulin is mislabeled as lambda-tubulin in the figure.
      4. Insets would be helpful for images Figure 1C, S1C, 2A, 4B, 7A, 7C.
      5. Quantification of fluorescence intensity is missing for Figure S2 C.
      6. The title for Figure S2 is misleading as it suggests there is a change in cilia disassembly factors upon loss of TTBK2, while the data show no changes in any of the factors assessed.

      Significance

      Although we now have some understanding of how cilium assembly is initiated, how the cilium is maintained at steady state remains poorly understood. Therefore, this study exploring the role of TTBK2 in ciliary structure maintenance is timely and will be of interest to cilia biologists. TTBK2 has previously been implicated in cilium maintenance, and the link between TTBK2 and IFT recruitment, and tubulin post-translational modifications has been previously described using hypomorphic mutants of TTBK2. Though this study specifically looks TTBK2's role in cilium maintenance at steady state, these previous studies (referenced in the manuscript) do diminish the novelty of the manuscript. Mechanistic details of how TTBK2 regulates actin, IFT dynamics and tubulin post-translational modifications to control cilium stability remain unknown but are important avenues for future research.

      Reviewers' expertise: cilia and centrosome biology, microscopy.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      TTBK2 is kinase mutated in spinocerebellar ataxia type 11 (SCA11). It is well characterized for its functions and molecular mechanism of action during cilium assembly and ciliary signaling. In this manuscript, Nguyen et al. investigated the role of TTBK2 during cilium stability using mouse embryonic fibroblasts derived from Ttbk2cmut embryos. This system allowed them to inducibly deplete TTBK2 in ciliated cells and thus, address the specific functions of TTBK2 during cilium maintenance and stability in ciliated cells. Upon TTBK2 loss, the ciliary axoneme was destabilized in part via an increased frequency of cilia breaks and primary cilia was lost, which was shown by live imaging experiments. To dissect the mechanism of axoneme destabilization, they performed rescue experiments with drug treatments as well as quantified of basal body, satellite and ciliary abundance of key ciliogenesis factors and tubulin modifications. Based on results from these experiments, the authors concluded that altered actin dynamics, reduction in axonemal polyglutamylation as well as changes in satellite-associated PCM1 and OFD1 and IFT levels at the basal body together underlies the axonemal destabilization phenotypes associated with TTBK2. Overall, the manuscript is well-written and the presented data is robust.

      I list below three major concerns I have on the manuscript along with detailed explanation. Although questions addressed in the manuscript and the tools the authors generated will be of general interest, the presented data falls short in supporting the major conclusions of the manuscript that pertain to the mechanisms by which TTBK2 regulate cilium stability and maintenance.

      1. Previous papers from the Goetz lab showed that TTBK2 is important for the structure and stability of the ciliary axoneme (i.e. reduced polyglutamylation of cilia in Ttbk2 hypomorphic mutants and null cells, disorganized axonemal microtubules). Although authors study the roles of TTBK2 in cilium stability with temporal control and identify altered centriolar satellite composition and actin dynamics as potential mechanisms, TTBK2's function in this process is not unexpected.
      2. The authors suggest that TTBK2 regulate cilium stability through parallel pathways that operate via actin, centriolar satellites, autophagy and IFT machinery. The presented data is not sufficient to assess whether these are direct or indirect consequences of TTBK2 depletion, which results in lack of a coherent model for how TTBK2 operates in ciliated cells. For example, what is the regulatory/functional link between TTBK2, actin and myosin VI during cilium maintenance? The authors discuss that TTBK2 BioID data includes actin-binding proteins and suggest actin polymerization as one potential mechanism. To gain insight into how TTBK2 alters actin dynamics, they can follow-up on the BioID hits to explain how TTBK2 depletion alters actin dynamics. Alternatively, they can treat cells with specific inhibitors of actin polymerization to determine whether axonemal destabilization phenotypes are rescued.
      3. The authors define changes in centriolar satellite composition as a consequence of TTBK2 depletion based on reduced PCM1 and elevated OFD1 and CEP290 intensity at the pericentrosomal region in TTBK2-depleted cells. Centriolar satellites are composed of about 200 proteins and a significant number of these proteins are implicated in ciliogenesis including the previously characterized interactors of TTBK2. Changes in PCM1, OFD1 and CEP290 levels in the 1 uM ROI authors defined around the basal body is not sufficient to conclude that satellite composition is altered and that this change underlies the axoneme destabilization and disassembly. Proteomic pulldown of PCM1 before and after tamoxifen addition will reveal how the satellite proteome is affected by TTBK2 depletion and will strengthen authors' conclusions.

      Below are other comments I have on the data and its analysis and presentation:

      1. Fig. 1B: TTBK2 at the basal body was assessed as "positive" or "negative". Instead of classification into two groups, quantification of the basal body levels of TTBK2 in a time course manner will be more informative in correlating phenotype with TTBK2 depletion.
      2. Fig. 1C: In addition to percentage of ciliated cells, the cilium length should also be quantified in a time course manner to determine how TTBK2 depletion leads to cilium disassembly by 48-72 h. For representative images presented, insets are required.
      3. Fig. S1A: Western blot quantification of TTBK2 levels in addition to mRNA levels will be informative in assessing changes in protein levels upon tamoxifen addition.
      4. Statistical analysis for Fig. 2B is required. How many cilia / experimental replicates were quantified in Fig. 2B?
      5. Fig. S2: Bowie et al. 2018 paper reported increased Kif2a levels at the basal body as one possible mechanism for cilium instability in TTBK2 mutant cells. However, TTBK2 depletion in ciliated cells does not have a similar effect. How do the authors explain this difference on effects of TTBK2 in basal body Kif2a levels?
      6. How did the authors quantify between budding and axonemal events in Fig. 2? In general, the methods section for analysis of the microscopy data should be written in a more detailed way to be able to assess the presented data.
      7. Acetylated tubulin, but not glut tubulin, ciliary levels are decreased upon TTBK2 depletion. Can such change directly affect cilium stability? What triggers changes in glutamylation upon TTBK2 depletion?
      8. "Loss of TTBK2 results in an increase in actin activity" (pg.8) is an overconclusion based on the presented data. What is the effect of TTBK2 depletion on actin levels and organization? Specifically, the authors can also stain for actin in the cilia to determine whether it underlies the increased excision events reported by live imaging of cilia. Given that Nager et al. 2017 paper identified actin-myosin activity as a mechanism for ciliary ectocytosis, this will be interesting to test using similar assays to quantify actin dynamics in this paper. Moreover, Yeyati et al. 2018 paper on dissecting KDM3A's function during actin dynamics and cilium stability used quantitative approaches that can be adapted by the authors.
      9. Quantification of centriolar satellite levels of PCM1, OFD1 and CEP290 can be done in a different way to more specifically identify the satellite pools of these proteins. The quantification of their pericentrosomal levels was done by drawing 1 uM ROI around the centrosome. Therefore, the levels might represent changes in the centrosomal pool of these proteins, but not the satellite pool, which would then change the author's conclusions. A method that the authors can adapt is the Gupta et al. Cell 2015 paper. Such quantification will ensure that the authors are not drawing their conclusions based on changes in basal body levels of the proteins. Moreover, the representative images presented for centriolar satellite pools of these proteins in Fig. 5, Fig. 6 and Fig. S4 should be modified to include not only the basal body pool but the whole cell including an inset. Since satellites are distributed throughout the cell, presenting whole cell images is important to assess the remaining pool beyond the basal body.
      10. Does TTBK2 depletion alter the cellular abundance of CEP290, OFD1 and PCM1? This might underlie the changes in the basal body abundance of these proteins.
      11. Fig. 4C-E: Graphs are too small compared to figures.
      12. In multiple parts of the manuscript, the authors stated that the mechanisms of TTBK2 during cilium initiation is not known. Including major papers from the Goetz lab, there are many studies in literature that defines how TTBK2 regulates cilium initiation. The major unknowns relates to its functions during cilium maintenance and disassembly.

      Significance

      Although cilium assembly has been studied with extensive detail, relatively less is known about them mechanisms of cilium maintenance. This is in part due to lack of tools to manipulate protein expression in ciliated cells. The MEF cells used in this study is an elegant tool to address questions related to cilium maintenance and stability. Moreover, the live imaging experiments performed in TTBK2 depleted ciliated cells are excellent experiments in showing the spatiotemporal events that lead to axoneme destabilization. By identifying TTBK2 as a critical regulator of these processes, the results of the manuscript advances our understanding of how cilium is maintained as well as to the molecular defects that underlie SCA11. The topic is also of general interest to cell and developmental biologists.

      As a reviewer, my expertise is on questions that pertain to the biogenesis of centrosome and cilium and we extensively use cell biology, proteomics and biochemistry approaches.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      The manuscript by Neville et al addresses the link between the localization and the activity of the so-called "Pins complex" or "LGN complex", that has been shown to regulate mitotic spindle orientation in most animal cell types and tissues. In most cell types, the polarized localization of the complex in the mitotic cell (which can vary between apical and basolateral, depending on the context) localizes pulling forces to dictate the orientation. The authors reexplore the notion that this polarized localization of the complex is sufficient to dictate spindle orientation, and propose that an additional step of "activation" of the complex is necessary to refine positioning of the spindle.

      The experiments are performed in the follicular epithelium (FE), an epithelial sheet of cell that surrounds the drosophila developing oocyte and nurse cells in the ovarium. Like in many other epithelia, cell divisions in the FE are planar (the cell divides in the plane of the epithelium). The authors first confirm that planar divisions in this epithelium depends on the function of Pins and its partner mud, and that the interaction between the two partners is necessary, like in many other epithelial structures. Planar divisions are often associated with a lateral/basolateral "ring" of the Pins complex during mitosis. The authors show that in the FE, Pins is essentially apical in interphase and becomes enriched at the lateral cortex during mitosis, however a significant apical component remains, whereas mud is almost entirely absent from the apical cortex. Pins being "upstream" of mud in the complex, this is a first hint that the localization of Pins is not sufficient to dictate the localization of mud and of the pulling forces.

      The authors then replace wt Pins, whose cortical anchoring strongly relies on its interaction with Gai subunits, with a constitutively membrane anchored version (via a N-terminal myristylation). They show that the localization of myr-Pins mimics that of wt-Pins, with a lateral enrichment in mitosis, and a significant apical component. Since a Myr-RFP alone shows a similar distribution, they conclude that the restricted localization of Pins in mitosis is a consequence of general membrane characteristics in mitosis, rather than the result of a dedicated mechanism of Pins subcellular restriction. Remarkably, Myr-Pins also rescues Pins loss-of-function spindle orientation defects.

      They further show that the cortical localization of Pins does not require its interaction with Dlg (unlike what has been suggested in other epithelia). However, spindle orientation requires Dlg, and in particular it requires the direct Dlg/Pins interaction. The activity of Dlg in the FE appears to be independent from khc73 and Gukholder, two of its partners involved in its activity in microtubule capture and spindle orientation in other cell types. Based on all these observations, the authors propose that Dlg serves as an activator that controls Pins activity in a subregion of its localization domain (in this case, the lateral cortex of the mitotic FE cell). They propose to test this idea by relocalizing Pins at the apical cortex, using Inscuteable ectopic expression. With the tools that they use to drive Inscuteable expression, they obtain two populations of cells. One population has a stronger apical that basolateral Insc distribution, and the spindle is reoriented along the apical-basal axis; the other population has higher basolateral than apical levels of Insc distribution, and the spindle remains planar. The authors write that Pins localization is unchanged between the two subsets of cells (although I do not entirely agree with them on that point, see below), and that although Mud is modestly recruited to the apical cortex in the first population, it remains essentially basolateral in both. In this situation, the localization of Insc in the cell is therefore a better predictor of spindle orientation than that of Pins or Mud. Remarkably, removing Dlg in an Insc overexpression context leads to a dramatic shift towards apical-basal reorientation of the spindle, suggesting that loss of Dlg-dependent activation of the lateral Pins complex reveals an Insc-dependent apical activation of the complex. Overall, I find the demonstration convincing and the conclusion appropriate. One of the limitations of the study is the use of different drivers and reporters for the localization of Pins, which makes it hard to compare different situations, but not to the point that it would jeopardize the main conclusions. I do not have major remarks on the paper, only a few minor observations and suggestion of simple experiments that would complete the study.

      Minor:

      What happens to Pins and Mud in Dlg mutant cells that overexpress Insc and behave as InscA? Are they still essentially lateral, or are they more efficiently recruited to the apical cortex?

      This is a terrific question. Of course we would love to know and intend to find out.

      One way to do this (consistent with the manuscript) would be to generate flies that are Dlg[1P20], FRT19A/RFP-nls, hsflp, FRT19A; TJ-GAL4/+; Pins-Tom, GFP-Mud/UAS-Insc. (Note that these flies would only allow us to image Mud; we would have to repeat the experiment using GFP FRT19A; hsflp 38 to see Pins. This isn’t ideal given that we’d like to image both together). Generating these flies is a major technical challenge because of the number of transgenes and chromosomes involved.

      Our preferred way to do this would be to generate flies that are Dlg[1P20]/Dlg[2]; TJ-GAL4/+; Pins-Tom, GFP-Mud/UAS-Insc. So far, we’ve been unsuccessful. We are now undertaking a modified crossing scheme that we hope will solve the problem, though we aren’t overly optimistic about the outcome. We find that the temperature-sensitive mutation Dlg[2] presents an activation barrier; while we are able to generate flies that are Dlg[2] / FM7 in combination with transgenes and/or mutations on other chromosomes, we do not always recover the Dlg[2] / Y males (which must develop at 18degrees) from these complex genotypes.

      In the longer term (outside the scope of revision), we are working to develop more tools for imaging Mud and Pins that we hope will help answer this question.

      Regarding the competition between Pins and Insc for dictating the apical versus basolateral localization of Insc, the Insc-expression threshold model could be easily tested in Pins62/62 mutants, where it is expected that only InscA localization should be observed, even at 25{degree sign}C (unless Pins is required for the cortical recruitment of Insc, as it is the case in NBs - see Yu et al 2000 for example).

      This is another great experiment and one we’d love to carry out. Again, the genetics are currently challenging, only because both UAS-Inscuteable and FRT82B pinsp62 are on the third chromosome. (Right now we’re trying to hop UAS-Inscuteable to the second).

      However, we do have another idea for testing the threshold model, which is to repeat the experiment in which we express UAS-Insc in cells that are DlgIP20/IP20 at 25oC. Because the relevant cells (UAS-Insc OX in Dlg mitotic clones) are relatively rare, we have not yet been able to collect enough examples to make a firm conclusion. However, our preliminary results (only six cells so far!) suggest that more InscB cells are observed at the lower temperature, consistent with the threshold model.

      I do not agree with the authors on P.10 and Figure 6A-D, when they claim that the apical enrichment of Pins is equivalent in both InscA and InscB cells. The number of measured cells is very low, and the ratio of apical/lateral Pins differs between the two sets of cells. The number of cells should be increased and the ratios compared with a relevant statistic method.

      Totally fair. We are working to add more data to these panels (6B and 6D). The trend observed in 6D may be softening in agreement with the reviewer’s prediction, although we currently don’t yet have enough new data points to be confident in that conclusion. Therefore, we have not yet updated the manuscript, though we expect to do so during the revision period. We will also add a statistical comparison. Importantly, as the reviewer suggested, this does not alter our conclusions.

      A lot of the claims on Pins localization rely on overexpression (generally in a Pins null background) of tagged Pins expressed from different promoters or drivers, and fused to different fluorescent tags. Therefore, it is difficult to evaluate to which extent the localization reflects an endogenous expression level, and to compare the different situations. As the cortical localization of Pins relies on interaction with cortical partners (mostly GDP-bound Gai) which are themselves in limiting quantity in the cell, and in the case of Gai-GDP, regulated by Pins GDI activity, this poses a problem when comparing their distribution, because the expression level of Pins may contribute to its cortical/cytoplasmic ratio, but also to its lateral/apical distribution. Although I understand that the authors have been using tools that were already available for this study, I think it would be more convincing if all the Pins localization studies were performed with endogenously tagged Pins, even those with Myr localization sequences. In an age of CRISPR-Cas-dependent homologous recombination, I think the generation of such alleles should have been possible. Although this would probably not change the main claims of the paper, it would have made a more convincing case for the localization studies.

      We don’t disagree at all with this point. We did indeed try to stick with the published UAS-Pins-myr-GFP, not only for convenience but because it allows us to make comparisons to other studies using the same tool (Chanet et al Current Biology 2017 and Camuglia et al eLife 2022). Another consideration is that we used only one driver across our experiments (Traffic jam-GAL4). It is quite weak at the developmental stages that we examine, meaning that overexpression is not a major concern. (Indeed we have struggled with the opposite problem).

      We certainly take the reviewer’s comment seriously and we therefore described it in the manuscript. We are currently working to develop endogenous tools using CRISPR.

      Paragraph added to Discussion – Limitations of our Study:

      “Another technical consideration is that our work makes use of transgenes under the control of Traffic jam-GAL4. While this strategy allows us to compare our results with previous work employing the same or similar tools, a drawback is that we cannot guarantee that Traffic jam-GAL4 drives equivalent expression to the endogenous Pins promoter (Chanet et al., 2017, Camuglia et al., 2022). However, given that Traffic jam-GAL4 is fairly weak at the developmental stages examined, we are not especially concerned about overexpression effects.”

      The authors should indicate in the figure legends or in the methods that the spindle orientation measurements for controls for Pins62/62 are reused between figures 1, 3, 4, 5, 6 , and between figure 3, 4 and 5, respectively.

      Absolutely. Added to the Methods section.

      Reviewer #1 (Significance (Required)):

      Altogether, this study makes a convincing case that the localization of the core members of the pulling force complex, Pins and Mud, is not entirely sufficient to localize active force generation, and that the complex must be activated locally, at least in the FE. The notion of activation of the Pins/LGN complex has probably been on many people's mind for years: Pins/LGN works as a closed/open switch depending on the number of Gai subunits it interacts with, it must be phosphorylated, etc... suggesting that not all cortical Pins/LGN was active and involved in force generation. However the study presented here shows an interesting case where localization and activation are clearly disconnected. The authors show how Dlg plays this role in physiological conditions in the FE, and use ectopic expression of Insc to show that, at least in an artificial context, Insc can have the same "activating activity" (or at least an activating activity that is stronger than its apical recruitment capability and stronger than Dlg's activating activity). It is to my knowledge the first case of such a clear dissociation. In their discussion, the authors are careful not to generalize the observation to other tissues. Although I did not reexplore all that has been published on the Pins/LGN-NuMA/Mud complex over the last 20 years, my understanding is that despite interesting cases of distribution of the complex like that of Mud in the tricellular junction in the notum, the localization model can still explain most of the phenotypes that have been described without invoking an activation step. If it is the case, then the activation model is another variation (an interesting one!) on the regulation of the core machinery, which are plentiful as the authors indicate in their introduction, and is maybe specific to the FE; if not, then it would be interesting to push the discussion further by reexamining previous results in other systems, and pinpointing those phenotypes that could be better explained with an activation step.

      Overall, I find this is an elegant piece of work, which should be of interest to many cell and developmental biologists beyond the community of spindle orientation aficionados.

      Reviewer #2 (Evidence, reproducibility and clarity (Required)): Summary: The manuscript by Neville et al. addressed the mechanism how conserved spindle regulators (Pins/Mud/Gai/Dynein) control spindle orientation in the proliferating epithelia by revising "the canonical model", using the Drosophila follicular epithelium (FE). The authors examined the epistatic relationship among Pins, Mud and Dlg in FE and found that Pins controls the cortical localization of Mud by utilizing mutant analyses, and suggested their localization does not fully overlap using the newly generated knock-in allele. They also showed that Pins relocalization during mitosis depends on cortical remodeling, or passive model, where Pins localization changes with other membrane-anchored proteins. Their data further suggest that Pins cortical localization is not influenced by Dlg, but Pins-interacting domain of Dlg does affect spindle orientation. Based on these results, the authors propose that Dlg controls spindle orientation not by redistributing Pins, but by promoting (or "activating" from their definition) Pins-dependent spindle orientation. Interestingly, ectopic expression of Inscuteable (Insc) suggested that Insc localization, either apical or lateral, correlates with spindle orientation, and their localization is a dominant indicator of spindle orientation, compared to the localization of Pins and Mud, implicating potentially distinct roles of activation and localization of the spindle complex. Overall their genetic experiments are well-designed and provide stimulation for future research. However, their evidence is suggestive, but not conclusive for their proposal. I have several concerns about their conclusion and would like to request more detailed information as well as to propose additional experiments.

      Major concerns: 1. This report lacks technical and experimental details. As the typical fly paper, the authors need to show the exact genotypes of flies they used for experiments. This needs to be addressed for Figures 1-6, and Supplemental Figures. Especially, which Gal4 drivers were used for UAS-Pins wt or mutant constructs in Figure 4 with pins mutant background, Khc73, GUKH mutant backgrounds. Which exact flies were used for mutant clone experiments for Supplemental Figure 3? (A for typical mosaic, and B for MARCM). Without these details, it is impossible to evaluate results and reproduce by others.

      We take this concern very seriously!

      • We listed the GAL4 driver (Traffic jam-GAL4) in the first section of the Materials and Methods: Expression was driven by Traffic Jam-GAL4 (Olivieri et al., 2010). The transgene and relevant citation have been added to Table 1.
      • We explained the background stock for the MARCM experiment in the Materials and Methods: Mosaic Analysis with a Repressible Cell Marker (after the method of Lee and Luo) was carried out using GFP-mCD8 (under control of an actin promoter) as the marker. The transgene and relevant citation have been added to Table 1.
      • In line with other fly studies (eg. Nakajima et al., Nature 2013) and our own Drosophila work (Bergstralh et al Current Biology 2013, Bergstralh*, Lovegrove*, St Johnston NCB 2015, Bergstralh et al Development 2016, Finegan et al EMBO J 2019, Cammarota*, Finegan* et al Current Biology 2020) we were careful to show the relevant genotype components in each figure.
      • We included a fully referenced Supplementary Table (Table 1 – Drosophila genetics) listing every mutant allele or transgene with a citation and a note about availability. We have expanded this table in response to the author’s concern (see above).

        Related to the comment 1, how did the author perform "clonal expression of Ubi-Pin-YFP" in page 5? As far as I understand, Ubi-Pin-YFP is expressed ubiquitously by the ubiquitin promoter.

      The reviewer makes a good point. We regret that we did not make this experiment more clear. Ubi-Pins-YFP was recombined onto an FRT chromosome (FRT82B). We made mitotic clones.

      We have clarified this in the Methods section as follows:

      “Mitotic clones of Ubi-Pins-YFP were made by recombining the Ubi-Pins-YFP transgene onto the FRT82B chromosome”

      1. In page 6, if Pins relocalization is passive and is associated with membrane-anchored protein remodeling during mitosis, its relocalization can be suppressed by disrupting the process of mitotic remodeling (mitotic rounding). The authors should test this by either genetic disruption or pharmacological treatment for the actomyosin should cause defects in Pins relocalization, which bolster their conclusion.

      We agree that this is a cool experiment and are happy to give it another shot. However, we do note that interpretation could be difficult. We don’t know that mitotic rounding and membrane-anchored protein remodeling during mitosis are inextricably linked. Notably, the remodeling we describe reflects cell polarity; apical components are evidently moved to the lateral cortex. This is contrary to understanding of rounding, which reflects isotropic actomyosin activity (Chanet et al., (2017) Curr.Biol. & Rosa et al., (2015) Dev. Cell.). Therefore we don’t understand what a “negative” result would mean, or for that matter that a “positive” result would be safe to interpret.

      We have attempted many strategies to prevent cell rounding in the follicular epithelium, none of which have successfully prevented rounding. 1) We attempted to genetically knockdown Moesin in the FE and did not see an effect on cell rounding. However we couldn’t confirm knockdown and therefore are not confident in this manipulation. 2) It is difficult to interpret the result of genetically disrupting Myosin, because it causes pleiotropic effects, such as inhibition of the cell cycle, and disruption of monolayer architecture. 3) We treated egg chambers with Y-27632 (a Rok-inhibitor) and examined its effect on mitotic cell rounding and on cytokinesis, which are Rok-dependent processes. Our experiments were performed using manually-dissociated ovarioles treated for 45 minutes in Schneider Cell Medium supplemented with insulin. Even at our maximum concentration of 1mM Y-27632, several orders of magnitude above the Ki, we are unable to see any effect on mitotic cell shape or actin accumulation at the mitotic cortex and did not observe any evidence of defective cytokinesis. We also did not observe defects in spindle organization or orientation, as would be expected from failed rounding. We therefore do not believe that the inhibitor works in this tissue. One possible explanation is that the follicle cells are secretory, and likely to pass molecules taken up from the media quickly into the germline. Therefore, we do not anticipate that we can perform this experiment to our satisfaction.

      1. The critical message in this manuscript is that the core spindle complex mediated by Pins-Mud controls spindle orientation by "activation", but not localization. The findings that Pins and Mud localization is not influenced by Insc and that ecotpic Insc expression and genetic Mud depletion (Figure 6) might support their proposal, but these results just suggest their localization does not matter. I wonder how the authors could conclude and define "activation". What does this activation mean in the context of spindle orientation? Can the authors test activation by enzymatic activity or assess dynamics of spindle alignment?

      We intend for the critical message of the manuscript to be that “The spindle orienting machinery requires activation, not just localization.” We absolutely do not make the claim that localization is not important, only that it is not sufficient. The reviewer recognizes this point here and in a subsequent comment: “The authors showed that Pins and Mud localization themselves are not sufficient for the control of spindle orientation with genetic analyses.”

      We also do not claim that Pins and/or Mud localization are not impacted by Inscuteable. On the contrary, we plainly see and report that they are; the intensity profiles in Figure 6 are distinct from those in Figure 2, as discussed in the text.

      We appreciate the reviewer’s point about activation. Since we do not understand these proteins to be enzymes, we aren’t sure what enzymatic activity would be tested. The dynamics of spindle alignment in this slowly developing system are prohibitively difficult to measure: the mitotic index is very low (~2%) and only a very small fraction of those cells will be in a focal plane that permits accurate live imaging in the apical-basal axis. Alternative modes of activation include conformational change and/or a connection with other important molecules. The simplest possibility would be that Dlg allows Pins to bind Mud, but so far our data do not support it. We have added the following paragraph to our discussion:

      “The mechanism of activation remains unclear. While the most straightforward possibility is that Dlg promotes interaction between Pins and Mud, our results show that Mud is recruited to the cortex even when Dlg is disrupted (Figure 4D). Alternatively, Discs large may promote a conformational change in the spindle-orientation complex and/or a change in complex composition. Furthermore, the Inscuteable mechanism is not likely to work in the same way. Dlg binds to a conserved phosphosite in the central linker domain of Pins and should therefore allow for Pins to simultaneously interact with Mud (Johnston et al., 2009). Contrastingly, binding between Pins and Inscuteable is mediated by the TPR domains of Pins, meaning that Mud is excluded (Culurgioni et al., 2011; 2018). While a stable Pins-Inscuteable complex has been suggested to promote localization of a separate Pins-Mud-dynein complex, our work raises the possibility that it might also or instead promote activation.”

      1. In page 7-8, although Pins-S436D rescue spindle orientation, but Pins-S436A does not in pins null clones background, Pins localization is not influenced by Dlg. This questions how exactly Pins and Dlg can interact, and how Dlg affect Pins function. Related to this observation, in the embryonic Pins:Tom localization in dlg mutant does not provide strong evidence to support their conclusion given the experimental context is different from previous study (Chanet et al., 2017).

      We agree with the reviewer. Our data (this paper and previous papers) and the work of others indicate that this interaction is important for spindle orientation (Bergstralh et al., 2013a; Saadaoui et al., 2014; Chanet et al., 2017). However, we show here that Dlg doesn’t obviously impact Pins localization (as proposed in our earlier paper), but does impact the ability of the spindle orientation machinery to work (hence activity).

      The reviewer makes a very good point. Our experimental context is different from the previous study concerning Pins and Dlg in embryos: Chanet et al (2017) performed their work in the embryonic head, whereas we look at divisions in the ventral embryonic ectoderm. These are distinct mitotic zones (Foe et al. (1989) Development) and exhibit distinct epithelial morphologies. We show that Pins:Tom localizes at the mitotic cell cortex in Dlg[2]/Dlg[1P20] in cells in the ventral embryonic ectoderm. Our only conclusion from this experiment is that Pins:Tom can localize without the Dlg GUK domain in another cell type (outside the follicular epithelium). In the current preliminary revision we have softened our claim as follows:

      “We also examined the relationship between Pins and Dlg in the Drosophila embryo. A previous study showed that cortical localization of Pins in embryonic head epithelial cells is lost when Dlg mRNA is knocked down (Chanet et al., 2017). We find that Pins:Tom localizes to the cortex in the ventral ectoderm of early embryos from Dlg1P20/Dlg2 mothers, indicating that Pins localization in the ventral embryonic ectoderm epithelium does not require direct interaction with Dlg. We therefore speculate that Dlg plays an additional role in that tissue, upstream of Pins (Figure 4G).

      Our intention is to elaborate on our findings with additional data from embryos. To this end we have already acquired preliminary control data investigating the spindle angle with respect to the plane of the epithelium, and are in the process of examining spindle angles in dlg mutant embryonic tissue.

      In page 11, the authors state "... that activation of pulling in the FE requires Dlg". I was not convinced by anything related to "pulling". There is no evidence to support "pulling" or such dynamic in this paper, just showing Mud localization, correct?

      We appreciate the reviewer’s concern. The original sentence read that “We interpret [our data] to mean that interaction between Pins and Dlg, which is required for pulling, stabilizes the lateral pulling machinery even if Dlg is not a direct anchor.” This statement is based on work across multiple systems, including the C. elegans embryo (Grill et al Nature 2001), the Drosophila pupal notum (Bosveld et al, Nature 2016), and HeLa cells (Okumura et al eLife 2018), which shows that Mud/dynein-mediated pulling (on astral microtubules) orients/positions spindles. This is described in the introduction.

      To address the reviewer’s particular concern, we have replaced “pulling” with “spindle-orentation machinery,” so that this sentence now reads …“activation of the spindle-orientation machinery in the FE requires Dlg.”

      1. Ectopic expression of Insc (Figure 6) provided a new idea and hypothesis, but the conclusion is more complicated given that Insc is not expressed in normal FE. For example, the statement that "Inscuteable and Dlg mediate distinct and competitive mechanism for activation of the spindle-orienting machinery in follicle cells" is probably right, but it does not show anything meaningful since Insc does not exist in normal FE. Is Dlg in a competitive situation during mitosis of FE? If so, which molecules are competitive against Dlg? The important issue is to provide a new interpretation of how spindle orientation is controlled epithelial cells. I strongly recommend to add models in this manuscript for clarity.

      We considered the addition of model cartoons very carefully in preparing the original manuscript, and again after review. While we are certainly not going to “dig in” on this point, our concern is that model figures would obscure rather than clarify the message. As the reviewer points out, we do not understand how activation works, and as discussed in the manuscript we don’t think it’s likely to work the same way in follicle cells (Dlg) as it does in neuroblasts (Insc). Therefore model figure(s) are premature.

      We do not agree with the statement that "Inscuteable and Dlg mediate distinct and competitive mechanism for activation of the spindle-orienting machinery in follicle cells… does not show anything meaningful.” This is a remarkable finding because it suggests that there is more than one way to activate Pins. Given the critical importance of spindle orientation in the developing nervous system, and the evolutionary history of the Dlg-Pins interaction, we think that this finding supports a model in which the Dlg-Pins interaction evolved in basal organisms, and a second Inscuteable-Pins interaction evolved subsequently to support neural complexity. These ideas are raised in the Discussion.

      The reviewer also writes that “The important issue is to provide a new interpretation of how spindle orientation is controlled epithelial cells.” We find this concern perplexing, since the reviewer clearly recognizes that we have provided a new interpretation: Dlg is not a localization factor but rather a licensing factor for Pins-dependent spindle orientation.

      Minor comments: 8. Some sections were not written well in the manuscript. "It does not" in page 6. "These predictions are not met". I just couldn't understand what they stand for. Their writing has to be improved.

      Again, we are not going to dig in here, but we would prefer to retain the original language, which in our opinion is fairly clear. Our study is hypothesis-driven and based on assumptions made by the current model. We used direct language to help the reviewer understand what happened when we tested those assumptions.

      1. In page 9, Supplementary Figure 4 should be cited in the paragraph (A potential strategy for..), not Supplemental Figure 1A, and 1B.

      Good catch, thank you! We have corrected this.

      1. In page 10, the authors examine aPKC localization in Insc expressing context of FE. Does aPKC localization correlate with Insc localization (Insc dictates aPKC?)? aPKC is not involved in spindle orientation from the author's report (Bergstralh et al., 2013), so it does not likely provide any supportive evidence.

      I’m afraid we don’t entirely understand this comment. The interdependent relationship between aPKC and Inscuteable localization is long-established in the literature and was previously addressed in the follicle epithelium (Bergstralh et al. 2016). We do not make the claim here that aPKC governs spindle orientation. We are emphasizing that the difference between InscA and InscB cells extends to the relocalization of polarity components involved in Insc localization. As described in the manuscript, these data are provided to support our threshold model:

      “In agreement with interdependence between Inscuteable and the Par complex, we find that aPKC is stabilized at the apical cortex in InscA cells but enriched at the lateral cortex in InscB cells (Figure 6E). This finding is consistent with an Inscuteable-expression threshold model; below the threshold, Pins dictates lateral localization of Inscuteable and aPKC. Above the threshold, Inscuteable dictates apical localization of Pins and aPKC.”

      1. In Dicussion page 12, "In addition, we find that while the LGN S408D (Drosophila S436D) variant is reported to act as a phosphomimetic, expression of this variant has no obvious effect on division orientation (Johnston et al., 2012)". Where is the evidence for this? I interpret that this phosphomimetic form can rescue like wt-Pins not like unphospholatable mutant S436A, so it means that have an effect on spindle orientation, correct?

      The reviewer makes a good point. We regret the confusion. We mean to point out that the S436D variant is no different from the wild type. We have amended the text to clarify:

      “In addition, we find that while the LGN S408D (Drosophila 436D) variant is reported to act as a phosphomimetic, this variant does not cause an obvious mutant phenotype in the follicular epithelium (Johnston et al., 2012). What then is the purpose of this modification? Since the phosphosite is highly conserved through metazoans, one possibility to consider is that the phosphorylation regulates the spindle orientation role of Pins, whereas unphosphorylated Pins plays a different role (Schiller and Bergstralh, 2021).”

      Reviewer #2 (Significance (Required)):

      The authors showed that Pins and Mud localization themselves are not sufficient for the control of spindle orientation with genetic analyses. While the authors tried to challenge the concept of "canonical model", there is no clear demonstration of "activation" of the spindle complex. I appreciate their genetic evidence and new results, and understand the message that Pins and Mud effects are beyond localization, but there is no alternative mechanism to support their model. At the current stage, their evidence provides more hypothesis, not conclusion. Based on my expertise in Developmental and Cell biology, I suggest that the work has an interest in audience who studies spindle machinery, but for general audience.

      We think that the reviewer fundamentally shares our perspective on the study. Our work tests assumptions made by the canonical model and shows that they aren’t always met (meaning that the question of how spindle orientation works in epithelia at least is still unsolved), and that in the FE at least one component (Dlg) has been misunderstood. We reach a major conclusion, which is that localization of Pins is not enough to predict spindle orientation in the FE.

      It’s absolutely true that the precise molecular role of Dlg has not been solved by our study. This is a major question for the lab, and we are currently undertaking biochemical work to address it. It’s probably more work than we can (or should) do on our own, which is just one reason to share our current results with colleagues.

      One fundamental reason for undertaking this study is that 25 years of spindle orientation studies released into an environment in which “positive” conclusions are the bar for publication success may have burdened the field with claims that are overly-speculative. We appear to have contributed to this problem ourselves in 2013. With that in mind we contend that providing an alternative molecular mechanism at this point is premature and would impair rather than improve the literature.

      Reviewer #3 (Evidence, reproducibility and clarity (Required)):

      Neville et al re-examine the role and regulation of Pins/LGN in Drosophila follicular epithelial cells. They argue that polar or bipolar enrichment of Pins localisation at the plasma membrane is not crucial for spindle orientation, and therefore propose that Pins must be somehow activated to function. These interpretations are not supported by the data. However, the data strongly suggest an alternative interpretation which is of major biological significance.

      As an initial point, we disagree with the summary above. We do not argue that enrichment of Pins is not crucial for spindle orientation. We argue that enrichment of Pins is not sufficient. This is why we titled the paper “The spindle orienting machinery requires activation, not just localization” instead of “The spindle orienting machinery requires activation, not localization.”

      Although we disagree with reviewer, we appreciate their criticism of our manuscript and are glad for the opportunity to clarify our findings. In our responses to the specific comments (below) we explain why our data contradict the reviewer’s model and what we will do to improve the manuscript.

      Comments:

      1. In the experiments on Dlg mutants (Fig 4D, S3) visualising Pins:Tom, the wild-type needs to be shown next to the Dlg mutant image, otherwise a comparison cannot be made. For example, Pins:Tom looks strongly enriched at the lateral membranes in the wild-type shown in Fig 2B&C, but much more weakly localised at the lateral membranes in Dlg1P20/2 mutants in Fig 4D. Thus, it looks like the Dlg GUK domain is required for full enrichment of Pins:Tom at lateral membranes, even if some low level of Pins can still bind to the plasma membrane in the absence of the Dlg GUK domain. Quantification would likely show a reduction in Pins:Tom lateral enrichment in the Dlg1P20/2 mutants - consistent with the spindle misorientation phenotype in these mutants.

      The reviewer raises a reasonable concern about Figure 4D. We noted the difficulty of imaging Pins:Tom, which is exceedingly faint, in our original manuscript. For technical reasons, only one copy of the transgene was imaged in the experiment presented in 4G (two copies were used in Figure 2B), and the lack of signal presented an even greater challenge. In the manuscript we went with the clearest image. To address the reviewer’s concern, we have added signal intensity plots to this figure showing that Pins:Tom and Pins-myr are both laterally enriched at mitosis in Dlg[1P20]/Dlg[2] mutants. These data have been added as a new panel (E) in Figure 4. We were also able to replace the pictures in 4D with new ones generated after review.

      1. In Fig 4E, the phosphomutant PinsS436A-GFP looks more strongly apical and less strongly lateral than the wildtype Pins-GFP, consistent with the spindle misorientation phenotype in S436A rescued pins mutants.

      The reviewer has an eagle eye! We did not detect a difference in localization across the three transgenes, though we were certainly looking for it (that’s why we generated these flies in the first place). Again, the strength of signal was a major challenge in these experiments, and we therefore went with the cleanest image. In response to the reviewer’s concern, we note that the S436A and S436D examples shown have equivalent apical signal, but only the S436A fails to rescue spindle orientation.

      Together, Reviewer Comments 1 and 2 suggest a model in which Dlg is required for lateral enrichment of Pins at mitosis. As described in the manuscript, this is the very model proposed in our own previous study (Bergstralh, Lovegrove, and St Johnston; 2013), and reiterated in a subsequent review article (Bergstralh, Dawney, and St Johnston; 2017). We point these publications out because the senior author of the current manuscript is not especially enthusiastic about showing himself to be wrong (twice!) in the literature. He therefore insisted on seeing multiple lines of evidence before making the counterargument:

      • The reviewer’s model (the 2013 model) is firstly challenged by work shown in Figure 3. We find that membrane-anchored proteins (even just myristoylated RFP!) demonstrate lateral enrichment at mitosis, regardless of whether or not they interact with the Dlg-GUK domain.
      • Even stronger evidence is shown in Figure 4F. Pins-myr-GFP is very plainly enriched at the lateral cortex in Dlg[IP20]/Dlg[2] mutant cells (now demonstrated with signal intensity plots in FIGURE 4E). However, the spindle doesn’t orient correctly (quantified in 4C). Since Dlg is impacting spindle orientation independently of Pins localization, these data support our “claim in the final sentence of the abstract ‘Local enrichment of Pins is not sufficient to determine spindle orientation; an activation step is also necessary’.”

        In the InscA examples, Pins:Tom looks apical. In the InscB examples, Pins:Tom looks more laterally localised, consistent with the spindle orientations in these experiments.

      These figures (6A-D) don’t only show/quantify Pins:Tom localization. They also show localization of GFP-Mud. Whereas Pins:Tom is certainly apically enriched in the InscA examples, the interesting finding is that GFP-Mud is not. In strong contrast, it instead shows a weak apical localization and a strong lateral enrichment. As described in the manuscript, this pattern of Mud localization predicts normal spindle orientation, which is not observed in these cells.

      Thus, these data appear to support the existing model that Pins enrichment at the plasma membrane is a key factor directing mitotic spindle orientation in these cells. The author's claim in the final sentence of the abstract "Local enrichment of Pins is not sufficient to determine spindle orientation; an activation step is also necessary" is not supported by the data.

      We are pleased that the reviewer shared this quote; our claim is that Pins localization is not sufficient, not that it is unnecessary (see above). We absolutely do not dispute that “Pins enrichment at the plasma membrane is a key factor directing mitotic spindle orientation.”

      The open question posed by the data is why GFP-Mud is excluded apically & basally during mitosis, while Pins:Tom is not. The simple alternative model is that Mud only localises to the plasma membrane where Pins is most strongly concentrated, such that Mud strongly amplifies any Pins asymmetry. Thus, even myr-Pins can still rescue a pins n mutant, because myr-Pins is still enriched laterally compared to apically (or basally).

      Thus, I would strongly suggest re-titling the manuscript to: "Mud/NuMA amplifies minor asymmetries in Pins localisation to orient the mitotic spindle".

      Well, that is a good-looking title, and we’re therefore sorry to decline the suggestion. However, as described above, Figure 4D shows that Pins enrichment does not always predict spindle orientation. More importantly, Figure 6A (cited by the reviewer in Comment 3) very plainly shows that Mud does not “only locali[ze] to the plasma membrane where Pins is most strongly concentrated.” In this picture – and across multiple InscA cells (Figure 6B) - Pins is strongly concentrated at the apical surface, whereas Mud is not.

      Mud/NuMA presumably achieves this amplification by binding to the plasma membrane only where Pins is concentrated above a critical threshold level. This would mean a non-linear model based on cooperativity among Pins monomers that increases the binding avidity to Mud above the threshold concentration of Pins monomers.

      This is essentially a minor revision of the standard model, which we expected would hold true in the FE. As described above, it is not supported by our data.

      Reviewer #3 (Significance (Required)):

      The manuscript is focused on the question of mitotic spindle orientation in epithelial cells, which is a fundamental unsolved problem in biology. The data reported are impressive and important, providing new insights into how the key spindle orientation factors Mud/NuMA and Pins/LGN localise during mitosis in epithelia. I recommend publication after major revisions.

      We are delighted that the reviewer finds our data impressive and important, and our experiments insightful. We understand that the “major revisions” requested are meant to bring the paper in line with their model (our own earlier model). Since the data in our original manuscript contradict that model, the revisions are instead focused on clarifying and strengthening our message.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      Neville et al re-examine the role and regulation of Pins/LGN in Drosophila follicular epithelial cells. They argue that polar or bipolar enrichment of Pins localisation at the plasma membrane is not crucial for spindle orientation, and therefore propose that Pins must be somehow activated to function. These interpretations are not supported by the data. However, the data strongly suggest an alternative interpretation which is of major biological significance.

      Comments:

      1. In the experiments on Dlg mutants (Fig 4D, S3) visualising Pins:Tom, the wild-type needs to be shown next to the Dlg mutant image, otherwise a comparison cannot be made. For example, Pins:Tom looks strongly enriched at the lateral membranes in the wild-type shown in Fig 2B&C, but much more weakly localised at the lateral membranes in Dlg1P20/2 mutants in Fig 4D. Thus, it looks like the Dlg GUK domain is required for full enrichment of Pins:Tom at lateral membranes, even if some low level of Pins can still bind to the plasma membrane in the absence of the Dlg GUK domain. Quantification would likely show a reduction in Pins:Tom lateral enrichment in the Dlg1P20/2 mutants - consistent with the spindle misorientation phenotype in these mutants.
      2. In Fig 4E, the phosphomutant PinsS436A-GFP looks more strongly apical and less strongly lateral than the wildtype Pins-GFP, consistent with the spindle misorientation phenotype in S436A rescued pins mutants.
      3. In the InscA examples, Pins:Tom looks apical. In the InscB examples, Pins:Tom looks more laterally localised, consistent with the spindle orientations in these experiments.

      Thus, these data appear to support the existing model that Pins enrichment at the plasma membrane is a key factor directing mitotic spindle orientation in these cells. The author's claim in the final sentence of the abstract "Local enrichment of Pins is not sufficient to determine spindle orientation; an activation step is also necessary" is not supported by the data.

      The open question posed by the data is why GFP-Mud is excluded apically & basally during mitosis, while Pins:Tom is not. The simple alternative model is that Mud only localises to the plasma membrane where Pins is most strongly concentrated, such that Mud strongly amplifies any Pins asymmetry. Thus, even myr-Pins can still rescue a pins mutant, because myr-Pins is still enriched laterally compared to apically (or basally).

      Thus, I would strongly suggest re-titling the manuscript to: "Mud/NuMA amplifies minor asymmetries in Pins localisation to orient the mitotic spindle".

      Mud/NuMA presumably achieves this amplification by binding to the plasma membrane only where Pins is concentrated above a critical threshold level. This would mean a non-linear model based on cooperativity among Pins monomers that increases the binding avidity to Mud above the threshold concentration of Pins monomers.

      Significance

      The manuscript is focused on the question of mitotic spindle orientation in epithelial cells, which is a fundamental unsolved problem in biology. The data reported are impressive and important, providing new insights into how the key spindle orientation factors Mud/NuMA and Pins/LGN localise during mitosis in epithelia. I recommend publication after major revisions.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      Summary:

      The manuscript by Neville et al. addressed the mechanism how conserved spindle regulators (Pins/Mud/Gai/Dynein) control spindle orientation in the proliferating epithelia by revising "the canonical model", using the Drosophila follicular epithelium (FE). The authors examined the epistatic relationship among Pins, Mud and Dlg in FE and found that Pins controls the cortical localization of Mud by utilizing mutant analyses, and suggested their localization does not fully overlap using the newly generated knock-in allele. They also showed that Pins relocalization during mitosis depends on cortical remodeling, or passive model, where Pins localization changes with other membrane-anchored proteins. Their data further suggest that Pins cortical localization is not influenced by Dlg, but Pins-interacting domain of Dlg does affect spindle orientation. Based on these results, the authors propose that Dlg controls spindle orientation not by redistributing Pins, but by promoting (or "activating" from their definition) Pins-dependent spindle orientation. Interestingly, ectopic expression of Inscuteable (Insc) suggested that Insc localization, either apical or lateral, correlates with spindle orientation, and their localization is a dominant indicator of spindle orientation, compared to the localization of Pins and Mud, implicating potentially distinct roles of activation and localization of the spindle complex. Overall their genetic experiments are well-designed and provide stimulation for future research. However, their evidence is suggestive, but not conclusive for their proposal. I have several concerns about their conclusion and would like to request more detailed information as well as to propose additional experiments.

      Major concerns:

      1. This report lacks technical and experimental details. As the typical fly paper, the authors need to show the exact genotypes of flies they used for experiments. This needs to be addressed for Figures 1-6, and Supplemental Figures. Especially, which Gal4 drivers were used for UAS-Pins wt or mutant constructs in Figure 4 with pins mutant background, Khc73, GUKH mutant backgrounds. Which exact flies were used for mutant clone experiments for Supplemental Figure 3? (A for typical mosaic, and B for MARCM). Without these details, it is impossible to evaluate results and reproduce by others.
      2. Related to the comment 1, how did the author perform "clonal expression of Ubi-Pin-YFP" in page 5? As far as I understand, Ubi-Pin-YFP is expressed ubiquitously by the ubiquitin promoter.
      3. In page 6, if Pins relocalization is passive and is associated with membrane-anchored protein remodeling during mitosis, its relocalization can be suppressed by disrupting the process of mitotic remodeling (mitotic rounding). The authors should test this by either genetic disruption or pharmacological treatment for the actomyosin should cause defects in Pins relocalization, which bolster their conclusion.
      4. The critical message in this manuscript is that the core spindle complex mediated by Pins-Mud controls spindle orientation by "activation", but not localization. The findings that Pins and Mud localization is not influenced by Insc and that ecotpic Insc expression and genetic Mud depletion (Figure 6) might support their proposal, but these results just suggest their localization does not matter. I wonder how the authors could conclude and define "activation". What does this activation mean in the context of spindle orientation? Can the authors test activation by enzymatic activity or assess dynamics of spindle alignment?
      5. In page 7-8, although Pins-S436D rescue spindle orientation, but Pins-S436A does not in pins null clones background, Pins localization is not influenced by Dlg. This questions how exactly Pins and Dlg can interact, and how Dlg affect Pins function. Related to this observation, in the embryonic Pins:Tom localization in dlg mutant does not provide strong evidence to support their conclusion given the experimental context is different from previous study (Chanet et al., 2017).
      6. In page 11, the authors state "... that activation of pulling in the FE requires Dlg". I was not convinced by anything related to "pulling". There is no evidence to support "pulling" or such dynamic in this paper, just showing Mud localization, correct?
      7. Ectopic expression of Insc (Figure 6) provided a new idea and hypothesis, but the conclusion is more complicated given that Insc is not expressed in normal FE. For example, the statement that "Inscuteable and Dlg mediate distinct and competitive mechanism for activation of the spindle-orienting machinery in follicle cells" is probably right, but it does not show anything meaningful since Insc does not exist in normal FE. Is Dlg in a competitive situation during mitosis of FE? If so, which molecules are competitive against Dlg? The important issue is to provide a new interpretation of how spindle orientation is controlled epithelial cells. I strongly recommend to add models in this manuscript for clarity.

      Minor comments:

      1. Some sections were not written well in the manuscript. "It does not" in page 6. "These predictions are not met". I just couldn't understand what they stand for. Their writing has to be improved.
      2. In page 9, Supplementary Figure 4 should be cited in the paragraph (A potential strategy for..), not Supplemental Figure 1A, and 1B.
      3. In page 10, the authors examine aPKC localization in Insc expressing context of FE. Does aPKC localization correlate with Insc localization (Insc dictates aPKC?)? aPKC is not involved in spindle orientation from the author's report (Bergstralh et al., 2013), so it does not likely provide any supportive evidence.
      4. In Dicussion page 12, "In addition, we find that while the LGN S408D (Drosophila S436D) variant is reported to act as a phosphomimetic, expression of this variant has no obvious effect on division orientation (Johnston et al., 2012)". Where is the evidence for this? I interpret that this phosphomimetic form can rescue like wt-Pins not like unphospholatable mutant S436A, so it means that have an effect on spindle orientation, correct?

      Significance

      The authors showed that Pins and Mud localization themselves are not sufficient for the control of spindle orientation with genetic analyses. While the authors tried to challenge the concept of "canonical model", there is no clear demonstration of "activation" of the spindle complex. I appreciate their genetic evidence and new results, and understand the message that Pins and Mud effects are beyond localization, but there is no alternative mechanism to support their model. At the current stage, their evidence provides more hypothesis, not conclusion. Based on my expertise in Developmental and Cell biology, I suggest that the work has an interest in audience who studies spindle machinery, but for general audience.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      The manuscript by Neville et al addresses the link between the localization and the activity of the so-called "Pins complex" or "LGN complex", that has been shown to regulate mitotic spindle orientation in most animal cell types and tissues. In most cell types, the polarized localization of the complex in the mitotic cell (which can vary between apical and basolateral, depending on the context) localizes pulling forces to dictate the orientation The authors reexplore the notion that this polarized localization of the complex is sufficient to dictate spindle orientation, and propose that an additional step of "activation" of the complex is necessary to refine positioning of the spindle.

      The experiments are performed in the follicular epithelium (FE), an epithelial sheet of cell that surrounds the drosophila developing oocyte and nurse cells in the ovarium. Like in many other epithelia, cell divisions in the FE are planar (the cell divides in the plane of the epithelium). The authors first confirm that planar divisions in this epithelium depends on the function of Pins and its partner mud, and that the interaction between the two partners is necessary, like in many other epithelial structures. Planar divisions are often associated with a lateral/basolateral "ring" of the Pins complex during mitosis. The authors show that in the FE, Pins is essentially apical in interphase and becomes enriched at the lateral cortex during mitosis, however a significant apical component remains, whereas mud is almost entirely absent from the apical cortex. Pins being "upstream" of mud in the complex, this is a first hint that the localization of Pins is not sufficient to dictate the localization of mud and of the pulling forces. The authors then replace wt Pins, whose cortical anchoring strongly relies on its interaction with Gai subunits, with a constitutively membrane anchored version (via a N-terminal myristylation). They show that the localization of myr-Pins mimics that of wt-Pins, with a lateral enrichment in mitosis, and a significant apical component. Since a Myr-RFP alone shows a similar distribution, they conclude that the restricted localization of Pins in mitosis is a consequence of general membrane characteristics in mitosis, rather than the result of a dedicated mechanism of Pins subcellular restriction. Remarkably, Myr-Pins also rescues Pins loss-of-function spindle orientation defects. They further show that the cortical localization of Pins does not require its interaction with Dlg (unlike what has been suggested in other epithelia). However, spindle orientation requires Dlg, and in particular it requires the direct Dlg/Pins interaction. The activity of Dlg in the FE appears to be independent from khc73 and Gukholder, two of its partners involved in its activity in microtubule capture and spindle orientation in other cell types. Based on all these observations, the authors propose that Dlg serves as an activator that controls Pins activity in a subregion of its localization domain (in this case, the lateral cortex of the mitotic FE cell). They propose to test this idea by relocalizing Pins at the apical cortex, using Inscuteable ectopic expression. With the tools that they use to drive Inscuteable expression, they obtain two populations of cells. One population has a stronger apical that basolateral Insc distribution, and the spindle is reoriented along the apical-basal axis; the other population has higher basolateral than apical levels of Insc distribution, and the spindle remains planar. The authors write that Pins localization is unchanged between the two subsets of cells (although I do not entirely agree with them on that point, see below), and that although Mud is modestly recruited to the apical cortex in the first population, it remains essentially basolateral in both. In this situation, the localization of Insc in the cell is therefore a better predictor of spindle orientation than that of Pins or Mud. Remarkably, removing Dlg in an Insc overexpression context leads to a dramatic shift towards apical-basal reorientation of the spindle, suggesting that loss of Dlg-dependent activation of the lateral Pins complex reveals an Insc-dependent apical activation of the complex.

      Overall, I find the demonstration convincing and the conclusion appropriate. One of the limitations of the study is the use of different drivers and reporters for the localization of Pins, which makes it hard to compare different situations, but not to the point that it would jeopardize the main conclusions. I do not have major remarks on the paper, only a few minor observations and suggestion of simple experiments that would complete the study

      Minor:

      What happens to Pins and Mud in Dlg mutant cells that overexpress Insc and behave as InscA? Are they still essentially lateral, or are they more efficiently recruited to the apical cortex?

      Regarding the competition between Pins and Insc for dictating the apical versus basolateral localization of Insc, the Insc-expression threshold model could be easily tested in Pins62/62 mutants, where it is expected that only InscA localization should be observed, even at 25{degree sign}C (unless Pins is required for the cortical recruitment of Insc, as it is the case in NBs - see Yu et al 2000 for example)

      I do not agree with the authors on P.10 and Figure 6A-D, when they claim that the apical enrichment of Pins is equivalent in both InscA and InscB cells. The number of measured cells is very low, and the ratio of apical/lateral Pins differs between the two sets of cells. The number of cells should be increased and the ratios compared with a relevant statistic method.

      A lot of the claims on Pins localization rely on overexpression (generally in a Pins null background) of tagged Pins expressed from different promoters or drivers, and fused to different fluorescent tags. Therefore, it is difficult to evaluate to which extent the localization reflects an endogenous expression level, and to compare the different situations. As the cortical localization of Pins relies on interaction with cortical partners (mostly GDP-bound Gai) which are themselves in limiting quantity in the cell, and in the case of Gai-GDP, regulated by Pins GDI activity, this poses a problem when comparing their distribution, because the expression level of Pins may contribute to its cortical/cytoplasmic ratio, but also to its lateral/apical distribution. Although I understand that the authors have been using tools that were already available for this study, I think it would be more convincing if all the Pins localization studies were performed with endogenously tagged Pins, even those with Myr localization sequences. In an age of CRISPR-Cas-dependent homologous recombination, I think the generation of such alleles should have been possible. Although this would probably not change the main claims of the paper, it would have made a more convincing case for the localization studies.

      The authors should indicate in the figure legends or in the methods that the spindle orientation measurements for controls or Pins62/62 are reused between figures 1, 3, 4, 5, 6 , and between figure 3, 4 and 5, respectively

      Significance

      Altogether, this study makes a convincing case that the localization of the core members of the pulling force complex, Pins and Mud, is not entirely sufficient to localize active force generation, and that the complex must be activated locally, at least in the FE.

      The notion of activation of the Pins/LGN complex has probably been in many people's mind for year: Pins/LGN works as a closed/open switch depending on the number of Gai subunits it interacts with, it must be phosphorylated, etc... suggesting that not all cortical Pins/LGN was active and involved in force generation. However the study presented here shows an interesting case where localization and activation are clearly disconnected. The authors show how Dlg plays this role in physiological conditions in the FE, and use ectopic expression of Insc to show that, at least in an artificial context, Insc can have the same "activating activity" (or at least an activating activity that is stronger than its apical recruitment capability and stronger than Dlg's activating activity). It is to my knowledge the first case of such a clear dissociation. In their discussion, the authors are careful not to generalize the observation to other tissues. Although I did not reexplore all that has been published on the Pins/LGN-NuMA/Mud complex over the last 20 years, my understanding is that despite interesting cases of distribution of the complex like that of Mud in the tricellular junction in the notum, the localization model can still explain most of the phenotypes that have been described without invoking an activation step. If it is the case, then the activation model is another variation (an interesting one!) on the regulation of the core machinery, which are plentiful as the authors indicate in their introduction, and is maybe specific to the FE; if not, then it would be interesting to push the discussion further by reexamining previous results in other systems, and pinpointing those phenotypes that could be better explained with an activation step.

      Overall, I find this is an elegant piece of work, which should be of interest to many cell and developmental biologists beyond the community of spindle orientation aficionados.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      We thank for reviewers for their feedback and were pleased they think that the manuscript is “of great interest to the scientific community”. The reviewers agree that the manuscript addresses an important question and that the identification of ASNS as a potential vulnerability of late-stage colorectal cancer is significant. The reviewers agree that our findings would be substantially strengthened by validation in state-of-the-art organoid model systems. We agree with this and are currently liaising with collaborators (Owen Sansom, Beatson Institute and Laura Thomas, Swansea University) to replicate our findings in both mouse and human colorectal organoid models. We will determine the sensitivity of colorectal organoid models to ASNS inhibition across a range of tumorigenicities and mutational profiles representing different stages of the adenoma-carcinoma progression. We believe these experiments will substantially strengthen the manuscript and lend weight to our finding that late-stage adenocarcinoma cells are vulnerable to ASNS inhibition.

      This is the predominant concern across reviewers, we are confident we can address this and all other, relatively minor, concerns as detailed below.

      Please find below a point-by-point reply to the reviewer’s comments. Reviewer comments are in italicized text and our responses follow.

      Reviewer #1

      • All of the findings in this manuscript are limited to in vitro observations, we know that most of the in vitro findings can not be translated in vivo. The manuscript would significantly benefit from in vivo experiments using the cells described in Fig.1 A and confirming the in vitro findings.*

      We agree that validation of our results in a more physiological context would significantly elevate our manuscript. In order to address this, we intend to use both human and mouse colorectal organoid models (please see detailed description of this in response to reviewer 2). We have decided to take this approach rather than conduct in vivoexperiments using the AA series (C1, SB, 10C and M) for two main reasons. Firstly, the C1 and SB cell lines do not form tumours in mice, consistent with them representing early colorectal adenoma cells. As such, we are not able to use the entire series in in vivo experiments. Secondly, we are keen to demonstrate replication of our findings in an alternative model. An organoid model would offer increased functional relevance, whilst allowing us to retain the ability to validate our observed metabolic dependencies across the adenoma to carcinoma sequence. We hope the reviewer agrees that these experiments would address their concerns.

      • The authors should provide proliferation data for the cell lines they used in this manuscript (C1, SB, 10C and M). In Fig. 1 B they show clear differences in EACR, can the authors provide data on glucose uptake differences in these analyzed cell lines.*

      We agree that proliferation and glucose uptake data would be a useful addition to the manuscript. We will provide doubling times for the cell lines used in this study and will measure glucose uptake by analysing extracellular glucose levels in the cell culture media from each of the cell lines.

      • In Figure 2 C the authors should provide isotope tracing data for the upper glycolysis (e.g. glucose and glucose-6-P) and alanine. In Figure 2 D the authors should provide the isotope tracing data for glutamine and glutamate.*

      We have data for glycolytic intermediates; glycerol-3-phosphate and dihydroxyacetone phosphate (DHAP) and alanine and will add them to the figures as requested.

      • Do the authors see any sign of reductive carboxylation in their U-13C glutamine experiments?*

      We observe only a low level of reductive carboxylation across the AA series cell lines (

      • Can the authors speculate how the C1, SB, 10C and M cell lines would react when glucose would be replaced with galactose in the culture environment and forcing the cells to increase oxidative phosphorylation (OXPHOS).*

      We would speculate that the cells would react similarly to our experiments in low glucose conditions displayed in Fig 3A-K. Given that M cells were shown to be the most flexible with regards to fuel source, we would expect them to be able to survive and proliferate more efficiently than the other cell lines in challenging culture conditions. Additionally, we would expect the C1s to survive well in galactose conditions, given that they rely less on glycolysis for ATP production and have significantly higher spare respiratory capacity compared to the more progressed cell lines.

      • Can the authors comment whether C1, SB, 10C and M cell lines show differences in coping with oxidative stress?*

      Again, we would speculate that the M cells would cope with exposure to oxidative stress best, given their metabolic flexibility. However, we would aim to test this by measuring the cellular response to hydrogen peroxide (which would induce oxidative stress) across all cell lines.

      • In the ASNS knockdown experiments do the authors detect an increase in glucose uptake in ASNS deficient cells.*

      This is an interesting question; we will address it by comparing extracellular glucose levels in C1 and M cells transfected with control and siRNA targeting ASNS.

      • Can the authors provide gene expression data that would explain the metabolic switch between early and late-stage adenocarcinoma? Do the authors detect any differences in mTORC1 activation among the C1, SB, 10C and M cell lines? ASNS is an ATF4 target, can the authors provide any expression data on ATF4 in their cell lines.*

      To address the first question, using our proteomics data, we have generated heatmaps showing protein abundance data from key metabolic pathways including glycolysis, the TCA cycle and the electron transport chain in the C1, SB and M cell lines. These data show an array of variation in protein expression of these pathways between the C1, SB and M cells, with no clear up or downregulation of these pathways as a whole, but rather more intricate regulation of clusters of proteins within the pathways. These data align well with the metabolomic data presented in Figure 2 and will allow us to investigate the mechanisms underlying the metabolic switch. These heat maps will be incorporated into the manuscript. Using the heatmaps we will identify and discuss key nodes we predict to explain the metabolic switch between early and late-stage adenocarcinoma. We will then determine whether manipulation of these nodes impact the metabolic phenotype of the cells experimentally. For example, the heat maps have highlighted that ENO3 or enolase 3 is strongly upregulated in the SB and M cells in comparison to the C1 cells and may be involved in driving the metabolic switch. Indeed, ENO3 has previously been found to promote colorectal cancer progression by enhancing glycolysis (Chen et al, Med Oncol, 2022), consistent with what we see here. To test this, we will knock down ENO3 across the cell line series and determine the impact on cellular phenotype and metabolism (using Seahorse extracellular flux analysis).

      With regards to mTORC1 activation, we have further analysed our proteomics data from C1, SB and M cells and have found that the M cells show significantly higher serine 235/236 phosphorylation of ribosomal S6 protein, a common readout for mTORC1 activation, compared to C1 and SB cells. Further, we aim to carry out immunoblotting across the four cell lines to analyse phospho-S6 (relative to total S6), 4E-BP1 and phospho-ULK-1 (relative to total ULK-1) levels.

      With regards to ATF4, using our proteomics data we have generated a heatmap of gene expression changes of ATF4 target genes in C1, SB and M cells that we will provide in supplementary material . These data suggest that there does not appear to be any clear pattern of enhanced or reduced ATF4 transcriptional activity across the cell lines, with different clusters of genes within this signature up or downregulated across the series. Moreover, Ingenuity Pathway Analysis (IPA) revealed that the ATF4 pathway showed an activation z-score of -0.41 (p=0.0134) in SB versus C1 cells, and 0.35 (p=0.00051) in M versus C1 cells (where a threshold of +/- 2 indicates activation/suppression of the pathway, respectively), confirming there is no clear regulation of this pathway between the cell lines. In addition, we will carry out immunoblotting for ATF4 expression levels across the cell line series.

      Reviewer #2

      *Major comments: *

      *Early CRC *

      *Molecular understanding of CRC is obviously of great interest and importance for the clinics. However, tumors of early stages are almost exclusively resected and not treated with systemic agents. Hence, the argument by the authors that the metabolic understanding of early CRC is of clinical relevance is somewhat misleading. Overall, it would have been much more clinically relevant to investigate the multiple steps of later stages during CRC progression. How about metabolic changes during metastasis. Deep mechanistic understanding of process during metastasis has striking clinical relevance. *

      We agree with the reviewer that understanding metastatic progression is of clinical relevance and should indeed be investigated in more detail. Using our model, we do shed light on a vulnerability of late-stage adenocarcinoma cells (sensitivity to asparagine synthetase (ASNS) inhibition). Indeed, we show that ASNS expression is elevated in both colorectal tumour and metastatic tissue in comparison to normal suggesting that our study may have revealed a vulnerability with utility for treating late stage (and potentially metastatic) tumours. The reviewer raises an important issue with the way we frame the utility of the model in the manuscript text. We will rewrite this to emphasise its utility in identifying late-stage vulnerabilities and the clinical value of this approach. We maintain that the molecular understanding of colorectal cancer across all stages of its progression will provide a valuable contribution to the field but agree that we should be more specific with regards to the clinical utility of our findings.

      *Model system *

      The cell lines used in this study are not state-of-the-art to investigate the complex process during CRC progression. The original paper is from 1993 in which the cell lines were generated does not allow understanding of the characteristics of these cell lines. Recently, multiple models have been established, for example in organoids, to investigate the progression of CRC much more reliably. There are systems that use CRISPR/CAS9 edited human organoids that follow the genetic alterations of CRC progression with accompanied phenotypes. Further, extensive biobanks of organoids from patients are available (also commercially) which better represent the stages of CRC. Similarly, the question raised above of how representative this progression cell line set is needs to addressed. The mutagen-induced progression could generate various alterations that are not detected in patients, hence create an artificial system. Overall, biological replicates are missing.

      We thank the reviewer for their critique and agree that our manuscript would be significantly strengthened if we were able to replicate our key findings in another model. We agree that the cell line series we have used here has limitations and we will make sure these are discussed by adding a ‘Limitations’ section to the ‘Discussion’. We maintain that the cell line series is a valuable tool in which to effectively identify metabolic vulnerabilities for further research. A key advantage of this system is that it is a human cell line series of the same lineage. In addition, we can easily conduct metabolomics and stable isotope tracer analysis allowing us to investigate cellular metabolic activity and manipulate any identified pathways easily. As such, the cell line series is an effective tool in which to identify potential vulnerabilities, but we agree that these vulnerabilities need to be validated in state-of-the-art organoid systems for the impact of the work to be clearer.

      To address this, in collaboration with Owen Sansom (Beatson Institute) and Laura Thomas (Swansea University), we aim to validate our identified metabolic dependency in mouse and human colorectal organoids respectively. We will determine the sensitivity of colorectal organoid models across a range of tumorigenicities and mutational profiles representing different stages of the adenoma-carcinoma progression to asparagine synthetase (ASNS) inhibition. We believe these experiments will substantially strengthen the manuscript and lend weight to our finding that late-stage adenocarcinoma cells are vulnerable to ASNS inhibition.

      *Gene Expression analysis *

      In Figure 5 C and D is the expression of ASNS to stages and overall survival from online available datasets correlated. Its unclear what the difference between tumor and metastatic in C means. The labelling in D is too small. Is the difference between the two groups significant? Are these patients only at a specific stage? It seems not that ASNS is a strong prognosticator; further stratification is needed to clarify the role of ASNS in CRC.

      The data displayed in Fig 5C and 5D are from separate datasets so are not correlated. In Fig 5C ‘Tumour’ refers to gene expression from the primary tumour site (in this case the colorectum), whereas ‘Metastatic’ refers to gene expression from a metastatic tumour (from which the primary tumour was of colorectal origin). We will make this clearer in the text and figure legend. We will also make the labelling on the survival plot in D clearer, indicating that the difference between the two groups is significant and displaying the p value clearly.

      The data included in the survival plots in 5D encompass all tumour stages. We have further analysed these data, adjusting for tumour stage. We found that high ASNS expression in later stage tumours (stage 3 and 4) is associated with poorer overall survival, whereas there is no significant difference in overall survival in earlier stage tumours (stage 1 and 2) in relation to ASNS expression. We plan to add this to the supplementary materials and discuss in the main text as it is consistent with our findings from the AA cell line series.

      *Western Blot controls *

      For the Western Blots in Figure 6 A and C the total S6 and ULK1 controls are missing what is needed to assess the effect on pS6 and pULK1 correctly.

      We will add total S6 and ULK1 controls to these figures.

      In the same panels, the KO efficacy is not very high in A (-ASN). However, this is crucial to make the conclusion that this cell line (C1) is not dependent on ASNS.

      The average knockdown efficiency in the C1 cells is 72% across n=3 experiments. Therefore, levels of ASNS are significantly reduced. However, to further validate this finding, we will use L-Albizziine, a competitive inhibitor of ASNS, at the same concentration in both C1 and M cells to eliminate any issues surrounding variation in knockdown efficiency and to replicate the results obtained using ASNS siRNA. These data will be included in supplementary material.

      *Minor comments: *

      *Statistical analysis of proliferation assays *

      The statistical significance for proliferation assays are missing.

      The statistical significance at the final timepoints of the proliferation assays are displayed on bar graphs in Supplementary Figure 5 (Figure S5B and C). We will add these to the proliferation curves in the main figure.

      Reviewer #3

      *A major concern is the model used in this study: *

      Sodium butyrate and the carcinogen N-methyl-N-nitro-nitrosoguanidine (MNNG) were used for the transformation. I believe this model was developed by one of the co-authors of the study, A.C. Williams in the 1990s. The relevance of the model for in vivo colon carcinogenesis is not entirely clear to me and I miss information why in particular sodium butyrate and MNNG were used. I am not an expert on colon carcinogenesis but I did not have the impression that this model has been widely adopted and I miss detailed information on the model itself as well as a critical discussion of its limitations.

      We thank the reviewer for raising these concerns and will include a ‘Limitations’ section in the manuscript ‘Discussion’ to elaborate on both the utility and the limitations of this model system. As described in response to concerns raised by reviewer #1 and reviewer #2, we plan to validate our findings in organoid models of colorectal tumourigenesis to strengthen the discoveries made using the AA cell line series.

      With regards to the use of sodium butyrate and MNNG for transformation of the C1 cells, justification was provided in the original paper describing generation of the cell line model series (Williams et al, Cancer Research. 1990). Sodium butyrate is naturally occurring in the gut and was used for the transformation of the C1 cells as it had been proposed to play a role in promoting colorectal tumorigenesis through upregulating carcinoembryonic antigen (CEA) expression and enhancing proliferation in adenoma cells able to resist growth arrest following treatment (Berry et al, Carcinogenesis. 1988). At the time of generating the cell line series, few reagents were known to induce transformation in human epithelial cells. However, MNNG was one of those and had been previously used to transform keratinocytes (Rhim et al, Science. 1986). Crucially, tumours formed in mice from xenografted 10C cells were found to be heterogeneous, displaying areas of differentiation with glandular organisation, the presence of functional goblet cells enabling mucin production, as well as areas of poorly or undifferentiated cells. Furthermore, cytogenetic analyses revealed that genetic changes in the cell line progression model such as chromosome 18q loss and KRAS activation replicate those seen in CRC patients (Williams et al, Oncogene. 1993). Together, these characteristics recapitulate human tumours in vivo, validating the use of sodium butyrate and MNNG in generating an in vitro CRC cell line model that represents human colorectal tumorigenesis.

      Figure 6: total levels of ribosomal S6 protein and ULK1 should be detected, quantified and used for normalization.

      We agree with the reviewer, we will add total S6 and ULK1 controls to these figures.

      Can you measure ASN upon inhibition of autophagy? Does it go down further?

      This is an interesting question, and we will address this experimentally by measuring ASN levels following treatment with chloroquine in the C1 and M cell lines. We will do this using stable isotope labelling and mass spectrometry and include the results in supplementary material.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      Legge and colleagues metabolically characterize an in vitro colon carcinogenesis model based on the development of the adenoma cell line PC/AA to a tumorigenic phenotype. They find differences in the use of glucose and glutamine in the different cell lines and a dependency of what they call late-stage adenocarcinoma cells on asparagine (ASN) synthesis, which is not present in their early stage cell line. The study is well-written and interesting.

      A major concern is the model used in this study:

      Sodium butyrate and the carcinogen N-methyl-N-nitro-nitrosoguanidine (MNNG) were used for the transformation. I believe this model was developed by one of the co-authors of the study, A.C. Williams in the 1990s. The relevance of the model for in vivo colon carcinogenesis is not entirely clear to me and I miss information why in particular sodium butyrate and MNNG were used. I am not an expert on colon carcinogenesis but I did not have the impression that this model has been widely adopted and I miss detailed information on the model itself as well as a critical discussion of its limitations.

      The seahorse and the stable isotope labelling experiments appear fine to me.

      Figure 6: total levels of ribosomal S6 protein and ULK1 should be detected, quantified and used for normalization.

      Can you measure ASN upon inhibition of autophagy? Does it go down further?

      Significance

      The identification of ASN synthesis as a potential vulnerability of advanced colon cancer is potentially significant but needs to be confirmed in other models.

      Differences in ASN sensing between early and late stage colon cancer cells as well as the role of autophagy are potentially interesting and merit further investigation.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      The manuscript by Legge and colleagues describes the metabolic rewiring during colorectal cancer (CRC) progression. While earlier stages depend on glycolysis but maintain oxidative metabolism later stages are more plastic and can be maintained in nutrient-poor environments. The study addresses a very important open question towards the progression of CRC, however the stated clinical relevance is relatively little. The strongest limitation is the used model system to describe the step-wise progression of CRC what makes it difficult to understand how important the findings of this study are for the very heterogonous disease CRC.

      Major comments:

      Early CRC

      Molecular understanding of CRC is obviously of great interest and importance for the clinics. However, tumors of early stages are almost exclusively resected and not treated with systemic agents. Hence, the argument by the authors that the metabolic understanding of early CRC is of clinical relevance is somewhat misleading. Overall, it would have been much more clinically relevant to investigate the multiple steps of later stages during CRC progression. How about metabolic changes during metastasis. Deep mechanistic understanding of process during metastasis has striking clinical relevance.

      Model system

      The cell lines used in this study are not state-of-the-art to investigate the complex process during CRC progression. The original paper is from 1993 in which the cell lines were generated does not allow understanding of the characteristics of these cell lines. Recently, multiple models have been established, for example in organoids, to investigate the progression of CRC much more reliably. There are systems that use CRISPR/CAS9 edited human organoids that follow the genetic alterations of CRC progression with accompanied phenotypes. Further, extensive biobanks of organoids from patients are available (also commercially) which better represent the stages of CRC. Similarly, the question raised above of how representative this progression cell line set is needs to addressed. The mutagen-induced progression could generate various alterations that are not detected in patients, hence create an artificial system. Overall, biological replicates are missing.

      Gene Expression analysis

      In Figure 5 C and D is the expression of ASNS to stages and overall survival from online available datasets correlated. Its unclear what the difference between tumor and metastatic in C means. The labelling in D is too small. Is the difference between the two groups significant? Are these patients only at a specific stage? It seems not that ASNS is a strong prognosticator; further stratification is needed to clarify the role of ASNS in CRC.

      Western Blot controls

      For the Western Blots in Figure 6 A and C the total S6 and ULK1 controls are missing what is needed to assess the effect on pS6 and pULK1 correctly. In the same panels, the KO efficacy is not very high in A (-ASN). However, this is crucial to make the conclusion that this cell line (C1) is not dependent on ASNS

      Minor comments:

      Statistical analysis of proliferation assays

      The statistical significance for proliferation assays are missing.

      Significance

      The described topic is very relevant and of great interest to the field. However, I see the major limitation in the applied system to decode metabolic dependencies. If the key points were validated for example in state-of-the-art organoid systems, the impact of the work would be much clearer. I have to note that my expertise in the field of metabolism is relative little. My expertise lays in modelling CRC and its plasticity/heterogeneity with a strong asset to the translational space.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      Legge et al. provide novel metabolic liabilities in colorectal cancer progression. They identified that during colorectal tumor progression cancer cells shift from glycolytic to oxidative metabolism that enables cancer cells to advance. Using stable isotope tracing experiments with U-13C glucose and U-13C glutamine they showed that the contribution of these carbon sources changes from colorectal adenoma to carcinoma progression. In their in vitro model they identified that late-stage colorectal adenocarcinoma cells (M) display metabolic plasticity which leads to resistance to changes in nutrient supply compared to early stage adenoma cells. Proteomic analysis revealed that amino acid metabolism is highly dysregulated during carcinoma progression. The authors identified ASNS and regulation of asparagine availability as novel metabolic target for late-stage adenocarcinoma.

      Overall, this is a very interesting and important manuscript describing a previously unknown metabolic liability in late-stage adenocarcinoma. The authors also nicely demonstrate how cancer metabolism is adapting and changing during cancer progression. These findings are clearly of high relevance in the context of better understanding of how metastatic cancer cells gain abilities to metastasize. Therefore, the findings presented here would advance the field. However, there are some open questions in the study design and the current set of data as listed below.

      1. All of the findings in this manuscript are limited to in vitro observations, we know that most of the in vitro findings can not be translated in vivo. The manuscript would significantly benefit from in vivo experiments using the cells described in Fig.1 A and confirming the in vitro findings.
      2. The authors should provide proliferation data for the cell lines they used in this manuscript (C1, SB, 10C and M). In Fig. 1 B they show clear differences in EACR, can the authors provide data on glucose uptake differences in these analyzed cell lines.
      3. In Figure 2 C the authors should provide isotope tracing data for the upper glycolysis (e.g. glucose and glucose-6-P) and alanine. In Figure 2 D the authors should provide the isotope tracing data for glutamine and glutamate.
      4. Do the authors see any sign of reductive carboxylation in their U-13C glutamine experiments?
      5. Can the authors speculate how the C1, SB, 10C and M cell lines would react when glucose would be replaced with galactose in the culture environment and forcing the cells to increase oxidative phosphorylation (OXPHOS).
      6. Can the authors comment whether C1, SB, 10C and M cell lines show differences in coping with oxidative stress?
      7. In the ASNS knockdown experiments do the authors detect an increase in glucose uptake in ASNS deficient cells.
      8. Can the authors provide gene expression data that would explain the metabolic switch between early and late-stage adenocarcinoma? Do the authors detect any differences in mTORC1 activation among the C1, SB, 10C and M cell lines? ASNS is an ATF4 target, can the authors provide any expression data on ATF4 in their cell lines.

      Referees cross-commenting

      The comments from the other reviewers are fair and would significantly improve the quality of the manuscript. Overall all three reviewers think that this manuscript is of great interest for the scientific community.

      Significance

      Overall, this is a very interesting and important manuscript describing a previously unknown metabolic liability in late-stage adenocarcinoma. The authors also nicely demonstrate how cancer metabolism is adapting and changing during cancer progression. These findings are clearly of high relevance in the context of better understanding of how metastatic cancer cells gain abilities to metastasize. Therefore, the findings presented here would advance the field.

      The findings are novel and have not been described in this detail before.

      The findings would be of importance for a broad audience and ideally will help to identify novel pharmacological inhibitors that could be used in patients.

      My expertise is in cancer metastasis, cancer metabolism and translational/clinical medicine.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      The authors do not wish to provide a response at this time.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      Summary

      This manuscript attempts to link different aspects of HDAC1 function to Plasmodium falciparum biology. HDAC1 is essential so is likely to have important functions in parasite development.

      The emphasis is upon the potential gene regulation aspects of HDAC1 function, but it is well known that acetylation of other proteins is regulated by HDAC1 orthologues. While they examine the genome occupancy of HDAC1, it's not clear whether the phenotypic effects described can be ascribed to effects upon histone modifications. For RNA-seq analysis and ChIPseq, they generally use one time point so they have not controlled for potential differences in cell cycle to explain differences in gene expression or genome occupancy. These weaknesses in the experimental design make it difficult to evaluate the significance of their data with artemesinin and drug resistant lines.

      The authors suggest that CKII is important for regulating the function of HDAC1. This is biologically plausible, but the link could be more convincing. In addition, the evidence that the potential gene regulation effects are critical for the phenotype observed could be stronger.

      Major comments:

      Figure 1: They perform phosphorylation studies with recombinant CKII and HDAC1, but they do not demonstrate whether the phosphorylated residues correspond to the predicted residues S391, S397 and S440 or if mutation of the predicted residues affects activity.

      The inhibitor data are consistent with the predicted effects, but kinase inhibitors do not always have the same target in vivo or in cells as they do in protein assays. Concentrations of inhibitors used should be provided in the materials and methods.

      They also claim that CK2 and HDAC1 interact in parasites (p5). They do not provide data to support this statement, nor do they provide any data about other proteins that might be interacting with HDAC1. If they were able to purify enough HDAC1 for mass spec identification, they should provide further documentation about interacting proteins and potential post-translational modifications.

      In addition, they should provide more detailed characterization with Western/IFA of when HDAC1 is expressed and whether CKII is always expressed at the same time.

      Overall the importance and significance of CKII in regulation of HDAC1 activity is not clear and would be much strengthened if experiments performed with recombinant protein could be replicated in IP parasite lysates with appropriate controls and a time series.

      Figure 2: Using an HDAC1 GFP line they perform ChIP-seq. The ChIP-seq experiments seem to be well performed with high correlation between replicates but were performed at a single time point in the life cycle of erythrocytic stages. It's not clear if the distribution or abundance of HDAC1 changes during the cell cycle, though they suggest it does, and given changes noted in genome occupancy, one cannot determine if the differences seen could be completely explained by parasites being in different stages of the cell cycle with different levels of HDAC1. They show enrichment of different pathways, but do not comment on whether these are just pathways that are enriched in trophozoites.

      Figure 3 They characterize the growth rate of parasites treated with sublethal concentrations of HDAC1 inhibitor and see effects. The images presented in panel A are not good quality and parasite morphology is difficult to evaluate. They perform RNA-seq at a single time point and the choice of time point and drug concentration used is not justified. Changes are reported but again with a single time point, it's difficult to interpret the significance of the changes-are these dying parasites or parasites slowly progressing through the life cycle? To really understand the effects of these drugs a better characterization of dose response and time point series is needed.

      Figure 4 Upon overexpression of PfHDAC1-GFPglmS there appear to be more parasites. It is unclear if this due to more merozoites per schizont, better invasion with more rings. Again, better characterization of time points would be helpful to understand how overexpression of HDAC1 affects proliferation.

      Figure 5. They state that there is less HDAC1 in art resistant lines, but given that they have not provided any information about cell cycle expression of HDAC1 and growth of these lines in comparison to wild-type, it is unclear if there are differences in biology or if the cells differ where they are in the cell cycle.

      This is particularly important because of the known differences of artemisinin effects depending upon cell cycle stage.

      Figure 6 Genome occupancy data are difficult to interpret given possible differences in cell cycle.

      Minor comments:

      The general quality of images and gels should be improved.

      More information should be provided about the validation and specificity of the in house HDAC1 antibodies.

      Concentrations of inhibitors used should be provided.

      Referees cross-commenting

      There is consensus amongst all reviewers that the experiments as presented cannot be readily interpreted and are lacking adequate controls. The amount of experimental work and further analysis is considerable.

      Significance

      Understanding gene expression and the role of HDAC1 is potentially significant, particularly if these can be linked to important biological processes such as artemisinin resistance. Potentially the audience would be broad. The link between these processes is not well supported by the data as currently presented.

      Expertise: epigenetics, parasite gene expression.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      In this study, Kanyal et al present a functional analysis of the Plasmodium falciparum Histone deacetylase 1 (PfHDAC1). PfHDAC1 is the only predicted class I HDAC in P. falciparum and has been shown to be the target of several established and novel compounds with anti-malarial activity across parasite stages. In this work, the authors showed that recombinant HDAC1 is phosphorylated in the presence of CKII in vitro and can de-acetylate P. falciparum histones (although no loading control was presented for this latter assay). ChIPseq of GFP tagged HDAC1 identifies target sites relating to diverse cellular processes, and sublethal treatment with the proposed HDAC1 inhibitor rhomidepsin has an impact on cell cycle progression, suggesting that HDAC1 may act in cell cycle control. However, overexpression of Histone deacetylase seems to enhance parasite multiplication by increasing invasion gene expression, which seems counterintuitive as overexpression is expected to cause decreased histone acetylation and thereby gene repression, and hence this pattern may be due to indirect effects, which the authors acknowledge but the relevance of which they do not discuss further. Interestingly, HDAC1 expression is reduced in Art resistant parasites and inhibition of HDAC1 (at what concentrations?) increases ART resitance both in wt and in K13 mutant parasites, suggesting regulation of HDAC1 may be involved in adapting to artemisinin treatment. ChIPseq of artemisinin resistant versus sensitive parasites suggests that HDAC1 is relocated to various different loci, although replicates for this experiment seem to be missing and hence the validity of these results would need further support, particularly because ChIP results conducted with anti-HDAC1 antibodies and anti-GFP antibodies seem to diverge considerably. Lastly, the authors propose that artemisinin treatment results in mistrageting of HDAC1 but find no correlation with gene expression. Generally, the study raises some interesting aspects related to a function of HDAC1 in artemisinin resistance but would benefit from more rigorous analyses and comparisons of the NGS data presented in correlation to each other (e.g. ChIP anti-GFP vs ChIP anti-HDAC1) as well as to published data sets (e.g. Huang et al). Sometimes it is difficult to assess which data set the authors refer to and whether transcriptional data were derived from RNA harvested in parallel to ChIPseq (matched) or whether they were performed independently or by others. Also, many assays seem to lack replicates and controls as outlined below.

      Major comments:

      • Transcriptomic data of parasites treated with Romidepsin are presented as a proxy for HDAC1 function and indicate deregulation of invasion pathways, however what is the evidence that romidepsin targets (exlusively) HDAC1? This could for example be addressed by comparing the Romidepsin IC50 in HDAC1 overexpressing parasites versus parasites with WT levels of HDAC1.
      • How do the rhomidepsin treatment data correlate with JX21108 RNAseq results, a validated HDAC1 targeting compound? The authors need to thoroughly cross evaluate their data with the RNAseq data set from HDAC1 knockdown parasites and JX21108 treated parasites presented in Huang et al, 2020.
      • What is the overlap between genes deregulated after rhomidepsin treatment and ChIPseq targets?
      • What are the target genes that show strong enrichment in the gene body in Fig. 2E? How are the data sorted? It is expected that HDAC1 may affect gene expression differently when it is present in the gene body to when it is present in the promoter region, therefore it would be useful to stratify the target genes by peak position relative to genetic elements.
      • How do the anti-GFP ChIPseq data in K13WT strains (496 target genes, Fig 5) correlate with the anti-HDAC1 ChIPseq data (1409 target genes Fig 2 and 6)? There seems to be limited overlap in the target sites in number and quality, but it is difficult to assess just from looking at gene numbers and GO analyses. The data sets need to be more thoroughly cross-validated. What proportion of peaks overlap and where?
      • How many replicates were performed for each experiment? Many of the Figures showing recombinant assays and ChIPseq assays seem to represent only a single biological replicate (e.g. Fig 1E histone deacetylation assay, Fig. 5A, Fig 6C: ChIP under Artemisinin treatment).
      • Several critical controls are missing, for example Figure 1E/ Suppl. Figure 2D loading control (anti-H3). How was densitometry normalized?
      • What was the parasite age in RNAseq of HDAC1-GFP-GlmS parasites? Were the two data sets from different parasite lines adjusted for parasite age? How many replicates for RNAseq?
      • The data in Figure 6A Lanes 1-5 are evidently the same as shown in Fig 1D. The presentation of Art treated data as a single lane 6 without direct reference is not convincing as this does not allow a direct comparison of loading and between conditions.
      • How does histone acetylation change in response to Art treatment?

      Minor comments:

      • Page 4 top paragraph: check whether Ref 16 and 17 are correctly cited here.
      • In all Figures: specify drug concentrations and number of replicates.
      • What concentrations of etinostat, DHA, Romidepsin were used to treat parasites? Please provide exact concentrations of treatments ( not just +, ++, for example for TBB Fig 1, Artemisinin 6A), what was the "continuous sublethal dosage of romidepsin" exactly, what is the IC50 of romidepsin?
      • What is referred to as control in Fig. 1E?
      • Fig 4F please specify in the figure legend what the control was
      • Fig 4G the labelling of the circus plot is unreadably small.
      • Figure 5G and H: what RNAseq data set is shown here? Are these matched RNAseq data from these ChIP assays or other?
      • The calculation of how the growth curves were corrected as "GFP-glmS corrected growth curves" is unclear, please provide exact formula. Generally, the multiplication rates even in untreated conditions appear rather low in all experimetns (for example Fig 4D, only less than 2-fold growth after 1 cycle, 4 fold growth after 2 cycles.... Do the parasites under the normal growth conditions really only duplicate in each cycle? This seems a very low multiplication rate even for static in vitro culture of P. falciparum.
      • What is the relevance of the 2xFKBP in the tagging construct?

      Referees cross-commenting

      All reviewers agree that the manuscript in its current form would benefit from the addition of controls and replicates as well as additional time points for RNAseq and ChIP experiements.

      Significance

      Generally, the study raises some interesting aspects related to a function of HDAC1 in artemisinin resistance but would benefit from more rigorous analyses and comparisons of the NGS data presented in correlation to each other (e.g. ChIP anti-GFP vs ChIP anti-HDAC1) as well as to published data sets (e.g. Huang et al). Sometimes it is difficult to assess which data set the authors refer to and whether transcriptional data were derived from RNA harvested in parallel to ChIPseq (matched) or whether they were performed independently or by others. Also, many assays seem to lack replicates and controls as outlined below.

      My personal field of research is chromatin biology and antigenic variation in malaria parasites.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      This study characterises a Plasmodium class I Histone deacetylase (PfHDAC1). The manuscript reports a wide range of experiments - some of them complex and involved, but not all of these experiments appear to be well controlled, and some are insufficiently described to know if they have been appropriately designed and interpreted. A link to HDAC1 regulation and artemisinin resistance is advanced, but the evidence here is very indirect and inconclusive.

      The study shows that HDAC1 interacts with PfCKII- a homologue of the mammalian casein kinase known to interact with mammalian HDAC1. They also demonstrate that, at least in vitro, HDAC1 can serve as a substrate for phosphorylation by PfCKII, and that this phosphorylation impacts HDAC1's deacetylation of histones. Such assays where a kinase is provided with a single, abundant substrate in vitro, are not always rigourous tests for kinase specificity, but do in this case at least indicate that HDAC1 associated with its activity.

      Major issues:

      1. The authors conduct CHiP seq experiments on a GFP tagged HDAC. It is unclear from the methods and results section what control is used in these experiments. The ENCODE consortium has established minimum standards (Landt et al 2012) for conducting and reporting CHiP seq experiments, and states that the "recommended control for epitope-tagged measurements is an immunoprecipitation using the same antibody against the epitope tag in otherwise identical cells that do not express the tagged factor.". These experiments appear to lack that control and the enrichments reported should be approached with caution in the absence of such a control.
      2. The genes with apparently altered ChiP seq were subjected to gene ontology enrichment analysis, and the authors report potential enrichments - which appear to impact a range of unconnected biological pathways throughout the parasite and throughout the lifecycle, despite the CHIP seq being conducted only at a single time stage. No mention is made of correction for multiple hypothesis testing, known to present a considerable problem for such analyses, and no correction is described for background GO distributions in the P. falciparum genome, so again it's unknown if or how that was performed. The reported enriched categories must be also treated with considerable caution given the absence of description of these crucial steps. The authors report from this section that HDAC1 is associated with stress responses, but really, by their criteria, HDAC1 is associated with 1/3 of the whole genome, so it's a bit selective to regard it as a stress regulator
      3. The authors preform a well-designed series of transfection experiments with modulation of HDAC1 to show that an overexpression of HDAC1 leads to increased growth rate, and that this increase reduces when the overexpression of HDAC1 is inducibly repressed. However, I found the presentation of results from these experiments difficult to understand and there is considerable transformation of the data prior to plotting - they would be easier to understand if no background subtraction to normalise for GFP were conducted, and if all strains were plotted on the same axes. A potential confounding factor in this experiment is that many lines overexpressing GFP grow more slowly, and that this growth defect can be localisation dependent, so that over-expression of GFP alone may cause a different growth penalty than GFP on a nuclear protein. I am uncertain that the conclusion of 50% faster growth is a safe one based on these graphs - at some time intervals the over-expressor appears to grow just as slow or even slower (as a percentage of the previous timepoint) than the control, and these appear to have been based on technical replicates of a single biological experiment. The authors contend that the growth rate is due to changed expression of invasion genes (among many other substrate gene categories) giving rise to enhanced invasion - such a phenomenon is readily testable, and the authors should dissect this if they wish to substantiate the frankly surprising claim that overexpression of HDAC leads to increased growth rate.
      4. The authors also report an apparent down regulation of HDAC abundance in artemisinin resistant parasites. This conflicts with previous global proteomic analyses of artemisinin resistant parasites which found no such change in HDAC1 regulation or abundance (eg Siddiqui et al 2017, Yang et al 2019). Stage matching is a particular challenge in such experiments given the differences in cycle progression between ARTR and ARTS parasites, and it isn't clear that this has been adequately controlled for to have confidence in these results, particularly given their contradiction of previous analyses. The abundance of PfHDAC1 changes considerably throughout the asexual intraerythrocytic cycle, (out of synch with the control used here actin), so potential stage-mismatch might contribute to apparent differences here. Again, explicit mention of replicates is lacking. The authors also mention genes regulated by HDAC1 as including genes related to processes related to artemisin resistance, but this is hard to sustain - indeed with so many genes apparently substrates of HDAC1 it would be highly surprising if there were no overlap with some genes in pathways related to artemisin resistance. An accompanying experiment demonstrating an increase in survival (of both ART resistant and ART sensitive lines) in an artemisinin ring stage survival assay is intriguing, after using a possible inhibitor of HDAC but these results are hard to reconcile with a dynamic transcriptional response. (Why was this done with an uncharacterised inhibitor, rather than the more specific HDAC1 overexpressor/knockdown system? An accompanying RNAseq analysis is described, but the analysis is piecemeal and selective, with the authors pointing out candidate genes representing categories plausibly linked to artemisinin resistance. I found this section unconvincing and indirect - lots of genes are changed in these experiments, and so they inevitably include some that are feasibly linked to artemisinin resistance, but the one gene convincingly known to modulate resistance, K13, isn't mentioned, and presumably wasn't specifically changed in this analysis.
      5. A previous study by the laboratory of Christian Doerig (Eukaryot Cell. 2010 Jun; 9(6): 952-959.) reported that HDAC1 activity (unclear which of the HDACs) is associated with Pfcrk-3). This activity may not correspond to the HDAC1 characterised here, but deserves some discussion.
      6. The Western blots are letterboxed and in some cases appear to crop out bands on the limit of the image (eg Fig 5, 6). Please provide fuller pictures of the blots and indicate the relevant bands if there are several background bands.

      Minor issues

      The text uses breaking spaces for the gap between genus abbreviation and species throughout. Replace with non-breaking spaces. Abstract: "is correlated with parasitemia progression" - Unclear meaning. Reword. Introduction "closes in on 400,000 deaths annually" Unclear meaning/vernacular usage. Reword. Very long paragraph on pages 3-4. Reorder logical flow and break into smaller paragraphs to make this more easily read. "Given the evidence of the role of HDAC inhibition in the emergence of chemotherapeutic resistance in mammalian system" - needs a reference - no mention of this phenomenon up until this point of the manuscript

      Referees cross-commenting

      I agree with the other reviewers comments. Although the manuscript contains a very large number of complex experiments, necessary controls, sufficient replicates, and appropriate analysis are missing from many of the experiments.

      I appreciate that the experiments referred to would require a very substantial time and resource commitment to complete, but in their current form, many of these experiments are not safely interpretable.

      Significance

      This manuscript makes major claims for HDAC1, in particular for its role in artemisinin resistance. Such a link would be significant, but I regard few of these claims as having been robustly substantiated in this manuscript. The CHIP-seq evidence is of interest as a useful dataset, particularly if accompanied by relevant controls

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      General Comments

      We thank all reviewers for providing very detailed, knowledgeable, and informative reviews.

      All reviewers were complementary about the data and the rigor of the study. Reviewers 2 and 3 commented on the significance of the work, and their assessments were complementary, specifically about the fact that it bridges several previous studies and links these to kinase-phosphatase regulation on the BUB complex. We agree that this a major strength of the work. That is why we also believe the comment by reviewer 1 that “most of the phenotypes/observations are consistent with the literature and not surprising” is actually a strength and not a weakness. Sometimes manuscripts that bring together various different findings into one conceptual model can be very powerful, even if each finding in isolation is not so surprising. In this case, the concept that a dual kinase-phosphatase module integrates two major mitotic processes will, we believe, prove to be a significant breakthrough that helps to explain how these processes are properly integrated at kinetochores.

      The main criticism of all reviewers related to the interpretations and writing style, which in general, we felt were valid. We will take on board all these comments, reword the manuscript during revision, and provide a detailed response to each of these points at resubmission.

      In terms of points requiring new experiments, there were 3 in total:

      1) Reviewers 1 and 3 raised an important issue about the feedback loop which will be addressed with new experiments to uncouple the feedback.

      2) Reviewer 2 made an important point about KNL1 levels, including a good suggestion to perform FRAP analysis to examine BUB complex dynamics when MELT numbers are increased. We will carry out this experiment prior to revision.

      3) Reviewer 1 had a second major comment regarding the modulation of MELT number and how this cannot be directly linked to PLK1/PP2A levels. We have 3 new experiments to add regarding this, performed already, which are discussed in the section below.

      All other comments were textual points that in most case we felt were valid. They showed that all reviewers had a very good grasp of the paper, the concepts, and the field in general. So, we finish by thanking all reviewers again for their thorough and detailed assessments of our manuscript. The comments they raised will help us to improve the manuscript after revision.

      Description of the planned revisions

      Three main points:

      1) The role of the feedback loop [reviewers 1 and 3]:

      The general issue is explained succinctly by reviewer 3’s comment:

      “The argument linking the negative feedback loop to biological functions is not straightforward. The authors provide evidence in Figure 1 for regulatory pathways between docked PLK1 and bound PP2A. However, their assays in Figure 2 bypass the feedback loop by directly modulating PP2A activity. These experiment supports an argument that the kinase/phosphatase activity balance is important, but do not address the feedback loop specifically (which could potentially be done using mutations that disrupt the feedback regulation). The claim that "a homeostatic feedback loop maintains an optimal balance of PLK1 and PP2A on the BUB complex" is too strong because there is no direct evidence connecting the feedback loop to optimal function.”

      This is a good point that we will address at revision. We demonstrate that the enzymes regulate each other on the BUB complex in figure 1 (PLK1 recruits PP2A, and PP2A removes PLK1), which balances their levels on the BUB complex. To determine consequences of upsetting this balance we locked either the kinase-bound or phosphatase-bound states (Figure 2). Importantly, this is required to assess direct phenotypes associated with each, but it does not directly demonstrate the role of the feedback loop. To do this we will generate mutants, as suggested, and analyse their phenotypes.

      We will mutate the PLK1 binding site (T620A) and recover the PLK1-regulated sites in the KARD motif to phospho-mimicking aspartates (S676D/T680D), analyzing effects on PLK1/PP2A recruitment, chromosome alignment and SAC strength. We predict that this will remove PLK1 and recover some PP2A, but to lower levels overall than the BUBR1-B56 fusion. In that case the phenotypes will probably be milder, but that would not change the overall conclusions.

      We maintain that locking PLK1 on its phospho-binding site (in BUBR1-DPP2A) is the ideal scenario to test direct PLK1 roles, but we will also now create alanine mutants of the PLK1 site (S676A/T680A) and the CDK1 site (S670A) to address the feedback loops controlled by CDK1 and PLK1. Our prediction is that these will skew the balance towards PLK1, without fully removing PP2A, again likely to produce milder intermediate phenotypes.

      It is definitely worth testing these predictions, because it would directly address the role of the feedback loop and it would avoid relying solely on “artificially high levels” as mentioned by reviewer 1. One final point on this however, the PLK1 recruitment in DPP2A cells is not artificial – it is PLK1 bound to its native phospho-motif when PP2A is unbound (without any feedback from PP2A this phospho-site and PLK1 binding increase to the observed maximal levels). The fusion of B56 is admittedly less optimal, but this does still lock the phosphatase-bound state in a set stoichiometry, crucially in the absence of kinase. This is required to assess direct phosphatase effects. These PLK1/PP2A levels may well be higher than observed physiologically on the BUB complex when considering the behavior of all BUBR1 molecules, since we doubt they ever reach 1:1 stoichiometry with either PLK1 or PP2A. However, the feedback loop is operating within individual molecules (figure 1), which may well individually flip between PLK1 or PP2A bound states. This may occur on certain molecules at specific times. Therefore, locking the PLK1.PP2A-bound state on all molecules is, in our opinion, still a valid and useful perturbation to assess function of these two states.

      2) The increase recruitment of BUB1-PLK1/PP2A when MELT numbers are increased [reviewer 2]

      "While in the 12x and 19x mutant conditions there are more molecules of BUBs per Knl1, the overall BUB levels are the same as in wild-type controls. Since the MELT repeat used throughout the paper is a consensus sequence that is likely optimal for BUB binding, it is possible that the phenotypes of the 12x and 19x mutants are explained because of an increase in the affinity of BUBs for Knl1 rather than overall levels. This would also help explain why Knl1 and BUBs are observed at the spindle midzone in the 19x mutant (Fig. S4)"

      The reviewer raises an important issue here, when stating that increasing MELT numbers decreases KNL1 kinetochore recruitment. This has the net effect of normalizing overall BUB1-PLK1/PP2A kinetochore levels, even though BUB1-PLK1/PP2A recruitment per KNL1 molecule is increased. That is why we were careful to state BUB1-PLK1/PP2A were increased “on each KNL1 molecule” and not “on kinetochores” when referring to the effect in the 12x/19x MELT mutant. However, this could easily be misinterpreted so this point will be clarified at revision.

      The issue of why the phenotype is so dependent on kinase/phosphatase level per KNL1 molecules is an important one however, which has puzzled us until now. We think the suggestion to look at turnover by FRAP is a good one, because enhanced binding strength could underlie the phenotype here, and potentially explain the lack of disassembly at anaphase. We will perform these experiments at revision to see if they can clarify the issue.

      3) The link between MELT number and PLK1/PP2A levels [Reviewer 1]

      “My second comment relates to the fact that the two parts of the paper are not directly linked although the authors try to do this. They nicely manipulate the MELT repeats on KNL1 to change the number of Bub complexes. However, they cannot directly link the data to changes in Plk1 and PP2A-B56 levels only as many other things are changing. By increasing MELT numbers Bub complex and Mad1/Mad2 levels increase as well as an example and this makes interpretations complicated. To me these experiments are not addressing the main conclusions of the paper.”

      We do not agree with this overall assessment, but there are two elements to this comment: the effect of modulating MELT number on SAC strength (and its link to PLK1) or on KT-MT stability (and link to P2A). We will therefore discuss each separately:

      For SAC regulation, we feel that the data is clear and the interpretations are justified, although we will add new data to support this point after revision. Increasing MELT number causes defects in MELT-BUB dissociation and SAC silencing (4a-c). Importantly, these phenotypes can be completely rescued by inhibiting PLK1 (4d-e). So, we do link the effects of high MELT number to PLK1 activity. Our interpretation is that when MELT numbers are increased the ability of PLK1 to phosphorylate these motifs and maintain the SAC platform is enhanced (when MPS1 is inhibited pharmacologically or upon KT-MT attachment). So, whilst it is true that many factors, such as the kinetochore levels of BUB/MAD1/MAD2, are crucial for the SAC, the ability of PLK1 to maintain these levels (via pMELT-BUB1) is crucial and that changes as MELT number increases. This contributes directly to the observe SAC silencing phenotype, as confirmed by the complete rescue of this phenotype after PLK1 inhibition.

      We did also explore the possibility that increased BUB1 activity could also contribute to SAC strengthening, for example, by enhancing Aurora B recruitment to centromeres. However, BUB1 inhibition did not alter SAC strength or MELT dephosphorylation kinetics. We will add this data after revision.

      We also evaluated the levels of phosphorylated MAD1-pT716, which is important for MCC assembly (Ji et al. 2017, Ji et al. 2018, Faesen, 2017). Our data show that WT and 19xMELT exhibit similar MAD1-pT716 levels during a nocodazole arrest and following MPS1 inhibition. In summary, the main changes we observe are elevated BUB1 levels due to MELT phosphorylation, and increased BUB1 phosphorylation on pT461 (as shown in Figure 4h). All this points towards a localized effect of PLK1 on/around the BUB complex. We will add this data and make this point clearly at revision.

      For KT-MT attachment regulation, we agree that we do not have a similar way to inhibit PP2A-B56 activity to rescue hyperstable microtubule attachment when MELT numbers are high. For this, we require a way to rapidly inhibit PP2A-B56 activity after attachments have formed, something that is not technical feasible at the present. We can also not say for certain that reduced MELT numbers destabilize microtubule due to lack of PP2A, however we feel this is the most like interpretation for the following reasons. The phenotype of removing PP2A from BUBR1 or removing the MELT from KNL1 (along with all associated factors), is identical: mutant cells have comparable chromosome misalignment due to unattached kinetochores (compare 2F-I with 5A-D). Therefore, the additional factors lost by removing the MELTs cannot be having such a strong impact in KT-MT attachment. The obvious factor that could affect attachment strength is again BUB1, via Aurora B recruitment to centromeres. However, loss of BUB1 (after MELT removal) is predicted to enhance attachment stability (reduced Aurora B) and not decrease it, as we observe. So, whilst we cannot definitely conclude that modulating MELT number affect attachment stability via PP2A, we feel that this is certainly the most likely explanation. We will state this clearly in the revised text.

      Description of analyses that authors prefer not to carry out

      “SAC strength of BubR1 WT, ΔC and B56γ was analysed in the presence of nocodazole + MPS1i. It would be interesting to see what the phenotypes are without MPS1i [Reviewer 1]”

      In the absence of MPS1i basal MELT phosphorylation increases (DC) or decreases (B56g) as predicted (Figure 2d; compare timepoint 0 all conditions). This does not cause any change to SAC strength when all kinetochores are unattached in nocodazole (not shown). The sensitize SAC assay (nocodazole + MPSi) has been used by many groups (originally Santaguida et al, 2011; Saurin et al, 2011), because it reduces SAC signals from all unattached kinetochores which would otherwise produce a saturated response. In this case, we specifically chose a dose of MPS1 inhibitor that gave a partial SAC response from which we could observe either strengthening or weakening – a key point of the assay. Indeed, this showed that the SAC was strengthened (DC) or weakened (B56g), as predicted (Figure 2E). The only other way to do this, which has been used by some in the literature, is to use a low dose of nocodazole which prevents all kinetochore from signaling to the SAC. We specifically wanted to avoid this situation because then you cannot untangle the effects on SAC and KT-MT attachment stability – this was crucial in our case.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      A dividing cell relies on both error correction and spindle assembly checkpoints (SACs) to ensure accurate chromosome segregation. The PLK1-PP2A pair resides at the interface of the two pathways and makes these pathways robust and responsive. By generating fusion proteins and mutagenesis to perturb PLK1 and PP2A activities in HeLa cells, the authors found that both enzymes constitute a negative feedback loop on the scaffold BubR1. The docked PLK1 phosphorylates the PP2A binding site to recruit PP2A, while the PLK1 docking site is dephosphorylated after PP2A recruitment. They also manipulate kinetochore recruitment of PP2A to show effects on the SAC and on kinetochore-microtubule attachments. Independently, by varying active MELT repeats on KNL1, the authors found that decreasing MELT repeats weakens the SAC with unstable attachments, while increasing MELT repeats strengthens the SACs with hyperstable attachments. Thus, the recruited level of BubR1 determines SAC strength and attachment stability. The data included in this paper are solid, and the concepts are interesting, but these potential strengths of the manuscript are obscured because the logical progression and presentation are difficult to follow.

      Major comments:

      1. The first three paragraphs of the introduction lead up to the question: "Why the same phosphatase complex is used for both process is still not clearly understood". One conceptually simple answer is that the SAC should be silenced as attachments are stabilized, so it makes sense to use the same enzyme to accomplish both tasks. If the authors have something else in mind, they should clarify.
      2. The argument linking the negative feedback loop to biological functions is not straightforward. The authors provide evidence in Figure 1 for regulatory pathways between docked PLK1 and bound PP2A. However, their assays in Figure 2 bypass the feedback loop by directly modulating PP2A activity. These experiment supports an argument that the kinase/phosphatase activity balance is important, but do not address the feedback loop specifically (which could potentially be done using mutations that disrupt the feedback regulation). The claim that "a homeostatic feedback loop maintains an optimal balance of PLK1 and PP2A on the BUB complex" is too strong because there is no direct evidence connecting the feedback loop to optimal function.
      3. The paragraph starting with "Given the roles of PLK1 and PP2A ...": How does the kinase-dominant situation destabilize KT-MT attachments? Is it by inhibiting PP2A or by phosphorylating some kinetochore components? The former pathway is unclear because the authors show that PLK1 promotes PP2A recruitment in Figure 1.
      4. The paragraph starting with "In summary, a balanced recruitment of PLK1 and PP2A ...": What is meant by "phosphorylation sites that block KT-MT attachment" (used twice in the paragraph)? Block means prevent binding, as opposed to activities that destabilize attachment by promoting unbinding. Which do the authors mean? The following is also unclear: "kinetochores are no longer responsive to MT attachment". If attachment is blocked, as stated in the previous sentence, then what does it mean to say that kinetochores are not responsive to attachment (which never occurred if it was blocked)?
      5. Figures 1-2 and Figures 3-5 are separate concepts, but this is never explained clearly in the manuscript. Specifically, Figures 1-2 focus on the antagonism between PLK1 and PP2A activities, whereas Figures 3-5 focus on changing both activities in the same direction (either increase or decrease). There is no transition from one part to the other. Both concepts should be explained and the hypotheses stated clearly.
      6. Several words are used ambiguously. "Homeostasis" is vague, and it is unclear what exactly the authors mean. As discussed above, the meaning seems different for figures 1-2 vs figures 3-5. "Reciprocal changes" is also unclear (and seems misleading) because the perturbations of PLK1 and PP2A levels are in the same direction (more MELT motifs means more binding sites for both). For "preserved" (description of figure 4F), it's unclear if the authors refer to the Bub1 and BubR1 levels at metaphase or the change between prometaphase and metaphase. The authors should clarify what they mean and how it is measured.
      7. "too much kinase-phosphatase module would cause a strong SAC and hyperstable KT-MT attachment, and too little would cause a weak SAC and hypostable KT-MT attachments": The reasoning behind these predictions is not clear. For example, why does high phosphatase not silence the SAC as explained earlier in the manuscript?
      8. The mitotic exit assay in Figure 4G is hard to interpret. Mitotic duration depends on establishing correct attachments and then silencing the SAC. 19xMELT could affect both. A better measurement of SAC silencing would be time from metaphase alignment to anaphase.
      9. The paragraph starting "In summary, PLK1 is able to phosphorylate MELTs to recruit Bub1": The authors should clarify what was already known and what advance they are making. Similarly, the sentence starting with "Therefore, the number of MELT motifs ..." should also clarify the advance relative to previous findings.

      Minor comments:

      1. Please include pages numbers (and line numbers are also helpful).
      2. Previous literature (PMID 17785528) suggests that phosphorylation of pT620 is important for KT-MT regulation but not SAC signaling. Can the authors comment on this?
      3. SAC silencing seems more appropriate than "mitotic exit" in the last sentence of the second paragraph.
      4. Figure 1 would be clearer with images and the relevant quantifications together in the same panel.
      5. In the first paragraph of Results, the authors primarily explain the impacts of PP2A on SAC silencing but not on KT-MT attachment, even though the topic sentence seems equally weighted to both.
      6. Some terms are not defined when first introduced, such as the KARD domain and B56gamma.
      7. Figure 1JK: how were mitotic cells enriched and harvested?
      8. Figure 2C: a log scale may help show changes in both directions.
      9. Chromosome alignment assays in Figure 2 are not so informative because perturbation either way can generate misaligned chromosomes. The primary figures are dense with data, so these results can be made supplemental.
      10. Figure 3F: can the authors comment on the B56gamma decrease between nocodazole and MG132 conditions?
      11. Figure 4A: the data are difficult to interpret as presented. It is not clear whether SAC signaling changes monotonically with number of MELT repeats. It would be better to plot MELT number vs a summary statistic (such as time to 50% mitotic exit or something else that the authors find informative).
      12. Figure 6. "uncouplr" should be "uncouple".
      13. Missing references in bibliography: Ghongane et al 2014, Roy et al. 2020.

      Significance

      The proposed model is conceptually significant, and this mechanistic work bridges several previous findings. Biochemical studies suggest that KNL1 harbors PLK1-PP2A and Bub complex, and functional studies suggest that truncation on MELT motifs generates mitotic errors (PMID 24363448, 24344183). Furthermore, biochemical and functional assays suggest that PLK1 is a key regulator of the SAC (PMID 33125045). In this work, the authors link functional consequences to biochemical interactions among KNL1, BubR1, PLK1, and PP2A, which is an advance.

      This work should appeal to the kinetochore and cell cycle communities, but the logical flow needs to be improved.

      My most relevant expertise is in mitotic kinases and regulation of kinetochore microtubules.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      In this manuscript by Corno et al the authors investigate how the kinase/phosphatase balance is regulated at kinetochores during mitosis. When kinetochores are unattached, mitotic kinases signal through the spindle assembly checkpoint (SAC) to prevent progression through mitosis. Once attachments have occurred, the activities of kinetochore phosphatases silence the SAC and stabilize kinetochore-microtubule attachments to promote exit from mitosis. Key regulators of this signaling are the BUB proteins Bub1 and BubR1, which recruit the kinase Plk1. BubR1 also recruits the phosphatase PP2A-B56 in a Plk1-dependent manner. By analyzing the recruitment of Plk1 and PP2A-B56 at unattached kinetochores, the authors uncovered a mechanism by which Plk1 and PP2A-B56 negatively regulate each other's recruitment, thereby maintaining an optimal kinase/phosphatase balance. Disrupting this balance can lead to either a hyperactive SAC or premature stabilization of erroneous attachments.

      Overall, this is a very careful study and the data is clear and consistent. My only comments are in regards to the interpretation of the Knl1 data on the manuscript.

      Comments

      • In figures 3 and 4, the authors engineer a system to manipulate the levels of BUBs at the kinetochore by modulating the number of MELT repeats on Knl1. For this, they mutate all 19 MELT repeats on Knl1 and then add back discreet number of MELT motifs that follow a consensus sequence. They find that a 6x mutant, which contains 6 repeats of this consensus MELT motif, is sufficient to rescue the functions of Knl1 on the SAC and on chromosome alignment. However, 12x and 19x MELT repeat versions show an increased SAC response and increased stability of kinetochore-microtubule attachments. The authors interpret this as a result of increased kinetochore levels of BUBs, and therefore, increased levels of both Plk1 and PP2A-B56 (Fig. 3). However, from their representative images in Fig. S3A, it does not appear as if BUB levels are significantly increased in cells expressing the 12x and 19x Knl1 mutants, compared to wild-type controls. Considering that in the 12x and 19x mutants Knl1 recruitment is reduced by more than half of controls (Fig. S3B) and because the authors normalized their BUB kinetochore intensity levels by the Knl1 values, it makes it seem as if BUB kinetochore levels are increased in the cell under these conditions. While in the 12x and 19x mutant conditions there are more molecules of BUBs per Knl1, the overall BUB levels are the same as in wild-type controls. Since the MELT repeat used throughout the paper is a consensus sequence that is likely optimal for BUB binding, it is possible that the phenotypes of the 12x and 19x mutants are explained because of an increase in the affinity of BUBs for Knl1 rather than overall levels. This would also help explain why Knl1 and BUBs are observed at the spindle midzone in the 19x mutant (Fig. S4). To distinguish between these possibilities, the authors might consider doing FRAP experiments using fluorescently labelled Bub1 or BubR1 and measure BUB protein dynamics at kinetochores.
      • Also in regards to the 12x and 19x mutants, because these reduce Knl1 kinetochore levels, this fact alone might explain some of the observed phenotypes, such as the mild defects in chromosome alignment (Fig. S5).

      Significance

      This is a significant advancement in our understanding of how the spindle assembly checkpoint is regulated by kinases and phosphatases at the kinetochore. The authors used very precise manipulations to dissect how these components are balanced and they uncovered a very interesting negative feedback mechanism. They also provided significant evidence for the importance of this balance in normal mitotic progression. This work will be of broad interest to cell biologists, as well as cancer biologists.

      My expertise is on the fields of cell biology, mitosis and cell division mechanisms.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      The proper segregation of chromosomes during mitosis depends on correct kinetochore-microtubule (KT-MT) attachments which is monitored by the spindle assembly checkpoint (SAC). The Bub complex composed of the Bub1-Bub3 and BubR1-Bub3 complexes plays an important role in regulating KT-MT by recruiting Plk1 and PP2A-B56 as well as the SAC components Mad1/Mad2 and Cdc20. The Bub complex is recruited to kinetochores by Bub3 binding directly to phosphorylated MELT repeats on KNL1. The MELT repeats are predominantly phosphorylated by Mps1 but can also be phosphorylated by Plk1.

      Here the authors investigate the Plk1 and PP2A-B56 module on BubR1 further. It is already known that Plk1 is recruited to BubR1 T620 (a Cdk1 site) and that this is important for proper chromosome segregation. Furthermore, BubR1 binds to PP2A-B56 through and LxxIxE motif that is phosphorylated by Plk1 to stimulate binding. The main message of the paper is that the Plk1-PP2A-B56 module on BubR1 is crucial for integrating SAC and KT-MT attachments and that a homeostatic negative feedback loop between Plk1 and PP2A-B56 exists to limit the levels of these enzymes. As outlined below I do not think that their experimental evidence/setup can be used to draw these conclusions. Overall, I have limited comments on the technical execution of experiments as this is overall done well but more on interpretations of results and what conclusions can be drawn. Also, most of the phenotypes/observations are consistent with the literature and not suprising.

      Major comments:

      The authors generate a scenario where high levels of Plk1 are recruited to BubR1 by removing the entire C-terminus to remove the PP2A-B56 binding site and a situation of high PP2A-B56 by replacing the BubR1 C-term with B56gamma. Firstly, these are crude mutants generating extreme situations - specifically the fusion of B56gamma which likely creates artificially high levels of BubR1-B56gamma making it difficult to make conclusions on the physiological levels. These mutants are then analysed in a number of assays and phenotypic consequences analysed in the presence of nocodazole + Mps1 to evaluate SAC strength. It would be interesting to see what the phenotypes are without Mps1 inhibition. I cannot see in any way how the authors from two end points (high kinase or high phosphatase) can reach a conclusion that a homeostatic negative feedback loop exists between these enzymes that is critical for integrating SAC and KT-MT interactions. They can only conclude on what happens if you have too much kinase or phosphatase but no data are addressing what happens if you manipulate the cross-talk on BubR1. The experiments to do must be to carefully tune the proposed cross talk and then monitor what happens. This can be done by bypassing Plk1 regulation of the PP2A-B56 binding site or increasing the strength of the Plk1 binding site. Furthermore, there is no data to show that cross-talk is changing in response to changes in KT-MT attachment status - is the levels and activities of Plk1/PP2A-B56 on BubR1 changing. Yes Plk1 and PP2A-B56 can regulate each other on BubR1 but is this regulated as proposed.

      My second comment relates to the fact that the two parts of the paper are not directly linked although the authors try to do this. They nicely manipulate the MELT repeats on KNL1 to change the number of Bub complexes. However, they cannot directly link the data to changes in Plk1 and PP2A-B56 levels only as many other things are changing. By increasing MELT numbers Bub complex and Mad1/Mad2 levels increase as well as an example and this makes interpretations complicated. To me these experiments are not addressing the main conclusions of the paper.

      Specific comments:

      1. I would caution the interpretation of phenotypes being suppressed by Plk1 inhibitors. This does not address whether it is BubR1 bound Plk1 that is specifically affected - several Plk1 substrates could be contributing. Similar for Mad1 phosphorylation they cannot conclude that it is Plk1 bound to BubR1 phosphorylating Mad1.
      2. On page 4 the authors write: "We sought to modulate MELT numbers in a way that would allow BUB complex levels to be increased or decreased in a graded manner, thereby causing reciprocal changes to PLK1 and PP2A levels." I do not see how this will result in reciprocal levels as total Bub complex levels are increased.
      3. Page 7 first paragraph authors write: "remained high despite inhibition of Mps1". This is not completely correct as levels are dropping dramatically after 5/10 min of Mps1 inhibition. Total drop seems more than WT situation.
      4. Page 7 second paragraph authors write: "implying the elevated PLK1 in this situation (Figure 3E) is also able to better amplify MELT signalling..." This cannot be concluded as the starting levels are so much higher in 19XMELT than WT and there is no data to show this is due to more Plk1 bound to BuBR1.
      5. Page 7 second section authors write: "Figure 5B shows that KNL1deltaMELT causes severe chromosome misalignments, as expected, given the PP2A-B56 binding to KNL1 is inhibited in this situation". Multiple things are changing so this cannot be interpreted only as a readout of PP2A-B56. With no MELTs there is no recruitment of SAC proteins.
      6. Page 7 second section authors write: "Therefore, the number of MELT motifs is crucial for determining the stability of KT-MT attachments, most probably by setting the levels of PP2A-B56..." Again many things are changing so impossible to interpret data in light of PP2A-B56.
      7. One possibility not mentioned by authors is that PP1 bound to KNL1 cannot act as efficiently on some MELT repeats and that the dephosphorylation by PP1 of the 19xMELT is different from KNL1 WT which would impact on their results.

      Significance

      See above.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      The authors do not wish to provide a response at this time.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      This study finds that probucol enhances mitophagy and mitochondrial quality control, suggesting its target ABCA1 may be a good target for the treatment of Parkinson's disease. Using an AI approach based on reported enhancers of mitophagy, they identify a list of 79 compounds to test in an assay based on Parkin- and CCCP-mediated mitophagy. One of the hits is probucol, an inhibitor of ABCA1, an ATP-dependent lipid transporter. Probucol causes a slight increase in mitochondrial turnover in HeLa cells, and increases Paraquat-driven mitophagy in flies. To explore the effects of lipids on the probucol-induced effects on mitophagy, it is observed that overexpression of human ABCA1 in flies suppresses the effect of Paraquat, and that inhibitors of DGAT reduces mitophagy as well, which may result from altered lipid droplets metabolism. Probucol alleviates motor phenotypes in fly and zebrafish PD models induced with mitochondrial dysfunction. The rough-eye fly phenotype observed with overexpression of Rho-7 (PARL ortholog) is modulated by ABCA expression, in addition to modulation of Parkin/PINK1. Finally, probucol appears to work at late stage mitophagy by modify LC3 lipidation and increasing lysosomal areas.

      Overall, this is an interesting paper, which makes a good case for the consideration of probucol as a potential treatment for PD. This is an improved version of a manuscript from the same group I had reviewed for another journal, and many of the issues raised have been resolved since. Yet, I remain to be convinced about some points:

      Major points

      1. The data provided does not support the claim that the AI selection of compounds had anything to do with the "high-rate" of success. To be able to claim this, there should be a comparison with a randomly selected set of ~80 compounds from the 3231 candidates, and show that for those, there is a lower chance of finding hits, if any at al. This section needs to be improved and a more compelling case presented. Just to be clear, it doesn't take anything away from the rest of the paper, but the authors make claim about this AI method that I don't believe are justified. Either provide more data or change the text and tone down the claims about the AI method.
      2. The effects of probucol on LD area and mitophagy in cells are interesting, but the data presented are not sufficient to claim that the effects are ABCA1-dependent. To do this, they must measure LD area and mitophagy in cells with shRNA against ABCA1, followed by CCCP and probucol (or DMSO). Probucol should have no effect when ABCA1 is knocked down. The experiments shown in Appendix Fig. S4 don't exactly show that; S4C lacks probucol treatment, and S4D/E measure mitochondrial volume, which is not mitophagy. Furthermore, it would important to show at least one dose-response curve for probucol in mitophagy, in cells. What is the IC50? Does it match that of the known Kd for ABCA1? This would be further evidence that the effects of probucol are "on-target".
      3. In Figure 5A, what is the baseline climbing % WITHOUT paraquat? This is important to show to provide a comparison point for the level of rescue induced by probucol.
      4. The epistatic relationships for the rough eye phenotype (REP) are confusing and need to be better explained/presented. A diagram showing the effect of each gene on the phenotype would be useful. Also, given that the effect of probucol in cells are Parkin/PINK1-independent, it is somewhat confusing to find that hABC1 effects are Parkin-dependent for the REP. Please clarify.
      5. In Figure 7E, again, data for the baseline climbing % is lacking. Furthermore, it is not clear why the % climbing of ABCA RNAi+DMSO+PQ (bottom graph) is higher than the control condition mCherry RNAi+DMSO (top graph). Are these % for the bottom and top graphs comparable? If not, then the bottom graph should also include a baseline condition without paraquat. Finally, why is paraquat not reducing climbing in ABCA RNAi or Atg7 RNAi? Controls are lacking in these experiments (as in Figure 5A above).

      Minor point

      1. In Figure 5C, experiment with SR3677 is shown, but mentioned nowhere in the text. I understand this is a ROCK inhibitor, but this should be mentioned.

      Significance

      Nature and significance: This is an interesting report, but there is no major conceptual advance in our understanding of mitophagy and neurodegeneration. Nonetheless, the discovery of a new potential target (ABCA1) for treating mitochondrial dysfunction of worth reporting.

      Comparison with existing knowledge: the report is original, but there have been a few reports of the effect of perbucol in Parkinson's model (e.g. Ray et al 2014, Cell Death Discov, PMID 24407237), or ABCA1 variants (Ya & Lu, 2017, Med Sci Monitor). Those should be acknowledged.

      Audience: researchers in the field of Parkinson's research, but also mitophagy and lipid metabolism.

      My expertise: Parkin/PINK1 pathway, mitophagy, pharmacology, structural biology.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      In their manuscript, Moskal et al. performed an AI-based screen to find potential mitophagy inducers and subsequently test them in model organisms of human neurodegenerative disorders, whereby mitophagy induction might be beneficial. The authors found that probucol, a retired lipid-lowering drug, is a candidate mitophagy inducer at least in cell culture and flies. Furthermore, they reported physiological benefits in association with probucol treatment to flies fed paraquat, a toxin that causes loss of dopaminergic neurons. This manuscript has some potential especially as it implicates an unknown target for mitophagy, ABCA. However, the paper can't be published in its current form for the several reasons:

      Major comments:

      The sequence in which the experiments were presented in this paper is illogical and sometimes confusing: (i) in page 5, when the mitophagy-inducing effect of probucol was shown in paraquat-treated flies, the corresponding physiological relevance of this observation, ie effects on climbing ability and survival, should have been reported immediately and not later on in another section of the manuscript. Since paraquat induces mitophagy, It is not very intuitive to imagine that further increase in response to probucol is beneficial. This leaves the reader wondering whether further increase in mitophagy is beneficial or detrimental. In fact, excessive mitochondrial clearance has been shown to render caloric restriction - the most robust antiaging and autophagy-inducing intervention, detrimental (PMID: 30929899). (ii) Similarly, causality testing of the role of ABCA-autophagy axis in mediating the salutary effects of probucol in flies, which were reported in the very end of the manuscript should have been mentioned early on upon introducing such health-promoting effects. (iii) Another example is also LC3 lipidation and lysosome abundance, which support the pro-autophagic effect of probucol. Instead of being reported with other evidence supporting mitophagy induction at the beginning of the manuscript (page 5) were kept for no obvious reason to be mentioned in the very end of the results (page 9) after all other mechanistic and in vivo physiological testing results were reported!

      As such, the manuscript needs extensive re-writing, thereby also removing unnecessary data that only distracts from the main message. By that, I mainly refer to the rough eye model induced by expression of rhomboid-7 in the fly eye. The sudden shift towards using the rho-7 fly eye model along with extensive characterization of the role of pink1 and parkin is distracting from the main objective of the study: finding a novel mitophagy inducer in probucol and describe its mechanism of action. Instead of reporting causality testing of autophagy in paraquat-treated flies, where probucol induced mitophagy, the authors decided to discuss the fly eye model and go on to show the role of mitophagy, pink1 and parkin in this model. I suggest removing this model from the current manuscript and dedicate a future manuscript to the experiments performed there because they do not serve the purpose of the study. In fact, mitophagy induction in this model is harmful. As such, this model only dilutes the message and lowers confidence in the robustness of the reported cascade of events involving probucol>ABCA>mitophagy>physiological benefits.

      Regardless, the experiments testing causality of autophagy and ABCA in Fig. 7e are misleading. There are no corresponding negative controls showing the benefits of probucol in absence of ABCA and Atg7 RNAi. The authors should not rely on a different set of experiments (Fig. 5a-b) done at a different time and another cohort of flies.

      The authors applied an interesting screening approach using semantic textual similarity to a pre-defined list of positive controls. These positive controls comprised of 7 mitophagy inducers that primarily act on the NAD+-sirtuin pathway. NAD+, as also sirtuins, induce a myriad of effects, not only mitophagy. In fact, some might even argue that autophagy/mitophagy are only partly involved in the effects of these compounds (PMID: 34843394). Why did not the authors expand their positive control list to include other classes of mitophagy inducers? the reference (ref. 10) used has many other potential positive controls that do not necessarily increase apoptosis and mitochondrial damage. Furthermore, the sematic screen has been limited to papers published until 2014. Why was that the case? In fact, a crude Pubmed (not Medline) search using the term "mitophagy" returns 935 hits (till 2014), while from 2015 onwards it returns more than 5800 papers! This clearly shows that much more has been done after 2014. The search should be expanded, otherwise the authors are missing out on all major development that happened in the field.

      The authors also reported that they filtered out the candidate molecules with any association to either the term "apoptosis" or "mitochondrial damage". How could you differentiate between causation or protection from mitochondrial damage when a compound is mention in the context of apoptosis/mito damage using semantic fingerprint?

      How does ABCA1 KO and overexpression affect the pro-mitophagic action of probucol? This has been shown for DGAT, but not for ABCA which is a central finding in this manuscript.

      • In page 1, the following statement is problematic: "we focused on the ultimate endpoint of mitophagy-clearance of damaged mitochondria from cells. Ultimately, if this step is improved, then the negative consequences of mitochondrial damage in the dopaminergic neurons may be mitigated". Increasing the clearance of damaged mitochondria is not necessarily beneficial. In fact, excessive clearance of damaged mitochondria renders autophagy inducing interventions harmful as mentioned above. It is also not clear whether and how the authors could tell that only damaged mitochondria were sequestrated. Even in absence of mitophagy induction at baseline (in absence of CCCP), this does not imply that only damaged mitochondria are cleared when damage is induced. Lack of evidence is not an evidence for lack of an effect.
      • In page 4, the authors report that "the degradation of VDAC1 was increased at several time points by probucol treatment, but not in the absence of mitochondrial damage (Figure 2D, E)" the graph shows DSMO and probucol not CCCP vs DSMO, is this a typo?
      • Fig 7A-B is very confusing. Why did not the authors use protease inhibitors to properly evaluate autophagy flux if that was the purpose? also how come starvation does not induce autophagy in these cells? what was the time point tested? Were the cells starved as a positive (or worse: negative) control?
      • The authors reported that their screen could efficiently predict olaparbi upon leaving it out (top 3.9% of the 3231 compounds screened). How did the other 6 positive controls fair in this cross validation using the leave-one-out approach? please report this for the other 6 positive compounds as well.

      Minor

      • rather small sample size in most of the experiments with n=3-4 (eg, Fig 5 D, E F and G).
      • Some figures do not show the data points and thus it is not possible to tell how big was the exact sample size (eg, Fig. 5A)
      • how do the authors explain the discrepancy between Fig. 4G and Fig. 3D where PQ increased % of red-only/total mito area in one but not in the other?
      • How can the results in Fig 6 quantified? If qualitative then many more representative images should have been presented.
      • There appears to be a deleted lane from the western blot in Fig S2A. This needs to be declared in the legend, along with a justification.
      • Western blots in general do not show the molecular weight. Please add this throughout the manuscript
      • A lot of abbreviations are mentioned without spelling out what they stand for, eg, CCCP, ABCA, DGAT.
      • Typo in page 1: the loss of which is (not are) responsible for the classical motor..
      • Line numbers were not included in the submitted manuscript, thus I could not provide the authors with the exact position of any of the issues mentioned above.

      Significance

      Despite reporting novel findings, the manuscript has major flaws in terms of experimental approach and presentation of the results. The authors need to revise their screen, as also restructure the manuscript to be better reflect the findings, thereby improving the significance of both the physiological and mechanistic value of the study.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      Summary:

      In the manuscript by Moskal et al, the authors utilize an AI-based approach to identify mitophagy modulating compounds based on parameters from already FDA-approved drugs. From this screen, the authors find that the compound Probucol enhances stress-induced mitophagy. It appears to do this via its canonical target, ABCA1, via a PINK1/Parkin-independent mechanism. Importantly, the authors show that probucol improves phenotypes in fly and animal models with mitochondrial perturbations, suggesting that this pathway may hold some therapeutic value.

      Major comments:

      • I will mention that I have already reviewed a version of this manuscript at another location and here the authors have addressed my previous concerns.
      • The key conclusions are robust and shown in multiple cell types and models.
      • I do not have any requests for additional experiments, given that those present already sufficiently support the claims of the paper.

      Minor comments:

      • I am a little confused over the descriptions of the rough eye phenotype in Fig. 6. In the text on p7, the authors state that rho-7 overexpression causes the eyes to appear rough. Yet in the figure the eyes appear smoother - indeed the legend says they have "glossy appearing eyes". This seems the opposite to rough - unless I am missing something? Perhaps rewording the text would help with this.

      Significance

      • Here the authors identify a small molecule, probucol, that enhances mitophagy and in doing so implicate the ABCA1 pathway of lipid transport in this process. A great strength of the work is that in vivo data (in flies and fish) are obtained, which has clear disease-relevance. The manuscript is timely, in that lipid signaling and lipid droplets are being shown to have a strong regulatory role in autophagy.
      • The authors use a novel AI-based approach to identify mitophagy-inducing compounds, and while this seems a good approach, I do not feel I have the expertise here to critically review this aspect. It is also noteworthy that the initial assay was designed to look at modulators of Parkin-dependent mitophagy, but the compound discovered appears to act independently of PINK1/Parkin.
      • My main expertise is in autophagy and mitophagy cell biology and I do think the findings in this manuscript will be of interest to this field and those focussed on therapeutic approaches for diseases where impaired mitochondrial function has been implicated.
      • The manuscript does lack a mechanistic understanding of the mode of action of probucol - how it is enhancing mitophagy is not clear. However, it is up to the authors and editors of the destination journal as to whether more work is done here, or in a follow-up study.
    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      Summary:

      Ciliates extensively rearrange their somatic genome every time a new somatic nucleus develops from the zygotic germline nucleus. In this manuscript, Feng et al report the sequencing, assembly and annotation of the germline and somatic genomes of Euplotes woodruffi and the germline genome of Tetmemena sp. (whose somatic genome was sequenced and assembled by the same lab in 2015). They present a comparative analysis of developmentally programmed genome rearrangements in these two species and in the model ciliate Oxytricha trifallax. Their major findings are that:

      (i) E. woodruffi and Tetmemena sp. eliminate a smaller fraction of their germline genome (~54%) from their somatic macronucleus (MAC) than O. trifallax (>80%)

      (ii) Transposable elements (TE) represent a smaller fraction of the germline genome (~2%) in the first two ciliates than in O. trifallax (~15%). TEs are mainly located at the boundaries of germline chromosomes and in intergenic regions, but can also be found inside IESs

      (iii) Several thousands of genes are scrambled in the germline genome of all three species

      The authors have also addressed the possible origin of gene scrambling. They report an interesting association with local paralogy and propose a model for the emergence of the odd-even pattern of gene unscrambling between two paralogous copies.

      Major comments:

      1. Based on the statistics presented in Table 1, genome assemblies are of good quality, with a reasonable N50 size of germline (MIC) contigs. It seems, however, that no entire MIC chromosome could be assembled, since no two-telomere contig is mentioned in the list. As proposed by the authors (p.7) the presence of numerous TEs at the boundaries of MIC contigs (Fig S1) may have hindered the assembly of MIC chromosome ends. I would have appreciated to have more information on the "other repeats" (which seem to differ from tandem repeats according to Fig 2) and their location along MIC contigs.

        Subcategories of “other repeats” were included in Table S2 based on Repeatmasker annotations. We now analyzed the locations of other repeats in MIC contigs and include those as well in new Figure S1B. About 30% of “other” transposable elements are present at the boundaries of MIC contigs, which may also hinder the assembly. Notably, 35-45% of “other TEs” are in assembled, intergenic regions.

      The definition of "Internal Eliminated Sequences" (IES) is not clear. The authors make a distinction between IESs and TEs. I understand that IESs are DNA segments that separate two macronuclear-destined sequences (MDS) in the germline genome. Thus they appear to be restricted to those regions that eventually yield gene-sized MAC chromosomes. IESs are eliminated between two pointers that may not be identical on both sides in case of scrambled genes. Some clarification is needed here.

      To illustrate my point: I found the statement "with many TE insertions within IESs, suggesting that TE insertions may have generated IESs" particularly confusing (p. 9 lines 5-6). Does this mean that IESs extend beyond the ends of inserted TEs? The legend of Fig S1 should also be clarified.

      We clarified the text and legend. IESs can extend beyond the ends of inserted TEs, even if the original IES is a decayed TE, due to subsequent sequence evolution at the boundaries or if the original insertion was into an existing IES. David Prescott referred to sequence evolution at the edges of IESs as “pointer sliding” (ref.36).

      p. 10 lines 2-4 and Fig S2: Could the authors explain the difference they make between MDS (in the text) and CDS (in Fig S2)? My understanding is that a CDS is the entire gene coding sequence and may be made of multiple MDSs. If this is correct, the sentence should read "We compared the number of MDSs between single-copy orthologs for single-gene MAC chromosomes across the three species and found that the orthologs have similar CDS lengths".

      Yes, we made the correction.

      p. 12 lines 10-15: the discovery that paralogous MDSs can be found in scrambled genomic loci is interesting. If the two paralogs can be distinguished based on the number of substitutions, it would be informative to go back to individual reads and check whether each of the two copies can be incorporated in the unscrambled CDS (and at which frequency). Would the pointers be compatible with this?

      The paralogous MDSs in the MIC are often not identical. The copy with the highest similarity is assigned as “preliminary match” by SDRAP (ref. 52), and others are assigned as “additional matches”. To validate SDRAP assignments, we did pairwise BLASTN alignments (“-task megablast”) of paralogous MIC MDSs and their corresponding MAC MDSs. We confirmed that in the three species, the preliminary match has the best or equally best pid (percentage of identity) in most cases. Therefore, the MDS assigned as preliminary match is more likely the paralog incorporated into the MAC chromosome.

      We used genome assemblies of Euplotes woodruffi, which had the highest Nanopore coverage, to further investigate the frequency of MDS incorporation. We followed the reviewer’s suggestion and called SNP variants on both MAC and MIC genomes. For MAC SNP calling, we used Illumina reads as input for freebayes (ref a). For MIC SNP calling, we used Nanopore reads, instead of Illumina reads, to avoid non-specific short-read mapping on paralogous MDSs and to avoid the presence of any contaminating MAC reads. Variants were called and phased by PEPPER-Margin-DeepVariant (ref b), a new tool published in 2021 in Nature Methods, which has been reported to have similar accuracy to Illumina read variant calling, especially at high read coverage. We used the parameter “--pepper_min_coverage_threshold 20” to call confident variants when at least 20 reads cover the position. Only 92 MIC SNPs in the paralogous MDSs passed all filters of the program. Using this small set of MIC SNPs, we were unfortunately unable to distinguish which paralogous MIC MDS was incorporated into the MAC. Therefore, we cannot infer with what frequency one paralogous MDS is incorporated over another, until they become sufficiently diverged, which is compatible with the model.

      a. Garrison E, Marth G. Haplotype-based variant detection from short-read sequencing. arXiv preprint arXiv:1207.3907. 2012 Jul 17.

      b. Shafin K, Pesout T, Chang PC, Nattestad M, Kolesnikov A, Goel S, Baid G, Kolmogorov M, Eizenga JM, Miga KH, Carnevali P. Haplotype-aware variant calling with PEPPER-Margin-DeepVariant enables high accuracy in nanopore long-reads. Nature methods. 2021 Nov;18(11):1322-32.

      The hypothesis that odd-even scrambled loci have evolved from paralogous genes in E. woodruffi is supported by the existence of paralogous MDSs, length conservation of MDS/IES pairs and sequence similarity between corresponding MDS and IES in a pair. The correlations presented for Oxytricha and Tetmemena are much less convincing (Fig S5D and E). I recommend that the authors are even more cautious in their statement on p.13 ("For Oxytricha and Tememena, the MDS and IES lengths for such MDS/IES pairs also correlate positively, but more moderately").

      Thank you, we rephrased the text.

      p. 15 last paragraph: Why did the authors focus only on TBEs inserted in non-scrambled IESs to look for orthologous TBE insertions? Is there a reason to believe that no recent TBE insertion occurred at other genomic loci? Or was it only for practical reasons? It is also not clear to me whether the authors have considered full-length TBEs or the presence of at least one TBE ORF.

      This analysis was limited for practical reasons, because we identify position conservation of TBEs by aligning protein sequences of MAC genes. We only consider TBEs inserted in non-scrambled IESs in exons. It would be difficult and less meaningful to align completely non-coding MIC-limited regions.

      Partial TBEs are also included if they contain at least one TBE ORF (detected by BLAST).

      Furthermore, TE insertion cannot explain the origin of scrambled IESs, and TEs rarely map to scrambled IESs (Figure S1A), but there is a clear evolutionary model for the origin of nonscrambled IESs from decay of TBEs (ref. 49). Initial purifying selection would act on the TE to maintain its ability to self-excise, whereas we advocate for a different model for the origin of scrambled IESs by decay of paralogous MDSs.

      p. 16: the authors report that some introns of E. woodruffi map "near" Oxytricha/Tetmemena pointers. How near? Based on the information provided by the authors, I don't think this observation necessarily implies that IESs were converted to introns (or reciprocally) during evolution. If this were true, shouldn't at least one intron boundary coincide exactly with a pointer? The authors should clarify this (also in the discussion, on p. 20, top paragraph).

      We used a 20bp window (~7 amino acids), as described in the Methods, and added that to the Results. Full detail is provided in the Methods section, “Ortholog comparison pipeline and Monte Carlo simulations”. 103 E. woodruffi introns are within 20bp from the midpoint of Oxytricha/Tetmemena pointers. Among these, 43 intron boundaries overlap an Oxytricha or Tetmemena pointer. We observed 306 cases of precisely matching boundaries between any two species, where the exon junction of one species maps inside the MDS/IES pointer of another species, although we would only expect the boundaries of introns and IESs to coincide so precisely if they were recent conversions. Hence we feel that a window analysis is informative.

      p. 19 2nd paragraph: the suggested mechanism explaining the 5' bias of IESs in E. woodruffi genes is unclear. How could germline recombination take place between a MIC chromosome and a MAC reverse transcript or nanochromosome? This would imply that DNA could be imported in the MIC. Is there evidence that this might occur?

      The ability of TEs to invade the MIC demonstrates that even foreign DNA can be incorporated into the MIC. Since MAC DNA is present at high copy number, it offers a potential source for a recombination template that could erase IESs, as could an errant reverse transcript of one of the long noncoding template RNAs. Any of these would be infrequent events that would matter on an evolutionary time scale even if developmentally rare.

      According to Figure 1, no scrambled genes have been reported in Paramecium tetraurelia. Within the frame of the proposed model, this is somewhat unexpected because this ciliate went through several whole genome duplications during evolution and harbors many paralogous gene pairs. Is there a reason why no gene scrambling took place in Paramecium?

      Paramecium uses only TA dinucleotide pointers for IES elimination, unlike the rich diversity of pointers in spirotrichous ciliates. This limitation in its machinery may explain why no scrambled loci have been observed in Paramecium, despite the abundance of paralogs. Our model suggests that local MIC paralogy is associated with the origin of scrambling. But most of the paralogy reported in Paramecium is at the level of whole chromosomes in the MAC (ref. 104) rather than local MIC paralogy.

      Minor comments:

      p. 4 (4th bottom line): To my knowledge, ref #28 presents a draft (incomplete) MIC assembly of the Paramecium genome.

      Thank you, we added reference 29 and adjusted the wording describing the quality of MIC genome draft assemblies.

      p. 7 (last paragraph): "encoding" should be replaced by "carrying"

      Thank you, we made the change.

      p. 10 (2nd paragraph): insert a missing "o" into "nanochromosomes"

      Thank you, corrected.

      p. 10 (same paragraph): the weak 5' bias of IES distribution in Tetmemena should be shown (either as an additional panel in Fig 3 or in a Sup Figure.

      Thank you, we added it as Figure S2C.

      p. 24 2nd paragraph: "a" is missing in "Trinity, which is a software..."

      Thank you, we made the correction.

      CROSS-CONSULTATION COMMENTS

      I agree with most comments of reviewer 3.

      The authors have actually defined "TE" in the introduction (p. 6). Depending on the journal's rules for abbreviation use, it may not be necessary to define it again in the results section

      Reviewer #1 (Significance (Required)):

      Ciliates are unicellular models to study developmentally programmed genome rearrangements at the mechanistic, genome-wide and evolutionary levels. These aspects have so far mostly been addressed in three species: P. tetraurelia and Tetrahymena thermophila on the one hand, the spirotrichous ciliate O. trifallax on the other.

      One new piece of information that can be found in the present manuscript is the assembly and annotation of the germline genome of two novel species: Tetmemena sp, closely related to Oxytricha, and the more distant E. woodruffi. Feng et al establish that, similar to other ciliates, Tetmemena and Euplotes eliminate TEs and other germline-specific sequences during programmed genome rearrangements. They also undergo extensive gene unscrambling, which results in IES removal and MDS reordering to assemble coding sequences.

      A TE origin was discussed previously for Paramecium (Arnaiz et al PLoS Genet; Sellis et al 2021 PLoS Biol) and Tetrahymena IESs (Hamilton et al 2016 eLife). While this may also hold true in spirotrichous ciliatesThe present manuscript proposes a completely new evolutionary scenario for IESs from scrambled genes. Here, Feng et al establish that scrambled genes of spirotrichous ciliates tend to be associated with local paralogy. They provide evidence supporting that IESs from scrambled genes may have evolved from paralogous MDSs.

      Although I am more an expert in the molecular mechanisms involved in genome rearrangements, I feel that the work reported here should draw the attention of a broader audience interested in genome dynamics and evolution, beyond the specific field of spirotrichous ciliate biology.

      Reviewer #3 (Evidence, reproducibility and clarity (Required)):

      Feng et al. provide a solid analysis of the evolution of genome rearrangement in spirotrich ciliates. The authors applied a variety of state-of-the-art sequencing and bioinformatic methods to investigate the intriguing and extremely complex patterns of genome architecture in this protist lineage. Methods (including statistical analyses) are adequate and explained in detail. Results and discussions reflect careful, clever analysis of the data and excellent linkage with the literature. Figures and tables complement the text in a compelling way. I have only minor suggestions:

      Summary: more gradually introduce Spirotrichea and the phylogenetic relationship among the three species analyzed. This would better position the reader to understand the evolutionary context you are working in. Also, it would be helpful to more clearly differentiate novel vs. existing data. A suggestion: "This study focuses on three spirotrich species: two in the family Oxytrichidae (Oxytricha trifallax and Tetmemena sp) and Euplotes woodruffi as an outgroup. To complement existing data, we sequenced, assembled and annotated the germiline and somatic genomes of E. woodruffi and the germline genome of Tetmemena sp."

      Thank you, we clarified the summary (abstract).

      Introduction, first paragraph: Replace "The species in this study..." for a more precise statement, such as "The three spirotrich species studied here..."

      Thank you, we have made this statement more precise.

      p. 4: This sentence is unclear: "These useful tools provide partial insight to guide selection of species for full genome sequencing, which allows construction of complete rearrangement maps of a MIC genome onto a MAC genome for a reference species."

      Thank you, we have clarified this sentence.

      p. 8: define TE on first mention.

      Defined on page 6.

      Table 1. Indicate which MIC and MAC data are from this study.

      References are included for published data and a note has been added to indicate data from this study.

      Reviewer #3 (Significance (Required)):

      The present work represents a significant advance in the field of evolutionary genomics. The focus of the paper is on ciliates, an ancient (2 billion-year old) and highly diverse eukaryotic phylum that presents many peculiarities, including sex, nuclear dimorphism, genome rearrangement, high numbers of paralogs and transposons, etc. While some data exist on a few model ciliates of disparate phylogenetic position, this work focuses on two species taxonomically placed in the same family, plus a more distant outgroup within the same class. This gives a novel dimension to this study, that goes beyond exploring genome architecture in a single clade. Instead, it allows to explore evolutionary trends in genome rearrangement among relatively closely related species. This paper should be of high interest not only for ciliate biologists (like me), but also in relation to comparative genomics of protists/eukaryotes and germ-soma biology. I highly recommend publication.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      Feng et al. provide a solid analysis of the evolution of genome rearrangement in spirotrich ciliates. The authors applied a variety of state-of-the-art sequencing and bioinformatic methods to investigate the intriguing and extremely complex patterns of genome architecture in this protist lineage. Methods (including statistical analyses) are adequate and explained in detail. Results and discussions reflect careful, clever analysis of the data and excellent linkage with the literature. Figures and tables complement the text in a compelling way. I have only minor suggestions:

      • Summary: more gradually introduce Spirotrichea and the phylogenetic relationship among the three species analyzed. This would better position the reader to understand the evolutionary context you are working in. Also, it would be helpful to more clearly differentiate novel vs. existing data. A suggestion: "This study focuses on three spirotrich species: two in the family Oxytrichidae (Oxytricha trifallax and Tetmemena sp) and Euplotes woodruffi as an outgroup. To complement existing data, we sequenced, assembled and annotated the germiline and somatic genomes of E. woodruffi and the germline genome of Tetmemena sp."

      • Introduction, first paragraph: Replace "The species in this study..." for a more precise statement, such as "The three spirotrich species studied here..."

      • p. 4: This sentence is unclear: "These useful tools provide partial insight to guide selection of species for full genome sequencing, which allows construction of complete rearrangement maps of a MIC genome onto a MAC genome for a reference species."

      • p. 8: define TE on first mention.

      • Table 1. Indicate which MIC and MAC data are from this study.

      Significance

      The present work represents a significant advance in the field of evolutionary genomics. The focus of the paper is on ciliates, an ancient (2 billion-year old) and highly diverse eukaryotic phylum that presents many peculiarities, including sex, nuclear dimorphism, genome rearrangement, high numbers of paralogs and transposons, etc. While some data exist on a few model ciliates of disparate phylogenetic position, this work focuses on two species taxonomically placed in the same family, plus a more distant outgroup within the same class. This gives a novel dimension to this study, that goes beyond exploring genome architecture in a single clade. Instead, it allows to explore evolutionary trends in genome rearrangement among relatively closely related species. This paper should be of high interest not only for ciliate biologists (like me), but also in relation to comparative genomics of protists/eukaryotes and germ-soma biology. I highly recommend publication.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      This reviewer did not leave any comments

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      Summary:

      Ciliates extensively rearrange their somatic genome every time a new somatic nucleus develops from the zygotic germline nucleus. In this manuscript, Feng et al report the sequencing, assembly and annotation of the germline and somatic genomes of Euplotes woodruffi and the germline genome of Tetmemena sp. (whose somatic genome was sequenced and assembled by the same lab in 2015). They present a comparative analysis of developmentally programmed genome rearrangements in these two species and in the model ciliate Oxytricha trifallax. Their major findings are that:

      (1) E. woodruffi and Tetmemena sp. eliminate a smaller fraction of their germline genome (~54%) from their somatic macronucleus (MAC) than O. trifallax (>80%)

      (2) Transposable elements (TE) represent a smaller fraction of the germline genome (~2%) in the first two ciliates than in O. trifallax (~15%). TEs are mainly located at the boundaries of germline chromosomes and in intergenic regions, but can also be found inside IESs

      (3) Several thousands of genes are scrambled in the germline genome of all three species

      The authors have also addressed the possible origin of gene scrambling. They report an interesting association with local paralogy and propose a model for the emergence of the odd-even pattern of gene unscrambling between two paralogous copies.

      Major comments:

      (1) Based on the statistics presented in Table 1, genome assemblies are of good quality, with a reasonable N50 size of germline (MIC) contigs. It seems, however, that no entire MIC chromosome could be assembled, since no two-telomere contig is mentioned in the list. As proposed by the authors (p.7) the presence of numerous TEs at the boundaries of MIC contigs (Fig S1) may have hindered the assembly of MIC chromosome ends. I would have appreciated to have more information on the "other repeats" (which seem to differ from tandem repeats according to Fig 2) and their location along MIC contigs.

      (2) The definition of "Internal Eliminated Sequences" (IES) is not clear. The authors make a distinction between IESs and TEs. I understand that IESs are DNA segments that separate two macronuclear-destined sequences (MDS) in the germline genome. Thus they appear to be restricted to those regions that eventually yield gene-sized MAC chromosomes. IESs are eliminated between two pointers that may not be identical on both sides in case of scrambled genes. Some clarification is needed here.

      To illustrate my point: I found the statement "with many TE insertions within IESs, suggesting that TE insertions may have generated IESs" particularly confusing (p. 9 lines 5-6). Does this mean that IESs extend beyond the ends of inserted TEs? The legend of Fig S1 should also be clarified.

      (3) p. 10 lines 2-4 and Fig S2: Could the authors explain the difference they make between MDS (in the text) and CDS (in Fig S2)? My understanding is that a CDS is the entire gene coding sequence and may be made of multiple MDSs. If this is correct, the sentence should read "We compared the number of MDSs between single-copy orthologs for single-gene MAC chromosomes across the three species and found that the orthologs have similar CDS lengths".

      (4) p. 12 lines 10-15: the discovery that paralogous MDSs can be found in scrambled genomic loci is interesting. If the two paralogs can be distinguished based on the number of substitutions, it would be informative to go back to individual reads and check whether each of the two copies can be incorporated in the unscrambled CDS (and at which frequency). Would the pointers be compatible with this?

      (5) The hypothesis that odd-even scrambled loci have evolved from paralogous genes in E. woodruffi is supported by the existence of paralogous MDSs, length conservation of MDS/IES pairs and sequence similarity between corresponding MDS and IES in a pair. The correlations presented for Oxytricha and Tetmemena are much less convincing (Fig S5D and E). I recommend that the authors are even more cautious in their statement on p.13 ("For Oxytricha and Tememena, the MDS and IES lengths for such MDS/IES pairs also correlate positively, but more moderately").

      (6) p. 15 last paragraph: Why did the authors focus only on TBEs inserted in non-scrambled IESs to look for orthologous TBE insertions? Is there a reason to believe that no recent TBE insertion occurred at other genomic loci? Or was it only for practical reasons? It is also not clear to me whether the authors have considered full-length TBEs or the presence of at least one TBE ORF.

      (7) p. 16: the authors report that some introns of E. woodruffi map "near" Oxytricha/Tetmemena pointers. How near? Based on the information provided by the authors, I don't think this observation necessarily implies that IESs were converted to introns (or reciprocally) during evolution. If this were true, shouldn't at least one intron boundary coincide exactly with a pointer? The authors should clarify this (also in the discussion, on p. 20, top paragraph).

      (8) p. 19 2nd paragraph: the suggested mechanism explaining the 5' bias of IESs in E. woodruffi genes is unclear. How could germline recombination take place between a MIC chromosome and a MAC reverse transcript or nanochromosome? This would imply that DNA could be imported in the MIC. Is there evidence that this might occur?

      (9) According to Figure 1, no scrambled genes have been reported in Paramecium tetraurelia. Within the frame of the proposed model, this is somewhat unexpected because this ciliate went through several whole genome duplications during evolution and harbors many paralogous gene pairs. Is there a reason why no gene scrambling took place in Paramecium?

      Minor comments:

      • p. 4 (4th bottom line): To my knowledge, ref #28 presents a draft (incomplete) MIC assembly of the Paramecium genome.

      • p. 7 (last paragraph): "encoding" should be replaced by "carrying"

      • p. 10 (2nd paragraph): insert a missing "o" into "nanochromosomes"

      • p. 10 (same paragraph): the weak 5' bias of IES distribution in Tetmemena should be shown (either as an additional panel in Fig 3 or in a Sup Figure.

      • p. 24 2nd paragraph: "a" is missing in "Trinity, which is a software..."

      CROSS-CONSULTATION COMMENTS

      I agree with most comments of reviewer 3.

      The authors have actually defined "TE" in the introduction (p. 6). Depending on the journal's rules for abbreviation use, it may not be necessary to define it again in the results section

      Significance

      • Ciliates are unicellular models to study developmentally programmed genome rearrangements at the mechanistic, genome-wide and evolutionary levels. These aspects have so far mostly been addressed in three species: P. tetraurelia and Tetrahymena thermophila on the one hand, the spirotrichous ciliate O. trifallax on the other.

      • One new piece of information that can be found in the present manuscript is the assembly and annotation of the germline genome of two novel species: Tetmemena sp, closely related to Oxytricha, and the more distant E. woodruffi. Feng et al establish that, similar to other ciliates, Tetmemena and Euplotes eliminate TEs and other germline-specific sequences during programmed genome rearrangements. They also undergo extensive gene unscrambling, which results in IES removal and MDS reordering to assemble coding sequences.

      • A TE origin was discussed previously for Paramecium (Arnaiz et al PLoS Genet; Sellis et al 2021 PLoS Biol) and Tetrahymena IESs (Hamilton et al 2016 eLife). While this may also hold true in spirotrichous ciliatesThe present manuscript proposes a completely new evolutionary scenario for IESs from scrambled genes. Here, Feng et al establish that scrambled genes of spirotrichous ciliates tend to be associated with local paralogy. They provide evidence supporting that IESs from scrambled genes may have evolved from paralogous MDSs.

      • Although I am more an expert in the molecular mechanisms involved in genome rearrangements, I feel that the work reported here should draw the attention of a broader audience interested in genome dynamics and evolution, beyond the specific field of spirotrichous ciliate biology.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Manuscript number: RC-2022-01541

      Corresponding author(s): Hubert Hilbi

      1. General Statements

      Upon infection of eukaryotic host cells, Legionella pneumophila forms a unique compartment, the Legionella-containing vacuole (LCV). While the role of vesicle trafficking pathways for LCV formation has been quite extensively studied, the role of putative membrane contact sites (MCS) between the LCV and the ER has been barely addressed. In our study, we provide a comprehensive analysis of the localization and function of protein and lipid components of LCV-ER MCS in the genetically tractable amoeba Dictyostelium discoideum.

      We would like to thank the 3 reviewers for their thorough and constructive reviews. Overall, the reviewers state that the study is of interest to researchers in the field of Legionella and other intracellular pathogens (Reviewer 2), as well as to cell biologists (Reviewer 3). Reviewer 1 does not ask for additional experiments but is critical about the overall structure of the manuscript and the proteomics approach. As requested by the reviewer, we have substantially restructured the revised manuscript, now clearly outline the hypotheses put forward in the study and streamlined the proteomics data. Reviewer 2 asks for additional experiments to support our model of LCV-ER MCS. In the revised manuscript, we have included additional experiments addressing lipid exchange at the MCS, and we plan to perform further co-localization experiments. Reviewer 3 appreciates the comprehensive LCV proteomics and asks for only minor revisions, which we have incorporated in the revised version of the manuscript. We include below a point-by-point response to all the comments made by the reviewers.

      2. Description of the planned revisions

      Reviewer #2

      Major comment

      1) MCS contain protein complexes or a group of proteins, but the proteins here are studied in isolation and do not support the model shown in Figure 7. Co-localization studies of the putative LCV-ER MCS proteins are critical, especially given that the authors hypothesize the proteins are working together to modulate PI(4)P levels.

      Response: As suggested by the reviewer, we will perform additional co-localization experiments with MCS components. To this end, we will construct mCherry-Vap, and we will co-transfect the parental D. discoideum strain Ax3 with plasmids producing mCherry-Vap and OSBP8-GFP or GFP-OSBP11. Using these dually fluorescence labelled D. discoideum strains, the co-localization of Vap with the OSBPs will be assessed at 1, 2, and 8 h post infection. The data will be presented as fluorescence micrographs, and co-localization of Vap with the OSBPs will be quantified using Pearson’s correlation coefficient and fluorescence intensity profiles. The data will be outlined in the text (l. 258 ff.) and shown in the new Fig. 2 and__ Fig. S4__.

      3. Description of the revisions that have already been incorporated in the transferred manuscript

      Reviewer #1 (Evidence, reproducibility and clarity):

      In the manuscript by Vormittag, et al., the authors perform proteomics identification of proteins associated with the Legionella-containing vacuole (LCV) in the model amoeba Dictyostelium discoideum comparing WT to atlastin knockout mutants. The authors find approximately half the D. discoideum proteome associated with the LCV, but there was enrichment of some proteins on the WT relative to the mutant. They focus on proteins involved in forming membrane contact sites (MCS) that previously were shown to be important for expansion of the Chlamydia-containing vacuole. Most significant are the oxysterol binding proteins (OSBP) and VapA (similar to that seen in Chlamydia). The authors show differential association of these proteins with either the LCV or presumably the ER associated with the LCV. Using a linear scale over 8 days, they show that mutations in some of the MCS reduce yields in two of the OSPB knockout mutants and the growth rate of the vap mutant is slowed but ultimate yield is increased. Using some nice microscopy techniques, they measure LCV size, and the osbK mutant appears particular small relative to other strains, whereas the osbH mutant generates large vacuoles. This doesn't necessarily correlate with the PI4P quantities on the vacuoles (which is higher in all of them), but I am not totally sure how this is measured, and whether is it PI4P/pixel or PI4P/LCV. In all cases, this was reduced by Sac1 mutation. Surprisingly, even though there was uniform increase in PI4P in each of the mutants, loss of PI4P only affects localization of some of the proteins. Finally, in what seems to be a peripherally related experiment, the authors show that a pair of Legionella translocated effectors are required to maintain PI4P levels, although it is not clear how this is related to the other data in the manuscript.

      It is not clear from the manuscript if the authors are just cataloging things or trying to test a hypothesis. This is an extremely difficult manuscript to read and reconstruct what the authors showed. I really think that the only people who will understand what is written are people who are familiar with the work in Chlamydia starting in 2011 in Engel's and Derre's laboratories, which clearly showed that MCS and most specifically Vap/OSBPs are involved in vacuole expansion. If the authors could rewrite the manuscript along these lines, perhaps comparing their data to the Chlamydia data it would help a lot. Otherwise, I don't think anyone else will understand why they are focusing on these things. I don't recommend new experiments (although re-analyzing data is necessary), but the manuscript has to be taken apart and claims removed, and data be interpreted properly. Otherwise, the manuscript seems like just a clearing house for data.

      Response: Thank you for the concise summary of our data and pointing out the need to restructure the manuscript and to clearly outline the hypotheses underlying the study. According to the reviewer’s suggestions, we have now re-structured the manuscript. In the revised manuscript the story unfolds from the observation that the ER tightly associates with (isolated) LCVs, and the proteomics approach is used as a validation of the presence of MCS proteins at the LCV-ER MCS.

      As suggested by the reviewer, we now highlight the seminal work on Chlamydia by the Engel and Derré laboratories not in the Discussion section (as in the original version of the manuscript) but already in the Introduction section (l. 142-148). We believe that it makes a stronger case to start out an analysis of LCV-ER MCS with a Legionella-specific cell biological finding (LCV-ER association) and an unbiased proteomics approach, as compared to a more derivative and defensive approach starting out with what is known about Chlamydia.

      The reviewer’s comment “This is an extremely difficult manuscript to read” appears overly harsh and conflicts with the positive evaluation of Reviewer #2 and Reviewer #3. Finally, we respectfully disagree with the reviewer’s statement that experiments characterizing L. pneumophila effectors implicated in the formation and function of LCV-ER MCS are peripheral. These experiments significantly contribute to a mechanistic understanding of how L. pneumophila forms and exploits LCV-ER MCS, and they are central for studies on pathogen-host interactions. The studies are analogous to the work on Chlamydia effectors by the Engel and Derré laboratories, but the mode of action of Legionella and Chlamydia effectors is obviously different. Another important distinction of our work to the studies on Chlamydia is the use of the genetically tractable amoeba, D. discoideum, which allows an analysis of LCV-ER MCS by fluorescence microscopy at high spatial resolution.

      Specific comments

      1. The problems start with the first figure, in which the authors state that almost half the D. discoideum proteome is LCV-associated. I doubt that this is correct, and they should base this on some selective criterion. Furthermore in Fig. 1A, they show Venn diagrams for how they whittled this down, but the Supplemental Dataset gives us no clue on how this was done. I can only sit down myself with the dataset and try to figure that out, but that is an unreasonable expectation for the reader. The dataset provided should have a series of sheets, describing how the large protein set was whittled down and how they were sorted, so the reader can evaluate how robust the final results were. To me (at least), if they said: "look we got this surprising result that suggests MCS are involved in promoting LCV formation, and although this is well recognized in Chlamydia but poorly recognized in Legionella", that would be satisfactory to me.

      Response: According to the reviewer’s suggestions, we have now thoroughly re-structured the manuscript. In the revised manuscript the story unfolds from the observation that the ER tightly associates with LCVs in infected cells and with isolated LCVs. The proteomics approach is now used as a validation of the presence of MCS proteins at the LCV-ER MCS and relegated to the Supplementary Information section (former Fig. 1, now Fig. S3).

      For the proteomics analysis, all protein identifications have been filtered for robustness applying a constant FDR (false discovery rates) of protein and PSM (peptide spectrum match) of 0.01, which is a commonly accepted threshold in the field. Moreover, two identified unique peptides were required for protein identification. The parallel application of both filter criteria results in very robust and reliable data sets. This is outlined in the Material and Methods section (l. 683-693).

      In the data set of LCV-associated proteins, 2,434 D. discoideum proteins have been identified (Table S1). This is 18.5% of the total of 13,126 predicted D. discoideum proteins (UniprotKB) and considerably less than “almost half the D. discoideum proteome”, as stated by the reviewer. Moreover, 1,224 L. pneumophila proteins have been identified (among 3,024 predicted L. pneumophila proteins in the database). This is a reasonable number of proteins identified from an intracellular vacuolar pathogen, given the LCV isolation and proteomics methods applied. We now outline these findings more extensively in the Results section (l. 207-213). Moreover, to render Table S1 more reader-friendly, we added to the datasheet “All data” the datasheets “Dictyostelium”, “Legionella” and “Info”.

      The Venn diagram in Fig. S3A (previously Fig. 1A) does not show a subset of proteins “whittled down” from the entire proteomes, but simply summarizes LCV-associated proteins, which were either identified exclusively in the parental strain Ax3 but not in the Δsey1 mutant strain, or only in Δsey1 but not in Ax3, thus identifying possible candidates relevant for the LCV-ER MCS. This information is now outlined more clearly in the text (l. 238-241). Moreover, we now explicitly define in the Material and Methods section (l. 697-704) the “on” and “off” proteins shown in Fig. S3A.

      The overall rational for the comparative proteomics approach was our previous finding that compared to the D. discoideum parental strain Ax3, the Δsey1 mutant strain accumulates less ER around LCVs (PMID: 28835546, 33583106). This finding suggests that formation of the LCV-ER MCS might be compromised in the Δsey1 mutant strain. This hypothesis is now outlined at the beginning of the Results paragraph (l. 204-207).

      I am clueless regarding how Fig. 6 fits with the rest of the manuscript. If this is about MCS, there is no demonstration these effectors are directly involved in MCS other than the somewhat diffuse argument that there is some correlative connection to PI4P levels, that I am not particularly convinced by.

      Response: The PtdIns(4)P gradient between two different cellular membranes is an intrinsic feature of MCS. To date, a quantification of PtdIns(4)P levels on LCVs in response to the presence or absence of specific L. pneumophila effectors is lacking. Accordingly, we opted for quantifying the PtdIns(4)P levels on LCVs in presence and absence of an L. pneumophila effector putatively generating PtdIns(4)P on LCVs, the phosphoinositide 4-kinase LepB, or titrating PtdIns(4)P on LCVs, the PtdIns(4)P-binding ubiquitin ligase SidC. To address the concerns of Reviewer 1 and Reviewer 3 (see below), we now outline in detail the rational to assess the role of LepB and SidC for MCS function (l. 385-387). Importantly, we now also provide data that at LCV-ER MCS PtdIns(4)P/cholesterol lipid exchange is functionally important (new Fig. 6 and Fig. S10). In the revised version of the manuscript, this new data is preceding the experiments with the L. pneumophila effectors, which should render our choice of effectors more comprehensible to the reader and increase the flow of the manuscript.

      Line 146 and associated paragraph. We don't need a catalog of proteins in narrative. There is more detail in the narrative than there is in the tables and figures, which would be a more appropriate way to present the data.

      Response: As suggested by the reviewer, we summarized the LCV-associated D. discoideum proteins and considerably reduced the list in the text (l. 214-230).

      Line 186. There is nothing wrong with pursuing MCS based on the idea that this was seen before with Chlamydia and you wanted to test if this was a previously unappreciated aspect of Legionella biology. I don't see the rationale based on the proteomics, partly because I don't understand how the proteomics dataset was parsed.

      Response: As suggested by the reviewer, we thoroughly re-structured the manuscript and now highlight the seminal work on Chlamydia by the Engel and Derré laboratories already in the Introduction section (not in the Discussion section as in the original version of the manuscript). We believe that it makes a stronger case to start out an analysis of LCV-ER MCS with a Legionella-specific cell biological finding (LCV-ER association) and an unbiased proteomics approach, as compared to a more derivative and defensive approach starting out with what is known about Chlamydia.

      Figure 3: These growth curves are super-weird. I am not used to looking at 8 days of logarithmic growth in a linear scale and seeing no (apparent) growth for 4 days. Considering all the microscopy data are performed in the first 18 hrs of infection, it’s hard to see how this is related to data at 8 days post infection. If this were plotted in logarithmic scale, as microbiologists are used to doing, then perhaps we could see a connection. Also, in some cases, it might be helpful to calculate a growth rate, because it’s possible the author may now see some effects by comparing logarithmic growth rates.

      Response: We have been characterizing growth of L. pneumophila in D. discoideum in several studies using growth curves with RFU vs. time plotted in linear scale (e.g., Finsel et al., 2013, Cell Host Microbe 14:38; Rothmeier et al., 2013, PloS Pathog 9: e1003598; Swart et al., 2020, mBio 11: e00405-20). The D. discoideum-L. pneumophila infection model is peculiar, since the amoebae do not survive temperatures beyond 26 degC. This is substantially below the optimal growth temperature of L. pneumophila (35-40 degC). This means that - due to the many genetic tools available - D. discoideum is an excellent model to investigate cell biological aspects of the infection at early time points (ca. 1-18 h p.i.), but the amoebae are not an optimal system to quantify (several rounds) of intracellular growth.

      Figure 2: The images don't necessarily show what the bar graphs show. In particular, look at Osp8. That image doesn't make sense to me.

      Response: The individual channels of the merged images in Fig. 1 (formerly Fig. 2) are shown in Fig. S2. By looking at the individual channels, it becomes clear that OSBP8-GFP co-localizes with calnexin-mCherry (overlapping signals), but not with P4C-mCherry or AmtA-mCherry (adjacent signals). Co-localization was quantified in a non-biased manner by Pearson’s correlation coefficient. To further visualize co-localization, we now also provide fluorescence intensity profiles for all confocal micrographs (amended Fig. 1).

      In summary, I think the authors hit on something that is probably important for Legionella biology, but it’s not clear what they want to show. They are very invested in connecting everything to PI4P levels, which may or may not be correct, but it seems to me that perhaps taking more care in showing the importance of the Vap/OSPB nexus in supporting Legionella growth should be the first priority.

      Response: Given the importance of the PtdIns(4)P gradient for lipid exchange at MCS, we believe it is justified to put considerable emphasis on this lipid. To further substantiate a functional role of PtdIns(4)P at LCV-ER MCS, we now also show that an increase in PtdIns(4)P at the LCV correlates with a decrease of cholesterol (new Fig. 6 and Fig. S10). The inverse correlation of these two lipids is in agreement with the notion that cholesterol is a counter lipid of PtdIns(4)P at LCV-ER MCS.

      It is not clear from the manuscript if the authors are just cataloging things or trying to test a hypothesis.

      Response: In the revised version of the manuscript, we put forward several specific hypotheses, which we then tested in our study (l. 152-155).

      If I understand Fig. 1, only one of the candidates (VapA) was verified as being more enriched in WT relative to atlastin mutants. This argues even more strongly that the authors have to describe their criteria for choosing these candidates.

      Response: As outlined above (specific point 1), we have now re-structured the manuscript according to the reviewer’s suggestions. In the revised manuscript the story unfolds from the observation that the ER tightly associates with LCVs in infected cells and with isolated LCVs. The proteomics approach is now used as a validation of the presence of MCS proteins at the LCV-ER MCS and relegated to the Supplementary Information section (formerly Fig. 1, now Fig. S3). We consider the proteomics approach a powerful hypothesis generator, and the experimental identification of several MCS proteins by proteomics validated the cell biological and bioinformatics insights.

      Reviewer #1 (Significance (Required)):

      As stated above, the manuscript can't decide if it’s about MCS or PI4P, and I would argue strongly that the emphasis on PI4P detracts from the manuscript, as well as its inability to draw connection to previous work that is likely to be important.

      Response: We respectfully disagree with the reviewer on this important point and hold that proteins as well as lipids are crucial functional determinants of MCS. The PtdIns(4)P gradient is a pivotal process for lipid exchange at MCS. Therefore, we believe it is justified to put considerable emphasis on this lipid. In the Introduction section, we now specify several hypotheses on the localization and function of lipids and proteins at LCV-ER MCS (l. 152-155). Moreover, we now also refer to the previous work on Chlamydia MCS in the Introduction section (l. 142-148).

      Reviewer #2 (Evidence, reproducibility and clarity):

      Summary of paper and major findings

      Membrane contact sites (MCS) are locations where two membranes are in close proximity (10-80nm). MCS have a defined protein composition which tether the membranes together and function in small molecule and lipid exchange. Typically, MCS proteins contain structural (e.g., tethers) and functional (e.g., exchange lipids) proteins, in addition to proteins which regulate the structure and function of the MCS. In this manuscript, Vormittag et al describe protein components of MCS between the Legionella-containing vacuole (LCV) and the host endoplasmic reticulum (ER) in the amoeba Dictyostelium. Proteomics of isolated LCVs followed by microscopy analysis identified several proteins which localize to either the LCV-associated ER (OSBP8), the LCV (OSBP11), or both (VAP and Sac1). The mammalian homologs of these proteins have been shown to play important roles in ER MCS, with VAP serving a structural role, Sac1 a PI(4P) phosphatase regulating PI(4)P levels, and OSBP8 and OSBP11 lipid transferring proteins. Given the importance of PI(4)P in formation and maintenance of the Legionella-containing vacuole, the authors used dicty mutants to determine the importance of these proteins in bacterial growth, LCV size, and PI(4)P levels on the LCV. While VAP and OSBP11 appear to promote Legionella infection, OSBP8 appears to restriction infection, although all identified MCS components appear to play a role in decreasing PI(4P) shortly after infection. Finally, VAP and OSBP8 localization to the LCV is PI(4)P-dependent. Overall, the authors conclude that these MCS components play a role in modulating PI(4)P levels on the LCV.

      Overall, this is an interesting study further exploring the role of PI(4)P in LCV-ER interactions, and how PI(4)P levels are regulated. The figures are clearly presented, there is an impressive amount of data, and rigor appears to be strong with appropriate replicates and statistical analysis. The phenotypes are often mild, but the authors are careful to not overinterpret the data. While this is an interesting study, additional experiments are necessary to support the overall model and the text needs to put the findings into the larger context.

      Response: We would like to thank the reviewer for this positive and constructive assessment. We performed and planned additional experiments to further strengthen the study and support our model.

      Major comments

      1) MCS contain protein complexes or a group of proteins, but the proteins here are studied in isolation and do not support the model shown in Figure 7. Co-localization studies of the putative LCV-ER MCS proteins are critical, especially given that the authors hypothesize the proteins are working together to modulate PI(4)P levels.

      Response: To further explore the possible interactions between Vap and OSBP proteins, we plan co-localization experiments using D. discoideum strains producing mCherry-Vap and either OSBP8-GFP or GFP-OSBP11, as outlined above (Section 2, new__ Fig. 2__ and Fig. S4).

      Moreover, we included additional data on PtdIns(4)P/cholesterol lipid exchange (Fig. 6 __and Fig. S10__), which have been incorporated into the model (amended Fig. 8). Based on the available data, we do not postulate direct interactions between Vap and OSBP proteins. The previous model, which now has been amended, might have been misleading in that respect.

      2) The phenotypes are relatively mild, suggesting functional redundancy. Double knockouts, particularly in VAP and OSBP11, may generate a stronger phenotype that better supports the hypothesis and demonstrate the importance during infection.

      Response: Thank you for this interesting suggestion. Please see Section 4 below for our arguments, why we believe that this intriguing approach is beyond the scope of the current study.

      3) The timing of PI(4)P and MCS protein localization during infection is critical to understanding how MCS might be functioning. Based on Figure 6C, PI(4)P levels decrease on the LCV during infection, but this is not fully explained in the context of what's known in the literature and what is observed the previous figures. How does localization of different MCS components change during infection, and does this correlate with the changes in growth or LCV size? A better description in the Introduction on LCV-associated PI(4)P levels would be beneficial in orienting the reader to why PI(4)P levels are modulated.

      Response: As suggested by the reviewer, we added to the Introduction section more detail about the kinetics of PtdIns(4)P accumulation on LCVs (l. 65-71), and we discuss the limited spatial resolution of the IFC approach (formerly Fig. 6C, now Fig. 7C; l. 407-408). Importantly, we also provide new data showing that within 2 h p.i. an increase in PtdIns(4)P at the LCV coincides with a decrease of cholesterol (new Fig. 6 and Fig. S10). The new data is put into this context in the Discussion section (l. 449-454).

      4) OSW-1 has other targets besides OSBPs, and depleting Sac1 and Arf1 in A549 cells is not specifically targeting the MCS, as these proteins have other functions. The data in mammalian cells is not convincing and should be removed.

      Response: As suggested by the reviewer, we removed the data on depleting Sac1 in A549 cells (Fig. 3D, and Fig. S6BC). We propose to leave the pharmacological data on inhibition of L. pneumophila replication by OSW-1 in the manuscript, but to clearly point out that OSW-1 has other targets besides OSBPs (l. 297-299).

      Minor comments

      1) Figure 2 is missing details on number of experiments/replicates and statistical analysis.

      Response: Thank you for having noted this oversight. The number of independent experiments and statistical analysis have now been added to Fig. 1 (formerly Fig. 2) (l. 1009-1010).

      2) Can the authors hypothesize why VAP promotes growth early during infection, but appears to restrict growth at later timepoints (Figure 3A)?

      Response: Thank you for raising this intriguing point. The opposite effects on growth of Vap at early and later timepoints during infection might be explained by interactions with antagonistic OSBPs. Vap likely co-localizes with OSBP8 as well as with OSBP11 on the limiting LCV membrane or the ER, respectively (experiment to be performed; Fig. 2 and__ Fig. S4__). The absence of OSBP8 (ΔosbH) or OSBP11 (ΔosbK) causes larger or smaller LCVs, and increased or reduced intracellular replication of L. pneumophila, respectively. Thus, OSBP8 seems to restrict and OSBP 11 seems to promote intracellular replication. Accordingly, if Vap affects or interacts with OSBP11 early and with OSBP8 later during infection, opposite effects on growth of Vap might be explained. These reflections are now outlined in the Discussion section (l. 431-441).

      3) There is a large amount of data, which makes it difficult at times to follow. I suggest adding additional information to table 1, including LCV size and whether or not the protein's localization is PI(4)P-dependent.

      Response: Thank you for this suggestion. As proposed by the reviewer, we added the additional information to Table 1 (PtdIns(4)P-dependency of protein localization, LCV size).

      Reviewer #2 (Significance (Required)):

      Membrane contact sites during bacterial infection are a growing area of research. In Legionella, several papers point to the presence of MCS. Further, PI(4)P is known to be an important component on the LCV. This paper shows that MCS protein members are important in modulating LCV PI(4)P levels. The model as presented is not completely supported by the data as co-localization experiments are needed, along with more detailed analysis of how PI(4)P levels change over infection and the role of these MCS proteins in that process. This study will be of interest to those studying Legionella and other vacuolar pathogens. Area of expertise is on membrane contact sites and lipid biology.

      Response: Thank you very much for the overall positive and constructive evaluation.

      Reviewer #3 (Evidence, reproducibility and clarity):

      The authors perform proteomic analysis of Legionella-containing vacuoles. The observe association of membrane contact site (MCS) proteins including VAP, OSBPs, and Sac1. Functional data indicates that these proteins contribute to PI4P levels on LCVs and their ability to acquire lipid from the ER to enable LCV expansion/stability. Overall, the paper is an important contribution to the field and builds upon a growing appreciation for MCS in establishment of intracellular niches by microbial pathogens. I have only minor comments for the authors consideration.

      Response: We would like to thank the reviewer for this enthusiastic assessment.

      Minor comments:

      -line 145, "This approach revealed 3658 host or bacterial proteins identified on LCVs...". This number seems high... how does it compare to prior proteomic studies of pathogen-containing vacuoles?

      Response: As outlined above (reviewer 1, point 1), we have now changed the text (l. 207-213): “This approach revealed 2,434 LCV-associated D. discoideum proteins (Table S1), of a total of 13,126 predicted D. discoideum proteins (UniprotKB). Moreover, 1,224 L. pneumophila proteins were identified (among 3,024 predicted L. pneumophila proteins), which is a reasonable number of proteins identified from an intracellular bacterial pathogen within its vacuole with the proteomics methods applied (Herweg et al, 2015; Schmölders et al., 2017).”

      • line 160. Can the authors comment on why mitochondrial proteins are observed in their proteomic analysis? Are these non-specific background signals or reflecting relevant organelle contact?

      Response: The dynamics of mitochondrial interactions with LCVs and the effects of L. pneumophila infection on mitochondrial functions have been thoroughly analyzed (PMID: 28867389). This seminal work is now cited in the text (l. 227-230).

      • line 268. It is reported that LCVs are smaller with MCS disruption at 2 and 8 h p,i.. Does this also lead to instability or rupture of LCVs? And related to this why would LCVs be bigger at 16h with MCS disruption?

      Response: MCS components affect LCV size positively or negatively. E.g., the absence of OSBP8 (ΔosbH) or OSBP11 (ΔosbK) causes larger or smaller LCVs, and increased or reduced intracellular replication of L. pneumophila, respectively. However, as outlined in the Discussion section (l. 442-454), we believe that the relatively small size likely reflects a structural remodeling of the pathogen vacuole rather than a substantial LCV expansion. LCV rupture takes place only very late in the infection cycle (beyond 48 h) and is followed by lysis of the host amoeba (PMID: 34314090).

      • lines 288 and 299 "data not shown" this data should be included in a supplemental figure.

      Response: The data on the localization of GFP-Sac1 and GFP-Sac1_ΔTMD are included in the Figs. 1A, 4A, 5AD, S2A, S7A, and__ S9__ (l. 328, l. 339).

      • line 327. The authors choose to focus on the role of LepB and SidC in MCS modulation. The rationale for choosing these two amongst the ca 330 effectors was not given. Were other effectors also examined?

      Response: LepB and SidC were chosen due to their activities producing or titrating PtdIns(4)P, respectively, and their LCV localization. This rational is now given in the text (l. 385-387). No other effectors were examined up to this point.

      Reviewer #3 (Significance (Required)):

      Comprehensive LCV proteomics of interest to field of cellular microbiology. Studies of MCS broadly relevant to cell biologists.

      Response: Thank you very much for the overall very positive evaluation.

      4. Description of analyses that authors prefer not to carry out

      Reviewer #2

      Major comment

      2) The phenotypes are relatively mild, suggesting functional redundancy. Double knockouts, particularly in VAP and OSBP11, may generate a stronger phenotype that better supports the hypothesis and demonstrate the importance during infection.

      Response: Thank you for raising the important question of functional redundancy. We now outline this concept in the Discussion section (l. 427-429). A further analysis of the genetic and biochemical relationship between Vap and OSBP11 or OSBP8 are without doubt some of the most interesting aspects of further studies on the topic of LCV-ER MCS.

      The construction of a D. discoideum double mutant strain is time consuming and usually takes 1-2 months. Provided that a Vap/OSBP11 double deletion mutant strain is viable and can be generated, it takes another 1-2 months to thoroughly characterize the strain regarding intracellular replication of L. pneumophila (Fig. 3), LCV size (Fig. 4), and PtdIns(4)P score (Fig. 5). Moreover, there is already a large amount of data in the paper (to quote Reviewer #2), and therefore, adding new data might makes it even harder to follow the story and focus on the key points. Finally, we believe that the planned colocalization experiments (Reviewer #2, point 1) and the new data on lipid exchange kinetics (new Fig. 6 and Fig. S10) fit the current story more coherently, and thus, are more straightforward and informative than the generation and characterization of double mutant strains. For these reasons, we believe that the generation and characterization of D. discoideum double mutant strains is beyond the scope of the current study.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      The authors perform proteomic analysis of Legionella containing vacuoles. The observe association of membrane contact site (MCS) proteins including VAP, OSBPs, and Sac1. Functional data indicates that these proteins contribute to PI4P levels on LCVs and their ability to acquire lipid from the ER to enable LCV expansion/stability. Overall the paper is an important contribution to the field and builds upon a growing appreciation for MCS in establishment of intracellular niches by microbial pathogens. I have only minor comments for the authors consideration.

      Minor comments:

      • line 145, "This approach revealed 3658 host or bacterial proteins identified on LCVs...". This number seems high... how does it compare to prior proteomic studies of pathogen-containing vacuoles?
      • line 160. Can the authors comment on why mitochondrial proteins are observed in their proteomic analysis? Are these non-specific background signals or reflecting relevant organelle contact?
      • line 268. It is reported that LCVs are smaller with MCS disruption at 2 and 8 h p,i.. Does this also lead to instability or rupture of LCVs? And related to this why would LCVs be bigger at 16h with MCS disruption?
      • lines 288 and 299 "data not shown" this data should be included in a supplemental figure
      • line 327. The authors choose to focus on the role of LepB and SidC in MCS modulation. The rationale for choosing these two amongst the ca 330 effectors was not given. Were other effectors also examined?

      Significance

      Comprehensive LCV proteomics of interest to field of cellular microbiology. Studies of MCS broadly relevant to cell biologists.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      Summary of paper and major findings

      Membrane contact sites (MCS) are locations where two membranes are in close proximity (10-80nm). MCS have a defined protein composition which tether the membranes together and function in small molecule and lipid exchange. Typically, MCS proteins contain structural (e.g., tethers) and functional (e.g., exchange lipids) proteins, in addition to proteins which regulate the structure and function of the MCS. In this manuscript, Vormittag et al describe protein components of MCS between the Legionella containing vacuole (LCV) and the host endoplasmic reticulum (ER) in the amoeba Dictyostelium. Proteomics of isolated LCVs followed by microscopy analysis identified several proteins which localize to either the LCV-associated ER (OSBP8), the LCV (OSBP11), or both (VAP and Sac1). The mammalian homologs of these proteins have been shown to play important roles in ER MCS, with VAP serving a structural role, Sac1 a PI(4P) phosphatase regulating PI(4)P levels, and OSBP8 and OSBP11 lipid transferring proteins. Given the importance of PI(4)P in formation and maintenance of the Legionella Containing Vacuole, the authors used dicty mutants to determine the importance of these proteins in bacterial growth, LCV size, and PI(4)P levels on the LCV. While VAP and OSBP11 appear to promote Legionella infection, OSBP8 appears to restriction infection, although all identified MCS components appear to play a role in decreasing PI(4P) shortly after infection. Finally, VAP and OSBP8 localization to the LCV is PI(4)P-dependent. Overall, the authors conclude that these MCS components play a role in modulating PI(4)P levels on the LCV.

      Overall, this is an interesting study further exploring the role of PI(4)P in LCV-ER interactions, and how PI(4)P levels are regulated. The figures are clearly presented, there is an impressive amount of data, and rigor appears to be strong with appropriate replicates and statistical analysis. The phenotypes are often mild, but the authors are careful to not overinterpret the data. While this is an interesting study, additional experiments are necessary to support the overall model and the text needs to put the findings into the larger context.

      Major comments

      1. MCS contain protein complexes or a group of proteins, but the proteins here are studied in isolation and do not support the model shown in Figure 7. Co-localization studies of the putative LCV-ER MCS proteins are critical, especially given that the authors hypothesize the proteins are working together to modulate PI(4)P levels.
      2. The phenotypes are relatively mild, suggesting functional redundancy. Double knockouts, particularly in VAP and OSBP11, may generate a stronger phenotype that better supports the hypothesis and demonstrate the importance during infection.
      3. The timing of PI(4)P and MCS protein localization during infection is critical to understanding how MCS might be functioning. Based on Figure 6C, PI(4)P levels decrease on the LCV during infection, but this is not fully explained in the context of what's known in the literature and what is observed the previous figures. How does localization of different MCS components change during infection, and does this correlate with the changes in growth or LCV size? A better description in the Introduction on LCV-associated PI(4)P levels would be beneficial in orienting the reader to why PI(4)P levels are modulated.
      4. OSW-7 has other targets besides OSBPs, and depleting Sac1 and Arf1 in A549 cells is not specifically targeting the MCS, as these proteins have other functions. The data in mammalian cells is not convincing and should be removed.

      Minor comments

      1. Figure 2 is missing details on number of experiments/replicates and statistical analysis.
      2. Can the authors hypothesize why VAP promotes growth early during infection, but appears to restrict growth at later timepoints (Figure 3A)?
      3. There is a large amount of data, which makes it difficult at times to follow. I suggest adding additional information to table 1, including LCV size and whether or not the protein's localization is PI(4)P-dependent.

      Significance

      Membrane contact sites during bacterial infection are a growing area of research. In Legionella, several papers point to the presence of MCS. Further, PI(4)P is known to be an important component on the LCV. This paper shows that MCS protein members are important in modulating LCV PI(4)P levels. The model as presented is not completely supported by the data as co-localization experiments are needed, along with more detailed analysis of how PI(4)P levels change over infection and the role of these MCS proteins in that process. This study will be of interest to those studying Legionella and other vacuolar pathogens.

      Area of expertise is on membrane contact sites and lipid biology.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      In the manuscript by Vormittag, et al., the authors perform proteomics identification of proteins associated with the Legionella-containing vacuole (LCV) in the model amoeba Dictyostelium discoideum comparing WT to atlastin knockout mutants. The authors find approximately half the D. discoideum proteome associated with the LCV, but there was enrichment of some proteins on the WT relative to the mutant. They focus on proteins involved in forming membrane contact sites (MCS) that previously were shown to be important for expansion of the Chlamydia-containing vacuole. Most significant are the oxysterol binding proteins (OSBP) and VapA (similar to that seen in Chlamydia). The authors show differential association of these proteins with either the LCV or presumably the ER associated with the LCV. Using a linear scale over 8days, they show that mutations in some of the MCS reduce yields in two of the OSPB knockout mutants and the growth rate of the vap mutant is slowed but ultimate yield is increased. Using some nice microscopy techniques, they measure LCV size, and the osbK mutant appears particular small relative to other strains, whereas the osbH mutant generates large vacuoles. This doesn't necessarily correlate with the PI4P quantities on the vacuoles (which is higher in all of them), but I am not totally sure how this is measured, and whether is it PI4P/pixel or PI4P/LCV. In all cases, this was reduces by Sac1 mutation. Surprisingly, even though there was uniform increase in PI4P in each of the mutants, loss of PI4P only affects localization of some of the proteins. Finally, in what seems to be a peripherally related experiment, the authors show that a pair of Legionella translocated effectors are required to maintain PIF4P levels, although it is not clear how this is related to the other data in the manuscript.

      It is not clear from the manuscript if the authors are just cataloging things or trying to test a hypothesis. This is an extremely difficult manuscript to read and reconstruct what the authors showed. I really think that the only people who will understand what is written are people who are familiar with the work in Chlamydia starting in 2011 in Engel's and Derre's laboratories, which clearly showed that MCS and most specifically Vap/OSBPs are involved in vacuole expansion. If the authors could rewrite the manuscript along these lines, perhaps comparing their data to the Chlamydia data it would help a log. Otherwise, I don't think anyone else will understand why they are focusing on these things. I don't recommend new experiments (although re-analyzing data is necessary), but the manuscript has to be taken apart and claims removed, and data be interpreted properly. Otherwise, the manuscript seems like just a clearing house for data.

      1. The problems start with the first figure, in which the authors state that almost half the D. discoideum proteome is LCV-associated. I doubt that this is correct, and they should base this on some selective criterion. Furthermore in Fig. 1A, they show Venn diagrams for how they whittled this down, but the Supplemental Dataset gives us no clue on how this was done. I can only sit down myself with the dataset and try to figure that out, but that is an unreasonable expectation for the reader. The dataset provided should have a series of sheets, describing how the large protein set was whittled down and how they were sorted, so the reader can evaluate how robust the final results were. To me (at least), if they said: "look we got this surprising result that suggests MCS are involved in promoting LCV formation, and although this is well recognized in Chlamydia but poorly recognized in Legionella", that would be satisfactory to me.
      2. I am clueless regarding how Fig. 6 fits with the rest of the manuscript. If this is about MCS, there is no demonstration these effectors are directly involved in MCS other than the somewhat diffuse argument that there is some correlative connection to PI4P levels, that I am not particularly convinced by.
      3. Lin 146 and associated paragraph. We don't need a catalog of proteins in narrative. There is more detail in the narrative than there is in the tables and figures, which would be a more appropriate way to present the data.
      4. Line 186. There is nothing wrong with pursuing MCS based on the idea that this was seen before with Chlamydia and you wanted to test if this was a previously unappreciated aspect of Legionella biology. I don't see the rationale based on the proteomics, partly because I don't understand how the proteomics dataset was parsed.
      5. Figure 3: These growth curves are super-weird. I am not used to looking at 8 days of logarithmic growth in a linear scale, and seeing no (apparent) growth for 4 days. Considering all the microscopy data are performed in the first 18 hrs of infection, its hard to see how this is related to data at 8 days post infection. If this were plotted in logarithmic scale, as microbiologists are used to doing, then perhaps we could see a connection. Also, in some cases, it might be helpful to calculate a growth rate, because its possible the author may now see some effects by comparing logarithmic growth rates.
      6. Figure 2: The images don't necessarily show what the bar graphs show. In particular, look at Osp8. That image doesn't make sense to me.

      In summary, I think the authors hit on something that is probably important for Legionella biology, but its not clear what they want to show. They are very invested in connecting everything to PI4P levels, which may or may not be correct, but it seems to me that perhaps taking more care in showing the importance of the Vap/OSPB nexus in supporting Legionella growth should be the first priority.

      It is not clear from the manuscript if the authors are just cataloging things or trying to test a hypothesis.

      If I understand Fig. 1, only one of the candidates (VapA) was verified as being more enriched in WT relative to atlastin mutants. This argues even more strongly that the authors have to describe their criteria for choosing these candidates

      Significance

      As stated above, the mansucript can't decide if its about MCS or PI4P, and I would argue strongly that the emphasis on PI4P detracts from the manuscript, as well as its inability to draw connection to previous work that is likely to be important.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      This paper examines the formation and repair of micronuclei in non-cancerous cells, specifically in mouse embryonic fibroblasts. This work was performed completely in culture and used a combination of western blot, confocal and superresolution microscopy to assess the contents of micronuclei over a repair period of 5 hours after 2 hours of induction of double strand breaks by treatment with etoposide. The authors found that the bodies colocalised with LC3, Beclin 1 and lysosomes suggestive of autophagy. However no evidence of autophagic flux has been demonstrated.

      Major issues are as follows:

      Figure 2

      A - Any sense of the autophagic flux? LC3B - I and LC3B - II seem to be in equal quantities most of the time. Maybe using the tandem LC3 in this system could provide further insight. Also remove the violin plots from this graph and from G and H, as there are too few data points.

      Thank you for your comment. We have evidence of a functional autophagic flux, since we observed an increasing number of acidic vesicles stained with Lysotracker in response to DNA damage, which were reduced after DNA repair. Some of the micronuclei were also co-stained with Lysotracker, suggesting their lysosomal degradation. We reorganized the data in the revised figure 2A to communicate better these observations. We reproduce here the dynamic of Lysotracker stain, please notice an increase in the abundance of acidic vesicles after 2h of DNA damage. A further evidence of activation of functional autophagy is the dynamic intracellular distribution of both LC3 and BECN1, indicative of autophagy induction. Please notice in revised Figure 2A that LC3 surrounding vesicles increases after 2h of DNA damage and diminish when DNA is repaired. BECN1 in control MEFs is highly concentrated inside the nucleus, predominantly at the nucleolus, and after DNA damage it redistributes towards the cytoplasm. Finally after DNA repair, BECN1 appears highly concentrated at the nucleus again. These dynamic changes correlate with autophagosomes formation and successful fusion with lysosomes. In the revised manuscript we removed the violin plot as suggested. Since the elimination of nuclear components occurs in a subset of cells, the role of the autophagic machinery needs to be analyzed cell by cell. We considered better to eliminate also the Western blot, as an analysis of the whole population does not provide information relevant for this study.

      • Can you reduce the brightness in the merge image, as I cannot see DAPI nor a convincing Beclin-1/LC3 co-localisation.

      Thank you for the observation. We improved the quality of the images and reorganized Figure 2 to convincingly show BECN1 and LC3 co-localization, together with Lysotracker, in nuclear alterations (buds and micronuclei). We modified the results text accordingly.

      • Although the data is convincing, It would be clearer if the brightness of the merge image was reduced.

      Thank you for your comment. We improved the images shown, these data is now integrated in new Figure 2A.

      • Is the significant result the difference between 5h R Control si and 5h R Atg7? if so, there is no significant change in micronuclei as the same time point, can you explain this disconnect? are the buds being degraded prior to becoming micronuclei?

      That is correct, we found no statistical significant difference in the number of micronuclei formed silencing Atg7, although there was a trend to reduce them. To consolidate the role of autophagy in nuclear buds and micronuclei formation, we studied Atg4-/- MEFs. We confirmed a statistical significant reduction of buds formation when autophagy is impaired (new Figure 2G). However, we observed that the number of micronuclei increased after 2h of DNA damage in Atg4-/- MEFs, suggesting that autophagy does not contribute to micronuclei formation but elimination. Together, our results suggest that the origin of buds and micronuclei are mechanistically different. A difference in the biogenesis of buds and micronuclei has been previously suggested studying cells cultured under strong stress conditions that induce DNA amplification, as well as in cells under folic acid deficiency. While interstitial DNA without telomere was more prevalent in buds than in micronuclei, telomeric DNA was more frequently observed in micronuclei (Fennech et al. 2011, Mutagenesis 26:125-132). We agree with the reviewer, it seems that not all the buds become micronuclei.

      Figure 3 A - nice microscopy showing the co-localisation of TOP2A and LC3-GFP. I'm interested in DAPI being on some bodies and not others. Do you have any sense of the dynamics of this?

      Thank you for the interesting question. Since removal of nuclear alterations as nuclear buds and micronuclei is a very dynamic process, we detect nuclear damaged material in the cytoplasm are at different degradation stages. Nucleases could be degrading DNA in micronuclei. Another possibility to the lack of DAPI signal in some micronuclei containing TOP2A and GFP-LC·is that TOP2A could be expelled from the nucleus with undetectable fragments of DNA or even without DNA, as a renewal process. We believe that nuclear buds can form without extruding DNA in some cases, perhaps to modulate proteostasis in addition to protect genome stability. In the revised manuscript we discuss this possibility further.

      G - c shows a strand of mostly TOP2B coming from the nucleus. Is there any evidence that this occurs using either confocal microscopy or super resolution approaches. Could you try Z-stack to find these?

      Thank you for the suggestion, we analyzed Z-stack images and tried to observe it also by immunofluorescence. We could detect some tubular signal connecting the nucleolus with a micronucleus containing TOP2B and BECN1 (arrow head in Fig 3B reproduced below), although we cannot be certain we are detecting the same nuclear extrusion mechanism by Electron Microscopy than by immunofluorescence.

      Figure 4 C - is there a significant increase in FBL negative bodies, this would make sense if FBN is being degraded in the micronuclei during the repair process

      We found that the number of micronuclei without FBL increased with statistical significant difference by Two-way-ANOVA followed by Dunnett´s multiple comparison test (P=0.463 comparing cells with 2h of DNA damage with control cells; P=0.0017 comparing cells after 5h of DNA repair with untreated cells; n=5). We agree with the reviewer, a possible explanation is that FBL is being degraded in micronuclei during the repair process. Although it could also be possible that nucleolar is less sensitive to Etoposide poisoning, or that nucleolar DDR is mechanistically different.

      • Would it be possible to increase the n of these experiments to confirm either no change in FBL/LC3 co-loc, or evidence of increase?

      Thank you for the suggestion. We repeated the experiment two more times to increase the n to 5. We found no statistical difference in the number of nuclear buds or micronuclei containing both FBL and LC3 during DNA damage and repair. Therefore it seems that the release of nucleolar components is not enhanced by Etoposide-induced DSB, suggesting that nucleolar DDR is a unique response, independent of DDR elsewhere in the genome (reviewed in Nucleic Acids Research, 2020, Vol. 48, No. 17 9449–9461 doi: 10.1093/nar/gkaa713).

      Minor issues:

      Figure 4 and 5 legends are in a different font.

      Thank you. We correct the font in the current manuscript.

      Reviewer #1 (Significance (Required)):

      There is little specific data on the role of autophagy in clearing micronuclei in cancer cells, so this may be suggestive of a new mechanism that occur during normal cellular homeostasis. There are known links between lamin A defects and the formation of micronuclei, but not explicitly that the micronuclei are also Lamin A positive. it is likely that analogous processes occur in both cancer and non-cancer, so the impact of these data is not clear to me. This paper may be of interest to researchers interested in nuclear structure and DNA damage, but based on the data presented the significance is limited.

      The significance of the present work is to discover that autophagy is relevant both during physiological DNA damage and in response to an exogenous DNA damaging agent, to extrude damaged DNA, TOP2cc and Fibrillarin from the nucleus. This knowledge is relevant since insufficiencies on autophagy imply a risk of genomic instability, which in turn could drive the cell into a senescent or malignant state. We present data showing that autophagy regulates the dynamic formation and elimination of nuclear buds and micronuclei in a mechanistically differentiated way. While autophagy contributes to nuclear buds formation, it is necessary for micronuclei elimination. Our data suggest that nucleophagy could be also a mechanism to alleviate basal nucleolar stress. As the reviewer noticed, some micronuclei did not have DNA. It is conceivable then that nuclear buds and micronuclei form also for a proteostatic function, not necessarily involving DNA damage elimination. We believe the significance of our work contributes to our understanding of the cell, as well as to cancer research. Whether common mechanisms between cancerous and normal cells occur is relevant to know, to consider the specificity of potential therapeutic approaches.

      I don't have sufficient expertise to evaluate the super resolution microscopy beyond assessing the images.

      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      Peer review of the manuscript with the number RC-2021-01181 by Muciño-Hernandez G et. al. at Review Commons and with the tittle "Nucleophagy contributes to genome stability 1 though TOP2cc and nucleolar components degradation"

      1. Summary Muciño-Hernandez G et. al. show in this manuscript that mouse embryonic fibroblasts (MEFs) have basal levels of nuclear buds and micronuclei, which are indicators of genomic DNA damage. These basal levels of nuclear buds and micronuclei in MEFs increased after Etoposide treatment, which is known to induce DNA Double stranded Breaks (DSD). Interestingly, the nuclear buds and micronuclei co-localize with makers for nucleophagy (BECN1 and LC3) and acidic vesicles, suggesting that they are cleared by nucleophagy. The authors propose that basal levels of nucleophagy clear basal levels of genomic DNA damage that occurs as result from DNA-dependent biological processes in the cell nucleus, thereby contributing to nuclear stability of MEFs under physiological conditions. These basal levels of nucleophagy increase after the action of factors that induce DNA damage and nuclear stress. The concepts proposed by Muciño-Hernandez G et. al. are novel, since most of the current published data on nucleophagy related to DNA damage have been obtained under pathological conditions, e.g. implementing cancer cells.

      The authors use in their manuscript various molecular biology techniques to obtain data that support their claims, including Western Blot analysis of protein extracts from MEFs, immunostaining on MEFs and neutral comet assays, complemented with state of the art imaging techniques, such as confocal microscopy, immunoelectron microscopy and super resolution microscopy. The quality of the data is sound. The structure of the manuscript support the understanding of the reader. However, I would like to suggest several improvements that will help to increase the quality of the manuscript, in order that fits to the standards of articles recently published in journals affiliated to Review Commons, such as the Journal of Cell Biology, the EMBO Journal or eLife.

      1. Major comments

      2.1 The authors have to improve the description of the results. Especially the description of those Figure panels containing plots that were generated using data from several experiments has to be improved.

      One example is the description of the Figure 1D, which is in the lanes 137-151 of the current version of the manuscript. Whereas the authors describe in lanes 137-147 observations related to representative pictures of confocal microscopy after immunostaining presented in Figure 1D (left), the description of the quantification from 9 independent experiments presented in the plots in Figure 1D (right) comes relatively short in lanes 147-150 without mentioning any of the values implemented for creating the plots.

      "Interestingly, while the frequency of nuclear buds gradually increased after DNA damage and during DNA repair, the frequency of micronuclei also increased after DNA damage, but diminished upon DNA repair."

      The other plots presented in the different figure panels across the manuscript are described in a similar manner. I would like to suggest to the authors to improve their manuscript by including during the description of their results the values that were implemented for the degeneration of the plots presented in the manuscript. For example, in the specific case of Figure 1D above:

      "Interestingly, the percentage of MEFs with nuclear buds gradually increased from XY% ({plus minus} XY SD) in control non-treated (Ctrl) MEFs to XY% ({plus minus} XY SD; P=XY) after 2 h Etoposide-induced DSB in MEFs and XY% ({plus minus} XY SD; P=XY) after DNA repair take place in MEFSs 5 h upon stop of Etoposide treatment (Figure 1D, right). In contrast, the percentage of MEFs with micronuclei significantly increased from XY% ({plus minus} XY SD) in Ctrl MEFs to XY% ({plus minus} XY SD; P=XY) after 2 h Etoposide-induced DSB, whereas it was reduced to XY% ({plus minus} XY SD; P=XY) 5 h after stop of Etoposide treatment (Figure 1D, right)."

      Descriptions of the plots as mentioned above will make the text more intuitive for the reader, and they will make possible to read the Results Section without switching to the Figure Legends or the Material and Methods Section or to Supplementary Files. Even though the representative pictures from different microscopy techniques presented in the manuscript are of good quality and support the claims of the authors, it is important to mention that the quantifications presented in the plots demonstrate the statistical significance of these representative pictures. Thus, the authors should consistently include in the manuscript during the description of theirs results all the information (mean values, standard error of the means, P values, n values, etc.) that support their interpretation of the results and demonstrate the statistical significance of their claims.

      Thank you for your clear and valuable advice. We followed it and in the revised manuscript we included the data in the results section.

      2.2 Following a similar line of argumentation as in the previous point, the authors should provide as Supplementary Material an Excel file containing a statistical summary, including all statistical relevant information from each one of the plots presented in each Figure panel, such as n values, P values, Test implemented, values used for the plots, numbers of experiments, etc. The information could be organized in the Excel file in different data sheets according to the Figure panels, in order that the reader can easily navigate through the data. In the current version of the manuscript, one cannot find the values used for the generation of the plots presented in the manuscript in any of the submitted files.

      Thank your for this suggestion. We have included in Table S1 an Excel file with a data sheet for each Figure panel, containing all the data collected and the statistical analysis performed.

      Minor comments

      3.1 In general, prior studies were appropriately referenced. Only few references has to be added.

      Line 48: Add to the already included reference "Dobersch et al., 2021" also the reference Singh et al., 2015 PMID 26045162.

      Thank you, we added this reference.

      Line 53: Add the corresponding reference after the word "respectively".

      We added the corresponding reference.

      Line 82: Add the corresponding reference after the word "them".

      We added the corresponding reference.

      Line 125: Add the corresponding reference after the word "cells".

      We added the corresponding reference.

      Line 130: The expression "...by analyzing the recruitment of the phosphorylated histone γH2AX..." is the first time that the authors mention in the manuscript the DNA damage maker γH2AX. I suggest that is better introduced as " ... by analyzing the recruitment of the DNA damage marker γH2AX (histone variant H2A.X phosphorylated a serine 139, Rogakou EP, et al., 1998, PMID 9488723) to DSB sites."

      Thank you very much for your suggestion. In the revised manuscript we corrected the text as suggested.

      Line 199: Add the corresponding reference after the word "formation".

      We added the corresponding reference.

      Line 205: Add the corresponding reference after the word "cells".

      We added the corresponding reference.

      3.2 The use of the English language is appropriate throughout the manuscript. However, there are minor errors in the use of punctuation marks, in the use of prepositions and typos. I will list some of them below. However, I would like to recommend that manuscript is corrected by an English native speaker.

      Thank you for your careful review of our manuscript. We corrected all the errors listed. A college proficient in English has reviewed the revised manuscript.

      Line 41: "...and reproductive systems; genome instability also..." the semicolon can be replaced by a period.

      Line 43: "Since early in development DNA is under constant endogenous..." between "development" and "DNA" there should a comma.

      The sentence in lanes 53-55 has to be rephrased.

      Lines 62-63: the expression "...throughout life." should be substituted.

      Line 70: The abbreviation "rDNA" has to be explained the first time that is used.

      Lines 81-82: It has to be explained for the scientist that is not specialized in the field of nucleophagy, how the integrity of the genome is threatened by micronuclei and nuclei-derived material.

      √ Lines 106-110: The sentence is long. It would be easier to understand for the reader if this sentence is divided into two sentences.

      Lines 121-122: The subtitle should be rephrased.

      Lines 132-138: The sentence is long. It would be easier to understand for the reader if this sentence is divided into two sentences, e.g. with a period before the word "hence".

      Lines 143-144: "... in a subpopulation of healthy, untreated cells...". The interpretation of "healthy" might be subjective. I would like to suggest substituting in the complete manuscript the word "healthy" by "control".

      Line 163: The abbreviation for γH2AX was already introduced in line 130.

      Line 182: A comma after "cell lines" is missed.

      Line 183: delete "either". √ Lines 190-194: The sentence is long. It would be easier to understand for the reader if this sentence is divided into two sentences, e.g. with a period after the word "decreased" in line 191.

      Line 218: I assume that instead of "bus", it should be "buds".

      Line 220: I assume that instead of "iRNA", it should be "siRNA". In addition, it is the first time that the abbreviation is used. Thus, I suggest introducing it as "...was silenced by specific small interfering RNA (siRNA) previous to ..."

      Line 327: delete the word "chronic".

      Line 344: I assume that instead of "(figures 4C)", it should be "(Figure 4D)".

      3.3 The structure of the Figures is ok for the peer review process and it might be optimized during editing of the manuscript. Nevertheless, I would like to suggest to the authors to increase the lettering size throughout all the figures. It will make the figures more intuitive.

      Thank you for the suggestion. We increase the font size of the figures.

      Reviewer #2 (Significance (Required)):

      Significance

      The work presented by Muciño-Hernandez G et. al. will be clearly a significant contribution to the scientific community working on autophagy, DNA damage repair and cancer, among others. It will be of interest to a broad spectrum of scientists, as I will elaborate in the following lines. The authors propose that MEFs have basal levels of genomic DNA damage under physiological conditions, which are cleared by basal levels of nucleophagy. On one hand, these findings are in line with various publications demonstrating that DNA-dependent biological processes in the cell nucleus, such as transcription, replication, recombination, and repair, involve intermediates with DNA breaks that may compromise the integrity of DNA. Thus, there must be mechanisms that ensure the integrity of the genome during these processes under physiological conditions, one of them seems to be nucleophagy. This perspective might explain the fact that proteins and histone modifications that were initially characterized during DNA repair also play a role during transcription, recombination, and replication. For example, phosphorylated H2AX at S139 (γH2AX) is often used as a marker for DNA-DSB [PMID 9488723]. However, accumulating evidences suggest additional functions of this histone modification [PMIDs 19377486; 22628289; 23382544]. In addition, McManus et al. [PMID 16030261] analyzed the dynamics of γH2AX in normal growing mammalian cells and found γH2AX in all phases of cell cycle with a maximum during M phase, suggesting that γH2AX may contribute to the fidelity of the mitotic process, even in the absence of ectopic- induced DNA damage. Further, Singh et al [PMID 26045162] and Dobersch et al [PMID 33594057] report that γH2AX plays a role in transcriptional activation in response to TGFB-signaling. Moreover, classical DNA-repair complexes have been linked to DNA demethylation and transcriptional activation [PMIDs 17268471; 28512237; 25901318], and DNA-DSB is known to induce ectopic transcription that is essential for repair, supporting a tight mechanistic correlation between transcription, DNA damage, and repair [PMID 24207023]. Perhaps, the authors might consider introducing several of the aspects and the citations written above into the Discussion section of the revised version of their manuscript. On the other hand, most of the published data related to nucleophagy have been obtained from cancer cells. Muciño-Hernandez G et. al. obtained their data implementing MEFs to demonstrate that the proposed mechanisms take also place under non-pathological conditions, what is one of the novel aspects of the present work.

      I hope that my suggestions help the authors to improve their manuscript, thereby reaching the standards of manuscripts recently published in journals affiliated to Review Commons AND increasing the impact of their contribution to the scientific community.

      Thank you very much for your suggestions. They helped us to present now a much-improved manuscript. We hope the revised work is now suitable for publication in the Journal of Cell Science.

      Reviewer #3 (Evidence, reproducibility and clarity (Required)):

      In this manuscript, Muciño-Hernández and colleagues suggest that basal formation of nuclear buds and micronuclei increases in primary mouse embryonic fibroblasts following etoposide-induced double strand breaks (DSBs). The study combines the use of biochemical methodologies with confocal and super resolution microscopy in an effort to explore the contribution of nucleophagy to genome stability. The authors provide evidence that autophagy is induced upon etoposide treatment. They detected GFP-LC3 and BECN1 signals in nuclear buds and micronuclei even in untreated control and to a higher extent in etoposide-treated cells. Then, the authors examined whether nucleophagy is required for the removal of nuclear buds and micronuclei, by treating fibroblasts with control and Atg7 siRNA. The authors claim that the percentage of cells with micronuclei or nuclear buds decrease upon Atg7 knockdown, suggesting that components of the autophagy machinery induce the formation of these nuclear abnormalities. Moreover, Type II DNA Topoisomerases (TOP2A and TOP2B) and the ribosomal protein fibrillarin were detected in nuclear buds and micronuclei in fibroblasts treated or not with etoposide. Again in this case, GFP-LC3 was detected in fibrillarin-containing nuclear alterations. Based on these observations, the authors suggest that nucleophagy contributes to the elimination of chromosomal fragments or nucleolar bodies exiting the nucleus under DNA damage -inducing conditions. Specifically, they propose a key role for nucleophagy in maintaining genome stability by eliminating Type II DNA Topoisomerase cleavage complex (TOP2cc) and nucleolar components such as fibrillarin.

      While it seems that there is a relationship between nuclear-extruded TOP2 with endogenous BECN1 and GFP-LC3 suggesting autophagic engagement, inconsistencies of fluorescent images between different figures indicate possible technical problems/limitations (please see specific comments, below), compromising authors' claims. LC3 immunoblotting and GFP-LC3 localization results appear over-interpreted (comments below). Neither TOP2 nor Fibrillarin have been shown to be actual autophagic substrates. Also, the link between genomic stability, micronuclei formation and autophagy has been previously reported (Zhao et al., PMID: 33752561).

      An additional major concern is relates to nucleophagy being a selective type of autophagy. As such it requires efficient recognition and sequestration of the nuclear material destined to be degraded. Cargo specificity is mediated by receptor proteins, but no evidence for such receptors is provided in this study. Moreover, there is no real mechanistic insight on how nucleophagy mediates genome stability and how this can be interpreted in terms of cell survival under physiological and stress conditions. In other words, the biological significance of the findings presented has not been addressed.

      Specific comments are summarized below:

      The authors suggest that autophagy is induced after etoposide treatment and during the DNA repair process. However, the Western blot presented in Fig. 2A is not convincing and quantification does not support a significant autophagy induction in any of these cases. Autophagy appears to be induced 1h after etoposide removal, as evidenced LC3II/LC3 I increase (Fig. 2A and S2A). Nevertheless, all these changes should be more rigorously assessed.

      Thank you for the observation. We removed the analysis of LC3II/LC3I by Western blot in the revised manuscript because a basal and induced elimination of nuclear components by the autophagic machinery occurs only in a subset of cells. It needs to be analyzed cell by cell. Pooling together all the cells dilutes the observation. Nevertheless, the dynamic intracellular distribution of both LC3 and BECN1 indicate autophagy induction. Please notice in revised Figure 2A that LC3 surrounding vesicles increases after 2h of DNA damage and diminish when DNA is repaired. BECN1 in control MEFs is highly concentrated inside the nucleus, at the nucleolus as it co-localized with Fibrillarin (new Figure 4E), and after DNA damage it redistributes towards the cytoplasm. Finally after DNA repair, BECN1 appears highly concentrated at the nucleus again. A further evidence of a functional autophagic flux, is the observation of an increasing number of acidic vesicles stained with Lysotracker in response to DNA damage, which were reduced after DNA repair. Some of the micronuclei were also co-stained with Lysotracker, suggesting their lysosomal degradation.

      Line 190 and Fig. 2A: It is totally unclear whether "autophagy activation" takes place during the two waves described. There is no LC3B-I to LC3B-II conversion to initially suggest "autophagy activation". It rather suggests that autophagy is stalled. Fig. 2F shows that GFP-LC3 is strongly fluorescent into the lysotracker-stained lysosomes, further pointing to possible functional or technical problems.

      As pointed out by reviewer 1, the images presented in original Figure 2F were over-exposed. In the current version we replaced those images with new images of better quality. We also reorganized the presentation of the data, and in revised Figure 2A we present photos where more convincingly can be observed a co-localization of BECN1 with LC3, with o without Lysotracker signal in nuclear buds and micronuclei. We also performed immunolocalization of endogenous LC3 (new Figure 2D) to rule out a possible misinterpretation of GFP-LC3 aggregates. As explained before, we removed original Figure2A.

      Fig. 2B and Sup. Fig. 2B: BECN1 staining looks problematic. There is extreme BECN1 accumulation in the nucleus. Are those nuclear patterns of endogenous BECN1 and GFP-LC3 normal (see also minor comment 6 and 7)? Is there literature supporting such a distribution?

      Yes, it has been documented BECN1 localization in the nucleus during development and in response to DNA damage stimuli such as ionizing radiation, and with a function related to DNA repair alternative to autophagosome formation (Fei Xu, et al. 2017, Scientific Reports | 7:45385 | DOI: 10.1038/srep45385). In the current manuscript we also detected endogenous LC3, to avoid a possible artifact with GFP-LC3 expression. We observed endogenous LC3 also localized in the nucleus (new Figure 2D).

      It is hard to imagine how BECL1 is implicated in a (here hypothetical) nuclear lamina degradation event driven by LC3-lamin B1 direct interaction (Dou et al., 2015). BECL1 is an upstream to LC3 component and is a subunit of the PI3K complex catalyzing the local PI3P generation. The above should cause recruitment of the downstream autophagic machinery. Other subunits of the same complex or downstream effectors should be identified at the same spots to support authors' claims.

      Our proposal that BECN1 is contributing to nucleophagy is supported by its co-localization with LC3 and Lysotracker stained vesicles (new figure 2A), as well as with TOP2 (Figure 3A-C). We appreciate the interesting idea of the reviewer; we certainly did not analyze the presence of BECN1 interacting partners. We agree, further studies analyzing their localization could complement our current findings. Supporting our work, others have observed UVRAG in the nucleus, specifically in centromeric regions, and it also has a role in DNA repair through its interaction with DNA-PK (Dev Cell. 2012 May 15; 22(5): 1001–1016. doi: 10.1016/j.devcel.2011.12.027). Given the anti-tumorigenic role of several autophagic molecules, it is tempting to speculate that several of them could have triple roles in the nucleus: directly interacting with DNA repair machinery, eliminating unrepairable DNA damaged and preventing excessive protein accumulation in the nucleus. Further experiments are necessary to probe this hypothesis, but are beyond the scope of the present manuscript.

      U, 2h D and 5h R images of whole cells are necessary. The authors should also provide representative images of cells under different conditions i.e. control, etoposide-treatment and during DNA repair. Along similar lines, untreated control cells are not included in Fig. 2E and F. These images are needed for a better comparison between normal and DNA damage-inducing conditions.

      The reviewer is right. In the revised Figure 2 we included representative images of control cell, Etoposide-treatment and during DNA repair cells. Images of whole cells are now shown in supplementary Figure 2S.

      The authors state that autophagy is required for nuclear buds and micronuclei formation. However, the data shown in Fig. 2G and H are hardly convincing given that the statistical difference between cells treated with control and Atg7 siRNA is not strong (for example, *p˂0.5, 5h after etoposide removal). To provide further support to this notion, they should use cells from autophagy defective mutants and examine the appearance of nuclear abnormalities across different conditions compared to control cells.

      We agree with the reviewer and followed his/her suggestion. We established collaboration with Dr. Sandra Cabrera, who kindly shared with us Atg4b-/- mice from which we isolated MEFs to compare side by side with WT MEFs the appearance of nuclear abnormalities. We confirmed a statistical significant reduction in the formation of nuclear buds in both conditions: silencing the expression of Atg7 by siRNA and in Atg4b-/- MEFs, suggesting that the autophagic machinery contributes to buds formation (new Figure 2F-G). Interestingly, we observed a different result analyzing micronuclei. While we found no statistical significant difference in the percentage of cells with micronuclei silencing the expression of Atg7 by siRNA, we found a statistical significant increment of cells with micronuclei in Atg4b-/- MEFs (new Figure 2F-G). This apparently discrepant result suggests that nuclear buds and micronuclei have a different mechanistic origin. A difference in the biogenesis of buds and micronuclei has been previously suggested studying cells cultured under strong stress conditions that induce DNA amplification, as well as in cells under folic acid deficiency. While interstitial DNA without telomere was more prevalent in buds than in micronuclei, telomeric DNA was more frequently observed in micronuclei (Fennech et al. 2011, Mutagenesis 26:125-132).

      Lines 223-228: The role of autophagic machinery in the formation of nuclear buds is not supported and furthermore hard to conceptualize. How the components of autophagy are implicated during the nuclear buds and micronuclei formation? Colocalization of autophagic proteins might mean that autophagy is engaged at some point after or during the above formation. The causal, mechanistic and temporal aspects of the above budding and nucleophagic events need experimental support and/or more accurate interpretation.

      We agree with the reviewer, and now we expressed our interpretation with more caution. The role of autophagic machinery in the formation of nuclear buds is supported by the following findings: a) the localization of LC3 and BECN1 in nuclear buds; b) the inhibition of Atg7 expression by specific siRNAs reduced the number of cells with buds and c) Atg4b-/- MEFs had reduced number of cells with buds (new Figure 2G). How the components of autophagic machinery are implicated in nuclear buds formation is an interesting question and deserves further investigation, beyond the scope of the present manuscript.

      The authors claim that nucleophagy eliminates topoisomerase cleavage complex because TOP2A and TOP2B appear to more extensively co-localize with GFP-LC3 and BECN1 after etoposide-induced DSBs. However, the quantification presented in Fig. 3D-F to support this statement does not, in general, show a statistically significant difference in fibroblasts across different conditions (normal, etoposide treatment, etoposide removal).

      Autophagic elimination of TOP2 protein is supported by the following findings: 1) both BECN1 and LC3 were detected in micronuclei in acidic vesicles (labeled with Lysotracker), which is indicative of the autolysosomal nature of the cytoplasmic compartment containing TOP2 (Figure 2A); 2) TOP2B was found by electron microscopy in some cells exiting the nucleus surrounded by LC3 (Figure 3G); 3) TOP2B accumulated in cells lacking ATG4, as expected if it is degraded by autophagy (Figure 3H).

      Why would BECLIN colocalise with TOP2B in Figure 3g, given that beclin is involved in the initiation process?

      We think that BECN1 is involved in additional functions to the initiation process of bud formation. For example, it has been shown by others that BECN interacts with TOP2 (Dev Cell. 2012 May 15; 22(5): 1001–1016. doi: 10.1016/j.devcel.2011.12.027). It could be working as an autophagic receptor targeting TOP2cc to buds and micronuclei. We are aware that further studies are necessary to test this hypothesis, but they are beyond the scope of this manuscript.

      Fig. 4A and B: There is no enrichment of GFP-LC3 in "the nuclear alterations containing Fibrillarin" as stated in lines 341-343 comparing to the rest of the cellular GFP fluorescence.

      It is true that there is not a local enrichment of GFP-LC3 as those normally reported as LC3 puncta in response to autophagy induction by starvation, for example. Nevertheless we are confident of the specificity of the observation, as not every nuclear alteration was found having GFP-LC3. We detected GFP-LC3 in 72% (mean ± 3.61 SD) of the nuclear alterations containing Fibrillarin in untreated cells, in 65.7% (mean ± 1.97 SD) of cells with 2h of DNA damage and in 90.33% (mean ±6.36 SD) after 5 h of DNA repair (in 5 independent experiments).

      Moreover, there is no statistical significance in Fig. 4C and D measurements limiting the safety of authors' conclusions in lines 341-346.

      We agree with reviewer´s observation. We repeated these experiments two more times and did not find a statistical significant difference in the percentage of cells with nuclear lesions containing Fibrillarin and GFP-LC3 after DNA damage nor after DNA repair. These results suggest that nucleolar DDR is a particular response, independent of DDR elsewhere in the genome, as has been suggested (reviewed in Nucleic Acids Research, 2020, Vol. 48, No. 17 9449–9461; doi: 10.1093/nar/gkaa713). An alternative is that the release of nucleolar components is not enhanced by Etoposide at the dose and time used in this work.

      Lines 368-370: As discussed by the authors and reported in previous publication (Xu et al., 2017), "BECN1 interacts directly with TOP2B, which leads to the activation of DNA repair proteins, and the formation of NR and DNA-PK repair complexes", independent of its role in autophagy. Currently, there are no rigorous findings supporting the contribution of BECN1 (as a functional constituent of the core autophagic machinery) to nuclear damaged material extrusion (lines 382-384).

      We agree with the reviewer in that we did not perform an assay to demonstrate that BECN1 is contributing to TOP2 nuclear extrusion as a functional constituent of the core autophagic machinery. Nevertheless, the following data support the proposal of an autophagic elimination of TOP2cc: 1) TOP2B was detected in micronuclei containing BECN1 (Figure 3B); 2) BECN1 was found in micronuclei containing LC3 and in an acidic vesicle (labeled with Lysotracker), indicative of the autolysosomal nature of the compartment (Figure 2A); 3) TOP2 was found in some cells exiting the nucleus surrounded by LC3 (Figure 3G); d) TOP2 accumulated in cells lacking ATG4, suggesting its autophagic degradation (Figure 3H).

      Lines 435-441 and Fig. 5: The current findings do not support the proposed model. It is hard to support and conceptualize the statement "proteasome and nucelophagy function in a dynamic way inside the nucleus".

      The reviewer is right. We made a mistake integrating an interpretation within the summary of the actual findings of this work. We correct the text in the current version.

      In Fig. 5, LC3 appears to decorate inner nuclear membrane and probably to interact with some of the other proteins depicted, which is misleading.

      We agree with the reviewer. We removed the scheme in the current manuscript.

      Beclin-1 appears to interact with Fibrillarin (Nucleolus).

      This is correct. We observed by immunofluorescence a co-localization of BECN1 with Fibrillarin (new Figure E), and demonstrated by co-immunoprecipitation that they are constituents of a complex (new Figure F).

      Most of the differences in Sup. Fig. 3 lack statistical significance compromising the authors' claims.

      We agree with the reviewer. To perform a separated statistical analysis of the percentage of cells with nuclear buds or micrnonuclei did not provide further information. We eliminated this analysis in the current version.

      Many conclusions are drawn by colocalisation-immunofluorescence analysis. Co-immunoprecipitation experiments should also be performed to show that TOP2B and fibrillarin interact with LC3/autophagic machinery.

      Thank you for your suggestion. We performed immunoprecipitation analysis and confirmed an interaction of Fibrillarin with BECN1, this result is now presented in Figure 4F. We found no co-immunoprecipitation of LC3 with either Fibrillarin or TOP2A, nor of TOP2B with BECN1.

      Additionally, colocalisation analysis should be performed using tools such as Pearson's correlation and is an initial indication of nucleophagy. In the case of fibrillarin, immunofluorescence images do not indicate colocalisation, they need to be repeated.

      The transport of Fibrillarin out of the nucleus by micronuclei formation and its autophagic degradation implies that both proteins are contained in the same vesicular compartment, it does not necessarily requires a direct interaction of Fibrillarin with LC3. Therefore, a co-localization detected by Pearson´s analysis is not a necessary confirmation of the nucelophagic degradation of Fibrillarin. Actually, Fibrillarin does not seem to interact with LC3, since we could not detect both proteins by co-immunoprecipitation. Nevertheless, we observed a nucleolar localization of BECN1 overlapping with Fibrillarin (new Figure 4E), and we confirm by co-immunoprecipitation the presence of both BECN1 and Fibrillarin in a complex (new Figure 4F). Following reviewer´s advice, we repeated two more times the analysis of Fibrillarin immunolocalization. We corroborated its localization in micronuclei and nuclear buds in 5.86% (mean ± 5.03 SD) of untreated cells, indicating a basal level of nucleolar material exclusion from the nucleus. Interestingly, the percentage of cells with Fibrillarin in nuclear alterations did not increased with statistical significance with Etoposide treatment. At 2 h of DNA damage we observed only a slight increase to 6.8% (mean ± 4.03 SD) of cells having nuclear buds and micronuclei with Fibrillarin, while the number of cells with nuclear lesions increased to 30.6% (mean ± 4.2 SD). Similarly, the proportion of cells having Fibrillarin in nuclear lesions after 5 h of DNA repair increased only to 7.66 % (mean ±6.08 SD), while the total number of cells having nuclear buds and micronuclei increased to 38.42% (mean ± 9.3SD). These results suggest that nucleolar components are constantly sent out of the nucleus as a homeostatic process, and not significantly in response to Etoposide-induced DSB.

      Measurement of LC3/fibrillarin positive puncta should be performed, under basal conditions, genotoxic, and nucleolar stress under control and Atg7 knockdown conditions.

      Since we observed no statistical significant change in the number of micronuclei with Fibrillarin under Etoposide-induced DSB nor DNA repair, we did not perform the suggested experiment.

      Moreover, if nuclear proteins described are substrates of autophagy, then their levels would decrease upon autophagic induction i.e. starvation or in this case DNA damage and nucleolar stress. Thus, western blot analysis of relative protein levels can be performed.

      Thank you for the suggestion. Since only 5% of the cells have micronuclei with Fibrillarin, and this proportion did not increased significantly in response to DNA damage, it is unlikely to detect a difference in the amount of Fibrillarin in response to autophagy manipulation performing a population analysis (as it is in a Western blot). Nevertheless, we compared Fibrillarin abundance by Western blot in WT MEFs vs. Atg4-/- MEFs untreated (U), treated for 2 h with Etoposide (D) and after 5 h of DNA repair (5) shown in the top panel of the follow figure. As expected, we found no statistical significant difference determined by 2way-ANOVA followed by Sidak´s multiple comparisons test (n=3). Ajusted P values are shown for each comparison (left graph).

      On the other hand, since the percentage of cells with TOP2B in micronuclei and nuclear buds increased in response to DNA damage and during DNA repair, it was possible to detect a statistical significant accumulation of TOP2B in cells lacking ATG4 after 5h of DNA repair (bottom panel and right graph in the figure above). This observation is now included in new Figure 3H. Supporting our finding, TOP2A is reduced in cancerous cells grown under glucose deprivation (Alchanati, I., et al. 2009. PLoS One. 4:e8104).

      Endogenous LC3 nuclear buds should also be detected to verify nucleophagy as GFP-LC3 has been shown to aggregate, causing artifacts under certain conditions.

      We agree with the reviewer. We detected endogenous LC3 by immunofluorescence. This result is now included in Figure 2D.

      Minor comments

      In the Discussion section, the paragraph focused on the role of the ubiquitin-proteasome system is not substantiated by the data presented in the manuscript. Along similar lines, formation of aggresomes following etoposide treatment and their subsequent removal has not been monitored.

      We apologized for the confusion, we corrected the text to now clearly distinguish which are our findings and which are published data that we just attempt to relate.

      Western blots of better quality should be provided with assigned markers of protein size.

      The Western blots shown have markers of protein size.

      There are several language errors in the text that need to be corrected. Several sentences are too long and confusing or must be re-phrased. For example, see the lines: 123-125, 209-210,212, 218,221-222.

      We apologize for our language errors. We corrected all errors indicated and asked colleges proficient in English to review our text.

      Fig. 1B. Place "μm" into parenthesis.

      Sup. Fig. 1B: Replace "gH2AX" with "γH2AX".

      Fig. 1D: Separate DAPI and γH2AX channel images would be informative.

      We now show also separated channels.

      Fig. 2E: Enlarged separate DAPI, GFP-LC3 and lamin A/C channel images would be informative.

      We now show also separated channels.

      Line 218: Replace "bus" with "buds".

      Fig. 2B, 2E, 2F, 3A and probably Sup. Fig. 2B represent MEFs treated for 2h with etoposide. The pattern of GFP-LC3 in 2B looks extensively nuclear and almost absent from cytoplasm.

      We confirmed our finding detecting endogenous LC3.

      In addition, Fig. 2B and 3B represent MEFs treated for 2h with Etoposide. The pattern of endogenous BECN1 in Fig. 2B looks extensively nuclear and almost absent from cytoplasm. In Fig. 3B the pattern is notably different.

      BECN1 pattern of distribution is rather similar, predominantly in the nucleolus. We demonstrate it further by detecting BECN1 overlapping localization with Fibrillarin (new Figure 4E) and co-immunoprecipitation (new Figure 4F).

      Sup. Fig. 2C: Index box is not properly aligned.

      Thank you. We reviewed the alignment of each index box and reorganized the figure in the revised manuscript to add the whole blots of the new experiments we performed to analyze MEFs Atg4-/-.

      Lines 154, 343 and 837: Replace "DBS" with "DSB".

      Thank you, we corrected these typos.

      Fig. 4 panels are not clearly cited at the text.

      We apologize, we reviewed that they are clearly cited now.

      Line 220: siRNA

      Thank you, we corrected the text.

      Lines 373-374: References "Lenain et al., 2015" and "Li et al., 2019" are missing.

      Thank you for noticing it, we added the missing references. We use EndNote X9, we did not expect it to fail.

      Lines 400-401 and 407: Probably the second "Latonen, 2011" reference needs "et al".

      It is correct. We now cite this paper properly.

      Line 427: Do authors refer to Fig. 1E rather than Fig. 2B?

      Yes, we are sorry for this mistake. Thank you for pointing it out.

      Line 434: Correct "clearance" spelling.

      Thank you, we corrected it.

      Reviewer #3 (Significance (Required)):

      The authors suggest that nucleophagy contributes to the elimination of chromosomal fragments or nucleolar bodies exiting the nucleus under DNA damage -inducing conditions. Specifically, they propose a key role for nucleophagy in maintaining genome stability by eliminating Type II DNA Topoisomerase cleavage complex (TOP2cc) and nucleolar components such as fibrillarin.

      However, neither TOP2 nor Fibrillarin have been shown to be actual autophagic substrates. Also, the link between genomic stability, micronuclei formation and autophagy has been previously reported (Zhao et al., PMID: 33752561).

      We found nuclear buds and micronuclei with markers of different stages of the autophagic pathway, suggesting an active role of autophagy proteins in buds formation, and micronuclei removal. We detected TOP2 and Fibrillarin in micronuclei and propose their elimination by nucleophagy by the following findings: 1) both BECN1 and LC3 were detected in micronuclei in acidic vesicles (labeled with Lysotracker), which is indicative of autolysosomes (Figure 2A); 2) TOP2B was found by electron microscopy in some cells exiting the nucleus surrounded by LC3 (Figure 3G); 3) TOP2B accumulated in cells lacking ATG4, as expected if it is degraded by autophagy (Figure 3H); 4) BECN1 has a dynamic cytoplasmic-nucelar traffic in response to DNA damage; 5) BECN1co-localized with Fibrillaron in nucleolus and both proteins were co-immunoprecupitated.

      The link between genomic stability, micronuclei formation and autophagy has been previously reported only in cancerous cells. Considering that physiological DNA damage occurs constantly in the cell, basal nucleophagy is potentially fundamental to maintain cells healthy.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      In this manuscript, Muciño-Hernández and colleagues suggest that basal formation of nuclear buds and micronuclei increases in primary mouse embryonic fibroblasts following etoposide-induced double strand breaks (DSBs). The study combines the use of biochemical methodologies with confocal and super resolution microscopy in an effort to explore the contribution of nucleophagy to genome stability. The authors provide evidence that autophagy is induced upon etoposide treatment. They detected GFP-LC3 and BECN1 signals in nuclear buds and micronuclei even in untreated control and to a higher extent in etoposide-treated cells. Then, the authors examined whether nucleophagy is required for the removal of nuclear buds and micronuclei, by treating fibroblasts with control and Atg7 siRNA. The authors claim that the percentage of cells with micronuclei or nuclear buds decrease upon Atg7 knockdown, suggesting that components of the autophagy machinery induce the formation of these nuclear abnormalities. Moreover, Type II DNA Topoisomerases (TOP2A and TOP2B) and the ribosomal protein fibrillarin were detected in nuclear buds and micronuclei in fibroblasts treated or not with etoposide. Again in this case, GFP-LC3 was detected in fibrillarin-containing nuclear alterations. Based on these observations, the authors suggest that nucleophagy contributes to the elimination of chromosomal fragments or nucleolar bodies exiting the nucleus under DNA damage -inducing conditions. Specifically, they propose a key role for nucleophagy in maintaining genome stability by eliminating Type II DNA Topoisomerase cleavage complex (TOP2cc) and nucleolar components such as fibrillarin.

      While it seems that there is a relationship between nuclear-extruded TOP2 with endogenous BECN1 and GFP-LC3 suggesting autophagic engagement, inconsistencies of fluorescent images between different figures indicate possible technical problems/limitations (please see specific comments, below), compromising authors' claims. LC3 immunoblotting and GFP-LC3 localization results appear over-interpreted (comments below). Neither TOP2 nor Fibrillarin have been shown to be actual autophagic substrates. Also, the link between genomic stability, micronuclei formation and autophagy has been previously reported (Zhao et al., PMID: 33752561).

      An additional major concern is relates to nucleophagy being a selective type of autophagy. As such it requires efficient recognition and sequestration of the nuclear material destined to be degraded. Cargo specificity is mediated by receptor proteins, but no evidence for such receptors is provided in this study. Moreover, there is no real mechanistic insight on how nucleophagy mediates genome stability and how this can be interpreted in terms of cell survival under physiological and stress conditions. In other words, the biological significance of the findings presented has not been addressed.

      Specific comments are summarized below:

      The authors suggest that autophagy is induced after etoposide treatment and during the DNA repair process. However, the Western blot presented in Fig. 2A is not convincing and quantification does not support a significant autophagy induction in any of these cases. Autophagy appears to be induced 1h after etoposide removal, as evidenced LC3II/LC3 I increase (Fig. 2A and S2A). Nevertheless, all these changes should be more rigorously assessed.

      Line 190 and Fig. 2A: It is totally unclear whether "autophagy activation" takes place during the two waves described. There is no LC3B-I to LC3B-II conversion to initially suggest "autophagy activation". It rather suggests that autophagy is stalled. Fig. 2F shows that GFP-LC3 is strongly fluorescent into the lysotracker-stained lysosomes, further pointing to possible functional or technical problems.

      Fig. 2B and Sup. Fig. 2B: BECN1 staining looks problematic. There is extreme BECN1 accumulation in the nucleus. Are those nuclear patterns of endogenous BECN1 and GFP-LC3 normal (see also minor comment 6 and 7)? Is there literature supporting such a distribution? It is hard to imagine how BECL1 is implicated in a (here hypothetical) nuclear lamina degradation event driven by LC3-lamin B1 direct interaction (Dou et al., 2015). BECL1 is an upstream to LC3 component and is a subunit of the PI3K complex catalyzing the local PI3P generation. The above should cause recruitment of the downstream autophagic machinery. Other subunits of the same complex or downstream effectors should be identified at the same spots to support authors' claims. U, 2h D and 5h R images of whole cells are necessary. The authors should also provide representative images of cells under different conditions i.e. control, etoposide-treatment and during DNA repair. Along similar lines, untreated control cells are not included in Fig. 2E and F. These images are needed for a better comparison between normal and DNA damage-inducing conditions.

      The authors state that autophagy is required for nuclear buds and micronuclei formation. However, the data shown in Fig. 2G and H are hardly convincing given that the statistical difference between cells treated with control and Atg7 siRNA is not strong (for example, *p˂0.5, 5h after etoposide removal). To provide further support to this notion, they should use cells from autophagy defective mutants and examine the appearance of nuclear abnormalities across different conditions compared to control cells.

      Lines 223-228: The role of autophagic machinery in the formation of nuclear buds is not supported and furthermore hard to conceptualize. How the components of autophagy are implicated during the nuclear buds and micronuclei formation? Colocalization of autophagic proteins might mean that autophagy is engaged at some point after or during the above formation. The causal, mechanistic and temporal aspects of the above budding and nucleophagic events need experimental support and/or more accurate interpretation.

      The authors claim that nucleophagy eliminates topoisomerase cleavage complex because TOP2A and TOP2B appear to more extensively co-localize with GFP-LC3 and BECN1 after etoposide-induced DSBs. However, the quantification presented in Fig. 3D-F to support this statement does not, in general, show a statistically significant difference in fibroblasts across different conditions (normal, etoposide treatment, etoposide removal). Why would BECLIN colocalise with TOP2B in Figure 3g, given that beclin is involved in the initiation process?

      Fig. 4A and B: There is no enrichment of GFP-LC3 in "the nuclear alterations containing Fibrillarin" as stated in lines 341-343 comparing to the rest of the cellular GFP fluorescence. Moreover, there is no statistical significance in Fig. 4C and D measurements limiting the safety of authors' conclusions in lines 341-346.

      Lines 368-370: As discussed by the authors and reported in previous publication (Xu et al., 2017), "BECN1 interacts directly with TOP2B, which leads to the activation of DNA repair proteins, and the formation of NR and DNA-PK repair complexes", independent of its role in autophagy. Currently, there are no rigorous findings supporting the contribution of BECN1 (as a functional constituent of the core autophagic machinery) to nuclear damaged material extrusion (lines 382-384).

      Lines 435-441 and Fig. 5: The current findings do not support the proposed model. It is hard to support and conceptualize the statement "proteasome and nucelophagy function in a dynamic way inside the nucleus". In Fig. 5, LC3 appears to decorate inner nuclear membrane and probably to interact with some of the other proteins depicted, which is misleading. Beclin-1 appears to interact with Fibrillarin (Nucleolus).

      Most of the differences in Sup. Fig. 3 lack statistical significance compromising the authors' claims.

      Many conclusions are drawn by colocalisation-immunofluorescence analysis. Co-immunoprecipitation experiments should also be performed to show that TOP2B and fibrillarin interact with LC3/autophagic machinery. Additionally, colocalisation analysis should be performed using tools such as Pearson's correlation and is an initial indication of nucleophagy. In the case of fibrillarin, immunofluorescence images do not indicate colocalisation, they need to be repeated. Measurement of LC3/fibrillarin positive puncta should be performed, under basal conditions, genotoxic, and nucleolar stress under control and Atg7 knockdown conditions. Moreover, if nuclear proteins described are substrates of autophagy, then their levels would decrease upon autophagic induction i.e. starvation or in this case DNA damage and nucleolar stress. Thus, western blot analysis of relative protein levels can be performed.

      Endogenous LC3 nuclear buds should also be detected to verify nucleophagy as GFP-LC3 has been shown to aggregate, causing artifacts under certain conditions.

      Minor comments

      In the Discussion section, the paragraph focused on the role of the ubiquitin-proteasome system is not substantiated by the data presented in the manuscript. Along similar lines, formation of aggresomes following etoposide treatment and their subsequent removal has not been monitored.

      Western blots of better quality should be provided with assigned markers of protein size.

      There are several language errors in the text that need to be corrected. Several sentences are too long and confusing or must be re-phrased. For example, see the lines: 123-125, 209-210,212, 218,221-222.

      Fig. 1B. Place "μm" into parenthesis.

      Sup. Fig. 1B: Replace "gH2AX" with "γH2AX".

      Fig. 1D: Separate DAPI and γH2AX channel images would be informative.

      Fig. 2E: Enlarged separate DAPI, GFP-LC3 and lamin A/C channel images would be informative.

      Line 218: Replace "bus" with "buds".

      Fig. 2B, 2E, 2F, 3A and probably Sup. Fig. 2B represent MEFs treated for 2h with etoposide. The pattern of GFP-LC3 in 2B looks extensively nuclear and almost absent from cytoplasm.

      In addition, Fig. 2B and 3B represent MEFs treated for 2h with Etoposide. The pattern of endogenous BECN1 in Fig. 2B looks extensively nuclear and almost absent from cytoplasm. In Fig. 3B the pattern is notably different.

      Sup. Fig. 2C: Index box is not properly aligned.

      Lines 154, 343 and 837: Replace "DBS" with "DSB".

      Fig. 4 panels are not clearly cited at the text.

      Line 220: siRNA

      Lines 373-374: References "Lenain et al., 2015" and "Li et al., 2019" are missing.

      Lines 400-401 and 407: Probably the second "Latonen, 2011" reference needs "et al".

      Line 427: Do authors refer to Fig. 1E rather than Fig. 2B?

      Line 434: Correct "clearance" spelling.

      Significance

      The authors suggest that nucleophagy contributes to the elimination of chromosomal fragments or nucleolar bodies exiting the nucleus under DNA damage -inducing conditions. Specifically, they propose a key role for nucleophagy in maintaining genome stability by eliminating Type II DNA Topoisomerase cleavage complex (TOP2cc) and nucleolar components such as fibrillarin.

      However, neither TOP2 nor Fibrillarin have been shown to be actual autophagic substrates. Also, the link between genomic stability, micronuclei formation and autophagy has been previously reported (Zhao et al., PMID: 33752561).

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      Peer review of the manuscript with the number RC-2021-01181 by Muciño-Hernandez G et. al. at Review Commons and with the tittle "Nucleophagy contributes to genome stability 1 though TOP2cc and nucleolar components degradation"

      1. Summary

      Muciño-Hernandez G et. al. show in this manuscript that mouse embryonic fibroblasts (MEFs) have basal levels of nuclear buds and micronuclei, which are indicators of genomic DNA damage. These basal levels of nuclear buds and micronuclei in MEFs increased after Etoposide treatment, which is known to induce DNA Double stranded Breaks (DSD). Interestingly, the nuclear buds and micronuclei co-localize with makers for nucleophagy (BECN1 and LC3) and acidic vesicles, suggesting that they are cleared by nucleophagy. The authors propose that basal levels of nucleophagy clear basal levels of genomic DNA damage that occurs as result from DNA-dependent biological processes in the cell nucleus, thereby contributing to nuclear stability of MEFs under physiological conditions. These basal levels of nucleophagy increase after the action of factors that induce DNA damage and nuclear stress. The concepts proposed by Muciño-Hernandez G et. al. are novel, since most of the current published data on nucleophagy related to DNA damage have been obtained under pathological conditions, e.g. implementing cancer cells.

      The authors use in their manuscript various molecular biology techniques to obtain data that support their claims, including Western Blot analysis of protein extracts from MEFs, immunostaining on MEFs and neutral comet assays, complemented with state of the art imaging techniques, such as confocal microscopy, immunoelectron microscopy and super resolution microscopy. The quality of the data is sound. The structure of the manuscript support the understanding of the reader. However, I would like to suggest several improvements that will help to increase the quality of the manuscript, in order that fits to the standards of articles recently published in journals affiliated to Review Commons, such as the Journal of Cell Biology, the EMBO Journal or eLife.

      2. Major comments

      2.1 The authors have to improve the description of the results. Especially the description of those Figure panels containing plots that were generated using data from several experiments has to be improved.

      One example is the description of the Figure 1D, which is in the lanes 137-151 of the current version of the manuscript. Whereas the authors describe in lanes 137-147 observations related to representative pictures of confocal microscopy after immunostaining presented in Figure 1D (left), the description of the quantification from 9 independent experiments presented in the plots in Figure 1D (right) comes relatively short in lanes 147-150 without mentioning any of the values implemented for creating the plots.

      "Interestingly, while the frequency of nuclear buds gradually increased after DNA damage and during DNA repair, the frequency of micronuclei also increased after DNA damage, but diminished upon DNA repair."

      The other plots presented in the different figure panels across the manuscript are described in a similar manner. I would like to suggest to the authors to improve their manuscript by including during the description of their results the values that were implemented for the degeneration of the plots presented in the manuscript. For example, in the specific case of Figure 1D above:

      "Interestingly, the percentage of MEFs with nuclear buds gradually increased from XY% ({plus minus} XY SD) in control non-treated (Ctrl) MEFs to XY% ({plus minus} XY SD; P=XY) after 2 h Etoposide-induced DSB in MEFs and XY% ({plus minus} XY SD; P=XY) after DNA repair take place in MEFSs 5 h upon stop of Etoposide treatment (Figure 1D, right). In contrast, the percentage of MEFs with micronuclei significantly increased from XY% ({plus minus} XY SD) in Ctrl MEFs to XY% ({plus minus} XY SD; P=XY) after 2 h Etoposide-induced DSB, whereas it was reduced to XY% ({plus minus} XY SD; P=XY) 5 h after stop of Etoposide treatment (Figure 1D, right)."

      Descriptions of the plots as mentioned above will make the text more intuitive for the reader, and they will make possible to read the Results Section without switching to the Figure Legends or the Material and Methods Section or to Supplementary Files. Even though the representative pictures from different microscopy techniques presented in the manuscript are of good quality and support the claims of the authors, it is important to mention that the quantifications presented in the plots demonstrate the statistical significance of these representative pictures. Thus, the authors should consistently include in the manuscript during the description of theirs results all the information (mean values, standard error of the means, P values, n values, etc.) that support their interpretation of the results and demonstrate the statistical significance of their claims.

      2.2 Following a similar line of argumentation as in the previous point, the authors should provide as Supplementary Material an Excel file containing a statistical summary, including all statistical relevant information from each one of the plots presented in each Figure panel, such as n values, P values, Test implemented, values used for the plots, numbers of experiments, etc. The information could be organized in the Excel file in different data sheets according to the Figure panels, in order that the reader can easily navigate through the data. In the current version of the manuscript, one cannot find the values used for the generation of the plots presented in the manuscript in any of the submitted files.

      3. Minor comments

      3.1 In general, prior studies were appropriately referenced. Only few references has to be added.

      Line 48: Add to the already included reference "Dobersch et al., 2021" also the reference Singh et al., 2015 PMID 26045162.

      Line 53: Add the corresponding reference after the word "respectively".

      Line 82: Add the corresponding reference after the word "them".

      Line 125: Add the corresponding reference after the word "cells".

      Line 130: The expression "...by analyzing the recruitment of the phosphorylated histone γH2AX..." is the first time that the authors mention in the manuscript the DNA damage maker γH2AX. I suggest that is better introduced as " ... by analyzing the recruitment of the DNA damage marker γH2AX (histone variant H2A.X phosphorylated a serine 139, Rogakou EP, et al., 1998, PMID 9488723) to DSB sites."

      Line 199: Add the corresponding reference after the word "formation".

      Line 205: Add the corresponding reference after the word "cells".

      3.2 The use of the English language is appropriate throughout the manuscript. However, there are minor errors in the use of punctuation marks, in the use of prepositions and typos. I will list some of them below. However, I would like to recommend that manuscript is corrected by an English native speaker.

      Line 41: "...and reproductive systems; genome instability also..." the semicolon can be replaced by a period.

      Line 43: "Since early in development DNA is under constant endogenous..." between "development" and "DNA" there should a comma.

      The sentence in lanes 53-55 has to be rephrased.

      Lines 62-63: the expression "...throughout life." should be substituted.

      Line 70: The abbreviation "rDNA" has to be explained the first time that is used.

      Lines 81-82: It has to be explained for the scientist that is not specialized in the field of nucleophagy, how the integrity of the genome is threatened by micronuclei and nuclei-derived material.

      Lines 106-110: The sentence is long. It would be easier to understand for the reader if this sentence is divided into two sentences.

      Lines 121-122: The subtitle should be rephrased.

      Lines 132-138: The sentence is long. It would be easier to understand for the reader if this sentence is divided into two sentences, e.g. with a period before the word "hence".

      Lines 143-144: "... in a subpopulation of healthy, untreated cells...". The interpretation of "healthy" might be subjective. I would like to suggest substituting in the complete manuscript the word "healthy" by "control".

      Line 163: The abbreviation for γH2AX was already introduced in line 130.

      Line 182: A comma after "cell lines" is missed.

      Line 183: delete "either".

      Lines 190-194: The sentence is long. It would be easier to understand for the reader if this sentence is divided into two sentences, e.g. with a period after the word "decreased" in line 191.

      Line 218: I assume that instead of "bus", it should be "buds".

      Line 220: I assume that instead of "iRNA", it should be "siRNA". In addition, it is the first time that the abbreviation is used. Thus, I suggest introducing it as "...was silenced by specific small interfering RNA (siRNA) previous to ..."

      Line 327: delete the word "chronic".

      Line 344: I assume that instead of "(figures 4C)", it should be "(Figure 4D)".

      3.3 The structure of the Figures is ok for the peer review process and it might be optimized during editing of the manuscript. Nevertheless, I would like to suggest to the authors to increase the lettering size throughout all the figures. It will make the figures more intuitive.

      Significance

      4. Significance

      The work presented by Muciño-Hernandez G et. al. will be clearly a significant contribution to the scientific community working on autophagy, DNA damage repair and cancer, among others. It will be of interest to a broad spectrum of scientists, as I will elaborate in the following lines. The authors propose that MEFs have basal levels of genomic DNA damage under physiological conditions, which are cleared by basal levels of nucleophagy. On one hand, these findings are in line with various publications demonstrating that DNA-dependent biological processes in the cell nucleus, such as transcription, replication, recombination, and repair, involve intermediates with DNA breaks that may compromise the integrity of DNA. Thus, there must be mechanisms that ensure the integrity of the genome during these processes under physiological conditions, one of them seems to be nucleophagy. This perspective might explain the fact that proteins and histone modifications that were initially characterized during DNA repair also play a role during transcription, recombination, and replication. For example, phosphorylated H2AX at S139 (γH2AX) is often used as a marker for DNA-DSB [PMID 9488723]. However, accumulating evidences suggest additional functions of this histone modification [PMIDs 19377486; 22628289; 23382544]. In addition, McManus et al. [PMID 16030261] analyzed the dynamics of γH2AX in normal growing mammalian cells and found γH2AX in all phases of cell cycle with a maximum during M phase, suggesting that γH2AX may contribute to the fidelity of the mitotic process, even in the absence of ectopic- induced DNA damage. Further, Singh et al [PMID 26045162] and Dobersch et al [PMID 33594057] report that γH2AX plays a role in transcriptional activation in response to TGFB-signaling. Moreover, classical DNA-repair complexes have been linked to DNA demethylation and transcriptional activation [PMIDs 17268471; 28512237; 25901318], and DNA-DSB is known to induce ectopic transcription that is essential for repair, supporting a tight mechanistic correlation between transcription, DNA damage, and repair [PMID 24207023]. Perhaps, the authors might consider introducing several of the aspects and the citations written above into the Discussion section of the revised version of their manuscript. On the other hand, most of the published data related to nucleophagy have been obtained from cancer cells. Muciño-Hernandez G et. al. obtained their data implementing MEFs to demonstrate that the proposed mechanisms take also place under non-pathological conditions, what is one of the novel aspects of the present work.

      I hope that my suggestions help the authors to improve their manuscript, thereby reaching the standards of manuscripts recently published in journals affiliated to Review Commons AND increasing the impact of their contribution to the scientific community.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      This paper examines the formation and repair of micronuclei in non-cancerous cells, specifically in mouse embryonic fibroblasts. This work was performed completely in culture and used a combination of western blot, confocal and superresolution microscopy to assess the contents of micronuclei over a repair period of 5 hours after 2 hours of induction of double strand breaks by treatment with etoposide. The authors found that the bodies colocalised with LC3, Beclin 1 and lysosomes suggestive of autophagy. However no evidence of autophagic flux has been demonstrated.

      Major issues are as follows:

      Figure 2 A - Any sense of the autophagic flux? LC3B - I and LC3B - II seem to be in equal quantities most of the time. Maybe using the tandem LC3 in this system could provide further insight. Also remove the violin plots from this graph and from G and H, as there are too few data points. B. Can you reduce the brightness in the merge image, as I cannot see DAPI nor a convincing Beclin-1/LC3 co-localisation. F. Although the data is convincing, It would be clearer if the brightness of the merge image was reduced. G. Is the significant result the difference between 5h R Control si and 5h R Atg7? if so, there is no significant change in micronuclei as the same time point, can you explain this disconnect? are the buds being degraded prior to becoming micronuclei?

      Figure 3 A - nice microscopy showing the co-localisation of TOP2A and LC3-GFP. I'm interested in DAPI being on some bodies and not others. Do you have any sense of the dynamics of this? G - c shows a strand of mostly TOP2B coming from the nucleus. Is there any evidence that this occurs using either confocal microscopy or super resolution approaches. Could you try Z-stack to find these?

      Figure 4 C - is there a significant increase in FBL negative bodies, this would make sense if FBN is being degraded in the micronuclei during the repair process D. Would it be possible to increase the n of these experiments to confirm either no change in FBL/LC3 co-loc, or evidence of increase?

      Minor issues:

      Figure 4 and 5 legends are in a different font.

      Significance

      There is little specific data on the role of autophagy in clearing micronuclei in cancer cells, so this may be suggestive of a new mechanism that occur during normal cellular homeostasis. There are known links between lamin A defects and the formation of micronuclei, but not explicitly that the micronuclei are also Lamin A positive. it is likely that analogous processes occur in both cancer and non-cancer, so the impact of these data is not clear to me. This paper may be of interest to researchers interested in nuclear structure and DNA damage, but based on the data presented the significance is limited.

      I don't have sufficient expertise to evaluate the super resolution microscopy beyond assessing the images.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      The authors do not wish to provide a response at this time.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      In this manuscript, Joshi et al investigate the intracellular behavior of PGRP-LE for the activation of the NF-kB pathway in Drosophila enterocytes undergoing pathogen infection. The authors identify that, upon enteric infection, PGRP-LE aggregates to form a microscopic structure of puncta, which colocalize with Rab5. The authors further analyze the role of Rab5 for the NF-kB pathway and suggest that Rab5-dependent pathway represents one of two distinct routes for the activation of the NF-kB pathway based on the observation that RNAi-mediated knockdown of Rab5 selectively downregulates PGRP-SC1, which results in systemic immune response. Generally, the manuscript provides convincing experimental results to support the authors' arguments raising an interesting cell biological aspect of PGRP-LE for the well-known immune pathway. However, in my opinion, there are some ambiguous points as well. I would like to have several suggestions to strengthen the manuscript.

      Major comments

      1. To identify the role of Rab5, the authors performed an RNAi-mediated knockdown experiment and found that the expression of PGRP-SC1 is downregulated but the expression of other target genes such as AttacinD are not affected. The authors concluded that the expression of PGRP-SC1 is under the control of a Rab5-dependent route while other targets are regulated by Rab5-independent route. However, an alternative interpretation would be that Rab5 is required for all target genes and the observed differential expression of the targets is due to residual activity of Rab5 after RNAi-mediated knockdown. If the authors show that RNAi-mediated Rab5 knockdown almost deplete Rab5 expression, it would be helpful for the authors' argument. Also, this alternative explanation is worth to be provided in the discussion section.
      2. The authors show that enterocytes with Rab5 knockdown still produce enlarged puncta without any further characterization. However, the identity of this subcellular structure would be an important piece of information to support the authors' argument concerned with a Rab5-independent route, which is largely a speculation at the moment. So, I would recommend to investigate whether the enlarged puncta colocalize with any known endosome and/or autophagosome markers. This information will enable to understand the Rab5-independent NF-kB activation pathway (e.g. by manipulating this pathway) in enterocytes.

      Minor comments

      It would be helpful for general readers to have an additional figure with a simple drawing of the authors' working model.

      Significance

      This paper showed for the first time a Rab5-dependent PGRP-LE aggregation that act as a signaling hub to finely modulate NF-kB pathway. As NF-kappaB is an evolutionarily conserved transcription factor that is essential for the immune activation from Drosophila to mammals, the present information would be of interest to a broad audience.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      Summary:

      The manuscript presented by Joshi et al presents a body of results describing the aggregation of the peptidoglycan receptor PGRP-LE, which is an intracellular protein, in response to intestinal infection by oral ingestion in Drosophila. This study is based on the generation of two CRISPR/Cas9 mutant lines in which the PGRP-LE sequence has been fused to the V5 epitope (inserted into the PGRP domain) or the fluorescent protein eGFP (added at the C-terminal position). In each case, the "sensor protein" is expressed under the control of the endogenous promoter that ensures a physiological expression of the sensor.

      As expected from the literature, the authors show that the expression of each of the two PGRP-LE sensors is strongly induced in the digestive tract by the ingestion of the bacterium Erwinia carotorova carotorova (E.cc), which is known to produce a strong activation of the NF-kB signaling cascade under these infection conditions. In this study, the authors show that PGRP-LE-V5 sensors form clusters in the immunocompetent domains of the gut, particularly in the R4 domain where NF-kB activation is known to be primarily dependent on PGRP-LE. This clustering is not observed in clones with little or no expression of PGRP-LE due to RNAi-mediated knockdown of gene expression. The transcription of endogenous PGRP-LE or that of the PGRP-LE-V5 and eGFP sensors is not increased by the infection, allowing the authors to propose that the PGRP-LE protein pre-existing in the intestinal cells relocalizes into clusters or aggregates. These aggregates are also marked by the Rab5 protein, a marker of early endosomes, but not by the Rab7 marker, a marker of late endosomes. The expression of the antimicrobial peptide AttD is similar in the presence of the sensors as in control flies, which indicates that the immune response is not drastically affected by these sensors. Moreover, the kinetics of receptor aggregation parallels that of NF-kB pathway activation followed by AttD expression.

      Ingestion of E. coli or commensal bacteria or PGN, which do not induce a significant immune response according to the literature and data reproduced here by the authors, do not induce receptor aggregation either. Surprinsingly, heat-killed E.cc bacteria, which induce no or a very slight expression of AttD cause more but smaller aggregates of PGRP-LE. Moreover, these aggregates are not labeled by the Rab5 protein. The authors show that this aggregation of PGRP-LE is not affected by the down-regulation of the HH pathway, and is correctly induced by a uracil auxotrophic Ecc mutant. The expression of RNAi directed against the dFADD protein, an adaptor of the PGRP-LC membrane receptor contributing to the activation of the Imd/NF-kB pathway, does not alter this aggregation either. Finally, the authors observed that a set of genes whose expression in response to E.cc is dependent on PGRP-LE shows a differential dependence on Rab5 expression: while PGRP-SC1 expression is affected by Rab5 silencing, this is not the case for PGRP-LB or PGRP-SC2 expression. Furthermore, directed Rab5 knock-down in the adult gut induces an exacerbated immune response in the fat body. The combined action of PGRP-LE and Rab5 would therefore be necessary for the activation of PGRP-SC1 but not of PGRP-LB or PGRP-SC2. From these results the authors propose the existence of two pathways of activation of NF-kB target genes downstream of PGRP-LE, depending or not on an endosomal Rab5 signaling platform. The authors also propose that the amount of PGN may control the choice of Rab5-dependent or Rab5-independent pathway activation.

      Major comments:

      The authors have constructed beautiful genetic tools (PGRP-LE sensors). They present a set of convincing results concerning the formation of PGRP-LE protein aggregates in response to E.cc infection under different infection conditions or genetic backgrounds. Nevertheless, the study remains essentially descriptive and based on immunofluorescence and expression studies of a small set of genes responsive to the NF-kB pathway. To better support the hypotheses and conclusions, deep sequencing studies would be very powerful to reveal whether the differential expression observed for the target genes PGRP-SC1 versus PGRP-SC2 and PGRP-LB is also true for a large set of genes of the immune response, which would make the results more accurate. It would also be interesting to study more genetic conditions, e.g. affecting the endocytic pathway, proteasomal degradation or autophagy in order to determine the fate of aggregates and the mechanisms of their removal/resolution. Furthermore, biochemical studies, such as immunoblots, would allow following the fate of PGRP-LE at the protein level. The authors indeed show that the expression of PGRP-LE gene is not induced by E.cc but one can wonder if the protein is stabilized. They propose that PGRP-LE is not recycled because it does not colocalize with Rab7, but it might be also degraded by the lysosomal pathway rather than recycled. It would be interesting to test if aggregates are removed by the lysosomal pathway or by autophagy. Moreover, a recycling via Rab7 is maybe not expected for a protein that is not localized on the plasma membrane. A kinetic study including co-staining with Rab7 would better support the conclusion that there is no colocalization with Rab7. Otherwise, they may miss the right timing to observe this colocalization. Similarly, the absence of colocalization with Lamp1 at a given time does not allow concluding with certainty that PGRP-LE is not degraded by the lysosomal pathway. The 24h staining (Fig2A) sounds similar to a Lamp1 profile. One should therefore be more cautious in drawing conclusions about these co-staining experiments. Moreover, Rab7 and Lamp-1 staining are faint and miss RNAi controls to show the specificity of the staining.

      In conclusion, a corpus of additional experiments would be necessary to significantly advance the field and demonstrates the existence of a Rab5 signalization platform causing differential expression of target genes of the immune response. The expression of a large set of genes could be tested, some of the RNAi lines used needs to be better characterized, complementary genetic and biochemistry experiments would help to understand the fate of PGRP-LE, the effect of the Imd pathway could be more documented with other RNAi than FADD... The role of other components of the endocytic pathway tan Rab5 could be assayed with other RNAi (Rab7, ESCRT, ... ) to block the endocytic pathway and observe if it interferes with the aggregates. The authors could also possibly test the proposed hypothesis on the amount of PGN/bacteria that would be at the origin of a differential response.

      In the figure and figures legends and methods, the authors describe the aggregates as oligomers, but no experiment support this assumption. In the text, the authors stick with the nomenclature as clusters or aggregates which is more appropriate.

      Minor comments:

      • The abstract would benefit from being rewritten: the first half provides general information that is not strictly necessary, which prevents a more thorough description of the results. I disagree or misunderstand the statement "little is known about the subcellular events required to translate these early steps into downstream target gene transcription" because extensive studies of the fly immune response have been done.
      • Two spellings in the intro: PeptidoGlycaN or PeptidoGlycan. I suggest peptidoglycan
      • "the innate immune response that might otherwise be obscured by the action of the adaptive immune response": this is a rather archaic way of thinking because it is clear that the two responses are complex and intimately intertwined.
      • "to visualize PGN detection by PGRP": correct "by PGRP-LE". -avoid "to our surprise". -"locus-directed": I suggest "tissue directed" or "in a localized manner in the digestive tract".
      • Describe the purpose and procedure of smurf methodology.
      • As noted above, do not describe clusters as oligomers in the methods and figures and figure legends. -"PGRP-LE recruits Rab5 protein": do the authors suggest a direct interaction between the two products? If so, it would be interesting to test this with co-IP experiments. However, it is possible that the aggregates are internalized in the endosomal compartment, independently of any Rab5/PGRP-LC interaction. Therefore, the term "recruits" is confusing here. -To make the results accessible to a broader audience, the authors may clarify the drosophila-specific genetic tools used in this study (Flpout clones, Gal80ts conditional expression...)
      • In some cases, statistical analysis of RT-qPCR data are performed using a one-way ANOVA (fig 1H, 5A) whereas in others (fig 2H and L, 5B) a non-parametric Kruskal-Wallis test is used. The rationale for these discrepancies should be explained. Moreover, in all these experiments the data are compared to a control that is set to 100% and has no standard deviation. This violates some of the ANOVA assumptions (normality of the data points). To be correct, an outside control should be used to normalize the data (including the control to which the other genotypes are compared)
      • Could the authors better explain the rationale for using PGRP-LE::V5 in some experiments and PGRP-LE::GFP in others? -Fig 1H: in this experiment, according to the legend, all the genotypes are infected. So it's not clear how the authors conclude that infection does not activate PGRP-LE expression in the absence of a non-infected control. We may have missed some points. Furthermore, as stated above, the authors could also perform a Western blot to ensure that PGRP-LE translation is not activated, or the protein stabilized, following infection.
      • Fig 2A: The PGRP-LE aggregates a 24 hpi look different from the previous time points. It would be interesting to make a double staining with a Lamp1 antibody to check for colocalization at this late time points.
      • Fig 2H: attD induction by hk E.cc is indicated as not significantly different from uninfected control and presumably not from E. coli and PGN. So the statement "hk E.cc which induced a weak AttD transcription" in the text is not correct.
      • Fig 3: The RNAi lines used in this figure have no effect on PGRP-LE aggregation. To safely conclude that the corresponding proteins do not play a role in this process, the efficiency of the RNAi lines against their respective targets should be shown.
      • Fig 3A,B : why no quantification of the aggregates are presented in this particular figure?
      • Fig 4D: the pictures are too small, use the same magnification as in A and C

      Significance

      The studies presented in this manuscript are interesting and well done but remain mainly descriptive without sufficient data to support what could be a conceptual advance. Further work is needed to demonstrate that PGRP-LE would signal via two different pathways, dependent or not on Rab5 and the endocytic machinery. Further genetic and biochemical studies would allow to better describe these two putative signaling pathways leading to differential immune response genes expression, and/or the nature (oligomeric or not) and fate of PGRP-LE aggregates (endocytic-, lysosomal-, autophagic-patways,...). Such endosomal signaling platform has been described for the activation of the Toll pathway. Exacerbated immune response in the fat body following inactivation of Rab5, Fab1, and ESCRT components has been described earlier suggesting that accurate termination of IMD signaling also requires the endocytic machinery.

      This study concerns fly scientists interested in the fine understanding of the signaling mechanisms of the innate immune response and may have a wider audience in the community of scientists interested in the molecular mechanisms of cell signaling in eukaryotic cells in response to external stimuli, and the role of endocytic trafficking in this response. Our expertise (reviewer and co-reviewer) covers the NF-kB-dependent immune response and some aspects of intracellular trafficking.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      Summary:

      The authors used CRISPR engineering to drop a V5 or GFP tag into teh PGRP-LE locus (protein fusions) to monitor the behavior of this intracellular peptidoglycan sensing receptor in the drosophila midgut. They show that upon immune stimulation with Ecc that PGRP-LE forms some sort of aggregate or punctae that is dynamic during the 24 hour of infection monitored. A similar response is not seen with live E. coli but a week and smaller response is observed with heat killed E. coli, for unclear reasons. These punctae appear to form independent of the classic IMD signaling components, suggesting it is upstream event in the pathway which is consistent with early studies showing the PGRP-LE multimerizes (infinitely) upon binding PGN and also that it forms amyloid fibrils doing signaling. The Ecc punctae tightly colocalize with Rab5 but not Rab7 or other early endosome markers, but in the absence of Rab5 the PGRP-LE punctae are greatly enlarged. Rab5 was found to critical for induction of PGRP-SC1 but not the classic IMD pathway AMP, Attain.

      While the conclusions of the report are intriguing and the development of these tools is very exciting, the conclusions are not fully convincing. To start, the author wish to conclude that PGRP-LE localization is altered with Ecc infection but they have not excluded that the expression of the protein is sharply upregulated. I.e. in the uninfected animals there is not really any PGRP-LE observed (1D). The try to tackle this by looking at mRNA expression, but this data lacks the unaffected control. [In fact, the uninfected control is missing on most of the gene expression data, which is a troubling omission and makes it hard to really understand what the data shows.]. Moreover, the mRNA levels do not necessarily corresponding to the protein levels, i.e. there could be post translation control. So, overall, the authors need to provide more compelling evidence that PGRP-LE is relocalized upon Ecc challenge rather than upregulated.

      Moreover, the paper contains some seeming contradictory findings that the authors make little effort explain. For example, they conclude "These results suggest that although smaller PGRP-LE aggregates can form normally in the absence of Rab5, the latter is required for proper bigger E.cc mediated PGRP-LE aggregates" because E. coli induced PGRP-LE clusters don't colocalize with Rab5, yet in the absence of Rab5, the Ecc cluster are super-enlarged (4F). This makes no sense with the conclusions.

      Finally, the interaction and function of the Rab5 interaction is underdeveloped and lacks insight. For example, why is Rab5 required for the induction of one target gene but not another? And, why not characterize this more completely? Why is there not Rab5 vesicle with E. coli feeding or even uninfected? The cell biology requires more in-depth consideration. From 4E, the authors wish to conclude that the Rab5 vesicle are induced by Ecc (even in the absence of PGRP-LE) yet the uninfected control is not shown. IN a simple world, would not one would expect Rab5 endosomes in all cells, at least to some level?

      And, focusing on the big picture, the authors claim that it is "not easily testible" if the PGRP-LE aggregates are amyloidal, as suggested by earlier publications. This could actually be tested by staining with amyloid specific dies and/or suitable mutants engineered int he RHIM domain. This would be very informative if the authors could extend this work to examine this question.

      Minor comments:

      All the colocalization data should be quantified as in 4B. It is not true that DAP = Gram negative. Gram-positive bacilli also have DAP PGN. The wording in the Introduction should be adjusted. The text needs a careful proofreading.

      Referees cross-commenting

      I think the comments from #2 and myself are aligned. Working is interesting, tools are especially exciting, but the studies are descriptive and under-developed. I will further add, I found the absence of uninfected controls for many assays a major problem.

      Significance

      The significance of this work lies in the development of powerful tools to track an intracellular innate immune receptor in an intact animals. The connection to Rab5 is curious and likely an important advance in our understanding of the cell biology of this pathway, but is under-developed. The significance is this difficult to know for certain. The Drosophila immunity field, and the insect immunity field more broadly, will be keenly interested in this study. The wider NF-κB/innate immune field will also be interested in these findings, given teh similarity between this pathway and NOD1/NOD2 immune sensing in mammals.

      My area of expertise is the Drosophila immune response and this manuscript is very much in my wheelhouse.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      Avar et al report on the development of a high-throughput method to screen modifiers of prion replication in cell lines using a genome-wide siRNA library. They identified a number of hits and further studied one candidate, the ribonucleoprotein Hnrnpk. The authors convincingly show the interest of their method. However, the claims that the ribonucleoprotein Hnrnpk impact prion propagation need to be more quantitatively and statistically substantiated.

      1. * A large part of the manuscript is dedicated to the validation of the high-throughput assay (called QUIPPER). QUIPPER is made in 384-plates and provides great technological improvement. It works with different prion-permissive cell lines and different prion strains. QUIPPER is an antibody-FRET-based assay that detects a specific population of PrPSc that resists phospholipase C (PIPLC) treatment. Historically, PIPLC has been shown to cleave cell surface PrPC while preserving PrPSc (which is endocytic or inaccessible). I would recommend that the authors quantify the proportion of PIPLC-resistant PrPSc (PrPPIPLC) versus total PrPSc in their different models. First, PrPPIPLC proportion may be cell and strain dependent. Second and most importantly, as siRNA effects are studied using PrPPIPLC as readout, it is crucial to know if this form is a bona fide surrogate of PrPSc and infectivity or only a specific, subcellular, potentially minor form of PrPSc. This is particularly important as the effects of Hnrnpk knock-down in QUIPPER and western blot sounds discordant; in QUIPPER, the effects are strong (> 5-fold) while by western blot, the effects are much more modest (We addressed this issue in several ways; firstly, we quantified the proportion of PIPLC-resistant PrP (PrPPLC) versus PrPSc in two different models (Fig. 1B and D). Secondly, we directly compared residual infectivity of cells treated with PK or PIPLC (Figure 1C), using the standard scrapie cell assay. The results show that infectivity is retained upon PIPLC treatment. In addition, we assessed the 161 hits obtained via QUIPPER using PrPSc as a readout (Fig. 3B).

      To provide further data on the robustness of our PIPLC-based readout, we have performed western blotting of infected and uninfected cells upon PIPLC treatment and assessed the band patterns following PIPLC administration. This Figure is now incorporated in the manuscript as Supp. Fig. 1C and demonstrates that upon PIPLC digestion of NBH and RML infected CAD5 and GT-1/7 cells, PrP is barely detectable in the non-infected cells, while it is in the prion infected ones. The blots also show that the PIPLC-resistant PrP (PrPPLC) is resistant to PK digestion. These new data, together with those provided in Fig. 1B and Figure 1C, show that PrPPLC is equivalent to PrPSc in terms of PK resistance and infectivity.

      The reviewer pointed out a discordance between Western Blotting and QUIPPER. Although it is not clearly stated, we think the reviewer may be suggesting a discordance based on Fig. 3D. We would like to point out that Fig. 3D does not report fold changes as the reviewer is suggesting, but Z-scores, measured by standard deviations from the mean, not allowing to infer fold-changes. We quantified the effect of NT and HNRNPK targeting siRNAs on prion levels (Fig. 4A) and saw a three-fold change. We believe that the quantifications provided in the new version of the manuscript alleviate the concerns regarding any discordance.

      Technically, this is quite easy as it necessitates, after PIPLC treatment, the quantification of PrPSc in the supernatant versus PrPSc in the cell pellet. In Fig. 1C, the authors show that PrPPIPLC is infectious in a cell-scrapie assay. Using this approach, they could also quantify the infectivity of these species relative to the total infectivity content.

      We addressed this in Supplementary Fig. 1C as depicted above. Supplementary Fig. 1C shows the alikeness of the PrP species measured via the QUIPPER vs. the canonical PK digestion: upon digestion with PIPLC following a PK treatment, we detect PrPSc. Therefore, the experiment demonstrates that PrPPLC is alike in nature to PrPSc. The difference between the PK digested (lanes 3&4) vs PIPLC treated then PK digested lanes (lanes 7&8) is the PrPSc that is released into the media following PIPLC digestion.

      • *

      • The authors identified a list of prion modifiers candidate. Surprisingly, the authors did not perform a pathways analysis to identify potential pathways that could impact prion propagation.*

      Despite extensive efforts, there were no pathways that were enriched in our 40 hits, which is mentioned in the discussion part of the manuscript. Two analyses (for the 161 candidates and 40 hits) are now added to Supplementary Fig. 3C and pasted below.

      • *

      • The authors then studied in more details one hit, the ribonucleoprotein Hnrnpk. They studied the impact of Hnrnpk knock-down on PrPC and PrPres levels in different cell lines. These data (Fig 4 and Fig S4) lack quantitative (on a higher number of wells) and statistical analyses. The western blot that are shown suggest that PrPC levels are slightly increased by the siRNA and that the increase in PrPres levels is modest, barely significant given the western blot method. Same comment after PSA treatment, at least in PG127-infected hovS cells.*

      We performed a quantification on the western blots for all figures mentioned by the reviewers throughout the manuscript. These are incorporated to the manuscript for the figures: Fig. 4A, Fig. 4B, Supplementary Fig. 4A, Supplementary Fig. 4C, Supplementary Fig. 4D, Supplementary Fig. 4F, Supplementary Fig. 4G.

      Additionally, statistical analyses have been incorporated into the manuscript in these figures: Fig. 4C, Fig. 4D, Fig. 4E, Fig, 4F, Fig, 4G, Fig, 4H, Supplementary Fig. 4F. The analyses and the quantitative data demonstrate the effect of Hnrnpk downregulation and PSA treatment on prion levels to be significant. Moreover, we also addressed the regulation of prions via HNRNPK using vacuoles as a read-out as well as with a different mode of regulating HNRNPK expression using shRNAs. All these results, point to HNRNPK as a true modulator of PrPSc.

      In Figure 4A and B, the use of POM1 and/or POM2 to detect PrPC / PrPres is confusing. POM2 is supposed to detect mostly full-length PrPC (Fig 4A top panel), but more than 3 glycoforms are detected. In Fig 4B, POM1 is used for PrPC but because it has a central epitope, it detects both PrPC and PrPSc.

      Both antibodies are able to recognize both PrPC and PrPSc as it has been shown in many publications from the Aguzzi lab as well as other labs in the field. https://pubmed.ncbi.nlm.nih.gov/19060956/

      Note also in Fig 4B, that DMSO alone seems to impact PrPC levels in PG127-infected hovS cells. This advocates again for a more quantitative analysis.

      We have quantified the western blots using the DMSO control as standard value. As DMSO was used to dilute PSA, this should take into account potential effects coming from DMSO (Fig. 4D, Fig. 4F, Fig. 4H and Supplementary Fig. 4F).

      • Psammaplysene A (PSA) is a pharmacological Hnrnpk binder. The authors used this molecule to further demonstrate that Hnrnpk is involved in prion propagation. I disagree with the author's conclusion that "PSA effect does seem to be limited when HNRNPK shRNAs are applied". In Fig S4D, 1µM PSA seems do decrease PrPres levels at similar levels whether the shRNA is applied or not. Again quantification and statistical analyses from several independent experiments would help supporting the authors conclusions.*

      We assessed this point carefully by quantification of the western blots (Fig. 4H) and providing statistical data (Student’s t-test) from three experiments. As we see a threefold lower decrease of prions with and without Hnrnpk regulation when PSA is present, we concluded that the effect we see from PSA should be arising through Hnrnpk. However, we cannot conclusively delineate the effect of PSA, because Hnrnpk ablation is not possible due to essentiality of Hnnrpk. This has now been added to the discussion portion of our manuscript.

      • The authors finally tested PSA on organotypic brain slices (in that case, they provide statistical results) and on flies infected with ovine PG137 prions. PSA administration significantly reduced the locomotor deficits prion-infected flies. The authors quantified the effects of PSA on prion accumulation in flies. Because the overall levels were not detectable by immunoblot, they used a cell-free assay termed RT-QuIC to address prion seeding activity in fly heads. I have specific comments about these experiments:
      • Maybe I missed it, but I could not find which recombinant PrP is used in RT-QuIC assay.*

      This information is provided in the M&M section of the manuscript at hand. The relevant section on P25 reads, where HaPrP23-231 refers to hamster PrP:

      The reaction buffer of the RT-QuIC consisted of 1 mM EDTA (Life Technologies), 10 μM thioflavin T, 170 mM NaCl, and 1× PBS (incl. 130 mM NaCl) and HaPrP23-231 filtered using 100-kD centrifugal filters (Pall Nanosep OD100C34) at a concentration of 0.1 mg/ml.

      In addition, we added this information to the main text as well.

      - This is important as recombinant PrP self-polymerize after a period of time and here the authors have left the RT-QuIC assay running for unusually long period of times (RT-QuIC are stopped after 24h-48h).

      For prions, long RT-QuIC experiments are often performed (also see: https://pubmed.ncbi.nlm.nih.gov/32598380/, https://journals.asm.org/doi/10.1128/mBio.02451-14, https://www.nature.com/articles/s41598-021-84527-9, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3458796/ and others).

      In addition, this is controlled for in all experiments performed in the lab, as the prion-negative sample containing the same RT-QuIC substrate does not become positive after the entire duration of the assay (Fig. 5D).

      - Instead of titrating prion seeding activity by endpoint titration, the authors quantified PSA activity by measuring the effect on another parameter of the RT-QuIC, the length of the lag phase before the conversion reaction is visible. While this is an interesting criterion, reduction of seeding activity must be shown to unequivocally demonstrate that PSA has delayed prion pathogenesis in flies.

      Based on the data presented in the manuscript, we assessed prion pathogenesis in flies using a well-established climbing assay, demonstrating that treatment with PSA significantly improves locomotor behavior, which has been shown to be directly linked to prion levels and is known to have even greater sensitivity then the traditional mouse bioassay (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5998032/, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113635/, https://link.springer.com/article/10.1007/s00441-022-03586-0).. The RT-QuIC represented here represents itself as a secondary read-out to the climbing assay, for which Lag-time quantification is used routinely (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893511/, https://www.nature.com/articles/s41598-017-10922-w, https://journals.asm.org/doi/10.1128/mBio.02451-14, https://www.nature.com/articles/s41598-021-87295-8). Our results effectively highlight the overlap between the complementary read-outs.

      - Can the authors exclude any interfering effect of PSA on the RT-QuIC reaction, given the amount of material used to seed the reaction (1:20 diluted head homogenates)?

      We do not know how much PSA has reached the Drosophila brain, therefore, the experiment suggested by the reviewer cannot be tied to a 1:20 dilution. However, the concern of the reviewer is valid, and we therefore performed a spiking experiment of a prion positive sample using 1uM PSA (the highest amount used to treat cells, for which we saw a strong prion-reducing effect). We did not see an interference in the RT-QuIC signal due to PSA in the reaction. This has been incorporated into Figure 5D.

      • could the authors comment on the fact that HNRNPK knock-out is not possible and that their siRNA and shRNA are not affecting the cell viability?*

      To select hits during the screen process, we apply a viability filter, excluding siRNAs that reduce viability by more than 50% when compared to the non-targeting control siRNA (Supplementary Fig. 1F). For GT-1/7 cells we do not see any effect on viability of siRNA treatment after 96h. However, as downregulation of HNRNPK worsens the cytopathological vacuolation in the hovS model, as shown in Supp. Fig 4A, we do see an effect on cell fitness using both siRNA as well as shRNA. In addition, as knocking down HNRNPK will not lead to its complete loss, the remaining levels might be enough to sustain viability. Moreover, the longest knockdown experiment we performed is 7 days, we cannot exclude that longer exposure would have an impact on viability, but this question is not in the scope of the paper.

      • In the discussion the authors do not discuss how Hnrnpk could impact prion propagation. This may deserve a comment as this protein is present in the nucleus. As PrPC has been also identified in this compartment, can this specific form be involved in prion pathogenesis?*

      We additionally elaborated on potential ways of how Hnrnpk might impact prion propagation in the discussion, which includes potential nuclear PrPSc as well as with regards to our data obtained from the sequencing efforts shown in Fig. 4I. In addition, we investigated some functional targets of Hnrnpk how they are affected by PSA, which is now added to Supp. Fig 4G.

      Reviewer #1 (Significance (Required)):

      The QUIPPER method is a great conceptual and technological approach that could be applied to genome-wide analyses and screening for therapeutic molecules.

      * The study will interest a general audience interested in neurodegenerative diseases linked to protein misfolding. There are commonalities in pathways and modifiers of the conversion. Further PrP has emerged as a receptor for alpha-synuclein (Parkinson disease) and A-beta peptides (Alzheimer's disease).

      Expertise key words: prion diseases - prion pathogenesis in cell models*

      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      Prions are protein-based infectious agents that underlie neurodegenerative disease. For prion diseases (e.g., mad cow disease), the infectious agent is the cellular prion protein (PrPc). It exists in a normal conformation and carries out its normal cellular function. However, when it becomes misfolded and aggregates it can adopt an altered conformation, referred to as the prion conformation, or PrPSc. PrPSc aggregates can template the conversion of other PrPc molecules into the PrPSc form. In this way the prions can propagate from one cell to the next and throughout an organism. Prion diseases are truly devastating and identifying ways of stopping prion propagation is of great interest. In this manuscript by Aguzzi and colleagues, the authors designed a way to screen for prion propagation modifiers in mammalian cells. They built a highly sensitive readout of PrPSc propagation and adapted it to a 384-well plate format in adherent cells. They then used this to perform a genomewide siRNA screen, looking for genes that increased or decreased PrPSc propagation when knocked down.

      * They identified nearly 1,200 modulators of prion propagation and then subjected them to various validations and filtering to focus on only those hits that affected PrPSc but not PrPc (though hits that affect levels of PrPc could certainly be interesting). All this led to 40 genes (20 that increased and 20 that decreased prion propagation.*

      * Among these 40, the authors focused on one hit, hnRNPK, an essential RNA-binding protein with diverse cellular functions. They provide evidence that reducing levels of hnRNPK leads to increase prion levels.*

      * They next move to a marine compound called Psammaplysene A (PSA), which had previously been shown to have some neuroprotective properties and to be able to bind to hnRNPK. Because of the latter observation, the authors test if PSA can affect prion levels. They show that indeed treatment of their cell line prion infection model, or an organotypic slice model, or a fly model with PSA is sufficient to decrease prion levels.*

      * The authors propose that PSA works to reduce prion levels by increasing the activity of hnRNPK and that this also implies a role of RNA (because hnRNPK is an RNA-binding protein) in prion propagation. * In a nutshell, in my opinion the design and execution of this genomewide screen is ingenious and has yielded a treasure trove of potential prion modifiers. The ability to distinguish between modifiers of Prpc and PrpSc is super powerful. However, the follow-up and focus on hnRNPK and its connections (which seem tenuous) to the marine compound PSA are incomplete and raise more questions than answers. In its present form, it is hard to assess the potential significance of hnRNPK in prion propagation. I have some comments and suggestions for the authors to consider.

      * 1.To my eye, Fig. 4A looks like Hnrnpk siRNA leads to slightly increased levels of PrPc (detected with POM2 antibody) and this could explain the increase in PrPSc levels. Can the authors assess Prnp RNA levels and the effects of their siRNAs on Prnp expression? It would also be useful to provide quantification of immunoblots if possible.*

      We quantified the western blots as mentioned in our response to reviewer 1. The quantifications are now provided for figures: Fig. 4A and Supplementary Fig. 4A, showing that the increase in prion levels is much stronger than that of PrPC. These confirm the results from the screen as seen in Fig. 3D. In addition, we would again like to point out that the use of shRNAs to knockdown HNRNPK did not yield the increase in PrPC levels aforementioned, as evident by Supplementary Fig. 4D which demonstrates a decrease of PrPC, despite increasing PrPSc levels. Moreover, we show quantification of RNA levels upon downregulation of Hnrnpk and with PSA, which show that downregulation of Hnrnpk via siRNAs indeed increases Prnp mRNA levels and that PSA does not change RNA levels of neither Hnrnpk nor Prnp (Fig. 4C).

      • In Supplemental Fig. 4B it also looks like knocking down Hnrnpk results in decreased PrPc levels in this experiment and its not clear how robust the increase in PrPSc levels are. Quantification of these experiments, if possible, would be helpful.*

      Please see response above. We now provide quantification to all western blots.

      • The authors treat with PSA, which is supposed to bind to Hnrnpk. They state that this treatment does not affect PrPc levels but to my eye Supplemental Fig. 4C looks like highest doses of PSA cause a decrease in PrPc levels. Quantification of the immunoblots would also be useful here.*

      Please see response above. We now provide quantification to all western blots and added a sentence to the manuscript.

      • The authors use Hnrnpk knockdown along with PSA to test if the effects of PSA depend on Hnrnpk. They see PSA decreases PrPSc levels and that this is, to my eye, only slightly attenuated by Hnrnpk reduction. I interpret these results slightly different than the authors. To me, it seems that this result indicates that PSA's effects are (mostly) independent of Hnrnpk.*

      Addressed in point 4 from reviewer one.

      • In the original paper identifying PSA and hnRNPK physical interaction, RNA-binding was important. In the authors' assays, does Hnrnpk's effect on prions depend on RNA-binding? Specific mutations to the RNA-binding domains can be made to assess this.*

      This is a very interesting point. We did try to obtain data to support this claim, however, due to the essentiality as well as tight control of Hnrnpk expression, we were not able to express different forms of Hnrnpk and acquire conclusive data. Therefore, it is currently being pursued how Hnrnpk might affect prion propagation in the scope of another publication.

      • The genetic interaction in the vacuolation phenotype between Prnp and Hnrnpk that the authors report is very interesting (Supplemental Fig. 4A). It seems like this system and phenotype could be useful for the authors in exploring mechanisms by which HnrnpK is functioning.*

      • *

      We absolutely agree to the reviewer’s comment. As mentioned above a second publication is under way to investigate the mechanisms of Hnrnpk’s antiprion function, which is not in the scope of this study.

      • The authors propose that PSA increases activity of Hnrnpk but does it change any Hnrnpk RNA targets from their RNA sequencing? Some functional readout of Hnrnpk function would be useful here to test this hypothesis.*

      Although we do suspect RNA binding has an important role in the anti-prion function of Hnrnpk, we cannot exclude other modalities which Hnrnpk might be function through, such as DNA binding and protein-protein interactions. Therefore, to answer this question, a considerable effort that explores each of the potential of these modalities with regards to the anti-prion function of Hnrnpk would be needed. This extensive effort, however, is out of the scope of the manuscript at hand. However, we investigated the effect of PSA on some known functional targets of Hnrnpk (as suggested by the reviewer) from our sequencing efforts and added this analysis as Supplementary Fig. 4H to the manuscript. These results suggest that PSA leads to an increase of the expression of DNA targets of Hnrnpk, potentially suggesting a modality of action. Moreover, we amended the discussion with regards to potential pathways that might be yielding the effect seen as evidenced by the RNAseq data.

      • In the Introduction, the authors mention two yeast papers in introducing the concept of using unicellular model organisms to perform modifier screens. The first paper (Outeiro and Lindquist, 2003) is a classic but does not contain a yeast screen. The other one does include a loss of function screen in yeast (for polyQ toxicity modifiers) but those results seems to be due to loss of the [RNQ+] prion from certain deletion strains instead of from specific roles of modifier genes, so that paper might not be the best exemplar of yeast modifier screens.*

      We sincerely thank the reviewer for their careful readthrough of the manuscript, the portion that refers to the manuscripts as screens was amended and two new citations for appropriate yeast screens were added to the manuscript.

      • The authors asked if any of their hits from their screen had human genetics connections to neurodegeneration. They mention one of their hits Dock3 right after saying that no hit reached statistical significance after multiple testing corrections. This seems a bit misleading since any time one makes a list of anything there will always be, by definition, one at the top of the list.*

      We amended the wording to improve clarity of the manuscript.

      • The authors perform RNA sequencing on prion infected cells that either had Hnrnpk siRNA or PSA and since these two treatments had opposite effects they looked for genes that went in the corresponding directions. They didn't find anything significant when looking for genes downregulated by Hnrnpk siRNA and upregulated by PSA. They did find glucose metabolism genes when looking in the opposite direction. The significance of this finding is unclear and the authors do not expand on it.*

      Addressed in point 7 of reviewers 1 and 2, we expanded the discussion portion of the manuscript with regards to these results.

      • To me, the data with PSA seem more robust than the Hnrnpk data and it seems that the authors are trying to perhaps over-fit them together. It is possible that PSA affects prion levels independent of Hnrnpk function. This would not dampen my enthusiasm at all for this finding and could be of interest to those in the prion field, in which the search for anti-prion compounds is of great interest.*

      Upon statistical analysis of the result in Fig 4H, we see a three-fold decrease of PSA activity upon HNRNPK downregulation, suggesting PSA activity might be linked to HNRNPK. However, the reviewers point is well taken and we emphasized the value of understanding the function of PSA or mimicry of its effect as potential therapy in the future.

      ***Cross-commenting:**

      All three reviewers seem to appreciate the novelty and impact of the new QUIPPER method the authors have developed to discover modifiers of prion propagation. All three reviewers also seem to be somewhat less convinced by the connection to hnRNPK, including how the compound PSA's anti-prion effects involve hnRNPK (or not).*

      * In my opinion, this manuscript presents important and novel work and a really ingenious new method to study prion propagation, which will be broadly useful to the prion field. I feel that the hnRNPK data could be strengthened, especially with more quantitative analyses. The PSA treatment data are compelling but it seems that the effects might be independent of hnRNPK and that the authors are trying to force a connection which might not be there.*

      * Reviewer #2 (Significance (Required)):*

      * *** Define your field of expertise with a few keywords to help the authors contextualize your point of view. Indicate if there are any parts of the paper that you do not have sufficient expertise to evaluate. ****

      I have expertise in neurodegenerative disease, protein misfolding, yeast modifier screens, CRISPR modifier screens in human cells, and RNA-binding proteins. I have general knowledge about prions, including PrP, but I am not a prion expert.*

      Reviewer #3 (Evidence, reproducibility and clarity (Required)):

      The authors conducted an arrayed RNAi-based genome-wide high-throughput screening of all protein-coding modifier genes that affect prion propagation in cultured cells (murine and human cell lines) using a novel quantitative high throughput QUIPPER assay that they developed. They identified 1191 genes, of which 40 selectively affect PrPSc. Half of the 40 genes seem to inhibit PrPSc (limiter) whereas the other half do the opposite (stabilizers). One of the strong limiters is Hnrnpk, is an essential small heterogeneous nuclear ribonucleoprotein that has been implicated in a few protein misfolding diseases. The biological relevance of the findings is demonstrated by the detection of previously reported modifier genes as well as thorough verification of Hnrnpk as an effective prion limiter that seems to be independent of the two prion strains or host species (mouse and human cell lines as well as Drosophila).

      * The manuscript is very well written, the approach is novel, very well verified, and effective, the data are solid, and the main conclusions convincing.*

      * Two issues need to be discussed.*

      * Major comments:*

      * First, some genes encoding proteins involved in PrP processing, such as ADAM10 and ADAM8, are known to affect PrPC levels, but they are not among the modifier genes identified. Based on Table 2, ADAM8 expression is very low in the GT-1/7 cells. This points to one of the caveats of the RNAi screening approach in that potential roles of low expressing genes in the cell lines used could be missed. Although it is beyond the scope of this manuscript, it would be helpful to add discussions on complimentary screening enhancing gene expression and the use of more cell lines that will allow identification of more modifiers.*

      We thank the reviewer for their concern. The point regarding the screen being less sensitive for genes that are low-expressed in the cell line in question is valid. Upon advancing of the CRISPR-based technologies and the improvement of these technologies to be used in combination with prions, we see their value. We added a sentence to the discussion, talking about gene activation as a future alternative to perform a complimentary screen.

      Second, the statement that PSA's anti-prion effect potentially arises through enhancing the activity of HNRNPK makes sense, but it is also possible that PSA can directly inhibit prion replication as well. It would be helpful to calculate the percentage of reduction in PrPSc by PSA treatment and the percentages compared between shNT and shHNRNK cells.

      We thank the reviewer for the careful read through of the manuscript. The point was addressed for reviewer 1 point 4. In addition, if PSA is added to the RT-QuIC, it does not prevent aggregate formation, indicating that PSA is unlikely to directly inhibit prion replication, but rather depends on a cellular host-intrinsic molecule for its activity. However, we also elaborate more on the possibility of potential other mechanisms for Hnrnpk and PSA’s function on regulating prion levels in the discussion section of our manuscript.

      Minor comments:

      * First, Figure 1C shows that the relative intensity for RML CAD5 cell lysate infected cells is less than with PIPLC treated or PK treated, which seems to be the opposite of what is expected, because PIPLC or PK treatment should not increase infectivity. Please explain.*

      We agree with the reviewer that the results were surprising. For the practicality of the screen, we wanted to show that the treatment does not eliminate the infectious species, which we were able to demonstrate. However, the increase of infectivity could stem from many different factors, e.g. the amount of duration of PK treatment might not harm but instead rather expose the infectious species, or PIPLC might remove cell surface molecules that could prevent infection of cells. However, as there are a plethora of possible scenarios and it was not relevant for the study at hand, we did not go into further detail.

      Second, in Fig S1 e, the labels are too small to read. In Fig 3D, it would be easier to match the stabilizer or limiter genes with the corresponding Z score dots if the genes with a negative Z scores are labelled on the left side while genes with positive Z scores be labelled on the right side.

      We amended the figures as per the reviewer’s suggestion.

      Third, The following sentence on page 11 is confusing: "20 out of these 40 candidates reduce prion propagation upon silencing, and 20 candidates enhanced prion propagation, and henceforward are called stabilizers or limiters, respectively (Fig. 3D-E, Supplementary Table 1)." Did the author mean to say "....and 20 candidates enhanced prion propagation upon silencing, and hence..."?

      We reworded the sentence according to the reviewer’s comment.

      * Fourth, In the subheading "Hnrnpk expression limits of prion propagation in mouse and human cells", "of" should be deleted.*

      We addressed this in the main manuscript file.

      ***Cross-commenting:**

      I agree with Reviewer #2's assessment that more quantification will be helpful and the link between the effect of PSA treatment and hnRNPK can be strengthened. I want to stress that the knockdown data clearly shows the involvement of hnRNPK as a prion limiter in cultured cells. The question on PSA does affect the interpretation of the ex vivo and in vivo data.*

      * The blot in Fig. S4c seems to show some decrease in PrPC levels in NBH-treated GT-1/7 cells. This blot needs to be quantified to confirm whether the PrPC level is changed by PSA treatments. Whether PSA directly inhibits prion replication can be relatively easily assessed in RT-QuIC reactions. Alternative to the use of PSA, RNAi-mediated hnRNPK knockdown can also be done on cultured tissue slices or in brain, but this will require a lot more time and efforts and may be too much to ask for in this manuscript.*

      Quantifications for blots were added throughout the manuscript and the text was amended accordingly, and all the points mentioned have been addressed throughout this response letter.

      Reviewer #3 (Significance (Required)):

      * The findings are novel and very significant. They identified a large number of modifier genes, and established a solid foundation for future studies on prion modifier genes to study prion replication and pathogenesis and for novel therapies against prions and potentially some other protein misfolding diseases. HNRNPK seems to be good target for therapeutic intervention and PSA may be a good candidate for prion treatment. The novel QUIPPER assay can be used to screen for anti-prion compounds and potentially adapted to study other misfolding proteins associated with cells.*

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      The authors conducted an arrayed RNAi-based genome-wide high-throughput screening of all protein-coding modifier genes that affect prion propagation in cultured cells (murine and human cell lines) using a novel quantitative high throughput QUIPPER assay that they developed. They identified 1191 genes, of which 40 selectively affect PrPSc. Half of the 40 genes seem to inhibit PrPSc (limiter) whereas the other half do the opposite (stabilizers). One of the strong limiters is Hnrnpk, is an essential small heterogeneous nuclear ribonucleoprotein that has been implicated in a few protein misfolding diseases. The biological relevance of the findings is demonstrated by the detection of previously reported modifier genes as well as thorough verification of Hnrnpk as an effective prion limiter that seems to be independent of the two prion strains or host species (mouse and human cell lines as well as Drosophila).

      The manuscript is very well written, the approach is novel, very well verified, and effective, the data are solid, and the main conclusions convincing. Two issues need to be discussed.

      Major comments:

      First, some genes encoding proteins involved in PrP processing, such as ADAM10 and ADAM8, are known to affect PrPC levels, but they are not among the modifier genes identified. Based on Table 2, ADAM8 expression is very low in the GT-1/7 cells. This points to one of the caveats of the RNAi screening approach in that potential roles of low expressing genes in the cell lines used could be missed. Although it is beyond the scope of this manuscript, it would be helpful to add discussions on complimentary screening enhancing gene expression and the use of more cell lines that will allow identification of more modifiers.

      Second, the statement that PSA's anti-prion effect potentially arises through enhancing the activity of HNRNPK makes sense, but it is also possible that PSA can directly inhibit prion replication as well. It would be helpful to calculate the percentage of reduction in PrPSc by PSA treatment and the percentages compared between shNT and shHNRNK cells.

      Minor comments:

      First, Figure 1C shows that the relative intensity for RML CAD5 cell lysate infected cells is less than with PIPLC treated or PK treated, which seems to be the opposite of what is expected, because PIPLC or PK treatment should not increase infectivity. Please explain.

      Second, in Fig S1 e, the labels are too small to read. In Fig 3D, it would be easier to match the stabilizer or limiter genes with the corresponding Z score dots if the genes with a negative Z scores are labelled on the left side while genes with positive Z scores be labelled on the right side.

      Third, The following sentence on page 11 is confusing: "20 out of these 40 candidates reduce prion propagation upon silencing, and 20 candidates enhanced prion propagation, and henceforward are called stabilizers or limiters, respectively (Fig. 3D-E, Supplementary Table 1)." Did the author mean to say "....and 20 candidates enhanced prion propagation upon silencing, and hence..."?

      Fourth, In the subheading "Hnrnpk expression limits of prion propagation in mouse and human cells", "of" should be deleted.

      Cross-commenting:

      I agree with Reviewer #2's assessment that more quantification will be helpful and the link between the effect of PSA treatment and hnRNPK can be strengthened. I want to stress that the knockdown data clearly shows the involvement of hnRNPK as a prion limiter in cultured cells. The question on PSA does affect the interpretation of the ex vivo and in vivo data.

      The blot in Fig. S4c seems to show some decrease in PrPC levels in NBH-treated GT-1/7 cells. This blot needs to be quantified to confirm whether the PrPC level is changed by PSA treatments. Whether PSA directly inhibits prion replication can be relatively easily assessed in RT-QuIC reactions. Alternative to the use of PSA, RNAi-mediated hnRNPK knockdown can also be done on cultured tissue slices or in brain, but this will require a lot more time and efforts and may be too much to ask for in this manuscript.

      Significance

      The findings are novel and very significant. They identified a large number of modifier genes, and established a solid foundation for future studies on prion modifier genes to study prion replication and pathogenesis and for novel therapies against prions and potentially some other protein misfolding diseases. HNRNPK seems to be good target for therapeutic intervention and PSA may be a good candidate for prion treatment. The novel QUIPPER assay can be used to screen for anti-prion compounds and potentially adapted to study other misfolding proteins associated with cells.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      Prions are protein-based infectious agents that underlie neurodegenerative disease. For prion diseases (e.g., mad cow disease), the infectious agent is the cellular prion protein (PrPc). It exists in a normal conformation and carries out its normal cellular function. However, when it becomes misfolded and aggregates it can adopt an altered conformation, referred to as the prion conformation, or PrPSc. PrPSc aggregates can template the conversion of other PrPc molecules into the PrPSc form. In this way the prions can propagate from one cell to the next and throughout an organism. Prion diseases are truly devastating and identifying ways of stopping prion propagation is of great interest. In this manuscript by Aguzzi and colleagues, the authors designed a way to screen for prion propagation modifiers in mammalian cells. They built a highly sensitive readout of PrPSc propagation and adapted it to a 384-well plate format in adherent cells. They then used this to perform a genomewide siRNA screen, looking for genes that increased or decreased PrPSc propagation when knocked down.

      They identified nearly 1,200 modulators of prion propagation and then subjected them to various validations and filtering to focus on only those hits that affected PrPSc but not PrPc (though hits that affect levels of PrPc could certainly be interesting). All this led to 40 genes (20 that increased and 20 that decreased prion propagation.

      Among these 40, the authors focused on one hit, hnRNPK, an essential RNA-binding protein with diverse cellular functions. They provide evidence that reducing levels of hnRNPK leads to increase prion levels.

      They next move to a marine compound called Psammaplysene A (PSA), which had previously been shown to have some neuroprotective properties and to be able to bind to hnRNPK. Because of the latter observation, the authors test if PSA can affect prion levels. They show that indeed treatment of their cell line prion infection model, or an organotypic slice model, or a fly model with PSA is sufficient to decrease prion levels.

      The authors propose that PSA works to reduce prion levels by increasing the activity of hnRNPK and that this also implies a role of RNA (because hnRNPK is an RNA-binding protein) in prion propagation.

      In a nutshell, in my opinion the design and execution of this genomewide screen is ingenious and has yielded a treasure trove of potential prion modifiers. The ability to distinguish between modifiers of Prpc and PrpSc is super powerful. However, the follow-up and focus on hnRNPK and its connections (which seem tenuous) to the marine compound PSA are incomplete and raise more questions than answers. In its present form, it is hard to assess the potential significance of hnRNPK in prion propagation. I have some comments and suggestions for the authors to consider.

      1. To my eye, Fig. 4A looks like Hnrnpk siRNA leads to slightly increased levels of PrPc (detected with POM2 antibody) and this could explain the increase in PrPSc levels. Can the authors assess Prnp RNA levels and the effects of their siRNAs on Prnp expression? It would also be useful to provide quantification of immunoblots if possible.
      2. In Supplemental Fig. 4B it also looks like knocking down Hnrnpk results in decreased PrPc levels in this experiment and its not clear how robust the increase in PrPSc levels are. Quantification of these experiments, if possible, would be helpful.
      3. The authors treat with PSA, which is supposed to bind to Hnrnpk. They state that this treatment does not affect PrPc levels but to my eye Supplemental Fig. 4C looks like highest doses of PSA cause a decrease in PrPc levels. Quantification of the immunoblots would also be useful here.
      4. The authors use Hnrnpk knockdown along with PSA to test if the effects of PSA depend on Hnrnpk. They see PSA decreases PrPSc levels and that this is, to my eye, only slightly attenuated by Hnrnpk reduction. I interpret these results slightly different than the authors. To me, it seems that this result indicates that PSA's effects are (mostly) independent of Hnrnpk.
      5. In the original paper identifying PSA and hnRNPK physical interaction, RNA-binding was important. In the authors' assays, does Hnrnpk's effect on prions depend on RNA-binding? Specific mutations to the RNA-binding domains can be made to assess this.
      6. The genetic interaction in the vacuolation phenotype between Prnp and Hnrnpk that the authors report is very interesting (Supplemental Fig. 4A). It seems like this system and phenotype could be useful for the authors in exploring mechanisms by which HnrnpK is functioning.
      7. The authors propose that PSA increases activity of Hnrnpk but does it change any Hnrnpk RNA targets from their RNA sequencing? Some functional readout of Hnrnpk function would be useful here to test this hypothesis.
      8. In the Introduction, the authors mention two yeast papers in introducing the concept of using unicellular model organisms to perform modifier screens. The first paper (Outeiro and Lindquist, 2003) is a classic but does not contain a yeast screen. The other one does include a loss of function screen in yeast (for polyQ toxicity modifiers) but those results seems to be due to loss of the [RNQ+] prion from certain deletion strains instead of from specific roles of modifier genes, so that paper might not be the best exemplar of yeast modifier screens.
      9. The authors asked if any of their hits from their screen had human genetics connections to neurodegeneration. They mention one of their hits Dock3 right after saying that no hit reached statistical significance after multiple testing corrections. This seems a bit misleading since any time one makes a list of anything there will always be, by definition, one at the top of the list.
      10. The authors perform RNA sequencing on prion infected cells that either had Hnrnpk siRNA or PSA and since these two treatments had opposite effects they looked for genes that went in the corresponding directions. They didn't find anything significant when looking for genes downregulated by Hnrnpk siRNA and upregulated by PSA. They did find glucose metabolism genes when looking in the opposite direction. The significance of this finding is unclear and the authors do not expand on it.
      11. To me, the data with PSA seem more robust than the Hnrnpk data and it seems that the authors are trying to perhaps over-fit them together. It is possible that PSA affects prion levels independent of Hnrnpk function. This would not dampen my enthusiasm at all for this finding and could be of interest to those in the prion field, in which the search for anti-prion compounds is of great interest.

      Cross-commenting:

      All three reviewers seem to appreciate the novelty and impact of the new QUIPPER method the authors have developed to discover modifiers of prion propagation. All three reviewers also seem to be somewhat less convinced by the connection to hnRNPK, including how the compound PSA's anti-prion effects involve hnRNPK (or not).

      In my opinion, this manuscript presents important and novel work and a really ingenious new method to study prion propagation, which will be broadly useful to the prion field. I feel that the hnRNPK data could be strengthened, especially with more quantitative analyses. The PSA treatment data are compelling but it seems that the effects might be independent of hnRNPK and that the authors are trying to force a connection which might not be there.

      Significance

      Define your field of expertise with a few keywords to help the authors contextualize your point of view. Indicate if there are any parts of the paper that you do not have sufficient expertise to evaluate.

      I have expertise in neurodegenerative disease, protein misfolding, yeast modifier screens, CRISPR modifier screens in human cells, and RNA-binding proteins. I have general knowledge about prions, including PrP, but I am not a prion expert.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      Avar et al report on the development of a high-throughput method to screen modifiers of prion replication in cell lines using a genome-wide siRNA library. They identified a number of hits and further studied one candidate, the ribonucleoprotein Hnrnpk. The authors convincingly show the interest of their method. However, the claims that the ribonucleoprotein Hnrnpk impact prion propagation need to be more quantitatively and statistically substantiated.

      1. A large part of the manuscript is dedicated to the validation of the high-throughput assay (called QUIPPER). QUIPPER is made in 384-plates and provides great technological improvement. It works with different prion-permissive cell lines and different prion strains. QUIPPER is an antibody-FRET-based assay that detects a specific population of PrPSc that resists phospholipase C (PIPLC) treatment. Historically, PIPLC has been shown to cleave cell surface PrPC while preserving PrPSc (which is endocytic or inaccessible). I would recommend that the authors quantify the proportion of PIPLC-resistant PrPSc (PrPPIPLC) versus total PrPSc in their different models. First, PrPPIPLC proportion may be cell and strain dependent. Second and most importantly, as siRNA effects are studied using PrPPIPLC as readout, it is crucial to know if this form is a bona fide surrogate of PrPSc and infectivity or only a specific, subcellular, potentially minor form of PrPSc. This is particularly important as the effects of Hnrnpk knock-down in QUIPPER and western blot sounds discordant; in QUIPPER, the effects are strong (> 5-fold) while by western blot, the effects are much more modest (< 2-fold). Technically, this is quite easy as it necessitates, after PIPLC treatment, the quantification of PrPSc in the supernatant versus PrPSc in the cell pellet. In Fig. 1C, the authors show that PrPPIPLC is infectious in a cell-scrapie assay. Using this approach, they could also quantify the infectivity of these species relative to the total infectivity content.
      2. The authors identified a list of prion modifiers candidate. Surprisingly, the authors did not perform a pathways analysis to identify potential pathways that could impact prion propagation.
      3. The authors then studied in more details one hit, the ribonucleoprotein Hnrnpk. They studied the impact of Hnrnpk knock-down on PrPC and PrPres levels in different cell lines. These data (Fig 4 and Fig S4) lack quantitative (on a higher number of wells) and statistical analyses. The western blot that are shown suggest that PrPC levels are slightly increased by the siRNA and that the increase in PrPres levels is modest, barely significant given the western blot method. Same comment after PSA treatment, at least in PG127-infected hovS cells. In Figure 4A and B, the use of POM1 and/or POM2 to detect PrPC / PrPres is confusing. POM2 is supposed to detect mostly full-length PrPC (Fig 4A top panel), but more than 3 glycoforms are detected. In Fig 4B, POM1 is used for PrPC but because it has a central epitope, it detects both PrPC and PrPSc.

      Note also in Fig 4B, that DMSO alone seems to impact PrPC levels in PG127-infected hovS cells. This advocates again for a more quantitative analysis. 4. Psammaplysene A (PSA) is a pharmacological Hnrnpk binder. The authors used this molecule to further demonstrate that Hnrnpk is involved in prion propagation. I disagree with the author's conclusion that "PSA effect does seem to be limited when HNRNPK shRNAs are applied". In Fig S4D, 1µM PSA seems do decrease PrPres levels at similar levels whether the shRNA is applied or not. Again quantification and statistical analyses from several independent experiments would help supporting the authors conclusions. 5. The authors finally tested PSA on organotypic brain slices (in that case, they provide statistical results) and on flies infected with ovine PG137 prions. PSA administration significantly reduced the locomotor deficits prion-infected flies. The authors quantified the effects of PSA on prion accumulation in flies. Because the overall levels were not detectable by immunoblot, they used a cell-free assay termed RT-QuIC to address prion seeding activity in fly heads. I have specific comments about these experiments: - Maybe I missed it, but I could not find which recombinant PrP is used in RT-QuIC assay. - This is important as recombinant PrP self-polymerize after a period of time and here the authors have left the RT-QuIC assay running for unusually long period of times (RT-QuIC are stopped after 24h-48h). - Instead of titrating prion seeding activity by endpoint titration, the authors quantified PSA activity by measuring the effect on another parameter of the RT-QuIC, the length of the lag phase before the conversion reaction is visible. While this is an interesting criterion, reduction of seeding activity must be shown to unequivocally demonstrate that PSA has delayed prion pathogenesis in flies. - Can the authors exclude any interfering effect of PSA on the RT-QuIC reaction, given the amount of material used to seed the reaction (1:20 diluted head homogenates)? 6. could the authors comment on the fact that HNRNPK knock-out is not possible and that their siRNA and shRNA are not affecting the cell viability? 7. In the discussion the authors do not discuss how Hnrnpk could impact prion propagation. This may deserve a comment as this protein is present in the nucleus. As PrPC has been also identified in this compartment, can this specific form be involved in prion pathogenesis?

      Significance

      The QUIPPER method is a great conceptual and technological approach that could be applied to genome-wide analyses and screening for therapeutic molecules.

      The study will interest a general audience interested in neurodegenerative diseases linked to protein misfolding. There are commonalities in pathways and modifiers of the conversion. Further PrP has emerged as a receptor for alpha-synuclein (Parkinson disease) and A-beta peptides (Alzheimer's disease).

      Expertise key words: prion diseases - prion pathogenesis in cell models

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      All the Reviewer’s comments are reproduced below, with our responses interspersed in [[brackets]]. Citations from the revised manuscript are included in “quotation marks”. The website accepts input only as plain text. Consequently, we had to transform the mathematical expressions into plain text. We apologize for the reduced readability.

      Reviewer #1

      1) The authors state that: "the conductance density mediated by the expression of the mutant was 2.5 times smaller than the wild type, although we transfected the same amount of plasmid DNA (Fig. 2E). Assuming that protein expression is independent of the mutation, the observation suggested that the unitary proton flux ratio RC of wild type to mutant channel was equal to 2.5" (lines 82‐85).

      Macroscopic conductance (G) depends on channel number (N), microscopic or unitary conductance (γ), and open probability (PO) by G=N γ PO. The authors assume that the level of WT and D174A mutant protein expression on plasma membrane, which determines N, are equal; however, this critical assumption does not appear to have been tested.

      The fact that conductance density (nS/pF) is plotted in Fig. 2E does not alter this caveat because this procedure normalizes the data only for cell surface area (i.e., size). The authors' conclude that "The conductance density relationship (Fig. 2E) compares the maximal conduction of both constructs; this is the fully open channel (open probability ≈ 1)"(lines 87‐88). However, neither raw currents nor G‐V data are shown. Typically, currents measured at large, near‐saturating PO are used to compare the relative conductances of WT and mutant ion channels. The currents shown in Fig. 2A and 2B exhibit prominent 'droop' at even modest depolarizing potentials (+10 mV for D174A and +30 mV for WT), indicating that the proton gradient has been substantially perturbed by the flow of ge depolarizing voltages needed to drive channels to near‐maximal PO. Furthermore, there is no evidence that maximal PO itself is also not different in WT and D174A channels. Indeed, maximal PO for native Hv1 channels measured using variance analysis is reported by significantly smaller than 1.0, and assuming that PO = 1.0 for either WT or D174A is therefore not well supported. Maximal could be altered by the D174A mutation, which has a clear and strong effect on channel gating evidenced by the large (‐70 mV) negative shift in threshold potential reported both here and previously in the literature. Effects of mutations on maximal PO due to altered gating behavior could be separate and distinct from any change in plasma membrane channel number (N). 3 Lastly, because D174A channels have a much higher PO than WT at 0 mV, the mutant will necessarily conduct inward proton currents at the physiological resting membrane potential (RMP) in tsa‐201 cells (perhaps ‐30 mV?). Inwardly directed proton currents will therefore cause intracellular acidification under resting conditions.

      The constitutive acid load in cells expressing D174A, but not WT, is likely to have a variety of physiological consequences, including decreased protein expression or plasma membrane targeting of D174A. There is evidence that another constitutively open Hv1 mutant (R205H) also generates smaller currents macroscopic conductance than WT, and this phenomenon is likely to result from decreased cell surface expression. To conclude that the microscopic conductances of WT and D174A are unequal, the authors must demonstrate that N is not different. The authors' conclusion that D174A "conducts protons at a lower rate" (line 89) is therefore not well supported by the experimental data.

      [[

      We toned down our conclusions from the experiments to accommodate the reviewer's criticism: (page 4): " Consequently, the mutant channel is nearly fully open (Fig. 2D), readily seen when the membrane potential is 0 mV and external voltage is absent. The high open probability of the D174 mutant under symmetrical pH conditions is readily seen in the tail current amplitude reaching a quasi-saturation (Fig. 2A). The resulting outward currents have a higher amplitude in the wild-type (Fig. 2A+B). Interestingly, the conductance density mediated by the expression of the mutant was 2.5 times smaller than the wild type, although we transfected the same amount of plasmid DNA (Fig. 2E). Our observation suggests a reduced flux through the mutant if we assume that protein abundance in the plasma membrane is independent of the mutation."]]

      2) The authors indirectly measure apparent proton flux rates (λD) in LUVs containing WT and D174A mutant Hv1 channels using a fluorescence‐based approach, and conclude that λD is 2.4 times smaller for D174A than WT. However, the method for estimating λD is not performed under voltage clamp, and the driving force for proton current is neither known nor measured.

      [[

      The reviewer is mistaken. The method for estimating λD is performed under voltage clamp, and the driving force for proton current is known.

      Page 6: “To obtain λD, we encapsulated c_k^i=150 mM KCl in the HV1 containing large unilamellar vesicles (LUVs) and exposed these vesicles to a buffer with a K+ concentration c_k^o= 3 mM. The addition of valinomycin facilitated K+ efflux, thereby inducing a membrane potential, ψ. ψ constituted the driving force for H+ uptake. It can be calculated according to the Goldman equation:

      ψ = -RT/F ln ((c_k^i+(P_H/P_K ) c_H^i)/(c_k^o+(P_H/P_K ) c_H^o ))

      (1)

      The ratio of the HV1 mediated proton permeability P_H to the valinomycin-mediated potassium permeability P_K is always smaller than 0.04. We base our conclusion on the observation that the CCCP-mediated proton permeability represents an upper limit for P_H since CCCP always induces a faster vesicular proton uptake than HV1 (Fig. 3). Accordingly, the maximum value of P_H/P_K can be estimated as the ratio of valinomycin to CCCP conductivities. The respective values are equal to 1.6 10-3 Ω-1 cm2 [1] and 4 10-6 Ω-1 cm-2 [2]. At pH 7.5, we find c_H^o=10^(-7.5) M, i.e., c_k^o ≫ (P_H/P_K )c_H^o. Similarily, c_k^I ≫ (P_H/P_K ) c_H^i for a broad range of intravesicular pH. With these simplifications, Eq. 1 transforms into the Nernst equation yielding:

      ψ = -RT/F ln (c_k^i)/(c_k^o )=-100 mV

      (2)

      ψ of such size may decrease intravesicular pH by nearly two units. Such acidification does not violate c_k^i ≫ (P_H/P_K ) c_H^i so that ψ remains constant throughout the experiment. That is, the vesicle experiments proceed under voltage clamp conditions. The simple explanation is that, due to the small proton concentration and the limited buffer capacity, the K+ conductance exceeds H+ conductance under all conditions. The conclusion is in line with simulations (32), confirming that the membrane potential is driven very near the Nernst potential for K+.”]]

      The authors state that "Transmembrane voltage constituted the driving force for proton uptake into LUVs (Figure M). It resulted from facilitated K+ efflux out of the vesicles (30)", (lines 261‐262), but this voltage is unknown and not likely to equal the Nernst equilibrium potential for K+ once Hv1 channels begin to open.

      [[

      The reviewer is mistaken. The voltage is known (see the equations above). The opening of the HV1 channels does not alter the potential because c_k^o ≫ (P_H/P_K ) c_H^o and c_k^i ≫ (P_H/P_K ) c_H^i for a broad range of intravesicular pH (see above).]]

      Once Hv1 channels begin to open, intra‐lumenal pH (pHi) will necessarily occur during the experiment. Such changes are likely exacerbated by a) the low proton buffering capacity of the system (5 mM HEPES) and b) the absence of any counter‐charge pathway to balance the effect of proton charge movement on the membrane potential.

      [[

      Vesicle acidification occurs. It signifies the presence of functional proton channels. Nevertheless, the membrane potential does not change (see Equation 1 above). The statement b) is not correct because the outward K+ movement counters the inward-directed proton charge movement.]]

      Given the small volume of LUVs, even a relatively modest difference in either membrane potential or pHi could substantially alter the driving force for proton movement. Together, these factors are highly likely to result in a rapid and potentially large change in the driving force for proton flux.

      [[

      As outlined above, membrane potential stays invariant. Vesicle acidification changes the driving force for proton flux. The steady state is reached when the electrochemical potentials for protons on the two sides of the membrane are equal to each other.]]

      Driving force changes may also be different for WT and D174A because their relative PO may be different under the experimental conditions used here. Because D174A activates at much more negative voltages, it is likely to open more quickly and to a higher PO than WT at early times after depolarization is initiated by addition of valinomycin (Fig. 3A). This fact will likely result in a larger initial inward current being carried by D174A than WT channels. The result would be a more rapid acidification of LUVs by D174A.

      [[

      The reviewer is mistaken. Assuming a transport rate of 20,000 potassium ions per second (G. Stark, B. Ketterer, R. Benz and P. Läuger; Biophys. J. 1971 Vol. 11 Pages 981-981) and a membrane capacity of 1 μF cm-2, it takes valinomycin about 10 ms to drive the vesicular potential to near Nernst values. Activation of the proton channel is at least 10 times slower. Thus, both mutant channel and wild type channel may open at roughly the same instant. The driving force is sufficient to open both channels to the same probability.]]

      The experimental data in Fig. 3A are consistent with the expectation that the proton gradient and driving force more rapidly approach equilibrium for D174A than WT channels: the apparent rate of AMCA fluorescence change is slower in D174A. Although the authors correctly interpret the experimental data to mean that the apparent λD is slower for D174A, they do not rule out the artifactual explanation for the measured differences. Indeed, the observation in Fig. 3A that AMCA fluorescence change eventually reaches a plateau and is not affected by CCCP means that the proton gradient has become exhausted during the experiment, and directly demonstrates that the proton driving force is uncontrolled under the current experimental conditions.

      [[

      The reviewer's interpretation of our results is flawed. Instead of becoming exhausted, the proton gradient builds up during the experiment. Initially, extravesicular and intravesicular pH values are equal to each other. Valinomycin-mediated K+ efflux results in a membrane potential that drives Hv1-mediated H+ influx.

      Page 8: “The number NC of reconstituted HV1 dimers per vesicle determines the acidification rate λ, i.e., the time that elapses before reaching the steady state. The final intraluminal pH is independent of NC. Similarly, CCCP addition in the steady state does not change the intraluminal pH of HV1-containing vesicles. But CCCP will affect the intraluminal pH of vesicles deprived of HV1 since H+ background permeability is too small to allow vesicle acidification within the time allotted for the experiment. Consequently, only HV1-free vesicles will acidify upon CCCP addition. That is, CCCP addition allows estimating the fraction of vesicles deprived of HV1.”]]

      In contrast to the authors' statement that "Our experiments with the purified and reconstituted channels corroborated the conclusion (Fig. 3A)", (lines 92‐93) it is not clear that unitary proton flux rates/unitary conductances are actually different in WT and D174A.

      [[

      The reviewer is mistaken. Since we measured under voltage clamp conditions, ensured rapid installment of the membrane potential, and selected a potential large enough to allow for the same open probability of wild-type and mutant channels, the measured transport rates, λ, are valid. Moreover, we determined the number of HV1 channels per vesicle and thus calculated the transport rate of an individual channel, λD. Since λD is different for WT and D174A, the unitary proton flux rates/unitary conductances are actually different in the wild type and mutant.]]

      3) The presumed differences in unitary conductances (i.e., 'transport rate') between WT and D174A are used to estimate Arrhenius activation energies (Ea): ("The difference in measures transport rates allows a rough estimation of the Arrhenius 128 activation energy Ea for HV1‐mediated proton flow. It amounts to 40 kJ/mol for the wild type and 23 kJ for the mutant. Thus, Ea exceeds the corresponding 15 kJ/mol barrier measured for gramicidin A (32, 33)", (lines 128‐130). The method for determining Ea in the current work is not well‐described. In Ref. 32, the authors estimate Arrhenius activation energy (Ea = 20 kJ/mol) for gramicidin D (not gramicidin A) from the slope of a line fit to measurements of currents at various temperatures. Here, the authors measure AMCA fluorescence decay rates at 4 °C and 23 °C and observe a similar temperature‐dependent difference in WT and D174A (Fig. S2). Given that the data indicate that WT and D174A are similarly temperature‐dependent, it is unclear how the authors arrive at different Ea values. The authors' conclusion that "The increment in Ea suggests that the transport mechanism may be different from a pure Grotthuss type, where the proton uses an uninterrupted water wire to cross the membrane", (lines 131‐133) therefore does not appear to be well‐supported.

      [[

      We removed both the calculation and discussion of activation energies. Knowledge and discussion of activation energies distract from the scope of the manuscript. We show the experiments at different temperatures solely to demonstrate that Hv1 and D174A facilitate proton transport at a decreased temperature where the background conductivity of the lipid bilayer to water is small.]]

      4) The authors report no difference in water permeability in WT vs. D174A (Fig. 5 and S1) and interpret the results to mean that proton currents are not associated with measurable bulk water flow. A similar conclusion was reached for native Hv1 channels using deuterium substitution (DeCoursey & Cherny, 1997).

      [[

      The comment of the reviewer is misleading:

      • Equal water permeabilities of WT and D174A would not exclude an association between proton currents and water flow. Accordingly, our manuscript does not contain the stipulated interpretation.
      • DeCoursey & Cherny (1997) did not evaluate bulk water flow through proton channels. They compared D+ and H+ currents across the plasma membrane of rat alveolar epithelial cells. Page 2: “Comparing deuterium ion and proton currents through the plasma membrane of rat alveolar epithelial cells, DeCoursey & Cherny (22) found an isotope effect exceeding that for hydrogen bond cleavage in bulk water. It suggested the involvement of an amino acid side chain in proton conduction (22). Alternatively, altered properties of confined water could have been responsible for the higher isotope effect.”]]

      However, the absence of bulk water flow does not itself rule out the possibility that 'trapped' waters within the Hv1 pore do not themselves carry the measured proton current. If intra‐pore water molecules are tethered by hydrogen bonds with protein atoms, they may not move when Hv1 channels open.

      [[

      The reviewer’s comment contains one misinterpretation and one unfounded statement:

      1. We never stated that 'trapped' waters within the Hv1 pore do not themselves carry the measured proton current. On the contrary, we envisioned the trapped waters delivering the protons to one or more titratable amino acid side chains and accepting the protons from them.
      2. The reviewer’s view that intra‐pore water molecules tethered by hydrogen bonds with protein atoms may not move when Hv1 channels open is a misconception. Page 12 bottom: “The contrasting opinion that instead of a channel obstruction hydrogen bonds may immobilize the pore water (19) is not convincing. First, the lifetime of a hydrogen bond is in the ps range while HV1’s mean open time exceeds 100 ms (41). Thus, hydrogen bonds may break more than 1011 times during the open state, rendering them unfit for tethering intraluminal water molecules. Second, the effect of hydrogen bonds between water molecules and pore residues is limited to decreased water mobility in narrow channels (23). Their number, NH, allows for predicting pf (26). Specifically, every H-bond donating or receiving pore-lining residue contributes an average increment ΔΔG╪ of 0.1 kcal/mol to the Gibbs free energy of activation ΔG╪ (24). Equation (1) allows the calculation of ΔG╪:

      ΔG╪= N_H ΔΔG╪ + ΔΔG╪_i (13)

      where ΔΔG╪_i = 2 kcal/mol (24). Since N_H = 6 (Fig. S1) in the open HV1 conformation, Eq. 1 predicts ΔG╪ = 2.6 kcal/mol. Eq. (2) allows calculating HV1’s pf from this value (42):

      p_f = v_0 v_w exp(-ΔG╪/RT) (14)

      where vw = 3 × 10−23 cm3 is the volume of one water molecule and ν0 is the universal attempt frequency, ν0 = kB∙T/h ≈ 6.2 × 1012 s−1 at room temperature (kB is Boltzmann’s and h is Planck’s constant).”]]

      Proton transfer through a hydrogen‐bonded network of waters requires only that the electronic structure of the network be rearranged during proton transfer; water is not required. As in the previous study (DeCoursey & Cherny, 1997), the lack of water flux reported here demonstrates seems to reinforce the notion that H+ moves separately from its waters of hydration (i.e., hydronium, H3O+, is not the permeant species) and does not necessarily imply information about the mechanism of proton transfer (i.e., side chain ionization vs. Grotthuss‐type transfer in a water‐wire).

      [[

      The reviewer is mixing two unrelated issues. Of course, proton transport may be separated from mass transfer. Yet, charge transfer may or may not include one or several titratable amino acid side chains. If proton side chain ionization is not involved in proton transfer, a water wire must exist that connects the aqueous solutions on both sides of the membrane. In this case, an osmotic gradient will drive water molecules through the open channel. Since we did not observe such water flux, we conclude that the water wire is interrupted by at least one side chain. Thus, our experiments imply information about the mechanism of proton transfer.]]

      The authors state that: 1) "every H‐bond donating or receiving pore‐lining residue would have contributed an increment ΔΔ𝐺‡ of 0.1 kcal/mol to the Gibbs free energy of activation Δ𝐺‡ (25)" (lines 145‐147), and 2) calculating NH from this Δ𝐺‡ allows estimation of the channel's unitary water permeability (Eqn. 2). Although hydrogen bonding patterns will undoubtedly alter the free energy for channel activation, this is not the same free energy change as that for proton transfer.

      [[

      The reviewer's remark is in line with the previous and the current versions of our manuscript.]]

      Hv1 gating involves conformational changes that are both voltage and Δ pH-dependent, and the D174A mutation is known to alter the voltage dependence of gating (Fig. 2 and previous studies). The effect of D174A on Hv1 unitary conductance, however, is speculated but not unambiguous (see above).

      [[

      Our experiments unambiguously demonstrate the effect of D174A on Hv1 unitary conductance. The interpretation of the experiments is straightforward – there is no speculation involved. The contrasting opinion of the reviewer rests on his misinterpretations of (i) our measurements of proton transport rate λD for wild-type and mutant (see above) and the CCCP-effect (see above).]]

      In the absence of definitive experimental data showing differences in the unitary conductance of WT vs. D174A, the authors' assumption that water permeability would be strongly temperature‐dependent (lines 154‐160) seems premature and their ensuing conclusion tenuous: "pore residues interrupt the HV1 spanning water wire, trapping the water molecules inside the HV1 channel. In contrast to water, protons cross the pore by hopping from one acidic residue to another through one or more bridging water molecules (Fig. 6)" (lines 161‐164).

      [[

      The reviewer chooses to misinterpret our lines. We did not assert that water permeability through the Hv1 channel would be strongly temperature‐dependent. We referred to the well-known fact that there is a strong temperature dependence of lipid bilayer water permeability - in contrast to the tiny effect of temperature on the water permeation across aqueous channels.

      Page 11, bottom: “Considering the stark dependence of the activation energy for background water flow across lipid bilayers (24), we repeated the experiments at a decreased temperature of 4°C. Thanks to the low background water permeability at 4°C, even tiny contributions of HV1 to Pf should be detectable. Yet, the channels did not contribute to the water flow through the vesicular membrane even though channel water permeability but weakly depends on temperature (24).”]]

      Furthermore, the authors calculate the number of hydrogen bonds (NH) that pore waters could form with pore lining residues based on an X‐ray structure of a chimeric proton channel protein (pdb: 3WKV) that is: a) manifests discontinuous transmembrane water density and is known to represent a non‐conductive conformation, b) contains residues from Ci‐VSP in the critical S2‐S3 linker that form part of the proton transfer pathway, and c) exhibits structural features (i.e., highly conserved ionizable residues such as D185 and R205, which like D174 are reported to dramatically alter Hv1 gating, are packed into a solvent‐free crevice) that are inconsistent with physiological function. Given that all Hv1 ionizable mutant combinations tested so far (the sole exception of D112V ‐ other nonionizable substitutions at D112 are tolerated) remain functional (Musset, Smith et al., 2011, Ramsey, Mokrab et al., 2010), the identities of water‐interacting residues speculative.

      [[

      We substituted the X‐ray structure of the chimeric proton channel protein for the AlphaFold structure. We now provide views of the open and closed conformations in the Supplement based on the homology structure (13). Microsecond-long molecular dynamics simulations have optimized the latter.

      The experimental observation of mutants’ functionality (with the sole exception of D112V) supports our view that proton transfer occurs through a hydrogen‐bonded network of waters that is only once (at D112) interrupted by an amino acid side chain. The nature of the amino acids interacting with the proton transferring water molecules is of little importance.]]

      Interpreting differences in the calculated NH based on pdb: 3WKV therefore seems unlikely to reveal fundamentally important insights into Hv1 function. The author's conclusion that "The observation rules out the formation of an uninterrupted water chain spanning the open channel from the aqueous solution at one side of the membrane to the other. NH would have governed water mobility if such a water wire had formed (24)", (lines 143‐145) therefore does not appear to be strongly supported.

      [[

      We did not base our conclusion of an obstructed water pathway on the analysis of structural models. In contrast, the conclusion is the result of our experiments. The structural models permitted the prediction of the expected water permeability. Depending on the model and the channel conformation, we find NH values between six and 16. All of these NH values translate into water permeabilities exceeding gramicidin’s water permeability. Thus, we would have been able to detect the water flux through an unobstructed proton channel.]]

      Reviewer #2:

      Summary: Voltage‐gated proton channels are peculiar members of the voltage‐gated ion channel family due to their absence of canonical pore. Instead, protons permeate through their voltage‐sensing domain. The mechanisms of proton permeation in Hv1 channels are still unclear, with currently two competing hypotheses: (i) hopping through titrable residues within the protein; or (ii) via Grotthuss mechanism involving proton jumping through a continuous water wire. So far, these hypotheses were only tackled by computation. The authors therefore aimed to experimentally test the two hypotheses. To do so, the authors measured the transport rates of protons and water through wild‐type and mutant D174A Hv1 reconstituted in lipid vesicles. Overall, the presented data are convincing and support their conclusion that proton conduction through the channel is not solely mediated by water transport. However, there are several aspects of the paper that I did not understand and would require clarification.

      [[

      We thank the reviewer for the positive evaluation.]]

      Major comments: My major concern is about the relevance of using the D174A mutant. The authors explain at the beginning of the paper that Hv1‐D174A is open at 0 mV, which allows measuring proton flux in systems in which voltage cannot be controlled. However, it seems from the proton flux experiments that wild‐type Hv1 can conduct protons perfectly well in the used experimental paradigm. So why test a mutant? It is actually not clear why wild‐type Hv1 can conduct protons in the proton conduction assay.

      [[

      We introduced the D174A mutation to measure water flux in a setting where the membrane potential is zero. We only performed the proton flux measurements to show that our reconstituted HV1 channels are functional. HV1 can conduct protons because we establish a transmembrane potential in the proton conduction assay. That is, only initially, extravesicular and intravesicular pH values are equal. Valinomycin addition results in a K+ efflux that, in turn, generates a membrane potential. This potential drives the HV1-mediated H+ influx.]]

      The authors should clearly state the trans‐membrane potential created by the K+ gradient across the vesicle, as well as the pH inside and outside the vesicle, and related these conditions to their electrophysiology data to give us an idea of the open probability of wild‐type Hv1 in the conditions used in the proton conduction assays. This is critical to be able to compare the relative rates of proton transport between the wild‐type and the mutant.

      [[Page 6, bottom:

      " ...we encapsulated c_k^i=150 mM KCl in the HV1 containing large unilamellar vesicles (LUVs) and exposed these vesicles to a buffer with a K+ concentration c_k^o= 3 mM. The addition of valinomycin facilitated K+ efflux, thereby inducing a membrane potential, ψ. ψ constituted the driving force for H+ uptake. It can be calculated according to the Goldman equation:

      ψ = -RT/F ln ((c_k^i+(P_H/P_K ) c_H^i)/(c_k^o+(P_H/P_K ) c_H^o ))

      (1)

      The ratio of the HV1 mediated proton permeability P_H to the valinomycin-mediated potassium permeability P_K is always smaller than 0.04. We base our conclusion on the observation that the CCCP-mediated proton permeability represents an upper limit for P_H since CCCP always induces a faster vesicular proton uptake than HV1 (Fig. 3). Accordingly, the maximum value of P_H/P_K can be estimated as the ratio of valinomycin to CCCP conductivities. The respective values are equal to 1.6 10-3 Ω-1 cm2 [1] and 4 10-6 Ω-1 cm-2 [2]. At pH 7.5, we find c_H^o=10^(-7.5) M, i.e., c_k^o ≫ (P_H/P_K )c_H^o. Similarily, c_k^I ≫ (P_H/P_K ) c_H^i for a broad range of intravesicular pH. With these simplifications, Eq. 1 transforms into the Nernst equation yielding:

      ψ = -RT/F ln (c_k^i)/(c_k^o )=-100 mV

      (2)

      ψ of such size may decrease intravesicular pH by nearly two units.

      Such acidification does not violate so that remains constant throughout the experiment. That is, the vesicle experiments proceed under voltage clamp conditions. The simple explanation is that, due to the small proton concentration and the limited buffer capacity, the K+ conductance exceeds H+ conductance under all conditions. The conclusion is in line with simulations (32), confirming that the membrane potential is driven very near the Nernst potential for K+.”]]

      Similarly, the buffers and pH used for the water transport assay are not explicitly mentioned. Are they the same as for the proton transport assay or are the buffers inside and outside the vesicle symmetrical?

      [[

      We added the information about buffers and pH used to the legend. Except for 150 mM sucrose, the internal and external solutions were identical: 150 mM KCl, 5 mM HEPES (pH 7.5), and 0.5 mM EGTA.]]

      Finally, in the introduction the authors base their assumptions about water transport on an X‐ray structure of Hv1 in a closed conformation (3WKV). I do not think it is relevant to study permeation, which in theory should only happen in an open state. If the authors want to make assumptions about the number of hydrogen bonds in the pore and how many water molecules are in the pore (and I don't think they need to do it), they should rather base their assumptions on the computational models of Hv1 open state.

      [[

      We thank the reviewer for the advice. We added a figure to the Supplement. It shows Hv1 models from long-timescale molecular dynamics simulations (Geragotelis et al, Proc Natl Acad Sci U S A 2020 Vol. 117 Issue 24 Pages 13490-13498). The open structure reveals NH=6. We used this value for our calculations.]]

      Minor comments:

      1) Figure 6: the authors should precise that the model of proton conduction through Hv1 is just an assumption. The structural features of Hv1 open state are indeed unknown.

      [[We modified the figure based on the simulation results of Geragotelis et al. We indicated in the legend that the scheme is based on HV1 homology models.]]

      2) Page 9, lines 170‐171 "Drastically prolonged tail current kinetics might reflect a decreased voltage‐dependence of the deactivation in the D174 mutant". Or rather the prolonged kinetics reflect the stabilization of the open state by the mutation (as stated by the authors just after).

      [[Page 14:

      “Drastically prolonged tail current kinetics might reflect (i) a decreased voltage dependence of the deactivation in the D174A mutant or (ii) a stabilized open state (14).”]]

      3) Supplementary figures are displayed in an odd fashion. Figure S3 should be placed before Figures S1 and S2.

      [[We added two more Supplementary Figures and displayed them in the order of text mentionings.]]

      4) In Figure 2, displaying the current trace corresponding to the 0 mV voltage step would improve readability of the figure, by showing that Hv1‐D174A mutants conduct protons at 0 mV and not wt Hv1.

      [[

      We show the current trace corresponding to the 0 mV voltage step for the D174A mutant in panel A and the trace for the wild-type in panel B of Fig. 2.]]

      5) Figure 2 legend "Pronounced inward H+ currents activate negatively to the reversal potential (here ‐70 mV)". I think the authors mean "Here 0 mV", ‐70 mV is the threshold potential. Panel (c), I guess the EH vs Vrev plot is for D174A mutants but it is not mentioned in the legend

      [[

      We corrected the legend. “Pronounced inward H+ currents activate negatively (here – 70 mV) to reversal potential (here – 8 mV), indicating a high open probability of the D174A mutant at 0 mV.” And “Comparison of calculated Nernst potential for protons (EH) and measured reversal potential (Vrev) for the D174A mutant.”]]

      6) Page 4, line 89: the fact that D174A conducts protons at a lower rate is, at this point, based on a lot on assumption. I would just correct the last sentence by saying "Thus, D174A, while opening with less depolarization, seems to conduct protons at a lower rate"

      [[We toned down our statement and inserted a phrase very close to the one suggested.

      Page 5: “Our observation suggests a reduced flux through the mutant if we assume that the protein expression level is independent of the mutation.”]]

      7) Page 6, line 107. The word "therefore" is not necessary

      [[ok]]

      8) Page 7, line 128: "of" in "measures of transport" is missing

      [[We deleted the paragraph.]]

      9) Page 12, lines 261‐262: "Figure M" ??

      [[“Inset of Figure 3A”]]

      CROSS‐CONSULTATION COMMENTS I agree with the two other reviewer's comments. I think our reviews more or less raise the same weaknesses in the study.

      Significance

      This paper addresses a single question with a clearly defined experimental paradigm. Once the issues addressed, the paper should bring important significance to the field of voltage‐gated ion channels since the nature of proton conduction in Hv1 was not known. It could help explain ion conduction in some channelopathies involving ion conduction through the voltage‐sensing domain. The audience is mainly the voltage‐gated ion channel community, as well as the community of membrane permeation mechanisms My field of expertise is in ion channel structure‐function and pharmacology. I have little expertise in the described proton and water flow assays. Therefore I do not have sufficient expertise to evaluate the detailed experimental protocol that led to the measurements.

      Reviewer #3:

      Summary: This study addresses a fundamental question about the mechanism of proton conduction in the voltage gated proton channel Hv1 i.e., whether protons hop through an uninterrupted water wire, or move by other means involving titratable channel residues. The authors argue that an uninterrupted water wire entails a certain rate of water movement through the open channel, which they estimate to be around 10‐12 cm3s‐1 based on a structural model of Hv1 and previous work on other channels. They then measure water permeability of LUVs containing a purified Hv1 mutant expected to be open at 0 mV via light scattering, and proton flux using a pH sensitive fluorescent dye. They calculate a water permeability much lower than predicted and conclude that the water in the conduction pathway does not form an uninterrupted water wire. The manuscript is written clearly, and the experimental measurements are convincing.

      [[We thank the reviewer for the positive evaluation.]]

      There are nonetheless some ambiguities in the way the formation of water wires is discussed.

      Major comments: A protein like Hv1 is larger and more complex than small peptides like gramicidin. In this context, transient water wires, frequently interrupted by titratable residues, or by steric hindrance from hydrophobic sidechains etc. are likely. Can the authors provide an estimate for the maximum frequency and lifetime of uninterrupted proton wires compatible with their measurements? This would be helpful to evaluate whether short‐lived uninterrupted water wires could contribute significantly to proton conduction or not. Trapping usually implies restricted movement. So, for how long do water molecules need to stay inside the channel in order to be considered trapped? Are the water molecules really trapped or simply forming broken wires?

      [[Page 13, bottom:

      “The question arises whether the obstacle in the water pathway is permanent. HV1’s titratable residues or steric hindrance from fluctuating sidechains may frequently interrupt otherwise intact water wires. Yet, our calculations (Eqs. 7 – 11) show that proton diffusion from the bulk solution to the pore mouth is the transport limiting step. Undoubtedly, transient closure would have caused a detectable pore resistance because part of the protons arriving at the pore mouth could not enter the pore. If the pore was closed longer than one ps, an arriving H+ may diffuse out of the capture zone and vanish into the bulk:

      t_c=(r_0^2)/6D = 10^(-16)/(6 × 8.65 × 10^(-5) ) s = 2 × 10^(-13) s

      (16)

      where tc denotes the time a proton requires to diffuse a distance equal to the capture radius r0. Since transient closures would give rise to experimentally undetected pore resistance, they must be ruled out. The observation agrees well with noise experiments, where Lorentzian time constants, albeit smaller than the time constants for H+ current activation but larger than 0.1 s were observed (41).

      We provided the calculations showing the diffusion limitations on page 9:

      “…we show that the transport limiting step is H+ diffusion to the pore (access resistance) and not transport through the pore. Therefore, we first calculate the maximum current Imax permitted by diffusion for a constantly open pore (35):

      I_max=2π F r_o D_H c_H

      (7)

      where F, r0, DH, and cH are Faraday's constant, the capture radius, the H+ diffusion constant, and the H+ concentration, respectively. The only unknown parameter is r0. Taking the gA estimate r0 = 0.87 Å (36), disregarding buffer effects and assuming DH = 8.65×105 cm2s-1, we find:

      I_max=2π (9.6 ×10^4 As)/mol × 0.87 × 10^(-8) cm × 8.65 x 10^(-5) (cm^2 s^(-1) × 4 × 10^(-7.5) mol)/(1000 cm^3 )

      (8)

      I_max=5.6 × 10^(-17) A

      (9)

      Eq. 8 considers that the approximately 25 % charged lipids in the bilayer induce an increase in surface proton concentration, i.e. it accounts for a surface potential of roughly -40 mV in 150 mM salt. The maximal unitary rate would then be equal to:

      q_max = 5.6 × 10^(-17) C/s/1.6 × 10^(-19) C =348 s^(-1)

      (10)

      Here we used the r0 value determined for gA (36). Acidic moieties at the entrance of HV1 and proton surface migration along the lipid bilayer could serve to increase that value (37, 38). The observation suggests transport limitations by poor proton availability. Calculation of the channel resistance, Rch (35), confirms the hypothesis:

      R_ch = R_pore+R_access =[l_ch+(π a_ch)/2] ρ/(π a_ch^2 )

      (11)

      where R_pore is the resistance of the pore proper and R_access is the access resistance. Assuming a channel radius, a_ch, of 0.15 nm, a length, l_ch of 4 nm and solution resistivity (H+ as the sole conducted ion at bulk pH of 7.5 and a surface potential of -40 mV), ρ, of 2×105 Ω cm, we find R_ch = 4×1013 Ω. Thus, the resulting current, Iρ, that we may expect for the vesicular membrane potential of 100 mV is equal to 3×10-15 A. Accordingly, Iρ exceeds Imax by more than one order of magnitude. Consequently, we may safely conclude that HV1 conductance is limited by proton availability under our conditions. ”]]

      The main conclusion of the paper rests on the negative results from the water permeability assay of Fig. 5. It is recommended to include a positive control (e.g., with gramicidin A), run under the same conditions and similar number of channels per LUV, to show how the results should look like in case of significant water permeability.

      [[We included the gramicidin measurements (Fig. 6) as requested.]]

      Figure 6 show a simplified scheme of proton transport with trapped water molecules in Hv1. Panel A represents a resting state (nonconductive); panel B represents an open state (conductive), favored by the D174A mutation. So, what makes B conductive and A nonconductive? Is it the presence of two salt bridges in B vs. three salt bridges in A? This should be clarified.

      [[

      We modified the figure based on the simulation results of Geragotelis et al. We indicate with arrows the parts of the channel where the proton is free to move and crosses the sites with insurmountable energy barriers.

      Legend to the figure (now Fig. 8): “In the region of the selectivity filter adjacent to D112, the channel is too narrow to let water molecules pass (see also Fig. S1). Yet, the proton may bypass the electrostatic barrier of the open channel at D112 (18), i.e., jump between the two neighboring water molecules. Removal of D174 shifts the voltage sensitivity so that most channels are already open at a transmembrane potential of 0 mV. B) The closed channel. It neither allows water nor proton transport. In its new location, D112 provides an insurmountable electrostatic barrier to proton passage.”]]

      Minor comments: The interpretation of Fig. 2E strongly depends on the assumption that the D174A mutation does not alter membrane trafficking. It is recommended to check the validity of this assumption, e.g., by colocalization with a plasma membrane marker. Images of SDS‐PAGE results for the studied Hv1 proteins should be provided to show preparation purity.

      [[

      We toned down the interpretation of Fig. 2E. As it stands now, Fig. 2 shows that the mutant (i) is functional and (ii) has a high open probability at 0 mV. These conclusions are independent on membrane trafficking. We included images of SDS page results for the studied HV1 proteins in the Supplement.]]

      CROSS‐CONSULTATION COMMENTS I agree with the comments from the other two reviewers. My major point is that refuting major water permeability in Hv1 is not the same thing as refuting that protons can be conducted by transient water wires, unless it is proved that the transient water wires cannot sustain enough proton movement to account for the single channel conductance. Reviewer #3 (Significance (Required)): The Hv1 channel plays important roles in the human body, including the immune, respiratory, and reproductive systems. Despite recent advances in understanding the mechanism of proton conduction by Hv1, whether or not protons hop within a continuous water wire in the open channel is a subject of debate (DeCoursey J. Physiol. 2017, Bennett & Ramsey J. Physiol. 2017). This work provides important insights on the debate by refuting the existence of a water wire that can sustain large water permeability. The findings reported here will be of interest to ion channel biophysicist like this reviewer, but also to biologists studying cellular pH homeostasis and the pathophysiology of Hv1.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      Summary:

      This study addresses a fundamental question about the mechanism of proton conduction in the voltage gated proton channel Hv1 i.e., whether protons hop through an uninterrupted water wire, or move by other means involving titratable channel residues. The authors argue that an uninterrupted water wire entails a certain rate of water movement through the open channel, which they estimate to be around 10-12 cm3s-1 based on a structural model of Hv1 and previous work on other channels. They then measure water permeability of LUVs containing a purified Hv1 mutant expected to be open at 0 mV via light scattering, and proton flux using a pH sensitive fluorescent dye. They calculate a water permeability much lower than predicted and conclude that the water in the conduction pathway does not form an uninterrupted water wire. The manuscript is written clearly, and the experimental measurements are convincing. There are nonetheless some ambiguities in the way the formation of water wires is discussed.

      Major comments:

      A protein like Hv1 is larger and more complex than small peptides like gramicidin. In this context, transient water wires, frequently interrupted by titratable residues, or by steric hindrance from hydrophobic sidechains etc. are likely. Can the authors provide an estimate for the maximum frequency and lifetime of uninterrupted proton wires compatible with their measurements? This would be helpful to evaluate whether short-lived uninterrupted water wires could contribute significantly to proton conduction or not.

      Trapping usually implies restricted movement. So, for how long do water molecules need to stay inside the channel in order to be considered trapped? Are the water molecules really trapped or simply forming broken wires?

      The main conclusion of the paper rests on the negative results from the water permeability assay of Fig. 5. It is recommended to include a positive control (e.g., with gramicidin A), run under the same conditions and similar number of channels per LUV, to show how the results should look like in case of significant water permeability.

      Figure 6 show a simplified scheme of proton transport with trapped water molecules in Hv1. Panel A represents a resting state (nonconductive); panel B represents an open state (conductive), favored by the D174A mutation. So, what makes B conductive and A nonconductive? Is it the presence of two salt bridges in B vs. three salt bridges in A? This should be clarified.

      Minor comments:

      The interpretation of Fig. 2E strongly depends on the assumption that the D174A mutation does not alter membrane trafficking. It is recommended to check the validity of this assumption, e.g., by colocalization with a plasma membrane marker.

      Images of SDS-PAGE results for the studied Hv1 proteins should be provided to show preparation purity.

      Referees cross-commenting

      I agree with the comments from the other two reviewers. My major point is that refuting major water permeability in Hv1 is not the same thing as refuting that protons can be conducted by transient water wires, unless it is proved that the transient water wires cannot sustain enough proton movement to account for the single channel conductance.

      Significance

      The Hv1 channel plays important roles in the human body, including the immune, respiratory, and reproductive systems. Despite recent advances in understanding the mechanism of proton conduction by Hv1, whether or not protons hop within a continuous water wire in the open channel is a subject of debate (DeCoursey J. Physiol. 2017, Bennett & Ramsey J. Physiol. 2017). This work provides important insights on the debate by refuting the existence of a water wire that can sustain large water permeability. The findings reported here will be of interest to ion channel biophysicist like this reviewer, but also to biologists studying cellular pH homeostasis and the pathophysiology of Hv1.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      Summary:

      Voltage-gated proton channels are peculiar members of the voltage-gated ion channel family due to their absence of canonical pore. Instead, protons permeate through their voltage-sensing domain. The mechanisms of proton permeation in Hv1 channels are still unclear, with currently two competing hypotheses: (i) hopping through titrable residues within the protein; or (ii) via Grotthuss mechanism involving proton jumping through a continuous water wire. So far, these hypotheses were only tackled by computation. The authors therefore aimed to experimentally test the two hypotheses. To do so, the authors measured the transport rates of protons and water through wild-type and mutant D174A Hv1 reconstituted in lipid vesicles. Overall, the presented data are convincing and support their conclusion that proton conduction through the channel is not solely mediated by water transport. However, there are several aspects of the paper that I did not understand and would require clarification.

      Major comments:

      My major concern is about the relevance of using the D174A mutant. The authors explain at the beginning of the paper that Hv1-D174A is open at 0 mV, which allows measuring proton flux in systems in which voltage cannot be controlled. However, it seems from the proton flux experiments that wild-typet Hv1 can conduct protons perfectly well in the used experimental paradigm. So why test a mutant? It is actually not clear why wild-type Hv1 can conduct protons in the proton conduction assay. The authors should clearly state the trans-membrane potential created by the K+ gradient across the vesicle, as well as the pH inside and outside the vesicle, and related these conditions to their electrophysiology data to give us an idea of the open probability of wild-type Hv1 in the conditions used in the proton conduction assays. This is critical to be able to compare the relative rates of proton transport between the wild-type and the mutant. Similarly, the buffers and pH used for the water transport assay are not explicitly mentioned. Are they the same as for the proton transport assay or are the buffers inside and outside the vesicle symmetrical? Finally, in the introduction the authors base their assumptions about water transport on an X-ray structure of Hv1 in a closed conformation (3WKV). I do not think it is relevant to study permeation, which in theory should only happen in an open state. If the authors want to make assumptions about the number of hydrogen bonds in the pore and how many water molecules are in the pore (and I don't think they need to do it), they should rather base their assumptions on the computational models of Hv1 open state.

      Minor comments:

      1. Figure 6: the authors should precise that the model of proton conduction through Hv1 is just an assumption. The structural features of Hv1 open state are indeed unknown.
      2. Page 9, lines 170-171 "Drastically prolonged tail current kinetics might reflect a decreased voltage-dependence of the deactivation in the D174 mutant". Or rather the prolonged kinetics reflect the stabilization of the open state by the mutation (as stated by the authors just after).
      3. Supplementary figures are displayed in an odd fashion. Figure S3 should be placed before Figures S1 and S2.
      4. In Figure 2, displaying the current trace corresponding to the 0 mV voltage step would improve readability of the figure, by showing that Hv1-D174A mutants conduct protons at 0 mV and not wt Hv1.
      5. Figure 2 legend "Pronounced inward H+ currents activate negatively to the reversal potential (here -70 mV)". I think the authors mean "Here 0 mV", -70 mV is the threshold potential. Panel (c), I guess the EH vs Vrev plot is for D174A mutants but it is not mentioned in the legend
      6. Page 4, line 89: the fact that D174A conducts protons at a lower rate is, at this point, based on a lot on assumption. I would just correct the last sentence by saying "Thus, D174A, while opening with less depolarization, seems to conduct protons at a lower rate"
      7. Page 6, line 107. The word "therefore" is not necessary
      8. Page 7, line 128: "of" in "measures of transport" is missing
      9. Page 12, lines 261-262: "Figure M" ??

      Referees cross-commenting

      I agree with the two other reviewer's comments. I think our reviews more or less raise the same weaknesses in the study.

      Significance

      This paper addresses a single question with a clearly defined experimental paradigm. Once the issues addressed, the paper should bring important significance to the field of voltage-gated ion channels since the nature of proton conduction in Hv1 was not known. It could help explain ion conduction in some channelopathies involving ion conduction through the voltage-sensing domain.

      The audience is mainly the voltage-gated ion channel community, as well as the community of membrane permeation mechanisms.

      My field of expertise is in ion channel structure-function and pharmacology. I have little expertise in the described proton and water flow assays. Therefore I do not have sufficient expertise to evaluate the detailed experimental protocol that led to the measurements.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      1. The authors state that: "the conductance density mediated by the expression of the mutant was 2.5 times smaller than the wild type, although we transfected the same amount of plasmid DNA (Fig. 2E). Assuming that protein expression is independent of the mutation, the observation suggested that the unitary proton flux ratio RC of wild type to mutant channel was equal to 2.5" (lines 82-85).

      Macroscopic conductance (G) depends on channel number (N), microscopic or unitary conductance (), and open probability (PO) by G=NPO. The authors assume that the level of WT and D174A mutant protein expression on plasma membrane, which determines N, are equal; however, this critical assumption does not appear to have been tested. The fact that conductance density (nS/pF) is plotted in Fig. 2E does not alter this caveat because this procedure normalizes the data only for cell surface area (i.e., size).

      The authors' conclude that "The conductance density relationship (Fig. 2E) compares the maximal conduction of both constructs; this is the fully open channel (open probability ≈ 1)"(lines 87-88). However, neither raw currents nor G-V data are shown. Typically, currents measured at large, near-saturating PO are used to compare the relative conductances of WT and mutant ion channels. The currents shown in Fig. 2A and 2B exhibit prominent 'droop' at even modest depolarizing potentials (+10 mV for D174A and +30 mV for WT), indicating that the proton gradient has been substantially perturbed by the flow of ge depolarizing voltages needed to drive channels to near-maximal PO. Furthermore, there is no evidence that maximal PO itself is also not different in WT and D174A channels. Indeed, maximal PO for native Hv1 channels measured using variance analysis is reported by significantly smaller than 1.0, and assuming that PO = 1.0 for either WT or D174A is therefore not well supported. Maximal could be altered by the D174A mutation, which has a clear and strong effect on channel gating evidenced by the large (-70 mV) negative shift in threshold potential reported both here and previously in the literature. Effects of mutations on maximal PO due to altered gating behavior could be separate and distinct from any change in plasma membrane channel number (N). Lastly, because D174A channels have a much higher PO than WT at 0 mV, the mutant will necessarily conduct inward proton currents at the physiological resting membrane potential (RMP) in tsa-201 cells (perhaps -30 mV?). Inwardly directed proton currents will therefore cause intracellular acidification under resting conditions. The constitutive acid load in cells expressing D174A, but not WT, is likely to have a variety of physiological consequences, including decreased protein expression or plasma membrane targeting of D174A. There is evidence that another-constitutively open Hv1 mutant (R205H) also generates smaller currents macroscopic conductance than WT, and this phenomenon is likely to result from decreased cell surface expression. To conclude that the microscopic conductances of WT and D174A are unequal, the authors must demonstrate that N is not different The authors' conclusion that D174A "conducts protons at a lower rate" (line 89) is therefore not well supported by the experimental data. 2. The authors indirectly measure apparent proton flux rates (D) in LUVs containing WT and D174A mutant Hv1 channels using a fluorescence-based approach, and conclude that D is 2.4 times smaller for D174A than WT. However, the method for estimating D is not performed under voltage clamp, and the driving force for proton current is neither known nor measured. The authors state that "Transmembrane voltage constituted the driving force for proton uptake into LUVs (Figure M). It resulted from facilitated K+ efflux out of the vesicles (30)", (lines 261-262), but this voltage is unknown and not likely to equal the Nernst equilibrium potential for K+ once Hv1 channels begin to open.

      Once Hv1 channels begin to open, intra-lumenal pH (pHi) will necessarily occur during the experiment. Such changes are likely exacerbated by a) the low proton buffering capacity of the system (5 mM HEPES) and b) the absence of any counter-charge pathway to balance the effect of proton charge movement on the membrane potential. Given the small volume of LUVs, even a relatively modest difference in either membrane potential or pHi could substantially alter the driving force for proton movement. Together, these factors are highly likely to result in a rapid and potentially large change in the driving force for proton flux.

      Driving force changes may also be different for WT and D174A because their relative PO may be different under the experimental conditions used here. Because D174A activates at much more negative voltages, it is likely to open more quickly and to a higher PO than WT at early times after depolarization is initiated by addition of valinomycin (Fig. 3A). This fact will likely result in a larger initial inward current being carried by D174A than WT channels. The result would be a more rapid acidification of LUVs by D174A.

      The experimental data in Fig. 3A are consistent with the expectation that the proton gradient and driving force more rapidly approach equilibrium for D174A than WT channels: the apparent rate of AMCA fluorescence change is slower in D174A. Although the authors correctly interpret the experimental data to mean that the apparent D is slower for D174A, they do not rule out the artifactual explanation for the measured differences. Indeed, the observation in Fig. 3A that AMCA fluorescence change eventually reaches a plateau and is not affected by CCCP means that the proton gradient has become exhausted during the experiment, and directly demonstrates that the proton driving force is uncontrolled under the current experimental conditions.

      In contrast to the authors' statement that "Our experiments with the purified and reconstituted channels corroborated the conclusion (Fig. 3A)", (lines 92-93) it is not clear that unitary proton flux rates/unitary conductances are actually different in WT and D174A. 3. The presumed differences in unitary conductances (i.e., 'transport rate') between WT and D174A are used to estimate Arrhenius activation energies (Ea): ("The difference in measures transport rates allows a rough estimation of the Arrhenius 128 activation energy Ea for HV1-mediated proton flow. It amounts to 40 kJ/mol for the wild type and 23 kJ for the mutant. Thus, Ea exceeds the corresponding 15 kJ/mol barrier measured for gramicidin A (32, 33)", (lines 128-130).

      The method for determining Ea in the current work is not well-described. In Ref. 32, the authors estimate Arrhenius activation energy (Ea = 20 kJ/mol) for gramicidin D (not gramicidin A) from the slope of a line fit to measurements of currents at various temperatures. Here, the authors measure AMCA fluorescence decay rates at 4{degree sign}C and 23{degree sign}C and observe a similar temperature-dependent difference in WT and D174A (Fig. S2). Given that the data indicate that WT and D174A are similarly temperature-dependent, it is unclear how the authors arrive at different Ea values. The authors' conclusion that "The increment in Ea suggests that the transport mechanism may be different from a pure Grotthuss type, where the proton uses an uninterrupted water wire to cross the membrane", (lines 131-133) therefore does not appear to be well-supported. 4. The authors report no difference in water permeability in WT vs. D174A (Fig. 5 and S1) and interpret the results to mean that proton currents are not associated with measurable bulk water flow. A similar conclusion was reached for native Hv1 channels using deuterium substitution (DeCoursey & Cherny, 1997). However, the absence of bulk water flow does not itself rule out the possibility that 'trapped' waters within the Hv1 pore do not themselves carry the measured proton current. If intra-pore water molecules are tethered by hydrogen bonds with protein atoms, they may not move when Hv1 channels open. Proton transfer through a hydrogen-bonded network of waters requires only that the electronic structure of the network be rearranged during proton transfer; water is not required. As in the previous study (DeCoursey & Cherny, 1997), the lack of water flux reported here demonstrates seems to reinforce the notion that H+ moves separately from its waters of hydration (i.e., hydronium, H3O+, is not the permeant species) and does not necessarily imply information about the mechanism of proton transfer (i.e., side chain ionization vs. Grotthuss-type transfer in a water-wire).

      The authors state that: 1) "every H-bond donating or receiving pore-lining residue would have contributed an increment ΔΔ𝐺‡ of 0.1 kcal/mol to the Gibbs free energy of activation Δ𝐺‡ (25)" (lines 145-147), and 2) calculating NH from this Δ𝐺‡ allows estimation of the channel's unitary water permeability (Eqn. 2). Although hydrogen bonding patterns will undoubtedly alter the free energy for channel activation, this is not the same free energy change as that for proton transfer. Hv1 gating involves conformational changes that are both voltage and pH-dependent, and the D174A mutation is known to alter the voltage dependence of gating (Fig. 2 and previous studies). The effect of D174A on Hv1 unitary conductance, however, is speculated but not unambiguous (see above). In the absence of definitive experimental data showing differences in the unitary conductance of WT vs. D174A, the authors' assumption that water permeability would be strongly temperature-dependent (lines 154-160) seems premature and their ensuing conclusion tenuous: "pore residues interrupt the HV1 spanning water wire, trapping the water molecules inside the HV1 channel. In contrast to water, protons cross the pore by hopping from one acidic residue to another through one or more bridging water molecules (Fig. 6)" (lines 161-164).

      Furthermore, the authors calculate the number of hydrogen bonds (NH) that pore waters could form with pore-lining residues based on an X-ray structure of a chimeric proton channel protein (pdb: 3WKV) that is: a) manifests discontinuous transmembrane water density and is known to represent a non-conductive conformation, b) contains residues from Ci-VSP in the critical S2-S3 linker that form part of the proton transfer pathway, and c) exhibits structural features (i.e., highly conserved ionizable residues such as D185 and R205, which like D174 are reported to dramatically alter Hv1 gating, are packed into a solvent-free crevice) that are inconsistent with physiological function. Given that all Hv1 ionizable mutant combinations tested so far (the sole exception of D112V - other non-ionizable substitutions at D112 are tolerated) remain functional (Musset, Smith et al., 2011, Ramsey, Mokrab et al., 2010), the identities of water-interacting residues speculative. Interpreting differences in the calculated NH based on pdb: 3WKV therefore seems unlikely to reveal fundamentally important insights into Hv1 function. The author's conclusion that "The observation rules out the formation of an uninterrupted water chain spanning the open channel from the aqueous solution at one side of the membrane to the other. NH would have governed water mobility if such a water wire had formed (24)", (lines 143-145) therefore does not appear to be strongly supported.

      References

      Bennett AL, Ramsey IS (2017a) CrossTalk opposing view: proton transfer in Hv1 utilizes a water wire, and does not require transient protonation of a conserved aspartate in the S1 transmembrane helix. J Physiol

      Bennett AL, Ramsey IS (2017b) Rebuttal from Ashley L. Bennett and Ian Scott Ramsey. J Physiol

      De La Rosa V, Bennett AL, Ramsey IS (2018) Coupling between an electrostatic network and the Zn(2+) binding site modulates Hv1 activation. J Gen Physiol

      De La Rosa V, Ramsey IS (2018) Gating Currents in the Hv1 Proton Channel. Biophys J 114: 2844-2854

      DeCoursey TE (2017) CrossTalk proposal: Proton permeation through HV 1 requires transient protonation of a conserved aspartate in the S1 transmembrane helix. J Physiol 595: 6793-6795

      DeCoursey TE, Cherny VV (1997) Deuterium isotope effects on permeation and gating of proton channels in rat alveolar epithelium. J Gen Physiol 109: 415-34

      Musset B, Smith SM, Rajan S, Morgan D, Cherny VV, Decoursey TE (2011) Aspartate 112 is the selectivity filter of the human voltage-gated proton channel. Nature 480: 273-7

      Ramsey IS, Mokrab Y, Carvacho I, Sands ZA, Sansom MS, Clapham DE (2010) An aqueous H+ permeation pathway in the voltage-gated proton channel Hv1. Nat Struct Mol Biol 17: 869-75

      Ramsey IS, Moran MM, Chong JA, Clapham DE (2006) A voltage-gated proton-selective channel lacking the pore domain. Nature 440: 1213-6

      Randolph AL, Mokrab Y, Bennett AL, Sansom MS, Ramsey IS (2016) Proton currents constrain structural models of voltage sensor activation. Elife 5: e18017

      Significance

      Here the authors attempt to ascertain whether water molecules may mediate proton transfer in the voltage-gated proton channel Hv1 using a combination of whole-cell voltage clamp electrophysiology, protein purification, reconstitution, and pH-dependent AMCA fluorescence measurement and estimates of water permeability, and hydrogen bond calculations based on an X-ray structure of a chimeric Hv1 proton channel model protein. The authors address an important question that is fundamental to the exquisitely proton-selective Hv1 channel and which may be applicable to other proton transporting proteins.

      Although there is high potential for significance to a wide range of experimenters studying biologically fundamental mechanisms of proton transport, the experimental data fail to strongly support most of the authors main conclusions, and it is unclear whether the work represents a technial advance for the field. Previous work in the literature has described two main hypotheses for the proton transport mechanism in Hv1:

      • A) an intra-protein transmembrane water wire that allows permeating H+ to move along a chain of hydrogen-bonded water molecules and does not require explicit ionization of any particular amino acid side chain (Bennett & Ramsey, 2017a, Bennett & Ramsey, 2017b, Ramsey et al., 2010), and
      • B) Explicit ionization of a conserved side chain in the S1 helix (D112 in human Hv1) is required for proton transfer in Hv1 channels (DeCoursey, 2017, Musset et al., 2011). The Reviewer is an expert in the field, having originally identified and functionally characterized Hv1 channels in 2006 (Ramsey, Moran et al., 2006), contributed to the identification of key side chains and structural determinants of Hv1 function (De La Rosa, Bennett et al., 2018, Ramsey et al., 2010, Randolph, Mokrab et al., 2016), measured gating currents in Hv1 (De La Rosa & Ramsey, 2018), and authored the hypothesis that Hv1 utilizes a water-wire type mechanism for proton transfer (Ramsey et al., 2010).
    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      August 17, 2022

      RE: Review Commons Refereed Preprint #RC-2022-01442

      Dear Editor of the EMBO Journal,

      Please find our updated manuscript and response to the reviewers’ comments. We appreciate the effort that the reviewers have put into the evaluation of our manuscript.

      We are happy with the potential importance the reviewers realise in the study:

      Reviewer 1: The finding that ubiquitination occurs inside mitochondria would be an important conceptual advance, which would open new perspectives both for ubiquitination and mitochondrial biology

      Reviewer 2: This work would represent a significant/exceptional discovery if supported by compelling data.

      Reviewer 3: the results are interesting and very important, as mentioned in the major comments section…

      With regard to the major comments raised by the reviewers, you will find below our specific response point by point with explanations and suggested novel experiments (highlighted in yellow). In summary we suggest the following actions to fully support our model:

      • We will perform a-complementation with ubiquitin (lacking the GG motif) fused at its C-terminus to the short fragment of b-galactosidase (a). Blue colonies with ωm will indicate import.
      • As shown in Figure S2, now added to the manuscript, we show detection of ubiquitinated proteins and mono ubiquitin in extracts of mitochondria pre-treated with trypsin.
      • A bio-archives address of our other manuscript will be provided.
      • The use of a-complementation for protein localization was developed by us 15 years ago and since then has been used by us and other groups verifying its use as a screening tool. One point is clear, ωm or ωc do not leak into other subcellular compartments. Nevertheless, in the research of specific genes validation is important. Yes!!! ωm and ωc are exclusively located in mitochondria or the cytosol respectively.
      • We will highly purify mitochondria on gradients and treat them with protease.
      • We cannot be sure that we will be able to detect a protein with ubiquitin modifying activity which functions solely on certain proteins in mitochondria, so publication cannot rely on this.
      • Repeat mass spectrometry with careful editing will be undertaken as suggested by the reviewer.
      • We will attempt to perform protease protection assays in the presence of specific detergents.

      Before tackling the very tough revision, we would like to know if EMBO Journal would positively consider acceptance of our manuscript based on the review and planned revision.

      Prof. Ophry Pines Microbiology & Molecular Genetics Hebrew University of Jerusalem Jerusalem 91220 Israel


      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      Summary:

      In this manuscript, Zhang et al. investigate whether ubiquitination occurs inside mitochondria of the budding yeast S. cerevisiae. They first observe thanks to a sensitive complementation assay that several components of the yeast ubiquitination (and deubiquitination) machinery can localize inside mitochondria. To be able to specifically probe ubiquitin conjugates assembled inside mitochondria they fused HA-tagged ubiquitin to a mitochondrial targeting sequence. Using this construct, they demonstrate that ubiquitin conjugates can be assembled in mitochondria. A series of elegant experiments demonstrates that the pattern of ubiquitin conjugates depends on the mitochondrial localization and the activity of the ubiquitin conjugating enzyme Rad6. Altogether, these results convincingly demonstrate that ubiquitination can occur inside yeast mitochondria when ubiquitin is intentionally targeted inside this organelle. It however remains unclear whether mitochondrial ubiquitination occurs in endogenous conditions (without targeting ubiquitin into this compartment) and whether it affects mitochondrial functions.

      Response: Regarding the question whether mitochondrial ubiquitination occurs in endogenous conditions, we feel that this is obvious based on our results. We detect numerous ubiquitination related enzymes (E1, E2, E3, DUB) eclipsed in mitochondria but none of the proteasome subunits. As pointed out by the reviewer “these results convincingly demonstrate that ubiquitination can occur inside yeast mitochondria”. With that said, additional data will be incorporated into the manuscript as suggested by the reviewer and can be seen below.

      Major comments:

      1) The materials and methods section is lacking important information (western blot protocol, details of antibodies, strains, plasmids...). It is thus difficult to evaluate how several experiments were performed and how their design (e.g. the promoters chosen to express tagged proteins) could impact the interpretation of the results. This is a major issue that needs to be corrected. The main text should also explicitly indicate whether tagged proteins used in the alpha-complementation assay are overexpressed or not.

      Response: The materials and methods section will be updated accordingly.

      2) Despite the previous comment, the data presented in the manuscript convincingly demonstrate that multiple components of the ubiquitination machinery can localize within mitochondria and that ubiquitin conjugates can be assembled in mitochondria when ubiquitin is modified to be intentionally targeted into this compartment. However, little data is shown to support the hypothesis that ubiquitin conjugates can be assembled in mitochondria when ubiquitin is not fused to a mitochondrial targeting sequence. Thus, in my opinion, the evidences presented in the current manuscript are not sufficient to conclude that ubiquitin conjugates are assembled in mitochondria in endogenous conditions (as this is done implicitly). Additional evidences are needed to draw this conclusion (see some experimental suggestions hereafter). Without further evidences, the speculative aspects of the claim that "ubiquitination occurs in the mitochondrial matrix" should be discussed explicitly.

      Response: See the discussion above why we are confident that ubiquitination occurs in mitochondria. Our major problem with ubiquitin and the ubiquitination enzymes is that they are eclipsed in mitochondria. We propose as suggested by the reviewer (item 4 of his review) to perform a-complementation with ubiquitin fused at its C-terminus to the short fragment of b-galactosidase (a). Blue colonies with ωm will indicate import.

      3) The authors used a mass spectrometry approach to identify mitochondrial ubiquitination substrates. However, they have not yet succeeded in identifying a substrate whose modification is specifically regulated by a given component of the mitochondrial ubiquitination machinery. They have also not identified a phenotype or process impacted by mitochondrial ubiquitination. Thus, at this stage, the biological consequences of mitochondrial ubiquitination remain elusive.

      __Response: __We have not identified a substrate whose modification is dependent on a given component of the mitochondrial ubiquitination machinery, even though we have tried. Again, the problem is low levels of these proteins eclipsed in mitochondria. Even when we do find a protein that is ubiquitinated (e.g. Aco1) its ubiquitination is not exclusively dependent on Rad6. Thus, different ubiquitin enzymes may have the same substrates.

      4) The authors have not directly investigated whether ubiquitin itself (without a mitochondrial targeting sequence) localizes in mitochondria. I encourage them to address this question since it would provide an important piece of evidence suggesting that mitochondrial ubiquitination can occur in endogenous conditions. This could be done using the alpha-complementation assay and the results could be presented within Figure 1. Ideally this experiment should be performed without overexpressing ubiquitin. Note that if the authors decide to use a C-terminally tagged form of ubiquitin for this experiment, the GG motif of ubiquitin should be mutated to avoid cleavage of the alpha tag by cellular DUBs. This form of ubiquitin will not be conjugatable, but this is not an issue for this experiment since its aim is to determine whether ubiquitin can be targeted to mitochondria, not to probe conjugates.

      Response: We will perform experiments as suggested by the reviewer including ubiquitin fused at its C-terminus to the short fragment of b-galactosidase (a), see item 2. We have previously made a PreSu9-Ubi lacking a GG motif but now will look at a different combination of this and other constructs.

      5) In the top panels of Figure 2 and S1, free ubiquitin is well detectable in the total and cytosolic fractions. It is however not clear to me whether it is also detectable in the concentrated mitochondrial fraction. If yes and if it would be resistant to trypsin digestion, it would provide additional evidence that endogenous ubiquitin can be targeted to the mitochondrial matrix (see previous comment).

      Response: See Item 6.

      6) The data shown in the top panel of Figure 2 and S1 also suggest that free ubiquitin is less concentrated in mitochondria than in the cytosol (since it is more difficult to detect in the concentrated mitochondrial fraction than in the cytosolic fraction, see previous comment). It is thus possible that the use of preSu9-HA-Ubi (or preFum1-HA-Ubi) lead to an artificially high intra-mitochondrial concentration of free ubiquitin. As the concentration of free ubiquitin is known to impact ubiquitination processes, I encourage the authors to compare the relative levels of free ubiquitin present in the mitochondrial fraction prepared from WT and preSu9-HA-Ubi (or preFum1-HA-Ubi) expressing cells. If free ubiquitin is detectable in mitochondrial fractions and resistant to trypsin (see previous comment), this could be done by repeating the experiment shown in Figure 3B and probing the blot with an antibody that recognizes free ubiquitin.

      Response to 5 and 6: Detection of ubiquitin in mitochondria is extremely difficult even when mitochondria are 15-fold concentrated versus the cytosol and when HA-Ubi is overexpressed. Thus, ubiquitin is eclipsed in mitochondria. Nevertheless, as shown in the Figure below which was not part of the submitted manuscript yet was performed in parallel to experiments done early on, shows detection of very weak bands of free ubiquitin in extracts of mitochondria pre-treated with trypsin.

      Endogenous ubiquitination pattern in mitochondria of _Δrad6 _cells is restored to normal by Rad6-α. __WT or Δrad6 cells containing a Rad6-α construct or an empty plasmid were subjected to subcellular fractionation. Mitochondrial fractions with or without trypsin treatment, were probed for ubiquitin by WB. Aco1 is a matrix mitochondrial protein, and Tom70 is a mitochondrial outer membrane protein (MOM) facing the cytosol.

      7) I strongly encourage the authors to provide more data indicating that "ubiquitination occurs in mitochondria" by performing experiments that do not rely on the use of the preSu9-HA-Ubi or other forms of ubiquitin that are intentionally targeted to mitochondria. For instance, they could analyse the pattern of HA-Ubi conjugates of trypsin digested mitochondrial fractions prepared from wt, rad6-delta, and rad6-delta complemented with preSu9-Rad6-alpha-SL17. Note that if trypsin digested mitochondrial fractions are too contaminated by ubiquitinated proteins present outside mitochondria to perform this experiment, the authors may use the unspecific DUB Usp2 as an alternative protease to strip ubiquitinated proteins from the mitochondria periphery.

      Response: Concentrated mitochondrial extracts from WT and Δrad6 cells untreated or treated with trypsin were probed with anti-ubiquitin antibodies (Figure above). A very weak band corresponding to free ubiquitin can be detected in extracts of mitochondria treated with trypsin but these are very weak and are on the limit of detection.

      Minor comments:

      1) Overall, the manuscript is well organized and easy to follow. The text is clearly written; the figures are well annotated.

      2) The authors should provide full images of all the blots with anti-ubiquitin and anti-HA antibodies so that one can see the bands corresponding to free ubiquitin (or free HA-Ubi). For instance, in Figure 3B, it is not possible to see the presence (or absence) of the band corresponding to free HA-Ubi because the very bottom of the image is cut.

      3) The authors should indicate whether the MTS of Su9 (and Fum1) are expected to be cleaved after import of preSu9-HA-Ubi (and preFum1-HA-Ubi) in mitochondria. They should also label on the corresponding immunoblots the presence (or absence) of the band corresponding to the free preSu9-HA-Ubi (and preFum1-HA-Ubi) (or HA-Ubi if the MTS is expected to be cleaved from these constructs).

      4) In Figure 3B, the ubiquitin conjugates produced with preSu9-HA-Ubi and preFum1-HA-Ubi have different migration patterns. I think this should be explicitly mentioned and discussed. Could it be due to the presence of lysine residues in the Su9 or Fum1 MTS that could lead to the assembly of artificial ubiquitin chains?

      5) The authors indicate that "endogenous Rad6 [...] is expressed at very low levels and can hardly be detected in the mitochondrial fraction by WB (Figure S5)". I did not manage to observe the band corresponding to endogenous Rad6 in the mitochondrial fraction in the pdf. The authors should provide a more contrasted or better quality image.

      CROSS-CONSULTATION COMMENTS I agree with reviewer 2 that proper validation of the complementation assay is crucial for this manuscript. I was myself wondering whether it uses endogenously tagged proteins or whether it is based on an overexpression system. I imagine this information will be detailed in the manuscript in preparation mentioned by the authors. I am therefore wondering whether it would be possible to ask the authors to provide the draft of this manuscript (or at least the validation part).

      Response: A bio-archives address of our other manuscript will be provided upon resubmission. See other issues referred to the response Reviewer 2.

      I agree with most comments of reviewer 3. Regarding the hypothesis that preSu9-HA-Ubi could form aggregates on the cytosolic surface of the mitochondria, I think that the results presented on Figure 7B rather argue against it (since they indicate that Rad6 localized inside mitochondria can restore the pattern of ubiquitin conjugates). That's why (in my opinion) the major question the author now need to adress is whether intra-mitochondrial ubiquitination occurs in endogenous conditions (ie without forcing ubiquitin into this compartment and without E2 or E3 overexpression).

      Response: See response to the other reviewers

      Reviewer #1 (Significance (Required)):

      The finding that ubiquitination occurs inside mitochondria would be an important conceptual advance, which would open new perspectives both for ubiquitination and mitochondrial biology research. However, the significance of the current manuscript is limited because the presented evidences heavily rely on the use of artificial conditions (ubiquitin tagged with a mitochondrial-targeting sequence) that may trigger irrelevant ubiquitination events. The significance would be much higher if the authors would provide further evidences indicating that intra-mitochondrial ubiquitination occurs in endogenous conditions and/or if they had identified a mitochondrial process specifically impacted by mitochondrial ubiquitination.

      Expertise of the reviewer: Ubiquitination, Yeast biology, protein-protein interactions. No specific expertise in mitochondrial biology

      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      In the manuscript by Yu et al., the authors test the concept that certain proteins are unevenly distributed within distinct cell compartments. Due to this localization discrepancy, protein detection in some subcellular compartments can be "eclipsed" by a predominant subset of specific protein localizing in another cell compartment their actual distribution. Therefore, tiny amounts of physiologically relevant proteins could be biologically relevant. Still, their function in some locations can be overlooked (or eclipsed) because of the high expression level of the same protein in another subcellular compartment(s). Although, this concept is not particularly novel. For example, it is already known that many different proteins can localize to distinct cellular locations (e.g., permanent mitochondrial and peroxisomal localization of many proteins or transient localization of particular proteins to separate cell compartments). The authors apply a yeast system and an α-complementation assay to test further the role of such eclipsed proteins in mitochondrial biology. Specifically, they focus on the ubiquitin (Ub, or as abbreviated incorrectly in this manuscript; Ubi) conjugation pathway, components of which have never been convincingly shown to localize inside the mitochondria. This work proposes that certain ubiquitination events can occur inside yeast mitochondria. This work would represent a significant/exceptional discovery if supported by compelling data. However, the major problem with this work is that the conclusions are based on the ectopic expression of distinct proteins. This approach is not failproof in precise protein expression/delivery to the specific subcellular locations and is likely to result in a non-specific localization. Thus, the problem of eclipsed proteins is addressed by the methodology that may lead to the artificial generation of eclipsed overexpressed proteins. A more effective approach would be if the authors found a way to study this issue with endogenous proteins. The need for overexpression of mitochondria-targeted ubiquitin makes it challenging to reconcile the physiological role of these fundings. In addition, some critical technical issues and omissions further reduce the potential impact of this work (see Specific comments below). For example, strong evidence of mitochondria fraction purity and additional evidence that all the essential constructs used in this work are not misdirected to a different compartment are needed.

      Response: “Although, this concept is not particularly novel” is a very disappointing remark by the reviewer!! While dual targeting of proteins has been known for many, many years, how widespread the phenomenon was unknown and thought to be negligible. We are leaders for the last 30 years in the field of dual targeting and distribution and in particular distribution of single translation products. We coined the terms “echoforms” and “eclipsed distribution” and developed methods to detect and screen for dual targeting. The concept of eclipsed distribution and in particular eclipsed targeting to mitochondria is very new, and is leading to a novel perception of the mitochondrial proteome (see MS submission). While the reviewer appears to be an expert on ubiquitination, we are experts on dual targeting.

      • Ub was abbreviated incorrectly in this manuscript, Ubi. __Response: __This will be corrected.

      Other comments will be referred to in the response to Specific comments.

      Specific comments 1. The authors should demonstrate beyond doubt that the ω components of their assay (ω-C, which supposedly stays in the cytosol-ONLY and the ω-M component, which seemingly remains in the mitochondria-ONLY) are in the compartment that the authors claim. These two proteins are transfected into yeast cells and overexpressed. Therefore it is possible that they leak to other, not intended, subcellular compartments. The authors assume that ω-M and ω-C are exclusively located either in the mitochondria or the cytosol. However, this should be shown as validation of the assay. The indicated reference from 2005 (Ref.13) and others are irrelevant since assays have variations and are often researcher/lab dependent. This validation is very important since a misallocation of the overexpressed ω-M or ω-C, leaking into other subcellular compartments, may cause misdetection of the α-constructs.

      Response: The use of a-complementation for protein localization was developed by us 15 years ago and since then has been used by us and other groups verifying its use as a screening tool. One point is clear, ωm or ωc do not leak into other subcellular compartments. Nevertheless, in the research of specific genes validation is important. Yes!!! ωm and ωc are exclusively located in mitochondria or the cytosol respectively.

      It is not surprising that Ub conjugates are detected in mitochondrial fractions. It could be due to ubiquitination of the OMM (coming from the cytosol) or perhaps since the subcellular fractions were not pure mitochondria free from contamination (the likely culprit could be the ER). The mitochondrial fractions in this work were obtained by 10,000 g separation between cytosolic and mitochondrial crude fractions. Indeed, these 10,000 g crude fractions are highly impure with membranes from other compartments (i.e., microsomes, lysosomes, and so on). Therefore, more sophisticated purification methods should be used. In addition, the authors should also test these fractions for non-mitochondrial proteins from other membrane organelles.

      Response: We agree with the reviewer and therefore will take the following approaches:

      1. i) We will treat isolated mitochondria with protease in order to remove adhering proteins and digest OMM proteins…… see attached figure.
      2. ii) We will highly purify mitochondria on gradients and this will be straight forward since we are now employing such methods in other projects in the lab. iii) Matrix protein enrichment (by mass spec) is associated with IP for preSu9-HA-Ub conjugates which is three-fold higher than for HA-Ub. In any case the fact that we identify conjugates of proteins not known to be mitochondrial, strongly supports our thesis.

      Figure 2. Coomassie blue staining does not show any signal in the "M" fraction. It can be interpreted that the authors do not get any mitochondria there, and therefore the lack of Ub signal is due to the absence of the protein in the samples. Using the same amount of protein from each fraction would probably reduce the necessity of 15x enrichment.

      Response: The Coomassie blue staining does show a signal in the "M" fraction which is weak yet when a 15x enrichment is run, the protein level by Coomassie blue staining is similar to the cytosolic fraction.

      Figure 3. It is puzzling why the HA-UBQ presence is so strong in the crude mitochondrial fraction, but the preSu9-HA-Ub signal (mito-matrix) is comparatively weak. These data suggest that the crude mito-fraction could be highly contaminated with OTHER membranes. On the other hand, the preSu9-HA-UBQ signal is no more than 1-5% of the total mitochondrial signal. The high enrichment of the HA-Ubi in both cytosols and the mitochondria could indicate the OMM ubiquitination or (again) contamination by other compartments. The constructs with MTS are detected in the mitochondria. However, the localization of tagged MTS-Ubi in a non-targeted compartment (e.g., cytosol) should be excluded by additional exposure times. Because the manuscript talks about eclipsed proteins, this is important.

      Response: The HA-Ub is strong in the mitochondrial fraction, in the absence of trypsin, but is very weak in the presence of the protease indicating that most of the ubiquitinated proteins are externally attached to mitochondria. In contrast, PreSu9-HA-Ub is imported into the mitochondrial matrix and is protected from trypsin. This manuscript refers to “eclipsed in mitochondria” (not the cytosol) and this is true for ubiquitination enzymes as well as for ubiquitin.

      Figure 3C-E. These data indeed suggest that the Ub-conjugates could be formed inside the mitochondria. However, the above-discussed possibility that other than mitochondria compartments co-sediment in the 10,000g fractions makes the data interpretation highly challenging.

      __Response: __We will highly purify mitochondria on gradients and this will be straight forward since we are now employing such methods in other projects in the lab.

      Figure 4. Unsurprisingly, mitochondrial targeting of Ub leads to detecting some co-immunoprecipitating mitochondrial proteins. However, these data do not support the notion that Ub conjugation machinery acts inside the mitochondria and that the target proteins are indeed conjugated with Ub (the interaction with Ub is not equal to being conjugated). At the minimum, the authors should provide a validation that some of the detected mitochondrial matrix proteins are indeed ubiquitinated. To this end, purified mitochondria could be used for the candidate protein IP under denaturing conditions and then blotted for the candidate protein and Ub.

      __Response: __As shown in Table S2 and figure S7, forms of Ilv5, a mitochondrial protein, are ubiquitinated in WT and Drad6 cells. These modified forms of Ilv5 can be eluted from mitochondrial extracts of WT and Drad6 cells. However, the ubiquitination of ilv5 is not dependent or effected by the Drad6 mutation. We cannot be sure that we will be able to detect a protein with ubiquitin modifying activity which functions solely on certain proteins in mitochondria.

      Figure 5. The knock-out of the E2 Rad6 causes a change in the mitochondria ubiquitination pattern. This is an interesting observation, but again it does not prove that the change in the mitochondrial ubiquitination is due to the activity of Rad6 inside of the mitochondria, as opposed to ubiquitination of the OMM proteins or contaminating fractions. One also wonders why overexpression of mitochondria-targeted Ub would be necessary to detect the ubiquitination if this process was physiologically relevant, especially given that detecting endogenous Ub is not challenging. Furthermore, the apparent increase in ubiquitination in E2 mutant cells (Fig. 5) should also be addressed in more detail. Finally, data from one WB is shown, and quantification of several independent experiments should also be provided.

      __Response: __We show in the MS that RAD6 is exclusively targeted to mitochondria (Su9MTS) while unimported molecules are degraded (SL17; degron). This hybrid Rad6 can restore the WT ubiquitin pattern, while a rad6 active site mutant cannot.

      Figure 6. Can the authors provide Western blot data showing the expression of Rad6? Furthermore, quantifying these rescue experiments is necessary to make this conclusion more solid.

      Response: Even though we did not succeed in making good Rad6 antisera, we can clearly detect Rad6-a fusion proteins (Figure 7B).

      Figure 7. The authors found that preSu9-Rad6-α have problems being imported into the mitochondria matrix; therefore, they rebuild it as a preSu9-Rad6-α-SL17 protein. SL17 is a degron that targets the cytosolic protein (not imported into the mitochondria) to the proteasome and degraded (Figs. 7A-B-C). These issues could be a red flag for the rest of the manuscript, suggesting that other constructs (that were not critically evaluated for their localization in this work) could leak to different cellular compartments.

      Response: The wording used by the reviewer is particularly disturbing since current understanding in cell biology of eukaryotic cells does not accept “leaking” of proteins to different cellular compartments. One wouldn’t want DNAses, RNAses, Proteases etc leaking from one compartment to another. The localization of proteins to different cellular compartments involves very precise signals on the proteins, and specific cellular components, such as translocases, are required to target proteins to their exact destination. This is true for Rad6; it contains an MTS like sequence which when removed blocks import of the protein into mitochondria. Rad6 according to our analysis is an eclipsed dual targeted protein, so it no surprise that it is in two compartments and the trick with the SL17 degron solves the problem.

      The manuscript needs to be carefully edited, some references are in the not correct format, and there are issues with figure labels.

      Response: Careful editing will be undertaken as suggested by the reviewer.

      CROSS-CONSULTATION COMMENTS I agree with a great summary by reviewer 1. This discovery should be validated by top-quality data.

      Reviewer #2 (Significance (Required)):

      In the manuscript by Yu et al., the authors test the concept that certain proteins are unevenly distributed within distinct cell compartments. Due to this localization discrepancy, protein detection in some subcellular compartments can be "eclipsed" by a predominant subset of specific protein localizing in another cell compartment their actual distribution. Therefore, tiny amounts of physiologically relevant proteins could be biologically relevant. Still, their function in some locations can be overlooked (or eclipsed) because of the high expression level of the same protein in another subcellular compartment(s). Although, this concept is not particularly novel. For example, it is already known that many different proteins can localize to distinct cellular locations (e.g., permanent mitochondrial and peroxisomal localization of many proteins or transient localization of particular proteins to separate cell compartments). The authors apply a yeast system and an α-complementation assay to test further the role of such eclipsed proteins in mitochondrial biology. Specifically, they focus on the ubiquitin (Ub, or as abbreviated incorrectly in this manuscript; Ubi) conjugation pathway, components of which have never been convincingly shown to localize inside the mitochondria. This work proposes that certain ubiquitination events can occur inside yeast mitochondria. This work would represent a significant/exceptional discovery if supported by compelling data. However, the major problem with this work is that the conclusions are based on the ectopic expression of distinct proteins. This approach is not failproof in precise protein expression/delivery to the specific subcellular locations and is likely to result in a non-specific localization. Thus, the problem of eclipsed proteins is addressed by the methodology that may lead to the artificial generation of eclipsed overexpressed proteins. A more effective approach would be if the authors found a way to study this issue with endogenous proteins. The need for overexpression of mitochondria-targeted ubiquitin makes it challenging to reconcile the physiological role of these fundings. In addition, some critical technical issues and omissions further reduce the potential impact of this work (see Specific comments above). For example, strong evidence of mitochondria fraction purity and additional evidence that all the essential constructs used in this work are not misdirected to a different compartment are needed.

      Reviewer #3 (Evidence, reproducibility and clarity (Required)):

      Summary: In this study, the authors detected a set of components of a ubiquitination system in the mitochondrial matrix in budding yeast using the subcellular compartment-dependent α-complementation assay. The authors detected the conjugates of mitochondrial targeting signal sequence-directed HA-Ub (preSu9-HA-Ub) in the mitochondrial matrix. The immunoprecipitates of the preSu9-HA-Ubi conjugates were highly enriched for the mitochondrial matrix proteins. Subsequently, the authors focused on the Rad6 E2 ubiquitin conjugating enzyme in the mitochondrial matrix and evaluated its inactivation-altered ubiquitination pattern in the organelle. The authors conclude that ubiquitination occurs in the mitochondrial matrix because of the eclipsed targeted components of the ubiquitination machinery.

      Major comments: The authors argued that the proteins that were modified with preSu9-HA-Ubi, which was forced to be imported into the mitochondria, are present in the mitochondrial matrix, because these species are resistant to trypsin digestion. However, it was possible that they formed severe aggregates on the cytosolic surface of the mitochondria, and hence, were resistant to the proteinase. In other words, a small amount of proteins that were not imported into the mitochondria could be deposited on the cytosolic surface of the mitochondria, where they were modified with preSu9-HA-Ubi by cytosolic Rad6. To confirm if the preSu9-HA-Ubi-modified proteins were really present in the mitochondrial matrix, they should perform the protease protection assay in the presence of an appropriate detergent (Figure 3D). In addition, subcellular fractionation of the organelle by density gradient centrifugation, indirect immunofluorescence microscopic analysis of the preSu9-HA-Ubi conjugates, and/or experiments on the in vitro import of preSu9-HA-Ubi and Rad6 into the mitochondria would strongly support the authors conclusion. Other experiments that might support the authors conclusion would be to test whether the band pattern for the preSu9-HA-Ubi conjugates changes when the mitochondrial import is impaired.

      Response: We will attempt to perform 1) Protease protection assay in the presence of a detergent (Figure 3D). 2) Subcellular fractionation of the organelle by density gradient centrifugation. 3) In vitro import of Rad6 into the mitochondria.

      Minor comments: In Figure 3B, the molecular weight distributions of the preSu9-HA-Ubi conjugates and those of the preFum-HA-Ubi conjugates are different. Is there any reason for this difference?

      In Figure 3E, the position of "-" (MG132) for lane 1 is not correct.

      In Figure 6A: The band pattern for preSu9-HA-Ubi (lane 13) in the rad6-delta cells expressing Ubc8-alpha is different from that of the wild-type cells expressing Ubc8-alpha (lane 12) as well as that obtained from the rad6-delta cells harboring empty plasmids (lane 9). Is there any explanation for this observation?

      In Figure 7B and S6: The level of preSu9-Rad6-alpha-SL17 in the rad6-delta cells is always lower than that in the wild-type cells (compare lanes 13 and 10 in Figure 7B, and lanes 13 and 12 in Figure S6). Is there any explanation for this observation? The protease protection assay (with detergent control) is needed to fully confirm that preSu9-Rad6-alpha-SL17 is present in the mitochondria.

      In Figure S7, the authors presented the matrix proteins, Ilv5 and Aco1, detected in the preSu9-HA-Ubi IPed samples and described this observation in the main text. However, the authors also showed the blots for Idh1 and Fum1, which were also pulled down with preSu9-HA-Ubi from the WT cells more than from the rad6-delta cells. Is this correct? If so, please elucidate this observation in the main text.

      Figure 8D and 8E are not cited in the main text. Although there are no explanations for these figures in the main text, it looks like Rad6-deltaN11-alpha resides in the mitochondrial fraction. However, the alpha-complementation assay suggests that it resides in the cytosol. Please explain this discrepancy.

      First page of the discussion section, item 6): E2 Rad6, but not E3 Rad6?

      Figure S7: HA-Ub (cytosolic form) control is needed in addition to the empty vector control.

      Figure S7, left panel: There is an unnecessary line break in "Hsp60" and "Ilv5."

      Figure S7, right panel: There is an unnecessary line break in "Hsp60."

      CROSS-CONSULTATION COMMENTS I agree with comments of reviewer 1 and 2. -Validation of the complementation assay. -I also think that it is important to address whether intra-mitochondrial ubiquitination can be observed with endogenous level of ubiquitin. If even a small amount of preSu9-HA-Ub is mistargeted to the cytosol, proteins at the cytosolic side of mitochondrial outer membrane could be ubiquitinated and detected in the mitochondrial fraction. -Preparation of mitochondria with more sophisticated purification methods (i.e. high resolution density gradient) would be needed to separate mitochondria from ER and other organelles. -More information is needed in the materials and methods section.

      Reviewer #3 (Significance (Required)): Significance Although the results are interesting and very important, as mentioned in the major comments section, additional experiments are needed to support their model. However, researchers working on the mitochondrial biology and ubiquitin systems might be interested in and influenced by the reported findings.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      Summary:

      In this study, the authors detected a set of components of a ubiquitination system in the mitochondrial matrix in budding yeast using the subcellular compartment-dependent α-complementation assay. The authors detected the conjugates of mitochondrial targeting signal sequence-directed HA-Ub (preSu9-HA-Ub) in the mitochondrial matrix. The immunoprecipitates of the preSu9-HA-Ubi conjugates were highly enriched for the mitochondrial matrix proteins. Subsequently, the authors focused on the Rad6 E2 ubiquitin conjugating enzyme in the mitochondrial matrix and evaluated its inactivation-altered ubiquitination pattern in the organelle. The authors conclude that ubiquitination occurs in the mitochondrial matrix because of the eclipsed targeted components of the ubiquitination machinery.

      Major comments:

      The authors argued that the proteins that were modified with preSu9-HA-Ubi, which was forced to be imported into the mitochondria, are present in the mitochondrial matrix, because these species are resistant to trypsin digestion. However, it was possible that they formed severe aggregates on the cytosolic surface of the mitochondria, and hence, were resistant to the proteinase. In other words, a small amount of proteins that were not imported into the mitochondria could be deposited on the cytosolic surface of the mitochondria, where they were modified with preSu9-HA-Ubi by cytosolic Rad6. To confirm if the preSu9-HA-Ubi-modified proteins were really present in the mitochondrial matrix, they should perform the protease protection assay in the presence of an appropriate detergent (Figure 3D). In addition, subcellular fractionation of the organelle by density gradient centrifugation, indirect immunofluorescence microscopic analysis of the preSu9-HA-Ubi conjugates, and/or experiments on the in vitro import of preSu9-HA-Ubi and Rad6 into the mitochondria would strongly support the authors conclusion. Other experiments that might support the authors conclusion would be to test whether the band pattern for the preSu9-HA-Ubi conjugates changes when the mitochondrial import is impaired.

      Minor comments:

      • In Figure 3B, the molecular weight distributions of the preSu9-HA-Ubi conjugates and those of the preFum-HA-Ubi conjugates are different. Is there any reason for this difference?

      • In Figure 3E, the position of "-" (MG132) for lane 1 is not correct.

      • In Figure 6A: The band pattern for preSu9-HA-Ubi (lane 13) in the rad6-delta cells expressing Ubc8-alpha is different from that of the wild-type cells expressing Ubc8-alpha (lane 12) as well as that obtained from the rad6-delta cells harboring empty plasmids (lane 9). Is there any explanation for this observation?

      • In Figure 7B and S6: The level of preSu9-Rad6-alpha-SL17 in the rad6-delta cells is always lower than that in the wild-type cells (compare lanes 13 and 10 in Figure 7B, and lanes 13 and 12 in Figure S6). Is there any explanation for this observation? The protease protection assay (with detergent control) is needed to fully confirm that preSu9-Rad6-alpha-SL17 is present in the mitochondria.

      • In Figure S7, the authors presented the matrix proteins, Ilv5 and Aco1, detected in the preSu9-HA-Ubi IPed samples and described this observation in the main text. However, the authors also showed the blots for Idh1 and Fum1, which were also pulled down with preSu9-HA-Ubi from the WT cells more than from the rad6-delta cells. Is this correct? If so, please elucidate this observation in the main text.

      • Figure 8D and 8E are not cited in the main text. Although there are no explanations for these figures in the main text, it looks like Rad6-deltaN11-alpha resides in the mitochondrial fraction. However, the alpha-complementation assay suggests that it resides in the cytosol. Please explain this discrepancy.

      • First page of the discussion section, item 6): E2 Rad6, but not E3 Rad6?

      • Figure S7: HA-Ub (cytosolic form) control is needed in addition to the empty vector control.

      • Figure S7, left panel: There is an unnecessary line break in "Hsp60" and "Ilv5."

      • Figure S7, right panel: There is an unnecessary line break in "Hsp60."

      CROSS-CONSULTATION COMMENTS

      I agree with comments of reviewer 1 and 2.

      • Validation of the complementation assay.
      • I also think that it is important to address whether intra-mitochondrial ubiquitination can be observed with endogenous level of ubiquitin. If even a small amount of preSu9-HA-Ub is mistargeted to the cytosol, proteins at the cytosolic side of mitochondrial outer membrane could be ubiquitinated and detected in the mitochondrial fraction.
      • Preparation of mitochondria with more sophisticated purification methods (i.e. high resolution density gradient) would be needed to separate mitochondria from ER and other organelles.
      • More information is needed in the materials and methods section.

      Significance

      Significance

      Although the results are interesting and very important, as mentioned in the major comments section, additional experiments are needed to support their model. However, researchers working on the mitochondrial biology and ubiquitin systems might be interested in and influenced by the reported findings.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      In the manuscript by Yu et al., the authors test the concept that certain proteins are unevenly distributed within distinct cell compartments. Due to this localization discrepancy, protein detection in some subcellular compartments can be "eclipsed" by a predominant subset of specific protein localizing in another cell compartment their actual distribution. Therefore, tiny amounts of physiologically relevant proteins could be biologically relevant. Still, their function in some locations can be overlooked (or eclipsed) because of the high expression level of the same protein in another subcellular compartment(s). Although, this concept is not particularly novel. For example, it is already known that many different proteins can localize to distinct cellular locations (e.g., permanent mitochondrial and peroxisomal localization of many proteins or transient localization of particular proteins to separate cell compartments). The authors apply a yeast system and an α-complementation assay to test further the role of such eclipsed proteins in mitochondrial biology. Specifically, they focus on the ubiquitin (Ub, or as abbreviated incorrectly in this manuscript; Ubi) conjugation pathway, components of which have never been convincingly shown to localize inside the mitochondria. This work proposes that certain ubiquitination events can occur inside yeast mitochondria. This work would represent a significant/exceptional discovery if supported by compelling data. However, the major problem with this work is that the conclusions are based on the ectopic expression of distinct proteins. This approach is not failproof in precise protein expression/delivery to the specific subcellular locations and is likely to result in a non-specific localization. Thus, the problem of eclipsed proteins is addressed by the methodology that may lead to the artificial generation of eclipsed overexpressed proteins. A more effective approach would be if the authors found a way to study this issue with endogenous proteins. The need for overexpression of mitochondria-targeted ubiquitin makes it challenging to reconcile the physiological role of these fundings. In addition, some critical technical issues and omissions further reduce the potential impact of this work (see Specific comments below). For example, strong evidence of mitochondria fraction purity and additional evidence that all the essential constructs used in this work are not misdirected to a different compartment are needed.

      Specific comments

      1. The authors should demonstrate beyond doubt that the ω components of their assay (ω-C, which supposedly stays in the cytosol-ONLY and the ω-M component, which seemingly remains in the mitochondria-ONLY) are in the compartment that the authors claim. These two proteins are transfected into yeast cells and overexpressed. Therefore it is possible that they leak to other, not intended, subcellular compartments. The authors assume that ω-M and ω-C are exclusively located either in the mitochondria or the cytosol. However, this should be shown as validation of the assay. The indicated reference from 2005 (Ref.13) and others are irrelevant since assays have variations and are often researcher/lab dependent. This validation is very important since a misallocation of the overexpressed ω-M or ω-C, leaking into other subcellular compartments, may cause misdetection of the α-constructs.
      2. It is not surprising that Ub conjugates are detected in mitochondrial fractions. It could be due to ubiquitination of the OMM (coming from the cytosol) or perhaps since the subcellular fractions were not pure mitochondria free from contamination (the likely culprit could be the ER). The mitochondrial fractions in this work were obtained by 10,000 g separation between cytosolic and mitochondrial crude fractions. Indeed, these 10,000 g crude fractions are highly impure with membranes from other compartments (i.e., microsomes, lysosomes, and so on). Therefore, more sophisticated purification methods should be used. In addition, the authors should also test these fractions for non-mitochondrial proteins from other membrane organelles.
      3. Figure 2. Coomassie blue staining does not show any signal in the "M" fraction. It can be interpreted that the authors do not get any mitochondria there, and therefore the lack of Ub signal is due to the absence of the protein in the samples. Using the same amount of protein from each fraction would probably reduce the necessity of 15x enrichment.
      4. Figure 3. It is puzzling why the HA-UBQ presence is so strong in the crude mitochondrial fraction, but the preSu9-HA-Ub signal (mito-matrix) is comparatively weak. These data suggest that the crude mito-fraction could be highly contaminated with OTHER membranes. On the other hand, the preSu9-HA-UBQ signal is no more than 1-5% of the total mitochondrial signal. The high enrichment of the HA-Ubi in both cytosols and the mitochondria could indicate the OMM ubiquitination or (again) contamination by other compartments. The constructs with MTS are detected in the mitochondria. However, the localization of tagged MTS-Ubi in a non-targeted compartment (e.g., cytosol) should be excluded by additional exposure times. Because the manuscript talks about eclipsed proteins, this is important.
      5. Figure 3C-E. These data indeed suggest that the Ub-conjugates could be formed inside the mitochondria. However, the above-discussed possibility that other than mitochondria compartments co-sediment in the 10,000g fractions makes the data interpretation highly challenging.
      6. Figure 4. Unsurprisingly, mitochondrial targeting of Ub leads to detecting some co-immunoprecipitating mitochondrial proteins. However, these data do not support the notion that Ub conjugation machinery acts inside the mitochondria and that the target proteins are indeed conjugated with Ub (the interaction with Ub is not equal to being conjugated). At the minimum, the authors should provide a validation that some of the detected mitochondrial matrix proteins are indeed ubiquitinated. To this end, purified mitochondria could be used for the candidate protein IP under denaturing conditions and then blotted for the candidate protein and Ub.
      7. Figure 5. The knock-out of the E2 Rad6 causes a change in the mitochondria ubiquitination pattern. This is an interesting observation, but again it does not prove that the change in the mitochondrial ubiquitination is due to the activity of Rad6 inside of the mitochondria, as opposed to ubiquitination of the OMM proteins or contaminating fractions. One also wonders why overexpression of mitochondria-targeted Ub would be necessary to detect the ubiquitination if this process was physiologically relevant, especially given that detecting endogenous Ub is not challenging. Furthermore, the apparent increase in ubiquitination in E2 mutant cells (Fig. 5) should also be addressed in more detail. Finally, data from one WB is shown, and quantification of several independent experiments should also be provided.
      8. Figure 6. Can the authors provide Western blot data showing the expression of Rad6? Furthermore, quantifying these rescue experiments is necessary to make this conclusion more solid.
      9. Figure 7. The authors found that preSu9-Rad6-α have problems being imported into the mitochondria matrix; therefore, they rebuild it as a preSu9-Rad6-α-SL17 protein. SL17 is a degron that targets the cytosolic protein (not imported into the mitochondria) to the proteasome and degraded (Figs. 7A-B-C). These issues could be a red flag for the rest of the manuscript, suggesting that other constructs (that were not critically evaluated for their localization in this work) could leak to different cellular compartments.
      10. The manuscript needs to be carefully edited, some references are in the not correct format, and there are issues with figure labels.

      CROSS-CONSULTATION COMMENTS

      I agree with a great summary by reviewer 1. This discovery should be validated by top-quality data.

      Significance

      In the manuscript by Yu et al., the authors test the concept that certain proteins are unevenly distributed within distinct cell compartments. Due to this localization discrepancy, protein detection in some subcellular compartments can be "eclipsed" by a predominant subset of specific protein localizing in another cell compartment their actual distribution. Therefore, tiny amounts of physiologically relevant proteins could be biologically relevant. Still, their function in some locations can be overlooked (or eclipsed) because of the high expression level of the same protein in another subcellular compartment(s). Although, this concept is not particularly novel. For example, it is already known that many different proteins can localize to distinct cellular locations (e.g., permanent mitochondrial and peroxisomal localization of many proteins or transient localization of particular proteins to separate cell compartments). The authors apply a yeast system and an α-complementation assay to test further the role of such eclipsed proteins in mitochondrial biology. Specifically, they focus on the ubiquitin (Ub, or as abbreviated incorrectly in this manuscript; Ubi) conjugation pathway, components of which have never been convincingly shown to localize inside the mitochondria. This work proposes that certain ubiquitination events can occur inside yeast mitochondria. This work would represent a significant/exceptional discovery if supported by compelling data. However, the major problem with this work is that the conclusions are based on the ectopic expression of distinct proteins. This approach is not failproof in precise protein expression/delivery to the specific subcellular locations and is likely to result in a non-specific localization. Thus, the problem of eclipsed proteins is addressed by the methodology that may lead to the artificial generation of eclipsed overexpressed proteins. A more effective approach would be if the authors found a way to study this issue with endogenous proteins. The need for overexpression of mitochondria-targeted ubiquitin makes it challenging to reconcile the physiological role of these fundings. In addition, some critical technical issues and omissions further reduce the potential impact of this work (see Specific comments above). For example, strong evidence of mitochondria fraction purity and additional evidence that all the essential constructs used in this work are not misdirected to a different compartment are needed.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      Summary:

      In this manuscript, Zhang et al. investigate whether ubiquitination occurs inside mitochondria of the budding yeast S. cerevisiae. They first observe thanks to a sensitive complementation assay that several components of the yeast ubiquitination (and deubiquitination) machinery can localize inside mitochondria. To be able to specifically probe ubiquitin conjugates assembled inside mitochondria they fused HA-tagged ubiquitin to a mitochondrial targeting sequence. Using this construct, they demonstrate that ubiquitin conjugates can be assembled in mitochondria. A series of elegant experiments demonstrates that the pattern of ubiquitin conjugates depends on the mitochondrial localization and the activity of the ubiquitin conjugating enzyme Rad6. Altogether, these results convincingly demonstrate that ubiquitination can occur inside yeast mitochondria when ubiquitin is intentionally targeted inside this organelle. It however remains unclear whether mitochondrial ubiquitination occurs in endogenous conditions (without targeting ubiquitin into this compartment) and whether it affects mitochondrial functions.

      Major comments:

      1) The materials and methods section is lacking important information (western blot protocol, details of antibodies, strains, plasmids...). It is thus difficult to evaluate how several experiments were performed and how their design (e.g. the promoters chosen to express tagged proteins) could impact the interpretation of the results. This is a major issue that needs to be corrected. The main text should also explicitly indicate whether tagged proteins used in the alpha-complementation assay are overexpressed or not.

      2) Despite the previous comment, the data presented in the manuscript convincingly demonstrate that multiple components of the ubiquitination machinery can localize within mitochondria and that ubiquitin conjugates can be assembled in mitochondria when ubiquitin is modified to be intentionally targeted into this compartment. However, little data is shown to support the hypothesis that ubiquitin conjugates can be assembled in mitochondria when ubiquitin is not fused to a mitochondrial targeting sequence. Thus, in my opinion, the evidences presented in the current manuscript are not sufficient to conclude that ubiquitin conjugates are assembled in mitochondria in endogenous conditions (as this is done implicitly). Additional evidences are needed to draw this conclusion (see some experimental suggestions hereafter). Without further evidences, the speculative aspects of the claim that "ubiquitination occurs in the mitochondrial matrix" should be discussed explicitly.

      3) The authors used a mass spectrometry approach to identify mitochondrial ubiquitination substrates. However, they have not yet succeeded in identifying a substrate whose modification is specifically regulated by a given component of the mitochondrial ubiquitination machinery. They have also not identified a phenotype or process impacted by mitochondrial ubiquitination. Thus, at this stage, the biological consequences of mitochondrial ubiquitination remain elusive.

      4) The authors have not directly investigated whether ubiquitin itself (without a mitochondrial targeting sequence) localizes in mitochondria. I encourage them to address this question since it would provide an important piece of evidence suggesting that mitochondrial ubiquitination can occur in endogenous conditions. This could be done using the alpha-complementation assay and the results could be presented within Figure 1. Ideally this experiment should be performed without overexpressing ubiquitin. Note that if the authors decide to use a C-terminally tagged form of ubiquitin for this experiment, the GG motif of ubiquitin should be mutated to avoid cleavage of the alpha tag by cellular DUBs. This form of ubiquitin will not be conjugatable, but this is not an issue for this experiment since its aim is to determine whether ubiquitin can be targeted to mitochondria, not to probe conjugates.

      5) In the top panels of Figure 2 and S1, free ubiquitin is well detectable in the total and cytosolic fractions. It is however not clear to me whether it is also detectable in the concentrated mitochondrial fraction. If yes and if it would be resistant to trypsin digestion, it would provide an additional evidence that endogenous ubiquitin can be targeted to the mitochondrial matrix (see previous comment).

      6) The data shown in the top panel of Figure 2 and S1 also suggest that free ubiquitin is less concentrated in mitochondria than in the cytosol (since it is more difficult to detect in the concentrated mitochondrial fraction than in the cytosolic fraction, see previous comment). It is thus possible that the use of preSu9-HA-Ubi (or preFum1-HA-Ubi) lead to an artificially high intra-mitochondrial concentration of free ubiquitin. As the concentration of free ubiquitin is known to impact ubiquitination processes, I encourage the authors to compare the relative levels of free ubiquitin present in the mitochondrial fraction prepared from wt and preSu9-HA-Ubi (or preFum1-HA-Ubi) expressing cells. If free ubiquitin is detectable in mitochondrial fractions and resistant to trypsin (see previous comment), this could be done by repeating the experiment shown in Figure 3B and probing the blot with an antibody that recognizes free ubiquitin.

      7) I strongly encourage the authors to provide more data indicating that "ubiquitination occurs in mitochondria" by performing experiments that do not rely on the use of the preSu9-HA-Ubi or other forms of ubiquitin that are intentionally targeted to mitochondria. For instance, they could analyse the pattern of HA-Ubi conjugates of trypsin digested mitochondrial fractions prepared from wt, rad6-delta, and rad6-delta complemented with preSu9-Rad6-alpha-SL17. Note that if trypsin digested mitochondrial fractions are too contaminated by ubiquitinated proteins present outside mitochondria to perform this experiment, the authors may use the unspecific DUB Usp2 as an alternative protease to strip ubiquitinated proteins from the mitochondria periphery.

      Minor comments:

      1) Overall, the manuscript is well organized and easy to follow. The text is clearly written; the figures are well annotated.

      2) The authors should provide full images of all the blots with anti-ubiquitin and anti-HA antibodies so that one can see the bands corresponding to free ubiquitin (or free HA-Ubi). For instance, in Figure 3B, it is not possible to see the presence (or absence) of the band corresponding to free HA-Ubi because the very bottom of the image is cut.

      3) The authors should indicate whether the MTS of Su9 (and Fum1) are expected to be cleaved after import of preSu9-HA-Ubi (and preFum1-HA-Ubi) in mitochondria. They should also label on the corresponding immunoblots the presence (or absence) of the band corresponding to the free preSu9-HA-Ubi (and preFum1-HA-Ubi) (or HA-Ubi if the MTS is expected to be cleaved from these constructs).

      4) In Figure 3B, the ubiquitin conjugates produced with preSu9-HA-Ubi and preFum1-HA-Ubi have different migration patterns. I think this should be explicitly mentioned and discussed. Could it be due to the presence of lysine residues in the Su9 or Fum1 MTS that could lead to the assembly of artificial ubiquitin chains?

      5) The authors indicate that "endogenous Rad6 [...] is expressed at very low levels and can hardly be detected in the mitochondrial fraction by WB (Figure S5)". I did not manage to observe the band corresponding to endogenous Rad6 in the mitochondrial fraction in the pdf. The authors should provide a more contrasted or better quality image.

      CROSS-CONSULTATION COMMENTS

      • I agree with reviewer 2 that proper validation of the complementation assay is crucial for this manuscript. I was myself wondering whether it uses endogenously tagged proteins or whether it is based on an overexpression system. I imagine this information will be detailed in the manuscript in preparation mentioned by the authors. I am therefore wondering whether it would be possible to ask the authors to provide the draft of this manuscript (or at least the validation part).

      • I agree with most comments of reviewer 3. Regarding the hypothesis that preSu9-HA-Ubi could form aggregates on the cytosolic surface of the mitochondria, I think that the results presented on Figure 7B rather argue against it (since they indicate that Rad6 localized inside mitochondria can restore the pattern of ubiquitin conjugates). That's why (in my opinion) the major question the author now need to adress is whether intra-mitochondrial ubiquitination occurs in endogenous conditions (ie without forcing ubiquitin into this compartment and without E2 or E3 overexpression).

      Significance

      The finding that ubiquitination occurs inside mitochondria would be an important conceptual advance, which would open new perspectives both for ubiquitination and mitochondrial biology research. However, the significance of the current manuscript is limited because the presented evidences heavily rely on the use of artificial conditions (ubiquitin tagged with a mitochondrial-targeting sequence) that may trigger irrelevant ubiquitination events. The significance would be much higher if the authors would provide further evidences indicating that intra-mitochondrial ubiquitination occurs in endogenous conditions and/or if they had identified a mitochondrial process specifically impacted by mitochondrial ubiquitination.

      Expertise of the reviewer: Ubiquitination, Yeast biology, protein-protein interactions. No specific expertise in mitochondrial biology

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Reviewer #1:


      1) The authors could consider qualifying the observations as preliminary as no

      mechanistic data or longer-term pathophysiology is investigated. Indeed, the latter is well

      beyond the current scope and may require generation of cell-type specific STING ki mice.

      • *

      Thank you for the comment. We have qualified our observations as preliminary (line 662).

      Indeed, generating cell-type specific STING ki mice is part of our future plans.

      2) The authors consistently write "NF-kB/inflammasomes" - these two pathways (although

      related) are quite distinct and should not be lumped together in such a way.

      • *

      Thank you for this important note, we now corrected the text (for example see section headings in the Results section, lines 338 and 415).

      3) Line 79: "NRLP3" should be corrected to NLRP3.

      • *

      Line 210: age of "adult mice" in weeks should be state in the text and figure legend.

      Thank you, corrected.

      4) Line 262: In Figure 3B and D the images look very different and there is no indication of

      what a positive inclusion is? This should be indicated on the image.

      • *

      Thank you for the suggestion. We replaced the corresponding panels with new images, where we show the nuclei with blue, and the Thioflavin S staining with magenta pseudo-color (current Figure 3E). We marked the outline of Thioflavin S positive cells with yellow. An inset showing the magnification of some neurons with inclusions is also presented.

      5) Line 280: The data of Ifi44 should also be mentioned in the text.

      • *

      Thank you. We performed new experiments to show the gene expression changes in the

      striatum and in the substantia nigra, therefore majority of the gene expression data from the cortex has been moved to the supplementary material (supplemental Figures 3 and 5), and is not discussed in detailed in the current manuscript.

      6) Line 290: Figure 4, Examining IL-1B and Caspase-1 transcripts is not a readout of

      inflammasome activation. pro-IL1B is upregulated in response to NFkB activity. Inflammasome

      activation is commonly examined in other methods e.g. via ASC puncta formation (imaging

      based), active IL-1B secretion (ELISA), Caspase-1 and IL-1B cleavage via western blot

      Thank you for this suggestion, we performed new experiments and added the data as Figure 6.

      • We performed Western blot analysis to detect IL-1β cleavage and NLRP3 proteins from the striatum (Figure 6C-E). 2) We quantified the number of ASC puncta within microglia and astroglia from striatal sections (Figure 6F-I). 3). 3) We also measured the protein levels of several additional immune mediators in the striatum of STING ki and KO animals (supplemental Figure 6, summary heatmap is on Figure 7A). 7) Line 310: The NF-kB subunit examined should be stated (p65?). Furthermore, IRF3

      translocation might be a better readout for STING activation.

      • *

      We indeed detected the p65 subunit of NF-kB (antibody is listed in the supplemental Table), and now it is also indicated in the text (line 366). We also performed subcellular fractionation and quantified IRF3 in the nuclear and cytoplasmic fractions. The data is now added on Figure 6A, B.

      8) Discussion: Given the findings here suggest a strong role for NF-kB, a short discussion

      of IFN vs non-IFN responses from STING should be included. There have been a number of

      seminal papers demonstrating the importance of non-IFN STING responses of late as well as

      much evidence from SAVI mice to suggest some non-IFN driven pathologies.

      • *

      Thank you for the suggestion. The data on inflammasomes were given a separate section in the results (from line 395). In the discussion, from line 535 we discuss the IFN dependent response and from line 548 we discuss the non-IFN driven pathways.

      9) Discussion: Is there any evidence from the human SAVI patients of neuroinflammation

      etc. This should be mentioned either way in the discussion

      • *

      Thank you for this comment. The manifestation of neurological symptoms is not a core feature of the human SAVI disease. Some patients suffer from various neurological symptoms e.g. calcification of basal ganglia, spastic diplegia and episodes of seizure (Fremond et al., 2021). We inserted a short text in discussion (lines 532-534).

      10) Discussion: There is a large body of work demonstrating STING-induced cell death in

      numerous cell types. Despite this it is not mentioned nor discussed but should be. It could

      represent how dopaminergic neurons are lost in the STING ki mice.

      • *

      Thank you for pointing out the gap in our discussion. We added additional text in lines 604-618.

      11) The resolution/quality of some of the imaging is not great but this may be due to PDF

      Compression

      Thank you, we upload the figures with higher resolution.

      Reviewer #2:


      1) The authors base their conclusions (line 215-216) on the neuroinflammatory status of

      their mice strongly on an assessment of the Iba1 and GFAP-positive area fraction. Increase of

      Iba1 and GFAP areas does not necessarily correlate with an increased cytokine production and

      release by the cells. Therefore, in addition the measurement of cytokine mRNAs it would be

      necessary to measure cytokines also on protein level (see also #4 and #5).

      • *

      Thank you for this suggestion, we measured the protein levels of several immune mediators with LEGENDplex™ assay from the striatum, and the new data are included as Figure 7A and supplemental Figure 6.

      2) In the same context: Is the increase of Iba1 and GFAP- covered area due to increased

      proliferation of microglia and astrocytes or due to increased expression of these markers in

      activated glia? How is the number of Iba1/GFAP-positive cells affected?

      • *

      We quantified the number of glia cells in the striatum and in the substantia nigra of adult STING WT and STING ki mice, and, parallel with higher immunoreactivity for the corresponding markers, we detected increased number of cells as well. The quantifications are now included in supplemental Figure 1.

      3) Nowadays we know that microglia and astrocytes can exist in a variety of activated

      states which can be either beneficial or detrimental. An analysis of disease-associated

      microglial markers (Keren-Shaul et al. 2017) would give a good picture of the state microglia are

      in.

      • *

      Thank you for the suggestion. In addition to the panel of immune modulators at the protein level (supplemental Figure 6), we performed qPCR analysis of additional “M1” marker (Nos2) and additional “M2” markers (Il4, Fizz2, Ym1) (Gong et al., 2019). The data is included in Figure 7A and shown in supplemental figure 6. The findings are described from line 431.

      4) It also would be of interest to determine which cell type is responsible for the observed

      neurodegeneration. Which cytokines are released by microglia or astrocytes upon STING

      activation? Even in vitro experiments would help here to get a more profound understanding.

      • *

      We agree with the suggestion, however, the further in vitro experiments are beyond the scopes of this study and will be the basis of a future project.

      5) In line 273 the authors describe that STING is known to activate NFkB and the

      inflammasome. As proof that this is also occurring in their mouse, they perform qPCR analysis

      of whole brain IL-1b, TNF-a and Casp1 expression. While this analysis indicates that there is

      indeed an increased mRNA production of proinflammatory cytokines in the brains of STING ki

      mice, it does not give any indication whether the inflammasome is active or not. The inflammasome is a protein complex largely regulated on protein level. Meaning an assessment

      of the cleavage of Caspase 1 on protein level or the presence of cleaved IL-1b in comparison to

      uncleaved Pro-IL-1b by Western Blot as well as a staining for the number of inflammasomes

      would be required to draw these conclusions.

      • *

      Thank you for the suggestion. We performed additional experiments: 1) Western blot to detect pro-IL1b and IL1b and NLRP3 proteins from the striatum (Figure 6C-E), and 2) we quantified the number of ASC puncta within microglia and astroglia from striatal sections (Figure 6F-I).

      6) To conclude that NFkb/inflammasome pathway is the most active/crucial in astrocytes

      (line 354) a staining for ASC inflammasomes would be of importance, especially as astrocytes

      normally do not express NLRP3.

      • *

      Thank you for this comment. We stained brain sections for ASC specks and for microglia (Iba1) and astroglia (GFAP) markers (Figure 6F-I). Although amount of ASC specks in astroglia was lower than in microglia, we found still a substantial amount of ASC specks in astroglia in the brains of STING ki animals.

      7) As already shown for ALS (Yu et al., 2020) and Parkin KO (Sliter et al. 2018), the authors want to

      further assess the relevance of the STING pathway to PD (line 27-28). Therefore, an in-depth analysis of

      key PD hallmarks beyond phosphorylated a-synuclein, loss the other was parkin/PINK related (so TDP

      deleted) of TH-stained neurons and dopamine reduction is needed. In the discussion the authors

      hypothesize that autophagy (line 467) may be linked to the observed phenotype. Therefore,

      assessment of autophagy/mitophagy as well as mitochondrial dysfunction and mtDNA should

      be analysed. In the same line of thought it would be important to know if and how the observed

      dopamine reduction effects mouse behaviour, thus mice should be subjected to the Rotarod or

      pole or beam walk test.

      • *

      Thank you for these suggestions. In the work by Yu et al. and Sliter et al., the STING pathway was shown to mediate neurodegeneration resulting from TDP-43 pathology and mitochondrial damage. Our work is complementary by investigating the effects of constitutive activation of STING. We have therefore focused on the signaling pathways downstream of STING. As mentioned above, the most important next step will be to separate the contributions of neuronal and glial cells by generating cell type specific STING activation. Of course, it will be interesting to see at a later time point whether STING activation feeds back. We also speculate that STING activation may also cause TDP-43 pathology. Yet, this will be part of a future study. To acknowledge that the pathology is not specific to alpha-synuclein, we added a short statement from line 634.

      With respect to the comprehensive analysis of the PD phenotype, our work includes the

      classical parameters of TH neuron number, TH fiber density, dopamine concentration and

      synuclein pathology. With respect to mouse behavior, we note that the STING ki mice have severe inflammation in the lung, kidney and other (peripheral) organs, reduced body weight and reduced lifespan (Luksch et al., 2019; Motwani et al., 2019; Siedel et al., 2020). Motor deficits cannot be attributed to dopamine neuron degeneration and for this reason were not included (stated in the Discussion, lines 624-625). In order to expand the description of the PD phenotype we now included measurements of cytosolic reactive oxygen species, mitochondrial oxygen species and nitric oxide, which result from inflammation and are known to affect dopaminergic neurons (new Figure 8).

      Reviewer #3:


      1) The method for quantification of TH-positive cells is not sufficient. They just described

      how they stained every fifth sections but did not mention how they count. This is a critical point

      and they should carefully provide information more than just referring their previous paper.

      Counting of dopaminergic neurons and quantification of fibers was described in a dedicated section of the methods. This section has now been expanded (from line 154).

      2) It is not persuasive that they did not investigate local inflammation in SN. They

      presented increased microglia and astrocytes in the striatum but not analyzed these cells in SN

      • *

      Indeed, we measured neuroinflammation in the substantia nigra as well, however, although increased in STING ki mice, it was less pronounced than neuroinflammation in the striatum. We now include the quantification of area fraction as well as cell number counting of microglia and astroglia in the substantia nigra of STING WT and STING ki animals (supplemental Figure 1), and also the expression of inflammatory mediators in Figure 4.

      3) In Figure 3, they analyzed alpha-synuclein phosphorylation and beta-sheet structure in

      the striatum. This is funny from the aspect of Parkinson's disease, which dominantly affects SN.

      They should perform similar experiments with SN samples. In a different aspect, the aggregates

      detected by Thio S may not be alpha-synuclein and could be tau, TDP43 or other substances.

      Phospho-synuclein of course does not mean aggregation, so they can consider electron

      microscopy.

      • *

      We agree with the reviewer. To complement our data, we therefore performed solubility assay both from the striatum and from the substantia nigra to quantify the ratio of alpha-synuclein in the Triton X-100 soluble and insoluble fractions (Figure 3C, D) as previously (Szego et al., 2022; Szegő et al., 2019). Additionally, we quantified phosphorylated alpha-synuclein from the substantia nigra as well Figure 3A,B).

      We also agree with the reviewer that the presence of Thioflavin S-positive inclusions may also contain other, beta-sheet forming proteins and noted this from line 634.

      4) Figure 5, pSTAT3 increased in Iba1-negative cells, which seem neurons from the size of

      nuclei. First, the authors should investigate the identity of pSTAT3-positive cells with GFAP and

      MAP2. If pSTAT3 is actually increased in neurons, what does it mean in the pathology? For

      instance, in viral infection, STAT3 activation triggers suicide of neurons to prevent further

      proliferation of viral particles in neurons. Is it homologous or other function?

      • *

      Thank you for this suggestion. The brain sections were stained for Iba1 and GFAP. pSTAT3 nuclear staining indeed increased in non-glia cells, based on the morphology, we think in neurons. However, detailed characterization of the signal is out of the scopes of this (preliminary) study.

      5) In Figure 6 and overall, cell types in which the activation of three signaling pathways,

      were mixed up and hard to understand the actual situation in the brain.

      • *

      In our model, STING is activated in all cells. Consequently, we cannot determine the origin of immune mediators found elevated in the STING ki mice. This will require cell type specific STING activation. In order to react to the reviewer’s comment and be clearer, we have added more details about the brain region and age of mice used for each analysis also in the figures.

      6) In the method section, the original paper for generation of heterozygous STING N153S

      KI mice should be Warner et al, JEM 2017.

      • *

      We used a STING N153S ki mouse strain that was independently generated in the Technical University Dresden (Luksch et al., 2019).

      7) NF-κB stains seem located in cytoplasm in Figure 5B.

      • *

      We agree: especially in the young STING ki mice, cytoplasmic NF-kB staining is increased

      compared to STING WT mice. To quantify nuclear translocation, however, we counted the

      number of those cells where NF-kB signal was overlapping with the nuclear Hoechst staining.

      8) In Figure 4 and 6, why the authors evaluate gene expressions in frontal cortex instead of

      SN or striatum.

      • *

      As noted in several comments, we show here that the STING-induced pathology involves

      dopaminergic neurons, but believe that it is not specific for the dopaminergic system given that STING-ki is ubiquitously expressed. For practical reasons, we have used cortical samples for the expression analysis. For consistency, we now performed additional qPCR measurement from the striatum and from the substantia nigra and included them as new Figure 4 and supplemental Figure 6N-Q. The previous data from the cortex was moved to the supplemental Figures 3 and 5. Additionally, we measured the levels of several inflammatory modulators from the striatum of STING ki and KO animals (Figure 7A and supplemental figure 6A-M).

      9) In some groups (Sting-ki;ifnar1-/- in Fig 6C, 6E), the values were separated to two

      groups, which makes readers to doubt on soundness of their genotyping.

      • *

      Our genotyping protocol is highly standardized, and the genotype of the animals were correctly assigned. Here we provide an example of gel images showing the products after PCR reactions for the STING N153S allele (Figure 1a), STING WT allele (Figure 1b), Ifnara WT allele (Figure 1c) and lack of Ifnara allele (Figure 1d) of the same animals. We note that a bimodal distribution of phenotypes is often observed in Ifnar-/- mice.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      In this manuscript, the authors tried to investigate the role of STING in neurodegeneration of dopaminergic neurons with heterozygous STING N153S knock-in mice and their offspring mated with IFNAR or Casp1 KO mice. They observed preliminarily the reduction of dopaminergic neurons (TH-positive cells) in substantia nigra (SN), and added further investigation mostly based on morphological analysis. Though the topic they investigated is highly important, their data remain in preliminary states and are not well organized from the aspect of brain regions and cell types (i.e., neuron, astrocyte or microglia). It is a pity that they did not provide sufficient results for this important question.<br /> The rationale for that they focused on alpha-synuclein but not on other neurodegenerative disease proteins is not strong. Collectively, although their data have not reached to construction of a hypothesis, depending on the level of journal, the manuscript could be publishable after extensive additional experiments and rigorous revision.

      Major points

      1. The method for quantification of TH-positive cells is not sufficient. They just described how they stained every fifth sections but did not mention how they count. This is a critical point and they should carefully provide information more than just referring their previous paper.
      2. It is not persuasive that they did not investigate local inflammation in SN. They presented increased microglia and astrocytes in the striatum but not analyzed these cells in SN.
      3. In Figure 3, they analyzed alpha-synuclein phosphorylation and beta-sheet structure in the striatum. This is funny from the aspect of Parkinson's disease, which dominantly affects SN. They should perform similar experiments with SN samples. In a different aspect, the aggregates detected by Thio S may not be alpha-synuclein and could be tau, TDP43 or other substances. Phospho-synuclein of course does not mean aggregation, so they can consider electron microscopy.
      4. Figure 5, pSTAT3 increased in Iba1-negative cells, which seem neurons from the size of nuclei. First, the authors should investigate the identity of pSTAT3-positive cells with GFAP and MAP2. If pSTAT3 is actually increased in neurons, what does it mean in the pathology? For instance, in viral infection, STAT3 activation triggers suicide of neurons to prevent further proliferation of viral particles in neurons. Is it homologous or other function?
      5. In Figure 6 and overall, cell types in which the activation of three signaling pathways, were mixed up and hard to understand the actual situation in the brain.

      Minor points

      1. In the method section, the original paper for generation of heterozygous STING N153S KI mice should be Warner et al, JEM 2017.
      2. NF-κB stains seem located in cytoplasm in Figure 5B.
      3. In Figure 4 and 6, why the authors evaluate gene expressions in frontal cortex instead of SN or striatum.
      4. In some groups (Sting-ki;ifnar1-/- in Fig 6C, 6E), the values were separated to two groups, which makes readers to doubt on soundness of their genotyping.

      Significance

      • Conceptual for the field.
      • Genetic analysis of the hyperactive STING mouse model in neurodegeneration is new.
      • Researchers in the field of neurodegeneration and immunology audience might be interested.
      • Neurodegeneration, innate immunity, molecular biology, neuropathology, neurology.
    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      Summary:

      Szegö et al. show that constitutive activation of the stimulator of interferon genes (STING) by the gene variant N153S in a heterozygous mouse model leads to reduction of dopaminergic neurons and increased glial cell activation. The comparison of juvenile (5 weeks) and adult (20 weeks) mice nicely shows that increased glial cell activation preceded the neurodegeneration induced by STING activation. Assessment of cytokine mRNA expression as well as phosphorylated a-synuclein revealed increased pathology in adult STING ki mice. The authors identified NF-kB, Casp1 as well as nuclear pSTAT to be upregulated in these mice. Using a conclusive step-by-step assessment of the STING cascade components, the authors show that glial activation and dopaminergic neuron degeneration partially depend both on Casp1 and Ifnar1.

      Major points:

      1. The authors base their conclusions (line 215-216) on the neuroinflammatory status of their mice strongly on an assessment of the Iba1 and GFAP-positive area fraction. Increase of Iba1 and GFAP areas does not necessarily correlate with an increased cytokine production and release by the cells. Therefore, in addition the measurement of cytokine mRNAs it would be necessary to measure cytokines also on protein level (see also #4 and #5).
      2. In the same context: Is the increase of Iba1 and GFAP- covered area due to increased proliferation of microglia and astrocytes or due to increased expression of these markers in activated glia? How is the number of Iba1/GFAP-positive cells affected?
      3. Nowadays we know that microglia and astrocytes can exist in a variety of activated states which can be either beneficial or detrimental. An analysis of disease-associated microglial markers (Keren-Shaul et al. 2017) would give a good picture of the state microglia are in.
      4. It also would be of interest to determine which cell type is responsible for the observed neurodegeneration. Which cytokines are released by microglia or astrocytes upon STING activation? Even in vitro experiments would help here to get a more profound understanding.
      5. In line 273 the authors describe that STING is known to activate NFkB and the inflammasome. As proof that this is also occurring in their mouse, they perform qPCR analysis of whole brain IL-1b, TNF-a and Casp1 expression. While this analysis indicates that there is indeed an increased mRNA production of proinflammatory cytokines in the brains of STING ki mice, it does not give any indication whether the inflammasome is active or not. The inflammasome is a protein complex largely regulated on protein level. Meaning an assessment of the cleavage of Caspase 1 on protein level or the presence of cleaved IL-1b in comparison to uncleaved Pro-IL-1b by Western Blot as well as a staining for the number of inflammasomes would be required to draw these conclusions.
      6. To conclude that NFkb/inflammasome pathway is the most active/crucial in astrocytes (line 354) a staining for ASC inflammasomes would be of importance, especially as astrocytes normally do not express NLRP3.
      7. As already shown for ALS (Yu et al., 2020) and Parkin KO (Sliter et al. 2018), the authors want to further assess the relevance of the STING pathway to PD (line 27-28). Therefore, an in-depth analysis of key PD hallmarks beyond phosphorylated a-synuclein, loss of TH-stained neurons and dopamine reduction is needed. In the discussion the authors hypothesize that autophagy (line 467) may be linked to the observed phenotype. Therefore, assessment of autophagy/mitophagy as well as mitochondrial dysfunction and mtDNA should be analysed. In the same line of thought it would be important to know if and how the observed dopamine reduction effects mouse behaviour, thus mice should be subjected to the Rotarod or pole or beam walk test.

      Significance

      The manuscript is well written and clearly structured. The data are convincing and correlate well with earlier works, however they lack novelty. The findings that STING exhibits proinflammatory (Abdullah et al. 2018; Sharma et al., 2020; Glück et al., 2017; Yu et al. 2020, 2021) and neurodegenerative effects (e.g. the rescue of neuron loss and motoric defect shown in STING-KO Parkin mutator mice by Sliter et al. 2018) were already shown. The later paper points out already the relevance of STING in PD. All pathway components investigated here were already known to be triggered by STING and/or are known for their involvement in neurodegeneration and an unbiased screening for novel pathways triggered by STING, which could have revealed new perspectives, was not included. An assessment of the following aspects would give a missing novel insight into the role of STING in neurodegeneration.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      Summary:

      In the paper by Szego et al., the authors examined the contribution of the innate immune receptor STING to neuroinflammation and the degeneration of dopaminergic neurons. To do this they utilised a systemic mouse model of STING-associated vasculopathy with onset in infancy (SAVI) driven by a gain-of-function knock-in (ki) mutation in STING (N153S in this case). This mouse model has been well characterised previously with a focus on the major pathologies commonly observed in the human SAVI patients (e.g. Interstitial Lung Disease, pulmonary fibrosis) but little has been done to examine neuroinflammation in this setting. As such, the approach is a good one and the observations made suggest that aberrant STING activation, in addition to driving neuroinflammation, causes loss of dopaminergic neurons and may contribute to aSyn pathology. Overall this is an interesting observation study but lacks any mechanistic insights into how STING may mediate these processes and if what the functional consequences of STING-induced neuroinflammation are for the animal - If aged do they ultimately acquire a PD-like phenotype?

      Major comments:

      • Based on the data presented the key conclusions from the authors are convincing and not overstated.
      • The authors could consider qualifying the observations as preliminary as no mechanistic data or longer-term pathophysiology is investigated. Indeed, the latter is well beyond the current scope and may require generation of cell-type specific STING ki mice.
      • The data and the methods are presented in such a way that ensure they are reproducible.
      • All the experiments appear to be adequately replicated and appropriate statistical analysis has been applied.

      Minor comments:

      • The authors consistently write "NF-kB/inflammasomes" - these two pathways (although related) are quite distinct and should not be lumped together in such a way.
      • Line 79: "NRLP3" should be corrected to NLRP3.
      • Line 210: age of "adult mice" in weeks should be state in the text and figure legend.
      • Line 262: In Figure 3B and D the images look very different and there is no indication of what a positive inclusion is? This should be indicated on the image.
      • Line 280: The data of Ifi44 should also be mentioned in the text.
      • Line 290: Figure 4, Examining IL-1B and Caspase-1 transcripts is not a readout of inflammasome activation. pro-IL1B is upregulated in response to NFkB activity. Inflammasome activation is commonly examined in other methods e.g. via ASC puncta formation (imaging based), active IL-1B secretion (ELISA), Caspase-1 and IL-1B cleavage via western blot.
      • Line 310: The NF-kB subunit examined should be stated (p65?). Furthermore, IRF3 translocation might be a better readout for STING activation.
      • Discussion: Given the findings here suggest a strong role for NF-kB, a short discussion of IFN vs non-IFN responses from STING should be included. There have been a number of seminal papers demonstrating the importance of non-IFN STING responses of late as well as much evidence from SAVI mice to suggest some non-IFN driven pathologies.
      • Discussion: Is there any evidence from the human SAVI patients of neuroinflammation etc. This should be mentioned either way in the discussion.
      • Discussion: There is a large body of work demonstrating STING-induced cell death in numerous cell types. Despite this it is not mentioned nor discussed but should be. It could represent how dopaminergic neurons are lost in the STING ki mice.
      • The resolution/quality of some of the imaging is not great but this may be due to PDF compression.

      Significance

      • The findings represent a conceptual advance in the field by placing STING as a central mediator in neurological immune dysregulation. This work is of note as it provides evidence of a direct role for STING activity in neuroinflammation which has been otherwise implicated via genetic depletion in other studies in mouse models of PD and ALS.
      • This manuscript is of particular interest to researchers in the innate immunity/immunology fields, neuroinflammation and far beyond due to the enormous attention currently surrounding the cGAS-STING pathway in disease and the rationale design of STING agonists and inhibitors aimed at improving outcomes in numerous inflammatory disease pathologies.
      • Define your field of expertise with a few keywords to help the authors contextualize your point of view. Indicate if there are any parts of the paper that you do not have sufficient expertise to evaluate.
        • I have over ten years' experience in the innate immunity field. Most relevant to this manuscript, I have a strong research program on STING and have an excellent molecular understanding of the pathway as well as the literature surrounding cGAS-STING in disease pathology. I have a basic understanding of neuroinflammation but am by no means an expert in that area. Hence, I cannot fully assess if the authors have used the best methods to make their conclusions.
    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      The authors do not wish to provide a response at this time.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      In this paper by the Vagner lab, co-transcriptional cleavage (CoTC) is discovered as a mechanism to ensure 3'-end processing of selected genes under conditions of global inhibition of 3'-end processing under DNA damage conditions.

      While global inhibition of 3'-end processing acts as a fail-safe mechanism to ensure that mutations arising from DNA damage are not propagated (and instead repaired), the expression of repair genes must be maintained under these conditions. In an elegant serious of experiments, Sfaxi and coauthors have identified CoTC as a mechanism, which allows specific pre-mRNAs to escape 3'-end processing inhibition in response to UV-induced DNA damage.

      This is an important discovery, the article reads well and most of the experiments are technically sound. That having said, I think the authors did not 'sell' this important finding very well. While they initially started their studies based on processing of the p53 pre-mRNA, they later performed RNAseq (Figure 5&6) to identify further genes that are regulated in a CoTC-dependent manner - analogous to the p53 pre-mRNA. In doing so, the authors identify and validate further CoTC-dependent genes. Given the global RNAseq approach that the authors have undertaken but not yet fully exhausted, there are probably more genes hidden that are processed in a similar way.

      I would recommend harvesting the hidden treasure to more comprehensively understand CoTC-dependent processing and its relation to DNA damage conditions. In my opinion, it would be important to perform

      1. GO enrichment analyses of the 108 pre-mRNAs more effectively processed under UV and address the question whether DNA damage repair-related terms can be retrieved
      2. study of further DNA-damaging conditions to address the question if similar patterns and genes can be retrieved under these conditions
      3. complementary analysis of data derived from tumor genome databases whether mutations in the identified CoTC-sites are enriched (which one would expect)

      Finally I wonder, whether a small scheme illustrating conventional versus CoTC processing could enhance access for a broader readership.

      Minor Comments:

      Page 4, 2nd paragraph, last sentence: what is "vcxPAS"?

      Page 6, 2nd paragraph, the TBP RNA is not explained.

      Page 6, 2nd paragraph and following paragraphs. The PCF11-depletion experiments to sort out conventional versus CoTC-dependence is not very well controlled: it is surprising to see that depletion of PCF11, which is already absent under UV (Fig. 1A), seems to modulate processing of TBP under this condition (Fig. 1E). In order to turn this into a bona fide positive control for the entire experimental set-up, it is relevant to show that there are residual PCF11-levels under UV that can be further downregulated by siRNAs under this condition (currently this is not supported by the WB data in Fig. 1B).

      Page 8, 1st paragraph, last sentence: I find the reference to GAPDH and WDR13 as part of a figure that comes far below is a bit confusing

      Page 9, last paragraph, page 10, 1st paragraph: What does the analysis of WDR12, GAPDH and TBP exactly control for?

      Figure 3. Overall, I find the information shown in Fig. 3 somewhat confusing and wonder whether the quality can be improved (partial co-localization of spots, are the spots shown in D -UV an artifact? Etc.)

      Figure 4. I find the composition of panels C and D not very intuitive (I would reorganize the data such that each panel shows the RNA and protein expression data for each candidate individually (panel C for p53 and panel D for p21, respectively)

      Figure 5, panel B: The figure shows that the by far largest number of genes (>3000/3722) is not differentially regulated under UV compared to no-UV conditions. Does this question the commonly made statement that 3'-end processing is globally inhibited under UV quoted here (page 14, 2nd paragraph) and elsewhere?

      Referees cross-commenting

      @reviewer 1 & 3: I fully agree; the PCF11 depletion under UV-conditions is clearly visible. Thank you!

      Significance

      This is an important study to better understand the function and target genes of CoTC-mediated 3'-end processing. It thereby extends earlier studies mainly adressing the underlying molecular mechanisms and rationalizes the function (and evolution) of this gene regulatory principle.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      DNA damage leads to transient inhibition of 3' end processing and a marked reduction of cellular Pcf11 levels, a component of the cleavage factor II (CF II). In previous work, St¬ephan Vagner and colleagues described that p53 mRNA escapes the 3' end processing inhibition through the actions of the DHX36 RNA-helicase and the heterogenous RNA binding protein hnRNP H/F. However, this previous work failed to identify a mechanism through which DHX36 and hnRNP H/F would mediate the escape. In this work Stephane Vagner and his colleagues describe now how a sequence located 1200 nt downstream of the P53 poly(A) signal (PAS) is required to alleviate p53 mRNA from the general DNA-damage-dependent 3' end processing block. The presence of this element makes p53 mRNA 3' end processing independent from CTD-serine-2-phosphorylation and the CFII factor Pcf 11. As a high proportion of non-cleaved p53 pre-mRNA can be found in the nucleoplasm, the authors suggest that this element may be a co-transcriptional cleavage inducing site (CoTC). Deletion of this element renders p53 mRNA susceptible to DNA-damage-induced 3' end processing inhibition and leads to a p53 protein reduction after UV-exposure. Consequently, expression of down-stream targets of p53 is also reduced. The authors identify 9 more candidates for CoTC in other genes encoding for proteins required for the DNA-damage response.

      Major points:

      Although Figures 4 and S7 clearly show how long the RNA is that is retained on the chromatin, it is not clear, how long the RNA is that is released into the nucleoplasm. A Co-TC mechanism would pose that either nucleoplasmic CPSF-mediated cleavage and/or nucleoplasmic exonucleolytic degradation preceded nucleoplasmic polyadenylation. Neither of these points has been addressed by the current manuscript. This could be addressed by transcript reverse transcription analysis with nuclear RNA, in the background of an exosome ko to see if this would allow stabilisation of the un-cleaved RNA and its detection in the nucleoplasmic fraction.

      Minor points:

      It would be good if the site of action of DHX36 and hnRNP H/F could be repeated and put into context with the Co-TC element.

      Introduction; I feel the pause-type termination is probably better explained in either Cortazar et al 2019 or Gromak et al 2006.

      There may be a typo towards the end of the second paragraph: vcxPAS. If this is not a typo, it would be helpful to have this explained better.

      Figure 1A/B the conclusion: "These observations suggest that PCF11 might be dispensable for pre-mRNA 3' end processing following UV-induced DNA damage" is in contradiction to the general 3' end processing defect following DNA-damage that the authors cite. This statement is only understandable with the prior knowledge of p53 mRNA being able to escape this inhibition. I feel it would be helpful to rephrase this.

      Figure 1 E): shifting the entire axis up, is to my reading counterintuitive. I would show all graphs at the same scale.

      Williamson et al (Svejstrup) 2017 showed through DRB-washed PRO-seq profiles that Pol II elongation speed is reduced for at least 8 hrs following UV-exposure, resulting in depletion from Pol II in gene bodies and concentration towards the gene beginnings (transcript start sites, TSS). It would be helpful to have an idea how the transcriptional profile looks on p53 at the time point of analysis - and at which time point after DNA-damage insult the 3' end processing inhibition starts. Such study could also form the beginning of a more in-depth analysis on how the CoTC is mediated. Such an in-depth analysis should also probe the chromatin crosslinking of RNA Pol II, as well as 3' end factors at the regular PAS and downstream Co-TC element. The fact that the smFISH shows signal for the downstream probes of Rad53, suggests that Pol II regularly transcribes to these positions. Could there be another PAS-dependent termination signal in further downstrea areas?

      Figure 5) the sequencing procedure should be explained better in the main text. From the text it is not clear, what sort of sequencing was performed.

      Referees cross-commenting

      @ Reviewer #1:

      Generally agree with Reviewer 1. 2) Figure 3B : I agree that this experiment would benefit from better description. In fact, wouldnt one expect to be there signal in Figure 3D after UV, since cleavage is inhibited? Unless Williamson et al is taken into account, showing that transcription is generally slowed.

      @ Reviewer #3:

      Generally find all these suggestions are very valid and would increase the value of the manuscript. I am not sure if I understand correctly/agree with two comments:

      If understood correctly, this reviewer suggests that there is no Pcf11 under UV treatment conditions as suggested in Figure 1A. However, Figure 1B might show a longer Western Blot exposure or have more material loaded, showing that there is some Pcf11 available for si-mediated knockdown.

      Figure 5 Panel B. I would agree that this panel is not very well explained. My interpretation so far has been in quartiles (left top, less cleaved, less total; top right less cleaved, more total upon UV versus bottom left more cleaved, downregulated and bottom right more cleaved upreagulated upon UV). In which case a significant number of transcripts is no cleaved upon UV. To help with interpretation at least a longer legend could be added.

      Significance

      This manuscript is overall convincing and adds more gravitas to the highly debated observation of co-transcriptional cleavage events. Although this study is by no means mechanistically exhaustive, it shows that the proposed mechanism may be true for the genes of DNA-damage repair factors that need to be "exempted" from the general DNA-damage-induced inhibition of 3' end cleavage. This opens up the exciting possibility that co-transcriptional elements can be used under specific, controlled environmental conditions. Although alternative explanations are possible to explain these pre-mRNA's release from the chromatin, 3' end processing at the regular poly(A) signal is for these RNAs clearly inhibited.

      For a complete classification as Co-TC element however, additional experiments would be required. I am not adding these to the major or minor points, as these in my eyes would constitute a new story. The original literature on CoTC (West et al 2004, Teixeira et al 2004), posed that a Co-TC event provides a 5'phospho entry site that could be used by a molecular torpedo (Xrn2). Part of the controversy about Co-TC cleavage is the question of how such a 5'phospho-end could chemically be generated by autocatalytic cleavage. To substantiate the claim that these elements are indeed Co-TC cleavage events either generated by auto-catalytic cleavage or another enzymatic function, the authors should test if they promote termination in this homologous, as well as a heterologous context.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      Sfaxi et al., significantly extended a current knowledge of the mechanism and the function of co-transcriptional RNA cleavage (CoTC). First, the authors focused on TP53 genes to study the CoTC. They showed TP53 transcripts are cleaved independently of PCF11 and Pol II CTD Ser2 phosphorylation in the UV-treated cells, concluding RNA cleavage at polyadenylation site (PAS) of the TP53 gene occurs post-transcriptionally. This strongly suggests that TP53 gene transcription termination is regulated by CoTC. They also showed a biological importance of the CoTC on TP53 gene expression. Depletion of the potential TP53 CoTC genomic region impaired mRNA and protein levels of p53 and its target p21. This deregulated G1-S phase progression in cell cycle following UV treatment. Finally they extended these findings to other genes by the novel screening approach of the CoTC.

      Minor comments:

      1. P4, Second paragraph, Another model~; Two more papers need to be cited. "Dye and Proudfoot 2001 Cell" "West et al., 2008 Mol Cell"
      2. Figure 3B; The authors should explain more about foci detected by probes A and B.
      3. P10, Last line, strong decrease~; (Figures 4E and ~) -> (Figure 4E, right panels, and~)
      4. Figure 5C; The author should show the entire image of the RNA-seq reads in the gene region, but not just in the windows described in Figure 5A. Also, TP53 and GAPDH genes need to be shown for the controls.

      Referees cross-commenting

      I totally agree with Reviewer #2.

      Significance

      Overall this paper is well described and written. In my view, this will bring important information to the transcription termination field.

      Note, I am not sure that the authors need to include the generality of the CoTC in Figures 5 and 6 since their RNA-seq analysis and its validation for biological functions are incomplete. Therefore I feel that focusing on the TP53 gene may enhance the impact of this paper.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Manuscript number: RC-2022-01481R

      Corresponding author(s): Sebastian Voigt. Mirko Trilling, David Schwefel

      1. General Statements [optional]

      -

      2. Description of the planned revisions

      Reviewer #1: Evidence, reproducibility and clarity

      Using proteome profiling of rat CMV infected cells, the authors of this study identify the E27 protein of rat cytomegalovirus as being crucial for proteasomal degradation of STAT2. Since E27 shares 56% sequence identity to the previously characterized STAT2 antagonist M27 of murine CMV the authors investigated association of E27 with the Cullin4-RING UbL CRL4. Using gel filtration chromatography they provide evidence that E27 forms a stable ternary complex with DDB1 and STAT2 suggesting that E27 bridges STAT2 to DDB1 which is further corroborated by data from cross-linking mass spectrometry. A cross-linked DDB1/DDA1/E27/STAT2 complex was then used for cryo-EM imaging experiments. The subsequent single particle analysis yielded a density map at 3.8 A resolution that was further used to generate an E27 molecular model. At this point it should be noted that resolution was not very high and data form AlphaFold2 prediction and CLMS experiments were necessary to build a model which was described as having "sufficient quality", however, no quality parameters are included for this model. In this model, a cryptic zinc-binding motif was identified that turned out to be well conserved in M27. At this point the study switches to a mutational analysis of M27: MCMV mutants either lacking M27 or bearing an AxAxxAA triple mutation were investigated both in cell culture and in animal models. Surprisingly, the M27-AxAxxA mutant while exhibiting attenuated IFN inhibition was still more active than an M27 deletion mutant. Later during the study it is postulated that this may be due to the fact that E27 binding to STAT2 abrogates the interaction with IRF9, however, this is only predicted from modeling and no experimental data are provided for this hypothesis. Furthermore, modeling approaches were used to predict how E27 replaces endogenous CRL4 substrate receptors and how E27 recruits STAT2 to mediate CRL4-catalysed ubiquitin transfer.

      Reviewer #1: Significance

      __Reviewer #1: __This is an interesting and well written paper describing for the first time in molecular detail how a cytomegalovirus-encoded interferon antagonist degrades STAT2 by mimicking the molecular surface properties of cellular CRL4 substrate receptors.

      This study should be of broad interest for both virologists and structural biologists.

      Authors Response: We thank the reviewer for the insightful and constructive evaluation. We are very grateful for highlighting the significance of our work.

      Reviewer #1: Major points

      __Reviewer #1: __To my opinion the authors should perform mutational analysis in the context of E27 and RCMV. I accept that switching to M27 may be easier due to established procedures for MCMV mutagenesis and analysis, however, since all structural work is primarily done on E27 it would be consequent to confirm these structural predictions in the context of E27 before switching to a related protein.

      Authors Response: As the Reviewer appreciated, there were multiple reasons for the switch from RCMV-E E27 to MCMV M27. Most importantly, the MCMV in vivo infection model in mice is very well-established. Please also note that MCMV is applied far more often by virologists and immunologist as a standard model. Thus, the extension of our findings from RCMV to MCMV increases the relevance and outreach of the study. By performing the experiments in the MCMV context, we also aimed to emphasise that the function of the zinc-binding motif, which structurally organises the DDB1-binding domain, is functionally conserved among E27/M27-like proteins. Obviously, Reviewer #1 could ask why we do not solve the structure of M27 parallel to E27. With the sole exception of E27, none of the rodent M27 homologues could be produced recombinantly in a soluble form, preventing the purification and structure analysis of M27.

      Since we agree with Reviewer #1 that the extension from E27 to M27 may read “a bit rough” without a mutational analysis in the E27 context, we will construct RCMV-E E27 mutants leading to Cys=>Ala exchanges in the Zn-binding motif. An analysis of the interaction between DDB1 and these E27 mutants will be included in the revised manuscript.

      __Reviewer #1: __Moreover, data on the replication of the generated E27 deletion RCMV should be included in the manuscript (i.e. growth curves).

      Authors Response: RCMV mutants lacking the E27 gene exhibit an impaired replication. According to the suggestion, the growth curves will be part of the revised manuscript.

      Reviewer #1: The hypothesis that STAT2/E27 interaction is sterically incompatible with IRF9 binding is only based on structural prediction. It would help if the authors could present experimental evidence for such a mechanism.

      Authors Response: The hypothesis is based on three lines of argumentation: (i) structural data regarding the binding interface between STAT2 and E27 covering the known STAT2-IRF9 interface (Fig. 7F) (Rengachari et al., 2018). (ii) The finding that M27 mutants incapable to bind DDB1 and induce STAT2 degradation along the ubiquitin proteasome pathway retain a residual capacity to inhibit ISRE signaling, suggesting that the binding of M27 to STAT2 suffices to elicit some signaling inhibitory functions (Fig. 7G). (iii) To elicit their function, CRL4 substrate receptors such as E27 interact with two partners. As we discussed elsewhere (Le-Trilling and Trilling, 2020), a simultaneous development of two independent traits violates evolutionary and probability theories. Thus, these receptors must acquire their binding interfaces sequentially, and the first interaction must provide an evolutionary advantage allowing the fixation of the allele in the population. Afterwards, the second binding interface evolves. Thus, a hypothesis in which E27/M27 precursors evolved the capacity to bind STAT2, preventing its association with IRF9 thereby establishing relevant but incomplete IFN inhibition (before the DDB1 interface was invented leading to STAT2 degradation by the proteasome), provides a parsimonious explanation for all these findings without violating evolutionary constraints. To corroborate our argumentation, we will analyse if E27 indeed displaces IRF9 from STAT2 by analytical gel filtration and/or co-immunoprecipitation experiments.

      Reviewer #2: Evidence, reproducibility and clarity

      __Reviewer #2: __The manuscript entitled "Structure and mechanism of a novel cytomegaloviral DCAF mediating interferon antagonism" by Dr. Schwefel and colleagues cleverly combines biochemistry, mass-spectrometry, Cryo-EM and cell biology to dissect how RCMV-E hijacks its hosts ubiquitylation machinery to mediate proteasomal degradation of STAT2, a key player driving the antiviral IFN response. They identify E27 as DDB1-binding element, which is able promote CRL4-dependent ubiquitylation of STAT2, and demonstrate its effect on STAT2 levels by knockout RCMV-E strains. These findings are supported by in vitro reconstitution of the DDB1/E27/STAT2 complex and analyses via XL-MS and Cryo-EM. The obtained data are then powerfully validated and analysed in mutational strains via infection of homologue in vivo models. The results collectively explain how E27 mimics endogenous CRL4 substrate receptors, thereby recruiting STAT2 to be targeted by CLR4 for ubiquitylation in a NEDD8-dependent manner.

      Overall this is an important study that provides convincing insights on how rodent CMVs antagonize their host interferon response by exploiting its ubiquitin-proteasome system.

      The manuscript is well written and its introduction is extraordinarily comprehensive. There are a few minor points for the authors to consider below.

      Authors Response: We thank the reviewer for this very positive assessment.

      Reviewer #2: Significance

      Reviewer #2: The work of Schwefel and colleagues combines several powerful state-of-the art techniques to dissect the mechanism of the viral protein E27 and, for the first time, provides a rational for its ability to act as STAT2 antagonist. They performed outstanding structure-function analyses of the ubiquitin system, including the first global proteomic profiling of RCMV-infected cells, setting the standard for its human counterpart as rodent CMVs are commonly used as infection models. The manuscript is highly suitable for publication in any of the journals associated with the review commons platform.

      Authors Response: Again, we thank the reviewer for these kind words and the appreciation of our work.

      Reviewer #2: CROSS-CONSULTATION COMMENTS

      Reviewer #2: This reviewer agrees that at least testing mutants in the E27 in some assays would be appropriate.

      Authors Response: As detailed in the response to Reviewer #1, we will generate RCMV-E E27 mutants targeting the Zn-binding motif by site-directed mutagenesis. An analysis of the interaction between DDB1 and these E27 mutants will be included in the revised manuscript.

      Reviewer #3: Evidence, reproducibility and clarity

      __Reviewer #3: __Le-Trilling et al. present the first proteomic analysis of RCMV-infected cells, where they identified STAT2 as one of the most heavily downregulated (and degraded) proteins. This analysis showed that RCMV mediated degradation of STAT2 is conserved in closely related species used as animal models (rat and mouse) and human, despite the intra-host adaptation of each CMV. They also identify E27 as the RCMV factor that targets STAT2 for degradation, that exhibits ~50% homology with MCMV pM27. This study also identifies a Zinc binding motif in E27 using Cryo-EM which is conserved in other CMV species and is potentially involved in antagonising Type I and III responses.

      Reviewer #3: Significance

      __Reviewer #3: __The present work provides the first proteomics analysis of RCMV infection in rat cells, comparing infected vs non-infected rat fibroblasts to access potential RCMV targets. Then, it focuses on the characterisation of RCMV E27 and its role targeting and interacting with STAT2 (plus recruiting the Cul4 complex for STAT2 degradation). Finally, it provides the Cryo-EM structure of E27 and its CMV homologues, and the structure of the complex of E27 with elements of the CUL4 complex and STAT2. This is the first time that E27 function and structure are characterised. These are all novel findings - although the mouse homologue M27 has previously been found to interact with and degrade STAT2 (published by some of the same authors in Plos pathogens in 2011, (https://doi.org/10.1371/journal.ppat.1002069). Therefore the chief novel information is the structural studies.

      The manuscript will be of interest to researchers working with human and animal herpesviruses.

      My field of expertise is in Virology, Innate Immunity and host-virus interactions from an evolutionary perspective. I do not have expertise in Cryo-EM, so I could not evaluate the methods used in the section.

      __Authors Response: __We thank the reviewer for the positive evaluation of our work and its significance.

      Reviewer #3: Major points

      __Reviewer #3: __1. The authors claim the identification of a Zinc-binding motif in the protein E27 (RCMV) using Cryo-EM, then validation of the phenotype with MCMV WT, delM27 and M27 AxAxxA. To justify the change to MCMV to perform the functional validation, they stated "MCMV M27, the closest E27 homologue, exhibits 56% and 76% amino acid sequence identity and similarity, respectively (Fig. S4B). E27 and M27 AlphaFold2 structure predictions are almost indistinguishable (RMSD of 1.195 Å, 6652 aligned atoms) (Figs. 3B, S4A), and structural alignment of these predictions demonstrated conservation of side chain positions involved in zinc-binding (Fig. 3C). Thus, M27 represents a valid model to study functional consequences of interference with the zinc coordination motif through site-directed mutagenesis, and to test the predictive power of our E27/M27 model". Although they rationalise the change to MCMV to validate the functional outcomes of the newly identified zinc binding motif with alignments and Cryo-EM data, it falls within the DDB1 binding region that is less conserved (Fig S4B). The addition of a mouse model here provides a solid result but given the aim of the paper is to provide a proper characterisation of RCMV and elucidate some inter-species adaptations, I strongly recommend the validation with E27 here given the potential impact of this motif. Rather than having to repeat this in a rat model (which would clearly be a large amount of work), this could simply be achieved by constructing the relevant deletion / mutant viruses and assessing in vitro in a relevant cell line (readout - either virus titre or luciferase assay as shown in Figure 3G/H).

      __Authors Response: __Please also see our responses to the other reviewers. Briefly, we will apply side-directed mutagenesis to alter the CxCxxC motif in E27 that binds the zinc ion, and analyse the interaction of these E27 mutants with DDB1. In this context, we would like to add that almost two thirds of E27 residues in direct contact with DDB1 are at least type-conserved in M27, and the zinc-coordinating side chains are totally conserved (Fig. 3C). Together with a predicted similar structural organization of the respective binding regions (Fig. S11), and in light of our MCMV mutagenesis results (Fig. 7), it is highly likely that the DDB1-binding mode is conserved between E27 and M27. As mentioned above, we will put this assumption to the test in the revision process.

      __Reviewer #3: __Furthermore, in Figure 2, the GF assay was performed using full-length DDB1, however CLMS was performed using DDB1 delBPB (interchange between these two proteins continues in the remainder of the paper). This should be at least justified, and preferably one or other of wt DDB1 and DDB1 delBPB used in the GF or CLMS assay where this has not yet been performed. Later on in the results section (Fig 5E), the authors use wt DDB1 while in fig 4 they used the delBPB to describe the interaction with E27 - would be relevant to have consistency across the paper and some supplementary data that could support using one or the other in each assay.

      __Authors Response: __Protein complex preparations including full length DDB1 did not yield cryo-EM reconstructions at appropriate resolution for model building, almost certainly due to the known flexibility of the DDB1 BPB, impeding proper alignment of the cryo-EM particle images. This is why we switched to DDB1ΔBPB. Importantly, the structure model including full length DDB1 (Fig. S12B) clearly demonstrates that the BPB is located on the opposite side of the E27 binding interface on DDB1 (where it is situated to flexibly connect to the CUL4 scaffold to create the ubiquitination zone around immobilised substrates [Fig. 6]). This rules out an involvement of DDB1 BPB in E27- and/or STAT2-binding processes. Several previous studies have employed DDB1ΔBPB to facilitate structure determination, and have successfully applied the resulting structural models for functional follow-up experiments in the context of complete CRL4 assemblies (Bussiere et al., 2020; Petzold et al., 2016; Slabicki et al., 2020). Nevertheless, we will repeat GF experiments with DDB1ΔBPB for consistency and include these data in the revised manuscript.

      Reviewer #3: Minor points

      __Reviewer #3: __2. Although they present sufficient detail in the methods, further details in the text should be given as to the number of repeats performed in each case, and whether the data shown is representative or based on an average of repeats (preferably the latter; if representative, the data for other repeats should be shown in supplementary information).

      Authors Response: We will add this information in the revised version of the manuscript.

      3. Description of the revisions that have already been incorporated in the transferred manuscript

      Reviewer #1: Major points

      __Reviewer #1: __Resolution of the cryoEM structure is rather low and many predictions of the manuscript are based on modeling using AlphaFold2 prediction. The authors describe their model as of "sufficient quality", however, no quality measures are included in the manuscript. At least the discussion should address limitations of the used approach.

      Authors Response: While we apologize for not sufficiently describing our quality measures, we respectfully disagree regarding the conclusion. Our resolution (3.8 Å, map 1) lies well within the 3–4 Å resolution range of the vast majority of structures deposited to the Electron Microscopy Data Bank during the last five years (https://www.emdataresource.org/statistics.html). Nevertheless, de novo modelling in this resolution regime is challenging. This is why we sought additional guidance through cross-linking mass spectrometry (XL-MS) restraints and AlphaFold2. Please also note that modelling of E27 was not based solely on the AlphaFold2 prediction. Instead, a partial model corresponding to the α-domain was manually built in map 1, guided by XL-MS information (see Methods - “Model building and refinement” and Fig. S5B, grey cartoon). This partial model proved to be in very good agreement with AlphaFold2 predictions (RMSD of 1.489 Å, 2764 aligned atoms). Only after this initial sanity check, the computational prediction was used for model completion, adjustment, and refinement.

      We now added graphical overviews of model fits in Figs. S5 and S10. Furthermore, we included detailed views of the fit of relevant side chains involved in intermolecular interaction to the experimental density (Fig. S7, S9). We also calculated and listed quality indicators of the model-to-map fit in Table S1 (correlation coefficients and model resolution based upon model-map FSC). To ensure the validity of our atomic model using an alternative method besides cryo-EM and XL-MS, we have performed site-directed mutagenesis of critical binding regions in E27, followed by in vitro reconstitution and analytical GF (Fig. S7B, C, S9B, C). The text was revised accordingly (see p10 [ll22] and p14 [ll26]).


      __Reviewer #1: __The authors identify a cryptic zinc-binding motif in E27 that is conserved in homologous proteins. For this reviewer it is not clear: is there experimental evidence for zinc binding of E27 or can the presence of zinc reliably be detected in their structural data? If not, it would be worth to confirm zinc binding.

      Authors Response: Our structural data show a tetragonal metal coordination geometry, involving three cysteine side chains and one histidine side chain, with coordination bond lengths of 2.2 Å between the histidine nitrogen and the metal ion, and of 2.4 Å between the cysteine sulfurs and the metal ion. The density feature cannot be explained by another type of side chain interaction, e.g. a disulfide bond, because this would lead to a steric clash with the remaining adjacent side chains. Based on the knowledge on metal-binding sites in proteins and metal-coordination chemistry, these characteristics indicate the presence of a structural zinc-binding site for the following reasons: (i) after magnesium, zinc is the second most prevalent metal in the Protein Data Bank (https://metalpdb.cerm.unifi.it/getSummary), however, magnesium is coordinated octahedrally by oxygen ligands (Tang and Yang, 2013); (ii) the most abundant zinc ligands are cysteine and histidine; (iii) the most abundant zinc coordination number is four ligands; (iv) the average coordination bond lengths are 2.12±0.19 Å and 2.33±0.12Å for nitrogen-zinc and sulfur-zinc interactions, respectively (Ireland and Martin, 2019; Laitaoja et al., 2013), which is in very good agreement with our structural observations. We included this argumentation in the revised manuscript (see p9 [ll21]), and added Fig. S5C for visualization.


      Reviewer #2: Minor points


      Reviewer #2: Page 2, line 3. "Here," should be inserted before "Global proteome profiling..." to highlight the work of this manuscript.

      Authors Response: We changed the text accordingly.

      Reviewer #2: Page 3, line 21. "IFNs" instead of "IFN"

      Authors Response: We changed the text accordingly.

      Reviewer #2: Page 4, lines 9,15,27. "Ubiquitin Ligases (UbL)" is not a common abbreviation and could be mistaken for Ubl (Ubiquitin-like proteins). Possible abbreviation is "E3s" for Ubiquitin E3 ligases

      Authors Response: We have amended the respective abbreviations accordingly.

      Reviewer #2: Page 4 line 25. "RBX1" is the more common term for "ROC1"

      Authors Response: This has been corrected throughout the manuscript.

      Reviewer #2: Page 5 lines 1-9. Citing of the first structure of DDB1 in complex with a viral protein is recommended. (Ti Li et al. Cell 2006)

      Authors Response: We thank the reviewer for this important suggestions and cited this landmark publication.

      Reviewer #2: Figure 1 a) STAT2 dot is cut off in second panel. I recommend highlighting STAT2 in both panels.

      We amended the figure accordingly. We furthermore additionally highlighted the “STAT2” text in both panels by increasing the font size and putting it in bold type.

      Reviewer #2: Page 7 line 17. "Cross-linking MS (CLMS)" is commonly abbreviated as (XL-MS)

      Authors Response: We changed the text accordingly.

      Reviewer #2: Figure 2 a-c) These panels could benefit from thinner lines in order to increase visibility of chromatograms and cross-links.

      Authors Response: The panels were changed accordingly.

      Reviewer #2: Figure 2 a-b) Could the authors elaborate on why STAT2 is stoichiometrically

      underrepresented in the SDS-PAGE of the E27/DDB1/STAT2 complex?

      Authors Response: We applaud Reviewer #2 for their in-depth examination. Honestly, we were also puzzled by this. Based on the cryo-EM single particle analysis, we found an explanation: We separated a major contamination in silico during 2D classification (~12% of all particles). Out of curiosity, we reconstructed a density map from these particles (now shown in Fig. S3). The map was identical to a previous cryo-EM structure of the E. coli protein ArnA (Yang et al., 2019), a notorious contaminant in E. coli Ni-NTA protein purifications (Andersen et al., 2013). ArnA migrates similar to E27 on the SDS-PAGE, the band runs just a little bit faster (compare fraction 6 [ArnA] and fractions 8/9 [E27] from the SDS-PAGE of the analytical GF run of E27 in isolation, Fig. 2A, green trace). However, in analytical GF, ArnA elutes at higher molecular weight fractions, since it forms a hexamers (Ve~10.2 ml). Incidentally, this elution volume of the ArnA hexamer almost equals the one of DDB1 or DDB1ΔBPB/DDA1/E27/STAT2 complexes. This leads to a superposition of ArnA and E27 bands in the respective SDS-PAGE lanes corresponding to GF fraction 6. Accordingly, we conclude that it is actually not STAT2 that is underrepresented, but rather E27 seems overrepresented due to SDS-PAGE band overlap with the ArnA contaminant. We have now indicated the contaminant in Fig. 2A, amended the legend, and extended Fig. S3 to indicate at which point of the cryo-EM analysis the contaminating ArnA particles were separated, and to show the ArnA model to map fit.

      In addition to this, it might be that potential STAT2 degradation products (marked by ** in Fig. 2), which seem to co-migrate with STAT2/E27 complexes, occupy FL STAT2 binding sites on E27.

      Reviewer #2: Paragraph "The E27 structure.." page 9. Placing this paragraph after the overall

      structure is recommended.

      Authors Response: Accordingly, we have now moved this section to the end of the results section.

      Reviewer #2: Figure 3 a) The grey mesh being laid over the ribbon structures is not contributing to the overall visibility. Adding a panel of the cryo-EM structure alone in cost of alphafold models is recommended.

      Figure 4a) same issue with grey mesh

      Authors Response: Thank you very much for the very good suggestions. We have removed the mesh representation, and included panels just showing the segmented cryo-EM map in the new Fig. 3A.

      Reviewer #2: c) panels could benefit from fewer amino acids being labeled/shown

      Authors Response: We understand the motives of the Reviewer. However, we would prefer to depict all relevant side chain interactions in these panels. The rearrangement of the figure, i.e. showing the overview of the interacting regions before the detailed panels, should make them more accessible (new Fig. 3B).

      __Reviewer #2: __d) may want to avoid red-green coloring to improve for colorblindness

      Authors Response: We are deeply sorry for our ignorance in this regard. We changed the colors accordingly (see new Fig. 3B, C).

      __Reviewer #2: __Figure 6a) s.a grey mesh

      Authors Response: We removed the mesh representations and included panels just showing the segmented cryo-EM density in the new Fig. 5C.


      Reviewer #2: CROSS-CONSULTATION COMMENTS

      __Reviewer #2: __A 3.8 A overall resolution map and the approach to fitting may be suitable, but it is unclear from the authors' figures whether the side-chains shown in the figures are clearly visible in the map or if they are modeled by some other approach. Side chains should ideally be visible in the maps if shown in figures, and if not, close-ups of the corresponding regions of the maps should be shown with sufficient depthcue to allow the reader to gauge how the map corresponds to the model.

      Authors Response: This is a crucial point. As mentioned in the response to Reviewer #1, major point 2, we have now included very detailed views of the fit of relevant side chains involved in intermolecular interaction to the experimental density (Fig. S7, S9).

      __Reviewer #2: __Along these lines, the figures with the mesh maps do not clearly show how well the model fits the map. This needs to be clearly visible in figures, and ideally maps and models provided to reviewers in order for the reviewers to gauge the level of accuracy of the fit.

      Authors Response: Please see our response to Reviewer #1, major point 2. Briefly, we have now included graphical overviews of model fits in Figs. S5 and S10. We also calculated and listed quality indicators of the model-to-map fit in Table S1 (correlation coefficients and model resolution based upon model-map FSC). To ensure the validity of our atomic model using an alternative method besides cryo-EM and XL-MS, we have performed site-directed mutagenesis of critical binding regions in E27, followed by in vitro reconstitution and analytical GF (Fig. S7B, C, S9B, C). The text was extended accordingly (see p10 [ll22] and p14 [ll26]).

      __Reviewer #2: __At minimum, the authors have nicely assembled proteomics and cell biological data indicating that E27 hijacks CRL4 to turn over Stat2 in rat cells in a manner paralagous to M27 hijacking in mouse cells, biophysical/structural data for a model of a CUL4-DDB1-E27-Stat2 complex, and mutagenesis of a putative zinc binding site in M27.

      I feel most of the issues raised by all 3 reviewers could be addressed in the text, with more clarity about the structural models, and better explanation for why the construct with proteins from various organisms were used for structural studies (the authors had made human DDB1 before, and it expressed well, and perhaps didn't consider to make from rat? Or this mixture expressed, purified best? Gave best quality EM data?).

      Authors Response: We thank Reviewer #2 for her/his overall assessment. As mentioned in the two cross-consultation comments before, and in the response to Reviewer #1, major point 2, we strived to provide adequate measures allowing to judge the quality of our structural models in the present updated version of the manuscript. In addition, as indicated in the response to reviewer #3, major point 2, we have now added Fig. S12 and extended the Discussion to explain and justify the use of different protein constructs.

      __Reviewer #2: __Also, the presentation of the zinc binding site should come after the overall structure. As for the use of MCMV to assess the role of the zinc binding site, placing this last in the text might allow this to flow better.

      Authors Response: Thank you very much for this suggestion. The manuscript has been restructured as recommended: details of the zinc-binding motif and the MCMV assays are now shown in Fig. 7 and described in the text just before the Discussion.



      Reviewer #3: Major points

      __Reviewer #3: __2. Given that previous data in mice showed that the E27 homologue pM27 binds a component of host Cullin4-RING UbLs (CRL4), to induce the poly-ubiquitination of STAT2, the current study also addressed if this mechanism was preserved in RCMV. Yet, they seemed to do this with E27, rnSTAT2 and hsDDB1 - Page 7 lines 1 to 3: "These results prompted us to explore the association of E27 with Rattus norvegicus (rn) STAT2 and Homo sapiens (hs) DDB1 in vitro. Importantly, 1128 of 1140 amino acids are identical between hsDDB1 and rnDDB1 (...)". They identify the residues and regions where the DDB1 is different between both species, but should provide a structure/alignment with this highlighted. In addition, DDB1 is a DNA damage protein that is annotated in the Rattus norvegicus genome. The authors should justify the assays between rnSTAT2-hsDDB1 instead of using the both proteins from rn, and present the equivalent data for rnDDB1 in the paper.

      Authors Response: Among the 12 alterations between human and rat DDB1, 4 are type-conserved (Fig. S12A). Thus, >99% of amino acids are identical or similar. We mapped all exchanges on a model of full length human DDB1 bound to E27 and the rat STAT2 CCD. None are involved in intermolecular interactions (Fig. S12B, C). Please note that due to the high conservation of DDB1 across eukaryotes, this inter-species approach has been used by us and others to study DDB1-containing complexes (e.g., the SV5V, WHX, SIV Vpx and Vpr, zebrafish DDB2, and chicken CRBN proteins have been in vitro reconstituted with human DDB1 for structural characterisation) and valid biological conclusions have been drawn from these studies (Angers et al., 2006; Banchenko et al., 2021; Fischer et al., 2014; Fischer et al., 2011; Li et al., 2006; Li et al., 2010; Schwefel et al., 2015; Schwefel et al., 2014; Wu et al., 2015).


      Reviewer #3: Minor points

      __Reviewer #3: __1. In fig 5D, the authors present the H-box alignment, where it is clear that this motif is not conserved. The lack of H-box conservation should be discussed in the results and discussion, to provide an explanation for the competition/binding observed.

      Authors Response: We respectfully disagree. There is conservation of amino acid side chains, regarding their physicochemical properties, observable in the H-box motif. Furthermore, the secondary structure is conserved. Please note, that the H-box is not our invention but rather represented a well-accepted motif known in the field, see e.g., (Li et al., 2010). We extended the discussion to cover this point (p21 [ll15]).


      __Reviewer #3: __3. The authors commence their abstract justifying the study on the grounds of the usefulness of rodent HCMV counterparts as common infection models for HCMV. They should return to this theme in the discussion - what is the usefulness of their findings with regards to HCMV (particularly given the relatively low homology between E27 and HCMV pUL27, and the alternative mechanism for STAT2 antagonism encoded by HCMV UL145)?

      Authors Response: We extended the discussion in this regard. Briefly, our data, to our knowledge for the first time, reveal that RCMV (like MCMV) exploits CRL4 to induce proteasomal degradation of STAT2. With pUL145, HCMV relies on an analogous protein. In clear contrast to HCMV, RMCV and MCMV are both amenable to in vivo experiments in small animal models. Over 40 years ago, HCMV has been called the troll of transplantation due to its grim impact on immunosuppressed individuals after transplantation surgery (Balfour, 1979). Despite tremendous efforts, HCMV still harms and kills graft recipients. While MCMV allows various experiments regarding general principles of cytomegaloviral pathogenesis and antiviral immunity, one shortcoming is that the mouse obviously is a rather small animal, preventing various chirurgical and solid organ transplantation (SOT) procedures. In clear contrast, SOT procedures that are indispensable for human medicine can be recapitulated in rat models. Thus, according to our opinion, our work lays the molecular foundation for future studies addressing the relevance of STAT2 and CMV-induced STAT2 degradation in rat SOT models.

      4. Description of analyses that authors prefer not to carry out

      -

      • *

      References

      Andersen, K.R., Leksa, N.C., and Schwartz, T.U. (2013). Optimized E. coli expression strain LOBSTR eliminates common contaminants from His-tag purification. Proteins 81, 1857-1861.

      Angers, S., Li, T., Yi, X., MacCoss, M.J., Moon, R.T., and Zheng, N. (2006). Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery. Nature 443, 590-593.

      Balfour, H.H., Jr. (1979). Cytomegalovirus: the troll of transplantation. Arch Intern Med 139, 279-280.

      Banchenko, S., Krupp, F., Gotthold, C., Burger, J., Graziadei, A., O'Reilly, F.J., Sinn, L., Ruda, O., Rappsilber, J., Spahn, C.M.T., et al. (2021). Structural insights into Cullin4-RING ubiquitin ligase remodelling by Vpr from simian immunodeficiency viruses. PLoS pathogens 17, e1009775.

      Bussiere, D.E., Xie, L., Srinivas, H., Shu, W., Burke, A., Be, C., Zhao, J., Godbole, A., King, D., Karki, R.G., et al. (2020). Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex. Nat Chem Biol 16, 15-23.

      Fischer, E.S., Bohm, K., Lydeard, J.R., Yang, H., Stadler, M.B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G.M., et al. (2014). Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 512, 49-53.

      Fischer, E.S., Scrima, A., Bohm, K., Matsumoto, S., Lingaraju, G.M., Faty, M., Yasuda, T., Cavadini, S., Wakasugi, M., Hanaoka, F., et al. (2011). The molecular basis of CRL4DDB2/CSA ubiquitin ligase architecture, targeting, and activation. Cell 147, 1024-1039.

      Ireland, S.M., and Martin, A.C.R. (2019). ZincBind-the database of zinc binding sites. Database (Oxford) 2019.

      Laitaoja, M., Valjakka, J., and Janis, J. (2013). Zinc coordination spheres in protein structures. Inorg Chem 52, 10983-10991.

      Le-Trilling, V.T.K., and Trilling, M. (2020). Ub to no good: How cytomegaloviruses exploit the ubiquitin proteasome system. Virus Res 281, 197938.

      Li, T., Chen, X., Garbutt, K.C., Zhou, P., and Zheng, N. (2006). Structure of DDB1 in complex with a paramyxovirus V protein: viral hijack of a propeller cluster in ubiquitin ligase. Cell 124, 105-117.

      Li, T., Robert, E.I., van Breugel, P.C., Strubin, M., and Zheng, N. (2010). A promiscuous alpha-helical motif anchors viral hijackers and substrate receptors to the CUL4-DDB1 ubiquitin ligase machinery. Nature structural & molecular biology 17, 105-111.

      Petzold, G., Fischer, E.S., and Thoma, N.H. (2016). Structural basis of lenalidomide-induced CK1alpha degradation by the CRL4(CRBN) ubiquitin ligase. Nature 532, 127-130.

      Rengachari, S., Groiss, S., Devos, J.M., Caron, E., Grandvaux, N., and Panne, D. (2018). Structural basis of STAT2 recognition by IRF9 reveals molecular insights into ISGF3 function. Proceedings of the National Academy of Sciences of the United States of America 115, E601-E609.

      Schwefel, D., Boucherit, V.C., Christodoulou, E., Walker, P.A., Stoye, J.P., Bishop, K.N., and Taylor, I.A. (2015). Molecular Determinants for Recognition of Divergent SAMHD1 Proteins by the Lentiviral Accessory Protein Vpx. Cell host & microbe 17, 489-499.

      Schwefel, D., Groom, H.C., Boucherit, V.C., Christodoulou, E., Walker, P.A., Stoye, J.P., Bishop, K.N., and Taylor, I.A. (2014). Structural basis of lentiviral subversion of a cellular protein degradation pathway. Nature 505, 234-238.

      Slabicki, M., Kozicka, Z., Petzold, G., Li, Y.D., Manojkumar, M., Bunker, R.D., Donovan, K.A., Sievers, Q.L., Koeppel, J., Suchyta, D., et al. (2020). The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. Nature 585, 293-297.

      Tang, S., and Yang, J.J. (2013). Magnesium Binding Sites in Proteins. In Encyclopedia of Metalloproteins, R.H. Kretsinger, V.N. Uversky, and E.A. Permyakov, eds. (New York, NY: Springer New York), pp. 1243-1250.

      Wu, Y., Koharudin, L.M., Mehrens, J., DeLucia, M., Byeon, C.H., Byeon, I.J., Calero, G., Ahn, J., and Gronenborn, A.M. (2015). Structural Basis of Clade-specific Engagement of SAMHD1 (Sterile alpha Motif and Histidine/Aspartate-containing Protein 1) Restriction Factors by Lentiviral Viral Protein X (Vpx) Virulence Factors. The Journal of biological chemistry 290, 17935-17945.

      Yang, M., Chen, Y.S., Ichikawa, M., Calles-Garcia, D., Basu, K., Fakih, R., Bui, K.H., and Gehring, K. (2019). Cryo-electron microscopy structures of ArnA, a key enzyme for polymyxin resistance, revealed unexpected oligomerizations and domain movements. J Struct Biol 208, 43-50.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      Le-Trilling et al. present the first proteomic analysis of RCMV-infected cells, where they identified STAT2 as one of the most heavily downregulated (and degraded) proteins. This analysis showed that RCMV mediated degradation of STAT2 is conserved in closely related species used as animal models (rat and mouse) and human, despite the intra-host adaptation of each CMV. They also identify E27 as the RCMV factor that targets STAT2 for degradation, that exhibits ~50% homology with MCMV pM27. This study also identifies a Zinc binding motif in E27 using Cryo-EM which is conserved in other CMV species and is potentially involved in antagonising Type I and III responses.

      Major and minor concerns to be addressed:

      Major points

      1. The authors claim the identification of a Zinc-binding motif in the protein E27 (RCMV) using Cryo-EM, then validation of the phenotype with MCMV WT, delM27 and M27 AxAxxA. To justify the change to MCMV to perform the functional validation, they stated "MCMV M27, the closest E27 homologue, exhibits 56% and 76% amino acid sequence identity and similarity, respectively (Fig. S4B). E27 and M27 AlphaFold2 structure predictions are almost indistinguishable (RMSD of 1.195 Å, 6652 aligned atoms) (Figs. 3B, S4A), and structural alignment of these predictions demonstrated conservation of side chain positions involved in zinc-binding (Fig. 3C). Thus, M27 represents a valid model to study functional consequences of interference with the zinc coordination motif through site-directed mutagenesis, and to test the predictive power of our E27/M27 model". Although they rationalise the change to MCMV to validate the functional outcomes of the newly identified zinc binding motif with alignments and Cryo-EM data, it falls within the DDB1 binding region that is less conserved (Fig S4B). The addition of a mouse model here provides a solid result but given the aim of the paper is to provide a proper characterisation of RCMV and elucidate some inter-species adaptations, I strongly recommend the validation with E27 here given the potential impact of this motif. Rather than having to repeat this in a rat model (which would clearly be a large amount of work), this could simply be achieved by constructing the relevant deletion / mutant viruses and assessing in vitro in a relevant cell line (readout - either virus titre or luciferase assay as shown in Figure 3G/H).
      2. Given that previous data in mice showed that the E27 homologue pM27 binds a component of host Cullin4-RING UbLs (CRL4), to induce the poly-ubiquitination of STAT2, the current study also addressed if this mechanism was preserved in RCMV. Yet, they seemed to do this with E27, rnSTAT2 and hsDDB1 - Page 7 lines 1 to 3: "These results prompted us to explore the association of E27 with Rattus norvegicus (rn) STAT2 and Homo sapiens (hs) DDB1 in vitro. Importantly, 1128 of 1140 amino acids are identical between hsDDB1 and rnDDB1 (...)". They identify the residues and regions where the DDB1 is different between both species, but should provide a structure/alignment with this highlighted. In addition, DDB1 is a DNA damage protein that is annotated in the Rattus norvegicus genome. The authors should justify the assays between rnSTAT2-hsDDB1 instead of using the both proteins from rn, and present the equivalent data for rnDDB1 in the paper. Furthermore, in Figure 2, the GF assay was performed using full-length DDB1, however CLMS was performed using DDB1 delBPB (interchange between these two proteins continues in the remainder of the paper). This should be at least justified, and preferably one or other of wt DDB1 and DDB1 delBPB used in the GF or CLMS assay where this has not yet been performed. Later on in the results section (Fig 5E), the authors use wt DDB1 while in fig 4 they used the delBPB to describe the interaction with E27 - would be relevant to have consistency across the paper and some supplementary data that could support using one or the other in each assay.

      Minor points:

      1. In fig 5D, the authors present the H-box alignment, where it is clear that this motif is not conserved. The lack of H-box conservation should be discussed in the results and discussion, to provide an explanation for the competition/binding observed.
      2. Although they present sufficient detail in the methods, further details in the text should be given as to the number of repeats performed in each case, and whether the data shown is representative or based on an average of repeats (preferably the latter; if representative, the data for other repeats should be shown in supplementary information).
      3. The authors commence their abstract justifying the study on the grounds of the usefulness of rodent HCMV counterparts as common infection models for HCMV. They should return to this theme in the discussion - what is the usefulness of their findings with regards to HCMV (particularly given the relatively low homology between E27 and HCMV pUL27, and the alternative mechanism for STAT2 antagonism encoded by HCMV UL145)?

      Significance

      The present work provides the first proteomics analysis of RCMV infection in rat cells, comparing infected vs non-infected rat fibroblasts to access potential RCMV targets. Then, it focuses on the characterisation of RCMV E27 and its role targeting and interacting with STAT2 (plus recruiting the Cul4 complex for STAT2 degradation). Finally, it provides the Cryo-EM structure of E27 and its CMV homologues, and the structure of the complex of E27 with elements of the CUL4 complex and STAT2. This is the first time that E27 function and structure are characterised. These are all novel findings - although the mouse homologue M27 has previously been found to interact with and degrade STAT2 (published by some of the same authors in Plos pathogens in 2011, (https://doi.org/10.1371/journal.ppat.1002069). Therefore the chief novel information is the structural studies.

      The manuscript will be of interest to researchers working with human and animal herpesviruses.

      My field of expertise is in Virology, Innate Immunity and host-virus interactions from an evolutionary perspective. I do not have expertise in Cryo-EM, so I could not evaluate the methods used in the section.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      The manuscript entitled "Structure and mechanism of a novel cytomegaloviral DCAF mediating interferon antagonism" by Dr. Schwefel and colleagues cleverly combines biochemistry, mass-spectrometry, Cryo-EM and cell biology to dissect how RCMV-E hijacks its hosts ubiquitylation machinery to mediate proteasomal degradation of STAT2, a key player driving the antiviral IFN response. They identify E27 as DDB1-binding element, which is able promote CRL4-dependent ubiquitylation of STAT2, and demonstrate its effect on STAT2 levels by knockout RCMV-E strains. These findings are supported by in vitro reconstitution of the DDB1/E27/STAT2 complex and analyses via XL-MS and Cryo-EM. The obtained data are then powerfully validated and analysed in mutational strains via infection of homologue in vivo models. The results collectively explain how E27 mimics endogenous CRL4 substrate receptors, thereby recruiting STAT2 to be targeted by CLR4 for ubiquitylation in a NEDD8-dependent manner.

      Overall this is an important study that provides convincing insights on how rodent CMVs antagonize their host interferon response by exploiting its ubiquitin-proteasome system. The manuscript is well written and its introduction is extraordinarily comprehensive. There are a few minor points for the authors to consider below.

      Minor points:

      Page 2, line 3. "Here," should be inserted before "Global proteome profiling..." to highlight the work of this manuscript.

      Page 3, line 21. "IFNs" instead of "IFN"

      Page 4, lines 9,15,27. "Ubiquitin Ligases (UbL)" is not a common abbreviation and could be mistaken for Ubl (Ubiquitin-like proteins). Possible abbreviation is "E3s" for Ubiquitin E3 ligases

      Page 4 line 25. "RBX1" is the more common term for "ROC1"

      Page 5 lines 1-9. Citing of the first structure of DDB1 in complex with a viral protein <br /> is recommended. (Ti Li et al. Cell 2006)

      Figure 1 a) STAT2 dot is cut off in second panel. I recommend highlighting STAT2 <br /> in both panels.

      Page 7 line 17. "Cross-linking MS (CLMS)" is commonly abbreviated as (XL-MS)

      Figure 2 a-c) These panels could benefit from thinner lines in order to increase visibility of chromatograms and cross-links.

      Figure 2 a-b) Could the authors elaborate on why STAT2 is stoichiometrically underrepresented in the SDS-PAGE of the E27/DDB1/STAT2 complex?

      Paragraph "The E27 structure.." page 9. Placing this paragraph after the overall structure is recommended.

      Figure 3 a) The grey mesh being laid over the ribbon structures is not contributing to the overall visibility. Adding a panel of the cryo-EM structure alone in cost of alphafold models is recommended.

      Figure 4a) same issue with grey mesh c) panels could benefit from fewer amino acids being labeled/shown d) may want to avoid red-green coloring to improve for colorblindness

      Figure 6a) s.a grey mesh

      Referees cross-commenting

      A 3.8 A overall resolution map and the approach to fitting may be suitable, but it is unclear from the authors' figures whether the side-chains shown in the figures are clearly visible in the map or if they are modeled by some other approach. Side chains should ideally be visible in the maps if shown in figures, and if not, close-ups of the corresponding regions of the maps should be shown with sufficient depthcue to allow the reader to gauge how the map corresponds to the model.

      Along these lines, the figures with the mesh maps do not clearly show how well the model fits the map. This needs to be clearly visible in figures, and ideally maps and models provided to reviewers in order for the reviewers to gauge the level of accuracy of the fit.

      At minimum, the authors have nicely assembled proteomics and cell biological data indicating that E27 hijacks CRL4 to turn over Stat2 in rat cells in a manner paralagous to M27 hijacking in mouse cells, biophysical/structural data for a model of a CUL4-DDB1-E27-Stat2 complex, and mutagenesis of a putative zinc binding site in M27.

      I feel most of the issues raised by all 3 reviewers could be addressed in the text, with more clarity about the structural models, and better explanation for why the construct with proteins from various organisms were used for structural studies (the authors had made human DDB1 before, and it expressed well, and perhaps didn't consider to make from rat? Or this mixture expressed, purified best? Gave best quality EM data?). Also, the presentation of the zinc binding site should come after the overall structure.

      As for the use of MCMV to assess the role of the zinc binding site, placing this last in the text might allow this to flow better. This reviewer agrees that at least testing mutants in the E27 in some assays would be appropriate.

      Significance

      The work of Schwefel and colleagues combines several powerful state-of-the art techniques to dissect the mechanism of the viral protein E27 and, for the first time, provides a rational for its ability to act as STAT2 antagonist. They performed outstanding structure-function analyses of the ubiquitin system, including the first global proteomic profiling of RCMV-infected cells, setting the standard for its human counterpart as rodent CMVs are commonly used as infection models. The manuscript is highly suitable for publication in any of the journals associated with the review commons platform.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      Summary:

      Using proteome profiling of rat CMV infected cells, the authors of this study identify the E27 protein of rat cytomegalovirus as being crucial for proteasomal degradation of STAT2. Since E27 shares 56% sequence identity to the previously characterized STAT2 antagonist M27 of murine CMV the authors investigated association of E27 with the Cullin4-RING UbL CRL4. Using gel filtration chromatography they provide evidence that E27 forms a stable ternary complex with DDB1 and STAT2 suggesting that E27 bridges STAT2 to DDB1 which is further corroborated by data from cross-linking mass spectrometry. A cross-linked DDB1/DDA1/E27/STAT2 complex was then used for cryo-EM imaging experiments. The subsequent single particle analysis yielded a density map at 3.8 A resolution that was further used to generate an E27 molecular model. At this point it should be noted that resolution was not very high and data form AlphaFold2 prediction and CLMS experiments were necessary to build a model which was described as having "sufficient quality", however, no quality parameters are included for this model. In this model, a cryptic zinc-binding motif was identified that turned out to be well conserved in M27. At this point the study switches to a mutational analysis of M27: MCMV mutants either lacking M27 or bearing an AxAxxAA triple mutation were investigated both in cell culture and in animal models. Surprisingly, the M27-AxAxxA mutant while exhibiting attenuated IFN inhibition was still more active than an M27 deletion mutant. Later during the study it is postulated that this may be due to the fact that E27 binding to STAT2 abrogates the interaction with IRF9, however, this is only predicted from modeling and no experimental data are provided for this hypothesis. Furthermore, modeling approaches were used to predict how E27 replaces endogenous CRL4 substrate receptors and how E27 recruits STAT2 to mediate CRL4-catalysed ubiquitin transfer.

      Major comments:

      1. To my opinion the authors should perform mutational analysis in the context of E27 and RCMV. I accept that switching to M27 may be easier due to established procedures for MCMV mutagenesis and analysis, however, since all structural work is primarily done on E27 it would be consequent to confirm these structural predictions in the context of E27 before switching to a related protein. Moreover, data on the replication of the generated E27 deletion RCMV should be included in the manuscript (i.e. growth curves).
      2. Resolution of the cryoEM structure is rather low and many predictions of the manuscript are based on modeling using AlphaFold2 prediction. The authors describe their model as of "sufficient quality", however, no quality measures are included in the manuscript. At least the discussion should address limitations of the used approach.
      3. The authors identify a cryptic zinc-binding motif in E27 that is conserved in homologous proteins. For this reviewer it is not clear: is there experimental evidence for zinc binding of E27 or can the presence of zinc reliably be detected in their structural data? If not, it would be worth to confirm zinc binding.
      4. The hypothesis that STAT2/E27 interaction is sterically incompatible with IRF9 binding is only based on structural prediction. It would help if the authors could present experimental evidence for such a mechanism.

      Significance

      This is an interesting and well written paper describing for the first time in molecular detail how a cytomegalovirus-encoded interferon antagonist degrades STAT2 by mimicking the molecular surface properties of cellular CRL4 substrate receptors.

      This study should be of broad interest for both virologists and structural biologists.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Manuscript number: RC-2022-01528

      Corresponding author(s): Elena Taverna and Tanja Vogel

      1. General Statements [optional]

      We thank the reviewers for the comments and points they raised. We think what we have been asked is a doable task for us and we are confident we will manage to address all points in a satisfactory manner.

      2. Description of the planned revisions

      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      Reviewer’s comment: The manuscript investigated the role of DOT1L during neurogenesis especially focusing on the earlier commitment from APs. Using tissue culture method with single-cell tracing, they found that the inhibition of DOT1L results in delamination of APs, and promotes neuronal differentiation. Furthermore, using single cell RNA-seq, they seek possible mechanisms and changes in cellular state, and found a new cellular state as a transient state. Among differentially expressed genes, they focused on microcephaly-related genes, and found possible links between epigenetic changes led by DOT1L inhibition and epigenetic inhibition by PRC2. Based on these findings, they suggested that DOT1L could regulate neural fate commitment through epigenetic regulation. Overall, it is well written and possible links from epigenetic to metabolic regulation are interesting. However, there are several issues across the manuscript.

      Response to Reviewer and planned revision:

      We thank the reviewer’s 1 for her/his comments and constructive criticism.

      We hope the revision plan will address the points raised by the reviewer in a satisfactory manner.

      Major issues:

      * *Reviewer’s comment: 1) It is not clear whether the degree of H3K79 methylation (or other histones) changes during development, and whether DOT1L is responsible for those changes. It is necessary to show the changes in histone modifications as well as the levels of DOT1L from APs to BPs and neurons, and to what extent the treatment of EPZ change the degree of histone methylation.

      Response to Reviewer and planned revision:

      • As for the level of DOT1L protein We tried several commercially available antibodies, but they do not work in the mouse, even after multiple attempts and optimization. So, unfortunately we will not be able to provide this piece of information.

      • As for the level of DOT1L mRNA We will provide info regarding the DOT1L mRNA level in APs, BPs and neurons by using scRNAseq data from E12, E14, E16 WT cerebral cortex.

      • As for the levels of H3K79methylation, we did not intend to claim that the histone methylation is responsible for the reported fate transition. We will edit the text to avoid any possible confusion. If it is deemed to be necessary to address the point raised by the reviewer, we do have 3 options, that we here in order of priority and ease of execution from our side.

      • immunofluorescence with an Ab against H3K79me2 using CON and EPZ-treated hemispheres.

      • FACS sort APs, BPs and neurons from CON and EPZ-treated hemispheres, followed by immunoblot for H3K79me2 to assess the H3K79me2 levels. As for the FACS sorting, we will use a combinatorial sorting in the lab on either a TUBB3-GFP or a GFP-reporter line using EOMES-driven mouse lines. This strategy has already been employed in the lab by Florio et al., 2015 and we will use it with minor modifications.
      • scCut&Tag for H3K79me2 from CON and EPZ-treated hemispheres. This option entails a collaboration with the Gonzalo Castelo-Branco lab in Sweden and might therefore require additional time to be established and carried out. Reviewer’s comment:

      Furthermore, the study mainly used pharmacological bath application. DOT1L has anti-mitotic effect, thus it is not clear whether the effect is coming from the inhibition of transmethylation activity.

      Response to Reviewer and planned revision:

      In a previous work we used a genetic model (DOT1L KO mouse) that showed microcephaly (Franz et al. 2019). For this study, we wanted to fill a gap in knowledge by understating if the DOT1L effect was mediated by its enzymatic activity. For this reason, we choose to use the pharmacological inhibition with EPZ, whose effect on DOT1L activity has been extensively reported and documented in literature (EPZ is a drug currently in phase clinical 3 studies).

      The stringent focus of this study on the pharmacological inhibition is thus a step toward understanding what specific roles DOT1L can play, both as scaffold or as enzyme.

      Here, we concentrate on the enzymatic function and the scaffolding function is beyond the scope of this specific study. We can further discuss and elaborate on the rationale behind this in the revised manuscript.

      Reviewer’s comment:

      In addition, the study assumed that the effect of EPZ is cell autonomous. However, if EPZ treatment can change the metabolic state in a cell, it would be possible that observed effects was non-cell autonomous. It would be important to address if this effect is coming in a cell-autonomous manner by other means using focal shRNA-KD by IUE.

      Response to Reviewer and planned revision:

      We did not claim that the effect of EPZ is cell autonomous, we are actually open on this point, as we consider both explanations to be potentially valid. We will edit the text to avoid any possible confusion on what we assume and what not.

      As a general consideration, it is entirely possible that the effects are non-cell autonomous. We will comment and elaborate on that in the revised manuscript.

      If the reviewer/journal considers this a point that must be addressed experimentally, then we will proceed as follows:

      • DOT1L shRNA-KD via in utero electroporation, followed by either
      • in situ hybridization for ASNS to check if ASNS transcript is increased upon DOT1L shRNA-KD compared to CON
      • FACS sorting of the positive electroporated cells (CON and DOT1L shRNA-KD), followed by qPCR to assess the levels of ASNS
      • If the reviewer wants us to check for a more downstream effect on fate, then we will immuno-stain the DOT1L shRNA-KD and CON with TUBB3 AB and/or TBR1 AB (as already done in the present version of the manuscript). Reviewer’s comment: 2) The possible changes in cell division and differentiation were found by very nice single-cell tracing system. However, changes in division modes occurring in targeted APs such as angles of mitotic division and the expression of mitotic markers were not addressed. These information is critical information to understand mechanisms underlying observed phenotype, delamination, differentiation and fate commitment.

      Response to Reviewer and planned revision:

      Previous effects of DOT1L manipulation on the mitotic spindle were observed in a previous paper, using DOT1L KO mouse (Franz et al. 2019). Considering that in our experiments we do use a pharmacological inhibition, we will address this point by quantifying the spindle angle in CON and EPZ-treated cortical hemispheres.

      We will co-stain for DAPI to visualize the DNA/chromosomes, and for phalloidin (filamentous actin counterstain) that allows for a precise visualization of the apical surface and of the cell contour, as it stains the cell cortex.

      Of note, the protocols we are referring to are already established in the lab, based on published work from the Huttner lab (Taverna et al, 2012; Kosodo et al, 2005).

      Reviewer’s comment: 3) The scRNA-seq analysis indicated interesting results, but was not fully clear to explain the observed results in histology. In fact, in single cell RNA-seq, the author claimed that cells in TTS are increased after EPZ treatment, which are more similar to APs. However, in histological data, they found that EPZ treatment increased neuronal differentiation. These data conflicts, thus I wonder whether "neurons" from histology data are actually neurons? Using several other markers simultaneously, it would be important to check the cellular state in histology upon the inhibition/KD of DOT1L.

      Response to Reviewer and planned revision:

      The reviewer’s comment is valid, and we indeed found that TTS cells are an intermediate state between APs and neurons in term of transcriptional profile. This is the reason why we called this cell cluster transient transcriptional state.

      We plan to address this point by staining for TBR1 and/or CTIP2 in CON and EPZ-treated hemispheres and to expand with this EOMES and SOX2 co-staining.

      Minor issues:

      Reviewer’s comment: Figure 1 - It is not clear delaminated cells are APs, BPs or some transient cells (Sox2+ Tubb3+??). It is important to use several cell type-specific and cell cycle markers simulnaneously to characterize cell-type specific identity of the analysed cells by staining. These applied to Fig1B,D,E,F,G,as well as Fig2,3.

      Response to Reviewer and planned revision:

      We will address this point by using a combinatorial staining scheme for several fate markers such as TUBB3, EOMES and SOX2, as suggested by the reviewer.

      Reviewer’s comment: - Please provide higher magnification images of labelled cells (Fig 1H)

      Response to Reviewer and planned revision:

      In the revised manuscript, we will provide higher magnification for the staining.

      Reviewer’s comment: - Please provide clarification on the criteria of Tis21-GFP+ signal thresholding.

      Response to Reviewer and planned revision:

      In the revised manuscript, we will provide a clarification on the criteria of Tis21-GFP+ signal thresholding.

      Reviewer’s comment: - Splitting the GFP signal between ventricular and abventricular does not convincingly support the "more basal and/or differentiated" states after EPZ treatment.

      Response to Reviewer and planned revision:

      We will provide a clarification regarding this point.

      Reviewer’s comment: - Please explain the presence of Tis21-GFP+ cells at the apical VZ.

      Response to Reviewer and planned revision:

      Tis21-GFP+ cells at the apical VZ has been extensively reported in the literature, since the first paper by Haubensak et al. regarding the generation of the Tis21-GFP+ line. In a nutshell, T Tis21-GFP+ cells are present throughout the VZ (therefore also in the apical portion) as neurogenic, Tis21-GFP positive cells are undergoing mitosis at the apical surface. Indeed, the presence of Tis-21 GFP signal have been extensively used by the Huttner lab and collaborators to score apical neurogenic mitosis. In addition, since AP undergo interkinetic nuclear migration, it follows that Tis21-GFP+ nuclei are going to be present throughout the entire VZ.

      In the revised manuscript, we will explain this point and cite additional literature.

      Reviewer’s comment: - Order the legends in same order as the bars.

      Response to Reviewer and planned revision:

      We will follow reviewers’ recommendation and order the legends accordingly.

      Reviewer’s comment: Figure 2 -Fig 2B) The difference between CON and EPZ apical contacts is not clear and does not match with the graph in Fig 2E.

      Response to Reviewer and planned revision:

      We will explain Fig. 2B in more detail and provide additional images in the revised manuscript.

      Reviewer’s comment: -Supp Fig 2 - are these injected slices cultured in control conditions? Please include this in the text and figure/figure legend

      Response to Reviewer and planned revision:

      In the revised manuscript, the text will be changed to address this point and provide clearer info.

      Reviewer’s comment: Fig 2C) The EPZ-treated DxA555+ cells exhibit morphological change of cell shape. Is this phenotype? please comment on the image shown for EPZ treatment panel.

      Response to Reviewer and planned revision:

      We thank the reviewer for having raised this point.

      The change in morphology might be a consequence of delamination and or of cell fate. In the revised manuscript, we will certainly better comment on this very relevant point and expand the discussion accordingly.

      Reviewer’s comment: Fig 2F - 2G) Data presented on EOMES+ and TUBB3+ % are counterintuitive. The authors claimed that TUBB3+ cells are increased and neuronal differentiation is promoted. However, no changes in EOMES+ are observed. What is the explanation? Did the author check the double positive cells? These could be TSS cells?

      Response to Reviewer and planned revision:

      We thank the reviewer to have raised this point.

      As envisioned by the reviewer, we suspect that the counterintuitive data might be due to TSS cell, which based on our scRNAseq data are expressing at the same time several cell type specific markers. It is possible that, since the treatment with EPZ is 24h long, cells (like the TTS cluster) have no time to completely eliminate the EOMES protein. If that were to be the case, then we would expect to still detect (as we indeed do) EOMES immunoreactivity.

      To address this point, we will:

      • analyze scRNA-seq data and check which is the extent of co-expression of Eomes and Tubb3 mRNAs in the TTS population.
      • Check for EOMES and TUBB3 double positive cells in the microinjection experiment. Reviewer’s comment: Figure 2 and Figure 3) the number of pairs analyzed for EPZ is twice as that of Con for comparison of the parameters taken into account. Please include n of each graph in the figure legend of the specific panel if not the same for all panels in that figure (i.e. for figure 3)

      Response to Reviewer and planned revision:

      We will revise the text accordingly.

      Reviewer’s comment:

      Figure 3) The data indicated that the number of daughter cell pairs in EPZ samples is almost double than Control. Is this the phenotype? More numbers of daughter cells in EPZ treated samples were observed from the same number of injections? or the number of injected cells were different?

      Response to Reviewer and planned revision:

      Due to technical reasons, we indeed performed a higher number of injections in EPZ-treated slices. We think this is the main reason behind the difference in number.

      If the reason were to be biological, one would expect to see the same trend in IUE experiments, but this is actually not the case. This does suggest/corroborate the idea that the reason behind the difference is mainly technical.

      Reviewer’s comment: Figure 4)

      • Please clarify if the single cell transcriptomic analysis has been performed only once, and if yes, how statistical testing to compare the cell proportion is carried out with only one batch. Fig 4G)

      Response to Reviewer and planned revision:

      As for the scRNAseq on microinjected cells:

      the scRNA-seq analysis was done once using cells pooled from 3 different microinjection experiments performed in 3 different days.

      As for the scRNAseq on IUE cells:

      The scRNA-seq analysis was done once using cells pooled from 2-3 different IUE experiments performed in 3 different days.

      For all scRNAseq experiments the statistical testing is achieved by intrasample comparisons according to established bioinformatics pipelines. We will better explain this point in the revised manuscript.

      Reviewer’s comment: Figure 4 and 5) - Figures are not supportive of the statement regarding APs' neurogenic potential upon DOT1L inhibition. TSS transcriptomic profile resembles more progenitors than neurons. Please comment on TSS neurogenic capacity taking into account the provided GO and RNAseq.

      Response to Reviewer and planned revision:

      We thank Reviewer 1 for raising this point, It is indeed true that TTS resemble more AP than neurons (as indicated in the Fig. S5B, C). We took that to indicate the fact that these cells are transient and therefore still maintain some AP features. Interestingly, TTS downregulate cell division markers, suggesting a restriction of proliferative potential, as one would expect for cells with an increased neurogenic potential. We will discuss this point in the revised manuscript.

      Reviewer’s comment: - Please provide GO analysis for APs and BPs.

      Response to Reviewer and planned revision:

      Following the reviewer’s suggestion, we will incorporate a more careful and in-depth analysis in the revised version of the manuscript.

      Reviewer’s comment: - Reconstruct figure 5A by listing genes in the same order in both Con and EPZ and prioritize EPZ-Con differences instead of cell-cell differences.

      Response to Reviewer and planned revision:

      We will revise Figure 5A based on the reviewer’s comment.

      Reviewer’s comment:

      Moreover, the presented genes in the heatmap is not the same in two conditions (i.e. NEUROG1 is present in EPZ but absent in Con). Please justify.

      Response to Reviewer and planned revision:

      This observation is based on different activities of transcription factor networks in the control and EPZ condition. They are not supposed to be the same as the cell states are altered and different TF are expressed and active upon the treatment in the diverse cell types. In a revised manuscript we will justify this point.

      Reviewer’s comment: Fig 5D)

      • Please explain why binding of EZH2 on the promoter of Asns is strongly reduced in comparison to a mild significant reduction of H3K79me/H3K27me3 in EPZ compared to Control.

      Response to Reviewer and planned revision:

      Several explanations are possible

      First, the variation can be due to batch effects.

      Second, the acute reduction of EZH2 might not be directly accompanied by a reduced histone mark, which is reduced either by cell division or by demethylases. The two processes of getting rid of the mark might be slower than the reduction of EZH2 presence at the respective site.

      Based on the reviewer’s comment, we will explain this point in the revised manuscript.

      • *

      Reviewer’s comment:

      Also is the changed directly medicated by DOT1L?

      Please test whether DOT1L can bind the promoter of Asns.

      Response to Reviewer and planned revision:

      To address this relevant issue we will proceed with the following protocol:

      • electroporate a tagged version of DOT1L into ESCs
      • select ESCs and differentiate them into NPC_48h.
      • treat NPC with DMSO (Con) or EPZ
      • harvest CON and EPZ-treated NPC
      • perform ChIP-qPCR DOT1L at the Asns promoter Reviewer’s comment: Please provide the expression patterns of DOT1L and Asns during neuronal differentiation.

      Response to Reviewer and planned revision:

      As for Dot1l

      Dot1l expression was shown in Franz et al 2019, by ISH from E12.5 to E18.5.

      As for Asns

      We will provide E14.5 in situ staining of Asns in the developing mouse brain using the Gene Paint database (see Figure below).

      We will also show immunostainings for ASNS at mid-neurogenesis, provided that Ab against ASNS works in the mouse.

      Other General comments:

      Reviewer’s comment: Please Indicate VZ, SVZ and CP on the side of the pictures/ with dot lines in the pictures both for primary figures and supplementary.

      Response to Reviewer and planned revision:

      We will revise the figures accordingly.

      Reviewer’s comment: - The Results and figures sometimes do not support the statement made by the authors

      Response to Reviewer and planned revision:

      We will carefully check on this and eliminate any overinterpretation or non-supported statements from the text.

      • Schemes are not informative/explanatory enough, i.e. time windows of treatment and sample collection, culture conditions details.

      Response to Reviewer and planned revision:

      We will revise the schemes to include more details. In particular, we plan to add a supplementary figure with a detailed visual description of the protocol, to match the detailed description presented in the materials and methods.

      Reviewer’s comment: - A more extensive characterization of TTS cells in terms of differentiation progression and integration would be enlightening

      Response to Reviewer and planned revision:

      In general, we are facing two main challenges while studying the TTS population: one is the lack of a specific marker gene for TTS, the other is the relatively small size of the TTS subpopulation.

      For these reasons, our ability to carry on an in-depth analysis of this cell state is limited.

      Considering the reviewer’s comment, in the revised manuscript we will expand the analysis ad characterization of the differentiation potential of TTS using RNA velocity trajectory.

      We can also expand the discussion on this point.

      Reviewer’s comment: - Picture quality can be improved, provide high magnification images.

      Response to Reviewer and planned revision:

      We will revise the figures to include higher magnification images.

      Reviewer #1 (Significance (Required)):

      Reviewer’s comment: The study could be important for the specific field in neural development. It aims to understand mutations in respective genes and brain malformation. If the link between epigenetic and metabolic changes is clearly shown, it will be interesting. However, the current manuscript is still rather descriptive, and clear mechanistic insights were not provided. The study have potentials and additional data will strength the value of study.

      Response to Reviewer and planned revision:

      We will address the direct impact of DOT1L and H3K79me2 on the Asns gene locus during the revision (see the rationale of the experimental strategy also in the revision plan above). We hope we will thus provide a mechanistic link between epigenetics and altered metabolome.

      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      Reviewer’s comment: Appiah et al. present a concise manuscript that provides details and possible mechanisms of their previous work (Franz et al., 2019; Ferrari et al., 2020). The study uses diverse lines of investigation to arrive at most conclusions. However, as interesting as the data is, we find that at the present state, it is not sufficient to prove that, indeed, the asparagine metabolism is regulated by DOTL1/PRC2 crosstalk. The neurogenic shift presented in the first part of the paper is not comprehensive and, therefore, not very convincing. The quality of images provided in the main and supplementary data is less than ideal. Additional data analysis and interpretation of the scRNA seq data may be needed. The authors finally conclude with rescue experiments done in culture and in-vivo, which we believe is the stand-out part of this study. Overall the manuscript has some interesting observations that are often over-interpreted with less supporting data. The manuscript reads well but requires additional data and changes in the claims/interpretation to be suited for publication.

      Response to Reviewer and planned revision:

      In the revised manuscript, we hope we will address the comments and concerns raised by the reviewer in a satisfactory manner. Comments

      Reviewer’s comment: 1) Abstract: Is this statement correct: "DOT1L inhibition led to increased neurogenesis driven by a shift from asymmetric self-renewing to symmetric neurogenic divisions of APs. AP undergoes symmetric division for self-renewal and asymmetric neurogenic divisions.

      Response to Reviewer and planned revision:

      Based on the current literature (cit. Huttner and Kriegstein), AP undergo:

      • symmetric division for proliferative division at early stages of neurogenesis
      • asymmetric self-renewing division, generating an AP and a BP at mid neurogenesis. This division is also described as neurogenic, as it produces a BP, that is a step further than AP in term of neurogenic potential.
      • symmetric consumptive division at late neurogenesis To avoid any possible confusion, we will re-phrase the sentence to include the adjective “consumptive” and specify the composition of the progeny.

      In the revised manuscript, the sentence will read as follow:

      "DOT1L inhibition led to increased neurogenesis driven by a shift of APs from asymmetric self-renewing (generating one AP and one BP) to symmetric consumptive divisions (generating two neurons)"

      Reviewer’s comment: All the data is based on treatments with EPZ (DOTL1 inhibitor), yet no information is shown to support its targeted activity in this system. A proof of principle in the chosen experimental system is missing; for instance, examining the activity or protein level of DOTL1 and decreased methylation of the target(s) is essential.

      Response to Reviewer and planned revision:

      EPZ is a well characterized drug, that has been used previously in our lab and by others as well.

      As for our lab, the information regarding the inhibitor, its activity and efficiency in inhibiting DOT1L towards H3K79me2 was shown in Franz et al. Supplementary Fig. S6 D, E.

      In the present manuscript, an additional confirmation that EPZ targets DOT1L in regard to its H3K79me2 activity is shown in Fig. 5D.

      We would refer to this information more explicitly in a revised manuscript.

      Reviewer’s comment: 2) Figure 1: The scoring of centrosomes and cilia is insufficient to conclude delamination and increase in basal fates. The effect could be on ciliogenesis or centrosome tethering to the apical end-feet of the AP, and other possible explanations for this observation also exist. The images are too small; larger images or graphic representations could be helpful in addition to the data.

      Response to Reviewer and planned revision:

      We did not intend to claim that the change in centrosome location demonstrate delamination, but only that it suggests delamination. This criterion has been extensively used as a proxy for delamination by several labs working on the cell biology of neurogenesis, such Huttner and Gotz labs. If the issue persists, we can re-phrase in a more cautious way the text referring to Figure 1 to highlight that the data only suggest delamination.

      Response to Reviewer and planned revision:

      To make a statement regarding delamination, I would like to see either the dynamics of delamination (organotypic slices images), staining with BP markers, or morphological changes of AP (staining that will reveal loss of adherence) or comparable data to support the observation. In my opinion Supp. Figure 1 is insufficient; the single image is not convincing; I would like to see 3D reconstruction and better-quality images.

      Response to Reviewer and planned revision:

      We can certainly provide better images and co-stain with relevant markers.

      We think it is beyond the scope of the manuscript embarking in live imaging as we are not studying the dynamics of delamination per se.

      Reviewer’s comment: Tis21 data (1H), again of low quality, is only a single piece of evidence and the conclusion "suggesting that the acquisition of a basal fate was paralleled by a switch to neurogenesis" is premature. I think other cell cycle exit reporters, Fucci markers, pHis, BrdU, NeuroD, or Tbr2 reporters (Li et al., 2020, (Haydar and Sestan labs)) to name a few, are necessary to establish the conclusions. The authors should show other markers such as PAX6, EOMES, or other upper-layer markers upon cell cycle exit in the SVZ/CP. These additional experiments will assist in cell fate analysis.

      Response to Reviewer and planned revision:

      We completely understand the points raised by the reviewer, and we plan to address them by co-staining with PAX6/SOX2, PH3 and/or EOMES.

      We think establishing the Fucci or EOMES mouse system is beyond the scope of the manuscript. In addition, given the present setting of all labs involved, it would be logistically unattainable (see also comments in the section below).

      We think the co-staining scheme and plan will be informative enough to satisfactory address the concerns raised by the reviewer.

      Reviewer’s comment: 2) Figure 2: The microinjection experiments are elegant; the images, however, do not complement the experiment. The images of the microinjected cells seem not to be reconstructed from z-stacked optical slices, so often, processes are not continuous (panel B, for example); therefore, it is not clear if an apical process is indeed missing or just not seen.

      Response to Reviewer and planned revision:

      The mentioned images are reconstructed from continuous Z-stacks, as we always do given the type of data. We can provide better reconstructions and/or additional images.

      Reviewer’s comment:

      The data analysis should include other parameters; BrdU staining could have given information on cell cycle exit, PAX6, SOX2, and EOMES on the location of the cells in the VZ/sVZ. The quality of images showing EOMES and TUBB3 staining is so low that it makes the reader doubt the validity of the quantifications. "Taken together, these data suggest that the inhibition of DOT1L might favor the acquisition of a neuronal over BP cell fate" This interpretation should be subjected to more investigations. It is possible that this treatment just accelerates the AP-> BP -> Neuronal fate. The author's claim needs to be backed by additional experiments or be changed.

      Response to Reviewer and planned revision:

      To address this point, we will include in the revised manuscript staining and co-staining with PAX6, SOX2 (see also response above) and provide a BrdU labeling experiment.

      Reviewer’s comment: 3) Figure 3: The experiment concept and its performance are impressive, yet the data is insufficient. The images in A that are supposed to be representative show two cells; their location is not clear, and the expression of GFP is not clear; in fact, both pairs seem to be GFP negative (not clear what is the threshold for background). Staining with anti-GFP and a second method to follow neurogenesis is necessary.

      Response to Reviewer and planned revision:

      We did use different staining methods and schemes to follow neurogenesis. As specified above, we will deepen our analysis by using additional markers, such as TBR1.

      Reviewer’s comment: 4) On page 9, lines 8-10, the authors claim that their number of cells was "sufficient" for single-cell analysis; the numbers are Response to Reviewer and planned revision:

      In the revised manuscript, we will include the analysis of how many cells are needed to identify cluster of 6 cell types in this paradigm, based for example on the algorithms developed in Treppner et al. 2021.

      Reviewer’s comment: 5) The authors use Seurat and RaceID without their appropriate citations in the first mention during the results. The authors also stop immediately after DEG analysis along with clustering. The authors could analyze their RNA-seq data with a trajectory; to say the least, the identification/characterization of TTS and neurons as Neurons I, II, and III are insufficient. There could be multiple ways to show the "fate" of cells in the isolated FACS, which the authors have missed.

      Response to Reviewer and planned revision:

      We will include the respective citations in a revised manuscript. We provide already differentiation trajectories but will include other methods, including scVelo of FateID to extend the trajectory analyses. We kindly ask the reviewer to also refer to the comments above regarding the TTs cluster characterization as part of our effort to provide a better picture of the different clusters.

      Reviewer’s comment: 6) The authors detected candidates like Fgfr3, Nr2f1, Ofd1, and Mme as part of their treated (different approaches) datasets (from their DEG analysis). They correctly cite Huang et al., 2020 but fail to give us a sense of the consequences of these gene dysregulations. The authors can also validate if these proteins are expressed in their treated cells.

      Response to Reviewer and planned revision:

      In the revised manuscript we will comment on the function of the four genes mentioned.

      In addition, we will validate the expression of these genes on protein and transcriptional level through immunostainings -provided that antibodies are working in our system- or smFISH, respectively.

      Reviewer’s comment: 7) The authors list a few GO terms (page 10, lines 1-10) and associate them with reduced proliferation; they must cite relevant studies. The authors can also add supplementary data showing which genes in their data correspond to these GO terms.

      Response to Reviewer and planned revision:

      We thank the reviewer for pointing out the missing citations.

      We of course agree on the need to add them, and we will do so in the revised manuscript.

      Reviewer’s comment: 8) On Page 11, lines 3-7, the authors describe their method to arrive at the 17 targets with TF activity from the previous analysis. Can the authors describe the method used to correlate the two? The reviewer understands this could be MEME analysis or analysis of earlier datasets of Ferrari et al. 2020. But it must be explicitly stated, and a few examples in supplementary need to be exemplified as this analysis is key to discovering the three metabolic genes.

      Response to Reviewer and planned revision:

      In the revised manuscript, we will clarify the exact analysis that resulted in the identification of the 17 target genes, using the specific tool for gene network analysis, that is based on our scRNA-seq data alone, but not on the Ferrari et al 2020 data set.

      3. Description of the revisions that have already been incorporated in the transferred manuscript

      n/a

      4. Description of analyses that authors prefer not to carry out

      Reviewer’s comment: Tis21 data (1H), again of low quality, is only a single piece of evidence and the conclusion "suggesting that the acquisition of a basal fate was paralleled by a switch to neurogenesis" is premature. I think other cell cycle exit reporters, Fucci markers, pHis, BrdU, NeuroD, or Tbr2 reporters (Li et al., 2020, (Haydar and Sestan labs)) to name a few, are necessary to establish the conclusions. The authors should show other markers such as PAX6, EOMES, or other upper-layer markers upon cell cycle exit in the SVZ/CP. These additional experiments will assist in cell fate analysis.

      Response to Reviewer and planned revision:

      As pointed out above, we think establishing the Fucci or EOMES mice system is beyond the scope of the manuscript as it will not provide more information than the ones we will obtain from systematic and extensive co-staining experiments. In addition, all labs involved are facing a logistic issue (animal house not ready yet, construction works etc) that made the importing and setting up of the colony unattainable for the next 6-10months. If the reviewer and/or the editorial board think this is a major point compromising the entire revision, we kindly ask to contact us again so that we can discuss the issue and arrive to a shared conclusion.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      Appiah et al. present a concise manuscript that provides details and possible mechanisms of their previous work (Franz et al., 2019; Ferrari et al., 2020). The study uses diverse lines of investigation to arrive at most conclusions. However, as interesting as the data is, we find that at the present state, it is not sufficient to prove that, indeed, the asparagine metabolism is regulated by DOTL1/PRC2 crosstalk. The neurogenic shift presented in the first part of the paper is not comprehensive and, therefore, not very convincing. The quality of images provided in the main and supplementary data is less than ideal. Additional data analysis and interpretation of the scRNA seq data may be needed. The authors finally conclude with rescue experiments done in culture and in-vivo, which we believe is the stand-out part of this study. Overall the manuscript has some interesting observations that are often over-interpreted with less supporting data. The manuscript reads well but requires additional data and changes in the claims/interpretation to be suited for publication.

      Comments

      1. Abstract: Is this statement correct: "DOT1L inhibition led to increased neurogenesis driven by a shift from asymmetric self-renewing to symmetric neurogenic divisions of APs". AP undergoes symmetric division for self-renewal and asymmetric neurogenic divisions.

      All the data is based on treatments with EPZ (DOTL1 inhibitor), yet no information is shown to support its targeted activity in this system. A proof of principle in the chosen experimental system is missing; for instance, examining the activity or protein level of DOTL1 and decreased methylation of the target(s) is essential. <br /> 2. Figure 1: The scoring of centrosomes and cilia is insufficient to conclude delamination and increase in basal fates. The effect could be on ciliogenesis or centrosome tethering to the apical end-feet of the AP, and other possible explanations for this observation also exist. The images are too small; larger images or graphic representations could be helpful in addition to the data.

      To make a statement regarding delamination, I would like to see either the dynamics of delamination (organotypic slices images), staining with BP markers, or morphological changes of AP (staining that will reveal loss of adherence) or comparable data to support the observation. In my opinion Supp. Figure 1 is insufficient; the single image is not convincing; I would like to see 3D reconstruction and better quality images.

      Tis21 data (1H), again of low quality, is only a single piece of evidence and the conclusion "suggesting that the acquisition of a basal fate was paralleled by a switch to neurogenesis" is premature. I think other cell cycle exit reporters, Fucci markers, pHis, BrdU, NeuroD, or Tbr2 reporters (Li et al., 2020, (Haydar and Sestan labs)) to name a few, are necessary to establish the conclusions. The authors should show other markers such as PAX6, EOMES, or other upper-layer markers upon cell cycle exit in the SVZ/CP. These additional experiments will assist in cell fate analysis. 2. Figure 2: The microinjection experiments are elegant; the images, however, do not complement the experiment. The images of the microinjected cells seem not to be reconstructed from z-stacked optical slices, so often, processes are not continuous (panel B, for example); therefore, it is not clear if an apical process is indeed missing or just not seen. The data analysis should include other parameters; BrdU staining could have given information on cell cycle exit, PAX6, SOX2, and EOMES on the location of the cells in the VZ/sVZ. The quality of images showing EOMES and TUBB3 staining is so low that it makes the reader doubt the validity of the quantifications. <br /> "Taken together, these data suggest that the inhibition of DOT1L might favor the acquisition of a neuronal over BP cell fate" This interpretation should be subjected to more investigations. It is possible that this treatment just accelerates the AP-> BP -> Neuronal fate. The author's claim needs to be backed by additional experiments or be changed. 3. Figure 3: The experiment concept and its performance are impressive, yet the data is insufficient. The images in A that are supposed to be representative show two cells; their location is not clear, and the expression of GFP is not clear; in fact, both pairs seem to be GFP negative (not clear what is the threshold for background). Staining with anti-GFP and a second method to follow neurogenesis is necessary. 4. On page 9, lines 8-10, the authors claim that their number of cells was "sufficient" for single-cell analysis; the numbers are <500 for all samples. The authors need to justify this statement or articles that carefully analyze the number required for such a conclusion as references. 5. The authors use Seurat and RaceID without their appropriate citations in the first mention during the results. The authors also stop immediately after DEG analysis along with clustering. The authors could analyze their RNA-seq data with a trajectory; to say the least, the identification/characterization of TTS and neurons as Neurons I, II, and III are insufficient. There could be multiple ways to show the "fate" of cells in the isolated FACS, which the authors have missed. 6. The authors detected candidates like Fgfr3, Nr2f1, Ofd1, and Mme as part of their treated (different approaches) datasets (from their DEG analysis). They correctly cite Huang et al., 2020 but fail to give us a sense of the consequences of these gene dysregulations. The authors can also validate if these proteins are expressed in their treated cells. 7. The authors list a few GO terms (page 10, lines 1-10) and associate them with reduced proliferation; they must cite relevant studies. The authors can also add supplementary data showing which genes in their data correspond to these GO terms. 8. On Page 11, lines 3-7, the authors describe their method to arrive at the 17 targets with TF activity from the previous analysis. Can the authors describe the method used to correlate the two? The reviewer understands this could be MEME analysis or analysis of earlier datasets of Ferrari et al. 2020. But it must be explicitly stated, and a few examples in supplementary need to be exemplified as this analysis is key to discovering the three metabolic genes.

      Significance

      Appiah et al. present a concise manuscript that provides details and possible mechanisms of their previous work (Franz et al., 2019; Ferrari et al., 2020). The study uses diverse lines of investigation to arrive at most conclusions. However, as interesting as the data is, we find that at the present state, it is not sufficient to prove that, indeed, the asparagine metabolism is regulated by DOTL1/PRC2 crosstalk. The neurogenic shift presented in the first part of the paper is not comprehensive and, therefore, not very convincing. The quality of images provided in the main and supplementary data is less than ideal. Additional data analysis and interpretation of the scRNA seq data may be needed. The authors finally conclude with rescue experiments done in culture and in-vivo, which we believe is the stand-out part of this study.

      Overall the manuscript has some interesting observations that are often over-interpreted with less supporting data. The manuscript reads well but requires additional data and changes in the claims/interpretation to be suited for publication.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      The manuscript investigated the role of DOT1L during neurogenesis especially focusing on the earlier commitment from APs. Using tissue culture method with single-cell tracing, they found that the inhibition of DOT1L results in delamination of APs, and promotes neuronal differentiation. Furthermore, using single cell RNA-seq, they seek possible mechanisms and changes in cellular state, and found a new cellular state as a transient state. Among differentially expressed genes, they focused on microcephaly-related genes, and found possible links between epigenetic changes led by DOT1L inhibition and epigenetic inhibition by PRC2. Based on these findings, they suggested that DOT1L could regulate neural fate commitment through epigenetic regulation. Overall, it is well written and possible links from epigenetic to metabolic regulation are interesting. However there are several issues across the manuscript.

      Major issues:

      1. It is not clear whether the degree of H3K79 methylation (or other histones) changes during development, and whether DOT1L is responsible for those changes. It is necessary to show the changes in histone modifications as well as the levels of DOT1L from APs to BPs and neurons, and to what extent the treatment of EPZ change the degree of histone methylation. Furthermore, the study mainly used pharmacological bath application. DOT1L has anti-mitotic effect, thus it is not clear whether the effect is coming from the inhibition of transmethylation activity. In addition, the study assumed that the effect of EPZ is cell autonomous.However, if EPZ treatment can change the metabolic state in a cell, it would be possible that observed effects was non-cell autonomous. It would be important to address if this effect is coming in a cell-autonomous manner by other means using focal shRNA-KD by IUE.
      2. The possible changes in cell division and differentiation were found by very nice single-cell tracing system. However, changes in division modes occurring in targeted APs such as angles of mitotic division and the expression of mitotic markers were not addressed. These information is critical information to understand mechanisms underlying observed phenotype, delamination, differentiation and fate commitment .
      3. The scRNA-seq analysis indicated interesting results, but was not fully clear to explain the observed results in histology. In fact, in single cell RNA-seq, the author claimed that cells in TTS are increased after EPZ treatment, which are more similar to APs. However, in histological data, they found that EPZ treatment increased neuronal differentiation. These data conflicts, thus I wonder whether "neurons" from histology data are actually neurons? Using several other markers simultaneously, it would be important to check the cellular state in histology upon the inhibition/KD of DOT1L.

      Minor issues:

      Figure 1

      • It is not clear delaminated cells are APs, BPs or some transient cells (Sox2+ Tubb3+??). It is important to use several cell type-specific and cell cycle markers simulnaneously to characterize cell-type specific identity of the analysed cells by staining.These applied to Fig1B,D,E,F,G,as well as Fig2,3.

      • Please provide higher magnification images of labelled cells (Fig 1H)

      • Please provide clarification on the criteria of Tis21-GFP+ signal thresholding.
      • Splitting the GFP signal between ventricular and abventricular does not convincingly support the "more basal and/or differentiated" states after EPZ treatment.
      • Please explain the presence of Tis21-GFP+ cells at the apical VZ.
      • Order the legends in same order as the bars.

      Figure 2

      • Fig 2B) The difference between CON and EPZ apical contacts is not clear and does not match with the graph in Fig 2E.

      • Supp Fig 2 - are these injected slices cultured in control conditions? Please include this in the text and figure/figure legend

      Fig 2C) The EPZ-treated DxA555+ cells exhibit morphological change of cell shape. Is this phenotype? please comment on the image shown for EPZ treatment panel.

      Fig 2F - 2G) Data presented on EOMES+ and TUBB3+ % are counterintuitive. The authors claimed that TUBB3+ cells are increased and neuronal differentiation is promoted. However, no changes in EOMES+ are observed. What is the explanation? Did the author check the double positive cells? These could be TSS cells?

      Figure 2 and Figure 3) the number of pairs analyzed for EPZ is twice as that of Con for comparison of the parameters taken into account. Please include n of each graph in the figure legend of the specific panel if not the same for all panels in that figure (i.e. for figure 3)

      Figure 3)

      • The data indicated that the number of daughter cell pairs in EPZ samples is almost double than Control. Is this the phenotype? More numbers of daughter cells in EPZ treated samples were observed from the same number of injections? or the number of injected cells were different? Figure 4)
      • Please clarify if the single cell transcriptomic analysis has been performed only once, and if yes, how statistical testing to compare the cell proportion is carried out with only one batch. Fig 4G)

      Figure 4 and 5)

      • Figures are not supportive of the statement regarding APs' neurogenic potential upon DOT1L inhibition. TSS transcriptomic profile resembles more progenitors than neurons. Please comment on TSS neurogenic capacity taking into account the provided GO and RNAseq.
      • Please provide GO analysis for APs and BPs.

      Figure 5)

      • Reconstruct figure 5A by listing genes in the same order in both Con and EPZ, and prioritize EPZ-Con differences instead of cell-cell differences. Moreover, the presented genes in the heatmap is not the same in two conditions (i.e. NEUROG1 is present in EPZ but absent in Con). Please justify. Fig 5D)
      • Please explain why binding of EZH2 on the promoter of Asns is strongly reduced in comparison to a mild significant reduction of H3K79me/H3K27me3 in EPZ compared to Control. Also is the changed directly medicated by DOT1L? Please test whether DOT1L can bind the promoter of Asns.

      Please provide the expression patterns of DOT1L and Asns during neuronal differentiation.

      Other General comments: - Please Indicate VZ, SVZ and CP on the side of the pictures/ with dot lines in the pictures both for primary figures and supplementary. - The Results and figures sometimes do not support the statement made by the authors - Schemes are not informative/explanatory enough, i.e. time windows of treatment and sample collection, culture conditions details.. - A more extensive characterization of TTS cells in terms of differentiation progression and integration would be enlightening - Picture quality can be improved, provide high magnification images.

      Significance

      The study could be important for the specific field in neural development. It aims to understand mutations in respective genes and brain malformation. If the link between epigenetic and metabolic changes is clearly shown, it will be interesting. However, the current manuscript is still rather descriptive, and clear mechanistic insights were not provided. The study have potentials and additional data will strength the value of study.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      The authors do not wish to provide a response at this time.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      Summary:

      In this work, the authors investigate the effect of using mature mRNAs instead of only nascent mRNA (located at the transcription site) when estimating transcriptional kinetics parameters from single-molecule fluorescent in situ hybridization (smFISH) experiments. The authors find that using nascent mRNA and correcting for cell cycle effects yields more accurate parameter estimates than using mature mRNAs. The author performs smFISH experiments of the GAL10 gene in yeast to test their findings. Also, the authors test different methods to obtain parameter estimates in cases where there is no information about the location of the transcription site.

      Major comments:

      1.The authors make multiple claims of novelty that conflict with work described in some of their references, particularly: Skinner et al., eLife, 2016; Xu et al., Nature Methods, 2015 and Physical Review Letters, 2016 (References #26,27 and 24 in their manuscript). I could find several instances where the scope of their claims was unclear. Below I describe some cases:

      a.The title of this paper, "accurate inference of stochastic gene expression from nascent transcript heterogeneity" could also be the summary conclusion of the three works cited above. However, later in the Introduction of the manuscript, the authors state that their goal is to "understand the impact of post-transcriptional noise and cell-to-cell variability on the accuracy of transcriptional parameters inferred from mature mRNA data," a related yet different topic. I would change the title of the manuscript to reflect their main goal better.

      b.I would make their claims of novelty more specific. For example, at the end of the abstract, the authors claim that "our novel data curation method yields a quantitatively accurate picture of gene expression." Quantifying nascent mRNA using smFISH to obtain transcription kinetic parameters has been done before (the references above are an example) also developing the modeling tools to do so (for example, in Xu et al., Physical Review Letters, 2016). What is, exactly, the novelty in their approach? They need to make that explicit or soften their claims.

      c.In the Introduction, when discussing the effect of the cell cycle in parameter estimation, they write: "Since estimation of all transcriptional parameters (...) from nascent data as a function of the cell cycle phase has not been reported". However, the work they reference (Skinner et al., eLife, 2016) shows such measurements for multiple transcriptional parameters for different cell cycle stages. The original work may not have gone as far as the current work, but it is unclear what has been done before from the way the authors describe earlier literature.

      d.The authors develop a new formulation of the delay telegraph model to obtain kinetic parameters from the nascent RNA copy number statistics. They state in the SI that "Similar delay models have also been studied by other authors," however, the authors do not explain in which way their model differs from previous work. Does their approach have advantages over previously published models?

      2.There is a particular choice during their analysis that I find problematic. In section 2.3, the authors state "The transcription site is counted as 1 mRNA, regardless of its intensity, but has a negligible influence since the mean number of mature mRNA is much greater than 1" (the number should be spelled). It is unclear that statement is true for all possible kinetic parameters. It is also hard to evaluate that claim because the authors do not show images of transcription sites that would support it. Trying to find more information, I saw images from previous work from one of the authors ("Optimized protocol for single-molecule RNA FISH to visualize gene expression in S. cerevisiae", figure 4). Those images suggest that the opposite is the case: in the cell shown, the number of mRNAs in the transcription site is not negligible but instead seems to contain most of the mRNAs in the cell. Solving this problem would require the authors to remake their analysis without making this assumption.

      3.Overall, I think the current experiments are sufficient to support their claims. Also, the description of methods and references is appropriate to allow other researchers to reproduce their observations. Finally, the experiments are replicated, and enough cells are analyzed to provide enough statistical significance to their claims.

      Minor comments:

      1.In section 2.1.3, the authors mention using an optimization package written in Julia programing language. A reference to the package needs to be included, either an academic article or the website to the package.

      2.In the discussion, the authors state "In addition, live-cell measurements include cells in S phase, which are excluded in smFISH." I do not think that statement is correct. One would expect that a large enough sample of cells assayed with smFISH will contain a subpopulation containing cells in the S-phase.

      3.I find the overall presentation of figures and the analysis performed not optimal to convey their points. Below are some suggestions regarding presentation (and in some cases, analysis).

      Text suggestions:

      a.The meaning of the word "inference" seems to change across the manuscript. In the title, I understand that inference means "estimation," or more explicitly, estimating model parameters from experimental or simulated data. However, in the methods section, the authors write "Mature mRNA inference" and "Nascent mRNA inference." Do they mean "Estimating/Inferring model parameters from synthetic/experimental mature/nascent mRNA datasets"?

      b.In the Introduction, the authors use three different terms for cell cycle (cell cycle position, cell cycle stage, and cell cycle phase). It is unclear to me if they are referring to the same concept.

      Presentation suggestions:

      c.I would remove Figure 2C and put it in the Supplementary information. It shows procedure details that are not fundamental to understanding their claims.

      d.I would also relegate the tables in their six datasets in figure 1 and 2 to the Supplementary material. Tables are not very effective methods to present information.

      e.I do not think that figures 1c and 2d are needed. Comparing the results from stochastic simulations and the predictions from the models is an internal control that the researchers should do to test the accuracy of their SSA implementation; it does not convey a message related to the main conclusions of their work.

      f.I like figure 4a; it conveys one of the main points: not correcting for cell cycle can lead to considerable errors in parameter estimation. I would like to see a similar plot that conveys the difference in parameter estimation when using nascent vs. mature mRNA.

      g.Why do the authors have table 1 separated from figure 4 while adding the tables to figures 1 and 2? I would be consistent and move all tables to the supplementary material.

      Significance

      As described above, some claims do not seem novel considering the references in this manuscript. This is not a problem; the authors can soften their claims to novelty without compromising their other claims. Previous works that estimated mRNA transcription kinetic parameters by quantifying nascent mRNA recognized that using mature mRNA would incur in parameter estimation errors. They considered it evident that quantifying the process closer to the transcription site would improve estimates. Similarly, it was also apparent that adding missing information (the gene copy number based on cell cycle information) would improve parameter estimates. That is why the authors presenting those arguments as findings is unnecessary. However, it is true that here the authors are interested in the level of error, not the fact that getting more accurate (or relevant) measurement will improve estimates.

      An item that the authors may want to emphasize is their finding that it is possible to correct for measurements where the identity of the transcription site is unknown. All the works that they cite where nascent mRNA is measured using some method to localize the position of the transcription site. I mammalian cells and fly embryos, it is possible to label introns to identify mRNA located at the transcription site. That is not possible in many yeast genes or other microorganisms.

      Which audience would be most interested in this work? I think those searching for methods to quantify transcriptional kinetics in organisms where the identity of the transcription site cannot be measured by smFISH or other novel methods such as Cas-FISH.

      I performed studies of transcriptional kinetics in bacteria during my doctorate, and I continue utilizing smFISH in my research.

      Referees cross-commenting

      I agree with the assessment from the other reviewers. One of reviewer 2's requests (to perform simulations covering the parameter space) is particularly relevant given the main goals of the authors. All reviewers noted that the method used to quantify the number of RNA at the transcription site has shortcomings that need to be addressed

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      In the manuscript Fu and co-authors compare accuracy for 2 models that infer kinetics of the transcription from synthetic and experimental data. Specifically, they compare the telegraph model for mRNA and the delayed telegraph model for nascent RNA. They first provide the comparison for synthetically simulated data, and derive that the latter exhibits higher accuracy. Next they apply the model to experimental data from smFISH for PP7-GAL10 strain, and provide the framework to estimate the number of mRNAs and use the intensity at the transcriptional site to infer the number of bounds of polymerase during the transcription (nascent RNA). For the latter, I appreciate that they account for the fact that intensity throughout the transcription will depend on 'spatial' position of polymerase and incorporate this into the framework to infer nascent RNA levels. Additionally, for the experimental data they infer kinetics with and without accounting for cell cycle (accordingly 1 or 2 gene copies), and through comparing to life imaging data from Donovan et al., 2019, they suggest that the model that best describes experimental data is delayed telegraph for nascent RNA when accounted for cell cycle. Finally they provide 2 approaches - called rejection and fusion - to account for potential artifacts in estimation of nascent RNA levels from the intensity at transcriptional sites, and provide the comparison of how this approaches affect the overall fit.

      Whereas it is important to have a systematic understanding/comparison for both models as well as for how accounting of cell cycle might improve the overall accuracy, some of the aspects of the results/estimation of values from experimental data require more thorough analysis. Specifically, below I describe points to be addressed:

      Major points:

      Comparison of the models for simulated data. In the first two chapters of the results the authors compare simulations/parameter inference from the synthetic data for the telegraph-based model for mRNA and delayed telegraph model for nascent RNA, and conclude that the latter provides better accuracy. However, based on the relationship for mean relative error distribution as a function of fON, it seems to me that both models show very similar results, and the support of better accuracy for nascent RNA seems unclear to me. Additionally, simulations are performed for the concise number of parameter sets, and it is unclear how well/uniformly the chosen sets cover the parameter space. I suggest that more thorough analysis is required. One way to do so would be to perform simulations on the same set of parameters that comprehensively cover the parameter space for both models and compare mean error rates in pairwise fashion. Additionally, it might be worth considering comparing error rate for each parameter separately (i.e. for sigma-on, sigma-off and the production rate of mRNAs when promoter is on).

      An additional analysis of the accuracy of the estimated values from the experimental data. When it comes to experimental data, the overall fit of any proposed model will depend on both the suitability/correctness of a model to explain the process in question as well as the reliability of the estimates (inputs for the model) from the experiments. Specifically, it is possible that a model (either telegraph for mRNA or delayed telegraph for nascent RNA or both) to explain transcriptional kinetics is fairly accurate, but the input estimates (for accordingly mRNA or nascent RNA) are biased (due to technical artifacts from the experiment and/or the approach towards estimating those values), thus affecting the overall fit of a model and interpretation of the results.

      I appreciate that authors address one potential artifact in estimating nascent RNA, where it is possible that the intensity of nascent RNA is overestimated if it is mistakenly confused with mRNA. I suggest that the more detailed analysis of the accuracy for both the number of mRNA molecules and the intensity of nascent RNA is required to provide better insight in how reliably those values are estimated and accordingly whether models might perform poorly due to biased estimates.

      Specifically, I am wondering about next aspects:

      Mature mRNA: More detailed method section covering the estimate for background signal and spot detection. A potential proximity of mRNA molecules resulting in underestimation of the total number of mRNAs, and how this might affect the fit of the telegraph model. Even though smFISH has been widely used to estimate the number of mRNA molecules (as a total number of spots), the technique has been mostly applied to mammalian cells with considerably bigger cell size. Additionally, the usage of the total number of mRNA molecules in order to estimate transcriptional kinetics from the telegraph model seemingly requires a highly accurate estimate of the total number of molecules. Combined, it is not obvious if potential underestimation of mRNAs (specifically in cells with high number of mRNAs) via smFISH in budding yeast cells might lead to the misleading interpretation of the results. One way to assess whether such 'merging' takes place is to look into the distribution of intensities for cytoplasmic spots (per cell and/or all the cells in the whole field of view). If those distributions frequently show bi/multi-modal behavior, it is worth considering whether a proposed way to estimate mRNA number is suitable in for given model organism/growth conditions/gene, and further extend the analysis on simulated data to provide the robustness of the fit of the telegraph model for mRNAs in cases whether number of mRNAs is underestimated. A more minor issue, but authors state that, for each cell, the highest intensity of the nuclear spot will count as one mRNA, and that it has a negligible influence. I would appreciate a more thorough analytical explanation for this or an additional analysis on the simulated data to support how random +/-1 of mRNAs might affect results of the fit, specifically for cases with ~low average mRNA estimate.

      Nascent RNA: I might be missing something, but it seems that for cells in late G2 phase where nucleus is either strongly elongated (and looks like a sand clock) or even exhibits 2 separate nuclei connected with the chromatin bridge - 2 copies of the gene can be spatially resolved and therefore it might happen that 2 independent/separate brightest spots (one per each cell) amount to total estimate of nascent RNA in cases where promoter is on simultaneously in both copies? If so, depending on estimated in the study/prior literature-based estimates for sigma-on/off, the probability of simultaneous transcription might vary and this should be taken into account? This also might partially explain the phenomenon of lower transcriptional activity in G2 which is currently suggested to be explained with dosage compensation? Or are those cells considered as 2 cells in G1? If so, it needs to be specified in the text. Additionally, I suggest that images from microscopy can be provided as a supplement to aid clarity in how cell cycle, number of mRNAs and intensity for nascent RNA were estimated.

      Additional experimental validation and/or the discussion of the accuracy of the inference for a different range of parameters. The analysis of the experimental data consists of the (I presume highly comparable with Donovan et al., 2019) single condition (i.e. galactose concentration, glu/galactose ratio) resulting in a single parameter set for transcriptional kinetics. Specifically, it is estimated that sigma on and off will be comparable for the given set up, and therefore, based on simulated data, the estimates will be somewhat reliable for the cell cycle accounted delayed telegraph for nascent RNA. I wonder how in practice (i.e. estimated from the experiments) the same model will perform for a different set of parameters/different conditions. Ideally, I would suggest performing the similar experiment, but where sigma on/sigma off is expected to be different. One way to achieve this with the GAL10 / galactose set up is to tune the glu/gal ratio of the media. Even without a comparison to live-cell tracing, the analysis of estimated parameters for merged and cell cycle specific data can shed light on how suitable the model is for alternative parameters. Alternatively, if the experiment is currently not feasible, I would appreciate a more extensive discussion of the practical suitability of the cell-cycle specific delayed telegraph model for nascent RNA for alternative sets of transcriptional parameters. Considering that the comparison was performed only against 'simple' telegraph model and in introduction authors mention a variety of 'improved' models for mRNA, that account for various sources of heterogeneity, they might be more suitable for alternative set of transcriptional parameters, and might be more suitable that cell cycle specific delayed telegraph for nascent RNA.

      Overall, the main statements of the paper - that cell cycle specific inference from the experimental data using delayed telegraph model from nascent RNA performs best (compared to telegraph model from mRNA or not cell cycle specific) are supported, and I agree that understanding of the limitations of the currently popular models (telegraph for mRNA and/or not accounting for cell cycle) is an important addition to the field. I would be happy to further proceed with the revision/acceptance of the paper if the comments above are addressed/considered.

      Minor comments:

      Current method section is lacking the description of the growth media, which is an important aspect to specify when it comes to budding yeast (particularly when the sugar source is different from the standard glucose and/or results are compared to another publication). In the figure 2b I find the cartoon a little misleading - specifically why polymerase is bound when the promoter is off? If it is to illustrate the case when transcription/polymerase bound occured after promoter is switched off, why there are no polymerase to the right from the current one (as in in the case where promoter is on)? In table1 - there is a typo in the 2nd meta-row - I suspect it should say G2?

      Significance

      This paper is somewhat outside my core expertise, although closer to the expertise of my postdoc who assisted with the review.

      The work is interesting but the generalisability of the conclusions is somewhat limited, partially by the lack of experimental validation. Nevertheless, there are interesting aspects of the study and the area of research is important.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      Summary:

      In this study, the authors consider the problem of inferring transcription dynamics from smFISH data. They distinguish between two important experimental situations. The first one considers measurements of mature mRNAs, while the second one considers measurements of nascent mRNA through fluorescent probes targeting PP7 stem loops. The former problem has been previously dealt with extensively, but less work has been done on the context of the latter. The inference approaches are based on maximum likelihood estimation, from which point estimates for promoter-switching and transcription rates are obtained. The study focuses on steady state measurements only. The authors perform several analyses using synthetic data to understand the limitations of both approaches. They find that inference from nascent mRNA is more reliable than inference from mature mRNA distributions. Moreover, they show that accounting for different cell-cycle stages (G1 vs G2) is important and that pooling measurements across the cell-cycle can lead to quantitatively and even qualitatively different inferences. Both approaches are then used to analyze transcription in an experimental system in yeast, for which they find evidence of gene dosage compensation. I consider this an interesting and relevant study, which will appeal to the systems- and computational biology community. The paper is well written and the (computational) methods are described in detail. The experimental description is quite minimal and could profit from further details / explanations. I have several technical criticisms and questions, which I believe should be addressed before publication. Since I am a theorist, I will comment predominantly on the statistical / computational aspects.

      Major comments/questions:

      -A key reference that is missing is Fritzsch et al. Mol Syst Biol (2018). In this work, the authors have used nascent mRNA distributions and autocorrelations (obtained from live-imaging) to infer promoter- and transcription dynamics. I believe this work should be appropriately cited and discussed.

      Synthetic case study:

      -Inference and point estimates. The authors use a maximum-likelihood framework to extract point estimates of the parameters. Subsequently, relative absolute differences are used to assess the accuracy of the inference. However, as far as I have understood, this is performed for only a single simulated dataset, for each considered parameter configuration. The resulting metric, however, does not really capture the inference accuracy, since it is based on a single (random) realization of the MLE. I would recommend to at least repeat the inference multiple times for different realizations of the simulated dataset (per parameter configuration) to get a better feeling of the distribution of the MLE (e.g., its bias / variance). Alternatively, identifiability analyses based on the Fisher information could be performed for (some of) the different parameter configurations although this may be computationally more demanding.

      -It would be useful to include confidence intervals based on profile likelihoods also for the synthetic case study, in particular for the 6 reported datasets. I would also find it helpful to see comprehensive profile likelihood plots for the key results / parameter inferences in the supplement. This would also provide useful insights into the identifiability of the parameters.

      Experimental case study:

      -Validation against live-cell data. In the simulation of the autocorrelation function, what was the ratio of cells initialized in G1 / G2, respectively? I'd expect this to have direct influence on the simulated ACF. Moreover, a linear fit is used to correct for "non-stationary effects" in the ACF that supposedly stem from cell-cycle dynamics. First, I don't think this terminology is really accurate, since non-stationarity would lead to an ACF that depends on two parameters (tau_1 and tau_2). I suppose the goal of the linear correction is to remove slow / static population heterogeneity? If yes, wouldn't it be easier / more direct to also change the simulations to non-synchronized cell-cycles? In this case, they should also display the very slow / static components as displayed in the data, which would eliminate the need for the post-hoc correction. I was also wondering whether other statistics (e.g., mean, variance, distributions) match between the simulations and the live-cell experiment? This could provide further validation of the inferred parameters.

      -If I understood correctly, the signal intensity of the measured transcription spot is normalized by the median cytoplasmic spot brightness. Since the normalized intensity of a single complete transcript is 1, the cumulative intensity should give a lower bound on the nascent mRNAs. The histograms in Fig. 4b show intensity values in the range of 30, which would mean that at least 30 transcripts contribute to the transcription spot. The total number of nucleoplasmic and cytoplasmic mRNA, however, is in the range of 10 (Fig. 3a). I am probably missing something but how can we reconcile these numbers? The authors mention that the brightest spot just counts for one transcript, but argue that this has negligible influence on mature RNA counts. Could this be a possible explanation for the mismatch?

      Minor comments:

      -In the experimental case study, the authors argue that the "correct" inference result is the one that accounts for cell-cycle stage, while the other one termed "incorrect". I find this terminology too strong, since every estimate is subject to uncertainty.

      -Page 2: "... in a asynchronous population" -> "... in an asynchronous population"

      -Page 7: "...parameters sets 3 and 4" -> "...parameter sets 3 and 4"

      -Figures 5a and 6a: parameter names and units should go on the y-axis.

      Significance

      Quantifying kinetic parameters from incomplete and noisy experimental data is a core problem in systems biology. I therefore consider this manuscript to be very relevant to this field. The contribution of this manuscript is largely methodological, although its potential usefulness is demonstrated using experimental data in yeast.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      In recent years, the field has investigated crosstalk between cGMP and cAMP signaling (PMID: 29030485), lipid and cGMP signaling (PMID: 30742070), and calcium and cGMP signaling (PMID: 26933036, 26933037). In contrast to the Plasmodium field, which has benefited from proteomic experiments (ex: PMID 24594931, 26149123, 31075098, 30794532), second messenger crosstalk in T. gondii has been probed predominantly through genetic and pharmacological perturbations. The present manuscript compares the features of A23187- and BIPPO-stimulated phosphoproteomes at a snapshot in time. This is similar to a dataset generated by two of the authors in 2014 (PMID: 24945436), except that it now includes one BIPPO timepoint. The sub-min​​ute phosphoproteomic timecourse following A23187 treatment in WT and ∆cdpk3 parasites is novel and would seem like a useful resource.

      CDPK3-dependent sites were detected on adenylate cyclase, PI-PLC, guanylate cyclase, PDE1, and DGK1. This motivated study of lipid and cNMP levels following A23187 treatment. The four PDEs determined to have A23187-dependent phosphosites were characterized, including the two PDEs with CDPK3-dependent phosphorylation, which were found to be cGMP-specific. However, cGMP levels do not seem to differ in a CDPK3- or A23187-dependent manner. Instead, cAMP levels are elevated in ∆cdpk3 parasites. This would seem to implicate a feedback loop between CDPK3, the adenylyl cyclase, and PKA/PKG: CDPK3 activity reduces adenylyl cyclase activity, which reduces PKA activity, which increases PKG activity. The authors don't pursue this direction, and instead characterize PDE2, which does not have CDPK3-dependent phosphosites, and seems out of place in the study

      Response:

      We agree with reviewer 1 that a feedback loop between CDPK3, the adenylyl cyclase and PKA/PKG is certainly one of several possibilities (and we acknowledge this in the manuscript).

      We felt, however, that given the observation that A23187 and BIPPO treatment leads to phosphorylation of numerous PDEs (hinting at the presence of an Ca2+-regulated feedback loop), it was entirely relevant to study these in greater detail. Coupled with the A23187 egress assay on ΔPDE2 parasites - our findings suggest that PDE2 plays an important role in this signalling loop (an entirely novel finding). While PDE2 appears to exert its effects in a CDPK3-independent manner (indeed suggesting that CDPK3 might exert its effects on cAMP levels in a different fashion), this does not detract from the important finding that PDE2 is one of the (likely numerous) components that is regulated in a Ca2+-dependent feedback loop to regulate egress.

      We have modified our writing to better reflect the fact that our decision to pursue study of the PDEs was not solely CDPK3-centric.

      While we feel that our reasoning for studying the PDEs is solid, we appreciate that further clarification on the putative CDPK3-Adenylate cyclase link would make it easier for the reader to follow the rationale.

      We have not studied the direct link between CDPK3 and the Adenylate Cyclase β in more detail, as ACβ alone was shown to not play a major role in regulating lytic growth (Jia et al., 2017).

      **MAJOR COMMENTS**

      1.Some of the key conclusions are not convincing.

      The data presented in Figure 6E, F, and G and discussed in lines 647-679 are incongruent. In Figure 6E, the plaques in the PDE2+RAP image are hardly visible; how can it be that the plaques were accurately counted and determined not to differ from vehicle-treated parasites?

      Are the images in 6E truly representative? Was the order of PDE1 and PDE2 switched? The cited publication by Moss et al. 2021 (preprint) is not in agreement with this study, as stated. That preprint determined that parasites depleted of PDE2 had significantly reduced plaque number and plaque size (>95% reduction); and parasites depleted of PDE1 had a substantially reduced plaque size but a less substantial reduction in plaque number.

      Response:

      The plaques for PDE2+RAP were counted using a microscope since they are difficult to see by eye. We thank the reviewer for detecting our incorrect reference to Moss et al. (2021). This has been corrected in the text. We confirm, however, that the images in 6E are representative of what we observed and do indeed differ from what was seen by Moss et al.. We have acknowledged this clearly in the text.

      The differences cannot easily be explained other than by the different genetic systems used. Further studies of the individual PDEs will likely illuminate their role in invasion/ growth, but we feel this would be beyond the scope of this study.

      Unfortunately, the length of time required for PDE depletion (72h) is incompatible with most T. gondii cellular assays (typically performed within one lytic cycle, 40-48h). Although the authors performed the assays 3 days after initial RAP treatment, is there evidence that non-excised parasites don't grow out of the population. This should be straightforward to test: treat, wait 3 days, infect onto monolayers, wait 24-48h fix, and stain with anti-YFP and an anti-Toxoplasma counterstain. The proportion of the parasite population that had excised the PDE at the time of the cellular assays will then be known, and the reader will have a sense of how complete the observed phenotypes are. As a reader, I will regard the phenotypes with some level of skepticism due to the long depletion time, especially since a panel of PDE rapid knockdown strains (depletion in __Response:

      1. Cellular assays using KO parasites are commonly performed at the point at which protein depletion is detected. Both our western blots and plaque assay results demonstrate that, at the point of assay, there is no substantial outgrowth of non-excised parasites. The original manuscript also includes PCRs performed at the 72 hr time point (See Fig. 6B) to support this.
      2. We appreciate the reviewer’s comment re the panel of PDE KD strains. The reviewer notes that there are substantial limitations to conditional KO systems, which similarly applies to KD systems - there are notable pros and cons to each approach. When designing our strategy (pre-publication of the Moss et al., 2022), we made a deliberate decision to use conditional KO strains in light of the fact that residual protein levels in KD systems can cause significant problems, particularly for membrane proteins (all of the investigated PDEs have a transmembrane domain). Tagging of proteins with the degradation domain can have further issues, leading to protein mis-localisation, which we have experienced with several unrelated proteins in the lab.

        The authors should qualify some of their claims as preliminary or speculative, or remove them altogether.

      The claims in lines 240-260 are confusing. It seems likely that the two drug treatments have at least topological distinctions in the signaling modules, given that cGMP-triggered calcium release is thought to occur at internal stores, whereas A23187-mediated calcium influx likely occurs first at the parasite plasma membrane.The authors' proposed alternative, that treatment-specific phosphosite behavior arises from experimental limitations and "mis-alignment", is unsatisfying for the following reasons: (1) From the outset, the authors chose different time frames to compare the two treatments (15s for BIPPO vs. 50s for A23187); (2) the experiment comprises a single time point, so it does not seem appropriate to compare the kinetics of phosphoregulation. There is still value in pointing out which phosphosites appear treatment-specific under the chosen thresholds, but further claims on the basis of this single-timepoint experiment are too speculative. Lines 264-267 and 281-284 should also be tempered.

      Relatedly, graphing of the data in Figure 1G (accompanying the main text mentioned above) was confusing. Why is one axis a ratio, and the other log10 intensity? What does log10 intensity tell you without reference to the DMSO intensity? Wouldn't you want the L2FC(A23187) vs. L2FC(BIPPO) comparisons? Could you use different point colors to highlight these cases on plot 1E? Additionally, could you use a pseudocount to include peptides only identified in one treatment condition on the plot in 1E? (Especially since these sites are mentioned in lines 272-278 but are not on the plot)

      Response:

      1. The kinetics of the responses to A23187 and BIPPO are very different. This is why treatment timings are purposely different as they were selected to align pathways to a point where calcium levels peak just prior to calcium re-uptake. We make no mention of kinetic comparisons, and merely demonstrate that at the chosen timepoints, overall signalling correlation is very high. The observation that most of the sites that behave differently between conditions sit remarkably close to the threshold for differential regulation (in the treatment condition where they are not DR - see Fig. 1G) led us to speculate that many of these sites are likely on the cusp of differential regulation. While it is entirely possible that some of these differences are, in fact, treatment specific (and we clearly acknowledge this in the text), we simply state that we cannot confidently discern clear signalling features that allow us to distinguish between the two treatments. We feel that this is an entirely relevant observation given the observed preponderance of both A23187 and BIPPO-dependent DR phosphosites on proteins in the PKG signalling pathway (as current models place this upstream of Ca2+release).
      2. Log10 intensity only serves to spread the data for easier visualisation. The only comparison being made relates to the LFCs. Fig. 1Gi shows the LFC scores (x axis) for all sites regulated following A23187 treatment (for which peptides were also identified in BIPPO treatment). On this plot we have highlighted the sites that are differentially regulated following BIPPO but not A23187 treatment (with red showing the DRup and blue showing the DRdown sites). This demonstrates that many of the sites that are regulated following BIPPO but not A23187 treatment cluster close to the threshold for differential regulation in the A23187 dataset - suggesting that many of these sites are likely on the cusp of differential regulation. Fig. 1Gii shows the reverse. While we could highlight the above-mentioned sites on the plot in Fig. 1E, we do not feel that it would demonstrate our point as clearly.

      We feel that including a pseudocount on Fig. 1E for peptides lacking quantification in one treatment condition would be visually misleading as the direct correlation being made in Fig. 1E is BIPPO vs A23187 treatment. The sites mentioned in lines 272-278 in the original manuscript (now lines 268-276) are available in the supplement tables.

      3.Additional experiments would be essential to support the main claims of the paper.

      Genetic validation is necessary for the experiments performed with the PKA inhibitor H89. H89 is nonspecific even in mammalian systems (PMID: 18523239) and in this manuscript it was used at a high concentration (50 µM) The heterodimeric architecture of PKA in apicomplexans dramatically differs from the heterotetrameric enzymes characterized in metazoans (PMID: 29263246), so we don't know what the IC50 of the inhibitor is, or whether it inhibits competitively. Two inducible knockdown strains exist for PKA C1 (PMID: 29030485, 30208022). The authors could request one of these strains and construct a ∆cdpk3 in that genetic background, as was done for the PDE2 cKO strain. Estimated time: 3-4 weeks to generate strain, 2 weeks to repeat assays.

      Response:

      1. While we appreciate that H89 is not 100% specific for PKA, this is not our only line of evidence that cAMP levels are altered. We demonstrate that cAMP levels are elevated in CDPK3 KO parasites – further substantiating our finding.

      The H89 concentration used in our experiment is in keeping with/lower than the concentrations used in other Toxoplasma publications (Jia et al., 2017), and both the Toxoplasma and Plasmodium fields have shown convincingly that H89 treatment phenocopies cKD/cKO of PKA (see Jia et al., 2017; Flueck et al., 2019).

      While we agree that the genetic validation suggested by reviewer 1 would serve to further support our findings (though it would not provide further novel insights), the suggested time frame for experimental execution was not realistic. Line shipment, strain generation, subcloning and genetic validation would take substantially longer than 3-4 weeks.

      cGMP levels are found to not increase with A23187 treatment, which is at odds with a previous study (lines 524-560). The text proposes that the differences could arise from the choice of buffer: this study used an intracellular-like Endo buffer (no added calcium, high potassium), whereas Stewart et al. 2017 used an extracellular-like buffer (DMEM, which also contains mM calcium and low potassium). An alternative explanation is that 60 s of A23187 treatment does not achieve a comparable amount of calcium flux as 15 s of BIPPO treatment, and a calcium-dependent effect on cGMP levels, were it to exist, could not be observed at the final timepoint in the assay. The experiments used to determine the kinetics of calcium flux following BIPPO and A23187 treatments (Fig. 1B, C) were calibrated using Ringer's buffer, which is more similar to an extracellular buffer (mM calcium, low potassium). In this buffer, A23187 treatment would likely stimulate calcium entry from across the parasite plasma membrane, as well as across the membranes of parasite intracellular calcium stores. By contrast, A23187 treatment in Endo buffer (low calcium) would likely only stimulate calcium release from intracellular stores, not calcium entry, since the calcium concentration outside of the parasite is low. Because calcium entry no longer contributes to calcium flux arising from A23187 treatment, it is possible that the calcium fluxes of A23187-treated parasites at 60 s are "behind" BIPPO-treated parasites at 15 s. The researchers could control these experiments by *either* (i) performing the cNMP measurements on parasites resuspended in the same buffer used in Figure 1B, C (Ringer's) or (ii) measuring calcium flux of extracellular parasites in Endo buffer with BIPPO and A23187 to determine the "alignment" of calcium levels, as was done with intracellular parasites in Figure 1C. No new strains would have to be generated and the assays have already been established in the manuscript. Estimated time to perform control experiments with replicates: 2 weeks. This seems like an important control, because the interpretation of this experiment shifts the focus of the paper from feedback between calcium and cGMP signaling, which had motivated the initial phosphoproteomics comparisons, to calcium and cAMP signaling. Further, the lipidomics experiments were performed in an extracellular-like buffer, DMEM, so it's unclear why dramatically different buffers were used for the lipidomics and cNMP measurements.

      Response:

      While the initial calibration experiments to measure calcium flux were indeed performed in Ringer’s buffer, the parasites were intracellular. We therefore chose to measure cNMP concentrations of extracellular parasites syringe lysed in Endo buffer, which is better at mimicking intracellular conditions than any other described buffer.

      As the reviewer suggested, we measured the calcium flux of extracellular parasites in Endo buffer upon stimulation with either A23187 or BIPPO.

      We found that peak calcium response to BIPPO in Endo buffer was similar to that of intracellular parasites (~15 seconds post treatment) (See Supp Fig. 6A). Upon treatment with A23187, extracellular parasites in Endo buffer had a much faster response compared to their intracellular counterparts, with peak flux measured at ~25 seconds post treatment (see Supp Fig. 6B). This indeed does suggest that extracellular parasites in Endo buffer behave differently to A23187 compared to their intracellular counterparts. However, peak calcium response is still occuring within the experimental time course and is not being missed, as the reviewer worries. Moreover, since we are able to detect increased cAMP levels in A23187 treated parasites, Ca2+ flux appears sufficient to alter cNMP signalling.

      We did notice however that the intensity of the calcium flux was much weaker in Endo buffer compared to intracellular parasites (see Supp Fig. 6B). We found that this was due to the lack of host-derived Ca2+, since supplementation of Endo buffer with 1 uM CaCl2 restored the intensity of the calcium response to match that of intracellular parasites (see Supp Fig. 6C). We therefore decided to repeat our cGMP measurements, this time using extracellular parasites in Endo buffer supplemented with 1 uM CaCl2. However, we found no differences in cGMP levels in the response to ionophore under these conditions (now Supp Fig. 6D) compared to the previous experiments, so the conclusions from the previous data do not change.

      As for the lipidomics experiments, we chose to use DMEM so that our dataset could be compared with other published lipidomic datasets (Katris et al., 2020; Dass et al., 2021) where DMEM was also used as a buffer when measuring global lipid profiles of parasites.

      We now acknowledge in the paper that Endo buffer has its shortcomings, and that this could be the reason why we do not detect changes in cGMP concentrations. We do, however, believe that Endo buffer is the best alternative to intracellular parasites and is supported by its consistent use in numerous publications studying Toxoplasma signalling (McCoy et al., 2012; Stewart et al., 2017).

      Additional information is required to support the claim that PDE2 has a moderate egress defect (lines 681-687). T. gondii egress is MOI-dependent (PMID: 29030485). Although the parasite strains were used at the same MOI, there is no guarantee that the parasites successfully invaded and replicated. If parasites lacking PDE2 are defective in invasion or replication, the MOI is effectively decreased, which could explain the egress delay. Could the authors compare the MOIs (number of vacuoles per host cell nuclei) of the vehicle and RAP-treated parasites at t = 0 treatment duration to give the reader a sense of whether the MOIs are comparable?

      Response:

      Since PDE2 KO parasites have a substantial growth defect, we did notice that starting MOIs were consistently lower for the RAP-treated samples compared to the DMSO-treated samples. However, this was also the case for PDE1 KO parasites where we did not see an egress delay. We also found that the egress delay was still evident for ∆CDPK3 parasites, despite having higher starting MOIs than WT parasites in our experiments. Therefore there does not appear to be a link between starting MOIs and the egress delay.

      To be sure of our results, we also performed egress assays where we co-infected HFFs with mCherry-expressing WT parasites (WT ∆UPRT) and GFP-expressing PDE2 cKO parasites that were treated with either DMSO or RAP or ∆CDPK3 parasites. This recapitulated our previous findings, confirming the deletion of PDE2 leads to delay in A23187-mediated egress.

      4.A few references are missing to ensure reproducibility.

      The manuscript states that the kinetic lipidomics experiments were performed with established methods, but the cited publication (line 497) is a preprint. These are therefore not peer reviewed and should be described in greater detail in this manuscript, including any relevant validation.

      Response:

      We thank the reviewer for pointing this out. We have included a greater description of the methods used in the materials and methods section such that the experiment is reproducible, as per the reviewer’s suggestion. We decided to still make mention of the BioRxiv preprint since we thought it was appropriate for the reader to be informed of ongoing developments in the field.

      Please cite the release of the T. gondii proteomes used for spectrum matching (lines 972-973).

      Response:

      We have included this as per the reviewer’s suggestion.

      Please include the TMT labeling scheme so the analysis may be reproduced from the raw files.

      Response:

      We have included this as per the reviewer’s suggestion in Supp Fig. 3A.

      5.Statistical analyses should be reviewed as follows:

      Have the authors examined the possibility that some changes in phosphopeptide abundance reflect changes in protein abundance? This may be particularly relevant for comparisons involving the ∆cdpk3 strain. Did the authors collect paired unenriched proteomes from the experiments performed? Alternatively, there may be enriched peptides that did not change in abundance for many of the proteins that appear dynamically phosphorylated.

      Response:

      We did not collect unenriched proteomes from the experiments performed (although we did perform unenriched mixing checks to ensure equal loading between samples), and believe that this wasn’t a necessity for the following reasons:

      1. For within-line treatment analyses, treatment timings are so short (a maximum of 15-50s in the single timepoint experiment) that it would be unlikely to detect substantial changes in protein abundance. Moreover, these unlikely events would affect all phosphosites across a protein, and therefore be detectable.

      In our CDPK3 dependency timecourse experiments, we normalise both the WT and ∆CDPK3 strain to 0s, and measure signalling progression over time. Therefore, any difference at timepoints that are not “0” are not originating from basal differences. We also see a consistent increase/decrease in phosphosite detection across the sub-minute timecourse, further confirming that the observed changes are truly down to dynamic changes in phosphorylation and not protein levels.

      In the single timepoint CDPK3 dependency analyses (44 regulated sites identified, Data S2), we acknowledge that there could be some risk of altered starting protein abundance between lines. However, if protein abundance were responsible for the changes in phosphosite detection, we would expect all phosphosites across the protein to shift, and we do not observe this. Moreover, when we look at these CDPK3 dependent proteins and compare their phosphosite abundance in untreated WT and ∆CDPK3 lines, we find that for each protein, either all or the majority of phosphosites detected are unchanged (highlighting that there is no substantial difference in this protein’s abundance between lines). Where there are phosphosite differences between lines, these are only ever on single sites on a protein while most other sites are unchanged - implying that these are changes to basal phosphorylation states and not protein levels.

      It seems like for Figs. 3B and S5 the maximum number of clusters modeled was selected. Could the authors provide a rationale for the number of clusters selected, since it appears many of the clusters have similar profiles.

      The number of clusters is chosen automatically by the Mclust algorithm as the value that maximizes the Bayes Information Criterion (BIC). BIC in effect balances gains in model fit (increasing log-likelihood) against increasing the number of parameters (i.e. number of clusters).

      Please include figure panel(s) relating to gene ontology. Relevant information for readers to make conclusions includes p-value, fold-enrichment or gene ratio, and some sort of metric of the frequency of the GO term in the surveyed data set. See PMID: 33053376 Fig. 7 and PMID: 29724925 Fig. 6 for examples or enrichment summaries. Additionally, in the methods, specify (i) the background set, (ii) the method used for multiple test correction, (iii) the criteria constituting "enrichment", (iv) how the T. gondii genome was integrated into the analysis, (v) the class of GO terms (molecular function, biological process, or cellular component), (vi) any additional information required to reproduce the results (for example, settings modified from default).

      Response:

      We have included the additional information requested in the materials and methods.

      We purposely did not include GO figure panels as our analyses are being done across many clusters, making it very difficult to display this information cohesively. We have included all data in Tables S2-S5. These tables included all the relevant information on p-value, enrichment status, ratio in study/ratio in population, class of GO terms etc.

      The presentation of the lipidomics experiments in Figure 4A-C is confusing. First, the ∆cdpk3/WT ratio removes information about the process in WT parasites, and it's unclear why the scale centers on 100 and not 1. Second, the data in Figure S6 suggests a more modest effect than that represented in Fig. 4; is this due to day to day variability? How do the authors justify pairing WT and mutant samples as they did to generate the ratios?

      Response:

      This is a common strategy used by many metabolomics experts (Bailey et al., 2015; Dass et al., 2021; Lunghi et al., 2022). We had originally chosen to represent the data as a ratio since this form of representation helps get rid of the variability that arises between experiments and allows us to see very clear patterns which would otherwise go unnoticed. This variability arises from the amount of lipids in each sample which varies between parasites in a dish, the batch of FBS and DMEM used, and the solutions and even room temperature used to extract lipids on a given day.

      However, we agree with the reviewer that depicting the data in Figure 4A-C as a ratio of ∆CDPK3/WT parasites can be confusing, so we have now changed the graphs, plotting WT and ∆CDPK3 levels instead, and have moved the ratio of ∆CDPK3/WT to the Supplementary Figure 5.

      The significance test seems to be performed on the difference between the WT and ∆cdpk3 strains, but not relative to the DMSO treatment? Wouldn't you want to perform a repeated measures ANOVA to determine (i) if lipid levels change over time and (ii) if this trend differs in WT vs. mutant strain?

      Response:

      The reviewer correctly points out that ANOVA is often used for time courses, but we must point out that it is not always strictly appropriate since it can overlook the purpose of the individual experiment design, which in this case is, 1) to investigate the role of CDPK3 compared to the WT parental strain, and 2) specifically to find the exact point at which the DAG begins to change after stimulus to match the proteomics time course.

      Our data is clearly biassed towards earlier time points where we have 0, 5, 10, 30, 45 seconds where DAG levels are mostly unchanged compared to the single timepoint 60 seconds which shows a significant difference in DAG using our method of statistical comparison by paired two tailed t-test. Therefore, it would be unwise to use ANOVA when we really want to see when the A23187 stimulus takes effect, which appears to be after the 45 second mark. Therefore, analysing the data by ANOVA would likely provide a false negative result, where the result is non-significant but there is clearly more DAG in WT than CDPK3 after 60 seconds. T-tests are commonly used when comparing the same cell lines grown in the same conditions with a test/treatment, and in this case the test/treatment is CPDK3 present or absent (Lentini et al., 2020).

      In the main text, it would be preferable to see the data presented as the proteomics experiments were in Figure 4B and 4C, with fold changes relative to the DMSO (t = 0) treatment, separately for WT and ∆cdpk3 parasites.

      Response:

      We have now changed the way that we represent the data, plotting %mol instead of the ratio.

      Signaling lipids constitute small percentages of the overall pool (e.g. PMID: 26962945), so one might not necessarily expect to observe large changes in lipid abundance when signaling pathways are modulated. Is there any positive control that the authors could include to give readers a sense of the dynamic range? Maybe the DGK1 mutant (PMID: 26962945)?

      Response:

      DGK1 is maybe not a good example because the DGK1 KO parasites effectively “melt” from a lack of plasma membrane integrity ((Bullen et al., 2016), so this would likely be technically challenging. We don’t see the added value in including an additional mutant control since we can already see the dynamic change over time from no difference (0 seconds) to significant difference (60 seconds) between WT and CDPK3 for DAG and most other lipids. We already see a significant difference between WT and CDPK3 after 60 seconds for DAG, and we can clearly see in sub-minute timecourses the changes or not at the specific points where the A23187 is added (0-5 seconds), the parasites acclimatise, for the A23187 to take effect (10-30 seconds) and for the parasite lipid response to be visible by lipidomics (45-60 +seconds).

      Figure 4E: are the differences in [cAMP] with DMSO treatment and A23187 treatment different at any of the timepoints in the WT strain? The comparison seems to be WT/∆cdpk3 at each timepoint. Does the text (lines 562-568) need to be modified accordingly?

      Response:

      In WT (and ∆CDPK3) parasites, [cAMP] is significantly changed at 5s of A23187 treatment (relative to DMSO). We have modified our figures to include this analysis. The existing text accurately reflects this.

      Figure 6I: is the difference between PDE2 cKO/∆cdpk3 + DMSO or RAP significant?

      Response

      In our original manuscript, there was no statistical difference in [cAMP] between PDE2cKO/∆CDPK3+DMSO and PDE2cKO/∆CDPK3+DMSO+RAP, likely due to the variation between biological replicates. To overcome the issues in variability between replicates, we have now included more biological replicates (n=7). This has led to a significant difference in [cAMP] between PDE2cKO/∆CDPK3 DMSO- and RAP-treated parasites and between PDE2cKO DMSO- and RAP-treated parasites (now Fig. 6I).

      **MINOR COMMENTS**

      1.The following references should be added or amended:

      Lines 83-85: in the cited publication, relative phosphopeptide abundances of an overexpressed dominant-negative, constitutively inactive PKA mutant were compared to an overexpressed wild-type mutant. In this experimental setup, one would hypothesize that targets of PKA should be down-regulated (inactive/WT ratios). However, the mentioned phosphopeptide of PDE2 was found to be up-regulated, suggesting that it is not a direct target of PKA.

      Response:

      We thank the reviewer for spotting this error, we have now modified our wording.

      Cite TGGT1_305050, referenced as calmodulin in line 458, as TgELC2 (PMID: 26374117).

      Response:

      We have included this as per the reviewer’s suggestion.

      Cite TGGT1_295850 as apical annuli protein 2 (AAP2, PMID: 31470470).

      Response:

      We have included this as per the reviewer’s suggestion.

      Cite TGGT1_270865 (adenylyl cyclase beta, Acβ) as PMID: 29030485, 30449726.

      Response:

      We have included this as per the reviewer’s suggestion.

      Cite TGGT1_254370 (guanylyl cyclase, GC) as PMID: 30449726, 30742070.

      Response:

      We have included this as per the reviewer’s suggestion.

      Note that Lourido, Tang and David Sibley, 2012 observed that treatment with zaprinast (a PDE inhibitor) could overcome CDPK3 inhibition. The target(s) of zaprinast have not been determined and may differ from those of BIPPO (in identity and IC50). The cited study also used modified CDPK3 and CDPK1 alleles, rather than ∆cdpk3 and intact cdpk1 as used in this manuscript. That is to say, the signaling backgrounds of the parasite strains deviate in ways that are not controlled.

      Response:

      While it is true that zaprinast targets have not been unequivocally identified, zaprinast-induced egress is widely thought to be the result of PKG activation, a conclusion that is further supported by the finding that Compound 1 completely blocks zaprinast-induced egress (Lourido, Tang and David Sibley, 2012). Similarly, BIPPO-induced egress is inhibited by chemical inhibition of PKG by Compound 1 and Compound 2 (Jia et al., 2017). Moreover, like zaprinast, BIPPO has been clearly shown to partially overcome the ∆CDPK3 egress delay (Stewart et al., 2017).

      2.The following comments refer to the figures and legends:

      Part of the legend text for 1G is included under 1H.

      Response:

      This has been corrected

      Figure 1H: The legend mentions that some dots are blue, but they appear green. Please ensure that color choices conform to journal accessibility guidelines. See the following article about visualization for colorblind readers: https://www.ascb.org/science-news/how-to-make-scientific-figures-accessible-to-readers-with-color-blindness____/ . Avoid using red and green false-colored images; replace red with a magenta lookup table. Multi-colored images are only helpful for the merged image; otherwise, we discern grayscale better. Applies to Figures 1B, 5C, 6D. (Aside: anti-CAP seems an odd choice of counterstain; the variation in the staining, esp. at the apical cap, is distracting.)

      Response:

      We thank reviewer #1 for bringing this to our attention, and have modified our colour usage for all IFAs and Figures 1H and 3E.

      We chose CAP staining as the antibody is available in the laboratory and stains both the apical end (which has been shown to contain several proteins important for signalling as well as PDE9) and the parasite periphery, the location of CDPK3.

      Figure 1B: When showing a single fluorophore, please use grayscale and include an intensity scale bar, since relative values are being compared.

      Response:

      We have modified this as per the reviewer’s suggestion

      Figure 1C: it is difficult to compare the kinetics of the calcium response when the curves are plotted separately. Since the scales are the same, could the two treatments be plotted on the same axes, with different colors? Additionally, according to the legend, a red line seems to be missing in this panel.

      Response:

      Fig1C is not intended to compare kinetics, merely to show peak calcium release in each separate treatment condition. We have removed mention of a red line in the figure legend.

      Figure 2A: Either Figure S4 can be moved to accompany Figure 2A, or Figure 2A could be moved to the supplemental.

      Figure S4 has now been incorporated into Figure 2.

      Reviewer #1 (Significance (Required)):

      This manuscript would interest researchers studying signaling pathways in protozoan parasites, especially apicomplexans, as CDPK3 and PKG orthologs exist across the phylum. To my knowledge, it is the first study that has proposed a mechanism by which a calcium effector regulates cAMP levels in T. gondii. Unfortunately, the experiments fall short of testing this mechanism.

      Response:

      We thank reviewer #1 for their comments, but disagree with their assessment that the key points of the manuscript “fall short of experimental testing”.

      1. We demonstrate that, following both BIPPO and A23187 treatment, there is differential phosphorylation of numerous components traditionally believed to sit upstream of PKG activation (as well as several components within the PKG signalling pathway itself).
      2. We show that some of these sites are CDPK3 dependent, and that deletion of CDPK3 leads to changes in lipid signalling and an elevation in levels of cAMP (dysregulation of which is known to alter PKG signalling).
      3. We show that pre-treatment with a PKA inhibitor is able to largely rescue this phenotype.
      4. We demonstrate that a cAMP-specific PDE is phosphorylated following A23187 treatment (i.e. Ca2+ flux)
      5. We show that this cAMP specific PDE plays a role in A23187-mediated egress.
      6. While the latter PDE may not be directly regulated by CDPK3, these findings suggest that there are likely several Ca2+-dependent kinases that contribute to this feedback loop.

        Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      **Summary:**

      Provide a short summary of the findings and key conclusions (including methodology and model system(s) where appropriate).

      In this manuscript, Dominicus et al investigate the elusive role of calcium-dependent kinase 3 during the egress of Toxoplasma gondii. Multiple functions have already been proposed for this kinase by this group including the regulation of basal calcium levels (24945436) or of a tyrosine transporter (30402958). However, one of the most puzzling phenotypes of CDPK3 deficient tachyzoites is a marked delay in egress when parasites are stimulated with a calcium ionophore that is rescued with phosphodiesterase (PDE) inhibitors. Crosstalk between, cAMP, cGMP, lipid and calcium signalling has been previously described to be important in regulating egress (26933036, 23149386, 29030485) but the role of CDPK3 in Toxoplasma is still poorly understood.

      Here the authors first take an elegant phosphoproteomic approach to identify pathways differentially regulated upon treatment with either a PDE inhibitor (BIPPO) and a calcium ionophore (A23187) in WT and CDPK3-KO parasites. Not much difference is observed between BIPPO or A23187 stimulation which is interpreted by the authors as a regulation through a feed-back loop.

      The authors then investigate the effect of CDPK3 deletion on lipid, cGMP and cAMP levels. The identify major changes in DAG, phospholipid, FFAs, and TAG levels as well as differences in cAMP levels but not for cGMP. Chemical inhibition of PKA leads to a similar egress timing in CDPK3-KO and WT parasites upon A23187 stimulation.

      As four PDEs appeared differentially regulated in the CDPK3-KO line upon A23187, the authors investigate the requirement of the 4 PDEs in cAMP levels. They show diverse localisation of the PDEs with specificities of PDE1, 7 and 9 for cGMP and of PDE2 for cAMP. They further show that PDE1, 7 and 9 are sensitive to BIPPO. Finally, using a conditional deletion system, they show that PDE1 and 2 are important for the lytic cycle of Toxoplasma and that PDE2 shows a slightly delayed egress following A23187 stimulation.

      **Major comments:**

      -Are the key conclusions convincing?

      The title is supported by the findings presented in this study. However I am not sure to understand why the authors imply a positive feed back loop. This should be clarified in the discussion of the results.

      Response:

      We believe in a positive feedback loop as, upon A23187 treatment (resulting in a calcium flux), ΔCDPK3 parasites are able to egress, albeit in a delayed manner. This egress delay is substantially, but not completely, alleviated upon treatment with BIPPO (a PDE inhibitor known to activate the PKG signalling pathway). In conjunction with our phosphoproteomic data (where we see phosphorylation of numerous pathway components upstream of PKG upon BIPPO and A23187 treatment - both in a CDPK3 dependent and independent manner), these observations suggest that calcium-regulated proteins (CDPK3 among them) feed into the PKG pathway. As deletion of CDPK3 delays egress, it is reasonable to postulate that this feedback is one that amplifies egress signalling (i.e. is positive).

      The phosphoproteome analysis seems very strong and will be of interest for many groups working on egress. However, the key conclusion, i.e. that a substrate overlaps between PKG and CDPK3 is unlikely to explain the CDPK3 phenotype, seems premature to me in the absence of robustly identified substrates for both kinases.

      Response:

      We certainly do not fully exclude the possibility of a substrate overlap but do lean more heavily towards a feedback loop given (a) the inability to clearly detect treatment-specific signalling profiles and (b) the phospho targets observed in the A23187 and BIPPO phosphoproteomes. We have further clarified our reasoning, and overall tempered our language in the manuscript as per the reviewer’s suggestion.

      I am not sure there is a clear key conclusion from the lipidomic analysis and how it is used by the authors to build their model up. Major changes are observed but how could this be linked with CDPK3, particularly if cGMP levels are not affected?

      Response:

      Our phosphoproteomic analyses identify several CDPK3-dependent phospho sites on phospholipid signalling components (DGK1 & PI-PLC), suggesting that there is indeed altered signalling downstream of PKG. To test whether these lead to a measurable phenotype, we performed the lipidomics analysis. We did not pursue this arm of the signalling pathway any further as we postulated that the changes in the lipid signalling pathway were less likely to play a role in the feedback loop. Nevertheless, we felt that it was worthwhile to include these findings in our manuscript as they support the conclusions drawn from the phosphoproteomics - namely that lipid signalling is perturbed in CDPK3 mutants. We, or others, may follow up on this in future.

      We agree with the reviewer that it is surprising that cGMP levels remain unchanged in our experiments when we treat with A23187. Given the measurable difference in cAMP levels between WT and ΔCDPK3 parasites, we postulate that CDPK3 directly or indirectly downregulates levels of cAMP. This would, in turn, alter activity of the cAMP-dependent protein kinase PKAc. Jia et al. (2017) have shown a clear dependency on PKG for parasites to egress upon PKAc depletion, but were also unable to reliably demonstrate cGMP accumulation in intracellular parasites. Similarly, their hypothesis that dysregulated cGMP-specific PDE activity results in altered cGMP levels has not been proven (the PDE hypothesised to be involved has since been shown to be cAMP-specific).

      While it is possible that our collective inability to observe elevated cGMP levels is explained by the sensitivity limits of the assay, it is similarly possible that cAMP-mediated signalling is exerting its effects on the PKG signalling pathway in a cGMP-independent manner.

      The evidence that CDPK3 is involved in cAMP homeostasis seems strong. However, the analysis of PKA inhibition is a bit less clear. The way the data is presented makes it difficult to see whether the treatment is accelerating egress of CDPK3-KO parasites or affecting both WT and CDPK3-KO lines, including both the speed and extent of egress. This is important for the interpretation of the experiment.

      Response:

      Fig. 4F shows that there is a significant amount of premature egress in both WT and ∆CDPK3 parasites following 2 hrs of H89 pre-treatment (consistent with previous reports that downregulation of cAMP signalling stimulates premature egress). When we subsequently investigated A23187-induced egress rates of the remaining intracellular H89 pre-treated parasites (Fig. 4Gi-ii) we found that the ∆CDPK3 egress delay was largely rescued. We have moved Fig. 4F to the supplement (now Supp Fig. 5E) in order to avoid confusion between the distinct analyses shown in 4F (pre-treatment analyses) and 4G (egress experiment). These experiments provided a hint that cAMP signalling is affected, which we then validate by measuring elevated cAMP levels in CDPK3 mutant parasites.

      The biochemical characterisation of the four PDE is interesting and seems well performed. However, PDE1 was previously shown to hydrolyse both cAMP and cGMP (____https://doi.org/10.1101/2021.09.21.461320____) which raises some questions about the experimental set up. Could the authors possibly discuss why they do not observe similar selectivity? Could other PDEs in the immunoprecipitate mask PDE activity? In line with this question, it is not clear what % of "hydrolytic activity (%)" means and how it was calculated.

      The experiments describing the selectivity of BIPPO for PDE1, 7 and 9 as well as the biological requirement of the four tested PDEs are convincing.

      Response:

      We believe that the disagreement between our findings and those published by Moss and colleagues are due to the differences in experimental conditions. We performed our assays at room temperature for 1 hour with higher starting cAMP concentrations (1 uM) compared to them. They performed their assays at 37ºC for 2 hours with 10-fold lower starting cAMP concentrations (0.1 uM). We have now repeated this set of experiments using the Moss et al. conditions, and find that PDEs 1, 7 and 9 can be dual specific, while PDE2 is cAMP-specific, thereby recapitulating their findings (Now included in the revised manuscript under Supp Fig. 7B). However, we also now performed a timecourse PDE assay using our original conditions and show that the cAMP hydrolytic activity for PDE1 can only be detected following 4 hours of incubation, compared to cGMP activity that can be detected as early as 30 minutes, suggesting that it possesses predominantly cGMP activity (See Supp Fig. 7C). We therefore believe that our experimental setup is more stringent, because if one starts with a lower level of substrate and incubates for longer and at a higher temperature, even minor dual activity could make a substantial difference in cAMP levels. Our data suggests that the cAMP hydrolytic activity of PDEs 1, 7 and 9 is substantially lower than the cGMP hydrolytic activity that they display.

      We have also included a clear description of how % hydrolytic activity was calculated in the methods section.

      -Should the authors qualify some of their claims as preliminary or speculative, or remove them altogether?

      The claim that CDPK3 affects cAMP levels seems strong however the exact links between CDPK3 activity, lipid, cGMP and cAMP signalling remain unclear and it may be important to clearly state this.

      Response:

      We have modified our wording in the text to more clearly describe our current hypothesis and reasoning.

      -Would additional experiments be essential to support the claims of the paper? Request additional experiments only where necessary for the paper as it is, and do not ask authors to open new lines of experimentation.

      I think that the manuscript contains a significant amount of experiments that are of interest to scientists working on Toxoplasma egress. Requesting experiments to identify the functional link between above-mentioned pathways would be out of the scope for this work although it would considerably increase the impact of this manuscript. For example, would it be possible to test whether the CDPK3-KO line is more or less sensitive to PKG specific inhibition upon A23187 induced?

      -Are the suggested experiments realistic in terms of time and resources? It would help if you could add an estimated cost and time investment for substantial experiments.

      The above-mentioned experiment is not trivial as no specific inhibitors of PKG are available. Ensuring for specificity of the investigated phenotype would require the generation of a resistant line which would require significant work.

      __Response: __We agree that this would be an interesting experiment to further substantiate our findings. As indicated by the reviewer, however, the lack of specific inhibitors of PKG means a resistant line would likely be required to ensure specificity.

      -Are the data and the methods presented in such a way that they can be reproduced?

      It is not clear how the % of hydrolytic activity of the PDE has been calculated.

      Response: We have included a clearer description of how % hydrolytic activity was calculated in the methods section.

      -Are the experiments adequately replicated and statistical analysis adequate?

      This seems to be performed to high standards.

      **Minor comments:**

      -Specific experimental issues that are easily addressable.

      I do not have any comments related to minor experimental issues.

      -Are prior studies referenced appropriately?

      Most of the studies relevant for this work are cited. It is however not clear to me why some important players of the "PKG pathway" are not indicated in Fig 1H and Fig 3E, including for example UGO or SPARK.

      Response:

      We have modified Fig 1H and 3E to include all key players involved in the PKG pathway.

      -Are the text and figures clear and accurate?

      While all the data shown here is impressive and well analysed, I find it difficult to read the manuscript and establish links between sections of the papers. The phosphoproteome analysis is interesting and is used to orientate the reader towards a feedback mechanism rather than a substrate overlap. But why do the authors later focus on PDEs and not on AC or CNBD, as in the end, if I understand well, there is no evidence showing a link between CDPK3-dependent phosphorylation and PDE activity upon A23187 stimulation?

      Response:

      We thank reviewer#2 and appreciate their constructive feedback re the flow of the manuscript.

      Our key findings from the phosphoproteomics study were that 1) BIPPO and A23187 treatment trigger near identical signalling pathways, 2) that both A23187 and BIPPO treatment leads to phosphorylation of numerous components both upstream and downstream of PKG signalling (hinting at the presence of an Ca2+-regulated feedback loop) and 3) several of the abovementioned components are phosphorylated in a CDPK3 dependent manner.

      While several avenues of study could have been pursued from this point onwards, we chose to focus on the feedback loop in a broader sense as its existence has important implications for our general understanding of the signalling pathways that govern egress.

      We reasoned that, given the differential phosphorylation of 4 PDEs following A23187 and BIPPO treatment (none of which had been studied in detail previously), it was relevant to study these in greater detail.

      Coupled with the A23187 egress assay on PDE2 knockout parasites - our findings suggest that PDE2 plays a role in the abovementioned Ca2+ signalling loop. While PDE2 may not exert its effects in a CDPK3-dependent manner (and CDPK3 may, therefore, alter cAMP levels in a different fashion), this does not detract from the important finding that PDE2 is one of the (likely numerous) components that is regulated in a Ca2+-dependent feedback loop to facilitate rapid egress.

      We have modified our wording to better reflect our rationale for studying the PDEs irrespective of their CDPK3 phosphorylation status.

      While we feel that our reasoning for studying the PDEs is solid, we do appreciate that further clarification on the putative CDPK3-Adenylate cyclase link would elevate the manuscript substantially. However, given the data that the ACb is not playing a sole role in the control of egress, this is likely a non-trivial task and requires substantial work.

      It is also unclear how the authors link CDPK3-dependent elevated cAMP levels with the elevated basal calcium levels they previously described. This is particularly difficult to reconcile particularly in a PKG independent manner.

      Response:

      We previously postulated that elevated Ca2+ levels allowed ΔCDPK3 mutants to overcome a complete egress defect, potentially by activating other CDPKs (e.g. CDPK1). It is similarly plausible that elevated Ca2+ levels in ΔCDPK3 parasites may lead to elevated cAMP levels in order to prevent premature egress.

      As noted in our previous responses, we acknowledge that our inability to detect cGMP is surprising. However, given the clarity of our cAMP findings, and the phosphoproteomic evidence to suggest that various components in the PKG signalling pathway are affected, we postulate that we are either unable to reliably detect cGMP due to sensitivity issues, or that cAMP is exerting its regulation on the PKG pathway in a cGMP-independent manner. As noted previously, while the link between cAMP and PKG signalling has been demonstrated by Jia et al., it is not entirely clear how this is mediated.

      The presentation of the lipidomic analysis is also not really clear to me. Why do the authors show the global changes in phospholipids and not a more detailed analysis?

      Response:

      We performed a detailed phospholipid profile of WT and ∆CDPK3 parasites under normal culture conditions. However, due to the sheer quantity of parasites required for this detailed analysis, we were unable to measure individual phospholipid species in our A23187 timecourse. We therefore opted to measure global changes following A23187 stimulation.

      As the authors focus on the PI-PLC pathway, could they detail the dynamics of phosphoinositides? I understand that lipid levels are affected in the mutant but I am not sure to understand how the authors interpret these massive changes in relationship with the function of CDPK3 and the observed phenotypes.

      Response:

      Our phosphoproteomic analyses identified several CDPK3-dependent phospho sites on phospholipid signalling components (DGK1 & PI-PLC), suggesting that (in keeping with all of our other data), there is altered signalling downstream of PKG. To test whether these changes lead to a measurable phenotype, we performed the lipidomics analysis. Following stimulation with A23187, we found a delayed production of DAG in ∆CDPK3 parasites compared to WT parasites. Since DAG is required for the production of PA, which in turn is required for microneme secretion, our finding can explain why microneme secretion is delayed in ∆CDPK3 parasites, as previously reported (Lourido, Tang and David Sibley, 2012; McCoy et al., 2012).

      We did not follow this arm of the signalling pathway any further as we postulated that the changes in the lipid signalling pathway were less likely to play a role in the feedback loop. Nevertheless, we felt that it was worthwhile to include these findings in our manuscript as they support the conclusions drawn from the phosphoproteomics - namely that lipid signalling is perturbed in CDPK3 mutants. We, or others, may follow up on this in future.

      Finally, the characterisation of the PDEs is an impressive piece of work but the functional link with CDPK3 is relatively unclear. It would also be important to clearly discuss the differences with previous results presented in this this preprint: https://doi.org/10.1101/2021.09.21.461320____.

      My understanding is while the authors aim at investigating the role of CDPK3 in A23187 induced egress, the main finding related to CDPK3 is a defect in cAMP homeostasis that is not linked to A23187. Similarly, the requirements of PDE2 in cAMP homeostasis and egress is indirectly linked to CDPK3. Altogether I think that important results are presented here but divided into three main and distinct sections: the phosphoproteomic survey, the lipidomic and cAMP level investigation, and the characterisation of the four PDEs. However, the link between each section is relatively weak and the way the results are presented is somehow misleading or confusing.

      Response:

      As mentioned in a previous response, we chose to study PDEs in greater detail because of our observation that both A23187 and BIPPO treatments lead to their phosphorylation (hinting at the presence of a Ca2+regulated feedback loop). We were particularly intrigued to study the cAMP specific PDE, as CDPK3 KO parasites suggested that cAMP may play a role in the Ca2+ feedback mechanism. As PDE2 may not be directly regulated by CDPK3, Ca2+ appears to exert its feedback effects in numerous ways. We have modified our wording to better reflect our rationale for studying the PDEs irrespective of their CDPK3 phosphorylation status.

      -Do you have suggestions that would help the authors improve the presentation of their data and conclusions?

      This is a very long manuscript written for specialists of this signalling pathway and I would suggest the authors to emphasise more the important results and also clearly state where links are still missing. This is obviously a complex pathway and one cannot elucidate it easily in a single manuscript.

      Response:

      We have included an additional summary in our conclusions to better illustrate our findings and clarify any missing links.

      Reviewer #2 (Significance (Required)):

      -Describe the nature and significance of the advance (e.g. conceptual, technical, clinical) for the field.

      This is a technically remarkable paper using a broad range of analyses performed to a high standard.

      -Place the work in the context of the existing literature (provide references, where appropriate).

      The cross-talk between cAMP, cGMP and calcium signalling is well described in Toxoplasma and related parasites. Here the authors show that, in Toxoplasma, CDPK3 is part of this complex signalling network. One of the most important finding within this context is the role of CDPK3 in cAMP homeostasis. With this in mind, I would change the last sentence of the abstract to "In summary we uncover a feedback loop that enhances signalling during egress and links CDPK3 with several signalling pathways together."

      Response:

      In light of feedback received from several reviewers, we have made our wording less CDPK3 centric - as our findings relate in part to CDPK3 and, in a broader sense, to a Ca2+ driven feedback loop.

      The genetic and biochemical analyses of the four PDEs are remarkable and highlight consistencies and inconsistencies with recently published work that would be important to discuss and will be of interest for the field.

      __Response: __We thank reviewer#2 and agree that the PDE findings are of significant importance to the field.

      While I understand the studied signalling pathway is complex, I think it would be important to better describe the current model of the authors. In the discussion, the authors indicate that "the published data is not currently supported by a model that fits most experimental results." I would suggest to clarify this statement and discuss whether their work helps to reunite, correct or improve previous models.

      __Response: __We have expanded on the abovementioned statement to clarify that the presence of a feedback loop is a major pillar of knowledge required for the complete interpretation of existing signalling data.

      Could the authors also speculate about a potential role of PDE/CDPK3 in host cell invasion as cAMP signalling has be shown to be important for this process (30208022 and 29030485)?

      __Response: __Existing literature (Jia et al., 2017) suggests that perturbations to cAMP signalling play a very minor role in invasion since parasites where either ACα or ACβ are deleted show no impairment in invasion levels. We currently do not have substantial data on invasion, and are not sure that pursuing this is valuable given the minor phenotypes observed in other studies.

      -State what audience might be interested in and influenced by the reported findings.

      This paper is of great interest to groups working on the regulation of egress in Toxoplasma gondii and other related apicomplexan pathogens.

      -Define your field of expertise with a few keywords to help the authors contextualize your point of view. Indicate if there are any parts of the paper that you do not have sufficient expertise to evaluate.

      I am working on the cell biology of apicomplexan parasites.

      Reviewer #3 (Evidence, reproducibility and clarity (Required)):

      **Summary:**

      Dominicus et al aimed to identify the intersecting components of calcium, cyclic nucleotides (cAMP, cGMP) and lipid signaling through phosphoproteomic, knockout and biochemical assays in an intracellular parasite, Toxoplasma gondii, particularly when its acutely-infectious tachyzoite stage exits the host cells. A series of experimental strategies were applied to identify potential substrates of calcium-dependent protein kinase 3 (CDPK3), which has previously been reported to control the tachyzoite egress. According to earlier studies (PMID: 23226109, 24945436, 5418062, 26544049, 30402958), CDPK3 regulated the parasite exit through multiple phosphorylation events. Here, authors identified differentially-regulated (DR) phosphorylation sites by comparing the parasite samples after treatment with a calcium ionophore (A23178) and a PDE inhibitor (BIPPO), both of which are known to induce artificial egress (induced egress as opposed to natural egress). When the DCDPK3 mutant was treated with A23187, its delayed egress phenotype did not change, whereas BIPPO restored the egress to the level of the parental (termed as WT) strain, probably by activating PKG.

      The gene ontology enrichment of the up-regulated clusters revealed many probable CDPK3-dependent DR sites involved in cyclic nucleotide signaling (PDE1, PDE2, PDE7, PDE9, guanylate and adenylate cyclases, cyclic nucleotide-binding protein or CNBP) as well as lipid signaling (PI-PLC, DGK1). Authors suggest lipid signaling as one of the factors altered in the CDPK3 mutant, albeit lipidomics (PC, PI, PS, PT, PA, PE, SM) showed no significant change in phospholipids. To reveal how the four PDEs indicated above contribute to the cAMP and cGMP-mediated egress, they examined their biological significance by knockout/knockdown and enzyme activity assays. Authors claim that PDE1,7,9 proteins are cGMP-specific while PDE2 is cAMP-specific, and BIPPO treatment can inhibit PDE1-cGMP and PDE7-cGMP, but not PDE9-cGMP. Given the complexity, the manuscript is well structured, and most experiments were carefully designed. Undoubtedly, there is a significant amount of work that underlies this manuscript; however, from a conceptual viewpoint, the manuscript does not offer significant advancement over the current knowledge without functional validation of phosphoproteomics data (see below). A large body of work preceding this manuscript has indicated the crosstalk of cAMP, cGMP, calcium and lipid signaling cascades. This work provides a further refinement of the existing model In a methodical sense, the work uses established assays, some of which require revisiting to reach robust conclusions and avoid misinterpretation. The article is quite interesting from a throughput screening point of view, but it clearly lacks the appropriate endorsement of the hits.The authors accept that identifying the phosphorylation of a protein does not imply a functional role, which is a major drawback as there is no experimental support for any phosphorylation site of the protein identified through phosphoproteomics. In terms of the mechanism, it is not clear whether and how lipid turnover and cAMP-PKA signaling control the egress phenotype (lack of a validated model at the end of this study).

      Response:

      We thank reviewer #3 for their comments, but respectfully disagree with their assessment that the work presented does not advance current knowledge.

      1. We demonstrate that, following both BIPPO and A23187 treatment, there is differential phosphorylation of numerous components traditionally believed to sit upstream of PKG activation (as well as numerous components within the PKG signalling pathway itself). While it may have been inferred from previous studies that A23187 and BIPPO signalling intersect, this has never been unequivocally demonstrated - nor has a feedback loop ever been shown.

      We provide a novel A23187-driven phosphoproteome timecourse that further bolsters the model of a Ca2+-driven feedback loop.

      We show that deletion of CDPK3 leads to a delay in DAG production upon stimulation with A23187.

      We show that some of the abovementioned sites are CDPK3 dependent, and that deletion of CDPK3 leads to elevated levels of cAMP (dysregulation of which is known to alter PKG signalling).

      We show that pre-treatment with a PKA inhibitor is able to largely rescue this phenotype.

      We demonstrate that a cAMP-specific PDE is phosphorylated following A23187 treatment (i.e. Ca2+ flux)

      We show that this cAMP specific PDE plays a role in egress.

      While the latter PDE may not be directly regulated by CDPK3, these findings suggest that there are likely several Ca2+-dependent kinases that contribute to this feedback loop.

      We also firmly disagree with the reviewer’s assertion that without phosphosite characterisation, we have no support for our model. Following treatment with A23187 (and BIPPO), we clearly show broad, systemic changes (both CDPK3 dependent and independent) across signalling pathways previously deemed to sit upstream of calcium flux. Given the vast number of proteins involved in these signalling pathways, and the multitude of differentially regulated phosphosites identified on each of them, it is highly likely that the signalling effects we observe are combinatorial. Accordingly, we believe that mutating individual sites on individual proteins would be a very costly endeavour which is unlikely to substantially advance our understanding of signalling during egress. Moreover, introducing multiple point mutations in a given protein to ablate phosphorylation may lead to protein misfolding and would therefore not be informative. One of the key aims of this study was to assess how egress signalling pathways are interconnected, and we believe we have been able to show strong support for a Ca2+-driven feedback mechanism in which both CDPK3 and PDE2 play a role through the regulation of cAMP.

      While we agree with the reviewer’s statement that a large body of work preceding this manuscript has indicated the crosstalk of cAMP, cGMP, calcium and lipid signalling cascades, a feedback loop has not previously been shown. We believe that this finding is absolutely central to facilitate the complete interpretation of existing signalling data. Furthermore, no previous studies have gone to this level of detail in either proteomics or lipidomics to analyse the calcium signal pathway in any apicomplexan parasite. We argue that the novelty in our manuscript is that it is a carefully orchestrated study that advances our understanding of the signalling network over time with subcellular precision. The kinetics of signalling is not well understood and we believe that our study is likely the first to include both proteomic and lipidomic analyses over a timecourse during the acute lytic cycle stage of the disease. In doing so, we found evidence for a feedback loop that controls the signalling network spatiotemporally, and we characterise elements of this feedback in the same study.

      **Major Comments:**

      Based on the findings reported here there is little doubt that BIPPO and A23187-induced signaling intersect with each other, as very much expected from previous studies. The authors selected the 50s and 15s post-treatment timing of A23187 and BIPPO, respectively for collecting phosphoproteomics samples. At these time points, which were shown to peak cytosolic Ca2+, parasites were still intracellular (Line #171). How did authors make sure to stimulate the entire signaling cascade adequately, particularly when parasites do not egress within the selected time window? There is significant variability between phosphosite intensities of replicates (Line #186), which may also be attributed to insufficient triggers for the egress across independent experiments. This work must be supported by in vitro egress assays with the chosen incubation periods of BIPPO and ionophore treatment (show the induced % egress of tachyzoites in the 50s and 15s).

      Response:

      1. We appreciate that the reviewer acknowledges that our data clearly shows that BIPPO and A23187-induced signalling intersect. While this may have been expected from previous studies, this has not previously been shown - and is therefore valuable to the field. Specifically, the fact that A23187-treatment leads to phosphorylation of targets normally deemed to sit upstream of calcium release is entirely novel and adds a substantial layer of information to our understanding of how these signalling pathways work together.

      Treatments were purposely selected to align pathways to a point where calcium levels peak just prior to calcium reuptake. At these chosen timepoints, we clearly show that overall signalling correlation is very high. We know from our egress assays using identical treatment concentrations (Fig. 2C), that the stimulations used are sufficient to result in complete egress. We are simply comparing signalling pathways at points prior to egress.

      As mentioned in point 2, we show convincingly that the treatments used are sufficient to trigger complete egress. As detailed clearly in the text, we believe that these variations in intensities between replicates are due to slight differences in timing between experiments (this is inevitable given the very rapid progression of signalling, and the difficulty of replicating exact sub-minute treatment timings). We demonstrate that the reporter intensities associated with DR sites correlate well across replicates (Supp Fig. 3C), suggesting that despite some replicate variability, the overall trends across replicates is very much consistent. This allows us to confidently average scores to provide values that are representative of a site’s phosphorylation state at the timepoint of interest.

      The reviewer’s suggestion that we should demonstrate % egress at the 50s and 15s treatment timepoints is obsolete - we state clearly in the text that parasites have not egressed at these timepoints. Our egress assays (Fig. 2C) further support this.

      The authors discuss that CDPK3 controls the cAMP level and PKA through activation of one or more yet-to-be-identified PDEs(s). cAMP could probably also be regulated by an adenylate cyclase, ACbeta that was found to have CDPK3-dependent phosphorylation sites. If CDPK3 is indeed a regulator of cAMP through the activation of PDEs or ACbeta, it would be expected that the deletion of CDPK3 would perturb the cAMP level, resulting in dysregulation of PKAc1 subunit, which in turn would dysregulate cGMP-specific PDEs (PMID: 29030485) and thereby PKG. All these connections need to explain in a more clear manner with experimental support (what is positive and what is negatively regulated by C____DPK3).

      Response:

      1. We do not firmly state that CDPK3 regulates cAMP by phosphorylation of a PDE - this is one of the possibilities addressed. We acknowledge the possibility that this could also be via the adenylate cyclase (see line 792).

      PMID: 29030485 demonstrates clearly a link between cAMP signalling and PKG signalling, but does not demonstrate how this is mediated. The authors postulate that a cGMP-specific PDE is dysregulated given their observation that PDE2 is differentially phosphorylated in a constitutively inactive PKA mutant, however this was not validated experimentally. We and others (Moss et al., 2022), however, demonstrate that PDE2 is cAMP-specific. This suggests that the model built by PMID: 29030485 requires revisiting. We acknowledge clearly in the text that Jia et al. have shown a link between cAMP and PKG signalling, and hypothesise that CDPK3’s modulation of cAMP levels may affect this (this is in keeping with our phosphoproteomic data).

      Moreover, the egress defect is not due to a low influx of calcium in the cytosol because when the ionophore A23187 was added to the CDPK3 mutant, its phenotype was not recovered. Rather, the defect may be due to the low or null activity of PKG that would activate PI4K to generate IP3 and DAG. The latter would be used as a substrate by DGK to generate PA that is involved in the secretion of micronemes and Toxoplasma egress. In this context, authors should evaluate the role of CDPK3 in the secretion of micronemes that is directly related to the egress of the parasite.

      1. We agree with the reviewer on their point about calcium influx, and have already acknowledged in the text that the feedback loop does not control release of Ca2+ from internal stores as disruption of CDPK3 does not lead to a delay in Ca2+

      We agree, and clearly address in the text, that the egress defect could be due to altered PKG/phospholipid pathway signalling.

      (Lourido, Tang and David Sibley, 2012; McCoy et al., 2012) have both previously shown that microneme secretion is regulated by CDPK3. We therefore do not deem it necessary to repeat this experiment, but have made clearer mention of their findings in our writing.

      When the Dcdpk3 mutant with BIPPO treatment was evaluated, it was observed that the parasite recovered the egress phenotype. It is concluded that CDPK3 could probably regulate the activity of cGMP-specific PDEs. CDPK3 could (in)activate them, or it could act on other proteins indirectly regulating the activity of these PDEs. Upon inactivation of PDEs, an increase in the cGMP level would activate PKG, which will, in turn, promote egress. From the data, it is not clear whether any phosphorylation by CDPK3 would activate or inactivate PDEs, and if so, then how (directly or indirectly). To reach unambiguous interpretation, authors should perform additional assays.

      Response:

      As mentioned previously, given the abundance of differentially regulated phosphosites, we do not believe that mutating individual sites on individual proteins is a worthwhile or realistic pursuit.

      We clearly show systematic A23187-mediated phosphorylation of key signalling components in the PKA/PKG/PI-PLC/phospholipid signalling cascade, and demonstrate that several of these are CDPK3-dependent. We demonstrate that CDPK3 alters cAMP levels (and that the ∆CDPK3 egress delay in A23187 treated parasites is largely rescued following pre-treatment with a PKA inhibitor). We similarly demonstrate that A23187 treatment leads to phosphorylation of numerous PDEs, including the cAMP specific PDE2, and show that PDE2 knockout parasites show an egress delay following A23187 treatment. While PDE2 may not be directly regulated by CDPK3 (suggesting other Ca2+ kinases are also involved), these findings collectively demonstrate the existence of a calcium-regulated feedback loop, in which CDPK3 and PDE2 play a role (by regulating cAMP).

      We acknowledge that we have not untangled every element of this feedback loop, and do not believe that it would be realistic to do so in a single study given the number of sites phosphorylated and pathways involved. We do believe, however, that we have shown clearly that the feedback loop exists - this in itself is entirely novel, and of significant importance to the field.

      On a similar note, a possible experiment that can be done to improve the work would be to treat the CDPK3 mutant with BIPPO in conjunction with a calcium chelator (BAPTA-AM) to reveal, which proteins are phosphorylated prior to activation of the calcium-mediated cascades?

      Response:

      We agree that this would be an interesting experiment to carry out but would involve significant work. This could be pursued in another paper or project but is beyond the scope of this work.

      The manuscript claims that PDE1, PDE7, PDE9 are cGMP specific, and BIPPO inhibits only cGMP-specific PDEs. All assays are performed with 1-10 micromolar cAMP and cGMP for 1h. There is no data showing the time, protein and substrate dependence. Given the suboptimal enzyme assays, authors should re-do them as suggested here. (1) Repeat the pulldown assay with a higher number of parasites (50-100 million) and measure the protein concentration. (2) Set up the PDE assay with saturating amount of cAMP and cGMP, which is critical if the PDE1,7,9 have a higher Km Value for cAMP (means lower affinity) compared to cGMP. An adequate amount of substrate and protein allows the reaction to reach the Vmax. Once you have re-determined the substrate specificity (revise Fig 5D), you should retest BIPPO (Fig 5E) in the presence of cAMP and cGMP. It is very likely that you would find the same result as PDE9 and PfPDEβ (BIPPO can inhibit both cAMP and cGMP-specific PDE), as described previously

      We have repeated our assay using the exact same conditions outlined by Moss et al. This involved using a similar number of parasites, a longer incubation time of 2 hours at a higher temperature (37ºC) and with a lower starting concentration of cAMP (0.1 uM). We demonstrate that we are able to recapitulate both the Moss et al. and Vo et al. (see Supp Fig. 7B). However, we noticed that these reactions were not carried out with saturating cAMP/cGMP concentrations, since all reactions had reached 100% completion at the end of the assay whereby all substrate was hydrolysed. We therefore believe that based on our original assay, as well as the new PDE1 timecourse that we have performed (Supp Fig. 7C), that PDEs 1, 7 and 9 display predominantly cGMP hydrolysing activity, with moderate cAMP hydrolysing activity.

      We also repeated the BIPPO inhibition assay using the Moss et al. conditions, and still observe that the cGMP activity of PDE1 is the most potently inhibited of all 4 PDEs. We also see moderate inhibition of the cAMP activities of PDE1 and PDE9, suggesting that cAMP hydrolytic activity can also be inhibited. Interestingly, the cGMP hydrolytic activities of PDEs 7 & 9, which were previously inhibited using our original assay conditions, no longer appear to be inhibited. This is likely due to the longer incubation time, which masks the reduced activities of these two PDEs following treatment with BIPPO.

      The authors did not identify any PKG substrate, which is quite surprising as cAMP signaling itself could impact cGMP. Authors should show if they were able to observe enhanced cGMP levels in BIPPO-treated sample (which is expected to stimulate cGMP-specific PDEs). The author mention their inability to measure cGMP level but have they analyzed cGMP in the positive control (BIPPO-treated parasite line)? Why have they focused only on CDPK3 mutant, whereas in their phosphoproteomic data they could see other CDPKs too? It could be that other CDPK-mediated signaling differs and need PKA/PKG for activation.

      In the title, the authors have mentioned that there is a positive feedback loop between calcium release, cyclic nucleotide and lipid signaling, which is quite an extrapolation as there is no clear experimental data supporting such a positive feedback loop so the author should change the title of the paper.

      Response:

      1. As addressed in our previous response to the reviewer, PMID: 29030485 demonstrates clearly a link between cAMP signalling and PKG signalling, but does not confirm how this is mediated. The authors surmise that a cGMP-specific PDE is dysregulated (although the PDE hypothesised to be involved has since been shown to be cAMP-specific), but are similarly unable to detect changes in cGMP levels. This suggests that their model may be incomplete.

      The BIPPO treatment experiment suggested by the reviewer was already included in the original manuscript (see Fig. 4D in original manuscript, now Fig. 4E). With BIPPO treatment we are able to detect changes in cGMP levels.

      We did not deem it to be within the scope of this study to study every single other CDPK. We chose to study CDPK3, as its egress phenotype was of particular interest given its partial rescue following BIPPO treatment. We reasoned that its study may lead us to identify the signalling pathway that links BIPPO and A23187 induced signalling.

      As addressed in greater detail in our response to reviewer #2, the fact that the feedback loop appears to stimulate egress implies that it is positive.

      **Minor Comments:**

      Materials & Methods

      Explanation of parameters is not clear (Line #360-367). Phosphoproteomics with A23187 (8 micromolar) treatment in CDPK3-KO and WT, for 15, 30 and 60s at 37{degree sign}C incubation with DMSO control. Simultaneously passing the DR and CDPK3 dependency thresholds: CDPK3-dependent phosphorylation

      __Response: __We have modified the wording to make this clearer as per the reviewer’s suggestion.

      Line #368: At which WT-A23187 timepoint did the authors identify 2408 DR-up phosphosites (15s, 30s or 60s)? Or consistently in all? It should be clarified?

      __Response: __As already stated in the manuscript (see line 366 in original manuscript, now line 1047), phosphorylation sites were considered differentially regulated if at any given timepoint their log2FC surpassed the DR threshold.

      A23187 treatment of the CDPK3-KO mutant significantly increased the cAMP levels at 5 sec post-treatment, but BIPPO did not show any change. The authors concluded that BIPPO presumably does not inhibit cAMP-specific PDEs. However, the dual-specific PDEs are known to be inhibited by BIPPO, as shown recently (____https://www.biorxiv.org/content/10.1101/2021.09.21.461320v1____). Authors do confirm that BIPPO-treatment can inhibit hydrolytic activity of PfPDEbeta for cAMP as well as cGMP (Line #612). Besides, it was shown in Fig 5E that BIPPO can partially though not significantly block cAMP-specific PDE2. The statements and data conflict each other under different subtitles and need to be reconciled. Elevation of basal cAMP level in the CDPK3 mutant indicates the perturbation of cAMP signaling, however BIPPO data requires additional supportive experiments to conclude its relation with cAMP or dual-specific PDE.

      Response:

      1. The manuscript to which the reviewer refers does not use BIPPO in any of their experiments. They show that continuous treatment with zaprinast blocks parasite growth in a plaque assay, but do not test whether zaprinast specifically blocks the activity of any of the PDEs.

      Having repeated the PDE assay using the Moss et al. conditions (as outlined above), we are now able to recapitulate their findings, showing that PDEs 1, 7 and 9 can display dual hydrolytic activity while PDE2 is cAMP specific. As explained further above, we believe that our original set of experiments are more stringent than the Moss *et al. * To confirm this, we also performed an additional experiment, incubating PDE1 for varying amounts of time using our original conditions (1 uM cAMP or 10 uM cGMP, at room temperature). This revealed that PDE1 is much more efficient at hydrolysing cGMP, and only begins to display cAMP hydrolysing capacity after 4 hours of incubation.

      We also measured the inhibitory capacity of BIPPO on the PDEs using the Moss *et al. * During the longer incubation time, it seems that BIPPO is unable to inhibit PDEs 7 and 9, while with the more stringent conditions it was able to inhibit both PDEs. We reasoned that since BIPPO is unable to inhibit these PDEs fully, the residual activity over the longer incubation period would compensate for the inhibition, eventually leading to 100% hydrolysis of the cNMPs. We also see that while the cGMP hydrolysing capacity of PDE1 is completely inhibited, its cAMP hydrolysing capacity is only partially inhibited. These findings and the fact that PDE2 is not inhibited by BIPPO are in line with our experiments where we measured [cAMP] and showed that treatment with BIPPO did not lead to alterations in [cAMP].

      The method used to determine the substrate specificity of PDE 1,2,7 and 9 resulted in the hydrolytic activity of PDE2 towards cAMP, while the remaining 3 were determined as cGMP-specific. However, PDE1 and PDE9 have been reported as being dual-specific (Moss et al, 2021; Vo et al, 2020), which questions the reliability of the preferred method to characterize substrate specificity by the authors. It is also suggested to use another ELISA-based kit to double check the results.

      Response:

      As outlined above, we have repeated the assay using the conditions described by Moss et al. (lower starting concentrations of cAMP, 2 hour incubation period at 37ºC) and find that we are able to recapitulate the results of both Moss et al. and Vo et al.. However, using the Moss et al. conditions, the PDEs have hydrolysed 100% of the cyclic nucleotide, suggesting that these conditions are less stringent than the ones we used originally using higher starting concentrations of cAMP and incubating for 1 hour only at room temperature. With enzymatic assays it is always important to perform them at saturating conditions (as already suggested by the reviewer) and therefore we believe that our original conditions are more stringent than the results using the Moss et al. conditions.

      Line #607-608: Authors found PDE9 less sensitive to BIPPO-treatment and concluded PDE2 as refractory to BIPPO inhibition; however, the reduction level of activity seems similar as seen in PDE9-BIPPO treated sample? This strong statement should be replaced with a mild explanation.

      __Response: __We have tempered our wording as per the reviewer’s suggestion

      Figures and legends:

      The introductory model in Fig S1 is difficult to understand and ambiguous despite having it discussed in the text. For example, CDPK1 is placed, but only mentioned at the beginning, and the role of other CDPKs is not clear. In addition, the arrows in IP3 and PKG are confusing. The location of guanylate and adenylate cyclase is wrong, and so on... The figure should include only the egress-related signaling components to curate it. The illustration of host cell in orange color must be at the right side of the figure in connection with the apical pole of the parasite (not on the top). Figure legend should also be rearranged accordingly and citations of the underlying components should be included (see below).

      __Response: __We have modified Supp Fig. 1 as per the suggestions of reviewer#2 and #3. We have now modified the localisations of the proteins and have also removed the lines showing the cross talk between pathways. We have also highlighted to the reader that this is only a model and may not represent the true localisations of the proteins, despite our best efforts.

      In Figure 5D, would you please provide the western blot analysis of samples before and after pulling down to demonstrate the success of your immunoprecipitation assay. Mention the protein concentration in your PDE enzyme assay. Please refer to the M&M comments above to re-do the enzyme assays.

      Response:

      We have now included western blots for the pull downs of PDEs 1, 2, 7 and 9 (Supp Fig. 7A). We chose not to measure protein concentrations of samples since all experiments were performed using the same starting parasite numbers, and we do not see large differences in activities between biological replicates of the PDEs.

      Figure legend 1C: Line #194: There is no red-dotted line shown in graph! Correct it!

      __Response: __We have modified this.

      Figure 4Gi-ii: Shouldn't it be labelled i: H89-treatment and ii: A23178, respectively instead of DMSO and H89? (based on the text Line #579).

      __Response: __Our labelling of Fig. 4Gi-ii is correct as panel i parasites were pre-treated with DMSO, while panel ii parasites were pre-treated with H89. Subsequent egress assays on both parasites were then performed using A23187.

      We have modified the figures to include mention of A23187 on the X axis, and modified the figure legend to clarify pre-treatment was performed with DMSO and H89 respectively.

      Bibliography:

      Line #57 and 58: Citations must be selected properly! Carruthers and Sibley 1999 revealed the impact of Ca2+ on the microneme secretion within the context of host cell attachment and invasion, not egress as indicated in the manuscript! Similar case is also valid for the reference Wiersma et al 2004; since the roles of cyclic nucleotides were suggested for motility and invasion. Also notable in the fact that several citations describing the localization, regulation and physiological importance of cAMP and cGMP signaling mediators (PMID: 30449726 , 31235476 , 30992368 , 32191852 , 25555060 , 29030485 ) are either completely omitted or not appropriately cited in the introduction and discussion sections.

      Response:

      We have modified the citations as per the reviewer’s suggestions. We now cite Endo et al., 1987 for the first use of A23187 as an egress trigger, and Lourido, Tang and David Sibley, 2012 for the role of cGMP signalling in egress. We also cite all the GC papers when we make first mention of the GC. We have also removed the Howard et al., 2015 citation (PMID: 25555060) when referring to the fact that BIPPO/zaprinast can rescue the egress delay of ∆CDPK3 parasites.

      Grammar/Language

      Line #31: After "cAMP levels" use comma

      Response:

      We have modified this.

      36: Sentence is not clear. Does conditional deletion of all four PDEs support their important roles? If so, the role in egress of the parasite?

      Response:

      We have clarified our wording as per the reviewer’s suggestion. We state that PDEs 1 and 2 display an important role in growth since deletion of either these PDEs leads to reduced plaque growth. We have not investigated exactly what stage of the lytic cycle this is.

      40: "is a group involving" instead of "are"

      Response:

      We found no mention of “a group involving” in our original manuscript at line 40 or anywhere else in the manuscript, so we are unsure what the reviewer is referring to.

      108: isn't it "discharge of Ca++ from organelle stores to cytosol"?

      __Response: __We thank the reviewer for spotting this error. We have now modified this sentence.

      120: "was" instead of "were"

      __Response: __Since the situation we are referencing is hypothetical, then ‘were’ is the correct tense.

      Reviewer #3 (Significance (Required)):

      There is a significant amount of work that underlies this manuscript; however, from a conceptual viewpoint, the manuscript does not offer significant advancement over the current knowledge without functional validation of phosphoproteomics data. In terms of the mechanism, it is not clear whether and how lipid turnover and cAMP-PKA signaling control the egress phenotype (lack of a validated model at the end of this study).In a methodical sense, the work uses established assays, some of which require revisiting to reach robust conclusions and avoid misinterpretation.

      Compare to existing published knowledge

      A large body of work preceding this manuscript has indicated the crosstalk of cAMP, cGMP, calcium and lipid signaling cascades. This work provides a further refinement of the existing model. The article is quite interesting from a throughput screening point of view, but it clearly lacks the appropriate endorsement of the hits.

      Response:

      Please refer to our first response to reviewer #3 for our full rebuttal to these points. We respectfully disagree with the assessment that the work presented does not advance current knowledge.

      Audience

      Field specific (Apicomplexan Parasitology)

      Expertise

      Molecular Parasitology

      References

      Bailey, A. P. et al. (2015) ‘Antioxidant Role for Lipid Droplets in a Stem Cell Niche of Drosophila’, Cell. The Authors, 163(2), pp. 340–353. doi: 10.1016/j.cell.2015.09.020.

      Bullen, H. E. et al. (2016) ‘Phosphatidic Acid-Mediated Signaling Regulates Microneme Secretion in Toxoplasma Article Phosphatidic Acid-Mediated Signaling Regulates Microneme Secretion in Toxoplasma’, Cell Host & Microbe, pp. 349–360. doi: 10.1016/j.chom.2016.02.006.

      Dass, S. et al. (2021) ‘Toxoplasma LIPIN is essential in channeling host lipid fluxes through membrane biogenesis and lipid storage’, Nature Communications. Springer US, 12(1). doi: 10.1038/s41467-021-22956-w.

      Endo, T. et al. (1987) ‘Effects of Extracellular Potassium on Acid Release and Motility Initiation in Toxoplasma gondii’, The Journal of Protozoology, 34(3), pp. 291–295. doi: 10.1111/j.1550-7408.1987.tb03177.x.

      Flueck, C. et al. (2019) Phosphodiesterase beta is the master regulator of camp signalling during malaria parasite invasion, PLoS Biology. doi: 10.1371/journal.pbio.3000154.

      Howard, B. L. et al. (2015) ‘Identification of potent phosphodiesterase inhibitors that demonstrate cyclic nucleotide-dependent functions in apicomplexan parasites’, ACS Chemical Biology, 10(4), pp. 1145–1154. doi: 10.1021/cb501004q.

      Jia, Y. et al. (2017) ‘ Crosstalk between PKA and PKG controls pH ‐dependent host cell egress of Toxoplasma gondii ’, The EMBO Journal, 36(21), pp. 3250–3267. doi: 10.15252/embj.201796794.

      Katris, N. J. et al. (2020) ‘Rapid kinetics of lipid second messengers controlled by a cGMP signalling network coordinates apical complex functions in Toxoplasma tachyzoites’, bioRxiv. doi: 10.1101/2020.06.19.160341.

      Lentini, J. M. et al. (2020) ‘DALRD3 encodes a protein mutated in epileptic encephalopathy that targets arginine tRNAs for 3-methylcytosine modification’, Nature Communications. Springer US, 11(1). doi: 10.1038/s41467-020-16321-6.

      Lourido, S., Tang, K. and David Sibley, L. (2012) ‘Distinct signalling pathways control Toxoplasma egress and host-cell invasion’, EMBO Journal. Nature Publishing Group, 31(24), pp. 4524–4534. doi: 10.1038/emboj.2012.299.

      Lunghi, M. et al. (2022) ‘Pantothenate biosynthesis is critical for chronic infection by the neurotropic parasite Toxoplasma gondii’, Nature Communications. Springer US, 13(1). doi: 10.1038/s41467-022-27996-4.

      McCoy, J. M. et al. (2012) ‘TgCDPK3 Regulates Calcium-Dependent Egress of Toxoplasma gondii from Host Cells’, PLoS Pathogens, 8(12). doi: 10.1371/journal.ppat.1003066.

      Moss, W. J. et al. (2022) ‘Functional Analysis of the Expanded Phosphodiesterase Gene Family in Toxoplasma gondii Tachyzoites’, mSphere. American Society for Microbiology, 7(1). doi: 10.1128/msphere.00793-21.

      Stewart, R. J. et al. (2017) ‘Analysis of Ca2+ mediated signaling regulating Toxoplasma infectivity reveals complex relationships between key molecules’, Cellular Microbiology, 19(4). doi: 10.1111/cmi.12685.

      Vo, K. C. et al. (2020) ‘The protozoan parasite Toxoplasma gondii encodes a gamut of phosphodiesterases during its lytic cycle in human cells’, Computational and Structural Biotechnology Journal. The Author(s), 18, pp. 3861–3876. doi: 10.1016/j.csbj.2020.11.024.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      Summary:

      Dominicus et al aimed to identify the intersecting components of calcium, cyclic nucleotides (cAMP, cGMP) and lipid signaling through phosphoproteomic, knockout and biochemical assays in an intracellular parasite, Toxoplasma gondii, particularly when its acutely-infectious tachyzoite stage exits the host cells. A series of experimental strategies were applied to identify potential substrates of calcium-dependent protein kinase 3 (CDPK3), which has previously been reported to control the tachyzoite egress. According to earlier studies (PMID: 23226109, 24945436, 5418062, 26544049, 30402958), CDPK3 regulated the parasite exit through multiple phosphorylation events. Here, authors identified differentially-regulated (DR) phosphorylation sites by comparing the parasite samples after treatment with a calcium ionophore (A23178) and a PDE inhibitor (BIPPO), both of which are known to induce artificial egress (induced egress as opposed to natural egress). When the CDPK3 mutant was treated with A23187, its delayed egress phenotype did not change, whereas BIPPO restored the egress to the level of the parental (termed as WT) strain, probably by activating PKG. The gene ontology enrichment of the up-regulated clusters revealed many probable CDPK3-dependent DR sites involved in cyclic nucleotide signaling (PDE1, PDE2, PDE7, PDE9, guanylate and adenylate cyclases, cyclic nucleotide-binding protein or CNBP) as well as lipid signaling (PI-PLC, DGK1). Authors suggest lipid signaling as one of the factors altered in the CDPK3 mutant, albeit lipidomics (PC, PI, PS, PT, PA, PE, SM) showed no significant change in phospholipids. To reveal how the four PDEs indicated above contribute to the cAMP and cGMP-mediated egress, they examined their biological significance by knockout/knockdown and enzyme activity assays. Authors claim that PDE1,7,9 proteins are cGMP-specific while PDE2 is cAMP-specific, and BIPPO treatment can inhibit PDE1-cGMP and PDE7-cGMP, but not PDE9-cGMP. Given the complexity, the manuscript is well structured, and most experiments were carefully designed. Undoubtedly, there is a significant amount of work that underlies this manuscript; however, from a conceptual viewpoint, the manuscript does not offer significant advancement over the current knowledge without functional validation of phosphoproteomics data (see below). A large body of work preceding this manuscript has indicated the crosstalk of cAMP, cGMP, calcium and lipid signaling cascades. This work provides a further refinement of the existing model. In a methodical sense, the work uses established assays, some of which require revisiting to reach robust conclusions and avoid misinterpretation. The article is quite interesting from a throughput screening point of view, but it clearly lacks the appropriate endorsement of the hits. The authors accept that identifying the phosphorylation of a protein does not imply a functional role, which is a major drawback as there is no experimental support for any phosphorylation site of the protein identified through phosphoproteomics. In terms of the mechanism, it is not clear whether and how lipid turnover and cAMP-PKA signaling control the egress phenotype (lack of a validated model at the end of this study).

      Major Comments:

      Based on the findings reported here there is little doubt that BIPPO and A23187-induced signaling intersect with each other, as very much expected from previous studies. The authors selected the 50s and 15s post-treatment timing of A23187 and BIPPO, respectively for collecting phosphoproteomics samples. At these time points, which were shown to peak cytosolic Ca2+, parasites were still intracellular (Line #171). How did authors make sure to stimulate the entire signaling cascade adequately, particularly when parasites do not egress within the selected time window? There is significant variability between phosphosite intensities of replicates (Line #186), which may also be attributed to insufficient triggers for the egress across independent experiments. This work must be supported by in vitro egress assays with the chosen incubation periods of BIPPO and ionophore treatment (show the induced % egress of tachyzoites in the 50s and 15s).

      The authors discuss that CDPK3 controls the cAMP level and PKA through activation of one or more yet-to-be-identified PDEs(s). cAMP could probably also be regulated by an adenylate cyclase, ACbeta that was found to have CDPK3-dependent phosphorylation sites. If CDPK3 is indeed a regulator of cAMP through the activation of PDEs or ACbeta, it would be expected that the deletion of CDPK3 would perturb the cAMP level, resulting in dysregulation of PKAc1 subunit, which in turn would dysregulate cGMP-specific PDEs (PMID: 29030485) and thereby PKG. All these connections need to explain in a more clear manner with experimental support (what is positive and what is negatively regulated by CDPK3). Moreover, the egress defect is not due to a low influx of calcium in the cytosol because when the ionophore A23187 was added to the CDPK3 mutant, its phenotype was not recovered. Rather, the defect may be due to the low or null activity of PKG that would activate PI4K to generate IP3 and DAG. The latter would be used as a substrate by DGK to generate PA that is involved in the secretion of micronemes and Toxoplasma egress. In this context, authors should evaluate the role of CDPK3 in the secretion of micronemes that is directly related to the egress of the parasite.

      When the cdpk3 mutant with BIPPO treatment was evaluated, it was observed that the parasite recovered the egress phenotype. It is concluded that CDPK3 could probably regulate the activity of cGMP-specific PDEs. CDPK3 could (in)activate them, or it could act on other proteins indirectly regulating the activity of these PDEs. Upon inactivation of PDEs, an increase in the cGMP level would activate PKG, which will, in turn, promote egress. From the data, it is not clear whether any phosphorylation by CDPK3 would activate or inactivate PDEs, and if so, then how (directly or indirectly). To reach unambiguous interpretation, authors should perform additional assays. On a similar note, a possible experiment that can be done to improve the work would be to treat the CDPK3 mutant with BIPPO in conjunction with a calcium chelator (BAPTA-AM) to reveal, which proteins are phosphorylated prior to activation of the calcium-mediated cascades? The manuscript claims that PDE1, PDE7, PDE9 are cGMP specific, and BIPPO inhibits only cGMP-specific PDEs. All assays are performed with 1-10 micromolar cAMP and cGMP for 1h. There is no data showing the time, protein and substrate dependence. Given the suboptimal enzyme assays, authors should re-do them as suggested here. (1) Repeat the pulldown assay with a higher number of parasites (50-100 million) and measure the protein concentration. (2) Set up the PDE assay with saturating amount of cAMP and cGMP, which is critical if the PDE1,7,9 have a higher Km Value for cAMP (means lower affinity) compared to cGMP. An adequate amount of substrate and protein allows the reaction to reach the Vmax. Once you have re-determined the substrate specificity (revise Fig 5D), you should retest BIPPO (Fig 5E) in the presence of cAMP and cGMP. It is very likely that you would find the same result as PDE9 and PfPDEβ (BIPPO can inhibit both cAMP and cGMP-specific PDE), as described previously.

      The authors did not identify any PKG substrate, which is quite surprising as cAMP signaling itself could impact cGMP. Authors should show if they were able to observe enhanced cGMP levels in BIPPO-treated sample (which is expected to stimulate cGMP-specific PDEs). The author mention their inability to measure cGMP level but have they analyzed cGMP in the positive control (BIPPO-treated parasite line)? Why have they focused only on CDPK3 mutant, whereas in their phosphoproteomic data they could see other CDPKs too? It could be that other CDPK-mediated signaling differs and need PKA/PKG for activation. In the title, the authors have mentioned that there is a positive feedback loop between calcium release, cyclic nucleotide and lipid signaling, which is quite an extrapolation as there is no clear experimental data supporting such a positive feedback loop so the author should change the title of the paper.

      Minor Comments:

      Materials & Methods

      Explanation of parameters is not clear (Line #360-367). Phosphoproteomics with A23187 (8 micromolar) treatment in CDPK3-KO and WT, for 15, 30 and 60s at 37{degree sign}C incubation with DMSO control. Simultaneously passing the DR and CDPK3 dependency thresholds: CDPK3-dependent phosphorylation

      Line #368: At which WT-A23187 timepoint did the authors identify 2408 DR-up phosphosites (15s, 30s or 60s)? Or consistently in all? It should be clarified?

      A23187 treatment of the CDPK3-KO mutant significantly increased the cAMP levels at 5 sec post-treatment, but BIPPO did not show any change. The authors concluded that BIPPO presumably does not inhibit cAMP-specific PDEs. However, the dual-specific PDEs are known to be inhibited by BIPPO, as shown recently (https://www.biorxiv.org/content/10.1101/2021.09.21.461320v1). Authors do confirm that BIPPO-treatment can inhibit hydrolytic activity of PfPDEbeta for cAMP as well as cGMP (Line #612). Besides, it was shown in Fig 5E that BIPPO can partially though not significantly block cAMP-specific PDE2. The statements and data conflict each other under different subtitles and need to be reconciled. Elevation of basal cAMP level in the CDPK3 mutant indicates the perturbation of cAMP signaling, however BIPPO data requires additional supportive experiments to conclude its relation with cAMP or dual-specific PDE.

      The method used to determine the substrate specificity of PDE 1,2,7 and 9 resulted in the hydrolytic activity of PDE2 towards cAMP, while the remaining 3 were determined as cGMP-specific. However, PDE1 and PDE9 have been reported as being dual-specific (Moss et al, 2021; Vo et al, 2020), which questions the reliability of the preferred method to characterize substrate specificity by the authors. It is also suggested to use another ELISA-based kit to double check the results.

      Line #607-608: Authors found PDE9 less sensitive to BIPPO-treatment and concluded PDE2 as refractory to BIPPO inhibition; however, the reduction level of activity seems similar as seen in PDE9-BIPPO treated sample? This strong statement should be replaced with a mild explanation.

      Figures and legends:

      The introductory model in Fig S1 is difficult to understand and ambiguous despite having it discussed in the text. For example, CDPK1 is placed, but only mentioned at the beginning, and the role of other CDPKs is not clear. In addition, the arrows in IP3 and PKG are confusing. The location of guanylate and adenylate cyclase is wrong, and so on... The figure should include only the egress-related signaling components to curate it. The illustration of host cell in orange color must be at the right side of the figure in connection with the apical pole of the parasite (not on the top). Figure legend should also be rearranged accordingly and citations of the underlying components should be included (see below). In Figure 5D, would you please provide the western blot analysis of samples before and after pulling down to demonstrate the success of your immunoprecipitation assay. Mention the protein concentration in your PDE enzyme assay. Please refer to the M&M comments above to re-do the enzyme assays.

      Figure legend 1C: Line #194: There is no red-dotted line shown in graph! Correct it!

      Figure 4Gi-ii: Shouldn't it be labelled i: H89-treatment and ii: A23178, respectively instead of DMSO and H89? (based on the text Line #579)

      Bibliography: Line #57 and 58: Citations must be selected properly! Carruthers and Sibley 1999 revealed the impact of Ca2+ on the microneme secretion within the context of host cell attachment and invasion, not egress as indicated in the manuscript! Similar case is also valid for the reference Wiersma et al 2004; since the roles of cyclic nucleotides were suggested for motility and invasion. Also notable in the fact that several citations describing the localization, regulation and physiological importance of cAMP and cGMP signaling mediators (PMID: 30449726, 31235476, 30992368, 32191852, 25555060, 29030485) are either completely omitted or not appropriately cited in the introduction and discussion sections.

      Grammar/Language Line #31: After "cAMP levels" use comma 36: Sentence is not clear. Does conditional deletion of all four PDEs support their important roles? If so, the role in egress of the parasite? 40: "is a group involving" instead of "are" 108: isn't it "discharge of Ca++ from organelle stores to cytosol"? 120: "was" instead of "were"

      Significance

      There is a significant amount of work that underlies this manuscript; however, from a conceptual viewpoint, the manuscript does not offer significant advancement over the current knowledge without functional validation of phosphoproteomics data. In terms of the mechanism, it is not clear whether and how lipid turnover and cAMP-PKA signaling control the egress phenotype (lack of a validated model at the end of this study).In a methodical sense, the work uses established assays, some of which require revisiting to reach robust conclusions and avoid misinterpretation.

      Compare to existing published knowledge

      A large body of work preceding this manuscript has indicated the crosstalk of cAMP, cGMP, calcium and lipid signaling cascades. This work provides a further refinement of the existing model. The article is quite interesting from a throughput screening point of view, but it clearly lacks the appropriate endorsement of the hits.

      Audience

      Field specific (Apicomplexan Parasitology)

      Expertise

      Molecular Parasitology

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      Summary:

      Provide a short summary of the findings and key conclusions (including methodology and model system(s) where appropriate).

      In this manuscript, Dominicus et al investigate the elusive role of calcium-dependent kinase 3 during the egress of Toxoplasma gondii. Multiple functions have already been proposed for this kinase by this group including the regulation of basal calcium levels (24945436) or of a tyrosine transporter (30402958). However, one of the most puzzling phenotypes of CDPK3 deficient tachyzoites is a marked delay in egress when parasites are stimulated with a calcium ionophore that is rescued with phosphodiesterase (PDE) inhibitors. Crosstalk between, cAMP, cGMP, lipid and calcium signalling has been previously described to be important in regulating egress (26933036, 23149386, 29030485) but the role of CDPK3 in Toxoplasma is still poorly understood.

      Here the authors first take an elegant phosphoproteomic approach to identify pathways differentially regulated upon treatment with either a PDE inhibitor (BIPPO) and a calcium ionophore (A23187) in WT and CDPK3-KO parasites. Not much difference is observed between BIPPO or A23187 stimulation which is interpreted by the authors as a regulation through a feed-back loop. The authors then investigate the effect of CDPK3 deletion on lipid, cGMP and cAMP levels. The identify major changes in DAG, phospholipid, FFAs, and TAG levels as well as differences in cAMP levels but not for cGMP. Chemical inhibition of PKA leads to a similar egress timing in CDPK3-KO and WT parasites upon A23187 stimulation.

      As four PDEs appeared differentially regulated in the CDPK3-KO line upon A23187, the authors investigate the requirement of the 4 PDEs in cAMP levels. They show diverse localisation of the PDEs with specificities of PDE1, 7 and 9 for cGMP and of PDE2 for cAMP. They further show that PDE1, 7 and 9 are sensitive to BIPPO. Finally, using a conditional deletion system, they show that PDE1 and 2 are important for the lytic cycle of Toxoplasma and that PDE2 shows a slightly delayed egress following A23187 stimulation.

      Major comments:

      -Are the key conclusions convincing?

      The title is supported by the findings presented in this study. However I am not sure to understand why the authors imply a positive feed back loop. This should be clarified in the discussion of the results. The phosphoproteome analysis seems very strong and will be of interest for many groups working on egress. However, the key conclusion, i.e. that a substrate overlaps between PKG and CDPK3 is unlikely to explain the CDPK3 phenotype, seems premature to me in the absence of robustly identified substrates for both kinases.

      I am not sure there is a clear key conclusion from the lipidomic analysis and how it is used by the authors to build their model up. Major changes are observed but how could this be linked with CDPK3, particularly if cGMP levels are not affected?

      The evidence that CDPK3 is involved in cAMP homeostasis seems strong. However, the analysis of PKA inhibition is a bit less clear. The way the data is presented makes it difficult to see whether the treatment is accelerating egress of CDPK3-KO parasites or affecting both WT and CDPK3-KO lines, including both the speed and extent of egress. This is important for the interpretation of the experiment.

      The biochemical characterisation of the four PDE is interesting and seems well performed. However, PDE1 was previously shown to hydrolyse both cAMP and cGMP (https://doi.org/10.1101/2021.09.21.461320) which raises some questions about the experimental set up. Could the authors possibly discuss why they do not observe similar selectivity? Could other PDEs in the immunoprecipitate mask PDE activity? In line with this question, it is not clear what % of "hydrolytic activity (%)" means and how it was calculated. The experiments describing the selectivity of BIPPO for PDE1, 7 and 9 as well as the biological requirement of the four tested PDEs are convincing.

      -Should the authors qualify some of their claims as preliminary or speculative, or remove them altogether?

      The claim that CDPK3 affects cAMP levels seems strong however the exact links between CDPK3 activity, lipid, cGMP and cAMP signalling remain unclear and it may be important to clearly state this.

      -Would additional experiments be essential to support the claims of the paper? Request additional experiments only where necessary for the paper as it is, and do not ask authors to open new lines of experimentation.

      I think that the manuscript contains a significant amount of experiments that are of interest to scientists working on Toxoplasma egress. Requesting experiments to identify the functional link between above-mentioned pathways would be out of the scope for this work although it would considerably increase the impact of this manuscript. For example, would it be possible to test whether the CDPK3-KO line is more or less sensitive to PKG specific inhibition upon A23187 induced?

      -Are the suggested experiments realistic in terms of time and resources? It would help if you could add an estimated cost and time investment for substantial experiments.

      The above-mentioned experiment is not trivial as no specific inhibitors of PKG are available. Ensuring for specificity of the investigated phenotype would require the generation of a resistant line which would require significant work.

      -Are the data and the methods presented in such a way that they can be reproduced?

      It is not clear how the % of hydrolytic activity of the PDE has been calculated.

      -Are the experiments adequately replicated and statistical analysis adequate?

      This seems to be performed to high standards.

      Minor comments:

      -Specific experimental issues that are easily addressable.

      I do not have any comments related to minor experimental issues.

      -Are prior studies referenced appropriately?

      Most of the studies relevant for this work are cited. It is however not clear to me why some important players of the "PKG pathway" are not indicated in Fig 1H and Fig 3E, including for example UGO or SPARK.

      -Are the text and figures clear and accurate?

      While all the data shown here is impressive and well analysed, I find it difficult to read the manuscript and establish links between sections of the papers. The phosphoproteome analysis is interesting and is used to orientate the reader towards a feedback mechanism rather than a substrate overlap. But why do the authors later focus on PDEs and not on AC or CNBD, as in the end, if I understand well, there is no evidence showing a link between CDPK3-dependent phosphorylation and PDE activity upon A23187 stimulation? It is also unclear how the authors link CDPK3-dependent elevated cAMP levels with the elevated basal calcium levels they previously described. This is particularly difficult to reconcile particularly in a PKG independent manner.

      The presentation of the lipidomic analysis is also not really clear to me. Why do the authors show the global changes in phospholipids and not a more detailed analysis? As the authors focus on the PI-PLC pathway, could they detail the dynamics of phosphoinositides? I understand that lipid levels are affected in the mutant but I am not sure to understand how the authors interpret these massive changes in relationship with the function of CDPK3 and the observed phenotypes.

      Finally, the characterisation of the PDEs is an impressive piece of work but the functional link with CDPK3 is relatively unclear. It would also be important to clearly discuss the differences with previous results presented in this this preprint: https://doi.org/10.1101/2021.09.21.461320. My understanding is while the authors aim at investigating the role of CDPK3 in A23187 induced egress, the main finding related to CDPK3 is a defect in cAMP homeostasis that is not linked to A23187. Similarly, the requirements of PDE2 in cAMP homeostasis and egress is indirectly linked to CDPK3. Altogether I think that important results are presented here but divided into three main and distinct sections: the phosphoproteomic survey, the lipidomic and cAMP level investigation, and the characterisation of the four PDEs. However, the link between each section is relatively weak and the way the results are presented is somehow misleading or confusing.

      -Do you have suggestions that would help the authors improve the presentation of their data and conclusions?

      This is a very long manuscript written for specialists of this signalling pathway and I would suggest the authors to emphasise more the important results and also clearly state where links are still missing. This is obviously a complex pathway and one cannot elucidate it easily in a single manuscript.

      Significance

      -Describe the nature and significance of the advance (e.g. conceptual, technical, clinical) for the field.

      This is a technically remarkable paper using a broad range of analyses performed to a high standard.

      -Place the work in the context of the existing literature (provide references, where appropriate).

      The cross-talk between cAMP, cGMP and calcium signalling is well described in Toxoplasma and related parasites. Here the authors show that, in Toxoplasma, CDPK3 is part of this complex signalling network. One of the most important finding within this context is the role of CDPK3 in cAMP homeostasis. With this in mind, I would change the last sentence of the abstract to "In summary we uncover a feedback loop that enhances signalling during egress and links CDPK3 with several signalling pathways together."

      The genetic and biochemical analyses of the four PDEs are remarkable and highlight consistencies and inconsistencies with recently published work that would be important to discuss and will be of interest for the field.

      While I understand the studied signalling pathway is complex, I think it would be important to better describe the current model of the authors. In the discussion, the authors indicate that "the published data is not currently supported by a model that fits most experimental results." I would suggest to clarify this statement and discuss whether their work helps to reunite, correct or improve previous models.

      Could the authors also speculate about a potential role of PDE/CDPK3 in host cell invasion as cAMP signalling has be shown to be important for this process (30208022 and 29030485)?

      -State what audience might be interested in and influenced by the reported findings.

      This paper is of great interest to groups working on the regulation of egress in Toxoplasma gondii and other related apicomplexan pathogens.

      -Define your field of expertise with a few keywords to help the authors contextualize your point of view. Indicate if there are any parts of the paper that you do not have sufficient expertise to evaluate.

      I am working on the cell biology of apicomplexan parasites.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      In recent years, the field has investigated crosstalk between cGMP and cAMP signaling (PMID: 29030485), lipid and cGMP signaling (PMID: 30742070), and calcium and cGMP signaling (PMID: 26933036, 26933037). In contrast to the Plasmodium field, which has benefited from proteomic experiments (ex: PMID 24594931, 26149123, 31075098, 30794532), second messenger crosstalk in T. gondii has been probed predominantly through genetic and pharmacological perturbations. The present manuscript compares the features of A23187- and BIPPO-stimulated phosphoproteomes at a snapshot in time. This is similar to a dataset generated by two of the authors in 2014 (PMID: 24945436), except that it now includes one BIPPO timepoint. The sub-minute phosphoproteomic timecourse following A23187 treatment in WT and ∆cdpk3 parasites is novel and would seem like a useful resource.

      CDPK3-dependent sites were detected on adenylate cyclase, PI-PLC, guanylate cyclase, PDE1, and DGK1. This motivated study of lipid and cNMP levels following A23187 treatment. The four PDEs determined to have A23187-dependent phosphosites were characterized, including the two PDEs with CDPK3-dependent phosphorylation, which were found to be cGMP-specific. However, cGMP levels do not seem to differ in a CDPK3- or A23187-dependent manner. Instead, cAMP levels are elevated in ∆cdpk3 parasites. This would seem to implicate a feedback loop between CDPK3, the adenylyl cyclase, and PKA/PKG: CDPK3 activity reduces adenylyl cyclase activity, which reduces PKA activity, which increases PKG activity. The authors don't pursue this direction, and instead characterize PDE2, which does not have CDPK3-dependent phosphosites, and seems out of place in the study.

      MAJOR COMMENTS

      1.Some of the key conclusions are not convincing.

      The data presented in Figure 6E, F, and G and discussed in lines 647-679 are incongruent. In Figure 6E, the plaques in the PDE2+RAP image are hardly visible; how can it be that the plaques were accurately counted and determined not to differ from vehicle-treated parasites? Are the images in 6E truly representative? Was the order of PDE1 and PDE2 switched? The cited publication by Moss et al. 2021 (preprint) is not in agreement with this study, as stated. That preprint determined that parasites depleted of PDE2 had significantly reduced plaque number and plaque size (>95% reduction); and parasites depleted of PDE1 had a substantially reduced plaque size but a less substantial reduction in plaque number.

      Unfortunately, the length of time required for PDE depletion (72h) is incompatible with most T. gondii cellular assays (typically performed within one lytic cycle, 40-48h). Although the authors performed the assays 3 days after initial RAP treatment, is there evidence that non-excised parasites don't grow out of the population? This should be straightforward to test: treat, wait 3 days, infect onto monolayers, wait 24-48h fix, and stain with anti-YFP and an anti-Toxoplasma counterstain. The proportion of the parasite population that had excised the PDE at the time of the cellular assays will then be known, and the reader will have a sense of how complete the observed phenotypes are. As a reader, I will regard the phenotypes with some level of skepticism due to the long depletion time, especially since a panel of PDE rapid knockdown strains (depletion in < 18h) has recently been generated (Moss et al. 2021 preprint) using strains that have been used by several groups in the field since 2017 (PMID: 28465425). Although the experiments aren't wrong per se; the genetic system used here has substantial limitations, which are not appropriately controlled in the experiments or discussed in the text.

      2.The authors should qualify some of their claims as preliminary or speculative, or remove them altogether.

      The claims in lines 240-260 are confusing. It seems likely that the two drug treatments have at least topological distinctions in the signaling modules, given that cGMP-triggered calcium release is thought to occur at internal stores, whereas A23187-mediated calcium influx likely occurs first at the parasite plasma membrane. The authors' proposed alternative, that treatment-specific phosphosite behavior arises from experimental limitations and "mis-alignment", is unsatisfying for the following reasons: (1) From the outset, the authors chose different time frames to compare the two treatments (15s for BIPPO vs. 50s for A23187); (2) the experiment comprises a single time point, so it does not seem appropriate to compare the kinetics of phosphoregulation. There is still value in pointing out which phosphosites appear treatment-specific under the chosen thresholds, but further claims on the basis of this single-timepoint experiment are too speculative. Lines 264-267 and 281-284 should also be tempered.

      Relatedly, graphing of the data in Figure 1G (accompanying the main text mentioned above) was confusing. Why is one axis a ratio, and the other log10 intensity? What does log10 intensity tell you without reference to the DMSO intensity? Wouldn't you want the L2FC(A23187) vs. L2FC(BIPPO) comparisons? Could you use different point colors to highlight these cases on plot 1E? Additionally, could you use a pseudocount to include peptides only identified in one treatment condition on the plot in 1E? (Especially since these sites are mentioned in lines 272-278 but are not on the plot)

      3.Additional experiments would be essential to support the main claims of the paper.

      Genetic validation is necessary for the experiments performed with the PKA inhibitor H89. H89 is nonspecific even in mammalian systems (PMID: 18523239) and in this manuscript it was used at a high concentration (50 µM). The heterodimeric architecture of PKA in apicomplexans dramatically differs from the heterotetrameric enzymes characterized in metazoans (PMID: 29263246), so we don't know what the IC50 of the inhibitor is, or whether it inhibits competitively. Two inducible knockdown strains exist for PKA C1 (PMID: 29030485, 30208022). The authors could request one of these strains and construct a ∆cdpk3 in that genetic background, as was done for the PDE2 cKO strain. Estimated time: 3-4 weeks to generate strain, 2 weeks to repeat assays.

      cGMP levels are found to not increase with A23187 treatment, which is at odds with a previous study (lines 524-560). The text proposes that the differences could arise from the choice of buffer: this study used an intracellular-like Endo buffer (no added calcium, high potassium), whereas Stewart et al. 2017 used an extracellular-like buffer (DMEM, which also contains mM calcium and low potassium). An alternative explanation is that 60 s of A23187 treatment does not achieve a comparable amount of calcium flux as 15 s of BIPPO treatment, and a calcium-dependent effect on cGMP levels, were it to exist, could not be observed at the final timepoint in the assay. The experiments used to determine the kinetics of calcium flux following BIPPO and A23187 treatments (Fig. 1B, C) were calibrated using Ringer's buffer, which is more similar to an extracellular buffer (mM calcium, low potassium). In this buffer, A23187 treatment would likely stimulate calcium entry from across the parasite plasma membrane, as well as across the membranes of parasite intracellular calcium stores. By contrast, A23187 treatment in Endo buffer (low calcium) would likely only stimulate calcium release from intracellular stores, not calcium entry, since the calcium concentration outside of the parasite is low. Because calcium entry no longer contributes to calcium flux arising from A23187 treatment, it is possible that the calcium fluxes of A23187-treated parasites at 60 s are "behind" BIPPO-treated parasites at 15 s. The researchers could control these experiments by either (i) performing the cNMP measurements on parasites resuspended in the same buffer used in Figure 1B, C (Ringer's) or (ii) measuring calcium flux of extracellular parasites in Endo buffer with BIPPO and A23187 to determine the "alignment" of calcium levels, as was done with intracellular parasites in Figure 1C. No new strains would have to be generated and the assays have already been established in the manuscript. Estimated time to perform control experiments with replicates: 2 weeks. This seems like an important control, because the interpretation of this experiment shifts the focus of the paper from feedback between calcium and cGMP signaling, which had motivated the initial phosphoproteomics comparisons, to calcium and cAMP signaling. Further, the lipidomics experiments were performed in an extracellular-like buffer, DMEM, so it's unclear why dramatically different buffers were used for the lipidomics and cNMP measurements.

      Additional information is required to support the claim that PDE2 has a moderate egress defect (lines 681-687). T. gondii egress is MOI-dependent (PMID: 29030485). Although the parasite strains were used at the same MOI, there is no guarantee that the parasites successfully invaded and replicated. If parasites lacking PDE2 are defective in invasion or replication, the MOI is effectively decreased, which could explain the egress delay. Could the authors compare the MOIs (number of vacuoles per host cell nuclei) of the vehicle and RAP-treated parasites at t = 0 treatment duration to give the reader a sense of whether the MOIs are comparable?

      4.A few references are missing to ensure reproducibility.

      The manuscript states that the kinetic lipidomics experiments were performed with established methods, but the cited publication (line 497) is a preprint. These are therefore not peer reviewed and should be described in greater detail in this manuscript, including any relevant validation.

      Please cite the release of the T. gondii proteomes used for spectrum matching (lines 972-973).

      Please include the TMT labeling scheme so the analysis may be reproduced from the raw files.

      5.Statistical analyses should be reviewed as follows:

      Have the authors examined the possibility that some changes in phosphopeptide abundance reflect changes in protein abundance? This may be particularly relevant for comparisons involving the ∆cdpk3 strain. Did the authors collect paired unenriched proteomes from the experiments performed? Alternatively, there may be enriched peptides that did not change in abundance for many of the proteins that appear dynamically phosphorylated.

      It seems like for Figs. 3B and S5 the maximum number of clusters modeled was selected. Could the authors provide a rationale for the number of clusters selected, since it appears many of the clusters have similar profiles.

      Please include figure panel(s) relating to gene ontology. Relevant information for readers to make conclusions includes p-value, fold-enrichment or gene ratio, and some sort of metric of the frequency of the GO term in the surveyed data set. See PMID: 33053376 Fig. 7 and PMID: 29724925 Fig. 6 for examples or enrichment summaries. Additionally, in the methods, specify (i) the background set, (ii) the method used for multiple test correction, (iii) the criteria constituting "enrichment", (iv) how the T. gondii genome was integrated into the analysis, (v) the class of GO terms (molecular function, biological process, or cellular component), (vi) any additional information required to reproduce the results (for example, settings modified from default).

      The presentation of the lipidomics experiments in Figure 4A-C is confusing. First, the ∆cdpk3/WT ratio removes information about the process in WT parasites, and it's unclear why the scale centers on 100 and not 1. Second, the data in Figure S6 suggests a more modest effect than that represented in Fig. 4; is this due to day to day variability? How do the authors justify pairing WT and mutant samples as they did to generate the ratios? The significance test seems to be performed on the difference between the WT and ∆cdpk3 strains, but not relative to the DMSO treatment? Wouldn't you want to perform a repeated measures ANOVA to determine (i) if lipid levels change over time and (ii) if this trend differs in WT vs. mutant strain? In the main text, it would be preferable to see the data presented as the proteomics experiments were in Figure 4B and 4C, with fold changes relative to the DMSO (t = 0) treatment, separately for WT and ∆cdpk3 parasites. Signaling lipids constitute small percentages of the overall pool (e.g. PMID: 26962945), so one might not necessarily expect to observe large changes in lipid abundance when signaling pathways are modulated. Is there any positive control that the authors could include to give readers a sense of the dynamic range? Maybe the DGK1 mutant (PMID: 26962945)?

      Figure 4E: are the differences in [cAMP] with DMSO treatment and A23187 treatment different at any of the timepoints in the WT strain? The comparison seems to be WT/∆cdpk3 at each timepoint. Does the text (lines 562-568) need to be modified accordingly?

      Figure 6I: is the difference between PDE2 cKO/∆cdpk3 + DMSO or RAP significant?

      MINOR COMMENTS

      1.The following references should be added or amended:

      Lines 83-85: in the cited publication, relative phosphopeptide abundances of an overexpressed dominant-negative, constitutively inactive PKA mutant were compared to an overexpressed wild-type mutant. In this experimental setup, one would hypothesize that targets of PKA should be down-regulated (inactive/WT ratios). However, the mentioned phosphopeptide of PDE2 was found to be up-regulated, suggesting that it is not a direct target of PKA.

      Cite TGGT1_305050, referenced as calmodulin in line 458, as TgELC2 (PMID: 26374117).

      Cite TGGT1_295850 as apical annuli protein 2 (AAP2, PMID: 31470470).

      Cite TGGT1_270865 (adenylyl cyclase beta, Acβ) as PMID: 29030485, 30449726.

      Cite TGGT1_254370 (guanylyl cyclase, GC) as PMID: 30449726, 30742070.

      Note that Lourido, Tang and David Sibley, 2012 observed that treatment with zaprinast (a PDE inhibitor) could overcome CDPK3 inhibition. The target(s) of zaprinast have not been determined and may differ from those of BIPPO (in identity and IC50). The cited study also used modified CDPK3 and CDPK1 alleles, rather than ∆cdpk3 and intact cdpk1 as used in this manuscript. That is to say, the signaling backgrounds of the parasite strains deviate in ways that are not controlled.

      2.The following comments refer to the figures and legends:

      Part of the legend text for 1G is included under 1H.

      Figure 1H: The legend mentions that some dots are blue, but they appear green. Please ensure that color choices conform to journal accessibility guidelines. See the following article about visualization for colorblind readers: https://www.ascb.org/science-news/how-to-make-scientific-figures-accessible-to-readers-with-color-blindness/ . Avoid using red and green false-colored images; replace red with a magenta lookup table. Multi-colored images are only helpful for the merged image; otherwise, we discern grayscale better. Applies to Figures 1B, 5C, 6D. (Aside: anti-CAP seems an odd choice of counterstain; the variation in the staining, esp. at the apical cap, is distracting.)

      Figure 1B: When showing a single fluorophore, please use grayscale and include an intensity scale bar, since relative values are being compared.

      Figure 1C: it is difficult to compare the kinetics of the calcium response when the curves are plotted separately. Since the scales are the same, could the two treatments be plotted on the same axes, with different colors? Additionally, according to the legend, a red line seems to be missing in this panel.

      Figure 2A: Either Figure S4 can be moved to accompany Figure 2A, or Figure 2A could be moved to the supplemental.

      Significance

      This manuscript would interest researchers studying signaling pathways in protozoan parasites, especially apicomplexans, as CDPK3 and PKG orthologs exist across the phylum. To my knowledge, it is the first study that has proposed a mechanism by which a calcium effector regulates cAMP levels in T. gondii. Unfortunately, the experiments fall short of testing this mechanism.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Manuscript number: RC-2022-01384

      Corresponding author(s): Mary O’Riordan and Basel Abuaita

      1. General Statements [optional]

      We appreciated the positive feedback and helpful suggestions from the reviewers that pointed to a need for more clarity regarding the central focus of the study. Our goal was to take an unbiased approach to evaluating the role of neutrophils during S. Typhimurium (STM) infection of human intestinal epithelial cells (IEC), using human intestinal organoids as a model. An abundance of data point to important inflammatory roles for neutrophils during STM infection of human intestine but the critical mechanisms involved have not been fully elucidated. New data now included in the revised manuscript provide strong support for human PMN-derived IL1-beta as a driver of epithelial cell shedding in STM-infected HIOs, consistent with known differences in local inflammation between human and mouse infection, and this is the focus of the current study. Our data did not support a significant role for human neutrophils in controlling luminal bacterial numbers, but instead the primary human PMNs robustly stimulated epithelial cell responses that led to decreased intraepithelial bacteria. Several recent studies have suggested that caspase-1 is not a critical inflammasome component during STM infection of IEC, which instead use non-canonical inflammasomes, including caspases-4 and -11. Our data point to a human neutrophil-intrinsic function for caspase-1 and IL1-beta that contributes to the inflammatory tone of the intestinal milieu early in STM infection.

      2. Point-by-point description of the revisions

      Reviewer #1

      Major comments:

      Some important links are missing to fully support the mechanistic model proposed:* *

      1- PMN activity

      The authors may strengthen their evidence of PMN activities presented in lines 135 to 143 and in Fig.S2 and S3. In particular, the authors claim that PMNs form NETs in PMN-HIOs but the evidence displayed are limited. In fact, Fig S2 shows the same condition and same staining as Fig 1B but the MPO-positive structures are different. Clarification in the text or the figure would be welcome. Besides, as the authors insist on the relevance of NETs in the discussion, it seems that a clear demonstration and characterization of these structures in the PMN-HIO model would highly benefit the manuscript.

      While we commented on NETs in our original manuscript, our conclusions do not rely on the presence or absence of NETs. We have therefore removed the NET data and the reference to NETs. While NETs are potentially interesting in the context of intestinal infection, we understand the reviewer's concern about NETs and anticipate that a more quantitative characterization of NETs may be challenging given the structure and variability of the PMN-HIOs.

      Regarding the analyses of the culture supernatants (Fig.S3), only 3 out of the 5 displayed datasets are commented on in the text. The data obtained for BD2 and N-Gal should be either commented or removed from the figure. The author further suggests that Elafin expression in presence of PMN may restrict PMNs' ability to kill Salmonella. Repeating the experiment displayed in Fig S1 in the presence of Elafin as well as in the presence of the supernatant extracted from HIOs and PMN-HIOs would clarify the potential inhibition of PMN killing capacity in the PMN-HIO model.

      We now include a sentence on the antimicrobials BD2 and N-GAL to the text (line 135-136). Elafin is one of many molecules that could potentially affect the ability of PMNs to kill Salmonella. We repeated the experiments in S3 Fig with recombinant Elafin. There was a very weak effect on killing in the presence of Elafin, however Elafin can also kill Salmonella directly, complicating interpretation of these experiments. We have now added a sentence in the Discussion to speculate that Elafin is one example of how the epithelium may inhibit the ability of PMNs to kill (line 366-372). These data are not central to our main conclusions and are only intended to provide context to the reader about possible explanations for why PMNs can kill Salmonella directly, but do not significantly alter total bacterial numbers in the HIO model.

      The author proposed that infected and uninfected cells are extracted from the epithelium due to PMN activation, suggesting that Salmonella infection of epithelial cells is only indirectly involved in cell shedding. This is an interesting hypothesis that could be tested by measuring cell shedding in a non-infected but PMN-activated (for instance with PMA) PMN-HIO model. This would clarify further the role of PMN in controlling epithelial response to the infection.

      We tested this possibility by microinjecting LPS into the lumen of PMN-HIOs (S6 Fig). There was significantly less TUNEL+ signal in LPS-injected PMN-HIOs compared to STM-infected PMN-HIOs, suggesting that active Salmonella infection is required for shedding of both infected and uninfected cells in the presence of PMNs__. __

      2- Specificity of RNA-seq profiling:

      The authors analyzed the transcriptomic profiling of PMN-HIOs and HIOs infected or not. While these experiments bring to light an interesting difference in inflammasome/cell death transcriptomic programs at the scale of the co-culture model, it is not possible to conclude from which cell type these transcriptomic shifts emerge. To clarify this, the authors stain the co-culture for ASC and observe that ASC-positive cells are PMNs. They conclude that PMNs are most likely the primary site of caspase-1 dependent production of IL1. While their model is theoretically consistent, more direct proofs are necessary to conclude on the cell-type specific transcriptomic program during infection of PMN-HIO and could be obtained by FACS sorting of the cells prior to RNA-seq, for instance using MPO to detect PMNs and E-cadherin to detect epithelial cells.

      We now provide evidence that pretreating PMNs with an irreversible Caspase-1 inhibitor before co-culturing with STM-infected HIOs prevented accumulation of luminal TUNEL+ cells (Fig 6B,C). Additionally, IL-1β treatment in the absence of PMNs recapitulated the cell death phenotype of the infected PMN-HIOs (Fig 6D,E) suggesting Caspase-1 activity in PMNs and IL-1β production are necessary for epithelial cell death in the PMN-HIOs.

      3- Roles of cytokine

      After showing an increased expression/release of IL1 and IL1RA in infected PMN-HIOs, the authors move on to testing the role of caspases on cell shedding. Yet, they do not test the impact of IL1 and IL1RA on cell shedding. As, according to their proposed model, IL1 is acting upstream of caspase-1 to promote cell shedding, testing cell shedding in infected PMN-HIOs in the presence of an IL1 inhibitor would clarify that link. The author also proposed that the decrease of IL33 in PMN-HIOs compared to HIOs could be due to PMN processing, which would give an additional role to PMNs in controlling the epithelial response to infection. In the context of this manuscript, it would be highly relevant to test this hypothesis by measuring the rate of cleaved IL-33.

      We now provide data to address these questions about IL-1 signaling. HIOs were microinjected with recombinant IL-1β during STM infection and PMN-HIOs were also treated with IL1RA during STM infection. Cell shedding was measured under these conditions in Fig. 6D-F. Cell shedding was dependent on IL-1 signaling and the model has been updated to reflect this.

      We also concentrated supernatants from STM-infected HIOs and PMN-HIOs, probed for cleaved IL33 via western blot and did see some cleavage. However, without being able to block this process it is not possible to conclude what role cleaved IL33 has during infection in the PMN-HIO and IL-1β seems to be sufficient to drive the cell shedding phenotype. Since the status of IL33 is not central to our conclusions, we have removed these data from the manuscript.

      4- Roles of caspase

      The interpretations of the role of Caspases to restrict bacteria burden are unclear and should be revised (see also minor comment). It appears that both Caspase-1 and Caspase-3 are necessary for efficient cell shedding (Fig4B), Caspase-1 (but not Caspase-3) decreases intraluminal bacteria burden (Fig4C) and Caspase-3 (but not Caspase-1) decreases epithelium-associated bacteria (Fig4D). To reconcile these observations with the hypothesis that cell shedding is responsible for the decrease of intraluminal and epithelium-associated bacterial burden, one may propose that caspase-3 (but not caspase-1) induces cell shedding of mainly non-infected cells (possibly bacteria-associated) and caspase-1 (but not caspase-3) induced cell shedding of infected cells. This could be tested by measuring the % of infected extruded cells upon caspase inhibitor treatments. In addition, these data don't allow to propose that Caspase-3 activation happens downstream of Caspase-1 as suggested by the authors in their abstract figure.

      It is difficult to accurately quantify the percent infected cells that are extruded since both infected and uninfected cells are extruded into a luminal space full of bacteria, which may associate with uninfected cells post-extrusion. However, we did observe cells positive for cleaved Caspase-3 when HIOs were treated with IL-1β leading us to infer that Caspase-1 mediated cytokine signaling through IL1R can trigger downstream Caspase-3 activation (Fig. 6G). We have expanded the Discussion to talk about differing roles of Caspases on bacterial burden and association with the epithelium (lines 374-397).

      Minor comments:

      The majority of the points listed below can be addressed with further analyses of pre-acquired data sets:

      Fig1E/1F/4D: each green dot is not likely to be individual bacteria but rather a cluster of bacterium (based on their size). So the y-axis in Fig 1E and Fig4D should not be #STM.

      Y-axis labels have been changed to #STM objects

      Fig2A: Variations in organoid size and epithelial thickness can be observed between figures. In particular, in Fig 2A, the HIO seems much younger than the other ones displayed in the manuscript.

      There is considerable natural variability between HIOs and between batches, a phenomenon observed by many HIO researchers (Hofer et al. Nature Reviews Materials 2021). HIOs were all treated the same way prior to infection, and based on our extensive observations, epithelial thickness does not correlate significantly with a particular experimental condition, as we now show in S10 Fig.

      Line 176 to 178, the authors mentioned the TUNEL+ cells in the mesenchyme but rule out the possibility that this phenotype could be infection or PMN-dependent because it is observed in the different conditions. As the picture displayed in Fig2A suggests high differences in the number of TUNEL+ cells in the mesenchyme under the 4 tested conditions, the authors should still quantify this phenomenon (possibly in the supplementary).

      This is likely an artifact of culturing and not due to the infection or PMNs. There is variability between HIO batches in the amount of TUNEL signal in mesenchymal cells (for example HIOs in Fig 4A and 5A have very low or no TUNEL positivity in the mesenchyme).

      "DAPI" should be written in blue.

      This has been corrected.

      Fig2C: Could the authors comment on the % of E-cadherin cells that are also TUNEL+? Is it 100%?

      On average about 75% of TUNEL+ cells are E-cadherin+. We think that this may be an underestimate because E-cadherin staining intensity decreases in many cells after shedding. This is commented on in the text (lines 178-179).

      Fig 2D: The point made on lines 182 to 186 that HIOs contain TUNEL + cells retained in the epithelial lining in the absence of PMNs is not very strongly supported by Fig 2D. Quantification of the number of intraepithelial TUNEL+ cells in the 4 compared conditions would make a more solid case.

      We quantified TUNEL intensity in epithelial cells retained in the monolayer (S7 Fig). We do note that there is some variability in this phenotype that correlates with different batches of HIOs__.__

      Fig2E: This experiment should be completed with a quantification of the percentage of TUNEL+ cells that are also cleaved caspase3-positive. The data, as currently displayed, do not prove that the cells negative for cleaved caspase 3 are apoptotic cells and thus do not support the sentence "suggesting that multiple forms of cell death were occurring in the PMN-HIO" (line 194).

      Cells negative for cleaved Caspase-3 that are TUNEL+ may be undergoing some other form of cell death that is not Caspase-3 dependent, such as necrosis. This possibility is consistent with the decreased TUNEL signal observed upon inhibition of Caspase-4 (Fig 5A,B)__. __However, we have reworded our conclusion to identify more clearly what the data indicate, and where we are drawing inferences.

      Fig3A: "IL1RN" should be changed for "IL1RA (IL1RN)" for consistency with Fig 3B.

      The heatmap shows gene expression data so IL1RN is more consistent with the gene nomenclature. However, we have added an asterisk to the label on the heatmap, along with a sentence in the figure legend to elucidate.

      Fig 4C: The authors should provide the percentage of infected cells rather than the number of bacteria per cell (this information can be included in supplementary).

      Percent infected cells has been moved to Fig 4C and the number of bacteria per cell has been moved to Fig 4D__.__

      FigS2: The different thicknesses of the epithelial layer observed between PBS and STM panels suggest a difference in scale. This may be double-checked by the authors.

      The images are scaled similarly – as noted earlier (S10 Fig), there is considerable natural variability between HIOs that is not correlated with any experimental condition in this study.

      Line 197-199, the authors claimed that uninfected cells may be observed in the cell lumen. This seems hard to observe/conclude at this resolution. The authors may show a non-infected cell at higher magnification. __

      We have added higher magnification images, uninfected cells are indicated with white arrows in S8 Fig.

      Discussion: Some important points should be added to the discussion. In particular, what is the fate of intracellular salmonellae after cell shedding? Can the bacterium survive cell apoptosis and burst out of the cell to re-infect the epithelium or be transferred to phagocytic cells during the clearance of intraluminal apoptotic cells? Previous studies showed that cytosolic hyper-replication could fuel cell shedding. The importance of bacterial load in PMN-induced cell shedding could be discussed.

      We have expanded the discussion to elaborate on what may happen to shed cells. One useful feature of the HIOs is that the enclosed lumen allows us to capture the cells to fully measure the extent of cell shedding, however in the intestine where there is flow these cells would be washed away and could help to reduce bacterial load in the intestine. This point is now made in lines 386-388 in the discussion.

      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      Major concerns

      1) The authors show that only ~5% of the neutrophils have migrated to the lumen, which is a barely noticeable increase compared to PBS treated organoids. Does this reflect that the mucosal layer of the organoids might not produce neutrophil chemoattractants and that neutrophil recruitment during Salmonella is a bystander effect from a different cell type?

      This number indicates that PMNs are ~5% of total cells in the PMN-HIO (including epithelial and mesenchymal cells) during Salmonella infection (not that only 5% of PMNs added migrated). Moreover, PMNs were added to a well containing multiple HIOs. We also show that HIOs do produce neutrophil chemoattractants during infection (S1 Fig).

      2) How quickly are neutrophils recruited to the HIOs? The authors show one time point of 8 hours. Related to the relatively low number of neutrophils seen in their HIOs, is this perhaps a result of the time point they chose? Will they see more neutrophils recruited if they go longer?

      It is likely that 5% of total cells in the PMN-HIO represents a significant recruitment of PMNs, and our data clearly indicate a marked effect on the infected epithelium. PMNs can cause substantial tissue damage, and their recruitment and activation is known to be tightly regulated. Due to the short-lived nature of human PMNs it would be difficult to extend this experiment to later timepoints. We have experimentally characterized PMN migration at 24h and by that time, most of the PMNs that we observe are non-viable, thus we focused our studies earlier.

      3) The authors show that PMNs did not kill STM in their organoids, but they do in pure culture. Is this simply because of the low levels of neutrophils present in their HIOs, which would result in lower concentrations of antimicrobials being produced in the HIO lumen? If the authors are able to get higher levels of neutrophils in their HIOs, would they see increased bacterial killing?

      Neutrophils have both inflammatory signaling and microbicidal functions. For example, Cho, et al (PLoS Pathogens 2012) find that neutrophil-derived IL-1 beta is sufficient to support abscess formation in the innate immune response to Staphylococcus aureus soft tissue infection. Similarly, a recent study showed that activation of neutrophils by keratinocyte defensins in a S. aureus skin infection led to neutrophil IL1 beta and CXCL2 release that amplified antibacterial defenses (Dong, et al Immunity 2022). Moreover, in the native environment of the gut with extensive microbiome colonization, direct neutrophil microbicidal activity might be less effective against infection than signaling. Recruitment of higher levels of neutrophils in vivo or in the HIO might exacerbate damage of the epithelial barrier. In the discussion, we speculate there may be proteins, like Elafin, that are upregulated during infection and inhibit some neutrophil functions as a trade-off to control host tissue damage. We reason that our data strongly support an inflammatory signaling role for neutrophils to promote innate immune responses of the intestinal epithelium.

      4) Related to the above point, if the authors treat their HIOs with known neutrophil chemoattractants, can they increase the number of neutrophils that migrate into their organoids?

      High levels of chemoattractants are already being produced in the HIO in response to infection (S1 Fig). The most effective number of neutrophils in the context of intestinal infection may not be the highest number, given that neutrophils can cause tissue damage. Since we see a marked phenotype with the neutrophils that are recruited, we propose that this PMN-HIO model reveals important inflammatory signaling roles for PMNs to promote intestinal epithelial immune function.

      5) The authors speculate that Salmonella may "employ specific mechanisms to overcome PMN effector functions in the HIO luminal environment". Are any such mechanisms known? If so, the authors could test this hypothesis by repeating these experiments with Salmonella mutants in which these mechanisms are ablated. In this case, they should see increased killing of Salmonella by PMNs in the HIO lumen.

      The focus of this study was to test how PMNs contribute to the host response against wildtype Salmonella. In the PMN-HIO model, we find that neutrophils direct a robust epithelial cell extrusion response, impacted intracellular bacterial numbers, and that Salmonella luminal colonization is not affected by PMNs. Thus, our data are pointing to an important inflammatory role for neutrophils in the infected intestine. Indeed, reliance on direct bactericidal mechanisms in the intestinal lumen which in vivo would be colonized with the microbiota might be a losing strategy for neutrophils, which would be hugely outnumbered.

      6) Furthermore there is no information of the activation status of the neutrophils. How does the surface expression of CD16 CD62L, CD66 and CD11b look between the migrated and non-migrated and between infected and uninfected controls? Did the neutrophils de-granulate? Are they CD63+ or is the high levels of NGAL and S100 proteins an effect of lysis? The authors should also be careful in claiming that there is NETosis as the image in the supplement look more like an artifact than actual NETs.

      Our new findings suggest that IL-1 production by PMNs is the biggest factor in driving the cell death phenotype. We have also added a figure with CD63 staining. We were able to visualize some localization of CD63 to the cell surface of PMNs, consistent with degranulation (S4 Fig).

      7) Why does ASC translocate to the nucleus? Is the IL-1b cleavage mediated through Caspase-1 or Caspase-11? The neutrophils stained positive in the lumen appear to be intact, does this mean that pyroptosis does not occur, or does the IL-1b come from cells that did not migrate through the mucosal membrane? Staining for IL-1 and the different caspases might help resolve this question.

      ASC does not appear to be translocating to the nucleus. In Fig 3D the green signal (ASC) is primarily excluded from the DAPI-stained area. In this human model, Caspase-11 is not present, and inhibition of Caspase-1 is sufficient to block the cell shedding phenotype (Fig. 5A,B and Fig. 6B,C). We are unable to distinguish whether IL-1 is being produced by intact PMNs or PMNs that are undergoing pyroptosis. Unfortunately, there are not suitable antibodies for fixed immunofluorescence staining for cleaved Caspase-1, and as a secreted protein, IL-1 beta likely will not remain localized with the producer cell.

      8) The authors comment that there is substantial TUNEL staining in the mesenchyme independent of STM or PMNs, however, there is no explanation for why this happens. Does this have any downstream effects on the neutrophils that doesn't migrate towards the lumen?

      TUNEL positivity in the mesenchyme is likely an artifact of culturing and we have noted this in the text (line 169-172). The extent of TUNEL+ mesenchymal cells appears to be dependent on the batch of HIOs as not all HIOs exhibit this phenotype (for example Figs 4A and 6B). In contrast, the extent of TUNEL+ luminal cells is significantly dependent on the presence of PMNs and Salmonella.

      Minor comments

      1) The authors should remove that MPO is neutrophil-specific, monocytes are known to have higher MPO expression than neutrophils.

      In this controlled co-culture system there are no monocytes, therefore we have modified our text to indicate that MPO is used as a neutrophil marker in the PMN-HIOs (line 161).

      2) If the authors performed flow cytometry as they say, they should provide the flow plots and the gating strategy they used in the supplement.

      Representative flow plots for the data presented in Fig 1A are now included in S2 Fig. The data shown in Figs. 1A and S2 Fig are not gated.

      Reviewer #3 (Evidence, reproducibility and clarity (Required)):

      Major Comments

      1.Overall the study is convincing and it is well-conducted. This reviewer found it surprising that the PMNs did not alter the total levels of STM in the HIOs as neutrophils are expected to control the infection. Can the authors elaborate on if the intraepithelial numbers are reduced, what happens to STM in the lumen? It would be convincing if the authors can extend the infection timeline to see if the neutrophils are capable of killing luminal STM. *

      One of the limitations of the HIO model is the lack of flow in the lumen. It is likely that shed cells would be removed from the body following extrusion in vivo. In the HIOs, since the cells are trapped in the lumen, Salmonella could then reinvade and so this phenotype might be even stronger in a model that incorporates flow. We have added this point to the discussion (lines 387-390). Due to the short-lived nature of PMNs, it is difficult to extend the infection beyond 8h. While in vitro experiments with just neutrophils and STM as we and others have performed might set the expectation that neutrophils would alter luminal bacterial levels, there is little to no direct evidence that neutrophil bactericidal activity is critical in the context of the intestinal environment (vs. releasing ROS or inflammatory signals that may have complex indirect effects). Indeed, an advantage of the HIO model is that we are able to test the function of neutrophils in a multi-component system, but one that is still sufficiently simplified that we can do some mechanistic analysis.

      2-It would be powerful to conduct the caspase inhibition on neutrophils prior to HIO co-culturing to convincingly show that the effects of caspase inhibition effect neutrophils which in turn effect the epithelium disrupting the epithelial load of STM.

      We appreciated this suggestion. We pretreated the PMNs with a Caspase-1 inhibitor for 1h prior to co-culture with infected HIOs. We found that this was sufficient to block TUNEL cell accumulation in the lumen of infected PMN-HIOs. These results are now presented in Fig 6B,C.

      3- While other caspases are well-established to be involved in Salmonella-related cell death and epithelial shedding, why did the authors picked caspase 3 but not caspase 4/5 to show activation in Fig 2?

      We have now also tested the role of Caspase-4 on cell shedding using z-LEVD-fmk inhibitor. Consistent with prior published studies, we found that Caspase-4 inhibition reduced the accumulation of TUNEL-positive cells in the PMN-HIO lumen. These results are presented in Fig 5. There are no detectable levels of Caspase-5 in the HIOs (S9 Fig).

      Minor comments

      Fig 1C It is not clear how the total bacterial burden was determined. Please include details such as the timepoint and sufficient details of the technique both in the results section and the legend.

      These details have been added in the figure legend (line 605-607). Briefly, HIOs were washed with PBS and homogenized in PBS at 8hpi. CFU/HIO were enumerated by serial dilution and plating on LB agar.

      • Fig S2. Authors claim that the PMNs form NETs in the lumen, however, the marker used in the immunostaining is MPO. Although a NETting is seen in the images, MPO staining is not sufficient to claim these are NETs. Additional staining is required to show if the neutrophils in the lumen are intact or formed NETs*.

      As noted in response to Reviewer #1, although we commented on NETs in our original manuscript, our conclusions do not rely on the presence or absence of NETs and our new data implicates PMN IL-1 as necessary and sufficient for the cell shedding phenotype. We have therefore removed the NET data and the reference to NETs. While NETs are potentially interesting in the context of intestinal infection, we understand the reviewer's concern about NETs and anticipate that a more quantitative characterization of NETs may be challenging given the structure and variability of the PMN-HIOs.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      The manuscript by Lawrance et al investigates a novel human intestinal organoid (HIO) model to elucidate the mechanisms of STM infection especially at the epithelium level. Previously, several studies had identified that epithelial cell death and extrusion of S. enterica infected cells regulate the infection outcome by reducing epithelial bacterial burden and restricting the infection to the intestine. However the mechanisms that drive this phenotype is not well understood. In this study authors use HIOs to investigate these interactions. HIOs were microinjected with STM and then seeded with primary human polymorphonuclear leukocytes (PMN-HIOs), specifically neutrophils and analyzed for bacterial growth and host cell survival. Authors made the critical observation that adding PMNs to infected HIOs lead to epithelial shedding and reduced bacterial burden that could be blocked by Caspase-1 or Caspase-3 inhibition. Overall, this is a novel study and establishes a novel model to study the PMN-epithelium interactions in the context of pathogens.

      Major Comments

      1. Overall the study is convincing and it is well-conducted. This reviewer found it surprising that the PMNs did not alter the total levels of STM in the HIOs as neutrophils are expected to control the infection. Can the authors elaborate on if the intraepithelial numbers are reduced, what happens to STM in the lumen? It would be convincing if the authors can extend the infection timeline to see if the neutrophils are capable of killing luminal STM.
      2. It would be powerful to conduct the caspase inhibition on neutrophils prior to HIO co-culturing to convincingly show that the effects of caspase inhibition effect neutrophils which in turn effect the epithelium disrupting the epithelial load of STM.
      3. While other caspases are well-established to be involved in Salmonella-related cell death and epithelial shedding, why did the authors picked caspase 3but not caspase 4/5 to show activation in Fig 2?

      Minor comments

      1. Fig 1C It is not clear how the total bacterial burden was determined. Please include details such as the timepoint and sufficient details of the technique both in the results section and the legend.
      2. Fig S2. Authors claim that the PMNs form NETs in the lumen, however, the marker used in the immunostaining is MPO. Although a NETting is seen in the images, MPO staining is not sufficient to claim these are NETs. Additional staining is required to show if the neutrophils in the lumen are intact or formed NETs.

      Significance

      see above

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      The authors have submitted a manuscript aiming to distinguish the role of neutrophils during the onset of Salmonella infection. In contrast to the expected results, the authors propose that the neutrophils have a regulatory role in mediating intestinal integrity rather than antimicrobial effects. However, the data supporting this statement are not provided. Although the authors provide some very interesting findings there are some flaws that need to be addressed.

      Major concerns

      1. The authors show that only ~5% of the neutrophils have migrated to the lumen, which is a barely noticeable increase compared to PBS treated organoids. Does this reflect that the mucosal layer of the organoids might not produce neutrophil chemoattractants and that neutrophil recruitment during Salmonella is a bystander effect from a different cell type?
      2. How quickly are neutrophils recruited to the HIOs? The authors show one time point of 8 hours. Related to the relatively low number of neutrophils seen in their HIOs, is this perhaps a result of the time point they chose? Will they see more neutrophils recruited if they go longer?
      3. The authors show that PMNs did not kill STM in their organoids, but they do in pure culture. Is this simply because of the low levels of neutrophils present in their HIOs, which would result in lower concentrations of antimicrobials being produced in the HIO lumen? If the authors are able to get higher levels of neutrophils in their HIOs, would they see increased bacterial killing?
      4. Related to the above point, if the authors treat their HIOs with known neutrophil chemoattractants, can they increase the number of neutrophils that migrate into their organoids?
      5. The authors speculate that Salmonella may "employ specific mechanisms to overcome PMN effector functions in the HIO luminal environment". Are any such mechanisms known? If so, the authors could test this hypothesis by repeating these experiments with Salmonella mutants in which these mechanisms are ablated. In this case, they should see increased killing of Salmonella by PMNs in the HIO lumen.
      6. Furthermore there is no information of the activation status of the neutrophils. How does the surface expression of CD16 CD62L, CD66 and CD11b look between the migrated and non-migrated and between infected and uninfected controls? Did the neutrophils de-granulate? Are they CD63+ or is the high levels of NGAL and S100 proteins an effect of lysis? The authors should also be careful in claiming that there is NETosis as the image in the supplement look more like an artifact than actual NETs.
      7. Why does ASC translocate to the nucleus? Is the IL-1b cleavage mediated through Caspase-1 or Caspase-11? The neutrophils stained positive in the lumen appear to be intact, does this mean that pyroptosis does not occur, or does the IL-1b come from cells that did not migrate through the mucosal membrane? Staining for IL-1 and the different caspases might help resolve this question.
      8. The authors comment that there is substantial TUNEL staining in the mesenchyme independent of STM or PMNs, however, there is no explanation for why this happens. Does this have any downstream effects on the neutrophils that doesn't migrate towards the lumen?

      Minor comments

      1. The authors should remove that MPO is neutrophil-specific, monocytes are known to have higher MPO expression than neutrophils.
      2. If the authors performed flow cytometry as they say, they should provide the flow plots and the gating strategy they used in the supplement.

      Significance

      The addition of neutrophils to human intestinal organoids in the context of infection with a bacterial pathogen is an advance in the field. The findings would be of interest to many fields of research including host-pathogen interactions, innate immunity and neutrophil experts. Based on my expertise in innate immunity and bacterial pathogenesis, I believe that i can offer appropriate suggestions for improving the study.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      Summary:

      To address the question of the role of neutrophils in controlling epithelial cell response during bacterial infection, the authors developed an ambitious model of human intestinal organoid (HIO) micro-injected with Salmonella and co-cultured with polymorphonuclear leukocytes (PMNs). They could observe the transmigration of PMNs within the HIO lumen upon infection, associated with an increased epithelial cell extrusion and a decreased association of extracellular salmonellae with the epithelium. The authors analyzed the specific transcriptomic signature of PMN-HIOs during infection as well as the cytokine release. They further linked the cell shedding phenotype with Caspase 1 and Caspase 3 cleavage, the decreased intraluminal bacteria burden with Caspase-1 activity, and the decreased Salmonella association with the epithelium with Caspase 3 activity.

      Major comments:

      Some important links are missing to fully support the mechanistic model proposed:

      1- PMN activity

      The authors may strengthen their evidence of PMN activities presented in lines 135 to 143 and in Fig.S2 and S3. In particular, the authors claim that PMNs form NETs in PMN-HIOs but the evidence displayed are limited. In fact, Fig S2 shows the same condition and same staining as Fig 1B but the MPO-positive structures are different. Clarification in the text or the figure would be welcome. Besides, as the authors insist on the relevance of NETs in the discussion, it seems that a clear demonstration and characterization of these structures in the PMN-HIO model would highly benefit the manuscript.

      Regarding the analyses of the culture supernatants (Fig.S3), only 3 out of the 5 displayed datasets are commented on in the text. The data obtained for BD2 and N-Gal should be either commented or removed from the figure. The author further suggests that Elafin expression in presence of PMN may restrict PMNs' ability to kill Salmonella. Repeating the experiment displayed in Fig S1 in the presence of Elafin as well as in the presence of the supernatant extracted from HIOs and PMN-HIOs would clarify the potential inhibition of PMN killing capacity in the PMN-HIO model.

      The author proposed that infected and uninfected cells are extracted from the epithelium due to PMN activation, suggesting that Salmonella infection of epithelial cells is only indirectly involved in cell shedding. This is an interesting hypothesis that could be tested by measuring cell shedding in a non-infected but PMN-activated (for instance with PMA) PMN-HIO model. This would clarify further the role of PMN in controlling epithelial response to the infection.

      2- Specificity of RNA-seq profiling:

      The authors analyzed the transcriptomic profiling of PMN-HIOs and HIOs infected or not. While these experiments bring to light an interesting difference in inflammasome/cell death transcriptomic programs at the scale of the co-culture model, it is not possible to conclude from which cell type these transcriptomic shifts emerge. To clarify this, the authors stain the co-culture for ASC and observe that ASC-positive cells are PMNs. They conclude that PMNs are most likely the primary site of caspase-1 dependent production of IL1. While their model is theoretically consistent, more direct proofs are necessary to conclude on the cell-type specific transcriptomic program during infection of PMN-HIO and could be obtained by FACS sorting of the cells prior to RNA-seq, for instance using MPO to detect PMNs and E-cadherin to detect epithelial cells.

      3- Roles of cytokine

      After showing an increased expression/release of IL1 and IL1RA in infected PMN-HIOs, the authors move on to testing the role of caspases on cell shedding. Yet, they do not test the impact of IL1 and IL1RA on cell shedding. As, according to their proposed model, IL1 is acting upstream of caspase-1 to promote cell shedding, testing cell shedding in infected PMN-HIOs in the presence of an IL1 inhibitor would clarify that link. The author also proposed that the decrease of IL33 in PMN-HIOs compared to HIOs could be due to PMN processing, which would give an additional role to PMNs in controlling the epithelial response to infection. In the context of this manuscript, it would be highly relevant to test this hypothesis by measuring the rate of cleaved IL-33.

      4- Roles of caspase

      The interpretations of the role of Caspases to restrict bacteria burden are unclear and should be revised (see also minor comment). It appears that both Caspase-1 and Caspase-3 are necessary for efficient cell shedding (Fig4B), Caspase-1 (but not Caspase-3) decreases intraluminal bacteria burden (Fig4C) and Caspase-3 (but not Caspase-1) decreases epithelium-associated bacteria (Fig4D). To reconcile these observations with the hypothesis that cell shedding is responsible for the decrease of intraluminal and epithelium-associated bacterial burden, one may propose that caspase-3 (but not caspase-1) induces cell shedding of mainly non-infected cells (possibly bacteria-associated) and caspase-1 (but not caspase-3) induced cell shedding of infected cells. This could be tested by measuring the % of infected extruded cells upon caspase inhibitor treatments. In addition, these data don't allow to propose that Caspase-3 activation happens downstream of Caspase-1 as suggested by the authors in their abstract figure.

      Minor comments:

      The majority of the points listed below can be addressed with further analyses of pre-acquired data sets:

      Fig1E/1F/4D: each green dot is not likely to be individual bacteria but rather a cluster of bacterium (based on their size). So the y-axis in Fig 1E and Fig4D should not be #STM.

      Fig2A: Variations in organoid size and epithelial thickness can be observed between figures. In particular, in Fig 2A, the HIO seems much younger than the other ones displayed in the manuscript. Line 176 to 178, the authors mentioned the TUNEL+ cells in the mesenchyme but rule out the possibility that this phenotype could be infection or PMN-dependent because it is observed in the different conditions. As the picture displayed in Fig2A suggests high differences in the number of TUNEL+ cells in the mesenchyme under the 4 tested conditions, the authors should still quantify this phenomenon (possibly in the supplementary). "DAPI" should be written in blue.

      Fig2C: Could the authors comment on the % of E-cadherin cells that are also TUNEL+? Is it 100%?

      Fig 2D: The point made on lines 182 to 186 that HIOs contain TUNEL + cells retained in the epithelial lining in the absence of PMNs is not very strongly supported by Fig 2D. Quantification of the number of intraepithelial TUNEL+ cells in the 4 compared conditions would make a more solid case.

      Fig2E: This experiment should be completed with a quantification of the percentage of TUNEL+ cells that are also cleaved caspase3-positive. The data, as currently displayed, do not prove that the cells negative for cleaved caspase 3 are apoptotic cells and thus do not support the sentence "suggesting that multiple forms of cell death were occurring in the PMN-HIO" (line 194).

      Fig3A: "IL1RN" should be changed for "IL1RA (IL1RN)" for consistency with Fig 3B.

      Fig 4C: The authors should provide the percentage of infected cells rather than the number of bacteria per cell (this information can be included in supplementary).

      FigS2: The different thicknesses of the epithelial layer observed between PBS and STM panels suggest a difference in scale. This may be double-checked by the authors. Line 197-199, the authors claimed that uninfected cells may be observed in the cell lumen. This seems hard to observe/conclude at this resolution. The authors may show a non-infected cell at higher magnification.

      Discussion: Some important points should be added to the discussion. In particular, what is the fate of intracellular salmonellae after cell shedding? Can the bacterium survive cell apoptosis and burst out of the cell to re-infect the epithelium or be transferred to phagocytic cells during the clearance of intraluminal apoptotic cells? Previous studies showed that cytosolic hyper-replication could fuel cell shedding. The importance of bacterial load in PMN-induced cell shedding could be discussed.

      Significance

      The manuscript is very clearly written and easy to follow for a broad audience. The model developed is cutting-edge and allows both testing previously established knowledge in a more physiological model and addressing new questions. In addition, this model may be adapted to other pathogens and is thus widely relevant to the fields of host-pathogen interactions and immunity. Using this model, the authors could investigate the cross-talk between the epithelium and neutrophils during Salmonella infection.

      Yet, the mechanisms proposed by the authors remain at a speculative level and are not clearly/fully demonstrated by the data. In particular, the mechanistic investigation of caspase signaling linked to PMN-induced epithelial cell shedding is limited.

      In conclusion, the model put in place by the authors opens many interesting opportunities, some of which are addressed by the authors but not investigated in-depth within this manuscript. Addressing the major points aforementioned would however extend the mechanical understanding of PMN implication in epithelial defense, making the manuscript more suited for mechanism-oriented journals with broad audience.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      This is already a full revision, not a revision plan. All points were carefully addressed. TMF

      July 28, 2022

      RE: Review Commons Refereed Preprint #RC-2022-01555

      Dear Dr. Fuchs,

      Thank you for sending your manuscript entitled "Dissecting the invasion of Galleria mellonella by Yersinia enterocolitica reveals metabolic adaptations and a role of a phage lysis cassette in insect killing" to Review Commons. We have now completed the peer review of the manuscript. Please find the full set of reports below.

      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      In this manuscript Saenger et al. concentrate on the pathophysiological details of insect larvae infection by Yersinia enterocolitica. The authors studied the colonisation, proliferation, tissue invasion, and killing activity of the bacteria in Galleria mellonella larvae. Their study provides valuable evidence for the biological relevance of Tc toxins and a neighboring holin-endolysin cassette during establishment of Y. enterocolitica infection in Galleria mellonella larvae through the oral route. The findings of the authors provide important novel insights, that can be used for the development of Tc toxins as biopesticides.

      In general, this is a nice study. The data and the methods are presented well so that they can be reproduced and the key conclusions convincing.

      Unfortunately, the manuscript is sloppily written in some places, including grammatical and formatting errors. Citations regarding the structure and mechanism of action of Tc toxins are arbitrarily chosen, often taking the wrong ones and important aspects are left out. I highly recommend that the authors read the review of Roderer and Raunser 2019 that nicely describes and summarizes the molecular mechanism of Tc toxins.

      Answer: We have now improved the writing of the manuscript and corrected several errors and typos. In particular, the review by Roderer and Raunser, as well as other literature in the field, is now considered and cited in the text.

      The abstract ends with a speculation: "Suggesting that this dual lysis cassette is an example for a phage-related function that has been adapted for the release of a bacterial toxin" - this is likely true, but not proven in this work. What if it is used for the release of something else like extracellular DNA needed for biofilm formation (see https://doi.org/10.1038/ncomms11220)?

      Answer: This sentence was carefully written as a hypothesis strengthened by the data obtained in our study. Experimental evidence for this assumption is the strong correlation of toxin and HE cassette phenotypes of mutants (see abstract), the highly conserved localisation of the cassette within Tc loci of distinct bacterial genera (see discussion for literature), and the synchronic regulation of both the toxin and the lysis genes (manuscript in preparation). Moreover, strain W22703 is unable to form biofilms in contact with invertebrates (Spanier et al., AEM 2010). There, also in accordance with other reviewers, we would like to keep this statement in the text. However, to address this interesting point, we now mention the finding of Turnbull et al. in the discussion (see last paragraph).

      In addition to that, several outstanding issues must be addressed:

      1. Line 45 3-D structural analysis of the tripartite Tc suggests a 4:1:1 stoichiometry of the A, B and C subunits, with the A subunit forming a cage-like pentamer that associates with a tightly bound 1:1 sub-complex of B and C. This is wrong. The stoichiometry is 5:1:1 and the structure is not a cage. The statement was taken from citation 3. However, citation 3 should not be used, since the stoichiometry as well as the structure that was determined there is wrong. Use Landsberg et al. 2012 PNAS, Gatsogiannis et al. 2013 Nature instead.

      Answer: We apologize for misunderstanding the literature. Reference Lee et al. was removed here, and the two papers plus Meusch et al. (Nature, 2014) are now cited. The stoichiometry was corrected, “cage” was removed.

      "Few bacteria are known to successfully colonize and infect invertebrates" - needs a reference.

      Answer: This was modified to “Several bacteria…”, and we cite the recent paper by Weber and Fuchs (in press) that in Table 7g lists more than 40 bacterial species pathogenic towards insects.

      "Their oral insecticidal activity is comparable to that of the Bacillus thuringiensis- (Bt)- toxin" - reference missing.

      Answer: The reference is now cited (Bowen et al., Science 1998). Please see the last paragraph of the paper.

      "Type a, type b and type c" subunits is not usual for the literature. Please use TcA, TcB, TcC. A-, B-, and C-components should be abbreviated as TcA, TcB and TcC respectively in order to be in line with recent literature on the topic.

      Answer: This was corrected accordingly.

      Is TccC an ADP-ribosyltransferase or does it have a different biochemical activity?

      Answer: This is unknown with respect to the Tc of Y. enterocolitica. In the introduction, we now refer on P. luminescens and do not further attribute such a function to the TcC of Y. enterocolitica. In the abstract, we replaced “ADP-ribosylating” with “toxic”.

      "The toxic and highly variable carboxyl-terminus of TccC that has recently been demonstrated to ADP-ribosylate actin and Rho-GTPases" - this is only certain for TccC3 and TccC5 from P. luminescens. There are many such C-termini, called HVRs which have not had their activities determined yet, see here: https://doi.org/10.1371/journal.ppat.1009102

      Answer: We agree and cite this article. See also the response to comment 5 above.

      "is probably followed by receptor-mediated endocytosis" - more recent references exist for the receptor binding of Tc toxins.

      Answer: We added two references pointing to glycans as receptors of the Tc (line 52).

      "A pH decrease then triggers the injection of a translocation channel formed by the pentameric TcaA subunits into the endosomal vacuole, followed by the subsequent release of the BC subcomplex into the cytosol of the target cell" - this again is incorrect. Please read the above mentioned review and correct this passage accordingly.

      Answer: We agree. This phrase was rewritten to “The attachment of the Tc to the host cell membrane is either followed by receptor-mediated endocytosis or release of the ADP-ribosyltransferase into the target cell {Landsberg, 2011 #738;Sheets, 2011 #742}{Meusch, 2014 #788}. In a pH-dependent manner, the TcA translocation channel injected into the membrane of the host cell. Conformational changes then allow the toxic component to be released into the translocation channel of TcA and from there into the cytosol {Meusch, 2014 #788}{Roderer, 2019 #871}.” (Lines 51-56)

      What is meant by "environmental Yersinia species"?

      Answer: This was corrected to “…and in Y. mollaretii.”

      In the relevant W22703 pathogenicity island sequence (https://www.ncbi.nlm.nih.gov/nuccore/AJ920332) previously submitted by the same group, something odd is going on with the TcA component: it appears to be split into three polypeptides (tcaA, tcaB1, tcaB2). In the manuscript you state TcA is made up from only tcaA and tcaB. Could you please address this?

      Answer: Shotgun sequencing was performed 15 years ago, and mapping revealed a frameshift within tcaB that resulted in the split annotation of tcaB. Even if this frameshift is not the result of a sequencing error, it obviously does not result in Tc inactivation. As this frameshift was not identified in most other Tc-PAI of yersiniae, we assume our statement to be correct.

      "And their products were recently shown to act as a holin and an endolysin, respectively" - missing reference.

      Answer: The reference is now cited (Springer et al., JB 2018).

      "Its Tc proteins are produced at environmental temperatures, but silenced at 37{degree sign}C." versus "Remarkably, HolY and ElyY lyse Y. enterocolitica at body temperature, but not at 15{degree sign}C". Please address the issue that HolY/ElyY lyse the bacteria at temperatures where Tc proteins are not produced.

      Answer: In the absence of in vitro conditions activating the HE gene cassette, we used the pBAD system to artificially overexpress the two genes and showed cell lysis at 37°C, but not at 15°C (Springer et al., JB, 2018). This finding points to a lack of cell lysis as prerequisite for TC release and strengthens the hypothesis of a new secretion system as now corroborated in the last paragraph of the discussion. To avoid confusion of readers, the sentence was removed from the manuscript.

      "Nematodes, which are easily maintained in the laboratory without raising ethical issues, have successfully been used to identify virulence-related genes in a broad set of bacterial pathogens" - what is the relevance of this for the current manuscript?

      Answer: Invertebrates are introduced here as infection models. Nematodes are mentioned here for two reasons: yersiniae are nematocidal due to the Tc, and their immune system is less elaborated than that of G. mellonella, thus explaining its preferred use as insect model. We shortened the sentence by deleting the phrase in commas.

      Fig. 1C - no description is given for the labels 1-8.

      Answer: This is given below figures 1E-H. The labels are valid for all figure panels to ease reading.

      "The hemolymph of these cadavers was found full of Y. enterocolitica cells" - injected CFUs are provided here, but not final CFUs in the cadavers (although referred to in a later section). Please address this.

      Answer: These were preliminary experiments to identify the optimal infection dose. Hemolymph content was plated, but cell numbers in the hemolymph were not enumerated. This sentence therefore now reads: “…and the hemolymph of these cadavers contained Y. enterocolitica cells.” (lines 113-114).

      What is the inducing agent used for pACYC-tcaA and pACYC-HE? Why would "slight leakiness of the pBAD-promoter" make pBAD-tccC non-inducible? Were colonies taken from the cadavers to verify that the bacteria still contained these plasmids?

      Answer: Within pACYC, the genes tcaA and hlyY/elyY (HE) are under control of their own promoters as indicated in Table S2. In general, pACYC vectors are often and successfully used for complementation due to middle copy number.

      This now reads “Due to the slight leakiness of the pBAD-promoter, arabinose was not added to further induce tccC transcription.” (lines 133-134).

      The presence of the plasmids in vivo was confirmed by periodic plating on selective and non-selective plates, not revealing differences in cell numbers.

      Can the authors please address the TD50 of 1.83 days for W22703 ΔHE/pACYC-HE versus 3.67 days for WT bacteria? This would mean that the former kill larvae twice as fast as usual. I would not call this "did not significantly differ in their insecticidal activity".

      Answer: This statement is indeed not very intuitive given the variations of the TD50-values. However, the significance here (and elsewhere in the text) is based on a statistical calculation. For the Kaplan-Meier-plot, we used an application (K.T.Bogen, Advances in Molecular Toxicology, 2016; Exponent Health Sciences, Oakland, CA, United States; Johann Kummermehr, Klaus-Rüdiger Trott, Stem Cells, 1997; Academic Press, London, San Diego) based on all data of a graph. However, to consider this point and to not confuse the readers, the phrase was modified to “…did not significantly differ in their insecticidal activity from that of the parental strain W22703 after one week, demonstrating…” (lines 135-138).

      Fig. 2 is missing survival data for larvae infected with tcaA, HE, and tccC KO bacteria.

      Answer: These data are shown and are equal to the LB-control, e. g. the survival rate of larvae infected with strains W22703 lacking HE, tcaA, or tccC were 100%.

      "And a slight colouring of some of the larvae from one h p.i. on (data not shown)" - best show the data or remove this statement.

      Answer: Although we observed this phenomenon regularly, monitoring and documentation cannot be provided and would not substantially strengthen the manuscript. We therefore deleted this phrase.

      The infection of larvae by W22703 ΔtccC/pBAD-tccC is missing, the other bacterial variants are present. Please address this.

      Answer: Infections with W22703 DtccC are not shown to not overload the figure, please see the panel below. W22703 DtccC/pBAD-tccC infections have not been documented by photos. Figure legend 3 now reads “Infections with W22703 DtccC and DtccC/pBAD-tccC are not shown.”

      "initially proliferated from an application dose of 4.0 × 105 CFU and 4.0 × 105 CFU, respectively, to 2.2 × 106 CFU and 2.8 × 106 CFU, but could not be detected from day three on. This finding strongly suggests that TcaA is involved in adherence to epithelial cells and thus in midgut colonization". Please address the "initially proliferated" (which day post-infection?), their elimination from the larvae (how, why?), why the tccC KO bacteria were more virulent than tcaA KO bacteria, and where the suggestion about TcaA involvement specifically in adherence comes from.

      Answer: “initially proliferated” was rewritten to “proliferated within the first day p.i.”. (line 163)

      Elimination: This now reads “…was completely absent six days p.i., probably due to passage through the gut followed by excretion”. (lines 161-162)

      In our view, the tccC knockout mutant is not more virulent than W22703 DtcaA (se Fig. 2), but replicates during the first day post infection, whereas the cell numbers of the tcaA KO mutant strongly decrease already within the first 24 h p.i.. This prompted us to speculate that Tc is involved in two infection steps, e.g. adherence and hemocyte inactivation. For clarity, this sentence was modified to: “This discrepancy suggests that TcaA is involved in adherence to epithelial cells and thus in midgut colonization, without requiring TccC.” (lines 165-166)

      In Fig. 4, the CFUs for W22703 ΔtccC/pBAD-tccC are essentially the same as for the other rescued KOs and WT, while in the text a point about weaker growth is made. Is this justified? Also, even though the CFU data is present here, data on infection of larvae by W22703 ΔtccC/pBAD-tccC is missing unlike the other bacterial variants. Please explain.

      Answer: We agree that this part of the results is misleading. We want to stress that the complementation very well restores the phenotype of the wildtype. The weaker growth of DtccC may be due to the distinct vector system used here. This part was there shortened and rephrased to: “When larvae were infected with 4.0 × 105 CFU of the DtcaA and DHE mutants, and with 1.4 × 106 CFU of strain W22703 DtccC/pBAD-tccC, all of which carrying the deleted genes on recombinant plasmids, the bacterial burden at days one to six p.i. increased approximately to that of the parental strain W22703 applied with 9.0 × 105 CFU, indicating a successful complementation of the gene deletions.”

      ” (lines 166-170).

      Missing data on W22703 ΔtccC/pBAD-tccC infection in Fig. 3, please the answer to point 20 above.

      Fig. 6b - The presence of an anti-RFP signal is not obvious in any of the bottom row images. The top row images are missing the same kind of annotation provided for Fig. 6a, without which non-histologists will find understanding the figure difficult.

      Answer: The anti-RFP signal is visible only on the left photo of the bottom panel, and not in the other three photos as explained in the text. We understand that the signals are not very strong, but they are visible on the screen.

      "In the absence of the lysis cassette, however, TcaA::Rfp was not detected despite the presence of W22703 ΔHE tcaA::rfp cells." + "To test whether or not the promoter of the lysis cassette is active in vivo, we infected G. mellonella larvae with strain W22703 PHE::rfp. Although Y. enterocolitica cells densely proliferated within the hemolymph (FIG. 6B), no staining signal that would point to the presence of TcaA was obtained, possibly due to no or weak PHE activity." Does this mean that without HE, tcaA does not express?

      Answer: No, we performed Western Blots showing that TcaA is detected in cells lacking HE. Therefore, a negative feedback regulation (e. g. increasing intracellular amounts of TcaA repress its own transcription) can be excluded. This is also in line with the low transcriptional activity of the lysis cassette in vivo (new Fig. S1B).

      "These data suggest that the HE cassette is responsible for the extracellular activity of the insecticidal Tc." Please explain how the preceding paragraph leads to this conclusion.

      Answer: This was poorly written and now reads “…for the transport…” (line 224).

      "As expected, bacterial cells, e.g. Y. enterocolitica, are visible in the hemolymph obtained from W22703-infected animals, but not in all other preparations." - which figure are the authors referring to?

      Answer: We have indeed identified, but not immunostained, bacterial cells in those preparations, but they are not visible in Fig. 7. This sentence was removed. However, the presence of W22703, but not its tc-PAIYe-mutants, in the hemolymph is demonstrated in Fig. 6A.

      "To delineate the transcriptional profile of Y. enterocolitica during infection of G. mellonella, we applied immunomagnetic separation to isolate Y. enterocolitica from the larvae 12 h and 24 h after infection" - do the authors store the bacteria for up to 24 h at 4 {degree sign}C, as indicated in the methods section?

      Answer: Yes, the probes were stabilized with RNAlater and then stored up to 24 h to synchronize all samples of one experiment.

      "The endolysin located within Tc-PAIYe was significantly up-regulated after 24 h, but not after 12 h, pointing to its possible role in the release of the Tc" - I could not find the endolysin in Table S1. Could the authors mark it clearly? Also, why is the holin also not upregulated?

      Answer: The endolysin gene is lacking in Table S1 due to its FC=1.02. We now added a table to Fig. S1 that shows the FC values of all genes from Tc-PAIYe. The FC-value of holin gene is 0.87, thus pointing to a very slight transcription of this lysis gene as discussed, thus preventing cell death.

      "This is in line with the fact that a T3SS is lacking in strain W22703" - Is a complete genomic sequence available for this strain, so readers could validate this statement?

      Answer: The genome sequence is available, and the reference is now cited (line 358). The common virulence plasmid of yersiniae, pYV that encodes the T3SS, is missing in this strain. We do not mention here the presence of a second, but probably incomplete, chromosomally encoded T3SS in strain W22703 do not overload the manuscript.

      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      This is a very, very nice study as it actually describes the role of different Tc toxin components in a model infection system using an important bacterium- really for the first time in a properly controlled manner. The mutants lacking either the syringe (AB) or the bullet (C) make 'sense' for a loss of function perspective. The description of the phage cassette in loss of function is also interesting and could do with some more speculation? For example, some groups of Photorhabdus bacteria release their oral toxicity (Tc's) into their bacterial supernatants- whereas in others it remains cell associated. The likely role of this phage cassette in this process should be discussed (is cell suicide required for release?).

      Answer: We now discuss the possibly role of the lysis cassette in more detail, including the possibility that a subpopulation commits cell suicide (see lines 375-396).

      Reviewer #2 (Significance (Required)):

      This is highly significant finding as despite all of the very elegant structural studies done on these important toxins there is still very little work in vivo. These studies clearly show the role of the different components of these ABC toxins in vivo. It should be published with priority.

      Congratulations to the authors.

      Reviewer #3 (Evidence, reproducibility and clarity (Required)):

      Summary: The authors analyze the phases of infection of Galleria mellonella by Yersinia enterocolitica following forced oral feeding. They study different phases of infection, including survival within the gut and invasion of the hemolymph. By analyzing differences in the genes up- and down regulated, they show that for example transporters for food sources from the hemocoel are regulated for making those sources available for the bacteria.

      Major comments: This is an interesting paper demonstrating genes of Y. enterocolitica dependent for colonization, growth and crossing of the epithelial gut barrier in G. mellonella.

      Major points which have to be addressed:

      Introduction: line 54: the BC subcomplex is not released into the cytosol! It is only the hypervariable region (enzymatic part) which enters the cytosol. This has to be corrected.

      Answer: This has been corrected accordingly.

      Fig.2/3: Why have different CFU been used for the distinct bacterial strains? This does not allow a direct comparison of their toxicity. For me the dead larvae shown in Fig. 3 are not represented in Fig 2 (data are not concordant), because of the loss before day one depicted in Fig. 2: The curves should be normalized to the same starting point (should be 100 %)?

      Answer: We would like to stress here that infection doses are hard to reproduce if frozen and diluted stocks are used. We decided for overnight culture to better mimic natural conditions and controlled each culture for its viable cell numbers by plating. Moreover, we choose the infection doses in a conservative manner, e.g. the number of mutants was higher than that of the parental strain.

      The data of Fig. 3 are concordant with Fig. 2 for two reasons: First, this experiments was performed in replicates with a total of 36 larvae per strain (see Fig. 2 legend), so that representative photos are shown. Second, larvae were considered dead if they failed to respond to touch, and many larvae without strong sign of melanisation were already killed.

      We analysed the algorithmus of the Kaplan-Meier-plot. All graphs start at 100%, this is now mentioned in the legend. There are no data between day 0 and day 1, and a stepwise graph is essential for this plot.

      Fig. 3: Why is the strain W22703 delta tccC/pBAD - tccC missing in the data set?

      Infections with W22703 DtccC are not shown to not overload the figure, please see the panel below. Answer: W22703 DtccC/pBAD-tccC infections have not been documented by photos. Figure legend 4 now reads “Infections with W22703 DtccC and DtccC/pBAD-tccC are not shown.”

      Minor: line 221: "the" is doubled

      Answer: This has been corrected accordingly.

      Reviewer #3 (Significance (Required)):

      The manuscript shows the use of G. mellonella as a straight foreward method to study gene functions of pathogenic bacteria, a significant knowledge for scientists of the field.

      Reviewer #4 (Evidence, reproducibility and clarity (Required)):

      Summary: Provide a short summary of the findings and key conclusions (including methodology and model system(s) where appropriate).

      Answer: There are already three sections that summarize the results and the methods applied, namely the abstract, the last paragraph of the introduction, and the conclusion following the discussion. In our view, a further summary would overload the manuscript. Nevertheless, depending on the journal the manuscript will be published in, an additional authors´ summary would be provided.

      Outlines proposed role of lysis cassette in oral infection of Galleria as a model insect for host pathogen interaction, data which is fortified through use of histology and RNAseq.

      Introduction could extend to additional background eg Aleniz et al and other entomopathogen transcriptome data, more so other studies using Yersinia and Galleria as a model (refer references provided in the below comments)

      Answer: We again carefully screened PubMed for studies in the field and added few papers. However, in vivo transcriptome analyses are still rare, as indicated by a lack of a respective investigations with the highly relevant entomopathogen Photorhabdus luminescens. The literature suggested by the reviewer is now cited in the introduction and the discussion (see below for details).

      The strength of the paper lies in understanding the progression of the disease in the insect host as mentioned L316-317 and clearance of the bacteria via in TcaA mutant

      Major comments: - Are the key conclusions convincing? Yes for mode of action Fig 5 could have additional panels -this is a strength of the paper

      Answer: We agree that this time course is a strength of the paper, and we carefully selected representative photos. There are several to be shown, but to our view, they are rather illustrative than providing a substantial additional value.

      Fig 6 legend could better describe the observed insect components

      Answer: The insect components are now indicated in Fig. 6B and in Fig. 5.

      Figure 7 may be lost in PDF conversion -the figure appears un resolved? are there more high resolution photos

      Answer: Fig. 7 was present in the merged PDF provided by the publisher. We used the photos with the best resolution.

      • Should the authors qualify some of their claims as preliminary or speculative, or remove them altogether? the data provided is in places rudimentary (i.e. validation of the role of the lysis cassette in virulence) and could be bolstered with the construction and use of a lysis translational reporter etc I was left unsure how the HE::rfp and TcA::rfp constructs were made. I had assumed red florescent protein however it appears an antibody is used. This needs to be clarified as I then found it hard to interpret the results.

      Answer: The transcriptional PHE::rfp fusion is mentioned in the results section, but immunostaining failed probably due to a very low promoter activity (line 223). This is well in line with the transcriptome data. Please see a detailed answer how the HE::rfp and tcaA::rfp were constructed below. We applied the RFP-antibody for two reasons: first, fluorescence microscopy did not reveal clear red fluorescence in the tissue sections, and second, a TcaA antibody failed to match quality criteria for this purpose.

      It appear l114-125 that their may be enough data to derive a LD50 values and or LT value at a fixed dose - if so reporting this data of interest. It may also allude as to why a 10e5 dose was selected for subsequent expts

      Answer: This is an interesting point. The LD50 (dose of cells that kills 50% of all larvae) is usually not calculated in publications in this field of research, because its calculation requires a very huge separate data set that cannot be used to answer the questions addressed here. Such a dat set is not available. We published the dose-dependent toxicity of Y.enterocolitica W22703 upon subcutaneous injection, and from these data, we determined a LD50 for this strain of approximately 2 x 104 cells. The paper is cited in our manuscript. The 10E05 dose was selected due to our preliminary work and the reproducibility of the experimental phenotypes.

      • Would additional experiments be essential to support the claims of the paper? Request additional experiments only where necessary for the paper as it is, and do not ask authors to open new lines of experimentation. Use of lysis the reporter - discuss commonalties of the in host transcriptome with other Yersinia Galleria systems eg Paulson etc al (refer below). Are there any thoughts on the host range of this Yersinia and can this be placed in a pathogen host evolutionary context?

      Answer: Paulson et al. are now cited twice in the text. The host range of Yersinia enterocolitica has not been investigated to our knowledge. However, its nematocidal activity has been described by Spanier et al., and Manduca sexta larvae, the tobacco hornworm, is also killed by W22703 (see references). Moreover, there are two copies of tccC in the genome of strain W22703 encoding the cytotoxic Tc subunit with its hypervariable C-terminus that is assumed to contribute to host specificity. This is discussed in very detail by Song et al. (see references).

      Evolution: Yes, this has been addressed by Waterfield et al. 2004 (see references) where insects are hypothesized as a source of emerging pathogens. We placed our findings in the context of this article in lines 91-94 and 305-310.

      • Are the suggested experiments realistic in terms of time and resources? It would help if you could add an estimated cost and time investment for substantial experiments. Yes

      • Are the data and the methods presented in such a way that they can be reproduced? yes but I think some vector construction methodology is missing e.g. ::rfp (refer above)

      Answer: The plasmids used to construct the two strains W22703 tcaA::rfp and W22703 PHE::rfp are listed in Table S2. References for details are given (Starke et. al., 2013, Starke and Fuchs, 2014). Briefly, we used a suicide vector (pUTs) carrying the gene encoding the red fluorescent protein (RFP). This vector replicates in E. coli helper strains such as SM10, but not in Y. enterocolitica. Strain SM10 is now listed in Table 2. Following conjugation, the construct is chromosomally inserted upon recombination via the fragments cloned into the plasmid. In case of tcaA, we cloned the 3´-end of the gene to generate a translational fusion, and in case of HE its promoter, resulting in a transcriptional fusion with the reporter RFP.

      Fig 2 I am a little lost mortality seems quick on day 0 is this a result of aberrant injection damage mortality or are the authors observing a different effect across mutants through the initial 24 hours? If data available could this time plot be extended out 0-24 hours. The dash used for W222703 tcaA /TccC look similar can a different symbol be used.

      Answer: The reviewer is right that the mortality is high on the first day. However, larvae monitoring for up to nine days is a standard in the literature. No data are available for a better resolution of the first 24 h that, however, were investigated in more detail in the time course of Fig. 5. Moreover, we observed changes in motility and colouring of some of the larvae from one h p.i. on (data not shown). Aberrant injection damage was avoided, and damaged larvae or larvae that not completely took up the infection solution were not further considered in the experiment. This is mentioned in lines 107-109.

      A different symbol is now used for W222703 DtccC /pBAD-tccC.

      • Are the experiments adequately replicated and statistical analysis adequate? Yes

      Minor comments: - Specific experimental issues that are easily addressable. - Are prior studies referenced appropriately? Other entomopathogenic transcriptome studies could be compared to and or cross referenced (I have provided references in the response

      Answer: Repetition of our answer above: We again carefully screened PubMed for studies in the field and added few papers. However, in vivo transcriptome analyses are still rare, as indicated by a lack of a respective investigations with the highly relevant entomopathogen Photorhabdus luminescens. The literature suggested by the reviewer is now cited in the introduction and the discussion (see below for details).

      I am unsure on the use of immuno pulldown and efficiency of recovering the Yersinia using this method as opposed to direct sequencing total RNA has this method been used in other systems,

      Answer: Isolating RNA from in vivo probes of infected insects encounters two challenges: first, a possible contamination with commensal bacteria, and a too high amount of host RNA that reduces the number of sequence reads. This might be the reason for the relatively low sequence depth found in related papers in the field of in vivo transcriptomics. We overcame these problems by immunomagnetic separation that is easily applicable and enriches the samples with respect to Yersinia cells, this is now mentioned in the results. We also cite a study (Prax et al., in which we established the protocol of IMS.

      • Are the text and figures clear and accurate? Yes though in places better naming of insect components could be listed

      Answer: This was done, see above.

      • Do you have suggestions that would help the authors improve the presentation of their data and conclusions?

      As listed above potential use of reporters and or comparison and transcriptome analysis to other systems and an evolutionary pathogen host context (refer comments above) would strengthen the manuscript

      Answer: Please see answer to comments above. We explained the use of the reporter fusions, and put the transcriptome analysis into the context of related studies.

      Minor comments as per below When first mentioned good to state the larval instar used

      Answer: We used larvae of instar 5-6 according to Jorjao et al. (2018), this is now mentioned and cited in the M&M section, line 434.

      l 78 lon protease? what type? this is an important SOS protease affecting many regulatory systems please clarify

      Answer: This is a Lon A endopeptidase, and its function for the temperature-dependent activity of the lysis cassette has ben described (Springer et al. 2021, see references). Its relevance for the thermodependent regulation of Yersinia virulence has been documented by Herbst et al. (PMID: 19468295) and Jackson et al. (https://doi.org/10.1111/j.1365-2958.2004.04353.x).

      l103-113 an description of the elemental tract which is depicted, perhaps this could be placed in the Fig. 1 figure legend

      Answer: We agree and substantially shortened the first paragraph of the results. Relevant aspects are now mentioned in Figure legend 2, redundancies with the figure legend were removed.

      l 133 use of the word larvae in place of the word animals might be more appropriate

      Answer: This was corrected accordingly.

      l 133 clarify delta HE mutant description when first mentioned

      Answer: The abbreviation HE is now introduced in the introduction in line 74.

      Lines 220-234 hard to follow mainly as I am unsure how then strains are constructed, perhaps clarify what rfp is how was it made :: demotes and insertion but yet then they seek to detect TcaA? I could not find the methodology on its or HE::rfp construction

      Answer: The plasmids used to construct the two strains W22703 tcaA::rfp and W22703 PHE::rfp are listed in Table S2. References for details is given (Starke et. Al., 2013, Starke et al. 2014). Briefly, we used a suicide vector (pUTs) carrying the gene encoding the red fluorescent protein (RFP). Following conjugation, the construct is chromosomally inserted upon recombination via the fragments cloned into the plasmid. In case of tcaA, we cloned the 3´-end of the gene to generate a translational fusion, and in case of HE its promoter, resulting in a transcriptional fusion with the reporter RFP.

      Please see above why we used RFP-antibodies to detect TcaA.

      l247 immuno-magnetic separation to isolate Yersinia - is there an efficiency behind this method, might be good to mention (I am unfamiliar with this technique)

      Answer: We here repeat our answer to the point above: Isolating RNA from in vivo probes of infected insects encounters two challenges: first, a possible contamination with commensal bacteria, and a too high amount of host RNA that reduces the number of sequence reads. This might be the reason for the relatively low sequence depth found in related papers in the field of in vivo transcriptomics. We overcame these problems by immunomagnetic separation that is easily applicable and enriches the samples with respect to Yersinia cells, this is now mentioned in the results. We also cite a study (Prax et al., in which we established the protocol of IMS.

      l313 alludes to role of Tca in hemoceol which contradicts an earlier statements in l 130 please clarify

      Answer: The reviewer is right. The sentence in former line 130 (now lines 123-124) was corrected to “…suggesting that the Tc plays a main role in the initial phases of infection”. This statement does not exclude its activity towards hemocytes. Moreover, subcutaneous infection is very artificial and was therefore replaced by oral application in our study to mimic natural routes of infection. This is now elaborated in more detail in the discussion (Lines 305-310).

      For clarity table 1 could colour highlight (different colours) tc and lysis genes

      Answer: We now added a table to Fig. S1 that shows the FC values of all genes from Tc-PAIYe.

      CROSS-CONSULTATION COMMENTS I am in agreement with all points of reviewer 1 who has a clear understanding on Tc toxin composition TcA pentamer etc. Being familiar to the field I regret I did not pick up on these errors

      Answer: This has been corrected according to R1.

      Point 13 agree and should possibly bring in other researchers who have used Galleria as a model. It also needs to be kept in mind that the target host for many Tcs has yet to be determined hence the importance of oral activity of this isolate

      Answer: This has been corrected according to R1.

      I am similarly in agreement with comments of reviewer 3

      Reviewer 4 I over looked the LT50 data -- apologies but agree with reviewer 1 where WT should be the more potent strain --I still think if possible LD50 for WT would be of value more so to define its oral activity

      Answer: We repeat our answer from above. This is an interesting point. The LD50 (dose of cells that kills 50% of all larvae) is usually not calculated in publications in this field of research, because its calculation requires a very huge separate data set that cannot be used to answer the questions addressed here. Such a dat set is not available. We published the dose-dependent toxicity of Y.enterocolitica W22703 upon subcutaneous injection, and from these data, we determined a LD50 for this strain of approximately 2 x 104 cells. The paper is cited in our manuscript. The 10E05 dose was selected due to our preliminary work and the reproducibility of the experimental phenotypes.

      Reviewer #4 (Significance (Required)):

      SECTION B - Significance ========================

      • Describe the nature and significance of the advance (e.g. conceptual, technical, clinical) for the field.

      Extends from work of Fuchs - research group Extends from work of Palmer et al on lysis cassettes as potential T10SS Extends from work off Vesga Pseudomonas and Paulson Yersinia(refs provided below) on insect transcriptomics

      Of interest and possibly understated is the oral activity of enterocolitica in the insect host as mentioned L316-317 and how this might relate to the lifestyle/evolution of this microbe further elaboration here would be of interest

      Answer: We agree that this is an important aspect. Therefore, we added the following sentences here: “In contrast to subcutaneous injection in the use of insect larvae as model for bacterial virulence properties towards mammals, oral application mimics natural routes of infection that in particular take place during the bioconversion of animal cadavers by bacteria, fungi, and larvae {Carter, 2007 #879}. Together with the broad cytocidal host spectrum of bacterial toxins {Mendoza-Almanza, 2020 #880}, investigation of yet neglected natural infections of invertebrates will contribute to a better understanding of microbial pathogenicity {Waterfield, 2004 #480}.” (lines 305-310)

      • Place the work in the context of the existing literature (provide references, where appropriate).

      Relevant Transcriptome papers which could be referred to in the discussion i.e. are similar genes in play or is their a point of difference? https://doi.org/10.1093/g3journal/jkaa024;https://doi.org/10.1038/s41396-020-0729-9; https://doi.org/10.1099/mic.0.000311

      Answer: Paulson et al. mainly address virulence factors, whereas metabolism is not uncovered. We now cite similarities with respect to hemolysis and iron scavenging. The focus of Vesga et al. is on the interaction of a plant pathogen with wheat and two insect hosts, including their transcriptome. Although metabolic details are missing, there is an interesting overlap with the paper by Vesga et al. (hemocoel as permissive environment for proliferation) and a difference (upregulation of chitinases was not observed) that are now cited in the discussion. The Alenzi paper mainly investigated the general virulence of Y. enterocolitica strain. We cite its finding on the importance of motility, thus confirming our transcriptome analysis.

      • State what audience might be interested in and influenced by the reported findings. The oral activity of enterocolitica towards Galleria of interest and an evolutionary context insect vs mammalian activity in the discussion could be provided. Potential role of TcaA in gut association For the targeted journal I feel additional technical data is required and a broader context to other global systems (bacterial species) provided

      Answer: All points were addressed carefully and in detail. We refer to our answers to points detailed above.

      • Define your field of expertise with a few keywords to help the authors contextualize your point of view. Indicate if there are any parts of the paper that you do not have sufficient expertise to evaluate. Reviewers expertise entomopathogens, their toxins and pathogen ecology
    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #4

      Evidence, reproducibility and clarity

      Summary:

      Provide a short summary of the findings and key conclusions (including methodology and model system(s) where appropriate).

      Outlines proposed role of lysis cassette in oral infection of Galleria as a model insect for host pathogen interaction, data which is fortified through use of histology and RNAseq. Introduction could extend to additional background eg Aleniz et al and other entomopathogen transcriptome data, more so other studies using Yersinia and Galleria as a model (refer references provided in the below comments) The strength of the paper lies in understanding the progression of the disease in the insect host as mentioned L316-317 and clearance of the bacteria via in TcaA mutant

      Major comments:

      • Are the key conclusions convincing?

      Yes for mode of action

      Fig 5 could have additional panels -this is a strength of the paper

      Fig 6 legend could better describe the observed insect components

      Figure 7 may be lost in PDF conversion -the figure appears un resolved? are there more high resolution photos - Should the authors qualify some of their claims as preliminary or speculative, or remove them altogether?

      the data provided is in places rudimentary (i.e. validation of the role of the lysis cassette in virulence) and could be bolstered with the construction and use of a lysis translational reporter etc I was left unsure how the HE::rfp and TcA::rfp constructs were made. I had assumed red florescent protein however it appears an antibody is used. This needs to be clarified as I then found it hard to interpret the results. It appear l114-125 that their may be enough data to derive a LD50 values and or LT value at a fixed dose - if so reporting this data of interest. It may also allude as to why a 10e5 dose was selected for subsequent expts - Would additional experiments be essential to support the claims of the paper? Request additional experiments only where necessary for the paper as it is, and do not ask authors to open new lines of experimentation.

      Use of lysis the reporter - discuss commonalties of the in host transcriptome with other Yersinia Galleria systems eg Paulson etc al (refer below). Are there any thoughts on the host range of this Yersinia and can this be placed in a pathogen host evolutionary context? - Are the suggested experiments realistic in terms of time and resources? It would help if you could add an estimated cost and time investment for substantial experiments.

      Yes

      • Are the data and the methods presented in such a way that they can be reproduced? yes but I think some vector construction methodology is missing e.g. ::rfp (refer above)

      Fig 2 I am a little lost mortality seems quick on day 0 is this a result of aberrant injection damage mortality or are the authors observing a different effect across mutants through the initial 24 hours? If data available could this time plot be extended out 0-24 hours. The dash used for W222703 tcaA /TccC look similar can a different symbol be used. - Are the experiments adequately replicated and statistical analysis adequate?

      Yes

      Minor comments:

      • Specific experimental issues that are easily addressable.
      • Are prior studies referenced appropriately?

      Other entomopathogenic transcriptome studies could be compared to and or cross referenced (I have provided references in the response

      I am unsure on the use of immuno pulldown and efficiency of recovering the Yersinia using this method as opposed to direct sequencing total RNA has this method been used in other systems,<br /> - Are the text and figures clear and accurate?

      Yes though in places better naming of insect components could be listed - Do you have suggestions that would help the authors improve the presentation of their data and conclusions?

      as listed above potential use of reporters and or comparison and transcriptome analysis to other systems and an evolutionary pathogen host context (refer comments above) would strengthen the manuscript

      Minor comments as per below

      When first mentioned good to state the larval instar used l 78 lon protease? what type? this is an important SOS protease affecting many regulatory systems please clarify

      l103-113 an description of the elemental tract which is depicted, perhaps this could be placed in the Fig. 1 figure legend

      l 133 use of the word larvae in place of the word animals might be more appropriate

      l 133 clarify delta HE mutant description when first mentioned

      Lines 220-234 hard to follow mainly as I am unsure how then strains are constructed, perhaps clarify what rfp is how was it made :: demotes and insertion but yet then they seek to detect TcaA? I could not find the methodology on its or HE::rfp construction

      l247 immuno-magnetic separation to isolate Yersinia - is there an efficiency behind this method, might be good to mention (I am unfamiliar with this technique)

      l313 alludes to role of Tca in hemoceol which contradicts an earlier statements in l 130 please clarify

      For clarity table 1 could colour highlight (different colours) tc and lysis genes

      Referees cross-commenting

      I am in agreement with all points of reviewer 1 who has a clear understanding on Tc toxin composition TcA pentamer etc. Being familiar to the field I regret I did not pick up on these errors

      Point 13 agree and should possibly bring in other researchers who have used Galleria as a model. It also needs to be kept in mind that the target host for many Tcs has yet to be determined hence the importance of oral activity of this isolate

      I am similarly in agreement with comments of reviewer 3

      Reviewer 4 I over looked the LT50 data -- apologies but agree with reviewer 1 where WT should be the more potent strain --I still think if possible LD50 for WT would be of value more so to define its oral activity

      Significance

      • Describe the nature and significance of the advance (e.g. conceptual, technical, clinical) for the field.

      Extends from work of Fuchs - research group

      Extends from work of Palmer et al on lysis cassettes as potential T10SS

      Extends from work off Vesga Pseudomonas and Paulson Yersinia(refs provided below) on insect transcriptomics

      Of interest and possibly understated is the oral activity of enterocolitica in the insect host as mentioned L316-317 and how this might relate to the lifestyle/evolution of this microbe further elaboration here would be of interest - Place the work in the context of the existing literature (provide references, where appropriate).

      Relevant Transcriptome papers which could be referred to in the discussion i.e. are similar genes in play or is their a point of difference?

      Amber R Paulson, Maureen O'Callaghan, Xue-Xian Zhang, Paul B Rainey, Mark R H Hurst, In vivo transcriptome analysis provides insights into host-dependent expression of virulence factors by Yersinia entomophaga MH96, during infection of Galleria mellonella, G3 Genes|Genomes|Genetics, Volume 11, Issue 1, January 2021, jkaa024, https://doi.org/10.1093/g3journal/jkaa024

      Vesga, P., Flury, P., Vacheron, J. et al. Transcriptome plasticity underlying plant root colonization and insect invasion by Pseudomonas protegens. ISME J 14, 2766-2782 (2020). https://doi.org/10.1038/s41396-020-0729-9

      Dhahi Alenizi, Tamara Ringwood, Alya Redhwan, Bouchra Bouraha, Brendan W. Wren, Michael Prentice, Alan McNally (2016) All Yersinia enterocolitica are pathogenic: virulence of phylogroup 1 Y. enterocolitica in a Galleria mellonella infection model https://doi.org/10.1099/mic.0.000311 - State what audience might be interested in and influenced by the reported findings.

      The oral activity of enterocolitica towards Galleria of interest and an evolutionary context insect vs mammalian activity in the discussion could be provided. Potential role of TcaA in gut association

      For the targeted journal I feel additional technical data is required and a broader context to other global systems (bacterial species) provided - Define your field of expertise with a few keywords to help the authors contextualize your point of view. Indicate if there are any parts of the paper that you do not have sufficient expertise to evaluate.

      Reviewers expertise entomopathogens, their toxins and pathogen ecology

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      Summary:

      The authors analyze the phases of infection of Galleria mellonella by Yersinia enterocolitica following forced oral feeding. They study different phases of infection, including survival within the gut and invasion of the hemolymph. By analyzing differences in the genes up- and down regulated, they show that for example transporters for food sources from the hemocoel are regulated for making those sources available for the bacteria.

      Major comments:

      This is an interesting paper demonstrating genes of Y. enterocolitica dependent for colonization, growth and crossing of the epithelial gut barrier in G. mellonella.

      Major points which have to be addressed: Introduction: line 54: the BC subcomplex is not released into the cytosol! It is only the hypervariable region (enzymatic part) which enters the cytosol. This has to be corrected.

      Fig.2/3: Why have different CFU been used for the distinct bacterial strains? This does not allow a direct comparison of their toxicity. For me the dead larvae shown in Fig. 3 are not represented in Fig 2 (data are not concordant), because of the loss before day one depicted in Fig. 2: The curves should be normalized to the same starting point (should be 100 %)? Fig. 3: Why is the strain W22703 delta tccC/pBAD - tccC missing in the data set? Minor: line 221: "the" is doubled

      Significance

      The manuscript shows the use of G. mellonella as a straight foreward method to study gene functions of pathogenic bacteria, a significant knowledge for scientists of the field.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      This is a very, very nice study as it actually describes the role of different Tc toxin components in a model infection system using an important bacterium- really for the first time in a properly controlled manner. The mutants lacking either the syringe (AB) or the bullet (C) make 'sense' for a loss of function perspective. The description of the phage cassette in loss of function is also interesting and could do with some more speculation?

      For example, some groups of Photorhabdus bacteria release their oral toxicity (Tc's) into their bacterial supernatants- whereas in others it remains cell associated. The likely role of this phage cassette in this process should be discussed (is cell suicide required for release?).

      Significance

      This is highly significant finding as despite all of the very elegant structural studies done on these important toxins there is still very little work in vivo. These studies clearly show the role of the different components of these ABC toxins in vivo. It should be published with priority.

      Congratulations to the authors.

    5. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      In this manuscript Saenger et al. concentrate on the pathophysiological details of insect larvae infection by Yersinia enterocolitica. The authors studied the colonisation, proliferation, tissue invasion, and killing activity of the bacteria in Galleria mellonella larvae. Their study provides valuable evidence for the biological relevance of Tc toxins and a neighboring holin-endolysin cassette during establishment of Y. enterocolitica infection in Galleria mellonella larvae through the oral route. The findings of the authors provide important novel insights, that can be used for the development of Tc toxins as biopesticides.

      In general, this is a nice study. The data and the methods are presented well so that they can be reproduced and the key conclusions convincing.

      Unfortunately, the manuscript is sloppily written in some places, including grammatical and formatting errors. Citations regarding the structure and mechanism of action of Tc toxins are arbitrarily chosen, often taking the wrong ones and important aspects are left out. I highly recommend that the authors read the review of Roderer and Raunser 2019 that nicely describes and summarizes the molecular mechanism of Tc toxins. The abstract ends with a speculation: "Suggesting that this dual lysis cassette is an example for a phage-related function that has been adapted for the release of a bacterial toxin" - this is likely true, but not proven in this work. What if it is used for the release of something else like extracellular DNA needed for biofilm formation (see https://doi.org/10.1038/ncomms11220)?

      In addition to that, several outstanding issues must be addressed:

      1. Line 45 3-D structural analysis of the tripartite Tc suggests a 4:1:1 stoichiometry of the A, B and C subunits, with the A subunit forming a cage-like pentamer that associates with a tightly bound 1:1 sub-complex of B and C. This is wrong. The stoichiometry is 5:1:1 and the structure is not a cage. The statement was taken from citation 3. However, citation 3 should not be used, since the stoichiometry as well as the structure that was determined there is wrong. Use Landsberg et al. 2012 PNAS, Gatsogiannis et al. 2013 Nature instead.
      2. "Few bacteria are known to successfully colonize and infect invertebrates" - needs a reference.
      3. "Their oral insecticidal activity is comparable to that of the Bacillus thuringiensis- (Bt)- toxin" - reference missing.
      4. "Type a, type b and type c" subunits is not usual for the literature. Please use TcA, TcB, TcC. A-, B-, and C-components should be abbreviated as TcA, TcB and TcC respectively in order to be in line with recent literature on the topic.
      5. Is TccC an ADP-ribosyltransferase or does it have a different biochemical activity?
      6. "The toxic and highly variable carboxyl-terminus of TccC that has recently been demonstrated to ADP-ribosylate actin and Rho-GTPases" - this is only certain for TccC3 and TccC5 from P. luminescens. There are many such C-termini, called HVRs which have not had their activities determined yet, see here: https://doi.org/10.1371/journal.ppat.1009102
      7. "is probably followed by receptor-mediated endocytosis" - more recent references exist for the receptor binding of Tc toxins.
      8. "A pH decrease then triggers the injection of a translocation channel formed by the pentameric TcaA subunits into the endosomal vacuole, followed by the subsequent release of the BC subcomplex into the cytosol of the target cell" - this again is incorrect. Please read the above mentioned review and correct this passage accordingly.
      9. What is meant by "environmental Yersinia species"?
      10. In the relevant W22703 pathogenicity island sequence (https://www.ncbi.nlm.nih.gov/nuccore/AJ920332) previously submitted by the same group, something odd is going on with the TcA component: it appears to be split into three polypeptides (tcaA, tcaB1, tcaB2). In the manuscript you state TcA is made up from only tcaA and tcaB. Could you please address this?
      11. "And their products were recently shown to act as a holin and an endolysin, respectively" - missing reference.
      12. "Its Tc proteins are produced at environmental temperatures, but silenced at 37{degree sign}C." versus "Remarkably, HolY and ElyY lyse Y. enterocolitica at body temperature, but not at 15{degree sign}C". Please address the issue that HolY/ElyY lyse the bacteria at temperatures where Tc proteins are not produced.
      13. "Nematodes, which are easily maintained in the laboratory without raising ethical issues, have successfully been used to identify virulence-related genes in a broad set of bacterial pathogens" - what is the relevance of this for the current manuscript?
      14. Fig. 1C - no description is given for the labels 1-8.
      15. "The hemolymph of these cadavers was found full of Y. enterocolitica cells" - injected CFUs are provided here, but not final CFUs in the cadavers (although referred to in a later section). Please address this.
      16. What is the inducing agent used for pACYC-tcaA and pACYC-HE? Why would "slight leakiness of the pBAD-promoter" make pBAD-tccC non-inducible? Were colonies taken from the cadavers to verify that the bacteria still contained these plasmids?
      17. Can the authors please address the TD50 of 1.83 days for W22703 ΔHE/pACYC-HE versus 3.67 days for WT bacteria? This would mean that the former kill larvae twice as fast as usual. I would not call this "did not significantly differ in their insecticidal activity".
      18. Fig. 2 is missing survival data for larvae infected with tcaA, HE, and tccC KO bacteria.
      19. "And a slight colouring of some of the larvae from one h p.i. on (data not shown)" - best show the data or remove this statement.
      20. The infection of larvae by W22703 ΔtccC/pBAD-tccC is missing, the other bacterial variants are present. Please address this.
      21. "initially proliferated from an application dose of 4.0 × 105 CFU and 4.0 × 105 CFU, respectively, to 2.2 × 106 CFU and 2.8 × 106 CFU, but could not be detected from day three on. This finding strongly suggests that TcaA is involved in adherence to epithelial cells and thus in midgut colonization". Please address the "initially proliferated" (which day post-infection?), their elimination from the larvae (how, why?), why the tccC KO bacteria were more virulent than tcaA KO bacteria, and where the suggestion about TcaA involvement specifically in adherence comes from.
      22. In Fig. 4, the CFUs for W22703 ΔtccC/pBAD-tccC are essentially the same as for the other rescued KOs and WT, while in the text a point about weaker growth is made. Is this justified? Also, even though the CFU data is present here, data on infection of larvae by W22703 ΔtccC/pBAD-tccC is missing unlike the other bacterial variants. Please explain.
      23. Fig. 6b - The presence of an anti-RFP signal is not obvious in any of the bottom row images. The top row images are missing the same kind of annotation provided for Fig. 6a, without which non-histologists will find understanding the figure difficult.
      24. "In the absence of the lysis cassette, however, TcaA::Rfp was not detected despite the presence of W22703 ΔHE tcaA::rfp cells." + "To test whether or not the promoter of the lysis cassette is active in vivo, we infected G. mellonella larvae with strain W22703 PHE::rfp. Although Y. enterocolitica cells densely proliferated within the hemolymph (FIG. 6B), no staining signal that would point to the presence of TcaA was obtained, possibly due to no or weak PHE activity." Does this mean that without HE, tcaA does not express?
      25. "These data suggest that the HE cassette is responsible for the extracellular activity of the insecticidal Tc." Please explain how the preceding paragraph leads to this conclusion.
      26. "As expected, bacterial cells, e.g. Y. enterocolitica, are visible in the hemolymph obtained from W22703-infected animals, but not in all other preparations." - which figure are the authors referring to?
      27. "To delineate the transcriptional profile of Y. enterocolitica during infection of G. mellonella, we applied immunomagnetic separation to isolate Y. enterocolitica from the larvae 12 h and 24 h after infection" - do the authors store the bacteria for up to 24 h at 4 {degree sign}C, as indicated in the methods section?
      28. "The endolysin located within Tc-PAIYe was significantly up-regulated after 24 h, but not after 12 h, pointing to its possible role in the release of the Tc" - I could not find the endolysin in Table S1. Could the authors mark it clearly? Also, why is the holin also not upregulated?
      29. "This is in line with the fact that a T3SS is lacking in strain W22703" - Is a complete genomic sequence available for this strain, so readers could validate this statement?

      Significance

      See above

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      We thank the both the reviewers for their constructive comments. Please see our point-by-point response to all the comments.

      *Reviewer #1 (Evidence, reproducibility and clarity (Required)): *

      • Summary *
      • The authors of this manuscript confirm data found by others by determining replication kinetics of the ancestral B.6 SARS-CoV-2 virus, Delta and Omicron BA.1 and BA.2 in Calu-3 cells. The authors quantify barrier integrity between variants and interferon induction to conclude that Delta is more cytopathic and induced less interferon than Omicron, possibly leading to its increased pathogenesis. In addition the authors identify CuCl2 and FeSO4 as potential antivirals. *

      *Major comments *

      1. *__Reviewer comment: __The author's argue that Omicron's slower replication on Calu-3 cells correlates with mild disease, however many publications show that Omicron replicates more efficiently/ rapidly in primary human airway cultures: *
      2. Hui et al., (Nature, 2022) doi: https://doi.org/10.1038/s41586-022-04479-6*
      3. Peacock et al., (bioRxiv) doi: https://doi.org/10.1101/2021.12.31.474653*
      4. Lamers et al., (bioRxiv) doi: https://doi.org/10.1101/2022.01.19.476898 * Response: Previous reports including the citations indicated by the reviewer have shown that the Omicron variant replicates at a lower levels in lung tissue as compared to cells of bronchial origin or upper respiratory tract. In fact, Omicron variant was shown not to productively infect at all in alveolar type II cells. Omicron replication was severely compromised in Calu-3 cells grown in 96-well plates (https://doi.org/10.1080/22221751.2021.2023329) which is consistent with our observations.

      *__Reviewer comment: __Can the authors explain why air-liquid grown Calu-3 cells appear to display similar viral titers for Omicron and Delta at 24 and 36 h.p.i (Figure 5B), however lower viral replication in Figure 3B? If the cells in Figure 3B are submerged, then the authors should identify why ALI grown Calu-3 cells are more susceptible to Omicron. *

      Response: Cells were grown in plastic multi-well plates for growth curve experiments shown in Figure 3. The cells in this condition are not polarized and the virus titers are the total amount of virus released into the culture supernatant. The infection conditions in Figure 5 is under air-liquid culture conditions, from polarized cells. Therefore, the virus titers are only from the basolateral chamber. The outcomes of figure 3 and figure 5 are not comparable due to these technical differences. We will add this explanation in the results section.

      *__Reviewer comment: __The authors suggest that Delta disrupts epithelial barrier integrity to a larger extent compared to B.6 and Omicron, however this may be due to fewer infected cells (despite equal viral titers, the nucleocapsid staining in Figure 2 and 5C suggests fewer infected cells). Have the authors imaged B.6 or Omicron at a later timepoint (or normalized virus input for equal infected cells) to determine barrier integrity when the amount of infected cells is equal? Alternatively, the authors should discuss this as a possible limitation of their study, especially since they argue this is a major reason why Delta has a growth advantage (lines 345 to 349). *

      Response: We performed confocal imaging of transwells from air-liquid interface model using a 20X objective and have obtained data to show that the percent of infected cells is similar between Omicron and Delta variant. We will include this data in the revised manuscript. In an in vitro system, once the infection is set in, the infected cells eventually die and the TEER reaches background levels. We are proposing a delay in disruption of barrier integrity most probably due to lower cytopathogenicity of the Omicron variant. As per the reviewer’s suggestion, we will discuss the possible limitation of the models and provide additional interpretations.

      Minor comments *A) __Reviewer comment: __Line 118: Implications of this sentence are too strong. The authors have not shown the causality of Ct values and transmission, therefore they should reword the sentence: "indicating a high viral burden in patients during this period resulting in increased transmission of the virus among the contacts" to "likely attributing to increased transmission..." *

      Response: We will correct this.

      *__B) Reviewer comment: __Line 289: The authors suggest that infection with the Omicron variant generated higher levels of antibodies to the Delta variant, however these individuals are already vaccinated and elicit cross-neutralizing antibodies against Delta even before their Omicron infection. Therefore the Delta response is boosted and the Omicron response is essentially a primary response since vaccination elicits almost no cross-protection in itself. Therefore the authors should compare primary Delta infected individuals to primary Omicron infected individuals to determine cross-protection levels. *

      Response: We agree with the reviewer’s argument. Please note that the two vaccines used in India are against the ancestral virus (inactivated) or the spike protein expressed by the adenovirus vector backbone. As over 90% of the population in India have been fully vaccinated with these two vaccines and a majority of them may also have been infected with delta variant and now with omicron, it is practically impossible to compare primary delta cases vs primary omicron cases at this stage. As part of another study in mid 2021, after the second wave of COVID-19 infections due to the Delta variant in India, we randomly selected 55 samples which had a detectable FRNT50 value for the delta variant, to test for their ability to neutralize the Omicron variant. Only twenty of the 55 samples had detectable levels of neutralizing antibodies against the Omicron variant. By assigning a FRNT50 value of 10 for the samples which had no detectable levels of antibodies in the starting dilution (1:20) of the assay, we obtained a GMT of 22.5 (95% CI: 16, 31) for these 55 samples. This value was 20-fold lower than the GMT of Delta variant which was 404 (95% CI:248, 658). This clearly indicates that even during the peak of delta wave, there were barely any cross-reactive antibodies to the Omicron variant. This study was recently published [NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-022-31170-1]. It would be interesting to eventually compare the antibody responses in reinfections with other sub-lineages of Omicron variant which is beyond the scope of our manuscript. We will add this description in the results and discussion section of the revised manuscript.

      *C) __Reviewer comment: __There appears to be no reference to Figure 6G, however this reference is most likely missing from line 306. *

      Response: Thank you for bringing this to our notice. We will insert the reference to Figure 6G.

      *D) __Reviewer comment: __Line 359-362: The authors suggest that waning antibody titers increase susceptibility to new variants of concern, however their cohort already possessed very low antibody titers against Omicron a month after vaccination (Figure 7F) suggesting they could be equally susceptible to Omicron 1 and 6 months after vaccination. *

      Response: Please note that nine out of 15 samples had FRNT50 value above the level of detection after vaccination in June 2021. The number of samples positive for Omicron antibodies reduced to six out of 15 by Dec 2021 suggesting that relatively more people were without protective antibodies for Omicron variant by Dec 2021. Around 70% of the population was seropositive by Aug 2021 (https://doi.org/10.1016/j.ijid.2021.12.353) and most adults in India received both doses of their vaccine after June 2021 which would have boosted the humoral and cellular response to SARS-CoV-2. This is corroborated in a recently published report, where we showed that 36 out of 55 previously infected subjects had neutralizing antibodies for the Omicron variant after receiving a single dose of inactivated vaccine. Therefore, in the context of hybrid immunity in India, we speculate that waning antibody titers could have played a significant role in the emergence and spread of Omicron variant in addition to the ability of the Omicron variant to escape neutralization, replicate more efficiently in the upper respiratory tract etc., The fact that booster doses of vaccines developed against the ancestral virus/viral protein was capable of increasing the level of neutralizing antibodies to omicron variant suggests that the level of antibodies above a certain threshold may play a significant role in protecting against the omicron variant.

      Reviewer #1 (Significance (Required)):

      • __Reviewer comment: __Many of the conclusions based on replication and barrier integrity may not represent the situation in primary human tissues and does not explain the rapid spread of Omicron. In addition, interferon induction has already been described for these variants and this finding is not novel. The manuscripts most interesting and novel finding is the role of CuCl2 and FeSO4 as antivirals. It would be interesting to test these salts in primary human airway cultures. *

      Response: The study was conducted in the months of Jan-March 2022 and the first version of the results were uploaded on a preprint server in March 2022. The process of journals handling the manuscript and obtaining reviews is not under our control. We cannot argue to defend the comments on novelty when the Omicron variant is barely six months old and new variants continue to emerge. The deluge of publications should not result in reviewers branding most of the efforts as not novel or insignificant. We have been trying since three months to obtain primary cells but the distributors are unable to supply the same. We will continue to try to obtain cells from one or the other source. Transwells are back-ordered with expected delivery dates in three months. Meanwhile, we now have HBEC3-KT cells which are normal human bronchial epithelial cells immortalized with CDK4 and hTERT. We will perform the inhibition experiments in these cell lines to convince the reviewers.

      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      *In the manuscript entitled "BA.1 and BA.2 sub-lineages of Omicron variant have comparable replication kinetics and susceptibility to neutralization by antibodies" the authors assess the kinetics of growth of SARS-CoV-2 variants in Calu-3 cells and their effects on epithelial junction, and the interferon response. The authors also analyze the capacity of metal salts to block SARS CoV-2 replication in Calu-3 cells. Finally, the authors characterize the ability of vaccinated and/or COVID-19 patients to develop neutralizing antibodies to different variants using FRNT and specific binding assays (ELISA). *

      • The paper largely confirms several previous reports on the replication capacity and interferon responses of the different variants. Although the title and abstract focus on the Omicron sub-lineages, the paper is mostly focused on comparing original CoV2, with Kappa, Delta and Omicron. *
      • Figures 1-5 compare the replication kinetics, interferon responses, and epithelial barrier disruption of Kappa, Delta and the original Omicron (B.1.1.529) to the original B6 variant. On a separate note, Figure 7 shows the ability of metal salts (especially iron, copper, and zinc) to block viral RNA-dependent RNA polymerase activity (RdRp) in vitro. The authors also show the effect on virus replication in Calu-3 cells (Delta and Omicron B.1.1.529 only). The data mainly focus on the variants, the Delta and the Omicron (BA.1.1.529 and not the BA.1 and BA.2 sub-lineages) except in Fig 6A, B, G. *

      • __Reviewer comment: __Most importantly, a major limitation of the paper is that when human samples are analyzed, the authors assume that the patients have been infected with a specific variant according to the "peak" of infection, but sequencing is never performed. When neutralization and binding of antibodies are analyzed, the information on the patients is unclear - for example, were the patients exposed to Delta or Omicron or any of their sub-lineages? What was the vaccination status of SARS CoV-2 positive patients? And why non-tested individuals showing symptoms were included in the study (lines 302-304)? *

      Response: We thank the reviewer for the comments. Over 90% of the population in India is vaccinated. All the participants of the study have been vaccinated in 2021. The participants were enrolled into the study almost 4 weeks after recovery from illness. We have enrolled participants who have reported to have had fever or COVID-19-like symptoms in the preceding weeks with or without confirmed RT-PCR test results. Testing is an individual and voluntary choice now. Therefore, it would be difficult to find RT-PCR confirmed cases. Our assumption about exposure is based on a nationwide sequencing effort of thousands of samples every week and this approach is reliable and credible. As indicated in the text and in the supplementary figure, Omicron lineages BA.1 followed by BA.2 were the circulating virus lineages since Jan 2021 in India.

      *__Reviewer comment: __The authors show that BA.1 and BA.2 have similar replication kinetics in Calu-3 cells and induce similar neutralizing antibodies in the patients tested. However, there is a large disconnection with the rest of the paper that is mostly focused on Kappa, Delta, and Omicron B.1.1.529. Also, no comparisons between these variants and BA.1 or BA.2 have been shown. Similarly, a large assumption in the paper is that the patients who tested positive for COVID-19 have had "natural Omicron infection" (lines 36-37; lines 307-311) when it could be any other variants or Omicron sub-lineages as well. *

      Response: Please note that the B.1.1.529 which was used at the beginning of the study is the BA.1 sub-lineage which has been compared with Kappa and Delta variants. BA.2 emerged at later stages and therefore we have compared the kinetics and neutralization titer between BA.1 and BA.2. It is unreasonable to expect to repeat all the comparisons with BA.2 considering the cost and challenges of working in a BSL-3 environment. The initial version of this data was uploaded on preprint server in March 2022 when only two sub-lineages of Omicron namely BA.1 and BA.2 existed. Our data from the national SARS-CoV-2 sequencing consortium clearly shows that there were no other sub-lineages circulating at that time.

      Reviewer #2 (Significance (Required)):

      *__Reviewer comment: __In light of the fact that most of the paper does not look at the subvariants BA.1 and BA.2 of Omicron- either the authors compare BA.1 and BA.2 more comprehensively with Omicron B.1.1.529 or rewrite the conclusions and claims of the current paper. Similar to the experiments comparing B6 with Kappa, Delta and Omicron, Omicron B.1.1.529 should be compared similarly to BA.1 and BA.2 in a separate figure. In any case, the novelty compared to other papers -also cited by the authors- remains limited. *

      Response: We will revise the conclusions and claims of the paper as per the suggestions. Please see our response to reviewer 1 with regards to the novelty of our observations. The B.1.1.529 variant was later classified as the BA.1 variant. Our study was uploaded on the preprint server in March 2022 and the entire review process has taken four months. It is unfair to now demand comparison of BA.2 with Kappa or Delta variant which does not add any additional value to our observations.

      *__Reviewer comment: __In addition to the concerns mentioned above, there are more pressing variants circulating right now, such as BA.4 and BA.5. These variants are not referred in the paper. It might be beyond the scope of the paper, but including more analyses with BA.1, BA.2 (as the ones done with B.1.1.529) and adding some key data with BA.3, BA.4, BA.5 might substantially increase the relevance and importance of the paper. *

      Response: Please see our comments above. Our efforts are continuing in this direction to further look at antibody responses and replication kinetics of newer variants which have emerged recently. However, the scarcity of positive clinical samples and lower probability of getting samples that would be suitable for virus isolation are the challenges we are dealing with. We think testing newer variants which have emerged during the review process is certainly valuable but is extremely difficult under the current circumstances. We will have to apply to seek import permits to obtain these sub-lineages or enrol patients with symptoms and keep testing them to isolate, culture the virus and obtain whole genome sequence. We will have to establish neutralization assays with newer sub-variants to test in parallel with other Omicron lineages. All this is beyond the scope of our manuscript and will take few months of paper work and experimentation.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      In the manuscript entitled "BA.1 and BA.2 sub-lineages of Omicron variant have comparable replication kinetics and susceptibility to neutralization by antibodies" the authors assess the kinetics of growth of SARS-CoV-2 variants in Calu-3 cells and their effects on epithelial junction, and the interferon response. The authors also analyze the capacity of metal salts to block SARS CoV-2 replication in Calu-3 cells. Finally, the authors characterize the ability of vaccinated and/or COVID-19 patients to develop neutralizing antibodies to different variants using FRNT and specific binding assays (ELISA).

      The paper largely confirms several previous reports on the replication capacity and interferon responses of the different variants. Although the title and abstract focus on the Omicron sub-lineages, the paper is mostly focused on comparing original CoV2, with Kappa, Delta and Omicron. Figures 1-5 compare the replication kinetics, interferon responses, and epithelial barrier disruption of Kappa, Delta and the original Omicron (B.1.1.529) to the original B6 variant. On a separate note, Figure 7 shows the ability of metal salts (especially iron, copper, and zinc) to block viral RNA-dependent RNA polymerase activity (RdRp) in vitro. The authors also show the effect on virus replication in Calu-3 cells (Delta and Omicron B.1.1.529 only). The data mainly focus on the variants, the Delta and the Omicron (BA.1.1.529 and not the BA.1 and BA.2 sub-lineages) except in Fig 6A, B, G.

      Most importantly, a major limitation of the paper is that when human samples are analyzed, the authors assume that the patients have been infected with a specific variant according to the "peak" of infection, but sequencing is never performed. When neutralization and binding of antibodies are analyzed, the information on the patients is unclear - for example, were the patients exposed to Delta or Omicron or any of their sub-lineages? What was the vaccination status of SARS CoV-2 positive patients? And why non-tested individuals showing symptoms were included in the study (lines 302-304)?

      The authors show that BA.1 and BA.2 have similar replication kinetics in Calu-3 cells and induce similar neutralizing antibodies in the patients tested. However, there is a large disconnection with the rest of the paper that is mostly focused on Kappa, Delta, and Omicron B.1.1.529. Also, no comparisons between these variants and BA.1 or BA.2 have been shown. Similarly, a large assumption in the paper is that the patients who tested positive for COVID-19 have had "natural Omicron infection" (lines 36-37; lines 307-311) when it could be any other variants or Omicron sub-lineages as well.

      Significance

      In light of the fact that most of the paper does not look at the subvariants BA.1 and BA.2 of Omicron- either the authors compare BA.1 and BA.2 more comprehensively with Omicron B.1.1.529 or rewrite the conclusions and claims of the current paper. Similar to the experiments comparing B6 with Kappa, Delta and Omicron, Omicron B.1.1.529 should be compared similarly to BA.1 and BA.2 in a separate figure. In any case, the novelty compared to other papers -also cited by the authors- remains limited.

      In addition to the concerns mentioned above, there are more pressing variants circulating right now, such as BA.4 and BA.5. These variants are not referred in the paper. It might be beyond the scope of the paper, but including more analyses with BA.1, BA.2 (as the ones done with B.1.1.529) and adding some key data with BA.3, BA.4, BA.5 might substantially increase the relevance and importance of the paper.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      Summary

      The authors of this manuscript confirm data found by others by determining replication kinetics of the ancestral B.6 SARS-CoV-2 virus, Delta and Omicron BA.1 and BA.2 in Calu-3 cells. The authors quantify barrier integrity between variants and interferon induction to conclude that Delta is more cytopathic and induced less interferon than Omicron, possibly leading to its increased pathogenesis. In addition the authors identify CuCl2 and FeSO4 as potential antivirals.

      Major comments

      1. The author's argue that Omicron's slower replication on Calu-3 cells correlates with mild disease, however many publications show that Omicron replicates more efficiently/ rapidly in primary human airway cultures: Hui et al., (Nature, 2022) doi: https://doi.org/10.1038/s41586-022-04479-6 Peacock et al., (bioRxiv) doi: https://doi.org/10.1101/2021.12.31.474653 Lamers et al., (bioRxiv) doi: https://doi.org/10.1101/2022.01.19.476898
      2. Can the authors explain why air-liquid grown Calu-3 cells appear to display similar viral titers for Omicron and Delta at 24 and 36 h.p.i (Figure 5B), however lower viral replication in Figure 3B? If the cells in Figure 3B are submerged, then the authors should identify why ALI grown Calu-3 cells are more susceptible to Omicron.
      3. The authors suggest that Delta disrupts epithelial barrier integrity to a larger extent compared to B.6 and Omicron, however this may be due to fewer infected cells (despite equal viral titers, the nucleocapsid staining in Figure 2 and 5C suggests fewer infected cells). Have the authors imaged B.6 or Omicron at a later timepoint (or normalized virus input for equal infected cells) to determine barrier integrity when the amount of infected cells is equal? Alternatively, the authors should discuss this as a possible limitation of their study, especially since they argue this is a major reason why Delta has a growth advantage (lines 345 to 349).

      Minor comments

      Line 118: Implications of this sentence are too strong. The authors have not shown the causality of Ct values and transmission, therefore they should reword the sentence: "indicating a high viral burden in patients during this period resulting in increased transmission of the virus among the contacts" to "likely attributing to increased transmission..."

      Line 289: The authors suggest that infection with the Omicron variant generated higher levels of antibodies to the Delta variant, however these individuals are already vaccinated and elicit cross-neutralizing antibodies against Delta even before their Omicron infection. Therefore the Delta response is boosted and the Omicron response is essentially a primary response since vaccination elicits almost no cross-protection in itself. Therefore the authors should compare primary Delta infected individuals to primary Omicron infected individuals to determine cross-protection levels. There appears to be no reference to Figure 6G, however this reference is most likely missing from line 306.

      Line 359-362: The authors suggest that waning antibody titers increase susceptibility to new variants of concern, however their cohort already possessed very low antibody titers against Omicron a month after vaccination (Figure 7F) suggesting they could be equally susceptible to Omicron 1 and 6 months after vaccination.

      Significance

      Many of the conclusions based on replication and barrier integrity may not represent the situation in primary human tissues and does not explain the rapid spread of Omicron. In addition, interferon induction has already been described for these variants and this finding is not novel. The manuscripts most interesting and novel finding is the role of CuCl2 and FeSO4 as antivirals. It would be interesting to test these salts in primary human airway cultures.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      The authors do not wish to provide a public response at this time.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      Summary:

      Synapses are the sites that mediate chemical signal transduction from axons to the dendrites of other neurons. At the axonal side of the synapse, called the presynapse, the arrival of action potentials triggers the fusion of synaptic vesicles filled with neurotransmitters with the plasma membrane. These neurotransmitters will then be detected by receptors located at the post-synapse at the dendrite.

      In this manuscript, the authors set out to study the nanoarchitecture of the actin cytoskeleton at presynapses. They argue that this is challenging due to the much higher density of actin at the postsynapse. Therefore, they use an established approach in which polylysine-coated beads can induce structures at the axon that resemble presynapses. The authors first further characterize these presynapse-like structures by measuring the intensity of different presynaptic proteins. They report the presence bassoon, synapsin, synoptophysin, vamp2 at levels that are about half the level found at real synapses (Figure 1). 67% of induced hemisynapses are enriched for actin and the level of synaptic markers is higher in the presence of actin (Figure 2). Furthermore, actin-enriched hemisynapses also display more vesicle recycling than induced hemisynapses without actin enrichment.

      Next, the intensity of synaptic markers is measured after treatment with drugs that stabilize or destabilize actin (Fig. 4), or drugs that inhibit the actin nucleators Arp2/3 or Formin (Fig. 5), which reveals some differences that could suggest the existence of different types of actin-based assemblies. The super-resolution microscopy in Figures 6 and 7 indeed nicely demonstrate that existence of actin as either dense clouds or clearly resolved fibers. Overall, this is an interesting manuscript that uses a simplified model system to study the organization of actin at presynapse-like structures. The super-resolution images provide exciting evidence for the existence of distinct actin structures in different parts of the presynapse, which provides many avenues for further research. Overall, the data appear solid and well-quantified. However, I do have a number of comments about the relevance of the model system and the presentation and interpretation of the data.

      Major comments

      Model system

      1. The authors use the bead-triggered formation of synaptic-like presynaptic structures, because they argue that the post-synaptic actin would overwhelm any actin signal from the presynapses. This is demonstrated in Figure S1, where the authors use 20 div neurons and show that post-synaptic actin is brighter than presynaptic actin. However, this demonstration raises a number of questions. Why did they authors demonstrate this with 20 div neurons, whereas the rest of the manuscript focusses on neurons that are much younger (9 div)? These younger neurons typically have much less dendritic spines and the cultures are easier to navigate due to the lower density of axons. In their examples, the authors also mostly highlight excitatory synapses located at actin-rich dendritic spines and it is not directly evident that this is also true for inhibitory synapses that typically connect to the dendritic shaft. For example, the example shown in Figure 6B suggests that actin density is higher at the pre-synapse than at the post-synapse. According to the authors 20-40% of synapses in their culture are inhibitory synapses, so I would encourage the authors to try to get more data on real synapses, perhaps at 9 div. In my view, demonstration of the existence of the proposed actin structure at bonafide synapses would make the author's claims much stronger.
      2. Related to the earlier point, the authors also acknowledge that alternative approaches, such as expression of lifeAct or GFP-actin would be possible to probe presynaptic actin organization at real synapses, but that these constructs can only be used at low levels in order to prevent artefacts. While in principle this is correct, recent successes in establishing knock-in approaches in differentiated neurons (i.e. HITI, ORANGE) have shown that endogenous actin can be tagged with small tags. Therefore knock-in of small epitope tags, such as HA or ALFA, would be a relatively straightforward way to selectively label presynaptic actin in real synapses. As mentioned above, demonstration of the existence of the proposed actin structure at bonafide synapses would make the author's claims much stronger.
      3. The authors show that various key presynaptic proteins are about half as abundant on the synaptic-like presynaptic structure compared to real synapses. They argue that this might reflect the fact that the bead-induced synapse-like structures were analyzed two days after addition of the beads, whereas the real synapses might already have matured longer. This could easily be tested by altering the incubation time of beads and/or by analyzing how the average intensity of synapses develops over time. In addition, it is important to know how the intensity of actin compares between real synapses (NS) and induced synapses, because some images suggests that the enrichment at induced synapses is higher than at real synapses. This could suggest that the actin structures found at induced synapses might be specific to these induced hemisynapses. Data presentation
      4. In Figure 1, the authors classify induced hemisynapses as either enriched for actin or not and then move on to analyze the intensity of bassoon, synapsin, synoptophysin, vamp2 for the two classes of hemisynapses. This promotes a very binary view of the structures they induce, whereas I assume that the intensity of actin will vary from structure to structure. Therefore, it would be more useful to plot the intensity of bassoon, synapsin, synoptophysin, vamp2 as a function of the intensity of actin. This could reveal that there are two clear regimes, but a least that would provide a justification for the classification into A+ and A-.
      5. In Figure 3, vesicular cycling is compared between actin-enriched and non-enriched induced hemisynapses. It would be good to include a comparison with real synapses.

      Biological interpretation

      1. The title of the manuscript is "Distinct nano-structures support a multifunctional role of actin at presynapses". I agree that the identification of distinct structures supports the idea that they have distinct functions, but I do not think that the current manuscript really demonstrates that the distinct nano-structures support different roles. The result that actin stabilization and disassembly both affect vesicular cycling is taken as support for the idea that distinct actin structures coexist within the presynapse. In my view, it mostly demonstrates that a dynamic actin cytoskeleton is needed for vesicular cycling. Given the role of actin dynamics in endocytosis, this is not really a surprise. Likewise, the authors interpret the experiments in Fig. 5, where different actin nucleators are inhibited, as further evidence for distinct presynaptic structures. Although these might well exist, I am not sure if these experiment reveal that. Inhibition of Arp2/3 has very little effect, whereas inhibition of formins leads to more actin. Overall, these pharmacological experiments are very hard to interpret and do not directly promote the idea that different nucleators generate presynaptic actin networks with distinct functions.
      2. The imaging in Figure 6 and 7 is very nice and does provide new insights into the organization of actin at induced hemi-synapses. While I certainly do understand the desire to name these structures, it is currently not clear what the structural difference would be between an actin mesh and an actin corral, and between an actin rail and an actin trail. Intuitively, one would think that meshes and corrals are generated by Arp2/3 based nucleation, while rails and trails are generate by formins. However, the analysis in Figure 7 does not really support this thinking. It could be that the quantification in Figure 7 a bit too coarse grained, because it mostly looks if structures are present or not. A more subtle analysis would analyze the intensities or sizes of meshes, rails and corrals and plot those in different conditions. Did the authors try something like that?
      3. I do agree with the speculation that corrals could be used to confine vesicles (and perhaps to fish them out of the flow of axonal transport by actin-binding tethering factors), while the rails could facilitate local transport to the active zone. While the authors hypothesize that the actin mesh could inhibit vesicle release, another option is that it promotes endocytosis.

      Questions related to the major comment - Are the key conclusions convincing?

      The data is convincing, some of the data is over-interpreted. - Should the authors qualify some of their claims as preliminary or speculative, or remove them altogether?

      See my specific comments above. - Would additional experiments be essential to support the claims of the paper? Request additional experiments only where necessary for the paper as it is, and do not ask authors to open new lines of experimentation.

      It would be fantastic if the authors can provide evidence for the structures they describe by the analysis of real synapses, for example by using knock-in approaches. Without additional data, the authors should reconsider some of their claims and interpretations and provide a more balanced discussion. - Are the suggested experiments realistic in terms of time and resources? It would help if you could add an estimated cost and time investment for substantial experiments.

      It is my understanding that the team has successfully achieved endogenous tagging of actin, but they might have good reasons for not using it for the current story. - Are the data and the methods presented in such a way that they can be reproduced?

      Most procedures are well-documented. Some of the classification strategies are not extensively outlined. - Are the experiments adequately replicated and statistical analysis adequate?

      Yes, the supplemental tables with replicate number etc is very useful.

      Minor comments

      1. In Figure 4, the effect of actin destabilization or stabilization on the level of synaptic proteins is examined. Here the axis labels are a bit confusing. The label "swin A-" suggests that there were also swin A+ synapses that were not analyzed. Similarly, the cuc A+ label suggest the exclusion of cuc A- synapses. Were there still A+ / A- synapses upon treatment of swin/cuc, respectively? If so, what happened to the relative abundance of A+/A- in these conditions?
      2. The last paragraph of the result section should be part of the discussion section.

      Referees cross-commenting

      Overall, all three reviewer provide very similar feedback.

      • a need for more careful interpretation of the induced structures and their relevance to real synapses.
      • more characterization of the induced hemi-synapses in terms of localization (mostly on axons), actin density compared to real synapses, intensity of synaptic proteins at different days after induction, etc. A key concern is that the identified actin structures are specific for these induced structures.
      • a need for more careful interpretation of the effects of the various drug treatments, as well as the formation and function of the various actin structures
      • an encouragement to try to selectively label presynaptic actin using genetic approaches

      Significance

      This work provides exciting evidence for the existence of distinct actin structures in different parts of the presynapse, which provides many avenues for further research. While the structure and dynamics of the presynapse has been studied for decades, little is known about the organization of the actin cytoskeleton at these key sites of neuronal signal transmission.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      Bingham et al., studied the composition and nano-structure of presynaptic elements induced by polylysine beads. By isolating the presynaptic element from the actin-rich postsynaptic compartment, this system makes it possible to study the organization of actin structures at high resolution. Using a combination of pharmacological interventions and super-resolution imaging, the authors distinguish three different types of actin structures at presynaptic elements.

      Overall, this is a very careful study, using an innovative approach and state-of-the-art imaging techniques to visualize actin structures in presynaptic structures. The characterization of bead-induced presynaptic structures is elaborate and provides support that these structures can be used as a proxy of 'natural' synapses. The imaging, particularly the super-resolution imaging if of very high standard and convincing. The writing is overall clear and pleasant to read. Nevertheless, a number of concerns prevent strong conclusions from this study about how different actin structures support the structure and function of natural synapses.

      • The characterization of bead-induced structures is quite extensive and also literature suggests that these structures are 'functional' in the sense that vesicle recycling çan be detected. Nevertheless, from the images it is not clear that these structures are always formed on axons. It seems the beads also induce presynaptic elements on dendrites, which would be highly artificial and prevent strong conclusions about axonal actin organization. Can the authors provide support that these "presynaptic structures" are preferentially formed on axons?
      • The key observation of this paper is the existence of distinct actin structures highlighted in figures 6 and 7. These structures are indeed distinguishable by eye and could be of interest, but it remains unclear how these were defined. This is not described in the methods section, which makes it difficult to interpret the value of this observation. Were any (quantitative) criteria defined to outline these structures?
      • The pharmacological intervention experiments in Figure 7D show modest, non-significant effects. More support that these structures are truly distinct and functional is required or conclusions about the existence of distinct actin assemblies should be reworded. Also see points below.
      • A main concern is to what extent the contacts with the bead induce specific actin structures that are not representative of actin structures in natural synapses. The artificial, strong recruitment of heparan sulfate glycans could potentially induce the clustering of all kinds of adhesion complexes that promote actin polymerization/branching etc. and overrules the fine scale distribution of adhesion molecules and other presynaptic proteins in natural synapses. It thus remains unclear how specific and relevant these actin assemblies are for synapses. When comparing the natural synapse and induced synapse in Figure 6B and C it seems that particularly the 'actin rails' seem to originate from the bead contact (while similar structures cannot be seen in the natural synapse) and could thus reflect strong actin polymerization induced simply by the contact with the bead. More support that the observation of distinct actin structures is reminiscent of structures found at natural synapses is required. Experiments to show that such structures for instance do not form on non-neuronal cells could be considered. Experiments at natural synapses would of course be preferred. Have the authors considered genetic approaches to label actin in isolated cells? In that manner the presynaptic compartment could also easily be distinguished from the postsynaptic dendritic spines. A number of actin reporters (LifeAct, Ftractin, Utrophin, etc) are available, and albeit these have their limitations, if carefully used, these could be used to demonstrate similar structures. Alternatively, several CRISPR/Cas9 genome editing approaches are now available (HiUGE, ORANGE, TKIT, CRISPIE) that enable visualization of endogenous actin in isolated neurons.
      • Since actin structures are responding to changes in neuronal activity, the (selective) modulation of these three types of actin assemblies to short- and/or long-term changes in neuronal activity would be of great interest and help support the functional relevance of this observation.

      Minor:

      • The term "presynapse" is not very commonly used in literature to indicate the presynaptic compartment. Particularly in this case it is a bit misleading as it suggests there is also a corresponding postsynaptic element. I would recommend to use 'presynaptic compartment' or alike.
      • Reference to Glebov et al., Cell Reports 2017 is missing, even though this is a highly relevant study using SMLM to study active zone organization and the role of actin dynamics in regulating AZ composition.
      • The labels in the images with the purple font on the black background (e.g., "Bassoon" in Figure 1A) are hardly visible
      • The graphs should include an indication of statistical significance
      • The term "concentration" is sometimes used when intensity measurements are done, but that is not appropriate in that case and should be rephrased to e.g. "relative amount" or alike.
      • In abstract: "dependance" > "dependence
      • Page 1: "Decade of research" > "Decades of research
      • Page 4: "not at high" > "not as high"
      • On page 10, "dependant" > "dependent'
      • On page 14, "recruitment of neuroligin1" , the authors mean "neurexin1"?

      Referees cross-commenting

      I agree with the comments of the other reviewers, I see overall very similar comments. This is a strong and valuable study, but the main conclusions need more experimental support. Particularly, more quantitative characterisation of the induced synapses is needed and more support that the proposed classification of actin structures is representative of structures found in physiological synapses. For the last point, genetic labelling of actin structures in physiologic synapses is indeed strongly encouraged as also indicated by reviewer #3.

      Significance

      This study provides a detailed characterization of bead-induced presynaptic structures that allow the investigation of presynaptic actin structures at unprecedented resolution. The authors suggest that the presence of distinct actin structures at presynaptic specializations serve different functions to sustain synaptic transmission. These findings are of great interest for molecular and cellular neuroscientists interested in presynaptic mechanisms, but also more generally audience interested in super-resolution microscopy and/or the actin cytoskeleton.

      I have experience in molecular and cellular neuroscience, synaptic transmission, and diverse microscopy techniques.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      Summary

      While phalloidin has been widely used to stain actin, its major limitation is that it labels both the presynaptic and postsynaptic actin structures, making it difficult to properly the comparatively less dense actin characterize within the presynapse. To overcome these difficulties, Bingham et al. made use of the well-established presynaptic induction model that utilises polylysine-coated beads to induce rapid formation of functionals synapses. They apply wide field fluorescence imaging showing that actin is enriched in these bead-induced synapses and apply actin nucleation and polymerisation inhibitors to characterise essential role of actin in maintaining the levels of other presynaptic components. Further, they apply nanoscale STORM and PAINT imaging to uncover distinct actin structures within the presynapse and how this is regulated by nucleation mechanisms.

      Major Comments

      • After the seeding beads in DIV 9-10 neurons the authors fix the neurons 48 hours later and indicate that they have functional synapses (S+) with protein presynaptic protein intensity less than natural synapses (Fig. 1). A key argument made by the authors is that the natural synapses are older than the bead-induced S+ ones. The expectation therefore then is that if the fix the neurons 72 or 96 hours after bead treatment, then the S+ should have a higher intensity than synapses after 48 hours. The authors should provide a time graded increase in synaptic component intensity to solidify their argument.
      • Based on Fig.2 and Fig.3, the authors indicate actin enrichment in a subset of bead-induced synapses. The authors however did not provide a reasoning for why there is no actin enrichment in up to 30% of beads-induced synapses.
      • Does shorter time treatment (for example 30 mins) of the induced synapses with swinholide and cucurbitacin E similarly reduce the intensity of presynaptic components?
      • Using the CK666 actin nucleation inhibitor, the authors should provide supplemental information of no changes in intensity to other synaptic vesicle proteins (for example SV2) and to that of other presynaptic plasma membrane proteins such as Syntaxin-1 and Munc13.
      • The authors should expand their STORM experiments to verify other data acquired with wide field fluorescence microscope such as actin enrichment (Fig.2) in bead-induced synapses

      Minor Comments

      • The authors should cite Rust et al., 2006 Nat. Methods as reference to first mention of STORM in paragraph 2 of the introduction.
      • In Fig.S1, the authors indicate the dashed yellow lines as the presynapse. A better label, that stains the entire length of the presynapse might be needed to convincingly indicate presynaptic actin (dashed yellow lines) outside the bassoon labelling.
      • The authors should provide quantification for the FM1-43 dye loading experiments in Fig.S2E and F.
      • The author should provide representative images for the data from natural synapses in Fig.S5 for control, swinholide A, cucurbitacin E, CK666 and SMIFH2 treatments.

      Referees cross-commenting

      I agree with the comments from the other two reviewers that more work needs to be done to sufficiently justify the conclusions made.

      Significance

      • A key highlight that Bingham et al brings to the field is that they push the field forward from previous classical work done by the Zhuang lab (Xu et al., 2013 Science) where they showed novel data on the periodic organisation of actin cytoskeleton. This was done especially by provided a mechanism (bead induced synapse production) to narrow down on viewing presynaptic actin without overlapping 'noise' from postsynaptic region.
      • Applying multiple nanoscale advanced imaging (STORM and PAINT) also helped solidify their data and provide hitherto unseen characterisation of actin structures.
      • This manuscript will provide key insight to all scientists in the field of cell biology and cancer research that work on precisely characterising the cytoskeletal structure of the cell.
      • Key words of field of expertise: Super-resolution microscopy, Neuroscience, Dementia, Synapse, Drosophila
    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Reply to the reviewers

      1. General Statements

      It is the common view of all three reviewers that we have not utilized adequate in vitro/biochemical evidence to support the idea that SATB1 protein undergoes liquid-liquid phase separation. We do agree with the reviewers that our manuscript lacks biochemical evidence to support such notion. Though we find it quite interesting and we would like to suggest for the first time in the field of chromatin organization and function, based upon the action of SATB1, that this protein does exist in at least two polypeptide isoforms (764 and 795 amino acids long) which display different phase separation propensity and therefore confer different actions in regulating the (patho)physiological properties of a murine T cell.

      Every single research group that works on SATB1, considered so far only a single protein isoform, that is, the shorter isoform of 764 amino acids and no tools, such as isoform-specific antibodies have been developed to discriminate the two isoforms and thus being able to assign unique functions to each isoform. We do understand that such a report, suggesting the presence of two protein isoforms, with potentially quite diverse functions, would question (not necessarily by the authors of this manuscript, since no such comment is included in our manuscript) the conclusions drawn in the literature assigning all biochemical properties to a single, short isoform of SATB1. Moreover, all the genetically modified mice that have been analyzed so far (including our group), deleted both Satb1 isoforms. Our future research approaches should, from now on, consider unraveling the isoform-specific functions of SATB1 and their involvement in physiology and disease. This could also deem useful to explain the quite diverse, both positive and negative effects of SATB1 in transcription regulation. Another major objection of the reviewers was that we should provide cumulative supporting evidence for the existence of the long SATB1 isoform, or at least evaluate the specificity of our custom-made antibody.

      Taking under consideration the aforementioned constructive criticism of the three reviewers we would like to perform (most of the suggested experiments have already been performed) additional experiments to support our claims in the manuscript. These experiments are described below as a point-by-point reply to each point raised by the reviewers.

      In line with the aforementioned rationale, we propose the title of our manuscript to change into “Two SATB1 isoforms display different phase separation propensity”, if our manuscript is considered for publication.

      1. Description of the planned revisions

      **Reviewer #1**:

      4) Lack of in vitro reconstitution experiments with purified long and short SATB1

      **PLANNED EXPERIMENT #1**

      We do realize this shortcoming of our work. We have to note that purifying recombinant SATB1 protein is quite a challenging task, yet we 1. cloned both Satb1 cDNAs for the long and short isoforms, 2. we successfully expressed both proteins in great quantity and quality and we are willing to perform these experiments if our work is considered for publication.

      This proposed experiment has also been requested by Reviewers #2 and #3.

      **Reviewer #2**:

      1. Moreover, an important and direct experiment would be to clone the long isoform in a suitable vector and overexpress in the cell line (as done for the canonical isoform in Supp Fig 1a). This would unequivocally show the efficacy of the antibody and thus the following usage of the same for various assays.

      **PLANNED EXPERIMENT #2**

      This is a great suggestion. We have cloned the long and short Satb1 cDNAs in pEGFP-C1 vector. We will transfect these plasmids in NIH 3T3 fibroblasts and we will perform Western blot analysis, utilizing the antibody raised against the extra 31 amino acids long peptide present only in the long SATB1 isoform, for the following samples: 1. NIH-3T3 whole cell protein extracts, 2. protein extracts from NIH 3T3 fibroblasts transiently transfected with the pEGFP-C1 plasmid, 3. protein extracts from NIH 3T3 fibroblasts transiently transfected with the pEGFP-long_Satb1_ plasmid and 4. protein extracts from NIH 3T3 fibroblasts transiently transfected with the pEGFP-short_Satb1_ plasmid.

      This experiment will consist another proof regarding the specificity of the antibody raised against the extra 31 amino acids long peptide present only in the long SATB1 isoform.

      **Minor comments:**

      1. On pg 6, related to Figure 1, the authors mention 'It should also be noted that when investigating the SATB1 protein levels, we have to bear in mind that the antibodies targeting the N-terminus of SATB1 protein cannot discriminate between the short and long isoforms'. The authors reason that their sizes are too close. It is indeed possible, and widely studied in biochemistry to assess various factors on protein migration (such as PTMs). The authors should validate this aspect (as it is important as per their premise) and perform separation based on charge as well and also use a commercial antibody to validate the same.

      (Experiments already performed)

      We have adapted the text so that it does not imply that the two isoforms cannot be separated by size. This part in lines 102-107 then reads: “It should also be noted that when investigating the SATB1 protein levels, we have to bear in mind that the antibodies targeting the N-terminus of SATB1 protein cannot discriminate between the short and long isoforms, thus we can only compare the amount of the long SATB1 isoform to the total SATB1 protein levels in vivo conditions. To overcome this limitation and to specifically validate the presence of the long SATB1 protein isoform in primary murine T cells, we designed a serial immunodepletion-based experiment (Fig. 1e, Supplementary Fig. 1a).”

      Moreover, in the revised version of the manuscript we now provide a number of additional proofs supporting the presence of the long isoform and also the specificity of the long isoform-specific antibody. As evident in the text cited above, in the revised Fig. 1e,f and revised Supplementary Fig. 1a,b; we present two immunodepletion experiments which should alone address the Reviewer’s concerns. Moreover, we added Supplementary Fig. 1c; demonstrating that the long isoform-specific antibody does not detect any protein in cells with conditionally depleted SATB1 (Satb1_fl/fl_Cd4-Cre+), supporting its specificity. The custom-made and publicly available antibodies targeting all SATB1 isoforms were also verified in Supplementary Fig. 1d. Moreover, the long isoform and all isoform antibodies display similar localization in the nucleus (Supplementary Fig. 1e; their co-localization based on super-resolution microscopy is also quantified in Supplementary Fig. 5a).

      In our accompanying revised manuscript Zelenka et al., 2022 (https://doi.org/10.1101/2021.07.09.451769), we will provide yet another piece of evidence, consisting of bacterially expressed short and long SATB1 protein isoforms detected by western blot using either the long isoform-specific or the non-selective all SATB1 isoform antibodies.

      **PLANNED EXPERIMENT #3**

      Although we think that in the revised version of the manuscript, we have provided enough proof about the existence of the long isoform in primary murine thymocytes we would like to try the following approach as suggested by this Reviewer.

      The pI of the two SATB1 isoform is quite similar. The pI of the short SATB1 isoform is 6.09 and for the long SATB1 isoform is 6.18. We will perform 2D PAGE coupled to Western blotting utilizing the antibodies detecting the long and all SATB1 isoforms. Given the fact that both isoforms are post-translationally modified to a various degree, it will be extremely difficult to discriminate between the long and short unmodified versus the long and short post-translationally modified proteins especially in the absence of a specific antibody only for the short isoform.

      **Reviewer #3**

      1. Hexanediol is another assay frequently used in phase-separation studies. However, hexanediol has many deleterious effects on the cell, even at a fraction of the concentration normally used in phase-separation studies. Authors should show controls of cell viability, control proteins that do not phase-separate, etc. See https://www.jbc.org/article/S0021-9258(21)00027-2/fulltext.

      Secondly, hexanediol treatment should cause phase-separated protein aggregates to disperse. It is difficult to determine from the images whether or not the aggregates actually disperse or there is just less protein. In any case, small aggregates remain even after treatment, and this appears different from most other hexanediol experiments reported in the literature where the signals become more dispersed and uniform. This is likely because the samples are fixed.

      One of the main features of using hexanediol in phase-separation is to show that upon washout, LLPS aggregates can reform. Because the cells are fixed, the critical aspect of this assay is not performed. A washout and LLPS recovery would control for cell viability issues described above and would provide the opportunity to show that total SATB1 protein levels did not change, but its distribution did, which is the essence of this assay in the context of LLPS. This review from the Tjian group is very informative and may be a good resource:

      http://genesdev.cshlp.org/content/33/23-24/1619

      In line with our reply to point #1 of this Reviewer (page 26 of this document), we should again emphasize that we utilized the hexanediol treatment in primary murine developing T cells as this is the only way to investigate the properties of SATB1 speckles under physiological conditions. This also explains why some small insoluble structure remains after the hexanediol treatment. Note that under physiological conditions, there is a contribution of several protein variants (such as differential PTMs) out of which some will tend to form more stable structures while others could undergo LLPS. It is not clear how the washout experiment could be applied in the primary cell conditions that include cell fixation as the heterogeneity and big variation among cells would make such data analysis highly unreliable.

      **PLANNED EXPERIMENT #1**

      As we answered to point #4 of Reviewer 1 (page 2), we propose the following experiment. Although the purification of recombinant SATB1 protein is quite a challenging task, yet we 1. cloned both Satb1 cDNAs for the long and short isoforms, 2. we successfully expressed both proteins in great quantity and quality and we are willing to perform in vitro reconstitution experiments if our work is considered for publication.

      1. The major difference between the long and short isoform of SATB1 is the 31aa segment within the IDR. However the authors find that neither the long or short isoform SATB1 forms LLPS aggregates, and the IDR alone forms aggregates in the cytoplasm (Fig5) but they do not respond to Cry2 light activation. When forced to localize to the nucleus, it does not form aggregates as well (Fig6). The short isoform also did not form any aggregates. These results seem to argue against any isoform specific phase-separation. This experiment seems critical for the story, yet it does not support their overall conclusions. The authors might consider using a different cell line or perhaps do an in vitro assay using purified protein.

      I am not certain what to make of the cytoplasmic aggregation, which appears to not form upon localization to the nucleus. Because of this, it is difficult to place weight on the significance of the S635A mutation and the role that a phosphorylation of SATB1 contributes to phase-separation, let alone function There are many additional points of concern, but the ones listed above are perhaps the most significant in terms of the overall conclusions of the paper.

      In Fig. 5c we show that the full length long SATB1 isoform often aggregates unlike the short isoform. These data are accompanied with the results for the IDR region, where the situation is even more obvious (Fig. 5f,g). However, in the latter, we have to bear in mind the absence of the multivalent N-terminal part of the protein which seems to be essential for the overall phase behavior of the protein as indicated in Fig. 4b,c.

      **PLANNED EXPERIMENT #1**

      To further support LLPS of SATB1, we are considering performing the following in vitro experiment, as we answered to point #4 of Reviewer 1 (page 2). Although the purification of recombinant SATB1 protein is quite a challenging task, yet we 1. cloned both Satb1 cDNAs for the long and short isoforms, 2. we successfully expressed both proteins in great quantity and quality and we are willing to perform in vitro reconstitution experiments if our work is considered for publication.

      1. Description of the revisions that have already been incorporated in the transferred manuscript

      **Reviewer #1 (Evidence, reproducibility and clarity)**:

      This paper looks at an important nuclear matrix protein SATB1, which is a well known global chromatin organizer and help chromatin loop attach to the nuclear matrix. The paper starts with identification of novel short and long form of SATB1. Both the isoform consist of a prion like low complexity domains, but the long isoform additionally contain an extra EPF domain next the Prion like low complexity domain. The paper reports that in murine cells the long isoform is 3-4 fold more abundant than the short isoform. By using STED microscopy they show SATB1 foci lie next to transcription sites in the nucleus. They conclude by looking at the spherical shape of the SATB1 foci and the susceptibility of SATB1 staining after 1,6 hexanediol treatment that SATB1 forms the small foci in the nucleus due to LLPS. The authors also use RAMAN spectroscopy to conclude a change in nuclear chemical space in absence of SATB1 but without much explanation about which chemical bond or nuclear sub structure change correspond to the change in principal component analysis from Raman spectroscopy. The authors use the light inducible aggregation cry2 tag with the PrD domain of SATB1 and compare it with the Cry2-FUS-LC domain to conclude that the SATB1 LC domain can undergo LLPS. The authors hint at involvement of RNA and also DNA in the LLPS of the SATB1 but without going into any detail. Reviewer: The paper reports that in murine cells the long isoform is 3-4 fold more abundant than the short isoform.

      Actually, in page 5 (lines 94-96) of the manuscript we write: “We confirmed that in murine thymocytes the steady state mRNA levels of the short Satb1 transcripts were about 3-5 fold more abundant compared to the steady state mRNA levels of the long Satb1 transcripts (Fig. 1d).” Although the steady state mRNA levels of the long isoform are less abundant compared to the shorter isoforms, the long isoform protein levels are almost comparable to the short isoform as deduced based on immunofluorescence experiments. Moreover, Using our two immunodepletion experiments we quantified the difference, estimating the long isoform being 1.5× to 2.62× less abundant than the short isoform (Fig. 1f and Supplementary Fig. 1b; compare lanes 2 & 3 at the lower panel). • Regarding the RAMAN spectroscopy experiments please see Minor Comment #1 of this Reviewer (page 10).

      The key conclusions of the paper are- A) SATB1 undergoes LLPS. But this conclusion is drawn after correlative experiments as detailed below-

      This conclusion is indeed made based on correlative experiments only for the primary murine T cells, which do not allow for any targeted experiments. However, the use of in vitro cell lines allowed us to validate these findings using the optogenetic approaches, utilizing additional experimentation.

      1) observation of spherical punctae by STED-which could also seem spherical due to their small size. The resolution limit achieved by the STED microscopy used in this paper is not determined or mentioned clearly.

      In the revised version of the manuscript, we have specified the resolution of our systems, for STED in Lines 745-746: ”This system enables super-resolution imaging with 35 nm lateral and 130 nm axial resolution.” and for SIM in Lines 759-761: “Images were acquired over the majority of the cell volume in z-dimension with 15 raw images per plane (five phases, three angles), providing ~120-135 nm lateral and ~340-350 nm axial resolution for 488/568 nm lasers, respectively.” The size of the observed speckles is thus above the resolution limit with sizes ranging between 40-80 nm.

      The resolution of our systems is routinely verified by the following methods: The resolution of our OMX (SIM-3D) system was tested using ARGO-SIM slide containing a pattern of 36 µm long lines with gradually increasing spacing ranging from (left to right) 0 to 390 nm, with a step of 30 nm (Fig. 1 below). Our SIM system was able to clearly resolve two lines separated by 120 nm.

      2) No live cell FRAP experiment with fluorescent SATB1 long or short isoform to show that these foci are liquid like

      We did perform FRAP experiments for the SATB1 N-terminus optogenetic construct as demonstrated in Fig. 4f. We did not perform FRAP in the primary murine T cells as this is not technically feasible without creating a new mouse line with fluorescently labeled protein. In the revised version of the manuscript, we additionally performed FRAP experiments for the full length short and long isoform of SATB1 labeled with EGFP and transfected into the NIH-3T3 cell line (Supplementary Figure 6f).

      5) LLPS is strongly coupled to the cellular concentration of the proteins. Authors should quantify the cellular concentration of the long and short isoform in the cells.

      We did consider protein concentration in our analyses of optogenetic constructs in Fig. 4b,d,e and Supplementary Fig. 6a,b,c. Quantifying the physiological cellular concentration of short and long SATB1 protein isoforms in primary T cells is impossible due to the inherent inability to discriminate between the isoforms by two antibodies, in the absence of Satb1 isoform-specific knockout mice.

      However, an approximation of the cellular concentration can be obtained from our immunodepletion experiments. On top of the original immunodepletion experiment that we now present in Supplementary Fig. 1a,b; in the revised version of the manuscript we have repeated the experiment in Fig. 1e,f. Comparison of the two bands for the long and short SATB1 isoforms in the lower panel of the western blot figures suggest that the long SATB1 isoform protein levels are 1.5× to 2.62× less abundant than the short isoform, according to the original and new immunodepletion experiment, respectively. This is now also included in the main text in Lines 110-116: “This experiment can also be used for approximation of the cellular protein levels of SATB1 isoforms in primary murine thymocytes. Comparison of the two bands for long (lane 2) and short SATB1 (lane 3) isoform in the lower panel of Fig. 1f and Supplementary Fig. 1b, suggests that the long SATB1 isoform protein levels may be about 1.5× to 2.62× less abundant than the short isoform, according to the two replicates of our immunodepletion experiment, respectively.”

      Major conclusion B)- SATB1 regulates transcription and splicing.

      This was also shown previously and in this paper they show the close proximity of the transcription site and SATB1 foci by microscopy. Hexanediol treatment which lead to loss of colocalization between FU foci and SATB1 is also taken as an evidence in regulation of transcription is not right as the transcription foci itself can be dissolved using 1,6 Hexanediol. Although the rate of transcription is not measured quantitatively.

      As mentioned in comment #3 (page 29) of this Reviewer, unfortunately there is no better tool to investigate these questions in primary cells than using microscopy approaches in conjunction with hexanediol treatment. However, we should also note that there is an accompanying manuscript from our group that is currently being under revision in another journal (preprint available: Zelenka et al., 2021; https://doi.org/10.1101/2021.07.09.451769). In the preprint manuscript, we showed that: 1. the long SATB1 isoform binding sites have increased chromatin accessibility than what expected by chance (Fig. 3b), 2. there is a drop in chromatin accessibility at SATB1 binding sites in Satb1 cKO mouse (Fig. 3c) and 3. this drop in chromatin accessibility is especially evident at the transcription start sites of genes (Supplementary Fig. 1i)

      We believe that, together these data suggest a direct involvement of SATB1 in transcription regulation. Also note the vast transcriptional deregulation that occurs in Satb1 cKO T cells, affecting the expression of nearly 2000 genes (Fig. 2f, this revised manuscript). That is why we believe that the co-localization analysis, using super-resolution microscopy, presented in Fig. 2c and quantified in Fig. 3g, represents a nice additional support to our claims. Moreover, in the revised version of the manuscript we now present a positive correlation between SATB1 binding and deregulation of splicing (Supplementary Fig. 4d) which also supports its direct involvement in the regulation of transcriptional and co-transcriptional processes.

      In the revised version of the manuscript we have made this clear in Lines 182-194: “Satb1 cKO animals display severely impaired T cell development associated with largely deregulated transcriptional programs as previously documented19,37,38. In our accompanying manuscript19, we have demonstrated that long SATB1 isoform-specific binding sites (GSE17344619) were associated with increased chromatin accessibility compared to randomly shuffled binding sites (i.e. what expected by chance), with a visible drop in chromatin accessibility in Satb1 cKO. Moreover, the drop in chromatin accessibility was especially evident at the transcription start site of genes, suggesting that the long SATB1 isoform is directly involved in transcriptional regulation. Consistent with these findings and with SATB1’s nuclear localization at sites of active transcription, we identified a vast transcriptional deregulation in Satb1 cKO with 1,641 (922 down-regulated, 719 up-regulated) differentially expressed genes (Fig. 2f). Specific examples of transcriptionally deregulated genes underlying SATB1-dependent regulation are provided in our accompanying manuscript19. Additionally, there were 2,014 genes with altered splicing efficiency (Supplementary Fig. 4d-e; Supplementary File 3-4). We should also note that the extent of splicing deregulation was directly correlated with long SATB1 isoform binding (Supplementary Fig. 4d).”

      Major conclusion C)-Post transcriptional modification is important for SATB1 function.

      This point is just barely touched upon in the last figure of the paper

      We would not call the identification of the novel phosphorylation site as a main conclusion of our manuscript. Though, it is already known that posttranslational modifications of SATB1 are important for its function as they can function as a molecular switch rendering SATB1 into either an activator or a repressor (Kumar et al., 2006; https://doi.org/10.1016/j.molcel.2006.03.010).

      In the revised manuscript, we support the effect of serine phosphorylation on the DNA binding capacity of SATB1 by another experiment. We have performed DNA affinity purification experiments utilizing primary thymocyte nuclear extracts treated with phosphatase (Supplementary Fig. 7b). We found that SATB1’s capacity to bind DNA (RHS6 hypersensitive site of the TH2 LCR) is lost upon treatment with phosphatase (Supplementary Fig. 7c). These results are in line with the data presented in Supplementary Fig. 7d, indicating the lost ability of SATB1 to bind DNA upon mutating the discovered phosphorylation site S635. Given the importance of posttranslational modifications of proteins on LLPS, we found it relevant to include it in our manuscript. Even more so, when we identified SATB1 aggregation, upon mutation of this phospho site (Fig. 6d).

      Overall I find that the major conclusion-point A and B, is based on very indirect experiments and needs much more convincing data and the role of SATB1 LLPS in cells should be demonstrated more rigorously. And conclusion C is barely described and needs a lot more cell biological and genetic evidence.

      One of the major assets of our work is that most of our data are based on the analysis of primary murine T cells and thus investigating the biological roles of the endogenous SATB1 protein, under physiological conditions. We apologize that we did not make it clear to this Reviewer, that our system has certain inherent limitations due to the utilization of primary cells.

      I do not recommend publishing the paper in current state. The story needs much more experiment to convincingly prove the major conclusions. Further, the MS needs more careful thinking and presentation to make it streamlined.

      We hope that in the revised version we have significantly improved the quality of our manuscript by implementing the suggested changes.

      Minor comments: One of the major flaw of the paper is the use too many techniques without proper explanation. E.g. use of STED and RAMAN microscopy need controls and explanation on what is being quantified. The use of Raman microscopy to quantify the nuclear environment of nucleus is not related to the chromatin organization or LLPS of SATB1 at all. And no information is provided at all which aspect of nuclear organization is being measured in Raman and what it means for the LLPS of SATB1.

      We do provide quite a thorough explanation of Raman spectroscopy and the underlying quantification in Lines 224-231: “we employed Raman spectroscopy, a non-invasive label-free approach, which is able to detect changes in chemical bonding. Raman spectroscopy was already used in many biological studies, such as to predict global transcriptomic profiles from living cells42, and also in research of protein LLPS and aggregation43–47. Thus we reasoned that it may also be used to study phase separation in primary T cells. We measured Raman spectra in primary thymocytes derived from both WT and Satb1 cKO animals and compared them with spectra from cells upon 1,6-hexanediol treatment. Principal component analysis of the resulting Raman spectra clustered the treated and non-treated Satb1 cKO cells together, while the WT cells clustered separately (Fig. 3h).” We also do provide controls as the method was performed on both treated and untreated WT and Satb1 cKO cells.

      Regarding the RAMAN spectroscopy experiments we now provide more information on the changes of chemical bonds altered between wild type and Satb1 cKO thymocytes. Following principal component analysis, we have extracted the two main principal components that were used for the clustering of our data. The differences are presented in Supplementary Fig. 5d.

      We do realize that RAMAN spectroscopy, although a quite novel approach utilized to study LLPS, has not been used to study LLPS in live cells. If deemed proper we are willing to avoid presenting these results in this manuscript.

      Similarly for Hexanediol treatment, duration of treatment is missing. Hexanediol can also dissolve the liquid like transcription foci. And hence a decrease in correlation between SATB1 foci and FU foci cannot be taken as a measure of SATB1 foci connection to transcription alone

      The duration of hexanediol treatment was 5 minutes as presented in Line 724 and in the revised version of the manuscript also in Lines 1206-1207. We should also note that additionally, we performed experiments with different hexanediol concentrations and timing varying from 1 minute to 10 minutes with results consistent with the data presented.

      It is not very clear how many times the STED or Raman microscopy is done on how many samples and biological replicates. Similarly for RNA sequencing number of samples and description of controls are missing. Also if the sequencing data is made publicly available is not clear.

      Data availability is clearly stated in Lines 506-509: “RNA-seq experiments and SATB1 binding sites are deposited in Gene Expression Omnibus database under accession number GSE173470 and GSE173446, respectively. The other datasets generated and/or analyzed during the current study are available upon request.”

      The Reviewer’s token is “wjwtmeeeppovzqx”.

      RNA sequencing was performed in a biological triplicate for each genotype as stated in the GEO repository and now also in Line 566 of the revised manuscript.

      In Lines 180-181, we also state that it was performed on Satb1 cKO animals and WT mice as a control: “we performed stranded-total-RNA-seq experiments in wild type (WT) and Satb1fl/flCd4-Cre+ (Satb1 cKO) murine thymocytes”.

      In Lines 739-740, we now also state that all imaging approaches were performed on at least two biological replicates (different mice) and please also note the fact that all findings were based on data from both STED and 3D-SIM methods, allowing to minimize detection of artifacts. In the Raman spectroscopy figure, each point represents measurements from an individual cell and for each condition we used 2-5 biological replicates (Lines 831-832 & Line 1169).

      Similarly, in Lines 129-132 we provided a quite detailed description of differences between STED and 3D-SIM, even though these techniques are not that rare as Raman spectroscopy in biology research.

      Additional control is needed to report the resolution limit of Superresolution techniques-STED and 3D-SIM systems used by them.

      We have already provided this information in our reply to comment #1 of this Reviewer (pages 6-7): In the revised version of the manuscript, we have specified the resolution of our systems, for STED in Lines 745-746: ”This system enables super-resolution imaging with 35 nm lateral and 130 nm axial resolution.” and for SIM in Lines 759-761: “Images were acquired over the majority of the cell volume in z-dimension with 15 raw images per plane (five phases, three angles), providing ~120-135 nm lateral and ~340-350 nm axial resolution for 488/568 nm lasers, respectively.” The resolution of our systems is routinely verified by the following methods: The resolution of our OMX (SIM-3D) system was tested using ARGO-SIM slide containing a pattern of 36 µm long lines with gradually increasing spacing ranging from (left to right) 0 to 390 nm, with a step of 30 nm (Fig. 1 below). Our SIM system was able to clearly resolve two lines separated by 120 nm.

      Would be very helpful if the zonation was plotted for the FluoroUridine (FU) also to show that Zone1 (heterochromatin) is completely depleted of FU, and is present in other regions.

      In the revised version of the manuscript, we performed the suggested analysis and in Supplementary Fig. 3a we now show that indeed FU is significantly less localized to Zone 1 (heterochromatin) and has the most abundant localization in Zones 3 and 4, similar to the localization of SATB1 protein, as demonstrated in Fig. 2b.

      Scale bar needed figure 3d

      In the revised version of the manuscript, we included scale bars which are both 0.5 µm (line 1213).

      Perfectly rounded SATB1 foci- this does not mean LLPS. For LLPs measurement, protein condensate dynamics measurement by FRAP or fusion experiments is required. What is the size of condensates? and cellular concentration of SATB1? Will SATB1 undergo LLPS in vitro at similar concentrations? does SATB1 interact with DNA or RNA to undergo LLPS ?

      We toned down this sentence which now reads: “Here we demonstrated its connection to transcription and found that it forms spherical speckles (Fig. 1g), markedly resembling phase separated transcriptional condensates. (Lines 200-202)”.

      Moreover, as explained in earlier replies to comments of this Reviewer, we cannot perform FRAP on primary murine T cells without generating a new mouse line. We did, however, use FRAP and other in vitro approaches including visualization of droplet fusion in ex vivo experiments utilizing cell lines. Moreover, we are willing to demonstrate the LLPS properties of SATB1 on in vitro purified SATB1 protein as indicated in the suggested experiment of Point#4 (page 2).

      After careful reading of the MS I conclude that the main conclusions of the paper are very preliminary and need much more detailed experiments. So does not qualify to get published at all at this stage.

      **Reviewer #1 (Significance)**:

      The present manuscript tries to connect the phase separation of SATB1 to understanding the mechanism of SATB1 function in cells. One of the major hallmarks of phase separation is dynamic, liquid-like behaviour and in absence of these measurements, it is very difficult to say that the current manuscript has made any contribution to showing that SATB1 can phase separate.

      The presence of 2 isoforms of SATB1 is a novel finding and the paper could have focused more on this. E.g. elucidate expression of the isoform during thymocyte development and maturation.

      As a reviewer my expertise are cell biology experiments, microscopy, in vitro reconstitution assays, RNA binding proteins, RNA and RBP condensate formation. And I feel that the reconstitution experiments are an important tool for understanding phase behaviour of proteins and also to gauge if this behaviour can occur or not in cellular concentration and conditions.

      I do not have sufficient expertise in Raman microscopy and hence the information provided in the MS on this part was not enough to understand the experiment and conclusions drawn from it.

      **Reviewer #2 (Evidence, reproducibility and clarity)**:

      The authors have reported the existence of a 'long' SATB1 isoform which also undergoes LLPS. The authors tried to draw multiple comparisons and pointed out distinction between phase properties of SATB1 isoforms. The authors also touch upon two functional roles of SATB1. Although a wide array of assays are used, the data presented and hence the manuscript makes multiple transitions into disparate hypotheses without diving deep into a single hypothesis. As a result, the connections drawn are unclear, and do not converge at best. The authors have used number of techniques, however, the results do not support their conclusions and they appear hastily drawn. It is not clear why the authors jump from one context to the other, discussing LLPS first, then transcription, splicing, post-translational modification and finally cancer. The link between all of these isn't clear and not fully supported by data. It appears that the authors wish to focus on Satb1's physiological role in development, hence the data on breast cancer is confusing. Thus, this work suffers from multiple pitfalls. Specific comments are given below:

      Major comments 1. Importantly, in Fig 1d, there is no statistics shown. There is no mention of number of replicates as well in the legends. Proper statistical evaluation is critical for interpreting this result.

      Please note that Fig. 1d only serves as a control to the sequencing experiment in Fig. 1b. In Line 566, we now state that for the RNA-seq: “A biological triplicate was used for each genotype.” To validate these data, we further designed a RT-qPCR experiment which was performed on three technical replicates from a male and female mouse. We now state this in Line 636. For the low number of samples, statistical tests are not accurate but we still added t test into the figure Fig. 1d and specified it also in the figure legend in Line 1169-1170.

      1. Figure 1f presents one of the weakest evidences in the manuscript. There are a number of corrections needed. Firstly, being their major and only validation figure for their custom antibody, the immunoblot is not clean, bands are fuzzy. Importantly, as the authors claim that the antibody is highly specific to 'long' SATB1, after the IP there should be only a single band (like input) of Satb1 long. But that does not seem to be the case, rather an array of bands are visible below (lane 2 top panel). This could easily mean that the shorter isoforms or non-specific protein bands are also pulled down with the 'long' form specific antibody. Therefore, raising a critical concern regarding the specificity of the antibody.

      • The long antibody was raised in mice inoculated with the extra peptide present in the long isoform only. Therefore, the capacity of this antibody precipitating the shorter isoforms, which do not express the sequence of the extra peptide (EP, Figure 1a) in not possible. • We have repeated the immunodepletion experiment and we now provide the results in Fig. 1f and Supplementary Fig. 1b. The western blot in Fig. 1f is now cleaner and supports quite convincingly the presence of a long SATB1 isoform. Given the lack of isoform-specific knockouts which we could utilize to immunoprecipitate or detect the different isoforms in a single cell (or cell population), the utilized approach of immunodepletion and subsequent western blotting is the approach we thought of implementing. • As shown in Fig. 1f and Supplementary Figure 1b, the long isoform SATB1 antibody has the capacity to recognize the long isoform in murine thymocyte protein extracts but not the short SATB1 isoform (please compare lane 3 in the two western blots utilizing either the antibody for the long isoform -top panel - or the antibody that detects both isoforms (lower panel). • We have performed Immunofluorescence experiments utilizing the antibody detecting the long SATB1 isoform in thymocytes isolated from either C57BL/6 or Satb1 cKO mice. The antibody is specific to the SATB1 protein since there is no signal in immunofluorescence experiments utilizing the knockout cells (Supplementary Figure 1c). • We have performed Immunofluorescence experiments utilizing thymocytes and the antibody detecting the long SATB1 or a commercially available antibody detecting all SATB1 isoforms. The pattern of SATB1 subnuclear localization is similar for both antibodies (Supplementary Figure 1e). • In our accompanying revised manuscript Zelenka et al., 2022 (https://doi.org/10.1101/2021.07.09.451769), we provide yet another piece of evidence, consisting of bacterially expressed short and long SATB1 protein isoforms detected by western blot using either the long isoform-specific or the non-selective all SATB1 isoforms antibodies. • Regarding the additional bands detected in the immunoprecipitation experiment presented in the original Supplementary Figure 1b (lane 2), it is not surprising that additional bands appear in a sample of protein extracts that is used for several hours for the immunoprecipitation experiments, while the “input” sample simply denotes protein extract that is frozen at -80oC right after the preparation of protein extracts until use. It is well-established that SATB1 is the target of proteases which might as well be active during the immunoprecipitation steps (2 consecutive immunoprecipitation steps take place). Therefore, the immunoprecipitated material cannot necessarily be a copy of the input material displaying a single protein band even if protease inhibitors are included in the buffers.

      Taken together the experiments described here we showed that the antibody raised against the extra 31 aa long peptide, present only in the long SATB1 isoform, is specific for this isoform.

      1. Related to Fig. 2 a, the authors state on Pg 5, '....the euchromatin and interchromatin regions (zones 3 & 4, Fig. 2a, b).' Although the DAPI correlation seems clear, there is no mention on how they reached the above said correlation. They should at least show a parallel speckle staining for HP1 or signature modification such as H3K4me9 STEDs for making supporting such a claim. DAPI alone is not sufficient. The authors should rectify the text thoroughly for many such interpretations without validation/reference or provide relevant data.

      This is a great suggestion we have again taken under consideration and we added the following experiments and the appropriate changes in the revised version of our manuscript. • We modified the text and added a reference to Miron et al., 2020 (https://doi.org/10.1126/sciadv.aba8811) supporting our claims regarding SATB1 localization in relation to DAPI staining. • We have also added new microscopy images for HP1, H3K4me3 and fibrillarin staining and quantified the localization of FU-stained sites of active transcription in nuclear zones, to further support our claims. • This whole modified part in Lines 139-167 then reads: “ “The quantification of SATB1 speckles in four nuclear zones, derived based on the relative intensity of DAPI staining, highlighted the localization of SATB1 mainly to the regions with medium to low DAPI staining (zones 3 & 4, Fig. 2a, b). A similar distribution of the SATB1 signal could also be seen from the fluorocytogram of the pixel-based colocalization analysis between the SATB1 and DAPI signals (Supplementary Fig. 2a). SATB1’s preference to localize outside heterochromatin regions was supported by its negative correlation with HP1β staining (Supplementary Fig. 2b). Localization of SATB1 speckles detected by antibodies targeting all SATB1 isoforms and/or only the long SATB1 isoform, revealed a significant difference in the heterochromatin areas (zone 1, Fig. 2b), where the long isoform was less frequently present (see also Fig. 2a and Fig. 3c). Although, this could indicate a potential difference in localization between the two isoforms, due to the inherent difficulty to distinguish the two based on antibody staining, we refrain to draw any conclusions. The prevailing localization of SATB1 corresponded with the localization of RNA-associated and nuclear scaffold factors, architectural proteins such as CTCF and cohesin, and generally features associated with euchromatin and active transcription32. This was also supported by colocalization of SATB1 with H3K4me3 histone mark (Supplementary Fig. 2c), which is known to be associated with transcriptionally active/poised chromatin. Given the localization of SATB1 to the nuclear zones with estimated transcriptional activity32 (Fig. 2b, zone 3), we investigated the potential association between SATB1 and transcription. We unraveled the localization of SATB1 isoforms and the sites of active transcription labeled with 5-fluorouridine. Sites of active transcription displayed a significant enrichment in the nuclear zones 3 & 4 (Supplementary Fig. 3a), similar to SATB1. As detected by fibrillarin staining, SATB1 also colocalized with nucleoli which are associated with active transcription and RNA presence (Supplementary Fig. 3b). Moreover, we found that the SATB1 signal was found in close proximity to nascent transcripts as detected by the STED microscopy (Fig. 2c). Similarly, the 3D-SIM approach indicated that even SATB1 speckles that appeared not to be in proximity with FU-labeled sites in one z-stack, were found in proximity in another z-stack (Supplementary Fig. 3c). Additionally, a pixel-based colocalization of SATB1 and sites of active transcription is quantified later in the text in Fig. 3g, supporting their colocalization.”

      1. The authors mention, '...of the different SATB1 isoforms, uncovered by the use of the two different antibodies, relied in the heterochromatin areas (zone 1), where the long isoform was less frequently...' There is no supporting figure number mentioned. The authors need to show a zone-by-zone comparison images for 'all iso' vs 'long' iso of SATB1. Just to reiterate, there is a need for a heterochromatin mark to unambiguously call out the distinction.

      We should remind that there is an inherent difficulty to accurately compare localization of short and long SATB1 isoforms in primary cells, especially due to the lack of Satb1 isoform-specific knockout mice. There is no way to detect only the short isoform in these primary cells as there are only antibodies targeting the long or all SATB1 isoforms. Therefore, we cannot set up additional experiments probing these questions.

      In line with this, in the revised version of the manuscript, we toned down our statements regarding the differential localization of the two isoforms in primary cells. We only refer to it as an indication and we support it by adding references to the relevant figures. This part now reads: “Localization of SATB1 speckles detected by antibodies targeting all SATB1 isoforms and/or only the long SATB1 isoform, revealed a significant difference in the heterochromatin areas (zone 1, Fig. 2b), where the long isoform was less frequently present (see also Fig. 2a and Fig. 3c). Although, this could indicate a potential difference in localization between the two isoforms, due to the inherent difficulty to distinguish the two based on antibody staining, we refrain to draw any conclusions. (Lines 145-150)”

      1. On the same lines, '....Given the localization of SATB1 to the nuclear zones with estimated transcriptional activity (Fig. 2b, zone 3)....' How was the region labelled as transcriptionally active? For the statistical analysis of speckle count for the two antibodies' staining, the claim posited is a bit bigger. This could simply be true for that cell. The authors thus need to statistically analyse the speckle counts for multiple cells. This needs to be done for all imaging statistics done in multiple figures throughout the manuscript.

      As mentioned in our reply to the two previous comments of this Reviewer, transcriptional activity in relation to the nuclear zonation is well established in the literature. To make this clear, we have now added the reference to Miron et al., 2020 (https://doi.org/10.1126/sciadv.aba8811) supporting our claims and additionally we have also included HP1, H3K4me3 and fibrillarin staining and quantification of FU signal in the nuclear zones. Moreover, it is not clear to which particular cell the comment refers to. The presented dots in Fig. 2b represent individual cells and the relative proportions of speckles in each nuclear zone are plotted on the y axis. In the revised version of the manuscript, we added into the figure the number of cells scored and we adapted the figure legend so that it is absolutely clear that we have analyzed multiple cells:

      “Nuclei of primary murine thymocytes were categorized into four zones based on the intensity of DAPI staining and SATB1 speckles in each zone were counted. Images used represented a middle z-stack from the 3D-SIM experiments. The graph depicts the differences between the long and all SATB1 isoforms’ zonal localization in nuclei of primary murine thymocytes. (Lines 1189-1193)”

      1. For figure 2c. the authors have used 5 Fluorouridine for nascent RNA speckles. 5FU is known to have a spread signal type (with strong association to nucleolus as well). This is not the case for the image presented 2c. The authors should resolve this by showing different sets of images.

      Developing and naive T cells are very unique in terms of their metabolic features and thus they should not be directly compared with other cell types. Therefore, we would not expect to see such a spread FU pattern as previously shown for other cell types. Having said that, we could not find any reference publication that utilized super-resolution microscopy to detect localization of FU-stained sites of active transcription in developing primary T cells. However, we performed additional immunofluorescence experiments to demonstrate the colocalization or its lack between SATB1 and HP1 (Supplementary Fig. 2b), H3K4me3 (Supplementary Fig. 2c) and fibrillarin (Supplementary Fig. 3b). Moreover, we provide additional regions of SATB1 and FU staining in Supplementary Fig. 3c. The modified text reads:

      “We unraveled the localization of SATB1 isoforms and the sites of active transcription labeled with 5-fluorouridine. Sites of active transcription displayed a significant enrichment in the nuclear zones 3 & 4 (Supplementary Fig. 3a), similar to SATB1. As detected by fibrillarin staining, SATB1 also colocalized with nucleoli which are associated with active transcription and RNA presence (Supplementary Fig. 3b). Moreover, we found that the SATB1 signal was found in close proximity to nascent transcripts as detected by the STED microscopy (Fig. 2c). Similarly, the 3D-SIM approach indicated that even SATB1 speckles that appeared not to be in proximity with FU-labeled sites in one z-stack, were found in proximity in another z-stack (Supplementary Fig. 3c). Additionally, a pixel-based colocalization of SATB1 and sites of active transcription is quantified later in the text in Fig. 3g, supporting their colocalization. (Lines 157-167)”

      1. Fig 2 d., the authors have suddenly jumped solely to 'all iso' Satb1 here for IP MS. Is there a reason for that? The authors either need to do this with 'long iso' antibody or remove the analysis from the manuscript as it does not add to their primary aim of the manuscript. Also, the authors have only selectively talked about two clusters? What about chromatin related proteins? It is quite intuitive to have highest enrichment of these given previous literature and even IP MS data by other groups. Thus, it is necessary to revise this thoroughly or remove it.

      We appreciate the acknowledgment by the Reviewer that our IP-MS data identified anticipated factors. In the revised version of the manuscript we modified the underlying text to accommodate references to these former findings revealing interactions between SATB1 and chromatin modifying complexes: “Apart from subunits of chromatin modifying complexes that were also detected in previous reports25,33–36, unbiased k-means clustering of the significantly enriched SATB1 interactors revealed two major clusters consisting mostly of proteins involved in transcription (blue cluster 1; Fig. 2d and Supplementary Fig. 4c) and splicing (yellow cluster 2; Fig. 2d and Supplementary Fig. 4c). (Lines 170-174)”

      Please note that many subunits of chromatin modifying and chromatin-related complexes are in fact characterized as transcription-related factors, therefore our statements are not in disagreement with the former findings. Note also that we provide Supplementary File 1 & 2 with comprehensive description of our IP-MS data for the readers’ convenience. Please also note that we are the first group to report on the existence of the long isoform. Therefore, we find it absolutely reasonable to perform IP-MS experiment for all SATB1 isoforms which can then be used for a comparison with other publicly available datasets. We believe that there is no contradiction in this experimental setup in relation to the rest of the manuscript. We discuss the two major clusters simply because they are the two major clusters identified as indicated in Fig. 2d. Additionally, in Supplementary Fig. 4c, we provide a comprehensive description of all significantly enriched interactors including their cluster annotation and thus anyone can investigate the data if needed.

      1. In relation to Fig. 2f, the authors have not mentioned any of the previously published work on Satb1 CD4 specific KO, not even the RNA seq studies the other groups have reported under the same condition. Only an unpublished reference of their own (preprint) is cited. It is imperative to show how much their data corroborates with other published studies. Additionally, what is the binding site status of dysregulated genes?

      In the revised version of the manuscript, we have included the references to other studies using the same Satb1 conditional knockout. Moreover, we have clarified the relationship between SATB1 binding and gene transcription. The modified part in Lines 182-194 now reads: “Satb1 cKO animals display severely impaired T cell development associated with largely deregulated transcriptional programs as previously documented19,37,38. In our accompanying manuscript19, we have demonstrated that long SATB1 isoform specific binding sites (GSE17344619) were associated with increased chromatin accessibility compared to randomly shuffled binding sites (i.e. what expected by chance), with a visible drop in chromatin accessibility in Satb1 cKO. Moreover, the drop in chromatin accessibility was especially evident at the transcription start site of genes, suggesting that the long SATB1 isoform is directly involved in transcriptional regulation. Consistent with these findings and with SATB1’s nuclear localization at sites of active transcription, we identified a vast transcriptional deregulation in Satb1 cKO with 1,641 (922 down-regulated, 719 up-regulated) differentially expressed genes (Fig. 2f). Specific examples of transcriptionally deregulated genes underlying SATB1-dependent regulation are provided in our accompanying manuscript19. Additionally, there were 2,014 genes with altered splicing efficiency (Supplementary Fig. 4d-e; Supplementary File 3-4). We should also note that the extent of splicing deregulation was directly correlated with long SATB1 isoform binding (Supplementary Fig. 4d).”

      1. In context of Figure 3a and b, the authors write .'...The long SATB1 isoform speckles evinced such sensitivity as demonstrated by a titration series with increasing concentrations of 1,6-hexanediol treatment followed...' Whereas it is apparent from the image at least that overall numbers of individual speckles are instead increased at both 2 and 5%. There is although a clear spreading of restricted speckles compared to the controls. The authors should revise their figures to substantiate the associated text. Furthermore, there needs to be 'all iso' SATB1 3D SIM imaging and not just quantitation for comparison. This is also true for panel c in order to demonstrate the effect.

      In the revised Fig. 3a we provide new images which better reflect the underlying data analysis. Moreover, in Fig. 3c and Fig. 3d we provide an additional comparison between SATB1 all isoforms and long isoform staining and their changes upon hexanediol treatment, detected by both the 3D-SIM and STED approaches. It is true that upon treatment, there tend to be more speckles, however these are much smaller as they are gradually being dissolved. Depending on the treatment duration, the cells are swollen which is reflected in increased spreading of speckles. Nevertheless, the nuclear size was considered in all the quantification analyses. We believe that the new images provide better evidence of SATB1’s sensitivity to hexanediol treatment.

      1. Fig. 3 d also does not clearly demonstrate what the authors have claimed '...hexanediol treatment highly decreased colocalization between...' The figure shows at best decreased signal intensity for both SATB1 and FU. We suggest that the authors should give a statistical analysis as well for the colocalization points between the two using multiple source images. Lastly, the two images shown (control and treated), there seems to be a clearly visible magnification difference. The authors should clarify this.

      • In the revised version of the manuscript in Figure 3d, we have provided scale bars, which are both 0.5 µm (line 1213). The difference observed by this Reviewer is actually the main reason why we provided this image. Figure 3d demonstrates that upon hexanediol treatment, the speckles are mostly missing or significantly reduced in size, for both FU and SATB1 staining. • Moreover, the suggested statistical analysis is also provided – in Figure 3e. In Figure 3e, we performed pixel-based colocalization analysis which is a method that allows both quantification and statistical comparison of colocalization between two factors and between different conditions. Please note especially the decreased colocalization between long SATB1 isoform and FU-stained sites of active transcription in the left graph, which is in agreement with our claims in the manuscript. • Moreover, our data are compared to a negative control, i.e. 90 degrees rotated samples, which is a common method in colocalization experiments as described for example in Dunn et al., 2011 (https://doi.org/10.1152/ajpcell.00462.2010). • Additionally, we provide Costes’ P values which are based on randomly scrambling the blocks of pixels (instead of individual pixels, because each pixel’s intensity is correlated with its neighboring pixels) in one image, and then measuring the correlation of this image with the other (unscrambled) image. Please see Costes et al., 2004 (https://doi.org/10.1529%2Fbiophysj.103.038422) for more details.

      1. Figure 3f. The authors show the PC plot for Raman spectroscopy for phase behaviour due to Satb1. The experiment and its related text seems misinterpreted; the authors write...' ese bonds were probably enriched for weak interactions responsible for LLPS that are susceptible to hexanediol treatment. This shifted the cluster of WT treated cells towards the Satb1 cKO cells. However, the remaining covalent bonds differentiated the WT samples from Satb1 cKO cells......' whereas the clusters are clearly far away in 3D for both WT and KO while being closer to their respective treatments. Which is also intuitive given the sensitivity of Raman spectroscopy. Thus, it is more likely to be treatment effect and KO effect as separate. Treatment of WT leads to KO like spectra is far-fetched. Thus, the authors need to show separate PCs and modify their text thoroughly.

      We do not present any 3D graph hence it is not clear what the Reviewer refers to. Please also note that as stated in Lines 817-818, we used a customized Raman Spectrometer. Therefore, this approach allowed us to measure Raman spectra at cellular and even sub-cellular levels. For example, solely by utilizing Raman spectroscopy, we can now distinguish euchromatin and heterochromatin, methylated and unmethylated DNA and RNA, etc. This, together with other reports, such as Kobayashi-Kirschvink et al., 2018 (https://doi.org/10.1016/j.cels.2018.05.015) and Kobayashi-Kirschvink et al., 2022 (https://doi.org/10.1101/2021.11.30.470655), indicate a potential use of Raman in biological research. In our manuscript, we used this method as a supplementary approach, however we do find it noteworthy. We should also emphasize that in the revised Raman spectroscopy Fig. 3h, each point represents measurements from an individual cell and for each condition we used 2-5 biological replicates (Lines 831-832 & Lines 1225-1226). We specifically refer to the principal component 1 (PC1) that differentiates the samples. Therefore, there are certain spectra (representing certain chemical bonding) that allowed us to differentiate between WT and Satb1 cKO. The same type of bonding was then affected when WT samples were treated with hexanediol and we also had controls to rule out the impact of hexanediol on the resulting spectra.

      1. In Fig 4. b, The authors have shown the propensity of SATB1 N terminus to phase separate using different optodroplet constructs. Although the imaging is clear, why are the regions selected not uniform when comparing various constructs?

      We have selected images that would best represent each category. Please note that this was live cell imaging of photo-responsive constructs, thus there are many limitations regarding the area selection. Very often, even the brief time of bright light exposure to localize cells may trigger protein clustering. Upon disassembly, every new light exposure of the same cell then triggers much faster assembly which skews the overall results. It is therefore desired to work fast, while neglecting selection of equally sized cells. Moreover, it is not clear how would the proposed change improve the quality of our manuscript.

      1. Figure 5a, the disassembly should be shown for 'long' SATB1 as well. On pg 13, the authors write '....cytoplasmic protein aggregation has been previously described for proteins containing poly-Q domains and PrLDs..' no reference given.

      • In the revised version of the manuscript, we present the assembly and disassembly for both short and long full length SATB1 optogenetic constructs. To increase clarity, we present the behavior of the short and long isoforms as two separate images in Figure 5a and Figure 5b, respectively. • Moreover, we provided references to the statement regarding aggregation of PrLD and poly-Q-containing proteins in Lines 305-309, which now reads: ”Since protein aggregation has been previously described for proteins containing poly-Q domains and PrLDs8,11,38,39, we next generated truncated SATB1 constructs encoding two of its IDR regions, the PrLD and poly-Q domain and in the case of the long SATB1 isoform also the extra peptide neighboring the poly-Q domain (Fig. 1a and 4a).”

      1. Fig. 5d, Is there an amino-acid specific reasoning to support the authors claim of the phase behaviour due to extra peptide? They need to show a proper control with equal extra (unrelated) peptide to show the specificity. Are the shorter isoform aggregates responsive to light?

      • We have referred to the amino acid composition bias in Fig. 5c. In the revised version of the manuscript, we made this clear by showing the composition bias in the new revised Fig. 5e. The related part of the main text then reads: “Computational analysis, using the algorithm catGRANULE37, of the protein sequence for both murine SATB1 isoforms indicated a higher propensity of the long SATB1 isoform to undergo LLPS with a propensity score of 0.390, compared to 0.379 for the short isoform (Fig. 5d). This difference was dependent on the extra peptide of the long isoform. Out of the 31 amino acids comprising the murine extra peptide, there are six prolines, five serines and three glycines – all of which contribute to the low complexity of the peptide region3 (Fig. 5e).” (Lines 298-304) • Moreover, we should note that the low complexity extra peptide of the long SATB1 isoform directly extends the PrLD and IDR regions as indicated in Fig. 4a and which we now directly state in Lines 304-305: “Moreover, the extra peptide of the long SATB1 isoform directly extends the PrLD and IDR regions as indicated in the Fig. 4a.” • We show in Fig. 4, that the N terminus of SATB1 undergoes LLPS. Since this part of SATB1 is shared by both isoforms, it is reasonable to assume that both isoforms would undergo LLPS. This is also in line with the observed photo-responsiveness of both short and long full length SATB1 isoforms in CRY2 optogenetic constructs in revised Fig. 5a,b, and similar FRAP results for both short and long full length SATB1 isoform constructs transiently transfected in NIH-3T3 cells in the revised Supplementary Fig. 6f. However, the main reason why we think that the difference in LLPS propensity between the isoforms is important is because the long isoform is more prone to aggregate compared to the short isoform, as documented in Fig 5c,f,g and Supplementary Fig. 5f.

      1. Fig 6c., It is important that authors show the data for NLS+short iso data as well to prove their hypothesis.

      As shown in original Figure 5d, the long SATB1 isoform undergoes cytoplasmic aggregation, unlike the short SATB1 isoform (as shown in the same Figure). Therefore, an image of the NLS + short isoform would not be related to our hypothesis. Actually, we wanted to reverse the long SATB1 isoform’s relocation, from the aggregated form in the cytoplasm into the nucleus. Nevertheless, to show the complete picture, in the revised version of the manuscript in Figure 6c, we now provide data for both short and long SATB1 isoforms.

      1. Fig 6d., The authors claim that mutating a specific P site changes the phase behaviour of the 'short iso'. Does it also increase for the long isoform? The authors need to confirm this in order to verify the effect of a single P site outside of oligomerization domain. ...' phosphorylation status; when phosphorylated it remains diffused, whereas unphosphorylated SATB1 is localized to PML bodies....' This being an important premise, thus should be moved to the results text.

      In the revised version of the manuscript, we moved the part regarding PML in the results section, as suggested by the Reviewer. Moreover, we included additional experiments probing the impact of association between PML and two SATB1 full length isoforms on their dynamics. The modified section in Lines 357-368 now reads: “In relation to this, a functional association between SATB1 and PML bodies was already described in Jurkat cells64. We should note that PML bodies represent an example of phase separated nuclear bodies65 associated with SATB1. Targeting of SATB1 into PML bodies depends on its phosphorylation status; when phosphorylated it remains diffused, whereas unphosphorylated SATB1 is localized to PML bodies66. This is in line with the phase separation model as well as with our results from S635A mutated SATB1, which has a phosphorylation blockade promoting its phase transitions and inducing aggregation. To further test whether SATB1 dynamics are affected by its association with PML, we co-transfected short and long full length SATB1 isoforms with PML isoform IV. The dynamics of long SATB1 isoform was affected more dramatically by the association with PML than the short isoform (Supplementary Fig. 7e), which again supports a differential behavior of the two SATB1 isoforms.”

      Moreover, given the localization of the discussed phosphorylation site in the DNA binding region of SATB1 we did test its impact on DNA binding as documented in the revised Supplementary Fig. 7d. Additionally, as we have noted in our answer in Major Comment C of this reviewer, to further support the effect of serine phosphorylation on the DNA binding capacity of SATB1 we have performed DNA affinity purification experiments utilizing primary thymocyte nuclear extracts treated with phosphatase (Supplementary Fig. 7b) We found that SATB1’s capacity to bind DNA (RHS6 hypersensitive site of the TH2 LCR) is lost upon treatment with phosphatase (Supplementary Fig. 7c).

      1. Pg 16,. The authors have tried to explain multiple things (concepts of self-regulation, accessibility) which is quite tangential. There is no inference to Fig 6f., which is showing the opposite to what the authors had postulated. This portion should either be removed or explained with a rationale. The writing also needs to be revised thoroughly in this section. Similarly, the discussion should also be modified.

      The rationale for the original Fig. 6f (revised Fig. 6g) was described in great detail in Lines 330-343 of the original manuscript. It is not clear why the Reviewer assumes that it shows the opposite to our hypothesis. As we explained, the increased accessibility allows faster read-through by RNA polymerase, and thus the exon with higher accessibility is more likely to be skipped. The exact relationship is shown in the revised Fig. 6g where the increased accessibility is associated with the expression of the short isoform, whereas the long isoform expression needs lower chromatin accessibility which allows the splicing machinery to act on the specific exon to be included. We reason that these findings are important and relevant because: 1) we suggest a potential regulatory mechanism for the SATB1 isoforms production. This is highly relevant to this manuscript given the fact that this is the first report on the existence of the long SATB1 isoform, and 2) the differential production of the long/short SATB1 isoforms has a potential relevance to breast cancer prognosis. In the revised version of the manuscript we added Fig. 6f, which now indicates the differential chromatin accessibility in human breast cancer patients and accordingly the expression of the long SATB1 isoform are associated with worse patient prognosis as indicated in Fig. 6h and Supplementary Fig. 8a,b. In the revised version of the manuscript, we substantially modified the text in Lines 374-408, to make the relevance of all these conclusions clear. The modified text now reads: “Therefore, we reasoned that a more plausible hypothesis would be based on the regulation of alternative splicing. In our accompanying manuscript19, we have reported that the long SATB1 isoform DNA binding sites display increased chromatin accessibility than what expected by chance (Fig. 3b in 19), and chromatin accessibility at long SATB1 isoform binding sites is reduced in Satb1 cKO (Fig. 3c in 19), collectively indicating that long SATB1 isoform binding promotes increased chromatin accessibility. We identified a binding site specific to the long SATB1 isoform19 right at the extra exon of the long isoform (Fig. 6e). Moreover, the study of alternative splicing based on our RNA-seq analysis revealed a deregulation in the usage of the extra exon of the long Satb1 isoform (the only Satb1 exon affected) in Satb1 cKO cells (deltaPsi = 0.12, probability = 0.974; Supplementary File 4). These data suggest that SATB1 itself is able to control the levels of the short and long Satb1 isoforms. A possible mechanism controlling the alternative splicing of Satb1 gene is based on its kinetic coupling with transcription. Several studies indicated how histone acetylation and generally increased chromatin accessibility may lead to exon skipping, due to enhanced RNA polymerase II elongation48,49. Thus the increased chromatin accessibility promoted by long SATB1 isoform binding at the extra exon of the long isoform, would increase RNA polymerase II read-through leading to decreased time available to splice-in the extra exon and thus favoring the production of the short SATB1 isoform in a negative feedback loop manner. This potential regulatory mechanism of SATB1 isoform production is supported by the increased usage of the extra exon in the absence of SATB1 in Satb1 cKO (Supplementary File 4). To further address this, we utilized the TCGA breast cancer dataset (BRCA) as a cell type expressing SATB150. ATAC-seq experiments for a series of human patients with aggressive breast cancer51 revealed differences in chromatin accessibility at the extra exon of the SATB1 gene (Fig. 6f). In line with the “kinetic coupling” model of alternative splicing, the increased chromatin accessibility at the extra exon (allowing faster read-through by RNA polymerase) was positively correlated with the expression of the short SATB1 isoform and slightly negatively correlated with the expression of the long SATB1 isoform (Fig. 6f). Moreover, we investigated whether the differential expression of SATB1 isoforms was associated with poor disease prognosis. Worse pathological stages of breast cancer and expression of SATB1 isoforms displayed a positive correlation for the long isoform but not for the short isoform (Fig. 6g and Supplementary Fig. 6c). This was further supported by worse survival of patients with increased levels of long SATB1 isoform and low levels of estrogen receptor (Supplementary Fig. 6d). Overall, these observations not only supported the existence of the long SATB1 isoform in humans, but they also shed light at the potential link between the regulation of SATB1 isoforms production and their involvement in pathological conditions.”

      1. The authors should not draw conclusions based on any data which is not shown '....ed differences in chromatin accessibility at the extra exon of the SATB1 gene (data not shown), suggesting its potential involvement in alternative splicing regulation according to the "kinetic coupling" model...'. This has led to overspeculation and needs correction.

      In the revised version of the manuscript, we included the ATAC-seq data from human breast cancer patients in the revised Fig. 6f. The legend of this figure now reads: “Human TCGA breast cancer (BRCA) patient-specific ATAC-seq peaks51 span the extra exon (EE: extra exon; labeled in green) of the long SATB1 isoform. Note the differential chromatin accessibility in seven selected patients, emphasizing the heterogeneity of SATB1 chromatin accessibility in cancer. Chromatin accessibility at the promoter of the housekeeping gene DNMT1 is shown as a control. (Lines 1281-1285)” Accordingly, we have also modified the main text: “ATAC-seq experiments for a series of human patients with aggressive breast cancer68 revealed differences in chromatin accessibility at the extra exon of the SATB1 gene (Fig. 6f). In line with the “kinetic coupling” model of alternative splicing, the increased chromatin accessibility at the extra exon (allowing faster read-through by RNA polymerase) was positively correlated with the expression of the short SATB1 isoform and slightly negatively correlated with expression of the long SATB1 isoform (Fig. 6g).” (Lines 395-339)”

      Minor comments: 1. On pg 4, the authors state 'Here, we utilized primary murine T cells, in which we have identified two full-length SATB1 protein isoforms.' Whereas only one 'long' isoform is identified and the other is the canonical version. The authors should correct the statement.

      In the revised version of the manuscript, we modified this statement as follows: ”In this work, we utilized primary developing murine T cells, in which we have identified a novel full-length long SATB1 isoform and compared it to the canonical “short” SATB1 isoform.” (Lines 64-66)”

      1. Fig. 1 a , Is there a specific reason to generate a custom-made antibody for 'all' SATB1, using similar regions that are already commercially available. This becomes redundant otherwise, because there is no apparent difference in detection compared to the commercial one (Suppl. Fig 1a). Antibody generation strategy (1a) should be moved to supplementary. Additionally, authors have obtained the custom antibodies from a commercial source, therefore, the text should reflect the same alongside relevant details.

      The custom-made SATB1 antibody targeting the amino-terminal region of the protein has been developed in order to be utilized for detecting the native form of the protein. Unlike commercially available antibodies raised against either short peptides or denatured forms of the protein we have utilized the native form of the amino-terminal part of the protein for raising this antibody. To be honest, this antibody has been raised in order to be utilized in ChIP-seq experiments since no commercially available antibody is of high quality for this approach. Moreover, the original Figure 1a was utilized in order to provide an overview of the SATB1 protein structure which is highly relevant to understand its biophysical properties and not for presenting the strategy for raising a custom-made antibody for SATB1.

      1. Fig 3e: what is the control used here? In their Pearson correlation analysis, there seem to be significant reduction in control sets as well upon treatment. This needs to be clarified.

      We used scans rotated by 90° which served as a negative control, as stated in Line 769: “SATB1 scans rotated by 90° served as a negative control for the colocalization with FU.” Note that this is a commonly used control in colocalization experiments as described for example in Dunn et al., 2011 (https://doi.org/10.1152/ajpcell.00462.2010).

      Additionally, we provide Costes’ P values which are based on randomly scrambling the blocks of pixels (instead of individual pixels, because each pixel’s intensity is correlated with its neighboring pixels) in one image, and then measuring the correlation of this image with the other (unscrambled) image. Please see Costes et al., 2004 (https://doi.org/10.1529%2Fbiophysj.103.038422) for more details. Moreover, it was actually anticipated to see a decrease in colocalization upon hexanediol treatment even in the negative control, as hexanediol significantly reduces both SATB1 and FU speckles as established in Fig. 3a-d.

      1. Pg 10, the authors claim that '..., thus we reasoned that it may also be used to study phase separation...' But there have been numerous reports starting from 2018, which have utilized this technique in corelation to phase behaviour (albeit individual proteins). The authors should include proper citations as they are extending an idea from the same field to their specific need.

      In the revised version of the manuscript, we included relevant citations to support the use of Raman spectroscopy in LLPS research: “Raman spectroscopy was already used in many biological studies, such as to predict global transcriptomic profiles from living cells42, and also in research of protein LLPS and aggregation43–47. Thus we reasoned that it may also be used to study phase separation in primary T cells.” (Lines 225-228)”

      1. For Fig 5b, there should be a comparative image for 'short' isoform.

      In the revised Figure 5c we have included a comparative image for the short SATB1 isoform.

      1. In the context of Figure 5c, the authors claim ...' Note also the higher LLPS propensity of the human long SATB1 isoform compared to the murine SATB1...' Why suddenly human and mouse comparisons are drawn? This figure should be moved to supplementary.

      The comparison between the human and mouse SATB1 isoforms has been implemented because it is relevant for our claims regarding the increased SATB1 aggregation in human cells in relation to the revised Fig. 6f,g,h and Supplementary Fig. 6c,d. This is also discussed in Lines 479-482, which read: “This is particularly important given the higher LLPS propensity of the human long SATB1 isoform compared to the murine SATB1 (Fig. 5d). Therefore, human cells could be more susceptible to the formation of aggregated SATB1 structures which could be associated with physiological defects.”

      **Reviewer #3 (Evidence, reproducibility and clarity):**

      Zelenka et al., focus on a T cell genome-organizing protein, SATB1, to show that SATB1 undergoes liquid liquid phase-separation (LLPS), and distinct isoforms confer different LLPS-related biophysical properties. They generate a long-isoform specific antibody and conduct several experiments to test for LLPS and compare LLPS properties between the long-isoform relative to the whole SATB1 protein population. Given that SATB1 plays important roles in T cell development and in cancer, interrogating SATB1 biophysical properties is an important question. However, there are multiple problems with the experimental setup and data that weaken their support of the conclusions. I will detail some of the major issues below:

      Regarding phase-separation There are several assays to determine whether a protein undergoes LLPS. 1. One of the first the authors address is the spherocity or roundness. Indeed, formation of spherical droplets is one evidence of the liquid nature of a protein. However, the authors use fixed preparations (which can introduce artifacts), not free-floating protein, and determine roundness by showing a 2D image. Roundness should take into account the diffraction-limits of fluorescent imaging, as many structures can be imaged to appear round by the detector. There are quantifiable measurements that can be taken on 3D images to show roundness. This would best be shown using non-fixed protein.

      • We thank this Reviewer for several insightful comments. Although, we agree with most of them, we should highlight the main goal of our manuscript, i.e. to investigate the SATB1 protein with an emphasis on its physiological roles in primary developing murine T cells. We highlight this already in the introduction in Line 64 “In this work, we utilized primary developing murine T cells,...” and mainly also in the respective part of the result section: “To probe differences in phase separation in mouse primary cells, without any intervention to SATB1 structure and expression, we first utilized 1,6-hexanediol treatment, which was previously shown to dissolve the liquid-like droplets34.(Lines 203-205)”

      • We believe that this is a very important aspect of our study that should not be overlooked. The majority of proteins perhaps behave differently under physiological and in vitro conditions. However, due to the extensive post-translational modifications affecting the properties of SATB1, its completely different localization patterns between primary developing T cells and other cell types but especially cell lines and many other aspects, it was of utmost importance to focus our research on primary T cells. Unfortunately, this was accompanied with multiple difficulties, such as that we have to use fixed cells as this is the only way to visualize SATB1 in these cells. Alternatively, one could create a new mouse line expressing a fluorescently tagged SATB1 protein, but this is beyond the scope of our work.

      • However, we should also note that many LLPS-related studies do not pay any focus on primary physiological functions of proteins and they simply focus on the investigation of protein’s artificial behavior in in vitro conditions. Having said that, we too extended our experiments in primary cells to the ex vivo studies in cell lines to further support our claims. In these experiments, we utilized live cell imaging in Fig. 4-6, quantified the spherocity in Supplementary Fig. 6, showed the ability of speckles to coalesce in Fig. 4c and also used FRAP in Fig. 4f and also in the revised version of the manuscript in Supplementary Figure 6f. Moreover, we should note that most of these experiments were designed and performed during 2017 and 2018 conforming with the standards. We are well aware of the progress in the field and impact of fixation on LLPS, as described in Irgen-Gioro et al., 2022 (https://doi.org/10.1101/2022.05.06.490956), but after over seven months of review process in another journal we also believe that these aspects should be considered not to delay further progress of the SATB1 field.

      Regarding the isoform specificity of SATB1 biophysical properties 1. The authors generate a long isoform-specific antibody. However, the western blot is not convincing that this is indeed specific to the long isoform as there is a rather large smear. Can this be improved with antibody preabsorption? Since this is a key reagent for the manuscript, improvement in antibody quality is essential.

      The custom-made antibody for the long isoform has been raised against the unique 31 amino acids long peptide present in the long SATB1 isoform. The polyclonal serum has undergone affinity chromatography utilizing the immobilized peptide (antigen) to purify the antibody. In the revised version of the manuscript we have included another immunodepletion experiment with cleaner bands (Fig. 1f). Moreover, please read our answer to Major comment #2 of Reviewer 1 that follows: • The long antibody was raised in mice inoculated with the extra peptide present in the long isoform only. Therefore, the capacity of this antibody precipitating the shorter isoforms, which do not express the sequence of the extra peptide (EP, Figure 1a) in not possible.

      • We have repeated the immunodepletion experiment and we now provide the results in Fig. 1f and Supplementary Fig. 1b. The western blot in Fig. 1f is now cleaner and supports quite convincingly the presence of a long SATB1 isoform. Given the lack of isoform-specific knockouts which we could utilize to immunoprecipitate or detect the different isoforms in a single cell (or cell population), the utilized approach of immunodepletion and subsequent western blotting is the approach we thought of implementing.

      • As shown in Fig. 1f and Supplementary Figure 1b, the long isoform SATB1 antibody has the capacity to recognize the long isoform in murine thymocyte protein extracts but not the short SATB1 isoform (please compare lane 3 in the two western blots utilizing either the antibody for the long isoform -top panel - or the antibody that detects both isoforms (lower panel).

      • We have performed Immunofluorescence experiments utilizing the antibody detecting the long SATB1 isoform in thymocytes isolated from either C57BL/6 or Satb1 cKO mice. The antibody is specific to the SATB1 protein since there is no signal in immunofluorescence experiments utilizing the knockout cells (Supplementary Figure 1c).

      • We have performed Immunofluorescence experiments utilizing thymocytes and the antibody detecting the long SATB1 or a commercially available antibody detecting all SATB1 isoforms. The pattern of SATB1 subnuclear localization is similar for both antibodies (Supplementary Figure 1e).

      • In our accompanying revised manuscript Zelenka et al., 2022 (https://doi.org/10.1101/2021.07.09.451769), we provide yet another piece of evidence, consisting of bacterially expressed short and long SATB1 protein isoforms detected by western blot using either the long isoform-specific or the non-selective all SATB1 isoforms antibodies.

      • Regarding the additional bands detected in the immunoprecipitation experiment presented in the original Supplementary Figure 1b (lane 2), it is not surprising that additional bands appear in a sample of protein extracts that is used for several hours for the immunoprecipitation experiments, while the “input” sample simply denotes protein extract that is frozen at -80oC right after the preparation of protein extracts until use. It is well-established that SATB1 is the target of proteases which might as well be active during the immunoprecipitation steps (2 consecutive immunoprecipitation steps take place). Therefore, the immunoprecipitated material cannot necessarily be a copy of the input material displaying a single protein band even if protease inhibitors are included in the buffers.

      Taken together the experiments described here we showed that the antibody raised against the extra 31 aa long peptide, present only in the long SATB1 isoform, is specific for this isoform.

      1. Fig 4 Optodroplet experiment appears to show that the N-terminus of SATB1 can undergo LLPS. The results of this assay show that SATB1 has a domain that can undergo phase-separation in isolation, but it does not show that the protein itself is a phase-separating protein. The FRAP assay methods are not provided by the authors, but this is important, as continued light activation means proteins are continuously forming aggregates, and the bleaching for FRAP should be balanced with the levels of Cry2 activation. A very good description of the methods is described in the original Optodroplet paper: https://www.sciencedirect.com/science/article/pii/S009286741631666X?via%3Dihub#sec4

      We should note that we did follow the FRAP protocol provided by the recommended study Shin et al., 2017 (https://doi.org/10.1016/j.cell.2016.11.054). Indeed, these experiments are very tricky to perform and interpret, as every cell expresses slightly different amounts of protein which is directly associated with the different speed of optoDroplet formation, and thus its propensity to aggregate upon overactivation. On the other hand, there need to be continuous activation during the FRAP experiment as the lack of activation laser would result in fast disassembly of the optoDroplets, counteracting the FRAP results. Moreover, the optoDroplets actively move around the cell in all dimensions which makes the accurate measurement of signal intensity really challenging, even with an adjusted pinhole. Therefore, we do not think that FRAP is the best approach to examine the behavior of optoDroplets.

      Either way, we have now described the detailed FRAP protocol in Lines 889-898, which read: “For the FRAP experiments, cells were first globally activated by 488 nm Argon laser illumination (alongside with DPSS 561 nm laser illumination for mCherry detection) every 2 s for 180 s to reach a desirable supersaturation depth. Immediately after termination of the activation phase, light-induced clusters were bleached with a spot of ∼1.5 μm in diameter. The scanning speed was set to 1,000 Hz, bidirectionally (0.54 s / scan) and every time a selected point was photobleached for 300 ms. Fluorescence recovery was monitored in a series of 180 images while maintaining identical activation conditions used to induce clustering. Bleach point mean values were background subtracted and corrected for fluorescence loss using the intensity values from the entire cell. The data were then normalized to mean pre-bleach intensity and fitted with exponential recovery curve in Fiji or in frapplot package in R.”

      1. Description of analyses that authors prefer not to carry out

      **Reviewer #1**:

      Can they use the all and long isoform antibodies together, then subtract the signal from long isoform to conclude about the localization of the shorth isoform ?

      We thank the Reviewer for the suggestion, though given the differential efficiency of antibodies and other limitations of imaging experiments, we do not find the suggested experiment to have a potential to improve the quality of our manuscript. However, we should note that we have performed a pixel-based colocalization experiment between the signal detected by all isoform and long isoform SATB1 antibodies. Fluorocytogram of the pixel-based colocalization, based on 3D-SIM data is provided on the left, with quantified colocalization on the right of the revised Supplementary Fig. 5a.

      3) Lack of better staining with antibody against the long and short SATB1 isoforms after treatment with 1,6 Hexanediol. 1,6 Hexanediol treatment can change many other chromatin associated proteins to which SATB1 can be bound to indirectly. This experiment can

      We do understand the controversy and difficulties of experiments using 1,6-hexanediol treatment. However, we have to note that there is no better approach available for the investigation of LLPS in our primary murine T cells. We did use alternative approaches in ex vivo experiments, utilizing cell lines to validate our hypothesis without the involvement of 1,6-hexanediol.

      **Reviewer #2**:

      1. The authors mention, '...of the different SATB1 isoforms, uncovered by the use of the two different antibodies, relied in the heterochromatin areas (zone 1), where the long isoform was less frequently...' There is no supporting figure number mentioned. The authors need to show a zone-by-zone comparison images for 'all iso' vs 'long' iso of SATB1. Just to reiterate, there is a need for a heterochromatin mark to unambiguously call out the distinction.

      We should remind that there is an inherent difficulty to accurately compare localization of short and long SATB1 isoforms in primary cells, especially due to the lack of Satb1 isoform-specific knockout mice. There is no way to detect only the short isoform in these primary cells as there are only antibodies targeting the long or all SATB1 isoforms. Therefore, we cannot set up additional experiments probing these questions.

      In line with this, in the revised version of the manuscript, we toned down our statements regarding the differential localization of the two isoforms in primary cells. We only refer to it as an indication and we support it by adding references to the relevant figures. This part now reads: “Localization of SATB1 speckles detected by antibodies targeting all SATB1 isoforms and/or only the long SATB1 isoform, revealed a significant difference in the heterochromatin areas (zone 1, Fig. 2b), where the long isoform was less frequently present (see also Fig. 2a and Fig. 3c). Although, this could indicate a potential difference in localization between the two isoforms, due to the inherent difficulty to distinguish the two based on antibody staining, we refrain to draw any conclusions. (Lines 145-150)”

      1. Fig. 6a, The authors wished to see the effect of RNA on Satb1 nuclear localization. This is not related to the main theme of the paper, thus should be moved to supplementary (true for b as well). Importantly, the experiments should be performed with total cells to show the divergence of localization (like the paper the authors referred to) instead of matrix for clarity.

      • We did not wish to see the effect of RNA on SATB1 localization. In fact, there is a long history of SATB1 research that is inherently linked with the concept of nuclear matrix, a putative nuclear structure which is highly associated with nuclear RNAs. SATB1 was described many times as a nuclear matrix protein (https://doi.org/10.1016/0092-8674(92)90432-c; https://doi.org/10.1128/mcb.14.3.1852-1860.1994; https://doi.org/10.1074/jbc.272.17.11463; https://doi.org/10.1128/mcb.17.9.5275; https://doi.org/10.1021/bi971444j; https://doi.org/10.1083/jcb.141.2.335; https://doi.org/10.1101/gad.14.5.521; https://doi.org/10.1038/ng1146).

      • Moreover, our data discussed in comments 4-7 of this Reviewer, such as i. the localization of SATB1 to the nuclear zones associated with RNA and nuclear scaffold factors (Fig. 2b, Supplementary Fig. 1c), ii. colocalization of SATB1 with actively transcribed RNAs (Fig. 2c, Fig. 3g, Supplementary Fig. 2a, Supplementary Fig. 2c), iii. including its association with nucleoli (Supplementary Fig. 3b), and also iv. its computationally predicted interaction with Xist lncRNA (Agostini et al., 2013; https://doi.org/10.1093/nar/gks968) as a notable factor of nuclear matrix, all suggest that the interaction between RNA and SATB1 is plausible and potentially relevant for its function and/or at least its subnuclear localization. It is relevant even more so, when considering numerous reports on the ability of RNA-binding, poly-Q and PrLD-containing proteins to undergo LLPS https://doi.org/10.1016/j.molcel.2015.08.018; https://doi.org/10.1042/bcj20160499; https://doi.org/10.1016/j.cell.2018.03.002; https://doi.org/10.1016/j.cell.2018.06.006; https://doi.org/10.1093/nar/gkaa681), including RNAs specifically regulating LLPS behavior, especially for poly-Q and PrLD-containing proteins, such as SATB1 (https://doi.org/10.1126/science.aar7366; https://doi.org/10.1126/science.aar7432; https://doi.org/10.1016/j.ceb.2019.03.007; https://doi.org/10.1038/s41598-020-57994-9; https://doi.org/10.1016/j.molcel.2015.09.017; https://doi.org/10.1038/s41598-019-48883-x; https://doi.org/10.1038/s41467-019-11241-6).

      • It should also be noted that SAF and various hnRNPs, as the most prominent proteins of nuclear matrix were many times reported to phase separate (https://doi.org/10.1016/j.molcel.2019.10.001; https://doi.org/10.1074/jbc.ra118.005120; https://doi.org/10.1016/j.celrep.2019.12.080; https://doi.org/10.1038/s41467-019-09902-7; https://doi.org/10.1016/j.molcel.2017.12.022; https://doi.org/10.1074/jbc.tm118.001189). All these aspects show that the relation between nuclear matrix, SATB1 and RNA are quite relevant to our manuscript.

      • Moreover, in light of the aforementioned information, we believe that it is much clearer to follow the protocol we did – i.e. to remove soluble proteins by CSK treatment and then, upon RNase treatment, extract the released proteins using ammonium sulfate. In an experiment utilizing whole cells, one would need to microinject RNase A into the nucleus, which 1. is very challenging for primary T cells having a radius of 3-5 micrometers, 2. is of low throughput, 3. would not allow for released protein removal which would thus make the results hard to interpret. Please note that in the reference paper, the authors used cell lines overexpressing heterologous GFP-tagged proteins, which is not related to our setup.

      Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Reply to the Reviewers

      I thank the Referees for their...

      Referee #1

      1. The authors should provide more information when...

      Responses + The typical domed appearance of a hydrocephalus-harboring skull is apparent as early as P4, as shown in a new side-by-side comparison of pups at that age (Fig. 1A). + Though this is not stated in the MS 2. Figure 6: Why has only...

      Response: We expanded the comparison

      Minor comments:

      1. The text contains several...

      Response: We added...

      Referee #2

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      Zelenka et al., focus on a T cell genome-organizing protein, SATB1, to show that SATB1 undergoes liquid liquid phase-separation (LLPS), and distinct isoforms confer different LLPS-related biophysical properties. They generate a long-isoform specific antibody and conduct several experiments to test for LLPS and compare LLPS properties between the long-isoform relative to the whole SATB1 protein population. Given that SATB1 plays important roles in T cell development and in cancer, interrogating SATB1 biophysical properties is an important question. However, there are multiple problems with the experimental setup and data that weaken their support of the conclusions.

      I will detail some of the major issues below:

      Regarding phase-separation There are several assays to determine whether a protein undergoes LLPS.

      1. One of the first the authors address is the spherocity or roundness. Indeed, formation of spherical droplets is one evidence of the liquid nature of a protein. However, the authors use fixed preparations (which can introduce artifacts), not free-floating protein, and determine roundness by showing a 2D image. Roundness should take into account the diffraction-limits of fluorescent imaging, as many structures can be imaged to appear round by the detector. There are quantifiable measurements that can be taken on 3D images to show roundness. This would best be shown using non-fixed protein.
      2. Hexanediol is another assay frequently used in phase-separation studies. However, hexanediol has many deleterious effects on the cell, even at a fraction of the concentration normally used in phase-separation studies. Authors should show controls of cell viability, control proteins that do not phase-separate, etc. See https://www.jbc.org/article/S0021-9258(21)00027-2/fulltext. Secondly, hexanediol treatment should cause phase-separated protein aggregates to disperse. It is difficult to determine from the images whether or not the aggregates actually disperse or there is just less protein. In any case, small aggregates remain even after treatment, and this appears different from most other hexanediol experiments reported in the literature where the signals become more dispersed and uniform. This is likely because the samples are fixed. One of the main features of using hexanediol in phase-separation is to show that upon washout, LLPS aggregates can reform. Because the cells are fixed, the critical aspect of this assay is not performed. A washout and LLPS recovery would control for cell viability issues described above and would provide the opportunity to show that total SATB1 protein levels did not change, but its distribution did, which is the essence of this assay in the context of LLPS.

      This review from the Tjian group is very informative and may be a good resource: http://genesdev.cshlp.org/content/33/23-24/1619

      Regarding the isoform specificity of SATB1 biophysical properties

      1. The authors generate a long isoform-specific antibody. However, the western blot is not convincing that this is indeed specific to the long isoform as there is a rather large smear. Can this be improved with antibody preabsorption? Since this is a key reagent for the manuscript, improvement in antibody quality is essential.
      2. Fig 4 Optodroplet experiment appears to show that the N-terminus of SATB1 can undergo LLPS. The results of this assay show that SATB1 has a domain that can undergo phase-separation in isolation, but it does not show that the protein itself is a phase-separating protein. The FRAP assay methods are not provided by the authors, but this is important, as continued light activation means proteins are continuously forming aggregates, and the bleaching for FRAP should be balanced with the levels of Cry2 activation. A very good description of the methods is described in the original Optodroplet paper: https://www.sciencedirect.com/science/article/pii/S009286741631666X?via%3Dihub#sec4
      3. The major difference between the long and short isoform of SATB1 is the 31aa segment within the IDR. However the authors find that neither the long or short isoform SATB1 forms LLPS aggregates, and the IDR alone forms aggregates in the cytoplasm (Fig5) but they do not respond to Cry2 light activation. When forced to localize to the nucleus, it does not form aggregates as well (Fig6). The short isoform also did not form any aggregates. These results seem to argue against any isoform specific phase-separation. This experiment seems critical for the story, yet it does not support their overall conclusions. The authors might consider using a different cell line or perhaps do an in vitro assay using purified protein. I am not certain what to make of the cytoplasmic aggregation, which appears to not form upon localization to the nucleus. Because of this, it is difficult to place weight on the significance of the S635A mutation and the role that a phosphorylation of SATB1 contributes to phase-separation, let alone function.

      There are many additional points of concern, but the ones listed above are perhaps the most significant in terms of the overall conclusions of the paper.

      Significance

      If convincingly demonstrated, it can advance the field by understanding how SATB1 functions. However, the data are premature to relate SATB1 to the phase separation field. Audience interested in gene regulation and phase separation would pay attention to this paper, if successfully prepared.

      The field of expertise is phase separation, development, regulation of gene expression.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      The authors have reported the existence of a 'long' SATB1 isoform which also undergoes LLPS. The authors tried to draw multiple comparisons and pointed out distinction between phase properties of SATB1 isoforms. The authors also touch upon two functional roles of SATB1. Although a wide array of assays are used, the data presented and hence the manuscript makes multiple transitions into disparate hypotheses without diving deep into a single hypothesis. As a result, the connections drawn are unclear, and do not converge at best. The authors have used number of techniques, however, the results do not support their conclusions and they appear hastily drawn. It is not clear why the authors jump from one context to the other, discussing LLPS first, then transcription, splicing, post-translational modification and finally cancer. The link between all of these isn't clear and not fully supported by data. It appears that the authors wish to focus on Satb1's physiological role in development, hence the data on breast cancer is confusing. Thus, this work suffers from multiple pitfalls. Specific comments are given below:

      Major comments

      1. Importantly, in Fig 1d, there is no statistics shown. There is no mention of number of replicates as well in the legends. Proper statistical evaluation is critical for interpreting this result.
      2. Figure 1f presents one of the weakest evidences in the manuscript. There are a number of corrections needed. Firstly, being their major and only validation figure for their custom antibody, the immunoblot is not clean, bands are fuzzy. Importantly, as the authors claim that the antibody is highly specific to 'long' SATB1, after the IP there should be only a single band (like input) of Satb1 long. But that does not seem to be the case, rather an array of bands are visible below (lane 2 top panel). This could easily mean that the shorter isoforms or non-specific protein bands are also pulled down with the 'long' form specific antibody. Therefore, raising a critical concern regarding the specificity of the antibody.
      3. Moreover, an important and direct experiment would be to clone the long isoform in a suitable vector and overexpress in the cell line (as done for the canonical isoform in Supp Fig 1a). This would unequivocally show the efficacy of the antibody and thus the following usage of the same for various assays.
      4. Related to Fig. 2 a, the authors state on Pg 5, '....the euchromatin and interchromatin regions (zones 3 & 4, Fig. 2a, b).' Although the DAPI correlation seems clear, there is no mention on how they reached the above said correlation. They should at least show a parallel speckle staining for HP1 or signature modification such as H3K4me9 STEDs for making supporting such a claim. DAPI alone is not sufficient. The authors should rectify the text thoroughly for many such interpretations without validation/reference or provide relevant data.
      5. The authors mention, '...of the different SATB1 isoforms, uncovered by the use of the two different antibodies, relied in the heterochromatin areas (zone 1), where the long isoform was less frequently...' There is no supporting figure number mentioned. The authors need to show a zone-by-zone comparison images for 'all iso' vs 'long' iso of SATB1. Just to reiterate, there is a need for a heterochromatin mark to unambiguously call out the distinction.
      6. On the same lines, '....Given the localization of SATB1 to the nuclear zones with estimated transcriptional activity (Fig. 2b, zone 3)....' How was the region labelled as transcriptionally active? For the statistical analysis of speckle count for the two antibodies' staining, the claim posited is a bit bigger. This could simply be true for that cell. The authors thus need to statistically analyse the speckle counts for multiple cells. This needs to be done for all imaging statistics done in multiple figures throughout the manuscript.
      7. For figure 2c. the authors have used 5 Fluorouridine for nascent RNA speckles. 5FU is known to have a spread signal type (with strong association to nucleolus as well). This is not the case for the image presented 2c. The authors should resolve this by showing different sets of images.
      8. Fig 2 d., the authors have suddenly jumped solely to 'all iso' Satb1 here for IP MS. Is there a reason for that? The authors either need to do this with 'long iso' antibody or remove the analysis from the manuscript as it does not add to their primary aim of the manuscript. Also, the authors have only selectively talked about two clusters? What about chromatin related proteins? It is quite intuitive to have highest enrichment of these given previous literature and even IP MS data by other groups. Thus, it is necessary to revise this thoroughly or remove it.
      9. In relation to Fig. 2f, the authors have not mentioned any of the previously published work on Satb1 CD4 specific KO, not even the RNA seq studies the other groups have reported under the same condition. Only an unpublished reference of their own (preprint) is cited. It is imperative to show how much their data corroborates with other published studies. Additionally, what is the binding site status of dysregulated genes?
      10. In context of Figure 3a and b, the authors write .'...The long SATB1 isoform speckles evinced such sensitivity as demonstrated by a titration series with increasing concentrations of 1,6-hexanediol treatment followed...' Whereas it is apparent from the image at least that overall numbers of individual speckles are instead increased at both 2 and 5%. There is although a clear spreading of restricted speckles compared to the controls. The authors should revise their figures to substantiate the associated text. Furthermore, there needs to be 'all iso' SATB1 3D SIM imaging and not just quantitation for comparison. This is also true for panel c in order to demonstrate the effect.
      11. Fig. 3 d also does not clearly demonstrate what the authors have claimed '...hexanediol treatment highly decreased colocalization between...' The figure shows at best decreased signal intensity for both SATB1 and FU. We suggest that the authors should give a statistical analysis as well for the colocalization points between the two using multiple source images. Lastly, the two images shown (control and treated), there seems to be a clearly visible magnification difference. The authors should clarify this.
      12. Figure 3f. The authors show the PC plot for Raman spectroscopy for phase behaviour due to Satb1. The experiment and its related text seems misinterpreted; the authors write...' ese bonds were probably enriched for weak interactions responsible for LLPS that are susceptible to hexanediol treatment. This shifted the cluster of WT treated cells towards the Satb1 cKO cells. However, the remaining covalent bonds differentiated the WT samples from Satb1 cKO cells......' whereas the clusters are clearly far away in 3D for both WT and KO while being closer to their respective treatments. Which is also intuitive given the sensitivity of Raman spectroscopy. Thus, it is more likely to be treatment effect and KO effect as separate. Treatment of WT leads to KO like spectra is far-fetched. Thus, the authors need to show separate PCs and modify their text thoroughly.
      13. In Fig 4. b, The authors have shown the propensity of SATB1 N terminus to phase separate using different optodroplet constructs. Although the imaging is clear, why are the regions selected not uniform when comparing various constructs?
      14. Figure 5a, the disassembly should be shown for 'long' SATB1 as well. On pg 13, the authors write '....cytoplasmic protein aggregation has been previously described for proteins containing poly-Q domains and PrLDs..' no reference given.
      15. Fig. 5d, Is there an amino-acid specific reasoning to support the authors claim of the phase behaviour due to extra peptide? They need to show a proper control with equal extra (unrelated) peptide to show the specificity. Are the shorter isoform aggregates responsive to light?
      16. Fig. 6a, The authors wished to see the effect of RNA on Satb1 nuclear localization. This is not related to the main theme of the paper, thus should be moved to supplementary (true for b as well). Importantly, the experiments should be performed with total cells to show the divergence of localization (like the paper the authors referred to) instead of matrix for clarity.
      17. Fig 6c., It is important that authors show the data for NLS+short iso data as well to prove their hypothesis.
      18. Fig 6d., The authors claim that mutating a specific P site changes the phase behaviour of the 'short iso'. Does it also increase for the long isoform? The authors need to confirm this in order to verify the effect of a single P site outside of oligomerization domain. ...' phosphorylation status; when phosphorylated it remains diffused, whereas unphosphorylated SATB1 is localized to PML bodies....' This being an important premise, thus should be moved to the results text.
      19. Pg 16,. The authors have tried to explain multiple things (concepts of self-regulation, accessibility) which is quite tangential. There is no inference to Fig 6f., which is showing the opposite to what the authors had postulated. This portion should either be removed or explained with a rationale. The writing also needs to be revised thoroughly in this section. Similarly, the discussion should also be modified.
      20. The authors should not draw conclusions based on any data which is not shown '....ed differences in chromatin accessibility at the extra exon of the SATB1 gene (data not shown), suggesting its potential involvement in alternative splicing regulation according to the "kinetic coupling" model...'. This has led to overspeculation and needs correction.

      Minor comments:

      1. On pg 4, the authors state 'Here, we utilized primary murine T cells, in which we have identified two full-length SATB1 protein isoforms.' Whereas only one 'long' isoform is identified and the other is the canonical version. The authors should correct the statement.
      2. On pg 6, related to Figure 1, the authors mention 'It should also be noted that when investigating the SATB1 protein levels, we have to bear in mind that the antibodies targeting the N-terminus of SATB1 protein cannot discriminate between the short and long isoforms'. The authors reason that their sizes are too close. It is indeed possible, and widely studied in biochemistry to assess various factors on protein migration (such as PTMs). The authors should validate this aspect (as it is important as per their premise) and perform separation based on charge as well and also use a commercial antibody to validate the same.
      3. Fig. 1 a , Is there a specific reason to generate a custom-made antibody for 'all' SATB1, using similar regions that are already commercially available. This becomes redundant otherwise, because there is no apparent difference in detection compared to the commercial one (Suppl. Fig 1a). Antibody generation strategy (1a) should be moved to supplementary. Additionally, authors have obtained the custom antibodies from a commercial source, therefore, the text should reflect the same alongside relevant details.
      4. Fig 3e: what is the control used here? In their Pearson correlation analysis, there seem to be significant reduction in control sets as well upon treatment. This needs to be clarified.
      5. Pg 10, the authors claim that '..., thus we reasoned that it may also be used to study phase separation...' But there have been numerous reports starting from 2018, which have utilized this technique in corelation to phase behaviour (albeit individual proteins). The authors should include proper citations as they are extending an idea from the same field to their specific need.
      6. For Fig 5b, there should be a comparative image for 'short' isoform.
      7. In the context of Figure 5c, the authors claim ...' Note also the higher LLPS propensity of the human long SATB1 isoform compared to the murine SATB1...' Why suddenly human and mouse comparisons are drawn? This figure should be moved to supplementary.

      Significance

      The authors have made a few novel observations such as the existence of a 'long' isoform of Satb1 with an additional exon, formation of LLPS by this isoform. This study has the potential to be of relevance to the T cell development and transcription regulation community. However, the authors fall short of building a convincing case to this effect. This is primarily due to the fact that they have focused on diverse assays to collect data but not converged on a unique theme. Further, the authors have not mentioned any of the previously published work on Satb1 CD4 specific knockouts, not even the RNAseq studies the other groups have reported under the same conditions. Satb1 knockout model could have been used more effectively to convincingly demonstrate the role/s of the two Satb1 isoforms in T cell development and function.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      This paper looks at in important nuclear matrix protein SATB1, which is a well known global chromatin organizer and help chromatin loop attach to the nuclear matrix. The paper starts with identification of novel short and long form of SATB1. Both the isoform consist of a prion like low complexity domains, but the long isoform additionally contain an extra EPF domain next the Prion like low complexity domain. The paper reports that in murine cells the long isoform is 3-4 fold more abundant than the short isoform. By using STED microscopy they show SATB1 foci lie next to transcription sites in the nucleus. They conclude by looking at the spherical shape of the SATB1 foci and the susceptibility of SATB1 staining after 1,6 hexanediol treatment that SATB1 forms the small foci in the nucleus due to LLPS. The authors also use RAMAN spectroscopy to conclude a change in nuclear chemical space in absence of SATB1 but without much explanation about which chemical bond or nuclear sub structure change correspond to the change in principal component analysis from Raman spectroscopy. The authors use the light inducible aggregation cyr2 tag with the PrD domain of SATB1 and compare it with the Cry2-FUS-LC domain to conclude that the SATB1 LC domain can undergo LLPS. The authors hint at involvement of RNA and also DNA in the LLPS of the SATB1 but without going into any detail.

      The key conclusions of the paper are- A) SATB1 undergoes LLPS. But this conclusion is drawn after correlative experiments as detailed below-

      1. observation of spherical punctae by STED-which could also seem spherical due to their small size. The resolution limit achieved by the STED microscopy used in this paper is not determined or mentioned clearly.
      2. No live cell FRAP experiment with fluorescent SATB1 long or short isoform to show that these foci are liquid like
      3. Lack of better staining with antibody against the long and short SATB1 isoforms after treatment with 1,6 Hexanediol. 1, 6 Hexanediol treatment can change many other chromatin associated proteins to which SATB1 can be bound to indirectly. This experiment can
      4. Lack of in vitro reconstitution experiments with purified long and short SATB1
      5. LLPS is strongly coupled to the cellular concentration of the proteins. Authors should quantify the cellular concentration of the long and short isoform in the cells.

      Major conclusion B)- SATB1 regulates transcription and splicing.

      This was also shown previously and in this paper they show the close proximity of the transcription site and SATB1 foci by microscopy. Hexanediol tretamnt which lead to loss of colocalization between FU foci and SATB1 is also taken as an evidence in regulation of transcription is not right as the transcription foci itself can be dissolved using 1,6 Hexanediol. Although the rate of transcription is not measured quantitatively.

      Major conclusion C)-Post transcriptional modification is important for SATB1 function.

      This point is just barely touched upon in the last figure of the paper

      Overall I find that the major conclusion-point A and B , is based on very indirect experiments and needs much more convincing data and the role of SATB1 LLPS in cells should be demonstrated more rigorously. And conclusion C is barely described and needs a lot more cell biological and genetic evidence.

      I do not recommend publishing the paper in current state. The story needs much more experiment to convincingly prove the major conclusions. Further, the MS needs more careful thinking and presentation to make it streamlined.

      Minor comments:

      One of the major flaw of the paper is the use too many techniques without proper explanation. E.g. use of STED and RAMAN microscopy need controls and explanation on what is being quantified. The use of Raman microscopy to quantify the nuclear environment of nucleus is not related to the chromatin organization or LLPS of SATB1 at all. And no information is provided at all which aspect of nuclear organization is being measured in Raman and what it means for the LLPS of SATB1.

      Similarly for Hexanediol treatment, duration of treatment is missing. Hexanediol can also dissolve the liquid like transcription foci. And hence a decrease in correlation between SATB1 foci and FU foci cannot be taken as a measure of SATB1 foci connection to transcription alone

      It is not very clear how many times the STED or Raman microscopy is done on how many samples and biological replicates. Similarly for RNA sequencing number of samples and description of controls are missing. Also if the sequencing data is made publicly available is not clear.

      Can they use the all and long isoform antibodies together, then subtract the signal from long isoform to conclude about the localization of the shorth isoform ?

      Additional control is needed to report the resolution limit of Superresolution techniques-STED and 3D-SIM systems used by them.

      Would be very helpful if the zonation was plotted for the FluoroUridine(FU) also to show that Zone1 (heterochromatin) is completely depleted of FU, and is present in other regions.

      Scale bar needed figure 3d

      Perfectly rounded SATB1 foci- this does not mean LLPS. For LLPs measurement, protein condensate dynamics measurement by FRAP or fusion experiments is required. What is the size of condensates? and cellular concentration of SATB1 ? Will SATB1 undergo LLPS in vitro at similar concentrations? does SATB1 interact with DNA or RNA to undergo LLPS ?

      After careful reading of the MS I conclude that the main conclusions of the paper are very preliminary and need much more detailed experiments. So does not qualify to get published at all at this stage.

      Significance

      The present manuscript tries to connect the phase separation of SATB1 to understanding the mechanism of SATB1 function in cells. One of the major hallmarks of phase separation is dynamic, liquid-like behaviour and in absence of these measurements, it is very difficult to say that the current manuscript has made any contribution to showing that SATB1 can phase separate.

      The presence of 2 isoforms of SATB1 is a novel finding and the paper could have focussed more on this. E.g. elucidate expression of the isoform during thymocyte development and maturation.

      As a reviewer my expertise are cell biology experiments, microscopy, in vitro reconstitution assays, RNA binding proteins, RNA and RBP condensate formation. And I feel that the reconstitution experiments are an important tool for understanding phase behaviour of proteins and also to gauge if this behaviour can occur or not in cellular concentration and conditions. I do not have sufficient expertise in Raman microscopy and hence the information provided in the MS on this part was not enough to understand the experiment and conclusions drawn from it.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Reviewer #1 (Evidence, reproducibility and clarity):

      The manuscript describes the formation of supernumerary centriole protein assemblies ("cenpas") upon silencing of the E3 ubiquitin ligase TRIM37. These "cenpas" resemble centrioles, centriole precursors, or electron-dense striped structures, termed "tigers". Similar observations are made in cells from patients lacking functional alleles of TRIM37. The "cenpas" usually lack the full complement of centriolar proteins, but contain increased amounts of the pro-centriole marker centrobin. It is further shown that the formation of "cenpas" depends on centrobin, or on a parallel pathway involving Plk1 and SAS-6. Overall, the experiments in this study are of high technical quality and most of them are carefully controlled. The discovery of centrobin-containing striped protein assemblies ("tigers") is very interesting and provokes the question of their molecular composition and their mechanistic role in centriole assembly. Since striated fibres containing the protein rootletin have a similar periodicity of stripes (75nm) as the "tigers" in this study (Vlijm et al., PNAS 2018, 115:E2246-53), I was wondering whether the authors couldn't simply test for colocalization of their "tiger"-stripes with rootletin. A potential identity of "tigers" with striated fibres would help understanding the mechanisms of "cenpas" and centriole assembly upon depletion of TRIM37: striated fibres or "tigers" might be controlling the balance of centriole cohesion vs. disengagement and thereby centriole duplication, or they might play a role in the recruitment of additional proteins involved in pro-centriole assembly.

      We are grateful to the reviewer for this interesting suggestion. Accordingly, we will test the distribution of Rootletin and potentially CEP68 by immunofluorescence analysis of cells depleted of TRIM37.

      In the same context, did the authors correct for the experimentally induced sample expansion in Figure 5B, when comparing inter-stripe distances between U-ExM and EM samples?

      Yes, we did. We will clarify the text of the revised manuscript to make this more explicit.

      Other major points: The amount of TRIM37-depletion upon siRNA-treatment should be indicated prominently. I see in the "Materials and Methods" and in Fig. S4 that quantitative RT-PCR has been performed. Could Western blotting be performed to have direct information on the protein levels? Fig. 2C demonstrates that this is possible in cells from human patients, so why are there no data on the majority of other experiments in this manuscript?

      We previously reported Western blot analysis to estimate the extent of TRIM37 depletion upon siRNA treatment (Balestra et aI., 2013). However, following the suggestion of the reviewer, we will repeat this analysis for select experiments of this study.

      Moreover, what is the transfection efficiency in the siRNA experiments? Is there variability between cells that might explain variability in the "cenpas" phenotypes?

      The reviewer brings up an interesting point. However, in the absence of an antibody to detect endogenous TRIM37 by immunofluorescence analysis, we cannot provide an accurate figure in this case. We will mention this limitation explicitly in the text of the revised manuscript.

      Minor point: In line 353 (page 12), it is stated that centrobin in si-TRIM37 cells migrates slower (Fig. 4D), suggesting that TRIM37 regulates the post-translational state of centrobin. It looks to me as if the corresponding gel in Fig. 4D was "smiling" (see curvature of centrobin in the neighboring lane). I think that the authors should tone down their statement, or replace Fig. 4D with a more convincing image.

      We thank the reviewer for having noticed this. We will provide another gel that is not “smiling” -the difference in migration has been observed in a reproducible manner.

      Reviewer #1 (Significance):

      The findings of this manuscript are highly significant for our understanding of centriole biogenesis. They should be of interest to a large community of cell biologists working on mitosis and on the centrosome, and they are of further importance for biomedical research related to developmental growth abnormalities (Mulibrey nanism). The manuscript shows for the first time a mechanistic link between TRIM37-dependent control of centrobin protein levels, and their impact on the formation of centriole precursors during the cell cycle. The manuscript is well presented, and the relevant scientific literature is cited correctly. However, I would prefer that a potential relationship between "cenpas", "tigers", and the welldescribed rootletin-containing striated fibres be discussed, if not controlled by additional experiments.

      We thank the reviewer for her/his appreciation of our work and support for publication.

      Field of expertise of this reviewer: centrosome, microtubules, mitosis, cell culture, light and electron microscopy, biochemistry.

      Reviewer #2 (Evidence, reproducibility and clarity):

      In this work, the authors investigated roles of TRIM37 in regulation of centriole numbers. It was previously observed that depletion of TRIM37 results in supernumerary centrioles and centriole-like structures (Balestra et al., Dev. Cell, 2013; Meitinger et. al., 2016). Here, the authors characterized these centriolar protein assemblies (Cenpas). Cenpas were formed, following an atypical de novo pathway and eventually trigger centriole assembly. They observed that Centrobin is frequently present in Cenpas from the early stage and other centriolar components are sequentially recruited. Furthermore, they established that Cenpas formation upon TRIM37 depletion requires PLK4 activity. TRIM37 depletion also activates PLK1-dependent centriole multiplication. 1.They propose that the tiger structure acts as platform for PLK4-dependent Cenpas assembly. Cenpas may evolve into centriole-like structures after a stepwise incorporation of other centriolar proteins. Fig. 6E suggests that a series of events seem to occur within G2 phase. Therefore, this reviewer suggests to perform a detailed time-course experiments at G2 phase. According to the model, the Centrobin-positive tiger structures may appear first, and then a Centrobin- and centrin-2-double positive structure starts to appear.

      We fully agree with the reviewer that this is an important experiment, which we will perform by analyzing TRIM37 depleted cells at successive time points after release from a double thymidine block, using antibodies against Centrobin and Centrin.

      2.They claim that Mulibrey patient cells exhibited evidence of chromosome mis-segregation, as would be expected from multipolar spindle assembly, and conclude that Cenpas are present and active also in Mulibrey patient cells. Chromosome mis-segregation may be observed in the normal cells, too. Therefore, they have to perform statistical analysis on Fig. 2D.

      In response to this suggestion and to the related comment of reviewer 3 (see below), we will conduct additional immunofluorescence analysis and quantification of patient and normal cells, assessing the distribution of Centrin, Centrobin, microtubules and γ-tubulin, as well as scoring the extent of chromosome mis-segregation.

      3.In Fig. 2A, They claimed that mitotic microtubules were disrupted with the cold treatment for 30 min. In our experience, cold treatment for 30 min is not sufficient to disrupt mitotic microtubules. They may show control panel before microtubule regrowth.

      We will show the control panel as requested.

      Reviewer #2 (Significance):

      Significance of this work resides in identification and description of Cenpas as a novel centriole assembly pathway. The authors used cutting-edge microscopy techniques to visualize Cenpas. The manuscript raised more questions than answers. Nonetheless, it is worth to publish the manuscript after revision.

      We thank the reviewer for supporting publication after revision.

      Reviewer #3 (Evidence, reproducibility and clarity):

      Balestra and colleagues investigate the function of Trim 37 in centrosome biogenesis. Trim 37 is a ubiquitin ligase that has previously been identified by the authors as a regulator of centriole duplication. Mutations in Trim37 cause a rare syndrome named Mulibrey that is responsible for a severe form of dwarphism Here they show that depletion of Trim37 in human cells results in the assembly of structures that they name Cenpas. They follow the possibility that Trim37 localises to the centrosome, which might inhibit the assembly of these structures. Further they show that Trim37 depleted cells (or in patient fibroblasts ) assemble multipolar mitosis. Further analysis shows that what the authors defined as abnormal centriole structures are formed in Trim37 depleted cells. These structures recruit centrobin, a daughter centriole component and this process requires the activity of PLK4 and PLK1. Major comments: This study characterizes Trim37 and its possible role in centriole biogenesis. Most conclusions are convincing, although some of the claims taken by the authors might require more data to be corroborated.

      1)The major point to be taken into consideration in my opinion relates with the Cenpas structure. According to the beautiful cryo-EM data shown on Fig 3, I wonder why the authors describe these structures as centriole like- or centriole related. I think these appear very different from centrioles and this might be even quite interesting if these structures nucleate microtubules and can participate in mitotic spindle assembly.

      We have a different opinion on this point. Most of the “centriole-like” or “centriole-related” structures do resemble the organelle, in that they contain microtubule bundles and are of a related size (in addition to bearing centriolar markers). However, recognizing that the distinction between these two categories of structures is somewhat arbitrary, we will combine them into the most prudent term “centriole-related”, and further explain in the revised manuscript that they comprise a range of structures.

      The authors correlate these non-canonical centriole structures as possible microtubule nucleators that might be responsible for multipolar configurations like in Fig 2D. This correlation has to be established. In Figure 2D, the authors analyze configurations of mitotic cells in terms of centrosome number and characterized frequency of extra foci. To me the foci they show are quite different in nature. Poles 1 and 3 have both centrin and g-tubulin (presumably centrioles), pole 2 has only a tiny amount of centrin and no g-tubulin, while pole 4 appears to contain both but less of each protein. So the question is are they all nucleating microtubules and participating in spindle assembly? This is particularly important in light of what the authors then mention, which is the occurrence of chromosome mis-segreation in patient cells (this is not shown). Also they describe these extra poles, and then say that Cenpas are active in patient cells. But, active in which manner? By nucleating microtubules? First, in either siRNA cells or in patient cells the authors should analyze microtubules and show that all the extra poles (made of non-canonical centriole) nucleate microtubules and participate in spindle assembly.

      In response to this suggestion and to the related comment of reviewer 2 (see above), we will conduct additional immunofluorescence analysis and quantification of patient and normal cells, assessing the distribution of Centrin, Centrobin, microtubules and γ-tubulin, as well as scoring the extent of chromosome mis-segregation.

      If they want to propose that this might be the cause of genome integrity loss in patients (as stated in the abstract and suggested a few times throughout the paper) they have to show that cells divide abnormally and generate aneuploidy progeny.

      See response just above.

      2) Another important point that is only partially addresses is the function of Trim37 in stabilizing centrobin. Does Trim37 ubiquitinates centrobin? While the western blot on Figure 4 shows an increase at 8hrs in Trim37 RNAi, this is also the case for tubulin (Fig 4E). But the overall levels appear only slightly increased when compared to its levels at time point zero (Fig. 4F). I can see that in siRNA Ctrl Trim 37 levels go down, but it is still present so how do they explain the lack of Cenpas in this case? Is there a threshold that supports centriole duplication without any major defect but accumulation of a certain level of centrobin then generates Cenpas? Can the authors generate Cenpas just by over-expressing centrobin directly?

      It appears from the comment of the reviewer that we were not sufficiently clear here. The experiment reported in Figure 4E and 4F is done in the presence of cycloheximide to analyze the half-life of Centrobin in control conditions and upon TRIM37 depletion. We will clarify the text in the revised manuscript to facilitate understanding.

      In Figure 2, they analyze configurations of mitotic cells in terms of centrosome number and characterized frequency of extra foci. To me the foci they show are quite different in nature. Poles 1 and 3 have both centrin and g-tubulin (presumably centrioles), pole 2 has only a tiny mount of centrin and no g-tubulin, while pole 4 appears to contain both but less of each protein. So the question is are they all nucleating microtubules and participating in spindle assembly? This is particularly important in light of what the authors then mention, which is the occurrence of chromosome mis-segreation in patient cells without showing it. Also they describe these extra poles, and then say that Cenpas are active in patient cells. But, active in which manner? By nucleating microtubules? This has to be shown. Also analysis of mitosis should be included to back up a defect in chromosome segregation and also to identify which type of defect.

      The above section is a copy/paste mistake (as indicated also in a correspondence between Review Commons and the reviewer).

      So in conclusion, the link between Cenpas and multipolarity has to be better investigated in my opinion. This should not be time consuming and also not extremely costly. Authors should label spindle MTs in patient fibroblasts to show that indeed Cenpas are nucleating microtubules. Ideally Cenpas would be distinguished by centrobin labeling. In siRNA depleted cells maybe time lapse microscopy can be used to image mitosis and show a correlation between Cenpas and multipolarity?

      As mentioned above, we will conduct additional immunofluorescence analysis and quantification of patient and normal cells, assessing the distribution of Centrin, Centrobin, microtubules and γ-tubulin, as well as scoring the extent of chromosome mis-segregation.

      The data is presented without statistical analysis on the figures only on Fig legends, This is really difficult for the reader. The number of experiments and cells analyzed maybe should be also included in each Figure.

      We had kept this information to the legends merely to have lean figures, but will consider moving it to the figure panels in the revised manuscript.

      Minor comments: Some picture lack scale bars

      Apologies. This will be fixed.

      the localization of GFP-Trim37. On Figure 1 the authors describe a different localization when fused to a NES localization. It is true that a dotty signal is seen on the panel of NES (Figure 1D), but a nuclear signal is not seen on Trim-GFP in any of the images provided. Shouldn't this be the case?

      There is some GFP-TRIM37 nuclear signal in the left panel of Figure 1D, although it is very weak. We will explore the possibility of providing an inset with adjusted brightness/contrast to emphasize this point.

      Fig 1C is missing a siCtrl.

      The control quantification will be included (no extra centrioles are present in this case).

      Why Trim37GFP does not rescue completely the assembly of the extra foci?

      In general, there can be many reasons why rescue in such an experimental setting is not complete, including slightly different protein levels, distribution, or interaction with partner proteins. Such possibilities will be discussed explicitly in the revised manuscript.

      In Fig 6E, are the authors sure that in the condition of siTRim3 plus si Centrobin and Plk1 inhibition, cells are not stuck in S-phase? This might explain the lack of being in a permissive G2 phase to generate Cenpas?

      Although Plk1 inhibition is not expected to block cells in S phase, we cannot rule out this possibility from the data currently available. Therefore, we plan to conduct FACS analysis in a repeat of this experiment to assess cell cycle status.

      The data is presented without statistical analysis on the figures. This can be found on figure legends, but it is better to include on the figures to facilitate the reader's job. The number of experiments and cells analyzed maybe should be also included in each Figure?

      As mentioned above also, we had kept this information to the legends merely to have lean figures, but will consider moving it to the figure panels in the revised manuscript.

      Reviewer #3 (Significance):

      Interesting findings and quite novel since a role for Trim 37 in centriole biogenesis has never been reported. Also quite interesting the possible link between multipolarity (needs better characterization) and Mulibrey syndrome.

      We thank the reviewer for recognizing the interest and novelty of our work

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      Balestra and colleagues investigate the function of Trim 37 in centrosome biogenesis. Trim 37 is a ubiquitin ligase that has previously been identified by the authors as a regulator of centriole duplication. Mutations in Trim37 cause a rare syndrome named Mulibrey that is responsible for a severe form of dwarphism Here they show that depletion of Trim37 in human cells results in the assembly of structures that they name Cenpas. They follow the possibility that Trim37 localises to the centrosome, which might inhibit the assembly of these structures. Further they show that Trim37 depleted cells (or in patient fibroblasts ) assemble multipolar mitosis. Further analysis shows that what the authors defined as abnormal centriole structures are formed in Trim37 depleted cells. These structures recruit centrobin, a daughter centriole component and this process requires the activity of PLK4 and PLK1.

      Major comments:

      This study characterizes Trim37 and its possible role in centriole biogenesis. Most conclusions are convincing, although some of the claims taken by the authors might require more data to be corroborated.

      1. The major point to be taken into consideration in my opinion relates with the Cenpas structure. According to the beautiful cryo-EM data shown on Fig 3, I wonder why the authors describe these structures as centriole like- or centriole related. I think these appear very different from centrioles and this might be even quite interesting if these structures nucleate microtubules and can participate in mitotic spindle assembly. The authors correlate these non-canonical centriole structures as possible microtubule nucleators that might be responsible for multipolar configurations like in Fig 2D. This correlation has to be established. In Figure 2D, the authors analyze configurations of mitotic cells in terms of centrosome number and characterized frequency of extra foci. To me the foci they show are quite different in nature. Poles 1 and 3 have both centrin and g-tubulin (presumably centrioles), pole 2 has only a tiny amount of centrin and no g-tubulin, while pole 4 appears to contain both but less of each protein. So the question is are they all nucleating microtubules and participating in spindle assembly? This is particularly important in light of what the authors then mention, which is the occurrence of chromosome mis-segreation in patient cells (this is not shown). Also they describe these extra poles, and then say that Cenpas are active in patient cells. But, active in which manner? By nucleating microtubules? First, in either siRNA cells or in patient cells the authors should analyze microtubules and show that all the extra poles (made of non-canonical centriole) nucleate microtubules and participate in spindle assembly. If they want to propose that this might be the cause of genome integrity loss in patients (as stated in the abstract and suggested a few times throughout the paper) they have to show that cells divide abnormally and generate aneuploidy progeny.
      2. Another important point that is only partially addresses is the function of Trim37 in stabilizing centrobin. Does Trim37 ubiquitinates centrobin? While the western blot on Figure 4 shows an increase at 8hrs in Trim37 RNAi, this is also the case for tubulin (Fig 4E). But the overall levels appear only slightly increased when compared to its levels at time point zero (Fig. 4F). I can see that in siRNA Ctrl Trim 37 levels go down, but it is still present so how do they explain the lack of Cenpas in this case? Is there a threshold that supports centriole duplication without any major defect but accumulation of a certain level of centrobin then generates Cenpas? Can the authors generate Cenpas just by over-expressing centrobin directly?

      So in conclusion, the link between Cenpas and multipolarity has to be better investigated in my opinion. This should not be time consuming and also not extremely costly. Authors should label spindle microtubules in patient fibroblasts to show that indeed Cenpas are nucleating microtubules. Ideally Cenpas would be distinguished by centrobin labeling. In siRNA depleted cells maybe time lapse microscopy can be used to image mitosis and show a correlation between Cenpas and multipolarity?

      Minor comments:

      Some picture lack scale bars

      the localization of GFP-Trim37. On Figure 1 the authors describe a different localization when fused to a NES localization. It is true that a dotty signal is seen on the panel of NES (Figure 1D), but a nuclear signal is not seen on Trim-GFP in any of the images provided. Shouldn't this be the case?

      Fig 1C is missing a siCtrl. Why Trim37GFP does not rescue completely the assembly of the extra foci?

      In Fig 6E, are the authors sure that in the condition of siTRim3 plus si Centrobin and Plk1 inhibition, cells are not stuck in S-phase? This might explain the lack of being in a permissive G2 phase to generate Cenpas?

      The data is presented without statistical analysis on the figures. This can be found on figure legends, but it is better to include on the figures to facilitate the reader's job. The number of experiments and cells analyzed maybe should be also included in each Figure?

      Significance

      Interesting findings and quite novel since a role for Trim 37 in centriole biogenesis has never been reported. Also quite interesting the possible link between multipolarity (needs better characterization) and Mulibrey syndrome.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      In this work, the authors investigated roles of TRIM37 in regulation of centriole numbers. It was previously observed that depletion of TRIM37 results in supernumerary centrioles and centriole-like structures (Balestra et al., Dev. Cell, 2013; Meitinger et. al., 2016). Here, the authors characterized these centriolar protein assemblies (Cenpas). Cenpas were formed, following an atypical de novo pathway and eventually trigger centriole assembly. They observed that Centrobin is frequently present in Cenpas from the early stage and other centriolar components are sequentially recruited. Furthermore, they established that Cenpas formation upon TRIM37 depletion requires PLK4 activity. TRIM37 depletion also activates PLK1-dependent centriole multiplication.

      1. They propose that the tiger structure acts as platform for PLK4-dependent Cenpas assembly. Cenpas may evolve into centriole-like structures after a stepwise incorporation of other centriolar proteins. Fig. 6E suggests that a series of events seem to occur within G2 phase. Therefore, this reviewer suggests to perform a detailed time-course experiments at G2 phase. According to the model, the Centrobin-positive tiger structures may appear first, and then a Centrobin- and centrin-2-double positive structure starts to appear.
      2. They claim that Mulibrey patient cells exhibited evidence of chromosome mis-segregation, as would be expected from multipolar spindle assembly, and conclude that Cenpas are present and active also in Mulibrey patient cells. Chromosome mis-segregation may be observed in the normal cells, too. Therefore, they have to perform statistical analysis on Fig. 2D.
      3. In Fig. 2A, They claimed that mitotic microtubules were disrupted with the cold treatment for 30 min. In our experience, cold treatment for 30 min is not sufficient to disrupt mitotic microtubules. They may show control panel before microtubule regrowth.

      Significance

      Significance of this work resides in identification and description of Cenpas as a novel centriole assembly pathway. The authors used cutting-edge microscopy techniques to visualize Cenpas. The manuscript raised more questions than answers. Nonetheless, it is worth to publish the manuscript after revision.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      The manuscript describes the formation of supernumerary centriole protein assemblies ("cenpas") upon silencing of the E3 ubiquitin ligase TRIM37. These "cenpas" resemble centrioles, centriole precursors, or electron-dense striped structures, termed "tigers". Similar observations are made in cells from patients lacking functional alleles of TRIM37. The "cenpas" usually lack the full complement of centriolar proteins, but contain increased amounts of the pro-centriole marker centrobin. It is further shown that the formation of "cenpas" depends on centrobin, or on a parallel pathway involving Plk1 and SAS-6.

      Overall, the experiments in this study are of high technical quality and most of them are carefully controlled. The discovery of centrobin-containing striped protein assemblies ("tigers") is very interesting and provokes the question of their molecular composition and their mechanistic role in centriole assembly. Since striated fibres containing the protein rootletin have a similar periodicity of stripes (75nm) as the "tigers" in this study (Vlijm et al., PNAS 2018, 115:E2246-53), I was wondering whether the authors couldn't simply test for co-localization of their "tiger"-stripes with rootletin. A potential identity of "tigers" with striated fibres would help understanding the mechanisms of "cenpas" and centriole assembly upon depletion of TRIM37: striated fibres or "tigers" might be controlling the balance of centriole cohesion vs. disengagement and thereby centriole duplication, or they might play a role in the recruitment of additional proteins involved in pro-centriole assembly. In the same context, did the authors correct for the experimentally induced sample expansion in Figure 5B, when comparing inter-stripe distances between U-ExM and EM samples?

      Other major points:

      The amount of TRIM37-depletion upon siRNA-treatment should be indicated prominently. I see in the "Materials and Methods" and in Fig. S4 that quantitative RT-PCR has been performed. Could Western blotting be performed to have direct information on the protein levels? Fig. 2C demonstrates that this is possible in cells from human patients, so why are there no data on the majority of other experiments in this manuscript? Moreover, what is the transfection efficiency in the siRNA experiments? Is there variability between cells that might explain variability in the "cenpas" phenotypes?

      Minor point:

      In line 353 (page 12), it is stated that centrobin in si-TRIM37 cells migrates slower (Fig. 4D), suggesting that TRIM37 regulates the post-translational state of centrobin. It looks to me as if the corresponding gel in Fig. 4D was "smiling" (see curvature of centrobin in the neighboring lane). I think that the authors should tone down their statement, or replace Fig. 4D with a more convincing image.

      Significance

      The findings of this manuscript are highly significant for our understanding of centriole biogenesis. They should be of interest to a large community of cell biologists working on mitosis and on the centrosome, and they are of further importance for biomedical research related to developmental growth abnormalities (Mulibrey nanism). The manuscript shows for the first time a mechanistic link between TRIM37-dependent control of centrobin protein levels, and their impact on the formation of centriole precursors during the cell cycle. The manuscript is well presented, and the relevant scientific literature is cited correctly. However, I would prefer that a potential relationship between "cenpas", "tigers", and the well-described rootletin-containing striated fibres be discussed, if not controlled by additional experiments.

      Field of expertise of this reviewer: centrosome, microtubules, mitosis, cell culture, light and electron microscopy, biochemistry.

  3. Jul 2022
    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      The authors do not wish to provide a response at this time.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      Summary

      The manuscript by Pal and Das has explored the regulation of LincRNAs by p53 and by the shorter p53 isoform 40p53. In particular, through a series of knockdown and overexpression studies (primarily in one cell line) they demonstrate that LINC00176 is regulated by 40p53 to a greater extent than full-length p53 and provide evidence that this is occurring at the transcriptional level as well as through direct modulation of the RNA stability. This study has provided novel insights into the role of ∆40p53 in regulating the lncRNA-miRNA axis and perhaps more importantly, demonstrates the functional differences between the full-length p53 and its smaller isoforms.

      Major Comments

      While the subject matter is extremely interesting and has provided new mechanistic insights into how the smaller forms of p53 modulate the functions of the full-length form, many of the results are overstated, have been performed in a single cell line and are not convincing in their current form.

      • It's completely unclear how the HCT 116 cell lines expressing only p53 or Δ40p53 were generated. It is stated that the expression of these isoforms is endogenous, yet there is not mention of siRNA to knock down either of the isoforms while maintaining high expression of the other isoform. I am a little confused by the approach used here to maintain endogenous expression of one or the other isoform specifically. Apologies if I have missed this.
      • Line 209: "which is analogous to WT p53 and Δ40p53 levels in cancer". Which studies are you referring to, most published studies seem to indicate that the opposite is true??
      • Line 211-213: "LINC00176 was positively correlated with p53 levels (Figure S1C, E, G). However, in tumor tissues, they were negatively correlated (Figure S1D, F, H)." This is completely overstated and untrue, needs to be reworded. The only correlation is in Supp Fig 1C. p53 is not significantly correlated with LINC00176 in any other figure (as demonstrated by your p-values and R values).
      • Line 225-26: "However, the fold change was highest in cells with Δ40p53 overexpression, suggesting that Δ40p53 might be a more important regulator than p53." Overstated - there is no statistically significant difference between p53 and Δ40p53.
      • Fig 1 doesn't make sense... If you transfect cells with siRNA to p53 (Fig 1E) wouldn't you expect an increase in LINC00176??
      • Western Blots are very cropped. Full length western blots should be provided.
      • Line 251-253- "In HCT116+/+ cells, LINC00176 was upregulated in the doxorubicin treated and glucose-deprived cells; however, in cells treated with thapsigargin, there was no significant change (Figure S2 A-F)." There is no increase in p53 expression in some of the figs shown in the supp figs- then are the levels really correlated with p53 expression??
      • "We observed a slight increase in the proportion of cells in G1 phase and a slight decrease in the proportion of cells in S phase with LINC00176 overexpression (Figure S5F)." This is not obvious at all- delete or reword.
      • "We found a decrease in the number of colonies after LINC00176 overexpression (Figure S5G) and an increase in the number of colonies after LINC00176 knockdown (Figure S5H)". Colony formation needs to be quantitated, otherwise, don't show it. The results are not obvious at all.
      • Almost all statistics reported in this manuscript need corrections for multiple comparisons. I am fairly certain if this is done, many of the comparisons will lose their significance.
      • All results should be validated in an additional cell line.
      • There is little insight given with respect to the literature regarding what the known functions of LINC00176 RNA are or with respect to the known functions of Δ40p53
      • Although Figure 5 starts to delve into the functional impacts of LINC00176, it doesn't really look at any particular function in enough detail for it to make a significant contribution to the results. For instance, the assessment of EMT genes in Figure 5 D-F doesn't really mean much if you haven't shown altered migration/invasion capacity. This needs to be demonstrated. There are no error bars on the proliferation rates (Fig 5G and H, Supp 5B-E). Cell cycle analysis- no stats and the changes look fairly minimal. Target genes such as p21 involved in p53 cell cycle function should be analysed. Colony formation assays need to be quantitated.
      • Figure 5 should be complemented by the examination of genes known to be involved in the p53 pathway or known to be regulated by Δ40p53. Additionally, Figure 4 should show if the expression of target genes regulated by the miRNAs is altered in these experiments.
      • In all figures (and in the methods section), it needs to be stated how many experiments and how many replicates the result is representing. Given the lack of error bars in 5G,H, I can only assume the experiment has been done once.

      Minor Comments

      • Cell cycle analysis can use much greater detail, both in the experimental and analysis details (page 7, 178-182). How were the results analysed? Gating examples should be shown in the supplementary data.
      • Line 104: siRNA directed to Δ40p53, in Figs 1/2. There are no details of the Δ40p53 siRNA used in these studies.
      • Line 124: "non-specific siRNA (Dharmacon) was used in the partial silencing of p53/Δ40p53 in the experiments as control. si" This doesn't make sense, the non-specific siRNA should not affect gene expression??
      • Line 219: "Given the distinctive functions of LINC00176 reported in the literature.......". Please qualify and provide appropriate references and examples.
      • I can't see the 14A construct in the materials and methods.
      • Fig 1, p-values need to be stated and keys to the ** need to be stated as well in the figure legend.
      • Line 233 "The levels of LINC00176 decreased in both cell lines after siRNA transfection (Figure 1E, G). However, we did not observe a significant decrease in LINC00176 in either cell line.....". Yet there is a star indicating significance in both figures?? Please correct this.
      • Western blots: It makes no sense to choose a housekeeping protein the same size as your protein of interest, as this can skew the results if your blot isn't properly stripped prior to re-probing and there may be some cross reactivity with your protein of interest if the same secondary is used for both that target and housekeeping. What was the rational for choosing B-actin?
      • Fig 2K- no mention of Bip or its relevance in the text.
      • Fig S3 Why is p53 MW so high (63kDa) compared to other figures throughout the manuscript.
      • A better description of the Actinomycin D experiments is needed. Why use this? What are you showing? It is not obvious to the reader and needs to be described.
      • The discussion is very poorly referenced overall and greater insight should be given with respect to the current literature and how this has advanced the field.
      • Software used to perform statistical analysis is not stated.
      • Figure 5 G and H needs error bars.
      • The English is poor throughout despite the statement that the manuscript has been checked by English language editors.

      Significance

      ∆40p53 is an important and often underappreciated isoform of p53. It's important regulatory functions are only beginning to be recognised and this study has provided some novel and exciting insights into the role of ∆40p53 in regulating the lncRNA-miRNA axis. However, overall, the experimental details are lacking and the results are overstated in several areas and require validation.

      This manuscript would particularly appeal to researchers in the p53 and lncRNA fields.

      My expertise is in the p53 field, cancer, cell and molecular biology.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      The authors investigate the interaction between LINC00176 and the translational isoform Δ40p53, exploring how Δ40p53, separately from full-length p53, regulates the expression of LINC00176 and what effects the lncRNA ,ay have on miRNAs and on various cellular processes such as growth and proliferation. Although this is an interesting study, it lacks depth and it feels very preliminary. Even though the main focus of the study lies on the transcriptional regulation of LINC00176 by p53, this process still needs further investigation0 Moreover, the experimental design is messy which is reflected on the figures as well. There is also a lack of depth on the role of the lncRNA in the cells and in miRNA regulation.

      Major comments:

      1. Despite the title mentioning miRNAs, the results regarding miRNAs (when investigating LINC00176's mechanism of action) seem almost like they belong in another study and there isn't much expansion on these results beyond the fact that the miRNAs identified are potential targets of LINC00176. Additionally, there is no substantial background on miRNAs and the ceRNA theory in the introduction.
      2. The authors should show in a figure how the screen was done and what other lncRNAs were discovered
      3. The TCGA data in Figures S1A and S1B are contradictory regarding the lncRNA expression.
      4. Figure S1C-H do not show clear correlation and in some cases there is no statistical significance.
      5. On figure 1, the authors mention that the HCT116-/- express the Δ40p53 isoform. Is this based on the way that the cells were generated (e.g., only the first nucleotides deleted)? Or, is the Δ40p53 stably expressed after ectopic expression in the HCT116-/- cells? It should be clarified.
      6. An HCT116-/- cell line with no Δ40p53 should be used as a negative control in Figure 1.
      7. The results on Figure 1A and 1I are contradictory. Explain
      8. For Figures 1E and 1G, the authors state in the results section that the siRNA KD of either p53 isoform does not lead to a significant decrease in LINC00176, but there are significance markers (p < 0.05) on both graphs.
      9. The WB in Figure 2J should be repeated
      10. There is no description of Figure 2K in the text.
      11. Figure 3: A Luciferase assay with the lncRNA promoter should be conducted. The p53 response element should also be mutated to confirm direct regulation of p53 on the promoter. A schematic of the promoter with p53 response elements is required.
      12. Figure S3 is based on a prediction from an algorithm and is not validated. Is Δ40p53 directly binding to the lncRNA? EMSA assay with purified protein and in vitro transcribed RNA is required. There can be no claims for direct p53-RNA interactions otherwise. Δ40p53 may regulate stability indirectly, through a different regulator. Is the lncRNA expressed in the cytoplasm or in the nucleus?
      13. There is no ChIP assay description in the methods
      14. The potential miRNA targets of LINC00176 identified in Figure 4 have functions involved in the processes of apoptosis, senescence, and autophagy in addition to cell proliferation and cell cycle regulation. It would be nice if they had done phenotypic assays for these processes in Figures 5/S5 as well. How does LINC00176 affect those cellular processes if its potential targets are known to be involved in them?
      15. Figure 4: Are the miRNAs regulated by the lncRNA also regulated after p53 knockdown? Is lincRNA the mediator? A rescue experiment is required.
      16. Figure 4: Multiple siRNAs for the lncRNA are required to make sure that there is no off-target effect.
      17. Figure 5: Why is shRNA used instead of siRNA? In both cases, transient transfection is used.
      18. Figure 5G-H: show the average of 3 repeats and not each repeat separately.
      19. Figure S5A: shLINC00176 leads to lower Δ40p53. Why? The authors should discuss
      20. Figure S5F: How many repeats is the graph showing? There are no stats and no apparent change in cell cycle.
      21. Figure S5G should be quantified.
      22. There should be a greater focus on the role of the lncRNA in the phenotype of the cells. Is the lncRNA playing any role in the migration and invasion of the cells? A xenograft model would greatly strengthen the study.
      23. Is the p53 knockdown phenotype rescued after o/e of the lncRNA?

      Minor comments:

      1. There are few mistakes such as typos and structural mistakes throughout the text.
      2. The siRNA for Δ40p53 is not specific for this isoform. It should be mentioned in the main body of the text. 'Ns psi' should be changed to 'si Nsp' or 'Nsp siRNA'.
      3. How many replicates were conducted for each experiment?
      4. Figure 2F: How are the stats are compared?
      5. Figures 2 J and 2K should be flipped.
      6. The models in figures 3 and 4 don't really add much. Since there is a graphical abstract at the end to show an overview of the paper's findings, these earlier models don't seem necessary.
      7. The labeling of Fig 3D is distracting. The labels on both the x-axis and the legend for the same things are unnecessary. Also, the fold enrichment in 3D in the control samples seems mild, especially compared to the levels that it was in 3B.
      8. The nomenclature of the antibodies is very confusing. I would prefer to just call them p53 antibody and just specify in the methods what specific antibodies were used for each assay.

      Significance

      This is an interesting topic. It is important to decipher the role and regulation of lncRNAs in the p53 pathway so as to understand how it mediates its function. There are numerous similar studies focusing on the role of lncRNAs in cancer but not so many in the role of p53-regulated lncRNAs. The audience of the study is broad, targeting both p53 and cancer biology as well as RNA biology interest. My expertise lies on cancer biology and RNA biology

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      Summary:

      Provide a short summary of the findings and key conclusions (including methodology and model system(s) where appropriate).

      In this manuscript of title "The "LINC" in between 40p53-miRNA axis in the regulation of cellular processes" authors identify long noncoding RNA LINC00176 as a target of delta40p53 and also as an interactor of delta40p53 protein. Modulation of LINC00176 leads to altered levels of a panel of miRNAs and of some epithelial-mesenchymal markers. Moreover, LINC00176 negatively regulates proliferation/viability.

      Major comments:

      • Are the key conclusions convincing?

      Despite the findings presented in this study are novel and relevant with regard to p53 function in cancer cells, the study is very preliminary and opens different lines of investigation that remain incomplete. Some examples: Authors identify a panel of miRNAs that may interact with LINC00176 but do not provide any functional impact of these miRNAs on cancer cell functions. Authors show modulation of epithelial-mesenchymal markers but do not provide evidence for changes in cell behavior (motility for example) Authors show that LINC00176 impacts on D40p53 protein level, but no statistical significance of this result nor description of the mechanism are provided. Importantly, the study is basically carried out using HCT116 p53-/- cells for the majority of the experiments. It would be worth trying to prove the relevance of the identified axis in the context of a cancer type, by analyzing the expression of D40p53 protein by WB and, concomitantly, the level of LINC00176 expression on the same samples. - Should the authors qualify some of their claims as preliminary or speculative, or remove them altogether?

      I have indicated this below - Would additional experiments be essential to support the claims of the paper? Request additional experiments only where necessary for the paper as it is, and do not ask authors to open new lines of experimentation.

      I have indicated this below - Are the suggested experiments realistic in terms of time and resources? It would help if you could add an estimated cost and time investment for substantial experiments. - Are the data and the methods presented in such a way that they can be reproduced?

      Yes - Are the experiments adequately replicated and statistical analysis adequate?

      I have indicated below some critical points in this regard

      There are several conclusions in the presented data that are not convincing, especially those from which the study stems. These are detailed below:

      Authors say that LINC00176 is expressed at lower level in tumor vs normal tissues in LUAD, LUSC and COAD (box plot supply fig 1b); however, plots from GEPIA presented in Suppl Fig 1A show exactly the opposite result. Moreover, box plots do not have asterisk, which is provided by GEPIA when results are significant, indicating that the presented differences in expression are not significant. I suggest to delete these results and revise the analysis which led to inconclusive contrasting results.

      Figure 1D: Please explain in the text why HCT116 p53-/- cells show highly expressed D40p53 to allow readers to easily follow the experiments.

      Suppl. Fig.1C-E-G: Authors say that in normal tissues, LINC00176 was positively correlated with p53 levels (line 212). Again, here only in LUAD the positive correlation is significant. They also say that "in tumor tissues they were negatively correlated" (line 213). This is discordant with data presented in Suppl. Fig.1D-F-H, where no negative correlation is present (negative corr. is indicated by minus sign preceding the correlation coefficient (R) in Pearson's / Spearman's analysis).

      "This observation suggests that LINC00176 may be positively regulated by WT p53 in normal conditions and negatively regulated by mutant p53 in tumor conditions" (line 214-215): this could be easily assessed as TP53 mutational status is publicly available in the TCGA datasets.

      Figure 1. It is not indicated whether the significance derives from three independent biological replicates. This should be addressed for all the experiments presented in the study.

      Figure 2I: Please indicate on the graph which comparison the asterisks refer to. Moreover, explain better in the text that induction caused by ER stress is not obtained in absence of D40p53.

      Figure 2K-J: Quality of the WB is poor. Moreover, as the b-actin seems down regulated by si-D40/Thaps the normalization over b-act is not so informative (numbers at the bottom of the panels).

      Figure 3: Enrichments of D40p53 in ChIP experiments are really small. Usually enrichments <2folds are not very reliable.

      Figure 4F-G: Please explain better in the text the pull-down results, describing which comparisons have been made to evaluate the results.

      Figure 5G-H: Please include significance for the viability assays

      Figure 5E: The finding that o/e of LINC00176 induces D40p53 is very interesting and it's worth reinforcing this by analyzing 3 biological replicates followed by quantification of WB results and statistical analysis. I strongly suggest to evaluate D40p53 protein in cells silenced for LINC00176 as well. Interaction D40p53/LINC00176 could be stabilizing on both sides. Evaluation of cells with modulated LINC00176 in presence/absence of cycloheximide would definitely prove this. Inclusion of evaluation of this aspect with regard also to p53 is encouraged.

      For all the presented experiments number of biological replicates evaluated should be indicated.

      Minor comments:

      • Specific experimental issues that are easily addressable.
      • Are prior studies referenced appropriately? Yes
      • Are the text and figures clear and accurate? Yes, unless indicated in the suggestions above
      • Do you have suggestions that would help the authors improve the presentation of their data and conclusions? I have already included this above

      Significance

      The study highlights that D40p53 protein, besides regulating microRNAs (as previously reported) is also involved in the control of lncRNAs. The findings provide an advancement in the understanding of D40p53 function in cancer cells.

      The study might be quite relevant for the scientific community (cancer/tumor suppressors) if evaluation of cancer samples will be included.

      My expertise falls in the p53/mutant-p53 and non-coding RNA fields so I think it is appropriate to evaluate this study.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Manuscript number: RC-2022-01488

      Corresponding author(s): Tobias Lange, Csaba Jeney

      1. General Statements

      First of all, we would like to thank the reviewers for their valuable comments on our manuscript. We appreciate your questions and comments and we tried to answer thoroughly all points raised.

      Consistent with the comments, we would like to shift the focus of this paper to the comparison of scRT-ddPCR with scRNA-seq signal distributions taking this scRNA-seq method as an exemplary but experimentally matching control. This is represented in the new title ”Validation of scRNA-seq by scRT-ddPCR using the example of ErbB2 in MCF7 cells”.

      A major point was in the comments the use of ERCC spike-ins. We carefully considered ERCC spike-ins during the design of the experiments but finally omitted this concept as the ERCC spike-ins were designed for relative quantification (fold changes) but not for absolute counts. Furthermore, it was shown that these controls have a high variability and high dropouts (Risso et al. 2014, Vallejos et al. 2017). We were also aware that ERCC spike-ins analysis can be biased by the apparent Poisson distribution and could thus complicate the (absolute) quantitative analysis. However, we are reconsidering including these controls, after external validation, in a subsequent publication.

      Besides that, to improve the manuscript it was suggested to split it into two publications, which we seriously considered but the validation of scRNA-seq data by scRT-ddPCR is now the major conclusion, and separate publications are necessary regarding the other improvements presented. Please find the answers below.

      We hope that we were able to answer all criticism sufficiently well and we are open for further discussion.

      2. Description of the planned revisions

      Reviewer 1

      Major concerns:

      The authors did not compare their results with standard SMART-seq2 in detection sensitivity (comparison on UMAP clustering is really trivial, and cannot serve the purpose)

      To further validate our workflow, we consider to compare signal distributions of ErbB2 and ACTB in MCF7 cells from Isakova et al. (2021) (GSE151334) with the distributions obtained from our approach (see Fig 4 a and b).

      Reviewer 2

      Minor concerns:

      Figure 1. B and C figure's axes are not easy to read even at highest zoom. At least the 400 bp in the x axis could be represented using a bigger font.

      Yes, we will increase the font size of Fig 1b and c.

      Figure S4. 'for in in range' needs some attention.

      It might become clearer using the expression “cycle 1000x” or “repeat 1000x”.

      Reviewer 3

      Major concerns:

      Single-cell SMART-Seq with SMART-Seq from "bulk" and "cl", which authors include in scRT-dPCR but not in scRNA-Seq

      The controls “bulk” and “cl” are designed to validate the lysis of a single cell after processing by F.SIGHT and I.DOT (see 3.2 Validation of scRT-ddPCR using bulk methods). Our results indicate that, independent of the method, we quantify the same absolute amount of ACTB and ErbB2 mRNA in single cells (Fig 3). To avoid confusion, we will thus remove the signal distribution of “bulk” and “cl” in Fig 4 a and b.

      Authors analysed scRNA-Seq data using "pseudo-bulk" differential expression analysis using DESeq2. Authors did not include more details about processing of the data, if they used standard DESeq2 protocol, or modified protocol recommended for scRNA-Seq data. It is hard to conclude if the chosen method is optimal, however I'm recommending to use method, which is standard for scRNA-Seq nowadays, like a Seurat with SCTransfrom.

      We have followed published settings of DESeq2, which can be specifically applied to single cell data, also described here. Indeed, after we checked our settings, we realized that we did not use the correct parameters and we have implemented the changes. However, this will not substantially affect our results and conclusions. The scripts of data processing are added to the supplementary material.

      Reviewer 3

      Minor concerns:

      Commercial kit SMART-Seq from Takara is not same as Smart-Seq2 protocol (line 198). Please do not use same name for commercial and academical protocols.

      We adjust the nomenclature to account for the differences.

      Can you include more details for processing of data?

      We revise the manuscript accordingly. Briefly, the aligners were wrapped into bash scripts and alignment was performed on each FASTQ file separately. As recommended in the documentation for kallisto and salmon, the mean read length and its standard deviation was calculated for each file. In alignments with STAR a genome index was created (as recommended). After alignment, the read table was created with FeatureCounts. We also share the scripts and settings for data processing as indicated above.

      Can you share whole script for data processing?

      Yes, we share the scripts for data processing in the supplementary material.

      Why you didn't't show any other cell type specific markers, which differ between chosen cell lines (lines 328/329)?

      The chosen cell lines are highly related; in breast cancer research, they are frequently used to control each other. This choice has advantages and drawbacks, as they differ principally in their ErbB2 expression. MCF7 and BT-474 serve as good controls in this study. An expansion to other differentially expressed genes is limited. However, we evaluated KRT8 and TFF1 (two marker genes for MCF7 cells (Isakova et al. 2021)) in scRNA-seq and ErbB2 in both scRNA-seq and scRT-ddPCR as key markers. We could highlight more marker genes between MCF7 and BT-474 cells on the basis of scRNA-seq data.

      I don't understand "missing normalization of counts" for comparison between different aligners. Especially, because counts are normalized during analysis using DESeq2 (line 396).

      We apologize for the misunderstandable terms, the signal distributions are constructed based on the values from Fig 2b (and not based on DESeq2), thus the unit of salmon and kallisto distributions is TPM, while for STAR distributions it is raw counts. This discrepancy in normalization of counts might contribute to the difference in distributions between STAR and kallisto as well as between STAR and salmon.

      Authors should change name "integrated workflow" into something else, because there is no integration of scRNA-Seq data with scRT-dPCR. They only compare results from this two methods.

      We consider to rename the publication, for instance, Validation of scRNA-seq by scRT-ddPCR using the example of ErbB2* in MCF7 cells. *

      There is no demonstration of needs of validation (line 416).

      Yes, we agree, the need for validation is only mentioned in the introduction (lines 69 to 75 and lines 82 to 85) but should be taken up here again.

      Are the differences in the log2FC real problem for single-cell experiments? Authors used different cells and different number of cells for comparison. Can it be source of different log2FC?

      Indeed, the amount of cells between scRNA-seq and scRT-ddPCR were different and we understand that this might introduce subsampling errors. Assessing that question we bootstrap and down-sample the scRNA-seq group to compare the same amount of cells between scRNA-seq and scRT-ddPCR and revise this part accordingly.

      3. Description of the revisions that have already been incorporated in the transferred manuscript

      Reviewer 1

      Minor concerns:

      Fig.1a,b, in ROI, there are overlap between "printed cells" and "detected particles"? How to distinguish between the two?

      Each dot in the 2D scatter plot is a detected particle during the dispensation process of the F.SIGHT (see representative images in Fig 1a). The particles can be of various origin: cell debris, cell aggregates, corpuscular materials from cell culture medium or cells. The ROI defines the morphological criteria (diameter and roundness) by which we define a particle as a cell. The overlap between detected particles, which can thus also be cells, and the printed cells is because of the fact that some cells are detected but not evaluated as single cells.

      Fig2d, what is the difference between DEG and "different genes"? The no. different genes is not specified for STAR?

      1. DEGs are significantly different genes, abs(log2FC)>1 and padj1 but padj>0.05. These genes are different but not significantly.
      2. For STAR, we did not obtain any genes of the latter category; all different genes are thus DEGs.

        It is not clear how the bulk samples(Fig.3,4) were prepared.

      Thank you for pointing this out. We revised the manuscript accordingly, briefly the total RNA was isolated from 1E6 cells, diluted and analyzed in a dPCR (as described in 2.2 Total RNA isolation and bulk cell lysis). The absolute mRNA counts per single cell were calculated by dividing the detected number of transcripts with the number of cells.

      Reviewer 2

      Minor concerns:

      P5, line 148 is not clear to me.

      1E6 cells were lysed using 500 µl of Actome’s proprietary lysis buffer (PICO-000010, Actome). This results in 2000 cells/µl of lysate. By addition of 49.5µl DPBS (100X dilution), the cell concentration is 20 cells/µl. Thus, dispensation of 50 nl using the I.DOT results in an equivalent amount of material of a single cell.

      Reviewer 3

      Major concerns:

      The conclusion from whole paper is confusing, because it is bringing several new information and methods, which would be better if they would presented separately. Mainly down-scaled SMART-Seq using i.DOT and F.SIGHT - it is novel and important. Single-cell dPCR combined with F.SIGHT, which can be presented separately without down-scaled SMART-Seq.

      We discovered that down-scaling does not significantly enhance the detection of low-abundant transcripts such as ErbB2 in MCF7 cells (Fig 4a) contrary to theoretical considerations (lines 77 to 82). To assess this bias, scRT-ddPCR was used to validate the representability of low-abundant transcripts in scRNAseq, ultimately, revealing a better resolution of the expression in single MCF7 cells (Fig 4a). We see scRT-ddPCR as the potential improvement in validating scRNA-seq data regardless of the scRNA-seq method used. For the sake of this paper, however, we used a unique combination of methods. We understand the value of the components themselves, and the validation of miniaturized scRNA-seq deserves a subsequent paper. The used combination of methods, albeit unique, was designed to reduce the technical and biological variability to minimum; the cells originate from the same population and the same instrumentation was used. This is better suited to support our claims regarding representability.

      Also to note, the scRT-ddPCR is a ground truth method that literally counts molecules. The only mathematical concept applied is Poisson statistics (Basu 2017), and no further data processing is necessary, which could influence data evaluation supporting its generality.

      It is hard to say, "what is important message of this manuscript".

      Low-abundant transcripts are often referred to as highly interesting and difficult to analyze especially regarding reproducibility (Fortunel et al. 2003, Schwender et al. 2014, Petrova et al. 2017, Taylor et al. 2017). Our data supports previous findings that dropouts in scRNA-seq are frequent (Luecken et al. 2019). Down-scaling of SMART-Seq2 does not significantly increase detection efficiency and reliability (Fig 4) despite the considerable assumptions described in lines 77 to 82. This part of the paper supports the previous findings. Additionally, we see the scRT-ddPCR method as a potential improvement in validating scRNAseq data regardless of the scRNA-seq method used.

      I don't understand, why authors present comparison of two RNA isolation protocol in RT-dPCR results.

      As described above, the “bulk” controls are needed to validate the full lysis of a single cell after processing by F.SIGHT and I.DOT (see 3.2 Validation of scRT-ddPCR using bulk methods). We assume that through total RNA isolation by commercially available and widely accepted kits, all mRNAs are released from the cells and are efficiently amplified. This serves as a reference value for the scRT-ddPCR method (Fig. 3b). To ensure the reliability of our reference value, we used two different commercial methods for total RNA isolation with unequivocal results (Fig S2d). These two methods, however, differ in sample preparation (DNase I digest vs no digest, enzymatic lysate homogenization vs mechanical lysate homogenization), in buffers and handling in general.

      More, the whole conclusion and results are made only from one experiment from two separated measurements. Authors should repeat experiment and check if differences in log2FC between scRNA-Seq and scRT-dPCR are same all the time.

      Single cell experiments are inherent biological replicates. We consider them to be a high number of parallels per experiment. They are processed parallely but separately, albeit using the same batch of chemicals and the same instrumentation. We purchased cells and chemicals from commercial sources assuming minimal possibility of error. The instruments were validated before use according to standard procedures.

      Reviewer 3

      Minor concerns:

      What is LBTW (line 154)?

      LBTW is a proprietary lysis buffer of Actome GmbH (line 146 and 147) (PICO-000010, Actome).

      Have you process/sort cells for scRT-dPCR and scRNA-Seq same day?

      Care has been taken to reduce the biological variability, so they were processed with minimal delay from the same dispensation cartridge and originate from the same cell culture flask.

      How you dilute RNA for ddPCR (line 180)?

      Total RNA from MCF7 cells was diluted 1:20, 1:50, 1:100 and 1:1000 with PBS, and ACTB and ErbB2 mRNAs were quantified in triplicates. Total RNA from BT-474 cells was diluted 1:50, 1:100, 1:1000 and 1:10000 with PBS, and ACTB and ErbB2 mRNAs were quantified in triplicates.

      And for scRT-dPCR?

      Single cells were not diluted. A single cell was dispensed directly into 0.5 µl lysis buffer, master mix was added and the scRT-ddPCR was performed.

      How many cells per condition you have sorted for SMART-Seq?

      84 cells were isolated for each cell line (Tab S1).

      How much time you need for collection of cells?

      The F.SIGHT requires a maximum of 8 min for the dispensation of 84 cells.

      How much time you need for pipetting of solution? Can it be problem for neutralization of tagmentation?

      The transposome activity was quenched by the addition of 0.5 µl of Neutralization buffer using the I.DOT. The I.DOT can dispense 96-wells per minute (Klinger et al. 2020).

      Have you use robot or have you manually cleaned cDNA with AMPure beads?

      The clean-up procedure was performed manually.

      Which magnetic separator you have used for clean-up?

      We used conventional neodym magnets for the separation of liquid and beads.

      384-well plate design and clean-up of 20 ul volume is not something standard, please specify it in the protocol.

      The procedure is described in the methods section lines 212 to 219.

      Have you pooled libraries before clean-up (line 238)?

      The cDNA libraries of single MCF7 and BT-474 cells were pooled separately.

      If yes, what was final volume?

      The final volume for each pooled library was ~420 µl (84 x ~5µl).

      How much AMPure beads you have used for clean-up?

      After cDNA amplification, we used 9 µl of AMPure bead suspension for clean-up. After library amplification, we used 0.6 to 1-fold volumes of the pooled library volume.

      Is it pooling reason of loosing of 30% cells from dataset?

      We isolated 84 single cells using the F.SIGHT. During quality control, we excluded ~30% of the cells from down-stream analyses (Tab S1). We applied the quality criteria as mentioned in lines 254 to 260. We think these are common criteria for filtering.

      Why you choose different cell types as you used for sequencing?

      In scRNA-seq and scRT-ddPCR (and in the corresponding controls), we used MCF7 and BT-474 cell lines. We chose these cell lines because of their well-described difference in ErbB2 expression (Durst et al. 2019) (lines 106 to 108 and lines 349 to 353).

      Why it is important that tagmented cDNA was 459/432bp long (Line 310)? Is it specific for down-scaled, or classical SMART-Seq? How to use this information?

      Jaeger et al. (2020) show examples of good quality tagmented cDNA libraries for down-scaled SMART-Seq2. Additionally, they mention that the peak should be within the range of 300 bp to 800 bp. Our tagmented cDNA library distribution (Fig 1c) exhibits remarkable similarity to the one shown by Jaeger et al. (2020) and the peak falls within the mentioned range. Thus, the tagmented cDNA obtained by our approach matches criteria for good quality tagemented cDNA library.

      Comparison in lines 354-355 is confusing.

      Using scRT-ddPCR, we could not detect a statistical difference in ACTB expression between the cell lines (Mann-Whitney test). MCF7 cells express 66±29 ACTB mRNAs per single cell and BT-474 cells express 114±80 ACTB mRNAs per single cell (Fig 3b).

      I don't know, what you wanted to say by showing number of copies od different genes in different cell lines.

      Absolute numbers of transcripts are very reliable, especially when they are generated by a method of ground truth relying on molecular counting (dPCR). Still some transcripts might not be transcribed into cDNA but partitioning increases their effective concentration (Basu 2017). Based on this, relative quantities can still be calculated. Additionally, absolute quantification eases data comparison as no standard is needed and dPCR has further advantages over qPCR (lines 97 to 103).

      I'm not sure that scRNA-Seq and scRT-ddPCR are truly orthogonal methods. Both methods are PCR based. (lines 381-382).

      While PCR is applied in both methods, we see the orthogonality of the methods in the independence of the detection events. dPCR provides a single molecular compartmentalization principle instead of scRNA-seq, where all mRNAs are transcribed competitively and simultaneously into cDNA. This results in multiple competing reactions and thus increases the propensity for dropouts. dPCR avoids that and directly provides molecular counts.

      At the end, it is not important if the gene has two times or three times higher expression. Important is preservation of the trend.

      In our view, trends are less informative measures than absolute counts, absolute counts are direct derivatives of chemical concentrations driving the chemical reactions in cells. Trends, however, can be reconstructed from absolute counts.

      Authors are analyzing relative expression of Actb and ErbB2 between two lines. Could be used scRT-qPCR instead of scRT-ddPCR? It could solve problem in the number of genes, which could be analyzed (line 438).

      Indeed, qPCR instruments usually offer a higher degree of multiplexing but we think that qPCR cannot deliver the sensitivity needed for the detection of low-abundant transcripts (see lines 97 to 103 and above). dPCR ensures the detection of single molecules, while qPCR has a variable sensitivity and would not be an orthogonal method according to our statement above. Furthermore, qPCR needs external standards for absolute quantification, while dPCR can absolutely quantify by molecular counting.

      Are the differences in the log2FC real problem for single-cell experiments? Authors used different cells and different number of cells for comparison. Can it be source of different log2FC?

      1. Difference in log2FCs might not be an exclusive problem for single-cell experiments (Rajkumar et al. 2015, von der Heyde et al. 2015, Everaert et al. 2017). However, we believe that in scRNA-seq differences are much more pronounced, especially regarding low-abundant transcripts, because of elevated amounts of technical noise and thus increased propensities for dropouts (Luecken et al. 2019).
      2. For the comparison of fold changes, we used two different cell lines, MCF7 and BT-474, but compared fold changes from expression of gene x in MCF7 cells versus expression of gene x in BT-474 cells. Fold changes from scRNA-seq and scRT-ddPCR were calculated this way and eventually compared.

        Why we need absolute numbers of copies of transcripts (lines 458-459)? I'm OK with relative quantity using RT-qPCR.

      Absolute numbers of transcripts are very reliable, especially when they are generated by a method of ground truth relying on molecular counting (dPCR). Based on this, relative quantities such as fold changes can still be calculated. As described above, dPCR has several advantages over qPCR. Furthermore, absolute amounts of mRNA per cell determine their chemical activity in a cell (Tang et al. 2011).

      Authors presented two novel application, which both separately can be important for single-cell transcriptomic analysis. One is down-scaled SMART-Seq, which save a money and brings full-length scRNA-Seq to more researchers. Second is scRT-ddPCR, which can ultimately increase sensitivity of single-cell methods. However, combination of both methods in one paper, without comparison of other technologies decrease impact and importance both of them. I.e. Pokhilko et. al (2021) presented targeted single-cell RNA-Seq, which increase sensitivity of Smart-Seq2 too.

      Pokhilko et al. (2021) also present a down-scaled version of SMART-Seq2 just as many other publications (Mora-Castilla et al. 2016, Jaeger et al. 2020, Isakova et al. 2021, Hahaut et al. 2022, Hagemann-Jensen et al. 2022). Pokhilko et al. (2021) use scRNA-seq data from Volpato et al. (2018), who use a manual, non-high-throughput method for single cell isolation. The F.SIGHT can gently isolate hundreds of single cells in a short period of time (see above) and records in parallel morphological characteristics, which can later be used to judge the cell’s integrity by neuronal networks (Riba et al. 2020) (see above: regarding the main conclusion of the paper and the planned follow-up paper, we highlight here that the focus was intended to be on the scRT-ddPCR method and its validation, and the miniaturized scRNA-seq was used to reduce the technical divergence of the methods).

      In my opinion, separated publication of both methods will be better. While down-scaled Smart-Seq2 is often discussed in Core Facilities to bring scRNA-Seq to more biologist and clinician, scRT-dPCR is very interesting but specific method.

      Although scRNA-seq is widely used, we could support recent findings (Luecken et al. 2019) that the detection of low-abundant transcripts is still challenging. Furthermore, we provide a proof-of-principle on how to validate the lack of representability of low-abundant transcripts in scRNA-seq: scRT-ddPCR.

      I'm focused in the RNA-Sequencing from sample preparation to data analysis. I'm helping people with optimization of the design to get as much information as possible. I wasn't able to say, if used statistical methods are correct.

      We carefully chose our statistical methods according to the suggestions in literature. We are open for specific scrutiny however.

      How you used DESeq2, BBKNN?

      1. The counts and transcript abundances were imported using the tximeta and tximport packages for data aligned with salmon and kallisto, respectively. Differential testing was carried out on the resulting count matrices with DESeq2 using LRT testing and other parameters set according to the recommendations of the DESeq2 vignette for testing single-cell data.
      2. For BBKNN clustering, a custom data set was constructed combining our data (salmon aligner) with a published data set containing MCF7 cells, fibroblasts and HEK293T cells (Isakova et al. 2021). For the analysis, the data set was imported in SCANPY. Cells with fewer than 200 genes expressed and genes expressed in less than three cells were excluded from the analysis. Counts per cell were normalized with SCANPY’s built-in normalization method. The data was log-transformed, scaled and a PCA was carried out, according to the standard workflow recommended in the SCANPY documentation. BBKNN was similarly carried out with the respective SCANPY method, the final plot was created after dimensionality reduction with UMAP.

        How you have processed published data?

      External data was concatenated with our data into a single AnnData object and analyzed according to the recommendations of the SCNAPY documentation.

      4. Description of analyses that authors prefer not to carry out

      Reviewer 1

      Major concerns:

      The authors did not compare their results with standard SMART-seq2 in detection sensitivity (comparison on UMAP clustering is really trivial, and cannot serve the purpose)

      Miniaturization of SMART-seq2 and related protocols is frequently applied (Mora-Castilla et al. 2016, Jaeger et al. 2020, Isakova et al. 2021, Hahaut et al. 2022, Hagemann-Jensen et al. 2022) ensuring high quality data and reducing costs per cell. Therefore, we think that there is sufficient evidence that miniaturized/down-scaled protocols deliver the same results compared with standard protocols.

      Fig3b, there are a total of four groups of comparison, two genes X two cell lines. In one of the four, i.e. ACTB in MCF7, the quantification among the three methods differ significantly. Given no ground truth here, it is hardly to judge the quality of their method. The author should add ERCC spike-in to control their experiments as stated in their Discussion.

      1. Yes, we are aware of this difference as described in lines 371 to 375 and relate this difference to a different passage number (Tab S4) as it was already shown that housekeeping genes underlie fluctuations, too (Kozera et al. 2013). However, the difference in absolute counts does not have a significant impact on the fold changes (Fig 4c).
      2. Risso et al. (2014) showed that ERCC control signals have a high variability, and Vallejos et al. (2017) found that only half of the spiked-in molecules are detected. Literature is not conclusive about the ErbB2 expression in MCF7 cells (Subik et al. 2010, Cui et al. 2012, Durst et al. 2019), so we applied scRT-ddPCR (a method of ground truth) on single MCF7 cells to reveal ErbB2 expression at highest available resolution. Upon these considerations ERCC control might have no impact on dPCR results.
      3. However, we understand that the ERCC controls, comprising a set of polyadenylated transcripts that are added to the scRNAseq analysis experiment during single-cell isolation, can replicate the effect of low abundance transcripts. Single cells have very low transcript counts; it is questionable to quantitatively recapitulate this effect. The apparent Poisson distribution of the ERCC counts, at that low level, can complicate the quantitative analysis of the results, while the single-cell analysis also has its inherent heterogeneity. In the case of the lack of conclusive quantitative nature of ERCC spike-in, see also above, internal transcripts also can serve this aim of the study. However, in a subsequent paper, we plan to compare the two methods. To our knowledge, such a comparison between scRNA-seq and scRT-ddPCR was never performed before, so we could not follow previous realizations here. Our findings support the hypothesis that scRNA-seq suffers from detection deficits at the lower detection end (Luecken et al. 2019).

        Fig4b, ACTB in BT-474, it seems that the scDDPCR resulted in more cells in the first bin than scRNA-seq. This is in contrast to their claim of higher detection sensitivity of the former.

      There are more cells in the first bins of the scRT-ddPCR histogram but on a statistical basis, the distributions do not significantly differ (Tab S6).

      To assess the performance of their methods in a more systematic manner, the authors should perform the single cell measurements with ERCC spike-in, and check at least 5-10 endogenous genes at different expression level, in addition to the spike-in RNAs. They should choose cell lines for which the absolute no. of RNA for some house-keep genes has been measured using imaging based methods.

      We thought we addressed these issues thoroughly in our discussion (ERCC spike-ins: lines 459 to 461 and more endogenous genes: lines 438 to 443 and see also above). In our view image-based methods suffer more technical ambiguities; however, they could serve as possible validation as they are orthogonal. Additionally, spatial resolution would be preserved but absolute quantification is not possible. Our scRT-ddPCR method was validated against bulk RNA isolation methods, which serve as established references regarding the RNA isolation. We accepted the RT-PCR as a reference as it has been thoroughly validated as a method providing precise nucleic acid counts.

      The two methods described in the manuscript represent little technical advance. In addition, the conclusion stated in the manuscript is also not sufficiently convincing. As such, it would be of little interest to limited group of audience.

      The two most frequently used methods for scRNA-seq are Chromium from 10X Genomics and Smart-Seq2-based protocols. In a direct comparison, Wang et al. (2021) showed that Smart-Seq2 is better suited for the detection of low abundant transcripts. We wanted to further enhance the sensitivity of SMART-seq2 by down-scaling; it was hypothesized that this increases the detection efficiency (Mora-Castilla et al. 2016). However, we were still not able to detect low-abundant transcripts such as ErbB2 in MCF7 cells (Fig 4a). Low-abundant transcripts are often referred to as highly interesting and difficult to analyze especially regarding reproducibility (Fortunel et al. 2003, Schwender et al. 2014, Petrova et al. 2017, Taylor et al. 2017). Our proposed scRT-ddPCR can reliably and absolutely quantify low-abundant transcripts offering a solution for the detection of such targets. The majority of similar workflows use scRT-qPCR (lines 82 to 86), although dPCR is much more sensitive and can detect fold changes down to 1.16-fold (Basu 2017).

      Reviewer 3

      Major concerns:

      Down-scaled SMART-Seq with standard SMART-Seq

      We compared our down-scaled SMART-Seq2 workflow to a validated, down-scaled SMART-Seq2 workflow (Isakova et al. 2021) using UMAP clustering. Furthermore, miniaturization of SMART-Seq2 and related protocols is common practice (Mora-Castilla et al. 2016, Jaeger et al. 2020, Isakova et al. 2021, Hahaut et al. 2022, Hagemann-Jensen et al. 2022). Therefore, we think that a UMAP comparison is sufficiently proving that our down-scaled protocols deliver reliable results. However, we see some possible improvement by comparing distributions of gene expressions (see above).

      Single-cell SMART-Seq with SMART-Seq from "bulk" and "cl", which authors include in scRT-dPCR but not in scRNA-Seq

      Smart-seq2 was designed to profile the transcriptome of single cells (Picelli et al. 2013, Picelli et al. 2014). Other methods are purely for comparison and validation and were not intended to be technological advancements.

      scRT-dPCR with scRT-qPCR

      qPCR is often used to validate fold changes from RNA-seq (Zucha et al. 2021). The differences between qPCR and dPCR are extensively described, for instance, in Basu (2017). In several comparisons between qPCR and dPCR or even RT-qPCR and RT-dPCR, the latter showed increased precision, reproducibility, higher sensitivity and high tolerance towards inhibitors (Alikian et al. 2017, Taylor et al. 2017). Thus, we assume that qPCR is not the method of choice for the detection of low-abundant transcripts such as ErbB2 in MCF7 cells (lines 97 to 103).

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      Summary:

      Authors compared differential expression of Actb and ErbB2 between cells from two cell lines MCF7 and BT-474. They used two new/optimized methods: down-scaled SMART-Seq and single-cell RT-dPCR. They demonstrated, that scRNA-Seq method is not sensitive enough method to properly quantify low abundant transcripts and we need additional method for it.

      Major comments:

      Authors are comparing results from two novel methods - down-scaled SMART-Seq and scRT-dPCR, without including standard protocol. I'm missing some additional experiments/comparison. The conclusion about one correct and one incorrect method are too strong, with many variables. Only one clear conclusion is about dropout in scRNA-Seq in comparison with scRT-dPCR. - Down-scaled SMART-Seq with standard SMART-Seq - Single-cell SMART-Seq with SMART-Seq from "bulk" and "cl", which authors include in scRT-dPCR but not in scRNA-Seq - scRT-dPCR with scRT-qPCR Authors analysed scRNA-Seq data using "pseudo-bulk" differential expression analysis using DESeq2. Authors did not include more details about processing of the data, if they used standard DESeq2 protocol, or modified protocol recommended for scRNA-Seq data. It is hard to conclude if the chosen method is optimal, however I'm recommending to use method, which is standard for scRNA-Seq nowadays, like a Seurat with SCTransfrom. The conclusion from whole paper is confusing, because it is bringing several new information and methods, which would be better if they would presented separately. Mainly down-scaled SMART-Seq using i.DOT and F.SIGHT - it is novel and important. Single-cell dPCR combined with F.SIGHT, which can be presented separately without down-scaled SMART-Seq. And comparison of different aligner for scRNA-Seq data analysis. It is hard to say, "what is important message of this manuscript". I don't understand, why authors present comparison of two RNA isolation protocol in RT-dPCR results. More, the whole conclusion and results are made only from one experiment from two separated measurements. Authors should repeat experiment and check if differences in log2FC between scRNA-Seq and scRT-dPCR are same all the time.

      Minor comments:

      Authors are commenting sensitivity The method part needs additional information.

      What is LBTW (line 154)?

      Have you process/sort cells for scRT-dPCR and scRNA-Seq same day?

      How you dilute RNA for ddPCR (line 180)? And for scRT-dPCR?

      Commercial kit SMART-Seq from Takara is not same as Smart-Seq2 protocol (line 198). Please do not use same name for commercial and academical protocols.

      How many cells per condition you have sorted for SMART-Seq?

      How much time you need for collection of cells?

      How much time you need for pipetting of solution? Can it be problem for neutralization of tagmentation? Have you use robot or have you manually cleaned cDNA with AMPure beads?

      Which magnetic separator you have used for clean-up? 384-well plate design and clean-up of 20 ul volume is not something standard, please specify it in the protocol.

      Have you pooled libraries before clean-up (line 238)? If yes, what was final volume? How much AMPure beads you have used for clean-up? Is it pooling reason of loosing of 30% cells from dataset?

      Can you include more details for processing of data? How you used DESeq2, BBKNN? How you have processed published data? Why you choose different cell types as you used for sequencing? Can you share whole script for data processing?

      Why it is important that tagmented cDNA was 459/432bp long (Line 310)? Is it specific for down-scaled, or classical SMART-Seq? How to use this information?

      Why you didn't't show any other cell type specific markers, which differ between chosen cell lines (lines 328/329)?

      Comparison in lines 354-355 is confusing. I don't know, what you wanted to say by showing number of copies od different genes in different cell lines.

      I'm not sure that scRNA-Seq and scRT-ddPCR are truly orthogonal methods. Both methods are PCR based. (lines 381-382).

      I don't understand "missing normalization of counts" for comparison between different aligners. Especially, because counts are normalized during analysis using DESeq2 (line 396).

      Authors should change name "integrated workflow" into something else, because there is no integration of scRNA-Seq data with scRT-dPCR. They only compare results from this two methods.

      There is no demonstration of needs of validation (line 416). At the end, it is not important if the gene has two times or three times higher expression. Important is preservation of the trend.

      Authors are analyzing relative expression of Actb and ErbB2 between two lines. Could be used scRT-qPCR instead of scRT-ddPCR? It could solve problem in the number of genes, which could be analyzed (line 438).

      Are the differences in the log2FC real problem for single-cell experiments? Authors used different cells and different number of cells for comparison. Can it be source of different log2FC?

      Why we need absolute numbers of copies of transcripts (lines 458-459)? I'm OK with relative quantity using RT-qPCR.

      Significance

      Authors presented two novel application, which both separately can be important for single-cell transcriptomic analysis. One is down-scaled SMART-Seq, which save a money and brings full-length scRNA-Seq to more researchers. Second is scRT-ddPCR, which can ultimately increase sensitivity of single-cell methods. However, combination of both methods in one paper, without comparison of other technologies decrease impact and importance both of them. I.e. Pokhilko et. al (2021) presented targeted single-cell RNA-Seq, which increase sensitivity of Smart-Seq2 too.

      In my opinion, separated publication of both methods will be better. While down-scaled Smart-Seq2 is often discussed in Core Facilities to bring scRNA-Seq to more biologist and clinician, scRT-dPCR is very interesting but specific method.

      I'm focused in the RNA-Sequencing from sample preparation to data analysis. I'm helping people with optimization of the design to get as much information as possible. I wasn't able to say, if used statistical methods are correct.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      This study aimed to validate the lack of representability of lowly expressed genes by using an integrated workflow of downscaled Smar-seq2 and absolute quantitative, single-cell digital PCR. They addressed the issue of biased/mismatch of data of lowly expressed genes when comparing sc-RNA-seq and RTqPCR which arises due to dropouts of lowly expressed genes in scRNA-seq. They leveraged the sensitivity of scRT-ddPCR in addressing this issue.

      The team made a great effort to address the issues related to coverage and quantity of transcriptome analysis. by combining down-scaled sc RNA-seq and scST-ddPCR. They harnessed the inherent portioning of the dPCR which effectively increases the sensitivity that is lacking in sc RNA-seq when it comes to low-abundant mRNAs. They developed a novel, integrated workflow combining down-scaled, single-cell Smart-seq2 and absolute quantitative, single-cell digital PCR. They further validated the workflow by comparative clustering from published data sets and their scRT-ddPCR datasets by contrasting absolute mRNA counts to bulk methods.

      The key conclusions of the study are satisfying and supported by the experimental design and robust experiments. Data and methods are well-presented and are reproducible. The manuscript is articulate, and well-written, the data provided are of high standards and help the reader easier understand, especially the graphical abstract.

      I have no major comments, but a few minor changes are encouraged.

      1. Figure 1. B and C figure's axes are not easy to read even at highest zoom. At least the 400 bp in the x axis could be represented using a bigger font.
      2. Figure S4. 'for in in range' needs some attention.
      3. P5, line 148 is not clear to me.

      Significance

      scRNA-seq is a great tool for characterizing cells. However, the issue of losing the lowly expressed genes due to dropouts and also the variation in the fold change found between the bulk methods and ddPCR is one of the challenges. The authors took a nice strategy to address these issues through their effective workflow. The authors performed a thorough comparison between the data from scRNA-seq and ddPCR and their workflow showed to be very effective in addressing the issue of biased conclusions which substantiate their findings. Furthermore, by investigating the workflow in two different cell lines convincingly corroborates their results.

      This manuscript is well-written, experiments are thoroughly performed, the findings are convincing and it clearly is an important contribution to the scientific community. Great piece of work and I wish the authors all the best.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      The manuscript by Lange et.al described two methods, down-scaled sc-SMART-seq 2 and sc-droplet-based digital PCR for quantification of gene expression at single-cell level. By plate-based analysis of two cell lines, MCF-7 and BT-474, the authors claimed that their methods could achieve high sensitivity and accuracy in single cell gene expression quantification, in particular for the digital PCR strategy. In my opinion, this major conclusion is not sufficiently convincing, given that

      1. The authors did not compare their results with standard SMART-seq2 in detection sensitivity (comparison on UMAP clustering is really trivial, and cannot serve the purpose)
      2. Fig3b, there are a total of four groups of comparison, two genes X two cell lines. In one of the four, i.e. ACTB in MCF7, the quantification among the three methods differ significantly. Given no ground truth here, it is hardly to judge the quality of their method. The author should add ERCC spike-in to control their experiments as stated in their Discussion.
      3. Fig4b, ACTB in BT-474, it seems that the scDDPCR resulted in more cells in the first bin than scRNA-seq. This is in contrast to their claim of higher detection sensitivity of the former.

      To assess the performance of their methods in a more systematic manner, the authors should perform the single cell measurements with ERCC spike-in, and check at least 5-10 endogenous genes at different expression level, in addition to the spike-in RNAs. They should choose cell lines for which the absolute no. of RNA for some house-keep genes has been measured using imaging based methods.

      Minor concern

      1. Fig.1a,b, in ROI, there are overlap between "printed cells" and "detected particles"? How to distinguish between the two?
      2. Fig2d, what is the difference between DEG and "different genes"? The no. different genes is not specified for STAR?
      3. It is not clear how the bulk samples(Fig.3,4) were prepared.

      Significance

      The two methods described in the manuscript represent little technical advance. In addition, the conclusion stated in the manuscript is also not sufficiently convincing. As such, it would be of little interest to limited group of audience.

      I have been working in the field of genomics, in particularly transcrptomics for the last 20 years. In the last few years, my lab has been developing single-cell omics related methods.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.


      Reply to the Reviewers

      We appreciate the time and effort that the reviewers dedicated to providing feedback on our manuscript and are grateful for the insightful comments on and valuable improvements to our paper.

      Here is a point-by-point response to the reviewers’ comments and concerns.

      Reviewer #1 (Evidence, reproducibility and clarity (Required)): *

      Summary:

      In this manuscript, Kashiwagi and colleagues examine the role of the BAF complex subunit Smarce1 in mouse ESC. They utilize a gene trap methodology to generate a Smarce1-null cell line (m/m) as well as a Smarce1-rescue cell line (r/r) in which the gene trap is excised. The Smarce1-null cell line exhibited abnormal colony morphology and elevated Nanog expression.

      The authors use several approaches to examine the effects of Smarce1 loss on the chromatin characteristics of mouse ESC. Using salt extraction, they show that depletion of Smarce1 causes nucleosome instability, as marked by enhanced solubility of Histone H3. Using immunoprecipitation and sucrose gradient experiments, they suggest that decreased nucleosome stability is due to loss of Arid1a from the BAF complex and improper targeting of the complex to heterochromatin. This improper targeting of the BAF complex to heterochromatin causes a decompaction of heterochromatin foci, potentially due to disruption or displacement of the PRC2 complex. The changes alter the differentiation potential of the m/m mESC, which exhibit abnormal mesoderm differentiation and enhanced neural differentiation. Taken together, these data suggest that Smarce1 is a critical component of the BAF complex that is required for proper targeting of the complex within the chromatin environment.

      Major Comments: *

      • Throughout the manuscript, the authors make conclusive statements about differences in the intensity or pattern of bands in western blots or DNA gels. However, these statements are purely qualitative, and the authors fail to provide any information about the number of replicates performed. As such, there is no way to judge the statistical significance of the observed changes and it is difficult to have confidence in any of the conclusions drawn from these experiments. *

      Responses

      We thank the reviewer for the insightful comments. Many of the results presented in this paper were validated multiple times prior to the initial submission. We plan to compile these data, conduct further experiments, and perform quantitative analyses to demonstrate the reproducibility of our findings.

      *1. Figure 2b: requires validation through multiple replicates. Ideally, the bands would be quantified and data from multiple replicates can be used for statistical analysis. *

      Responses

      As suggested by the reviewer, we plan to present quantified data from multiple replicates.

      *2. Figure 2d: as depicted, it is impossible to draw any conclusions. To assess the stability or "looseness" of nucleosomes, the authors should perform lane densitometry to compare the relative intensity of the bands within the lanes as well as the spacing of the bands. *

      Responses

      We appreciate the reviewer’s critical comments. Because the nucleosome repeat length changes due to chromatin structure alteration, it is extremely important to compare the spacing of the bands between the wt, r/r, and m/m cells. As suggested by the reviewer, we plan to perform a quantitative analysis of the band intensity and band spacing.

      *3. Figure 3: the authors claim that Arid1a pulldown is decreased in the m/m cells whereas there is no change in BRD9 pulldown between the cell lines. However, there is a decrease in BRD9 pulldown in the r/r cell line that appears equal to the decrease of Arid1a in the m/m cells. Multiple replicates and quantification should be provided to validate the findings, otherwise the reported differences seem to just be judgement calls. *

      Responses

      As suggested by the reviewer, we plan to present quantitative data from multiple replicates to confirm the observations of the Arid1a and Brd9 pulldown assays.

      *4. Figure 3: the immunoprecipitations appear to be poorly normalized. For instance, there seems to be more Smarca4 in the m/m input but less Smarca4 in the pulldown. This could suggest that the immunoprecipitation in the m/m cells was less efficient than in the other two cell lines. Again, additional replicates of the experiment seem necessary. *

      Responses

      As suggested by the reviewer, we plan to present quantitative data from multiple replicates to normalize the efficiency of immunoprecipitation.

      5. Figure 4: Validation of the differences observed between the WT and m/m cell line requires multiple replicates of the experiment. Ideally, the bands can be quantified and the data could be presented as line plots or histograms.

      Responses

      As suggested by the reviewer, we plan to perform a quantitative analysis of the band intensity and present the results in a graph.

      6. Figure 6: same issues as Figure 2b. Additionally, the results for Ezh2, HDAC1, and Kap1 are quite different from those depicted in Figure 2b despite the experiment appearing to be identical. This further emphasizes the need for replication of these experiments.

      Responses

      We thank the reviewer for highlighting this important point. Regarding the data presented in Figure 2b, we analyzed undifferentiated ES cells, and Figure 6e depicts the results of an analysis of differentiated ES cells. It is known that heterochromatin formation is promoted during the differentiation of ES cells. Therefore, we believe that the heterochromatin components such as Ezh2, HDAC1, and Kap1 are more unstable in Figure 6e compared to Figure 2b. In the full revision, we plan to present the difference in heterochromatin formation between the undifferentiated ES cells and differentiated cells using DAPI-staining or an MNase sensitivity assay. Additionally, we observed by immunostaining that the co-localization of Kap1 to heterochromatin is inhibited in the differentiated m/m cells, which is consistent with the observation that Kap1 is more unstable in Figure 6e compared to Figure 2. We plan to present the Kap1 localization data in the full revision. As suggested by the reviewer, we plan to quantify the immunoblot data from multiple replicates and present the reproducibility of the findings illustrated in Figure 6e.

      *Additionally, the interpretation of the differentiation experiments in figure 5 is somewhat confusing and raises several questions:

      1. In C-E, the m/m embryoid bodies appear to have much denser outgrowths than the WT and r/r embryoid bodies. While panels A and B demonstrate that the m/m embryoid bodies are smaller, the images in C-E seem to suggest that there is much more proliferation in the m/m outgrowths. This could be due to the maintenance of stem cell characteristics suggested by the presence of more Nanog-positive cells. The authors should comment on this phenomenon. *

      Responses

      We thank the reviewer for this insightful comment. As highlighted by the reviewer, the maintenance of stem cell characteristics in the m/m cells, which is suggested by more Nanog-positive cells, may influence the proliferation of EB outgrowth. Conversely, we believe that the images in C-E alone are insufficient to assess the proliferation of EB outgrowth, and more observation fields must be analyzed. We plan to address this point by evaluating all areas of the EB outgrowth.

      *2. The authors should consider additional experiments to test the persistence of pluripotent cells in these assays. For instance, these outgrowths could be dissociated and replated in ESC growth conditions to examine the ability of the cells to form ESC-like colonies (which would indicate retention of pluripotency). *

      Responses

      We thank the reviewer for this valuable suggestion. We will examine the retention of pluripotency by investigating the proliferation of dissociated EB-outgrowth in the ESC growth condition. We also plan to evaluate the persistence of several pluripotency markers by qRT-PCR or immunostaining.

      3. The authors describe the m/m cells as having impaired mesodermal differentiation based on SMA staining and the morphology of SMA-positive cells. While the morphology of SMA-positive cells does look altered in the m/m cells, there is extensive SMA staining. Rather than "impaired" (which suggests that mesodermal differentiation is blocked), the authors should consider describing mesodermal differentiation as "abnormal" or "altered." Examination of alternative mesodermal markers would also be informative.

      Responses

      We thank the reviewer for the careful evaluation of the staining data. As suggested, we believe that the SMA staining in the m/m cells is “altered” rather than “impaired”. We will revise the manuscript accordingly during the full revision. We also plan to analyze the expression levels of other mesodermal markers by qRT-PCR to further assess the mesodermal differentiation of the m/m cells.

      *4. Are there m/m cells in this assay that are double-positive for SMA and BIII tubulin? This would be compelling evidence demonstrating that loss of Smarce1 disrupts normal differentiation pathways. *

      Responses

      We thank the reviewer for proposing an attractive model for a novel role of Smarce1 in the regulation of cell differentiation. We have carefully reevaluated our staining data. Although we did not conduct double staining of the m/m cells with anti-SMA and BIII tubulin antibodies, the morphologies of the SMA-positive cells and BIII tubulin-positive cells in a single staining are quite different. This suggests that double staining of the m/m cells with anti-SMA and BIII antibodies is unlikely. However, we believe that the present analysis is insufficient to evaluate the effect of the loss of Smarce1 on normal differentiation pathways. scRNA-seq will provide an overall picture of the effect of Smarce1 loss, which we plan to discuss in the full revision.

      Minor Comments:

      1. Sox2 expression levels should be added to figure 1d.

      Responses

      As suggested by the reviewers, we plan to add Sox2 expression levels to Figure 1d.

      *2. Please define the regions being targeted in the Oct4, Nanog, and Sox2 chip-pcrs. Are these the promoters, enhancers, gene bodies, etc…? *

      Responses

      We appreciate the reviewer’s comment. The promoter regions were analyzed in all the ChIP-PCRs. We will elaborate on this in the full revision.

      *3. The ChIP data in figure1e-k are difficult to read as presented. It would be helpful to group the data by target rather than cell line so that adjacent data points are directly comparable. *

      Responses

      We appreciate the reviewer’s comment. As suggested, we will group the ChIP data by the target regions in the full revision.

      4. On lines 378-379, the authors state there is minimal to no histone acetylation at IAP and LINE1. This clearly contradicts the data shown in Figure 1.

      Responses

      We appreciate the reviewer’s comment. Our description was misleading. We intended to say that the difference in histone acetylation at IAP and LINE1 was minimal (if detected at all) between the m/m and wt or r/r cells. We will clarify this point in the full revision.

      *5. Are other BAF subunits disrupted in the m/m cells? It would be useful to look at Smarcc1/2, BAF180, Smarcd1/2, in figure 3. *

      Responses

      We appreciate the reviewer’s comment. We believe that the investigation of other BAF subunits is important to substantiate our conclusion of the role of Smarce1 in BAF complex assembly. We plan to add the data for other BAF subunits to Figure 3 in the full revision.

      *6. Similarly, the authors mention in the discussion that impaired REST interaction may explain the enhanced neuronal differentiation observed in the m/m cells. In this case, the authors should consider including REST or Sin3a in figures 3 and 4. *

      Responses

      We thank the reviewer for the insightful comment. We plan to analyze the interaction between Rest and the BAF complex and Rest and chromatin and will present the results in the full revision. We believe that these experiments would be better performed on differentiated cells, as the Rest function would be more pronounced during neural differentiation.

      *7. Additional assays/markers for heterochromatin would strengthen the authors' conclusions about impaired heterochromatin formation. For instance, are overall H3K9me3 or H4K20me3 levels different in the m/m cells? What about HP1? *

      Responses

      As suggested by the reviewer, we plan to analyze the overall levels of heterochromatin markers and present the results in the full revision.

      Reviewer #1 (Significance (Required)): *

      This work could provide intriguing conceptual advances in the understanding of BAF complex function in mouse ESC. The authors provide sufficient context for this work in their introduction and discussion sections. As referenced in the manuscript, work from several labs has demonstrated the requirement for canonical BAF complexes in mouse ESC. Recent work has also demonstrated the existence of a non-canonical BAF complex that also functions in the maintenance of mouse ESC. SMARCE1 is specific to the canonical BAF complexes, and this work presented here potentially demonstrates the functional requirement for SMARCE1 in canonical BAF complex function. As such, this work is likely to influence an audience with interest in the molecular biology of the BAF complex and chromatin remodeling.

      *

      * Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      This manuscript is a follow-up on a Nature Methods from 2011 (reference 34) describing an astute method to rapidly generate homozygous mutant mouse ES cells. During this study, the authors noticed that inactivation of Smarce1/BAF57, a subunit of the SWI/SNF complex containing an HMG domain, resulted in abnormal morphology of the ES cells. Here, they have extended the characterization of this mutant, and shown that inactivation of BAF57 leaves essentially unaffected the expression of the pluripotency genes Oct3/4, Nanog, and Sox2, while also apparently preserving the MNase digestion patterns, and H3K9ac and H3K9me accumulation at repeats of the L1 or IAP families. In contrast, the mutation causes increased extractability of the Baf250/Arid1a SWI/SNF subunit, of histone H3, and of the transcriptional co-repressor KAP1. Finally, mutant cells were shown to differentiate into smaller embryoid bodies and failed to differentiate properly into mesodermal lineages. The differentiated cells were also found to contain pericentromeric heterochromatin foci of more elongated shape than in the wild types. Based on these observations, the authors propose that inactivation of Smarce1 decreaseb nucleosome stability and impaired heterochromatin formation during differentiation. Overall, the paper is technically sound. Yet, there is also a clear trend towards overinterpretation of the data, and the arguments in favor of a genome-wide impact on chromatin remain week. On the other hand, the impact of the Baf57 mutation on ES cell differentiation and on the extractability of Baf250 and KAP1 are convincing. *

      * Specific comments: *

      * Figure 1: There seems to be a contradiction between the conclusion from this figure (Increased H3K9ac levels at the Yamanaka gene promoters but not at repeats, suggesting a local impact on chromatin) and the overall conclusion from the paper, proposing a global decrease in stability of the nucleosomes. An ATAC-seq experiment would probably yield a more definitive conclusion. *

      Responses

      We thank the reviewer for the important comment. As described below, we believe that our explanation was insufficient. In the full revision, we plan to clarify our explanation as follows and conduct additional experiments to substantiate our findings.

      We proposed nucleosome instability of the m/m cells based on biochemical analysis. We should have emphasized here that at a salt concentration of 75 mM, at which chromatin is considered intact (Thoma F et al, J Cell Biol 1979, 83 : 403-427, Allan J et al, J Cell Biol 1981, 90 : 279-288), no difference was observed in the nucleosome stability between the wt and m/m cells either in the salt extraction assay (Figure 2B) or the MNase assay (Figure 2D). The difference in nucleosome instability was observed when the nucleosomes were artificially destabilized by increasing the salt concentration. From this observation, we can speculate that it may be difficult to detect the difference in the genomic status between the wt and m/m cells by ATAC-seq because ATAC-seq is performed under the condition where nucleosomes are intact.

      However, as the reviewer highlighted, we believe that further experiments are required to assess the extent of the genome-wide effect of the Smarce1 mutation. It is unclear from the current data whether nucleosome instability occurs globally or only in restricted regions of the genome. Additionally, it has not been proven whether nucleosome instability occurs in live cells. Therefore, we plan to investigate nucleosome instability by fluorescence recovery after photobleaching (FRAP) analysis using H2B-mCherry. If we observe increased incorporation of H2B-mCherry into chromatin in FRAP, we can say that nucleosome instability occurs globally in m/m cells. This would also prove that nucleosomes are indeed unstable in live cells. We have already established stable cell lines that express H2B-mCherry in the wt, m/m, and r/r cells and are ready to begin FRAP analysis.

      Figure 2: The increased extractability of Kap1 is difficult to see on panel 2B, while it is clear in the sucrose gradient experiments and in the differentiated cells. These sets of experiments (including ARID1a and histone H3) would therefore be much more ro*bust if the different species were quantified on biological replicates (to allow calculation of a p value). Also, the increased extractability of histone H3 is intriguing, pointing toward a global effect on chromatin, while the MNase experiment showing no impact on the nucleosome ladder argues against such an effect (same issue as for Figure 1). It may be worth exploring whether the extracted H3 is nucleosomal (or alternatively not yet incorporated into chromatin). This could eventually be done by a simple Coomassie staining of the different fractions, that would allow tracking of all the 4 histones simultaneously. *

      Responses

      We thank the reviewer for the important comment. As suggested, we plan to present quantitative data from multiple replicates. We also plan to conduct Coomassie staining to track all four histones in different fractions to examine whether extracted histones are incorporated or not yet incorporated into chromatin.

      Figure *3: It is not clear why the authors connect the sedimentation to a link with heterochromatin, as there is no correlation between distribution of the SWI/SNF subunits and that of histone H3 (while, in contrast, this experiment clearly documents some dissociation of Smarcc1 and the Arid proteins from the rest of the SWI/SNF complex). This should be discussed. Also, the lack of an effect of the BAF57 mutation on histone H3 sedimentation would be in favor of nucleosome remaining intact. *

      Responses

      (Note: Figure 3 in the reviewer's comment is most likely Figure 4.) Regarding the connection of the sedimentation to a link with heterochromatin, we believe our explanation was insufficient. At a salt concentration of 75 mM as shown, in Figure 4A, a higher-order chromatin structure is maintained (Thoma F et al, J Cell Biol 1979, 83 : 403-427, Allan J et al, J Cell Biol 1981, 90 : 279-288). Thus, the heterochromatin components would tend to distribute in the bottom fractions, while the euchromatin components and free proteins unbound to chromatin would tend to distribute in the top fractions. Since a portion of the esBAF components, such as Smarca4, Arid1a, and Smarcc1, migrated to the bottom fractions in the m/m cells (as evident in fraction 22 in Figure 4A), we interpreted this result as ectopic binding of the BAF complex to heterochromatin. In support on this interpretation, we possess an immunofluorescence data that shows an ectopic co-localization of Smarca4 with heterochromatin markers such as DAPI foci and H3K9me3 in differentiated m/m cells. Smarca4 is normally distributed throughout the nucleoplasm, not at heterochromatin. We plan to present this data in the full revision. A shift in the PRC2 components Ezh2 and Suz12 to the top fractions in the m/m cells is also consistent with the idea that ectopic heterochromatin localization of the BAF complex evicted PRC2 from the heterochromatin. However, we cannot discount the possibility that the migration of BAF components to the bottom fractions was caused by other factors, such as the binding of the Smarce1 (BAF57)-deficient BAF complex with a large protein complex. We will discuss this point in the full revision.

      Concerning the lack of effect of the Smarce1 mutation on histone H3 sedimentation, we thank the reviewer for highlighting this. A lack of histone H3 sedimentation at a salt concentration of 75 mM is expected because chromatin is generally considered to be intact under this condition, as mentioned above. Conversely, histone H3 is expected to shift toward the top fractions in the m/m cells at a salt concentration of 300 mM, given that the dissociation of histone H3 increased with increasing salt concentration (as shown in Figure 2B). The band images of histone H3 in Figure. 4B are partially saturated and were not appropriate for quantification. We plan to present adequate images and quantify the density of the histone bands in the results of replicated experiments.

      *Figure 6: The modified shape of the pericentromeric foci is remarkable. Their characterization would be greatly improved by 3D reconstruction on their confocal microscope. It will also be important to verify that the effect is not due to an impact of the Baf57 mutation on the cell cycle. A FACS analysis would probably be the best approach, staining with an anti-S10p antibody may also be informative. *

      Responses

      As suggested by the reviewer, we plan to conduct a 3D reconstruction of the microscopic data and cell cycle analysis.

      *Minor point: *

      *The information contained in Supplementary Figure 1 is essentially identical to that provided by Wettler et al, Genomics, 1999, one of the original cloning papers of the murine Smarce1. *

      Responses

      Yeast HNP6A and HNP6B are not presented in Wattler et al. (Genomics, 1999), whereas they were included in the similarity analysis in Supplementary Figure 1. We plan to modify Supplementary Figure 1 to clarify this difference in the full revision.

      Reviewer #3 (Evidence, reproducibility and clarity (Required)): *

      **This study utilizes mouse embryonic stem cells with homozygous disruption of Smarce1 and those with reversion of Smarce1 to determine the mechanistic function of Smarce1 on cBAF complex assembly, chromatin structure, pluripotency gene expression, and differentiation. The findings indicate that expression of the pluripotency gene, SOX2, increases, and that chromatin structure on Sox2, Nanog, and Oct3/4 becomes more permissible (as evidenced by histone modifications) upon Smarce1 disruption. Other studies suggest that loss of Smarce1 destabilizes nucleosomes and association of chromatin proteins with chromatin. Furthermore, there is disruption of heterochromatin structure and abnormalities in differentiation. *

      * Major Concerns: *

      * The key conclusion that Smarce1 deficiency impacts upon embryonic stem cell morphology, alters cBAF composition and results in changes in chromatin structure are convincing. However, additional experiments are needed to make many of the specific claims. *

      * 1. Fig. 2B indicates that Smarce1 deficiency destabilizes nucleosomes, yet Fig. 2D shows no change in nucleosome positioning. It is suggested that an ATAC-seq experiment be conducted to better determine changes in nucleosome positioning. *

      Responses

      The nucleosome instability shown in Fig. 2B and no change in nucleosome positioning shown in Fig. 2D seem to be contradictory, but this is due to a lack of an explanation on our part. In the full revision, we plan to include the following explanations and experiments.

      It is known that the higher-order structure of chromatin is preserved at a salt concentration of 75 mM (Thoma F et al, J Cell Biol 1979, 83 : 403-427, Allan J et al, J Cell Biol 1981, 90 : 279-288). The nucleosome positioning experiment illustrated in Fig. 2D was performed under this concentration. Conversely, the salt extraction assay depicted in Fig. 2B was performed at concentrations of 75 mM, 150 mM, 300 mM, and 450 mM. It should be emphasized here that under the same 75 mM salt concentration used in the experimental data presented in Fig. 2D, no difference was observed between the wt, m/m, and r/r in Fig. 2B. Therefore, it was assumed that there is little difference in histone-DNA binding between different cell types when looking at static images of chromatin. In contrast, as shown in Fig. 2B, histone dissociation was enhanced by increasing the salt concentration in the m/m cells. This suggests that histones move in and out of chromatin more dynamically in the m/m cells. To examine this dynamic state, we plan to perform FRAP using cells that express H2B-mCherry and quantify the fluidity of histone-DNA binding. We have already established stable cell lines that express H2B-mCherry in the wt, m/m, and r/r cells and are ready to begin FRAP analysis.

      As highlighted by the other reviewer, we did not compare the nucleosome repeat length between the wt, r/r, and m/m cells. Because the nucleosome repeat length changes due to chromatin structure alteration, we plan to measure the nucleosome repeat length of these cells.

      *2. Fig. 4A shows Arid1a but not Smarca4 migrated at fractions 4 and 6, suggesting that Arid1a is dissociated from the BAF complex. However, there was an increase in BAF components, Smarc1/2 and Smarca4 migrating to the bottom of the sucrose gradient despite the absence of Smarce1 and dissociation of Arid1a. The authors took the lack of size reduction in the complex to mean that in the absence of Smarce1 and dissociation of Arid1a, there is inappropriate interaction of the BAF complex with heterochromatin. Although this is a possibility, there are other possibilities that explain the observation. There could be an increase in PBAF association or association with other proteins that cause the shift. Co-localization studies, chromatin immunoprecipitations or cut and run could more clearly show that there are changes in the interaction of BAF components with heterochromatin. Also, the data is not convincing that there is an increase in the migration of PRC2 components to the top of the gradient. *

      Responses

      We thank the reviewer for their insightful comments. Regarding the interaction of the BAF components with heterochromatin in the m/m cells, we have the following supportive data which were not shown in our initial manuscript. Using immunostaining, we found an ectopic co-localization of Smarca4 with heterochromatin markers such as DAPI foci and H3K9me3 in differentiated m/m cells. Smarca4 is normally distributed throughout the nucleoplasm. Therefore, this observation supports an ectopic distribution of the BAF complex to heterochromatic regions in m/m cells. We plan to present this result in the full revision. As suggested by the reviewer, we believe that the possibility of the association of the BAF complex with other proteins remains, regardless of the results of the co-localization study. We plan to discuss this point in the full revision.

      Regarding the migration of the PRC2 components to the top of the gradient, we plan to present quantitative data from multiple replicates. We speculate that the PRC2 components that migrated to the top fractions are evicted from heterochromatic regions and exist in the nucleoplasm as chromatin-unbound proteins. To investigate this possibility, we plan to conduct FRAP analysis using EGFP-Ezh2. The quicker recovery of the fluorescent signal of EGFP-Ezh2 in m/m cells than wt and r/r cells would indicate an unstable association of Ezh2 with chromatin in m/m cells. The result would also support the notion of the ectopic migration of PRC2 to the top fractions.

      *3. Fig. 5 nicely shows changes that Smarce1 disruption causes changes in the ability of the ES cells to differentiate. However, to more convincingly show that Smarce1 compromises endodermal differentiation and enhances ectodermal differentiation, it will be important to look at expression of some lineage specific markers. *

      Responses

      As suggested by the reviewer, we will analyze the expression of several lineage-specific markers by qRT-PCR.

      *4. What is different about Fig. 6A compared to Fig. 2B? In combination, Figs 2B and Fig. 6A indicate that both BAF and PRC2 components and other repressor proteins have looser association with chromatin. How does this result in a shift in BAF components to heterochromatin compartments while PRC2 is lost from these compartments? Additional experiments are needed to support this claim especially since the changes in migration of PRC2 components is very small as shown in Fig. 4A. *

      Responses

      (Note: Fig. 6A in the reviewer's comment is most likely Fig. 6E.)

      We thank the reviewer for the important comment. Regarding the difference between Figure. 6 and Figure. 2B, we believe that our explanation was insufficient. Regarding the data presented in Figure 2B, we analyzed undifferentiated ES cells, and in Figure 6E, we analyzed differentiated ES cells. It is known that heterochromatin formation is promoted during the differentiation of ES cells. For this reason, we believe that heterochromatin components such as Ezh2, HDAC1, and Kap1 are more unstable in Figure 6 compared to Figure 2B. We plan to present the difference in heterochromatin formation between the undifferentiated ES cells and differentiated cells using DAPI-staining or an MNase sensitivity assay in the full revision. Additionally, we observed by immunostaining that co-localization of Kap1 to heterochromatin is inhibited in the differentiated m/m cells, which is consistent with the observation that Kap1 is more unstable in Figure 6E compared to Figure 2. We plan to show the Kap1 localization data in the full revision.

      Regarding the shift in the BAF components to heterochromatin compartments and the loss of PRC2 from these compartments, we believe that additional experiments are required to support this theory. As the reviewer observed, the migration of PRC2 to the top fractions is small in Figure 4A. We plan to conduct FRAP analysis using EGFP-Ezh2 to demonstrate an unstable association of Ezh2 with chromatin in m/m cells as mentioned above. Alternatively, we will perform a salt extraction assay of PRC2 in the differentiated cells to evaluate the strength of the interaction of PRC2 with chromatin in the m/m cells.

      Minor concerns:

      * 1. The Smarca4 co-IP in Fig. 3 should account for the apparent decrease in Smarca4 immunoprecipitation from the mutant ES cells as well as the variable inputs. It would be better to repeat this experiment to get more consistent inputs between the cell lines and more consistent Smarca4 IPs. Alternatively, quantitation of the IPs relative to inputs would help convince readers that there is a decreased association between Smarca4 and Arid1a but not Brd9. *

      Responses

      As suggested by the reviewer, we plan to present quantitative data from multiple replicates.

      2. In Fig. 4A , it looks like Arid1b also migrates at fractions 4 and 6 in mutant ES cells. There should be discussion on this.

      Responses

      We thank the reviewer for the important remark. As highlighted by the reviewer, Arid1b migrates toward the top fractions in mutant ES cells. We confirmed the reproducibility of this finding. As we mentioned in the Introduction section, Arid1b is not included in the esBAF complex and is thought to be incorporated into the BAF complex during differentiation. ES cells cultured in a serum-containing medium, which was used in this study, are known to fluctuate between undifferentiated and partially differentiated states. We believe that the effect of the loss of Smarce1 on the migration of Arid1b indicates the presence of an Arid1b-containing BAF complex in partially differentiated ES cells. We plan to discuss this point in the full revision.

      3. Throughout the text, it is claimed that GBAF is not affected, yet only BRD9 is interrogated. Without experiments on other GBAF subunits, it is better to conclude that one subunit is not affected rather than the whole GBAF complex.

      Responses

      We agree with the reviewer’s comment that the analysis of Brd9 alone is insufficient to make a conclusion regarding the GBAF complex. We plan to perform an immunoprecipitation assay for other GBAF subunits to clarify the effect of the loss of Smarce1 on the GBAF complex.

      *4. The figure legends should indicate how many independent experiments each dataset represents. *

      Responses

      As suggested by the reviewer, we will indicate the number of independent experiments in the figure legends in the full revision.

      *5. There should be discussion on the findings of this study in context with the recently published manuscript on the relationship between SMARCE1 and BRD9 (PMID: 35681054). *

      Responses

      We thank the reviewer for highlighting this important paper. As mentioned above, we plan to analyze other GBAF subunits to clarify the relationship between Smarce1 and Brd9. Based on those results, we will discuss our findings in light of the above-mentioned paper.

      Reviewer #3 (Significance (Required)): *

      Significance: This manuscript provides both technical and conceptual advances. The construction of embryonic stem cells with homozygous disruption and reversion of Smarce1 is a technical advance. Although a recent publication ( PMID: 35681054) just showed that Smarce1 disruption destabilizes cBAF complexes, there are other novel conceptual insights provided by this study that are significant. The mechanistic insights into Smarce1 function in embryonic stem cells should be of interest to the chromatin community. Furthermore, since Smarce1 is disrupted in meningiomas and in Coffin-Siros syndrome, it should be of interest to the cancer and developmental biology fields. My expertise is in SWI/SNF chromatin remodeling during cellular differentiation and in cancer. *

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      This study utilizes mouse embryonic stem cells with homozygous disruption of Smarce1 and those with reversion of Smarce1 to determine the mechanistic function of Smarce1 on cBAF complex assembly, chromatin structure, pluripotency gene expression, and differentiation. The findings indicate that expression of the pluripotency gene, SOX2, increases, and that chromatin structure on Sox2, Nanog, and Oct3/4 becomes more permissible (as evidenced by histone modifications) upon Smarce1 disruption. Other studies suggest that loss of Smarce1 destabilizes nucleosomes and association of chromatin proteins with chromatin. Furthermore, there is disruption of heterochromatin structure and abnormalities in differentiation.

      Major Concerns:

      The key conclusion that Smarce1 deficiency impacts upon embryonic stem cell morphology, alters cBAF composition and results in changes in chromatin structure are convincing. However, additional experiments are needed to make many of the specific claims.

      1. Fig. 2B indicates that Smarce1 deficiency destabilizes nucleosomes, yet Fig. 2D shows no change in nucleosome positioning. It is suggested that an ATAC-seq experiment be conducted to better determine changes in nucleosome positioning.
      2. Fig. 4A shows Arid1a but not Smarca4 migrated at fractions 4 and 6, suggesting that Arid1a is dissociated from the BAF complex. However, there was an increase in BAF components, Smarc1/2 and Smarca4 migrating to the bottom of the sucrose gradient despite the absence of Smarce1 and dissociation of Arid1a. The authors took the lack of size reduction in the complex to mean that in the absence of Smarce1 and dissociation of Arid1a, there is inappropriate interaction of the BAF complex with heterochromatin. Although this is a possibility, there are other possibilities that explain the observation. There could be an increase in PBAF association or association with other proteins that cause the shift. Co-localization studies, chromatin immunoprecipitations or cut and run could more clearly show that there are changes in the interaction of BAF components with heterochromatin. Also, the data is not convincing that there is an increase in the migration of PRC2 components to the top of the gradient.
      3. Fig. 5 nicely shows changes that Smarce1 disruption causes changes in the ability of the ES cells to differentiate. However, to more convincingly show that Smarce1 compromises endodermal differentiation and enhances ectodermal differentiation, it will be important to look at expression of some lineage specific markers.
      4. What is different about Fig. 6A compared to Fig. 2B? In combination, Figs 2B and Fig. 6A indicate that both BAF and PRC2 components and other repressor proteins have looser association with chromatin. How does this result in a shift in BAF components to heterochromatin compartments while PRC2 is lost from these compartments? Additional experiments are needed to support this claim especially since the changes in migration of PRC2 components is very small as shown in Fig. 4A.

      Minor concerns:

      1. The Smarca4 co-IP in Fig. 3 should account for the apparent decrease in Smarca4 immunoprecipitation from the mutant ES cells as well as the variable inputs. It would be better to repeat this experiment to get more consistent inputs between the cell lines and more consistent Smarca4 IPs. Alternatively, quantitation of the IPs relative to inputs would help convince readers that there is a decreased association between Smarca4 and Arid1a but not Brd9.
      2. In Fig. 4A , it looks like Arid1b also migrates at fractions 4 and 6 in mutant ES cells. There should be discussion on this.
      3. Throughout the text, it is claimed that GBAF is not affected, yet only BRD9 is interrogated. Without experiments on other GBAF subunits, it is better to conclude that one subunit is not affected rather than the whole GBAF complex.
      4. The figure legends should indicate how many independent experiments each dataset represents.
      5. There should be discussion on the findings of this study in context with the recently published manuscript on the relationship between SMARCE1 and BRD9 (PMID: 35681054).

      Significance

      This manuscript provides both technical and conceptual advances. The construction of embryonic stem cells with homozygous disruption and reversion of Smarce1 is a technical advance. Although a recent publication ( PMID: 35681054) just showed that Smarce1 disruption destabilizes cBAF complexes, there are other novel conceptual insights provided by this study that are significant. The mechanistic insights into Smarce1 function in embryonic stem cells should be of interest to the chromatin community. Furthermore, since Smarce1 is disrupted in meningiomas and in Coffin-Siros syndrome, it should be of interest to the cancer and developmental biology fields.

      My expertise is in SWI/SNF chromatin remodeling during cellular differentiation and in cancer.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      This manuscript is a follow-up on a Nature Methods from 2011 (reference 34) describing an astute method to rapidly generate homozygous mutant mouse ES cells. During this study, the authors noticed that inactivation of Smarce1/BAF57, a subunit of the SWI/SNF complex containing an HMG domain, resulted in abnormal morphology of the ES cells.

      Here, they have extended the characterization of this mutant, and shown that inactivation of BAF57 leaves essentially unaffected the expression of the pluripotency genes Oct3/4, Nanog, and Sox2, while also apparently preserving the MNase digestion patterns, and H3K9ac and H3K9me accumulation at repeats of the L1 or IAP families.

      In contrast, the mutation causes increased extractability of the Baf250/Arid1a SWI/SNF subunit, of histone H3, and of the transcriptional co-repressor KAP1. Finally, mutant cells were shown to differentiate into smaller embryoid bodies and failed to differentiate properly into mesodermal lineages. The differentiated cells were also found to contain pericentromeric heterochromatin foci of more elongated shape than in the wild types.

      Based on these observations, the authors propose that inactivation of Smarce1 decreaseb nucleosome stability and impaired heterochromatin formation during differentiation. Overall, the paper is technically sound. Yet, there is also a clear trend towards overinterpretation of the data, and the arguments in favor of a genome-wide impact on chromatin remain week. On the other hand, the impact of the Baf57 mutation on ES cell differentiation and on the extractability of Baf250 and KAP1 are convincing.

      Specific comments:

      Figure 1: There seems to be a contradiction between the conclusion from this figure (Increased H3K9ac levels at the Yamanaka gene promoters but not at repeats, suggesting a local impact on chromatin) and the overall conclusion from the paper, proposing a global decrease in stability of the nucleosomes. An ATAC-seq experiment would probably yield a more definitive conclusion.

      Figure 2: The increased extractability of Kap1 is difficult to see on panel 2B, while it is clear in the sucrose gradient experiments and in the differentiated cells. These sets of experiments (including ARID1a and histone H3) would therefore be much more robust if the different species were quantified on biological replicates (to allow calculation of a p value). Also, the increased extractability of histone H3 is intriguing, pointing toward a global effect on chromatin, while the MNase experiment showing no impact on the nucleosome ladder argues against such an effect (same issue as for Figure 1). It may be worth exploring whether the extracted H3 is nucleosomal (or alternatively not yet incorporated into chromatin). This could eventually be done by a simple Coomassie staining of the different fractions, that would allow tracking of all the 4 histones simultaneously.

      Figure 3: It is not clear why the authors connect the sedimentation to a link with heterochromatin, as there is no correlation between distribution of the SWI/SNF subunits and that of histone H3 (while, in contrast, this experiment clearly documents some dissociation of Smarcc1 and the Arid proteins from the rest of the SWI/SNF complex). This should be discussed. Also, the lack of an effect of the BAF57 mutation on histone H3 sedimentation would be in favor of nucleosome remaining intact.

      Figure 6: The modified shape of the pericentromeric foci is remarkable. Their characterization would be greatly improved by 3D reconstruction on their confocal microscope. It will also be important to verify that the effect is not due to an impact of the Baf57 mutation on the cell cycle. A FACS analysis would probably be the best approach, staining with an anti-S10p antibody may also be informative.

      Minor point:

      The information contained in Supplementary Figure 1 is essentially identical to that provided by Wettler et al, Genomics, 1999, one of the original cloning papers of the murine Smarce1.

      Significance

      Some interesting observations, but overall, a modest contribution to the field.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      Summary:

      In this manuscript, Kashiwagi and colleagues examine the role of the BAF complex subunit Smarce1 in mouse ESC. They utilize a gene trap methodology to generate a Smarce1-null cell line (m/m) as well as a Smarce1-rescue cell line (r/r) in which the gene trap is excised. The Smarce1-null cell line exhibited abnormal colony morphology and elevated Nanog expression.

      The authors use several approaches to examine the effects of Smarce1 loss on the chromatin characteristics of mouse ESC. Using salt extraction, they show that depletion of Smarce1 causes nucleosome instability, as marked by enhanced solubility of Histone H3. Using immunoprecipitation and sucrose gradient experiments, they suggest that decreased nucleosome stability is due to loss of Arid1a from the BAF complex and improper targeting of the complex to heterochromatin. This improper targeting of the BAF complex to heterochromatin causes a decompaction of heterochromatin foci, potentially due to disruption or displacement of the PRC2 complex. The changes alter the differentiation potential of the m/m mESC, which exhibit abnormal mesoderm differentiation and enhanced neural differentiation. Taken together, these data suggest that Smarce1 is a critical component of the BAF complex that is required for proper targeting of the complex within the chromatin environment.

      Major Comments:

      Throughout the manuscript, the authors make conclusive statements about differences in the intensity or pattern of bands in western blots or DNA gels. However, these statements are purely qualitative, and the authors fail to provide any information about the number of replicates performed. As such, there is no way to judge the statistical significance of the observed changes and it is difficult to have confidence in any of the conclusions drawn from these experiments.

      1. Figure 2b: requires validation through multiple replicates. Ideally, the bands would be quantified and data from multiple replicates can be used for statistical analysis.
      2. Figure 2d: as depicted, it is impossible to draw any conclusions. To assess the stability or "looseness" of nucleosomes, the authors should perform lane densitometry to compare the relative intensity of the bands within the lanes as well as the spacing of the bands.
      3. Figure 3: the authors claim that Arid1a pulldown is decreased in the m/m cells whereas there is no change in BRD9 pulldown between the cell lines. However, there is a decrease in BRD9 pulldown in the r/r cell line that appears equal to the decrease of Arid1a in the m/m cells. Multiple replicates and quantification should be provided to validate the findings, otherwise the reported differences seem to just be judgement calls.
      4. Figure 3: the immunoprecipitations appear to be poorly normalized. For instance, there seems to be more Smarca4 in the m/m input but less Smarca4 in the pulldown. This could suggest that the immunoprecipitation in the m/m cells was less efficient than in the other two cell lines. Again, additional replicates of the experiment seem necessary.
      5. Figure 4: Validation of the differences observed between the WT and m/m cell line requires multiple replicates of the experiment. Ideally, the bands can be quantified and the data could be presented as line plots or histograms.
      6. Figure 6: same issues as Figure 2b. Additionally, the results for Ezh2, HDAC1, and Kap1 are quite different from those depicted in Figure 2b despite the experiment appearing to be identical. This further emphasizes the need for replication of these experiments

      Additionally, the interpretation of the differentiation experiments in figure 5 is somewhat confusing and raises several questions:

      1. In C-E, the m/m embryoid bodies appear to have much denser outgrowths than the WT and r/r embryoid bodies. While panels A and B demonstrate that the m/m embryoid bodies are smaller, the images in C-E seem to suggest that there is much more proliferation in the m/m outgrowths. This could be due to the maintenance of stem cell characteristics suggested by the presence of more Nanog-positive cells. The authors should comment on this phenomenon.
      2. The authors should consider additional experiments to test the persistence of pluripotent cells in these assays. For instance, these outgrowths could be dissociated and replated in ESC growth conditions to examine the ability of the cells to form ESC-like colonies (which would indicate retention of pluripotency).
      3. The authors describe the m/m cells as having impaired mesodermal differentiation based on SMA staining and the morphology of SMA-positive cells. While the morphology of SMA-positive cells does look altered in the m/m cells, there is extensive SMA staining. Rather than "impaired" (which suggests that mesodermal differentiation is blocked), the authors should consider describing mesodermal differentiation as "abnormal" or "altered." Examination of alternative mesodermal markers would also be informative.
      4. Are there m/m cells in this assay that are double-positive for SMA and BIII tubulin? This would be compelling evidence demonstrating that loss of Smarce1 disrupts normal differentiation pathways.

      Minor Comments:

      1. Sox2 expression levels should be added to figure 1d
      2. Please define the regions being targeted in the Oct4, Nanog, and Sox2 chip-pcrs. Are these the promoters, enhancers, gene bodies, etc...?
      3. The ChIP data in figure1e-k are difficult to read as presented. It would be helpful to group the data by target rather than cell line so that adjacent data points are directly comparable.
      4. On lines 378-379, the authors state there is minimal to no histone acetylation at IAP and LINE1. This clearly contradicts the data shown in Figure 1.
      5. Are other BAF subunits disrupted in the m/m cells? It would be useful to look at Smarcc1/2, BAF180, Smarcd1/2, in figure 3.
      6. Similarly, the authors mention in the discussion that impaired REST interaction may explain the enhanced neuronal differentiation observed in the m/m cells. In this case, the authors should consider including REST or Sin3a in figures 3 and 4.
      7. Additional assays/markers for heterochromatin would strengthen the authors' conclusions about impaired heterochromatin formation. For instance, are overall H3K9me3 or H4K20me3 levels different in the m/m cells? What about HP1?

      Significance

      This work could provide intriguing conceptual advances in the understanding of BAF complex function in mouse ESC. The authors provide sufficient context for this work in their introduction and discussion sections. As referenced in the manuscript, work from several labs has demonstrated the requirement for canonical BAF complexes in mouse ESC. Recent work has also demonstrated the existence of a non-canonical BAF complex that also functions in the maintenance of mouse ESC. SMARCE1 is specific to the canonical BAF complexes, and this work presented here potentially demonstrates the functional requirement for SMARCE1 in canonical BAF complex function. As such, this work is likely to influence an audience with interest in the molecular biology of the BAF complex and chromatin remodeling.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Initial plan – Response to Reviewers’ Comments

      We thank the three reviewers for their comments, which on balance were very positive and supportive.

      The fundamental relevance and translational impact of our manuscript were reinforced by R1 and R3: The present study ”could provide important insight in the field of malaria vaccinology …” (R1), “…lead to a complete revision in how pre-erythrocytic vaccine candidates are identified and prioritized …” (R3) and “… greatly enhances our understanding of exactly how the dynamics, magnitude and quality of CD8+ T-cell responses are modulated by the timing of antigen expression …” (R3).

      R1 acknowledged our use of “using cutting edge molecular biology (techniques)” and our efforts to “… provide proof of the concept of vaccine design by evaluating if accessibility/immunogenicity of the antigen is a decisive feature on vaccine design …”. R3 emphasised that the “… manuscript is well written, concise and with a clear narrative…” and that “… conclusions drawn from the study are well supported by the data presented, and the experiments are thoroughly controlled and sufficiently replicated”.

      We have now revised the manuscript based on the reviewer’s comments and clarified valid concerns. Together, we consider the review process very helpful to further enhance the impact of our study. At this point, we have also prepared a Graphical Abstract that summarises the key findings of the manuscript.

      We address the Reviewer’s Comments below:

      Reviewer #1 (Evidence, reproducibility and clarity):

      1. General comments: … a little more of deep analysis of immune responses elicited by the transgenic parasites … how about TRM cells, what is the endogenous responses to SIINFKEL without transferring CD8 + T cells from OTI mice?

      … the potential of this study demands to be placed in the context of precedent studies that defined pre-erythrocytic stage CD8+ T cell responses. … the importance of CD8+ liver-resident memory CD8+ T cells from Health’s laboratory

      <![endif]-->

      We agree with the reviewer that the field of malaria pre-erythrocytic immunology is fast-moving. This is exemplified by the more recent identification of resident memory CD8+ T cells (TRM) that patrol hepatocytes against pathogens, including malaria pre-erythrocytic stages by the Heath laboratory. Whilst the focus of our current work is on assessing the timing of expression and immunogenicity of pre-erythrocytic antigens as crucial features for vaccine design, we concur with the reviewer that the analysis of TRM is of remarkable interest to the malaria field, which we believe is currently out of the scope of the current study. Nonetheless, we have now included this in the discussion to link the findings of our study with the evolving field of TRM (lines 409-420).

      Nevertheless, we characterised CD8+ T cells using techniques that are commonplace in studying immunological response in the malaria field, while also adapting our approach to probe responses using more physiological proxies.

      <![endif]-->

      Whilst we did not specifically phenotype for TRM, we measured CD8+ T cell responses in the livers of immunised mice, utilising isolation methods for intrahepatic or liver-infiltrating lymphocytes (Goossens et al., 1990, PMID: 2202764). CD8+ T cells from the livers of mice immunised by irradiated sporozoites delivered intravenously were analysed following adoptive transfer of naïve CD8+ T cells (Figure 3), as well as quantifying endogenous CD8+ T cells (Figure 4B-D). We also assessed CD8+ T cells from the livers of mice immunised with irradiated sporozoites delivered intradermally (as a proxy for the natural route of infection and parenteral vaccine administration; Figure 4E-G).

      As mentioned above, the response from endogenous CD8+ T cell, that is without adoptive transfer of naïve CD8+ T cells, are shown in Figure 4A-C (intravenous immunisation) and Figure 4D-F (intradermal immunisation).

      We apologise to the reviewer if these results were not obvious. Accordingly, we have reconfigured the figures to i) colour-coordinate intravenous from intradermal administration of sporozoites in Figure 4, and ii) to allow differentiation of pentamer staining from IFN-g production in Figure 3.

      1. … the strategy of gating on Fig2a, it is not clear if they want to track the responses from adoptively transferred CD8+ T cells to vaccine or the endogenous CD8+ T cell responses. In any case, the results is potentially interesting but need clarification.

      The purpose of adoptively transferring naïve CD8+ T cells was to augment the frequencies of naïve precursors. We used Kb-SIINFEKL pentamers to visualise the developing CD8+ T cell response, which is a combination of both OT-I and endogenous responses. As mentioned above, we have compared the kinetics of the CD8+ T response in mice administered with OT-I cells (Figure 3) or endogenous responses in the absence of OT-I cells (Figure 4).

      1. Fig 2: only the responses on the spleen are studied. In order to support the statement about the two different kinds of immunization, they should assess the responses on the liver.

      As pointed out by the reviewer, responses in the liver were not performed for Figure 2, but were assessed in Figures 3 to 5.

      1. … lack of methodology in flow cytometry analysis, a viability stain is not used, the gating is not determined by FMO … controls … For activation markers in order to assess the impact of the vaccination authors have to use gating that is already established by some of the papers they mentioned (i.e: Harty lab's studies), … the CD11a label should be CD11ahi and is not stated anywhere.

      In our gating strategies we relied on the population of cells with a larger FSC value (healthy cells). In previous experiments we established this population to represent the desired population by staining cells with and without Live/Dead dye. Accordingly, we have found this first gating strategy to be satisfactory and consistently excluded dead cells and cell debris.

      We apologise for not showing FMOs and have now included exemplary flow cytometry strategies in Supplementary Figure 2 and 5 to illustrate how we gated for CD8+ T cells from blood, spleen and liver. In addition to FMOs we gated for markers in our pentamer and surface stain panel and restimulation cytokine panel.

      We have focused on the enumeration of antigen-specific responses using KbSIINFEKL pentamer staining, and the measurement of the effector molecule IFN-g for the evaluation of responses to SIINFEKL. In both methodologies, responses were co-stained with CD8 and CD11a. The utilisation of the CD11a marker and identifying CD11ahi populations in models of infections were established by the Harty and Badovinac laboratories (Rai et al., 2009, PMID: 19933864). CD11ahi populations discriminate antigen-experienced but not inflammation-driven responses, particularly when analysing polyclonal populations of CD8+ T cells. We have referenced the original publication in the manuscript. Moreover, we have corrected mentions and labels of CD11a+ to CD11ahi throughout the manuscript. Thus, in addition to KbSIINFEKL pentamer and IFN-g stainings, the CD11a marker was used as a confirmatory marker for antigen-driven activation. Furthermore, we also stained the cells for canonical activation markers: CD49d, CD62L and CD44. It is notable that the numbers of CD11ahi, CD49dhi, CD62Llo, CD44hi co-stain with Kb-SIINFEKL pentamer (Figure 2 and Supplementary Figure 3), indicating that the identified cells are of effector/ effector memory phenotypes.

      1. Line 165: the statement "massive proliferative activity" is not supported by the figure, moreover there are numbers to support the statement.

      We have toned down the term from “massive” to “greater”. We have also altered the sentence to read “… immunisation with CSPSIINFEKL sporozoites led to greater expansion of Kb-SIINFEKL+ CD8+ T cells, 6x larger than that observed with UIS4SIINFEKL sporozoites…” (line 195-196), which is in agreement with that shown in Figure 2D, E.

      1. -->IFNg and other cytokines production seems too low and the stimulation assay is poorly performed because CD8 were restimulated ex-vivo only with SIINFEKL peptide in the absence of APC (antigen-presenting cells) with Brefeldin A. Also Authors omitted negative controls ( without SIINFEKL Brefeldin A) to be certain that IFNg production is du to SIINFEKL. Again we don't if they are OTI or endogenous cells.

      We have utilised stimulation and flow cytometry protocols that are widely used in the malaria pre-erythrocytic stage field (Hafalla et al., 2013, PMID: 23675294; Jagannathan et al., 2015, PMID: 25520427), as well as other fields (Hosking et al., 2014, PMID: 25015828, Nakiboneka et al., 2019, PMID: 30459072). Notably, CD8+ T cell responses to this eukaryotic pathogen have been widely published to be much lower, in contrast to those evoked by viral and bacterial pathogens (Schmidt et al., 2008, PMID: 18780790).

      As suggested, we have now included the corresponding negative controls (restimulation without peptide) in a new Supplementary Figure 6.

      1. Fig5. Are the cells from Fig5a,b SIINFEKL positive cells or only CD11a and IFNg? Are they OTI? Controls are missing to show a real IFNg production du to the ex vivo stimulation.

      The responses shown in Figure 5 were stimulated with SIINFEKL and stained for CD8+ (gated), CD11ahi, IFN-+. The mice did not receive OT-I cells, thus the data reflects the endogenous response.

      1. Fig 6. no percentages are shown in the cytometry plots, figure 6d and c seem to be inverted.

      We have now included the percentage in the flow cytometry plots. We apologise for the inversion of Figures 6C and D; this has now been corrected to match the figure legend.

      1. For the two strains, authors should show the patency in comparison whit WT parasites (currently presented as data not shown)

      We have now included the patencies of WT, CSPSIINFEKL and UIS4SIINFEKL parasites in Supplementary Figure 1f. The transgenic parasites exhibit similar patencies to WT parasites.

      1. Fig 6: how did the authors measure Sterile protection and Relative parasite load?

      We have detailed the measurements of sterile protection and relative parasite load (level) in the Methodology section. Both methodologies are standard procedures in the malaria pre-erythrocytic stage field.

      Reviewer #1 (Significance):

      The present study could provide important insight in the field of malaria vaccinology. By using cutting edge molecular biology to express the MCHI restricted epitope SIINFEKL a at different stages of the pre-erythrocytic stage of Plasmodium and used it as a surrogate marker to evaluate the CD8+T cell response to infection. The authors attempt to provide proof of the concept of vaccine design by evaluating if accessibility/immunogenicity of the antigen is a decisive feature on vaccine design. Nevertheless, the potential of this study demands to be placed in the context of precedent studies that defined pre-erythrocytic stage CD8+ T cell responses. the authors failed to fully exploit the tools that they developed (transgenic parasite) by overlooking the last studies describing the importance of CD8+ liver-resident memory CD8+ T cells from Health's laboratory or well characterized CD8 T cells responses defined by Harty's laboratory.

      If well place in the context (after revisions) this study will not only be fundamental to the malaria field but to other infectious diseases as well.

      Field of expertise: malaria immunology, vaccinology, immunomodulation, CD8+ T cell responses

      Reviewer #2 (Evidence, reproducibility and clarity):

      The manuscript b Mueller and Gibbins et al titled "Low immunogenicity of malaria pre-erythrocytic stages can be overcome by vaccination" compares how transgenic P. berghei parasites expressing SIINFEKL epitope from ovalbumin, as part of CSP or UIS4 present the respective epitope and how immune responses occur to each of the mutants, mostly in mice pre-treated with 2 x 10 OT-I cells expressing a SIINFEKL-specific TCR.

      their data show that when in their normal location CSP is much better than UIS4 to elicit an immune response., and that increasing UIS4 (by raising irradiated parasite numbers) does not greatly improve to reduce the difference.

      finally the authors show that mice immunized with ovalbumin can reduce liver infection of either CSPSIINFEKL or UIS4SIINFEKL sporozoite challenge infection

      the experiments presented by the authors are in my view well done and controlled, but i feel that sometimes conclusions are a bit beyond what the experimental readouts allow for.

      Reviewer #2 (Significance):

      1. In fig1 the authors show how mutants were made and that proteins with associated SIINFEKL to CSP or UIS4 localise to correct place. (could all be supplementary or Supplementary Figure 1c, d could be included in Fig1). In Fig2a is shown the gating of SIINFEKL-specific CD8+ T cells (could be supplementary).

      We deem the depiction of CSP and UIS4 in Figure 1B and C to be important for the concept and impact of the study. We would like to adhere to common practice in immunology studies and keep one representative flow cytometry gating strategy in the main paper (in Figure 2B), to illustrate an example of our analysis methods going forward.

      1. In Fig 2b the authors show that the highest CD8T cell specific for SIINFEKL is on the first day analysed (d4) and I would like to see how day 2 and 3 would look like.<br /> specially because proliferative differences don't seem massive to me, CFSE should decrease with each cell division and reach different fluorescence values if replication numbers differ. however here the CFSE fluorescence signal is similar on d5 fig 2c, indicating a similar number of replicative rounds, but probably a different starting numbers of cells that would replicate. Or that CFS labelling was too low to allow distinguishing the number of replicative rounds occuring in that time. so when the authors conclude that proliferative activity was 6x larger than that observed with UIS4SIINFEKL sporozoites, i think they would have to show before that numbers of cells prior to replication was the same

      This is a good suggestion, but unfortunately, we did not perform CFSE experiments on days 2 and 3. We agree that the resulting CD8+ T cell responses to both parasites seem to have similar replication rounds (number of cell division), yet the frequencies of those recruited to the immune response are much more elevated in the CSPSIINFEKL as compared UIS4SIINFEKL parasites (5.05 vs 0.84, respectively – as shown in Figure 2D). A better representation is shown in Figure 2E, which is gated on KbSIINFEKL+, CD11ahi, CD8+ T cells.

      For our study, we have used published and standard CFSE labelling protocols (Lundie et al., 2008, PMID: 18799734).

      In light of Reviewer 1 and 2 both commenting on our use of terminology regarding proliferation, we altered and corrected the text in the manuscript to address that there is a 6x increase (5.05 vs.0.84) in recruitment of SIINFEKL-specific CD8+ T cells rather than proliferation (line 195-196). The same number of cell divisions were undergone, however the level of expansion was greatly increased when mice were immunised with CSPSIINFEKL.

      1. I think it would be nice to show when is infection stopped in these two groups os mice, but looking at EEF in the liver if the two groups of mice.

      We believe that the reviewer is referring to the outcomes of the protection experiments. We utilised a widely used quantitative PCR method to quantify the EEF in the liver after challenge of vaccinated mice. We agree with the reviewer that it will be interesting to determine whether the kinetics of killing by vaccine-induced CD8+ T cells of CSPSIINFEKL and UIS4SIINFEKL parasites are different. While presently out of the scope, we would have to establish ex vivo quantitative imaging and hope to advance on this in the future.

      14 … could show that an adenovirus carrying UIS4 (and CSP) would result in the same as observed here with the ovalbumin one).**

      The vaccine efficacy of an Adenovirus vaccine expressing CSP has been established (Rodrigues et al., 1997, PMID: 9013969; Bruña-Romero et al., 2001, PMID: 11553779; Gilbert et al., 2002, PMID: 11803063. Since there are no known ‘immunodominant’ CD8+ T cell epitopes in UIS4 such a vaccine construct is likely to only serve as negative control.. We and others have previously systematically screened for CD8+ T cell epitopes in the pre-erythrocytic stages, including from UIS4, of Pb, but experimental testing yielded only few peptides, with none from UIS4.

      15 … discuss the advantages and problems of the two SPZ and PVM locations, assuming that indeed an adenovirus carrying UIS4/CSP would also result in similar protection upon challenge, regarding potential boost from natural Infection, and how variable/conserved each of the proteins are and what could be expected in field trials ion the falciparum counterpart.

      We have now included these points in the discussion. Thus far, the consensus in the field is that T cell responses to pre-erythrocytic stage antigens are low in endemic areas (Heide et al., 2019, PMID: 30949162), and there is a striking paucity of data on the impact of boosting (primary infection vs. multiple infections) in the field (Doolan et al., 1993, PMID: 7680226); Khusmith et al., 1999, PMID: 10774643). Previous work in rodent models has demonstrated that boosting of T cell responses to liver stage antigens is poor (Murphy et al., 2013, PMID: 23530242), and this was also documented for CSP (Hafalla et al., 2003, PMID: 12847268). With the very low responses to UIS4SIINFEKL, we reasoned whether they could be enhanced by increased dose of immunisation. However, Figure 5 rejected this hypothesis.

      It is noteworthy that we selected CSP and UIS4 as the best characterized representatives of sporozoite and EEF vacuolar antigens, respectively. Following up on the reviewer’s comments, it would be interesting to contrast the allelic diversity of sporozoite and EEF antigens, since this information will be important for vaccine design.

      Reviewer #3 (Evidence, reproducibility and clarity):

      1. The authors assume a reader familiarity with the use of ovalbumin, the SIINFEKL epitope, the transgenic T-cell receptor OT-1 mice and adoptive transfer experiments to assay immunogenicity. These concepts are not comprehensively introduced in the introduction, and the relationship between these tools are not delineated sufficiently to allow the non-expert reader to follow the logic and methodology of the experiments right from the start. Background information given in Results (Line 139-144, 204-208) and Discussion section, (Line 288-293) could with advantage be synthesized into one paragraph and presented in the introduction to bring all readers onboard from the start.

      We thank the reviewer for this important point and have now addressed this in the introduction which reads as follows:

      “To control for epitope specificity, we generated Pb transgenic parasites that incorporate the MHC class I H-2-Kb epitope SIINFEKL, from ovalbumin, in either the CSP or UIS4 protein. The resulting transgenic parasites develop normally as wild-type (WT) Pb in the mosquito vector and mammalian host. However, SIINFEKL would be expressed at the same time and space as its respective Plasmodium protein, enabling the CD8+ T cell response against these proteins to be tracked in an epitope-specific physiological manner. In line with previous studies (8,15), to augment low numbers of CD8+ T cell in the naïve response, cells from OT-I mice, which express SIINFEKL-specific TCRs on their CD8+ T cells, were initially adoptively transferred to mice prior to them receiving sporozoite immunisations” (lines 117-127).

      1. Results Page 11 Line 255-260, Figure legend Fig. 6 page 27 Line 258-665 The punchline of the paper is that the despite differences in immunogenicity between γ-irradiated CSP SIINFEKL or UIS4 SIINFEKL sporozoites, both CSP SIINFEKL or UIS4 SIINFEKL are targets of protective CD8+ T-cell responses resulting in sterile immunity in a challenge following vaccination with full-length ovalbumin in OT-I cell recipient mice. This section is a cornerstone for the conclusions of the paper and would benefit from being better supported by its explanatory text and presentation of data.

      Firstly, there is a mix up, between panel 6c and 6d, where 6c shows "% Sterile protection" and 6d shows "Parasite load in the liver", while it says the opposite in main text and figure legend.

      We apologise for this error, which has now been corrected. We also added more explanatory text in the results section to avoid reader’s missing the punchline and impact of our study, which reads as follows: “Strikingly, contrary to the differential CD8+ T cell responses induced by CSP and UIS4, there was no statistical difference in the protection observed when vaccinated mice were challenged with either CSPSIINFEKL or UIS4SIINFEKL sporozoites. Consistent with these findings, both groups of vaccinated mice challenged with either CSPSIINFEKL or UIS4SIINFEKL sporozoites exhibited sterile protection of comparable levels…” (lines 305-310).

      1. Secondly, while it is clear that qPCR is used to measure liver parasite load at 24 hours after challenge. It is not immediately clear from neither main text nor figure legend that sterile immunity is measured by microscopy on blood films. The use of the term "sterile immunity" naturally implies this to the initiated reader, but it should be spelled-out that this was the case and that it was monitored from day 3-14 following challenge, which is outlined only in the methods section. Rewriting and restructuring this section to make this clearer would greatly help guide the reader through the results. Currently it reads at first pass as if qPCR on liver samples harvested at 42 hours was used to generate the data in both 6C and 6D.

      We agree that this important point should be consistently described and have now added the necessary clarification in the results (line 310-311) and figure legend (line 799-800) to indicate that we used microscopy to assess blood smears for parasitaemia.

      19: Thirdly, protective efficacy here is given as a percentage of those mice that become protected, presumably remaining negative by day 14. Authors should provide the actual blood stage parasitaemia in graph or table format in Figure 6 or as a supplemental figure to show that sterile immunity is obtained and maintained until day 14, and that in the control groups patency develops as normal. This will also give clearer insight into how many mice developed patency in the control groups and at what point break-through was observed.

      We have now included prepatency in our manuscript to illustrate if and when non-vaccinated and vaccinated animals became parasitaemic. Mice were monitored up to day 14, after which they were deemed sterilely protected. This is found in the new Supplementary Table 2.

      1. In a similar vein, qualitative and / or quantitative presentation of microscopy data of EEFs (as presented in Figure 1C) would strengthen conclusions drawn from the qPCR parasite liver load data.

      We have included a graph detailing quantitative data of EEF counts as Supplementary Figure 1E.

      1. Fourthly, the authors should also comment on why there is such a great variation in the number of mice used in the different studied groups, it says maximum of n=11 mice per group but one group only has as n=3 mice and another n=4, and make a convincing argument this does not affect the conclusions drawn and statistical analysis undertaken.

      In this experiment (Figure 6D), we placed particular emphasis on the quantification of the liver load in AdOVA-immunized mice challenged with UIS4SIINFEKL sporozoites. We included cumulative data from multiple challenge experiments. The other groups of mice serve as controls and consistently displayed high parasite loads in non-immunized or WT sporozoite-challenged controls and very low parasite loads in CSPSIINFEKL sporozoite-challenged mice, respectively.

      1. Finally, the authors characterise CD8+ T-cell responses in absence of preceding OT-I adoptive transfer but do not report on whether the ovalbumin-immunization was tried on mice without preceding OT-I cell transplant. Was this tried? If not authors should discuss whether this is likely to be successful or not for readers to understand if both sporozoite and EEF presented antigens are likely to induce sterile immunity in a natural setting without artificial enrichment for epitope specific T-cells.

      We thank the reviewer for highlighting this point. We did not vaccinate mice in the absence of OT-I cells. Previous work with Py and Pb_CSP-based adenovirus vaccines yielded only up to 40% sterile immunity, despite up to 97% reduction in parasite load in the liver after challenge with viable sporozoites (Rodrigues et al, 1997, PMID: 9013969; Rodrigues et al., 1998, PMID: 9795385). Thus, we augmented the numbers of naïve antigen-specific CD8+ T cell precursors by adoptively transferring OT-I prior to vaccinating with recombinant adenovirus. This methodology was chosen in order to attain optimal levels of vaccine-induced _effector CD8+ T cells producing IFN-g in a single vaccination, and to obtain reliable frequencies comparable to those achieved by prime-boost vaccinations with recombinant adeno- followed vaccinia viruses, or with peptide-loaded dendritic cells followed by recombinant Listeria. Previous work by colleagues and ourselves have shown that in order to achieve sterile protection in both the Py- and Pb-Balb/c model, vaccine-induced CSP-specific CD8+ T cells must exceed a threshold of >1% of all CD8+ T cells in peripheral blood (Bruña-Romero et al., 2001, PMID: 11553779; González-Aseguinolaza et al., 2003, PMID: 14557672; Schmidt et al, 2011, 21460205). Moreover, B10 backgrounds (including C57BL/6) further increases the threshold necessary for sterile protection through a CD8+ T cell-extrinsic mechanism. In our current study, the mean frequencies of antigen-specific CD8+ T cells induced following adenovirus vaccination was 7.5% (Figure 6C), which translated to 80% sterile protection (combined data from CSSIINFEKL and UIS4SIINFEKL groups).

      In the current manuscript, we believe that we have successfully provided proof-of-concept evidence to assess the timing of expression and immunogenicity of pre-erythrocytic antigens as crucial parameters for vaccine design. Nonetheless, we have added a comment in the discussion on our chosen approach to test for vaccine efficacy, and on the importance of achieving relatively high levels of CD8+ T cells to enable high vaccine efficacy:

      “Regardless of their differing immunogenicities in the context of parasitic infection, we further demonstrated that both sporozoite and EEF antigens are effectively targeted by antigen-specific effector CD8+ T cells, which were generated by vaccination using priming and boosting with recombinant viruses expressing the epitope. This method of prime-boost using recombinant viruses has been consistently shown to induce high numbers of antigen-specific CD8+ T cells (39-43) necessary for protection(20). Importantly, mice harbouring similarly high levels of vaccine-induced, antigen-specific CD8+ T cells were comparably protected when challenged with either CSPSIINFEKL or UIS4SIINFEKL” (lines 371-379).

      1. Line 723, 725 clarify if data is from independent biological repeats, i.e. different infected mice fed to different pots of mosquitoes, in which case the data is sufficiently replicated.

      The mosquito infectivity is from 14 different mosquito feedings and the sporozoite numbers per mosquito were calculated from 18 (UIS4SIINFEKL and WT) and 21 (CSPSIINFEKL n=21) independent infections.

      1. Page 6 Line 132 Please show blood-stage infection data / growth rates for CSP SINFEKL and UIS4 SINFEKL compared to WT as supplemental figure, if available.

      We have now included prepatency data for the two transgenic parasites (Supplementary Figure 1f).

      1. Figure 1. If quantitative data is available for EEF, as indicated by the mean numbers with SD given within the microscopy pictures it would be nice to see these plotted. Does the reduced EEF numbers for CSP SINFEKL compared to UIS 4SINFEKL and WT mean anything? If not perhaps worth stating this in figure legend, or consider different presentation. Distracting when looking at the figure.

      We have generated a graph depicting the numbers of EEFs developing in vitro from sporozoite of Huh7 cells from two independent experiments. This is now found in Supplementary Figure 1E.

      1. Figure 2. Would benefit from a panel with a simple schematic that shows the overall experimental design with irradiation of sporozoites, OT-1 transfer, administration of parasites and sampling with the timings for each event clearly marked out.

      We thank Reviewer 3 for this suggestion and have now included timelines of our experimental design for Figure 2, as well Figures 3-6.

      1. Figure Panel 2b would benefit from the in-figure legend stating CSP SINFEKL + OT-1, UIS4 SINFEKL + OT-1, WT + OT-1 and OT-1 only. Similar to as in Figure 3.**

      We thank the reviewer for this suggestion. Since OT-1 transfer was done in all groups of mice, and, hence, is not a distinctive feature, we have instead included a timeline on top of the graph with clear colour coding showing administration of OT-I cells prior to sporozoite immunisation (Figure 2A). We believe this is sufficient to guide the reader through the figure. Similarly, we reduced the labelling in Figure 3, and instead added a timeline as a reference for the experimental design **(Figure 3A)

      1. Figure 3 and Figure 4. Label within figure more clearly what is being measured, i.e. what is the difference between panels a,b,c vs. d,e,f (e.g. intravenously v.s. intradermal administrations), gets confusing since Figure 3 and Figure 4 are very similar within the figures (a,b,c vs. d,e,f) and between the figures.

      We thank the reviewer for this suggestion and have now added colour coding to Figures 3 and 4 and an experimental schematic to guide the reader through the data. We have included segregation lines above the flow cytometry plots to further guide the reader, i.e. Figure 3B-D denotes Kb-SIINFEKL pentamer data, while Figure 3E-G denotes IFN-g production following restimulation. Further, in Figure 4 segregation lines have been added and labelled to allow easy discernibility of panels 4B-D (intravenous immunisation of sporozoites) vis-a-vis panels 4E-G (intradermal immunisation of sporozoites).

      1. Figure 3, 4, The Panel indicating letters (a, b, c, d...) become smaller as figures get bigger and become hard to read for Figure 3 and Figure 4.

      This has now been adjusted, as suggested.

      1. Line 158 - Throughout manuscript, when it says administration of WT, CSP SINFEKL and / or UIS4 SINFEKL sporozoites it would be good to always have it preceded by irradiated when referring to irradiated sporozoites, e.g. Line 158 and only use sporozoites on its own when referring to live sporozoites (or even better spell out also when using live sporozoites e.g. Line 255).

      We have followed the advice of the reviewer including "g-radiation attenuated” or “live” as appropriate (lines 188, 202-203, 216, 236, 248-249, 260-261, 280 and 299).

      1. The authors could measure the total amounts of IFN-ɣ being secreted in the tissues after immunization to both antigens and investigate if the level of other IFN-ɣ secreting cells might compensate for the weak response of CD8+ T cells, particularly against UIS4. If completed it has the potential to help the authors to in more detail understand the mechanism and contributing factors to the successful CD8+ T-cell targeting of UIS4. As antigen protection is dependent not only cellular response but also on antibody responses induced against the antigens, authors should analyze by ELISA IgG and IgM responses induced against the two antigens.

      We thank the reviewer for raising interest on possible future directions for our study. We have specifically engineered SIINFEKL to be a part of either CSP or UIS4 and utilised an OVA-expressing adenovirus to focus on CD8+ T cell responses. However, we agree with the great idea from the reviewer that justifies further work in dissecting the multifaceted mechanisms underlying CD8+ T cell-mediated protection to malaria pre-erythrocytic stages, as well as future combinations to assess contributions of antibody responses.

      1. Page 6 Line 121-123 he authors reason that addition of the SIINFEKL epitope to the immediate C-terminus of the UIS4 protein might confer enhanced antigen presentation through increase MHC-I antigen presentation. Supplementary experiments particularly a MHC I stabilization assay might help confirm this. Complementary experiments looking at MHC-II antigen presentation to APC would also be very relevant.

      We have appended the SIINFEKL to the C-terminus of the UIS4, based on earlier studies in Toxoplasma gondii that the potency of an immunodominant epitope was associated with its C-terminal location, allowing for enhanced presentation by infected cells. Whilst this information is not defined for UIS4, studies on the basic biology of pre-erythrocytic stages have demonstrated for several ETRAMPs (UIS4 is a member of the ETRAMP protein family) that the C-terminus faces the host-cell cytoplasm, which might enhance exposure to the MHC I machinery. Our findings showing that vaccine-induced effector CD8+ T cell responses eliminate both transgenic parasites, argues against potential defects in antigen processing and presentation of SIINFEKL in both systems.

      Again, we agree that future studies aiming at dissecting the molecular mechanisms of MHC-I antigen presentation in infected host cells and cross-presentation via MHC-II are warranted. Another long-standing goal of the community is to elude Plasmodium peptides from MHC molecules, similar to the pioneer work by Rammensee and co-workers. One potential, albeit challenging, research direction could be to focus on rare EEF-derived peptides, since they might proof to be excellent and hitherto neglected subunit vaccine candidates, as exemplified in the present proof-of-concept study.

      1. The authors have described the effect of both antigens in the response of CD8+ T cells and the generation of memory. A more detailed characterization of the differential phenotypes of memory in CD4 and CD8 T cells in the spleen and liver following immunostimulatory therapy would increase the relevance of the data presented.

      We entirely agree that a more detailed characterisation of the different phenotypes of not only memory CD8+, including TRM, but also CD4+ T cell responses, is warranted. Whilst these suggestions clearly inspire further work using the transgenic parasites of this study by colleagues and ourselves, we believe that these are out of the scope of the current study.

      Reviewer #3 (Significance):

      This paper would be of interest to malaria parasite biologists, immunologists and vaccinologists alike. The significance of this paper is three-fold. Firstly, the authors demonstrate contrasting immunogenic profiles between a sporozoite and EEF presented antigen. They comprehensively characterize respective CD8+ T-cells responses, with the sporozoite expressed antigen displaying enhanced immunogenicity compared to the the EEF expressed antigen. Secondly, the authors demonstrate that despite these stark differences in immunogenicity, both the sporozoite and EEF expressed antigens are effective targets of epitope specific CD8+ T-cell responses capable of eliciting sterile immunity. This has the important implication that low immunogenicity as defined by conventional immunological assay fails to capture all antigens that are capable of inducing sterile immunity, and thus could be prioritized as vaccine targets, but instead risks leading investigators down a path where so to speak "the baby is thrown out with the bath water". Thirdly, this work shows for the first time that EEF expressed antigens are potential vaccine targets, and thus effectively expands the pool of available pre-erythrocytic vaccine targets for the research community to explore.

      The data presented here should thereby lead to a complete revision in how pre-eryhtrocytic vaccine candidates are identified and prioritized. In terms of basic biology, the fact that CD8+ T-cells are critical in mediating immunity is been well established, however this paper greatly enhances our understanding of exactly how the dynamics, magnitude and quality of CD8+ T-cell responses are modulated by the timing of antigen expression.

      Keywords for main reviewer expertise: Malaria, Plasmodium berghei, genetic manipulation, host-parasite interactions

      Keywords for ECR co-reviewer expertise: Immunity, host-pathogen interactions.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      Summary

      The study by Müller et al. uses the rodent malaria parasite Plasmodium berghei, which gives access to the mouse in vivo infection model. The authors investigate the initiation and development of CD8+ T cell responses during parasite liver-stage infection when the peptide antigen SIINFEK is presented either early or late during liver-stage infection by fusing SIINFEK to the Circumsporozoite Protein (CSP SIINFEK) or the Up-regulated in Infective Sporozoites 4 protein (UIS4 SIINFEK). CSP is expressed already in the motile sporozoite that invades the liver while UIS4, is expressed only in the later exoerthrocytic forms developing in the infected hepatocytes.

      Using the SIINFEK peptide the authors can control for epitope differences between CSP and UIS4 and it allows them to use the OT-I transgenic mouse line that produces high numbers of CD8+ T-cells that specifically recognizes MHC class I presented ovalbumin (OT-I cells), which can be used in adoptive transfer experiments. Using this approach the authors provide detailed kinetic and phenotypic analysis of CD8+ T-cell responses to CSP SIINFEK and UIS4 SIINFEK antigen-specific response in vivo and ex vivo, chiefly using FACS. The authors found that despite having different timing of expression and immunogenicity both CSP SIINFEK and UIS4 SIINFEK induce similar levels of CD8+ mediated targeting, resulting in a high degree of sterile immunity in a vaccination challenge experiment.

      Major comments

      Overall the manuscript is well written, concise and with a clear narrative. The conclusions drawn from the study are well supported by the data presented, and the experiments are thoroughly controlled and sufficiently replicated. The manuscript is suited for publication but presentation of key concepts and data could be made clearer and impact enhanced if the authors address some of the following commentary.

      1. Introduction -The authors assume a reader familiarity with the use of ovalbumin, the SIINFEKL epitope, the transgenic T-cell receptor OT-1 mice and adoptive transfer experiments to assay immunogenicity. These concepts are not comprehensively introduced in the introduction, and the relationship between these tools are not delineated sufficiently to allow the non-expert reader to follow the logic and methodology of the experiments right from the start. Background information given in Results (Line 139-144, 204-208) and Discussion section, (Line 288-293) could with advantage be synthesized into one paragraph and presented in the introduction to bring all readers onboard from the start.
      2. Results Page 11 Line 255-260, Figure legend Fig. 6 page 27 Line 258-665 The punchline of the paper is that the despite differences in immunogenicity between γ-irradiated CSP SIINFEKL or UIS4 SIINFEKL sporozoites, both CSP SIINFEKL or UIS4 SIINFEKL are targets of protective CD8+ T-cell responses resulting in sterile immunity in a challenge following vaccination with full-length ovalbumin in OT-I cell recipient mice. This section is a cornerstone for the conclusions of the paper and would benefit from being better supported by its explanatory text and presentation of data.

      Firstly, there is a mix up, between panel 6C and 6D, where 6C shows "% Sterile protection" and 6D shows "Parasite load in the liver", while it says the opposite in main text and figure legend.

      Secondly, while it is clear that qPCR is used to measure liver parasite load at 24 hours after challenge. It is not immediately clear from neither main text nor figure legend that sterile immunity is measured by microscopy on blood films. The use of the term "sterile immunity" naturally implies this to the initiated reader, but it should be spelled-out that this was the case and that it was monitored from day 3-14 following challenge, which is outlined only in the methods section. Rewriting and restructuring this section to make this clearer would greatly help guide the reader through the results. Currently it reads at first pass as if qPCR on liver samples harvested at 42 hours was used to generate the data in both 6C and 6D.

      Thirdly, protective efficacy here is given as a percentage of those mice that become protected, presumably remaining negative by day 14. Authors should provide the actual blood stage parasitaemia in graph or table format in Figure 6 or as a supplemental figure to show that sterile immunity is obtained and maintained until day 14, and that in the control groups patency develops as normal. This will also give clearer insight into how many mice developed patency in the control groups and at what point break-through was observed.

      In a similar vein, qualitative and / or quantitative presentation of microscopy data of EEFs (as presented in Figure 1C) would strengthen conclusions drawn from the qPCR parasite liver load data.

      Fourthly, the authors should also comment on why there is such a great variation in the number of mice used in the different studied groups, it says maximum of n=11 mice per group but one group only has as n=3 mice and another n=4, and make a convincing argument this does not affect the conclusions drawn and statistical analysis undertaken.

      Finally, the authors characterise CD8+ T-cell responses in absence of preceding OT-I adoptive transfer but do not report on whether the ovalbumin-immunization was tried on mice without preceding OT-I cell transplant. Was this tried? If not authors should discuss whether this is likely to be successful or not for readers to understand if both sporozoite and EEF presented antigens are likely to induce sterile immunity in a natural setting without artificial enrichment for epitope specific T-cells. 3. Line 723, 725 clarify if data is from independent biological repeats, i.e. different infected mice fed to different pots of mosquitoes, in which case the data is sufficiently replicated.

      Minor comments:

      1. Page 6 Line 132 Please show blood-stage infection data / growth rates for CSP SINFEKL and UIS4 SINFEKL compared to WT as supplemental figure, if available.
      2. Figure 1. If quantitative data is available for EEF, as indicated by the mean numbers with SD given within the microscopy pictures it would be nice to see these plotted. Does the reduced EEF numbers for CSP SINFEKL compared to UIS 4SINFEKL and WT mean anything? If not perhaps worth stating this in figure legend, or consider different presentation. Distracting when looking at the figure.
      3. Figure 2. Would benefit from a panel with a simple schematic that shows the overall experimental design with irradiation of sporozoites, OT-1 transfer, administration of parasites and sampling with the timings for each event clearly marked out.
      4. Figure Panel 2b would benefit from the in-figure legend stating CSP SINFEKL + OT-1, UIS4 SINFEKL + OT-1, WT + OT-1 and OT-1 only. Similar to as in Figure 3.
      5. Figure 3 and Figure 4. Label within figure more clearly what is being measured, i.e. what is the difference between panels a,b,c vs. d,e,f (e.g. intravenously v.s. intradermal administrations), gets confusing since Figure 3 and Figure 4 are very similar within the figures (a,b,c vs. d,e,f) and between the figures.
      6. Figure 3, 4, The Panel indicating letters (a, b, c, d...) become smaller as figures get bigger and become hard to read for Figure 3 and Figure 4.
      7. Line 158 - Throughout manuscript, when it says administration of WT, CSP SINFEKL and / or UIS4 SINFEKL sporozoites it would be good to always have it preceded by irradiated when referring to irradiated sporozoites, e.g. Line 158 and only use sporozoites on its own when referring to live sporozoites (or even better spell out also when using live sporozoites e.g. Line 255).
      8. The authors could measure the total amounts of IFN-ɣ being secreted in the tissues after immunization to both antigens and investigate if the level of other IFN-ɣ secreting cells might compensate for the weak response of CD8+ T cells, particularly against UIS4. If completed it has the potential to help the authors to in more detail understand the mechanism and contributing factors to the successful CD8+ T-cell targeting of UIS4.

      Suggested extra experiments:

      1. As antigen protection is dependent not only cellular response but also on antibody responses induced against the antigens, authors should analyze by ELISA IgG and IgM responses induced against the two antigens
      2. Page 6 Line 121-123 he authors reason that addition of the SIINFEKL epitope to the immediate C-terminus of the UIS4 protein might confer enhanced antigen presentation through increase MHC-I antigen presentation. Supplementary experiments particularly a MHC I stabilization assay might help confirm this. Complementary experiments looking at MHC-II antigen presentation to APC would also be very relevant.
      3. The authors have described the effect of both antigens in the response of CD8+ T cells and the generation of memory. A more detailed characterization of the differential phenotypes of memory in CD4 and CD8 T cells in the spleen and liver following immunostimulatory therapy would increase the relevance of the data presented.

      Significance

      This paper would be of interest to malaria parasite biologists, immunologists and vaccinologists alike. The significance of this paper is three-fold. Firstly, the authors demonstrate contrasting immunogenic profiles between a sporozoite and EEF presented antigen. They comprehensively characterize respective CD8+ T-cells responses, with the sporozoite expressed antigen displaying enhanced immunogenicity compared to the the EEF expressed antigen. Secondly, the authors demonstrate that despite these stark differences in immunogenicity, both the sporozoite and EEF expressed antigens are effective targets of epitope specific CD8+ T-cell responses capable of eliciting sterile immunity. This has the important implication that low immunogenicity as defined by conventional immunological assay fails to capture all antigens that are capable of inducing sterile immunity, and thus could be prioritized as vaccine targets, but instead risks leading investigators down a path where so to speak "the baby is thrown out with the bath water". Thirdly, this work shows for the first time that EEF expressed antigens are potential vaccine targets, and thus effectively expands the pool of available pre-erythrocytic vaccine targets for the research community to explore.

      The data presented here should thereby lead to a complete revision in how pre-eryhtrocytic vaccine candidates are identified and prioritized. In terms of basic biology, the fact that CD8+ T-cells are critical in mediating immunity is been well established, however this paper greatly enhances our understanding of exactly how the dynamics, magnitude and quality of CD8+ T-cell responses are modulated by the timing of antigen expression.

      Keywords for main reviewer expertise: Malaria, Plasmodium berghei, genetic manipulation, host-parasite interactions

      Keywords for ECR co-reviewer expertise: Immunity, host-pathogen interactions.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      The manuscript b Mueller and Gibbins et al titled "Low immunogenicity of malaria pre-erythrocytic stages can be overcome by vaccination" compares how transgenic P. berghei parasites expressing SIINFEKL epitope from ovalbumin, as part of CSP or UIS4 present the respective epitope and how immune responses occur to each of the mutants, mostly in mice pre-treated with 2 x 10 OT-I cells expressing a SIINFEKL-specific TCR.

      their data show that when in their normal location CSP is much better than UIS4 to elicit an immune response., and that increasing UIS4 (by raising irradiated parasite numbers) does not greatly improve to reduce the difference.

      finally the authors show that mice immunized with ovalbumin can reduce liver infection of either CSPSIINFEKL or UIS4SIINFEKL sporozoite challenge infection

      the experiments presented by the authors are in my view well done and controlled, but i feel that sometimes conclusions are a bit beyond what the experimental readouts allow for.

      Significance

      In fig1 the authors show how mutants were made and that proteins with associated SIINFEKL to CSP or UIS4 localise to correct place. (could all be supplementary or Supplementary Figure 1c, d could be included in Fig1).

      In Fig2a is shown the gating of SIINFEKL-specific CD8+ T cells (could be supplementary). In Fig 2b the authors show that the highest CD8T cell specific for SIINFEKL is on the first day analysed (d4) and I would like o see how day 2 and 3 would look like. specially because proliferative differences don't seem massive to me, CFSE should decrease with each cell division and reach different fluorescence values if replication numbers differ. however here the CFSE fluorescence signal is similar on d5 fig 2c, indicating a similar number of replicative rounds, but probably a different starting numbers of cells that would replicate. Or that CFS labelling was too low to allow distinguishing the number of replicative rounds occuring in that time.

      so when the authors conclude that proliferative activity was 6x larger than that observed with UIS4SIINFEKL sporozoites, i think they would have to show before that numbers of cells prior to replication was the same

      Figs 3 and 4 show that response to CSP is stronger than response to UIS4, and in the spleen larger than in the liver and that this was true for mice adoptively transferred with OT-I cells prior to intravenously immunisation or without that, and that with the transfer responses were much higher.

      Fig 5 show that increasing # of irradiated UIS4SIINFEKL 8x does not bring levels of response to anywhere close than the observed against 1x CSPSIINFEKL.

      and fig 6 show that if a response is obtained (in the case with an adenovirus expressing ovalbumin which will generate e a response recognising SIINFEKL) both CSPSIINFEKL or UIS4SIINFEKL infection challenge can be blocked and protective immunity equally achieved.

      I think it would be nice to show when is infection stopped in these two groups os mice, but looking at EEF in the liver if the two groups of mice.

      Also the authors could show that an adenovirus carrying UIS4 (and CSP) would result in the same as observed here with the ovalbumin one).

      I also think the authors should discuss the advantages and problems of the two SPZ and PVM locations, assuming that indeed an adenovirus carrying UIS4/CSP would also result in similar protection upon challenge, regarding potential boost from natural Infection, and how variable/conserved each of the proteins are and what could be expected in field trials ion the falciparum counterpart.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      In this study by Müller et al, the authors study if immunogenicity is an adequate predictor for vaccine development in malaria and more precisely against malaria pre-erythrocytic stage. For that the used two different strains of the murine parasite Plasmodium berghei They based their study on the use of the MCH I restricted epitope SIINFEKL to follow CD8 T cell responses. For that, they integrated the sequence SIINFEKL sequence into the protein CSP expressed by the infective form sporozoite and at the end of the sequence of the protein UIS4 expressed exclusively by the exo-erythrocytic forms (EEF) of the parasite. They compared then the CD8+ T cell responses elicited by each strain of the parasite and came to the conclusion that whilst antigen origin results in very different immunogenicity responses both sporozoite and EEF expressed antigens elicit antigen-specific effector CD8+ T cell responses with a high level of protection.

      Major comments:

      Whilst rational of parasite strain design is adequate and well-performed and the concept of low immunogenicity novel potentially interesting, there are several methodological flaws that make the conclusions somewhat speculative and need to be addressed to really support the conclusions. Given the fact that authors are top-level scientists in the malaria vaccinology field, I am confident that they can address the following comments that will help to improve the manuscript and its impact;

      • General comment: this reviewer was expecting a little more of deep analysis of immune responses elicited by the transgenic parasites that authors developed and not only a superficial analysis, how about TRM cells, what is the endogenous responses to SIINFKEL without transferring CD8 + T cells from OTI mice? This should be addressed
      • Fig 2-3: Authors compared the CD8+ T cell responses elicited by the two different strains of P.berghei. In order to evaluated if the two strains allowed to track anti-SIINFEKL, they immunized mice with both irradiated parasite strains or their control WT. To track these responses mice were adoptively transferred with CD8+ T cells from OT-I mice and immunized with irradiated parasites. They track responses by using a SIINFEKL tetramer expressing CD8+ T cells in the blood and the marker for antigen-experienced T cells CD11a. The problem here is that with the strategy of gating on Fig2a, it is not clear if they want to track the responses from adoptively transferred CD8+ T cells to vaccine or the endogenous CD8+ T cell responses. In any case, the results is potentially interesting but need clarification.

        • Fig 2: only the responses on the spleen are studied. In order to support the statement about the two different kinds of immunization, they should assess the responses on the liver.
        • There is also a lack of methodology in flow cytometry analysis, a viability stain is not used, the gating is not determined by FMO (fluorescence minus one) controls and seems aleatory. For activation markers in order to assess the impact of the vaccination authors have to use gating that is already established by some of the papers they mentioned (i.e: Harty lab's studies), it is difficult to evaluate the responses if we don't know how many of the CD11a/Cd49d cells are Memory effector or effector (CD62L and CD44 markers). Moreover, the CD11a label should be CD11ahi and is not stated anywhere.

      Line 165: the statement "massive proliferative activity" is not supported by the figure, moreover there are numbers to support the statement. - IFNg and other cytokines production seems too low and the stimulation assay is poorly performed because CD8 were restimulated ex-vivo only with SIINFEKL peptide in the absence of APC (antigen-presenting cells) with Brefeldin A. Also Authors omitted negative controls ( without SIINFEKL Brefeldin A) to be certain that IFNg production is du to SIINFEKL. Again we don't if they are OTI or endogenous cells. - Fig5. Are the cells from Fig5a,b SIINFEKL positive cells or only CD11a and IFNg? Are they OTI? Controls are missing to show a real IFNg production du to the ex vivo stimulation. - Fig 6. no percentages are shown in the cytometry plots, figure 6d and c seem to be inverted. An interesting observation is that the level of protection against both strains of parasites is the same when vaccinated mice with AdOVA are challenged. The authors make the interpretation that immunogenicity does not predict effector responses. This is one of the central conclusions of the paper. The authors only show level of protection but don't characterize the phenotype of CD8+ T cells in the liver of vaccinated and challenged mice. Can cells from Fig6a be find in the liver? Are they liver TRm (resident memory CD8+ T cells), know to be an important class of cells for protection against malaria.

      Minor comments:

      • For the two strains, authors should show the patency in comparison whit WT parasites (currently presented as data not shown)
      • Gating strategy for markers is missing, FMO as well
      • Fig 6: how did the authors measure Sterile protection and Relative parasite load?

      Significance

      The present study could provide important insight in the field of malaria vaccinology. By using cutting edge molecular biology to express the MCHI restricted epitope SIINFEKL a at different stages of the pre-erythrocytic stage of Plasmodium and used it as a surrogate marker to evaluate the CD8+T cell response to infection. The authors attempt to provide proof of the concept of vaccine design by evaluating if accessibility/immunogenicity of the antigen is a decisive feature on vaccine design. Nevertheless, the potential of this study demands to be placed in the context of precedent studies that defined pre-erythrocytic stage CD8+ T cell responses. the authors failed to fully exploit the tools that they developed (transgenic parasite) by overlooking the last studies describing the importance of CD8+ liver-resident memory CD8+ T cells from Health's laboratory or well characterized CD8 T cells responses defined by Harty's laboratory.

      If well place in the context (after revisions) this study will not only be fundamental to the malaria field but to other infectious diseases as well.

      Field of expertise: malaria immunology, vaccinology, immunomodulation, CD8+ T cell responses

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Manuscript number: RC-2022-01501

      Corresponding author(s): Prachee Avasthi

      [The “revision plan” should delineate the revisions that authors intend to carry out in response to the points raised by the referees. It also provides the authors with the opportunity to explain their view of the paper and of the referee reports.

      • *

      The document is important for the editors of affiliate journals when they make a first decision on the transferred manuscript. It will also be useful to readers of the reprint and help them to obtain a balanced view of the paper.

      • *

      If you wish to submit a full revision, please use our "Full Revision" template. It is important to use the appropriate template to clearly inform the editors of your intentions.]

      1. General Statements [optional]

      This section is optional. Insert here any general statements you wish to make about the goal of the study or about the reviews.

      • *

      We thank the reviewers for their careful reading and evaluation of our manuscript. The reviewers have emphasized the need for several important changes which we plan to address.

      First, they request better evidence and specificity of the BCI target in Chlamydomonas. We have created double mutants between the dusp6 ortholog mutants and found severe defects in ciliogenesis similar to what we see with BCI treatment. We plan to include this data in the paper as well as the subsequent analyses we performed with the single dusp6 ortholog mutants. This data will provide stronger evidence that this pathway regulates ciliary length in Chlamydomonas aside from the other potential off target effects that could be impacting this pathway that we may be seeing through the use of BCI.

      Second, the reviewers have requested more consistency and clarity both in statistics and descriptions of the data and to expand upon our findings in the discussion. We will create a clear guideline for our use of statistics and adjust the descriptions of the data to fit this guideline more strictly and prevent overstating/oversimplifying results. We will also add more discussion and information related to off target effects of BCI, the importance of the subtle defects in NPHP4 protein expression in the transition zone, and the relevancy of the membrane trafficking data in light of this study.

      2. Description of the planned revisions

      Insert here a point-by-point reply that explains what revisions, additional experimentations and analyses are planned to address the points raised by the referees.


      Reviewer #1 (Evidence, reproducibility and clarity (Required)):____


      SUMMARY:____


      The authors investigated the effects of an allosteric inhibitor of DUSP (BCI) on cilia length regulation in Chlamydomonas. Among seven conclusions summarized in Fig. 7, BCI is found to severely disrupt cilia regeneration and microtubule reorganization. Additionally, changes in kinesin-II dynamic, ciliary protein synthesis, transition zone composition and membrane trafficking are also explored. All these aspects have been shown to affect cilia length regulation. Findings from this body of work may give insights on how MAPK, a major player in cilia length regulation, functions in various avenues. Additionally, the study of BCI and other specific phosphatase inhibitors may provide a unique addition to the toolset available to uncover this important and complicated mechanism.

      MAJOR COMMENTS

      Major comment 1____

      The addition of BCI increases phosphorylated MAPK in Chlamydomonas based on Fig 1B. However, the claim that BCI inhibits Chlamydomonas MKPs is not supported at all. SF1A shows CrMKP2, 3 and 5 are related to each other but distant from HsDUSP6 and DrDUSP6. At the same time, 2 out 3 predicted BCI interacting residues are different from the Hs and Dr DUSP6 in SF1B, contradicting "well conserved" in line 172. Consistently, mutants of these orthologs have little to no ciliary length and regeneration defects compared to BCI treatment (see major comment 6 about statistical significance). I am not convinced that BCI inhibits the identified orthologs or any MKPs in Chlamydomonas. It's possible that BCI inhibits a broad range of phosphatases including the ones listed and/or those for upstream kinases. But such a point is not demonstrated by the presented data.

      While BCI is predicted to interact with these residues, it is also predicted to interact with the “general acid loop backbone” by fitting in between the a7 helix and the acid loop backbone (Molina et al., 2009).

      MKP2 has ciliary length defects compared to wild type, though it regenerates normally. In addition, we have crossed these mutants together and have found that cells (2x3 12.2 and 3x5 29.4) cannot generate cilia. We will include this data in the supplement and perform follow up analyses on these double mutants. Because these structures are not 100% conserved, and we have changed the text to “partially conserved” to reflect this, it is possible that BCI is hitting all of these DUSPs rather than just one, or the DUSPs may serve compensatory functions that rescue ciliary length.

      Major comment 3____

      The claims that "BCI inhibits KAP-GFP protein expression" (line 271) and "BCI inhibits ciliary protein synthesis" (line 286) are not convincingly demonstrated. Overlooking that only KAP is investigated instead of kinesin-II, none of the relative intensity from the WB in 30 or 50 µM BCI and the basal body fluorescence intensity indicates a statistically significant difference. The washout made no difference in any of the assay and it's not explained how phosphatase inhibition by BCI might affect overall ciliary protein synthesis. The claims about protein expression may need a fair amount of effort and time investment to demonstrate, therefore I suggest leaving these out for this manuscript.

      Though it's very interesting to see that in SF 2C cilia in 20 µM BCI treatment can regeneration slowly. Line 162, the author claimed "In the presence of (30 µM) BCI, cilia could not regenerate at all (Fig 1E)". Since Fig 1E only extends to 2 hours, I think it's important to clarify if in 30 µM BCI cilia indeed can not generate even after 6 or 8 hours.

      We have altered the text to be more specific with our wording that KAP-GFP is investigated rather than kinesin-2, and we have added text to indicate that downstream phosphorylation events could impact transcription and translation of proteins necessary for ciliary maintenance. This interpretation of the data mentioned above is correct; KAP-GFP is not significantly altered at the basal bodies or in accordance with the steady state western blots. What we see here and demonstrated in Figure 2F-I is the depleted KAP-GFP protein which is not restored following a 2 hour regeneration in BCI. We likely do not see a difference in steady state conditions because the protein is not degraded, just being moved around in the cell. We can only see the difference when the majority of KAP-GFP, which the data suggests is mostly present in cilia, is physically removed through ciliary shedding. This protein is not replaced during a 2 hour regeneration which allows us to conclude that this protein is inhibited due to BCI.

      The washout made a small difference in the double regeneration whereby we begin to see cilia begin to form in washed out conditions, though this was not statistically significant. It is possible that BCI has a potent effect on the cell similar to how other drugs, such as colchicine, cannot be easily washed out. The purpose here is to show that regardless of the statistical significance, cells can begin to regenerate their cilia after BCI washout, though this occurs 4 hours after washout in doubly regenerated cells, and we do not see this potent effect on the singly regenerated cells in SF 2C. Though in SF2C, as mentioned, we do see slowly growing cilia, and this could, once again, be due to the potent inhibition BCI has on ciliary protein synthesis. We will confirm and clarify if 30 µM BCI cannot regenerate even after 6 or 8 hours.

      Major comment 5____

      It is very interesting that BCI disrupts microtubule reorganization induced by deciliation and colchicine. Data in Fig 6B and C are presented differently than those in SF 4C. For example, in SF 4C, BCI treatment for 60 min has close to 50 % cells with microtubule partially reorganized while in Fig 6C about 20% cells with microtubule fully (or combined?) reorganized. The nature of the difference is unclear to me without an assay comparing the two directly. Hence the implied claim that BCI affects colchicine induced microtubule reorganization differently than deciliation induced one is hard to interpret (line 398, line 388 vs line 403).


      The fact that taxol doesn't rescue cilia regeneration defect by BCI is very interesting. Here taxol treatment results in fully regenerated cilia while Junmin Pan's group (Wang et. al., 2013) reported much shorter regenerated cilia. It might be worthwhile to compare the experimental variance as this is a key data point in both instances. The relationship between cilia regeneration and microtubule dynamic is not in one direction. On one side, there's a significant upregulation of tubulin after deciliation. While many microtubule depolymerization factors such as katanin, kinesin-13 positively regulate cilia assembly (though not without exceptions). It is hard to determine that the BCI induced cilia regeneration defect can't be rescued by other forms of microtubule stabilization. Microtubule reorganization is one of the most striking defects related to BCI treatment. I suggest changing the oversimplified claim to a more limited one (such as "PTX stabilized microtubule ...") and an expansion on the discussion about microtubule dynamics and cilia length regulation beyond the use of taxol. Meanwhile, I strongly encourage authors to continue to investigate this aspect and its connection to the cilia regeneration.

      We will remove data regarding “partially” formed cytoplasmic microtubules and only include fully formed for each of these experiments for clarity.

      It is important to note the different taxol concentration used here. While Wang et al., 2013 used 40 µM taxol to study ciliary affects, we use 15 µM where stabilization still occurs. There have been reports of varied cell responses to higher vs. lower doses of taxol (see Ikui et al., 2005, Pushkarev 2009, Yeung 1999) mostly with regards to the cell’s mitotic/apoptotic response. We could be seeing altered responses at this lower concentration because Chlamydomonas cells also behave differently in higher vs. lower taxol concentrations. Thank you for your suggestions. We have adjusted the text to be more specific to PTX treatment as opposed to general stabilization.

      Major comment 7:____

      There are several places where the technical detail or presentation of the data are missing or clearly erroneous.

      Fig 1B: pMAPK and MAPK antibodies used in the WB are not described in the Material and methods. It's not clear if the same #9101, CST antibody used for RPE1 cell in Fig 1J is used.

      We have updated the materials and methods to include that this antibody was used for both RPE1 and Chlamydomonas cells.


      line 260 and Fig 3A state 20 µM BCI was used while Fig 3 legend repeatedly states 30 µM until (J). Also 30 µM in SF 2A.

      We have corrected the text to 20 µM BCI in the mentioned places.

      Fig 6C, the two lines under p value on top mostly likely start from the second column (B) instead of the first (D). Fig 6G, the line is perhaps intended for the second and fourth columns?

      We will make these comparisons more clear. We had performed a chi-square analysis and were comparing the difference between DMSO and BCI before PTX stabilization or MG132 treatment to after. We will add brackets to more clearly show these comparisons.

      Fig 6C, legends indicate bars representing each category. But only one bar is shown for each column. Same for 6G?

      This is the same as the previous comment for the way we represented the statistics. We will make this clearer with brackets to show the comparisons.

      Minor comments:____

      1. A number of small errors in text were noted above. Done.

      "orthologs" is misused in place of "ortholog mutants": line 176, 352, 421 (first), 879, 882, 898, 902, 938 , 939.

      Done.

      Capital names is misused as mutant names (e.g. "MKP2"should be "mkp2"): line 178, SF 1C, 1D and 1E, SF 3C, SF 6A

      Done.

      At several places such statistical analysis lines indicated are chosen confusingly. A simplest example is in Fig 1D, the comparison between 0 to 45 is less important than 0 to 30. Same as in Fig 1H, 1I. The line ends are inconsistent as well. They either end in the middle or the edge of the columns/data points (such as in SF 4B) and some with vertical lines (SF 2B, SF 4A, SF 6B). I suggest adding vertical lines pointing to the middle to indicate the compared datasets clearly.

      Thank you for this suggestion. We agree and will update the figures to reflect this and provide clarity for statistical comparisons.

      line 101 remove "the"

      Done.

      line 120 "modulate" to "alter"

      Done.

      line 198 "N=30" should be "N=3"

      Done.

      line 212. The legend for p value is likely for (G)

      Done.

      line 284, "singly" should be "single"

      Done.

      The dataset for "Pre" and "0m" in Fig 6D and 6E are clearly the same. Consider combining the two as in Fig 6C.

      This is correct. We will combine the data sets.

      Fig 6E, "BCI" on the X-axis should be "DMSO".

      This is correct. We will correct this.

      line 685, remove "?".

      Done.

      line 894: "Fig 3J" instead of "Fig 3H"

      Done.

      SF 1 legend, (C) and (D) are inverted.

      Done.

      SF 4A "Recovered" should be "Full"

      Done.

      SF 5, row 5, under second arrow perhaps missing +PTX

      Done. We greatly appreciate this close reading of the text and the list of changes making these errors easy to find. We will make these changes in the manuscript.

      Reviewer #1 (Significance (Required)):____


      Increasing evidence indicates that several MAPKs activated by phosphorylation negatively control cilia length while few studies focus on how MAPK dephosphorylation affects cilia length regulation, largely due to the unknown identity of the phosphatase(s) specifically involved in cilia length regulation. The authors set out to investigate the effect of BCI on cilia length control. BCI specifically inhibits DUSP1 and DUSP6, both of which are known MAPK phosphatase, and therefore may provide a unique opportunity to understand how MAPK pathway is controlled by specific phosphatase(s) activity in cilia length regulation.


      Overlooking some inconclusive results and oversimplified interpretations, I find the most striking findings are the BCI's effects including ciliogenesis, kinesin-2 ciliary dynamics and microtubule reorganization. I believe these findings have significant relevance to the stated goal (line 131) and conclusions (line 57) and readers may find them a good starting point for further investigation of the role phosphatases play in cilia length regulation.

      Cilia length regulation is a complicated mechanism that is affected by many aspects of the cell and functions differently in various systems. My field of expertise may be summarized by cilia biology, cilia length regulation, IFT, kinesin, kinases (MAPKs), microtubules. The membrane trafficking's role in cilia length regulation is somewhat unfamiliar to me. Additionally, the authors used a number of statistical tests and corrections in various assays. The nuance of these choices is not clear to me and neither explained to general readers.

      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      In their manuscript, "ERK pathway activation inhibits ciliogenesis and causes defects in motor behavior, ciliary gating, and cytoskeletal rearrangement," Dougherty et al investigate how BCI, an activator of MAPK signaling, regulates ciliary length. Despite advances in our understanding of the structure and function of cilia, a fundamental question remains as to what are the mechanisms that control ciliary length. This is a critical question because cilia undergo dynamic changes in structure during the cell cycle where they must disassemble as they enter the cell cycle and must rebuild after cell division. This work contributes to a growing body of work to determine mechanisms that regulate cilia length.

      The authors use a well-established model system, Chlamydomonas, to study cilia dynamics. This work expands on previous findings from these authors that inhibition of MAPK signaling using U0126 lengthens cilia as well as other publications that implicate MAPK signaling in controlling ciliary length. However, the authors only observe a few significant phenotypes with other subtle trends, leaving the conclusion regarding the role of MAPK signaling murky. Furthermore, it is unclear through what mechanism BCI impacts ciliary length. Several issues must be addressed:

      MAJOR ISSUES

      1. The basis for this study is the use of the ERK activator BCI, which the authors show activates MAPK signaling. While the authors do use putative DUSP6 ortholog mutants to corroborate some of the phenotypes, the majority of the data (and conclusions) uses BCI. However, there may be off target effects and the authors do not address this limitation of the study. The authors only use 1 pharmacological tool to manipulate MAPK signaling, so it is unclear whether these ciliary disruptions are specifically due to increased MAPK. It is necessary to clarify the following questions about BCI action to interpret the results:
      2. ____a.____ What are off target effects of BCI? Does BCI impact proliferation? Why is the BCI phenotype of cilia shortening transient and dose dependent? Why does the phenotype of cilia length and regeneration capacity in Chlamydomonas differ from both ortholog mutants and hTERT-RPE1 cells? While we do mention following supplemental figure 1 that other MKPs could be the target for BCI, we also cite Molina et al., 2009 who showed specificity for BCI hydrochloride in zebrafish. BCI targets primarily DUSP6, but also exhibited some activity towards DUSP1. In this study, the authors had also used zebrafish embryos to check expression of 2 other FGF inhibitors, spry 4 and XFD, in the presence of BCI but found that their effects were not reversed. In addition, they checked the ability for BCI to suppress activity of other phosphatases including Cdc25B, PTP1B, or DUSP3/VHR and found that BCI could not suppress these phosphatases. BCI inhibition has previously been found to be more specific to MAPK phosphatases. In addition, we have previously confirmed that U0126 has a slight lengthening effect on Chlamydomonas which further implicates this pathway in cilium length tuning (Avasthi et al. 2012).

      While cell proliferation assays maybe provide more support for MAPK signaling, it does not clarify lack of off target effects that could also contribute to this same phenotype. We do provide a cell proliferation assay for RPE1 cells where we show that higher concentrations of BCI result in cellular senescence as well (Fig 1I).

      The BCI phenotype of cilia shortening is likely transient and dose dependent due to its effect on ciliary protein synthesis demonstrated in Figure 3J. The increase in drug likely increases its substrate binding to exert its effects on the cell faster, even if this includes off target proteins.

      In RPE1 cells, we are likely seeing differences in regeneration capacity potentially due to their different mechanisms of ciliogenesis (RPE1 cells partake in intracellular ciliogenesis where axonemal assembly begins in the cytosol whereas Chlamydomonas cells partake in extracellular ciliogenesis where axonemal assembly begins after basal bodies dock to the apical membrane), or it could be that we’re missing a delay in regeneration in RPE1 cells after waiting 48 hours for ciliogenesis. We do not check this process sooner. There may be a defect that cells overcome. Additionally, among ortholog mutants and RPE1 compared to BCI-treated wild-type Chlamydomonas, there indeed could be off target effects or the drug could be targeting all of these MKPs rather than just one. We will add this to the discussion for clarity.

      Reviewer #2 (Significance (Required)):


      see above

      Reviewer #3 (Evidence, reproducibility and clarity (Required)):

      SUMMARY:

      In this study, the authors used a pharmacological approach to explore the function of ERK pathway in ciliogenesis. It has been reported that the alteration of FGF signaling causes abnormal ciliogenesis in several animal models including Xenopus, zebrafish, and mice. However, it remains elusive the molecular detail of how ERK pathway is associated with cilia assembling process. The authors found that the ERK1/2 activator/DUSP6 inhibitor, BCI inhibits ciliogenesis, highlighting the importance of ERK during ciliogenesis. Overall, this paper is well written, data are solid and convincing. This paper will be of great interest to many researchers who are interested in understanding ciliogenesis. The following comment is not mandatory requests but suggestions to improve the paper's significance and impact.

      MAJOR COMMENTS:

      - Combination of chemical blocker experiments were well controlled and data are solid. The authors are aware of the side effects of BCI, thus they carefully characterized the phenotypes of Mkp2/3/5 in Chlamydomonas. This reviewer wonders if the levels of ERK1/2 phosphorylation are activated in these mutants. Did the authors examine the levels of ERK1/2 phosphorylation in these mutants?

      While we do not include the data showing ERK activation in these mutants, we have checked pMAPK activation and found that it is not significantly upregulated in these mutants. This could likely be due to compensatory pathways preventing persistent pMAPK activation. For example, constant ERK activation can lead to negative feedback to regulate this signal for cell cycle progression (Fritsche-Guenther et al., 2011). The ERK pathway has not been fully elucidated in Chlamydomonas, but it is possible that these similar mechanisms are in place for MAPKs. We will include this data in the supplement.

      Reviewer #3 (Significance (Required)):


      Accumulated studies suggest that the FGF signaling pathway plays a pivotal role in ciliogenesis. Disruption of either FGF ligands or its FGF receptor results in defective ciliogenesis in Xenopus and zebrafish. On the other hand, FGF signaling negatively controls the length of cilia in chondrocytes that would cause skeletal dysplasias seen in achondroplasia. Therefore, there is strong evidence suggesting that FGF signaling participates in ciliogenesis in cell-type and tissue-context dependent manners. However, the detailed mechanism of the downstream of FGF signaling in ciliogenesis is still unclear. In this regard, this paper is beneficial for the cilia community to expand the knowledge of how ERK1/2 kinase contributes to the regulation of ciliogenesis.


      This reviewer therefore suggests that the authors may want to add more discussion to explain how their finding possibly moves the field forward to understand the pathogenesis of multiple ciliopathies.

      We will add a description of this to the discussion.

      3. Description of the revisions that have already been incorporated in the transferred manuscript

      Please insert a point-by-point reply describing the revisions that were already carried out and included in the transferred manuscript. If no revisions have been carried out yet, please leave this section empty.

      Reviewer 1:


      Major comment 4____

      A single panel in Fig 4A also can't support the shift in protein density in the TZ in line 317. As line 324 implies protein synthesis defect by BCI, the very minor (in amount and significance) reduction of the NPHP4 fluorescence should not be interpreted as any disruption at all to the transition zone. I suggest checking other TZ proteins such as CEP290 etc or leave this section out.

      Also, The additive effect from BFA and BCI treatment in Fig 5A suggests BCI affects cilia length independent of Golgi. The "actin puncta" and arpc4 mutant are not sufficiently introduced. And more importantly, how increase in the actin puncta explains the shorter cilia length caused by BCI while actin puncta are absent in arpc4 mutant with shorter cilia? Also, the Arl6 fluorescence signal "increase" is not significant in either time point. I suggest leaving this section out as well.

      We agree that one EM image cannot support a protein shift and have removed our observation in the text. However, we do see a statistically significant decrease in NPHP4 fluorescence in BCI treated cells which we consider a disruption in the sense that the structural composition is altered. We will change the word “disruption” to “alteration” for clarity. Though this is a minor defect, we believe it is still worth noting. We believe this data still adds to the model that though the EM-visible structure is unaltered, finer details within the transition zone are indeed altered and we cannot rule out that these smaller changes are not impacting protein entry into cilia. Awata et al. 2014 shows that NPHP4 is important for controlling trafficking of ciliary proteins at the transition zone, and its loss from the transition zone has been found to have effects in ciliary protein composition. Because we see decreased NPHP4 expression, we believe this is a notable finding as we see effects on the abundance of a protein which is known to affect ciliary protein composition and have therefore chosen to leave the data in the manuscript. We will adjust the language to most accurately describe our findings.

      We also agree with the interpretation that the additive effect seen from BFA and BCI treatment could suggest independent pathway collapse separate from the Golgi which we have mentioned in the manuscript.

      We have provided more information to introduce actin puncta and ARPC4 with regards to membrane trafficking. Bigge et al. 2020 shows that ARPC4, a subunit of the ARP2/3 complex which is an actin binding protein important for nucleating actin branches, has a role in ciliary assembly. ARPC4 mutants have repressed ability to regenerate their cilia. One feature they noticed in regenerating cells is the immediate formation of actin puncta which are reminiscent of yeast endocytic pits. This observation in addition to altered membrane uptake pathways in Chlamydomonas suggests that ciliogenesis involves reclaiming plasma membrane for use in ciliogenesis (because of the diffusion barrier preventing a contiguous membrane). Here, we incorporate this assay to assess the ability for the cell to reclaim membrane during BCI treatment and find that there is increased actin puncta. This could indicate that there is increased number of endocytic pits or alternatively that the lifetime of these pits is increased (perhaps due to incomplete endocytosis) such that we are able to detect more of them at a fixed point in time. While we cannot say which is happening here, we have previously found that these actin puncta are likely endocytic and needed to reclaim membrane for early ciliogenesis. An increase in these puncta may suggest dysregulated endocytosis in one way or another. ARPC4 cells cannot form the actin puncta in the first place, whereas we are seeing defects following puncta formation. We have taken out the Arl6 data.

      Major comment 6____

      Throughout this manuscript, the standard the authors used to interpret statistical significance is erratic. In a few instances, the threshold for p value is clearly indicated such as in Fig 1 legend. Though other times, much higher p values are considered differences. Here are some examples:

      SF 1C, p=0.1167 is considered "(mkp5) shorter than wildtype ciliary lengths" (also line 177 "SF 1C" instead of "SF 1D")

      Fig 3C, p=0.083 interpreted as "slightly less" in line 262 and possibly as "(KAP-GFP) not being able to enter (cilia)" in line 268

      Fig 3G, p=0.1087 is considered "not decrease after two hours" line 267

      SF 3C, p=0.2929 for mkp2 mutant (misuse of "orthologs" in line 352) is considered "fewer actin puncta compared to wild type cells" (line 352).

      SF 6B, p=0.1565for mkp3 mutant (line 421: misuse of "orthologs" and correct use of "ortholog mutants") is considered not be able to "fully reorganize their microtubules" (line 421).

      These instances sometimes serve as basis for major conclusions and should be clarified or more carefully characterized.

      We agree the interpretations are very erratic in places and greatly appreciate this detailed list making it easy to find and correct these interpretations. We have adjusted the text in the mentioned places to reflect these changes, and we have made a statement in the text and under statistical methods that say we consider p Reviewer 2:

      In multiple instances the conclusions are overstated, and the author must clarify the interpretation of the results to reflect the data presented. Here are some examples:

      • ____a.____ The conclusion that protein synthesis is disrupted is incorrect in two instances (line 258 and 275) as the experiments in figure 3 do not directly examine changes in synthesis (they look at cilia regeneration as a proxy). We show that KAP-GFP expression is not normal during regeneration at 120 minutes which suggests, in addition to the inability for cilia to grow in BCI, that synthesis is inhibited because this protein is not replaced. In addition, blocking the proteosome did not rescue this decrease in KAP-GFP expression indicating that this is not a matter of KAP-GFP protein being degraded rapidly. We use regeneration and KAP-GFP readout as a proxy for protein synthesis. We have clarified this in the text.

      • ____b.____ The conclusion that BCI disrupts membrane trafficking is too broad when the authors only examined trafficking of one membrane protein, Arl6. While we only looked at one membrane protein specifically, we assess other membrane trafficking paths. We looked at BCI vs. BFA to assess Golgi trafficking (Dentler 2010) in addition to formation of actin puncta which is used in Bigge et al. 2020 as an assay for membrane uptake from the plasma membrane for incorporation into cilia.

      • ____c.____ The conclusion that the transition zone is disrupted is too broad based on a decrease in the expression of one transition zone protein, NPHP4. We have changed the text to be more specific to NPHP4.

      Highlighting the overstatement, the conclusion of the header and figure caption on page 10 contradict one another. The manuscript states that "BCI partially disrupts the transition zone" (line 313) and that "The TZ structure is structurally unaltered with BCI treatment" (line 329).

      In the manuscript, we show that the EM-visible structure is indeed unaltered. Because we see a decrease in NPHP4 fluorescence, we concluded that while the EM-visible structure is unaltered, protein composition within the transition zone is altered which suggests that BCI partially disrupts the transition zone.

      Why is kinesin-2 the only target studied for ciliogenesis? Ciliogenesis is a complex process that involves many other critical proteins and investigating kinesin-2 alone is not sufficient to conclude why BCI prevents cilia assembly.

      We use kinesin-2 because it is the only ciliary anterograde motor in Chlamydomonas which is required for proper ciliogenesis. By assessing kinesin-2, we were able to address whether this protein alone was the cause for inhibited ciliary assembly (and we find that it’s not), whether its ability to enter was impacted (likely owing to defects in other protein entry), and we were able to use this protein to understand how its protein expression was affected. Because KAP-GFP is a cargo adaptor protein and interacts with IFT complexes and other cargoes, defects in this protein can have a wide range of implications. We agree and the data agree that kinesin-2 alone is not sufficient to conclude why BCI prevents cilia assembly. Because of this, we assessed other pathways including membrane trafficking and microtubule stabilization to better understand why we see defects in ciliary assembly. Certainly many other proteins are important in ciliogenesis and we hope that this study sparks further work in this area to identify additional causative explanations for impaired ciliogenesis upon MAPK activation..

      Tagged ciliary proteins are sensitive to disruptions in function and expression within cilia. It is important to include proper controls in the study using KAP-GFP Chlamydomonas cells to ensure that KAP-GFP maintains endogenous expression levels and normal function as untagged KAP. Furthermore, if this information is available through the resource where the cells were purchased, then this needs to be discussed.

      KAP-GFP expressing Chlamydomonas has previously been validated as described in Mueller et al., 2005. We will provide details in the text about validation of this strain.

      The authors need to provide clear explanations to a general audience of why this technique is used and how the authors reached the interpretations. There are several instances where the authors use techniques that are cited as fundamental papers in Chlamydomonas. Here are two examples:

      • ____a.____ It is unclear how the authors concluded that decreased frequency and velocity of train size shows that kinesin entry, specifically, is disrupted. We have expanded on this in the text. Please see response to reviewer 1, Major comment 2 above.

      • ____b.____ It was impossible to follow how the experiment where cells treated with cycloheximide could not regenerate their cilia following BCI treatment shows that BCI inhibits protein synthesis. We have adapted the text to be more clear regarding this experiment. In this experiment, we deplete the ciliary protein pool by forcing ciliary shedding two times. Following the first shedding, there is enough protein to assemble cilia to half length (Rosenbaum, 1969). We ensure that the protein pool is completely used up by inhibiting further ciliary protein synthesis with cycloheximide. For the second shedding event, completely new ciliary protein must be synthesized for ciliogenesis to occur which is why ciliogenesis takes much longer compared to a single regeneration where half of the ciliary protein pool still remains and can be immediately incorporated into cilia (SF 2C). In the presence of BCI, cilia cannot grow at all as expected; but 4 hours after BCI is washed out, we see ciliogenesis just beginning to occur which indicates that there is protein present for ciliogenesis to begin whereas in cells where BCI is not washed out, we do not see any ciliogenesis.

      The impact of BCI treatment on membrane trafficking as presented is confusing. BCI exacerbated the effects of BFA treatment on Golgi, yet the authors do not address that this could be an indirect effect of BCI or an off-target effect of BCI.

      This is addressed in the discussion (paragraph 4).

      The discussion section includes many interpretations of the results, but leaves the reader confused as to what the authors think might be happening. The manuscript would be far clearer if the authors would provide a working model for why BCI impacts cilia length. It is fine for this to be left for future work but, as the experts, the authors must have relevant thoughts to share with the field.

      Figure 7 provides a model with as much as we can conclude given the data; what we show is that BCI inhibits many different processes in the cell, but we do not necessarily show links between these processes to provide a complete working model of how these are all interconnected; we have provided a summary model that depicts the various, still disconnected processes that are inhibited by BCI. MAP kinases such as ERK have dozens of downstream targets both within and outside the nucleus. Ciliogenesis also is a complex process coordinating many cellular mechanisms. The intersection of these two seem to have a multi-fold effect that results in a dramatic ciliary phenotype through a combination of factors, however not one that fully explains the severity upon initial deciliation in BCI/MAPK activation. Further work is needed to identify the precise cause of completely inhibited cilium growth from zero length.

      MINOR ISSUES

      1. The title of the manuscript is inaccurate and overstates the pathway involvement in cilia. The authors do not directly show that ERK pathway activation causes the ciliary phenotypes due to the use of BCI, a drug that modulates ERK. We have adjusted the title to “The ERK activator, BCI, causes…”

      When discussing results of data that are not statistically significant it creates confusion to state that the results "increased/decreased slightly".

      We agree that references to statistics are inconsistent or confusing throughout the text and have adjusted these references accordingly.

      Reviewer 3:

      Major comment:

      - If the authors want to emphasize their finding is associated with MAP kinases, it would be also beneficial to examine other major MAP kinase pathways such as P38/JNK. If not, then this reviewer suggests revising the text as ERK through this manuscript to avoid confusions.

      Because the ERK pathway has not been fully elucidated in Chlamydomonas, we have refrained from using “ERK” as a descriptor because this particular MAPK shares equal identity with multiple MAPKs in Chlamydomonas. Further, BCI may be targeting more than one MAPK phosphatase resulting in the myriad phenotypes we have discovered. At this time, we lack a level of gene-level resolution to map to known MAPK pathways.

      • *

      4. Description of analyses that authors prefer not to carry out

      Please include a point-by-point response explaining why some of the requested data or additional analyses might not be necessary or cannot be provided within the scope of a revision. This can be due to time or resource limitations or in case of disagreement about the necessity of such additional data given the scope of the study. Please leave empty if not applicable.


      Reviewer 1:

      Major comment 2____

      The claim that "BCI treatment decreases kinesin-2 entry into cilia" (line 236) is a misinterpretation of the data presented. The data indicates KAP-GFP have reduced accumulation in cilia, decreased IFT (anterograde) frequency, velocity and injection size associated with BCI treatment. Though as shown in Fig 1D and Fig 2C, cilia length is also shorter due to BCI treatment. Ludington et. al, 2013 showed a negative correlation of cilia length and KAP injection rate in various treatments that affect cilia length. It's essential to rule out that the KAP dynamics reported in the current manuscript is not an outcome of shortened cilia in order to claim as line 236 seems to suggest. One way to demonstrate specific effect by BCI would be to compare KAP dynamic in cilia with equal or similar length, either by only selecting the shorter cilia from wt or use other treatments that are known to decrease cilia length (chemicals, cell cycle, mutants etc.). Given the capability and resource represented in this manuscript, I don't expect a significant cost and time investment for these experiments.

      Ludington et al., 2013 shows that injection size decreases with increasing length. Our data show that the shorter length cilia have decreased injection size and rate inconsistent with the cause being due to shortened length alone. In other words, in figure 2C and 2G, we see decreased KAP-GFP fluorescence in shorter cilia as opposed to greater fluorescent signal in shorter cilia seen in Ludington et al., 2013. This data, in combination with the decreasing frequency of KAP-GFP entry overtime in figure 2E and decreased velocity in figure 2F support decreased kinesin-2 entry into cilia. If entry was unaltered, we would expect increased KAP-GFP fluorescence in the cilia over time in BCI-treated cells.


      Reviewer 2:

      The authors state that the decreased length of cilia following BCI treatment could be a result of reduced assembly or increased assembly. Disruptions to cilia assembly and disassembly are not mutually exclusive and both must be evaluated. The authors do not test whether cilia disassembly is disrupted in BCI treatment and therefore, cannot conclude that BCI solely disrupts cilia assembly.

      While effects on disassembly remains a possibility, the striking inability to increase from zero length upon deciliation and the effects on anterograde IFT through the TIRFM assays suggest an affect on assembly. There may be effects on disassembly and likely many other cilia related processes not investigated but we feel it remains accurate to conclude that assembly is affected by BCI treatment.

      Reviewer 3:

      - If time allows, in addition to examining NPHP4, it would be beneficial to examine other TZ/TF markers such as CEP164 to confirm if BCI partially disrupts the TZ.

      Given the known outcomes of NPHP4 loss in Chlamydomonas (Awata et al., …) in affecting ciliary protein composition, we suspect the changes in NPHP4 abundance at the transition zone will have a significant impact and agree it would be interesting in a follow up study to see how other transition zone proteins (particularly ones known to interact with NPHP4 or others critical for TZ function) are impacted following BCI treatment.


      MINOR COMMENTS:

      - I suggest moving supplemental figure 1 to the main figure (Fig. 1?) so that the readers appreciate the author's careful examination of BCI through this manuscript.

      Thank you for your suggestion and kind critique. We have included this data in the supplement for consistency with mutant data in all of the other supplemental figures.


    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      Summary:

      In this study, the authors used a pharmacological approach to explore the function of ERK pathway in ciliogenesis. It has been reported that the alteration of FGF signaling causes abnormal ciliogenesis in several animal models including Xenopus, zebrafish, and mice. However, it remains elusive the molecular detail of how ERK pathway is associated with cilia assembling process. The authors found that the ERK1/2 activator/DUSP6 inhibitor, BCI inhibits ciliogenesis, highlighting the importance of ERK during ciliogenesis. Overall, this paper is well written, data are solid and convincing. This paper will be of great interest to many researchers who are interested in understanding ciliogenesis. The following comment is not mandatory requests but suggestions to improve the paper's significance and impact.

      Major comments:

      • Combination of chemical blocker experiments were well controlled and data are solid. The authors are aware of the side effects of BCI, thus they carefully characterized the phenotypes of Mkp2/3/5 in Chlamydomonas. This reviewer wonders if the levels of ERK1/2 phosphorylation are activated in these mutants. Did the authors examine the levels of ERK1/2 phosphorylation in these mutants?

      • If the authors want to emphasize their finding is associated with MAP kinases, it would be also beneficial to examine other major MAP kinase pathways such as P38/JNK. If not, then this reviewer suggests revising the text as ERK through this manuscript to avoid confusions.

      • If time allows, in addition to examining NPHP4, it would be beneficial to examine other TZ/TF markers such as CEP164 to confirm if BCI partially disrupts the TZ.

      Minor comments:

      • I suggest moving supplemental figure 1 to the main figure (Fig. 1?) so that the readers appreciate the author's careful examination of BCI through this manuscript.

      Significance

      Accumulated studies suggest that the FGF signaling pathway plays a pivotal role in ciliogenesis. Disruption of either FGF ligands or its FGF receptor results in defective ciliogenesis in Xenopus and zebrafish. On the other hand, FGF signaling negatively controls the length of cilia in chondrocytes that would cause skeletal dysplasias seen in achondroplasia. Therefore, there is strong evidence suggesting that FGF signaling participates in ciliogenesis in cell-type and tissue-context dependent manners. However, the detailed mechanism of the downstream of FGF signaling in ciliogenesis is still unclear. In this regard, this paper is beneficial for the cilia community to expand the knowledge of how ERK1/2 kinase contributes to the regulation of ciliongenesis.

      This reviewer therefore suggests that the authors may want to add more discussion to explain how their finding possibly moves the field forward to understand the pathogenesis of multiple ciliopathies.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      In their manuscript, "ERK pathway activation inhibits ciliogenesis and causes defects in motor behavior, ciliary gating, and cytoskeletal rearrangement," Dougherty et al investigate how BCI, an activator of MAPK signaling, regulates ciliary length. Despite advances in our understanding of the structure and function of cilia, a fundamental question remains as to what are the mechanisms that control ciliary length. This is a critical question because cilia undergo dynamic changes in structure during the cell cycle where they must disassemble as they enter the cell cycle and must rebuild after cell division. This work contributes to a growing body of work to determine mechanisms that regulate cilia length.

      The authors use a well-established model system, Chlamydomonas, to study cilia dynamics. This work expands on previous findings from these authors that inhibition of MAPK signaling using U0126 lengthens cilia as well as other publications that implicate MAPK signaling in controlling ciliary length. However, the authors only observe a few significant phenotypes with other subtle trends, leaving the conclusion regarding the role of MAPK signaling murky. Furthermore, it is unclear through what mechanism BCI impacts ciliary length. Several issues must be addressed:

      MAJOR ISSUES

      1. The basis for this study is the use of the ERK activator BCI, which the authors show activates MAPK signaling. While the authors do use putative DUSP6 ortholog mutants to corroborate some of the phenotypes, the majority of the data (and conclusions) uses BCI. However, there may be off target effects and the authors do not address this limitation of the study. The authors only use 1 pharmacological tool to manipulate MAPK signaling, so it is unclear whether these ciliary disruptions are specifically due to increased MAPK. It is necessary to clarify the following questions about BCI action to interpret the results:

      a) What are off target effects of BCI? Does BCI impact proliferation? Why is the BCI phenotype of cilia shortening transient and dose dependent? Why does the phenotype of cilia length and regeneration capacity in Chlamydomonas differ from both ortholog mutants and hTERT-RPE1 cells?

      1. In multiple instances the conclusions are overstated, and the author must clarify the interpretation of the results to reflect the data presented. Here are some examples:

      a) The conclusion that protein synthesis is disrupted is incorrect in two instances (line 258 and 275) as the experiments in figure 3 do not directly examine changes in synthesis (they look at cilia regeneration as a proxy).

      b) The conclusion that BCI disrupts membrane trafficking is too broad when the authors only examined trafficking of one membrane protein, Arl6.

      c) The conclusion that the transition zone is disrupted is too broad based on a decrease in the expression of one transition zone protein, NPHP4.

      1. Highlighting the overstatement, the conclusion of the header and figure caption on page 10 contradict one another. The manuscript states that "BCI partially disrupts the transition zone" (line 313) and that "The TZ structure is structurally unaltered with BCI treatment" (line 329).

      2. The authors state that the decreased length of cilia following BCI treatment could be a result of reduced assembly or increased assembly. Disruptions to cilia assembly and disassembly are not mutually exclusive and both must be evaluated. The authors do not test whether cilia disassembly is disrupted in BCI treatment and therefore, cannot conclude that BCI solely disrupts cilia assembly.

      3. Why is kinesin-2 the only target studied for ciliogenesis? Ciliogenesis is a complex process that involves many other critical proteins and investigating kinesin-2 alone is not sufficient to conclude why BCI prevents cilia assembly.

      4. Tagged ciliary proteins are sensitive to disruptions in function and expression within cilia. It is important to include proper controls in the study using KAP-GFP Chlamydomonas cells to ensure that KAP-GFP maintains endogenous expression levels and normal function as untagged KAP. Furthermore, if this information is available through the resource where the cells were purchased, then this needs to be discussed.

      5. The authors need to provide clear explanations to a general audience of why this technique is used and how the authors reached the interpretations. There are several instances where the authors use techniques that are cited as fundamental papers in Chlamydomonas. Here are two examples:

      a) It is unclear how the authors concluded that decreased frequency and velocity of train size shows that kinesin entry, specifically, is disrupted.

      b) It was impossible to follow how the experiment where cells treated with cycloheximide could not regenerate their cilia following BCI treatment shows that BCI inhibits protein synthesis.

      1. The impact of BCI treatment on membrane trafficking as presented is confusing. BCI exacerbated the effects of BFA treatment on Golgi, yet the authors do not address that this could be an indirect effect of BCI or an off-target effect of BCI.

      2. The discussion section includes many interpretations of the results, but leaves the reader confused as to what the authors think might be happening. The manuscript would be far clearer if the authors would provide a working model for why BCI impacts cilia length. It is fine for this to be left for future work but, as the experts, the authors must have relevant thoughts to share with the field.

      MINOR ISSUES

      1. The title of the manuscript is inaccurate and overstates the pathway involvement in cilia. The authors do not directly show that ERK pathway activation causes the ciliary phenotypes due to the use of BCI, a drug that modulates ERK.

      2. When discussing results of data that are not statistically significant it creates confusion to state that the results "increased/decreased slightly".

      Significance

      see above

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      Summary:

      The authors investigated the effects of an allosteric inhibitor of DUSP (BCI) on cilia length regulation in Chlamydomonas. Among seven conclusions summarized in Fig. 7, BCI is found to severely disrupt cilia regeneration and microtubule reorganization. Additionally, changes in kinesin-II dynamic, ciliary protein synthesis, transition zone composition and membrane trafficking are also explored. All these aspects have been shown to affect cilia length regulation. Findings from this body of work may give insights on how MAPK, a major player in cilia length regulation, functions in various avenues. Additionally, the study of BCI and other specific phosphatase inhibitors may provide a unique addition to the toolset available to uncover this important and complicated mechanism.

      Major comments:

      Major comment 1

      The addition of BCI increases phosphorylated MAPK in Chlamydomonas based on Fig 1B. However, the claim that BCI inhibits Chlamydomonas MKPs is not supported at all. SF1A shows CrMKP2, 3 and 5 are related to each other but distant from HsDUSP6 and DrDUSP6. At the same time, 2 out 3 predicted BCI interacting residues are different from the Hs and Dr DUSP6 in SF1B, contradicting "well conserved" in line 172. Consistently, mutants of these orthologs have little to no ciliary length and regeneration defects compared to BCI treatment (see major comment 6 about statistical significance). I am not convinced that BCI inhibits the identified orthologs or any MKPs in Chlamydomonas. It's possible that BCI inhibits a broad range of phosphatases including the ones listed and/or those for upstream kinases. But such a point is not demonstrated by the presented data.

      Major comment 2

      The claim that "BCI treatment decreases kinesin-2 entry into cilia" (line 236) is a misinterpretation of the data presented. The data indicates KAP-GFP have reduced accumulation in cilia, decreased IFT (anterograde) frequency, velocity and injection size associated with BCI treatment. Though as shown in Fig 1D and Fig 2C, cilia length is also shorter due to BCI treatment. Ludington et. al, 2013 showed a negative correlation of cilia length and KAP injection rate in various treatments that affect cilia length. It's essential to rule out that the KAP dynamics reported in the current manuscript is not an outcome of shortened cilia in order to claim as line 236 seems to suggest. One way to demonstrate specific effect by BCI would be to compare KAP dynamic in cilia with equal or similar length, either by only selecting the shorter cilia from wt or use other treatments that are known to decrease cilia length (chemicals, cell cycle, mutants etc.). Given the capability and resource represented in this manuscript, I don't expect a significant cost and time investment for these experiments.

      Major comment 3

      The claims that "BCI inhibits KAP-GFP protein expression" (line 271) and "BCI inhibits ciliary protein synthesis" (line 286) are not convincingly demonstrated. Overlooking that only KAP is investigated instead of kinesin-II, none of the relative intensity from the WB in 30 or 50 µM BCI and the basal body fluorescence intensity indicates a statistically significant difference. The washout made no difference in any of the assay and it's not explained how phosphatase inhibition by BCI might affect overall ciliary protein synthesis. The claims about protein expression may need a fair amount of effort and time investment to demonstrate, therefore I suggest leaving these out for this manuscript. Though it's very interesting to see that in SF 2C cilia in 20 µM BCI treatment can regeneration slowly. Line 162, the author claimed "In the presence of (30 µM) BCI, cilia could not regenerate at all (Fig 1E)". Since Fig 1E only extends to 2 hours, I think it's important to clarify if in 30 µM BCI cilia indeed can not generate even after 6 or 8 hours.

      Major comment 4

      A single panel in Fig 4A also can't support the shift in protein density in the TZ in line 317. As line 324 implies protein synthesis defect by BCI, the very minor (in amount and significance) reduction of the NPHP4 fluorescence should not be interpreted as any disruption at all to the transition zone. I suggest checking other TZ proteins such as CEP290 etc or leave this section out. Also, The additive effect from BFA and BCI treatment in Fig 5A suggests BCI affects cilia length independent of Golgi. The "actin puncta" and arpc4 mutant are not sufficiently introduced. And more importantly, how increase in the actin puncta explains the shorter cilia length caused by BCI while actin puncta are absent in arpc4 mutant with shorter cilia? Also, the Arl6 fluorescence signal "increase" is not significant in either time point. I suggest leaving this section out as well.

      Major comment 5

      It is very interesting that BCI disrupts microtubule reorganization induced by deciliation and colchicine. Data in Fig 6B and C are presented differently than those in SF 4C. For example, in SF 4C, BCI treatment for 60 min has close to 50 % cells with microtubule partially reorganized while in Fig 6C about 20% cells with microtubule fully (or combined?) reorganized. The nature of the difference is unclear to me without an assay comparing the two directly. Hence the implied claim that BCI affects colchicine induced microtubule reorganization differently than deciliation induced one is hard to interpret (line 398, line 388 vs line 403). The fact that taxol doesn't rescue cilia regeneration defect by BCI is very interesting. Here taxol treatment results in fully regenerated cilia while Junmin Pan's group (Wang et. al., 2013) reported much shorter regenerated cilia. It might be worthwhile to compare the experimental variance as this is a key data point in both instances. The relationship between cilia regeneration and microtubule dynamic is not in one direction. On one side, there's a significant upregulation of tubulin after deciliation. While many microtubule depolymerization factors such as katanin, kinesin-13 positively regulate cilia assembly (though not without exceptions). It is hard to determine that the BCI induced cilia regeneration defect can't be rescued by other forms of microtubule stabilization. Microtubule reorganization is one of the most striking defects related to BCI treatment. I suggest changing the oversimplified claim to a more limited one (such as "PTX stabilized microtubule ...") and an expansion on the discussion about microtubule dynamics and cilia length regulation beyond the use of taxol. Meanwhile, I strongly encourage authors to continue to investigate this aspect and its connection to the cilia regeneration.

      Major comment 6

      Throughout this manuscript, the standard the authors used to interpret statistical significance is erratic. In a few instances, the threshold for p value is clearly indicated such as in Fig 1 legend. Though other times, much higher p values are considered differences. Here are some examples: SF 1C, p=0.1167 is considered "(mkp5) shorter than wildtype ciliary lengths" (also line 177 "SF 1C" instead of "SF 1D") Fig 3C, p=0.083 interpreted as "slightly less" in line 262 and possibly as "(KAP-GFP) not being able to enter (cilia)" in line 268 Fig 3G, p=0.1087 is considered "not decrease after two hours" line 267 SF 3C, p=0.2929 for mkp2 mutant (misuse of "orthologs" in line 352) is considered "fewer actin puncta compared to wild type cells" (line 352). SF 6B, p=0.1565for mkp3 mutant (line 421: misuse of "orthologs" and correct use of "ortholog mutants") is considered not be able to "fully reorganize their microtubules" (line 421). These instances sometimes serve as basis for major conclusions and should be clarified or more carefully characterized.

      Major comment 7

      There are several places where the technical detail or presentation of the data are missing or clearly erroneous.

      • Fig 1B: pMAPK and MAPK antibodies used in the WB are not described in the Material and methods. It's not clear if the same #9101, CST antibody used for RPE1 cell in Fig 1J is used.
      • line 260 and Fig 3A state 20 µM BCI was used while Fig 3 legend repeatedly states 30 µM until (J). Also 30 µM in SF 2A.
      • Fig 6C, the two lines under p value on top mostly likely start from the second column (B) instead of the first (D). Fig 6G, the line is perhaps intended for the second and fourth columns?
      • Fig 6C, legends indicate bars representing each category. But only one bar is shown for each column. Same for 6G?

      Minor comments:

      1. A number of small errors in text were noted above.

      2. "orthologs" is misused in place of "ortholog mutants": line 176, 352, 421 (first), 879, 882, 898, 902, 938 , 939.

      3. Capital names is misused as mutant names (e.g. "MKP2"should be "mkp2"): line 178, SF 1C, 1D and 1E, SF 3C, SF 6A

      4. At several places such statistical analysis lines indicated are chosen confusingly. A simplest example is in Fig 1D, the comparison between 0 to 45 is less important than 0 to 30. Same as in Fig 1H, 1I. The line ends are inconsistent as well. They either end in the middle or the edge of the columns/data points (such as in SF 4B) and some with vertical lines (SF 2B, SF 4A, SF 6B). I suggest adding vertical lines pointing to the middle to indicate the compared datasets clearly.

      5. line 101 remove "the"

      6. line 120 "modulate" to "alter"

      7. line 198 "N=30" should be "N=3"

      8. line 212. The legend for p value is likely for (G)

      9. line 284, "singly" should be "single"

      10. The dataset for "Pre" and "0m" in Fig 6D and 6E are clearly the same. Consider combining the two as in Fig 6C.

      11. Fig 6E, "BCI" on the X-axis should be "DMSO".

      12. line 685, remove "?".

      13. line 894: "Fig 3J" instead of "Fig 3H"

      14. SF 1 legend, (C) and (D) are inverted.

      15. SF 4A "Recovered" should be "Full"

      16. SF 5, row 5, under second arrow perhaps missing +PTX

      Significance

      Increasing evidence indicates that several MAPKs activated by phosphorylation negatively control cilia length while few studies focus on how MAPK dephosphorylation affects cilia length regulation, largely due to the unknown identity of the phosphatase(s) specifically involved in cilia length regulation. The authors set out to investigate the effect of BCI on cilia length control. BCI specifically inhibits DUSP1 and DUSP6, both of which are known MAPK phosphatase, and therefore may provide a unique opportunity to understand how MAPK pathway is controlled by specific phosphatase(s) activity in cilia length regulation.

      Overlooking some inconclusive results and oversimplified interpretations, I find the most striking findings are the BCI's effects including ciliogenesis, kinesin-2 ciliary dynamics and microtubule reorganization. I believe these findings have significant relevance to the stated goal (line 131) and conclusions (line 57) and readers may find them a good starting point for further investigation of the role phosphatases play in cilia length regulation.

      Cilia length regulation is a complicated mechanism that is affected by many aspects of the cell and functions differently in various systems. My field of expertise may be summarized by cilia biology, cilia length regulation, IFT, kinesin, kinases (MAPKs), microtubules. The membrane trafficking's role in cilia length regulation is somewhat unfamiliar to me. Additionally, the authors used a number of statistical tests and corrections in various assays. The nuance of these choices is not clear to me and neither explained to general readers.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      We would like to thank the editor for the opportunity to submit our revised manuscript “Neuron- derived Thioredoxin-80: a novel regulator of type-I interferon response in microglia”. We thank the reviewers for their thorough analysis and thoughtful insights, we have considered all thequestions and issues aroused and modified the manuscript where appropriate and all changes in the manuscript are highlighted in yellow. We hope that this new improved version will be suitable for publication in an affiliated journal of Review Commons. Please find below a point-to-point description of the changes and the experiments that we plan to carry out.

      Reviewer #1:

      Major Comments:

      1.This work is potentially interesting, but the results are very preliminary. There is not a clear demonstration of the signaling pathways triggered by oxidative stress and leading to Trx80 production in neurons. The authors claim the role of Nrf2, but did not silence Nrf2, nor demonstrated the cascade downstream Nrf2 that is responsible for Trx80 production.

      This is a very valuable point raised by the reviewer. To better characterize the role of Nrf2 and the downstream cascade responsible for Trx80 production, we are currently running the following experiments:

      • We are silencing Nrf2 in neuronal primary cultures prior to 27-hydroxycholesterol (27-OHC) or Rotenone treatment. We will then measure Trx1 and Trx80 protein levels. We expect to see significant decrease in the protein levels of both Trx1 and Trx80 in control conditions, and a lack of effect of 27-OHC and rotenone in inducing an increase in their levels.

      Additionally, to confirm in our model that, as previously reported, ADAM10/17 α-secretases are responsible for the cleavage of Trx1 into Trx80, neuronal primary cultures will be treated with GW280264X, an inhibitor of ADAM10 and ADAM17 prior to 27-OHC or rotenone treatment. We expect to observe a decrease in the amount of Trx80 produced, whereas Trx1 protein levels should still increase in presence of 27-OHC and rotenone. We believe that these experiments will help to confirm the pathway responsible for the increased production of Trx80 downstream Nrf2 activation by 27-OHC or rotenone.

      Additionally, we will be more specific in the description of the oxidative-stress related signaling pathways that we describe from our RNAseq data, and determine whether know downstream targets of Nrf2 are indeed changing their expression levels upon 27OH treatment in neurons.

      1. In addition, Cyp27Tg mice show higher Trx80 levels only at a very old age and it is not at all shown that oxidative stress is responsible for Trx80 enhanced production in this mice model.

      We would like to point out that most of the studies regarding the oxidative effects caused by 27-OHC have been carried out in vitro, where it promotes the activation of cell survival pathways that appear to be modulated by Reactive Oxygen Species (ROS) (Vurusaner et al., 2018). Moreover, in vitro treatments with this oxysterol induce the expression of Nrf2 through extracellular signal-regulated kinase (ERK) and the phosphoinositide 3-kinase (PI3K)/Akt pathways (Vurusaner et al., 2016). Nrf2 is a transcription factors for many antioxidant proteins including heme oxygenase-1 (HO-1) that has also been found to be elevated upon 27-OHC treatment (Dasari et al., 2010). Despite this evidence in vitro, no study so far has evaluated 27-OHC-mediated oxidative stress in vivo.

      • To further clarify the pathways responsible for Trx80 production and its effects in Cyp27Tg in vivo we will perform fluorescence-activated-nuclei sorting (FANS) of neurons (Neun+), microglia (neun-, pu1+) and astrocytes (eaat1+, neun-) from 22 month old Cyp27 tg mouse cortex, followed by RNAseq analysis.
        1. The authors claim a role of Trx80 in promoting IRM phenotype in microglia. However, there is not any data showing its relevance in Alzheimer`s (AD progression).

      The role of IRMs in the brain is not yet completely understood. However, it has been reported that DNA damage (Hartlova and colleagues 2015) as well as amyloid plaques containing nucleic acids (Roy et al 2020) induce type-I interferon response in microglia. Dorman and colleagues have recently shown that type-I interferon responses in microglia can rapidly induce phagocytosis of damaged neurons (Dorman et al 2022). An increased phagocytic activity by microglia would also explain the decrease in amyloid-beta (Ab) previously reported in a Drosophila model overexpressing both human Trx80 and Ab42 (Gerenu et al., 2019).

      There are studies showing that type-I interferons and IRMs are present in human brain and actively play a role in aging and Alzheimer’s Disease (AD) (Roy et al 2020)(Olah et al., 2020). One potential model to explain the role of IRM and their relevance for AD is that exposure to damage associated molecular patterns (DAMPs) or secreted Trx80 from stressed neurons promote a type I-interferon response in microglia that subsequently triggers an autocrine loop that enhances phagocytic efficiency. Under physiological conditions, this mechanism might play an important role at dealing with bacterial and viral infections in the brain as well as removing debris and damaged and apoptotic neurons to keep a healthy brain homeostasis. However, these responses can become pathological if sustained high IFN-I levels trigger a exacerbated microglial response that leads to widespread cell death and neuroinflammation.

      Trx80 has been previously reported to be depleted in AD brains (Gil-Bea et al., 2012) and to decrease in APPNL-G-F mice, a mouse model of amyloid pathology as amyloid accumulation worsens. This pathology is characterized by a generalized loss of neurons, which as we show in our study, are the main producers of Trx80. Moreover, an increasing accumulation of amyloid pathology might as well explain the decrease in Trx80 and its effects on microglia. Evidence supporting this possibility come from studies showing that the presence of amyloid-plaques promote the generation of disease-associated microglia, which are transcriptionally different from IRMs (Sala-Frigerio et al., 2019)(Keren-Shaul et al., 2017). This shift in microglia phenotype might be preceded by a shift in the signaling mechanism that governs microglial functions, from a reduction in the production and secretion of neuronal Trx80 to the generation of a different type of signaling molecules that promote disease-associated microglial functions.

      Nevertheless, we agree with the reviewers that the main current limitation of this work is that it ha s been mainly performed in vitro. To better understand the involvement of Trx80 in regulating microglia function in vivo and its relevance in an AD context, we will:

      • Induce Trx80 production in neurons in vivo by performing stereotaxic injections in the prefrontal cortex of adeno-associated virus (AAVs) carrying the Trx80 sequence under the neuronal promoter synapsin, that will allow for Trx80 overexpression exclusively in neurons. We will analyze the effects of neuronal Trx80 overexpression on surrounding microglia by determining the expression of IRM signatures both by immunofluorescence and RT-qPCR.

      • We will also use this system to analyze the effects of Trx80 in APPNL-G-F mice, where we will determine the effects of Trx80 overproduction in neurons on amyloid pathology in the Trx80-transduced hemisphere compared to the opposite hemisphere of the same mouse that will be transduced with control virus. These mice develop plaques at 3 months, we will therefore perform injections in 2 month-old mice and determine the effects of Trx80 at 1, 2 and 4 weeks post-transduction.

      1. They show that Trem2 silencing in vitro prevents Trx80-dependent expression of genes characterizing IRM phenotype in microglia. Notably, they did not show any data about the expression of these genes in 3 and 10 months old APPNL-G-F mice, not in young and 22 months old Cyp27Tg. Enhanced Trx80 levels in 22 months old Cyp27Tg do parallel enhanced expression of IRM markers?

      We did not further look at the interferon response genes in the APPNL-G-F mice because their presence in this mouse model was previously reported at a single cell resolution in microglia (Sala-Frigerio et al., 2019). We will change the text in our manuscript to a more detailed explanation about this previously reported data on IRM gene expression at different ages of the APPNL-G-F mouse.

      Regarding IRM markers in Cyp27Tg mice, we did look at microglia expressing ISG15, an interferon response protein, in 22 months old Cyp27Tg mice and their age matched controls by immunofluorescence. As we report in Figure 4D, we found that 22 months old Cyp27Tg mice had a higher proportion of microglia ISG15 positive. Looking at other markers was limited due to antibody availability and specificity.

      As we mention in point 2, we will further determine the presence of IRMs by performing FANS of neurons, microglia and astrocytes from 22 month old Cyp27Tg mice. We expect that, even in theIRM population is small, by performing RNAseq analysis in a cell-specific manner, we will be able to find an increase in IRM molecular signatures in microglia.

      1. Is there brain inflammation in 22 months old 22 months old Cyp27Tg?

      We appreciate the point raised by the reviewer. 27-hydroxycholesterol (27-OHC) has been previously described to induce inflammation in the periphery (Umetani et al., 2014) as well as in the brain in the form of S100A8-RAGE signaling pathway (Loera-Valencia et al., 2021). However, to confirm this in our experimental model, we will run an V-PLEX Plus Mouse Cytokine 19-Plex Kit of inflammatory markers by ELISA (MSD). This panel will allow us to accurately measure the levels of IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p70, IL-15, IL-17A/F, IL-27p28/IL-30, IL-33, IP-10, KC/GRO, MCP-1, MIP-1α, MIP-2 and TNF-α in 22 months old Cyp27Tg and age-matched control brain homogenates from the prefrontal cortex.

      This point will further be clarified by the FANS-RNAseq experiment described above.

      1. Decreased levels of Trx80 in 10 months old APPNL-G-F mice do parallel decreased levels of IRM markers compared to age matched control mice?

      According to Sala-Frigerio and colleagues that evaluated the gene expression profile of microglia isolated from APPNL-G-F mice at single-cell resolution, IRM population progressively increases with age (Sala-Frigerio et al., 2019). This suggests that several factors other than exposure to Trx80, including DNA-damage accumulation, that has been previously reported to be associated with an IRM-like response in human brains (Mathys et al., 2017) might as well promote and sustain the IRM phenotype. Further research will be therefore necessary to fully understand the finely-tuned mechanisms that regulate microglia states, both with temporal and spatial resolution.

      alterations. The authors need to clarify the functional relevance of their data, so several experiments are necessary.

      We thank the reviewer for her/his comment, and we agree that studying the functional relevance of this system will help to greatly improve the quality of this work.

      As described in point 4., we will determine the functional relevance of Trx80 in vivo and whether it influences amyloid-beta-induced alterations by performing stereotaxic injections of AAVs carrying Trx80 before the first plaques appear in the mouse and at different time-points post transduction(1,2 and 4 weeks) to determine how Trx80-overexpression induced reactive microglia in vivo alters amyloid pathology-derived alterations.

      Reviewer #1:

      1. Minor comments: Figure 3f: in the text is written "neurons", while in the figure legends is written microglia.

      We apologize for this mistake and we have now changed the text accordingly (p.11, l. 258).

      CROSS-CONSULTATION COMMENTS

      Microglia are quite resistant to viral transduction so the 50% knockdown by siRNA further raises the question of their identity in culture

      We would like to apologize for the misunderstanding regarding the Trem2 silencing transduction since it is missing in the methodology part. We did not use viral transduction, we used siRNA mediated transduction (Horizon SMARTpool siRNA) as it has been previously and successfully used in primary microglia cultures (Ruan et al., 2022). We have now added this information to the methods part of the manuscript (p.6, l.137-142).

      The subject of study is potentially very interesting because of investigating the role of Tx80 in microgliaand showing that Trx80 acts through Trem2, which is implicated in AD. Microglia and oxidative stressare considered playing a key role in AD progression. However, data are very preliminary and thismanuscript does not present data showing the functional relevance of Trx80 in AD.

      • We agree and thank the reviewer for her/his comments. We believe that the newly planned experiments describe above will help to address the function of Trx80 in vivo and its relevance in an AD context (by determining its effect in the APPNL-G-F mouse model of amyloid pathology) will help to greatly improve this study.

      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      In this manuscript, Goikolea and colleagues aim to describe how neuronal thioredoxin-80 (Trx80)influences microglial reactivity. Because Trx80 levels track with age and amyloid pathology, understanding this signaling axis provides insight into the pathogenesis of AD. The authors show that pyramidal neuron expression of Trx80, rather than its precursor, is upregulated in aging and the APP mouse model of AD. They show that Trx80 induces interferon response gene induction in microglia cultures and that knockdown of Trem2 prevents this. This work has the potential to be very impactful.

      Minor points:

      One wonders if the discrepancy between gene, precursors, and Trx80 is due to lack of degradationof Trx80 with age. If anything is known about this, the authors might comment on its regulation inthe discussion.

      We apologize for the misunderstanding. We will improve our explanation on Trx80 regulation in thediscussion.

      Methods for siRNA knockdown appear to be missing.

      We apologize for this mistake. We have now included it in the text p.6, l.137-142).

      Reviewer #2 (Significance (Required)):

      This work has the potential to advance our understanding of how a known anti-oxidant Trx80 contributes to microglial states. Given the major limitation of being an in vitro study, the extrapolation of these findings into AD pathogenesis are not possible.

      We agree and thank the reviewer for her/his comments. We believe that the newly planned experiments describe above will help to address the function of Trx80 in vivo and its relevance in an AD context (by determining its effect in the APPNL-G-F mouse model of amyloid pathology)will help to greatly improve this study in this regard.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      In this manuscript, Goikolea and colleagues aim to describe how neuronal thioredoxin-80 (Trx80) influences microglial reactivity. Because Trx80 levels track with age and amyloid pathology, understanding this signaling axis provides insight into the pathogenesis of AD. The authors show that pyramidal neuron expression of Trx80, rather than its precursor, is upregulated in aging and the APP mouse model of AD. They show that Trx80 induces interferon response gene induction in microglia cultures and that knockdown of Trem2 prevents this. This work has the potential to be very impactful.

      The major limitation of this work is that it is conducted strictly in vitro or ex vivo - without return to the invivo state with cell-specific knockout of Trx80 and subsequent analyses of microglial phenotypes. This is of particular importance given that microglia are exquisitely sensitive to manipulation and there is increasing evidence that in vitro states (especially not those derived from mixed glial cultures) are not representative of true in vivo production. Microglia are quite resistant to viral transduction so the 50% knockdown by siRNA further raises the question of their identity in culture. If the authors cannot manipulate Trx80 in vivo in a cell specific way, they might consider using more highly purified more invivo like cultures such as those championed by Bohlen et al, Neuron, 2018.

      Minor points:

      One wonders if the discrepancy between gene, precursors, and Trx80 is due to lack of degradation of Trx80 with age. If anything is known about this, the authors might comment on its regulation in the discussion Methods for siRNA knockdown appear to be missing.

      Significance

      This work has the potential to advance our understanding of how a known anti-oxidant Trx80 contributes to microglial states.

      Given the major limitation of being an in vitro study, the extrapolation of these findings into AD pathogenesis are not possible.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      Summary:

      The manuscript entitled "Neuron-derived Thioredoxin-80: a novel regulator of type-I interferon response in microglia" demonstrates that neurons are the major source of Trx80, derived from the cleavage of Trx, into the brain. Trx80 production increases during normal aging. On the contrary, APPNL-G-F mice shows an opposite trend compared to wild type mice: Trx80 levels are significantly higher in 3 months old mice compared to age matched littermate, while significantly decreased in 10 months old APPNL-G-F mice compared to controls. The authors revealed that oxidative stress induced Trx80 production in neurons and this effect is Nrf2-dependent. Indeed, rotenone - an oxidative stress inducer- enhanced both Nrf2 expression and Trx80 levels. In agreement, 27-hydroxycholesterol (27-OHC), which promotes oxidative stress, promoted Trx80 production and Trx2 expression in neurons. In addition, 22 months old 27-OHC over-producing (Cyp27Tg) mice showed enhanced levels of Trx80. By gene expression analysis, the authors reported that Trx80 treated microglia showed a IRM gene expression profile, because of an enhanced expression of genes considered as IRN markers. They demonstrated in vitro that Trx80 promotes the IRN phenotype in microglia through Trem2. Knock down of Trem2 in microglia prevented Trx80-mediated enhanced expression of IRM markers.

      Major Comments:

      This work is potentially interesting, but the results are very preliminary. There is not a clear demonstration of the signaling pathways triggered by oxidative stress and leading to Trx80 production in neurons. The authors claim the role of Nrf2, but did not silence Nrf2, nor demonstrated the cascade downstream Nrf2 that is responsible for Trx80 production. In addition, Cyp27Tg mice show higher Trx80 levels only at a very old age and it is not at all shown that oxidative stress is responsible for Trx80 enhanced production in this mice model.

      The authors claim a role of Trx80 in promoting IRM phenotype in microglia. However, there is not any data showing its relevance in Alzheimer`s (AD progression). They show that Trem2 silencing in vitro prevents Trx80-dependent expression of genes characterizing IRM phenotype in microglia. Notably, they did not show any data about the expression of these genes in 3 and 10 months old APPNL-G-F mice, not in young and 22 months old Cyp27Tg. Enhanced Trx80 levels in 22 months old Cyp27Tg do parallel enhanced expression of IRM markers? There is brain inflammation in 22 months old 22 months old Cyp27Tg? Decreased levels of Trx80 in 10 months old APPNL-G-F mice do parallel decreased levels of IRM markers compared to age matched control mice? Which is the significance of this pathway in AD?

      It may be interesting to analyze whether microglia pre-treatment with Trx80 alters Abeta-induced alterations. The authors need to clarify the functional relevance of their data, so several experiments are necessary. Methods and data are sufficiently described.

      Minor comments:

      Figure 3f: in the text is written "neurons", while in the figure legends is written microglia

      Referees cross-commenting

      Comments to reviewer 2 opinion: "The major limitation of this work is that it is conducted strictly in vitro or ex vivo - without return to the invivo state with cell-specific knockout of Trx80 and subsequent analyses of microglial phenotypes. This is of particular importance given that microglia are exquisitely sensitive to manipulation and there is increasing evidence that in vitro states (especially not those derived from mixed glial cultures) are not representative of true in vivo production. Microglia are quite resistant to viral transduction so the 50% knockdown by siRNA further raises the question of their identity in culture. If the authors cannot manipulate Trx80 in vivo in a cell specific way, they might consider using more highly purified more invivo like cultures such as those championed by Bohlen et al, Neuron, 2018." I agree that in vivo experiments are necessary. Moreover, also the in vitro studies presented are preliminary.

      Significance

      The subject of study is potentially very interesting because of investigating the role of Tx80 in microglia and showing that Trx80 acts through Trem2, which is implicated in AD. Microglia and oxidative stress are considered playing a key role in AD progression. However, data are very preliminary and this manuscript does not present data showing the functional relevance of Trx80 in AD. The audience that maybe interested in the subject proposed by the authors are scientist working on: AD, aging, oxidative stress, microglia activation.

      My fields of expertise: Alzheimer, oxidative stress, TXNIP function, inflammation, neurodegeneration, microglia, gene expression

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      The authors do not wish to provide a response at this time.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #4

      Evidence, reproducibility and clarity

      In the manuscript "ATP induced conformational change of axonemal outer dynein arms studied by cryo-electron tomography", Noemi Zimmermann et al. built pseudo atomic models of outer dynein arms (ODA) from the native axonemes with and without ATP treatment using a combination of cryo-electron tomography (cryo-ET), sub-tomogram averaging and atomic model fitting analysis. The authors clearly distinguished several important conformations of ODA using their high-quality cryo-ET maps. The authors showed that in situ ODA conformation in post-power stroke state is different from in vitro ODA structures, either lacking B-tubule binding or A-tubule binding. In my opinion, this is a very important observation by taking the advantage of cryo-ET analysis on intact axonemes. Furthermore, by freezing the activated axoneme immediately after ATP treatment, the authors obtained the active pre-power stroke and an intriguing intermediate conformation of ODA. By generating pseudo atomic models, the authors were able to compare the structural changes in dynein heads and stalks among different states and highlighted geometrical constraints from neighboring MTDs on ODA. Overall, the findings by Noemi et al have provided really exciting insights into ODA conformational changes during the power stoke. I therefore highly recommend publication of the manuscript. However, before the official publication, I do have some comments and believe the authors can further improve their manuscript to make it more exciting to the field.

      1. The authors only showed the maps from sub-tomogram averages (Supply Fig 1). I suggest the authors also show a representative reconstruction of the whole tomogram as a supplementary figure so that we have a better overview of the reconstruction.
      2. Since this is a typical piece of structural work, I highly suggest the authors summarize their cryo-ET data collection and processing parameters as a supplementary table, such as standard microscopy parameters, image pixel sizes, number of tomograms, number of particles etc.
      3. On page 5 and Supplementary Figure 2H, I, the authors fitted Lis1 model to the additional density at the interface between AAA2 and AAA3. This is really intriguing. However, according the currently published Lis1-dynein structures (PMID: 28886386, PMID: 34994688), it seems that Lis1 interacts with dynein on AAA4 and AAA5. Can the authors discuss anything about the evolutionary conservation of Lis1 binding? In addition, the authors did not fit LC5 model into the density map. I am a bit worried that there might be some bias on Lis1. With the fast development of protein prediction tools like Alphafold and Rosetta fold, the authors would be able to have a nice prediction of the LC5 structure to fit the additional density. I therefore suggest the authors try to do so if it is technically feasible, and then discuss a bit more on this point.
      4. On Page 6, the authors mentioned that "neither of the two structures (MTBS1, MTBS2) represented our conformation of ODA". This is an interesting finding since in the reconstituted ODA array on MTD by Rao et al., 2021 paper, they observed both MTBS1 (MTBD: 0 nm; MTBD:0nm; MTBD:8nm) and MTBS2 (MTBD: 0 nm; MTBD:8nm; MTBD:8 nm) conformations (Here, 0nm and 8nm represent the relative longitudinal positions along the tubulin lattice among the three MTBDs). According to the post-ODA structure from this manuscript, the authors found all three heavy chains are in the post-2 states, or equivalently with MTBDs at the 8-nm position (MTBD: 8nm; MTBD:8nm; MTBD:8nm, Fig3G). The authors also mentioned that the conformations of minimum energy of ODA are different in vivo and in vitro in the discussion. On the other hand, many structures previously determined by X-ray and EM in vitro show that Post-1 were overwhelmingly preferred before Rao et al reported the Post-2 state. This raises a very interesting question, how many MTBS states can ODA actually adopt in vivo? In theory, the three MTBDs can be arranged in at least a certain subset of the eight states (000,001,010,100,011,101,110,111) if the distance between any two MTBDs is restricted to 8nm, and the movement of each MTBD is restricted along one direction. There might be more states if the movement is more than one step. Therefore, from the results of both this manuscript and Rao et al., 2021 paper, probably not all states could have been observed. I wonder if the authors can perform more 3D classification on their STA particles in the post-PS state to demonstrate and see if there is any chance to see more states in vivo. I was a bit surprised because I felt there might be more states in vivo than in vitro reconstitution. The idea that the two neighboring MTDs can restrict the ODA conformation is great. I suggest the authors discuss more about the possible effects from two neighboring instead of just a general concept of energy minimization (probably it is impossible to estimate the total energy of such a complex system under physiological conditions using any kind of currently available techniques).
      5. In Figure 4, the authors observe structural changes of ODA among different states. The figures clearly show the differences among post-PS, intermediate state, and pre-PS state. For the pre-PS and intermediate state, I wonder if the authors can map the two conformations back onto the raw tomograms and show how they look like in a relatively large region with more repeating units.
      6. In Figure 4, I really appreciate the authors pointing out the distortion (changes in distances and the rotation angles) between adjacent MTDs. To my knowledge, the distortion of neighboring MTDs during ODA power stroke cycle has not been well analyzed in many previous publications. To gain more insights on this part, I wonder if the authors can perform more quantitative analysis on all adjacent MTDs with and without ATP from their current data sets. There are some nice publications on filament distortion analysis using single particle approaches, including one from the Sindelar lab (PMID: 32636254, Fig 4 and 6). More specifically, since the authors already have the position and Euler angle information of each particle from the subtomogram averaging, it is possible to extract the distortion information from two adjacent MTDs. After extracting distortion information from all MTD pairs and plotting the data points in different ways, the authors may be able to correlate the ODA conformation, MTD bending and see whether they could find some intriguing patterns. The authors do not have to incorporate all their results from this analysis into the current manuscript since there are already many interesting things, but briefly showing some curvature distribution would be highly appreciated, and the authors can still publish other interesting results in their future publications.
      7. It seems the authors have not deposited their maps and PDBs (as they are XXXX's in the current manuscript). It would be nice to if they can do so at their earliest convenience.
      8. On page 5, the authors found an additional density next to the  dynein which could be Lis1 or LC5 (see also minor comment #1). Again, this is an advantage using cryo-ET. This observation is also missing from ODA SPA papers, and I appreciate the authors for the careful examination. Since there are several 96-nm MTD maps from previously studies from Chlamydomonas and Tetrahymena, I wonder if this additional density is also present from previous cryo-ET maps.
      9. On page 5, the sentence "one unit of the dimeric Homo sapiens Lis1 (PDB-5VLJ (Htet et al., 2020, p. 1)) and fitting it into our density allowed us to assess its likeability." The Lis1 model in PDB-5VLJ is from Saccharomyces cerevisiae, not from Home sapiens. In addition, the reference paper doesn't match the PDB-5VLJ. The authors should cite the correct paper.
      10. On page 6 Figure 2 legend D, B HC should be  HC.
      11. On page 8 Figure 3 legend "A and B) Rigid body fit of the whole MTBS1 map (Walton et al., 2021).". The citation here should be Rao et al., 2021.
      12. In Figure 5, the authors generated models for the pre-PS conformation of ODA. From the cryo-ET density map, the authors suggested that -MTBD was in a bent conformation, which was similar to the conformation in shulin-ODA. This is a novel observation. Since the authors have atomic models, I suggest the authors directly use the PDB models for better visualization of structural changes among post-PS ODA, intermediate ODA, and pre-PS ODA. A supplementary figure or movie will be very nice.
      13. On page 16 "EM grids" session, I suggest the authors provide slightly more details on their sample preparation, such as the concentration of the axoneme, blotting time, temperature, humidity etc.

      Significance

      Significance: This is a very nice manuscript for better understanding of the motile cilia system. It is a significant progress in the field with lots of interesting findings.

      Audience: People in the field of dynein, motile cilia, cytoskeleton and in cryo-ET technique as well.

      My expertise: I am very confident in reviewing this paper, both biologically and technically, and I have recently published in this field as well.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      Summary:

      The study attempts to reconcile cryo-EM SPA structures of ODAs with in situ tomographic reconstructions.

      Several key discrepancies between SPA structures and the native in situ structures (here) are highlighted in the study with a particular focus on the positions of various ODA motor head components (linker, tails etc.) during the powerstroke cycle.

      The study also highlights largely concordant inter and intra-ODA connections between previous SPA structures and the tomographic reconstructions.

      Major comments:

      Overall, the key conclusions are convincing. No additional experiments are suggested. The manuscript is acceptable provided minor comments below are addressed.

      Minor comments:

      The text could be improved throughout for improved clarity. Overall, the figures are good, but some panels are over-annotated which is confusing. Simplification or cartoon illustrations could add clarity to the figures.

      CROSS-CONSULTATION COMMENTS

      The paper still represents a significant and sufficient advance. Correction of factual errors flagged up by other reviewers (use of correct references and citations, correct species for Lis1 models used etc.) is required and essential prior to acceptance. Addition of more details in the sample preparation methods section would also be useful. Depositing PDBs and maps is recommended.

      Agree on the overall point of improving accessibility and readability of the text. Figures can be much improved to highlight the biological insights for the reader.

      The point of contention between extra density corresponding to either Lis1 or LC5 is valid. Tempering the assertion and removing bias towards Lis1 in the text would resolve this issue. The authors are putting forth a speculative model which is valid; this model can be tested in future work.

      Several minor comments highlighted by other reviewers are fair and should be addressed as best as possible.

      Several major comments highlighted by other reviewers (specifically: use of structure prediction and modeling, filament distortion analysis etc.) are well beyond the scope of the present work and do not advance the specific and main conclusions of the current study.

      Significance

      The study presents structures of ODAs during their powerstroke cycles in situ in their native context and integrates previous structural models of ODAs to provide novel insights.

      The identification of a Lis1 or LC5 like density adjacent to the alpha-HC and observation of a curved position of the beta-HC stalk in the native state adds further novelty to the study.

      The study will be of interest to researchers like myself working on cilia motility and dynein motors.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      • The authors report cryo-EM tomography of the axoneme of motile cilia in the presence and absence of ATP, providing new insight into the mechanism of action of the motors. They use crystal structures and information from single particle cryo-EM to fit these fragments into their new density obtained in situ, and show that distortions to these smaller structures are required for them to be accommodated in the complex and crowded environment of the axoneme. The movies provided show the relevant fits in 3D, which is important because the complexity of the structures makes 2D visualisations limited. Are the authors sufficiently confident in their atomistic models that they would be useful for other researchers, and if so are they planning to release them (e.g. as pdb files) with the paper, or on request?

      • There are potentially a few editorial additions and changes that the authors might consider making to improve the readability of the paper for non-specialists in the axoneme. For example, could they insert a sentence explaining what Shulin is and its biological significance? There are numerous abbreviations and acronyms throughout the manuscript - would it be helpful to maybe write some of those out in full where appropriate? In the very helpful Supplementary table containing the pdb IDs used to fit into the current structure, would it be useful to have a small picture of each system as one of the columns in this table? Would it also potentially be helpful to include a figure summarising the different types of dynein observed in this and other relevant studies - e.g the pre and post-powerstroke states, Shulin bound etc? This would help the reader to understand the magnitudes of the conformational changes between these various states that are under discussion. Could a schematic diagram representing the "winch" and "rotation" models be included potentially? In the Discussion section, I was not able to understand whether the winch or rotation models are most supported by the data in this paper, or whether a mixture of the two might be needed to understand axoneme mechanics, so further clarification of this would be helpful.

      • Please note that all of these comments are suggestions to improve accessibility and readability, and are not essential additions for the paper to be publishable.

      CROSS-CONSULTATION COMMENTS

      I was very interested to read the detailed and informative comments from the other referees. While I agree with referee 1 point 4 that the use of alpha-fold to predict how atomistic structures from different organisms may differ, and subsequent flexible fitting would be desirable, this in my opinion would be an enormous amount of work, and would be best reserved for subsequent publications. Sharing of the pdb files of the fitted structures obtained so far would open this mammoth task up to the rest of the community.

      Given the complexity of the axoneme, and the huge amount of expertise needed to obtain and process these tomograms, I did wonder if this community would consider forming a collaborative consortium where researchers worked together to construct a common model.

      Significance

      • The paper reports more complete and detailed structural information on the axoneme than (to my knowledge) has been obtained before. The fitting of atomistic level structures into the density to create a pseudo-atomic model is highly instructive.

      • To me, it was not in the least bit surprising that distortions from the structures obtained in isolation using single particle analysis are required for an optimal fit. In fact, theoretical work reported by Richardson et al, QRB 2020 showed for inner dynein arms that the crowded environment provided solely by the microtubule tracks within the axoneme modified the conformations of the dynein stalk that were accessible compared to a simple isolated dynein motor. While this study considers outer dynein arms, the conceptual physical rationale is equivalent to the findings here. In my opinion, the finding reported in this paper that considering fragments of biological ultrastructures is not necessarily equivalent to the whole functioning entity is both important and profound, and has implications beyond motile cilia, particularly as cryo-electron tomography enables us to visualise ever larger and more complex functional biological assemblies.

      • Please note that my area of expertise does not enable me to comment on the experimental procedures used to obtain the tomograms, as I am a computer modeller with an interest in dynein.

    5. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      Summary

      Zimmermann et al. provide a comparison between recent atomic models of the ODA determined by single particle cryo-EM and their conformation within intact axonemes by cryo-ET subtomogram averaging. They observed slight changes in the position of the motors for the structures of Kubo et al. and Walton et al., but the structure of Rao et al. required more changes, indicating that within the axoneme, the conformation of the ODA is influenced by the MTD on which it is docked, and the neighboring MTD to which its motors bind. They then use the information from their newly fit models to interpret cryo-ET maps of axonemes in the presence of ATP, which activates the ODA and other axonemal dyneins. They observe two states of the ODA, and describe how the position of the motor, linker, MTBD and LC tower change during the powerstroke cycle. A revised model of the ODA and the ability to describe conformational changes at the subunit level provides an advance on previous work and will be of interest to the dynein and cilia fields. However, the comments below must be addressed prior to publication, and additional work is needed to make the paper accessible.

      Major comments

      1. Greater clarity is needed in the introduction to explain the differences between the recent atomic models of the ODA. This is essential to understanding the paper, including Fig. 3. Arguably, the top half of Fig. S2 provides a stronger case for the study than any of the current main figures.

      2. In the manuscript, potential differences between Chlamydomonas and Tetrahymena ODAs are not considered but need to be explored. Comparison of Tetrahymena models within Chlamydomonas maps could result in misinterpretations.

      3. Systematic quantification of the fit-to-map should be provided for the models before and after refitting (together with evidence - see the point below - that the model has not been inappropriately distorted to fit the map). This information could be inserted into an expanded Supplementary Table.

      4. Because the revised pseudo-atomic model of the ODA is a chimera of PDBs from different organisms, it does not accurately represent the Chlamydomonas ODA. The modeling method also has the potential to introduce clashes between rigid-body fitted chains. Validation of the model is necessary, and alternative approaches to generate a more accurate model (e.g. AlphaFold and molecular dynamics flexible fitting) should be considered.

      5. Additional evidence needs to be provided to demonstrate that the intermediate state observed in Figure 4 is robustly detected and does not simply represent the data that doesn't fall into the "good" classes. In Fig. S1, the map looks very noisy and requires denoising. Are there other changes observed in the IDAs that would support the existence of an intermediate state?

      6. The speculation that the additional density bound to a-HC is Lis1 is not well-supported. Lis1 binds AAA4/5 (PDB: 5VH9), not AAA2/3. The fit of the Lis1 homolog into the cryo-ET density does not appear consistent with Lis1 binding the motor. The authors should consider other possibilities that could explain the additional density.

      Minor comments

      1. The results section "Post-PS structure and Fitting of the atomic models" is very dense. It should be split into subsections to help guide the reader through specific models or regions of the ODA.

      2. ODA numbering should be made consistent with previous papers (i.e. ODA1-4 as in Bui et al., 2012)

      3. The ODA-shulin model (PDB: 6ZYW) is inaccurately described as the state transported during IFT, but experimental confirmation of this hypothesis is lacking.

      4. The term TTH for tail-to-head contacts is too similar to T/TH for the tether/tetherhead complex and should be changed. An abbreviation may not be necessary.

      5. Please check to make sure that all figures and figure legends clearly specify which map/model/motor is being shown. This will make the figures easier to follow.

      6. The structures in Fig. 3 are from Rao et al., not Walton et al.

      7. Fig 5M-O is very difficult to interpret. Could the authors consider coloring by region, for one of the maps, or at least put the maps in a similar orientation to the ODA cores as in Fig 2?

      8. The final processing step in panel Fig S1B is confusing. Additional information is needed to explain the supervised classification step and how the final particle set was derived.

      9. Atomic resolution should not be used to describe structures determined to 4.3 Å resolution (e.g. EMD-11579).

      10. Supervised classification is not a method of validation

      11. Please check for grammatical and spelling errors throughout the manuscript.

      Significance

      While previous literature has interpreted ODA conformation in broad regions, this study goes farther by using recent atomic models to identify specific subunits that change conformations and interactions during the powerstroke. From my perspective as a structural biologist in the cilia field, I think this paper provides a conceptual advance to the study and interpretation of axonemes.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Reviewer #1

      • The authors claim that bin2 has a "confused" phenotype, which they define as high variability in shoot versus root lengths along with a low degree of response to water limitation. bin2-1 is a semi-dominant gain-of-function mutant, which can only be propagated as a heterozygote (homozygous individuals are viable, but don't produce seeds). There is no mention in the manuscript about genotyping or selection of homozygous bin2-1 individuals for the phenotyping assays. Could the high variability observed in fact be caused by the authors looking at a segregating population of bin2-1? * By propagating plants under optimal growth conditions over > 4 months at the TUMmesa ecotron, we were in fact able to obtain over 24 individual homozygous bin2-1 plants. We distinguish homo- and heterozygous seed by (i) adult phenotype (ii) segregation in the next generation (iii) root:shoot ratios from dark-grown seedlings on plate and (iv) sequencing of the TREE domain (as shown in Fig. 2e). Therefore, we are sure to have used only homozygous mutants in our analysis. This is now specified in the supplementary method S5.

      *The authors state that bin2 mutants had considerably more severe phenotypes than other BR biosynthesis, perception, or transcription factor mutants. This is like comparing apples to oranges, as the set of mutants they've examined consists of gain-of-function and partial loss-of-function alleles. Null alleles for BR biosynthesis (e.g. cpd, dwf4), perception (bri1brl1brl3 triple mutants) and transcription factors (bzr1bes1beh1-4 sextuple mutants) are described in the literature and would need to be tested before arriving at such a conclusion. *

      This is an important point and the nature of all alleles was and still is clearly outlined in Table S1 “Lines used in this study”. We have obtained and propagated bri1brl1brl3 triple mutant seed from Christian Hardtke (Kang et al., 2017), as well as null cpd alleles from NASC and these now complement or replace det2-1 and bri1-6 in our analysis. We compare null alleles, semi-dominant or dominant or higher order null alleles with each other. To make these comparisons clear we have highlighted these different allele types in the manuscript as depicted in the table, with null in regular font, semi-dominant or dominant in bold and higher order mutants underlined. This is described in Table S1 and in the figure legends, where applicable. We have not been able to obtain and propagate enough seed in the period of review to extend the analysis to sextuple transcription factor mutants. Therefore, we have removed the comparison between brassinosteroid mutants and now refer to the importance and role of the brassinosteroid pathway in general and, more specifically, to BR signaling rather than to BIN2.

      *For most of the phenotyping experiments a "RQ ratio" is presented. This is the ratio adjustment of the mutant/ratio adjustment of WT. While this derived quantity is useful for interpretation, we're missing plots of the raw data, and particularly those that show the underlying distribution of data points. *

      We understand that the RQratio (Fig. 4e) value is a step removed from the raw data. Please note that we also show the RQshoot (Fig. S8a) and the RQroot (Fig. S8b) in the supplement. We now depict violin plots in Fig. 4a-c and Fig. S7 as a best representation of the raw data, as follows

      Results page 10: “The violin plots compare organ length distributions in mutants versus the corresponding wild-type ecotype, which depicts dwarfism in some brassinosteroid mutants. It is also apparent that wild-type (Col-0) root length varies under water-deficit in the dark (Fig. S7). Although we have optimized protocols for PEG plates to the best of our ability, there is still a lot-to-lot and plate-to-plate variation. This emphasizes the need for normalizing each mutant line to its corresponding wild-type ecotype on the same (PEG) plate in the same experiment. To this end, the response to water stress in the dark was represented as a normalized response quotient (RQ), which is an indication of how much the mutant deviates from the corresponding wild type (Fig. 4e; see methods).”

      The RQhypocotyl, RQroot and RQratio are a necessary consequence of the variance in the data, and we consider them to be the most relevant metrics. Representative experiments were chosen from at least three replicates on the bases of RQ and P values (as specified in the legends of Fig. 3 and Fig. S10).

      Root growth involves both cell division in meristematic cells at the tip of the root and subsequent elongation as cells exit the meristem and begin to differentiate. The authors claim a nine-fold difference in CycB1,1:GUS in the root meristem in dark vs darkW, however their images show similar CycB1,1:GUS expression patterns. Furthermore, the meristems of darkW are actually smaller than dark, which would be unexpected if cell division *was increased. *

      We have reviewed the raw data again, applying blinding to avoid bias, and chosen a more representative image for the dark; the mitotic indexes are represented in a violin plot (Fig. 6c) to better show the distribution of datapoints. The conclusions are unchanged. We reimaged the wild-type under light, dark and darkW, specifically focusing on meristem properties and on final cell length. The results are presented in Fig. 6, Fig. S14, Fig. S15 and described as follows:

      Results page 14:

      “It is generally accepted that root growth correlates with the size of the root apical meristem (RAM; Beemster and Baskin 1998). Meristem size was assessed by computing the number of isodiametric and transition cells (González-García et al., 2011; Verbelen et al., 2006; Method S8). In addition, we applied a Gaussian mixed model of cell length to distinguish between short meristematic cells and longer cells in the elongation zone (Fig. S14; Fridman et al., 2021). Meristem size was shortest under water deficit in the dark (Fig. 6a; Fig. S15a,b) and, surprisingly, did not correlate well with final organ length (Fig. 1c; Fig. 6g). “

      Discussion page 16:

      “it appears counterintuitive that meristem size and organ length do not correlate in our conflict-of-interest scenario. Questions arise as to why the meristem is smaller under water deficit in the dark even though the mitotic index is higher than in the dark, and how growth is promoted under our additive stress scenarios. An important difference between our conditions and those described by others is that we germinated seed under limiting conditions in the dark in the absence of a carbon source… When water stress was applied in the dark, the mitotic index increased, but the newly produced meristematic cells immediately elongated, thereby exiting the meristem. As a consequence, meristem size remained small despite the increased number of mitotic cells. It appears that what our study shows is a novel paradigm for root growth under limiting conditions, which depends not only on shoot-versus-root trade-offs in the allocation of limited resources, but also on an ability to deploy different strategies for growth in response to abiotic stress cues.”

      We are not aware of any other study that has addressed root growth under water deficit in the dark and in the absence of a carbon source.

      • In addition, the authors claim that the longer root length in dark water stress was at least in part due to increased elongation (Fig. 7c). Elongation was only assessed by looking at the first elongating cell (~10-14um) and the differences found are on the order of magnitude of ~2um, but final cell size in Arabidopsis roots often reaches several hundred um. Therefore, a comparison of final cell size would be more appropriate. *

      Results page 14:

      “mature cell length… was highest in the dark, the condition with the shortest roots (Fig. 6b). Thus, neither meristem size nor mature cell length account for the fold-change in final organ length (Fig. 6g).”

      *Finally, the authors phenotype plt1/2 double mutants and show that they fail to elongate in response to water limitation. Their interpretation is that this supports a centralized control model for the root apical meristem. PLT1/2 are important determinants of meristem function and are necessary to maintain stem cell identity. Given the strong phenotype of plt1/2 double mutants it is not surprising that they are unable to elongate in response to this stimulus. This does not necessarily indicate that only the RAM controls root growth, but rather that functional stem cells are required for root growth, which also involves subsequent steps such as cell elongation. *

      This is an important point and we thank the reviewer for pointing it out. We now write:

      Results page 15:

      “Taken together, the cell length and anisotropy curves (Fig. 6) and genetic analyses (Fig. 6; Fig. S15f; Fig. S16) suggest that root length under our different environmental conditions is regulated by (i) the mitotic index, (ii) the timing of cell elongation or of exit from the meristem and (iii) cell geometry. We also conclude that these are differentially modulated to account for increased root length under different environmental conditions (Fig. 6c-e).”

      We also modulate the conclusion and model (Fig 7c) to state that RAM function accounts “in part” for root growth. However, it is to be noted that mature cell length in our study did not correlate with root length (Fig. 6b, 6g). Our conclusion is now reached not solely based on plt1plt2 but also on a careful and quantitative cellular analysis of the root apical meristem in the wild-type and in bin2-3bil1bil3 mutants. The major contribution of our study, however, is the difference between the different conditions, and the ability to respond to stimulus.

      *Reviewer #1 (Significance (Required)): *

      * While the study system and some of the findings in this manuscript are interesting, there are major flaws in the authors' primary claims. *

      Contested claims have been (i) deleted where unessential to the storyline or (ii) substantiated by independent methods.

      *Reviewer # 2 *

      1. I recommend to exchange shoot for hypocotyl when hypocotyls were examined to avoid to confuse the readers. We thank the reviewer for pointing this out and have exchanged shoot for hypocotyl throughout.

      2. The authors have chosen SnRK2 (and should also indicate it in all Figures as SnRK2, to not confuse the readers with SnRK1), and implement ABA signaling in parallel to BR action, but this must be proven in higher order mutants of both pathways, at the moment the results are to preliminary to allow conclusions. *

      We concur with the reviewer that higher order mutants between the BR and ABA pathways would be required to make this claim. We also concur that this would require numerous generations and therefore that it does not lie within the scope of this manuscript.

      • When the authors are interested in shoot dominance/photosynthetic activity, why didn't they look on snrk1 mutants, which are known to regulate those processes. *

      The issue of energy signaling is a key one, and we mention this in the final “perspective” paragraph of the discussion (p. 18) as follows:

      “As a limited budget is an essential component of our screen conditions, the role of energy sensing and signaling (Baena-González and Hanson, 2017) in growth tradeoffs will need to be elucidated.”

      • In Fig6d the authors propose a sketch of the mechanism, but the data of this study don't show direct interaction of the pathways and as indicated in the figure text parts of the information are taken from other papers, I recommend to remove this sketch or shift it to the supplements. * We concur with the reviewer and have deleted former panels 6d, 6e and 6f as well as reference to the mutants these included. We now focus on the BR pathway, as discussed below.

      *To discriminate the role of downstream BR signaling events from other roles of BIN2, I suggest to complement the data with pharmacological experiments (eBL or bikini where appropriate), and if possible to implement phenotyping of OE lines. *

      In response to this comment, we attempted bikinin experiments. Unfortunately, it is difficult to germinate seed on bikinin and seedlings grow poorly on this shaggy-like kinase inhibitor. As the assay relies on seed germination rather than on seedling transfer, applying bikinin was suboptimal. Because of the requirement for germination in the dark, and in lieu of eBL or PPZ or a combination thereof, we now include a null allele of a BR biosynthesis mutant, cpd, in Fig. 3b, to replace the leaky det2-1 mutant we had previously used.

      How many independent ko lines were tested, can the authors exclude that the BR independent phenotype indeed corresponds to BIN2 activity and not to a off target effect.

      Four independent bin2 mutants (B1, bin2-1, ucu1, dwarf12) were analyzed in our study. In total, 83000 M2 seed were used in our forward genetic screen; of these and for BIN2 the B1 line is the one we rescreened, mapped and characterized. We complemented B1 with bin2-1 and ucu1 alleles and compared it to bin2-1, ucu1 and dwarf12 alleles at the BIN2 locus; these three published mutant lines exhibited the same behavior as B1, including semi-dominance and phenotypes under single versus multiple stress conditions (Fig. 2c cf Fig. 3d; Fig. S6). Fine mapping (Fig. 2d), segregation analysis (Table S2), allele sequencing (Fig. 2e), backcrossing, outcrossing and complementation analysis provide independent lines of evidence that B1 is a BIN2 allele. Please note that the conclusions regarding BIN2 in this manuscript are based not on B1 but on the published bin2-1 and bin2-3bil1bil2 lines.

      We write results page 10:

      “We complemented B1 with bin2-1 and ucu1 alleles and compared it to bin2-1, ucu1 and dwarf12 (Perez-Perez et al., 2002; Choe et al., 2002) alleles at the BIN2 locus; these three published mutant lines exhibited the same behavior as B1, including semi-dominance and partial etiolation.”

      *I further recommend to exchange the pictures in Fig7a showing BRI1-GFP to pictures showing fewer cells, but with higher resolution. *

      We now show higher resolution images in Fig. 7b.

      • Regarding the implementation of photoreceptor mutants and the claim that photoreceptors are more abundant in shoot, I want to point out that the situation is more complex, as the root also reacts differently to light of different quality and quantity, with different responses in the meristem, by inhibiting cell proliferation, or in the elongation zone by triggering negative phototropism. this should be corrected in the text. *

      We are aware that light, especially when Arabidopsis is grown on media, is perceived by photoreceptors within the root system. Phototropic growth would not have affected measurements of root length as measurements were performed in ImageJ with the freehand tool. This is described in the methods on page 6, and in the supplementary method S5. For the model, we have now modulated our discussion as follows:

      Discussion p. 16-17:

      “ we postulate that a hypocotyl to root (basipetal) signal coordinates trade-offs in organ growth in response to light (Fig. 7c green arrow). However, and even though photoreceptors are considerably more abundant in the hypocotyl than in the root (van Gelderen et al., 2018), it needs to be borne in mind that photoreceptors in the root could be playing a role in root responses to light or to darkness (Mo et al., 2015).”

      *The data and methods are presented in a clear and sufficient way, as well as the statistical analysis. *

      We thank the reviewer for this positive assessment.

      *Altogether, the hypothesis and work amount are worth to be recognized, but the manuscript also resembles partially more a review and I would suggest to shorten those parts in the manuscript, reduce the amount of described lines and focus strictly on the BR pathway, in response to the environmental changes. Before implementing photoreceptors and ABA/SnRK2 pathway into the story to either test higher order mutants between the signaling pathways of interest or come up with a pharmacological screen connecting the data. Therefore I suggest to reduce the amount of mutants investigated and focus on BIN2 action, implementing also a pharmacological screen to track a fluorescent tagged BIN2 upon the mentioned treatments. And if possible to add proteomics and phosphoproteomics to understand better what changes are undergoing in the bin2 mutant vs WT upon stress. *

      We thank the reviewer for suggesting that we “focus strictly on the BR pathway, in response to the environmental changes”, as this has truly supported us in tightening the story line.

      We have removed the sections of the manuscript that resembled a review and focus entirely on the BR pathway, with additional or tighter mutants. We also look at BIN2 more closely and at a cellular level, with SEM micrographs for the hypocotyl and CSLM for the root tip. The BIN2 interactome on BIOGRID comprises 36 well annotated interactions (https://thebiogrid.org/12898/summary/arabidopsis-thaliana/bin2.html), of which 2 are documented by multiple lines of evidence and 27 are from low throughput studies. Adding adequately validated interactions to this exceeds the scope of this manuscript. Furthermore, as we no longer make the claim that BIN2 mutants are the most severely impacted (see response to reviewer #1), BIN2 is no longer the primary focus of this study; we now refer more loosely to the BR pathway, or to facets thereof referred to as BR biosynthesis, perception, signaling or BR-responsive gene expression. We have also updated and extended the reference list to include references on light perception and energy sensing or signaling. Phosphoproteomics is an important suggestion that we have also taken into the perspective.

      In brief, the manuscript has a new focus on what we consider is its true contribution: a cellular analysis of cell division, elongation and anisotropy in the wild type and in BR mutants under resting or additive stress conditions.

      *Reviewer #3 *

      1. *My major concern is that in the search of a decision mutant the authors performed the first screening not under 'a conflict of interest' scenario but under dark conditions. Can the authors explain the reasons behind this more clearly? * The reason we did not use the dark water stress condition as an initial but as a secondary screen is the variability of the response. In the new violin plots (Fig. 4a-c; Fig. S7), the variance especially in root length can be seen to be considerably greater in darkW than in dark even for the wild-type. This is why we initially screened individual M2 seed in the dark and then rescreened M3 populations under darkW conditions. Due to the relatively high variance, all conclusions in the manuscript are drawn on populations of seedlings rather than on individuals.

      We write in the results section on page 9:

      “We initially screened in the dark because the high variance in root growth under water deficit in the dark in the wild-type (see below) would obscure the distinction between putative mutants versus stochastically occurring wild-type seedlings with short roots under darkW.”

      • Related to above, the role of the BR pathway in etiolation has been well established with the prominent constitutive photomorphogenesis phenotypes of BR related mutants; since both bin2 alleles are impaired in light responses this mutant may behave in dark vs darkW, like a wildtype plant in light vs. lightW (maybe also partially as shown in SFig. 5a). However, the authors show that the growth tradeoff was not evident under light conditions (Fig 2). I think to conclude that bin2 is a decision mutant it requires more evidence to excluded that a defect in efficient sensing and signaling of dark conditions are not the primary source of the 'confused' phenotype. In addition to the phenotype in SFig. 5a where light responses are attenuated in B1 when compared to Wt, a comparison of gene expression analysis of some established light regulated genes could help to show that bin2 is able to efficiently sense the absence of light. *

      This is an important point. We have looked at the expression levels of the light responsive gene LHCB1.2 via qPCR in wild-type Ws-2 versus bin2-3bil1bil2. The data show that the gene expression is light-regulated in bin2-3bil1bil2 seedlings (Fig. S12) and are described in the Results on page 13.

      In addition, Fig. S10 and Fig. S11 are dedicated to a careful analysis of light responses in all the BR pathway mutants we analyze. In Fig. S10d, bin2-1 can be seen to have a significant (P-value We write, in the Results on page 13.

      “Interestingly, the BR mutant lines with the strongest etiolation phenotypes (cpd and bri1-116brl1brl3, Fig. S11a,b) in the dark were not the ones with the strongest deviation from the wild-type under water deficit in the dark (Fig. S8).”

      3. Cells that fail to elongate in the dark may cannot - or only to a limited extent - reduce further their cell length in the darkW conditions. Since BR-mutants fail to expand hypocotyl cells in the dark, an analysis of the hypocotyl epidermis cell length in bin2 mutants compared to wt in light vs dark vs darkW (as in Fig. 8c) could be a feasible experiment to exclude that the general BR-related cell elongation defects led to the confused phenotypes of this mutant.

      This is an excellent suggestion and we thank the reviewer for pointing it out. Accordingly, bin2-1 mutants were imaged via scanning electron microscopy (SEM) and cellular parameters assessed. We also investigated root meristem properties in bin2-3bil1bil2, which had the most aberrant root response to water stress in the dark (Fig. 3e; Fig. S8b). Our new observations are described in Fig. 5, Fig. 6h-j, Fig. S16 and in the results on pages 13-15 as follows:

      “To explore whether general BR-related cell elongation defects led to the confused phenotypes of some BR pathway mutants, we analysed bin2-1 mutants, which were among the most severely impaired hypocotyl response to water stress in the dark (Fig. S8a). The data show a most striking impact of bin2-1 on growth anisotropy, assessed in 2D as length/width (Fig. 5f). Indeed, in a comparison between dark and dark with water stress (darkW), the anisotropy of hypocotyl cells decreased considerably in the wild type (Fig. 5c), but showed no adjustment in bin2-1 (Fig. 5f). Cell length alone showed the elongation defect typical of bin2-1 mutants, with a much greater deviation from the wild type under darkW than under dark or light conditions; nonetheless, there was a significant length adjustment to water stress in the dark, even in bin2-1 (Fig. 5e). These observations suggest that the impaired bin2-1 hypocotyl response can be attributed to an inability to differentially regulate cell anisotropy in response to the simultaneous withdrawal of light and water. ….

      Meristem size and mature cell length followed the same trends in a comparison between bin2-3bil1bil2 (Fig. S16a, S16b) and the wild type (Fig. 6a, 6b), but the extent of elongation in cells proximal to the QC differed (Fig. S16c). Indeed, bin2-3bil1bil2 length and anisotropy curves lacked the steep slopes characteristic for darkW in the wild type (compare the green arrows in Fig. 6d, 6f & 6j to the purple arrows in Fig. 6j & Fig. S16c). We conclude that bin2-3bil1bil2 mutants fail to adjust their root length due to an inability to differentially regulate the elongation of meristematic cells in the root in response to water stress in the dark.”

      • The experiments with the BR-deficient and signaling mutant and the bypass mutant may suggest that BR hormone is playing a relative minor role in the 'decision activity' of BIN2. bri1-6 was described to respond like wildtype (page10 line 6-8). Since this seems because of normal root responses in dark vs. darkW (Fig. 5) it could also be caused by the role of BRL1 and BRL3 in root drought responses (Fabregas et al., 2018). To verify if functional BRL1 and BRL3 in bri1-6 could cause the root response to water stress an additional experiment with bri1,brl1,brl3 triple mutant is required; In my opinion this is very important to state if the BR input is at all required for BIN2 signal integration or not. *

      We have extended our analysis to include bri1brl1brl3 lines (Kang et al., 2017). These are dwarf mutants, yet able to respond to water stress in the dark with reduced hypocotyl and increased root growth (Figure panel former 5c replaced new Fig. 3c, shown left). Note that the lines have a null bri1-116 allele and segregate (bri1-/+ brl1-/- brl3 -/-)quite clearly, as was verified by propagating seedlings on plate after the scan on day 10 (Supplementary Method S5).

      ***Minor comments:** *

      *5. The authors separate conceptually growth tradeoffs in sensing, signaling, decision making and execution processes. A clearer explanation of the expected phenotypes from mutants in only decision making with and without stress would be interesting to add (page 8)? *

      We have now moved up phya phyb cry1 cry2 quadruple photoreceptor mutant and write:

      Results on page 9

      “Perception mutants would fail to perceive light or water stress; a good example of this is the phya phyb cry1 cry2quadruple photoreceptor mutant, which had a severely impaired light response (Fig. S4d), but a “normal” response to water stress in the dark (Fig. S4e). In contrast, execution mutants may have aberrantly short hypocotyls or roots that are nonetheless capable of differentially (and significantly) increasing in length depending on the stress conditions. Decision mutants would differ from perception or execution mutants as they would clearly perceive the single stress factors yet fail to adequately adjust their hypocotyl/root ratios in response to a gradient of single or multiple stress conditions. Failure to adjust organ lengths would be seen as a non-significant response, or as a significant response but in the wrong direction as compared to the wild-type. We thus used organ lengths, the hypocotyl/root ratio and the significance of the responses as decision read outs. We specifically looked for mutants in which at least one organ exceeded wild-type length under darkW.“

      Later in the results on page 11 and in the legend to Fig. 4 we pick up on this as follows:

      “For bin2-1, the response to water stress in the dark was severely impaired: the hypocotyl and root responses were non-significant …bin2-3bil1bil2 mutants fit the above definition of decision mutants as they have a significant root response but in the wrong direction as compared to the wild-type, as denoted by red asterisks (Fig. 3e)…

      Figure 4. … bin2-3bil1bil2 mutants qualified as decision mutants on 3 counts: (i) failure to adjust the hypocotyl/root ratio to darkW (the ratio for darkW is the same as for dark in panel c), (ii) low or non-significant P-value (see panel f below) and (iii) one organ (here the hypocotyl in panel a) exceeded wild-type length under darkW.”

      Line 26 page 17: BR responses in the epidermis of the hypocotyl have been shown to be already sufficient to control hypocotyl growth (Savaldi-Goldstein et al 2007), showing that not all cells of the hypocotyl need to receive the signal (at least in the case of brassinosteroids) We have deleted the sentence because it is too speculative. However, the issue of different tissue layers is now mentioned in the perspective on page 18, as follows:

      “3D imaging will be required to assess the impact of abiotic stress and/or of BR signalling on different cell files or tissue layers in the root (see Hacham et al., 2011; Fridman et al., 2014; Fridman et al., 2021; Graeff et al., 2021). .”

      Because of the importance of distinguishing between different cell files and cell layers, we have now removed the confocal images of BRI1-GFP under the different environmental conditions (formerly Fig. 7a); this needs to be extended to a 3D analysis, which is not within the scope of this manuscript.

      1. *Page 6 Line 11: In the volcano blots the mean RQ ratio is shown in Fig. 6c and 6f. *

      We thank the reviewer for pointing this out, we had accidentally written median RQratio, this has been rectified in the results text.

      *Some parts of the ms could be shortened and the amount of Fig. could be reduced. Fig. 1-3 could be merged as one figure showing the optimal conditions to analyze tradeoffs in shoot vs. root growth and all the conditions not suitable could be supplementary figures. *

      We concur with the reviewer and have merged the first three figures as suggested. Reviewer #2 has also requested that we slim the manuscript and all reviewers request that we strengthen our conclusions on the brassinosteroid pathway mutants. To reduce the number of figure panels, we have removed the analysis of all mutants that are not in the BR pathway, with the exception of the quadruple photoreceptor mutant in Fig. S4d,e and plethora mutants in Fig. S15. Nonetheless, incorporating the new data generated in response to reviewer comments leaves us with 7 main and 16 supplementary figures.

      *In the ms several experiments are described as 'screen' this is confusing with the forward genetic screen that was performed. *

      This is indeed ambiguous. We now use the terms “single versus multiple stress conditions/additive stress/conflict-of-interest scenario ” versus “forward genetic screen”.

      *Reviewer #3 (Significance (Required)): *

      * Mechanisms how growth trade-offs between multiple stresses are controlled are highly interesting. Growth vs. biotic stress tradeoffs have already been investigated and were found to be interdependent with light (Leone et al. 2014; Campos et al 2016; Fernandez-Milmanda et al. 2020) and hormone signaling (Lozano-Duran and Zifpel et al., 2016 and Ortiz-Morea et al 2020; van Butselaar and van den Ackerveken, 2020). Less is known about growth tradeoffs between two abiotic stress responses (Bechtold and Field, 2018; Hayes et al., 2019). The separation of root meristem growth and cell expansion in the hypocotyl is interesting. Whether the two directional root-to-shoot and shoot-to-root signals are independent or whether they may employ the same mechanism with a different output remains open. Different sensitivities of organs and cell types to BRs have for example been reported (Müssing et al. 2003 and Fridman et al. 2014). The findings that BIN2 most likely act to integrate multiple signals is in line with the reported roles of BIN2 to crosstalk with several pathways (reviewed by Nolan et al. 2020). In my point of view, it remains to be strengthened if this is through 'decision making' and not through signaling and execution. I think if the authors carefully separate the defects in bin2 this work will be interesting to many plant biologists. * We thank the reviewer for highlighting references we had not referred to in the former draft. The references pertaining to the growth versus defense trade-off are now included in the introduction (page 3) and the ones on abiotic stress factors in the Discussion on page 18:

      “In addition to its role in light and drought responses… BIN2 has been implicated in regulating hypocotyl elongation in response to far-red light and salt stress (Hayes et al., 2019). Studies on responses to abiotic stress factors have typically addressed growth arrest or tradeoffs between growth and acclimation (Bechtold and Field, 2018). Indeed, root growth is inhibited by, for example, phosphate deprivation or salt stress (Balzergue et al., 2017; West et al., 2004). Recent efforts have addressed strategies for engineering drought resistant or tolerant plants that do not negatively impact growth (Fàbregas et al., 2018; Yang et al., 2019). In contrast to other studies, here we look at two abiotic stress factors that promote organ growth. Indeed, hypocotyl growth is promoted by darkness or low light and primary root growth by water deficit in this study.”

      We emphasize the above point about decision making in the discussion. In the in the introduction and early on in the results we introduce conceptual frameworks for decision making. Yet after a forward genetic screen and mutant characterization, we revise this in the Discussion on page 18 as follows:

      “In the judgement and decision-making model for plant behaviour put forth by Karban and Orrock (2018), signal integration might be considered integral to judgement. ….Whether judgement and decision making can be distinguished from each other empirically remains unclear. As BR signalling regulates cell anisotropy and growth rates in the hypocotyl and root apical meristem, it may play a role not only in signal integration but also in the execution of decisions (or in an implementation of the action; González-García et al., 2011; Vilarrasa-Blasi et al., 2014). Thus, this study does not enable us to empirically distinguish between decision making on the one hand and signalling and execution on the other.”

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      Understanding decision making during growth tradeoffs is a very exciting goal for biologists. The ms by Kalbfuß et al. reports a role for BIN2 in signal integration during decision-making to balance root vs. hypocotyl growth. First the authors established a system to investigate differential growth decisions in arabidopsis seedlings. In this system they show that light signaling competes with resources for water stress adaptation, as the combination of dark and water stress promotes root growth at the expense of hypocotyl growth. In a forward genetic screen with the aim to identify decision mutants, a semidominant bin2 allele (identical to bin2-1) was identified that fails in controlling growth tradeoffs. Since mutants of the canonical BR signaling pathway through BZR1/BES1 and mutants of other known BIN2 interactors were not giving comparable phenotypes to bin2, the authors conclude that BIN2 likely integrates multiple signals to control root vs. shoot growth. Finally, the authors show that light vs. water stress are regulated as two independent modules.

      Major comments:

      My major concern is that in the search of a decision mutant the authors performed the first screening not under 'a conflict of interest' scenario but under dark conditions. Can the authors explain the reasons behind this more clearly?

      Related to above, the role of the BR pathway in etiolation has been well established with the prominent constitutive photomorphogenesis phenotypes of BR related mutants; since both bin2 alleles are impaired in light responses this mutant may behave in dark vs darkW, like a wildtype plant in light vs. lightW (maybe also partially as shown in SFig. 5a). However, the authors show that the growth tradeoff was not evident under light conditions (Fig 2). I think to conclude that bin2 is a decision mutant it requires more evidence to excluded that a defect in efficient sensing and signaling of dark conditions are not the primary source of the 'confused' phenotype. In addition to the phenotype in SFig. 5a where light responses are attenuated in B1 when compared to Wt, a comparison of gene expression analysis of some established light regulated genes could help to show that bin2 is able to efficiently sense the absence of light.

      Cells that fail to elongate in the dark may cannot - or only to a limited extent - reduce further their cell length in the darkW conditions. Since BR-mutants fail to expand hypocotyl cells in the dark, an analysis of the hypocotyl epidermis cell length in bin2 mutants compared to wt in light vs dark vs darkW (as in Fig. 8c) could be a feasible experiment to exclude that the general BR-related cell elongation defects led to the confused phenotypes of this mutant.

      The experiments with the BR-deficient and signaling mutant and the bypass mutant may suggest that BR hormone is playing a relative minor role in the 'decision activity' of BIN2. bri1-6 was described to respond like wildtype (page10 line 6-8). Since this seems because of normal root responses in dark vs. darkW (Fig. 5) it could also be caused by the role of BRL1 and BRL3 in root drought responses (Fabregas et al., 2018). To verify if functional BRL1 and BRL3 in bri1-6 could cause the root response to water stress an additional experiment with bri1,brl1,brl3 triple mutant is required; In my opinion this is very important to state if the BR input is at all required for BIN2 signal integration or not.

      Minor comments:

      The authors separate conceptually growth tradeoffs in sensing, signaling, decision making and execution processes. A clearer explanation of the expected phenotypes from mutants in only decision making with and without stress would be interesting to add (page 8)? Line 26 page 17: BR responses in the epidermis of the hypocotyl have been shown to be already sufficient to control hypocotyl growth (Savaldi-Goldstein et al 2007), showing that not all cells of the hypocotyl need to receive the signal (at least in the case of brassinosteroids)

      Page 6 Line 11: In the volcano blots the mean RQ ratio is shown in Fig. 6c and 6f.

      Some parts of the ms could be shortened and the amount of Fig. could be reduced. Fig. 1-3 could be merged as one figure showing the optimal conditions to analyze tradeoffs in shoot vs. root growth and all the conditions not suitable could be supplementary figures.

      In the ms several experiments are described as 'screen' this is confusing with the forward genetic screen that was performed.

      Some parts of the ms could be shortened and the amount of Fig. could be reduced. Fig. 1-3 could be merged as one figure showing the optimal conditions to analyze tradeoffs in shoot vs. root growth and all the conditions not suitable could be supplementary figures.

      In the ms several experiments are described as 'screen' this is confusing with the forward genetic screen that was performed.

      Significance

      Mechanisms how growth trade-offs between multiple stresses are controlled are highly interesting. Growth vs. biotic stress tradeoffs have already been investigated and were found to be interdependent with light (Leone et al. 2014; Campos et al 2016; Fernandez-Milmanda et al. 2020) and hormone signaling (Lozano-Duran and Zifpel et al., 2016 and Ortiz-Morea et al 2020; van Butselaar and van den Ackerveken, 2020). Less is known about growth tradeoffs between two abiotic stress responses (Bechtold and Field, 2018; Hayes et al., 2019). The separation of root meristem growth and cell expansion in the hypocotyl is interesting. Whether the two directional root-to-shoot and shoot-to-root signals are independent or whether they may employ the same mechanism with a different output remains open. Different sensitivities of organs and cell types to BRs have for example been reported (Müssing et al 2003 and Fridman et al. 2014). The findings that BIN2 most likely act to integrate multiple signals is in line with the reported roles of BIN2 to crosstalk with several pathways (reviewed by Nolan et al. 2020). In my point of view, it remains to be strengthened if this is through 'decision making' and not through signaling and execution. I think if the authors carefully separate the defects in bin2 this work will be interesting to many plant biologists.

      My expertise: plant development, signaling, brassinosteroids

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      The authors did a lot of work to characterize the regulatory role of BIN2, which is known to be a key hub of BR signaling, in a new role as modulator of environmental changes on plant growth. Including changing light conditions and thereby influence of photosynthesis on overall growth, shoot dominance, and root growth adaptation upon water stress, root dominance, the authors aim to describe its regulatory role.

      It is well known that shoot and root are communicating depending on environmental changes, and that both contribute in their own way to proper plant growth, and when resources are low or stress is compromising growth this has a big impact on above and under ground tissues all together. Furthermore, several so-called cellular hubs, as TOR or SnRK1 and others, are known to reorganize shoot vs root growth, by reconstructing manifold signaling cascades, and are themselves targeted by other signaling cascades.

      A lot of signaling pathways act interwoven in the regulation between shoot and root, and the authors also investigated several key players of those that are well described. But, to understand and prove their integrative role higher order mutants between those pathways are missing. This of course will take time and will be not considered for this manuscript.

      Nevertheless, following claims should be changed, when speaking about shoot versus root dominance. Most of the measurements were done of hypocotyls, in Fig4 clearly from shoots. I recommend to exchange shoot for hypocotyl when hypocotyls were examined to avoid to confuse the readers.

      The authors have chosen SnRK2 (and should also indicate it in all Figures as SnRK2, to not confuse the readers with SnRK1), and implement ABA signaling in parallel to BR action, but this must be proven in higher order mutants of both pathways, at the moment the results are to preliminary to allow conclusions. When the authors are interested in shoot dominance/photosynthetic activity, why didn't they look on snrk1 mutants, which are known to regulate those processes. In Fig6 d the authors propose a sketch of the mechanism, but the data of this study don't show direct interaction of the pathways and as indicated in the figure text parts of the information are taken from other papers, I recommend to remove this sketch or shift it to the supplements.

      To discriminate the role of downstream BR signaling events from other roles of BIN2, I suggest to complement the data with pharmacological experiments (eBL or bikini where appropriate), and if possible to implement phenotyping of OE lines. How many independent ko lines were tested, can the authors exclude that the BR independent phenotype indeed corresponds to BIN2 activity and not to a off target effect. I further recommend to exchange the pictures in Fig7a showing BRI1GFP to pictures showing fewer cells, but with higher resolution.

      Regarding the implementation of photoreceptor mutants and the claim that photoreceptors are more abundant in shoot, I want to point out that the situation is more complex, as the root also reacts differently to light of different quality and quantity, with different responses in the meristem, by inhibiting cell proliferation, or in the elongation zone by triggering negative phototropism. this should be corrected in the text.

      The data and methods are presented in a clear and sufficient way, as well as the statistical analysis.

      Altogether, the hypothesis and work amount are worth to be recognized, but the manuscript also resembles partially more a review and I would suggest to shorten those parts in the manuscript, reduce the amount of described lines and focus strictly on the BR pathway, in response to the environmental changes. Before implementing photoreceptors and ABA/SnRK2 pathway into the story to either test higher order mutants between the signaling pathways of interest or come up with a pharmacological screen connecting the data. Therefore I suggest to reduce the amount of mutants investigated and focus on BIN2 action, implementing also a pharmacological screen to track a fluorescent tagged BIN2 upon the mentioned treatments. And if possible to add proteomics and phosphoproteomics to understand better what changes are undergoing in the bin2 mutant vs WT upon stress.

      Significance

      The significance for the field would be to define BIN2 as another cellular hub orchestrating plant growth and especially shoot/hypocotyl vs root growth, but some more directed studies must be done to proof this claim. The scientific interest in shoot-root communication and how their communication is orchestrated by sugar-phytohormone-exogenous signal crosstalk is currently growing. The study consists of very interesting descriptive insights of plant growth adaptation upon additive stress response, but the direct interaction of all investigated players is missing. A pharmacological approach combined with Proteomics and Phosphoproteomics could support the hypothesis.

      The manuscripts refers to all relevant literature supporting the hypothesis, but as described in the previous section, there are studies published showing a more complex situation, especially when talking about light perception. In general, I recommend to slim the manuscript and thereby also the parts resembling a review with suggestive character and focus more on conclusions drawn from actual experiments.

      My research interest and expertise includes sugar-auxin crosstalk upstream of root growth adaptation, BR-auxin crosstalk, and light signaling upstream of plant growth adaptation.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      In this manuscript, the authors explore tradeoffs between root and shoot growth of seedlings in response to variable light and water availability. They first establish a scenario in which dark grown seedlings are exposed to water deficit via PEG treatments, which leads to a higher root/shoot ratio. An EMS mutagenesis screen was then performed. Mutants with an altered root/shoot ratio were selected and then rescreened for differential root/shoot ratios when exposed to water stress. From this screen, the authors identified a mutant, B1, that contains a semi-dominant gain-of-function mutation in BIN2. It turns out that B1 is allelic to the previous reported bin2-1 mutant, encoding a kinase that functions as an important negative regulator of Brassinosteroid signaling. This prompted the authors to explore the phenotypes of various BR signaling mutants as well as mutants in known BIN2 substrates. The authors claim that bin2 mutants have "confused" phenotypes. They then go on to propose a model that states that hypocotyl growth is regulated by a decentralized response whereas root growth is driven primarily by the root apical meristem. While the study system and some of the findings in this manuscript are interesting, there are major flaws in the author's primary claims that I detail below.

      1. The authors claim that bin2 has a "confused" phenotype, which they define as high variability in shoot versus root lengths along with a low degree of response to water limitation. bin2-1 is a semi-dominant gain-of-function mutant, which can only be propagated as a heterozygote (homozygous individuals are viable, but don't produce seeds). There is no mention in the manuscript about genotyping or selection of homozygous bin2-1 individuals for the phenotyping assays. Could the high variability observed in fact be caused by the authors looking at a segregating population of bin2-1?
      2. The authors state that bin2 mutants had considerably more severe phenotypes than other BR biosynthesis, perception, or transcription factor mutants. This is like comparing apples to oranges, as the set of mutants they've examined consists of gain-of-function and partial loss-of-function alleles. Null alleles for BR biosynthesis (e.g. cpd, dwf4), perception (bri1brl1brl3 triple mutants) and transcription factors (bzr1bes1beh1-4 sextuple mutants) are described in the literature and would need to be tested before arriving at such a conclusion.
      3. For most of the phenotyping experiments a "RQ ratio" is presented. This is the ratio adjustment of the mutant/ratio adjustment of WT. While this derived quantity is useful for interpretation, we're missing plots of the raw data, and particularly those that show the underlying distribution of data points.
      4. Root growth involves both cell division in meristematic cells at the tip of the root and subsequent elongation as cells exit the meristem and begin to differentiate. The authors claim a nine-fold difference in CycB1,1:GUS in the root meristem in dark vs darkW, however their images show similar CycB1,1:GUS expression patterns. Furthermore, the meristems of darkW are actually smaller than dark, which would be unexpected if cell division was increased.
      5. In addition, the authors claim that the longer root length in dark water stress was at least in part due to increased elongation (Fig. 7c). Elongation was only assessed by looking at the first elongating cell (~10-14um) and the differences found are on the order of magnitude of ~2um, but final cell size in Arabidopsis roots often reaches several hundred um. Therefore, a comparison of final cell size would be more appropriate.
      6. Finally, the authors phenotype plt1/2 double mutants and show that they fail to elongate in response to water limitation. Their interpretation is that this supports a centralized control model for the root apical meristem. PLT1/2 are important determinants of meristem function and are necessary to maintain stem cell identity. Given the strong phenotype of plt1/2 double mutants it is not surprising that they are unable to elongate in response to this stimulus. This does not necessarily indicate that only the RAM controls root growth, but rather that functional stem cells are required for root growth, which also involves subsequent steps such as cell elongation.

      Significance

      While the study system and some of the findings in this manuscript are interesting, there are major flaws in the authors' primary claims.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Manuscript number: RC-2020-00527

      Corresponding author(s): Iva M. Tolić

      1. General Statements [optional]

      We thank the reviewers for providing thoughtful and constructive feedback on our manuscript. Given that the reviewers proposed numerous experiments, and that at the time when we received the reviews, we acquired a STED superresolution microscope for the lab, we decided to perform all experiments using STED microscopy. This brought our paper to a higher level with unique image quality of human spindles. We used STED microscopy to repeat almost all the experiments from the original manuscript, as well as to perform new experiments, on cells immunostained for tubulin, with or without HAUS6/8 depletion. Because this resulted in much clearer visualization and more precise quantification of k-fibers and bridging fibers, we show the new STED images and the corresponding quantifications in the revised main figures (new Fig. 1, Fig. 2J,K, Fig. 3, Fig. 5), whereas the old confocal images and the related measurements from the original manuscript are largely moved to the Supplementary figures as supporting data.

      In addition to STED imaging, as a key part of the revision we took a functional approach where we tested how augmin depletion and the perturbation of bridging microtubules affects chromosome segregation and mitotic fidelity, as suggested by Reviewer 3. These exciting new results expanded the significance of our study, and we decided to include them in new Fig. 2 and reorganize the manuscript accordingly.

      Please note that due to the numerous experiments suggested by the reviewers and the optimization of the super-resolution microscope, along with covid-related interruptions and delays, this extensive revision has taken a year and a half, which we hope you will understand.

      Insert here any general statements you wish to make about the goal of the study or about the reviews.

      2. Point-by-point description of the revisions

      We thank the reviewers for providing insightful and constructive comments on our manuscript. We have carefully considered each point and have revised the paper as documented below, with reviewer comments in black and our response in blue.

      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      In the manuscript "Augmin regulates kinetochore tension and spatial arrangement of spindle microtubules by nucleating bridging fibers", Manenica et al. explore the impact of augmin-dependent microtubule nucleation on formation of a subset of spindle microtubules that bridge sister kinetochore fibers and investigate how this could affect the spindle forces and architecture. Using RNAi- and CRISPR-Cas9- based loss-of-function experimental approach, the authors propose that the bridging fibers are nucleated by augmin and that removal of augmin impairs proper spindle architecture, interkinetochore tension and microtubule poleward flux, specifically via its effect on the bridging fibers. Overall, the study is well designed and the manuscript well written. Expanding the knowledge on augmin contribution to the spindle functions and better understanding of the roles of bridging fibers would be important and of interest to cell biologists studying mitosis. Although this manuscript clearly shows that augmin depletion impairs the formation of bridging fibers (and other microtubules), the specific contribution of the bridging fibers to the augmin-dependent spindle functions is less clear.

      We thank the reviewer for this criticism. To address it, we have toned down the conclusions about the specific contribution of the bridging fibers throughout the revised manuscript.

      **Major comments:**

      1) Using cold treatment-induced microtubule destabilization, Zhu et al. (JCB 2008) showed that augmin depletion affected exclusively kinetochore microtubules. Since the bridging microtubules are usually not visible in the cold-treated spindles (due to being less stable/cold resistant compared to the k-fibers), it is unlikely that the observed effects were mainly associated with the bridging fibers. Thus, it would be important to further clarify the respective contribution of augmin to the formation of k-fibers and the bridging fibers. The cold-treatment experiment performed by Zhu et al. could be used in RPE1 and HeLa-PRC1-GFP cells to address the contribution of augmin nucleation to kinetochore- vs. bridging microtubules from another angle.

      Because of the above mentioned results by Zhu et al. it is difficult to grasp how augmin depletion could have a bigger effect on the bridging fibers than on the k-fibers, as concluded from the Fig. 2C data. In fact, Fig. 2A clearly shows a strong effect on k-fibers in spindles where the bridging fibers are reduced/missing.

      Also, Fig. 1 D and E suggest that HAUS8 siRNA exclusively affected the bridging fibers, leaving the k-fibers intact, which is again against the data reported in Zhu et al. 2008 and in contrast with the representing image shown in Fig. 1B. Even if the RNAi was less efficient compared to HAUS6 RNAi, as the authors proposed, this could still not explain the observed discrepancy.

      We thank the reviewer for this comment. To better address the contribution of augmin to either bridging or kinetochore microtubule nucleation, we repeated a major part of the experiments by using STED super-resolution microscopy on cells immunostained for tubulin, with or without HAUS6/8 depletion. STED imaging enabled much clearer visualization of k-fibers and bridging fibers (Fig. 1 and Fig. 3A), and confirmed our initial result that augmin depletion has a larger effect on bridging fibers than on k-fibers (Fig. 3D,E). Importantly, the new results for HAUS6 siRNA and HAUS8 siRNA were similar, and showed that the lack of augmin affects k-fibers to a certain extent in both cases (Fig. 3D,E). The data from the original manuscript, obtained by confocal microscopy, are now shown in Supplementary Fig. S3.

      To independently test the effect of augmin depletion on k-fibers, we also performed experiments with cold treatment as suggested, imaged the cells by STED microscopy, and analyzed the images as in Zhu et al. (Fig. 3F,G). These experiments were done on RPE1 cells that stably express CENP-A-GFP. Cold treatment in HeLa-PRC1-GFP cells was no longer needed, as STED imaging clearly showed the absence of bridging fibers in cold treated cells. The new results are described on page 12:

      “Quantification of STED images further revealed that HAUS6 depletion resulted in 68 ± 8% reduction of the bridging fiber signal intensity and 24 ± 6% reduction of the k-fiber signal intensity, with similar results obtained by HAUS8 depletion (Fig. 3D-E). These data indicate that augmin depletion affects not only k-fibers, but even more so bridging fibers. The contribution of augmin to the nucleation of k-fibers was independently tested by measuring their intensity in spindles exposed to cold treatment in which bridging fibers are removed (Fig. 3F). HAUS6 depletion resulted in a 37 ± 5% reduction of the k-fibers (Fig. 3G), which is consistent with a previous study (Zhu et al., 2008) and comparable to values under non-cold conditions.”

      2) The authors showed that kinetochore pairs in the outer parts of Augmin-depleted spindles have larger inter-kinetochore distance compared to those in the inner parts of spindles. They indirectly related this to a predominant presence of the bridging fibers in the outer parts, concluding that augmin regulates inter-kinetochore tension via nucleation of the bridging fibers. A more direct way would be to show the eventual positive correlation between the inter-kinetochore distance and the bridging- and k- fibers intensity. Also, it would be nice to include the quantifications and correlation data for inter-kinetochore distance, distance from the spindle axis and the bridging- and k- fibers intensities for the control cells too.

      We analyzed the new data and included the correlations in the altered manuscript. We explained the correlation data for the interkinetochore distance and the distance from the spindle axis as follows: “… we noticed that the interkinetochore distance was smaller in the inner part of the spindle in augmin-depleted cells (Fig. 5A-D, Supplementary Fig. S5B), where bridging fibers were most severely impaired (Fig. 3H and 4A). This was not the case in control cells, which showed no difference in interkinetochore distance between the inner and the outer part of the spindle (Fig. 5D, Supplementary Fig. S5B).”

      We also included the correlation data for the interkinetochore distance and the bridging and k-fibers intensity: “… we found that although the interkinetochore distance correlated both with bridging and k-fiber intensity after augmin depletion, the correlation with bridging fiber intensity was stronger (Supplementary Fig. S5D-E). Such correlations were absent in control cells (Supplementary Fig. S5D-E).”

      3) It is stated in the manuscript that the k-fibers without bridging fibers have shorter contour length compared to the k-fibers with bridging fibers, and that the curvature of k-fibers lacking the bridging fibers is drastically reduced. However, the data in Figure 5D and Table 1 show a slight effect on the contour length of the k-fibers lacking the bridging fibers compared to the ones containing the bridging fibers only in RPE1 siHAUS8 cells, while this effect seems to be missing in RPE1 HAUS8 KO cells, as well as in siHAUS6 in RPE1 and HeLa cells.

      Fig. 2 shows that the kinetochore pairs without the bridging fibers are located closer to the spindle axis. Thus, it is not clear whether the effect on curvature observed in the augmin depleted cells is independent of the position of kinetochore pairs within the spindle, as the spindle axis-proximal pairs would anyway have a bigger radius compared to the more distant ones.

      As these analyses were previously performed on bundles stained with SiR-tubulin and using confocal microscopy, we have now determined their curvature on spindles immunostained for tubulin and imaged by STED microscopy, where the shape of these bundles can be determined more precisely, in control and HAUS6 depleted cells. In the revised manuscript, only those spindles were taken for further analysis (Supplementary Fig. S3I-K). We revised the text as follows: “Whereas the bundles without kinetochores in HAUS6 siRNA-treated cells had a significantly longer contour when compared to all other bundle types (Supplementary Fig. S3J), k-fibers without bridging fibers in augmin-depleted cells had a significantly larger radius of curvature than any of the other bundle types in augmin-depleted or control cells (Supplementary Fig. S3K). Taken together, the outer interpolar bundles without associated kinetochores are excessively long and make the spindle wider, whereas k-fibers lacking a bridging fiber are overly straight, ultimately resulting in a diamond-like shape of the spindle.”

      As for Fig. 2, in all experiments regarding shape, we only analyzed the outermost bundles, so the potential effect of the position of kinetochore pairs within the spindle can be excluded. We explained that in the Methods section and highlighted it in the caption of the Supplementary Fig. 3I: “In control cells, only the outermost bundle was tracked. In HAUS6 siRNA treated cells, three different groups of outermost bundles were tracked: bundles with visible bridging fibers, bundles with no visible bridging fibers and curved bundles extending far from the metaphase plate” and “Examples of each bundle type are shown in insets. From left to right: the outermost bundle in control cells, the outermost bundle with a bridging fiber, the outermost bundle without a bridging fiber and the outermost bundle without kinetochores in HAUS6-depleted cells”, respectively.

      4) The authors reported that augmin depletion impairs microtubule poleward flux and conclude that this happens exclusively due to the perturbation of bridging fibers. While the results from this and other studies clearly show that augmin depletion perturbs spindle microtubules in general, it is not clear whether this had a stronger effect on the bridging microtubules (see the comments in point 1). Thus, the impact of augmin depletion on kinetochore microtubules or other antiparallel microtubules within the spindle (e.g. the ones recently shown in O'Toole et al., MBoC 2020) cannot be ruled out as a potential cause of the impaired microtubule flux. Also, Steblyanko et al. (EMBO J, 2020) showed that PRC1 depletion had no effect on microtubule poleward flux in metaphase cells. Since it has been previously shown by the authors of this manuscript that PRC1 depletion disrupts the formation of bridging fibers, it is unlikely that the bridging fibers are the main cause of the augmin depletion-mediated effect on the microtubule flux.

      We modified the text on poleward flux to include the contribution of both bridging and k-fibers. We also performed new experiments on U2OS cells and included references to the new work from our lab (Risteski et al., 2021), which was able to distinguish between the effect of augmin depletion on bridging and k-fibers. We also included a comment on PRC1 depletion: “Recent speckle microscopy experiments in RPE1 cells, which were able to separate the effect of augmin on poleward flux of bridging and k-fibers, revealed that both k-fibers and the remaining bridging fibers were significantly slowed down (Risteski et al., 2021 Preprint). Bridging fibers fluxed faster than k-fibers in control and augmin-depleted cells (Risteski et al., 2021 Preprint), supporting the model in which poleward flux is largely driven by sliding apart of antiparallel microtubules (Brust-Mascher et al., 2009; Mitchison, 2005; Miyamoto et al., 2004). We propose that augmin depletion results in slower flux of bridging fibers because the remaining bridging microtubules are likely nucleated at the poles, where microtubule depolymerization mechanisms might curb poleward flux speed (Ganem et al., 2005). In contrast, PRC1 depletion does not affect the flux (Risteski et al., 2021 Preprint; Steblyanko et al., 2020) even though it reduces bridging fibers (Kajtez et al., 2016; Polak et al., 2017), possibly because the remaining bridging microtubules are generated away from the poles via augmin and can thus flux freely.”

      Minor comments:

      1) Introduction: chromatin- and kinetochore- mediated generation of spindle microtubules are ignored when describing the origins of spindle microtubules in human somatic cells.

      We included the chromatin- and kinetochore-mediated generation of spindle microtubules in the Introduction. We revised the text as follows: “Spindle microtubules in human somatic cells are generated by several nucleation mechanisms, including centrosome-dependent and augmin-dependent nucleation (Kirschner and Mitchison, 1986; Pavin and Tolić, 2016; Petry, 2016; Prosser and Pelletier, 2017; Wu et al., 2008; Zhu et al., 2008), with an addition of chromatin- and kinetochore-dependent nucleation as a third mechanism that contributes to the directional formation of k-fibers (Maiato et al., 2004; Sikirzhytski et al., 2018; Tulu et al., 2006).”

      2) The authors proposed less efficient HAUS8 depletion as a potential reason of discrepancy between the siHAUS6 and siHAUS8 results. This should be shown by Western blot, like it is presented for the RNAi efficiency of siHAUS6.

      We agree with the reviewer that it would be best to include Western blot for the RNAi efficiency of siHAUS8. However, as we explained in the Methods section, commercially available HAUS8 antibodies resulted in no detectable bands in our hands, regardless of the modifications in the Western blot protocol. We explained this in Methods section, as follows: “Rabbit polyclonal HAUS8 antibody (diluted 1:1000, PA5-21331, Invitrogen and NBP2-42849, Novus Biologicals) resulted in no detectable bands under these conditions”. For this reason, we performed immunocytochemistry to determine the efficiency of siHAUS8. Discrepancy was now also addressed as a part of our new STED analysis, where depletion of HAUS6 and HAUS8 produced the same results.

      3) The measurements of total PRC1 intensities are mentioned in the manuscript text, but not shown in the figures.

      PRC1 measurements are now performed on both RPE1 and HeLa cells with corresponding graphs shown in Fig. 4C and Supplementary Fig. S4C.

      4) Supplementary Videos 3 and 4 are wrongly annotated as Supplementary Videos 1 and 2 in the text.

      As we have a new set of videos, this is no longer applicable.

      5) Given the spindle length phenotypes are opposite in HeLa and RPE1 cells, in order to be consistent with the other experiments it would be better to perform the PRC1 measurements in RPE1 cells (e.g. using the anti-PRC1 antibody as shown in Supplementary Fig. 3B).

      We have now performed size measurements in all three cell lines: RPE1 cells stably expressing CENP-A-GFP and Centrin1-GFP, RPE1 cells stably expressing PRC1-GFP and HeLa cells stably expressing PRC1-GFP treated with MG-132. These results are now shown in Supplementary Fig. S4J-K. The phenotypes remained the same as in the original experiments. We revised the text to better explain the observed differences as follows: “While the spindles in RPE1 cells shortened following augmin depletion, those in HeLa cells were longer (Supplementary Fig. S4J), consistent with previous observations on Drosophila S2 cells and Xenopus egg extracts (Goshima et al., 2007; Petry et al., 2011). This difference in spindle length might be due to the overlaps remaining the same length after augmin depletion in RPE1 cells, while being longer and thereby able to push the spindle poles further apart in HeLa cells (Supplementary Fig. S4K).”

      6) Why are the microtubule flux rates for RPE1-PA-GFP-α-tubulin cells measured in this study largely different than the rates reported for the same cell line in Dudka et al., Nat Comms 2018 and Dudka et al., Curr Biol 2019? In order to better understand this difference and strengthen the microtubule flux data, it would be helpful to increase the experimental numbers to match the ones used in the mentioned studies.

      We performed photoactivation experiments on a higher number of U2OS cells stably expressing CENP-A GFP, mCherry-tubulin and PA-tubulin (N = 30 measured photoactivation spots in 30 control and HAUS6-depleted cells, see Supplementary Fig. S3L-M). U2OS cells with labelled kinetochores and tubulin were used to exclude the potential effects of SiR-tubulin on poleward flux, as well as to better determine the position of the metaphase plate. The results in control cells are comparable to the poleward flux measured in the same cell line (Steblyanko et al., 2020).

      7) The number of cells used per each experiment should be clearly stated.

      In all experiments included in the main figures, we have now performed 3 independent experiments with at least 10 cells each. The numbers are also clearly stated in the captions of figures for all experiments.

      Reviewer #1 (Significance (Required)):

      This study expands the analysis of augmin contribution to the spindle functions and focuses on its role in formation of the bridging fibers, which is of interest to cell biologists studying mitosis. It clearly shows that in addition to its effect on the k-fibers, augmin depletion also impairs the formation of bridging fibers. However, the exact contribution of the bridging fibers to the spindle functions affected by augmin depletion remains unclear.

      We thank the reviewer for the thoughtful comments and hope that our new experiments clarified the contribution of the bridging fibers to the augmin-dependent spindle functions.

      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      **Summary:**

      The authors found that the microtubules in the bridging fibres of the mitotic spindle in a human cell line are predominantly supplied via augmin-dependent nucleation. On the other hand, the contribution of augmin to kinetochore fibre formation is ~40%. Augmin-depleted cells showed reduced inter-kinetochore tension and slower poleward flux of spindle microtubules, suggesting that bridging fibres play a role in these events. This study expands our knowledge on the role of augmin and augmin-mediated microtubules in animal somatic cells.

      **Major comments:**

      *-Are the key conclusions convincing?*

      Yes.

      *-Should the authors qualify some of their claims as preliminary or speculative, or remove them altogether?*

      In the current manuscript, the slower flux is attributed solely to the lack of bridging fibres in the augmin-depleted cells. This is an overinterpretation, as the augmin's role in the spindle is not limited to generating bridging fibres.

      We agree with the reviewer and modified this part in the Results section (part of Supplementary Fig. S3) to include the contribution of both bridging and k-fibers to poleward flux. We also included references to the new work from our lab (Risteski et al., 2021), which was able to distinguish between the effect on bridging and k-fibers: “Recent speckle microscopy experiments in RPE1 cells, which were able to separate the effect of augmin on poleward flux of bridging and k-fibers, revealed that both k-fibers and the remaining bridging fibers were significantly slowed down (Risteski et al., 2021 Preprint). Bridging fibers fluxed faster than k-fibers in control and augmin-depleted cells (Risteski et al., 2021 Preprint), supporting the model in which poleward flux is largely driven by sliding apart of antiparallel microtubules (Brust-Mascher et al., 2009; Mitchison, 2005; Miyamoto et al., 2004). We propose that augmin depletion results in slower flux of bridging fibers because the remaining bridging microtubules are likely nucleated at the poles, where microtubule depolymerization mechanisms might curb poleward flux speed (Ganem et al., 2005). In contrast, PRC1 depletion does not affect the flux (Risteski et al., 2021 Preprint; Steblyanko et al., 2020) even though it reduces bridging fibers (Kajtez et al., 2016; Polak et al., 2017), possibly because the remaining bridging microtubules are generated away from the poles via augmin and can thus flux freely.”

      *-Would additional experiments be essential to support the claims of the paper? Request additional experiments only where necessary for the paper as it is, and do not ask authors to open new lines of experimentation.*

      No.

      *-Are the suggested experiments realistic in terms of time and resources? It would help if you could add an estimated cost and time investment for substantial experiments.*

      N/A

      *-Are the data and the methods presented in such a way that they can be reproduced?*

      Yes.

      *-Are the experiments adequately replicated and statistical analysis adequate?*

      Yes.

      **Minor comments:**

      *-Specific experimental issues that are easily addressable.*

      None.

      *-Are prior studies referenced appropriately?*

      Yes.

      *-Are the text and figures clear and accurate?*

      1) Page 15: "To determine the curvature of the bundles, we ..... with all other bundles types (Fig. 5E)." - I could not understand this sentence well, and would like to ask for a revision.

      The text has now been changed to: “To gain insight into the contribution of each of these functionally distinct microtubule bundles to the maintenance of spindle geometry, we traced the outermost bundles in HAUS6 siRNA treated RPE1 cells imaged using STED microscopy and fitted a circle to the bundle outline (Supplementary Fig. S3I, see Methods)”.

      2) The following words may be too strong:

      Page 20: whereas k-fiber microtubules are "mainly" nucleated in an augmin-independent manner (could 61% contribution be called "mainly?").

      We revised this sentence on page 24 as follows: “K-fibers were also thinner, though to a lesser extent, indicating that they are largely nucleated in an augmin-independent manner, at the centrosome or kinetochores and chromosomes.”

      Page 21, bottom: "demonstrates".

      As we changed this section of the manuscript, this is no longer applicable.

      *-Do you have suggestions that would help the authors improve the presentation of their data and conclusions?*

      No.

      Reviewer #2 (Significance (Required)):

      *-Describe the nature and significance of the advance (e.g. conceptual, technical, clinical) for the field.*

      The presence of bridging fibres has been recognised for decades; however, until recently, little attention has been paid to this structure from a mechanistic and functional point of view. The Tolic lab has been shedding light on this structure for the past several years. The current study represents another step forward in the research of the origin and function of bridging fibres.

      *-Place the work in the context of the existing literature (provide references, where appropriate).*

      Augmin's critical contribution to microtubule nucleation in the human somatic spindle has been well documented, as cited by the authors. The current study is the first to show that augmin also contributes to bridging fibres. The >70% contribution may be more than expected, given that centrosomal microtubules frequently reach the spindle midzone.

      Reduced inter-kinetochore tension has also been documented, but previous studies attributed this exclusively to reduced number of kinetochore microtubules. The current study has revised this view.

      *-State what audience might be interested in and influenced by the reported findings.*

      Spindle researchers.

      *-Define your field of expertise with a few keywords to help the authors contextualize your point of view. Indicate if there are any parts of the paper that you do not have sufficient expertise to evaluate.*

      This review is written by a researcher who is familiar with the literature of the mitotic spindle.

      We thank the reviewer for an accurate summary of our work and perceptive comments.

      Reviewer #3 (Evidence, reproducibility and clarity (Required)):

      In this study Manenica et study how the presence of the augmin complex affects the overall spindle architecture and the different types of spindle microtubules. The authors propose that depletion of augmin affects particularly bridging microtubules, leading to their disappearance on sister-kinetochores located in the central part of the metaphase plate.

      Overall the manuscript is well written, clear and supported by excellent explanatory schemes. The main conclusion of the manuscript, i.e. that augmin plays an essential role in the formation of bridging microtubules is generally well supported by the data. A number of other conclusions, however, are less well supported by the data and would benefit from a number of additional experiments, repetitions or analysis. Specifically:

      1. Throughout all the figures the authors use a t-test, which is fine when comparing two conditions, but not for multiple experimental conditions. The authors should instead use an ANOVA test or apply a Bonferroni correction. This can strongly affect the significance of some of the reported results.

      We agree and have performed either ANOVA with post-hoc Tukey test or Mann-Whitney U-test instead of t-test where appropriate throughout the whole manuscript. The statistical analyses that were used are clearly stated in the captions of the figures.

      Another general concern is that the authors rely throughout the manuscript on live cell imaging data from few cells (5-10). Live cell imaging data has the advantage to avoid fixation artifacts, but the low sample size is a major concern, as for every experiment the authors rely on 10 cells (and for inter-kinetochore distances on 5) in three independent experiments overall. This means that two our of three of those independent experiments are based on 3 cells only, which is too low, given that siRNA depletions are known to be variable in their efficiencies. With such low number of cells, there is always the danger of an unconscious selection bias, which can skew a result. Just to take an example the spindle length, structure and density for HAUS-8 depleted RPE1 cells looks very different in the examples show in Figure 1B, 2A, or 5B.It is therefore essential to work with a higher sample size, at minimum 10 cells per independent experiment.

      This is a valid critique, which we addressed by performing 3 independent experiments with at least 10 cells each for all of our new analyses included in the main figures.

      Throughout all experiments the authors use 100nm Sir-Tubulin, which in our hands already leads to substantial changes in microtubule dynamics, as it stabilizes spindle microtubules. I understand why the authors did this, as they wanted to also stain for weak bridging fibers, but tt would be important to validate some of the obtained results with an independent approach, for example fixed-cell imaging and tubulin staining, to rule out artifacts introduced by SiR-tubulin.

      We thank the reviewer for this suggestion. To validate our results, we performed tubulin immunostaining, as suggested. Moreover, we imaged the immunostained cells by using super-resolution STED microscopy and included these results in the main figures (Fig. 1, Fig. 2J and K, Fig. 3, Fig. 5). The data obtained from cells stained with SiR-tubulin and imaged using live-cell confocal microscopy are now shown in Supplementary figures.

      Figure 1: Given that the authors later report that augmin affects more strongly bridging fibers in the central part of the spindle, how were the values in terms of microtubule densities obtained in the experiments in Figure 1: only on the outer microtubules, or overall in the spindle?

      Values in Figure 1 (now Figure 3) were obtained overall in the spindle. We described the selection in the text as follows: “We measured tubulin signal intensity of randomly selected bridging (Ib) and k-fibers (Ik) which had no other microtubules in their immediate neighborhood…”

      Figure 2: the authors conclude that depletion of augmin has a much stronger effect on the bridging fibers located in the central part of the spindle. This is a very interesting result, but it begs the question as to the origin of this difference. If the authors analyze in control cells the inter-kinetochore distances and the density of the bridging fibers of the kinetochores located in the central part of the metaphase plate vs those located at the outer part of the plate, do they already see a difference? In other words, is the effect of augmin due to already weaker bridging fibers in the central part of the spindle, or is the depletion effect indeed specific for those bridging fibers located in the middle. This analysis should be possible with the existing data (+ a higher sample size)

      This was now analyzed in the cells imaged using STED microscopy with a higher sample size. From our new data, it seems that the depletion effect is indeed specific for bridging fibers located in the middle as there was no significant difference between the interkinetochore distance in the inner and the outer part of the spindles in control cells (Fig. 5D and Supplementary Fig. S5B). The same trend can also be seen for bridging fiber density (Fig. 3H). We modified the text as follows: “However, we noticed that the interkinetochore distance was smaller in the inner part of the spindle in augmin-depleted cells (Fig. 5A-D, Supplementary Fig. S5B), where bridging fibers were most severely impaired (Fig. 3H and 4A). This was not the case in control cells, which showed no difference in interkinetochore distance between the inner and the outer part of the spindle (Fig. 5D, Supplementary Fig. S5B).”

      Figure 4: the authors study spindle width, length and diameter of the metaphase plate in a small number of cells (10). One concern is that these values might change as cells progress from late prometaphase to anaphase onset (metaphase plate width decreases for example). Given the low number of cells the authors do not know if they are comparing cells at similar mitotic times. To circumvent this issues, they could: either arrest the cells with MG132 for 1 hour, to obtain an end-point, or record these different values as cells progress through mitosis and thus be able to compare similar conditions.

      We agree with this suggestion, and we performed new experiments by arresting the cells with MG-132: “… in HeLa (Kajtez et al., 2016) and RPE1 (Asthana et al., 2021) cells stably expressing PRC1-GFP with and without MG-132 treatment (Fig. 4A-B, Supplementary Fig. S4A).” We measured spindle width, length and diameter of the metaphase plate in arrested RPE1 cells stably expressing CENP-A-GFP and Centrin1-GFP, RPE1 cells stably expressing PRC1-GFP, and HeLa cells stably expressing PRC1-GFP. We treated the cells with MG-132 for 30 minutes, as this was in our hands enough to arrest the cells, without causing other changes, e.g., problems with spindle orientation that occur after 1 hour of treatment. The results are now part of the Supplementary Fig. S4 and are obtained from three independent experiments with at least 10 cells per experiment.

      In the discussion the authors conclude that the longer bundles and the reduction in microtubule poleward flux is due to the absence of bridging microtubules. This is an over-interpretation as augmin could in theory affect these parameters independently of the bridging microtubules, longer bundles could be generally due to the reduced number of microtubules in the k-fibers and the bridging microtubules. A better control would be to affect bridging microtubules with an independent tool, such as PRC1 depletion, and to measure these paramenters in the same RPE1 cell line, since differences can arise from cell line to cell line as the authors also document in their study (for example spindle length in Figure 4).

      We modified the Discussion based on new results, so these statements are now in the Results section. For the long, curved bundles, we modified the sentence as follows: “These bundles likely arose either due to PRC1 crosslinking excessively long astral microtubules that were now able to reach the spindle midzone or due to PRC1 activity combined with the excess of free tubulin present as a consequence of less tubulin being incorporated in bridging and k-fibers.”

      Regarding the reduced poleward flux following augmin depletion, we revised the text as follows: “Recent speckle microscopy experiments in RPE1 cells, which were able to separate the effect of augmin on poleward flux of bridging and k-fibers, revealed that both k-fibers and the remaining bridging fibers were significantly slowed down (Risteski et al., 2021 Preprint). Bridging fibers fluxed faster than k-fibers in control and augmin-depleted cells (Risteski et al., 2021 Preprint), supporting the model in which poleward flux is largely driven by sliding apart of antiparallel microtubules (Brust-Mascher et al., 2009; Mitchison, 2005; Miyamoto et al., 2004). We propose that augmin depletion results in slower flux of bridging fibers because the remaining bridging microtubules are likely nucleated at the poles, where microtubule depolymerization mechanisms might curb poleward flux speed (Ganem et al., 2005). In contrast, PRC1 depletion does not affect the flux (Risteski et al., 2021 Preprint; Steblyanko et al., 2020) even though it reduces bridging fibers (Kajtez et al., 2016; Polak et al., 2017), possibly because the remaining bridging microtubules are generated away from the poles via augmin and can thus flux freely.”

      **Minor comment:**

      -the reported flux rate for control-depleted cells is substantially higher than the flux rates normally reported for human cells. This could be due to the experimental conditions (slight changes in temperature), but at minimum the authors should comment on this.

      We performed photoactivation experiments on a higher number of U2OS cells stably expressing CENP-A GFP, mCherry-tubulin and PA-tubulin (N = 30 measured photoactivation spots in 30 control and HAUS6-depleted cells, see Supplementary Fig. S3L-M). U2OS cells with labelled kinetochores and tubulin were used to exclude the potential effects of SiR-tubulin on poleward flux, as well as to better determine the position of the metaphase plate. The results in control cells are comparable to the poleward flux measured in the same cell line (Steblyanko et al., 2020).

      Reviewer #3 (Significance (Required)):

      The significance of the study is that the authors performed a detailed description of the effects of augmin depletion on the spindle architecture, in particular bridging fibers. Nevertheless, many of the reported results are already known (and as cited by the authors): the reduction in inter-kinetochore distances or the change in spindle architecture. The 3 main novel results, is the fact that augmin affects more bridging microtubules, particularly in the central part of the spindle, and that it also affect poleward microtubule flux, which limits the impact of this study to a specialized mitotic spindle audience. Nevertheless, if the authors address the reviewers concerns, this could be a nice, descriptive study for the mitotic field.

      One way to expand the significance of this study would be to test how augmin depletion and the lack of bridging microtubules in the central part of the metaphase plate affects chromosome segregation. Does the specific absence of bridges in this part lead to more lagging chromosomes, chromosome segregation errors, or micronuclei amongst sister chromatids located in the central part of the spindle? Is there a differential anaphase A speed for those kinetochore vs those at the periphery that still are associated to bridging fibers? Such a functional approach could allow to highlight the most interesting aspect of this study, the spatial difference in the effects of augmin depletion. Such experiments would, however, not be part of a revision, but rather a substantial enhancement of the present study.

      Patrick Meraldi

      This is a great idea! We performed new experiments to study lagging chromosomes and indeed found that they were more often found in the inner part of the spindle in HAUS6-depleted than in control cells, which is likely due to the specific impairment of bridging fibers in that area. We also found that lagging chromosomes typically had a lower interkinetochore distance and a higher kinetochore tilt just before the onset of anaphase, which is a signature of perturbed bridging fibers. We dedicated an entire new section on pages 6-11 and a new Fig. 2 to these exciting new results.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      In this study Manenica et study how the presence of the augmin complex affects the overall spindle architecture and the different types of spindle microtubules. The authors propose that depletion of augmin affects particularly bridging microtubules, leading to their disappearance on sister-kinetochores located in the central part of the metaphase plate.

      Overall the manuscript is well written, clear and supported by excellent explanatory schemes. The main conclusion of the manuscript, i.e. that augmin plays an essential role in the formation of bridging microtubules is generally well supported by the data. A number of other conclusions, however, are less well supported by the data and would benefit from a number of additional experiments, repetitions or analysis. Specifically:

      1.Throughout all the figures the authors use a t-test, which is fine when comparing two conditions, but not for multiple experimental conditions. The authors should instead use an ANOVA test or apply a Bonferroni correction. This can strongly affect the significance of some of the reported results

      2.Another general concern is that the authors rely throughout the manuscript on live cell imaging data from few cells (5-10). Live cell imaging data has the advantage to avoid fixation artifacts, but the low sample size is a major concern, as for every experiment the authors rely on 10 cells (and for inter-kinetochore distances on 5) in three independent experiments overall. This means that two our of three of those independent experiments are based on 3 cells only, which is too low, given that siRNA depletions are known to be variable in their efficiencies. With such low number of cells, there is always the danger of an unconscious selection bias, which can skew a result. Just to take an example the spindle length, structure and density for HAUS-8 depleted RPE1 cells looks very different in the examples show in Figure 1B, 2A, or 5B.It is therefore essential to work with a higher sample size, at minimum 10 cells per independent experiment.

      3.Throughout all experiments the authors use 100nm Sir-Tubulin, which in our hands already leads to substantial changes in microtubule dynamics, as it stabilizes spindle microtubules. I understand why the authors did this, as they wanted to also stain for weak bridging fibers, but tt would be important to validate some of the obtained results with an independent approach, for example fixed-cell imaging and tubulin staining, to rule out artifacts introduced by SiR-tubulin.

      4.Figure 1: Given that the authors later report that augmin affects more strongly bridging fibers in the central part of the spindle, how were the values in terms of microtubule densities obtained in the experiments in Figure 1: only on the outer microtubules, or overall in the spindle?

      5.Figure 2: the authors conclude that depletion of augmin has a much stronger effect on the bridging fibers located in the central part of the spindle. This is a very interesting result, but it begs the question as to the origin of this difference. If the authors analyze in control cells the inter-kinetochore distances and the density of the bridging fibers of the kinetochores located in the central part of the metaphase plate vs those located at the outer part of the plate, do they already see a difference? In other words, is the effect of augmin due to already weaker bridging fibers in the central part of the spindle, or is the depletion effect indeed specific for those bridging fibers located in the middle. This analysis should be possible with the existing data (+ a higher sample size)

      6.Figure 4: the authors study spindle width, length and diameter of the metaphase plate in a small number of cells (10). One concern is that these values might change as cells progress from late prometaphase to anaphase onset (metaphase plate width decreases for example). Given the low number of cells the authors do not know if they are comparing cells at similar mitotic times. To circumvent this issues, they could: either arrest the cells with MG132 for 1 hour, to obtain an end-point, or record these different values as cells progress through mitosis and thus be able to compare similar conditions.

      7.In the discussion the authors conclude that the longer bundles and the reduction in microtubule poleward flux is due to the absence of bridging microtubules. This is an over-interpretation as augmin could in theory affect these parameters independently of the bridging microtubules, longer bundles could be generally due to the reduced number of microtubules in the k-fibers and the bridging microtubules. A better control would be to affect bridging microtubules with an independent tool, such as PRC1 depletion, and to measure these paramenters in the same RPE1 cell line, since differences can arise from cell line to cell line as the authors also document in their study (for example spindle length in Figure 4).

      Minor comment:

      -the reported flux rate for control-depleted cells is substantially higher than the flux rates normally reported for human cells. This could be due to the experimental conditions (slight changes in temperature), but at minimum the authors should comment on this.

      Significance

      The significance of the study is that the authors performed a detailed description of the effects of augmin depletion on the spindle architecture, in particular bridging fibers. Nevertheless, many of the reported results are already known (and as cited by the authors): the reduction in inter-kinetochore distances or the change in spindle architecture. The 3 main novel results, is the fact that augmin affects more bridging microtubules, particularly in the central part of the spindle, and that it also affect poleward microtubule flux, which limits the impact of this study to a specialized mitotic spindle audience. Nevertheless, if the authors address the reviewers concerns, this could be a nice, descriptive study for the mitotic field.

      One way to expand the significance of this study would be to test how augmin depletion and the lack of bridging microtubules in the central part of the metaphase plate affects chromosome segregation. Does the specific absence of bridges in this part lead to more lagging chromosomes, chromosome segregation errors, or micronuclei amongst sister chromatids located in the central part of the spindle? Is there a differential anaphase A speed for those kinetochore vs those at the periphery that still are associated to bridging fibers? Such a functional approach could allow to highlight the most interesting aspect of this study, the spatial difference in the effects of augmin depletion. Such experiments would, however, not be part of a revision, but rather a substantial enhancement of the present study.

      Patrick Meraldi

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      Summary:

      The authors found that the microtubules in the bridging fibres of the mitotic spindle in a human cell line are predominantly supplied via augmin-dependent nucleation. On the other hand, the contribution of augmin to kinetochore fibre formation is ~40%. Augmin-depleted cells showed reduced inter-kinetochore tension and slower poleward flux of spindle microtubules, suggesting that bridging fibres play a role in these events. This study expands our knowledge on the role of augmin and augmin-mediated microtubules in animal somatic cells.

      Major comments:

      -Are the key conclusions convincing?

      Yes.

      -Should the authors qualify some of their claims as preliminary or speculative, or remove them altogether?

      In the current manuscript, the slower flux is attributed solely to the lack of bridging fibres in the augmin-depleted cells. This is an overinterpretation, as the augmin's role in the spindle is not limited to generating bridging fibres.

      -Would additional experiments be essential to support the claims of the paper? Request additional experiments only where necessary for the paper as it is, and do not ask authors to open new lines of experimentation.

      No.

      -Are the suggested experiments realistic in terms of time and resources? It would help if you could add an estimated cost and time investment for substantial experiments.

      N/A

      -Are the data and the methods presented in such a way that they can be reproduced?

      Yes.

      -Are the experiments adequately replicated and statistical analysis adequate?

      Yes.

      Minor comments:

      -Specific experimental issues that are easily addressable.

      None.

      -Are prior studies referenced appropriately?

      Yes.

      -Are the text and figures clear and accurate?

      1)Page 15: "To determine the curvature of the bundles, we ..... with all other bundles types (Fig. 5E)." - I could not understand this sentence well, and would like to ask for a revision.

      2)The following words may be too strong: Page 20: whereas k-fiber microtubules are "mainly" nucleated in an augmin-independent manner (could 61% contribution be called "mainly?").

      Page 21, bottom: "demonstrates".

      -Do you have suggestions that would help the authors improve the presentation of their data and conclusions?

      No.

      Significance

      -Describe the nature and significance of the advance (e.g. conceptual, technical, clinical) for the field.

      The presence of bridging fibres has been recognised for decades; however, until recently, little attention has been paid to this structure from a mechanistic and functional point of view. The Tolic lab has been shedding light on this structure for the past several years. The current study represents another step forward in the research of the origin and function of bridging fibres.

      -Place the work in the context of the existing literature (provide references, where appropriate).

      Augmin's critical contribution to microtubule nucleation in the human somatic spindle has been well documented, as cited by the authors. The current study is the first to show that augmin also contributes to bridging fibres. The >70% contribution may be more than expected, given that centrosomal microtubules frequently reach the spindle midzone. Reduced inter-kinetochore tension has also been documented, but previous studies attributed this exclusively to reduced number of kinetochore microtubules. The current study has revised this view.

      -State what audience might be interested in and influenced by the reported findings.

      Spindle researchers.

      -Define your field of expertise with a few keywords to help the authors contextualize your point of view. Indicate if there are any parts of the paper that you do not have sufficient expertise to evaluate.

      This review is written by a researcher who is familiar with the literature of the mitotic spindle.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      In the manuscript "Augmin regulates kinetochore tension and spatial arrangement of spindle microtubules by nucleating bridging fibers", Manenica et al. explore the impact of augmin-dependent microtubule nucleation on formation of a subset of spindle microtubules that bridge sister kinetochore fibers and investigate how this could affect the spindle forces and architecture. Using RNAi- and CRISPR-Cas9- based loss-of-function experimental approach, the authors propose that the bridging fibers are nucleated by augmin and that removal of augmin impairs proper spindle architecture, interkinetochore tension and microtubule poleward flux, specifically via its effect on the bridging fibers. Overall, the study is well designed and the manuscript well written. Expanding the knowledge on augmin contribution to the spindle functions and better understanding of the roles of bridging fibers would be important and of interest to cell biologists studying mitosis. Although this manuscript clearly shows that augmin depletion impairs the formation of bridging fibers (and other microtubules), the specific contribution of the bridging fibers to the augmin-dependent spindle functions is less clear.

      Major comments:

      1)Using cold treatment-induced microtubule destabilization, Zhu et al. (JCB 2008) showed that augmin depletion affected exclusively kinetochore microtubules. Since the bridging microtubules are usually not visible in the cold-treated spindles (due to being less stable/cold resistant compared to the k-fibers), it is unlikely that the observed effects were mainly associated with the bridging fibers. Thus, it would be important to further clarify the respective contribution of augmin to the formation of k-fibers and the bridging fibers. The cold-treatment experiment performed by Zhu et al. could be used in RPE1 and HeLa-PRC1-GFP cells to address the contribution of augmin nucleation to kinetochore- vs. bridging microtubules from another angle.

      Because of the above mentioned results by Zhu et al. it is difficult to grasp how augmin depletion could have a bigger effect on the bridging fibers than on the k-fibers, as concluded from the Fig. 2C data. In fact, Fig. 2A clearly shows a strong effect on k-fibers in spindles where the bridging fibers are reduced/missing.

      Also, Fig. 1 D and E suggest that HAUS8 siRNA exclusively affected the bridging fibers, leaving the k-fibers intact, which is again against the data reported in Zhu et al. 2008 and in contrast with the representing image shown in Fig. 1B. Even if the RNAi was less efficient compared to HAUS6 RNAi, as the authors proposed, this could still not explain the observed discrepancy.

      2)The authors showed that kinetochore pairs in the outer parts of Augmin-depleted spindles have larger inter-kinetochore distance compared to those in the inner parts of spindles. They indirectly related this to a predominant presence of the bridging fibers in the outer parts, concluding that augmin regulates inter-kinetochore tension via nucleation of the bridging fibers. A more direct way would be to show the eventual positive correlation between the inter-kinetochore distance and the bridging- and k- fibers intensity. Also, it would be nice to include the quantifications and correlation data for inter-kinetochore distance, distance from the spindle axis and the bridging- and k- fibers intensities for the control cells too.

      3)It is stated in the manuscript that the k-fibers without bridging fibers have shorter contour length compared to the k-fibers with bridging fibers, and that the curvature of k-fibers lacking the bridging fibers is drastically reduced. However, the data in Figure 5D and Table 1 show a slight effect on the contour length of the k-fibers lacking the bridging fibers compared to the ones containing the bridging fibers only in RPE1 siHAUS8 cells, while this effect seems to be missing in RPE1 HAUS8 KO cells, as well as in siHAUS6 in RPE1 and HeLa cells.

      Fig. 2 shows that the kinetochore pairs without the bridging fibers are located closer to the spindle axis. Thus, it is not clear whether the effect on curvature observed in the augmin depleted cells is independent of the position of kinetochore pairs within the spindle, as the spindle axis-proximal pairs would anyway have a bigger radius compared to the more distant ones.

      4)The authors reported that augmin depletion impairs microtubule poleward flux and conclude that this happens exclusively due to the perturbation of bridging fibers. While the results from this and other studies clearly show that augmin depletion perturbs spindle microtubules in general, it is not clear whether this had a stronger effect on the bridging microtubules (see the comments in point 1). Thus, the impact of augmin depletion on kinetochore microtubules or other antiparallel microtubules within the spindle (e.g. the ones recently shown in O'Toole et al., MBoC 2020) cannot be ruled out as a potential cause of the impaired microtubule flux. Also, Steblyanko et al. (EMBO J, 2020) showed that PRC1 depletion had no effect on microtubule poleward flux in metaphase cells. Since it has been previously shown by the authors of this manuscript that PRC1 depletion disrupts the formation of bridging fibers, it is unlikely that the bridging fibers are the main cause of the augmin depletion-mediated effect on the microtubule flux.

      Minor comments:

      1)Introduction: chromatin- and kinetochore- mediated generation of spindle microtubules are ignored when describing the origins of spindle microtubules in human somatic cells.

      2)The authors proposed less efficient HAUS8 depletion as a potential reason of discrepancy between the siHAUS6 and siHAUS8 results. This should be shown by Western blot, like it is presented for the RNAi efficiency of siHAUS6.

      3)The measurements of total PRC1 intensities are mentioned in the manuscript text, but not shown in the figures.

      4)Supplementary Videos 3 and 4 are wrongly annotated as Supplementary Videos 1 and 2 in the text.

      5)Given the spindle length phenotypes are opposite in HeLa and RPE1 cells, in order to be consistent with the other experiments it would be better to perform the PRC1 measurements in RPE1 cells (e.g. using the anti-PRC1 antibody as shown in Supplementary Fig. 3B).

      6)Why are the microtubule flux rates for RPE1-PA-GFP-α-tubulin cells measured in this study largely different than the rates reported for the same cell line in Dudka et al., Nat Comms 2018 and Dudka et al., Curr Biol 2019? In order to better understand this difference and strengthen the microtubule flux data, it would be helpful to increase the experimental numbers to match the ones used in the mentioned studies.

      7)The number of cells used per each experiment should be clearly stated.

      Significance

      This study expands the analysis of augmin contribution to the spindle functions and focuses on its role in formation of the bridging fibers, which is of interest to cell biologists studying mitosis. It clearly shows that in addition to its effect on the k-fibers, augmin depletion also impairs the formation of bridging fibers. However, the exact contribution of the bridging fibers to the spindle functions affected by augmin depletion remains unclear.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      The authors do not wish to provide a response at this time.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      The authors found that the expression of CXCR2 is decreased in patients with moderate COVID-19. However, the mechanisms were not explored. The hyperactivation status of neutrophils is not well defined, and proteomics data are not validated. The rationale for comparing healthy controls and severe COVID-19 patients is unclear. The manuscript in its current form raised more questions than answers.

      Major concerns:

      1. No information is available on the healthy control group. How do they compare to the COVID-19 group? Age-, sex-differences? Comorbidities?
      2. Figure 1E. While the decrease in the level of CXCR2 expression in the moderate group is statistically significant, the functional significance of this finding is unclear. The MFI mean value of approximately five hundred units is still high. Whether it would it be translated into decreased neutrophil migratory activity and tissue recruitment is unknown. As with any G-protein coupled receptor, the ligand-dependent stimulation of CXCR2 would induce its internalization. Do the authors consider the possibility of increased levels of CXCR2 ligands causing lower cell surface levels of CXCR2 in patients with moderate illness?
      3. The proteomic analysis would be helpful in the identification of potential mechanisms involved in the reduced level of CXCR2 in the moderate group. However, the authors have decided to perform this analysis on healthy controls and patients with severe COVID-19 illness, two groups with a similar level of CXCR2 expression.
      4. Figure 2. No information is available on the selection criteria for the samples used in proteomic analysis. How representative were those four healthy controls and three COVID-19 patients for their respective groups?
      5. Figure 2. It is unclear why the authors believe that the changes identified in proteomic analysis indicate the hyperactivation status of neutrophils. The analysis is performed by comparing neutrophils from the severe COVID-19 group against healthy control subjects. Would it be different for mild or moderate illness groups if compared to patients with severe illness or healthy subjects? Without these data, it is hard to understand if reported changes indicate hyperactivation.
      6. The authors' statement on neutrophil activation is not confirmed by any measurements in vitro or in vivo. It is unclear if these neutrophils produce more proinflammatory cytokines or reactive oxygen species? Are they more prone to undergo NETosis?

      Minor:

      1. It is unclear why the statistical approach in Figures 1A and B is different from the approach used in Figures 1C, D, and E.
      2. Figure 1A, flow cytometric dot plot: It is interesting to see that the immature neutrophils are represented by a distinct subset of CD10- cells. In other studies, including those cited by the authors, immature neutrophils are characterized by gradually decreased expression of CD10, not distinctly separated from mature neutrophils.
      3. In Supplemental Figure 1 - the gating strategy for singlets is mislabeled; should be FSC-A vs. FSC-H, but listed as FSC-A vs. SSC-A.
      4. It may increase the translational value of the study if the authors perform an analysis of immune markers against clinical parameters demonstrating the severity of illness, e.g., hospital length of stay or hospital-free days, patients in an intensive care unit (ICU) versus non-ICU, and lab tests, serum CRP, WBC, NLR.

      Significance

      In the current study, Rice et al. investigated the subpopulation of peripheral blood neutrophils obtained from patients with COVID-19 and healthy controls. The authors performed flow cytometric and proteomic analyses to determine the association between immunophenotype and activation of neutrophils and the severity of COVID-19 illness. The flow cytometric analysis is meticulously executed and informative and confirms previously published data on the immature status of circulating neutrophils in COVID-19.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      Summary

      In this manuscript, the authors used flow cytometry to investigate activity and phenotypic diversity of circulating neutrophils in acute and convalescent COVID-19 patients (acute COVID-19 patients: 34; healthy controls: 20). Further analysis indicated that hyperactivation of immature CD10- subpopulations in severe disease. Additionally, the authors found CXCR2 was down-regulated in moderately ill patients, and CD10- and CXCR2hi neutrophil subpopulations were enriched in severe disease. This work is interesting, yet the main problem of this work is that it lacks of novelty, and the conclusion was proposed without solid evidence.

      Major points:

      1. The author 's main conclusions were based on flow cytometry. However, they didn't validate the purity of neutrophiles sorted by their sorting strategy.
      2. The statical analysis should be checked by statisticians.
      3. The author indicated they detected decreased expression of CD10 from moderate and severe COVID-19 patients, and concluded the potential of its prognostic utility. However, this conclusion is not novel, previous research performed by Silvin et al. and others have presented the immunosuppressive profile of CD10lowCD101-CXCR4+/- neutrophils in severe form of COVID-19 (PMID: 32810439, PMID: 33968405).
      4. It seems that the author specifically picked CD10 to present its difference between patients and heathy controls, yet, for one thing the author didn't show how they detect the expression of CD10, did they perform western blotting, transcriptome or proteome? For another, the author did not show explain if CD10 is the only proteins or the top-ranked protein that show prognostic value.
      5. To further explore the neutrophil activation and chemotactic capacity, the author compared the proteomes of circulating neutrophils from severe and healthy controls. However, comparing to the published work, the sample numbers were too small, for there are only three severe patients enrolled, the author should include more samples for analysis.
      6. The author performed UMAP analysis, and conclude long term perturbations to the myeloid compartments of convalescent patients. This conclusion is too rash, the author should include clinical index, such as absolute neutrophil counts, neutrophil percentage for integrative analysis.
      7. The proteins that the author indicated to be neutrophil functional related are more likely to be functional universal. The author should include neutrophil specific datasets and screen out neutrophil specific markers for further analysis.
      8. The author utilized X-Shift analysis to analyze the distinct neutrophil phenotypes in different disease states, yet, only one or two markers can hardly describe the whole picture. The author should conduct single cell transcriptome or proteome to systematically depict the diverse neutrophile phenotypes in different disease status.
      9. There are multiple published papers describe the immune cell subsets of COVID-19 (PMID: 32838342, PMID: 33657410), the author should compare with them.

      Minor point:

      1. In table 1, the authors did not provide the p value among Mild, Moderate, and Severe groups.
      2. In Sup Fig 1B, Sup Fig 1C, Sup Fig 2E-G, I-K, Sup Fig 3D, the authors did not provide p value.
      3. The author assumed "Principle component analysis (PCA) demonstrated heterogeneity amongst the severe patients, which was explained by patient outcome (Fig 2C)." Again, too small sample numbers, can hardly show the diversity.
      4. In Fig2G, the authors descripted patient neutrophils, and not descripted which type of patients.
      5. The authors mentioned Fig1G in the sentence "Ingenuity pathway analysis (IPA) identified pathways related to chemotaxis, such as 'Signalling by Rho family GTPases', 'RhoA signalling' and 'Regulation of Actin-based Motility by Rho' as significantly enriched in patient neutrophils (Fig 2G), which aligns with maintained expression of CXCR2 (Fig 1G)", however we did not see the corresponding Fig1G.

      Significance

      The paper lacks arguments regarding the novelty of the findings, as well as context with the current literature available for COVID-19 (several examples of the available literature references are provided) including comparison to published single cell dataset of COVID-19 (PMID: 32838342, PMID: 33657410, PMID: 32810439, PMID: 33968405). The paper focused more on known example, which are indeed useful to assess their strategy, but failed to detail their findings about unknown protein candidate which would bring more value to the manuscript.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      The authors do not wish to provide a response at this time.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      Summary:

      The manuscript entitled "Proximity labelling identifies pro-migratory endocytic recycling cargo and machinery of the Rab4 and Rab11 families" by Wilson et al, presents an approach, BioID, able to identify and characterize protein complexes associated with Rab proteins in an ovarian cancer cell line. They started the study by coupling a proximity labelling method to mass spectrometry. By doing so they identified the interactomes associated with Rab4a, Rab11a and Rab25. Next, the authors proceeded to detect directly biotinylated peptides. Then, using knock sideways experiments, the authors validated novel links between Rab11/Rab25 and some of the direct interactors identified. Lastly, they propose that SH3BP5L and CRACR2A are required for migration of ovarian cancer cells, in 3D-cell derived matrix.

      Major comments:

      1) A major limitation of the study is the reliance on a single migratory cell line, the A2780 cell line. As such the authors should include additional cell lines for their key experiments throughout the manuscript.

      2) The authors state that BioID-Rabs are expressed at a "level close to endogenous". This should be quantified. Also, authors should clearly show that BioID-Rabs co-localize with the endogenous Rabs. So, immunofluorescence labelling of endogenous Rabs and markers for Early Endosomes (e.g. Rab5, EEA1, etc) and Recycling Endosomes should be performed.

      3) In the dot-plot of the high-confidence proximal analysis, the average intensity (represented in the circle colour) should be normalized by the abundance of protein.

      4) The knock sideways experiments validated high affinity prey interactions, including of sorting nexins with Rab4/11/25. SNX1 and SNX3 showed that they would only significantly redistribute in FKBP-GFP-Rab11a and FKBP-GFP-Rab25, respectively. Authors should comment on why the role of SNX1 and SNX3 was not assessed in migration studies.

      5) Knock sideways showed that Rab4 was unable to induce significant re-localization of CLINT1. This would suggest that CLINT1 would be a candidate less robust than others identified by BioID and validated by knock sideways experiments. Why did the authors decide to proceed to assess the role of CLINT1 in migration studies?

      6) Although the authors reported a lack of significant re-localization of CLINT1 by Rab4a, they state that "CLINT1 plays a role in Rab4 (but not Rab25) dependent migration in 3D-CDM". Can the authors comment on this?

      7) "CLINT1 was identified as a Rab4, -11 and -25 proximal protein (Figure 2)". The study would benefit from additional evidence showing that CLINT1 does not act downstream of Rab11 to control migration of A2780 cells.

      8) Authors should include immunofluorescence studies to better characterise the role of Rab4a, Rab11a and Rab25 networks in migration, adhesion and leading-edge related processes. Focal adhesions should be quantified, and actin cytoskeleton described. Such studies should be coupled to the cell migration studies. These would validate and support the conclusions drawn from the GO analysis.

      9) In the discussion, the authors mention two other papers in which "proximity labelling methods have proven an excellent tool for identification of protein complexes, including for Rab4 and Rab11". The authors should also discuss if there are overlapping results.

      Minor comments:

      1) Figure 1: Panel A is too small. Insets are hard to interpret. The size of the whole panel should be increased.

      2) Description of results regarding the trafficking machinery associated with Rab4a, Rab11a and Rab25 does not follow the same organization and structure as in Figure 2. The authors should try to match the organization of data and its description to improve readability.

      3) In Figure 4B and S4C there are two labels for 1 and 2.

      4) Figure S4E merge of GFP-FKBP Rab11a cells shows poor overlap. A replacement should be considered.

      5) There are several typos in the discussion and in Figure 7 ("CRACRA" should be CRACR2A)

      Significance

      • The manuscript presents an approach that allow the identification of Rab-associated networks and the direct comparison between GTAses. This is of relevance since we still lack robust methodologies to identify the endosomal trafficking machinery underlying migration in cancer cells. By not targeting Rab4 specific machinery (e.g. TBC1D5), the authors missed the opportunity to expand the knowledge regarding the machinery sustaining Rab4-dependent migration in cancer cells.

      • The work targets an audience interested in endosomal trafficking and protein recycling in cancer cell migration.

      • The reviewer is a translational cancer biologist with expertise in cytoskeleton, endosomal recycling, signaling and cancer.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      Wilson et al. submitted a paper entitled: "Proximity labelling identifies pro-migratory endocytic recycling cargo and machinery of the Rab4 and Rab11 families". The goal of the paper is to identify new interactors for RAB4/11 and 25 that could be involved in Rab-dependent migration. To do so, they used BioID of the aforementioned 3 Rabs in mesenchymal and migratory ovarian cancer cell line A2780. They validate some of the interactors using the knock-sideways technique and test the requirement of some interactor for migration/invasion in a 3D matrix. This is a very descriptive paper that could benefit from more in-depth mechanistic analysis of fewer candidates.

      Major comments:

      • For the most part, the data appears of excellent quality and most of the conclusions or interpretations are correct (see below for a few points that can be improved). Some key concepts are missing in the introduction. For example, the concept of GEFs and GAPs only appears later in the experimental section - this should be introduced earlier.

      • The description of the BioID data is poorly structured and descriptive, a recurring challenge with big data paper. One suggestion to improve the manuscript would be to exploit the best-known interactions to clearly benchmark the efficiency of the screens. Next the new interactions could be described and figure 2 could be better exploited in that respect (the mentioned complexes could be better drawn etc.). The text could also be more focused on fewer interactors such that it is more digestible for the readers. The major weakness of the manuscript, in my opinion, is the lack of depth in testing functionally some of the uncovered novel interactions.

      • Some additional experiments that would be needed to support the claim of novelty in the paper include testing the function of some of the tested interactions. For example, the novel GEF interactions would benefit from biochemical testing in addition to BioID. Likewise, the section on biotinylation and interaction domain mapping is interesting but is, as presented, a theory. Using one interaction to dissect in more details to support this claim is needed. Alternatively, can the authors demonstrate that this approach can be used to confirmed known protein domains involved in protein-protein interactions of these Rabs? Finally, the authors end their manuscript by screening candidates issued from their BioID which have not been implicated in migration/invasion before. This is somewhat preliminary and fails to provide some depth into the function of one of these potential interactions (domain mapping, knockdown rescue of wt or mutants etc.).

      • The authors use the knock-sideways technique to validate the strength of their interaction. This is a clever way to validate interaction in cellulo which could be difficult using conventional IP. However, it looks like the expression of FRB-MITO leads to mitochondria fragmentation and aggregation. Is it possible that this cause a bias in their quantification analysis because it becomes difficult to clearly delineate individual mitochondria? In some cases (ex. Fig 5C), the recruitment of the candidate is obvious. However, in other cases (ex. Figure 5A) the recruitment to the mitochondria is not very convincing and looks more like the candidates collapse around the aggregated mitochondria. The authors should therefore describe the limitations in more details.

      Minor comments:

      • The authors aim to identify new interactors involved in migration, but they performed the BioID on confluent cells where cell migration is likely limited. Would comparing a BioID performed on confluent cells with one where the cells are sparse enough to migrate possibly interesting to conduct? This could be discussed.

      • In Figure 1C, it is difficult to read the name on the candidates. The authors should fit the entire name in the nodes (maybe use an ellipse instead of a circle).

      • In Figure 1C and 2 the known interactors could be in a different color emphasize the new potential interactors.

      • Figure 4 is very heavy and the images are small making difficult to see the results clearly. Instead of showing 10 time points per condition, 3 or 4 time point with higher resolution images would have been more appropriate.

      • Methods: The methods are well described. It is a bit surprising that the BioID samples are run on SDS-PAGE and that bands are cut when on beads digestion is currently done by many lab for this technique.

      • Statistics: Statistics should be provided for all quantification, not only the one that are significant. For the non-significant, the P-value should be indicated on the figure.

      • The authors looked at endogenous Rab11 vs BioID-Rab11. Why no do it for the other 2 Rabs. Also, quantification of endo/exo expression should be done.

      Significance

      • The advance of this work is to expand the potential functional interactome of three Rabs involved in slow recycling of endosomes. Some novel interactions are reported and some screening approaches have been use to reveal functional ones (this could be improved).

      • This work is potentially important and part of the priorities in the field to ascribe the overlapping and specific interactions/functions of Rab subfamilies. Similar work has been done for Rho proteins and selected Ras oncogenes.

      • The work presented here would be of broad interest for people in the cell biology field.

      • The expertise of this reviewer is in Ras-superfamily proteins, proteomics, cell migration/invasion and as such was qualified to assess this manuscript in its entirety.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      From methodology and reproducibility point of view it is an excellent manuscript. It is also well-written.

      Significance

      • This is a manuscript that presents an in-depth analysis of potential interactome and cross-interactome of Rab11a, Rab4a and Rab25 GTPases. BioID and knock-sideway data presented in first half of the manuscript is very interesting and undoubtedly will be of a good use for many laboratories. However, authors tend to over-interpret some of their data, suggesting functional connections between specific Rabs and BioID hits without any additional data. Authors admit themselves that there are some disconnects between BioID and knock-sideways data. Furthermore, BioID measure proximity and not functional connection.
      • Second half of the manuscript focuses on taking some of the BioID hits and testing whether they are required for mediating cell migration. By itself, it is a great idea since that would provide that functional connection that is missing in the original BioID screen. Unfortunately, the data is limited to few knock-downs without any further analyses of the involvement of these proteins in regulating migration. Consequently, as it stands, this manuscript is essentially a BioID screen with limited insights or validation of specific "hits", thus, does not really lead to any new conclusions about cross-function of Rab11, Rab25 and Rab4 networks.

      • Additional comments:

      1) There are no blots shown (only boxes) for Figure S1C-D. Data in Figure S1 doe shown that BirA-Rab11a is expressed in similar levels as endogenous Rab11. However, no data supporting similar statement for Rab4 and Rab25 is shown.

      2) The presence of specific proteins in BioID does not mean that they either directly bind or regulate particular BirA-Rab. For example, authors state "DENND4C, related to Drosophila Rab11 GEF CRAG, was enriched to Rab11a, suggesting that this could be an alternate GEF for Rab11". There is no data supporting such a statement in this manuscript. Actually, DENND4C is better known GEF for Rab10. Rab10 is also known as Rab present in recycling endosomes, thus, could have easily be present in Rab11a-positive recycling endosomes. There are numerous similar statements in the manuscript that implies functional connections between Rabs and BioID "hits" without providing any other functional data.

      3) Authors should not use RCP term to refer to Rab11FIP1 since Rab11FIP1 is its established name and using other names only creates confusion. RCP term was first used to indicate that Rab11FIP1 can bind to both Rab4 and Rab11, the hypothesis that since then was proven to be incorrect.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      The authors do not wish to provide a response at this time.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      The metalloprotease ADAM17 is a key drug target for inflammatory diseases and tumors. The authors previously demonstrated that ADAM17 activity is controlled by iRhom proteins and by a largely uncharacterized protein called iTAP, which had been mostly investigated in vitro. The current manuscript extends the previous findings to in vivo functions, in particular in pathophysiological conditions. The authors demonstrate that iTAP-deficient mice are viable and largely without overt phenotypes under physiological conditions, but do show phenotypes upon inflammatory conditions and during tumorigenesis. During LPS-induced inflammation, iTAP-deficient mice are reported to show defects in epithelial repair functions. Upon lung tumor cell injection, iTAP-deficient mice revealed reduced tumor growth in a cell autonomous and a non-cell autonomous manner, raising the possibility to use iTAP as a potential new drug target for certain tumors.

      The study is novel, the manuscript is well written and easy to understand and the conclusions are largely justified by the data.

      My only major concern is the choice of the control LLC cells. The cells used are not the ideal control for the iTAP knock-out cells. Both wild-type and iTAP knock-out cells were transduced with a Cas9 expressing vector, as it should be. But only the knock-out cells were further transduced with a virus expressing the gRNAs against iTAP, whereas the control cells apparently were not transduced with a virus expressing control gRNAs. Three single cell clones of the iTAP ko cells were pooled for in vivo injection, whereas the parental pool (and not clones) where apparently used as a control. My concern is that the ko cells do not only differ from the wild-type cells due to the knock-out of iTAP, but potentially also due to other gene expression alterations resulting from the additional transduction of the knock-out cells with a gRNA virus and because of the selection of single cell clones. Such expression changes beyond the simple lack of iTAP may have a major influence on those tumor phenotypes in vivo, where these cells were used. Ideally, the authors would generate an additional, independent pool of iTAP knock-out cells and repeat one of the crucial in vivo experiments. As a time-saving alternative, the authors need to demonstrate that the iTAP knock-out cells are nearly identical to the control cells (with the exception of iTAP). This could be done by RNA sequencing or cell lysate proteomics or by blotting for several different proteins (at least 10 from different compartments) and demonstrating that there is no significant change in protein abundance - apart from iTAP.

      I do have a number of additional, but minor points.

      1. Indicate the concentrations of the used drugs (marimastat, PMA) in the figure legends.
      2. Indicate in the manuscript that LLC cells are of mouse origin.
      3. Page 6, top paragraph: it is not clear to me, whether there is an eye phenotype or not. Please rephrase this sentence.
      4. Figure legend 1: "...with 3 replicates per experiment". Indicate whether this refers to biological or technical replicates.
      5. Indicate in figure legends which statistical test was used.
      6. Fig. 2F. The y-axis label should be body weight and not body weight loss.
      7. Fig. 4C: the increase in the 75 kDa fragment upon iTAP OE is difficult to see. Can you quantify the increase? And also the reduction in the KO cells?

      Review Cross-commenting

      When reading the comments from reviewer 1 and 2, it is not always obvious to me which experiments must be done (as a requirement) and which ones are "just" nice to add. It would be great if this could be specified clearly in their reviews.

      Significance

      This study is exciting. It shows for the first time the pathophysiological role of iTAP in vivo and has major implications for ADAM17, which is a drug target in numerous diseases, in particular sepsis, inflammation and tumors. However, systemic ADAM17 inhibition induces severe side effects so that approaches are sought that allow a tissue-specific inhibition of ADAM17. One way to achieve this, is to block the protein iRhom2 which is a non-proteolytic subunit of an ADAM17-iRhom2 complex. Loss of iRhom2 allows a tissue-specific inhibition of ADAM17 specifically in immune cells, because other tissues express iRhom1 that can largely (but not fully) compensate for loss of iRhom2. Thus, iRhom2 inhibition is currently pursued in drug development. The current manuscript demonstrates an additional way (through iTAP) of selectively blocking pathophysiological functions of ADAM17 in tumors (and potentially sepsis), while maintaining physiological functions. This study is an important step towards the use of iTAP as a drug target. Thus, this study will be of interest to basic scientists studying ADAM17, its regulation, its substrate specificity and its physiological functions. The study will also be of interest to translational scientists in academia and pharma/biotech studying the numerous ADAM17-dependent diseases. A clear strength of the study is the inclusion of different disease models, where iTAP plays a role (protective or non-protective), and the demonstration that iTAP contributes to tumors both in the tumor niche and in the tumor itself. A limitation of the study is that the underlying mechanisms remain unclear apart from reduced ADAM17 activity. In particular, it remains open which substrate(s) contribute on the tumor side or the niche side. This lack of mechanistic insight is addressed in the discussion section, where a number of future follow-up experiments are suggested. Another central open mechanistic point is the question of why iTAP, that binds to both iRhom1 and iRhom2, apparently only affects iRhom2 function in vivo. Maybe iTAP only acts on iRhom2-dependent ADAM17 substrates? Despite these mechanistic weaknesses that need to be addressed in future studies, the study is exciting. I have expertise in ADAM17 and iRhoms, but cannot fully judge the tumor histology.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      Summary:

      In "The ADAM17 sheddase complex regulator iTAP modulates inflammation, epithelial repair, and tumor growth" the authors investigate the role of iTAP (FRMD8) in regulation of the ADAM17 sheddase complex. This manuscript is a follow-up to a previous study (Oikonomidi et al. 2018) in which the same group (and another group, Künzel et al. 2018) defined iTAP and generated an iTAP-deficient mouse model via CRISPR. The current work uses in vivo models of sepsis (LPS injection), colitis (DSS administration), and tumor growth and metastasis (LCC subcutaneous and IV transfer models) to further investigate the role of iTAP during disease. The authors find that mature ADAM17 levels were decreased in immune cells from iTAP-deficient mice and shedding of L-selectin was impaired. They next showed that iTAP KO mice have reduced TNF serum levels in a sepsis model. During experimental colitis, iTAP KO mice had higher levels of intestinal disease indicators. In a subcutaneous tumor model, iTAP KO mice showed decreased tumor burden. Furthermore, the authors observed tumor cell autonomous and cell-non-autonomous roles for iTAP in subcutaneous and IV LLC transfer models. While this study nicely adds to our knowledge about in vivo effects of iTAP-deficiency, it is largely descriptive with little investigation into the mechanisms by which iTAP/ADAM17 promote disease. Despite these limitations, the authors make claims about mechanism in the title, abstract, and text without data to support these statements. For example, one of the conclusions of the manuscript is that iTAP influences tumor growth via control of cell proliferation yet there are no data to support this claim. Therefore, I have serious reservations that need to be addressed before I could consider publication of this work.

      Major comments:

      Figure 1: The findings regarding L-selectin shedding are very clear and perhaps meaningful. However, a discussion putting these findings in context with the disease models used later in the manuscript is warranted. Currently, inclusion of these data does not add much to the story if not discussed or referenced later in the manuscript.

      Figure 2: The authors observe that iTAP KO mice have worse outcomes following DSS-colitis. In the text, they mention that iRhom2 KO mice do not phenocopy the iTAP KO mice following DSS-colitis, yet no explanation is offered. If the mechanism of iTAP is proposed to be through iRhom2 activity and ADAM17 shedding, you would expect the iRhom KOs to demonstrate similar intestinal phenotypes. The authors should comment on this discrepancy.

      Additionally, the conclusion about the importance of iTAP in intestinal repair would be better supported if the DSS colitis experiments were continued to later time points to include the recovery phase (once the mice return to original body weight), rather than just ending the experiment at peak repair.

      Figure 3: The authors make the statement that "...although inflammatory infiltrates were modest in the lungs of mice..." Is this based on histology alone? If the authors want to make this claim, they must assess immune infiltrates directly (e.g. using flow cytometry).

      The authors evaluate lung metastasis in the LLC subcutaneous model but any conclusion about metastasis cannot be made in this model without looking at primary tumors of a similar size. Metastasis tends to be associated with the size of the primary tumor so smaller primary tumors usually mean lower levels of metastasis (without being able to parse apart direct effects on the metastatic process). I assume that the data in Fig 3H are from mice with different tumor sizes--in order to properly evaluate this, the authors need to euthanize WT and KO animals with similar tumor burdens and compare metastatic burden.

      Including total mRNA levels of cytokines does not add to this figure. First, bulk levels of mRNA are not a good way to evaluate the state of a tumor (immune cell phenotype/activity would be better). Second, TNF and IL-6 were used in previous figures as readouts of ADAM17 activity (or not) and here are just markers of inflammation? This is confusing/contradictory. If included, this should be moved to the supplement.

      Figure 4: Claims about proliferation cannot be made here because the results as shown are not significant (Fig 4K). Additional readouts for proliferation should be used to support this conclusion.

      Similar to Figure 3, claims about metastasis cannot be made from these experiments without comparing mice with similar primary tumor burden. The metastasis data in Figure 5 are much more solid and convincing.

      Figure 5: The authors use Fig 5 K & L as evidence that tumor cells proliferated more or less rapidly, depending on expression levels of iTAP. The data do not support this statement. If I understand the methods correctly, this assay involves plating of 500K tumor cells and then harvesting after several days. Upon harvest, there were 100 fold fewer cells (~5K). To me this indicates effects on survival, not proliferation. Proliferation was never measured in this assay. Without these data, the authors can make no claim regarding the mechanisms of tumor cell autonomous functions of iTAP.

      Minor comments:

      The language regarding any results that are not statistically-significant need to be softened in the text. In several places, there are statements about non-significant results that are much too definitive and somewhat misleading. Non statistically-significant results can be useful to include to show trends (as in Fig 5 G-I), but the interpretation should not be overstated.

      The title is overstated. In this manuscript, the authors do not show clear mechanistic links for iTAP promoting epithelial repair (worse outcomes after DSS are not just caused by decreased repair). The strongest data in the manuscript are those regarding tumor growth. This should be highlighted in the title.

      Significance

      This work adds additional data to support the importance of iTAP/sheddase complex/ADAM17 in disease development. Most importantly, it suggests a role for iTAP in tumor progression. However, the mechanisms leading to increased tumor growth still remain unknown. Additional work is required to elucidate the molecular mechanisms underpinning these observations.

      The target audience of this work would include cancer biologists and experts studying growth factors and metallopeptidases. For context, my background is in tumor immunology and immune-stromal interactions.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      The study analyzes the function of the FREM domain containing protein Frmd8/iTAP, which the authors have identifies as a binding partner of iRhom2. This rhomboid pseudoprotease has earlier been identified as a binding partner of the membrane-bound metalloprotease ADAM17. The iRhom2 protein is necessary for trafficking of ADAM17 through the ER/Golgi network to eventually reach the cell surface. Apparently, the proteins Frmd8/iTAP, iRhom2 and ADAM17 form a sheddase complex. In the present study, the authors have used knock-out mice for the gene coding for Frmd8/iTAP to analyze the role of the Frmd8/iTAP protein in vivo. The authors found that maturation of ADAM17 in hematopoietic cells was impaired and that shedding of ADAM17 substrates was strongly reduced. In a DSS inflammatory bowel disease model, Frmd8/iTAP knock-out mice were slightly more affected than WT mice. When tumor cells were injected into WT or Frmd8/iTAP knock-out mice, tumors were smaller in the absence of the Frmd8/iTAP protein. The deficiency of Frmd8/iTAP in tumor cells resulted in less tumor growth whereas the overexpression of Frmd8/iTAP in tumor cells led to more tumor growth. I.v. injection of tumor cells deficient for Frmd8/iTAP led to significantly less metastases, tumor volume and tumor burden. Th authors suggest that therapeutic intervention at the level of Frmd8/iTAP might be helpful during inflammatory diseases or cancer.

      This is an interesting study, which addresses the important role of ADAM17 and the pathways controlled by this protease. There are, however, some points the authors should address.

      Major points:

      1. Although the Frmd8/iTAP protein was identified as a binding partner of the iRhom2/ADAM17 complex, it remains unclear whether this protein also serves as a binding partner of other proteins. When analyzing Frmd8/iTAP knock-out mice, this might be an important aspect, which is not addressed in the manuscript. Is Frmd8/iTAP always co-expressed with iRhom2 and ADAM17?
      2. It has been shown that iRhoms have additional clients apart from ADAM17. For instance, the adaptor protein STING has been reported to be constitutively associated with iRhom2. Therefore, it is possible that Frmd8/iTAP also plays a role in the STING pathway. This point needs to be addressed.
      3. All Western blots shown in the figures and supplemental figures should be quantified by a suitable software such as Image J.
      4. In Fig. 2C,D, the authors use a sepsis model and they show that Frmd8/iTAP knock-out mice have lower TNFa levels than WT mice. Is this also true for sIL-6R levels? Was survival of the mice affected by the absence of Frmd8/iTAP?
      5. In Fig. 2E-J, the authors employ a DSS-driven inflammatory bowel disease model. It has been shown before (Chalaris et al, 2010; cited in the manuscript) that the higher susceptibility of hypomorphic ADAM17 mice was related to reduced shedding of EGF-R ligands in this model. Therefore, the authors should address shedding of these ligands in Frmd8/iTAP knock-out mice.
      6. In the experiment shown in Fig. 5, the authors inject parental and Frmd8/iTAP knock-out LLC tumor cells into WT mice. The note that the number of metastases, tumor volume and tumor burden is dramatically decreased. In the study by Bolik et al, 2022 (cited in the manuscript) it has been shown that in hypomorphic ADAM17 mice, metastasis formation by LLC tumor cells was dramatically reduced. In this study it was also shown that ADAM17 activity in endothelial cells was responsible for this effect, which was at least in part mediated by TNF-RI and TNF-RII. This mechanistic difference should be addressed in the manuscript.
      7. Along the same line: when tumor cells are injected i.v., the cells need to extravasate before they can form tumors. The authors need to mechanistically address whether the effects of Frmd8/iTAP are on extravasation or on tumor growth (or both).

      Minor points:

      1. The authors name the protein Frmd8/iTAP sometimes as Frmd8 and sometimes as iTAP. This is confusing for the reader. Since the protein has been characterized under both names, the authors should stick to Frmd8/iTAP.
      2. Along the same line: the authors should stick to the name ADAM17 and not sometimes switch to the older name TACE.
      3. The authors use Frmd8/iTAP knock-out mice. It is not clear from the statement of p5, whether they use the mice described in Künzel et al, 2018 or the mice described in Oikonomidi et al, 2018. This should be clarified.
      4. Some references (e.g. Dong et al, 1999 and Gschwind et al, 2003) are incomplete.

      Significance

      Nature and significance of the advance:

      Knowledge about the susceptibility of Frmd8/iTAP knock-out mice to some disease models of inflammation and cancer.

      Compare to existing published knowledge:

      It was known before that Frmd8/iTAP plays a role in ADAM17 maturation and that the absence of Frmd8/iTAP leads to lower shedding of several substrates.

      Audience:

      ADAM17 governs important pathways such as TNFa, IL-6R, EGF-R and others and therefore, the regulation of ADAM17 activity is of interest to many readers.

      Your expertise:

      I work on the cytokine IL-6 and the IL-6 trans-signaling pathway, which relies on the soluble IL-6R, generated by ADAM17. Therefore I feel competent to review the manuscript.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      __Manuscript number: __RC-2022-01357

      __Corresponding author(s): __Peter Novick and Gang Dong

      1. General Statements [optional]

      We would like to thank both reviewers for their thorough and constructive evaluation and comments on our manuscript. Following their suggestions, we have reworked our manuscript and added several pieces of new data to address questions from them, including (1) evaluation of how M7 mutant of Sso2 affects its interaction with Sec3 using three independent methods (in vitro); (2) investigation of how the M7 mutant affects the interaction of Sso2 with Sec3 by co-immunoprecipitation (in vivo). We hope that, with all these further introduced changes, this manuscript will be suitable for publication in your journal. Detailed point-to-point responses are shown below.

      2. Point-by-point description of the revisions

      Reviewer #1 (Evidence, reproducibility and clarity (Required)): *

      Using the entire cytoplasmic domain of Sso2 and protein crystallization, Peer and colleagues show that two N-terminal peptides (NPY) of Sso2 synergistically interact with the Sec3 PH domain. This interaction provides an additional low affinity binding site to the previously published interface between the Sso2 four-helix bundle and the PH domain. Mutagenesis, in particular of both NPY motifs, results in reduced cell growth, in the accumulation of transport vesicles at the budding site, and in decreased secretion of invertase and Bgl2. The paper is well written, the data are convincing and the characterization of these novel peptide interaction sites clearly advances the field. Although, the exact role of the Sec3 NPY - Sec3 interaction still needs to be established, the overall functional relevance is apparent and thus the paper could be published with minor changes. *

      __Response: __We really appreciate the reviewer for his/her positive comments and clear/constructive feedbacks.

      *Nevertheless, the authors may consider to address the following issues to improve the manuscript. - To strictly exclude the possibility that the Sso2 NPY motif also interacts with other components of the exocytosis machinery (e.g. Sec1), thereby causing the observed phenotypes, Sec3 mutagenesis of the NPY motif-binding site would be required. *

      __Response: __It would be a good idea to generate reverse mutants on Sec3. However, the pocket on Sec3 bound by the NPY motifs of Sso2 is mostly hydrophobic and contains many semi-buried residues that are in close contact with other residues in the hydrophobic core of structure (including L78, Y82, I109, V112, V208, etc.; see Fig. S3D, E) and thus essential in maintaining the folding of Sec3. Making mutations on these residues would destabilize the folding of Sec3. This was why we have not done this as suggested by the reviewer.

      *- The authors suggest that the NPY-peptide binding contributes to the initial interaction/recruitment of Sso2 to the exocytosis site, defined by the localization of Sec3 (exocyst). Further data sustaining this concept/hypothesis could improve the impact of the manuscript. Thus, an experiment analyzing the co-distribution of the Sec3 with Sso2 would directly support the authors' conclusion. (In Figure 7, the authors already show the highly polarized distribution of Sec3-3xGFP.) The M7 mutant could impact the distribution of Sso2. In addition, it would be helpful to determine to which degree the Sso2 NPY - Sec3 PH domain interaction increases the overall affinity of Sso2 for the Sec3 PH domain; e.g. comparison of the binding of Sso2 (1-270) wt and M7 to Sec3 PH domain using ITC. *

      Responses:

      • We greatly value the reviewer’s suggestion. For the suggestion to investigate how the M7 mutant affects the co-distribution of Sso2 with Sec3 in yeast, we have tried a variety of conditions with both the original serum and affinity purified Sso antibodies. In neither case did we see a clear concentration at sites where we would expect to see Sec3, such as the tips of small buds. We were able to see some detectable concentration of HA-tagged Sso2 in small buds using anti-HA Ab, but it would be difficult to tag the M7 mutant at the same site since it is so close to the M7 mutation. We are also worried that the tag might interfere with Sec3 binding due to the proximity. Given the lack of detectable concentration of WT Sso2, it would not be possible to see a loss of localization in M7.
      • For the suggestion to check the binding of Sec3 with either the WT or M7 mutant of Sso2 (aa1-270), we have generated M7 mutant within the same fragment of Sso2 as the WT (i.e. aa1-270) and carefully checked how this M7 mutant affects the interaction of Sso2 with the Sec3 PH domain using three independent methods. Our ITC data show that WT Sso2 bound Sec3 very robustly, with a Kd of approximately 2 µM (Fig. 8C). Surprisingly, however, the M7 mutant of Sso2 (aa1-270) completely abolished its interaction with Sec3 (Fig. 8D). To further verify this observation, we carried out electrophoresis mobility shift assays (EMSA) and size-exclusion chromatography (SEC). Our EMSA data on a native PAGE gel shows that WT Sso2 (aa1-270) bound Sec3, whereas the M7 mutant did not (Fig. S5A, B). Similarly, our SEC data demonstrate that Sec3 was co-eluted with WT Sso2 in the higher molecular weight peak; in contrast, Sec3 and the M7 mutant of Sso2 (aa1-270) were eluted in separate peaks and no stable complex of the two was formed (Fig. S5C, D). All these new data confirm that the NPY motifs play an essential role in maintaining the stable interaction between Sso2 and Sec3, which would explain why the M7 mutant gave such dramatic phenotype in vivo (Fig. 4B-E; Fig. 5D-F; Fig. 6D, E). *Minor point: In the discussion, the authors should mention to which degree the NPY binding site within Sec3 is accessible for / occupied by other known exocyst components, or PI(4,5)P2, etc. *

      Response: __Thank you for the suggestion. A new diagram has been added to __Fig. 9E to compare the structures of the previously reported Sec3/Rho1 complex and the Sso2/Sec3 complex determined by us. It shows that the NPY binding site on Sec3 is on the opposite side of the membrane-binding surface patch. The NPY binding site is also far away from the Rho1 interacting site on Sec3 and thus does not interfere with Rho1 binding either.

      *Reviewer #1 (Significance (Required)):

      The manuscript significantly contributes to our understanding of how the vesicle tethering machinery interacts and coordinates the assembly of the membrane fusion machinery and will be of broad interest in the field of membrane trafficking. I am not an expert in X-ray crystallography. *

      __Response: __We sincerely appreciate this reviewer’s positive feedbacks.

      ***Referees cross-commenting**

      I agree with the comments of the other reviewer. It would be nice to show the effect of the M7 mutant in a reconstituted liposome fusion assay, but as already mentioned this may require an additional collaboration. Whether the relatively weak Sec3 - NPY interaction can be resolved in the liposome fusion assay needs to be shown.*

      __Response: __Please check our detailed answer to the other reviewer’s question about this.

      Reviewer #2 (Evidence, reproducibility and clarity (Required)): * The manuscript of Peer et al. Describe the structural characterization of the interaction of the syntaxin-like Sso2 protein with the exocyst subunit Sec3. The authors identify here a dual NPY motif at the N-terminal part of Sso2 that binds to Sec3 and thus confers functionality. Using x-ray crystallography, they show a nearly full-length Sso2 in complex with Sec3, which reveals how Sso2 binds to Sec3. Subsequent mutagenesis shows that both NPY motifs act together in binding, and are both required for functionality in vivo, using established assays in localization of exocyst subunits, secretion assays and growth tests. Their data suggest an overall model how Sso2 is efficiently recruited by exocyst to promote vesicle secretion.

      This is__ an overall very complete and clear manuscript__, where the authors nicely demonstrate, how the two NPY motifs both contribute to efficient Sso2 interaction with Sec3. Their data further show that each motif alone can contribute to function, whereas loss of both motifs (the M7 mutant) result in deficient binding. Likewise, their established assays to determine cellular importance of the NPY motifs in Sso2 show that trafficking and localization in the secretory pathway is strongly impaired in the mutant. I only have a few questions and suggestions. *

      __Response: __Thank you for the positive feedback.

      *1. The authors present in Figure 4 the mutants. I recommend to show the alignment of the mutants (M5,M6,M7) similar to panel A in Figure S4 here to orient the reader. They could also be listed in Figure 3, since the authors have here the sequences. *

      Response: __Alignment of M5-M7 has been added in __Fig. 4A as suggested. Thank you.

      2. The authors previously showed that Sso2 mutants affect the Sec3 driven assembly and also the fusion. I am wondering if they have the tools ready to also conduct this assay with their M7 mutant, which has the strongest defect. I am aware that this may be challenging if the tools are not established here as in the previous collaboration (Yue et al., 2017). It may provide additional information on the functional crosstalk.

      Responses:

      • Thank you for the suggestion. However, we do not think it is necessary to perform such assay based on our new results. As shown in 8C&D and Fig. S5, we found that the M7 mutant of Sso2 (aa1-270) completely abolished its interaction with Sec3, which is in contrast to the robust interaction between the WT Sso2 (aa1-270) and Sec3. Therefore, we expect that the M7 mutant would fail to accelerate liposome fusion in the same way as we had previously seen for the WT Sso2.
      • On the other hand, we have to admit that to perform such assay would indeed be challenging for us as the PhD student who had carried out the in vitro liposome fusion assay has left our previous collaborator’s lab and it would take quite a while to re-establish the assay in our own group and to optimize various parameters in that assay. *3. Along the same line, it would be good if the authors show that the mutation also impairs the interaction of Sec3 and Sso2 in vivo. *

      Response: __We appreciate the reviewer’s suggestion and have carried out co-immunoprecipitation of Sec3-3×Flag and Sso2 from yeast extract to find out how the M7 mutant affects Sso2’s interaction with Sec3 (__Fig. S6). Our results show that in contrast to the clear signal of WT Sso2 pulled down by Sec3-3×Flag, the pull-down band for the M7 mutant was much weaker and at a similar level to the negative control. This is consistent with what we saw in our in vitro binding assays (Fig. 8D; Fig. S5).

      *4. I really like the similarity of the different Munc18-Syntaxin interactions and the Sec3-Sso2 interaction. Do the authors think that Sec3 is an ancestral fragment of a Sec1 like protein, which just maintained this interaction? *

      __Response: __This is a very interesting idea. However, it seems too speculative to us to draw such conclusion. It could also be due to co-evolution in function for Sec3 to use a simpler structure (i.e. PH domain) to mimic syntaxin binding of SM proteins and to employ the extra “add-on” NPY motifs as a handle to facilitate and regulate their interaction.

      1. *Small mistake in the discussionResponses: "plasmas membrane" *

      __Response: __This has been corrected. Thank you.

      *Reviewer #2 (Significance (Required)): Important advance in our understanding of Exocyst function, which deserves publication. I only had minor issues that can be addressed quickly. *

      __Response: __We sincerely appreciate the reviewer’s positive feedbacks and constructive suggestions.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      The manuscript of Peer et al. Describe the structural characterization of the interaction of the syntaxin-like Sso2 protein with the exocyst subunit Sec3. The authors identify here a dual NPY motif at the N-terminal part of Sso2 that binds to Sec3 and thus confers functionality. Using x-ray crystallography, they show a nearly full-length Sso2 in complex with Sec3, which reveals how Sso2 binds to Sec3. Subsequent mutagenesis shows that both NPY motifs act together in binding, and are both required for functionality in vivo, using established assays in localization of exocyst subunits, secretion assays and growth tests. Their data suggest an overall model how Sso2 is efficiently recruited by exocyst to promote vesicle secretion.

      This is an overall very complete and clear manuscript, where the authors nicely demonstrate, how the two NPY motifs both contribute to efficient Sso2 interaction with Sec3. Their data further show that each motif alone can contribute to function, whereas loss of both motifs (the M7 mutant) result in deficient binding. Likewise, their established assays to determine cellular importance of the NPY motifs in Sso2 show that trafficking and localization in the secretory pathway is strongly impaired in the mutant. I only have a few questions and suggestions.

      1. The authors present in Figure 4 the mutants. I recommend to show the alignment of the mutants (M5,M6,M7) similar to panel A in Figure S4 here to orient the reader. They could also be listed in Figure 3, since the authors have here the sequences.
      2. The authors previously showed that Sso2 mutants affect the Sec3 driven assembly and also the fusion. I am wondering if they have the tools ready to also conduct this assay with their M7 mutant, which has the strongest defect. I am aware that this may be challenging if the tools are not established here as in the previous collaboration (Yue et al., 2017). It may provide additional information on the functional crosstalk.
      3. Along the same line, it would be good if the authors show that the mutation also impairs the interaction of Sec3 and Sso2 in vivo.
      4. I really like the similarity of the different Munc18-Syntaxin interactions and the Sec3-Sso2 interaction. Do the authors think that Sec3 is an ancestral fragment of a Sec1 like protein, which just maintained this interaction?
      5. Small mistake in the discussion: "plasmas membrane"

      Significance

      Important advance in our understanding of Exocyst function, which deserves publication. I only had minor issues that can be addressed quickly.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      Using the entire cytoplasmic domain of Sso2 and protein crystallization, Peer and colleagues show that two N-terminal peptides (NPY) of Sso2 synergistically interact with the Sec3 PH domain. This interaction provides an additional low affinity binding site to the previously published interface between the Sso2 four-helix bundle and the PH domain. Mutagenesis, in particular of both NPY motifs, results in reduced cell growth, in the accumulation of transport vesicles at the budding site, and in decreased secretion of invertase and Bgl2. The paper is well written, the data are convincing and the characterization of these novel peptide interaction sites clearly advances the field. Although, the exact role of the Sec3 NPY - Sec3 interaction still needs to be established, the overall functional relevance is apparent and thus the paper could be published with minor changes.

      Nevertheless, the authors may consider to address the following issues to improve the manuscript.

      • To strictly exclude the possibility that the Sso2 NPY motif also interacts with other components of the exocytosis machinery (e.g. Sec1), thereby causing the observed phenotypes, Sec3 mutagenesis of the NPY motif-binding site would be required.
      • The authors suggest that the NPY-peptide binding contributes to the initial interaction/recruitment of Sso2 to the exocytosis site, defined by the localization of Sec3 (exocyst). Further data sustaining this concept/hypothesis could improve the impact of the manuscript. Thus, an experiment analyzing the co-distribution of the Sec3 with Sso2 would directly support the authors' conclusion. (In Figure 7, the authors already show the highly polarized distribution of Sec3-3xGFP.) The M7 mutant could impact the distribution of Sso2. In addition, it would be helpful to determine to which degree the Sso2 NPY - Sec3 PH domain interaction increases the overall affinity of Sso2 for the Sec3 PH domain; e.g. comparison of the binding of Sso2 (1-270) wt and M7 to Sec3 PH domain using ITC.

      Minor point:

      In the discussion, the authors should mention to which degree the NPY binding site within Sec3 is accessible for / occupied by other known exocyst components, or PI(4,5)P2, etc.

      Significance

      The manuscript significantly contributes to our understanding of how the vesicle tethering machinery interacts and coordinates the assembly of the membrane fusion machinery and will be of broad interest in the field of membrane trafficking. I am not an expert in X-ray crystallography.

      Referees cross-commenting

      I agree with the comments of the other reviewer. It would be nice to show the effect of the M7 mutant in a reconstituted liposome fusion assay, but as already mentioned this may require an additional collaboration. Whether the relatively weak Sec3 - NPY interaction can be resolved in the liposome fusion assay needs to be shown.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      This study is interesting on finding that necroptosis may regulate axonal degeneration in the dentate gyrus, which led to the loss of synaptic transmission and plasticity and impaired the performance of mice in water maze. Genetic ablation of MLKL, a key factor for necroptotic pathway, or pharmacological inhibition of necroptosis with GSK'872, the inhibitor to another necroptotic key factor RIPK3, prevented mice from axonal degeneration, synapse dysfunction, and memory loss. They also tested long term potentiation (LTP) and found LTP that was disrupted in aged mice, was rescued by MLKL knockout or GSK'872 treatments. The authors further compared normally aged mice (more than 20 months old) with aged MLKL-knockout mice or aged mice with GSK'872 treatments for altered proteins by single-shot label-free mass spectrometry, and discovered that in 7000 detected proteins, 2516 proteins were increased while 2307 were decreased in the aging hippocampus. They carried out bioinformatic analysis and clustered these proteins for biofunctions of synaptic mechanisms, senescence, etc. With the bioinformatic analysis, they further examined cell senescence by SA-βgalactosidase (SA-βgal) staining and concluded that the cellular senescence was also rescued by necroptosis inhibition.

      Although it is an exciting idea that inhibiting necroptosis may be a potential approach to combating aging and rejuvenating the brain, I have many of concerns about the reliability and consistency of the data that did not show strong supports to the conclusion.

      Major comments:

      1. The authors used axonal degeneration as a major readout for brain aging. However, the conclusion of axonal degeneration was simply based on immunostaining. These staining results are not consistent in different parts, and their conclusion is hard to be supported by the representative images. It is not convincing that axonal integrity was altered as concluded by the authors as shown in the representative images of Fig. 1e, Fig. 2d, Fig. 3a, as well as those in the supplementary figures. Electron microscopy and other convincing means are necessary.

      We agree with the reviewer, we are performing new staining and incorporating new imaging techniques, including confocal microscopy to better define axons in different regions of the hippocampus. We propose to use Light Sheet Microscopy in clarified hippocampus in order to perform 3D analyses of the axons in the entire hippocampus (ongoing experiments). The Light Sheet microscope is currently available in our Center and we have settled the clarity protocol in brain tissue, particularly in the hippocampus (see pictures below of an hippocampi before and after the clarification protocol).

      As suggested by the reviewer, electron microscopy could be a very good addition, nevertheless this technique is not implemented in the laboratory at the moment. Nevertheless, we have initiated conversations with a possible collaborator in the UK to explore the possibility to perform 3D reconstructions at the EM level for a future publication.

      Similarly, they tested the involvement of necroptosis also simply by immunostaining of necroptotic key factors. These staining results were not consistent in different figures. Western blotting is better for the examination of protein level changes of MLKL, pMLKL, RIPK3, and pRIPK3.

      We will perform western blot for pMLKL and pRIPK3 in the different conditions, including different ages, aged Mlkl-KO and aged GSK-treated mice.

      It is very confusing which kind of neurons and which circuit is influenced by necroptosis. As emphasized in the description for Fig. 1b in Line 91, axonal degeneration was restricted to the hilus of dentate gyrus (revealed by Fluoro Jade C staining). However, synaptic transmission (Fig. 4a-f, Fig. 6a-e) and plasticity (Fig. 8c,d) were tested for CA3-CA1 projection, instead of DG-CA3 projection. Moreover, cellular senescence, as detected by SA-beta-gal in Fig. S11, was not in granule cells or hilar cells at the dentate gyrus.

      We agree with the reviewer. Considering his comments, we propose to extend our imaging analysis of axonal degeneration and necroptosis activation to the entire hippocampus, including CA1-CA3 subfields. We consider that recording CA1-CA3 circuit represents and overall response of the hippocampus, but also this subfield contains most of the axonal inputs of this brain region. We will now analyze by confocal microscopy Schaffer collaterals axons which correspond to those axons given off by CA3 pyramidal cells that project to CA1. We already showed by immunohistochemistry in Figure 2f that pMLKL levels are increased in Schaffer collaterals axons in aged mice, but we will perform 3D analysis of pMLKL in NF positive axons by immunofluorescence in this region.

      Axonal tracts for DG-CA3 projection were from granule cells at DG. However, pMLKL was found to be increased in hilar cells. In contrast, the authors concluded that pMLKL in granule cells at DG did not exhibit difference during aging (Line 115). The fact is pMLKL can be easily visualized in many cells including granule cells in adult mice that were not aged (Fig.2a, Fig. S1). Moreover, the signal of pMLKL in granule cells can be seen to be increased in aged mice, although they overlapped DAPI on it. These facts lead to a doubt that their immunostaining of pMLKL was not specific, or they did not analyze the signal accurately.

      As the reviewer remarked, we did not observe an increase in pMLKL levels in the granular cell layer of the DG (see the quantification below). Several reports have demonstrated that necroptosis is an axonal-self destruction program that is not necessarily involved in the death of the whole neuron, which suggests that pMLKL could be detected in aged axons without showing changes in the soma. We will include a paragraph in the discussion section to address this issue. By contrast, we did observe increased pMLKL in hilar cells, CA3 neurons and Schaffer collateral axons, as we demonstrated both by immunofluorescence and immunohistochemistry in Fig 2. In order to clarify the reviewer’s doubts regarding our images, we will include the same image presented in Fig 2, showing the pMLKL signal without DAPI. We will also include the pMLKL channel alone in main figures. Moreover, we believe that the new confocal analyses that we are currently performing will help us to better define necroptosis activation and axonal colocalization in the different subfields of the hippocampus.

      The pattern of non-pNF staining in Fig. 1c is not consistent with that in Fig. 3d, Fig. 5a.

      We will repeat these immunostainings and analyze the staining pattern of the non-pNF antibody to give a clear response to this comment, improving the extent of the analysis.

      Minor comments:

      For Fig. 3d,e and Fig. S4, GFAP staining is also suggested since astrocytes are the other glia that are easily reactive to inflammatory pathogenic conditions.

      This is an excellent suggestion. We are currently performing GFAP staining to establish astrocyte activation in the different conditions (aged wt, MLKL KO, and GSK intervention compared to vehicle in aged animals). This data will be included in a revised manuscript.

      Why was there no colocalization of pMLKL with NF in degenerating axonal tracts?

      We are performing confocal studies to study colocalization of these proteins. Indeed, colocalization was found but a better analysis is needed to demonstrate this, which will be included in a new version of the manuscript.

      Fig. 3a showed no hilar cells stained for pMLKL in aged mice, which is different from that shown in Fig. 2b.

      We have reviewed all the available images and there are some variabilities in aged mice that explain different patterns of pMLKL staining. This is not surprising considering the intrinsic heterogeneity of the aging process. Some mice show more axonal staining while other present clear staining in cell layer (soma) and axons. In a revised manuscript, we will include representative images of the different patterns observed.

      Images in Fig. S4 lack labels.

      Label on the figure indicates ‘Iba1’, but the color used does not allow to get a good view. Label will be changed to increase the contrast.

      Fig. S6, pRIPK3 staining pattern is different from that of pMLKL. They were not activated in the same cells?

      We observed pRIPK3 staining in the hilar cells of the hippocampus. We are currently performing double immunostaining against pMLKL and pRIPK3 to determine whether they colocalize within the same cell-type in the hippocampus.

      Fig. S7, pMLKL staining pattern is different from that in Fig. 2a,f?

      As we have detailed in point 8, this could be explained by the variability of the pMLKL staining in aged mice. In a revised manuscript we will review these images and include a supplementary image with the different staining patters found.

      Resolution for signaling pathway annotations in Fig. 8, Fig. S12, Fig. S13, and Fig. S14, is too low.

      We will increase resolution for this data. In addition, we will include the original images in our final version to avoid loss of quality during file conversion to PDF.

      The titles for Table S1 and S2 should be on the top of the tables.

      This has been corrected.

      Reviewer #1 (Significance (Required)):

      The finding that systemic administration of GSK'872 improved synaptic plasticity and mouse performances in water maze is exciting, indicating a potential medicine for brain rejuvenation.

      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      The authors (in the research group of Filipe Court in Chile) previously studied the contributions of the necroptosis pathway to the degeneration of axons following nerve damage. In this paper, the authors ask whether necroptosis pathway contributes to axon loss, inflammation and cognitive decline in naturally aging mice. The study presents some promising observations that suggest necroptosis is activated in the brain of aged mice and that inhibiting necroptosis through genetics or pharmacology can rescue some cognitive defects in aged mice. The potential implications are exciting, however the scope of what is presented thus far is preliminary. I'll list below several issues with both the experimental design and the presentation of data that strongly diminish from the potential conclusions and significance of this work.

      Major comments:

      1) The n is limited to 3 mice per condition in most of the experiments in this study, and it is not mentioned what sex the animals were. If data was pooled from both sexes than the n is not large enough to take into account potential sex differences. The absence of discussion of sex in the methods weakens my trust in the experimental design.

      WT mice of different ages are all male, purchased from Jackson Laboratory and shipped to Chile (USA). In a revised version, we will specify the sex of the mice in the methods section of the manuscript. This also applies for the group of mice used to pharmacologically inhibit necroptosis with GSK’872, which were also purchased from Jackson Labs. Regarding Mlkl-KO and their WT littermates we used both sexes. We will include a table detailing all the animals used and their age and sex in a revised manuscript. Moreover, as the reviewer suggested, we are currently increasing the n for morphological analysis from 3 to 5, which will be included in the new version of this work. For the behavioral experiments, we have used large group of animals. All details about this and sex of the KO animals will be included in a table with the raw data files.

      2)The studies are not thorough. For instance, there is only one age presented for the mlkl-KO mice. Do these mice still age-dependent changes in axon degeneration or inflammation markers?

      We have the data for other ages in the Mlkl-KO animals, which will be included in the revised manuscript.

      The strain background of the mlkl-KO mice is not mentioned and it is not clear what steps (if any) have been taken to control for strain background and rearing conditions. For instance, WT mice of different ages were purchased from Jackson labs while mlkl-KO mice were apparently bred in house.

      We will include this information in the revised manuscript. Mlkl knockout mice (Mlkl-KO) were kindly provided by Dr Douglas Green (St. Jude Children’s Research Hospital, Memphis, TN, USA). As we have described in the manuscript, the details regarding Mlkl-KO mice are cited in reference 71, which details the generation of Mlkl deficient mice and background. Age-matched control mice correspond to WT mice obtained by Mlkl heterozygous breeding in our animal facility. In addition, we systemically check genotype of mice (PCR-based genotyping protocol is now included in the method section of our manuscript).

      Reference 71. Murphy, J. M. et al. The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity 39, 443–453 (2013).

      3) For the inhibitor studies, use of littermates for the vehicle control would have been feasible, but it is not mentioned if this was done.

      As we detailed in point 1, we have used Jackson mice for the inhibitor studies. Mice were selected randomly for both vehicle and GSK’872 groups. We are currently increasing the number of mice (10 more animals per condition) for behavioral and morphological analyses in order to control for eventual variations.

      4) The Morris water tank test is a stressful condition for aged mice. Differences in performance could be confounded by differences in swimming ability and potentially stress response. Its a pity that this is the only behavioral test shown, since there are many others (eg Y-maze or novel object recognition) that would be appropriate for the questions posed.

      We evaluated swimming ability of mice and we did not observe differences between WT and KO mice of same age (see figure below), as we discussed in the manuscript. However, we agree with the reviewer that the use of other behavioral test to evaluate memory in aged mice without a stressful condition will improve the quality of our work and will help to support our data. Therefore, we will perform Y-maze and NOR in aged MLKL WT and KO mice as well as in aged animals treated with GSK-872.

      Minor comments:

      5) It is striking that some very relevant citations are absent. For instance, PMID: 34515928 (october 2021) noted a compelling increase in necroptosis markers in the aging CNS, and effects on neuroinflammation in aging mice. These conclusions have some overlap with conclusions in this study. The other study did not address contributions of necroptosis to cognitive or synaptic defects, so the current study still has some novelty, and is supported by other work that should be cited.

      This article was included in the introduction and discussion section of the original manuscript. As there are two version of the manuscript uploaded in bioRxiv file, is possible that the reviewer is referring to the first version (November 11). In fact, the second version (April 18) was uploaded to specifically include this reference.

      https://www.biorxiv.org/content/10.1101/2021.11.10.468052v2.full

      6) The methods used for analysis need to be described with more detail and rigor. For instance, how many sections are analyzed and where and how? How is normalization done and how is it determined that analogous regions are compared across animals and conditions? Likewise, the method for scoring axonal fragmentation needs to be described, and clarified where in the brain this is analyzed.

      We thank the reviewer for this suggestion. We will include a detailed description of the analysis performed, including the details referred by the reviewer and the new analyses.

      7) There are numerous typos, including impactful ones (such as legend of figure 1 where 'old' mice are 12-25 months).

      We will check and correct for typos in a revised version of the manuscript.

      8) Figure 8A is not legible. Perhaps the findings can be highlighted in a merged form on a single pathway cartoon.

      We will change the image as reviewer suggests. Moreover, we will include original images with better quality as raw data.

      Reviewer #2 (Significance (Required)):

      The investigation of the role of necroptosis in the CNS during aging is of high impact and has translational relevance, since necroptosis is a viable pathway for pharmaceutical targeting.

      The idea that it contributes to axonal degeneration and/or synaptic changes in the aging brain is novel and under-explored.

      • *
    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      The authors (in the research group of Filipe Court in Chile) previously studied the contributions of the necroptosis pathway to the degeneration of axons following nerve damage. In this paper, the authors ask whether necroptosis pathway contributes to axon loss, inflammation and cognitive decline in naturally aging mice. The study presents some promising observations that suggest necroptosis is activated in the brain of aged mice and that inhibiting necroptosis through genetics or pharmacology can rescue some cognitive defects in aged mice. The potential implications are exciting, however the scope of what is presented thus far is preliminary. I'll list below several issues with both the experimental design and the presentation of data that strongly diminish from the potential conclusions and significance of this work.

      Major comments:

      1) The n is limited to 3 mice per condition in most of the experiments in this study, and it is not mentioned what sex the animals were. If data was pooled from both sexes than the n is not large enough to take into account potential sex differences. The absence of discussion of sex in the methods weakens my trust in the experimental design.

      2) The studies are not thorough. For instance, there is only one age presented for the mlkl-KO mice. Do these mice still age-dependent changes in axon degeneration or inflammation markers? The strain background of the mlkl-KO mice is not mentioned and it is not clear what steps (if any) have been taken to control for strain background and rearing conditions. For instance, WT mice of different ages were purchased from Jackson labs while mlkl-KO mice were apparently bred in house.

      3) For the inhibitor studies, use of littermates for the vehicle control would have been feasible, but it is not mentioned if this was done.

      4) The Morris water tank test is a stressful condition for aged mice. Differences in performance could be confounded by differences in swimming ability and potentially stress response. Its a pity that this is the only behavioral test shown, since there are many others (eg Y-maze or novel object recognition) that would be appropriate for the questions posed.

      Minor comments:

      5) It is striking that some very relevant citations are absent. For instance, PMID: 34515928 (october 2021) noted a compelling increase in necroptosis markers in the aging CNS, and effects on neuroinflammation in aging mice. These conclusions have some overlap with conclusions in this study. The other study did not address contributions of necroptosis to cognitive or synaptic defects, so the current study still has some novelty, and is supported by other work that should be cited.

      6) The methods used for analysis need to be described with more detail and rigor. For instance, how many sections are analyzed and where and how? How is normalization done and how is it determined that analogous regions are compared across animals and conditions? Likewise, the method for scoring axonal fragmentation needs to be described, and clarified where in the brain this is analyzed.

      7) There are numerous typos, including impactful ones (such as legend of figure 1 where 'old' mice are 12-25 months).

      8) Figure 8A is not legible. Perhaps the findings can be highlighted in a merged form on a single pathway cartoon.

      Significance

      The investigation of the role of necroptosis in the CNS during aging is of high impact and has translational relevance, since necroptosis is a viable pathway for pharmaceutical targeting.

      The idea that it contributes to axonal degeneration and/or synaptic changes in the aging brain is novel and under-explored.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      This study is interesting on finding that necroptosis may regulate axonal degeneration in the dentate gyrus, which led to the loss of synaptic transmission and plasticity, and impaired the performance of mice in water maze. Genetic ablation of MLKL, a key factor for necroptotic pathway, or pharmacological inhibition of necroptosis with GSK'872, the inhibitor to another necroptotic key factor RIPK3, prevented mice from axonal degeneration, synapse dysfunction, and memory loss. They also tested long term potentiation (LTP) and found LTP that was disrupted in aged mice, was rescued by MLKL knockout or GSK'872 treatments. The authors further compared normally aged mice (more than 20 months old) with aged MLKL-knockout mice or aged mice with GSK'872 treatments for altered proteins by single-shot label-free mass spectrometry, and discovered that in 7000 detected proteins, 2516 proteins were increased while 2307 were decreased in the aging hippocampus. They carried out bioinformatic analysis and clustered these proteins for biofunctions of synaptic mechanisms, senescence, etc.. With the bioinformatic analysis, they further examined cell senescence by SA-βgalactosidase (SA-βgal) staining, and concluded that the cellular senescence was also rescued by necroptosis inhibition.

      Although it is an exciting idea that inhibiting necroptosis may be a potential approach to combating aging and rejuvenating the brain, I have many of concerns about the reliability and consistency of the data that did not show strong supports to the conclusion.

      Major comments:

      1. The authors used axonal degeneration as a major readout for brain aging. However, the conclusion of axonal degeneration was simply based on immunostaining. These staining results are not consistent in different parts, and their conclusion is hard to be supported by the representative images. It is not convincing that axonal integrity was altered as concluded by the authors as shown in the representative images of Fig. 1e, Fig. 2d, Fig. 3a, as well as those in the supplementary figures. Electromicroscopy and other convincing means are necessary.
      2. Similarly, they tested the involvement of necroptosis also simply by immunostaining of necroptotic key factors. These staining results were not consistent in different figures. Western blotting is better for the examination of protein level changes of MLKL, pMLKL, RIPK3, and pRIPK3.
      3. It is very confusing which kind of neurons and which circuit is influenced by necroptosis. As emphasized in the description for Fig. 1b in Line 91, axonal degeneration was restricted to the hilus of dentate gyrus (revealed by Fluoro Jade C staining). However, synaptic transmission (Fig. 4a-f, Fig. 6a-e) and plasticity (Fig. 8c,d) were tested for CA3-CA1 projection, instead of DG-CA3 projection. Moreover, cellular senescence, as detected by SA-beta-gal in Fig. S11, was not in granule cells or hilar cells at the dentate gyrus.
      4. Axonal tracts for DG-CA3 projection were from granule cells at DG. However, pMLKL was found to be increased in hilar cells. In contrast, the authors concluded that pMLKL in granule cells at DG did not exhibit difference during aging (Line 115). The fact is pMLKL can be easily visualized in many cells including granule cells in adult mice that were not aged (Fig.2a, Fig. S1). Moreover, the signal of pMLKL in granule cells can be seen to be increased in aged mice, although they overlapped DAPI on it. These facts lead to a doubt that their immunostaining of pMLKL was not specific, or they did not analyze the signal accurately.
      5. The pattern of non-pNF staining in Fig. 1c is not consistent with that in Fig. 3d, Fig. 5a.

      Minor comments:

      1. For Fig. 3d,e and Fig. S4, GFAP staining is also suggested since astrocytes are the other glia that are easily reactive to inflammatory pathogenic conditions.
      2. Why was there no colocalization of pMLKL with NF in degenerating axonal tracts?
      3. Fig. 3a showed no hilar cells stained for pMLKL in aged mice, which is different from that shown in Fig. 2b.
      4. Images in Fig. S4 lack labels.
      5. Fig. S6, pRIPK3 staining pattern is different from that of pMLKL. They were not activated in the same cells?
      6. Fig. S7, pMLKL staining pattern is different from that in Fig. 2a,f?
      7. Resolution for signaling pathway annotations in Fig. 8, Fig. S12, Fig. S13, and Fig. S14, is too low.
      8. The titles for Table S1 and S2 should be on the top of the tables.

      Significance

      The finding that systemic administration of GSK'872 improved synaptic plasticity and mouse performances in water maze is exciting, indicating a potential medicine for brain rejuvenation.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Manuscript number: RC-2021-01158

      Doi preprint: https://doi.org/10.1101/2021.11.16.468835

      Corresponding author(s): Salah, MECHERI

      [Please use this template only if the submitted manuscript should be considered by the affiliate journal as a full revision in response to the points raised by the reviewers.

      If you wish to submit a preliminary revision with a revision plan, please use our "Revision Plan" template. It is important to use the appropriate template to clearly inform the editors of your intentions.]

      1. General Statements [optional]

      This section is optional. Insert here any general statements you wish to make about the goal of the study or about the reviews.

      2. Point-by-point description of the revisions

      This section is mandatory. Please insert a point-by-point reply describing the revisions that were already carried out and included in the transferred manuscript.

      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      __Whole sporozoite vaccines confer sterilizing protection against Plasmodium infection. However, further improvements of whole sporozoite vaccines is needed and requires a thorough understanding of the immune processes that mediate protection and the deployment of novel strategies further augment protective immunity while limiting the impact of factors that are detrimental to protection. Work from the Mecheri laboratory and others had previously established that IL-6 signaling plays a critical role in the immune response to a liver stage infection; engagement of IL-6 signaling promotes the initial control of a liver stage infection and enhances the protective adaptive immune response. Given this potent protective role for IL-6, Belhimeur and colleagues design a parasite strain in rodent malaria parasites that encodes and secrete murine IL-6 during liver stage infection. They show that upon infection of wildtype mice, these transgenic parasites i) are unable to transition to blood stage infection, ii) produce Il-6 and iii) induce a durable adaptive immune response that can protect against sporozoite challenge. This study is novel and intriguing. However, a superficial analysis of the transgenic parasite strain, an incomplete analysis of the immune response to infection and the lack of data regarding the possibility of IL-6 mediated immunopathology have dampened this reviewer's enthusiasm for the work.

      **Major Concerns:** __

      1)The data in Figure 3b-3d clearly indicate that the IL-6 encoding transgenic parasites exhibit a defect in parasite development within HepG2 cells that is maintained in vivo. The authors propose that an arrest of these parasites in the liver stage precludes their transition to blood stage infection and that this arrest is dependent on IL-6 signaling. To better support that claim the authors should:

      a.Better characterize in vivo liver stage arrest using infected liver tissue analysis with immunofluorescence microscopy to determine when and how precisely IL-6 transgenic parasites are impacted in development.

      Done. New data in figure 3B, C, D

      b.Determine if arrested development of IL-6 transgenic parasites is truly dependent on IL-6 signaling using antibody blockade of IL-6 signaling and mice with genetic defects in IL-6 signaling.

      Experiments were done using anti-IL-6 receptor blocking antibodies, but did not work. This was commented in the text and shown in Supplementary Fig 2 .

      2)The authors claim that IL-6 production and secretion into the liver tissue augments the adaptive immune response to liver stage infection. This in turn results in a durable adaptive immune responses that protect against infection. However, the mechanistic underpinning of IL-6 signaling in the liver that is induced by their transgenic parasites and the impact on adaptive immune responses is poorly characterized:

      a.There is no evidence that the protective adaptive immune response induced by IL-6 trangenic parasite infection is dependent on IL-6 signaling. Is superior protection and immunogenicity lost in IL-6 signaling deficient animals that are infected with IL-6 transgenic parasites?

      Not addressed but the point is that IL-6 leads to attenuation.

      b.What elements of the adaptive immune response are impacted? One can imagine that IL-6 mediated killing of infected hepatocytes might introduce more parasite antigen that can be acquired by antigen presenting cells, or that IL-6 mediated pro-inflammatory signaling might regulate the maturation of antigen presenting cells, increased differentiation of helper T cells, the downregulation of regulatory T cell function and frequency and/or the differentiation of effector CD8 T cells into long-lived hepatic memory CD8 T cells. The authors should conduct a more comprehensive analysis of how parasite-encoded IL-6 impacts adaptive immunity.

      Done. An extensive analysis of CD4 and CD8 phenotype and status of activation is represented in Fig 9.

      3)While IL-6 transgenic parasites induce a potent and durable adaptive immune response, the authors should show how this compares to published whole sporozoite immunizations. The authors should determine if immunization with IL-6 transgenic parasites is superior to for example immunization with radiation-attenuated sporozoites and generically attenuated sporozoites.

      It not the point. The work presented here emphasizes the proof of concept that the proposed new strategy works. Follow up studies will compare this model to previous ones.

      4) IL-6 signaling is a major player in inflammatory diseases and the induction of immunopathology. As such the authors should carefully examine the duration and magnitude of IL-6 protein production in the liver, and serum after IL-6 Tg parasite infection and determine if IL-6 signaling promotes liver immunopathology.

      Not done but this point was discussed in the text. Also, we made it clear in the material and methods section that the way the construct was made, i.e the IL-6 production is time-frame restricted to the first 48h of liver infection, precisely because of the expression of IL-6 gene is under the control of LISP-2 promoter. Therefore there is no persistence of IL-6 production by liver stage parasites.

      Reviewer #1 (Significance (Required)):

      The paper is reporting a novel strategy to generate a whole sporozoite vaccine. Expression of IL6 in a transgenic parasite. This could be a significant contribution to the field if additional experiments as outlined in the critique are conducted.The work might also inform vaccine design for other pathogens.

      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      The manuscript describes the construction of a Plasmodium berghei that expresses murine interleukin-6 in exoerythrocytic (liver stage) parasites and the analysis of mice infected with sporozoites of this parasite line. They find that such parasites do not complete development in liver cells and therefore do not produce subsequent infection in red blood cells. The ability of prior infection with these parasites on the ability of the host to resist both wild type and heterologous species challenge is then examined.

      The key assumption that underlies the study is that the observed phenotypes result from parasite expression of bioactive IL-6 that functions to modulate the immune system. Other explanations are not considered, for example the over-expression of secreted IL-6 may prevent the complete maturation of the intracellular parasite by clogging up the parasite secretory pathway. The authors use the 'wild type' parasite as the control but not only does the wild type not express IL-6 it also does not express the human DHFR gene used as a selection system. A much better control parasite would be one that expresses a non-bioactive IL-6 so that the potential effects on parasite maturation can be differentiated from those on the mouse immune system. Another control to be considered would be comparison with a genetically attenuated parasite with a block in late stage development, and which does not produce a host cytokine.

      Interesting comment but key novel result is that co-infection studies show reversed phenotype of IL-6 transgenic parasites, likely due to counteracting Of IL-6 effect by Wild type parasites (Supplementary Fig 1)

      Another assumption is that IL-6 is secreted from the infected liver cell and mediates its effects, presumably by binding to its cell surface receptor. The expectation of Il-6 secretion from the parasite is that it would accumulate in the parasitophorous vacuole - how would it get out of the infected host cell? While evidence is provided of IL-6 in the in vitro culture supernatant of infected cells - this might arise from damaged cells in rather artificial conditions. Have the authors considered doing the experiment of concurrent mouse infection with both wild type and recombinant parasites? If the mechanism of parasite killing in infected liver cells is as proposed, then a reduction of wild type parasites in the subsequent asexual blood stage would be expected.

      Experiments done. We discussed both experiments: IL-6 receptor blocking antibody experiement (Suppl Fig 2), and mixed infection (Suppl Fig 1).

      Figure 3 indicates that IL-6 TgPbA/LISP2 parasites are as efficient or better than wild type parasites at invading host cells but then they do not develop to maturity. What is the evidence that the key factor in their ability to immunize the host is expression of IL-6 rather than the effect of an attenuated parasite?

      This is an interesting observation made by the reviewer. With the available data, we cannot really tell which of the two possibilities is operating in thin system. It could also be that the two option are interconnected.

      In this model malaria infection, it looks like there are two lethal outcomes: one associated with experimental cerebral malaria at relatively low blood stage parasitemia (which I understand is a controversial model for human cerebral malaria) and the second associated with high blood stage parasitemia. Some of the protocols affect which outcome occurs (see for example Fig 6), but this observation is not properly discussed.

      In many occasions, we did see in the past a discrepancy between anti-parasite immunity and anti-disease protection. In this particular experiment (Fig 6), we explored the dose effect of the IL-6 mutant. What is clear from this model is that at the high dose, 104 SPZ, we observe both anti-parasite and anti-disease protection and immunity, whereas at the lower doses, 103 and 102 SPZ, although there was no efficient anti-parasite immunity, mice did not die from cerebral malaria but much later from hyperparasitemia. We consider that the two low doses of IL-6 transgenic parasites did protect against disease expression.

      For the data presented in Fig 7, why was there a challenge with WT PbA sporozoites before the heterologous Py challenge? If this step is excluded is there still an effect against P. yoelii? Why was the parasite chosen for the heterologous challenge Py17XNL? Since this parasite is largely restricted to reticulocytes in the blood stream would a different effect have been observed if the heterologous challenge parasite was, for example, P. chabaudi?

      Out of scope.

      Although the expectation is that IL-6 expression would not occur in the asexual blood stage, I think it would be important to demonstrate experimentally that this is the case.

      Done. IL-6 transgenic parasite, when inoculated as infected erythrocytes have no development defect and grow normally in infected mice.

      In Fig. 4A the y-axis is labelled IL-6 rRNA when it should be IL-6 mRNA.

      Corrected

      Reviewer #2 (Significance (Required)):

      The significance of the report does depend on whether or not the experimental evidence is sufficient to support the claim that parasite expression of IL-6 is important in generating immunity. There has been a number of studies to show that infection with sporozoites that have been genetically attenuated to not complete subsequent development in the infected liver cell can provide immunity to subsequent infection; what is different about this study is that the authors specifically target the parasite to express a host protein that is likely to be important in acquisition of immunity. Therefore for the study to have high significance they have to show convincingly that it is the expression and activity of IL-6 that is important and I do not think this is the case with the experiments reported. If the authors are correct, then the idea of manipulating the host response by expression of host proteins by the parasite may be an attractive approach to dissect the key elements of immunity to sporozoite infection. At the moment, although there is a lot of focus on developing an attenuated whole sporozoite vaccine against malaria, and this study may provide proof of principle for including a host component in the parasite, there would still be long way to go before any practical application of this approach.

      The key message was toned down. As the formal demonstration that the expression and activity of IL-6 is direcxtly involved in IL-6 transgenic parasites to confer protective immunity, we suggest to tone down the message by saying that IL-6 attenuates parasite virulence, the mechanism being likely through IL6 signaling detrimental effect on parasite development.

      The audience would be those interested in parasite immunology.

      __

      Reviewer expertise: malaria parasite cell and molecular biology; host immunity.

      **Referees cross commenting** __

      __ I think all reviewers are of the opinion that there needs to be a better demonstration that the observed phenotype is mediated by expression and signaling of IL-6, for example by antibody blockade or using a mouse line with a genetic defect in IL-6 signaling. Looking at all the issues that have been raised by the reviewers and need to be addressed with further experimentation, my feeling is that this will take longer than 6 months.

      __

      Reviewer #3 (Evidence, reproducibility and clarity (Required)):

      __ **Summary** This study explores the expression of murine IL-6 by rodent Plasmodium berghei as a means to generate transgenic parasites whose development in the liver is arrested, which may be used as a genetically attenuated pre-erythrocytic vaccine against malaria. The authors conclude that IUL-6-expressing Plasmodium parasites elicit CSD8+ T-cell mediated immune responses that protect against a subsequent challenge with infectious sporozoites.

      **Major Comments** __

      In Figure 3, the authors show the results of qRT-PCR analysis of mouse livers infected with WT or transgenic parasites. They then use HepG2 cells to assess hepatic parasite numbers and development. Why didn't the authors assess this also in vivo, in liver sections of infected mice?

      Done. New data are presented in Fig 3B, C, D

      Linked to the above, a more complete analysis of the parasite's behavior in HepG2 cells should be provided. The authors write in the discussion that "IL-6 transgenic parasites develop perfectly well in cultured hepatocytic cells". Does this mean that they develop to the production of infectious merozoites? This could be confirmed by allowing the infected cultures to progress for 60-70 hours and then collecting the supernatants of these cultures and injecting them into naïve mice, to understand whether or not infectious merozoites are formed in vitro.

      New analysis demonstrate that IL-6 transgenic parasites actually display a developmental defect at the pre-erythrocytic stage in vivo.

      Figure 3C: The authors mention this result almost in passing but fail to provide an explanation for this observation. Why is the number of transgenic parasite EEFs approximately double that of WT parasite EEFs?

      A new figure 3 is provided and show that the EEF density (Fig 3B) was drastically reduced both at 24h and at 48h in mice infected with the IL-6 transgenic parasites as compared to those infected with WT PbA parasites, although the differences were not statistically significant. We also examined the size (Fig. 3C) of EEFs, and found the same tendency, namely a reduced size and diameter of IL-6 transgenic EEF as compared to those of WT PbA EEFs with a statistical difference only at 40h.

      Figure 3D: The EEF area units (mm2) on the YY axis are certainly wrong. However, they cannot be um2 either, as 15-30 um2 would be far too small for EEFs at 48 hours post-infection. What is it then?

      New data are now provided in a new Fig 3.

      The authors write "... suggest that the failure of IL-6 Tg-PbANKA/LISP2 parasites to develop in the liver of infected mice is likely due to an active anti-parasite immune response mediated by parasite-encoded IL-6 in vivo". I have several issues with this statement. 1) as mentioned above, the in vitro data cannot be used to draw definitive conclusions about the parasites' behavior in vivo; 2) the transgenic parasites do not "fail to develop in the liver of infected mice". If anything, they develop less than their WT counterparts, which is different from "failing to develop". Clarifying how much they do develop would be important (see next comment).

      We provide new in vivo data as to the development of IL-6 transgenic parasites. A new figure 3 is provided and show that the EEF density (Fig 3B) was drastically reduced both at 24h and at 48h in mice infected with the IL-6 transgenic parasites as compared to those infected with WT PbA parasites, although the differences were not statistically significant. We also examined the size (Fig. 3C) of EEFs, and found the same tendency, namely a reduced size and diameter of IL-6 transgenic EEF as compared to those of WT PbA EEFs with a statistical difference only at 40h. We replaced failure by a defect in development.

      In connection with the above, I would like to know more about the time when the development of IL-6 Tg-PbANKA/LISP2 parasites is arrested in vivo, in the liver. Are these early- or late-arresting parasites? Is the liver stage of infection compromised during parasite development or at egress? To clarify this, the manuscript would benefit from a timecourse analysis of liver sections of mice infected with this parasite, including data on EEF numbers and sizes up to and beyond 48 h after sporozoite inoculation.

      Done. See new figure 3.

      Still linked to the issue of parasite arrest in vivo and the possibility of breakthroughs, the manuscript would benefit from an experiment where mice were injected with a high number of transgenic sporozoites and parasitemia is monitored thereafter, much like what was done in Figure 2D, but starting off with a larger inoculum of at least 5 x 10^5 sporozoites.

      This was done and there was no breakthrough even with doses as high as 106 sporozoites

      While the results shown to suggest that secreted IL-6 restricts the parasite's liver stage development in vivo, this could be more definitely demonstrated by performing an infection with the transgenic parasites in the context of blocking or absence of the host's IL-6 receptor. This experiment was done but unfortunately did not work (Suppl. Fig 2). That is, the treatment of mice infected with IL-6 transgenic parasites with anti-IL-6 receptor blocking antibodies did not reverse the infection phenotype. This was also discuss in the manuscript.

      **Minor Comments**

      __

      The manuscript needs to be improved in terms of both language and format. Some examples, solely from the abstract, are listed below, but the manuscript needs to be appropriately revised in terms of language, grammar, punctuation and format throughout:__

      -Space missing between "P." and "berghei"

      Done

      -Gene names should be italicized

      Done

      -Rephrase "Considering IL-6 as a critical proinflammatory signal..." to "Considering that IL-6 is a critical proinflammatory signal..."

      Done

      -"transgenic IL-6 sporozoites" should be "transgenic IL-6-expressing P. berghei sporozoites"

      Done

      -"impairs Plasmodium infection at the liver stage" should be "impairs the liver stage of Plasmodium infection"

      Done

      INTRODUCTION

      The sentence "Among them, parasites lacking integrity of the parasitophorous vacuole, or late during development, and..." appears to be incomplete and needs rephrasing.

      Done

      The references used in sentence "During the last decade, in search of key mechanisms that determine the host inflammatory response, a set of host factors turned out to be critical for malaria parasite liver stage development (Mathieu et al., 2015); (Demarta-Gatsi et al., 2017; Demarta-Gatsi et al., 2016) (Grand et al., 2020)" do not all relate to the liver stage of infection. The authors need to select references that are relevant for their statement or else change the statement.

      Rephrased

      RESULTS

      I suggest the authors change the title of Results section "Transgenic P. berghei parasites expressing IL-6 during the liver stage lose infectivity to mice" not only to improve the quality of the English language employed but also to better clarify the notion that they are talking about hepatic infectivity.

      On the same section, please correct "timely specific timely".

      Done

      Transfectants are not "verified". If anything, the insertion of the gene in the parasite's genome is verified or, better still, confirmed.

      Done

      Sentence "The two lines behave similarly" is redundant.

      Done

      The legend of Figure 1 must include the definitions of all the acronyms in that figure.

      Acronyms in the whole manuscript are defined elsewhere

      "IL-6 transgenic sporozoites" is not an appropriate designation. If anything, they should be called IL-6-expressing P. berghei sporozoites".

      Done

      Figure 2 B: The YY axis should clarify that it refers to sporozoite numbers, as there are many other parasite stages in mosquitoes.

      Done

      Figure 2C: This scheme is hardly necessary. It would suffice to label the plots in D and E with the names of the parasite lines employed rather than "Group 1", "Group 2", "Group 3". The scheme is provided for more clarity and easy reading of the accompanying figures

      Figure 2D, 2E: Why didn't the authors use the same scale on the XX axis of the two plots?

      The qRT-PCR data per se do not substantiate the statement "Therefore, RT-qPCR analysis in the liver confirms that the loss of infectivity of IL-6 Tg-PbANKA/LISP2 SPZ is due to a defect in liver stage development in vivo", as a defect in invasion of hepatocytes cannot be excluded. The term "loss of infectivity" is also misleading. Do the authors mean loss of blood stage infectivity?

      Yes

      Sentence "... all parasites were able to invade and develop inside HepG2 cells." is misleading. The authors probably mean "parasites of both lines".

      Changed

      Figure 4: Why did the authors swap the order of the two experimental groups from one plot to the next? The same order should be used, to avoid confusion! Also, the authors should make the width of the bars in similar between the two plots.

      Done

      The authors should consider moving Figure 5 to the Supplementary materials.

      Reviewer #3 (Significance (Required)):

      *Nature and significance of the advance. Compare to existing published knowledge. Audience.*

      This study extends our current knowledge on genetically attenuated malaria vaccine candidates and validates the concept of suicide parasites for immunization against malaria. This paper will be of interest to researchers working on malaria vaccination, as well as all those interested in transgenic Plasmodium parasites, and the biology and immunology of liver stage infection by malaria parasites.

      *Your expertise.*

      The co-reviewer and the reviewer are experts on the liver stage of Plasmodium infection and on pre-erythrocytic malaria vaccination.

      **Referees cross commenting**

      I agree with all of Reviewers 1 and 2's remarks and, upon consideration, I would like to revise my "Estimated time to Complete Revisions" to become between 3 and 6 months

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      Summary

      This study explores the expression of murine IL-6 by rodent Plasmodium berghei as a means to generate transgenic parasites whose development in the liver is arrested, which may be used as a genetically attenuated pre-erythrocytic vaccine against malaria. The authors conclude that IUL-6-expressing Plasmodium parasites elicit CSD8+ T-cell mediated immune responses that protect against a subsequent challenge with infectious sporozoites.

      Major Comments

      In Figure 3, the authors show the results of qRT-PCR analysis of mouse livers infected with WT or transgenic parasites. They then use HepG2 cells to assess hepatic parasite numbers and development. Why didn't the authors assess this also in vivo, in liver sections of infected mice?

      Linked to the above, a more complete analysis of the parasite's behavior in HepG2 cells should be provided. The authors write in the discussion that "IL-6 transgenic parasites develop perfectly well in cultured hepatocytic cells". Does this mean that they develop to the production of infectious merozoites? This could be confirmed by allowing the infected cultures to progress for 60-70 hours and then collecting the supernatants of these cultures and injecting them into naïve mice, to understand whether or not infectious merozoites are formed in vitro.

      Figure 3C: The authors mention this result almost in passing but fail to provide an explanation for this observation. Why is the number of transgenic parasite EEFs approximately double that of WT parasite EEFs?

      Figure 3D: The EEF area units (mm2) on the YY axis are certainly wrong. However, they cannot be um2 either, as 15-30 um2 would be far too small for EEFs at 48 hours post-infection. What is it then?

      The authors write "... suggest that the failure of IL-6 Tg-PbANKA/LISP2 parasites to develop in the liver of infected mice is likely due to an active anti-parasite immune response mediated by parasite-encoded IL-6 in vivo". I have several issues with this statement. 1) as mentioned above, the in vitro data cannot be used to draw definitive conclusions about the parasites' behavior in vivo; 2) the transgenic parasites do not "fail to develop in the liver of infected mice". If anything, they develop less than their WT counterparts, which is different from "failing to develop". Clarifying how much they do develop would be important (see next comment).

      In connection with the above, I would like to know more about the time when the development of IL-6 Tg-PbANKA/LISP2 parasites is arrested in vivo, in the liver. Are these early- or late-arresting parasites? Is the liver stage of infection compromised during parasite development or at egress? To clarify this, the manuscript would benefit from a timecourse analysis of liver sections of mice infected with this parasite, including data on EEF numbers and sizes up to and beyond 48 h after sporozoite inoculation.

      Still linked to the issue of parasite arrest in vivo and the possibility of breakthroughs, the manuscript would benefit from an experiment where mice were injected with a high number of transgenic sporozoites and parasitemia is monitored thereafter, much like what was done in Figure 2D, but starting off with a larger inoculum of at least 5 x 10^5 sporozoites.

      While the results shown to suggest that secreted IL-6 restricts the parasite's liver stage development in vivo, this could be more definitely demonstrated by performing an infection with the transgenic parasites in the context of blocking or absence of the host's IL-6 receptor.

      Minor Comments

      The manuscript needs to be improved in terms of both language and format. Some examples, solely from the abstract, are listed below, but the manuscript needs to be appropriately revised in terms of language, grammar, punctuation and format throughout:

      -Space missing between "P." and "berghei"

      -Gene names should be italicized

      -Rephrase "Considering IL-6 as a critical proinflammatory signal..." to "Considering that IL-6 is a critical proinflammatory signal..."

      -"transgenic IL-6 sporozoites" should be "transgenic IL-6-expressing P. berghei sporozoites"

      -"impairs Plasmodium infection at the liver stage" should be "impairs the liver stage of Plasmodium infection"

      INTRODUCTION

      The sentence "Among them, parasites lacking integrity of the parasitophorous vacuole, or late during development, and..." appears to be incomplete and needs rephrasing.

      The references used in sentence "During the last decade, in search of key mechanisms that determine the host inflammatory response, a set of host factors turned out to be critical for malaria parasite liver stage development (Mathieu et al., 2015); (Demarta-Gatsi et al., 2017; Demarta-Gatsi et al., 2016) (Grand et al., 2020)" do not all relate to the liver stage of infection. The authors need to select references that are relevant for their statement or else change the statement.

      RESULTS

      I suggest the authors change the title of Results section "Transgenic P. berghei parasites expressing IL-6 during the liver stage lose infectivity to mice" not only to improve the quality of the English language employed but also to better clarify the notion that they are talking about hepatic infectivity.

      On the same section, please correct "timely specific timely".

      Transfectants are not "verified". If anything, the insertion of the gene in the parasite's genome is verified or, better still, confirmed.

      Sentence "The two lines behave similarly" is redundant.

      The legend of Figure 1 must include the definitions of all the acronyms in that figure.

      "IL-6 transgenic sporozoites" is not an appropriate designation. If anything, they should be called IL-6-expressing P. berghei sporozoites".

      Figure 2 B: The YY axis should clarify that it refers to sporozoite numbers, as there are many other parasite stages in mosquitoes.

      Figure 2C: This scheme is hardly necessary. It would suffice to label the plots in D and E with the names of the parasite lines employed rather than "Group 1", "Group 2", "Group 3".

      Figure 2D, 2E: Why didn't the authors use the same scale on the XX axis of the two plots?

      The qRT-PCR data per se do not substantiate the statement "Therefore, RT-qPCR analysis in the liver confirms that the loss of infectivity of IL-6 Tg-PbANKA/LISP2 SPZ is due to a defect in liver stage development in vivo", as a defect in invasion of hepatocytes cannot be excluded. The term "loss of infectivity" is also misleading. Do the authors mean loss of blood stage infectivity?

      Sentence "... all parasites were able to invade and develop inside HepG2 cells." is misleading. The authors probably mean "parasites of both lines".

      Figure 4: Why did the authors swap the order of the two experimental groups from one plot to the next? The same order should be used, to avoid confusion! Also, the authors should make the width of the bars in similar between the two plots.

      The authors should consider moving Figure 5 to the Supplementary materials.

      Significance

      Nature and significance of the advance. Compare to existing published knowledge. Audience.

      This study extends our current knowledge on genetically attenuated malaria vaccine candidates and validates the concept of suicide parasites for immunization against malaria. This paper will be of interest to researchers working on malaria vaccination, as well as all those interested in transgenic Plasmodium parasites, and the biology and immunology of liver stage infection by malaria parasites.

      Your expertise.

      The co-reviewer and the reviewer are experts on the liver stage of Plasmodium infection and on pre-erythrocytic malaria vaccination.

      Referees cross commenting

      I agree with all of Reviewers 1 and 2's remarks and, upon consideration, I would like to revise my "Estimated time to Complete Revisions" to become between 3 and 6 months

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      The manuscript describes the construction of a Plasmodium berghei that expresses murine interleukin-6 in exoerythrocytic (liver stage) parasites and the analysis of mice infected with sporozoites of this parasite line. They find that such parasites do not complete development in liver cells and therefore do not produce subsequent infection in red blood cells. The ability of prior infection with these parasites on the ability of the host to resist both wild type and heterologous species challenge is then examined.

      The key assumption that underlies the study is that the observed phenotypes result from parasite expression of bioactive IL-6 that functions to modulate the immune system. Other explanations are not considered, for example the over-expression of secreted IL-6 may prevent the complete maturation of the intracellular parasite by clogging up the parasite secretory pathway. The authors use the 'wild type' parasite as the control but not only does the wild type not express IL-6 it also does not express the human DHFR gene used as a selection system. A much better control parasite would be one that expresses a non-bioactive IL-6 so that the potential effects on parasite maturation can be differentiated from those on the mouse immune system. Another control to be considered would be comparison with a genetically attenuated parasite with a block in late stage development, and which does not produce a host cytokine.

      Another assumption is that IL-6 is secreted from the infected liver cell and mediates its effects, presumably by binding to its cell surface receptor. The expectation of Il-6 secretion from the parasite is that it would accumulate in the parasitophorous vacuole - how would it get out of the infected host cell? While evidence is provided of IL-6 in the in vitro culture supernatant of infected cells - this might arise from damaged cells in rather artificial conditions. Have the authors considered doing the experiment of concurrent mouse infection with both wild type and recombinant parasites? If the mechanism of parasite killing in infected liver cells is as proposed, then a reduction of wild type parasites in the subsequent asexual blood stage would be expected.

      Figure 3 indicates that IL-6 TgPbA/LISP2 parasites are as efficient or better than wild type parasites at invading host cells but then they do not develop to maturity. What is the evidence that the key factor in their ability to immunize the host is expression of IL-6 rather than the effect of an attenuated parasite?

      In this model malaria infection, it looks like there are two lethal outcomes: one associated with experimental cerebral malaria at relatively low blood stage parasitemia (which I understand is a controversial model for human cerebral malaria) and the second associated with high blood stage parasitemia. Some of the protocols affect which outcome occurs (see for example Fig 6), but this observation is not properly discussed.

      For the data presented in Fig 7, why was there a challenge with WT PbA sporozoites before the heterologous Py challenge? If this step is excluded is there still an effect against P. yoelii? Why was the parasite chosen for the heterologous challenge Py17XNL? Since this parasite is largely restricted to reticulocytes in the blood stream would a different effect have been observed if the heterologous challenge parasite was, for example, P. chabaudi?

      Although the expectation is that IL-6 expression would not occur in the asexual blood stage, I think it would be important to demonstrate experimentally that this is the case.

      In Fig. 4A the y-axis is labelled IL-6 rRNA when it should be IL-6 mRNA.

      Significance

      The significance of the report does depend on whether or not the experimental evidence is sufficient to support the claim that parasite expression of IL-6 is important in generating immunity. There has been a number of studies to show that infection with sporozoites that have been genetically attenuated to not complete subsequent development in the infected liver cell can provide immunity to subsequent infection; what is different about this study is that the authors specifically target the parasite to express a host protein that is likely to be important in acquisition of immunity. Therefore for the study to have high significance they have to show convincingly that it is the expression and activity of IL-6 that is important and I do not think this is the case with the experiments reported. If the authors are correct, then the idea of manipulating the host response by expression of host proteins by the parasite may be an attractive approach to dissect the key elements of immunity to sporozoite infection. At the moment, although there is a lot of focus on developing an attenuated whole sporozoite vaccine against malaria, and this study may provide proof of principle for including a host component in the parasite, there would still be long way to go before any practical application of this approach.

      The audience would be those interested in parasite immunology.

      Reviewer expertise: malaria parasite cell and molecular biology; host immunity.

      Referees cross commenting

      I think all reviewers are of the opinion that there needs to be a better demonstration that the observed phenotype is mediated by expression and signaling of IL-6, for example by antibody blockade or using a mouse line with a genetic defect in IL-6 signaling. Looking at all the issues that have been raised by the reviewers and need to be addressed with further experimentation, my feeling is that this will take longer than 6 months.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      Whole sporozoite vaccines confer sterilizing protection against Plasmodium infection. However, further improvements of whole sporozoite vaccines is needed and requires a thorough understanding of the immune processes that mediate protection and the deployment of novel strategies further augment protective immunity while limiting the impact of factors that are detrimental to protection. Work from the Mecheri laboratory and others had previously established that IL-6 signaling plays a critical role in the immune response to a liver stage infection; engagement of IL-6 signaling promotes the initial control of a liver stage infection and enhances the protective adaptive immune response. Given this potent protective role for IL-6, Belhimeur and colleagues design a parasite strain in rodent malaria parasites that encodes and secrete murine IL-6 during liver stage infection. They show that upon infection of wildtype mice, these transgenic parasites i) are unable to transition to blood stage infection, ii) produce Il-6 and iii) induce a durable adaptive immune response that can protect against sporozoite challenge. This study is novel and intriguing. However, a superficial analysis of the transgenic parasite strain, an incomplete analysis of the immune response to infection and the lack of data regarding the possibility of IL-6 mediated immunopathology have dampened this reviewer's enthusiasm for the work.

      Major Concerns:

      1)The data in Figure 3b-3d clearly indicate that the IL-6 encoding transgenic parasites exhibit a defect in parasite development within HepG2 cells that is maintained in vivo. The authors propose that an arrest of these parasites in the liver stage precludes their transition to blood stage infection and that this arrest is dependent on IL-6 signaling. To better support that claim the authors should:

      a.Better characterize in vivo liver stage arrest using infected liver tissue analysis with immunofluorescence microscopy to determine when and how precisely IL-6 transgenic parasites are impacted in development.

      b.Determine if arrested development of IL-6 transgenic parasites is truly dependent on IL-6 signaling using antibody blockade of IL-6 signaling and mice with genetic defects in IL-6 signaling.

      2)The authors claim that IL-6 production and secretion into the liver tissue augments the adaptive immune response to liver stage infection. This in turn results in a durable adaptive immune responses that protect against infection. However, the mechanistic underpinning of IL-6 signaling in the liver that is induced by their transgenic parasites and the impact on adaptive immune responses is poorly characterized:

      a.There is no evidence that the protective adaptive immune response induced by IL-6 trangenic parasite infection is dependent on IL-6 signaling. Is superior protection and immunogenicity lost in IL-6 signaling deficient animals that are infected with IL-6 transgenic parasites?

      b.What elements of the adaptive immune response are impacted? One can imagine that IL-6 mediated killing of infected hepatocytes might introduce more parasite antigen that can be acquired by antigen presenting cells, or that IL-6 mediated pro-inflammatory signaling might regulate the maturation of antigen presenting cells, increased differentiation of helper T cells, the downregulation of regulatory T cell function and frequency and/or the differentiation of effector CD8 T cells into long-lived hepatic memory CD8 T cells. The authors should conduct a more comprehensive analysis of how parasite-encoded IL-6 impacts adaptive immunity.

      3)While IL-6 transgenic parasites induce a potent and durable adaptive immune response, the authors should show how this compares to published whole sporozoite immunizations. The authors should determine if immunization with IL-6 transgenic parasites is superior to for example immunization with radiation-attenuated sporozoites and generically attenuated sporozoites.

      4) IL-6 signaling is a major player in inflammatory diseases and the induction of immunopathology. As such the authors should carefully examine the duration and magnitude of IL-6 protein production in the liver, and serum after IL-6 Tg parasite infection and determine if IL-6 signaling promotes liver immunopathology.

      Significance

      The paper is reporting a novel strategy to generate a whole sporozoite vaccine. Expression of IL6 in a transgenic parasite. This could be a significant contribution to the field if additional experiments as outlined in the critique are conducted.The work might also inform vaccine design for other pathogens.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      1. General Statements [optional]

      This section is optional. Insert here any general statements you wish to make about the goal of the study or about the reviews.

      Reviewers 1 & 3 make the very valid point that we do not have evidence for HDAC6 as the molecular target for the effects of ACY1215 on T cell development. We agree entirely, and do not claim to have defined the molecular target of ACY1215. However, these findings have direct relevance to the current use of ACY1215 as a cancer therapeutic. In addition, they provide a valuable new means of understanding the sequence of events in β-selection at higher resolution than was previously possible.

      A second major aspect of concern was whether the drug acted upon T cell development directly, or through effects on OP9 stromal cells. We hope you will agree that our new data (detailed below) has put that concern to rest.

      2. Point-by-point description of the revisions

      This section is mandatory. *Please insert a point-by-point reply describing the revisions that were already carried out and included in the transferred manuscript. *

      *Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      In this work, Russell and colleagues study the differentiation steps of thymocytes around the time of expression and function of the pre-TCR. They use CD2 as a new marker of an intermediate population of differentiation between DN3a thymocytes and DN4 thymocytes. The CD2+ thymocytes would be and a later stage of differentiation than the CD2 negative ones. In this way, they define a DN3b-Pre and a DN3b-Post populations. The study also aims to study the role of histone deacetylase HDAC6 in thymocytes differentiation at the time of pre-TCR signaling by using as a tool the inhibitor ACY1215 and conclude that HDAC plays an important role during the DN3-DN4 transition. The method the authors use to study consist of the sorting of precursor cells from fetal or adult thymuses and studying the effect of the inhibitor during differentiation in vitro promoted by interaction of the thymocytes with the OP9-DL1 cell line, a well-characterized cell line that expresses a ligand of Notch and promotes DN3 differentiation up to the DP stage. There are major concerns with the approach used by the researchers that make their conclusions unsustainable. 1) They use the inhibitor ACY1215 in the co-culture of thymocytes with OP9-DL1 cells to examine the effect of HDAC inhibition in thymocytes on their differentiation. However, the authors do not provide any control result showing that the effects detected on differentiation are not caused by the activity of the inhibitor on OP9-DL1 cells and not on thymocytes. This possibility is not excluded and if the inhibitor were acting on OP9 cells would invalidate completely the conclusions of the study.*

      * *We now include data that ACY1215 does not impact upon OP9-DL1 cell number or acetylation of tubulin, and that ACY1215-treated OP9-DL1 cells can fully support adhesion and differentiation of thymocytes (new Supp Fig 2 A-C). We have added two additional authors who contributed to these data. We believe these data provide strong evidence that ACY1215 exerts its effects directly on the developing T cells.

      * 2) The inhibitor is used at a single concentration (one has to search in the Methods section in order to find that it is 1 micromolar) and there is no evidence provided of dose-response effects. Furthermore, experiments are missing in which different doses of the inhibitor are tested on its potential targets and shown to have a selective impact on those targets at the concentration used in the study.*

      We do not believe these analysis are within the scope of the manuscript, the focus of which is the novel differentiation characteristics revealed by ACY1215, rather than the impact of the drug itself.

      3) The authors suggest that the inhibitor is a epigenetic regulator because it acts on the deacetylatio of histones but also that it acts on the formation of a potential immunological synapse by the pre-TCR expressing thymocytes with inhibition of the translocation of the microtubule organizing centre. By the end of the study, one does not know exactly how is the inhibitor acting on pre-T cell differentiation.

      * *We completely agree, this manuscript provides a starting point for dissecting the molecular mechanism for ACY1215 effects, and we have taken care to discuss the several possibilities that are currently in play. However, we believe the identification of an effect is a critical finding in its own right and has already proven valuable in uncovering novel events in β-selection.

      * 4) The authors seem to postulate a model in which the effect of the inhibitor on the immunological synapse and pre-TCR signaling affects the expression of Lef1 which itself modulates histone deacetylation. Therefore, the inhibition of HDAC6 would be acting on pre-TCR signaling upstream but also on the activity of Lef1 downstream. It seems that the approach is not sufficiently precise as to discriminate the site of action of the inhibitor*

      We propose this as one possible model. Dissecting the impact via Lef1 vs HDAC6 vs tubulin is beyond the scope of this paper.

      * 5) The authors use contour plots to display their data. This has the advantage of defining cell populations but on the other hand, hides the number of events that are defining the populations. This is for instance reflected in Figure 7 panel B where the CD5 vs surface TCRbeta plot of cultured DN3a thymocytes shows many different populations (in green) which are probably artifacts of the contour plot. Very likely such populations are formed by very few events

      *

      We have adjusted the contour densities. We also note that the histograms above and to the side of the contour plots are provide for ready comparison of proportions.

      * 6) I do not see a big effect of the inhibitor on Lef 1 expression (Figure 6A) and if the inhibitor has an effect at the DN3b-Pre stage why it should not have it at the DN3b-Post stage.

      *

      The effect of ACY1215 on Lef1 expression is clear in FL-derived DN3bPre (Fig 6Ai) and in thymus-derived DN3a and DN3bPre cells (Fig 6Aii,7A). Given previous findings that Lef1/TCF are required for progression through β-selection (Xu et al, 09 from the manuscript), these data suggest that the failure to upregulate Lef1 in some DN3bPre cells might prevent their traversal to DN4, explaining why DN3bPost cells don’t exhibit a loss of Lef1.

      * 7) Suppl. Fig. 11.-In DN3b-Post, expression of CD5 is higher than in DN3a but not so clearly higher than in DN3b-Pre. The effect of the inhibitor on DN3b-Post was that of reducing CD5 expression but not Lef1 expression. In this experiment, the effect of the inhibitor of Lef1 expression by DN3b-Pre is not seen. Quantitation? The inhibitor could be altering CD5 expression by inhibiting the synapse independent of Lef1 ?*

      This is an understandable misconception, and we have clarified in the text and by including a plot of CD5 vs Lef1 in Sup Fig 11. The effect of drug on Lef1 expression in DN3bPre is readily apparent (see reduction in Lef1Hi in the red contour plot LHS). However, by separating Lef1 high and low populations (RHS), we see Lef1Hi cells in the pink contours. This does not indicate a high proportion of Lef1Hi cells, merely that we enriched for them in the gating, as a means to assess any correlation with CD5. The reviewer is absolutely correct that the inhibitor could be altering CD5 expression by inhibiting the synapse independent of Lef1. However, the clear correlation of expression of Lef1 and CD5 in untreated cells, and the loss of that correlation after ACY1215 treatment, supports the notion that ACY1215 disrupts a functional association between expression of Lef1 and CD5.

      * 8) Figure 8.- The populations defined by CFSE staining are too broad in terms of fluorescence intensity as to determine number of cell divisions. It seems that there are only two populations: one that has not diluted CFSE and therefore has not divided and another that has diluted CFSE and has divided. How many times? we do not know. On the other hand, CD5 is increased in cells that have diluted CFSE. Have they expressed CD4, CD8, downregulated CD25, other markers indicating that the cells are not longer DN3a or DN3b? CD5 is upregulated after CFSE dilution not before dilution, so is CD5 expression cause or effect of differentiation..The effect of the inhibitor is not clear.*

      We agree the CFSE staining does not indicate number of divisions. We don’t agree that there are two populations, rather, a spread of CFSE indicating heterogeneity in the extent of proliferation, and a inverse correlation between CFSE and CD5 indicating that proliferation is associated with increasing CD5 expression. At this stage, we do not believe there is sufficient information to predict a causal relationship between these two markers. However, to our knowledge, the association is novel and provides a strong basis for further exploration, particularly in light of recent published findings that CD5 can act to tune the TCR signal at later stages of T cell development.

      * **Referees cross-commenting**

      Totally in agreement! The effect of the drug could be on the OP9-DL1 cells and not on thymocytes. This is not proven

      We hope you agree that our new data alleviates this concern, and supports a T cell autonomous impact of ACY1215.

      Reviewer #1 (Significance (Required)):

      With all the concerns about the method used by the authors to define subpopulations in DN3-DN4 transition and the involvement of HDAC6 activity I do not believe the paper will have a significant impact in the field. The authors will need to rethink their approaches in order to investigate the subject with sufficient guarantees. Perhaps using genetic approaches.*

      As agreed by Reviewers 2 and 3, new findings in the manuscript represent a substantial contribution to the field irrespective of the molecular target of ACY1215. Genetic approaches have their own drawbacks (including issues of compensation in the non-acute setting of most genetic modifications), and the clinical use of inhibitors such as ACY1215 mean these findings are significant irrespective of the molecular target.*

      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      While the authors appear to have initially set out to determine the role of HDAC6 at the beta-selection checkpoint of T cell development, they also came away with a new panel of markers that further delineate important stages of thymocyte differentiation, describing the sequential upregulation of CD28, the preTCR, Lef1 and CD5, and, subsequently, CD2 as cells pass the test verifying successful recombination of the T cell receptor (TCR) b chain. The authors used several approaches for this study; they took advantage of the well-characterized OP9-DL1 co-culture system to support differentiation of progenitor cells in the presence or absence of an HDAC6-specific inhibitor or they isolated progenitor populations of interest directly from a murine thymus for short term culture in the presence or absence of inhibitor. They identify an important role for HDAC6 at the b-selection checkpoint as evidenced by an accumulation of a subset of 'double negative 3' cells and attribute this, in part, to increased acetylation of a-tubulin at the preTCR synapse as well as dysregulated expression of and/or recruitment to the microtubule-organising centre of proteins essential for beta-selection signals. Possible disruption of preTCR signaling by an HDAC6 inhibitor appears to limit upregulation of regulatory molecules (e.g. CD5) and normal progression through this stage.

      I find the data presented and conclusions made to be largely convincing and that this manuscript represents a substantial contribution to the field. I recognize many of the challenges associated with this study that include assessing protein levels on small populations of cells, the heterogeneity of the cell populations (even if sorting a discrete subset, the requirement for culturing the cells +/- inhibitor invites differentiation), and the pleiotropic effects of HDAC inhibitors (HDACi). With few exceptions, we can accept these issues as the authors were clearly careful in their approaches, and there are limited other techniques that can be used to address some of these questions.*

      We thank the reviewer for their strong endorsement of the study. *


      Major comments.

      Given the effort already put into this paper, it might be worthwhile to ultimately show step-wise progression through the developmental intermediates described in this manuscript. A time course to assess differentiation of isolated DN3a cells in OP9-Dl1 coculture could be considered, for example. The authors clearly have the reagents and skills to carry out these experiments though the timing would be a factor in order to capture the appearance of discrete developmental intermediates. This would, in many ways, provide a straightforward summary of many of the reported results that would improve accessibility to a broader audience.

      *We agree that this would be of ultimate value. Unfortunately, it is not in the scope of this manuscript.

      The differences in protein levels stated are not always so obvious based on the contour plots and/or histograms; these are often subtle effects that can be obscured by the 'noise' that accompanies the analysis of protein levels on small populations of cells. Quantification of the data should be included when making conclusions about differences in expression levels of different markers. In addition, when quantification and statistics are provided, it is clear that at least three repeats were included, but without quantification, the reproducibility of the experiments are not known; the number of replicates for each experiment should be obviously stated.

      We have added quantification to Fig 6, Fig 7 and Fig S11 and included numbers to indicate number of replicates for each experiments.*

      Minor points.

      The impact of the inhibitor seems to be inconsistent in Fig. 6A i and ii; there is not much of an impact of the inhibitor in ii as I understand. There also seem to be significantly different expression patterns of Lef in the DN3bpre stage in the two models (OP9 vs ex vivo) - what is the explanation for this?*

      Lef1 does appear to be upregulated slightly earlier in ex vivo thymocytes compared to fetal liver derived cells, although most of the upregulation occurs in the DN3bPre stage in both systems. We are not sure of the explanation for this. Importantly both systems show clear reduction of Lef1 before, but not after, CD2 expression. * That the inhibitor leads to a 'loss of correlation' between Lef and CD5 levels is more obvious in Supp Fig 11 than as presented in Figure 7.*

      Perhaps, although it is still evident in Figure 7. We believe the effect is most striking when thymocytes were sorted for DN3a, and then treated for 2 days (Fig 7B), but we also see the effect at 1 day on fetal liver-derived cells (Supp Fig 11) and at 1 day for thymocytes (Fig 7B) * Consider adding a CD25lo population (e.g. DN4) as a reference in Supp. Fig. 12.*

      By definition DN3 and DN4 are delineated by expression of CD25, so all DN4 cells are lower for CD25 than any of the DN3 subsets. We have now made this clear with addition of DN4 in Supp Fig 12 as requested. * In reference to Fig. 5, the authors suggest the analysis of MTOC components in DN3a cells; are these Dn3a cells? DN3a cells were isolated and then cultured for a day +/- inhibitor. I presume there is some differentiation in these cultures that depends on the presence of the inhibitor. I am not suggesting that the authors need to redo this experiment but rather either acknowledge that these are not all DN3a cells (unless I am wrong here) by changing the wording, or add a marker to distinguish the subset (CD2?)*

      You are correct, we have changed the wording to say: DN3a cells were cultured for 1 day with and without ACY1215 (so would be predominantly DN3a and DN3bPre and not yet past β-selection; see Supp Fig 9).*

      Make note of the DN3b nomenclature used; I believe that 'pro' was used instead of 'post' at least once.*

      We apologize, and have corrected.*

      In Fig 1, the populations identified as CD4+ and CD8+ are likely immature populations; unless including TCRb staining to distinguish these, I suggest excluding them from the analysis. I think the DP population is sufficient here to get the point across.*

      We appreciate the advice and have removed the SP data.*

      In Supp Fig 2. the schematic does not appear to be consistent with legend (2 versus 4 d of culture).*

      We have corrected to 2D.*

      In Supp Fig 8a, the quantification of DN3a/b-pre/b-pro has a different experimental set up than in Fig 3bii but is written as if this is the quantification of the data as I understand it.*

      No, the quantification is for Fig 3bi.*

      In line 214/215, it is suggested that "Analysis of the cells immediately after extraction showed clearly distinct DN3a, DN3bPre and DN3bPost cells." but I did not find the data for this.*

      We have now made more clear that this data is at the top right of Fig 4) * Please confirm the experimental set up in Supp. Fig. 9. Why treat with inhibitor prior to isolating the subsets and then culturing again without inhibitor?*

      This is the correct set-up. The goal was to enrich sufficient DN3bPre cells to ensure a pure sort (taking advantage of the ACY1215 effect), and then to monitor their differentiation.*

      Eliminate conclusions made without specific reference to figures or to 'future' figures.

      *

      We have tried to find such conlusions, but not been able to.

      * In some histograms (e.g. 5), it was not obvious to me what the negative controls represented. Are these fluorescence minus one, isotype, other?

      *

      We have made more clear in the Figure Legends.

      * In the abstract, it is suggested that increases in a number of markers provides for escalating TCR signaling strength; CD5 is among these. As a negative regulator of TCR signals, this statement seems to be counterintuitive.*

      Apologies for this error, we have changed ‘escalating’ to ‘modulating’*

      The authors state that, "These data together indicate that CD5 serves as a link between TCRb expression and proliferation, ...." (line 325/326); how CD5 'links' the two is not clear.*

      We have changed the wording.*

      -It is written that "...at Day 8-10 of the co-culture, when cells from mouse fetal liver were predominantly at the DN3 stage of T cell development (Supp Fig 1B)...". Reconsider wording this statement as it appears as if the majority of cells actually express CD4 and/or CD8. *

      Thank you, we have done so.

      * **Referees cross-commenting**

      Reviewers 1 and 3 bring up important, obvious points that this reviewer missed in terms of the potential off-target effects of the HDACi on the stromal cell component of the co-culture system used for the experiments. It is difficult to determine the relevance of HDAC6 at this developmental checkpoint without additional controls*

      We hope you agree that we have allayed this concern with new controls.*

      Reviewer #2 (Significance (Required)):

      As an immunologist with an interest in the molecular and cellular mechanisms that regulate T cell development, I find this manuscript interesting for several reasons.

      One of the benefits of studying development and differentiation in the immune system is the ability to distinguish discrete developmental intermediates by flow cytometry using defined panels of cell surface and intracellular markers; this allows for the isolation of populations of cells for testing progenitor/progeny relationships, to identify the role of essential genes at various developmental stages and beyond. This manuscript adds important new markers that will allow researchers to more discretely tease apart important stages in T cell development during an important regulatory checkpoint.

      Not only is beta-selection an essential first step in ensuring a functional antigen receptor repertoire during T cell development, but its tight regulation is absolutely necessary due to the double-strand DNA breaks that accompany antigen receptor gene rearrangement and the massive proliferation that ensues after successful pairing of a functionally rearranged TCRb chain with the preTCRa; indeed, dysregulation at the beta-selection checkpoint can give rise to leukemia. This study provides new insight into potential mechanisms of beta-selection regulation.

      Thank you for this positive evaluation.

      Reviewer #3 (Evidence, reproducibility and clarity (Required)):

      Chann et al employ a pharmacologic inhibitor (ACY1215) to assess the role of HDAC6 as a molecular effector of differentiation during traversal of the b-selection checkpoint. Using this inhibitor, they detect an accumulation of cells at the DN3b stage that have failed to upregulate CD2. Consequently, they propose the existence of a new intermediate stage between induction of CD28 and CD2 and term these stages as DN3b-pre and DN3b-post. The proposal is that the arrest of development between these two stages results from interference with the normal pattern of induction of CD5 and Lef1. The experiments are thoughtfully designed and interpreted. However, there are a number of significant issues.

      1. HDAC6 ko mice have no thymic phenotype (Zhang MCB 08; Fig. 6) raising the possibility that all of the effects observed following ACY1215 treatment result from off-target activity. This calls the mechanistic analysis into question. One way to address this would be to treat HDAC6 deficient thymic progenitors with equivalent doses of drug to determine if the observed effects do not occur.*

      We agree that HDAC6 might not be the primary target, and have gone to considerable lengths to make this clear in the manuscript. Rather than focus specifically on HDAC6, we believe identification of all possible molecular targets (HDAC6, Lef1/TCF1, perhaps other acetylases, each conferring transcriptional or cytoskeletal regulation) will require extensive efforts not within the scope of this manuscript.

      * Equally important is that the analysis is essentially all descriptive with no interventions (gain or loss-of-function) to investigate the causal relationships of the correlations observed.

      *

      We don’t agree that the analysis is essentially all descriptive, since our findings derived from the application of ACY1215.

      * Some of the data interpretation is puzzling. For example, drug treatment results in an increased proportion of DN3b cells, which is interpreted to mean that drug promotes the DN3a to DN3b transition; however, based on the absolute counts, a more likely explanation is the the drug is killing the DN3a cells (Fig2a).*

      We certainly agree and state that DN3a cells are depleted by 1 day ACY1215, but do not believe this is due to death given the apoptisis analysis in Fig S4. Given that DN3 and DN4 cell numbers are equivalent even out to Day 4 when one would expect the DN3a depletion to have substantial effect, we suggest that this is ‘perhaps caused by precocious differentiation from DN3a to DN3b’. * **Referees cross-commenting**

      Is there consensus that w/o clear evidence pointing to on-target action of the drug on the intended target that the significance of the study is limited?

      We have confirmed that thymocytes are the cellular target. The molecular target will take much more work and is not the focus of this paper.

      Reviewer #3 (Significance (Required)):

      Because of the complete absence of a thymic phenotype of HDAC6-deficient mice, the significance ofe these findings is substantially in doubt.*

      There are many examples of key biological processes that were not revealed by a phenotype in the knockout, due to compensatory effects (pertinent to this paper: Lef1 being a clear example).

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      Chann et al employ a pharmacologic inhibitor (ACY1215) to assess the role of HDAC6 as a molecular effector of differentiation during traversal of the b-selection checkpoint. Using this inhibitor, they detect an accumulation of cells at the DN3b stage that have failed to upregulate CD2. Consequently, they propose the existence of a new intermediate stage between induction of CD28 and CD2 and term these stages as DN3b-pre and DN3b-post. The proposal is that the arrest of development between these two stages results from interference with the normal pattern of induction of CD5 and Lef1. The experiments are thoughtfully designed and interpreted. However, there are a number of significant issues.

      1. HDAC6 ko mice have no thymic phenotype (Zhang MCB 08; Fig. 6) raising the possibility that all of the effects observed following ACY1215 treatment result from off-target activity. This calls the mechanistic analysis into question. One way to address this would be to treat HDAC6 deficient thymic progenitors with equivalent doses of drug to determine if the observed effects do not occur.
      2. Equally important is that the analysis is essentially all descriptive with no interventions (gain or loss-of-function) to investigate the causal relationships of the correlations observed.
      3. Some of the data interpretation is puzzling. For example, drug treatment results in an increased proportion of DN3b cells, which is interpreted to mean that drug promotes the DN3a to DN3b transition; however, based on the absolute counts, a more likely explanation is the the drug is killing the DN3a cells (Fig2a).

      Referees cross-commenting

      Is there consensus that w/o clear evidence pointing to on-target action of the drug on the intended target that the significance of the study is limited?

      Significance

      Because of the complete absence of a thymic phenotype of HDAC6-deficient mice, the significance ofe these findings is substantially in doubt.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      While the authors appear to have initially set out to determine the role of HDAC6 at the beta-selection checkpoint of T cell development, they also came away with a new panel of markers that further delineate important stages of thymocyte differentiation, describing the sequential upregulation of CD28, the preTCR, Lef1 and CD5, and, subsequently, CD2 as cells pass the test verifying successful recombination of the T cell receptor (TCR) b chain. The authors used several approaches for this study; they took advantage of the well-characterized OP9-DL1 co-culture system to support differentiation of progenitor cells in the presence or absence of an HDAC6-specific inhibitor or they isolated progenitor populations of interest directly from a murine thymus for short term culture in the presence or absence of inhibitor. They identify an important role for HDAC6 at the b-selection checkpoint as evidenced by an accumulation of a subset of 'double negative 3' cells and attribute this, in part, to increased acetylation of a-tubulin at the preTCR synapse as well as dysregulated expression of and/or recruitment to the microtubule-organising centre of proteins essential for beta-selection signals. Possible disruption of preTCR signaling by an HDAC6 inhibitor appears to limit upregulation of regulatory molecules (e.g. CD5) and normal progression through this stage.

      I find the data presented and conclusions made to be largely convincing and that this manuscript represents a substantial contribution to the field. I recognize many of the challenges associated with this study that include assessing protein levels on small populations of cells, the heterogeneity of the cell populations (even if sorting a discrete subset, the requirement for culturing the cells +/- inhibitor invites differentiation), and the pleiotropic effects of HDAC inhibitors (HDACi). With few exceptions, we can accept these issues as the authors were clearly careful in their approaches, and there are limited other techniques that can be used to address some of these questions.


      Major comments.

      Given the effort already put into this paper, it might be worthwhile to ultimately show step-wise progression through the developmental intermediates described in this manuscript. A time course to assess differentiation of isolated DN3a cells in OP9-Dl1 coculture could be considered, for example. The authors clearly have the reagents and skills to carry out these experiments though the timing would be a factor in order to capture the appearance of discrete developmental intermediates. This would, in many ways, provide a straightforward summary of many of the reported results that would improve accessibility to a broader audience.

      The differences in protein levels stated are not always so obvious based on the contour plots and/or histograms; these are often subtle effects that can be obscured by the 'noise' that accompanies the analysis of protein levels on small populations of cells. Quantification of the data should be included when making conclusions about differences in expression levels of different markers. In addition, when quantification and statistics are provided, it is clear that at least three repeats were included, but without quantification, the reproducibility of the experiments are not known; the number of replicates for each experiment should be obviously stated.

      Minor points.

      The impact of the inhibitor seems to be inconsistent in Fig. 6A i and ii; there is not much of an impact of the inhibitor in ii as I understand. There also seem to be significantly different expression patterns of Lef in the DN3bpre stage in the two models (OP9 vs ex vivo) - what is the explanation for this?

      That the inhibitor leads to a 'loss of correlation' between Lef and CD5 levels is more obvious in Supp Fig 11 than as presented in Figure 7.

      Consider adding a CD25lo population (e.g. DN4) as a reference in Supp. Fig. 12.

      In reference to Fig. 5, the authors suggest the analysis of MTOC components in DN3a cells; are these Dn3a cells? DN3a cells were isolated and then cultured for a day +/- inhibitor. I presume there is some differentiation in these cultures that depends on the presence of the inhibitor. I am not suggesting that the authors need to redo this experiment but rather either acknowledge that these are not all DN3a cells (unless I am wrong here) by changing the wording, or add a marker to distinguish the subset (CD2?)

      Make note of the DN3b nomenclature used; I believe that 'pro' was used instead of 'post' at least once.

      In Fig 1, the populations identified as CD4+ and CD8+ are likely immature populations; unless including TCRb staining to distinguish these, I suggest excluding them from the analysis. I think the DP population is sufficient here to get the point across.

      In Supp Fig 2. the schematic does not appear to be consistent with legend (2 versus 4 d of culture).

      In Supp Fig 8a, the quantification of DN3a/b-pre/b-pro has a different experimental set up than in Fig 3bii but is written as if this is the quantification of the data as I understand it.

      In line 214/215, it is suggested that "Analysis of the cells immediately after extraction showed clearly distinct DN3a, DN3bPre and DN3bPost cells." but I did not find the data for this.

      Please confirm the experimental set up in Supp. Fig. 9. Why treat with inhibitor prior to isolating the subsets and then culturing again without inhibitor?

      Eliminate conclusions made without specific reference to figures or to 'future' figures.

      In some histograms (e.g. 5), it was not obvious to me what the negative controls represented. Are these fluorescence minus one, isotype, other?

      In the abstract, it is suggested that increases in a number of markers provides for escalating TCR signaling strength; CD5 is among these. As a negative regulator of TCR signals, this statement seems to be counterintuitive.

      The authors state that, "These data together indicate that CD5 serves as a link between TCRb expression and proliferation, ...." (line 325/326); how CD5 'links' the two is not clear.

      It is written that "...at Day 8-10 of the co-culture, when cells from mouse fetal liver were predominantly at the DN3 stage of T cell development (Supp Fig 1B)...". Reconsider wording this statement as it appears as if the majority of cells actually express CD4 and/or CD8.

      Referees cross-commenting

      Reviewers 1 and 3 bring up important, obvious points that this reviewer missed in terms of the potential off-target effects of the HDACi on the stromal cell component of the co-culture system used for the experiments. It is difficult to determine the relevance of HDAC6 at this developmental checkpoint without additional controls

      Significance

      As an immunologist with an interest in the molecular and cellular mechanisms that regulate T cell development, I find this manuscript interesting for several reasons.

      One of the benefits of studying development and differentiation in the immune system is the ability to distinguish discrete developmental intermediates by flow cytometry using defined panels of cell surface and intracellular markers; this allows for the isolation of populations of cells for testing progenitor/progeny relationships, to identify the role of essential genes at various developmental stages and beyond. This manuscript adds important new markers that will allow researchers to more discretely tease apart important stages in T cell development during an important regulatory checkpoint.

      Not only is beta-selection an essential first step in ensuring a functional antigen receptor repertoire during T cell development, but its tight regulation is absolutely necessary due to the double-strand DNA breaks that accompany antigen receptor gene rearrangement and the massive proliferation that ensues after successful pairing of a functionally rearranged TCRb chain with the preTCRa; indeed, dysregulation at the beta-selection checkpoint can give rise to leukemia. This study provides new insight into potential mechanisms of beta-selection regulation.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      In this work, Russell and colleagues study the differentiation steps of thymocytes around the time of expression and function of the pre-TCR. They use CD2 as a new marker of an intermediate population of differentiation between DN3a thymocytes and DN4 thymocytes. The CD2+ thymocytes would be and a later stage of differentiation than the CD2 negative ones. In this way, they define a DN3b-Pre and a DN3b-Post populations. The study also aims to study the role of histone deacetylase HDAC6 in thymocytes differentiation at the time of pre-TCR signaling by using as a tool the inhibitor ACY1215 and conclude that HDAC plays an important role during the DN3-DN4 transition. The method the authors use to study consist of the sorting of precursor cells from fetal or adult thymuses and studying the effect of the inhibitor during differentiation in vitro promoted by interaction of the thymocytes with the OP9-DL1 cell line, a well-characterized cell line that expresses a ligand of Notch and promotes DN3 differentiation up to the DP stage.

      There are major concerns with the approach used by the researchers that make their conclusions unsustainable.

      1. They use the inhibitor ACY1215 in the co-culture of thymocytes with OP9-DL1 cells to examine the effect of HDAC inhibition in thymocytes on their differentiation. However, the authors do not provide any control result showing that the effects detected on differentiation are not caused by the activity of the inhibitor on OP9-DL1 cells and not on thymocytes. This possibility is not excluded and if the inhibitor were acting on OP9 cells would invalidate completely the conclusions of the study.
      2. The inhibitor is used at a single concentration (one has to search in the Methods section in order to find that it is 1 micromolar) and there is no evidence provided of dose-response effects. Furthermore, experiments are missing in which different doses of the inhibitor are tested on its potential targets and shown to have a selective impact on those targets at the concentration used in the study.
      3. The authors suggest that the inhibitor is a epigenetic regulator because it acts on the deacetylatio of histones but also that it acts on the formation of a potential immunological synapse by the pre-TCR expressing thymocytes with inhibition of the translocation of the microtubule organizing centre. By the end of the study, one does not know exactly how is the inhibitor acting on pre-T cell differentiation.
      4. The authors seem to postulate a model in which the effect of the inhibitor on the immunological synapse and pre-TCR signaling affects the expression of Lef1 which itself modulates histone deacetylation. Therefore, the inhibition of HDAC6 would be acting on pre-TCR signaling upstream but also on the activity of Lef1 downstream. It seems that the approach is not sufficiently precise as to discriminate the site of action of the inhibitor
      5. The authors use contour plots to display their data. This has the advantage of defining cell populations but on the other hand, hides the number of events that are defining the populations. This is for instance reflected in Figure 7 panel B where the CD5 vs surface TCRbeta plot of cultured DN3a thymocytes shows many different populations (in green) which are probably artifacts of the contour plot. Very likely such populations are formed by very few events
      6. I do not see a big effect of the inhibitor on Lef 1 expression (Figure 6A) and if the inhibitor has an effect at the DN3b-Pre stage why it should not have it at the DN3b-Post stage.
      7. Suppl. Fig. 11.-In DN3b-Post, expression of CD5 is higher than in DN3a but not so clearly higher than in DN3b-Pre. The effect of the inhibitor on DN3b-Post was that of reducing CD5 expression but not Lef1 expression. In this experiment, the effect of the inhibitor of Lef1 expression by DN3b-Pre is not seen. Quantitation? The inhibitor could be altering CD5 expression by inhibiting the synapse independent of Lef1 ?
      8. Figure 8. The populations defined by CFSE staining are too broad in terms of fluorescence intensity as to determine number of cell divisions. It seems that there are only two populations: one that has not diluted CFSE and therefore has not divided and another that has diluted CFSE and has divided. How many times? we do not know. On the other hand, CD5 is increased in cells that have diluted CFSE. Have they expressed CD4, CD8, downregulated CD25, other markers indicating that the cells are not longer DN3a or DN3b? CD5 is upregulated after CFSE dilution not before dilution, so is CD5 expression cause or effect of differentiation.The effect of the inhibitor is not clear.

      Referees cross-commenting

      Totally in agreement! The effect of the drug could be on the OP9-DL1 cells and not on thymocytes. This is not proven

      Significance

      With all the concerns about the method used by the authors to define subpopulations in DN3-DN4 transition and the involvement of HDAC6 activity I do not believe the paper will have a significant impact in the field. The authors will need to rethink their approaches in order to investigate the subject with sufficient guarantees. Perhaps using genetic approaches.